[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ec447381a9274cb2925d3a6a913cd81a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[33, 35], [76, 78], [54, 56], [249, 251], [25, 27]], "char_spans": [[169, 175], [441, 447], [287, 293], [1456, 1462], [138, 144]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["translocation", 28], ["(", 42], ["t(9;22", 43], [")", 49], [")", 50], ["results", 52], ["in", 60], ["the", 63], ["molecular", 67], ["juxtaposition", 77], ["of", 91], ["two", 94], ["genes", 98], [",", 103], ["BCR", 105], ["and", 109], ["ABL", 113], [",", 116], ["to", 118], ["form", 121], ["an", 126], ["aberrant", 129], ["BCR", 138], ["-", 141], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["22", 165], [".", 167], ["BCR", 169], ["-", 172], ["ABL", 173], ["is", 177], ["critical", 180], ["to", 189], ["the", 192], ["pathogenesis", 196], ["of", 209], ["chronic", 212], ["myelogenous", 220], ["leukemia", 232], ["and", 241], ["a", 245], ["subset", 247], ["of", 254], ["acute", 257], ["leukemias", 263], [".", 272], ["The", 274], ["chimeric", 278], ["Bcr", 287], ["-", 290], ["Abl", 291], ["protein", 295], ["has", 303], ["constitutively", 307], ["elevated", 322], ["tyrosine", 331], ["phosphokinase", 340], ["activity", 354], [".", 362], ["This", 364], ["abnormal", 369], ["enzymatic", 378], ["activation", 388], ["is", 399], ["critical", 402], ["to", 411], ["the", 414], ["oncogenic", 418], ["potential", 428], ["of", 438], ["Bcr", 441], ["-", 444], ["Abl", 445], [".", 448], ["Initially", 450], [",", 459], ["protein", 461], ["kinases", 469], ["were", 477], ["thought", 482], ["to", 490], ["be", 493], ["poor", 496], ["therapeutic", 501], ["targets", 513], ["because", 521], ["of", 529], ["their", 532], ["ubiquitous", 538], ["nature", 549], ["and", 556], ["crucial", 560], ["role", 568], ["in", 573], ["many", 576], ["normal", 581], ["physiologic", 588], ["processes", 600], [".", 609], ["However", 611], [",", 618], ["the", 620], ["advent", 624], ["of", 631], ["imatinib", 634], ["mesylate", 643], ["(", 652], ["Gleevec", 653], [",", 660], ["Novartis", 662], ["Pharmaceuticals", 671], [",", 686], ["Basel", 688], [",", 693], ["Switzerland", 695], [")", 706], [",", 707], ["formerly", 709], ["known", 718], ["as", 724], ["STI571", 727], ["and", 734], ["CGP57148B", 738], [",", 747], ["demonstrated", 749], ["that", 762], ["designer", 767], ["kinase", 776], ["inhibitors", 783], ["could", 794], ["be", 800], ["specific", 803], [".", 811], ["This", 813], ["agent", 818], ["has", 824], ["shown", 828], ["striking", 834], ["activity", 843], ["in", 852], ["chronic", 855], ["myelogenous", 863], ["leukemia", 875], [".", 883], ["It", 885], ["also", 888], ["inhibits", 893], ["phosphorylation", 902], ["of", 918], ["Kit", 921], ["(", 925], ["stem", 926], ["-", 930], ["cell", 931], ["factor", 936], ["receptor", 943], [")", 951], ["and", 953], ["platelet", 957], ["-", 965], ["derived", 966], ["growth", 974], ["factor", 981], ["receptor", 988], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["has", 1014], ["shown", 1018], ["similar", 1024], ["impressive", 1032], ["responses", 1043], [",", 1052], ["with", 1054], ["little", 1059], ["host", 1066], ["toxicity", 1071], [",", 1079], ["in", 1081], ["gastrointestinal", 1084], ["stromal", 1101], ["tumors", 1109], [",", 1115], ["which", 1117], ["harbor", 1123], ["activating", 1130], ["Kit", 1141], ["mutations", 1145], [",", 1154], ["and", 1156], ["in", 1160], ["tumors", 1163], ["with", 1170], ["activated", 1175], ["platelet", 1185], ["-", 1193], ["derived", 1194], ["growth", 1202], ["factor", 1209], ["receptor", 1216], [".", 1224], ["The", 1226], ["studies", 1230], ["of", 1238], ["imatinib", 1241], ["mesylate", 1250], ["provide", 1259], ["proof", 1267], ["-", 1272], ["of", 1273], ["-", 1275], ["principle", 1276], ["for", 1286], ["using", 1290], ["aberrant", 1296], ["kinases", 1305], ["as", 1313], ["a", 1316], ["therapeutic", 1318], ["target", 1330], ["and", 1337], ["are", 1341], ["a", 1345], ["model", 1347], ["for", 1353], ["the", 1357], ["promise", 1361], ["of", 1369], ["molecular", 1372], ["therapeutics", 1382], [".", 1394], ["This", 1396], ["paper", 1401], ["reviews", 1407], ["the", 1415], ["current", 1419], ["knowledge", 1427], ["on", 1437], ["the", 1440], ["function", 1444], ["of", 1453], ["Bcr", 1456], ["-", 1459], ["Abl", 1460], ["and", 1464], ["its", 1468], ["normal", 1472], ["counterparts", 1479], ["(", 1492], ["Bcr", 1493], ["and", 1497], ["Abl", 1501], [")", 1504], [",", 1505], ["as", 1507], ["well", 1510], ["as", 1515], ["the", 1518], ["impact", 1522], ["of", 1529], ["this", 1532], ["knowledge", 1537], ["on", 1547], ["the", 1550], ["development", 1554], ["of", 1566], ["a", 1569], ["remarkably", 1571], ["successful", 1582], ["targeted", 1593], ["therapy", 1602], ["approach", 1610], [".", 1618]]}
{"context": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data. Impact of RLS on quality of life and health has been studied primarily in industrialized countries, particularly Europe and the United States. Many studies have relied exclusively on self-report of symptoms or have assessed only medical populations. Recently, interest has emerged on the impact of WED in rural, underserved populations globally. In a population-based survey conducted in rural Ecuador, we assessed the relationship of psychological distress to WED, evaluated with the Depression Anxiety Stress Scales-21. WED was diagnosed through a 2-phase method in which all residents were screened with the International Restless Legs Syndrome Study Group (IRLSSG) questionnaire and all suspected cases were subsequently confirmed through expert medical examination. WED severity was assessed with the IRLSSG rating scale. Of 665 persons (mean [SD] age, 59.5 [12.6] years; women, 386 [58%]), 76 had depression, 93 had anxiety, and 60 reported stress. Forty persons (6%) had WED, with 15 (38%) having severe disease. In a regression model adjusted for age and sex, the prevalence of depression, anxiety, and stress was about 3 times greater among persons with WED than the general population. Although cross-sectional data cannot establish causation, this study shows the large behavioral health burden associated with WED in an untreated, rural population.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "5dc7b7888b6a4035ae95f669a8d8cfff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[139, 141], [3, 5]], "char_spans": [[811, 832], [23, 44]]}]}], "context_tokens": [["Reported", 0], ["prevalence", 9], ["of", 20], ["restless", 23], ["legs", 32], ["syndrome", 37], ["(", 46], ["RLS", 47], [")", 50], [",", 51], ["also", 53], ["known", 58], ["as", 64], ["Willis", 67], ["-", 73], ["Ekbom", 74], ["disease", 80], ["(", 88], ["WED", 89], [")", 92], [",", 93], ["varies", 95], ["from", 102], ["country", 107], ["to", 115], ["country", 118], [",", 125], ["and", 127], ["methodologic", 131], ["inconsistencies", 144], ["limit", 160], ["comparison", 166], ["of", 177], ["data", 180], [".", 184], ["Impact", 186], ["of", 193], ["RLS", 196], ["on", 200], ["quality", 203], ["of", 211], ["life", 214], ["and", 219], ["health", 223], ["has", 230], ["been", 234], ["studied", 239], ["primarily", 247], ["in", 257], ["industrialized", 260], ["countries", 275], [",", 284], ["particularly", 286], ["Europe", 299], ["and", 306], ["the", 310], ["United", 314], ["States", 321], [".", 327], ["Many", 329], ["studies", 334], ["have", 342], ["relied", 347], ["exclusively", 354], ["on", 366], ["self", 369], ["-", 373], ["report", 374], ["of", 381], ["symptoms", 384], ["or", 393], ["have", 396], ["assessed", 401], ["only", 410], ["medical", 415], ["populations", 423], [".", 434], ["Recently", 436], [",", 444], ["interest", 446], ["has", 455], ["emerged", 459], ["on", 467], ["the", 470], ["impact", 474], ["of", 481], ["WED", 484], ["in", 488], ["rural", 491], [",", 496], ["underserved", 498], ["populations", 510], ["globally", 522], [".", 530], ["In", 532], ["a", 535], ["population", 537], ["-", 547], ["based", 548], ["survey", 554], ["conducted", 561], ["in", 571], ["rural", 574], ["Ecuador", 580], [",", 587], ["we", 589], ["assessed", 592], ["the", 601], ["relationship", 605], ["of", 618], ["psychological", 621], ["distress", 635], ["to", 644], ["WED", 647], [",", 650], ["evaluated", 652], ["with", 662], ["the", 667], ["Depression", 671], ["Anxiety", 682], ["Stress", 690], ["Scales-21", 697], [".", 706], ["WED", 708], ["was", 712], ["diagnosed", 716], ["through", 726], ["a", 734], ["2-phase", 736], ["method", 744], ["in", 751], ["which", 754], ["all", 760], ["residents", 764], ["were", 774], ["screened", 779], ["with", 788], ["the", 793], ["International", 797], ["Restless", 811], ["Legs", 820], ["Syndrome", 825], ["Study", 834], ["Group", 840], ["(", 846], ["IRLSSG", 847], [")", 853], ["questionnaire", 855], ["and", 869], ["all", 873], ["suspected", 877], ["cases", 887], ["were", 893], ["subsequently", 898], ["confirmed", 911], ["through", 921], ["expert", 929], ["medical", 936], ["examination", 944], [".", 955], ["WED", 957], ["severity", 961], ["was", 970], ["assessed", 974], ["with", 983], ["the", 988], ["IRLSSG", 992], ["rating", 999], ["scale", 1006], [".", 1011], ["Of", 1013], ["665", 1016], ["persons", 1020], ["(", 1028], ["mean", 1029], ["[", 1034], ["SD", 1035], ["]", 1037], ["age", 1039], [",", 1042], ["59.5", 1044], ["[", 1049], ["12.6", 1050], ["]", 1054], ["years", 1056], [";", 1061], ["women", 1063], [",", 1068], ["386", 1070], ["[", 1074], ["58", 1075], ["%", 1077], ["]", 1078], [")", 1079], [",", 1080], ["76", 1082], ["had", 1085], ["depression", 1089], [",", 1099], ["93", 1101], ["had", 1104], ["anxiety", 1108], [",", 1115], ["and", 1117], ["60", 1121], ["reported", 1124], ["stress", 1133], [".", 1139], ["Forty", 1141], ["persons", 1147], ["(", 1155], ["6", 1156], ["%", 1157], [")", 1158], ["had", 1160], ["WED", 1164], [",", 1167], ["with", 1169], ["15", 1174], ["(", 1177], ["38", 1178], ["%", 1180], [")", 1181], ["having", 1183], ["severe", 1190], ["disease", 1197], [".", 1204], ["In", 1206], ["a", 1209], ["regression", 1211], ["model", 1222], ["adjusted", 1228], ["for", 1237], ["age", 1241], ["and", 1245], ["sex", 1249], [",", 1252], ["the", 1254], ["prevalence", 1258], ["of", 1269], ["depression", 1272], [",", 1282], ["anxiety", 1284], [",", 1291], ["and", 1293], ["stress", 1297], ["was", 1304], ["about", 1308], ["3", 1314], ["times", 1316], ["greater", 1322], ["among", 1330], ["persons", 1336], ["with", 1344], ["WED", 1349], ["than", 1353], ["the", 1358], ["general", 1362], ["population", 1370], [".", 1380], ["Although", 1382], ["cross", 1391], ["-", 1396], ["sectional", 1397], ["data", 1407], ["can", 1412], ["not", 1415], ["establish", 1419], ["causation", 1429], [",", 1438], ["this", 1440], ["study", 1445], ["shows", 1451], ["the", 1457], ["large", 1461], ["behavioral", 1467], ["health", 1478], ["burden", 1485], ["associated", 1492], ["with", 1503], ["WED", 1508], ["in", 1512], ["an", 1515], ["untreated", 1518], [",", 1527], ["rural", 1529], ["population", 1535], [".", 1545]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Chaperone-mediated autophagy is one of several lysosomal pathways of proteolysis. This pathway is activated by physiological stresses such as prolonged starvation. Cytosolic proteins with particular peptide sequence motifs are recognized by a complex of molecular chaperones and delivered to lysosomes. No vesicular traffic is required for this protein degradation pathway, so it differs from microautophagy and macroautophagy. Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a. Levels of lamp2a in the lysosomal membrane are controlled by alterations in the lamp2a half-life as well as by the dynamic distribution of the protein between the lysosomal membrane and the lumen. Substrate proteins are unfolded before transport into the lysosome lumen, and the transport of substrate proteins requires a molecular chaperone within the lysosomal lumen. The exact roles of this lysosomal chaperone remain to be defined. The mechanisms of chaperone-mediated autophagy are similar to mechanisms of protein import into mitochondria, chloroplasts, and the endoplasmic reticulum.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "2af13c4b405e44c8820036a07143c462", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[100, 100], [89, 89]], "char_spans": [[630, 635], [560, 565]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["is", 29], ["one", 32], ["of", 36], ["several", 39], ["lysosomal", 47], ["pathways", 57], ["of", 66], ["proteolysis", 69], [".", 80], ["This", 82], ["pathway", 87], ["is", 95], ["activated", 98], ["by", 108], ["physiological", 111], ["stresses", 125], ["such", 134], ["as", 139], ["prolonged", 142], ["starvation", 152], [".", 162], ["Cytosolic", 164], ["proteins", 174], ["with", 183], ["particular", 188], ["peptide", 199], ["sequence", 207], ["motifs", 216], ["are", 223], ["recognized", 227], ["by", 238], ["a", 241], ["complex", 243], ["of", 251], ["molecular", 254], ["chaperones", 264], ["and", 275], ["delivered", 279], ["to", 289], ["lysosomes", 292], [".", 301], ["No", 303], ["vesicular", 306], ["traffic", 316], ["is", 324], ["required", 327], ["for", 336], ["this", 340], ["protein", 345], ["degradation", 353], ["pathway", 365], [",", 372], ["so", 374], ["it", 377], ["differs", 380], ["from", 388], ["microautophagy", 393], ["and", 408], ["macroautophagy", 412], [".", 426], ["Protein", 428], ["substrates", 436], ["bind", 447], ["to", 452], ["a", 455], ["receptor", 457], ["in", 466], ["the", 469], ["lysosomal", 473], ["membrane", 483], [",", 491], ["the", 493], ["lysosome", 497], ["-", 505], ["associated", 506], ["membrane", 517], ["protein", 526], ["(", 534], ["lamp", 535], [")", 539], ["type", 541], ["2a", 546], [".", 548], ["Levels", 550], ["of", 557], ["lamp2a", 560], ["in", 567], ["the", 570], ["lysosomal", 574], ["membrane", 584], ["are", 593], ["controlled", 597], ["by", 608], ["alterations", 611], ["in", 623], ["the", 626], ["lamp2a", 630], ["half", 637], ["-", 641], ["life", 642], ["as", 647], ["well", 650], ["as", 655], ["by", 658], ["the", 661], ["dynamic", 665], ["distribution", 673], ["of", 686], ["the", 689], ["protein", 693], ["between", 701], ["the", 709], ["lysosomal", 713], ["membrane", 723], ["and", 732], ["the", 736], ["lumen", 740], [".", 745], ["Substrate", 747], ["proteins", 757], ["are", 766], ["unfolded", 770], ["before", 779], ["transport", 786], ["into", 796], ["the", 801], ["lysosome", 805], ["lumen", 814], [",", 819], ["and", 821], ["the", 825], ["transport", 829], ["of", 839], ["substrate", 842], ["proteins", 852], ["requires", 861], ["a", 870], ["molecular", 872], ["chaperone", 882], ["within", 892], ["the", 899], ["lysosomal", 903], ["lumen", 913], [".", 918], ["The", 920], ["exact", 924], ["roles", 930], ["of", 936], ["this", 939], ["lysosomal", 944], ["chaperone", 954], ["remain", 964], ["to", 971], ["be", 974], ["defined", 977], [".", 984], ["The", 986], ["mechanisms", 990], ["of", 1001], ["chaperone", 1004], ["-", 1013], ["mediated", 1014], ["autophagy", 1023], ["are", 1033], ["similar", 1037], ["to", 1045], ["mechanisms", 1048], ["of", 1059], ["protein", 1062], ["import", 1070], ["into", 1077], ["mitochondria", 1082], [",", 1094], ["chloroplasts", 1096], [",", 1108], ["and", 1110], ["the", 1114], ["endoplasmic", 1118], ["reticulum", 1130], [".", 1139]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "Cells respond to stresses such as osmotic shock and heat shock by activating stress-activated protein kinases (SAPKs), including c-Jun N-terminal kinase (JNK) [1]. Activation of JNK requires phosphorylation of threonine and tyrosine residues in the TPY activation loop motif [2, 3] and can be reversed by the removal of either phosphate group. Numerous JNK phosphatases including dual-specificity phosphatases [4, 5], have been identified. Many stimuli activate JNK by increasing its rate of phosphorylation; however, JNK dephosphorylation is inhibited in cells after heat shock [6], suggesting that a JNK phosphatase(s) is inactivated. M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. We have previously expressed M3/6 in the mouse bone marrow cell line BAF3 in order to show that JNK activation by IL-3 is necessary for cell survival and proliferation [9]. Here we report that M3/6 dissociates from JNK and appears in an insoluble fraction after heat shock. These data identify M3/6 as a JNK phosphatase that is inactivated by heat shock and provide a molecular mechanism for the activation of JNK by heat shock.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "902996f009de41b18ed94ad607438522", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[37, 37], [69, 69], [99, 99], [115, 115], [173, 173], [89, 89], [153, 153], [190, 190], [130, 130], [31, 31], [207, 207]], "char_spans": [[178, 180], [353, 355], [518, 520], [602, 604], [917, 919], [462, 464], [798, 800], [1006, 1008], [690, 692], [154, 156], [1112, 1114]]}]}], "context_tokens": [["Cells", 0], ["respond", 6], ["to", 14], ["stresses", 17], ["such", 26], ["as", 31], ["osmotic", 34], ["shock", 42], ["and", 48], ["heat", 52], ["shock", 57], ["by", 63], ["activating", 66], ["stress", 77], ["-", 83], ["activated", 84], ["protein", 94], ["kinases", 102], ["(", 110], ["SAPKs", 111], [")", 116], [",", 117], ["including", 119], ["c", 129], ["-", 130], ["Jun", 131], ["N", 135], ["-", 136], ["terminal", 137], ["kinase", 146], ["(", 153], ["JNK", 154], [")", 157], ["[", 159], ["1].", 160], ["Activation", 164], ["of", 175], ["JNK", 178], ["requires", 182], ["phosphorylation", 191], ["of", 207], ["threonine", 210], ["and", 220], ["tyrosine", 224], ["residues", 233], ["in", 242], ["the", 245], ["TPY", 249], ["activation", 253], ["loop", 264], ["motif", 269], ["[", 275], ["2", 276], [",", 277], ["3", 279], ["]", 280], ["and", 282], ["can", 286], ["be", 290], ["reversed", 293], ["by", 302], ["the", 305], ["removal", 309], ["of", 317], ["either", 320], ["phosphate", 327], ["group", 337], [".", 342], ["Numerous", 344], ["JNK", 353], ["phosphatases", 357], ["including", 370], ["dual", 380], ["-", 384], ["specificity", 385], ["phosphatases", 397], ["[", 410], ["4", 411], [",", 412], ["5", 414], ["]", 415], [",", 416], ["have", 418], ["been", 423], ["identified", 428], [".", 438], ["Many", 440], ["stimuli", 445], ["activate", 453], ["JNK", 462], ["by", 466], ["increasing", 469], ["its", 480], ["rate", 484], ["of", 489], ["phosphorylation", 492], [";", 507], ["however", 509], [",", 516], ["JNK", 518], ["dephosphorylation", 522], ["is", 540], ["inhibited", 543], ["in", 553], ["cells", 556], ["after", 562], ["heat", 568], ["shock", 573], ["[", 579], ["6", 580], ["]", 581], [",", 582], ["suggesting", 584], ["that", 595], ["a", 600], ["JNK", 602], ["phosphatase(s", 606], [")", 619], ["is", 621], ["inactivated", 624], [".", 635], ["M3/6", 637], ["is", 642], ["a", 645], ["dual", 647], ["-", 651], ["specificity", 652], ["phosphatase", 664], ["selective", 676], ["for", 686], ["JNK", 690], ["[", 694], ["7", 695], [",", 696], ["8].", 698], ["We", 702], ["have", 705], ["previously", 710], ["expressed", 721], ["M3/6", 731], ["in", 736], ["the", 739], ["mouse", 743], ["bone", 749], ["marrow", 754], ["cell", 761], ["line", 766], ["BAF3", 771], ["in", 776], ["order", 779], ["to", 785], ["show", 788], ["that", 793], ["JNK", 798], ["activation", 802], ["by", 813], ["IL-3", 816], ["is", 821], ["necessary", 824], ["for", 834], ["cell", 838], ["survival", 843], ["and", 852], ["proliferation", 856], ["[", 870], ["9].", 871], ["Here", 875], ["we", 880], ["report", 883], ["that", 890], ["M3/6", 895], ["dissociates", 900], ["from", 912], ["JNK", 917], ["and", 921], ["appears", 925], ["in", 933], ["an", 936], ["insoluble", 939], ["fraction", 949], ["after", 958], ["heat", 964], ["shock", 969], [".", 974], ["These", 976], ["data", 982], ["identify", 987], ["M3/6", 996], ["as", 1001], ["a", 1004], ["JNK", 1006], ["phosphatase", 1010], ["that", 1022], ["is", 1027], ["inactivated", 1030], ["by", 1042], ["heat", 1045], ["shock", 1050], ["and", 1056], ["provide", 1060], ["a", 1068], ["molecular", 1070], ["mechanism", 1080], ["for", 1090], ["the", 1094], ["activation", 1098], ["of", 1109], ["JNK", 1112], ["by", 1116], ["heat", 1119], ["shock", 1124], [".", 1129]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA (siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "da99a2b47daf44bb94a87ccf477bf308", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[87, 89]], "char_spans": [[486, 518]]}]}], "context_tokens": [["Mgm1", 0], ["is", 5], ["a", 8], ["member", 10], ["of", 17], ["the", 20], ["dynamin", 24], ["family", 32], ["of", 39], ["GTP", 42], ["-", 45], ["binding", 46], ["proteins", 54], [".", 62], ["Mgm1", 64], ["was", 69], ["first", 73], ["identified", 79], ["in", 90], ["yeast", 93], [",", 98], ["where", 100], ["it", 106], ["affects", 109], ["mitochondrial", 117], ["morphology", 131], [".", 141], ["The", 143], ["human", 147], ["homologue", 153], ["of", 163], ["Mgm1", 166], ["is", 171], ["called", 174], ["OPA1", 181], [".", 185], ["Mutations", 187], ["in", 197], ["the", 200], ["OPA1", 204], ["gene", 209], ["are", 214], ["the", 218], ["prevailing", 222], ["cause", 233], ["of", 239], ["dominant", 242], ["optic", 251], ["atrophy", 257], [",", 264], ["a", 266], ["hereditary", 268], ["disease", 279], ["in", 287], ["which", 290], ["progressive", 296], ["degeneration", 308], ["of", 321], ["the", 324], ["optic", 328], ["nerve", 334], ["can", 340], ["lead", 344], ["to", 349], ["blindness", 352], [".", 361], ["Here", 363], ["we", 368], ["investigate", 371], ["the", 383], ["properties", 387], ["of", 398], ["the", 401], ["Mgm1/OPA1", 405], ["protein", 415], ["in", 423], ["mammalian", 426], ["cells", 436], [".", 441], ["We", 443], ["find", 446], ["that", 451], ["Mgm1/OPA1", 456], ["is", 466], ["localized", 469], ["to", 479], ["the", 482], ["mitochondrial", 486], ["intermembrane", 500], ["space", 514], [",", 519], ["where", 521], ["it", 527], ["is", 530], ["tightly", 533], ["bound", 541], ["to", 547], ["the", 550], ["outer", 554], ["surface", 560], ["of", 568], ["the", 571], ["inner", 575], ["membrane", 581], [".", 589], ["Overexpression", 591], ["of", 606], ["wild", 609], ["type", 614], ["or", 619], ["mutant", 622], ["forms", 629], ["of", 635], ["the", 638], ["Mgm1/OPA1", 642], ["protein", 652], ["cause", 660], ["mitochondria", 666], ["to", 679], ["fragment", 682], ["and", 691], [",", 694], ["in", 696], ["some", 699], ["cases", 704], [",", 709], ["cluster", 711], ["near", 719], ["the", 724], ["nucleus", 728], [",", 735], ["whereas", 737], ["the", 745], ["loss", 749], ["of", 754], ["protein", 757], ["caused", 765], ["by", 772], ["small", 775], ["interfering", 781], ["RNA", 793], ["(", 797], ["siRNA", 798], [")", 803], ["leads", 805], ["to", 811], ["dispersal", 814], ["of", 824], ["mitochondrial", 827], ["fragments", 841], ["throughout", 851], ["the", 862], ["cytosol", 866], [".", 873], ["The", 875], ["cristae", 879], ["of", 887], ["these", 890], ["fragmented", 896], ["mitochondria", 907], ["are", 920], ["disorganized", 924], [".", 936], ["At", 938], ["early", 941], ["time", 947], ["points", 952], ["after", 959], ["transfection", 965], ["with", 978], ["Mgm1/OPA1", 983], ["siRNA", 993], [",", 998], ["the", 1000], ["mitochondria", 1004], ["are", 1017], ["not", 1021], ["yet", 1025], ["fragmented", 1029], [".", 1039], ["Instead", 1041], [",", 1048], ["the", 1050], ["mitochondria", 1054], ["swell", 1067], ["and", 1073], ["stretch", 1077], [",", 1084], ["after", 1086], ["which", 1092], ["they", 1098], ["form", 1103], ["localized", 1108], ["constrictions", 1118], ["similar", 1132], ["to", 1140], ["the", 1143], ["mitochondrial", 1147], ["abnormalities", 1161], ["observed", 1175], ["during", 1184], ["the", 1191], ["early", 1195], ["stages", 1201], ["of", 1208], ["apoptosis", 1211], [".", 1220], ["These", 1222], ["abnormalities", 1228], ["might", 1242], ["be", 1248], ["the", 1251], ["earliest", 1255], ["effects", 1264], ["of", 1272], ["losing", 1275], ["Mgm1/OPA1", 1282], ["protein", 1292], [".", 1299]]}
{"context": "Objective. A study to determine if addition of palatal petechiae to Centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. Hypothesis. In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis. We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children. Methods. One hundred patients with a complaint of sore throat were enrolled in the study. All the patients were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. All the patients were given rapid strep tests, and throat cultures were sent. No antibiotics were given until culture results were obtained. Results. The sample size was 100 patients. All 100 had fever, sore throat, and erythema of tonsils. Twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. In total, 9 out of the 100 patients had positive throat cultures. We observed that petechiae over the palate, a very significant sign, is not included in the Centor Criteria. Palatal petechiae were present in 8 out of the 100 patients. Six out of these 8 with palatal petechiae had positive throat culture for strep (75%). Only 7 out of 20 with exudates had positive strep culture. Sixteen out of the 100 patients had rapid strep test positive. Those 84/100 who had negative rapid strep also had negative throat culture. Statistics. We used Fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant P value <.0001. Conclusion. Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "345cc6f39eb0472ebb37229e6f4e34b1", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[356, 357], [67, 68]], "char_spans": [[1984, 2008], [406, 430]]}]}], "context_tokens": [["Objective", 0], [".", 9], ["A", 11], ["study", 13], ["to", 19], ["determine", 22], ["if", 32], ["addition", 35], ["of", 44], ["palatal", 47], ["petechiae", 55], ["to", 65], ["Centor", 68], ["criteria", 75], ["adds", 84], ["more", 89], ["value", 94], ["for", 100], ["clinical", 104], ["diagnosis", 113], ["of", 123], ["acute", 126], ["strep", 132], ["pharyngitis", 138], ["in", 150], ["children", 153], [".", 161], ["Hypothesis", 163], [".", 173], ["In", 175], ["children", 178], [",", 186], ["Centor", 188], ["Criteria", 195], ["does", 204], ["not", 209], ["cover", 213], ["all", 219], ["the", 223], ["symptoms", 227], ["and", 236], ["signs", 240], ["of", 246], ["acute", 249], ["strep", 255], ["pharyngitis", 261], [".", 272], ["We", 274], ["hypothesize", 277], ["that", 289], ["addition", 294], ["of", 303], ["palatal", 306], ["petechiae", 314], ["to", 324], ["Centor", 327], ["Criteria", 334], ["will", 343], ["increase", 348], ["the", 357], ["possibility", 361], ["of", 373], ["clinical", 376], ["diagnosis", 385], ["of", 395], ["group", 398], ["A", 404], ["streptococcal", 406], ["pharyngitis", 420], ["in", 432], ["children", 435], [".", 443], ["Methods", 445], [".", 452], ["One", 454], ["hundred", 458], ["patients", 466], ["with", 475], ["a", 480], ["complaint", 482], ["of", 492], ["sore", 495], ["throat", 500], ["were", 507], ["enrolled", 512], ["in", 521], ["the", 524], ["study", 528], [".", 533], ["All", 535], ["the", 539], ["patients", 543], ["were", 552], ["examined", 557], ["clinically", 566], ["using", 577], ["the", 583], ["Centor", 587], ["Criteria", 594], [".", 602], ["They", 604], ["were", 609], ["also", 614], ["examined", 619], ["for", 628], ["other", 632], ["signs", 638], ["and", 644], ["symptoms", 648], ["like", 657], ["petechial", 662], ["lesions", 672], ["over", 680], ["the", 685], ["palate", 689], [",", 695], ["abdominal", 697], ["pain", 707], [",", 711], ["and", 713], ["skin", 717], ["rash", 722], [".", 726], ["All", 728], ["the", 732], ["patients", 736], ["were", 745], ["given", 750], ["rapid", 756], ["strep", 762], ["tests", 768], [",", 773], ["and", 775], ["throat", 779], ["cultures", 786], ["were", 795], ["sent", 800], [".", 804], ["No", 806], ["antibiotics", 809], ["were", 821], ["given", 826], ["until", 832], ["culture", 838], ["results", 846], ["were", 854], ["obtained", 859], [".", 867], ["Results", 869], [".", 876], ["The", 878], ["sample", 882], ["size", 889], ["was", 894], ["100", 898], ["patients", 902], [".", 910], ["All", 912], ["100", 916], ["had", 920], ["fever", 924], [",", 929], ["sore", 931], ["throat", 936], [",", 942], ["and", 944], ["erythema", 948], ["of", 957], ["tonsils", 960], [".", 967], ["Twenty", 969], ["of", 976], ["the", 979], ["100", 983], ["patients", 987], ["had", 996], ["tonsillar", 1000], ["exudates", 1010], [",", 1018], ["85/100", 1020], ["had", 1027], ["tender", 1031], ["anterior", 1038], ["cervical", 1047], ["lymph", 1056], ["nodes", 1062], [",", 1067], ["and", 1069], ["86/100", 1073], ["had", 1080], ["no", 1084], ["cough", 1087], [".", 1092], ["In", 1094], ["total", 1097], [",", 1102], ["9", 1104], ["out", 1106], ["of", 1110], ["the", 1113], ["100", 1117], ["patients", 1121], ["had", 1130], ["positive", 1134], ["throat", 1143], ["cultures", 1150], [".", 1158], ["We", 1160], ["observed", 1163], ["that", 1172], ["petechiae", 1177], ["over", 1187], ["the", 1192], ["palate", 1196], [",", 1202], ["a", 1204], ["very", 1206], ["significant", 1211], ["sign", 1223], [",", 1227], ["is", 1229], ["not", 1232], ["included", 1236], ["in", 1245], ["the", 1248], ["Centor", 1252], ["Criteria", 1259], [".", 1267], ["Palatal", 1269], ["petechiae", 1277], ["were", 1287], ["present", 1292], ["in", 1300], ["8", 1303], ["out", 1305], ["of", 1309], ["the", 1312], ["100", 1316], ["patients", 1320], [".", 1328], ["Six", 1330], ["out", 1334], ["of", 1338], ["these", 1341], ["8", 1347], ["with", 1349], ["palatal", 1354], ["petechiae", 1362], ["had", 1372], ["positive", 1376], ["throat", 1385], ["culture", 1392], ["for", 1400], ["strep", 1404], ["(", 1410], ["75", 1411], ["%", 1413], [")", 1414], [".", 1415], ["Only", 1417], ["7", 1422], ["out", 1424], ["of", 1428], ["20", 1431], ["with", 1434], ["exudates", 1439], ["had", 1448], ["positive", 1452], ["strep", 1461], ["culture", 1467], [".", 1474], ["Sixteen", 1476], ["out", 1484], ["of", 1488], ["the", 1491], ["100", 1495], ["patients", 1499], ["had", 1508], ["rapid", 1512], ["strep", 1518], ["test", 1524], ["positive", 1529], [".", 1537], ["Those", 1539], ["84/100", 1545], ["who", 1552], ["had", 1556], ["negative", 1560], ["rapid", 1569], ["strep", 1575], ["also", 1581], ["had", 1586], ["negative", 1590], ["throat", 1599], ["culture", 1606], [".", 1613], ["Statistics", 1615], [".", 1625], ["We", 1627], ["used", 1630], ["Fisher", 1635], ["'s", 1641], ["exact", 1644], ["test", 1650], [",", 1654], ["comparing", 1656], ["throat", 1666], ["culture", 1673], ["positive", 1681], ["and", 1690], ["negative", 1694], ["versus", 1703], ["presence", 1710], ["of", 1719], ["exudates", 1722], ["and", 1731], ["palatal", 1735], ["hemorrhages", 1743], ["with", 1755], ["positive", 1760], ["and", 1769], ["negative", 1773], ["throat", 1782], ["cultures", 1789], ["and", 1798], ["the", 1802], ["resultant", 1806], ["P", 1816], ["value", 1818], ["<", 1824], [".0001", 1825], [".", 1830], ["Conclusion", 1832], [".", 1842], ["Our", 1844], ["study", 1848], ["concludes", 1854], ["that", 1864], ["addition", 1869], ["of", 1878], ["petechiae", 1881], ["over", 1891], ["the", 1896], ["palate", 1900], ["to", 1907], ["Centor", 1910], ["Criteria", 1917], ["will", 1926], ["increase", 1931], ["the", 1940], ["possibility", 1944], ["of", 1956], ["diagnosing", 1959], ["acute", 1970], ["group", 1976], ["A", 1982], ["streptococcal", 1984], ["pharyngitis", 1998], ["in", 2010], ["children", 2013], [".", 2021]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Hereditary long QT syndrome (LQTS) is a genetically heterogeneous disease characterized by prolonged QT intervals and an increased risk for ventricular arrhythmias and sudden cardiac death. Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias. In this study, we investigate and discuss dominant-negative I(Ks) current reduction by a KCNQ1 deletion mutation identified in a RWS family. Single-strand conformation polymorphism analysis and direct sequencing were used to screen LQTS genes for mutations. Mutant KCNQ1 channels were heterologously expressed in Xenopus oocytes, and potassium currents were recorded using the two-microelectrode voltage clamp technique. A heterozygous deletion of three nucleotides (CTT) identified in the KCNQ1 gene caused the loss of a single phenylalanine residue at position 339 (KCNQ1-deltaF339). Electrophysiological measurements in the presence and absence of the regulatory beta-subunit KCNE1 revealed that mutant and wild type forms of an N-terminal truncated KCNQ1 subunit (isoform 2) caused much stronger dominant-negative current reduction than the mutant form of the full-length KCNQ1 subunit (isoform 1). This study highlights the functional relevance of the truncated KCNQ1 splice variant (isoform 2) in establishment and mode of inheritance in long QT syndrome. In the RWS family presented here, the autosomal-dominant trait is caused by multiple dominant-negative effects provoked by heteromultimeric channels formed by wild type and mutant KCNQ1-isoforms in combination with KCNE1.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "3c809ea1a7604eca9f5319c8cf28554b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[282, 284], [58, 60]], "char_spans": [[1640, 1657], [351, 368]]}]}], "context_tokens": [["Hereditary", 0], ["long", 11], ["QT", 16], ["syndrome", 19], ["(", 28], ["LQTS", 29], [")", 33], ["is", 35], ["a", 38], ["genetically", 40], ["heterogeneous", 52], ["disease", 66], ["characterized", 74], ["by", 88], ["prolonged", 91], ["QT", 101], ["intervals", 104], ["and", 114], ["an", 118], ["increased", 121], ["risk", 131], ["for", 136], ["ventricular", 140], ["arrhythmias", 152], ["and", 164], ["sudden", 168], ["cardiac", 175], ["death", 183], [".", 188], ["Mutations", 190], ["in", 200], ["the", 203], ["voltage", 207], ["-", 214], ["gated", 215], ["potassium", 221], ["channel", 231], ["subunit", 239], ["KCNQ1", 247], ["induce", 253], ["the", 260], ["most", 264], ["common", 269], ["form", 276], ["of", 281], ["LQTS", 284], [".", 288], ["KCNQ1", 290], ["is", 296], ["associated", 299], ["with", 310], ["two", 315], ["different", 319], ["entities", 329], ["of", 338], ["LQTS", 341], [",", 345], ["the", 347], ["autosomal", 351], ["-", 360], ["dominant", 361], ["Romano", 370], ["-", 376], ["Ward", 377], ["syndrome", 382], ["(", 391], ["RWS", 392], [")", 395], [",", 396], ["and", 398], ["the", 402], ["autosomal", 406], ["-", 415], ["recessive", 416], ["Jervell", 426], ["and", 434], ["Lange", 438], ["-", 443], ["Nielsen", 444], ["syndrome", 452], ["(", 461], ["JLNS", 462], [")", 466], ["characterized", 468], ["by", 482], ["bilateral", 485], ["deafness", 495], ["in", 504], ["addition", 507], ["to", 516], ["cardiac", 519], ["arrhythmias", 527], [".", 538], ["In", 540], ["this", 543], ["study", 548], [",", 553], ["we", 555], ["investigate", 558], ["and", 570], ["discuss", 574], ["dominant", 582], ["-", 590], ["negative", 591], ["I(Ks", 600], [")", 604], ["current", 606], ["reduction", 614], ["by", 624], ["a", 627], ["KCNQ1", 629], ["deletion", 635], ["mutation", 644], ["identified", 653], ["in", 664], ["a", 667], ["RWS", 669], ["family", 673], [".", 679], ["Single", 681], ["-", 687], ["strand", 688], ["conformation", 695], ["polymorphism", 708], ["analysis", 721], ["and", 730], ["direct", 734], ["sequencing", 741], ["were", 752], ["used", 757], ["to", 762], ["screen", 765], ["LQTS", 772], ["genes", 777], ["for", 783], ["mutations", 787], [".", 796], ["Mutant", 798], ["KCNQ1", 805], ["channels", 811], ["were", 820], ["heterologously", 825], ["expressed", 840], ["in", 850], ["Xenopus", 853], ["oocytes", 861], [",", 868], ["and", 870], ["potassium", 874], ["currents", 884], ["were", 893], ["recorded", 898], ["using", 907], ["the", 913], ["two", 917], ["-", 920], ["microelectrode", 921], ["voltage", 936], ["clamp", 944], ["technique", 950], [".", 959], ["A", 961], ["heterozygous", 963], ["deletion", 976], ["of", 985], ["three", 988], ["nucleotides", 994], ["(", 1006], ["CTT", 1007], [")", 1010], ["identified", 1012], ["in", 1023], ["the", 1026], ["KCNQ1", 1030], ["gene", 1036], ["caused", 1041], ["the", 1048], ["loss", 1052], ["of", 1057], ["a", 1060], ["single", 1062], ["phenylalanine", 1069], ["residue", 1083], ["at", 1091], ["position", 1094], ["339", 1103], ["(", 1107], ["KCNQ1-deltaF339", 1108], [")", 1123], [".", 1124], ["Electrophysiological", 1126], ["measurements", 1147], ["in", 1160], ["the", 1163], ["presence", 1167], ["and", 1176], ["absence", 1180], ["of", 1188], ["the", 1191], ["regulatory", 1195], ["beta", 1206], ["-", 1210], ["subunit", 1211], ["KCNE1", 1219], ["revealed", 1225], ["that", 1234], ["mutant", 1239], ["and", 1246], ["wild", 1250], ["type", 1255], ["forms", 1260], ["of", 1266], ["an", 1269], ["N", 1272], ["-", 1273], ["terminal", 1274], ["truncated", 1283], ["KCNQ1", 1293], ["subunit", 1299], ["(", 1307], ["isoform", 1308], ["2", 1316], [")", 1317], ["caused", 1319], ["much", 1326], ["stronger", 1331], ["dominant", 1340], ["-", 1348], ["negative", 1349], ["current", 1358], ["reduction", 1366], ["than", 1376], ["the", 1381], ["mutant", 1385], ["form", 1392], ["of", 1397], ["the", 1400], ["full", 1404], ["-", 1408], ["length", 1409], ["KCNQ1", 1416], ["subunit", 1422], ["(", 1430], ["isoform", 1431], ["1", 1439], [")", 1440], [".", 1441], ["This", 1443], ["study", 1448], ["highlights", 1454], ["the", 1465], ["functional", 1469], ["relevance", 1480], ["of", 1490], ["the", 1493], ["truncated", 1497], ["KCNQ1", 1507], ["splice", 1513], ["variant", 1520], ["(", 1528], ["isoform", 1529], ["2", 1537], [")", 1538], ["in", 1540], ["establishment", 1543], ["and", 1557], ["mode", 1561], ["of", 1566], ["inheritance", 1569], ["in", 1581], ["long", 1584], ["QT", 1589], ["syndrome", 1592], [".", 1600], ["In", 1602], ["the", 1605], ["RWS", 1609], ["family", 1613], ["presented", 1620], ["here", 1630], [",", 1634], ["the", 1636], ["autosomal", 1640], ["-", 1649], ["dominant", 1650], ["trait", 1659], ["is", 1665], ["caused", 1668], ["by", 1675], ["multiple", 1678], ["dominant", 1687], ["-", 1695], ["negative", 1696], ["effects", 1705], ["provoked", 1713], ["by", 1722], ["heteromultimeric", 1725], ["channels", 1742], ["formed", 1751], ["by", 1758], ["wild", 1761], ["type", 1766], ["and", 1771], ["mutant", 1775], ["KCNQ1-isoforms", 1782], ["in", 1797], ["combination", 1800], ["with", 1812], ["KCNE1", 1817], [".", 1822]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "The organization of chromatin into higher-order structures influences chromosome function and epigenetic gene regulation. Higher-order chromatin has been proposed to be nucleated by the covalent modification of histone tails and the subsequent establishment of chromosomal subdomains by non-histone modifier factors. Here we show that human SUV39H1 and murine Suv39h1--mammalian homologues of Drosophila Su(var)3-9 and of Schizosaccharomyces pombe clr4--encode histone H3-specific methyltransferases that selectively methylate lysine 9 of the amino terminus of histone H3 in vitro. We mapped the catalytic motif to the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity. Methylation of lysine 9 interferes with phosphorylation of serine 10, but is also influenced by pre-existing modifications in the amino terminus of H3. In vivo, deregulated SUV39H1 or disrupted Suv39h activity modulate H3 serine 10 phosphorylation in native chromatin and induce aberrant mitotic divisions. Our data reveal a functional interdependence of site-specific H3 tail modifications and suggest a dynamic mechanism for the regulation of higher-order chromatin.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d2b96659e02a4db4a080036e2a0c4128", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[99, 100]], "char_spans": [[644, 653]]}]}], "context_tokens": [["The", 0], ["organization", 4], ["of", 17], ["chromatin", 20], ["into", 30], ["higher", 35], ["-", 41], ["order", 42], ["structures", 48], ["influences", 59], ["chromosome", 70], ["function", 81], ["and", 90], ["epigenetic", 94], ["gene", 105], ["regulation", 110], [".", 120], ["Higher", 122], ["-", 128], ["order", 129], ["chromatin", 135], ["has", 145], ["been", 149], ["proposed", 154], ["to", 163], ["be", 166], ["nucleated", 169], ["by", 179], ["the", 182], ["covalent", 186], ["modification", 195], ["of", 208], ["histone", 211], ["tails", 219], ["and", 225], ["the", 229], ["subsequent", 233], ["establishment", 244], ["of", 258], ["chromosomal", 261], ["subdomains", 273], ["by", 284], ["non", 287], ["-", 290], ["histone", 291], ["modifier", 299], ["factors", 308], [".", 315], ["Here", 317], ["we", 322], ["show", 325], ["that", 330], ["human", 335], ["SUV39H1", 341], ["and", 349], ["murine", 353], ["Suv39h1", 360], ["-", 367], ["-mammalian", 368], ["homologues", 379], ["of", 390], ["Drosophila", 393], ["Su(var)3", 404], ["-", 412], ["9", 413], ["and", 415], ["of", 419], ["Schizosaccharomyces", 422], ["pombe", 442], ["clr4", 448], ["-", 452], ["-encode", 453], ["histone", 461], ["H3-specific", 469], ["methyltransferases", 481], ["that", 500], ["selectively", 505], ["methylate", 517], ["lysine", 527], ["9", 534], ["of", 536], ["the", 539], ["amino", 543], ["terminus", 549], ["of", 558], ["histone", 561], ["H3", 569], ["in", 572], ["vitro", 575], [".", 580], ["We", 582], ["mapped", 585], ["the", 592], ["catalytic", 596], ["motif", 606], ["to", 612], ["the", 615], ["evolutionarily", 619], ["conserved", 634], ["SET", 644], ["domain", 648], [",", 654], ["which", 656], ["requires", 662], ["adjacent", 671], ["cysteine", 680], ["-", 688], ["rich", 689], ["regions", 694], ["to", 702], ["confer", 705], ["histone", 712], ["methyltransferase", 720], ["activity", 738], [".", 746], ["Methylation", 748], ["of", 760], ["lysine", 763], ["9", 770], ["interferes", 772], ["with", 783], ["phosphorylation", 788], ["of", 804], ["serine", 807], ["10", 814], [",", 816], ["but", 818], ["is", 822], ["also", 825], ["influenced", 830], ["by", 841], ["pre", 844], ["-", 847], ["existing", 848], ["modifications", 857], ["in", 871], ["the", 874], ["amino", 878], ["terminus", 884], ["of", 893], ["H3", 896], [".", 898], ["In", 900], ["vivo", 903], [",", 907], ["deregulated", 909], ["SUV39H1", 921], ["or", 929], ["disrupted", 932], ["Suv39h", 942], ["activity", 949], ["modulate", 958], ["H3", 967], ["serine", 970], ["10", 977], ["phosphorylation", 980], ["in", 996], ["native", 999], ["chromatin", 1006], ["and", 1016], ["induce", 1020], ["aberrant", 1027], ["mitotic", 1036], ["divisions", 1044], [".", 1053], ["Our", 1055], ["data", 1059], ["reveal", 1064], ["a", 1071], ["functional", 1073], ["interdependence", 1084], ["of", 1100], ["site", 1103], ["-", 1107], ["specific", 1108], ["H3", 1117], ["tail", 1120], ["modifications", 1125], ["and", 1139], ["suggest", 1143], ["a", 1151], ["dynamic", 1153], ["mechanism", 1161], ["for", 1171], ["the", 1175], ["regulation", 1179], ["of", 1190], ["higher", 1193], ["-", 1199], ["order", 1200], ["chromatin", 1206], [".", 1215]]}
{"context": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. Here, we report on a 14-month-old boy with a reverse phenotype of Sotos syndrome due to the reciprocal duplication of the 5q35.3 region, including the NSD1 gene, detected by array CGH. The phenotype includes delayed bone age, microcephaly, seizures, and failure to thrive. Our case suggests that the gene dosage effect of the NSD1 gene is the likely cause for the reversed phenotype of Sotos syndrome in this patient.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "4dacfcd587cf4e6f8eed4e508e7a454e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[109, 110], [75, 76], [3, 4]], "char_spans": [[630, 638], [455, 463], [26, 34]]}]}], "context_tokens": [["Haploinsufficiency", 0], ["of", 19], ["the", 22], ["NSD1", 26], ["gene", 31], ["due", 36], ["to", 40], ["5q35", 43], ["microdeletions", 48], ["or", 63], ["intragenic", 66], ["mutations", 77], ["is", 87], ["the", 90], ["major", 94], ["cause", 100], ["of", 106], ["Sotos", 109], ["syndrome", 115], ["characterized", 124], ["by", 138], ["generalized", 141], ["overgrowth", 153], [",", 163], ["large", 165], ["hands", 171], ["and", 177], ["feet", 181], ["with", 186], ["advanced", 191], ["bone", 200], ["age", 205], [",", 208], ["craniofacial", 210], ["dysmorphic", 223], ["features", 234], [",", 242], ["learning", 244], ["disability", 253], [",", 263], ["and", 265], ["possible", 269], ["susceptibility", 278], ["to", 293], ["tumors", 296], [".", 302], ["Here", 304], [",", 308], ["we", 310], ["report", 313], ["on", 320], ["a", 323], ["14-month", 325], ["-", 333], ["old", 334], ["boy", 338], ["with", 342], ["a", 347], ["reverse", 349], ["phenotype", 357], ["of", 367], ["Sotos", 370], ["syndrome", 376], ["due", 385], ["to", 389], ["the", 392], ["reciprocal", 396], ["duplication", 407], ["of", 419], ["the", 422], ["5q35.3", 426], ["region", 433], [",", 439], ["including", 441], ["the", 451], ["NSD1", 455], ["gene", 460], [",", 464], ["detected", 466], ["by", 475], ["array", 478], ["CGH", 484], [".", 487], ["The", 489], ["phenotype", 493], ["includes", 503], ["delayed", 512], ["bone", 520], ["age", 525], [",", 528], ["microcephaly", 530], [",", 542], ["seizures", 544], [",", 552], ["and", 554], ["failure", 558], ["to", 566], ["thrive", 569], [".", 575], ["Our", 577], ["case", 581], ["suggests", 586], ["that", 595], ["the", 600], ["gene", 604], ["dosage", 609], ["effect", 616], ["of", 623], ["the", 626], ["NSD1", 630], ["gene", 635], ["is", 640], ["the", 643], ["likely", 647], ["cause", 654], ["for", 660], ["the", 664], ["reversed", 668], ["phenotype", 677], ["of", 687], ["Sotos", 690], ["syndrome", 696], ["in", 705], ["this", 708], ["patient", 713], [".", 720]]}
{"context": "Dendritic cells (DCs), professional antigen-presenting cells with the unique ability to initiate primary T-cell responses, are present in atherosclerotic lesions where they are exposed to oxidative stress that generates cytotoxic reactive oxygen species (ROS). A large body of evidence indicates that cell death is a major modulating factor of atherogenesis. We examined antioxidant defence systems of human monocyte-derived (mo)DCs and monocytes in response to oxidative stress. Oxidative stress was induced by addition of tertiary-butylhydroperoxide (tert-BHP, 30 min). Cellular responses were evaluated using flow cytometry and confocal live cell imaging (both using 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, CM-H(2)DCFDA). Viability was assessed by the neutral red assay. Total RNA was extracted for a PCR profiler array. Five genes were selected for confirmation by Taqman gene expression assays, and by immunoblotting or immunohistochemistry for protein levels. Tert-BHP increased CM-H(2)DCFDA fluorescence and caused cell death. Interestingly, all processes occurred more slowly in moDCs than in monocytes. The mRNA profiler array showed more than 2-fold differential expression of 32 oxidative stress-related genes in unstimulated moDCs, including peroxiredoxin-2 (PRDX2), an enzyme reducing hydrogen peroxide and lipid peroxides. PRDX2 upregulation was confirmed by Taqman assays, immunoblotting and immunohistochemistry. Silencing PRDX2 in moDCs by means of siRNA significantly increased CM-DCF fluorescence and cell death upon tert-BHP-stimulation. Our results indicate that moDCs exhibit higher intracellular antioxidant capacities, making them better equipped to resist oxidative stress than monocytes. Upregulation of PRDX2 is involved in the neutralization of ROS in moDCs. Taken together, this points to better survival skills of DCs in oxidative stress environments, such as atherosclerotic plaques.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "e0afb40c95bf43ecb23eaab63790e3b4", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[64, 64], [270, 270]], "char_spans": [[371, 381], [1644, 1654]]}]}], "context_tokens": [["Dendritic", 0], ["cells", 10], ["(", 16], ["DCs", 17], [")", 20], [",", 21], ["professional", 23], ["antigen", 36], ["-", 43], ["presenting", 44], ["cells", 55], ["with", 61], ["the", 66], ["unique", 70], ["ability", 77], ["to", 85], ["initiate", 88], ["primary", 97], ["T", 105], ["-", 106], ["cell", 107], ["responses", 112], [",", 121], ["are", 123], ["present", 127], ["in", 135], ["atherosclerotic", 138], ["lesions", 154], ["where", 162], ["they", 168], ["are", 173], ["exposed", 177], ["to", 185], ["oxidative", 188], ["stress", 198], ["that", 205], ["generates", 210], ["cytotoxic", 220], ["reactive", 230], ["oxygen", 239], ["species", 246], ["(", 254], ["ROS", 255], [")", 258], [".", 259], ["A", 261], ["large", 263], ["body", 269], ["of", 274], ["evidence", 277], ["indicates", 286], ["that", 296], ["cell", 301], ["death", 306], ["is", 312], ["a", 315], ["major", 317], ["modulating", 323], ["factor", 334], ["of", 341], ["atherogenesis", 344], [".", 357], ["We", 359], ["examined", 362], ["antioxidant", 371], ["defence", 383], ["systems", 391], ["of", 399], ["human", 402], ["monocyte", 408], ["-", 416], ["derived", 417], ["(", 425], ["mo)DCs", 426], ["and", 433], ["monocytes", 437], ["in", 447], ["response", 450], ["to", 459], ["oxidative", 462], ["stress", 472], [".", 478], ["Oxidative", 480], ["stress", 490], ["was", 497], ["induced", 501], ["by", 509], ["addition", 512], ["of", 521], ["tertiary", 524], ["-", 532], ["butylhydroperoxide", 533], ["(", 552], ["tert", 553], ["-", 557], ["BHP", 558], [",", 561], ["30", 563], ["min", 566], [")", 569], [".", 570], ["Cellular", 572], ["responses", 581], ["were", 591], ["evaluated", 596], ["using", 606], ["flow", 612], ["cytometry", 617], ["and", 627], ["confocal", 631], ["live", 640], ["cell", 645], ["imaging", 650], ["(", 658], ["both", 659], ["using", 664], ["5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein", 670], ["diacetate", 724], [",", 733], ["CM", 735], ["-", 737], ["H(2)DCFDA", 738], [")", 747], [".", 748], ["Viability", 750], ["was", 760], ["assessed", 764], ["by", 773], ["the", 776], ["neutral", 780], ["red", 788], ["assay", 792], [".", 797], ["Total", 799], ["RNA", 805], ["was", 809], ["extracted", 813], ["for", 823], ["a", 827], ["PCR", 829], ["profiler", 833], ["array", 842], [".", 847], ["Five", 849], ["genes", 854], ["were", 860], ["selected", 865], ["for", 874], ["confirmation", 878], ["by", 891], ["Taqman", 894], ["gene", 901], ["expression", 906], ["assays", 917], [",", 923], ["and", 925], ["by", 929], ["immunoblotting", 932], ["or", 947], ["immunohistochemistry", 950], ["for", 971], ["protein", 975], ["levels", 983], [".", 989], ["Tert", 991], ["-", 995], ["BHP", 996], ["increased", 1000], ["CM", 1010], ["-", 1012], ["H(2)DCFDA", 1013], ["fluorescence", 1023], ["and", 1036], ["caused", 1040], ["cell", 1047], ["death", 1052], [".", 1057], ["Interestingly", 1059], [",", 1072], ["all", 1074], ["processes", 1078], ["occurred", 1088], ["more", 1097], ["slowly", 1102], ["in", 1109], ["moDCs", 1112], ["than", 1118], ["in", 1123], ["monocytes", 1126], [".", 1135], ["The", 1137], ["mRNA", 1141], ["profiler", 1146], ["array", 1155], ["showed", 1161], ["more", 1168], ["than", 1173], ["2-fold", 1178], ["differential", 1185], ["expression", 1198], ["of", 1209], ["32", 1212], ["oxidative", 1215], ["stress", 1225], ["-", 1231], ["related", 1232], ["genes", 1240], ["in", 1246], ["unstimulated", 1249], ["moDCs", 1262], [",", 1267], ["including", 1269], ["peroxiredoxin-2", 1279], ["(", 1295], ["PRDX2", 1296], [")", 1301], [",", 1302], ["an", 1304], ["enzyme", 1307], ["reducing", 1314], ["hydrogen", 1323], ["peroxide", 1332], ["and", 1341], ["lipid", 1345], ["peroxides", 1351], [".", 1360], ["PRDX2", 1362], ["upregulation", 1368], ["was", 1381], ["confirmed", 1385], ["by", 1395], ["Taqman", 1398], ["assays", 1405], [",", 1411], ["immunoblotting", 1413], ["and", 1428], ["immunohistochemistry", 1432], [".", 1452], ["Silencing", 1454], ["PRDX2", 1464], ["in", 1470], ["moDCs", 1473], ["by", 1479], ["means", 1482], ["of", 1488], ["siRNA", 1491], ["significantly", 1497], ["increased", 1511], ["CM", 1521], ["-", 1523], ["DCF", 1524], ["fluorescence", 1528], ["and", 1541], ["cell", 1545], ["death", 1550], ["upon", 1556], ["tert", 1561], ["-", 1565], ["BHP", 1566], ["-", 1569], ["stimulation", 1570], [".", 1581], ["Our", 1583], ["results", 1587], ["indicate", 1595], ["that", 1604], ["moDCs", 1609], ["exhibit", 1615], ["higher", 1623], ["intracellular", 1630], ["antioxidant", 1644], ["capacities", 1656], [",", 1666], ["making", 1668], ["them", 1675], ["better", 1680], ["equipped", 1687], ["to", 1696], ["resist", 1699], ["oxidative", 1706], ["stress", 1716], ["than", 1723], ["monocytes", 1728], [".", 1737], ["Upregulation", 1739], ["of", 1752], ["PRDX2", 1755], ["is", 1761], ["involved", 1764], ["in", 1773], ["the", 1776], ["neutralization", 1780], ["of", 1795], ["ROS", 1798], ["in", 1802], ["moDCs", 1805], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["points", 1833], ["to", 1840], ["better", 1843], ["survival", 1850], ["skills", 1859], ["of", 1866], ["DCs", 1869], ["in", 1873], ["oxidative", 1876], ["stress", 1886], ["environments", 1893], [",", 1905], ["such", 1907], ["as", 1912], ["atherosclerotic", 1915], ["plaques", 1931], [".", 1938]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f7e5563396b64495a72b3ad4feedde3e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[89, 90], [39, 40], [51, 52]], "char_spans": [[517, 526], [250, 259], [315, 324]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The amino acid selenocysteine is encoded by UGA, usually a stop codon, thus requiring a specialized machinery to enable its incorporation into selenoproteins. The machinery comprises the tRNA(Sec), a 3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS), which is mandatory for recoding UGA as a Sec codon, the SECIS Binding Protein 2 (SBP2), and other proteins. Little is known about the molecular mechanism and, in particular, when, where, and how the SECIS and SBP2 contact the ribosome. Previous work by others used the isolated SECIS RNA to address this question. Here, we developed a novel approach using instead engineered minimal selenoprotein mRNAs containing SECIS elements derivatized with photoreactive groups. By cross-linking experiments in rabbit reticulocyte lysate, new information could be gained about the SBP2 and SECIS contacts with components of the translation machinery at various translation steps. In particular, we found that SBP2 was bound only to the SECIS in 48S pre-initiation and 80S pretranslocation complexes. In the complex where the Sec-tRNA(Sec) was accommodated to the A site but transpeptidation was blocked, SBP2 bound the ribosome and possibly the SECIS element as well, and the SECIS had flexible contacts with the 60S ribosomal subunit involving several ribosomal proteins. Altogether, our findings led to broadening our understanding about the unique mechanism of selenocysteine incorporation in mammals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "00475180d274498e9dad745b5ff8c048", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[176, 176], [59, 59], [125, 125], [90, 90], [214, 214], [221, 221], [44, 44], [151, 151], [104, 104]], "char_spans": [[997, 1001], [328, 332], [686, 690], [471, 475], [1206, 1210], [1237, 1241], [264, 268], [851, 855], [550, 554]]}]}], "context_tokens": [["The", 0], ["amino", 4], ["acid", 10], ["selenocysteine", 15], ["is", 30], ["encoded", 33], ["by", 41], ["UGA", 44], [",", 47], ["usually", 49], ["a", 57], ["stop", 59], ["codon", 64], [",", 69], ["thus", 71], ["requiring", 76], ["a", 86], ["specialized", 88], ["machinery", 100], ["to", 110], ["enable", 113], ["its", 120], ["incorporation", 124], ["into", 138], ["selenoproteins", 143], [".", 157], ["The", 159], ["machinery", 163], ["comprises", 173], ["the", 183], ["tRNA(Sec", 187], [")", 195], [",", 196], ["a", 198], ["3'-UTR", 200], ["mRNA", 207], ["stem", 212], ["-", 216], ["loop", 217], ["termed", 222], ["SElenoCysteine", 229], ["Insertion", 244], ["Sequence", 254], ["(", 263], ["SECIS", 264], [")", 269], [",", 270], ["which", 272], ["is", 278], ["mandatory", 281], ["for", 291], ["recoding", 295], ["UGA", 304], ["as", 308], ["a", 311], ["Sec", 313], ["codon", 317], [",", 322], ["the", 324], ["SECIS", 328], ["Binding", 334], ["Protein", 342], ["2", 350], ["(", 352], ["SBP2", 353], [")", 357], [",", 358], ["and", 360], ["other", 364], ["proteins", 370], [".", 378], ["Little", 380], ["is", 387], ["known", 390], ["about", 396], ["the", 402], ["molecular", 406], ["mechanism", 416], ["and", 426], [",", 429], ["in", 431], ["particular", 434], [",", 444], ["when", 446], [",", 450], ["where", 452], [",", 457], ["and", 459], ["how", 463], ["the", 467], ["SECIS", 471], ["and", 477], ["SBP2", 481], ["contact", 486], ["the", 494], ["ribosome", 498], [".", 506], ["Previous", 508], ["work", 517], ["by", 522], ["others", 525], ["used", 532], ["the", 537], ["isolated", 541], ["SECIS", 550], ["RNA", 556], ["to", 560], ["address", 563], ["this", 571], ["question", 576], [".", 584], ["Here", 586], [",", 590], ["we", 592], ["developed", 595], ["a", 605], ["novel", 607], ["approach", 613], ["using", 622], ["instead", 628], ["engineered", 636], ["minimal", 647], ["selenoprotein", 655], ["mRNAs", 669], ["containing", 675], ["SECIS", 686], ["elements", 692], ["derivatized", 701], ["with", 713], ["photoreactive", 718], ["groups", 732], [".", 738], ["By", 740], ["cross", 743], ["-", 748], ["linking", 749], ["experiments", 757], ["in", 769], ["rabbit", 772], ["reticulocyte", 779], ["lysate", 792], [",", 798], ["new", 800], ["information", 804], ["could", 816], ["be", 822], ["gained", 825], ["about", 832], ["the", 838], ["SBP2", 842], ["and", 847], ["SECIS", 851], ["contacts", 857], ["with", 866], ["components", 871], ["of", 882], ["the", 885], ["translation", 889], ["machinery", 901], ["at", 911], ["various", 914], ["translation", 922], ["steps", 934], [".", 939], ["In", 941], ["particular", 944], [",", 954], ["we", 956], ["found", 959], ["that", 965], ["SBP2", 970], ["was", 975], ["bound", 979], ["only", 985], ["to", 990], ["the", 993], ["SECIS", 997], ["in", 1003], ["48S", 1006], ["pre", 1010], ["-", 1013], ["initiation", 1014], ["and", 1025], ["80S", 1029], ["pretranslocation", 1033], ["complexes", 1050], [".", 1059], ["In", 1061], ["the", 1064], ["complex", 1068], ["where", 1076], ["the", 1082], ["Sec", 1086], ["-", 1089], ["tRNA(Sec", 1090], [")", 1098], ["was", 1100], ["accommodated", 1104], ["to", 1117], ["the", 1120], ["A", 1124], ["site", 1126], ["but", 1131], ["transpeptidation", 1135], ["was", 1152], ["blocked", 1156], [",", 1163], ["SBP2", 1165], ["bound", 1170], ["the", 1176], ["ribosome", 1180], ["and", 1189], ["possibly", 1193], ["the", 1202], ["SECIS", 1206], ["element", 1212], ["as", 1220], ["well", 1223], [",", 1227], ["and", 1229], ["the", 1233], ["SECIS", 1237], ["had", 1243], ["flexible", 1247], ["contacts", 1256], ["with", 1265], ["the", 1270], ["60S", 1274], ["ribosomal", 1278], ["subunit", 1288], ["involving", 1296], ["several", 1306], ["ribosomal", 1314], ["proteins", 1324], [".", 1332], ["Altogether", 1334], [",", 1344], ["our", 1346], ["findings", 1350], ["led", 1359], ["to", 1363], ["broadening", 1366], ["our", 1377], ["understanding", 1381], ["about", 1395], ["the", 1401], ["unique", 1405], ["mechanism", 1412], ["of", 1422], ["selenocysteine", 1425], ["incorporation", 1440], ["in", 1454], ["mammals", 1457], [".", 1464]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Amyloid precursor protein (APP) is strongly related to the onset of Alzheimer's disease. It possesses cleavage sites for beta- and gamma-secretases, and the resulting cleaved products (amyloid-beta peptides) are capable of causing neurotoxicity. Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene. Here, we characterized APPSL transgenic mice (APPSL-Tg) to determine the effects of this mutation. We observed that both the amount of insoluble amyloid-beta and the ratio of amyloid-beta 42/40 increased promptly in the brain during 6-16 months of age. Amyloid-beta plaques were observed in whole brain sections at 12 months. In contrast, the spatial memory assessed by the Morris water maze task was already impaired at 3 months, which suggested that the APPSL-Tg mice may represent an early-onset model of familial Alzheimer's disease. Furthermore, the levels of LAMP-1, a marker protein of lysosome, increased in the brain at 28 months. Such LAMP-1 protein was detected around the amyloid-beta plaques at the hippocampal regions of the APPSL-Tg mice. Our results suggested that the increase in LAMP-1 was enhanced by the accumulation of amyloid-beta occurring during aging. Our findings coincided with the pathological hallmarks of Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "d8237f9d763b42d483bb971b70dd1706", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[13, 15], [244, 246], [168, 170]], "char_spans": [[68, 86], [1277, 1295], [859, 877]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["APP", 27], [")", 30], ["is", 32], ["strongly", 35], ["related", 44], ["to", 52], ["the", 55], ["onset", 59], ["of", 65], ["Alzheimer", 68], ["'s", 77], ["disease", 80], [".", 87], ["It", 89], ["possesses", 92], ["cleavage", 102], ["sites", 111], ["for", 117], ["beta-", 121], ["and", 127], ["gamma", 131], ["-", 136], ["secretases", 137], [",", 147], ["and", 149], ["the", 153], ["resulting", 157], ["cleaved", 167], ["products", 175], ["(", 184], ["amyloid", 185], ["-", 192], ["beta", 193], ["peptides", 198], [")", 206], ["are", 208], ["capable", 212], ["of", 220], ["causing", 223], ["neurotoxicity", 231], [".", 244], ["Such", 246], ["cleavage", 251], ["is", 260], ["promoted", 263], ["by", 272], ["the", 275], ["Swedish", 279], ["and", 287], ["London", 291], ["mutations", 298], ["(", 308], ["APPSwe", 309], ["/", 315], ["Lon", 316], [")", 319], ["inside", 321], ["the", 328], ["APP", 332], ["gene", 336], [".", 340], ["Here", 342], [",", 346], ["we", 348], ["characterized", 351], ["APPSL", 365], ["transgenic", 371], ["mice", 382], ["(", 387], ["APPSL", 388], ["-", 393], ["Tg", 394], [")", 396], ["to", 398], ["determine", 401], ["the", 411], ["effects", 415], ["of", 423], ["this", 426], ["mutation", 431], [".", 439], ["We", 441], ["observed", 444], ["that", 453], ["both", 458], ["the", 463], ["amount", 467], ["of", 474], ["insoluble", 477], ["amyloid", 487], ["-", 494], ["beta", 495], ["and", 500], ["the", 504], ["ratio", 508], ["of", 514], ["amyloid", 517], ["-", 524], ["beta", 525], ["42/40", 530], ["increased", 536], ["promptly", 546], ["in", 555], ["the", 558], ["brain", 562], ["during", 568], ["6", 575], ["-", 576], ["16", 577], ["months", 580], ["of", 587], ["age", 590], [".", 593], ["Amyloid", 595], ["-", 602], ["beta", 603], ["plaques", 608], ["were", 616], ["observed", 621], ["in", 630], ["whole", 633], ["brain", 639], ["sections", 645], ["at", 654], ["12", 657], ["months", 660], [".", 666], ["In", 668], ["contrast", 671], [",", 679], ["the", 681], ["spatial", 685], ["memory", 693], ["assessed", 700], ["by", 709], ["the", 712], ["Morris", 716], ["water", 723], ["maze", 729], ["task", 734], ["was", 739], ["already", 743], ["impaired", 751], ["at", 760], ["3", 763], ["months", 765], [",", 771], ["which", 773], ["suggested", 779], ["that", 789], ["the", 794], ["APPSL", 798], ["-", 803], ["Tg", 804], ["mice", 807], ["may", 812], ["represent", 816], ["an", 826], ["early", 829], ["-", 834], ["onset", 835], ["model", 841], ["of", 847], ["familial", 850], ["Alzheimer", 859], ["'s", 868], ["disease", 871], [".", 878], ["Furthermore", 880], [",", 891], ["the", 893], ["levels", 897], ["of", 904], ["LAMP-1", 907], [",", 913], ["a", 915], ["marker", 917], ["protein", 924], ["of", 932], ["lysosome", 935], [",", 943], ["increased", 945], ["in", 955], ["the", 958], ["brain", 962], ["at", 968], ["28", 971], ["months", 974], [".", 980], ["Such", 982], ["LAMP-1", 987], ["protein", 994], ["was", 1002], ["detected", 1006], ["around", 1015], ["the", 1022], ["amyloid", 1026], ["-", 1033], ["beta", 1034], ["plaques", 1039], ["at", 1047], ["the", 1050], ["hippocampal", 1054], ["regions", 1066], ["of", 1074], ["the", 1077], ["APPSL", 1081], ["-", 1086], ["Tg", 1087], ["mice", 1090], [".", 1094], ["Our", 1096], ["results", 1100], ["suggested", 1108], ["that", 1118], ["the", 1123], ["increase", 1127], ["in", 1136], ["LAMP-1", 1139], ["was", 1146], ["enhanced", 1150], ["by", 1159], ["the", 1162], ["accumulation", 1166], ["of", 1179], ["amyloid", 1182], ["-", 1189], ["beta", 1190], ["occurring", 1195], ["during", 1205], ["aging", 1212], [".", 1217], ["Our", 1219], ["findings", 1223], ["coincided", 1232], ["with", 1242], ["the", 1247], ["pathological", 1251], ["hallmarks", 1264], ["of", 1274], ["Alzheimer", 1277], ["'s", 1286], ["disease", 1289], [".", 1296]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "To determine the validity of the rapid antigen test (RAT) OSOM StrepA Genzyme for the diagnosis of acute pharyngitis caused by group A beta-haemolytic strep (GABHS). Diagnostic techniques survey. Urban primary care centre, Spain. All patients over 14 years old seen in 6 surgeries with sore throat and 2 or more Centor criteria: pharyngotonsillar exudate, tender laterocervical nodes, absence of coughing, and/or history or presence of fever. Pharyngeal swabs were taken from all the patients, one for RAT and another to send for culture in the microbiology department. A total of 182 patients were evaluable, with a mean age of 30.6 (12.1) years of which 116 were women (63.7%); 63 patients had 2 Centor criteria; 83 had 3 and 36, the 4 criteria. The culture was positive in 102 patients (56%), with GABHS showing infection in forty (22%; 95% confidence interval [CI], 21.2-22.8). Group C Streptococcus was isolated in 26 patients (14.3%). GABHS was higher among patients with four Centor criteria (38.9% vs 25.3% observed among those with 3 criteria and 7.9% with 2 criteria; P<.001). Sensitivity of RAT was 95%, with a specificity of 93%, a positive predictive value of 79.2% and a negative predictive value of 98.5%. These results show the usefulness of RAT for diagnosing streptococcal pharyngitis. Its use should be spread to all primary care practices.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "e8f16ae3e5874a4181985bd826ce59f8", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[268, 269]], "char_spans": [[1277, 1301]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["validity", 17], ["of", 26], ["the", 29], ["rapid", 33], ["antigen", 39], ["test", 47], ["(", 52], ["RAT", 53], [")", 56], ["OSOM", 58], ["StrepA", 63], ["Genzyme", 70], ["for", 78], ["the", 82], ["diagnosis", 86], ["of", 96], ["acute", 99], ["pharyngitis", 105], ["caused", 117], ["by", 124], ["group", 127], ["A", 133], ["beta", 135], ["-", 139], ["haemolytic", 140], ["strep", 151], ["(", 157], ["GABHS", 158], [")", 163], [".", 164], ["Diagnostic", 166], ["techniques", 177], ["survey", 188], [".", 194], ["Urban", 196], ["primary", 202], ["care", 210], ["centre", 215], [",", 221], ["Spain", 223], [".", 228], ["All", 230], ["patients", 234], ["over", 243], ["14", 248], ["years", 251], ["old", 257], ["seen", 261], ["in", 266], ["6", 269], ["surgeries", 271], ["with", 281], ["sore", 286], ["throat", 291], ["and", 298], ["2", 302], ["or", 304], ["more", 307], ["Centor", 312], ["criteria", 319], [":", 327], ["pharyngotonsillar", 329], ["exudate", 347], [",", 354], ["tender", 356], ["laterocervical", 363], ["nodes", 378], [",", 383], ["absence", 385], ["of", 393], ["coughing", 396], [",", 404], ["and/or", 406], ["history", 413], ["or", 421], ["presence", 424], ["of", 433], ["fever", 436], [".", 441], ["Pharyngeal", 443], ["swabs", 454], ["were", 460], ["taken", 465], ["from", 471], ["all", 476], ["the", 480], ["patients", 484], [",", 492], ["one", 494], ["for", 498], ["RAT", 502], ["and", 506], ["another", 510], ["to", 518], ["send", 521], ["for", 526], ["culture", 530], ["in", 538], ["the", 541], ["microbiology", 545], ["department", 558], [".", 568], ["A", 570], ["total", 572], ["of", 578], ["182", 581], ["patients", 585], ["were", 594], ["evaluable", 599], [",", 608], ["with", 610], ["a", 615], ["mean", 617], ["age", 622], ["of", 626], ["30.6", 629], ["(", 634], ["12.1", 635], [")", 639], ["years", 641], ["of", 647], ["which", 650], ["116", 656], ["were", 660], ["women", 665], ["(", 671], ["63.7", 672], ["%", 676], [")", 677], [";", 678], ["63", 680], ["patients", 683], ["had", 692], ["2", 696], ["Centor", 698], ["criteria", 705], [";", 713], ["83", 715], ["had", 718], ["3", 722], ["and", 724], ["36", 728], [",", 730], ["the", 732], ["4", 736], ["criteria", 738], [".", 746], ["The", 748], ["culture", 752], ["was", 760], ["positive", 764], ["in", 773], ["102", 776], ["patients", 780], ["(", 789], ["56", 790], ["%", 792], [")", 793], [",", 794], ["with", 796], ["GABHS", 801], ["showing", 807], ["infection", 815], ["in", 825], ["forty", 828], ["(", 834], ["22", 835], ["%", 837], [";", 838], ["95", 840], ["%", 842], ["confidence", 844], ["interval", 855], ["[", 864], ["CI", 865], ["]", 867], [",", 868], ["21.2", 870], ["-", 874], ["22.8", 875], [")", 879], [".", 880], ["Group", 882], ["C", 888], ["Streptococcus", 890], ["was", 904], ["isolated", 908], ["in", 917], ["26", 920], ["patients", 923], ["(", 932], ["14.3", 933], ["%", 937], [")", 938], [".", 939], ["GABHS", 941], ["was", 947], ["higher", 951], ["among", 958], ["patients", 964], ["with", 973], ["four", 978], ["Centor", 983], ["criteria", 990], ["(", 999], ["38.9", 1000], ["%", 1004], ["vs", 1006], ["25.3", 1009], ["%", 1013], ["observed", 1015], ["among", 1024], ["those", 1030], ["with", 1036], ["3", 1041], ["criteria", 1043], ["and", 1052], ["7.9", 1056], ["%", 1059], ["with", 1061], ["2", 1066], ["criteria", 1068], [";", 1076], ["P<.001", 1078], [")", 1084], [".", 1085], ["Sensitivity", 1087], ["of", 1099], ["RAT", 1102], ["was", 1106], ["95", 1110], ["%", 1112], [",", 1113], ["with", 1115], ["a", 1120], ["specificity", 1122], ["of", 1134], ["93", 1137], ["%", 1139], [",", 1140], ["a", 1142], ["positive", 1144], ["predictive", 1153], ["value", 1164], ["of", 1170], ["79.2", 1173], ["%", 1177], ["and", 1179], ["a", 1183], ["negative", 1185], ["predictive", 1194], ["value", 1205], ["of", 1211], ["98.5", 1214], ["%", 1218], [".", 1219], ["These", 1221], ["results", 1227], ["show", 1235], ["the", 1240], ["usefulness", 1244], ["of", 1255], ["RAT", 1258], ["for", 1262], ["diagnosing", 1266], ["streptococcal", 1277], ["pharyngitis", 1291], [".", 1302], ["Its", 1304], ["use", 1308], ["should", 1312], ["be", 1319], ["spread", 1322], ["to", 1329], ["all", 1332], ["primary", 1336], ["care", 1344], ["practices", 1349], [".", 1358]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The McLeod syndrome is an X-linked neuroacanthocytosis manifesting with myopathy and progressive chorea. It is caused by mutations of the XK gene encoding the XK protein, a putative membrane transport protein of yet unknown function. In erythroid tissues, XK forms a functional complex with the Kell glycoprotein. Here, we present an immunohistochemical study in skeletal muscle of normal controls and a McLeod patient with a XK gene point mutation (C977T) using affinity-purified antibodies against XK and Kell proteins. Histological examination of the affected muscle revealed the typical pattern of McLeod myopathy including type 2 fiber atrophy. In control muscles, Kell immunohistochemistry stained sarcoplasmic membranes. XK immunohistochemistry resulted in a type 2 fiber-specific intracellular staining that was most probably confined to the sarcoplasmic reticulum. In contrast, there was only a weak background signal without a specific staining pattern for XK and Kell in the McLeod muscle. Our results demonstrate that the lack of physiological XK expression correlates to the type 2 fiber atrophy in McLeod myopathy, and suggest that the XK protein represents a crucial factor for the maintenance of normal muscle structure and function.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "f252703de7194f1983547f4bf860ba40", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [27, 27], [44, 44], [87, 87], [23, 23], [73, 73], [121, 121], [175, 175], [159, 159]], "char_spans": [[1150, 1151], [159, 160], [256, 257], [500, 501], [138, 139], [426, 427], [728, 729], [1056, 1057], [967, 968]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["manifesting", 55], ["with", 67], ["myopathy", 72], ["and", 81], ["progressive", 85], ["chorea", 97], [".", 103], ["It", 105], ["is", 108], ["caused", 111], ["by", 118], ["mutations", 121], ["of", 131], ["the", 134], ["XK", 138], ["gene", 141], ["encoding", 146], ["the", 155], ["XK", 159], ["protein", 162], [",", 169], ["a", 171], ["putative", 173], ["membrane", 182], ["transport", 191], ["protein", 201], ["of", 209], ["yet", 212], ["unknown", 216], ["function", 224], [".", 232], ["In", 234], ["erythroid", 237], ["tissues", 247], [",", 254], ["XK", 256], ["forms", 259], ["a", 265], ["functional", 267], ["complex", 278], ["with", 286], ["the", 291], ["Kell", 295], ["glycoprotein", 300], [".", 312], ["Here", 314], [",", 318], ["we", 320], ["present", 323], ["an", 331], ["immunohistochemical", 334], ["study", 354], ["in", 360], ["skeletal", 363], ["muscle", 372], ["of", 379], ["normal", 382], ["controls", 389], ["and", 398], ["a", 402], ["McLeod", 404], ["patient", 411], ["with", 419], ["a", 424], ["XK", 426], ["gene", 429], ["point", 434], ["mutation", 440], ["(", 449], ["C977", 450], ["T", 454], [")", 455], ["using", 457], ["affinity", 463], ["-", 471], ["purified", 472], ["antibodies", 481], ["against", 492], ["XK", 500], ["and", 503], ["Kell", 507], ["proteins", 512], [".", 520], ["Histological", 522], ["examination", 535], ["of", 547], ["the", 550], ["affected", 554], ["muscle", 563], ["revealed", 570], ["the", 579], ["typical", 583], ["pattern", 591], ["of", 599], ["McLeod", 602], ["myopathy", 609], ["including", 618], ["type", 628], ["2", 633], ["fiber", 635], ["atrophy", 641], [".", 648], ["In", 650], ["control", 653], ["muscles", 661], [",", 668], ["Kell", 670], ["immunohistochemistry", 675], ["stained", 696], ["sarcoplasmic", 704], ["membranes", 717], [".", 726], ["XK", 728], ["immunohistochemistry", 731], ["resulted", 752], ["in", 761], ["a", 764], ["type", 766], ["2", 771], ["fiber", 773], ["-", 778], ["specific", 779], ["intracellular", 788], ["staining", 802], ["that", 811], ["was", 816], ["most", 820], ["probably", 825], ["confined", 834], ["to", 843], ["the", 846], ["sarcoplasmic", 850], ["reticulum", 863], [".", 872], ["In", 874], ["contrast", 877], [",", 885], ["there", 887], ["was", 893], ["only", 897], ["a", 902], ["weak", 904], ["background", 909], ["signal", 920], ["without", 927], ["a", 935], ["specific", 937], ["staining", 946], ["pattern", 955], ["for", 963], ["XK", 967], ["and", 970], ["Kell", 974], ["in", 979], ["the", 982], ["McLeod", 986], ["muscle", 993], [".", 999], ["Our", 1001], ["results", 1005], ["demonstrate", 1013], ["that", 1025], ["the", 1030], ["lack", 1034], ["of", 1039], ["physiological", 1042], ["XK", 1056], ["expression", 1059], ["correlates", 1070], ["to", 1081], ["the", 1084], ["type", 1088], ["2", 1093], ["fiber", 1095], ["atrophy", 1101], ["in", 1109], ["McLeod", 1112], ["myopathy", 1119], [",", 1127], ["and", 1129], ["suggest", 1133], ["that", 1141], ["the", 1146], ["XK", 1150], ["protein", 1153], ["represents", 1161], ["a", 1172], ["crucial", 1174], ["factor", 1182], ["for", 1189], ["the", 1193], ["maintenance", 1197], ["of", 1209], ["normal", 1212], ["muscle", 1219], ["structure", 1226], ["and", 1236], ["function", 1240], [".", 1248]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "Mutations of the alpha-synuclein gene have shown to be relevant in some rare families with autosomal dominant Parkinson's disease (PD). Furthermore, alpha-synuclein protein is a major component of the Lewy bodies also in sporadic PD patients. Increased levels of wildtype alpha-synuclein in the cell leads to increased intracellular hydrogen peroxide levels and causes death of dopaminergic neurons in rat primary culture. Subsequently, oxidative stress has been directly linked with alpha-synuclein aggregation in vitro. This raises the question whether increased alpha-synuclein expression might be linked to higher susceptibility to PD and whether alpha-synuclein promoter polymorphisms are associated with PD. Here, two polymorphisms (-116C>G and -668T>C) of the alpha-synuclein promoter defining four haplotypes have been characterized in 315 German PD patients. The influence of the four haplotypes on gene expression was studied by CAT reporter gene assays in neuronal SK-N-AS cells. The -668C/-116G haplotype revealed significant higher CAT expression than the -668T/-116G or the -668T/-116C haplotype, respectively. Although the -668C/-116G haplotype was more common in PD patients, this difference was not significant.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "25ed7d746b414134b9454c0b72df2885", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[3, 5], [28, 30], [110, 112], [96, 98], [135, 137], [50, 52], [83, 85]], "char_spans": [[17, 31], [149, 163], [651, 665], [565, 579], [767, 781], [272, 286], [484, 498]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["the", 13], ["alpha", 17], ["-", 22], ["synuclein", 23], ["gene", 33], ["have", 38], ["shown", 43], ["to", 49], ["be", 52], ["relevant", 55], ["in", 64], ["some", 67], ["rare", 72], ["families", 77], ["with", 86], ["autosomal", 91], ["dominant", 101], ["Parkinson", 110], ["'s", 119], ["disease", 122], ["(", 130], ["PD", 131], [")", 133], [".", 134], ["Furthermore", 136], [",", 147], ["alpha", 149], ["-", 154], ["synuclein", 155], ["protein", 165], ["is", 173], ["a", 176], ["major", 178], ["component", 184], ["of", 194], ["the", 197], ["Lewy", 201], ["bodies", 206], ["also", 213], ["in", 218], ["sporadic", 221], ["PD", 230], ["patients", 233], [".", 241], ["Increased", 243], ["levels", 253], ["of", 260], ["wildtype", 263], ["alpha", 272], ["-", 277], ["synuclein", 278], ["in", 288], ["the", 291], ["cell", 295], ["leads", 300], ["to", 306], ["increased", 309], ["intracellular", 319], ["hydrogen", 333], ["peroxide", 342], ["levels", 351], ["and", 358], ["causes", 362], ["death", 369], ["of", 375], ["dopaminergic", 378], ["neurons", 391], ["in", 399], ["rat", 402], ["primary", 406], ["culture", 414], [".", 421], ["Subsequently", 423], [",", 435], ["oxidative", 437], ["stress", 447], ["has", 454], ["been", 458], ["directly", 463], ["linked", 472], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], ["aggregation", 500], ["in", 512], ["vitro", 515], [".", 520], ["This", 522], ["raises", 527], ["the", 534], ["question", 538], ["whether", 547], ["increased", 555], ["alpha", 565], ["-", 570], ["synuclein", 571], ["expression", 581], ["might", 592], ["be", 598], ["linked", 601], ["to", 608], ["higher", 611], ["susceptibility", 618], ["to", 633], ["PD", 636], ["and", 639], ["whether", 643], ["alpha", 651], ["-", 656], ["synuclein", 657], ["promoter", 667], ["polymorphisms", 676], ["are", 690], ["associated", 694], ["with", 705], ["PD", 710], [".", 712], ["Here", 714], [",", 718], ["two", 720], ["polymorphisms", 724], ["(", 738], ["-116C", 739], [">", 744], ["G", 745], ["and", 747], ["-668T", 751], [">", 756], ["C", 757], [")", 758], ["of", 760], ["the", 763], ["alpha", 767], ["-", 772], ["synuclein", 773], ["promoter", 783], ["defining", 792], ["four", 801], ["haplotypes", 806], ["have", 817], ["been", 822], ["characterized", 827], ["in", 841], ["315", 844], ["German", 848], ["PD", 855], ["patients", 858], [".", 866], ["The", 868], ["influence", 872], ["of", 882], ["the", 885], ["four", 889], ["haplotypes", 894], ["on", 905], ["gene", 908], ["expression", 913], ["was", 924], ["studied", 928], ["by", 936], ["CAT", 939], ["reporter", 943], ["gene", 952], ["assays", 957], ["in", 964], ["neuronal", 967], ["SK", 976], ["-", 978], ["N", 979], ["-", 980], ["AS", 981], ["cells", 984], [".", 989], ["The", 991], ["-668C/-116", 995], ["G", 1005], ["haplotype", 1007], ["revealed", 1017], ["significant", 1026], ["higher", 1038], ["CAT", 1045], ["expression", 1049], ["than", 1060], ["the", 1065], ["-668T/-116", 1069], ["G", 1079], ["or", 1081], ["the", 1084], ["-668T/-116C", 1088], ["haplotype", 1100], [",", 1109], ["respectively", 1111], [".", 1123], ["Although", 1125], ["the", 1134], ["-668C/-116", 1138], ["G", 1148], ["haplotype", 1150], ["was", 1160], ["more", 1164], ["common", 1169], ["in", 1176], ["PD", 1179], ["patients", 1182], [",", 1190], ["this", 1192], ["difference", 1197], ["was", 1208], ["not", 1212], ["significant", 1216], [".", 1227]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. To gain further insights into the molecular mechanisms of the disease, we evaluated at the molecular level, the perturbation linked to the FSHD genotype with no a priori on disease onset, severity or penetrance and prior to any infiltration by fibrotic or adipose tissue in biopsies from fetuses carrying a short pathogenic D4Z4 array (n = 6) compared with fetuses with a non-pathogenic D4Z4 array (n = 21). By measuring expression of several muscle-specific markers and 4q35 genes including the DUX4 retrogene by an RT-PCR and western blotting, we observed a global dysregulation of genes involved in myogenesis including MYOD1 in samples with <11 D4Z4. The DUX4-fl pathogenic transcript was detected in FSHD biopsies but also in controls. Importantly, in FSHD fetuses, we mainly detected the non-spliced DUX4-fl isoform. In addition, several other genes clustered at the 4q35 locus are upregulated in FSHD fetuses. Our study is the first to examine fetuses carrying an FSHD-linked genotype and reveals an extensive dysregulation of several muscle-specific and 4q35 genes at early development stage at a distance from any muscle defect. Overall, our work suggests that even if FSHD is an adult-onset muscular dystrophy, the disease might also involve early molecular defects arising during myogenesis or early differentiation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "4fc29c2642a542c698f2e6a566dc9c37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[221, 221], [38, 38], [234, 234], [7, 7], [184, 184], [194, 194], [79, 79], [271, 271]], "char_spans": [[1222, 1225], [219, 222], [1290, 1293], [33, 36], [1024, 1027], [1076, 1079], [458, 461], [1497, 1500]]}]}], "context_tokens": [["Facio", 0], ["-", 5], ["scapulo", 6], ["-", 13], ["humeral", 14], ["dystrophy", 22], ["(", 32], ["FSHD", 33], [")", 37], ["results", 39], ["from", 47], ["deletions", 52], ["in", 62], ["the", 65], ["subtelomeric", 69], ["macrosatellite", 82], ["D4Z4", 97], ["array", 102], ["on", 108], ["the", 111], ["4q35", 115], ["region", 120], [".", 126], ["Upregulation", 128], ["of", 141], ["the", 144], ["DUX4", 148], ["retrogene", 153], ["from", 163], ["the", 168], ["last", 172], ["D4Z4", 177], ["repeated", 182], ["unit", 191], ["is", 196], ["thought", 199], ["to", 207], ["underlie", 210], ["FSHD", 219], ["pathophysiology", 224], [".", 239], ["However", 241], [",", 248], ["no", 250], ["one", 253], ["knows", 257], ["what", 263], ["triggers", 268], ["muscle", 277], ["defect", 284], ["and", 291], ["when", 295], ["alteration", 300], ["arises", 311], [".", 317], ["To", 319], ["gain", 322], ["further", 327], ["insights", 335], ["into", 344], ["the", 349], ["molecular", 353], ["mechanisms", 363], ["of", 374], ["the", 377], ["disease", 381], [",", 388], ["we", 390], ["evaluated", 393], ["at", 403], ["the", 406], ["molecular", 410], ["level", 420], [",", 425], ["the", 427], ["perturbation", 431], ["linked", 444], ["to", 451], ["the", 454], ["FSHD", 458], ["genotype", 463], ["with", 472], ["no", 477], ["a", 480], ["priori", 482], ["on", 489], ["disease", 492], ["onset", 500], [",", 505], ["severity", 507], ["or", 516], ["penetrance", 519], ["and", 530], ["prior", 534], ["to", 540], ["any", 543], ["infiltration", 547], ["by", 560], ["fibrotic", 563], ["or", 572], ["adipose", 575], ["tissue", 583], ["in", 590], ["biopsies", 593], ["from", 602], ["fetuses", 607], ["carrying", 615], ["a", 624], ["short", 626], ["pathogenic", 632], ["D4Z4", 643], ["array", 648], ["(", 654], ["n", 655], ["=", 657], ["6", 659], [")", 660], ["compared", 662], ["with", 671], ["fetuses", 676], ["with", 684], ["a", 689], ["non", 691], ["-", 694], ["pathogenic", 695], ["D4Z4", 706], ["array", 711], ["(", 717], ["n", 718], ["=", 720], ["21", 722], [")", 724], [".", 725], ["By", 727], ["measuring", 730], ["expression", 740], ["of", 751], ["several", 754], ["muscle", 762], ["-", 768], ["specific", 769], ["markers", 778], ["and", 786], ["4q35", 790], ["genes", 795], ["including", 801], ["the", 811], ["DUX4", 815], ["retrogene", 820], ["by", 830], ["an", 833], ["RT", 836], ["-", 838], ["PCR", 839], ["and", 843], ["western", 847], ["blotting", 855], [",", 863], ["we", 865], ["observed", 868], ["a", 877], ["global", 879], ["dysregulation", 886], ["of", 900], ["genes", 903], ["involved", 909], ["in", 918], ["myogenesis", 921], ["including", 932], ["MYOD1", 942], ["in", 948], ["samples", 951], ["with", 959], ["<", 964], ["11", 965], ["D4Z4", 968], [".", 972], ["The", 974], ["DUX4-fl", 978], ["pathogenic", 986], ["transcript", 997], ["was", 1008], ["detected", 1012], ["in", 1021], ["FSHD", 1024], ["biopsies", 1029], ["but", 1038], ["also", 1042], ["in", 1047], ["controls", 1050], [".", 1058], ["Importantly", 1060], [",", 1071], ["in", 1073], ["FSHD", 1076], ["fetuses", 1081], [",", 1088], ["we", 1090], ["mainly", 1093], ["detected", 1100], ["the", 1109], ["non", 1113], ["-", 1116], ["spliced", 1117], ["DUX4-fl", 1125], ["isoform", 1133], [".", 1140], ["In", 1142], ["addition", 1145], [",", 1153], ["several", 1155], ["other", 1163], ["genes", 1169], ["clustered", 1175], ["at", 1185], ["the", 1188], ["4q35", 1192], ["locus", 1197], ["are", 1203], ["upregulated", 1207], ["in", 1219], ["FSHD", 1222], ["fetuses", 1227], [".", 1234], ["Our", 1236], ["study", 1240], ["is", 1246], ["the", 1249], ["first", 1253], ["to", 1259], ["examine", 1262], ["fetuses", 1270], ["carrying", 1278], ["an", 1287], ["FSHD", 1290], ["-", 1294], ["linked", 1295], ["genotype", 1302], ["and", 1311], ["reveals", 1315], ["an", 1323], ["extensive", 1326], ["dysregulation", 1336], ["of", 1350], ["several", 1353], ["muscle", 1361], ["-", 1367], ["specific", 1368], ["and", 1377], ["4q35", 1381], ["genes", 1386], ["at", 1392], ["early", 1395], ["development", 1401], ["stage", 1413], ["at", 1419], ["a", 1422], ["distance", 1424], ["from", 1433], ["any", 1438], ["muscle", 1442], ["defect", 1449], [".", 1455], ["Overall", 1457], [",", 1464], ["our", 1466], ["work", 1470], ["suggests", 1475], ["that", 1484], ["even", 1489], ["if", 1494], ["FSHD", 1497], ["is", 1502], ["an", 1505], ["adult", 1508], ["-", 1513], ["onset", 1514], ["muscular", 1520], ["dystrophy", 1529], [",", 1538], ["the", 1540], ["disease", 1544], ["might", 1552], ["also", 1558], ["involve", 1563], ["early", 1571], ["molecular", 1577], ["defects", 1587], ["arising", 1595], ["during", 1603], ["myogenesis", 1610], ["or", 1621], ["early", 1624], ["differentiation", 1630], [".", 1645]]}
{"context": "Several gene products are involved in co-translational insertion of selenocysteine by the tRNA(Sec). In addition, a stem-loop structure in the mRNAs coding for selenoproteins is essential to mediate the selection of the proper selenocysteine UGA codon. Interestingly, in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region, far downstream of the UGA codon. In view of unravelling the underlying complex mechanism, we have attempted to detect RNA-binding proteins with specificity for the SECIS element. Using mobility shift assays, we could show that a protein, present in different types of mammalian cell extracts, possesses the capacity of binding the SECIS element of the selenoprotein glutathione peroxidase (GPx) mRNA. We have termed this protein SBP, for Secis Binding Protein. Competition experiments attested that the binding is highly specific and UV cross-linking indicated that the protein has an apparent molecular weight in the range of 60-65 kDa. Finally, some data suggest that the SECIS elements in the mRNAs of GPx and another selenoprotein, type I iodothyronine 5' deiodinase, recognize the same SBP protein. This constitutes the first report of the existence of a 3' UTR binding protein possibly involved in the eukaryotic selenocysteine insertion mechanism.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22db25e825ff4bcfb783e89d2d7a8162", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[131, 131], [101, 101], [151, 151], [62, 62], [194, 194]], "char_spans": [[754, 758], [587, 591], [861, 865], [368, 372], [1097, 1101]]}]}], "context_tokens": [["Several", 0], ["gene", 8], ["products", 13], ["are", 22], ["involved", 26], ["in", 35], ["co", 38], ["-", 40], ["translational", 41], ["insertion", 55], ["of", 65], ["selenocysteine", 68], ["by", 83], ["the", 86], ["tRNA(Sec", 90], [")", 98], [".", 99], ["In", 101], ["addition", 104], [",", 112], ["a", 114], ["stem", 116], ["-", 120], ["loop", 121], ["structure", 126], ["in", 136], ["the", 139], ["mRNAs", 143], ["coding", 149], ["for", 156], ["selenoproteins", 160], ["is", 175], ["essential", 178], ["to", 188], ["mediate", 191], ["the", 199], ["selection", 203], ["of", 213], ["the", 216], ["proper", 220], ["selenocysteine", 227], ["UGA", 242], ["codon", 246], [".", 251], ["Interestingly", 253], [",", 266], ["in", 268], ["eukaryotic", 271], ["selenoprotein", 282], ["mRNAs", 296], [",", 301], ["this", 303], ["stem", 308], ["-", 312], ["loop", 313], ["structure", 318], [",", 327], ["the", 329], ["selenocysteine", 333], ["insertion", 348], ["sequence", 358], ["(", 367], ["SECIS", 368], [")", 373], ["element", 375], [",", 382], ["resides", 384], ["in", 392], ["the", 395], ["3'-untranslated", 399], ["region", 415], [",", 421], ["far", 423], ["downstream", 427], ["of", 438], ["the", 441], ["UGA", 445], ["codon", 449], [".", 454], ["In", 456], ["view", 459], ["of", 464], ["unravelling", 467], ["the", 479], ["underlying", 483], ["complex", 494], ["mechanism", 502], [",", 511], ["we", 513], ["have", 516], ["attempted", 521], ["to", 531], ["detect", 534], ["RNA", 541], ["-", 544], ["binding", 545], ["proteins", 553], ["with", 562], ["specificity", 567], ["for", 579], ["the", 583], ["SECIS", 587], ["element", 593], [".", 600], ["Using", 602], ["mobility", 608], ["shift", 617], ["assays", 623], [",", 629], ["we", 631], ["could", 634], ["show", 640], ["that", 645], ["a", 650], ["protein", 652], [",", 659], ["present", 661], ["in", 669], ["different", 672], ["types", 682], ["of", 688], ["mammalian", 691], ["cell", 701], ["extracts", 706], [",", 714], ["possesses", 716], ["the", 726], ["capacity", 730], ["of", 739], ["binding", 742], ["the", 750], ["SECIS", 754], ["element", 760], ["of", 768], ["the", 771], ["selenoprotein", 775], ["glutathione", 789], ["peroxidase", 801], ["(", 812], ["GPx", 813], [")", 816], ["mRNA", 818], [".", 822], ["We", 824], ["have", 827], ["termed", 832], ["this", 839], ["protein", 844], ["SBP", 852], [",", 855], ["for", 857], ["Secis", 861], ["Binding", 867], ["Protein", 875], [".", 882], ["Competition", 884], ["experiments", 896], ["attested", 908], ["that", 917], ["the", 922], ["binding", 926], ["is", 934], ["highly", 937], ["specific", 944], ["and", 953], ["UV", 957], ["cross", 960], ["-", 965], ["linking", 966], ["indicated", 974], ["that", 984], ["the", 989], ["protein", 993], ["has", 1001], ["an", 1005], ["apparent", 1008], ["molecular", 1017], ["weight", 1027], ["in", 1034], ["the", 1037], ["range", 1041], ["of", 1047], ["60", 1050], ["-", 1052], ["65", 1053], ["kDa", 1056], [".", 1059], ["Finally", 1061], [",", 1068], ["some", 1070], ["data", 1075], ["suggest", 1080], ["that", 1088], ["the", 1093], ["SECIS", 1097], ["elements", 1103], ["in", 1112], ["the", 1115], ["mRNAs", 1119], ["of", 1125], ["GPx", 1128], ["and", 1132], ["another", 1136], ["selenoprotein", 1144], [",", 1157], ["type", 1159], ["I", 1164], ["iodothyronine", 1166], ["5", 1180], ["'", 1181], ["deiodinase", 1183], [",", 1193], ["recognize", 1195], ["the", 1205], ["same", 1209], ["SBP", 1214], ["protein", 1218], [".", 1225], ["This", 1227], ["constitutes", 1232], ["the", 1244], ["first", 1248], ["report", 1254], ["of", 1261], ["the", 1264], ["existence", 1268], ["of", 1278], ["a", 1281], ["3", 1283], ["'", 1284], ["UTR", 1286], ["binding", 1290], ["protein", 1298], ["possibly", 1306], ["involved", 1315], ["in", 1324], ["the", 1327], ["eukaryotic", 1331], ["selenocysteine", 1342], ["insertion", 1357], ["mechanism", 1367], [".", 1376]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 +/- 4.9 mm Hg in control, 101.2 +/- 19.3 mm Hg in 0.1 microM, and 115.5 +/- 13.3 mm Hg in 1 microM SEA0400, means +/- SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e732552a8ada436c980aa2d6f437c42b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[36, 36], [13, 13], [266, 266]], "char_spans": [[198, 200], [57, 59], [1455, 1457]]}]}], "context_tokens": [["The", 0], ["Ca2", 4], ["+", 7], ["overload", 9], ["by", 18], ["Ca2", 21], ["+", 24], ["influx", 26], ["via", 33], ["Na+/Ca2", 37], ["+", 44], ["exchanger", 46], ["(", 56], ["NCX", 57], [")", 60], ["is", 62], ["a", 65], ["critical", 67], ["mechanism", 76], ["in", 86], ["myocardial", 89], ["ischemia", 100], ["/", 108], ["reperfusion", 109], ["injury", 121], [".", 127], ["We", 129], ["investigated", 132], ["protective", 145], ["effects", 156], ["of", 164], ["a", 167], ["novel", 169], ["selective", 175], ["inhibitor", 185], ["of", 195], ["NCX", 198], [",", 201], ["SEA0400", 203], [",", 210], ["on", 212], ["cardiac", 215], ["function", 223], ["and", 232], ["energy", 236], ["metabolism", 243], ["during", 254], ["ischemia", 261], ["and", 270], ["reperfusion", 274], [".", 285], ["Langendorff", 287], ["-", 298], ["perfused", 299], ["rat", 308], ["hearts", 312], ["were", 319], ["exposed", 324], ["to", 332], ["35", 335], ["minutes", 338], ["global", 346], ["ischemia", 353], ["and", 362], ["40", 366], ["minutes", 369], ["reperfusion", 377], [".", 388], ["Using", 390], ["31P", 396], ["nuclear", 400], ["magnetic", 408], ["resonance", 417], ["spectroscopy", 427], [",", 439], ["cardiac", 441], ["phosphocreatine", 449], ["(", 465], ["PCr", 466], [")", 469], [",", 470], ["ATP", 472], [",", 475], ["and", 477], ["pHi", 481], ["were", 485], ["monitored", 490], [".", 499], ["SEA0400", 501], ["did", 509], ["not", 513], ["change", 517], ["the", 524], ["basic", 528], ["cardiac", 534], ["function", 542], [",", 550], ["but", 552], ["improved", 556], ["the", 565], ["recovery", 569], ["of", 578], ["left", 581], ["ventricular", 586], ["developed", 598], ["pressure", 608], ["(", 617], ["LVDP", 618], [")", 622], ["after", 624], ["reperfusion", 630], ["(", 642], ["27.6", 643], ["+", 648], ["/-", 649], ["4.9", 652], ["mm", 656], ["Hg", 659], ["in", 662], ["control", 665], [",", 672], ["101.2", 674], ["+", 680], ["/-", 681], ["19.3", 684], ["mm", 689], ["Hg", 692], ["in", 695], ["0.1", 698], ["microM", 702], [",", 708], ["and", 710], ["115.5", 714], ["+", 720], ["/-", 721], ["13.3", 724], ["mm", 729], ["Hg", 732], ["in", 735], ["1", 738], ["microM", 740], ["SEA0400", 747], [",", 754], ["means", 756], ["+", 762], ["/-", 763], ["SE", 766], [",", 768], ["n", 770], ["=", 772], ["6", 774], [",", 775], ["P", 777], ["<", 779], ["0.05", 781], [")", 785], [".", 786], ["SEA0400", 788], ["reduced", 796], ["left", 804], ["ventricular", 809], ["end", 821], ["-", 824], ["diastolic", 825], ["pressure", 835], ["and", 844], ["increased", 848], ["coronary", 858], ["flow", 867], ["after", 872], ["reperfusion", 878], [".", 889], ["SEA0400", 891], ["improved", 899], ["the", 908], ["recoveries", 912], ["of", 923], ["cardiac", 926], ["phosphocreatine", 934], ["and", 950], ["ATP", 954], ["after", 958], ["reperfusion", 964], [",", 975], ["but", 977], ["did", 981], ["not", 985], ["affect", 989], ["pHi", 996], [".", 999], ["There", 1001], ["were", 1007], ["significant", 1012], ["linear", 1024], ["correlations", 1031], ["between", 1044], ["left", 1052], ["ventricular", 1057], ["developed", 1069], ["pressure", 1079], ["and", 1088], ["cardiac", 1092], ["phosphocreatine", 1100], ["(", 1116], ["r", 1117], ["=", 1119], ["0.79", 1121], [",", 1125], ["P", 1127], ["<", 1129], ["0.05", 1131], [")", 1135], [",", 1136], ["and", 1138], ["left", 1142], ["ventricular", 1147], ["developed", 1159], ["pressure", 1169], ["and", 1178], ["ATP", 1182], ["(", 1186], ["r", 1187], ["=", 1189], ["0.80", 1191], [",", 1195], ["P", 1197], ["<", 1199], ["0.05", 1201], [")", 1205], [".", 1206], ["However", 1208], [",", 1215], ["SEA0400", 1217], ["increased", 1225], ["the", 1235], ["incidence", 1239], ["and", 1249], ["duration", 1253], ["of", 1262], ["reperfusion", 1265], ["ventricular", 1277], ["arrhythmias", 1289], [".", 1300], ["SEA0400", 1302], ["added", 1310], ["only", 1316], ["after", 1321], ["reperfusion", 1327], ["also", 1339], ["improved", 1344], ["both", 1353], ["the", 1358], ["contractile", 1362], ["function", 1374], ["and", 1383], ["energy", 1387], ["metabolism", 1394], [".", 1404], ["It", 1406], ["is", 1409], ["concluded", 1412], ["that", 1422], ["the", 1427], ["selective", 1431], ["inhibition", 1441], ["of", 1452], ["NCX", 1455], ["may", 1459], ["be", 1463], ["effective", 1466], ["to", 1476], ["preserve", 1479], ["high", 1488], ["-", 1492], ["energy", 1493], ["phosphates", 1500], ["and", 1511], ["to", 1515], ["improve", 1518], ["cardiac", 1526], ["function", 1534], ["after", 1543], ["reperfusion", 1549], [",", 1560], ["but", 1562], ["may", 1566], ["not", 1570], ["be", 1574], ["able", 1577], ["to", 1582], ["prevent", 1585], ["fatal", 1593], ["arrhythmias", 1599], [".", 1610]]}
{"context": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. Present experiments were designed to study the effect of partial blockade of Na(+)/Ca(2+) exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Intracellular Ca(2+) transient and cell shortening were measured in ventricular myocytes loaded with Fura-2-AM fluorescent dye. Partial blockade of Na(+)/Ca(2+) exchanger was induced by superfusion of the cells with SEA0400 at a concentration of 0.3 microM. Amplitude of the intracellular Ca(2+) transient and cell shortening was significantly increased by SEA0400 in both field stimulated and voltage clamped myocytes, without significant elevation of diastolic Ca(2+) level and the decay time constant of the Ca(2+) transient. In patch clamped myocytes the SEA0400 induced increase in the Ca(2+) transient and cell shortening was accompanied by significant reduction of peak L-type Ca(2+) current. These effects can be explained by the autoregulative nature of cardiac Ca(2+) handling, as the reduced Ca(2+) efflux from the cell results in an increased Ca(2+) load to the sarcoplasmic reticulum leading to increased Ca(2+) release, which in turn may decrease the L-type Ca(2+) current by accelaration of Ca(2+) dependent inactivation of L-type Ca(2+) current. Our results suggest that complex changes in the Ca(2+) cycling can occur after selective pharmacological inhibition of the Na(+)/Ca(2+) exchanger.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "4fe2e279a8224262a6918b198e8b0ed1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[42, 45], [79, 82], [7, 10], [272, 275], [25, 28]], "char_spans": [[250, 271], [478, 499], [40, 61], [1515, 1536], [149, 170]]}]}], "context_tokens": [["SEA0400", 0], ["is", 8], ["a", 11], ["selective", 13], ["inhibitor", 23], ["of", 33], ["the", 36], ["Na(+)/Ca(2", 40], ["+", 50], [")", 51], ["exchanger", 53], ["having", 63], ["equal", 70], ["potencies", 76], ["to", 86], ["suppress", 89], ["both", 98], ["the", 103], ["forward", 107], ["and", 115], ["reverse", 119], ["mode", 127], ["operation", 132], ["of", 142], ["the", 145], ["Na(+)/Ca(2", 149], ["+", 159], [")", 160], ["exchanger", 162], [".", 171], ["Present", 173], ["experiments", 181], ["were", 193], ["designed", 198], ["to", 207], ["study", 210], ["the", 216], ["effect", 220], ["of", 227], ["partial", 230], ["blockade", 238], ["of", 247], ["Na(+)/Ca(2", 250], ["+", 260], [")", 261], ["exchanger", 263], ["on", 273], ["Ca(2", 276], ["+", 280], [")", 281], ["handling", 283], ["in", 292], ["isolated", 295], ["rat", 304], ["ventricular", 308], ["myocytes", 320], [".", 328], ["Intracellular", 330], ["Ca(2", 344], ["+", 348], [")", 349], ["transient", 351], ["and", 361], ["cell", 365], ["shortening", 370], ["were", 381], ["measured", 386], ["in", 395], ["ventricular", 398], ["myocytes", 410], ["loaded", 419], ["with", 426], ["Fura-2-AM", 431], ["fluorescent", 441], ["dye", 453], [".", 456], ["Partial", 458], ["blockade", 466], ["of", 475], ["Na(+)/Ca(2", 478], ["+", 488], [")", 489], ["exchanger", 491], ["was", 501], ["induced", 505], ["by", 513], ["superfusion", 516], ["of", 528], ["the", 531], ["cells", 535], ["with", 541], ["SEA0400", 546], ["at", 554], ["a", 557], ["concentration", 559], ["of", 573], ["0.3", 576], ["microM.", 580], ["Amplitude", 588], ["of", 598], ["the", 601], ["intracellular", 605], ["Ca(2", 619], ["+", 623], [")", 624], ["transient", 626], ["and", 636], ["cell", 640], ["shortening", 645], ["was", 656], ["significantly", 660], ["increased", 674], ["by", 684], ["SEA0400", 687], ["in", 695], ["both", 698], ["field", 703], ["stimulated", 709], ["and", 720], ["voltage", 724], ["clamped", 732], ["myocytes", 740], [",", 748], ["without", 750], ["significant", 758], ["elevation", 770], ["of", 780], ["diastolic", 783], ["Ca(2", 793], ["+", 797], [")", 798], ["level", 800], ["and", 806], ["the", 810], ["decay", 814], ["time", 820], ["constant", 825], ["of", 834], ["the", 837], ["Ca(2", 841], ["+", 845], [")", 846], ["transient", 848], [".", 857], ["In", 859], ["patch", 862], ["clamped", 868], ["myocytes", 876], ["the", 885], ["SEA0400", 889], ["induced", 897], ["increase", 905], ["in", 914], ["the", 917], ["Ca(2", 921], ["+", 925], [")", 926], ["transient", 928], ["and", 938], ["cell", 942], ["shortening", 947], ["was", 958], ["accompanied", 962], ["by", 974], ["significant", 977], ["reduction", 989], ["of", 999], ["peak", 1002], ["L", 1007], ["-", 1008], ["type", 1009], ["Ca(2", 1014], ["+", 1018], [")", 1019], ["current", 1021], [".", 1028], ["These", 1030], ["effects", 1036], ["can", 1044], ["be", 1048], ["explained", 1051], ["by", 1061], ["the", 1064], ["autoregulative", 1068], ["nature", 1083], ["of", 1090], ["cardiac", 1093], ["Ca(2", 1101], ["+", 1105], [")", 1106], ["handling", 1108], [",", 1116], ["as", 1118], ["the", 1121], ["reduced", 1125], ["Ca(2", 1133], ["+", 1137], [")", 1138], ["efflux", 1140], ["from", 1147], ["the", 1152], ["cell", 1156], ["results", 1161], ["in", 1169], ["an", 1172], ["increased", 1175], ["Ca(2", 1185], ["+", 1189], [")", 1190], ["load", 1192], ["to", 1197], ["the", 1200], ["sarcoplasmic", 1204], ["reticulum", 1217], ["leading", 1227], ["to", 1235], ["increased", 1238], ["Ca(2", 1248], ["+", 1252], [")", 1253], ["release", 1255], [",", 1262], ["which", 1264], ["in", 1270], ["turn", 1273], ["may", 1278], ["decrease", 1282], ["the", 1291], ["L", 1295], ["-", 1296], ["type", 1297], ["Ca(2", 1302], ["+", 1306], [")", 1307], ["current", 1309], ["by", 1317], ["accelaration", 1320], ["of", 1333], ["Ca(2", 1336], ["+", 1340], [")", 1341], ["dependent", 1343], ["inactivation", 1353], ["of", 1366], ["L", 1369], ["-", 1370], ["type", 1371], ["Ca(2", 1376], ["+", 1380], [")", 1381], ["current", 1383], [".", 1390], ["Our", 1392], ["results", 1396], ["suggest", 1404], ["that", 1412], ["complex", 1417], ["changes", 1425], ["in", 1433], ["the", 1436], ["Ca(2", 1440], ["+", 1444], [")", 1445], ["cycling", 1447], ["can", 1455], ["occur", 1459], ["after", 1465], ["selective", 1471], ["pharmacological", 1481], ["inhibition", 1497], ["of", 1508], ["the", 1511], ["Na(+)/Ca(2", 1515], ["+", 1525], [")", 1526], ["exchanger", 1528], [".", 1537]]}
{"context": "Centrioles are essential for the formation of cilia and flagella. They also form the core of the centrosome, which organizes microtubule arrays important for cell shape, polarity, motility and division. Here, we have used super-resolution 3D-structured illumination microscopy to analyse the spatial relationship of 18 centriole and pericentriolar matrix (PCM) components of human centrosomes at different cell cycle stages. During mitosis, PCM proteins formed extended networks with interspersed \u03b3-Tubulin. During interphase, most proteins were arranged at specific distances from the walls of centrioles, resulting in ring staining, often with discernible density masses. Through use of site-specific antibodies, we found the C-terminus of Cep152 to be closer to centrioles than the N-terminus, illustrating the power of 3D-SIM to study protein disposition. Appendage proteins showed rings with multiple density masses, and the number of these masses was strongly reduced during mitosis. At the proximal end of centrioles, Sas-6 formed a dot at the site of daughter centriole assembly, consistent with its role in cartwheel formation. Plk4 and STIL co-localized with Sas-6, but Cep135 was associated mostly with mother centrioles. Remarkably, Plk4 formed a dot on the surface of the mother centriole before Sas-6 staining became detectable, indicating that Plk4 constitutes an early marker for the site of nascent centriole formation. Our study provides novel insights into the architecture of human centrosomes and illustrates the power of super-resolution microscopy in revealing the relative localization of centriole and PCM proteins in unprecedented detail.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "9ac493dfeaa446d1b53b353bcedbf4eb", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[18, 18]], "char_spans": [[97, 106]]}]}], "context_tokens": [["Centrioles", 0], ["are", 11], ["essential", 15], ["for", 25], ["the", 29], ["formation", 33], ["of", 43], ["cilia", 46], ["and", 52], ["flagella", 56], [".", 64], ["They", 66], ["also", 71], ["form", 76], ["the", 81], ["core", 85], ["of", 90], ["the", 93], ["centrosome", 97], [",", 107], ["which", 109], ["organizes", 115], ["microtubule", 125], ["arrays", 137], ["important", 144], ["for", 154], ["cell", 158], ["shape", 163], [",", 168], ["polarity", 170], [",", 178], ["motility", 180], ["and", 189], ["division", 193], [".", 201], ["Here", 203], [",", 207], ["we", 209], ["have", 212], ["used", 217], ["super", 222], ["-", 227], ["resolution", 228], ["3D", 239], ["-", 241], ["structured", 242], ["illumination", 253], ["microscopy", 266], ["to", 277], ["analyse", 280], ["the", 288], ["spatial", 292], ["relationship", 300], ["of", 313], ["18", 316], ["centriole", 319], ["and", 329], ["pericentriolar", 333], ["matrix", 348], ["(", 355], ["PCM", 356], [")", 359], ["components", 361], ["of", 372], ["human", 375], ["centrosomes", 381], ["at", 393], ["different", 396], ["cell", 406], ["cycle", 411], ["stages", 417], [".", 423], ["During", 425], ["mitosis", 432], [",", 439], ["PCM", 441], ["proteins", 445], ["formed", 454], ["extended", 461], ["networks", 470], ["with", 479], ["interspersed", 484], ["\u03b3", 497], ["-", 498], ["Tubulin", 499], [".", 506], ["During", 508], ["interphase", 515], [",", 525], ["most", 527], ["proteins", 532], ["were", 541], ["arranged", 546], ["at", 555], ["specific", 558], ["distances", 567], ["from", 577], ["the", 582], ["walls", 586], ["of", 592], ["centrioles", 595], [",", 605], ["resulting", 607], ["in", 617], ["ring", 620], ["staining", 625], [",", 633], ["often", 635], ["with", 641], ["discernible", 646], ["density", 658], ["masses", 666], [".", 672], ["Through", 674], ["use", 682], ["of", 686], ["site", 689], ["-", 693], ["specific", 694], ["antibodies", 703], [",", 713], ["we", 715], ["found", 718], ["the", 724], ["C", 728], ["-", 729], ["terminus", 730], ["of", 739], ["Cep152", 742], ["to", 749], ["be", 752], ["closer", 755], ["to", 762], ["centrioles", 765], ["than", 776], ["the", 781], ["N", 785], ["-", 786], ["terminus", 787], [",", 795], ["illustrating", 797], ["the", 810], ["power", 814], ["of", 820], ["3D", 823], ["-", 825], ["SIM", 826], ["to", 830], ["study", 833], ["protein", 839], ["disposition", 847], [".", 858], ["Appendage", 860], ["proteins", 870], ["showed", 879], ["rings", 886], ["with", 892], ["multiple", 897], ["density", 906], ["masses", 914], [",", 920], ["and", 922], ["the", 926], ["number", 930], ["of", 937], ["these", 940], ["masses", 946], ["was", 953], ["strongly", 957], ["reduced", 966], ["during", 974], ["mitosis", 981], [".", 988], ["At", 990], ["the", 993], ["proximal", 997], ["end", 1006], ["of", 1010], ["centrioles", 1013], [",", 1023], ["Sas-6", 1025], ["formed", 1031], ["a", 1038], ["dot", 1040], ["at", 1044], ["the", 1047], ["site", 1051], ["of", 1056], ["daughter", 1059], ["centriole", 1068], ["assembly", 1078], [",", 1086], ["consistent", 1088], ["with", 1099], ["its", 1104], ["role", 1108], ["in", 1113], ["cartwheel", 1116], ["formation", 1126], [".", 1135], ["Plk4", 1137], ["and", 1142], ["STIL", 1146], ["co", 1151], ["-", 1153], ["localized", 1154], ["with", 1164], ["Sas-6", 1169], [",", 1174], ["but", 1176], ["Cep135", 1180], ["was", 1187], ["associated", 1191], ["mostly", 1202], ["with", 1209], ["mother", 1214], ["centrioles", 1221], [".", 1231], ["Remarkably", 1233], [",", 1243], ["Plk4", 1245], ["formed", 1250], ["a", 1257], ["dot", 1259], ["on", 1263], ["the", 1266], ["surface", 1270], ["of", 1278], ["the", 1281], ["mother", 1285], ["centriole", 1292], ["before", 1302], ["Sas-6", 1309], ["staining", 1315], ["became", 1324], ["detectable", 1331], [",", 1341], ["indicating", 1343], ["that", 1354], ["Plk4", 1359], ["constitutes", 1364], ["an", 1376], ["early", 1379], ["marker", 1385], ["for", 1392], ["the", 1396], ["site", 1400], ["of", 1405], ["nascent", 1408], ["centriole", 1416], ["formation", 1426], [".", 1435], ["Our", 1437], ["study", 1441], ["provides", 1447], ["novel", 1456], ["insights", 1462], ["into", 1471], ["the", 1476], ["architecture", 1480], ["of", 1493], ["human", 1496], ["centrosomes", 1502], ["and", 1514], ["illustrates", 1518], ["the", 1530], ["power", 1534], ["of", 1540], ["super", 1543], ["-", 1548], ["resolution", 1549], ["microscopy", 1560], ["in", 1571], ["revealing", 1574], ["the", 1584], ["relative", 1588], ["localization", 1597], ["of", 1610], ["centriole", 1613], ["and", 1623], ["PCM", 1627], ["proteins", 1631], ["in", 1640], ["unprecedented", 1643], ["detail", 1657], [".", 1663]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "U.K ambulance services assess patients with suspected stroke using the Face Arm Speech Test (FAST). The Recognition Of Stroke In the Emergency Room (ROSIER) tool has been shown superior to the FAST in identifying strokes in emergency departments but has not previously been tested in the ambulance setting. We investigated whether ROSIER use by ambulance clinicians can improve stroke recognition. Ambulance clinicians used the ROSIER in place of the FAST to assess patients with suspected stroke. As the ROSIER includes all FAST elements, we calculated a FAST score from the ROSIER to enable comparisons between the two tools. Ambulance clinicians' provisional stroke diagnoses using the ROSIER and calculated FAST were compared with stroke consultants' diagnosis. We used stepwise logistic regression to compare the contribution of individual ROSIER and FAST items and patient demographics to the prediction of consultants' diagnoses. Sixty-four percent of strokes and 78% of nonstrokes identified by ambulance clinicians using the ROSIER were subsequently confirmed by a stroke consultant. There was no difference in the proportion of strokes correctly detected by the ROSIER or FAST with both displaying excellent levels of sensitivity. The ROSIER detected marginally more nonstroke cases than the FAST, but both demonstrated poor specificity. Facial weakness, arm weakness, seizure activity, age, and sex predicted consultants' diagnosis of stroke. The ROSIER was not better than the FAST for prehospital recognition of stroke. A revised version of the FAST incorporating assessment of seizure activity may improve stroke identification and decision making by ambulance clinicians.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "14137672ed6a4876bd365f25ca43ab63", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [64, 64], [21, 21], [123, 123], [253, 253], [268, 268], [7, 7], [82, 82], [239, 239], [177, 177]], "char_spans": [[662, 667], [378, 383], [119, 124], [735, 740], [1525, 1530], [1620, 1625], [54, 59], [490, 495], [1446, 1451], [1074, 1079]]}]}], "context_tokens": [["U.K", 0], ["ambulance", 4], ["services", 14], ["assess", 23], ["patients", 30], ["with", 39], ["suspected", 44], ["stroke", 54], ["using", 61], ["the", 67], ["Face", 71], ["Arm", 76], ["Speech", 80], ["Test", 87], ["(", 92], ["FAST", 93], [")", 97], [".", 98], ["The", 100], ["Recognition", 104], ["Of", 116], ["Stroke", 119], ["In", 126], ["the", 129], ["Emergency", 133], ["Room", 143], ["(", 148], ["ROSIER", 149], [")", 155], ["tool", 157], ["has", 162], ["been", 166], ["shown", 171], ["superior", 177], ["to", 186], ["the", 189], ["FAST", 193], ["in", 198], ["identifying", 201], ["strokes", 213], ["in", 221], ["emergency", 224], ["departments", 234], ["but", 246], ["has", 250], ["not", 254], ["previously", 258], ["been", 269], ["tested", 274], ["in", 281], ["the", 284], ["ambulance", 288], ["setting", 298], [".", 305], ["We", 307], ["investigated", 310], ["whether", 323], ["ROSIER", 331], ["use", 338], ["by", 342], ["ambulance", 345], ["clinicians", 355], ["can", 366], ["improve", 370], ["stroke", 378], ["recognition", 385], [".", 396], ["Ambulance", 398], ["clinicians", 408], ["used", 419], ["the", 424], ["ROSIER", 428], ["in", 435], ["place", 438], ["of", 444], ["the", 447], ["FAST", 451], ["to", 456], ["assess", 459], ["patients", 466], ["with", 475], ["suspected", 480], ["stroke", 490], [".", 496], ["As", 498], ["the", 501], ["ROSIER", 505], ["includes", 512], ["all", 521], ["FAST", 525], ["elements", 530], [",", 538], ["we", 540], ["calculated", 543], ["a", 554], ["FAST", 556], ["score", 561], ["from", 567], ["the", 572], ["ROSIER", 576], ["to", 583], ["enable", 586], ["comparisons", 593], ["between", 605], ["the", 613], ["two", 617], ["tools", 621], [".", 626], ["Ambulance", 628], ["clinicians", 638], ["'", 648], ["provisional", 650], ["stroke", 662], ["diagnoses", 669], ["using", 679], ["the", 685], ["ROSIER", 689], ["and", 696], ["calculated", 700], ["FAST", 711], ["were", 716], ["compared", 721], ["with", 730], ["stroke", 735], ["consultants", 742], ["'", 753], ["diagnosis", 755], [".", 764], ["We", 766], ["used", 769], ["stepwise", 774], ["logistic", 783], ["regression", 792], ["to", 803], ["compare", 806], ["the", 814], ["contribution", 818], ["of", 831], ["individual", 834], ["ROSIER", 845], ["and", 852], ["FAST", 856], ["items", 861], ["and", 867], ["patient", 871], ["demographics", 879], ["to", 892], ["the", 895], ["prediction", 899], ["of", 910], ["consultants", 913], ["'", 924], ["diagnoses", 926], [".", 935], ["Sixty", 937], ["-", 942], ["four", 943], ["percent", 948], ["of", 956], ["strokes", 959], ["and", 967], ["78", 971], ["%", 973], ["of", 975], ["nonstrokes", 978], ["identified", 989], ["by", 1000], ["ambulance", 1003], ["clinicians", 1013], ["using", 1024], ["the", 1030], ["ROSIER", 1034], ["were", 1041], ["subsequently", 1046], ["confirmed", 1059], ["by", 1069], ["a", 1072], ["stroke", 1074], ["consultant", 1081], [".", 1091], ["There", 1093], ["was", 1099], ["no", 1103], ["difference", 1106], ["in", 1117], ["the", 1120], ["proportion", 1124], ["of", 1135], ["strokes", 1138], ["correctly", 1146], ["detected", 1156], ["by", 1165], ["the", 1168], ["ROSIER", 1172], ["or", 1179], ["FAST", 1182], ["with", 1187], ["both", 1192], ["displaying", 1197], ["excellent", 1208], ["levels", 1218], ["of", 1225], ["sensitivity", 1228], [".", 1239], ["The", 1241], ["ROSIER", 1245], ["detected", 1252], ["marginally", 1261], ["more", 1272], ["nonstroke", 1277], ["cases", 1287], ["than", 1293], ["the", 1298], ["FAST", 1302], [",", 1306], ["but", 1308], ["both", 1312], ["demonstrated", 1317], ["poor", 1330], ["specificity", 1335], [".", 1346], ["Facial", 1348], ["weakness", 1355], [",", 1363], ["arm", 1365], ["weakness", 1369], [",", 1377], ["seizure", 1379], ["activity", 1387], [",", 1395], ["age", 1397], [",", 1400], ["and", 1402], ["sex", 1406], ["predicted", 1410], ["consultants", 1420], ["'", 1431], ["diagnosis", 1433], ["of", 1443], ["stroke", 1446], [".", 1452], ["The", 1454], ["ROSIER", 1458], ["was", 1465], ["not", 1469], ["better", 1473], ["than", 1480], ["the", 1485], ["FAST", 1489], ["for", 1494], ["prehospital", 1498], ["recognition", 1510], ["of", 1522], ["stroke", 1525], [".", 1531], ["A", 1533], ["revised", 1535], ["version", 1543], ["of", 1551], ["the", 1554], ["FAST", 1558], ["incorporating", 1563], ["assessment", 1577], ["of", 1588], ["seizure", 1591], ["activity", 1599], ["may", 1608], ["improve", 1612], ["stroke", 1620], ["identification", 1627], ["and", 1642], ["decision", 1646], ["making", 1655], ["by", 1662], ["ambulance", 1665], ["clinicians", 1675], [".", 1685]]}
{"context": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "c1fed25571dd435caf919c7770d931d8", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[70, 113]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["exons", 21], ["encoding", 27], ["the", 36], ["tyrosine", 40], ["kinase", 49], ["domain", 56], ["of", 63], ["the", 66], ["epidermal", 70], ["growth", 80], ["factor", 87], ["receptor", 94], ["(", 103], ["EGFR", 104], [")", 108], ["gene", 110], ["are", 115], ["found", 119], ["in", 125], ["human", 128], ["lung", 134], ["adenocarcinomas", 139], ["and", 155], ["are", 159], ["associated", 163], ["with", 174], ["sensitivity", 179], ["to", 191], ["the", 194], ["tyrosine", 198], ["kinase", 207], ["inhibitors", 214], ["gefitinib", 225], ["and", 235], ["erlotinib", 239], [".", 248], ["Nearly", 250], ["90", 257], ["%", 259], ["of", 261], ["the", 264], ["EGFR", 268], ["mutations", 273], ["are", 283], ["either", 287], ["short", 294], [",", 299], ["in", 301], ["-", 303], ["frame", 304], ["deletions", 310], ["in", 320], ["exon", 323], ["19", 328], ["or", 331], ["point", 334], ["mutations", 340], ["that", 350], ["result", 355], ["in", 362], ["substitution", 365], ["of", 378], ["arginine", 381], ["for", 390], ["leucine", 394], ["at", 402], ["amino", 405], ["acid", 411], ["858", 416], ["(", 420], ["L858R", 421], [")", 426], [".", 427], ["To", 429], ["study", 432], ["further", 438], ["the", 446], ["role", 450], ["of", 455], ["these", 458], ["mutations", 464], ["in", 474], ["the", 477], ["initiation", 481], ["and", 492], ["maintenance", 496], ["of", 508], ["lung", 511], ["cancer", 516], [",", 522], ["we", 524], ["have", 527], ["developed", 532], ["transgenic", 542], ["mice", 553], ["that", 558], ["express", 563], ["an", 571], ["exon", 574], ["19", 579], ["deletion", 582], ["mutant", 591], ["(", 598], ["EGFR(DeltaL747-S752", 599], [")", 618], [")", 619], ["or", 621], ["the", 624], ["L858R", 628], ["mutant", 634], ["(", 641], ["EGFR(L858R", 642], [")", 652], [")", 653], ["in", 655], ["type", 658], ["II", 663], ["pneumocytes", 666], ["under", 678], ["the", 684], ["control", 688], ["of", 696], ["doxycycline", 699], [".", 710], ["Expression", 712], ["of", 723], ["either", 726], ["EGFR", 733], ["mutant", 738], ["leads", 745], ["to", 751], ["the", 754], ["development", 758], ["of", 770], ["lung", 773], ["adenocarcinomas", 778], [".", 793], ["Two", 795], ["weeks", 799], ["after", 805], ["induction", 811], ["with", 821], ["doxycycline", 826], [",", 837], ["mice", 839], ["that", 844], ["express", 849], ["the", 857], ["EGFR(L858R", 861], [")", 871], ["allele", 873], ["show", 880], ["diffuse", 885], ["lung", 893], ["cancer", 898], ["highly", 905], ["reminiscent", 912], ["of", 924], ["human", 927], ["bronchioloalveolar", 933], ["carcinoma", 952], ["and", 962], ["later", 966], ["develop", 972], ["interspersed", 980], ["multifocal", 993], ["adenocarcinomas", 1004], [".", 1019], ["In", 1021], ["contrast", 1024], [",", 1032], ["mice", 1034], ["expressing", 1039], ["EGFR(DeltaL747-S752", 1050], [")", 1069], ["develop", 1071], ["multifocal", 1079], ["tumors", 1090], ["embedded", 1097], ["in", 1106], ["normal", 1109], ["lung", 1116], ["parenchyma", 1121], ["with", 1132], ["a", 1137], ["longer", 1139], ["latency", 1146], [".", 1153], ["With", 1155], ["mice", 1160], ["carrying", 1165], ["either", 1174], ["EGFR", 1181], ["allele", 1186], [",", 1192], ["withdrawal", 1194], ["of", 1205], ["doxycycline", 1208], ["(", 1220], ["to", 1221], ["reduce", 1224], ["expression", 1231], ["of", 1242], ["the", 1245], ["transgene", 1249], [")", 1258], ["or", 1260], ["treatment", 1263], ["with", 1273], ["erlotinib", 1278], ["(", 1288], ["to", 1289], ["inhibit", 1292], ["kinase", 1300], ["activity", 1307], [")", 1315], ["causes", 1317], ["rapid", 1324], ["tumor", 1330], ["regression", 1336], [",", 1346], ["as", 1348], ["assessed", 1351], ["by", 1360], ["magnetic", 1363], ["resonance", 1372], ["imaging", 1382], ["and", 1390], ["histopathology", 1394], [",", 1408], ["demonstrating", 1410], ["that", 1424], ["mutant", 1429], ["EGFR", 1436], ["is", 1441], ["required", 1444], ["for", 1453], ["tumor", 1457], ["maintenance", 1463], [".", 1474], ["These", 1476], ["models", 1482], ["may", 1489], ["be", 1493], ["useful", 1496], ["for", 1503], ["developing", 1507], ["improved", 1518], ["therapies", 1527], ["for", 1537], ["patients", 1541], ["with", 1550], ["lung", 1555], ["cancers", 1560], ["bearing", 1568], ["EGFR", 1576], ["mutations", 1581], [".", 1590]]}
{"context": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7a4fa67d3e7042d388d3a34034a61556", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[11, 13]], "char_spans": [[71, 92]]}]}], "context_tokens": [["Rigel", 0], ["Pharmaceuticals", 6], ["Inc", 22], ["is", 26], ["developing", 29], ["fostamatinib", 40], [",", 52], ["a", 54], ["prodrug", 56], ["of", 64], ["the", 67], ["spleen", 71], ["tyrosine", 78], ["kinase", 87], ["(", 94], ["Syk", 95], [")", 98], ["inhibitor", 100], ["R-406", 110], [",", 115], ["for", 117], ["the", 121], ["potential", 125], ["treatment", 135], ["of", 145], ["autoimmune", 148], ["diseases", 159], ["such", 168], ["as", 173], ["rheumatoid", 176], ["arthritis", 187], ["(", 197], ["RA", 198], [")", 200], [",", 201], ["idiopathic", 203], ["thrombocytopenic", 214], ["purpura", 231], ["(", 239], ["ITP", 240], [")", 243], ["and", 245], ["B", 249], ["-", 250], ["cell", 251], ["lymphomas", 256], [".", 265], ["Syk", 267], ["is", 271], ["a", 274], ["key", 276], ["mediator", 280], ["of", 289], ["Fc", 292], ["and", 295], ["B", 299], ["-", 300], ["cell", 301], ["receptor", 306], ["signaling", 315], ["in", 325], ["inflammatory", 328], ["cells", 341], [",", 346], ["such", 348], ["as", 353], ["B", 356], ["-", 357], ["cells", 358], [",", 363], ["mast", 365], ["cells", 370], [",", 375], ["macrophages", 377], ["and", 389], ["neutrophils", 393], [".", 404], ["Preclinical", 406], ["studies", 418], ["of", 426], ["R-406", 429], ["or", 435], ["fostamatinib", 438], ["demonstrated", 451], ["a", 464], ["significant", 466], ["reduction", 478], ["in", 488], ["major", 491], ["inflammatory", 497], ["mediators", 510], ["such", 520], ["as", 525], ["TNFalpha", 528], [",", 536], ["IL-1", 538], [",", 542], ["IL-6", 544], ["and", 549], ["IL-18", 553], [",", 558], ["leading", 560], ["to", 568], ["reduced", 571], ["inflammation", 579], ["and", 592], ["bone", 596], ["degradation", 601], ["in", 613], ["models", 616], ["of", 623], ["RA", 626], [".", 628], ["In", 630], ["a", 633], ["phase", 635], ["II", 641], ["clinical", 644], ["trial", 653], [",", 658], ["fostamatinib", 660], ["treatment", 673], ["effectively", 683], ["improved", 695], ["American", 704], ["College", 713], ["of", 721], ["Rheumatology", 724], ["response", 737], ["rates", 746], ["in", 752], ["patients", 755], ["with", 764], ["RA", 769], [".", 771], ["Preclinical", 773], ["studies", 785], ["and", 793], ["phase", 797], ["II", 803], ["trials", 806], ["also", 813], ["suggested", 818], ["the", 828], ["potential", 832], ["of", 842], ["using", 845], ["fostamatinib", 851], ["for", 864], ["the", 868], ["treatment", 872], ["of", 882], ["ITP", 885], ["and", 889], ["B", 893], ["-", 894], ["cell", 895], ["lymphomas", 900], [",", 909], ["by", 911], ["increasing", 914], ["platelet", 925], ["counts", 934], ["and", 941], ["inducing", 945], ["response", 954], ["rates", 963], [",", 968], ["respectively", 970], [".", 982], ["Fostamatinib", 984], ["is", 997], ["orally", 1000], ["bioavailable", 1007], ["and", 1020], ["was", 1024], ["well", 1028], ["tolerated", 1033], ["in", 1043], ["phase", 1046], ["I", 1052], ["and", 1054], ["II", 1058], ["trials", 1061], [",", 1067], ["with", 1069], ["the", 1074], ["most", 1078], ["common", 1083], ["side", 1090], ["effect", 1095], ["being", 1102], ["gastrointestinal", 1108], ["symptoms", 1125], [".", 1133], ["At", 1135], ["the", 1138], ["time", 1142], ["of", 1147], ["publication", 1150], [",", 1161], ["phase", 1163], ["II", 1169], ["trials", 1172], ["for", 1179], ["fostamatinib", 1183], ["were", 1196], ["ongoing", 1201], ["in", 1209], ["patients", 1212], ["with", 1221], ["RA", 1226], [",", 1228], ["ITP", 1230], ["and", 1234], ["B", 1238], ["-", 1239], ["cell", 1240], ["lymphomas", 1245], [".", 1254], ["The", 1256], ["Syk", 1260], ["inhibitor", 1264], ["appears", 1274], ["to", 1282], ["be", 1285], ["a", 1288], ["promising", 1290], ["therapeutic", 1300], ["for", 1312], ["immunological", 1316], ["diseases", 1330], [",", 1338], ["but", 1340], ["further", 1344], ["data", 1352], ["are", 1357], ["required", 1361], ["to", 1370], ["establish", 1373], ["the", 1383], ["efficacy", 1387], ["and", 1396], ["long", 1400], ["-", 1404], ["term", 1405], ["safety", 1410], ["of", 1417], ["the", 1420], ["drug", 1424], ["in", 1429], ["humans", 1432], [".", 1438]]}
{"context": "In Russia, an intradermal Diaskintest\u00ae drug has been designed, which is a recombinant tuberculosis allergen based on M. tuberculosis-- specific proteins: ESAT-6 and CFP-10 produced by a genetically modified Escherichia coli culture. Diaskintest\u00ae test and Mantoux test with 2TE PPD-L were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection. Diaskintest\u00ae showed a high sensitivity not only in active tuberculosis, but also in occult, the so-called latent, tuberculosis infection. This is suggested by the following evidence. The high percentage (83.8%) of positive responses to Diaskintest\u00ae is noted in children and adolescents with tuberculosis, receiving an intensive course of chemotherapy. Negative tests were observed only in minor forms at the resolution stage. In the children who had completed treatment, positive tests were seen in 78.3%, moreover in those with prior tuberculosis of intrathoracic lymph nodes; negative tests were observed not earlier than 18 months after start of treatment. The highest sensitivity of Diaskintest\u00ae was shown in children with early primary tuberculosis infection and through family contact with bacteria-excreting subjects (91.7%). These children may be judged with the highest assurance to have latent tuberculosis infection, the population of which is in an active state at the moment of the study. The children with early primary tuberculosis infection, but in no family contact with bacteria-excreting individuals, showed a lower percentage of positive responses to Diaskintest\u00ae both before (37.5%) and after (10%) treatment, which suggests that there must be a lower bacterial burden in the child. A high percentage of positive responses to Diaskintest\u00ae (76.2%) were found in subjects with hyperergic reactions to tuberculin. These were in only 16.7% in the group of patients receiving preventive therapy. In children and adolescents with a persistent positive Mantoux test (for more than 3 years), the response to Diaskintest\u00ae was negative in most cases since in early infection when mycobacteria propagated, the reaction to the drug was positive, but as 3 years pass the probability of the infection transition to the persistence stage is high--at that time the response to Diaskintest\u00ae becomes negative. Diaskintest\u00ae induces no delayed hypersensitivity associated with BCG vaccination, suggesting its high specificity. There were no positive reactions in patients with nonspecific lung diseases.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "bceaab52532745f2b18e2703008352a9", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[16, 16], [80, 80], [67, 67], [21, 21], [58, 58], [93, 93], [106, 106], [213, 213], [180, 180], [137, 137], [265, 265], [241, 241]], "char_spans": [[86, 97], [483, 494], [399, 410], [120, 133], [350, 361], [565, 576], [621, 632], [1248, 1259], [1042, 1053], [798, 809], [1541, 1552], [1411, 1422]]}]}], "context_tokens": [["In", 0], ["Russia", 3], [",", 9], ["an", 11], ["intradermal", 14], ["Diaskintest", 26], ["\u00ae", 37], ["drug", 39], ["has", 44], ["been", 48], ["designed", 53], [",", 61], ["which", 63], ["is", 69], ["a", 72], ["recombinant", 74], ["tuberculosis", 86], ["allergen", 99], ["based", 108], ["on", 114], ["M.", 117], ["tuberculosis--", 120], ["specific", 135], ["proteins", 144], [":", 152], ["ESAT-6", 154], ["and", 161], ["CFP-10", 165], ["produced", 172], ["by", 181], ["a", 184], ["genetically", 186], ["modified", 198], ["Escherichia", 207], ["coli", 219], ["culture", 224], [".", 231], ["Diaskintest", 233], ["\u00ae", 244], ["test", 246], ["and", 251], ["Mantoux", 255], ["test", 263], ["with", 268], ["2TE", 273], ["PPD", 277], ["-", 280], ["L", 281], ["were", 283], ["concurrently", 288], ["carried", 301], ["out", 309], ["in", 313], ["300", 316], ["children", 320], ["and", 329], ["adolescents", 333], ["with", 345], ["tuberculosis", 350], ["and", 363], ["followed", 367], ["up", 376], ["in", 379], ["risk", 382], ["groups", 387], ["at", 394], ["a", 397], ["tuberculosis", 399], ["dispensary", 412], ["to", 423], ["determine", 426], ["the", 436], ["sensitivity", 440], ["of", 452], ["the", 455], ["new", 459], ["skin", 463], ["test", 468], ["in", 473], ["active", 476], ["tuberculosis", 483], ["infection", 496], [".", 505], ["Diaskintest", 507], ["\u00ae", 518], ["showed", 520], ["a", 527], ["high", 529], ["sensitivity", 534], ["not", 546], ["only", 550], ["in", 555], ["active", 558], ["tuberculosis", 565], [",", 577], ["but", 579], ["also", 583], ["in", 588], ["occult", 591], [",", 597], ["the", 599], ["so", 603], ["-", 605], ["called", 606], ["latent", 613], [",", 619], ["tuberculosis", 621], ["infection", 634], [".", 643], ["This", 645], ["is", 650], ["suggested", 653], ["by", 663], ["the", 666], ["following", 670], ["evidence", 680], [".", 688], ["The", 690], ["high", 694], ["percentage", 699], ["(", 710], ["83.8", 711], ["%", 715], [")", 716], ["of", 718], ["positive", 721], ["responses", 730], ["to", 740], ["Diaskintest", 743], ["\u00ae", 754], ["is", 756], ["noted", 759], ["in", 765], ["children", 768], ["and", 777], ["adolescents", 781], ["with", 793], ["tuberculosis", 798], [",", 810], ["receiving", 812], ["an", 822], ["intensive", 825], ["course", 835], ["of", 842], ["chemotherapy", 845], [".", 857], ["Negative", 859], ["tests", 868], ["were", 874], ["observed", 879], ["only", 888], ["in", 893], ["minor", 896], ["forms", 902], ["at", 908], ["the", 911], ["resolution", 915], ["stage", 926], [".", 931], ["In", 933], ["the", 936], ["children", 940], ["who", 949], ["had", 953], ["completed", 957], ["treatment", 967], [",", 976], ["positive", 978], ["tests", 987], ["were", 993], ["seen", 998], ["in", 1003], ["78.3", 1006], ["%", 1010], [",", 1011], ["moreover", 1013], ["in", 1022], ["those", 1025], ["with", 1031], ["prior", 1036], ["tuberculosis", 1042], ["of", 1055], ["intrathoracic", 1058], ["lymph", 1072], ["nodes", 1078], [";", 1083], ["negative", 1085], ["tests", 1094], ["were", 1100], ["observed", 1105], ["not", 1114], ["earlier", 1118], ["than", 1126], ["18", 1131], ["months", 1134], ["after", 1141], ["start", 1147], ["of", 1153], ["treatment", 1156], [".", 1165], ["The", 1167], ["highest", 1171], ["sensitivity", 1179], ["of", 1191], ["Diaskintest", 1194], ["\u00ae", 1205], ["was", 1207], ["shown", 1211], ["in", 1217], ["children", 1220], ["with", 1229], ["early", 1234], ["primary", 1240], ["tuberculosis", 1248], ["infection", 1261], ["and", 1271], ["through", 1275], ["family", 1283], ["contact", 1290], ["with", 1298], ["bacteria", 1303], ["-", 1311], ["excreting", 1312], ["subjects", 1322], ["(", 1331], ["91.7", 1332], ["%", 1336], [")", 1337], [".", 1338], ["These", 1340], ["children", 1346], ["may", 1355], ["be", 1359], ["judged", 1362], ["with", 1369], ["the", 1374], ["highest", 1378], ["assurance", 1386], ["to", 1396], ["have", 1399], ["latent", 1404], ["tuberculosis", 1411], ["infection", 1424], [",", 1433], ["the", 1435], ["population", 1439], ["of", 1450], ["which", 1453], ["is", 1459], ["in", 1462], ["an", 1465], ["active", 1468], ["state", 1475], ["at", 1481], ["the", 1484], ["moment", 1488], ["of", 1495], ["the", 1498], ["study", 1502], [".", 1507], ["The", 1509], ["children", 1513], ["with", 1522], ["early", 1527], ["primary", 1533], ["tuberculosis", 1541], ["infection", 1554], [",", 1563], ["but", 1565], ["in", 1569], ["no", 1572], ["family", 1575], ["contact", 1582], ["with", 1590], ["bacteria", 1595], ["-", 1603], ["excreting", 1604], ["individuals", 1614], [",", 1625], ["showed", 1627], ["a", 1634], ["lower", 1636], ["percentage", 1642], ["of", 1653], ["positive", 1656], ["responses", 1665], ["to", 1675], ["Diaskintest", 1678], ["\u00ae", 1689], ["both", 1691], ["before", 1696], ["(", 1703], ["37.5", 1704], ["%", 1708], [")", 1709], ["and", 1711], ["after", 1715], ["(", 1721], ["10", 1722], ["%", 1724], [")", 1725], ["treatment", 1727], [",", 1736], ["which", 1738], ["suggests", 1744], ["that", 1753], ["there", 1758], ["must", 1764], ["be", 1769], ["a", 1772], ["lower", 1774], ["bacterial", 1780], ["burden", 1790], ["in", 1797], ["the", 1800], ["child", 1804], [".", 1809], ["A", 1811], ["high", 1813], ["percentage", 1818], ["of", 1829], ["positive", 1832], ["responses", 1841], ["to", 1851], ["Diaskintest", 1854], ["\u00ae", 1865], ["(", 1867], ["76.2", 1868], ["%", 1872], [")", 1873], ["were", 1875], ["found", 1880], ["in", 1886], ["subjects", 1889], ["with", 1898], ["hyperergic", 1903], ["reactions", 1914], ["to", 1924], ["tuberculin", 1927], [".", 1937], ["These", 1939], ["were", 1945], ["in", 1950], ["only", 1953], ["16.7", 1958], ["%", 1962], ["in", 1964], ["the", 1967], ["group", 1971], ["of", 1977], ["patients", 1980], ["receiving", 1989], ["preventive", 1999], ["therapy", 2010], [".", 2017], ["In", 2019], ["children", 2022], ["and", 2031], ["adolescents", 2035], ["with", 2047], ["a", 2052], ["persistent", 2054], ["positive", 2065], ["Mantoux", 2074], ["test", 2082], ["(", 2087], ["for", 2088], ["more", 2092], ["than", 2097], ["3", 2102], ["years", 2104], [")", 2109], [",", 2110], ["the", 2112], ["response", 2116], ["to", 2125], ["Diaskintest", 2128], ["\u00ae", 2139], ["was", 2141], ["negative", 2145], ["in", 2154], ["most", 2157], ["cases", 2162], ["since", 2168], ["in", 2174], ["early", 2177], ["infection", 2183], ["when", 2193], ["mycobacteria", 2198], ["propagated", 2211], [",", 2221], ["the", 2223], ["reaction", 2227], ["to", 2236], ["the", 2239], ["drug", 2243], ["was", 2248], ["positive", 2252], [",", 2260], ["but", 2262], ["as", 2266], ["3", 2269], ["years", 2271], ["pass", 2277], ["the", 2282], ["probability", 2286], ["of", 2298], ["the", 2301], ["infection", 2305], ["transition", 2315], ["to", 2326], ["the", 2329], ["persistence", 2333], ["stage", 2345], ["is", 2351], ["high", 2354], ["--", 2358], ["at", 2360], ["that", 2363], ["time", 2368], ["the", 2373], ["response", 2377], ["to", 2386], ["Diaskintest", 2389], ["\u00ae", 2400], ["becomes", 2402], ["negative", 2410], [".", 2418], ["Diaskintest", 2420], ["\u00ae", 2431], ["induces", 2433], ["no", 2441], ["delayed", 2444], ["hypersensitivity", 2452], ["associated", 2469], ["with", 2480], ["BCG", 2485], ["vaccination", 2489], [",", 2500], ["suggesting", 2502], ["its", 2513], ["high", 2517], ["specificity", 2522], [".", 2533], ["There", 2535], ["were", 2541], ["no", 2546], ["positive", 2549], ["reactions", 2558], ["in", 2568], ["patients", 2571], ["with", 2580], ["nonspecific", 2585], ["lung", 2597], ["diseases", 2602], [".", 2610]]}
{"context": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established. The mice transcribed a sufficient amount of alpha-galactosidase mRNA, but the steady-state levels of the enzyme protein were decreased in liver, kidney and heart, only residual activity being detected in these tissues. The mice will be useful for the clarification of the defective regulation of the structurally altered enzyme protein expressed by the mutant gene at the organ or individual level as well as for the evaluation of drugs that stabilize and/or activate the mutant alpha-galactosidase.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "0b96af4f05454584acfec3b094cb01bf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[114, 116], [38, 40], [6, 8]], "char_spans": [[654, 672], [219, 237], [42, 60]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["expressing", 16], ["a", 27], ["human", 29], ["mutant", 35], ["alpha", 42], ["-", 47], ["galactosidase", 48], ["with", 62], ["an", 67], ["R301Q", 70], ["substitution", 76], [",", 88], ["which", 90], ["was", 96], ["found", 100], ["in", 106], ["a", 109], ["patient", 111], ["with", 119], ["a", 124], ["variant", 126], ["form", 134], ["of", 139], ["Fabry", 142], ["disease", 148], [",", 155], ["were", 157], ["established", 162], [".", 173], ["The", 175], ["mice", 179], ["transcribed", 184], ["a", 196], ["sufficient", 198], ["amount", 209], ["of", 216], ["alpha", 219], ["-", 224], ["galactosidase", 225], ["mRNA", 239], [",", 243], ["but", 245], ["the", 249], ["steady", 253], ["-", 259], ["state", 260], ["levels", 266], ["of", 273], ["the", 276], ["enzyme", 280], ["protein", 287], ["were", 295], ["decreased", 300], ["in", 310], ["liver", 313], [",", 318], ["kidney", 320], ["and", 327], ["heart", 331], [",", 336], ["only", 338], ["residual", 343], ["activity", 352], ["being", 361], ["detected", 367], ["in", 376], ["these", 379], ["tissues", 385], [".", 392], ["The", 394], ["mice", 398], ["will", 403], ["be", 408], ["useful", 411], ["for", 418], ["the", 422], ["clarification", 426], ["of", 440], ["the", 443], ["defective", 447], ["regulation", 457], ["of", 468], ["the", 471], ["structurally", 475], ["altered", 488], ["enzyme", 496], ["protein", 503], ["expressed", 511], ["by", 521], ["the", 524], ["mutant", 528], ["gene", 535], ["at", 540], ["the", 543], ["organ", 547], ["or", 553], ["individual", 556], ["level", 567], ["as", 573], ["well", 576], ["as", 581], ["for", 584], ["the", 588], ["evaluation", 592], ["of", 603], ["drugs", 606], ["that", 612], ["stabilize", 617], ["and/or", 627], ["activate", 634], ["the", 643], ["mutant", 647], ["alpha", 654], ["-", 659], ["galactosidase", 660], [".", 673]]}
{"context": "Histone variant H2A.Z-containing nucleosomes are incorporated at most eukaryotic promoters. This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. Here, we show that promoter-proximal nucleosomes are highly heterogeneous for H2A.Z in Saccharomyces cerevisiae, with substantial representation of nucleosomes containing one, two, or zero H2A.Z molecules. SWR1-catalyzed H2A.Z replacement in vitro occurs in a stepwise and unidirectional fashion, one H2A.Z-H2B dimer at a time, producing heterotypic nucleosomes as intermediates and homotypic H2A.Z nucleosomes as end products. The ATPase activity of SWR1 is specifically stimulated by H2A-containing nucleosomes without ensuing histone H2A eviction. Remarkably, further addition of free H2A.Z-H2B dimer leads to hyperstimulation of ATPase activity, eviction of nucleosomal H2A-H2B, and deposition of H2A.Z-H2B. These results suggest that the combination of H2A-containing nucleosome and free H2A.Z-H2B dimer acting as both effector and substrate for SWR1 governs the specificity and outcome of the replacement reaction.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "9473f38b4dee41f9afdbbe99bea8b018", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[20, 20], [180, 180], [111, 111]], "char_spans": [[140, 143], [1096, 1099], [696, 699]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["are", 45], ["incorporated", 49], ["at", 62], ["most", 65], ["eukaryotic", 70], ["promoters", 81], [".", 90], ["This", 92], ["incorporation", 97], ["is", 111], ["mediated", 114], ["by", 123], ["the", 126], ["conserved", 130], ["SWR1", 140], ["complex", 145], [",", 152], ["which", 154], ["replaces", 160], ["histone", 169], ["H2A", 177], ["in", 181], ["canonical", 184], ["nucleosomes", 194], ["with", 206], ["H2A.Z", 211], ["in", 217], ["an", 220], ["ATP", 223], ["-", 226], ["dependent", 227], ["manner", 237], [".", 243], ["Here", 245], [",", 249], ["we", 251], ["show", 254], ["that", 259], ["promoter", 264], ["-", 272], ["proximal", 273], ["nucleosomes", 282], ["are", 294], ["highly", 298], ["heterogeneous", 305], ["for", 319], ["H2A.Z", 323], ["in", 329], ["Saccharomyces", 332], ["cerevisiae", 346], [",", 356], ["with", 358], ["substantial", 363], ["representation", 375], ["of", 390], ["nucleosomes", 393], ["containing", 405], ["one", 416], [",", 419], ["two", 421], [",", 424], ["or", 426], ["zero", 429], ["H2A.Z", 434], ["molecules", 440], [".", 449], ["SWR1-catalyzed", 451], ["H2A.Z", 466], ["replacement", 472], ["in", 484], ["vitro", 487], ["occurs", 493], ["in", 500], ["a", 503], ["stepwise", 505], ["and", 514], ["unidirectional", 518], ["fashion", 533], [",", 540], ["one", 542], ["H2A.Z", 546], ["-", 551], ["H2B", 552], ["dimer", 556], ["at", 562], ["a", 565], ["time", 567], [",", 571], ["producing", 573], ["heterotypic", 583], ["nucleosomes", 595], ["as", 607], ["intermediates", 610], ["and", 624], ["homotypic", 628], ["H2A.Z", 638], ["nucleosomes", 644], ["as", 656], ["end", 659], ["products", 663], [".", 671], ["The", 673], ["ATPase", 677], ["activity", 684], ["of", 693], ["SWR1", 696], ["is", 701], ["specifically", 704], ["stimulated", 717], ["by", 728], ["H2A", 731], ["-", 734], ["containing", 735], ["nucleosomes", 746], ["without", 758], ["ensuing", 766], ["histone", 774], ["H2A", 782], ["eviction", 786], [".", 794], ["Remarkably", 796], [",", 806], ["further", 808], ["addition", 816], ["of", 825], ["free", 828], ["H2A.Z", 833], ["-", 838], ["H2B", 839], ["dimer", 843], ["leads", 849], ["to", 855], ["hyperstimulation", 858], ["of", 875], ["ATPase", 878], ["activity", 885], [",", 893], ["eviction", 895], ["of", 904], ["nucleosomal", 907], ["H2A", 919], ["-", 922], ["H2B", 923], [",", 926], ["and", 928], ["deposition", 932], ["of", 943], ["H2A.Z", 946], ["-", 951], ["H2B.", 952], ["These", 957], ["results", 963], ["suggest", 971], ["that", 979], ["the", 984], ["combination", 988], ["of", 1000], ["H2A", 1003], ["-", 1006], ["containing", 1007], ["nucleosome", 1018], ["and", 1029], ["free", 1033], ["H2A.Z", 1038], ["-", 1043], ["H2B", 1044], ["dimer", 1048], ["acting", 1054], ["as", 1061], ["both", 1064], ["effector", 1069], ["and", 1078], ["substrate", 1082], ["for", 1092], ["SWR1", 1096], ["governs", 1101], ["the", 1109], ["specificity", 1113], ["and", 1125], ["outcome", 1129], ["of", 1137], ["the", 1140], ["replacement", 1144], ["reaction", 1156], [".", 1164]]}
{"context": "In many genomic studies, one works with genome-position-dependent data, e.g. ChIP-chip or ChIP-Seq scores. Using conventional tools, it can be difficult to get a good feel for the data, especially the distribution of features. This article argues that the so-called Hilbert curve visualization can complement genome browsers and help to get further insights into the structure of one's data. This is demonstrated with examples from different use cases. An open-source application, called HilbertVis, is presented that allows the user to produce and interactively explore such plots. http://www.ebi.ac.uk/huber-srv/hilbert/.", "qas": [{"question": "Which R/bioconductor package utilizes the Hilbert curve in order to visualize genomic data?", "answers": ["HilbertVis"], "qid": "0d068226dea64534a6062b1fe2b2d4a6", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["bioconductor", 8], ["package", 21], ["utilizes", 29], ["the", 38], ["Hilbert", 42], ["curve", 50], ["in", 56], ["order", 59], ["to", 65], ["visualize", 68], ["genomic", 78], ["data", 86], ["?", 90]], "detected_answers": [{"text": "HilbertVis", "token_spans": [[94, 94]], "char_spans": [[488, 497]]}]}], "context_tokens": [["In", 0], ["many", 3], ["genomic", 8], ["studies", 16], [",", 23], ["one", 25], ["works", 29], ["with", 35], ["genome", 40], ["-", 46], ["position", 47], ["-", 55], ["dependent", 56], ["data", 66], [",", 70], ["e.g.", 72], ["ChIP", 77], ["-", 81], ["chip", 82], ["or", 87], ["ChIP", 90], ["-", 94], ["Seq", 95], ["scores", 99], [".", 105], ["Using", 107], ["conventional", 113], ["tools", 126], [",", 131], ["it", 133], ["can", 136], ["be", 140], ["difficult", 143], ["to", 153], ["get", 156], ["a", 160], ["good", 162], ["feel", 167], ["for", 172], ["the", 176], ["data", 180], [",", 184], ["especially", 186], ["the", 197], ["distribution", 201], ["of", 214], ["features", 217], [".", 225], ["This", 227], ["article", 232], ["argues", 240], ["that", 247], ["the", 252], ["so", 256], ["-", 258], ["called", 259], ["Hilbert", 266], ["curve", 274], ["visualization", 280], ["can", 294], ["complement", 298], ["genome", 309], ["browsers", 316], ["and", 325], ["help", 329], ["to", 334], ["get", 337], ["further", 341], ["insights", 349], ["into", 358], ["the", 363], ["structure", 367], ["of", 377], ["one", 380], ["'s", 383], ["data", 386], [".", 390], ["This", 392], ["is", 397], ["demonstrated", 400], ["with", 413], ["examples", 418], ["from", 427], ["different", 432], ["use", 442], ["cases", 446], [".", 451], ["An", 453], ["open", 456], ["-", 460], ["source", 461], ["application", 468], [",", 479], ["called", 481], ["HilbertVis", 488], [",", 498], ["is", 500], ["presented", 503], ["that", 513], ["allows", 518], ["the", 525], ["user", 529], ["to", 534], ["produce", 537], ["and", 545], ["interactively", 549], ["explore", 563], ["such", 571], ["plots", 576], [".", 581], ["http://www.ebi.ac.uk", 583], ["/", 603], ["huber", 604], ["-", 609], ["srv", 610], ["/", 613], ["hilbert/.", 614]]}
{"context": "Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300\u00a0mg per day) due to intolerance, in comparison to optimal-dose imatinib (\u2265300\u00a0mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420\u00a0days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720\u00a0days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "169d1ca25e78425dbd60b6192286d3dd", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[4, 6]], "char_spans": [[23, 29]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["the", 13], ["first", 17], ["BCR", 23], ["-", 26], ["ABL", 27], ["tyrosine", 31], ["kinase", 40], ["inhibitor", 47], ["to", 57], ["become", 60], ["clinically", 67], ["available", 78], [".", 87], ["In", 89], ["this", 92], ["study", 97], [",", 102], ["we", 104], ["retrospectively", 107], ["evaluated", 123], ["the", 133], ["long", 137], ["-", 141], ["term", 142], ["efficacy", 147], ["of", 156], ["low", 159], ["-", 162], ["dose", 163], ["imatinib", 168], ["(", 177], ["final", 178], ["maintenance", 184], ["dose", 196], ["<", 201], ["300", 202], ["mg", 206], ["per", 209], ["day", 213], [")", 216], ["due", 218], ["to", 222], ["intolerance", 225], [",", 236], ["in", 238], ["comparison", 241], ["to", 252], ["optimal", 255], ["-", 262], ["dose", 263], ["imatinib", 268], ["(", 277], ["\u2265300", 278], ["mg", 283], ["per", 286], ["day", 290], [")", 293], ["in", 295], ["patients", 298], ["with", 307], ["Philadelphia", 312], ["chromosome", 325], ["-", 335], ["positive", 336], ["chronic", 345], ["myeloid", 353], ["leukemia", 361], ["in", 370], ["the", 373], ["chronic", 377], ["phase", 385], [".", 390], ["The", 392], ["Kaplan", 396], ["-", 402], ["Meier", 403], ["estimates", 409], ["of", 419], ["the", 422], ["median", 426], ["time", 433], ["to", 438], ["complete", 441], ["cytogenetic", 450], ["response", 462], [",", 470], ["major", 472], ["molecular", 478], ["response", 488], [",", 496], ["and", 498], ["complete", 502], ["molecular", 511], ["response", 521], ["were", 530], ["longer", 535], ["for", 542], ["31", 546], ["patients", 549], ["receiving", 558], ["low", 568], ["-", 571], ["dose", 572], ["imatinib", 577], ["(", 586], ["360", 587], [",", 590], ["1360", 592], [",", 596], ["and", 598], ["1420", 602], ["days", 607], [",", 611], ["respectively", 613], [")", 625], ["than", 627], ["74", 632], ["patients", 635], ["receiving", 644], ["optimal", 654], ["-", 661], ["dose", 662], ["imatinib", 667], ["(", 676], ["170", 677], [",", 680], ["420", 682], [",", 685], ["and", 687], ["720", 691], ["days", 695], [",", 699], ["respectively", 701], [")", 713], [".", 714], ["However", 716], [",", 723], ["the", 725], ["differences", 729], ["in", 741], ["response", 744], ["shrank", 753], ["over", 760], ["time", 765], ["and", 770], ["progression", 774], ["-", 785], ["free", 786], ["survival", 791], ["were", 800], ["comparable", 805], ["between", 816], ["the", 824], ["two", 828], ["groups", 832], [".", 838], ["These", 840], ["findings", 846], ["suggest", 855], ["that", 863], ["long", 868], ["-", 872], ["term", 873], ["treatment", 878], ["with", 888], ["low", 893], ["-", 896], ["dose", 897], ["imatinib", 902], ["is", 911], ["an", 914], ["acceptable", 917], ["alternative", 928], ["for", 940], ["patients", 944], ["with", 953], ["intolerance", 958], ["to", 970], ["the", 973], ["optimal", 977], ["dose", 985], [".", 989]]}
{"context": "Embryonic neuroepithelia and adult subventricular zone (SVZ) stem and progenitor cells express nestin. We characterized a transgenic line that expresses enhanced green fluorescent protein (eGFP) specified to neural tissue by the second intronic enhancer of the nestin promoter that had several novel features. During embryogenesis, the dorsal telencephalon contained many and the ventral telencephalon few eGFP+ cells. eGFP+ cells were found in postnatal and adult neurogenic regions. eGFP+ cells in the SVZ expressed multiple phenotype markers, glial fibrillary acidic protein, Dlx, and neuroblast-specific molecules suggesting the transgene is expressed through the lineage. eGFP+ cell numbers increased in the SVZ after cortical injury, suggesting this line will be useful in probing postinjury neurogenesis. In non-neurogenic regions, eGFP was strongly expressed in oligodendrocyte progenitors, but not in astrocytes, even when they were reactive. This eGFP+ mouse will facilitate studies of proliferative neuroepithelia and adult neurogenesis, as well as of parenchymal oligodendrocytes.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "1f13212b55544ebc9031055963334233", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[41, 41], [14, 14]], "char_spans": [[261, 266], [95, 100]]}]}], "context_tokens": [["Embryonic", 0], ["neuroepithelia", 10], ["and", 25], ["adult", 29], ["subventricular", 35], ["zone", 50], ["(", 55], ["SVZ", 56], [")", 59], ["stem", 61], ["and", 66], ["progenitor", 70], ["cells", 81], ["express", 87], ["nestin", 95], [".", 101], ["We", 103], ["characterized", 106], ["a", 120], ["transgenic", 122], ["line", 133], ["that", 138], ["expresses", 143], ["enhanced", 153], ["green", 162], ["fluorescent", 168], ["protein", 180], ["(", 188], ["eGFP", 189], [")", 193], ["specified", 195], ["to", 205], ["neural", 208], ["tissue", 215], ["by", 222], ["the", 225], ["second", 229], ["intronic", 236], ["enhancer", 245], ["of", 254], ["the", 257], ["nestin", 261], ["promoter", 268], ["that", 277], ["had", 282], ["several", 286], ["novel", 294], ["features", 300], [".", 308], ["During", 310], ["embryogenesis", 317], [",", 330], ["the", 332], ["dorsal", 336], ["telencephalon", 343], ["contained", 357], ["many", 367], ["and", 372], ["the", 376], ["ventral", 380], ["telencephalon", 388], ["few", 402], ["eGFP+", 406], ["cells", 412], [".", 417], ["eGFP+", 419], ["cells", 425], ["were", 431], ["found", 436], ["in", 442], ["postnatal", 445], ["and", 455], ["adult", 459], ["neurogenic", 465], ["regions", 476], [".", 483], ["eGFP+", 485], ["cells", 491], ["in", 497], ["the", 500], ["SVZ", 504], ["expressed", 508], ["multiple", 518], ["phenotype", 527], ["markers", 537], [",", 544], ["glial", 546], ["fibrillary", 552], ["acidic", 563], ["protein", 570], [",", 577], ["Dlx", 579], [",", 582], ["and", 584], ["neuroblast", 588], ["-", 598], ["specific", 599], ["molecules", 608], ["suggesting", 618], ["the", 629], ["transgene", 633], ["is", 643], ["expressed", 646], ["through", 656], ["the", 664], ["lineage", 668], [".", 675], ["eGFP+", 677], ["cell", 683], ["numbers", 688], ["increased", 696], ["in", 706], ["the", 709], ["SVZ", 713], ["after", 717], ["cortical", 723], ["injury", 732], [",", 738], ["suggesting", 740], ["this", 751], ["line", 756], ["will", 761], ["be", 766], ["useful", 769], ["in", 776], ["probing", 779], ["postinjury", 787], ["neurogenesis", 798], [".", 810], ["In", 812], ["non", 815], ["-", 818], ["neurogenic", 819], ["regions", 830], [",", 837], ["eGFP", 839], ["was", 844], ["strongly", 848], ["expressed", 857], ["in", 867], ["oligodendrocyte", 870], ["progenitors", 886], [",", 897], ["but", 899], ["not", 903], ["in", 907], ["astrocytes", 910], [",", 920], ["even", 922], ["when", 927], ["they", 932], ["were", 937], ["reactive", 942], [".", 950], ["This", 952], ["eGFP+", 957], ["mouse", 963], ["will", 969], ["facilitate", 974], ["studies", 985], ["of", 993], ["proliferative", 996], ["neuroepithelia", 1010], ["and", 1025], ["adult", 1029], ["neurogenesis", 1035], [",", 1047], ["as", 1049], ["well", 1052], ["as", 1057], ["of", 1060], ["parenchymal", 1063], ["oligodendrocytes", 1075], [".", 1091]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "The study of cancer predisposition syndromes presents unique opportunities to gain insights into the genetic events associated with tumor pathogenesis. Individuals with two inherited cancer syndromes, neurofibromatosis 1 (NF1) and neurofibromatosis 2 (NF2), develop both benign and malignant tumors. The corresponding genes mutated in these two disorders encode tumor suppressor proteins, termed neurofibromin (NF1) and merlin (NF2), which function in novel ways to regulate cell growth and differentiation. Neurofibromin inhibits cell proliferation, at least in part, by modulating mitogenic pathway signaling through inactivation of p21-ras. In contrast, merlin may act as a membrane-associated molecular switch that regulates cell-cell and cell-matrix signals transduced by cell surface receptors. Significant progress in our understanding of the genetics and biology of NF1 and NF2 has elucidated the roles of these genes in tumor initiation and progression.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "15f2966fce5a4fd499e583236823391a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[63, 63], [31, 31], [143, 143]], "char_spans": [[411, 413], [222, 224], [874, 876]]}]}], "context_tokens": [["The", 0], ["study", 4], ["of", 10], ["cancer", 13], ["predisposition", 20], ["syndromes", 35], ["presents", 45], ["unique", 54], ["opportunities", 61], ["to", 75], ["gain", 78], ["insights", 83], ["into", 92], ["the", 97], ["genetic", 101], ["events", 109], ["associated", 116], ["with", 127], ["tumor", 132], ["pathogenesis", 138], [".", 150], ["Individuals", 152], ["with", 164], ["two", 169], ["inherited", 173], ["cancer", 183], ["syndromes", 190], [",", 199], ["neurofibromatosis", 201], ["1", 219], ["(", 221], ["NF1", 222], [")", 225], ["and", 227], ["neurofibromatosis", 231], ["2", 249], ["(", 251], ["NF2", 252], [")", 255], [",", 256], ["develop", 258], ["both", 266], ["benign", 271], ["and", 278], ["malignant", 282], ["tumors", 292], [".", 298], ["The", 300], ["corresponding", 304], ["genes", 318], ["mutated", 324], ["in", 332], ["these", 335], ["two", 341], ["disorders", 345], ["encode", 355], ["tumor", 362], ["suppressor", 368], ["proteins", 379], [",", 387], ["termed", 389], ["neurofibromin", 396], ["(", 410], ["NF1", 411], [")", 414], ["and", 416], ["merlin", 420], ["(", 427], ["NF2", 428], [")", 431], [",", 432], ["which", 434], ["function", 440], ["in", 449], ["novel", 452], ["ways", 458], ["to", 463], ["regulate", 466], ["cell", 475], ["growth", 480], ["and", 487], ["differentiation", 491], [".", 506], ["Neurofibromin", 508], ["inhibits", 522], ["cell", 531], ["proliferation", 536], [",", 549], ["at", 551], ["least", 554], ["in", 560], ["part", 563], [",", 567], ["by", 569], ["modulating", 572], ["mitogenic", 583], ["pathway", 593], ["signaling", 601], ["through", 611], ["inactivation", 619], ["of", 632], ["p21-ras", 635], [".", 642], ["In", 644], ["contrast", 647], [",", 655], ["merlin", 657], ["may", 664], ["act", 668], ["as", 672], ["a", 675], ["membrane", 677], ["-", 685], ["associated", 686], ["molecular", 697], ["switch", 707], ["that", 714], ["regulates", 719], ["cell", 729], ["-", 733], ["cell", 734], ["and", 739], ["cell", 743], ["-", 747], ["matrix", 748], ["signals", 755], ["transduced", 763], ["by", 774], ["cell", 777], ["surface", 782], ["receptors", 790], [".", 799], ["Significant", 801], ["progress", 813], ["in", 822], ["our", 825], ["understanding", 829], ["of", 843], ["the", 846], ["genetics", 850], ["and", 859], ["biology", 863], ["of", 871], ["NF1", 874], ["and", 878], ["NF2", 882], ["has", 886], ["elucidated", 890], ["the", 901], ["roles", 905], ["of", 911], ["these", 914], ["genes", 920], ["in", 926], ["tumor", 929], ["initiation", 935], ["and", 946], ["progression", 950], [".", 961]]}
{"context": "To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12\u2009weeks in patients with type 2 diabetes. This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to \u226410%] to receive 1, 5, 10, 25, or 50\u2009mg empagliflozin once daily (QD), or placebo, or open-label sitagliptin (100\u2009mg QD), added to metformin for 12\u2009weeks. The primary endpoint was change in HbA1c from baseline to week 12 (empagliflozin groups versus placebo). Reductions in HbA1c of -0.09 to -0.56% were observed with empagliflozin after 12\u2009weeks, versus an increase of 0.15% with placebo (baseline: 7.8-8.1%). Compared with placebo, empagliflozin doses from 5 to 50\u2009mg resulted in reductions in fasting plasma glucose (-2 to -28\u2009mg/dl vs. 5\u2009mg/dl with placebo; p\u2009<\u20090.0001) and body weight (-2.3 to -2.9\u2009kg vs. -1.2\u2009kg; p\u2009<\u20090.01). Frequency of adverse events was generally similar with empagliflozin (29.6-48.6%), placebo (36.6%) and sitagliptin (35.2%). Hypoglycaemia rates were very low and balanced among groups. Most frequent adverse events with empagliflozin were urinary tract infections (4.0% vs. 2.8% with placebo) and pollakiuria (2.5% vs. 1.4% with placebo). Genital infections were reported only with empagliflozin (4.0%). Once daily empagliflozin as add-on therapy to metformin was well tolerated except for increased genital infections and resulted in reductions in HbA1c, fasting plasma glucose and body weight in patients with type 2 diabetes inadequately controlled on metformin monotherapy.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "42c9f1c1eae84fa0885493a31db38248", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[11, 11]], "char_spans": [[63, 67]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["effects", 16], ["of", 24], ["the", 27], ["sodium", 31], ["glucose", 38], ["cotransporter", 46], ["2", 60], ["(", 62], ["SGLT2", 63], [")", 68], ["inhibitor", 70], ["empagliflozin", 80], ["added", 94], ["to", 100], ["metformin", 103], ["for", 113], ["12", 117], ["weeks", 120], ["in", 126], ["patients", 129], ["with", 138], ["type", 143], ["2", 148], ["diabetes", 150], [".", 158], ["This", 160], ["dose", 165], ["-", 169], ["ranging", 170], [",", 177], ["double", 179], ["-", 185], ["blind", 186], [",", 191], ["placebo", 193], ["-", 200], ["controlled", 201], ["trial", 212], ["randomized", 218], ["495", 229], ["participants", 233], ["with", 246], ["type", 251], ["2", 256], ["diabetes", 258], ["inadequately", 267], ["controlled", 280], ["on", 291], ["metformin", 294], ["[", 304], ["haemoglobin", 305], ["A1c", 317], ["(", 321], ["HbA1c", 322], [")", 327], [">", 329], ["7", 330], ["to", 332], ["\u226410", 335], ["%", 338], ["]", 339], ["to", 341], ["receive", 344], ["1", 352], [",", 353], ["5", 355], [",", 356], ["10", 358], [",", 360], ["25", 362], [",", 364], ["or", 366], ["50", 369], ["mg", 372], ["empagliflozin", 375], ["once", 389], ["daily", 394], ["(", 400], ["QD", 401], [")", 403], [",", 404], ["or", 406], ["placebo", 409], [",", 416], ["or", 418], ["open", 421], ["-", 425], ["label", 426], ["sitagliptin", 432], ["(", 444], ["100", 445], ["mg", 449], ["QD", 452], [")", 454], [",", 455], ["added", 457], ["to", 463], ["metformin", 466], ["for", 476], ["12", 480], ["weeks", 483], [".", 488], ["The", 490], ["primary", 494], ["endpoint", 502], ["was", 511], ["change", 515], ["in", 522], ["HbA1c", 525], ["from", 531], ["baseline", 536], ["to", 545], ["week", 548], ["12", 553], ["(", 556], ["empagliflozin", 557], ["groups", 571], ["versus", 578], ["placebo", 585], [")", 592], [".", 593], ["Reductions", 595], ["in", 606], ["HbA1c", 609], ["of", 615], ["-0.09", 618], ["to", 624], ["-0.56", 627], ["%", 632], ["were", 634], ["observed", 639], ["with", 648], ["empagliflozin", 653], ["after", 667], ["12", 673], ["weeks", 676], [",", 681], ["versus", 683], ["an", 690], ["increase", 693], ["of", 702], ["0.15", 705], ["%", 709], ["with", 711], ["placebo", 716], ["(", 724], ["baseline", 725], [":", 733], ["7.8", 735], ["-", 738], ["8.1", 739], ["%", 742], [")", 743], [".", 744], ["Compared", 746], ["with", 755], ["placebo", 760], [",", 767], ["empagliflozin", 769], ["doses", 783], ["from", 789], ["5", 794], ["to", 796], ["50", 799], ["mg", 802], ["resulted", 805], ["in", 814], ["reductions", 817], ["in", 828], ["fasting", 831], ["plasma", 839], ["glucose", 846], ["(", 854], ["-2", 855], ["to", 858], ["-28", 861], ["mg", 865], ["/", 867], ["dl", 868], ["vs.", 871], ["5", 875], ["mg", 877], ["/", 879], ["dl", 880], ["with", 883], ["placebo", 888], [";", 895], ["p", 897], ["<", 899], ["0.0001", 901], [")", 907], ["and", 909], ["body", 913], ["weight", 918], ["(", 925], ["-2.3", 926], ["to", 931], ["-2.9", 934], ["kg", 939], ["vs.", 942], ["-1.2", 946], ["kg", 951], [";", 953], ["p", 955], ["<", 957], ["0.01", 959], [")", 963], [".", 964], ["Frequency", 966], ["of", 976], ["adverse", 979], ["events", 987], ["was", 994], ["generally", 998], ["similar", 1008], ["with", 1016], ["empagliflozin", 1021], ["(", 1035], ["29.6", 1036], ["-", 1040], ["48.6", 1041], ["%", 1045], [")", 1046], [",", 1047], ["placebo", 1049], ["(", 1057], ["36.6", 1058], ["%", 1062], [")", 1063], ["and", 1065], ["sitagliptin", 1069], ["(", 1081], ["35.2", 1082], ["%", 1086], [")", 1087], [".", 1088], ["Hypoglycaemia", 1090], ["rates", 1104], ["were", 1110], ["very", 1115], ["low", 1120], ["and", 1124], ["balanced", 1128], ["among", 1137], ["groups", 1143], [".", 1149], ["Most", 1151], ["frequent", 1156], ["adverse", 1165], ["events", 1173], ["with", 1180], ["empagliflozin", 1185], ["were", 1199], ["urinary", 1204], ["tract", 1212], ["infections", 1218], ["(", 1229], ["4.0", 1230], ["%", 1233], ["vs.", 1235], ["2.8", 1239], ["%", 1242], ["with", 1244], ["placebo", 1249], [")", 1256], ["and", 1258], ["pollakiuria", 1262], ["(", 1274], ["2.5", 1275], ["%", 1278], ["vs.", 1280], ["1.4", 1284], ["%", 1287], ["with", 1289], ["placebo", 1294], [")", 1301], [".", 1302], ["Genital", 1304], ["infections", 1312], ["were", 1323], ["reported", 1328], ["only", 1337], ["with", 1342], ["empagliflozin", 1347], ["(", 1361], ["4.0", 1362], ["%", 1365], [")", 1366], [".", 1367], ["Once", 1369], ["daily", 1374], ["empagliflozin", 1380], ["as", 1394], ["add", 1397], ["-", 1400], ["on", 1401], ["therapy", 1404], ["to", 1412], ["metformin", 1415], ["was", 1425], ["well", 1429], ["tolerated", 1434], ["except", 1444], ["for", 1451], ["increased", 1455], ["genital", 1465], ["infections", 1473], ["and", 1484], ["resulted", 1488], ["in", 1497], ["reductions", 1500], ["in", 1511], ["HbA1c", 1514], [",", 1519], ["fasting", 1521], ["plasma", 1529], ["glucose", 1536], ["and", 1544], ["body", 1548], ["weight", 1553], ["in", 1560], ["patients", 1563], ["with", 1572], ["type", 1577], ["2", 1582], ["diabetes", 1584], ["inadequately", 1593], ["controlled", 1606], ["on", 1617], ["metformin", 1620], ["monotherapy", 1630], [".", 1641]]}
{"context": "Heat shock proteins (Hsp) are known to enhance cell survival under various stress conditions. In the heart, the small Hsp20 has emerged as a key mediator of protection against apoptosis, remodeling, and ischemia/reperfusion injury. Moreover, Hsp20 has been implicated in modulation of cardiac contractility ex vivo. The objective of this study was to determine the in vivo role of Hsp20 in the heart and the mechanisms underlying its regulatory effects in calcium (Ca) cycling. Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN. Furthermore, recombinant protein studies confirmed a physical interaction between AA 73 to 160 in Hsp20 and AA 163 to 330 in PP1. Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", "qas": [{"question": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", "answers": ["Protein phosphatase 1", "PP1"], "qid": "04c9df99ae544e2a96f40f77fd2378b2", "question_tokens": [["Which", 0], ["protein", 6], ["phosphatase", 14], ["has", 26], ["been", 30], ["found", 35], ["to", 41], ["interact", 44], ["with", 53], ["the", 58], ["heat", 62], ["shock", 67], ["protein", 73], [",", 80], ["HSP20", 82], ["?", 87]], "detected_answers": [{"text": "PP1", "token_spans": [[227, 227], [175, 175], [254, 254]], "char_spans": [[1374, 1376], [1031, 1033], [1513, 1515]]}]}], "context_tokens": [["Heat", 0], ["shock", 5], ["proteins", 11], ["(", 20], ["Hsp", 21], [")", 24], ["are", 26], ["known", 30], ["to", 36], ["enhance", 39], ["cell", 47], ["survival", 52], ["under", 61], ["various", 67], ["stress", 75], ["conditions", 82], [".", 92], ["In", 94], ["the", 97], ["heart", 101], [",", 106], ["the", 108], ["small", 112], ["Hsp20", 118], ["has", 124], ["emerged", 128], ["as", 136], ["a", 139], ["key", 141], ["mediator", 145], ["of", 154], ["protection", 157], ["against", 168], ["apoptosis", 176], [",", 185], ["remodeling", 187], [",", 197], ["and", 199], ["ischemia", 203], ["/", 211], ["reperfusion", 212], ["injury", 224], [".", 230], ["Moreover", 232], [",", 240], ["Hsp20", 242], ["has", 248], ["been", 252], ["implicated", 257], ["in", 268], ["modulation", 271], ["of", 282], ["cardiac", 285], ["contractility", 293], ["ex", 307], ["vivo", 310], [".", 314], ["The", 316], ["objective", 320], ["of", 330], ["this", 333], ["study", 338], ["was", 344], ["to", 348], ["determine", 351], ["the", 361], ["in", 365], ["vivo", 368], ["role", 373], ["of", 378], ["Hsp20", 381], ["in", 387], ["the", 390], ["heart", 394], ["and", 400], ["the", 404], ["mechanisms", 408], ["underlying", 419], ["its", 430], ["regulatory", 434], ["effects", 445], ["in", 453], ["calcium", 456], ["(", 464], ["Ca", 465], [")", 467], ["cycling", 469], [".", 476], ["Hsp20", 478], ["overexpression", 484], ["in", 499], ["intact", 502], ["animals", 509], ["resulted", 517], ["in", 526], ["significant", 529], ["enhancement", 541], ["of", 553], ["cardiac", 556], ["function", 564], [",", 572], ["coupled", 574], ["with", 582], ["augmented", 587], ["Ca", 597], ["cycling", 600], ["and", 608], ["sarcoplasmic", 612], ["reticulum", 625], ["Ca", 635], ["load", 638], ["in", 643], ["isolated", 646], ["cardiomyocytes", 655], [".", 669], ["This", 671], ["was", 676], ["associated", 680], ["with", 691], ["specific", 696], ["increases", 705], ["in", 715], ["phosphorylation", 718], ["of", 734], ["phospholamban", 737], ["(", 751], ["PLN", 752], [")", 755], ["at", 757], ["both", 760], ["Ser16", 765], ["and", 771], ["Thr17", 775], [",", 780], ["relieving", 782], ["its", 792], ["inhibition", 796], ["of", 807], ["the", 810], ["apparent", 814], ["Ca", 823], ["affinity", 826], ["of", 835], ["SERCA2a", 838], [".", 845], ["Accordingly", 847], [",", 858], ["the", 860], ["inotropic", 864], ["effects", 874], ["of", 882], ["Hsp20", 885], ["were", 891], ["abrogated", 896], ["in", 906], ["cardiomyocytes", 909], ["expressing", 924], ["nonphosphorylatable", 935], ["PLN", 955], ["(", 959], ["S16A", 960], ["/", 964], ["T17A", 965], [")", 969], [".", 970], ["Interestingly", 972], [",", 985], ["the", 987], ["activity", 991], ["of", 1000], ["type", 1003], ["1", 1008], ["protein", 1010], ["phosphatase", 1018], ["(", 1030], ["PP1", 1031], [")", 1034], [",", 1035], ["a", 1037], ["known", 1039], ["regulator", 1045], ["of", 1055], ["PLN", 1058], ["signaling", 1062], [",", 1071], ["was", 1073], ["significantly", 1077], ["reduced", 1091], ["by", 1099], ["Hsp20", 1102], ["overexpression", 1108], [",", 1122], ["suggesting", 1124], ["that", 1135], ["the", 1140], ["Hsp20", 1144], ["stimulatory", 1150], ["effects", 1162], ["are", 1170], ["partially", 1174], ["mediated", 1184], ["through", 1193], ["the", 1201], ["PP1-PLN", 1205], ["axis", 1213], [".", 1217], ["This", 1219], ["hypothesis", 1224], ["was", 1235], ["supported", 1239], ["by", 1249], ["cell", 1252], ["fractionation", 1257], [",", 1270], ["coimmunoprecipitation", 1272], [",", 1293], ["and", 1295], ["coimmunolocalization", 1299], ["studies", 1320], [",", 1327], ["which", 1329], ["revealed", 1335], ["an", 1344], ["association", 1347], ["between", 1359], ["Hsp20", 1367], [",", 1372], ["PP1", 1374], [",", 1377], ["and", 1379], ["PLN", 1383], [".", 1386], ["Furthermore", 1388], [",", 1399], ["recombinant", 1401], ["protein", 1413], ["studies", 1421], ["confirmed", 1429], ["a", 1439], ["physical", 1441], ["interaction", 1450], ["between", 1462], ["AA", 1470], ["73", 1473], ["to", 1476], ["160", 1479], ["in", 1483], ["Hsp20", 1486], ["and", 1492], ["AA", 1496], ["163", 1499], ["to", 1503], ["330", 1506], ["in", 1510], ["PP1", 1513], [".", 1516], ["Hsp20", 1518], ["is", 1524], ["a", 1527], ["novel", 1529], ["regulator", 1535], ["of", 1545], ["sarcoplasmic", 1548], ["reticulum", 1561], ["Ca", 1571], ["cycling", 1574], ["by", 1582], ["targeting", 1585], ["the", 1595], ["PP1-PLN", 1599], ["axis", 1607], [".", 1611], ["These", 1613], ["findings", 1619], [",", 1627], ["coupled", 1629], ["with", 1637], ["the", 1642], ["well", 1646], ["-", 1650], ["recognized", 1651], ["cardioprotective", 1662], ["role", 1679], ["of", 1684], ["Hsp20", 1687], [",", 1692], ["suggest", 1694], ["a", 1702], ["dual", 1704], ["benefit", 1709], ["of", 1717], ["targeting", 1720], ["Hsp20", 1730], ["in", 1736], ["heart", 1739], ["disease", 1745], [".", 1752]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA. To better understand the genetic basis of this response, we utilized a controlled in vitro system and Next Generation sequencing to determine and compare RNA expression profiles of the parental strain and an isogenic AtxA-deficient strain in a 2 \u00d7 2 factorial design with growth environments containing or lacking carbon dioxide. We found 15 pXO1-encoded genes and 3 chromosomal genes that were strongly regulated by the separate or synergistic actions of AtxA and carbon dioxide. The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner. Expression levels of the two small RNAs were found to be higher than that of any other gene differentially expressed in response to these conditions. Secondary structure and small RNA-mRNA binding predictions for the two small RNAs suggest that they may perform important functions in regulating B. anthracis virulence. A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "2ef046659f484e2c81027f2213ef0759", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[27, 27], [258, 258]], "char_spans": [[142, 144], [1566, 1568]]}, {"text": "bicarbonate", "token_spans": [[25, 25]], "char_spans": [[130, 140]]}]}], "context_tokens": [["Upon", 0], ["infection", 5], ["of", 15], ["a", 18], ["mammalian", 20], ["host", 30], [",", 34], ["Bacillus", 36], ["anthracis", 45], ["responds", 55], ["to", 64], ["host", 67], ["cues", 72], [",", 76], ["and", 78], ["particularly", 82], ["to", 95], ["elevated", 98], ["temperature", 107], ["(", 119], ["37", 120], ["\u00b0", 122], ["C", 123], [")", 124], ["and", 126], ["bicarbonate", 130], ["/", 141], ["CO2", 142], ["concentrations", 146], [",", 160], ["with", 162], ["increased", 167], ["expression", 177], ["of", 188], ["virulence", 191], ["factors", 201], ["that", 209], ["include", 214], ["the", 222], ["anthrax", 226], ["toxins", 234], ["and", 241], ["extracellular", 245], ["capsular", 259], ["layer", 268], [".", 273], ["This", 275], ["response", 280], ["requires", 289], ["the", 298], ["presence", 302], ["of", 311], ["the", 314], ["pXO1", 318], ["virulence", 323], ["plasmid", 333], ["-", 340], ["encoded", 341], ["pleiotropic", 349], ["regulator", 361], ["AtxA.", 371], ["To", 377], ["better", 380], ["understand", 387], ["the", 398], ["genetic", 402], ["basis", 410], ["of", 416], ["this", 419], ["response", 424], [",", 432], ["we", 434], ["utilized", 437], ["a", 446], ["controlled", 448], ["in", 459], ["vitro", 462], ["system", 468], ["and", 475], ["Next", 479], ["Generation", 484], ["sequencing", 495], ["to", 506], ["determine", 509], ["and", 519], ["compare", 523], ["RNA", 531], ["expression", 535], ["profiles", 546], ["of", 555], ["the", 558], ["parental", 562], ["strain", 571], ["and", 578], ["an", 582], ["isogenic", 585], ["AtxA", 594], ["-", 598], ["deficient", 599], ["strain", 609], ["in", 616], ["a", 619], ["2", 621], ["\u00d7", 623], ["2", 625], ["factorial", 627], ["design", 637], ["with", 644], ["growth", 649], ["environments", 656], ["containing", 669], ["or", 680], ["lacking", 683], ["carbon", 691], ["dioxide", 698], [".", 705], ["We", 707], ["found", 710], ["15", 716], ["pXO1-encoded", 719], ["genes", 732], ["and", 738], ["3", 742], ["chromosomal", 744], ["genes", 756], ["that", 762], ["were", 767], ["strongly", 772], ["regulated", 781], ["by", 791], ["the", 794], ["separate", 798], ["or", 807], ["synergistic", 810], ["actions", 822], ["of", 830], ["AtxA", 833], ["and", 838], ["carbon", 842], ["dioxide", 849], [".", 856], ["The", 858], ["majority", 862], ["of", 871], ["the", 874], ["regulated", 878], ["genes", 888], ["responded", 894], ["to", 904], ["both", 907], ["AtxA", 912], ["and", 917], ["carbon", 921], ["dioxide", 928], ["rather", 936], ["than", 943], ["to", 948], ["just", 951], ["one", 956], ["of", 960], ["these", 963], ["factors", 969], [".", 976], ["Interestingly", 978], [",", 991], ["we", 993], ["identified", 996], ["two", 1007], ["previously", 1011], ["unrecognized", 1022], ["small", 1035], ["RNAs", 1041], ["that", 1046], ["are", 1051], ["highly", 1055], ["expressed", 1062], ["under", 1072], ["physiological", 1078], ["carbon", 1092], ["dioxide", 1099], ["concentrations", 1107], ["in", 1122], ["an", 1125], ["AtxA", 1128], ["-", 1132], ["dependent", 1133], ["manner", 1143], [".", 1149], ["Expression", 1151], ["levels", 1162], ["of", 1169], ["the", 1172], ["two", 1176], ["small", 1180], ["RNAs", 1186], ["were", 1191], ["found", 1196], ["to", 1202], ["be", 1205], ["higher", 1208], ["than", 1215], ["that", 1220], ["of", 1225], ["any", 1228], ["other", 1232], ["gene", 1238], ["differentially", 1243], ["expressed", 1258], ["in", 1268], ["response", 1271], ["to", 1280], ["these", 1283], ["conditions", 1289], [".", 1299], ["Secondary", 1301], ["structure", 1311], ["and", 1321], ["small", 1325], ["RNA", 1331], ["-", 1334], ["mRNA", 1335], ["binding", 1340], ["predictions", 1348], ["for", 1360], ["the", 1364], ["two", 1368], ["small", 1372], ["RNAs", 1378], ["suggest", 1383], ["that", 1391], ["they", 1396], ["may", 1401], ["perform", 1405], ["important", 1413], ["functions", 1423], ["in", 1433], ["regulating", 1436], ["B.", 1447], ["anthracis", 1450], ["virulence", 1460], [".", 1469], ["A", 1471], ["majority", 1473], ["of", 1482], ["genes", 1485], ["on", 1491], ["the", 1494], ["virulence", 1498], ["plasmid", 1508], ["pXO1", 1516], ["that", 1521], ["are", 1526], ["regulated", 1530], ["by", 1540], ["the", 1543], ["presence", 1547], ["of", 1556], ["either", 1559], ["CO2", 1566], ["or", 1570], ["AtxA", 1573], ["separately", 1578], ["are", 1589], ["also", 1593], ["regulated", 1598], ["synergistically", 1608], ["in", 1624], ["the", 1627], ["presence", 1631], ["of", 1640], ["both", 1643], [".", 1647], ["These", 1649], ["results", 1655], ["also", 1663], ["elucidate", 1668], ["novel", 1678], ["pXO1-encoded", 1684], ["small", 1697], ["RNAs", 1703], ["that", 1708], ["are", 1713], ["associated", 1717], ["with", 1728], ["virulence", 1733], ["conditions", 1743], [".", 1753]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "The antennal lobe (primary olfactory center of insects) is completely reorganized during metamorphosis. This reorganization is accompanied by changing patterns of calcium signaling in neurons and glial cells. In the present study, we investigated the developmental distribution of a major calcium-dependent protein, viz., calcium/calmodulin-dependent protein kinase II (CaM kinase II), in the antennal lobe of the sphinx moth Manduca sexta by using a monoclonal antibody. During synaptogenesis (developmental stages 6-10), we found a redistribution of CaM kinase II immunoreactivity, from a homogeneous distribution in the immature neuropil to an accumulation in the neuropil of the glomeruli. CaM kinase II immunoreactivity was less intense in olfactory receptor axons of the antennal nerve and antennal lobe glial cells. Western blot analysis revealed a growing content of CaM kinase II in antennal lobe tissue throughout metamorphosis. Injection of the CaM kinase inhibitor KN-93 into pupae resulted in a reduced number of antennal lobe glial cells migrating into the neuropil to form borders around glomeruli. The results suggest that CaM kinase II is involved in glial cell migration.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "f06d0fa0fbbc473f94d4d0b3591a5676", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[53, 60]], "char_spans": [[322, 367]]}, {"text": "CaM kinase II", "token_spans": [[193, 195], [150, 152], [62, 64], [121, 123], [98, 100]], "char_spans": [[1139, 1151], [875, 887], [370, 382], [694, 706], [552, 564]]}]}], "context_tokens": [["The", 0], ["antennal", 4], ["lobe", 13], ["(", 18], ["primary", 19], ["olfactory", 27], ["center", 37], ["of", 44], ["insects", 47], [")", 54], ["is", 56], ["completely", 59], ["reorganized", 70], ["during", 82], ["metamorphosis", 89], [".", 102], ["This", 104], ["reorganization", 109], ["is", 124], ["accompanied", 127], ["by", 139], ["changing", 142], ["patterns", 151], ["of", 160], ["calcium", 163], ["signaling", 171], ["in", 181], ["neurons", 184], ["and", 192], ["glial", 196], ["cells", 202], [".", 207], ["In", 209], ["the", 212], ["present", 216], ["study", 224], [",", 229], ["we", 231], ["investigated", 234], ["the", 247], ["developmental", 251], ["distribution", 265], ["of", 278], ["a", 281], ["major", 283], ["calcium", 289], ["-", 296], ["dependent", 297], ["protein", 307], [",", 314], ["viz", 316], [".", 319], [",", 320], ["calcium", 322], ["/", 329], ["calmodulin", 330], ["-", 340], ["dependent", 341], ["protein", 351], ["kinase", 359], ["II", 366], ["(", 369], ["CaM", 370], ["kinase", 374], ["II", 381], [")", 383], [",", 384], ["in", 386], ["the", 389], ["antennal", 393], ["lobe", 402], ["of", 407], ["the", 410], ["sphinx", 414], ["moth", 421], ["Manduca", 426], ["sexta", 434], ["by", 440], ["using", 443], ["a", 449], ["monoclonal", 451], ["antibody", 462], [".", 470], ["During", 472], ["synaptogenesis", 479], ["(", 494], ["developmental", 495], ["stages", 509], ["6", 516], ["-", 517], ["10", 518], [")", 520], [",", 521], ["we", 523], ["found", 526], ["a", 532], ["redistribution", 534], ["of", 549], ["CaM", 552], ["kinase", 556], ["II", 563], ["immunoreactivity", 566], [",", 582], ["from", 584], ["a", 589], ["homogeneous", 591], ["distribution", 603], ["in", 616], ["the", 619], ["immature", 623], ["neuropil", 632], ["to", 641], ["an", 644], ["accumulation", 647], ["in", 660], ["the", 663], ["neuropil", 667], ["of", 676], ["the", 679], ["glomeruli", 683], [".", 692], ["CaM", 694], ["kinase", 698], ["II", 705], ["immunoreactivity", 708], ["was", 725], ["less", 729], ["intense", 734], ["in", 742], ["olfactory", 745], ["receptor", 755], ["axons", 764], ["of", 770], ["the", 773], ["antennal", 777], ["nerve", 786], ["and", 792], ["antennal", 796], ["lobe", 805], ["glial", 810], ["cells", 816], [".", 821], ["Western", 823], ["blot", 831], ["analysis", 836], ["revealed", 845], ["a", 854], ["growing", 856], ["content", 864], ["of", 872], ["CaM", 875], ["kinase", 879], ["II", 886], ["in", 889], ["antennal", 892], ["lobe", 901], ["tissue", 906], ["throughout", 913], ["metamorphosis", 924], [".", 937], ["Injection", 939], ["of", 949], ["the", 952], ["CaM", 956], ["kinase", 960], ["inhibitor", 967], ["KN-93", 977], ["into", 983], ["pupae", 988], ["resulted", 994], ["in", 1003], ["a", 1006], ["reduced", 1008], ["number", 1016], ["of", 1023], ["antennal", 1026], ["lobe", 1035], ["glial", 1040], ["cells", 1046], ["migrating", 1052], ["into", 1062], ["the", 1067], ["neuropil", 1071], ["to", 1080], ["form", 1083], ["borders", 1088], ["around", 1096], ["glomeruli", 1103], [".", 1112], ["The", 1114], ["results", 1118], ["suggest", 1126], ["that", 1134], ["CaM", 1139], ["kinase", 1143], ["II", 1150], ["is", 1153], ["involved", 1156], ["in", 1165], ["glial", 1168], ["cell", 1174], ["migration", 1179], [".", 1188]]}
{"context": "Patients receiving tumor necrosis factor alpha inhibitors for the treatment of rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) are at high risk of developing tuberculosis during treatment. This article gives the recommendations for the prevention and management of tuberculosis in patients with rheumatic diseases before initiating therapy with tumor necrosis factor alpha inhibitors. They are adapted considering the high prevalence of tuberculosis, high drug resistance of Mycobacterium tuberculosis, and extensive bacille Calmette-Gu\u00e9rin vaccination against tuberculosis in Lithuania. In order to reduce the risk of tuberculosis, the screening should be done before starting antitumor necrosis factor alpha therapy. This includes complete medical history and posterior-anterior, lateral chest radiography. Tuberculin skin test using the Mantoux method with 5 tuberculin units and interferon-gamma release assay should be performed in patients without posttuberculous radiological lesions. If Ghon's complex or untreated posttuberculous lesions are present, or if the results the Mantoux test or interferon-gamma release assay are positive, the patient should be treated for latent tuberculosis. For the treatment of latent tuberculosis, isoniazid and rifampicin are given for 3 months, and the introduction of antitumor necrosis factor alpha therapy is delayed at least for one month. In cases of suspected active Mycobacterium tuberculosis infection, tuberculosis should be confirmed microbiologically or morphologically, and adequate antituberculosis treatment should be initiated.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a96c132fbe5e40d5a762f6f9583a5c81", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[96, 96], [75, 75], [29, 29], [85, 85], [186, 186], [227, 227], [230, 230], [68, 68], [44, 44], [193, 193]], "char_spans": [[658, 669], [528, 539], [197, 208], [600, 611], [1223, 1234], [1470, 1481], [1494, 1505], [476, 487], [304, 315], [1265, 1276]]}]}], "context_tokens": [["Patients", 0], ["receiving", 9], ["tumor", 19], ["necrosis", 25], ["factor", 34], ["alpha", 41], ["inhibitors", 47], ["for", 58], ["the", 62], ["treatment", 66], ["of", 76], ["rheumatic", 79], ["diseases", 89], ["(", 98], ["rheumatoid", 99], ["arthritis", 110], [",", 119], ["psoriatic", 121], ["arthritis", 131], [",", 140], ["ankylosing", 142], ["spondylitis", 153], [")", 164], ["are", 166], ["at", 170], ["high", 173], ["risk", 178], ["of", 183], ["developing", 186], ["tuberculosis", 197], ["during", 210], ["treatment", 217], [".", 226], ["This", 228], ["article", 233], ["gives", 241], ["the", 247], ["recommendations", 251], ["for", 267], ["the", 271], ["prevention", 275], ["and", 286], ["management", 290], ["of", 301], ["tuberculosis", 304], ["in", 317], ["patients", 320], ["with", 329], ["rheumatic", 334], ["diseases", 344], ["before", 353], ["initiating", 360], ["therapy", 371], ["with", 379], ["tumor", 384], ["necrosis", 390], ["factor", 399], ["alpha", 406], ["inhibitors", 412], [".", 422], ["They", 424], ["are", 429], ["adapted", 433], ["considering", 441], ["the", 453], ["high", 457], ["prevalence", 462], ["of", 473], ["tuberculosis", 476], [",", 488], ["high", 490], ["drug", 495], ["resistance", 500], ["of", 511], ["Mycobacterium", 514], ["tuberculosis", 528], [",", 540], ["and", 542], ["extensive", 546], ["bacille", 556], ["Calmette", 564], ["-", 572], ["Gu\u00e9rin", 573], ["vaccination", 580], ["against", 592], ["tuberculosis", 600], ["in", 613], ["Lithuania", 616], [".", 625], ["In", 627], ["order", 630], ["to", 636], ["reduce", 639], ["the", 646], ["risk", 650], ["of", 655], ["tuberculosis", 658], [",", 670], ["the", 672], ["screening", 676], ["should", 686], ["be", 693], ["done", 696], ["before", 701], ["starting", 708], ["antitumor", 717], ["necrosis", 727], ["factor", 736], ["alpha", 743], ["therapy", 749], [".", 756], ["This", 758], ["includes", 763], ["complete", 772], ["medical", 781], ["history", 789], ["and", 797], ["posterior", 801], ["-", 810], ["anterior", 811], [",", 819], ["lateral", 821], ["chest", 829], ["radiography", 835], [".", 846], ["Tuberculin", 848], ["skin", 859], ["test", 864], ["using", 869], ["the", 875], ["Mantoux", 879], ["method", 887], ["with", 894], ["5", 899], ["tuberculin", 901], ["units", 912], ["and", 918], ["interferon", 922], ["-", 932], ["gamma", 933], ["release", 939], ["assay", 947], ["should", 953], ["be", 960], ["performed", 963], ["in", 973], ["patients", 976], ["without", 985], ["posttuberculous", 993], ["radiological", 1009], ["lesions", 1022], [".", 1029], ["If", 1031], ["Ghon", 1034], ["'s", 1038], ["complex", 1041], ["or", 1049], ["untreated", 1052], ["posttuberculous", 1062], ["lesions", 1078], ["are", 1086], ["present", 1090], [",", 1097], ["or", 1099], ["if", 1102], ["the", 1105], ["results", 1109], ["the", 1117], ["Mantoux", 1121], ["test", 1129], ["or", 1134], ["interferon", 1137], ["-", 1147], ["gamma", 1148], ["release", 1154], ["assay", 1162], ["are", 1168], ["positive", 1172], [",", 1180], ["the", 1182], ["patient", 1186], ["should", 1194], ["be", 1201], ["treated", 1204], ["for", 1212], ["latent", 1216], ["tuberculosis", 1223], [".", 1235], ["For", 1237], ["the", 1241], ["treatment", 1245], ["of", 1255], ["latent", 1258], ["tuberculosis", 1265], [",", 1277], ["isoniazid", 1279], ["and", 1289], ["rifampicin", 1293], ["are", 1304], ["given", 1308], ["for", 1314], ["3", 1318], ["months", 1320], [",", 1326], ["and", 1328], ["the", 1332], ["introduction", 1336], ["of", 1349], ["antitumor", 1352], ["necrosis", 1362], ["factor", 1371], ["alpha", 1378], ["therapy", 1384], ["is", 1392], ["delayed", 1395], ["at", 1403], ["least", 1406], ["for", 1412], ["one", 1416], ["month", 1420], [".", 1425], ["In", 1427], ["cases", 1430], ["of", 1436], ["suspected", 1439], ["active", 1449], ["Mycobacterium", 1456], ["tuberculosis", 1470], ["infection", 1483], [",", 1492], ["tuberculosis", 1494], ["should", 1507], ["be", 1514], ["confirmed", 1517], ["microbiologically", 1527], ["or", 1545], ["morphologically", 1548], [",", 1563], ["and", 1565], ["adequate", 1569], ["antituberculosis", 1578], ["treatment", 1595], ["should", 1605], ["be", 1612], ["initiated", 1615], [".", 1624]]}
{"context": "Mutations within the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL mutations appear to be restricted to the first twenty-four exons, resulting in the gain or loss of a cysteine amino acid. The role of other exonic NOTCH3 variation not involving cysteine residues and mutations in exons 25-33 in ischemic stroke remains unresolved. All 33 exons of NOTCH3 were sequenced in 269 Caucasian probands from the Siblings With Ischemic Stroke Study (SWISS), a 70-center North American affected sibling pair study and 95 healthy Caucasian control subjects. Variants identified by sequencing in the SWISS probands were then tested for association with ischemic stroke using US Caucasian controls collected at the Mayo Clinic (n=654), and further assessed in a Caucasian (n=802) and African American (n=298) patient-control series collected through the Ischemic Stroke Genetics Study (ISGS). Sequencing of the 269 SWISS probands identified one (0.4%) with small vessel type stroke carrying a known CADASIL mutation (p.R558C; Exon 11). Of the 19 common NOTCH3 variants identified, the only variant significantly associated with ischemic stroke after multiple testing adjustment was p.R1560P (rs78501403; Exon 25) in the combined SWISS and ISGS Caucasian series (Odds Ratio [OR] 0.50, P=0.0022) where presence of the minor allele was protective against ischemic stroke. Although only significant prior to adjustment for multiple testing, p.T101T (rs3815188; Exon 3) was associated with an increased risk of small-vessel stroke (OR: 1.56, P=0.008) and p.P380P (rs61749020; Exon 7) was associated with decreased risk of large-vessel stroke (OR: 0.35, P=0.047) in Caucasians. No significant associations were observed in the small African American series. Cysteine-affecting NOTCH3 mutations are rare in patients with typical ischemic stroke, however our observation that common NOTCH3 variants may be associated with risk of ischemic stroke warrants further study.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "5d67f3f3e8fc4a01a62f519db556744e", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[336, 336], [41, 41], [54, 54]], "char_spans": [[1821, 1828], [250, 257], [327, 334]]}]}], "context_tokens": [["Mutations", 0], ["within", 10], ["the", 17], ["NOTCH3", 21], ["gene", 28], ["cause", 33], ["cerebral", 39], ["autosomal", 48], ["dominant", 58], ["arteriopathy", 67], ["with", 80], ["subcortical", 85], ["infarcts", 97], ["and", 106], ["leukoencephalopathy", 110], ["(", 130], ["CADASIL", 131], [")", 138], [".", 139], ["CADASIL", 141], ["mutations", 149], ["appear", 159], ["to", 166], ["be", 169], ["restricted", 172], ["to", 183], ["the", 186], ["first", 190], ["twenty", 196], ["-", 202], ["four", 203], ["exons", 208], [",", 213], ["resulting", 215], ["in", 225], ["the", 228], ["gain", 232], ["or", 237], ["loss", 240], ["of", 245], ["a", 248], ["cysteine", 250], ["amino", 259], ["acid", 265], [".", 269], ["The", 271], ["role", 275], ["of", 280], ["other", 283], ["exonic", 289], ["NOTCH3", 296], ["variation", 303], ["not", 313], ["involving", 317], ["cysteine", 327], ["residues", 336], ["and", 345], ["mutations", 349], ["in", 359], ["exons", 362], ["25", 368], ["-", 370], ["33", 371], ["in", 374], ["ischemic", 377], ["stroke", 386], ["remains", 393], ["unresolved", 401], [".", 411], ["All", 413], ["33", 417], ["exons", 420], ["of", 426], ["NOTCH3", 429], ["were", 436], ["sequenced", 441], ["in", 451], ["269", 454], ["Caucasian", 458], ["probands", 468], ["from", 477], ["the", 482], ["Siblings", 486], ["With", 495], ["Ischemic", 500], ["Stroke", 509], ["Study", 516], ["(", 522], ["SWISS", 523], [")", 528], [",", 529], ["a", 531], ["70-center", 533], ["North", 543], ["American", 549], ["affected", 558], ["sibling", 567], ["pair", 575], ["study", 580], ["and", 586], ["95", 590], ["healthy", 593], ["Caucasian", 601], ["control", 611], ["subjects", 619], [".", 627], ["Variants", 629], ["identified", 638], ["by", 649], ["sequencing", 652], ["in", 663], ["the", 666], ["SWISS", 670], ["probands", 676], ["were", 685], ["then", 690], ["tested", 695], ["for", 702], ["association", 706], ["with", 718], ["ischemic", 723], ["stroke", 732], ["using", 739], ["US", 745], ["Caucasian", 748], ["controls", 758], ["collected", 767], ["at", 777], ["the", 780], ["Mayo", 784], ["Clinic", 789], ["(", 796], ["n=654", 797], [")", 802], [",", 803], ["and", 805], ["further", 809], ["assessed", 817], ["in", 826], ["a", 829], ["Caucasian", 831], ["(", 841], ["n=802", 842], [")", 847], ["and", 849], ["African", 853], ["American", 861], ["(", 870], ["n=298", 871], [")", 876], ["patient", 878], ["-", 885], ["control", 886], ["series", 894], ["collected", 901], ["through", 911], ["the", 919], ["Ischemic", 923], ["Stroke", 932], ["Genetics", 939], ["Study", 948], ["(", 954], ["ISGS", 955], [")", 959], [".", 960], ["Sequencing", 962], ["of", 973], ["the", 976], ["269", 980], ["SWISS", 984], ["probands", 990], ["identified", 999], ["one", 1010], ["(", 1014], ["0.4", 1015], ["%", 1018], [")", 1019], ["with", 1021], ["small", 1026], ["vessel", 1032], ["type", 1039], ["stroke", 1044], ["carrying", 1051], ["a", 1060], ["known", 1062], ["CADASIL", 1068], ["mutation", 1076], ["(", 1085], ["p", 1086], [".", 1087], ["R558C", 1088], [";", 1093], ["Exon", 1095], ["11", 1100], [")", 1102], [".", 1103], ["Of", 1105], ["the", 1108], ["19", 1112], ["common", 1115], ["NOTCH3", 1122], ["variants", 1129], ["identified", 1138], [",", 1148], ["the", 1150], ["only", 1154], ["variant", 1159], ["significantly", 1167], ["associated", 1181], ["with", 1192], ["ischemic", 1197], ["stroke", 1206], ["after", 1213], ["multiple", 1219], ["testing", 1228], ["adjustment", 1236], ["was", 1247], ["p", 1251], [".", 1252], ["R1560P", 1253], ["(", 1260], ["rs78501403", 1261], [";", 1271], ["Exon", 1273], ["25", 1278], [")", 1280], ["in", 1282], ["the", 1285], ["combined", 1289], ["SWISS", 1298], ["and", 1304], ["ISGS", 1308], ["Caucasian", 1313], ["series", 1323], ["(", 1330], ["Odds", 1331], ["Ratio", 1336], ["[", 1342], ["OR", 1343], ["]", 1345], ["0.50", 1347], [",", 1351], ["P=0.0022", 1353], [")", 1361], ["where", 1363], ["presence", 1369], ["of", 1378], ["the", 1381], ["minor", 1385], ["allele", 1391], ["was", 1398], ["protective", 1402], ["against", 1413], ["ischemic", 1421], ["stroke", 1430], [".", 1436], ["Although", 1438], ["only", 1447], ["significant", 1452], ["prior", 1464], ["to", 1470], ["adjustment", 1473], ["for", 1484], ["multiple", 1488], ["testing", 1497], [",", 1504], ["p", 1506], [".", 1507], ["T101", 1508], ["T", 1512], ["(", 1514], ["rs3815188", 1515], [";", 1524], ["Exon", 1526], ["3", 1531], [")", 1532], ["was", 1534], ["associated", 1538], ["with", 1549], ["an", 1554], ["increased", 1557], ["risk", 1567], ["of", 1572], ["small", 1575], ["-", 1580], ["vessel", 1581], ["stroke", 1588], ["(", 1595], ["OR", 1596], [":", 1598], ["1.56", 1600], [",", 1604], ["P=0.008", 1606], [")", 1613], ["and", 1615], ["p", 1619], [".", 1620], ["P380P", 1621], ["(", 1627], ["rs61749020", 1628], [";", 1638], ["Exon", 1640], ["7", 1645], [")", 1646], ["was", 1648], ["associated", 1652], ["with", 1663], ["decreased", 1668], ["risk", 1678], ["of", 1683], ["large", 1686], ["-", 1691], ["vessel", 1692], ["stroke", 1699], ["(", 1706], ["OR", 1707], [":", 1709], ["0.35", 1711], [",", 1715], ["P=0.047", 1717], [")", 1724], ["in", 1726], ["Caucasians", 1729], [".", 1739], ["No", 1741], ["significant", 1744], ["associations", 1756], ["were", 1769], ["observed", 1774], ["in", 1783], ["the", 1786], ["small", 1790], ["African", 1796], ["American", 1804], ["series", 1813], [".", 1819], ["Cysteine", 1821], ["-", 1829], ["affecting", 1830], ["NOTCH3", 1840], ["mutations", 1847], ["are", 1857], ["rare", 1861], ["in", 1866], ["patients", 1869], ["with", 1878], ["typical", 1883], ["ischemic", 1891], ["stroke", 1900], [",", 1906], ["however", 1908], ["our", 1916], ["observation", 1920], ["that", 1932], ["common", 1937], ["NOTCH3", 1944], ["variants", 1951], ["may", 1960], ["be", 1964], ["associated", 1967], ["with", 1978], ["risk", 1983], ["of", 1988], ["ischemic", 1991], ["stroke", 2000], ["warrants", 2007], ["further", 2016], ["study", 2024], [".", 2029]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Transcription coupled repair (TCR) is a nucleotide excision repair (NER) pathway that is dedicated to repair in the transcribed strand of an active gene. The genome overall NER is called global genomic repair (GGR). Elc1, the yeast homolog of the mammalian elongation factor elongin C, has been shown to be a component of a ubiquitin ligase complex that contains Rad7 and Rad16, two factors that are specifically required for GGR. Elc1 has also been suggested to be present in another ubiquitin ligase complex that lacks Rad7 and Rad16 and is involved in UV-induced ubiquitylation and subsequent degradation of RNA polymerase II. Here we show that elc1 deletion increases UV sensitivity of TCR-deficient cells but does not affect the UV sensitivity of otherwise wild type and GGR-deficient cells. Cells deleted for elc1 show normal NER in the transcribed strand of an active gene but have no detectable NER in the non-transcribed strand. Elc1 does not affect UV-induced mutagenesis when TCR is operative, but plays an important role in preventing the mutagenesis if TCR is defective. Furthermore, the levels of Rad7 and Rad16 proteins are not significantly decreased in elc1 cells, and overexpression of Rad7 and Rad16 individually or simultaneously in elc1 cells does not restore repair in the non-transcribed strand of an active gene. Our results suggest that Elc1 has no function in TCR but plays an important role in GGR. Furthermore, the role of Elc1 in GGR may not be subsidiary to that of Rad7 and Rad16.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e0f30444851747c08e3a6c06ba0be328", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[156, 157], [22, 23], [238, 239], [171, 172]], "char_spans": [[843, 860], [116, 133], [1299, 1316], [918, 935]]}]}], "context_tokens": [["Transcription", 0], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["nucleotide", 40], ["excision", 51], ["repair", 60], ["(", 67], ["NER", 68], [")", 71], ["pathway", 73], ["that", 81], ["is", 86], ["dedicated", 89], ["to", 99], ["repair", 102], ["in", 109], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["an", 138], ["active", 141], ["gene", 148], [".", 152], ["The", 154], ["genome", 158], ["overall", 165], ["NER", 173], ["is", 177], ["called", 180], ["global", 187], ["genomic", 194], ["repair", 202], ["(", 209], ["GGR", 210], [")", 213], [".", 214], ["Elc1", 216], [",", 220], ["the", 222], ["yeast", 226], ["homolog", 232], ["of", 240], ["the", 243], ["mammalian", 247], ["elongation", 257], ["factor", 268], ["elongin", 275], ["C", 283], [",", 284], ["has", 286], ["been", 290], ["shown", 295], ["to", 301], ["be", 304], ["a", 307], ["component", 309], ["of", 319], ["a", 322], ["ubiquitin", 324], ["ligase", 334], ["complex", 341], ["that", 349], ["contains", 354], ["Rad7", 363], ["and", 368], ["Rad16", 372], [",", 377], ["two", 379], ["factors", 383], ["that", 391], ["are", 396], ["specifically", 400], ["required", 413], ["for", 422], ["GGR", 426], [".", 429], ["Elc1", 431], ["has", 436], ["also", 440], ["been", 445], ["suggested", 450], ["to", 460], ["be", 463], ["present", 466], ["in", 474], ["another", 477], ["ubiquitin", 485], ["ligase", 495], ["complex", 502], ["that", 510], ["lacks", 515], ["Rad7", 521], ["and", 526], ["Rad16", 530], ["and", 536], ["is", 540], ["involved", 543], ["in", 552], ["UV", 555], ["-", 557], ["induced", 558], ["ubiquitylation", 566], ["and", 581], ["subsequent", 585], ["degradation", 596], ["of", 608], ["RNA", 611], ["polymerase", 615], ["II", 626], [".", 628], ["Here", 630], ["we", 635], ["show", 638], ["that", 643], ["elc1", 648], ["deletion", 653], ["increases", 662], ["UV", 672], ["sensitivity", 675], ["of", 687], ["TCR", 690], ["-", 693], ["deficient", 694], ["cells", 704], ["but", 710], ["does", 714], ["not", 719], ["affect", 723], ["the", 730], ["UV", 734], ["sensitivity", 737], ["of", 749], ["otherwise", 752], ["wild", 762], ["type", 767], ["and", 772], ["GGR", 776], ["-", 779], ["deficient", 780], ["cells", 790], [".", 795], ["Cells", 797], ["deleted", 803], ["for", 811], ["elc1", 815], ["show", 820], ["normal", 825], ["NER", 832], ["in", 836], ["the", 839], ["transcribed", 843], ["strand", 855], ["of", 862], ["an", 865], ["active", 868], ["gene", 875], ["but", 880], ["have", 884], ["no", 889], ["detectable", 892], ["NER", 903], ["in", 907], ["the", 910], ["non", 914], ["-", 917], ["transcribed", 918], ["strand", 930], [".", 936], ["Elc1", 938], ["does", 943], ["not", 948], ["affect", 952], ["UV", 959], ["-", 961], ["induced", 962], ["mutagenesis", 970], ["when", 982], ["TCR", 987], ["is", 991], ["operative", 994], [",", 1003], ["but", 1005], ["plays", 1009], ["an", 1015], ["important", 1018], ["role", 1028], ["in", 1033], ["preventing", 1036], ["the", 1047], ["mutagenesis", 1051], ["if", 1063], ["TCR", 1066], ["is", 1070], ["defective", 1073], [".", 1082], ["Furthermore", 1084], [",", 1095], ["the", 1097], ["levels", 1101], ["of", 1108], ["Rad7", 1111], ["and", 1116], ["Rad16", 1120], ["proteins", 1126], ["are", 1135], ["not", 1139], ["significantly", 1143], ["decreased", 1157], ["in", 1167], ["elc1", 1170], ["cells", 1175], [",", 1180], ["and", 1182], ["overexpression", 1186], ["of", 1201], ["Rad7", 1204], ["and", 1209], ["Rad16", 1213], ["individually", 1219], ["or", 1232], ["simultaneously", 1235], ["in", 1250], ["elc1", 1253], ["cells", 1258], ["does", 1264], ["not", 1269], ["restore", 1273], ["repair", 1281], ["in", 1288], ["the", 1291], ["non", 1295], ["-", 1298], ["transcribed", 1299], ["strand", 1311], ["of", 1318], ["an", 1321], ["active", 1324], ["gene", 1331], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["Elc1", 1362], ["has", 1367], ["no", 1371], ["function", 1374], ["in", 1383], ["TCR", 1386], ["but", 1390], ["plays", 1394], ["an", 1400], ["important", 1403], ["role", 1413], ["in", 1418], ["GGR", 1421], [".", 1424], ["Furthermore", 1426], [",", 1437], ["the", 1439], ["role", 1443], ["of", 1448], ["Elc1", 1451], ["in", 1456], ["GGR", 1459], ["may", 1463], ["not", 1467], ["be", 1471], ["subsidiary", 1474], ["to", 1485], ["that", 1488], ["of", 1493], ["Rad7", 1496], ["and", 1501], ["Rad16", 1505], [".", 1510]]}
{"context": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug. Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6e6cc6752f9047989d4703ae6d6c8051", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[80, 80], [5, 5], [46, 46]], "char_spans": [[469, 478], [27, 36], [270, 279]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["flumazenil", 27], ["were", 38], ["assessed", 43], ["in", 52], ["comparison", 55], ["to", 66], ["placebo", 69], ["in", 77], ["a", 80], ["double", 82], ["-", 88], ["blind", 89], ["randomised", 95], ["study", 106], ["of", 112], ["31", 115], ["adults", 118], ["intoxicated", 125], ["with", 137], ["benzodiazepines", 142], [".", 157], ["The", 159], ["criteria", 163], ["of", 172], ["efficacy", 175], ["were", 184], ["the", 189], ["degree", 193], ["of", 200], ["sedation", 203], [",", 211], ["and", 213], ["orientation", 217], ["in", 229], ["time", 232], ["and", 237], ["space", 241], [".", 246], ["Patients", 248], ["who", 257], ["received", 261], ["flumazenil", 270], ["awoke", 281], ["within", 287], ["minutes", 294], ["but", 302], ["central", 306], ["depression", 314], ["returned", 325], ["partly", 334], ["one", 341], ["hour", 345], ["later", 350], [",", 355], ["which", 357], ["reflects", 363], ["the", 372], ["short", 376], ["elimination", 382], ["half", 394], ["-", 398], ["life", 399], ["of", 404], ["the", 407], ["drug", 411], [".", 415], ["Side", 417], ["effects", 422], ["were", 430], ["few", 435], ["and", 439], ["the", 443], ["results", 447], ["indicate", 455], ["that", 464], ["flumazenil", 469], ["is", 480], ["effective", 483], ["in", 493], ["the", 496], ["primary", 500], ["management", 508], ["of", 519], ["benzodiazepine", 522], ["overdose", 537], ["and", 546], ["in", 550], ["states", 553], ["where", 560], ["benzodiazepines", 566], ["have", 582], ["been", 587], ["taken", 592], ["with", 598], ["other", 603], ["drugs", 609], [".", 614]]}
{"context": "Canonical primary microRNA (pri-miRNA) precursors are transcribed by RNA polymerase II and then processed by the Drosha endonuclease to generate approximately 60 nt pre-miRNA hairpins. Pre-miRNAs in turn are cleaved by Dicer to generate mature miRNAs. Previously, some short introns, called miRtrons, were reported to fold into pre-miRNA hairpins after splicing and debranching, and miRNAs can also be excised by Dicer cleavage of rare endogenous short hairpin RNAs. Here we report that the miRNAs encoded by murine gamma-herpesvirus 68 (MHV68) are also generated via atypical mechanisms. Specifically, MHV68 miRNAs are transcribed from RNA polymerase III promoters located within adjacent viral tRNA-like sequences. The resultant pri-miRNAs, which bear a 5' tRNA moiety, are not processed by Drosha but instead by cellular tRNase Z, which cleaves 3' to the tRNA to liberate pre-miRNA hairpins that are then processed by Dicer to yield the mature viral miRNAs.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "354a06365eb5430db7d04eb6bea5af55", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[12, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Canonical", 0], ["primary", 10], ["microRNA", 18], ["(", 27], ["pri", 28], ["-", 31], ["miRNA", 32], [")", 37], ["precursors", 39], ["are", 50], ["transcribed", 54], ["by", 66], ["RNA", 69], ["polymerase", 73], ["II", 84], ["and", 87], ["then", 91], ["processed", 96], ["by", 106], ["the", 109], ["Drosha", 113], ["endonuclease", 120], ["to", 133], ["generate", 136], ["approximately", 145], ["60", 159], ["nt", 162], ["pre", 165], ["-", 168], ["miRNA", 169], ["hairpins", 175], [".", 183], ["Pre", 185], ["-", 188], ["miRNAs", 189], ["in", 196], ["turn", 199], ["are", 204], ["cleaved", 208], ["by", 216], ["Dicer", 219], ["to", 225], ["generate", 228], ["mature", 237], ["miRNAs", 244], [".", 250], ["Previously", 252], [",", 262], ["some", 264], ["short", 269], ["introns", 275], [",", 282], ["called", 284], ["miRtrons", 291], [",", 299], ["were", 301], ["reported", 306], ["to", 315], ["fold", 318], ["into", 323], ["pre", 328], ["-", 331], ["miRNA", 332], ["hairpins", 338], ["after", 347], ["splicing", 353], ["and", 362], ["debranching", 366], [",", 377], ["and", 379], ["miRNAs", 383], ["can", 390], ["also", 394], ["be", 399], ["excised", 402], ["by", 410], ["Dicer", 413], ["cleavage", 419], ["of", 428], ["rare", 431], ["endogenous", 436], ["short", 447], ["hairpin", 453], ["RNAs", 461], [".", 465], ["Here", 467], ["we", 472], ["report", 475], ["that", 482], ["the", 487], ["miRNAs", 491], ["encoded", 498], ["by", 506], ["murine", 509], ["gamma", 516], ["-", 521], ["herpesvirus", 522], ["68", 534], ["(", 537], ["MHV68", 538], [")", 543], ["are", 545], ["also", 549], ["generated", 554], ["via", 564], ["atypical", 568], ["mechanisms", 577], [".", 587], ["Specifically", 589], [",", 601], ["MHV68", 603], ["miRNAs", 609], ["are", 616], ["transcribed", 620], ["from", 632], ["RNA", 637], ["polymerase", 641], ["III", 652], ["promoters", 656], ["located", 666], ["within", 674], ["adjacent", 681], ["viral", 690], ["tRNA", 696], ["-", 700], ["like", 701], ["sequences", 706], [".", 715], ["The", 717], ["resultant", 721], ["pri", 731], ["-", 734], ["miRNAs", 735], [",", 741], ["which", 743], ["bear", 749], ["a", 754], ["5", 756], ["'", 757], ["tRNA", 759], ["moiety", 764], [",", 770], ["are", 772], ["not", 776], ["processed", 780], ["by", 790], ["Drosha", 793], ["but", 800], ["instead", 804], ["by", 812], ["cellular", 815], ["tRNase", 824], ["Z", 831], [",", 832], ["which", 834], ["cleaves", 840], ["3", 848], ["'", 849], ["to", 851], ["the", 854], ["tRNA", 858], ["to", 863], ["liberate", 866], ["pre", 875], ["-", 878], ["miRNA", 879], ["hairpins", 885], ["that", 894], ["are", 899], ["then", 903], ["processed", 908], ["by", 918], ["Dicer", 921], ["to", 927], ["yield", 930], ["the", 936], ["mature", 940], ["viral", 947], ["miRNAs", 953], [".", 959]]}
{"context": "NuA4 (nucleosome acetyltransferase of H4) promotes transcriptional initiation of TFIID (a complex of TBP and TBP-associated factors [TAFs])-dependent ribosomal protein genes involved in ribosome biogenesis. However, it is not clearly understood how NuA4 regulates the transcription of ribosomal protein genes. Here, we show that NuA4 is recruited to the promoters of ribosomal protein genes, such as RPS5, RPL2B, and RPS11B, for TFIID recruitment to initiate transcription, and the recruitment of NuA4 to these promoters is impaired in the absence of its Eaf1p component. Intriguingly, impaired NuA4 recruitment in a \u0394eaf1 strain depletes recruitment of TFIID (a TAF-dependent form of TBP) but not the TAF-independent form of TBP to the promoters of ribosomal protein genes. However, in the absence of NuA4, SAGA (Spt-Ada-Gcn5-acetyltransferase) is involved in targeting the TAF-independent form of TBP to the promoters of ribosomal protein genes for transcriptional initiation. Thus, NuA4 plays an important role in targeting TFIID to the promoters of ribosomal protein genes for transcriptional initiation in vivo. Such a function is mediated via its targeted histone acetyltransferase activity. In the absence of NuA4, ribosomal protein genes lose TFIID dependency and become SAGA dependent for transcriptional initiation. Collectively, these results provide significant insights into the regulation of ribosomal protein gene expression and, hence, ribosome biogenesis and functions.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "513f317b2bbb49a488431854ec8b1291", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[148, 152]], "char_spans": [[814, 843]]}]}], "context_tokens": [["NuA4", 0], ["(", 5], ["nucleosome", 6], ["acetyltransferase", 17], ["of", 35], ["H4", 38], [")", 40], ["promotes", 42], ["transcriptional", 51], ["initiation", 67], ["of", 78], ["TFIID", 81], ["(", 87], ["a", 88], ["complex", 90], ["of", 98], ["TBP", 101], ["and", 105], ["TBP", 109], ["-", 112], ["associated", 113], ["factors", 124], ["[", 132], ["TAFs])-dependent", 133], ["ribosomal", 150], ["protein", 160], ["genes", 168], ["involved", 174], ["in", 183], ["ribosome", 186], ["biogenesis", 195], [".", 205], ["However", 207], [",", 214], ["it", 216], ["is", 219], ["not", 222], ["clearly", 226], ["understood", 234], ["how", 245], ["NuA4", 249], ["regulates", 254], ["the", 264], ["transcription", 268], ["of", 282], ["ribosomal", 285], ["protein", 295], ["genes", 303], [".", 308], ["Here", 310], [",", 314], ["we", 316], ["show", 319], ["that", 324], ["NuA4", 329], ["is", 334], ["recruited", 337], ["to", 347], ["the", 350], ["promoters", 354], ["of", 364], ["ribosomal", 367], ["protein", 377], ["genes", 385], [",", 390], ["such", 392], ["as", 397], ["RPS5", 400], [",", 404], ["RPL2B", 406], [",", 411], ["and", 413], ["RPS11B", 417], [",", 423], ["for", 425], ["TFIID", 429], ["recruitment", 435], ["to", 447], ["initiate", 450], ["transcription", 459], [",", 472], ["and", 474], ["the", 478], ["recruitment", 482], ["of", 494], ["NuA4", 497], ["to", 502], ["these", 505], ["promoters", 511], ["is", 521], ["impaired", 524], ["in", 533], ["the", 536], ["absence", 540], ["of", 548], ["its", 551], ["Eaf1p", 555], ["component", 561], [".", 570], ["Intriguingly", 572], [",", 584], ["impaired", 586], ["NuA4", 595], ["recruitment", 600], ["in", 612], ["a", 615], ["\u0394eaf1", 617], ["strain", 623], ["depletes", 630], ["recruitment", 639], ["of", 651], ["TFIID", 654], ["(", 660], ["a", 661], ["TAF", 663], ["-", 666], ["dependent", 667], ["form", 677], ["of", 682], ["TBP", 685], [")", 688], ["but", 690], ["not", 694], ["the", 698], ["TAF", 702], ["-", 705], ["independent", 706], ["form", 718], ["of", 723], ["TBP", 726], ["to", 730], ["the", 733], ["promoters", 737], ["of", 747], ["ribosomal", 750], ["protein", 760], ["genes", 768], [".", 773], ["However", 775], [",", 782], ["in", 784], ["the", 787], ["absence", 791], ["of", 799], ["NuA4", 802], [",", 806], ["SAGA", 808], ["(", 813], ["Spt", 814], ["-", 817], ["Ada", 818], ["-", 821], ["Gcn5-acetyltransferase", 822], [")", 844], ["is", 846], ["involved", 849], ["in", 858], ["targeting", 861], ["the", 871], ["TAF", 875], ["-", 878], ["independent", 879], ["form", 891], ["of", 896], ["TBP", 899], ["to", 903], ["the", 906], ["promoters", 910], ["of", 920], ["ribosomal", 923], ["protein", 933], ["genes", 941], ["for", 947], ["transcriptional", 951], ["initiation", 967], [".", 977], ["Thus", 979], [",", 983], ["NuA4", 985], ["plays", 990], ["an", 996], ["important", 999], ["role", 1009], ["in", 1014], ["targeting", 1017], ["TFIID", 1027], ["to", 1033], ["the", 1036], ["promoters", 1040], ["of", 1050], ["ribosomal", 1053], ["protein", 1063], ["genes", 1071], ["for", 1077], ["transcriptional", 1081], ["initiation", 1097], ["in", 1108], ["vivo", 1111], [".", 1115], ["Such", 1117], ["a", 1122], ["function", 1124], ["is", 1133], ["mediated", 1136], ["via", 1145], ["its", 1149], ["targeted", 1153], ["histone", 1162], ["acetyltransferase", 1170], ["activity", 1188], [".", 1196], ["In", 1198], ["the", 1201], ["absence", 1205], ["of", 1213], ["NuA4", 1216], [",", 1220], ["ribosomal", 1222], ["protein", 1232], ["genes", 1240], ["lose", 1246], ["TFIID", 1251], ["dependency", 1257], ["and", 1268], ["become", 1272], ["SAGA", 1279], ["dependent", 1284], ["for", 1294], ["transcriptional", 1298], ["initiation", 1314], [".", 1324], ["Collectively", 1326], [",", 1338], ["these", 1340], ["results", 1346], ["provide", 1354], ["significant", 1362], ["insights", 1374], ["into", 1383], ["the", 1388], ["regulation", 1392], ["of", 1403], ["ribosomal", 1406], ["protein", 1416], ["gene", 1424], ["expression", 1429], ["and", 1440], [",", 1443], ["hence", 1445], [",", 1450], ["ribosome", 1452], ["biogenesis", 1461], ["and", 1472], ["functions", 1476], [".", 1485]]}
{"context": "To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials. Male Lewis rats underwent MMT surgery and were treated weekly with tanezumab (0.1, 1 or 10\u2005mg/kg), isotype control or vehicle for 7, 14 or 28\u2005days. Gait deficiency was measured to assess weight-bearing on the operated limb. Joint damage was assessed via histopathology. A second arm, delayed onset of treatment (starting 3-8\u2005weeks after MMT surgery) was used to control for analgesia early in the disease process. A third arm, mid-tibial amputation, evaluated the dependency of the model on weight-bearing. Gait deficiency in untreated rats was present 3-7\u2005days after MMT surgery, with a return to normal weight-bearing by days 14-28. Prophylactic treatment with tanezumab prevented gait deficiency and resulted in more severe cartilage damage. When onset of treatment with tanezumab was delayed to 3-8\u2005weeks after MMT surgery, there was no increase in cartilage damage. Mid-tibial amputation completely prevented cartilage damage in untreated MMT rats. These data suggest that analgesia due to NGF inhibition during the acute injury phase is responsible for increased voluntary weight-bearing and subsequent cartilage damage in the rat MMT model. This model failed to replicate the hypotrophic bone response observed in tanezumab-treated patients with RPOA.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "50ae8202b2234d05a6012bace0a32fa7", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[6, 8]], "char_spans": [[38, 56]]}, {"text": "NGF", "token_spans": [[232, 232], [10, 10]], "char_spans": [[1214, 1216], [59, 61]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["the", 23], ["effects", 27], ["of", 35], ["nerve", 38], ["growth", 44], ["factor", 51], ["(", 58], ["NGF", 59], [")", 62], ["inhibition", 64], ["with", 75], ["tanezumab", 80], ["on", 90], ["rats", 93], ["with", 98], ["medial", 103], ["meniscal", 110], ["tear", 119], ["(", 124], ["MMT", 125], [")", 128], ["effectively", 130], ["model", 142], ["rapidly", 148], ["progressive", 156], ["osteoarthritis", 168], ["(", 183], ["RPOA", 184], [")", 188], ["observed", 190], ["in", 199], ["clinical", 202], ["trials", 211], [".", 217], ["Male", 219], ["Lewis", 224], ["rats", 230], ["underwent", 235], ["MMT", 245], ["surgery", 249], ["and", 257], ["were", 261], ["treated", 266], ["weekly", 274], ["with", 281], ["tanezumab", 286], ["(", 296], ["0.1", 297], [",", 300], ["1", 302], ["or", 304], ["10", 307], ["mg", 310], ["/", 312], ["kg", 313], [")", 315], [",", 316], ["isotype", 318], ["control", 326], ["or", 334], ["vehicle", 337], ["for", 345], ["7", 349], [",", 350], ["14", 352], ["or", 355], ["28", 358], ["days", 361], [".", 365], ["Gait", 367], ["deficiency", 372], ["was", 383], ["measured", 387], ["to", 396], ["assess", 399], ["weight", 406], ["-", 412], ["bearing", 413], ["on", 421], ["the", 424], ["operated", 428], ["limb", 437], [".", 441], ["Joint", 443], ["damage", 449], ["was", 456], ["assessed", 460], ["via", 469], ["histopathology", 473], [".", 487], ["A", 489], ["second", 491], ["arm", 498], [",", 501], ["delayed", 503], ["onset", 511], ["of", 517], ["treatment", 520], ["(", 530], ["starting", 531], ["3", 540], ["-", 541], ["8", 542], ["weeks", 544], ["after", 550], ["MMT", 556], ["surgery", 560], [")", 567], ["was", 569], ["used", 573], ["to", 578], ["control", 581], ["for", 589], ["analgesia", 593], ["early", 603], ["in", 609], ["the", 612], ["disease", 616], ["process", 624], [".", 631], ["A", 633], ["third", 635], ["arm", 641], [",", 644], ["mid", 646], ["-", 649], ["tibial", 650], ["amputation", 657], [",", 667], ["evaluated", 669], ["the", 679], ["dependency", 683], ["of", 694], ["the", 697], ["model", 701], ["on", 707], ["weight", 710], ["-", 716], ["bearing", 717], [".", 724], ["Gait", 726], ["deficiency", 731], ["in", 742], ["untreated", 745], ["rats", 755], ["was", 760], ["present", 764], ["3", 772], ["-", 773], ["7", 774], ["days", 776], ["after", 781], ["MMT", 787], ["surgery", 791], [",", 798], ["with", 800], ["a", 805], ["return", 807], ["to", 814], ["normal", 817], ["weight", 824], ["-", 830], ["bearing", 831], ["by", 839], ["days", 842], ["14", 847], ["-", 849], ["28", 850], [".", 852], ["Prophylactic", 854], ["treatment", 867], ["with", 877], ["tanezumab", 882], ["prevented", 892], ["gait", 902], ["deficiency", 907], ["and", 918], ["resulted", 922], ["in", 931], ["more", 934], ["severe", 939], ["cartilage", 946], ["damage", 956], [".", 962], ["When", 964], ["onset", 969], ["of", 975], ["treatment", 978], ["with", 988], ["tanezumab", 993], ["was", 1003], ["delayed", 1007], ["to", 1015], ["3", 1018], ["-", 1019], ["8", 1020], ["weeks", 1022], ["after", 1028], ["MMT", 1034], ["surgery", 1038], [",", 1045], ["there", 1047], ["was", 1053], ["no", 1057], ["increase", 1060], ["in", 1069], ["cartilage", 1072], ["damage", 1082], [".", 1088], ["Mid", 1090], ["-", 1093], ["tibial", 1094], ["amputation", 1101], ["completely", 1112], ["prevented", 1123], ["cartilage", 1133], ["damage", 1143], ["in", 1150], ["untreated", 1153], ["MMT", 1163], ["rats", 1167], [".", 1171], ["These", 1173], ["data", 1179], ["suggest", 1184], ["that", 1192], ["analgesia", 1197], ["due", 1207], ["to", 1211], ["NGF", 1214], ["inhibition", 1218], ["during", 1229], ["the", 1236], ["acute", 1240], ["injury", 1246], ["phase", 1253], ["is", 1259], ["responsible", 1262], ["for", 1274], ["increased", 1278], ["voluntary", 1288], ["weight", 1298], ["-", 1304], ["bearing", 1305], ["and", 1313], ["subsequent", 1317], ["cartilage", 1328], ["damage", 1338], ["in", 1345], ["the", 1348], ["rat", 1352], ["MMT", 1356], ["model", 1360], [".", 1365], ["This", 1367], ["model", 1372], ["failed", 1378], ["to", 1385], ["replicate", 1388], ["the", 1398], ["hypotrophic", 1402], ["bone", 1414], ["response", 1419], ["observed", 1428], ["in", 1437], ["tanezumab", 1440], ["-", 1449], ["treated", 1450], ["patients", 1458], ["with", 1467], ["RPOA", 1472], [".", 1476]]}
{"context": "Understanding the pathogenesis of CLL has uncovered a plethora of novel targets for human application of monoclonal antibodies, engineered T cells, or inhibitors of signal transduction pathways. The B-cell receptor signaling pathway is being actively explored as a therapeutic target in CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy. Other key components of the BCR pathway, namely PI3K-\u03b4, are also being targeted with novel therapies with promising results as well. Future trials would likely evaluate ibrutinib in the front-line setting. Moreover, improvements in allogeneic HCT mostly by continuing to reduce associated toxicity as well as incorporating cellular therapies such as autologous CLL tumor vaccines, among others, will continue to expand. This is also the case for the next generation of chimeric antigen receptor therapy for CLL once genetically modified T cells are available at broad scale and with improved efficacy. As our ability to further refine and integrate these therapies continues to improve, and we gain further knowledge from gene sequencing, we anticipate that treatment algorithms will continue to be revised to a more personalized approach to treat this disease with improved efficacy and devoid of unnecessary toxicity.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "e34cd287534b4fd788442be110013bba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[48, 48], [112, 112]], "char_spans": [[292, 300], [643, 651]]}]}], "context_tokens": [["Understanding", 0], ["the", 14], ["pathogenesis", 18], ["of", 31], ["CLL", 34], ["has", 38], ["uncovered", 42], ["a", 52], ["plethora", 54], ["of", 63], ["novel", 66], ["targets", 72], ["for", 80], ["human", 84], ["application", 90], ["of", 102], ["monoclonal", 105], ["antibodies", 116], [",", 126], ["engineered", 128], ["T", 139], ["cells", 141], [",", 146], ["or", 148], ["inhibitors", 151], ["of", 162], ["signal", 165], ["transduction", 172], ["pathways", 185], [".", 193], ["The", 195], ["B", 199], ["-", 200], ["cell", 201], ["receptor", 206], ["signaling", 215], ["pathway", 225], ["is", 233], ["being", 236], ["actively", 242], ["explored", 251], ["as", 260], ["a", 263], ["therapeutic", 265], ["target", 277], ["in", 284], ["CLL", 287], [".", 290], ["Ibrutinib", 292], [",", 301], ["an", 303], ["inhibitor", 306], ["of", 316], ["Bruton", 319], ["'s", 325], ["tyrosine", 328], ["kinase", 337], ["is", 344], ["showing", 347], ["impressive", 355], ["responses", 366], ["in", 376], ["heavily", 379], ["pre", 387], ["-", 390], ["treated", 391], ["high", 399], ["-", 403], ["risk", 404], ["CLL", 409], [",", 412], ["whether", 414], ["alone", 422], ["or", 428], ["in", 431], ["combination", 434], ["with", 446], ["MoAbs", 451], ["or", 457], ["chemotherapy", 460], [".", 472], ["Other", 474], ["key", 480], ["components", 484], ["of", 495], ["the", 498], ["BCR", 502], ["pathway", 506], [",", 513], ["namely", 515], ["PI3K", 522], ["-", 526], ["\u03b4", 527], [",", 528], ["are", 530], ["also", 534], ["being", 539], ["targeted", 545], ["with", 554], ["novel", 559], ["therapies", 565], ["with", 575], ["promising", 580], ["results", 590], ["as", 598], ["well", 601], [".", 605], ["Future", 607], ["trials", 614], ["would", 621], ["likely", 627], ["evaluate", 634], ["ibrutinib", 643], ["in", 653], ["the", 656], ["front", 660], ["-", 665], ["line", 666], ["setting", 671], [".", 678], ["Moreover", 680], [",", 688], ["improvements", 690], ["in", 703], ["allogeneic", 706], ["HCT", 717], ["mostly", 721], ["by", 728], ["continuing", 731], ["to", 742], ["reduce", 745], ["associated", 752], ["toxicity", 763], ["as", 772], ["well", 775], ["as", 780], ["incorporating", 783], ["cellular", 797], ["therapies", 806], ["such", 816], ["as", 821], ["autologous", 824], ["CLL", 835], ["tumor", 839], ["vaccines", 845], [",", 853], ["among", 855], ["others", 861], [",", 867], ["will", 869], ["continue", 874], ["to", 883], ["expand", 886], [".", 892], ["This", 894], ["is", 899], ["also", 902], ["the", 907], ["case", 911], ["for", 916], ["the", 920], ["next", 924], ["generation", 929], ["of", 940], ["chimeric", 943], ["antigen", 952], ["receptor", 960], ["therapy", 969], ["for", 977], ["CLL", 981], ["once", 985], ["genetically", 990], ["modified", 1002], ["T", 1011], ["cells", 1013], ["are", 1019], ["available", 1023], ["at", 1033], ["broad", 1036], ["scale", 1042], ["and", 1048], ["with", 1052], ["improved", 1057], ["efficacy", 1066], [".", 1074], ["As", 1076], ["our", 1079], ["ability", 1083], ["to", 1091], ["further", 1094], ["refine", 1102], ["and", 1109], ["integrate", 1113], ["these", 1123], ["therapies", 1129], ["continues", 1139], ["to", 1149], ["improve", 1152], [",", 1159], ["and", 1161], ["we", 1165], ["gain", 1168], ["further", 1173], ["knowledge", 1181], ["from", 1191], ["gene", 1196], ["sequencing", 1201], [",", 1211], ["we", 1213], ["anticipate", 1216], ["that", 1227], ["treatment", 1232], ["algorithms", 1242], ["will", 1253], ["continue", 1258], ["to", 1267], ["be", 1270], ["revised", 1273], ["to", 1281], ["a", 1284], ["more", 1286], ["personalized", 1291], ["approach", 1304], ["to", 1313], ["treat", 1316], ["this", 1322], ["disease", 1327], ["with", 1335], ["improved", 1340], ["efficacy", 1349], ["and", 1358], ["devoid", 1362], ["of", 1369], ["unnecessary", 1372], ["toxicity", 1384], [".", 1392]]}
{"context": "Minors with a stated age <18 years unaccompanied by a responsible adult form an increasing part of refugees to Europe. They are older than other asylum-seeking children and many come from countries with a high tuberculosis (TB) incidence. During the 2015 refugee crisis, 35,369 of 162,877 refugees (22%) seeking asylum in Sweden were unaccompanied minors, which gave us the opportunity to study their burden of TB infection and disease. Of the unaccompanied minors seeking asylum in Sweden during 2015, 2936 (8.3%) were allocated to northern Stockholm. Of these, 2422 were from countries with an incidence of TB exceeding 100/10 Of those screened, 349 had a positive test and were referred to the northern paediatric TB clinic at Astrid Lindgren Children's Hospital. Of these, 16 had TB disease and 278 latent tuberculosis infection (LTBI), while we considered 53 uninfected. In addition, eight sought medical attention with symptomatic TB outside the screening system. Cohort rates were 6.8% of LTBI and 0.5% of TB in minors from Afghanistan and 26-32% of LTBI and 3.4-3.5% of TB among those from Eritrea, Ethiopia or Somalia. We conclude that TB infection and disease is common among asylum-seeking unaccompanied minors, especially among those from the Horn of Africa.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4b0eb00ff2664722917b55ccb33b9689", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[153, 153], [39, 39]], "char_spans": [[810, 821], [210, 221]]}]}], "context_tokens": [["Minors", 0], ["with", 7], ["a", 12], ["stated", 14], ["age", 21], ["<", 25], ["18", 26], ["years", 29], ["unaccompanied", 35], ["by", 49], ["a", 52], ["responsible", 54], ["adult", 66], ["form", 72], ["an", 77], ["increasing", 80], ["part", 91], ["of", 96], ["refugees", 99], ["to", 108], ["Europe", 111], [".", 117], ["They", 119], ["are", 124], ["older", 128], ["than", 134], ["other", 139], ["asylum", 145], ["-", 151], ["seeking", 152], ["children", 160], ["and", 169], ["many", 173], ["come", 178], ["from", 183], ["countries", 188], ["with", 198], ["a", 203], ["high", 205], ["tuberculosis", 210], ["(", 223], ["TB", 224], [")", 226], ["incidence", 228], [".", 237], ["During", 239], ["the", 246], ["2015", 250], ["refugee", 255], ["crisis", 263], [",", 269], ["35,369", 271], ["of", 278], ["162,877", 281], ["refugees", 289], ["(", 298], ["22", 299], ["%", 301], [")", 302], ["seeking", 304], ["asylum", 312], ["in", 319], ["Sweden", 322], ["were", 329], ["unaccompanied", 334], ["minors", 348], [",", 354], ["which", 356], ["gave", 362], ["us", 367], ["the", 370], ["opportunity", 374], ["to", 386], ["study", 389], ["their", 395], ["burden", 401], ["of", 408], ["TB", 411], ["infection", 414], ["and", 424], ["disease", 428], [".", 435], ["Of", 437], ["the", 440], ["unaccompanied", 444], ["minors", 458], ["seeking", 465], ["asylum", 473], ["in", 480], ["Sweden", 483], ["during", 490], ["2015", 497], [",", 501], ["2936", 503], ["(", 508], ["8.3", 509], ["%", 512], [")", 513], ["were", 515], ["allocated", 520], ["to", 530], ["northern", 533], ["Stockholm", 542], [".", 551], ["Of", 553], ["these", 556], [",", 561], ["2422", 563], ["were", 568], ["from", 573], ["countries", 578], ["with", 588], ["an", 593], ["incidence", 596], ["of", 606], ["TB", 609], ["exceeding", 612], ["100/10", 622], ["Of", 629], ["those", 632], ["screened", 638], [",", 646], ["349", 648], ["had", 652], ["a", 656], ["positive", 658], ["test", 667], ["and", 672], ["were", 676], ["referred", 681], ["to", 690], ["the", 693], ["northern", 697], ["paediatric", 706], ["TB", 717], ["clinic", 720], ["at", 727], ["Astrid", 730], ["Lindgren", 737], ["Children", 746], ["'s", 754], ["Hospital", 757], [".", 765], ["Of", 767], ["these", 770], [",", 775], ["16", 777], ["had", 780], ["TB", 784], ["disease", 787], ["and", 795], ["278", 799], ["latent", 803], ["tuberculosis", 810], ["infection", 823], ["(", 833], ["LTBI", 834], [")", 838], [",", 839], ["while", 841], ["we", 847], ["considered", 850], ["53", 861], ["uninfected", 864], [".", 874], ["In", 876], ["addition", 879], [",", 887], ["eight", 889], ["sought", 895], ["medical", 902], ["attention", 910], ["with", 920], ["symptomatic", 925], ["TB", 937], ["outside", 940], ["the", 948], ["screening", 952], ["system", 962], [".", 968], ["Cohort", 970], ["rates", 977], ["were", 983], ["6.8", 988], ["%", 991], ["of", 993], ["LTBI", 996], ["and", 1001], ["0.5", 1005], ["%", 1008], ["of", 1010], ["TB", 1013], ["in", 1016], ["minors", 1019], ["from", 1026], ["Afghanistan", 1031], ["and", 1043], ["26", 1047], ["-", 1049], ["32", 1050], ["%", 1052], ["of", 1054], ["LTBI", 1057], ["and", 1062], ["3.4", 1066], ["-", 1069], ["3.5", 1070], ["%", 1073], ["of", 1075], ["TB", 1078], ["among", 1081], ["those", 1087], ["from", 1093], ["Eritrea", 1098], [",", 1105], ["Ethiopia", 1107], ["or", 1116], ["Somalia", 1119], [".", 1126], ["We", 1128], ["conclude", 1131], ["that", 1140], ["TB", 1145], ["infection", 1148], ["and", 1158], ["disease", 1162], ["is", 1170], ["common", 1173], ["among", 1180], ["asylum", 1186], ["-", 1192], ["seeking", 1193], ["unaccompanied", 1201], ["minors", 1215], [",", 1221], ["especially", 1223], ["among", 1234], ["those", 1240], ["from", 1246], ["the", 1251], ["Horn", 1255], ["of", 1260], ["Africa", 1263], [".", 1269]]}
{"context": "We evaluated the new, fully automated molecular BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay for detection of methicillin-resistant S. aureus in a low-prevalence (4.1%) setting. Sensitivity, specificity, and positive and negative predictive values were 93.9%, 99.2%, 83.8%, and 99.7%, respectively. The assay reported fewer unresolved results than the BD GeneOhm MRSA ACP assay.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "66854406960a4a4ba4cff23625202de8", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[22, 26]], "char_spans": [[129, 159]]}, {"text": "MRSA", "token_spans": [[16, 16], [74, 74]], "char_spans": [[100, 103], [382, 385]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["new", 17], [",", 20], ["fully", 22], ["automated", 28], ["molecular", 38], ["BD", 48], ["Max", 51], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["assay", 106], ["for", 112], ["detection", 116], ["of", 126], ["methicillin", 129], ["-", 140], ["resistant", 141], ["S.", 151], ["aureus", 154], ["in", 161], ["a", 164], ["low", 166], ["-", 169], ["prevalence", 170], ["(", 181], ["4.1", 182], ["%", 185], [")", 186], ["setting", 188], [".", 195], ["Sensitivity", 197], [",", 208], ["specificity", 210], [",", 221], ["and", 223], ["positive", 227], ["and", 236], ["negative", 240], ["predictive", 249], ["values", 260], ["were", 267], ["93.9", 272], ["%", 276], [",", 277], ["99.2", 279], ["%", 283], [",", 284], ["83.8", 286], ["%", 290], [",", 291], ["and", 293], ["99.7", 297], ["%", 301], [",", 302], ["respectively", 304], [".", 316], ["The", 318], ["assay", 322], ["reported", 328], ["fewer", 337], ["unresolved", 343], ["results", 354], ["than", 362], ["the", 367], ["BD", 371], ["GeneOhm", 374], ["MRSA", 382], ["ACP", 387], ["assay", 391], [".", 396]]}
{"context": "We have previously shown that NADPH oxidase (NOX) lies upstream of uncoupled endothelial nitric oxide synthase (eNOS), which is known to occur in diabetic endothelium. However, it remains unclear which specific NOX isoform(s) is responsible for eNOS uncoupling and endothelial dysfunction in diabetic mouse models. The aim of the present study was to test the hypothesis that one or more NOX isoform(s) mediate(s) diabetic uncoupling of eNOS, which has been shown to occur in patients with diabetes to contribute to endothelial dysfunction. Diabetes was induced by streptozotocin administration. The N (\u03c9)-nitro-L-arginine methyl ester (L-NAME)-sensitive superoxide production of aortic segments, reflective of eNOS uncoupling activity, was determined by electron spin resonance. The L-NAME-sensitive superoxide production was more than doubled in wild-type diabetic mice, implicating uncoupling of eNOS. This was abolished in diabetic p47 ( phox-/-) (also known as Ncf1 (-/-)) mice, but preserved in Nox2 (-/y) (also known as Cybb (-/-)) mice made diabetic. The eNOS uncoupling activity was markedly attenuated in diabetic mice transfected with Nox1 or Nox1 organiser 1 (Noxo1) short interfering RNA (siRNA), and abolished in Nox1 (-/y) diabetic mice. Diabetes-induced impairment in endothelium-dependent vasorelaxation was also significantly attenuated in the Nox1 (-/y) mice made diabetic. By contrast, Nox4 siRNA, or inhibition of mitochondrial complex I or III with rotenone or siRNA, respectively, had no effect on diabetic uncoupling of eNOS. Overexpression of Dhfr, or oral administration of folic acid to improve dihydrofolate reductase (DHFR) function, recoupled eNOS in diabetes to improve endothelial function. Our data demonstrate for the first time that the p47(phox) and NOXO1-dependent activation of NOX1, but not that of NOX2, NOX4 or mitochondrion, mediates diabetic uncoupling of eNOS. NOX1-null mice are protected from diabetic endothelial dysfunction. Novel approaches to inhibit NOX1 and/or improve DHFR function, may prove to have therapeutic potential for diabetic endothelial dysfunction.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "33aa8ce035c44ae2b854b9bd20914504", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[251, 251], [229, 229], [211, 211], [213, 213], [363, 363], [332, 332]], "char_spans": [[1362, 1365], [1227, 1230], [1146, 1149], [1154, 1157], [2001, 2004], [1816, 1819]]}]}], "context_tokens": [["We", 0], ["have", 3], ["previously", 8], ["shown", 19], ["that", 25], ["NADPH", 30], ["oxidase", 36], ["(", 44], ["NOX", 45], [")", 48], ["lies", 50], ["upstream", 55], ["of", 64], ["uncoupled", 67], ["endothelial", 77], ["nitric", 89], ["oxide", 96], ["synthase", 102], ["(", 111], ["eNOS", 112], [")", 116], [",", 117], ["which", 119], ["is", 125], ["known", 128], ["to", 134], ["occur", 137], ["in", 143], ["diabetic", 146], ["endothelium", 155], [".", 166], ["However", 168], [",", 175], ["it", 177], ["remains", 180], ["unclear", 188], ["which", 196], ["specific", 202], ["NOX", 211], ["isoform(s", 215], [")", 224], ["is", 226], ["responsible", 229], ["for", 241], ["eNOS", 245], ["uncoupling", 250], ["and", 261], ["endothelial", 265], ["dysfunction", 277], ["in", 289], ["diabetic", 292], ["mouse", 301], ["models", 307], [".", 313], ["The", 315], ["aim", 319], ["of", 323], ["the", 326], ["present", 330], ["study", 338], ["was", 344], ["to", 348], ["test", 351], ["the", 356], ["hypothesis", 360], ["that", 371], ["one", 376], ["or", 380], ["more", 383], ["NOX", 388], ["isoform(s", 392], [")", 401], ["mediate(s", 403], [")", 412], ["diabetic", 414], ["uncoupling", 423], ["of", 434], ["eNOS", 437], [",", 441], ["which", 443], ["has", 449], ["been", 453], ["shown", 458], ["to", 464], ["occur", 467], ["in", 473], ["patients", 476], ["with", 485], ["diabetes", 490], ["to", 499], ["contribute", 502], ["to", 513], ["endothelial", 516], ["dysfunction", 528], [".", 539], ["Diabetes", 541], ["was", 550], ["induced", 554], ["by", 562], ["streptozotocin", 565], ["administration", 580], [".", 594], ["The", 596], ["N", 600], ["(", 602], ["\u03c9)-nitro", 603], ["-", 611], ["L", 612], ["-", 613], ["arginine", 614], ["methyl", 623], ["ester", 630], ["(", 636], ["L", 637], ["-", 638], ["NAME)-sensitive", 639], ["superoxide", 655], ["production", 666], ["of", 677], ["aortic", 680], ["segments", 687], [",", 695], ["reflective", 697], ["of", 708], ["eNOS", 711], ["uncoupling", 716], ["activity", 727], [",", 735], ["was", 737], ["determined", 741], ["by", 752], ["electron", 755], ["spin", 764], ["resonance", 769], [".", 778], ["The", 780], ["L", 784], ["-", 785], ["NAME", 786], ["-", 790], ["sensitive", 791], ["superoxide", 801], ["production", 812], ["was", 823], ["more", 827], ["than", 832], ["doubled", 837], ["in", 845], ["wild", 848], ["-", 852], ["type", 853], ["diabetic", 858], ["mice", 867], [",", 871], ["implicating", 873], ["uncoupling", 885], ["of", 896], ["eNOS", 899], [".", 903], ["This", 905], ["was", 910], ["abolished", 914], ["in", 924], ["diabetic", 927], ["p47", 936], ["(", 940], ["phox-/-", 942], [")", 949], ["(", 951], ["also", 952], ["known", 957], ["as", 963], ["Ncf1", 966], ["(", 971], ["-/-", 972], [")", 975], [")", 976], ["mice", 978], [",", 982], ["but", 984], ["preserved", 988], ["in", 998], ["Nox2", 1001], ["(", 1006], ["-/y", 1007], [")", 1010], ["(", 1012], ["also", 1013], ["known", 1018], ["as", 1024], ["Cybb", 1027], ["(", 1032], ["-/-", 1033], [")", 1036], [")", 1037], ["mice", 1039], ["made", 1044], ["diabetic", 1049], [".", 1057], ["The", 1059], ["eNOS", 1063], ["uncoupling", 1068], ["activity", 1079], ["was", 1088], ["markedly", 1092], ["attenuated", 1101], ["in", 1112], ["diabetic", 1115], ["mice", 1124], ["transfected", 1129], ["with", 1141], ["Nox1", 1146], ["or", 1151], ["Nox1", 1154], ["organiser", 1159], ["1", 1169], ["(", 1171], ["Noxo1", 1172], [")", 1177], ["short", 1179], ["interfering", 1185], ["RNA", 1197], ["(", 1201], ["siRNA", 1202], [")", 1207], [",", 1208], ["and", 1210], ["abolished", 1214], ["in", 1224], ["Nox1", 1227], ["(", 1232], ["-/y", 1233], [")", 1236], ["diabetic", 1238], ["mice", 1247], [".", 1251], ["Diabetes", 1253], ["-", 1261], ["induced", 1262], ["impairment", 1270], ["in", 1281], ["endothelium", 1284], ["-", 1295], ["dependent", 1296], ["vasorelaxation", 1306], ["was", 1321], ["also", 1325], ["significantly", 1330], ["attenuated", 1344], ["in", 1355], ["the", 1358], ["Nox1", 1362], ["(", 1367], ["-/y", 1368], [")", 1371], ["mice", 1373], ["made", 1378], ["diabetic", 1383], [".", 1391], ["By", 1393], ["contrast", 1396], [",", 1404], ["Nox4", 1406], ["siRNA", 1411], [",", 1416], ["or", 1418], ["inhibition", 1421], ["of", 1432], ["mitochondrial", 1435], ["complex", 1449], ["I", 1457], ["or", 1459], ["III", 1462], ["with", 1466], ["rotenone", 1471], ["or", 1480], ["siRNA", 1483], [",", 1488], ["respectively", 1490], [",", 1502], ["had", 1504], ["no", 1508], ["effect", 1511], ["on", 1518], ["diabetic", 1521], ["uncoupling", 1530], ["of", 1541], ["eNOS", 1544], [".", 1548], ["Overexpression", 1550], ["of", 1565], ["Dhfr", 1568], [",", 1572], ["or", 1574], ["oral", 1577], ["administration", 1582], ["of", 1597], ["folic", 1600], ["acid", 1606], ["to", 1611], ["improve", 1614], ["dihydrofolate", 1622], ["reductase", 1636], ["(", 1646], ["DHFR", 1647], [")", 1651], ["function", 1653], [",", 1661], ["recoupled", 1663], ["eNOS", 1673], ["in", 1678], ["diabetes", 1681], ["to", 1690], ["improve", 1693], ["endothelial", 1701], ["function", 1713], [".", 1721], ["Our", 1723], ["data", 1727], ["demonstrate", 1732], ["for", 1744], ["the", 1748], ["first", 1752], ["time", 1758], ["that", 1763], ["the", 1768], ["p47(phox", 1772], [")", 1780], ["and", 1782], ["NOXO1-dependent", 1786], ["activation", 1802], ["of", 1813], ["NOX1", 1816], [",", 1820], ["but", 1822], ["not", 1826], ["that", 1830], ["of", 1835], ["NOX2", 1838], [",", 1842], ["NOX4", 1844], ["or", 1849], ["mitochondrion", 1852], [",", 1865], ["mediates", 1867], ["diabetic", 1876], ["uncoupling", 1885], ["of", 1896], ["eNOS", 1899], [".", 1903], ["NOX1-null", 1905], ["mice", 1915], ["are", 1920], ["protected", 1924], ["from", 1934], ["diabetic", 1939], ["endothelial", 1948], ["dysfunction", 1960], [".", 1971], ["Novel", 1973], ["approaches", 1979], ["to", 1990], ["inhibit", 1993], ["NOX1", 2001], ["and/or", 2006], ["improve", 2013], ["DHFR", 2021], ["function", 2026], [",", 2034], ["may", 2036], ["prove", 2040], ["to", 2046], ["have", 2049], ["therapeutic", 2054], ["potential", 2066], ["for", 2076], ["diabetic", 2080], ["endothelial", 2089], ["dysfunction", 2101], [".", 2112]]}
{"context": "Mutations in the alpha-synuclein gene have been linked to rare cases of familial Parkinson's disease (PD). Alpha-synuclein is a major component of Lewy bodies (LB), a pathological hallmark of PD. Transgenic mice and Drosophila expressing either wild-type or mutant human alpha-synuclein develop motor deficits, LB-like inclusions in some neurons, and neuronal degeneration. However, the relationship between abnormal aggregates of alpha-synuclein and human dopamine (DA) neuron degeneration remains unclear. In this report, we have investigated the influence of alpha-synuclein expression on DA neurons in primary culture of embryonic human mesencephalon. Two days after culture, human DA cells were transduced with wild-type or mutant human (Ala(53)Thr) alpha-synuclein adenoviruses and maintained for 5 days. Overexpression of mutant and wild-type human alpha-synuclein resulted in 49% (P<0.01) and 27% (P<0.05) loss of DA neurons, respectively, while not affecting viability of other cells in the culture. Overexpression of rat alpha-synuclein or GFP (green fluorescent protein) had no effect on DA neuron survival. Cytoplasmic inclusions of alpha-synuclein were detected immunohistochemically in DA cells transduced with mutant human alpha-synuclein, but not wild-type alpha-synuclein. These results show that overexpression of human alpha-synuclein, particularly the mutant form, can cause human DA neuron death, suggesting that alpha-synuclein may have a primary role in the pathogenesis of PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "5d3ed014bc4046eda811724747a7aa23", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[195, 197], [81, 83], [54, 56], [22, 24], [140, 142], [158, 160], [238, 240], [267, 269], [229, 231], [216, 218], [105, 107], [249, 251], [3, 5]], "char_spans": [[1031, 1045], [431, 445], [271, 285], [107, 121], [755, 769], [856, 870], [1273, 1287], [1434, 1448], [1238, 1252], [1145, 1159], [562, 576], [1338, 1352], [17, 31]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["alpha", 17], ["-", 22], ["synuclein", 23], ["gene", 33], ["have", 38], ["been", 43], ["linked", 48], ["to", 55], ["rare", 58], ["cases", 63], ["of", 69], ["familial", 72], ["Parkinson", 81], ["'s", 90], ["disease", 93], ["(", 101], ["PD", 102], [")", 104], [".", 105], ["Alpha", 107], ["-", 112], ["synuclein", 113], ["is", 123], ["a", 126], ["major", 128], ["component", 134], ["of", 144], ["Lewy", 147], ["bodies", 152], ["(", 159], ["LB", 160], [")", 162], [",", 163], ["a", 165], ["pathological", 167], ["hallmark", 180], ["of", 189], ["PD", 192], [".", 194], ["Transgenic", 196], ["mice", 207], ["and", 212], ["Drosophila", 216], ["expressing", 227], ["either", 238], ["wild", 245], ["-", 249], ["type", 250], ["or", 255], ["mutant", 258], ["human", 265], ["alpha", 271], ["-", 276], ["synuclein", 277], ["develop", 287], ["motor", 295], ["deficits", 301], [",", 309], ["LB", 311], ["-", 313], ["like", 314], ["inclusions", 319], ["in", 330], ["some", 333], ["neurons", 338], [",", 345], ["and", 347], ["neuronal", 351], ["degeneration", 360], [".", 372], ["However", 374], [",", 381], ["the", 383], ["relationship", 387], ["between", 400], ["abnormal", 408], ["aggregates", 417], ["of", 428], ["alpha", 431], ["-", 436], ["synuclein", 437], ["and", 447], ["human", 451], ["dopamine", 457], ["(", 466], ["DA", 467], [")", 469], ["neuron", 471], ["degeneration", 478], ["remains", 491], ["unclear", 499], [".", 506], ["In", 508], ["this", 511], ["report", 516], [",", 522], ["we", 524], ["have", 527], ["investigated", 532], ["the", 545], ["influence", 549], ["of", 559], ["alpha", 562], ["-", 567], ["synuclein", 568], ["expression", 578], ["on", 589], ["DA", 592], ["neurons", 595], ["in", 603], ["primary", 606], ["culture", 614], ["of", 622], ["embryonic", 625], ["human", 635], ["mesencephalon", 641], [".", 654], ["Two", 656], ["days", 660], ["after", 665], ["culture", 671], [",", 678], ["human", 680], ["DA", 686], ["cells", 689], ["were", 695], ["transduced", 700], ["with", 711], ["wild", 716], ["-", 720], ["type", 721], ["or", 726], ["mutant", 729], ["human", 736], ["(", 742], ["Ala(53)Thr", 743], [")", 753], ["alpha", 755], ["-", 760], ["synuclein", 761], ["adenoviruses", 771], ["and", 784], ["maintained", 788], ["for", 799], ["5", 803], ["days", 805], [".", 809], ["Overexpression", 811], ["of", 826], ["mutant", 829], ["and", 836], ["wild", 840], ["-", 844], ["type", 845], ["human", 850], ["alpha", 856], ["-", 861], ["synuclein", 862], ["resulted", 872], ["in", 881], ["49", 884], ["%", 886], ["(", 888], ["P<0.01", 889], [")", 895], ["and", 897], ["27", 901], ["%", 903], ["(", 905], ["P<0.05", 906], [")", 912], ["loss", 914], ["of", 919], ["DA", 922], ["neurons", 925], [",", 932], ["respectively", 934], [",", 946], ["while", 948], ["not", 954], ["affecting", 958], ["viability", 968], ["of", 978], ["other", 981], ["cells", 987], ["in", 993], ["the", 996], ["culture", 1000], [".", 1007], ["Overexpression", 1009], ["of", 1024], ["rat", 1027], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["or", 1047], ["GFP", 1050], ["(", 1054], ["green", 1055], ["fluorescent", 1061], ["protein", 1073], [")", 1080], ["had", 1082], ["no", 1086], ["effect", 1089], ["on", 1096], ["DA", 1099], ["neuron", 1102], ["survival", 1109], [".", 1117], ["Cytoplasmic", 1119], ["inclusions", 1131], ["of", 1142], ["alpha", 1145], ["-", 1150], ["synuclein", 1151], ["were", 1161], ["detected", 1166], ["immunohistochemically", 1175], ["in", 1197], ["DA", 1200], ["cells", 1203], ["transduced", 1209], ["with", 1220], ["mutant", 1225], ["human", 1232], ["alpha", 1238], ["-", 1243], ["synuclein", 1244], [",", 1253], ["but", 1255], ["not", 1259], ["wild", 1263], ["-", 1267], ["type", 1268], ["alpha", 1273], ["-", 1278], ["synuclein", 1279], [".", 1288], ["These", 1290], ["results", 1296], ["show", 1304], ["that", 1309], ["overexpression", 1314], ["of", 1329], ["human", 1332], ["alpha", 1338], ["-", 1343], ["synuclein", 1344], [",", 1353], ["particularly", 1355], ["the", 1368], ["mutant", 1372], ["form", 1379], [",", 1383], ["can", 1385], ["cause", 1389], ["human", 1395], ["DA", 1401], ["neuron", 1404], ["death", 1411], [",", 1416], ["suggesting", 1418], ["that", 1429], ["alpha", 1434], ["-", 1439], ["synuclein", 1440], ["may", 1450], ["have", 1454], ["a", 1459], ["primary", 1461], ["role", 1469], ["in", 1474], ["the", 1477], ["pathogenesis", 1481], ["of", 1494], ["PD", 1497], [".", 1499]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder resulting in the growth of a variety of tumours, and is inherited in an autosomal dominant pattern. Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours that commonly harbour oncogenic mutations in KIT or PDGFRA and are thought to arise from the interstitial cells of Cajal (ICC; the pacemaker cells of the gut). To characterise two patients with NF1 and GISTs. Two patients were genotyped for germline mutations in NF1. GISTs from both patients were genotyped for somatic mutations in KIT and PDGFRA. Loss of heterozygosity (LOH) of NF1 in one GIST was assessed by genotyping seven microsatellite markers spanning 2.39 Mb of the NF1 locus in the tumour and in genomic DNA. The known germline mutation in NF1 was confirmed in GIST DNA by sequencing. The copy number of the mutated NF1 allele was determined by multiplex ligand-dependent probe amplification. GISTs from both patients were of wild type for mutations in KIT and PDGFRA. In the GIST with adequate DNA, all seven markers were informative and showed LOH at the NF1 locus; sequencing of NF1 from that GIST showed no wild-type sequence, suggesting that it was lost in the tumour. Multiplex ligand-dependent probe amplification analysis showed that two copies of all NF1 exons were present. This is the first evidence of mitotic recombination resulting in a reduction to homozygosity of a germline NF1 mutation in an NF1-associated GIST. We hypothesise that the LOH of NF1 and lack of KIT and PDGFRA mutations are evidence of an alternative pathogenesis in NF1-associated GISTs.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "66fb49bd52204318bfa262bfd21dadd7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[272, 272], [109, 109], [125, 125], [86, 86], [74, 74], [155, 155], [237, 237], [4, 4], [140, 140], [199, 199], [204, 204], [259, 259]], "char_spans": [[1499, 1501], [606, 608], [702, 704], [488, 490], [419, 421], [853, 855], [1297, 1299], [26, 28], [777, 779], [1094, 1096], [1119, 1121], [1428, 1430]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["neurocutaneous", 36], ["disorder", 51], ["resulting", 60], ["in", 70], ["the", 73], ["growth", 77], ["of", 84], ["a", 87], ["variety", 89], ["of", 97], ["tumours", 100], [",", 107], ["and", 109], ["is", 113], ["inherited", 116], ["in", 126], ["an", 129], ["autosomal", 132], ["dominant", 142], ["pattern", 151], [".", 158], ["Gastrointestinal", 160], ["stromal", 177], ["tumours", 185], ["(", 193], ["GISTs", 194], [")", 199], ["are", 201], ["mesenchymal", 205], ["tumours", 217], ["that", 225], ["commonly", 230], ["harbour", 239], ["oncogenic", 247], ["mutations", 257], ["in", 267], ["KIT", 270], ["or", 274], ["PDGFRA", 277], ["and", 284], ["are", 288], ["thought", 292], ["to", 300], ["arise", 303], ["from", 309], ["the", 314], ["interstitial", 318], ["cells", 331], ["of", 337], ["Cajal", 340], ["(", 346], ["ICC", 347], [";", 350], ["the", 352], ["pacemaker", 356], ["cells", 366], ["of", 372], ["the", 375], ["gut", 379], [")", 382], [".", 383], ["To", 385], ["characterise", 388], ["two", 401], ["patients", 405], ["with", 414], ["NF1", 419], ["and", 423], ["GISTs", 427], [".", 432], ["Two", 434], ["patients", 438], ["were", 447], ["genotyped", 452], ["for", 462], ["germline", 466], ["mutations", 475], ["in", 485], ["NF1", 488], [".", 491], ["GISTs", 493], ["from", 499], ["both", 504], ["patients", 509], ["were", 518], ["genotyped", 523], ["for", 533], ["somatic", 537], ["mutations", 545], ["in", 555], ["KIT", 558], ["and", 562], ["PDGFRA", 566], [".", 572], ["Loss", 574], ["of", 579], ["heterozygosity", 582], ["(", 597], ["LOH", 598], [")", 601], ["of", 603], ["NF1", 606], ["in", 610], ["one", 613], ["GIST", 617], ["was", 622], ["assessed", 626], ["by", 635], ["genotyping", 638], ["seven", 649], ["microsatellite", 655], ["markers", 670], ["spanning", 678], ["2.39", 687], ["Mb", 692], ["of", 695], ["the", 698], ["NF1", 702], ["locus", 706], ["in", 712], ["the", 715], ["tumour", 719], ["and", 726], ["in", 730], ["genomic", 733], ["DNA", 741], [".", 744], ["The", 746], ["known", 750], ["germline", 756], ["mutation", 765], ["in", 774], ["NF1", 777], ["was", 781], ["confirmed", 785], ["in", 795], ["GIST", 798], ["DNA", 803], ["by", 807], ["sequencing", 810], [".", 820], ["The", 822], ["copy", 826], ["number", 831], ["of", 838], ["the", 841], ["mutated", 845], ["NF1", 853], ["allele", 857], ["was", 864], ["determined", 868], ["by", 879], ["multiplex", 882], ["ligand", 892], ["-", 898], ["dependent", 899], ["probe", 909], ["amplification", 915], [".", 928], ["GISTs", 930], ["from", 936], ["both", 941], ["patients", 946], ["were", 955], ["of", 960], ["wild", 963], ["type", 968], ["for", 973], ["mutations", 977], ["in", 987], ["KIT", 990], ["and", 994], ["PDGFRA", 998], [".", 1004], ["In", 1006], ["the", 1009], ["GIST", 1013], ["with", 1018], ["adequate", 1023], ["DNA", 1032], [",", 1035], ["all", 1037], ["seven", 1041], ["markers", 1047], ["were", 1055], ["informative", 1060], ["and", 1072], ["showed", 1076], ["LOH", 1083], ["at", 1087], ["the", 1090], ["NF1", 1094], ["locus", 1098], [";", 1103], ["sequencing", 1105], ["of", 1116], ["NF1", 1119], ["from", 1123], ["that", 1128], ["GIST", 1133], ["showed", 1138], ["no", 1145], ["wild", 1148], ["-", 1152], ["type", 1153], ["sequence", 1158], [",", 1166], ["suggesting", 1168], ["that", 1179], ["it", 1184], ["was", 1187], ["lost", 1191], ["in", 1196], ["the", 1199], ["tumour", 1203], [".", 1209], ["Multiplex", 1211], ["ligand", 1221], ["-", 1227], ["dependent", 1228], ["probe", 1238], ["amplification", 1244], ["analysis", 1258], ["showed", 1267], ["that", 1274], ["two", 1279], ["copies", 1283], ["of", 1290], ["all", 1293], ["NF1", 1297], ["exons", 1301], ["were", 1307], ["present", 1312], [".", 1319], ["This", 1321], ["is", 1326], ["the", 1329], ["first", 1333], ["evidence", 1339], ["of", 1348], ["mitotic", 1351], ["recombination", 1359], ["resulting", 1373], ["in", 1383], ["a", 1386], ["reduction", 1388], ["to", 1398], ["homozygosity", 1401], ["of", 1414], ["a", 1417], ["germline", 1419], ["NF1", 1428], ["mutation", 1432], ["in", 1441], ["an", 1444], ["NF1-associated", 1447], ["GIST", 1462], [".", 1466], ["We", 1468], ["hypothesise", 1471], ["that", 1483], ["the", 1488], ["LOH", 1492], ["of", 1496], ["NF1", 1499], ["and", 1503], ["lack", 1507], ["of", 1512], ["KIT", 1515], ["and", 1519], ["PDGFRA", 1523], ["mutations", 1530], ["are", 1540], ["evidence", 1544], ["of", 1553], ["an", 1556], ["alternative", 1559], ["pathogenesis", 1571], ["in", 1584], ["NF1-associated", 1587], ["GISTs", 1602], [".", 1607]]}
{"context": "{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag. The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). Selexipag and ACT-333679 evoked full relaxation of pulmonary artery from control and monocrotaline (MCT)-PAH rats, and ACT-333679 relaxed normal pulmonary artery contracted with either endothelin-1 (ET-1) or phenylephrine. In contrast, treprostinil evoked weaker relaxation than ACT-333679 of control pulmonary artery and failed to induce relaxation of pulmonary artery from MCT-PAH rats. Treprostinil did not evoke relaxation of normal pulmonary artery contracted with either ET-1 or phenylephrine. Expression of prostaglandin E(3) (EP(3)) receptor mRNA was increased in pulmonary artery from MCT-PAH rats. In contraction experiments, the selective EP(3) receptor agonist sulprostone evoked significantly greater contraction of pulmonary artery from MCT-PAH rats compared with control rats. The presence of a threshold concentration of ET-1 significantly augmented the contractile response to sulprostone in normal pulmonary artery. ACT-333679 did not evoke direct contraction of rat pulmonary artery, whereas treprostinil evoked concentration-dependent contraction that was inhibited by the EP(3) receptor antagonist (2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. Antagonism of EP(3) receptors also revealed a relaxant response to treprostinil in normal pulmonary artery contracted with ET-1. These data demonstrate that the relaxant efficacy of the selective IP receptor agonist selexipag and its metabolite ACT-333679 is not modified under conditions associated with PAH, whereas relaxation to treprostinil may be limited in the presence of mediators of disease.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "69acbdb73b2c414cb48a711bb6da31f1", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[59, 61]], "char_spans": [[395, 425]]}]}], "context_tokens": [["{", 0], ["4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic", 1], ["acid", 61], ["(", 66], ["ACT-333679", 67], [")", 77], ["is", 79], ["the", 82], ["main", 86], ["metabolite", 91], ["of", 102], ["the", 105], ["selective", 109], ["prostacyclin", 119], ["(", 132], ["PGI(2", 133], [")", 138], [")", 139], ["receptor", 141], ["(", 150], ["IP", 151], ["receptor", 154], [")", 162], ["agonist", 164], ["selexipag", 172], [".", 181], ["The", 183], ["goal", 187], ["of", 192], ["this", 195], ["study", 200], ["was", 206], ["to", 210], ["determine", 213], ["the", 223], ["influence", 227], ["of", 237], ["IP", 240], ["receptor", 243], ["selectivity", 252], ["on", 264], ["the", 267], ["vasorelaxant", 271], ["efficacy", 284], ["of", 293], ["ACT-333679", 296], ["and", 307], ["the", 311], ["PGI(2", 315], [")", 320], ["analog", 322], ["treprostinil", 329], ["in", 342], ["pulmonary", 345], ["artery", 355], ["under", 362], ["conditions", 368], ["associated", 379], ["with", 390], ["pulmonary", 395], ["arterial", 405], ["hypertension", 414], ["(", 427], ["PAH", 428], [")", 431], [".", 432], ["Selexipag", 434], ["and", 444], ["ACT-333679", 448], ["evoked", 459], ["full", 466], ["relaxation", 471], ["of", 482], ["pulmonary", 485], ["artery", 495], ["from", 502], ["control", 507], ["and", 515], ["monocrotaline", 519], ["(", 533], ["MCT)-PAH", 534], ["rats", 543], [",", 547], ["and", 549], ["ACT-333679", 553], ["relaxed", 564], ["normal", 572], ["pulmonary", 579], ["artery", 589], ["contracted", 596], ["with", 607], ["either", 612], ["endothelin-1", 619], ["(", 632], ["ET-1", 633], [")", 637], ["or", 639], ["phenylephrine", 642], [".", 655], ["In", 657], ["contrast", 660], [",", 668], ["treprostinil", 670], ["evoked", 683], ["weaker", 690], ["relaxation", 697], ["than", 708], ["ACT-333679", 713], ["of", 724], ["control", 727], ["pulmonary", 735], ["artery", 745], ["and", 752], ["failed", 756], ["to", 763], ["induce", 766], ["relaxation", 773], ["of", 784], ["pulmonary", 787], ["artery", 797], ["from", 804], ["MCT", 809], ["-", 812], ["PAH", 813], ["rats", 817], [".", 821], ["Treprostinil", 823], ["did", 836], ["not", 840], ["evoke", 844], ["relaxation", 850], ["of", 861], ["normal", 864], ["pulmonary", 871], ["artery", 881], ["contracted", 888], ["with", 899], ["either", 904], ["ET-1", 911], ["or", 916], ["phenylephrine", 919], [".", 932], ["Expression", 934], ["of", 945], ["prostaglandin", 948], ["E(3", 962], [")", 965], ["(", 967], ["EP(3", 968], [")", 972], [")", 973], ["receptor", 975], ["mRNA", 984], ["was", 989], ["increased", 993], ["in", 1003], ["pulmonary", 1006], ["artery", 1016], ["from", 1023], ["MCT", 1028], ["-", 1031], ["PAH", 1032], ["rats", 1036], [".", 1040], ["In", 1042], ["contraction", 1045], ["experiments", 1057], [",", 1068], ["the", 1070], ["selective", 1074], ["EP(3", 1084], [")", 1088], ["receptor", 1090], ["agonist", 1099], ["sulprostone", 1107], ["evoked", 1119], ["significantly", 1126], ["greater", 1140], ["contraction", 1148], ["of", 1160], ["pulmonary", 1163], ["artery", 1173], ["from", 1180], ["MCT", 1185], ["-", 1188], ["PAH", 1189], ["rats", 1193], ["compared", 1198], ["with", 1207], ["control", 1212], ["rats", 1220], [".", 1224], ["The", 1226], ["presence", 1230], ["of", 1239], ["a", 1242], ["threshold", 1244], ["concentration", 1254], ["of", 1268], ["ET-1", 1271], ["significantly", 1276], ["augmented", 1290], ["the", 1300], ["contractile", 1304], ["response", 1316], ["to", 1325], ["sulprostone", 1328], ["in", 1340], ["normal", 1343], ["pulmonary", 1350], ["artery", 1360], [".", 1366], ["ACT-333679", 1368], ["did", 1379], ["not", 1383], ["evoke", 1387], ["direct", 1393], ["contraction", 1400], ["of", 1412], ["rat", 1415], ["pulmonary", 1419], ["artery", 1429], [",", 1435], ["whereas", 1437], ["treprostinil", 1445], ["evoked", 1458], ["concentration", 1465], ["-", 1478], ["dependent", 1479], ["contraction", 1489], ["that", 1501], ["was", 1506], ["inhibited", 1510], ["by", 1520], ["the", 1523], ["EP(3", 1527], [")", 1531], ["receptor", 1533], ["antagonist", 1542], ["(", 1553], ["2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide", 1554], [".", 1621], ["Antagonism", 1623], ["of", 1634], ["EP(3", 1637], [")", 1641], ["receptors", 1643], ["also", 1653], ["revealed", 1658], ["a", 1667], ["relaxant", 1669], ["response", 1678], ["to", 1687], ["treprostinil", 1690], ["in", 1703], ["normal", 1706], ["pulmonary", 1713], ["artery", 1723], ["contracted", 1730], ["with", 1741], ["ET-1", 1746], [".", 1750], ["These", 1752], ["data", 1758], ["demonstrate", 1763], ["that", 1775], ["the", 1780], ["relaxant", 1784], ["efficacy", 1793], ["of", 1802], ["the", 1805], ["selective", 1809], ["IP", 1819], ["receptor", 1822], ["agonist", 1831], ["selexipag", 1839], ["and", 1849], ["its", 1853], ["metabolite", 1857], ["ACT-333679", 1868], ["is", 1879], ["not", 1882], ["modified", 1886], ["under", 1895], ["conditions", 1901], ["associated", 1912], ["with", 1923], ["PAH", 1928], [",", 1931], ["whereas", 1933], ["relaxation", 1941], ["to", 1952], ["treprostinil", 1955], ["may", 1968], ["be", 1972], ["limited", 1975], ["in", 1983], ["the", 1986], ["presence", 1990], ["of", 1999], ["mediators", 2002], ["of", 2012], ["disease", 2015], [".", 2022]]}
{"context": "Ehlers-Danlos syndrome (EDS), a heterogeneous group of inheritable connective tissue disorders, is attributed to mutations in connective tissue genes. These mutations cause defects in collagen. Collagen, a connective tissue protein that acts like glue, gives strength to the body and provides support and elasticity for movement. Thus, the altered gene affects the mechanical properties of skin, joints, ligaments, and blood vessels. Ehlers-Danlos syndrome is transmitted through autosomal dominant, autosomal recessive, or x-linked patterns of inheritance. The life expectancy of an affected infant varies with the type of EDS. This article provides an overview of the 6 major classifications of EDS, their unique clinical presentations, a focused physical assessment guide, considerations for nursing care, and resources for parents. Ehlers-Danlos syndrome can be a potentially debilitating syndrome. It requires preventative and protective measures starting at birth to preserve joint function to improve infant outcomes. Caring for patients with EDS requires an understanding of the potential associated complications to help minimize the physical and emotional impact of the syndrome and improve the quality of life for affected individuals.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10f8119b74f94e56b81c9c59ad105093", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [36, 37], [22, 23]], "char_spans": [[67, 83], [206, 222], [126, 142]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["(", 23], ["EDS", 24], [")", 27], [",", 28], ["a", 30], ["heterogeneous", 32], ["group", 46], ["of", 52], ["inheritable", 55], ["connective", 67], ["tissue", 78], ["disorders", 85], [",", 94], ["is", 96], ["attributed", 99], ["to", 110], ["mutations", 113], ["in", 123], ["connective", 126], ["tissue", 137], ["genes", 144], [".", 149], ["These", 151], ["mutations", 157], ["cause", 167], ["defects", 173], ["in", 181], ["collagen", 184], [".", 192], ["Collagen", 194], [",", 202], ["a", 204], ["connective", 206], ["tissue", 217], ["protein", 224], ["that", 232], ["acts", 237], ["like", 242], ["glue", 247], [",", 251], ["gives", 253], ["strength", 259], ["to", 268], ["the", 271], ["body", 275], ["and", 280], ["provides", 284], ["support", 293], ["and", 301], ["elasticity", 305], ["for", 316], ["movement", 320], [".", 328], ["Thus", 330], [",", 334], ["the", 336], ["altered", 340], ["gene", 348], ["affects", 353], ["the", 361], ["mechanical", 365], ["properties", 376], ["of", 387], ["skin", 390], [",", 394], ["joints", 396], [",", 402], ["ligaments", 404], [",", 413], ["and", 415], ["blood", 419], ["vessels", 425], [".", 432], ["Ehlers", 434], ["-", 440], ["Danlos", 441], ["syndrome", 448], ["is", 457], ["transmitted", 460], ["through", 472], ["autosomal", 480], ["dominant", 490], [",", 498], ["autosomal", 500], ["recessive", 510], [",", 519], ["or", 521], ["x", 524], ["-", 525], ["linked", 526], ["patterns", 533], ["of", 542], ["inheritance", 545], [".", 556], ["The", 558], ["life", 562], ["expectancy", 567], ["of", 578], ["an", 581], ["affected", 584], ["infant", 593], ["varies", 600], ["with", 607], ["the", 612], ["type", 616], ["of", 621], ["EDS", 624], [".", 627], ["This", 629], ["article", 634], ["provides", 642], ["an", 651], ["overview", 654], ["of", 663], ["the", 666], ["6", 670], ["major", 672], ["classifications", 678], ["of", 694], ["EDS", 697], [",", 700], ["their", 702], ["unique", 708], ["clinical", 715], ["presentations", 724], [",", 737], ["a", 739], ["focused", 741], ["physical", 749], ["assessment", 758], ["guide", 769], [",", 774], ["considerations", 776], ["for", 791], ["nursing", 795], ["care", 803], [",", 807], ["and", 809], ["resources", 813], ["for", 823], ["parents", 827], [".", 834], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], ["can", 859], ["be", 863], ["a", 866], ["potentially", 868], ["debilitating", 880], ["syndrome", 893], [".", 901], ["It", 903], ["requires", 906], ["preventative", 915], ["and", 928], ["protective", 932], ["measures", 943], ["starting", 952], ["at", 961], ["birth", 964], ["to", 970], ["preserve", 973], ["joint", 982], ["function", 988], ["to", 997], ["improve", 1000], ["infant", 1008], ["outcomes", 1015], [".", 1023], ["Caring", 1025], ["for", 1032], ["patients", 1036], ["with", 1045], ["EDS", 1050], ["requires", 1054], ["an", 1063], ["understanding", 1066], ["of", 1080], ["the", 1083], ["potential", 1087], ["associated", 1097], ["complications", 1108], ["to", 1122], ["help", 1125], ["minimize", 1130], ["the", 1139], ["physical", 1143], ["and", 1152], ["emotional", 1156], ["impact", 1166], ["of", 1173], ["the", 1176], ["syndrome", 1180], ["and", 1189], ["improve", 1193], ["the", 1201], ["quality", 1205], ["of", 1213], ["life", 1216], ["for", 1221], ["affected", 1225], ["individuals", 1234], [".", 1245]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "9a096b481413444ea01bcdaa55383924", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [55, 55], [78, 78]], "char_spans": [[0, 3], [360, 363], [489, 492]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["anemia", 16], ["is", 23], ["common", 26], ["in", 33], ["people", 36], ["with", 43], ["chronic", 48], ["kidney", 56], ["disease", 63], ["(", 71], ["CKD", 72], [")", 75], ["and", 77], ["its", 81], ["importance", 85], ["in", 96], ["supporting", 99], ["erythropoiesis", 110], ["is", 125], ["unquestioned", 128], ["especially", 141], ["in", 152], ["those", 155], ["patients", 161], ["treated", 170], ["with", 178], ["erythropoietin", 183], [".", 197], ["Clinical", 199], ["symptomatology", 208], ["such", 223], ["as", 228], ["fatigability", 231], [",", 243], ["cold", 245], ["intolerance", 250], [",", 261], ["failure", 263], ["to", 271], ["concentrate", 274], ["and", 286], ["poor", 290], ["effort", 295], ["intolerance", 302], ["is", 314], ["often", 317], ["attributed", 323], ["to", 334], ["anemia", 337], ["or", 344], ["uremia", 347], [".", 353], ["That", 355], ["iron", 360], ["deficiency", 365], [",", 375], ["per", 377], ["se", 381], [",", 383], ["can", 385], ["cause", 389], ["these", 395], ["symptoms", 401], ["is", 410], ["poorly", 413], ["recognized", 420], [".", 430], ["Clinical", 432], ["and", 441], ["animal", 445], ["studies", 452], ["that", 460], ["support", 465], ["the", 473], ["benefits", 477], ["of", 486], ["iron", 489], ["supplementation", 494], [",", 509], ["independent", 511], ["of", 523], ["increasing", 526], ["hemoglobin", 537], [",", 547], ["such", 549], ["as", 554], ["those", 557], ["on", 563], ["immune", 566], ["function", 573], [",", 581], ["physical", 583], ["performance", 592], [",", 603], ["thermoregulation", 605], [",", 621], ["cognition", 623], [",", 632], ["and", 634], ["restless", 638], ["leg", 647], ["syndrome", 651], ["and", 660], ["aluminum", 664], ["absorption", 673], ["is", 684], ["the", 687], ["subject", 691], ["of", 699], ["this", 702], ["narrative", 707], ["review", 717], [".", 723]]}
{"context": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria. Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses. The aim of the study was to determine the prevalence of the etiologic agents of superficial mycoses and the frequency of Corynebacterium minutissimum in interdigital foot infections. All the samples obtained from the 121 patients with interdigital foot infections were examined directly with the use of 20% potassium hydroxide mounts and Gram stain under the microscope and cultured on Sabouraud's dextrose agar plates. In identification of superficial mycoses, the rate was found to be 14% with the cultural method and 14% with direct microscopic examination. Using a combination of direct microscopic examination and culture, a 33.8% ratio was achieved. In the culture of these samples, the most isolated factor was Trichophyton rubrum (33.7%). In 24 of the patients (19.8%) Corynebacterium minutissimum was detected by Gram staining, in 6 of these patients Trichophyton rubrum was found, Trichophyton mentagrophytes was found in 2 and Trichosporon spp. was found in 1. The examination of interdigital foot lesions in the laboratory, the coexistence of erythrasma with dermatophytes and yeast should be considered.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f20fb69656624faba286b877bd7b0c35", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[20, 21], [50, 51], [167, 168]], "char_spans": [[136, 163], [328, 355], [984, 1011]]}]}], "context_tokens": [["Interdigital", 0], ["foot", 13], ["infections", 18], ["are", 29], ["mostly", 33], ["caused", 40], ["initially", 47], ["by", 57], ["dermatophytes", 60], [",", 73], ["yeasts", 75], ["and", 82], ["less", 86], ["frequently", 91], ["by", 102], ["bacteria", 105], [".", 113], ["Erythrasma", 115], ["caused", 126], ["by", 133], ["Corynebacterium", 136], ["minutissimum", 152], ["can", 165], ["be", 169], ["confused", 172], ["with", 181], ["superficial", 186], ["mycoses", 198], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["the", 218], ["study", 222], ["was", 228], ["to", 232], ["determine", 235], ["the", 245], ["prevalence", 249], ["of", 260], ["the", 263], ["etiologic", 267], ["agents", 277], ["of", 284], ["superficial", 287], ["mycoses", 299], ["and", 307], ["the", 311], ["frequency", 315], ["of", 325], ["Corynebacterium", 328], ["minutissimum", 344], ["in", 357], ["interdigital", 360], ["foot", 373], ["infections", 378], [".", 388], ["All", 390], ["the", 394], ["samples", 398], ["obtained", 406], ["from", 415], ["the", 420], ["121", 424], ["patients", 428], ["with", 437], ["interdigital", 442], ["foot", 455], ["infections", 460], ["were", 471], ["examined", 476], ["directly", 485], ["with", 494], ["the", 499], ["use", 503], ["of", 507], ["20", 510], ["%", 512], ["potassium", 514], ["hydroxide", 524], ["mounts", 534], ["and", 541], ["Gram", 545], ["stain", 550], ["under", 556], ["the", 562], ["microscope", 566], ["and", 577], ["cultured", 581], ["on", 590], ["Sabouraud", 593], ["'s", 602], ["dextrose", 605], ["agar", 614], ["plates", 619], [".", 625], ["In", 627], ["identification", 630], ["of", 645], ["superficial", 648], ["mycoses", 660], [",", 667], ["the", 669], ["rate", 673], ["was", 678], ["found", 682], ["to", 688], ["be", 691], ["14", 694], ["%", 696], ["with", 698], ["the", 703], ["cultural", 707], ["method", 716], ["and", 723], ["14", 727], ["%", 729], ["with", 731], ["direct", 736], ["microscopic", 743], ["examination", 755], [".", 766], ["Using", 768], ["a", 774], ["combination", 776], ["of", 788], ["direct", 791], ["microscopic", 798], ["examination", 810], ["and", 822], ["culture", 826], [",", 833], ["a", 835], ["33.8", 837], ["%", 841], ["ratio", 843], ["was", 849], ["achieved", 853], [".", 861], ["In", 863], ["the", 866], ["culture", 870], ["of", 878], ["these", 881], ["samples", 887], [",", 894], ["the", 896], ["most", 900], ["isolated", 905], ["factor", 914], ["was", 921], ["Trichophyton", 925], ["rubrum", 938], ["(", 945], ["33.7", 946], ["%", 950], [")", 951], [".", 952], ["In", 954], ["24", 957], ["of", 960], ["the", 963], ["patients", 967], ["(", 976], ["19.8", 977], ["%", 981], [")", 982], ["Corynebacterium", 984], ["minutissimum", 1000], ["was", 1013], ["detected", 1017], ["by", 1026], ["Gram", 1029], ["staining", 1034], [",", 1042], ["in", 1044], ["6", 1047], ["of", 1049], ["these", 1052], ["patients", 1058], ["Trichophyton", 1067], ["rubrum", 1080], ["was", 1087], ["found", 1091], [",", 1096], ["Trichophyton", 1098], ["mentagrophytes", 1111], ["was", 1126], ["found", 1130], ["in", 1136], ["2", 1139], ["and", 1141], ["Trichosporon", 1145], ["spp", 1158], [".", 1161], ["was", 1163], ["found", 1167], ["in", 1173], ["1", 1176], [".", 1177], ["The", 1179], ["examination", 1183], ["of", 1195], ["interdigital", 1198], ["foot", 1211], ["lesions", 1216], ["in", 1224], ["the", 1227], ["laboratory", 1231], [",", 1241], ["the", 1243], ["coexistence", 1247], ["of", 1259], ["erythrasma", 1262], ["with", 1273], ["dermatophytes", 1278], ["and", 1292], ["yeast", 1296], ["should", 1302], ["be", 1309], ["considered", 1312], [".", 1322]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions. This dynamic alteration in nucleosome structure provides a molecular mechanism to regulate transcription, gene silencing, chromosome segregation and DNA repair. Here we show that genetic instability, sensitivity to drugs impairing different cellular processes and genome-wide transcriptional misregulation in htz1Delta can be partially or totally suppressed if SWR1 is not formed (swr1Delta), if it forms but cannot bind to chromatin (swc2Delta) or if it binds to chromatin but lacks histone replacement activity (swc5Delta and the ATPase-dead swr1-K727G). These results suggest that in htz1Delta the nucleosome remodelling activity of SWR1 affects chromatin integrity because of an attempt to replace H2A with Htz1 in the absence of the latter. This would impair transcription and, either directly or indirectly, other cellular processes. Specifically, we show that in htz1Delta, the SWR1 complex causes an accumulation of recombinogenic DNA damage by a mechanism dependent on phosphorylation of H2A at Ser129, a modification that occurs in response to DNA damage, suggesting that the SWR1 complex impairs the repair of spontaneous DNA damage in htz1Delta. In addition, SWR1 causes DSBs sensitivity in htz1Delta; consistently, in the absence of Htz1 the SWR1 complex bound near an endonuclease HO-induced DSB at the mating-type (MAT) locus impairs DSB-induced checkpoint activation. Our results support a stepwise mechanism for the replacement of H2A with Htz1 and demonstrate that a tight control of this mechanism is essential to regulate chromatin dynamics but also to prevent the deleterious consequences of an incomplete nucleosome remodelling.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "d2627627aba84f99995af53314a00a58", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[171, 171], [219, 219], [74, 74], [234, 234], [204, 204], [1, 1], [127, 127]], "char_spans": [[1007, 1010], [1293, 1296], [483, 486], [1377, 1380], [1208, 1211], [4, 7], [758, 761]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["replaces", 17], ["the", 26], ["canonical", 30], ["histone", 40], ["H2A", 48], ["with", 52], ["the", 57], ["variant", 61], ["H2A.Z", 69], ["(", 75], ["Htz1", 76], ["in", 81], ["yeast", 84], [")", 89], ["at", 91], ["specific", 94], ["chromatin", 103], ["regions", 113], [".", 120], ["This", 122], ["dynamic", 127], ["alteration", 135], ["in", 146], ["nucleosome", 149], ["structure", 160], ["provides", 170], ["a", 179], ["molecular", 181], ["mechanism", 191], ["to", 201], ["regulate", 204], ["transcription", 213], [",", 226], ["gene", 228], ["silencing", 233], [",", 242], ["chromosome", 244], ["segregation", 255], ["and", 267], ["DNA", 271], ["repair", 275], [".", 281], ["Here", 283], ["we", 288], ["show", 291], ["that", 296], ["genetic", 301], ["instability", 309], [",", 320], ["sensitivity", 322], ["to", 334], ["drugs", 337], ["impairing", 343], ["different", 353], ["cellular", 363], ["processes", 372], ["and", 382], ["genome", 386], ["-", 392], ["wide", 393], ["transcriptional", 398], ["misregulation", 414], ["in", 428], ["htz1Delta", 431], ["can", 441], ["be", 445], ["partially", 448], ["or", 458], ["totally", 461], ["suppressed", 469], ["if", 480], ["SWR1", 483], ["is", 488], ["not", 491], ["formed", 495], ["(", 502], ["swr1Delta", 503], [")", 512], [",", 513], ["if", 515], ["it", 518], ["forms", 521], ["but", 527], ["can", 531], ["not", 534], ["bind", 538], ["to", 543], ["chromatin", 546], ["(", 556], ["swc2Delta", 557], [")", 566], ["or", 568], ["if", 571], ["it", 574], ["binds", 577], ["to", 583], ["chromatin", 586], ["but", 596], ["lacks", 600], ["histone", 606], ["replacement", 614], ["activity", 626], ["(", 635], ["swc5Delta", 636], ["and", 646], ["the", 650], ["ATPase", 654], ["-", 660], ["dead", 661], ["swr1-K727", 666], ["G", 675], [")", 676], [".", 677], ["These", 679], ["results", 685], ["suggest", 693], ["that", 701], ["in", 706], ["htz1Delta", 709], ["the", 719], ["nucleosome", 723], ["remodelling", 734], ["activity", 746], ["of", 755], ["SWR1", 758], ["affects", 763], ["chromatin", 771], ["integrity", 781], ["because", 791], ["of", 799], ["an", 802], ["attempt", 805], ["to", 813], ["replace", 816], ["H2A", 824], ["with", 828], ["Htz1", 833], ["in", 838], ["the", 841], ["absence", 845], ["of", 853], ["the", 856], ["latter", 860], [".", 866], ["This", 868], ["would", 873], ["impair", 879], ["transcription", 886], ["and", 900], [",", 903], ["either", 905], ["directly", 912], ["or", 921], ["indirectly", 924], [",", 934], ["other", 936], ["cellular", 942], ["processes", 951], [".", 960], ["Specifically", 962], [",", 974], ["we", 976], ["show", 979], ["that", 984], ["in", 989], ["htz1Delta", 992], [",", 1001], ["the", 1003], ["SWR1", 1007], ["complex", 1012], ["causes", 1020], ["an", 1027], ["accumulation", 1030], ["of", 1043], ["recombinogenic", 1046], ["DNA", 1061], ["damage", 1065], ["by", 1072], ["a", 1075], ["mechanism", 1077], ["dependent", 1087], ["on", 1097], ["phosphorylation", 1100], ["of", 1116], ["H2A", 1119], ["at", 1123], ["Ser129", 1126], [",", 1132], ["a", 1134], ["modification", 1136], ["that", 1149], ["occurs", 1154], ["in", 1161], ["response", 1164], ["to", 1173], ["DNA", 1176], ["damage", 1180], [",", 1186], ["suggesting", 1188], ["that", 1199], ["the", 1204], ["SWR1", 1208], ["complex", 1213], ["impairs", 1221], ["the", 1229], ["repair", 1233], ["of", 1240], ["spontaneous", 1243], ["DNA", 1255], ["damage", 1259], ["in", 1266], ["htz1Delta", 1269], [".", 1278], ["In", 1280], ["addition", 1283], [",", 1291], ["SWR1", 1293], ["causes", 1298], ["DSBs", 1305], ["sensitivity", 1310], ["in", 1322], ["htz1Delta", 1325], [";", 1334], ["consistently", 1336], [",", 1348], ["in", 1350], ["the", 1353], ["absence", 1357], ["of", 1365], ["Htz1", 1368], ["the", 1373], ["SWR1", 1377], ["complex", 1382], ["bound", 1390], ["near", 1396], ["an", 1401], ["endonuclease", 1404], ["HO", 1417], ["-", 1419], ["induced", 1420], ["DSB", 1428], ["at", 1432], ["the", 1435], ["mating", 1439], ["-", 1445], ["type", 1446], ["(", 1451], ["MAT", 1452], [")", 1455], ["locus", 1457], ["impairs", 1463], ["DSB", 1471], ["-", 1474], ["induced", 1475], ["checkpoint", 1483], ["activation", 1494], [".", 1504], ["Our", 1506], ["results", 1510], ["support", 1518], ["a", 1526], ["stepwise", 1528], ["mechanism", 1537], ["for", 1547], ["the", 1551], ["replacement", 1555], ["of", 1567], ["H2A", 1570], ["with", 1574], ["Htz1", 1579], ["and", 1584], ["demonstrate", 1588], ["that", 1600], ["a", 1605], ["tight", 1607], ["control", 1613], ["of", 1621], ["this", 1624], ["mechanism", 1629], ["is", 1639], ["essential", 1642], ["to", 1652], ["regulate", 1655], ["chromatin", 1664], ["dynamics", 1674], ["but", 1683], ["also", 1687], ["to", 1692], ["prevent", 1695], ["the", 1703], ["deleterious", 1707], ["consequences", 1719], ["of", 1732], ["an", 1735], ["incomplete", 1738], ["nucleosome", 1749], ["remodelling", 1760], [".", 1771]]}
{"context": "The similarities of the larval and nymph stages of the tick and louse (Pthirus pubis) may lead to misdiagnosis in rare cases of infestation of the eyelashes. The most frequent manifestations of tick in the eye are conjunctivitis, uveitis, keratitis, and vasculitis. Tick inoculation of the skin can locally lead to formation of granuloma and abscess. More concerning is the potential systemic sequelae that can result from transmission of zoonoses such as Lyme disease. P. pubis can cause pruritic eyelid margins or unusual blepharoconjunctivitis. We present a case of phthiriasis palpebrarum in a 4-year-old boy.", "qas": [{"question": "What is the cause of Phthiriasis Palpebrarum?", "answers": ["Pthirus pubis"], "qid": "d99ab786d2ec4d17b1540cf721370ef0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Phthiriasis", 21], ["Palpebrarum", 33], ["?", 44]], "detected_answers": [{"text": "Pthirus pubis", "token_spans": [[14, 15]], "char_spans": [[71, 83]]}]}], "context_tokens": [["The", 0], ["similarities", 4], ["of", 17], ["the", 20], ["larval", 24], ["and", 31], ["nymph", 35], ["stages", 41], ["of", 48], ["the", 51], ["tick", 55], ["and", 60], ["louse", 64], ["(", 70], ["Pthirus", 71], ["pubis", 79], [")", 84], ["may", 86], ["lead", 90], ["to", 95], ["misdiagnosis", 98], ["in", 111], ["rare", 114], ["cases", 119], ["of", 125], ["infestation", 128], ["of", 140], ["the", 143], ["eyelashes", 147], [".", 156], ["The", 158], ["most", 162], ["frequent", 167], ["manifestations", 176], ["of", 191], ["tick", 194], ["in", 199], ["the", 202], ["eye", 206], ["are", 210], ["conjunctivitis", 214], [",", 228], ["uveitis", 230], [",", 237], ["keratitis", 239], [",", 248], ["and", 250], ["vasculitis", 254], [".", 264], ["Tick", 266], ["inoculation", 271], ["of", 283], ["the", 286], ["skin", 290], ["can", 295], ["locally", 299], ["lead", 307], ["to", 312], ["formation", 315], ["of", 325], ["granuloma", 328], ["and", 338], ["abscess", 342], [".", 349], ["More", 351], ["concerning", 356], ["is", 367], ["the", 370], ["potential", 374], ["systemic", 384], ["sequelae", 393], ["that", 402], ["can", 407], ["result", 411], ["from", 418], ["transmission", 423], ["of", 436], ["zoonoses", 439], ["such", 448], ["as", 453], ["Lyme", 456], ["disease", 461], [".", 468], ["P.", 470], ["pubis", 473], ["can", 479], ["cause", 483], ["pruritic", 489], ["eyelid", 498], ["margins", 505], ["or", 513], ["unusual", 516], ["blepharoconjunctivitis", 524], [".", 546], ["We", 548], ["present", 551], ["a", 559], ["case", 561], ["of", 566], ["phthiriasis", 569], ["palpebrarum", 581], ["in", 593], ["a", 596], ["4-year", 598], ["-", 604], ["old", 605], ["boy", 609], [".", 612]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "The origin of brain tumors has attracted much controversy. Recent advances in neural stem cell biology coupled with the new concepts of central nervous system development have raised interesting possibilities regarding the oncogenic properties of neural stem/progenitor cells. To elucidate these putative properties further, the clinical materials from an infant brain tumor were analyzed, focusing on the relation with the neural stem/progenitor cells. The expression of neural stem/progenitor cell markers in the tumor cells and the cellular components of the infant brain tumor were examined using immunohistochemistry. The tumor cell biology was analyzed both in culture and in the grafted brain environment. Three main bodies of evidence were demonstrated indicating that the tumor was of possible subventricular zone postnatal or adult normal neural stem cell origin. First, in the tumor specimen we demonstrated the strong positive expression of the neural stem/progenitor cell markers, nestin and Musashi-1. Second, immunohistochemistry revealed the presence of neuronal, astrocytic, and immature precursor cells in the tumor tissue, similar to the cellular components of the subventricular zone, thereby pointing to the subventricular zone as the possible origin of the tumor. The subventricular zone also is one of the strong candidates for the location of postnatal/adult neural stem cells. This cellular evidence was strengthened further by the clinicoradiological findings that demonstrated the involvement of the subventricular zone of the lateral ventricle by the tumor. Third, in the in vitro and in vivo experiments, a dynamic shift in expression patterns between neural stem cells (nestin, Musashi-1) and differentiated cells (glial fibrillary acidic protein, neuron-specific Class III beta-tubulin) markers was seen, similar to the proposed behavior of postnatal/adult neural stem cells in situ. These findings suggest that this brain tumor originated from neural stem cells located in the subventricular zone, and the further possibility of the general oncogenic potential of neural stem cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "71a8f4bdfee54f928c7a8b69ef3ca448", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[161, 161], [278, 278]], "char_spans": [[994, 999], [1700, 1705]]}]}], "context_tokens": [["The", 0], ["origin", 4], ["of", 11], ["brain", 14], ["tumors", 20], ["has", 27], ["attracted", 31], ["much", 41], ["controversy", 46], [".", 57], ["Recent", 59], ["advances", 66], ["in", 75], ["neural", 78], ["stem", 85], ["cell", 90], ["biology", 95], ["coupled", 103], ["with", 111], ["the", 116], ["new", 120], ["concepts", 124], ["of", 133], ["central", 136], ["nervous", 144], ["system", 152], ["development", 159], ["have", 171], ["raised", 176], ["interesting", 183], ["possibilities", 195], ["regarding", 209], ["the", 219], ["oncogenic", 223], ["properties", 233], ["of", 244], ["neural", 247], ["stem", 254], ["/", 258], ["progenitor", 259], ["cells", 270], [".", 275], ["To", 277], ["elucidate", 280], ["these", 290], ["putative", 296], ["properties", 305], ["further", 316], [",", 323], ["the", 325], ["clinical", 329], ["materials", 338], ["from", 348], ["an", 353], ["infant", 356], ["brain", 363], ["tumor", 369], ["were", 375], ["analyzed", 380], [",", 388], ["focusing", 390], ["on", 399], ["the", 402], ["relation", 406], ["with", 415], ["the", 420], ["neural", 424], ["stem", 431], ["/", 435], ["progenitor", 436], ["cells", 447], [".", 452], ["The", 454], ["expression", 458], ["of", 469], ["neural", 472], ["stem", 479], ["/", 483], ["progenitor", 484], ["cell", 495], ["markers", 500], ["in", 508], ["the", 511], ["tumor", 515], ["cells", 521], ["and", 527], ["the", 531], ["cellular", 535], ["components", 544], ["of", 555], ["the", 558], ["infant", 562], ["brain", 569], ["tumor", 575], ["were", 581], ["examined", 586], ["using", 595], ["immunohistochemistry", 601], [".", 621], ["The", 623], ["tumor", 627], ["cell", 633], ["biology", 638], ["was", 646], ["analyzed", 650], ["both", 659], ["in", 664], ["culture", 667], ["and", 675], ["in", 679], ["the", 682], ["grafted", 686], ["brain", 694], ["environment", 700], [".", 711], ["Three", 713], ["main", 719], ["bodies", 724], ["of", 731], ["evidence", 734], ["were", 743], ["demonstrated", 748], ["indicating", 761], ["that", 772], ["the", 777], ["tumor", 781], ["was", 787], ["of", 791], ["possible", 794], ["subventricular", 803], ["zone", 818], ["postnatal", 823], ["or", 833], ["adult", 836], ["normal", 842], ["neural", 849], ["stem", 856], ["cell", 861], ["origin", 866], [".", 872], ["First", 874], [",", 879], ["in", 881], ["the", 884], ["tumor", 888], ["specimen", 894], ["we", 903], ["demonstrated", 906], ["the", 919], ["strong", 923], ["positive", 930], ["expression", 939], ["of", 950], ["the", 953], ["neural", 957], ["stem", 964], ["/", 968], ["progenitor", 969], ["cell", 980], ["markers", 985], [",", 992], ["nestin", 994], ["and", 1001], ["Musashi-1", 1005], [".", 1014], ["Second", 1016], [",", 1022], ["immunohistochemistry", 1024], ["revealed", 1045], ["the", 1054], ["presence", 1058], ["of", 1067], ["neuronal", 1070], [",", 1078], ["astrocytic", 1080], [",", 1090], ["and", 1092], ["immature", 1096], ["precursor", 1105], ["cells", 1115], ["in", 1121], ["the", 1124], ["tumor", 1128], ["tissue", 1134], [",", 1140], ["similar", 1142], ["to", 1150], ["the", 1153], ["cellular", 1157], ["components", 1166], ["of", 1177], ["the", 1180], ["subventricular", 1184], ["zone", 1199], [",", 1203], ["thereby", 1205], ["pointing", 1213], ["to", 1222], ["the", 1225], ["subventricular", 1229], ["zone", 1244], ["as", 1249], ["the", 1252], ["possible", 1256], ["origin", 1265], ["of", 1272], ["the", 1275], ["tumor", 1279], [".", 1284], ["The", 1286], ["subventricular", 1290], ["zone", 1305], ["also", 1310], ["is", 1315], ["one", 1318], ["of", 1322], ["the", 1325], ["strong", 1329], ["candidates", 1336], ["for", 1347], ["the", 1351], ["location", 1355], ["of", 1364], ["postnatal", 1367], ["/", 1376], ["adult", 1377], ["neural", 1383], ["stem", 1390], ["cells", 1395], [".", 1400], ["This", 1402], ["cellular", 1407], ["evidence", 1416], ["was", 1425], ["strengthened", 1429], ["further", 1442], ["by", 1450], ["the", 1453], ["clinicoradiological", 1457], ["findings", 1477], ["that", 1486], ["demonstrated", 1491], ["the", 1504], ["involvement", 1508], ["of", 1520], ["the", 1523], ["subventricular", 1527], ["zone", 1542], ["of", 1547], ["the", 1550], ["lateral", 1554], ["ventricle", 1562], ["by", 1572], ["the", 1575], ["tumor", 1579], [".", 1584], ["Third", 1586], [",", 1591], ["in", 1593], ["the", 1596], ["in", 1600], ["vitro", 1603], ["and", 1609], ["in", 1613], ["vivo", 1616], ["experiments", 1621], [",", 1632], ["a", 1634], ["dynamic", 1636], ["shift", 1644], ["in", 1650], ["expression", 1653], ["patterns", 1664], ["between", 1673], ["neural", 1681], ["stem", 1688], ["cells", 1693], ["(", 1699], ["nestin", 1700], [",", 1706], ["Musashi-1", 1708], [")", 1717], ["and", 1719], ["differentiated", 1723], ["cells", 1738], ["(", 1744], ["glial", 1745], ["fibrillary", 1751], ["acidic", 1762], ["protein", 1769], [",", 1776], ["neuron", 1778], ["-", 1784], ["specific", 1785], ["Class", 1794], ["III", 1800], ["beta", 1804], ["-", 1808], ["tubulin", 1809], [")", 1816], ["markers", 1818], ["was", 1826], ["seen", 1830], [",", 1834], ["similar", 1836], ["to", 1844], ["the", 1847], ["proposed", 1851], ["behavior", 1860], ["of", 1869], ["postnatal", 1872], ["/", 1881], ["adult", 1882], ["neural", 1888], ["stem", 1895], ["cells", 1900], ["in", 1906], ["situ", 1909], [".", 1913], ["These", 1915], ["findings", 1921], ["suggest", 1930], ["that", 1938], ["this", 1943], ["brain", 1948], ["tumor", 1954], ["originated", 1960], ["from", 1971], ["neural", 1976], ["stem", 1983], ["cells", 1988], ["located", 1994], ["in", 2002], ["the", 2005], ["subventricular", 2009], ["zone", 2024], [",", 2028], ["and", 2030], ["the", 2034], ["further", 2038], ["possibility", 2046], ["of", 2058], ["the", 2061], ["general", 2065], ["oncogenic", 2073], ["potential", 2083], ["of", 2093], ["neural", 2096], ["stem", 2103], ["cells", 2108], [".", 2113]]}
{"context": "Nerve growth factor (NGF) antagonism has long been proposed as a chronic pain treatment. In 2010, the FDA suspended clinical trials using tanezumab, a humanized monoclonal anti-NGF antibody, to treat osteoarthritis due to worsening joint damage in 16 patients. Increased physical activity in the absence of acute pain which normally prevents self-harm was purported as a potential cause. Such an adverse effect is consistent with an extension of tanezumab's primary mechanism of action by decreasing pain sensitivity below baseline levels. In animal inflammatory pain models, NGF antagonism decreases intraepidermal nerve fiber (IENF) density and attenuates increases in expression of nociception-related proteins, such as calcitonin gene-related peptide (CGRP) and substance P (SP). Little is known of the effects of NGF antagonism in noninflamed animals and the hypoalgesia that ensues. In the current study, we immunized rats with NGF or cytochrome C (cytC) and examined (1) nocifensive behaviors with thermal latencies, mechanical thresholds, the hot plate test, and the tail flick test, (2) IENF density, and (3) expression of CGRP, SP, voltage-gated sodium channel 1.8 (Nav1.8), and glutaminase in subpopulations of dorsal root ganglion (DRG) neurons separated by size and isolectin B4 (IB4) labeling. Rats with high anti-NGF titers had delayed responses on the hot plate test but no other behavioral abnormalities. Delayed hot plate responses correlated with lower IENF density. CGRP and SP expression was decreased principally in medium (400-800 \u03bcm(2)) and small neurons (<400 \u03bcm(2)), respectively, regardless of IB4 labeling. Expression of Nav1.8 was only decreased in small and medium IB4 negative neurons. NGF immunization appears to result in a more profound antagonism of NGF than tanezumab therapy, but we hypothesize that decreases in IENF density and nociception-related protein expression are potential mechanisms for tanezumab-induced hypoalgesia.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "589de266ea4f4f239030a2ea5f61bf8b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[165, 165], [251, 251], [335, 335], [100, 100], [4, 4], [324, 324], [33, 33], [145, 145]], "char_spans": [[934, 936], [1328, 1330], [1785, 1787], [576, 578], [21, 23], [1717, 1719], [177, 179], [818, 820]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["antagonism", 26], ["has", 37], ["long", 41], ["been", 46], ["proposed", 51], ["as", 60], ["a", 63], ["chronic", 65], ["pain", 73], ["treatment", 78], [".", 87], ["In", 89], ["2010", 92], [",", 96], ["the", 98], ["FDA", 102], ["suspended", 106], ["clinical", 116], ["trials", 125], ["using", 132], ["tanezumab", 138], [",", 147], ["a", 149], ["humanized", 151], ["monoclonal", 161], ["anti", 172], ["-", 176], ["NGF", 177], ["antibody", 181], [",", 189], ["to", 191], ["treat", 194], ["osteoarthritis", 200], ["due", 215], ["to", 219], ["worsening", 222], ["joint", 232], ["damage", 238], ["in", 245], ["16", 248], ["patients", 251], [".", 259], ["Increased", 261], ["physical", 271], ["activity", 280], ["in", 289], ["the", 292], ["absence", 296], ["of", 304], ["acute", 307], ["pain", 313], ["which", 318], ["normally", 324], ["prevents", 333], ["self", 342], ["-", 346], ["harm", 347], ["was", 352], ["purported", 356], ["as", 366], ["a", 369], ["potential", 371], ["cause", 381], [".", 386], ["Such", 388], ["an", 393], ["adverse", 396], ["effect", 404], ["is", 411], ["consistent", 414], ["with", 425], ["an", 430], ["extension", 433], ["of", 443], ["tanezumab", 446], ["'s", 455], ["primary", 458], ["mechanism", 466], ["of", 476], ["action", 479], ["by", 486], ["decreasing", 489], ["pain", 500], ["sensitivity", 505], ["below", 517], ["baseline", 523], ["levels", 532], [".", 538], ["In", 540], ["animal", 543], ["inflammatory", 550], ["pain", 563], ["models", 568], [",", 574], ["NGF", 576], ["antagonism", 580], ["decreases", 591], ["intraepidermal", 601], ["nerve", 616], ["fiber", 622], ["(", 628], ["IENF", 629], [")", 633], ["density", 635], ["and", 643], ["attenuates", 647], ["increases", 658], ["in", 668], ["expression", 671], ["of", 682], ["nociception", 685], ["-", 696], ["related", 697], ["proteins", 705], [",", 713], ["such", 715], ["as", 720], ["calcitonin", 723], ["gene", 734], ["-", 738], ["related", 739], ["peptide", 747], ["(", 755], ["CGRP", 756], [")", 760], ["and", 762], ["substance", 766], ["P", 776], ["(", 778], ["SP", 779], [")", 781], [".", 782], ["Little", 784], ["is", 791], ["known", 794], ["of", 800], ["the", 803], ["effects", 807], ["of", 815], ["NGF", 818], ["antagonism", 822], ["in", 833], ["noninflamed", 836], ["animals", 848], ["and", 856], ["the", 860], ["hypoalgesia", 864], ["that", 876], ["ensues", 881], [".", 887], ["In", 889], ["the", 892], ["current", 896], ["study", 904], [",", 909], ["we", 911], ["immunized", 914], ["rats", 924], ["with", 929], ["NGF", 934], ["or", 938], ["cytochrome", 941], ["C", 952], ["(", 954], ["cytC", 955], [")", 959], ["and", 961], ["examined", 965], ["(", 974], ["1", 975], [")", 976], ["nocifensive", 978], ["behaviors", 990], ["with", 1000], ["thermal", 1005], ["latencies", 1013], [",", 1022], ["mechanical", 1024], ["thresholds", 1035], [",", 1045], ["the", 1047], ["hot", 1051], ["plate", 1055], ["test", 1061], [",", 1065], ["and", 1067], ["the", 1071], ["tail", 1075], ["flick", 1080], ["test", 1086], [",", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["IENF", 1096], ["density", 1101], [",", 1108], ["and", 1110], ["(", 1114], ["3", 1115], [")", 1116], ["expression", 1118], ["of", 1129], ["CGRP", 1132], [",", 1136], ["SP", 1138], [",", 1140], ["voltage", 1142], ["-", 1149], ["gated", 1150], ["sodium", 1156], ["channel", 1163], ["1.8", 1171], ["(", 1175], ["Nav1.8", 1176], [")", 1182], [",", 1183], ["and", 1185], ["glutaminase", 1189], ["in", 1201], ["subpopulations", 1204], ["of", 1219], ["dorsal", 1222], ["root", 1229], ["ganglion", 1234], ["(", 1243], ["DRG", 1244], [")", 1247], ["neurons", 1249], ["separated", 1257], ["by", 1267], ["size", 1270], ["and", 1275], ["isolectin", 1279], ["B4", 1289], ["(", 1292], ["IB4", 1293], [")", 1296], ["labeling", 1298], [".", 1306], ["Rats", 1308], ["with", 1313], ["high", 1318], ["anti", 1323], ["-", 1327], ["NGF", 1328], ["titers", 1332], ["had", 1339], ["delayed", 1343], ["responses", 1351], ["on", 1361], ["the", 1364], ["hot", 1368], ["plate", 1372], ["test", 1378], ["but", 1383], ["no", 1387], ["other", 1390], ["behavioral", 1396], ["abnormalities", 1407], [".", 1420], ["Delayed", 1422], ["hot", 1430], ["plate", 1434], ["responses", 1440], ["correlated", 1450], ["with", 1461], ["lower", 1466], ["IENF", 1472], ["density", 1477], [".", 1484], ["CGRP", 1486], ["and", 1491], ["SP", 1495], ["expression", 1498], ["was", 1509], ["decreased", 1513], ["principally", 1523], ["in", 1535], ["medium", 1538], ["(", 1545], ["400", 1546], ["-", 1549], ["800", 1550], ["\u03bcm(2", 1554], [")", 1558], [")", 1559], ["and", 1561], ["small", 1565], ["neurons", 1571], ["(", 1579], ["<", 1580], ["400", 1581], ["\u03bcm(2", 1585], [")", 1589], [")", 1590], [",", 1591], ["respectively", 1593], [",", 1605], ["regardless", 1607], ["of", 1618], ["IB4", 1621], ["labeling", 1625], [".", 1633], ["Expression", 1635], ["of", 1646], ["Nav1.8", 1649], ["was", 1656], ["only", 1660], ["decreased", 1665], ["in", 1675], ["small", 1678], ["and", 1684], ["medium", 1688], ["IB4", 1695], ["negative", 1699], ["neurons", 1708], [".", 1715], ["NGF", 1717], ["immunization", 1721], ["appears", 1734], ["to", 1742], ["result", 1745], ["in", 1752], ["a", 1755], ["more", 1757], ["profound", 1762], ["antagonism", 1771], ["of", 1782], ["NGF", 1785], ["than", 1789], ["tanezumab", 1794], ["therapy", 1804], [",", 1811], ["but", 1813], ["we", 1817], ["hypothesize", 1820], ["that", 1832], ["decreases", 1837], ["in", 1847], ["IENF", 1850], ["density", 1855], ["and", 1863], ["nociception", 1867], ["-", 1878], ["related", 1879], ["protein", 1887], ["expression", 1895], ["are", 1906], ["potential", 1910], ["mechanisms", 1920], ["for", 1931], ["tanezumab", 1935], ["-", 1944], ["induced", 1945], ["hypoalgesia", 1953], [".", 1964]]}
{"context": "Mowat-Wilson syndrome is a recently delineated autosomal dominant developmental anomaly, whereby heterozygous mutations in the ZFHX1B gene cause mental retardation, delayed motor development, epilepsy and a wide spectrum of clinically heterogeneous features, suggestive of neurocristopathies at the cephalic, cardiac and vagal levels. However, our understanding of the etiology of this condition at the cellular level remains vague. This study presents the Zfhx1b protein expression domain in mouse embryos and correlates this with a novel mouse model involving a conditional mutation in the Zfhx1b gene in neural crest precursor cells. These mutant mice display craniofacial and gastrointestinal malformations that show resemblance to those found in human patients with Mowat-Wilson syndrome. In addition to these clinically recognized alterations, we document developmental defects in the heart, melanoblasts and sympathetic and parasympathetic anlagen. The latter observations in our mouse model for Mowat-Wilson suggest a hitherto unknown role for Zfhx1b in the development of these particular neural crest derivatives, which is a set of observations that should be acknowledged in the clinical management of this genetic disorder.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "9095328339f447188880bc5412e035d4", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[163, 163], [92, 92], [71, 71], [18, 18]], "char_spans": [[1052, 1057], [592, 597], [457, 462], [127, 132]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["recently", 27], ["delineated", 36], ["autosomal", 47], ["dominant", 57], ["developmental", 66], ["anomaly", 80], [",", 87], ["whereby", 89], ["heterozygous", 97], ["mutations", 110], ["in", 120], ["the", 123], ["ZFHX1B", 127], ["gene", 134], ["cause", 139], ["mental", 145], ["retardation", 152], [",", 163], ["delayed", 165], ["motor", 173], ["development", 179], [",", 190], ["epilepsy", 192], ["and", 201], ["a", 205], ["wide", 207], ["spectrum", 212], ["of", 221], ["clinically", 224], ["heterogeneous", 235], ["features", 249], [",", 257], ["suggestive", 259], ["of", 270], ["neurocristopathies", 273], ["at", 292], ["the", 295], ["cephalic", 299], [",", 307], ["cardiac", 309], ["and", 317], ["vagal", 321], ["levels", 327], [".", 333], ["However", 335], [",", 342], ["our", 344], ["understanding", 348], ["of", 362], ["the", 365], ["etiology", 369], ["of", 378], ["this", 381], ["condition", 386], ["at", 396], ["the", 399], ["cellular", 403], ["level", 412], ["remains", 418], ["vague", 426], [".", 431], ["This", 433], ["study", 438], ["presents", 444], ["the", 453], ["Zfhx1b", 457], ["protein", 464], ["expression", 472], ["domain", 483], ["in", 490], ["mouse", 493], ["embryos", 499], ["and", 507], ["correlates", 511], ["this", 522], ["with", 527], ["a", 532], ["novel", 534], ["mouse", 540], ["model", 546], ["involving", 552], ["a", 562], ["conditional", 564], ["mutation", 576], ["in", 585], ["the", 588], ["Zfhx1b", 592], ["gene", 599], ["in", 604], ["neural", 607], ["crest", 614], ["precursor", 620], ["cells", 630], [".", 635], ["These", 637], ["mutant", 643], ["mice", 650], ["display", 655], ["craniofacial", 663], ["and", 676], ["gastrointestinal", 680], ["malformations", 697], ["that", 711], ["show", 716], ["resemblance", 721], ["to", 733], ["those", 736], ["found", 742], ["in", 748], ["human", 751], ["patients", 757], ["with", 766], ["Mowat", 771], ["-", 776], ["Wilson", 777], ["syndrome", 784], [".", 792], ["In", 794], ["addition", 797], ["to", 806], ["these", 809], ["clinically", 815], ["recognized", 826], ["alterations", 837], [",", 848], ["we", 850], ["document", 853], ["developmental", 862], ["defects", 876], ["in", 884], ["the", 887], ["heart", 891], [",", 896], ["melanoblasts", 898], ["and", 911], ["sympathetic", 915], ["and", 927], ["parasympathetic", 931], ["anlagen", 947], [".", 954], ["The", 956], ["latter", 960], ["observations", 967], ["in", 980], ["our", 983], ["mouse", 987], ["model", 993], ["for", 999], ["Mowat", 1003], ["-", 1008], ["Wilson", 1009], ["suggest", 1016], ["a", 1024], ["hitherto", 1026], ["unknown", 1035], ["role", 1043], ["for", 1048], ["Zfhx1b", 1052], ["in", 1059], ["the", 1062], ["development", 1066], ["of", 1078], ["these", 1081], ["particular", 1087], ["neural", 1098], ["crest", 1105], ["derivatives", 1111], [",", 1122], ["which", 1124], ["is", 1130], ["a", 1133], ["set", 1135], ["of", 1139], ["observations", 1142], ["that", 1155], ["should", 1160], ["be", 1167], ["acknowledged", 1170], ["in", 1183], ["the", 1186], ["clinical", 1190], ["management", 1199], ["of", 1210], ["this", 1213], ["genetic", 1218], ["disorder", 1226], [".", 1234]]}
{"context": "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. These re-coding events affect coding potential, splice sites, and stability of mature mRNAs. ADAR is an essential gene, and studies in mouse, Caenorhabditis elegans, and Drosophila suggest that its primary function is to modify adult behavior by altering signaling components in the nervous system. By comparing the sequence of isogenic cDNAs to genomic DNA, we have identified and experimentally verified 27 new targets of Drosophila ADAR. Our analyses led us to identify new classes of genes whose transcripts are targets of ADAR, including components of the actin cytoskeleton and genes involved in ion homeostasis and signal transduction. Our results indicate that editing in Drosophila increases the diversity of the proteome, and does so in a manner that has direct functional consequences on protein function.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["adenosine deaminase, RNA-specific", "ADAR", "adenosine deaminase, RNA specific"], "qid": "39ab6d3436864e6ea8cc1a577a441db5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[106, 106], [13, 13], [123, 123], [49, 49]], "char_spans": [[606, 609], [73, 76], [698, 701], [264, 267]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[7, 11]], "char_spans": [[38, 70]]}]}], "context_tokens": [["Adenosine", 0], ["deaminases", 10], ["that", 21], ["act", 26], ["on", 30], ["RNA", 33], ["[", 37], ["adenosine", 38], ["deaminase", 48], [",", 57], ["RNA", 59], ["specific", 63], ["(", 72], ["ADAR", 73], [")", 77], ["]", 78], ["catalyze", 80], ["the", 89], ["site", 93], ["-", 97], ["specific", 98], ["conversion", 107], ["of", 118], ["adenosine", 121], ["to", 131], ["inosine", 134], ["in", 142], ["primary", 145], ["mRNA", 153], ["transcripts", 158], [".", 169], ["These", 171], ["re", 177], ["-", 179], ["coding", 180], ["events", 187], ["affect", 194], ["coding", 201], ["potential", 208], [",", 217], ["splice", 219], ["sites", 226], [",", 231], ["and", 233], ["stability", 237], ["of", 247], ["mature", 250], ["mRNAs", 257], [".", 262], ["ADAR", 264], ["is", 269], ["an", 272], ["essential", 275], ["gene", 285], [",", 289], ["and", 291], ["studies", 295], ["in", 303], ["mouse", 306], [",", 311], ["Caenorhabditis", 313], ["elegans", 328], [",", 335], ["and", 337], ["Drosophila", 341], ["suggest", 352], ["that", 360], ["its", 365], ["primary", 369], ["function", 377], ["is", 386], ["to", 389], ["modify", 392], ["adult", 399], ["behavior", 405], ["by", 414], ["altering", 417], ["signaling", 426], ["components", 436], ["in", 447], ["the", 450], ["nervous", 454], ["system", 462], [".", 468], ["By", 470], ["comparing", 473], ["the", 483], ["sequence", 487], ["of", 496], ["isogenic", 499], ["cDNAs", 508], ["to", 514], ["genomic", 517], ["DNA", 525], [",", 528], ["we", 530], ["have", 533], ["identified", 538], ["and", 549], ["experimentally", 553], ["verified", 568], ["27", 577], ["new", 580], ["targets", 584], ["of", 592], ["Drosophila", 595], ["ADAR", 606], [".", 610], ["Our", 612], ["analyses", 616], ["led", 625], ["us", 629], ["to", 632], ["identify", 635], ["new", 644], ["classes", 648], ["of", 656], ["genes", 659], ["whose", 665], ["transcripts", 671], ["are", 683], ["targets", 687], ["of", 695], ["ADAR", 698], [",", 702], ["including", 704], ["components", 714], ["of", 725], ["the", 728], ["actin", 732], ["cytoskeleton", 738], ["and", 751], ["genes", 755], ["involved", 761], ["in", 770], ["ion", 773], ["homeostasis", 777], ["and", 789], ["signal", 793], ["transduction", 800], [".", 812], ["Our", 814], ["results", 818], ["indicate", 826], ["that", 835], ["editing", 840], ["in", 848], ["Drosophila", 851], ["increases", 862], ["the", 872], ["diversity", 876], ["of", 886], ["the", 889], ["proteome", 893], [",", 901], ["and", 903], ["does", 907], ["so", 912], ["in", 915], ["a", 918], ["manner", 920], ["that", 927], ["has", 932], ["direct", 936], ["functional", 943], ["consequences", 954], ["on", 967], ["protein", 970], ["function", 978], [".", 986]]}
{"context": "Chronic pain arising from various pathological conditions such as osteoarthritis, low back or spinal injuries, cancer, and urological chronic pelvic pain syndromes presents significant challenges in diagnosis and treatment. Specifically, since the underlying cause of these pain syndromes is unknown or heterogeneous, physicians diagnose and treat patients based on the symptoms presented. Nerve growth factor (NGF) has been recognized as an important mediator of chronic pain in many pathological conditions, and has been shown to be upregulated in a subset of individuals suffering from such pain syndromes. These findings have led to the development of anti-NGF monoclonal antibodies such as tanezumab as potentially effective therapeutics for chronic pain. Although tanezumab has reached Phase II and III clinical trials, the trials of anti-NGF antibodies were halted due to safety concerns. Some of these trials of anti-NGF treatment have had statistically significant decreases in pain, while others have yielded inconclusive results. These findings are suggestive of, though do not prove, target (NGF) neutralization in chronic pain syndromes. A biomarker-driven anti-NGF clinical study layout is proposed that incorporates NGF measurements in the relevant samples before and after treatment, in addition to collecting the pain scores. This approach might not only confirm the mechanism of tanezumab's action in these chronic pain patients, but should establish NGF levels as a predictive biomarker for patients who can benefit from anti-NGF treatment, thereby creating a personalized approach to pain treatment.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "325680c55d7146c69a2cdebde92b66df", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[59, 61]], "char_spans": [[390, 408]]}, {"text": "NGF", "token_spans": [[154, 154], [138, 138], [198, 198], [246, 246], [108, 108], [260, 260], [184, 184], [206, 206], [63, 63]], "char_spans": [[925, 927], [845, 847], [1175, 1177], [1469, 1471], [661, 663], [1545, 1547], [1104, 1106], [1231, 1233], [411, 413]]}]}], "context_tokens": [["Chronic", 0], ["pain", 8], ["arising", 13], ["from", 21], ["various", 26], ["pathological", 34], ["conditions", 47], ["such", 58], ["as", 63], ["osteoarthritis", 66], [",", 80], ["low", 82], ["back", 86], ["or", 91], ["spinal", 94], ["injuries", 101], [",", 109], ["cancer", 111], [",", 117], ["and", 119], ["urological", 123], ["chronic", 134], ["pelvic", 142], ["pain", 149], ["syndromes", 154], ["presents", 164], ["significant", 173], ["challenges", 185], ["in", 196], ["diagnosis", 199], ["and", 209], ["treatment", 213], [".", 222], ["Specifically", 224], [",", 236], ["since", 238], ["the", 244], ["underlying", 248], ["cause", 259], ["of", 265], ["these", 268], ["pain", 274], ["syndromes", 279], ["is", 289], ["unknown", 292], ["or", 300], ["heterogeneous", 303], [",", 316], ["physicians", 318], ["diagnose", 329], ["and", 338], ["treat", 342], ["patients", 348], ["based", 357], ["on", 363], ["the", 366], ["symptoms", 370], ["presented", 379], [".", 388], ["Nerve", 390], ["growth", 396], ["factor", 403], ["(", 410], ["NGF", 411], [")", 414], ["has", 416], ["been", 420], ["recognized", 425], ["as", 436], ["an", 439], ["important", 442], ["mediator", 452], ["of", 461], ["chronic", 464], ["pain", 472], ["in", 477], ["many", 480], ["pathological", 485], ["conditions", 498], [",", 508], ["and", 510], ["has", 514], ["been", 518], ["shown", 523], ["to", 529], ["be", 532], ["upregulated", 535], ["in", 547], ["a", 550], ["subset", 552], ["of", 559], ["individuals", 562], ["suffering", 574], ["from", 584], ["such", 589], ["pain", 594], ["syndromes", 599], [".", 608], ["These", 610], ["findings", 616], ["have", 625], ["led", 630], ["to", 634], ["the", 637], ["development", 641], ["of", 653], ["anti", 656], ["-", 660], ["NGF", 661], ["monoclonal", 665], ["antibodies", 676], ["such", 687], ["as", 692], ["tanezumab", 695], ["as", 705], ["potentially", 708], ["effective", 720], ["therapeutics", 730], ["for", 743], ["chronic", 747], ["pain", 755], [".", 759], ["Although", 761], ["tanezumab", 770], ["has", 780], ["reached", 784], ["Phase", 792], ["II", 798], ["and", 801], ["III", 805], ["clinical", 809], ["trials", 818], [",", 824], ["the", 826], ["trials", 830], ["of", 837], ["anti", 840], ["-", 844], ["NGF", 845], ["antibodies", 849], ["were", 860], ["halted", 865], ["due", 872], ["to", 876], ["safety", 879], ["concerns", 886], [".", 894], ["Some", 896], ["of", 901], ["these", 904], ["trials", 910], ["of", 917], ["anti", 920], ["-", 924], ["NGF", 925], ["treatment", 929], ["have", 939], ["had", 944], ["statistically", 948], ["significant", 962], ["decreases", 974], ["in", 984], ["pain", 987], [",", 991], ["while", 993], ["others", 999], ["have", 1006], ["yielded", 1011], ["inconclusive", 1019], ["results", 1032], [".", 1039], ["These", 1041], ["findings", 1047], ["are", 1056], ["suggestive", 1060], ["of", 1071], [",", 1073], ["though", 1075], ["do", 1082], ["not", 1085], ["prove", 1089], [",", 1094], ["target", 1096], ["(", 1103], ["NGF", 1104], [")", 1107], ["neutralization", 1109], ["in", 1124], ["chronic", 1127], ["pain", 1135], ["syndromes", 1140], [".", 1149], ["A", 1151], ["biomarker", 1153], ["-", 1162], ["driven", 1163], ["anti", 1170], ["-", 1174], ["NGF", 1175], ["clinical", 1179], ["study", 1188], ["layout", 1194], ["is", 1201], ["proposed", 1204], ["that", 1213], ["incorporates", 1218], ["NGF", 1231], ["measurements", 1235], ["in", 1248], ["the", 1251], ["relevant", 1255], ["samples", 1264], ["before", 1272], ["and", 1279], ["after", 1283], ["treatment", 1289], [",", 1298], ["in", 1300], ["addition", 1303], ["to", 1312], ["collecting", 1315], ["the", 1326], ["pain", 1330], ["scores", 1335], [".", 1341], ["This", 1343], ["approach", 1348], ["might", 1357], ["not", 1363], ["only", 1367], ["confirm", 1372], ["the", 1380], ["mechanism", 1384], ["of", 1394], ["tanezumab", 1397], ["'s", 1406], ["action", 1409], ["in", 1416], ["these", 1419], ["chronic", 1425], ["pain", 1433], ["patients", 1438], [",", 1446], ["but", 1448], ["should", 1452], ["establish", 1459], ["NGF", 1469], ["levels", 1473], ["as", 1480], ["a", 1483], ["predictive", 1485], ["biomarker", 1496], ["for", 1506], ["patients", 1510], ["who", 1519], ["can", 1523], ["benefit", 1527], ["from", 1535], ["anti", 1540], ["-", 1544], ["NGF", 1545], ["treatment", 1549], [",", 1558], ["thereby", 1560], ["creating", 1568], ["a", 1577], ["personalized", 1579], ["approach", 1592], ["to", 1601], ["pain", 1604], ["treatment", 1609], [".", 1618]]}
{"context": "Deep brain stimulation (DBS) is the technique of neurostimulation of deep brain structures for the treatment of conditions such as essential tremor, dystonia, Parkinson's disease and chronic pain syndromes. The procedure uses implanted deep brain stimulation electrodes connected to extension leads and an implantable pulse generator (IPG). Hardware failure related to the DBS procedure is not infrequent, and includes electrode migration and disconnection. We describe a patient who received bilateral globus pallidus internus DBS for dystonia with initially good clinical response, but the device eventually failed. Radiographs showed multiple twisting of the extension leads with disconnection from the brain electrodes and a diagnosis of Twiddler's syndrome was made. Twiddler's syndrome was first described in patients with cardiac pacemakers. Patients with mental disability, elderly and obese patients are at increased risk. Twiddler's syndrome should be suspected whenever there is a failure of the DBS device to relieve symptoms previously responsive to stimulation. Surgical correction is usually required.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "ced1b7f9545a491eadf94408518db9dc", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[81, 83]], "char_spans": [[503, 526]]}]}], "context_tokens": [["Deep", 0], ["brain", 5], ["stimulation", 11], ["(", 23], ["DBS", 24], [")", 27], ["is", 29], ["the", 32], ["technique", 36], ["of", 46], ["neurostimulation", 49], ["of", 66], ["deep", 69], ["brain", 74], ["structures", 80], ["for", 91], ["the", 95], ["treatment", 99], ["of", 109], ["conditions", 112], ["such", 123], ["as", 128], ["essential", 131], ["tremor", 141], [",", 147], ["dystonia", 149], [",", 157], ["Parkinson", 159], ["'s", 168], ["disease", 171], ["and", 179], ["chronic", 183], ["pain", 191], ["syndromes", 196], [".", 205], ["The", 207], ["procedure", 211], ["uses", 221], ["implanted", 226], ["deep", 236], ["brain", 241], ["stimulation", 247], ["electrodes", 259], ["connected", 270], ["to", 280], ["extension", 283], ["leads", 293], ["and", 299], ["an", 303], ["implantable", 306], ["pulse", 318], ["generator", 324], ["(", 334], ["IPG", 335], [")", 338], [".", 339], ["Hardware", 341], ["failure", 350], ["related", 358], ["to", 366], ["the", 369], ["DBS", 373], ["procedure", 377], ["is", 387], ["not", 390], ["infrequent", 394], [",", 404], ["and", 406], ["includes", 410], ["electrode", 419], ["migration", 429], ["and", 439], ["disconnection", 443], [".", 456], ["We", 458], ["describe", 461], ["a", 470], ["patient", 472], ["who", 480], ["received", 484], ["bilateral", 493], ["globus", 503], ["pallidus", 510], ["internus", 519], ["DBS", 528], ["for", 532], ["dystonia", 536], ["with", 545], ["initially", 550], ["good", 560], ["clinical", 565], ["response", 574], [",", 582], ["but", 584], ["the", 588], ["device", 592], ["eventually", 599], ["failed", 610], [".", 616], ["Radiographs", 618], ["showed", 630], ["multiple", 637], ["twisting", 646], ["of", 655], ["the", 658], ["extension", 662], ["leads", 672], ["with", 678], ["disconnection", 683], ["from", 697], ["the", 702], ["brain", 706], ["electrodes", 712], ["and", 723], ["a", 727], ["diagnosis", 729], ["of", 739], ["Twiddler", 742], ["'s", 750], ["syndrome", 753], ["was", 762], ["made", 766], [".", 770], ["Twiddler", 772], ["'s", 780], ["syndrome", 783], ["was", 792], ["first", 796], ["described", 802], ["in", 812], ["patients", 815], ["with", 824], ["cardiac", 829], ["pacemakers", 837], [".", 847], ["Patients", 849], ["with", 858], ["mental", 863], ["disability", 870], [",", 880], ["elderly", 882], ["and", 890], ["obese", 894], ["patients", 900], ["are", 909], ["at", 913], ["increased", 916], ["risk", 926], [".", 930], ["Twiddler", 932], ["'s", 940], ["syndrome", 943], ["should", 952], ["be", 959], ["suspected", 962], ["whenever", 972], ["there", 981], ["is", 987], ["a", 990], ["failure", 992], ["of", 1000], ["the", 1003], ["DBS", 1007], ["device", 1011], ["to", 1018], ["relieve", 1021], ["symptoms", 1029], ["previously", 1038], ["responsive", 1049], ["to", 1060], ["stimulation", 1063], [".", 1074], ["Surgical", 1076], ["correction", 1085], ["is", 1096], ["usually", 1099], ["required", 1107], [".", 1115]]}
{"context": "Recombinant tissue plasminogen activator (rT-PA) is an effective treatment for acute ischaemic stroke when given within 3h of symptom onset but can be delayed as patients wait for a diagnosis. The ROSIER assessment tool (Fig. 1) has been found to be effective in diagnosing stroke but to date has only been tested when used by doctors. To compare registered nurses' ability to diagnose stroke using the ROSIER assessment tool with doctors' ability to diagnose stroke using traditional neurological assessment. A prospective audit of all suspected stroke patients (n=106) admitted to the stroke unit of a district general hospital over an eight month period, assessed by registered nurses trained to use the ROSIER assessment tool to identify stroke. Time from admission to the stroke unit until initial assessment by doctors and registered nurses. Comparison of initial diagnosis by doctors and registered nurses with final diagnosis by a consultant for stroke. Of 106 suspected stroke patients, 78 (73.5%) had a final diagnosis of stroke or transient ischaemic attack (TIA) and 28 (26.4%) had an alternative diagnosis. Six patients with TIA were subsequently excluded as they were asymptomatic at the time of assessment, leaving 100 participants in the validation phase of the study. Using the ROSIER tool registered nurses achieved a diagnostic sensitivity for stroke of 98% (95% confidence interval 88-99), positive predictive value (PPV) 83% (95% confidence interval 73-90). Doctors using standard neurological assessment had a similar diagnostic sensitivity of 94% (95% confidence interval 86-98), PPV 80% (95% confidence interval 70-88). The mean time from initial assessment by registered nurses using the ROSIER tool, until assessment by doctor on the stroke unit was 75 min (SD=65.8 min). Registered nurses working on a stroke unit using the ROSIER assessment tool are able to diagnose stroke with a degree of accuracy comparable to doctors using clinical neurological assessment. Prompt assessment of suspected stroke patients by registered nurses using the ROSIER tool could reduce delays in eligible stroke patients being assessed for rT-PA treatment.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "6f0bc4db6f3244efa75413fbbed77285", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[16, 16], [85, 85], [131, 131], [138, 138], [165, 165], [170, 170], [355, 355], [52, 52], [373, 373], [73, 73], [105, 105], [183, 183], [329, 329], [387, 387], [344, 344], [97, 97], [241, 241]], "char_spans": [[95, 100], [460, 465], [742, 747], [777, 782], [954, 959], [979, 984], [1895, 1900], [274, 279], [2021, 2026], [386, 391], [587, 592], [1032, 1037], [1760, 1765], [2112, 2117], [1829, 1834], [547, 552], [1363, 1368]]}]}], "context_tokens": [["Recombinant", 0], ["tissue", 12], ["plasminogen", 19], ["activator", 31], ["(", 41], ["rT", 42], ["-", 44], ["PA", 45], [")", 47], ["is", 49], ["an", 52], ["effective", 55], ["treatment", 65], ["for", 75], ["acute", 79], ["ischaemic", 85], ["stroke", 95], ["when", 102], ["given", 107], ["within", 113], ["3h", 120], ["of", 123], ["symptom", 126], ["onset", 134], ["but", 140], ["can", 144], ["be", 148], ["delayed", 151], ["as", 159], ["patients", 162], ["wait", 171], ["for", 176], ["a", 180], ["diagnosis", 182], [".", 191], ["The", 193], ["ROSIER", 197], ["assessment", 204], ["tool", 215], ["(", 220], ["Fig", 221], [".", 224], ["1", 226], [")", 227], ["has", 229], ["been", 233], ["found", 238], ["to", 244], ["be", 247], ["effective", 250], ["in", 260], ["diagnosing", 263], ["stroke", 274], ["but", 281], ["to", 285], ["date", 288], ["has", 293], ["only", 297], ["been", 302], ["tested", 307], ["when", 314], ["used", 319], ["by", 324], ["doctors", 327], [".", 334], ["To", 336], ["compare", 339], ["registered", 347], ["nurses", 358], ["'", 364], ["ability", 366], ["to", 374], ["diagnose", 377], ["stroke", 386], ["using", 393], ["the", 399], ["ROSIER", 403], ["assessment", 410], ["tool", 421], ["with", 426], ["doctors", 431], ["'", 438], ["ability", 440], ["to", 448], ["diagnose", 451], ["stroke", 460], ["using", 467], ["traditional", 473], ["neurological", 485], ["assessment", 498], [".", 508], ["A", 510], ["prospective", 512], ["audit", 524], ["of", 530], ["all", 533], ["suspected", 537], ["stroke", 547], ["patients", 554], ["(", 563], ["n=106", 564], [")", 569], ["admitted", 571], ["to", 580], ["the", 583], ["stroke", 587], ["unit", 594], ["of", 599], ["a", 602], ["district", 604], ["general", 613], ["hospital", 621], ["over", 630], ["an", 635], ["eight", 638], ["month", 644], ["period", 650], [",", 656], ["assessed", 658], ["by", 667], ["registered", 670], ["nurses", 681], ["trained", 688], ["to", 696], ["use", 699], ["the", 703], ["ROSIER", 707], ["assessment", 714], ["tool", 725], ["to", 730], ["identify", 733], ["stroke", 742], [".", 748], ["Time", 750], ["from", 755], ["admission", 760], ["to", 770], ["the", 773], ["stroke", 777], ["unit", 784], ["until", 789], ["initial", 795], ["assessment", 803], ["by", 814], ["doctors", 817], ["and", 825], ["registered", 829], ["nurses", 840], [".", 846], ["Comparison", 848], ["of", 859], ["initial", 862], ["diagnosis", 870], ["by", 880], ["doctors", 883], ["and", 891], ["registered", 895], ["nurses", 906], ["with", 913], ["final", 918], ["diagnosis", 924], ["by", 934], ["a", 937], ["consultant", 939], ["for", 950], ["stroke", 954], [".", 960], ["Of", 962], ["106", 965], ["suspected", 969], ["stroke", 979], ["patients", 986], [",", 994], ["78", 996], ["(", 999], ["73.5", 1000], ["%", 1004], [")", 1005], ["had", 1007], ["a", 1011], ["final", 1013], ["diagnosis", 1019], ["of", 1029], ["stroke", 1032], ["or", 1039], ["transient", 1042], ["ischaemic", 1052], ["attack", 1062], ["(", 1069], ["TIA", 1070], [")", 1073], ["and", 1075], ["28", 1079], ["(", 1082], ["26.4", 1083], ["%", 1087], [")", 1088], ["had", 1090], ["an", 1094], ["alternative", 1097], ["diagnosis", 1109], [".", 1118], ["Six", 1120], ["patients", 1124], ["with", 1133], ["TIA", 1138], ["were", 1142], ["subsequently", 1147], ["excluded", 1160], ["as", 1169], ["they", 1172], ["were", 1177], ["asymptomatic", 1182], ["at", 1195], ["the", 1198], ["time", 1202], ["of", 1207], ["assessment", 1210], [",", 1220], ["leaving", 1222], ["100", 1230], ["participants", 1234], ["in", 1247], ["the", 1250], ["validation", 1254], ["phase", 1265], ["of", 1271], ["the", 1274], ["study", 1278], [".", 1283], ["Using", 1285], ["the", 1291], ["ROSIER", 1295], ["tool", 1302], ["registered", 1307], ["nurses", 1318], ["achieved", 1325], ["a", 1334], ["diagnostic", 1336], ["sensitivity", 1347], ["for", 1359], ["stroke", 1363], ["of", 1370], ["98", 1373], ["%", 1375], ["(", 1377], ["95", 1378], ["%", 1380], ["confidence", 1382], ["interval", 1393], ["88", 1402], ["-", 1404], ["99", 1405], [")", 1407], [",", 1408], ["positive", 1410], ["predictive", 1419], ["value", 1430], ["(", 1436], ["PPV", 1437], [")", 1440], ["83", 1442], ["%", 1444], ["(", 1446], ["95", 1447], ["%", 1449], ["confidence", 1451], ["interval", 1462], ["73", 1471], ["-", 1473], ["90", 1474], [")", 1476], [".", 1477], ["Doctors", 1479], ["using", 1487], ["standard", 1493], ["neurological", 1502], ["assessment", 1515], ["had", 1526], ["a", 1530], ["similar", 1532], ["diagnostic", 1540], ["sensitivity", 1551], ["of", 1563], ["94", 1566], ["%", 1568], ["(", 1570], ["95", 1571], ["%", 1573], ["confidence", 1575], ["interval", 1586], ["86", 1595], ["-", 1597], ["98", 1598], [")", 1600], [",", 1601], ["PPV", 1603], ["80", 1607], ["%", 1609], ["(", 1611], ["95", 1612], ["%", 1614], ["confidence", 1616], ["interval", 1627], ["70", 1636], ["-", 1638], ["88", 1639], [")", 1641], [".", 1642], ["The", 1644], ["mean", 1648], ["time", 1653], ["from", 1658], ["initial", 1663], ["assessment", 1671], ["by", 1682], ["registered", 1685], ["nurses", 1696], ["using", 1703], ["the", 1709], ["ROSIER", 1713], ["tool", 1720], [",", 1724], ["until", 1726], ["assessment", 1732], ["by", 1743], ["doctor", 1746], ["on", 1753], ["the", 1756], ["stroke", 1760], ["unit", 1767], ["was", 1772], ["75", 1776], ["min", 1779], ["(", 1783], ["SD=65.8", 1784], ["min", 1792], [")", 1795], [".", 1796], ["Registered", 1798], ["nurses", 1809], ["working", 1816], ["on", 1824], ["a", 1827], ["stroke", 1829], ["unit", 1836], ["using", 1841], ["the", 1847], ["ROSIER", 1851], ["assessment", 1858], ["tool", 1869], ["are", 1874], ["able", 1878], ["to", 1883], ["diagnose", 1886], ["stroke", 1895], ["with", 1902], ["a", 1907], ["degree", 1909], ["of", 1916], ["accuracy", 1919], ["comparable", 1928], ["to", 1939], ["doctors", 1942], ["using", 1950], ["clinical", 1956], ["neurological", 1965], ["assessment", 1978], [".", 1988], ["Prompt", 1990], ["assessment", 1997], ["of", 2008], ["suspected", 2011], ["stroke", 2021], ["patients", 2028], ["by", 2037], ["registered", 2040], ["nurses", 2051], ["using", 2058], ["the", 2064], ["ROSIER", 2068], ["tool", 2075], ["could", 2080], ["reduce", 2086], ["delays", 2093], ["in", 2100], ["eligible", 2103], ["stroke", 2112], ["patients", 2119], ["being", 2128], ["assessed", 2134], ["for", 2143], ["rT", 2147], ["-", 2149], ["PA", 2150], ["treatment", 2153], [".", 2162]]}
{"context": "Ataxin-3, the disease protein in the neurodegenerative disorder Spinocerebellar Ataxia Type 3 or Machado Joseph disease, is a cysteine protease implicated in the ubiquitin proteasome pathway. It contains multiple ubiquitin binding sites through which it anchors polyubiquitin chains of different linkages that are then cleaved by the N-terminal catalytic (Josephin) domain. The properties of the ubiquitin interacting motifs (UIMs) in the C-terminus of ataxin-3 are well established. Very little is known, however, about how two recently identified ubiquitin-binding sites in the Josephin domain contribute to ubiquitin chain binding and cleavage. In the current study, we sought to define the specific contribution of the Josephin domain to the catalytic properties of ataxin-3 and assess how the topology and affinity of these binding sites modulate ataxin-3 activity. Using NMR we modeled the structure of diUb/Josephin complexes and showed that linkage preferences are imposed by the topology of the two binding sites. Enzymatic studies further helped us to determine a precise hierarchy between the sites. We establish that the structure of Josephin dictates specificity for K48-linked chains. Site 1, which is close to the active site, is indispensable for cleavage. Our studies open the way to understand better the cellular function of ataxin-3 and its link to pathology.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5e25c3d45f5646e79edcd84d6308a178", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [227, 227], [75, 75], [142, 142], [129, 129]], "char_spans": [[0, 7], [1344, 1351], [453, 460], [852, 859], [770, 777]]}]}], "context_tokens": [["Ataxin-3", 0], [",", 8], ["the", 10], ["disease", 14], ["protein", 22], ["in", 30], ["the", 33], ["neurodegenerative", 37], ["disorder", 55], ["Spinocerebellar", 64], ["Ataxia", 80], ["Type", 87], ["3", 92], ["or", 94], ["Machado", 97], ["Joseph", 105], ["disease", 112], [",", 119], ["is", 121], ["a", 124], ["cysteine", 126], ["protease", 135], ["implicated", 144], ["in", 155], ["the", 158], ["ubiquitin", 162], ["proteasome", 172], ["pathway", 183], [".", 190], ["It", 192], ["contains", 195], ["multiple", 204], ["ubiquitin", 213], ["binding", 223], ["sites", 231], ["through", 237], ["which", 245], ["it", 251], ["anchors", 254], ["polyubiquitin", 262], ["chains", 276], ["of", 283], ["different", 286], ["linkages", 296], ["that", 305], ["are", 310], ["then", 314], ["cleaved", 319], ["by", 327], ["the", 330], ["N", 334], ["-", 335], ["terminal", 336], ["catalytic", 345], ["(", 355], ["Josephin", 356], [")", 364], ["domain", 366], [".", 372], ["The", 374], ["properties", 378], ["of", 389], ["the", 392], ["ubiquitin", 396], ["interacting", 406], ["motifs", 418], ["(", 425], ["UIMs", 426], [")", 430], ["in", 432], ["the", 435], ["C", 439], ["-", 440], ["terminus", 441], ["of", 450], ["ataxin-3", 453], ["are", 462], ["well", 466], ["established", 471], [".", 482], ["Very", 484], ["little", 489], ["is", 496], ["known", 499], [",", 504], ["however", 506], [",", 513], ["about", 515], ["how", 521], ["two", 525], ["recently", 529], ["identified", 538], ["ubiquitin", 549], ["-", 558], ["binding", 559], ["sites", 567], ["in", 573], ["the", 576], ["Josephin", 580], ["domain", 589], ["contribute", 596], ["to", 607], ["ubiquitin", 610], ["chain", 620], ["binding", 626], ["and", 634], ["cleavage", 638], [".", 646], ["In", 648], ["the", 651], ["current", 655], ["study", 663], [",", 668], ["we", 670], ["sought", 673], ["to", 680], ["define", 683], ["the", 690], ["specific", 694], ["contribution", 703], ["of", 716], ["the", 719], ["Josephin", 723], ["domain", 732], ["to", 739], ["the", 742], ["catalytic", 746], ["properties", 756], ["of", 767], ["ataxin-3", 770], ["and", 779], ["assess", 783], ["how", 790], ["the", 794], ["topology", 798], ["and", 807], ["affinity", 811], ["of", 820], ["these", 823], ["binding", 829], ["sites", 837], ["modulate", 843], ["ataxin-3", 852], ["activity", 861], [".", 869], ["Using", 871], ["NMR", 877], ["we", 881], ["modeled", 884], ["the", 892], ["structure", 896], ["of", 906], ["diUb", 909], ["/", 913], ["Josephin", 914], ["complexes", 923], ["and", 933], ["showed", 937], ["that", 944], ["linkage", 949], ["preferences", 957], ["are", 969], ["imposed", 973], ["by", 981], ["the", 984], ["topology", 988], ["of", 997], ["the", 1000], ["two", 1004], ["binding", 1008], ["sites", 1016], [".", 1021], ["Enzymatic", 1023], ["studies", 1033], ["further", 1041], ["helped", 1049], ["us", 1056], ["to", 1059], ["determine", 1062], ["a", 1072], ["precise", 1074], ["hierarchy", 1082], ["between", 1092], ["the", 1100], ["sites", 1104], [".", 1109], ["We", 1111], ["establish", 1114], ["that", 1124], ["the", 1129], ["structure", 1133], ["of", 1143], ["Josephin", 1146], ["dictates", 1155], ["specificity", 1164], ["for", 1176], ["K48-linked", 1180], ["chains", 1191], [".", 1197], ["Site", 1199], ["1", 1204], [",", 1205], ["which", 1207], ["is", 1213], ["close", 1216], ["to", 1222], ["the", 1225], ["active", 1229], ["site", 1236], [",", 1240], ["is", 1242], ["indispensable", 1245], ["for", 1259], ["cleavage", 1263], [".", 1271], ["Our", 1273], ["studies", 1277], ["open", 1285], ["the", 1290], ["way", 1294], ["to", 1298], ["understand", 1301], ["better", 1312], ["the", 1319], ["cellular", 1323], ["function", 1332], ["of", 1341], ["ataxin-3", 1344], ["and", 1353], ["its", 1357], ["link", 1361], ["to", 1366], ["pathology", 1369], [".", 1378]]}
{"context": "Hallervorden-Spatz syndrome (HSS) is a rare autosomal recessive disorder clinically characterized by extrapyramidal signs and progressive dementia. In a typical case, the clinical symptoms become apparent during late childhood, and usually the course is protracted over a decade or more. We recently had an opportunity to study the brains of two cases of HSS with a clinical course of over 30 years. Case 1 was a 44-year-old female and case 2 was a 37-year-old male. Grossly, the brains showed severe fronto-temporal lobar atrophy with abundant spheroids and mild iron deposits in the globus pallidus, associated with features of motor neuron disease. In addition, there was diffuse sponginess in the atrophic cortex as well as widespread Alzheimer's neurofibrillary tangles (NFTs) and Lewy bodies (LBs) in the cortical and subcortical regions, including the spinal cord. Ultrastructurally, NFTs were composed of paired helical filaments, and LBs of central dense cores with radiating fibrils. Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein. In addition, diffuse, overlapping immunoreactivity of alpha-synuclein and phosphorylated tau was seen within the cytoplasm of many neurons. However, when LBs and NFTs coexisted within the same neurons, they were clearly segregated. The findings of our present cases as well as those reported in the literature may indicate that simultaneous and extensive occurrence of abnormal phosphorylation of tau and accumulation of alpha-synuclein may constitute cardinal pathological features of HSS with protracted clinical course.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "4a2d924caf4d464aa5a7837b4e6e320d", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[214, 216], [202, 204], [275, 277]], "char_spans": [[1220, 1234], [1149, 1163], [1587, 1601]]}]}], "context_tokens": [["Hallervorden", 0], ["-", 12], ["Spatz", 13], ["syndrome", 19], ["(", 28], ["HSS", 29], [")", 32], ["is", 34], ["a", 37], ["rare", 39], ["autosomal", 44], ["recessive", 54], ["disorder", 64], ["clinically", 73], ["characterized", 84], ["by", 98], ["extrapyramidal", 101], ["signs", 116], ["and", 122], ["progressive", 126], ["dementia", 138], [".", 146], ["In", 148], ["a", 151], ["typical", 153], ["case", 161], [",", 165], ["the", 167], ["clinical", 171], ["symptoms", 180], ["become", 189], ["apparent", 196], ["during", 205], ["late", 212], ["childhood", 217], [",", 226], ["and", 228], ["usually", 232], ["the", 240], ["course", 244], ["is", 251], ["protracted", 254], ["over", 265], ["a", 270], ["decade", 272], ["or", 279], ["more", 282], [".", 286], ["We", 288], ["recently", 291], ["had", 300], ["an", 304], ["opportunity", 307], ["to", 319], ["study", 322], ["the", 328], ["brains", 332], ["of", 339], ["two", 342], ["cases", 346], ["of", 352], ["HSS", 355], ["with", 359], ["a", 364], ["clinical", 366], ["course", 375], ["of", 382], ["over", 385], ["30", 390], ["years", 393], [".", 398], ["Case", 400], ["1", 405], ["was", 407], ["a", 411], ["44-year", 413], ["-", 420], ["old", 421], ["female", 425], ["and", 432], ["case", 436], ["2", 441], ["was", 443], ["a", 447], ["37-year", 449], ["-", 456], ["old", 457], ["male", 461], [".", 465], ["Grossly", 467], [",", 474], ["the", 476], ["brains", 480], ["showed", 487], ["severe", 494], ["fronto", 501], ["-", 507], ["temporal", 508], ["lobar", 517], ["atrophy", 523], ["with", 531], ["abundant", 536], ["spheroids", 545], ["and", 555], ["mild", 559], ["iron", 564], ["deposits", 569], ["in", 578], ["the", 581], ["globus", 585], ["pallidus", 592], [",", 600], ["associated", 602], ["with", 613], ["features", 618], ["of", 627], ["motor", 630], ["neuron", 636], ["disease", 643], [".", 650], ["In", 652], ["addition", 655], [",", 663], ["there", 665], ["was", 671], ["diffuse", 675], ["sponginess", 683], ["in", 694], ["the", 697], ["atrophic", 701], ["cortex", 710], ["as", 717], ["well", 720], ["as", 725], ["widespread", 728], ["Alzheimer", 739], ["'s", 748], ["neurofibrillary", 751], ["tangles", 767], ["(", 775], ["NFTs", 776], [")", 780], ["and", 782], ["Lewy", 786], ["bodies", 791], ["(", 798], ["LBs", 799], [")", 802], ["in", 804], ["the", 807], ["cortical", 811], ["and", 820], ["subcortical", 824], ["regions", 836], [",", 843], ["including", 845], ["the", 855], ["spinal", 859], ["cord", 866], [".", 870], ["Ultrastructurally", 872], [",", 889], ["NFTs", 891], ["were", 896], ["composed", 901], ["of", 910], ["paired", 913], ["helical", 920], ["filaments", 928], [",", 937], ["and", 939], ["LBs", 943], ["of", 947], ["central", 950], ["dense", 958], ["cores", 964], ["with", 970], ["radiating", 975], ["fibrils", 985], [".", 992], ["Discrete", 994], ["immunostaining", 1003], ["was", 1018], ["demonstrated", 1022], ["in", 1035], ["NFTs", 1038], ["and", 1043], ["neuropil", 1047], ["threads", 1056], ["with", 1064], ["various", 1069], ["antibodies", 1077], ["against", 1088], ["phosphorylated", 1096], ["tau", 1111], [",", 1114], ["and", 1116], ["in", 1120], ["LBs", 1123], ["with", 1127], ["antibody", 1132], ["against", 1141], ["alpha", 1149], ["-", 1154], ["synuclein", 1155], [".", 1164], ["In", 1166], ["addition", 1169], [",", 1177], ["diffuse", 1179], [",", 1186], ["overlapping", 1188], ["immunoreactivity", 1200], ["of", 1217], ["alpha", 1220], ["-", 1225], ["synuclein", 1226], ["and", 1236], ["phosphorylated", 1240], ["tau", 1255], ["was", 1259], ["seen", 1263], ["within", 1268], ["the", 1275], ["cytoplasm", 1279], ["of", 1289], ["many", 1292], ["neurons", 1297], [".", 1304], ["However", 1306], [",", 1313], ["when", 1315], ["LBs", 1320], ["and", 1324], ["NFTs", 1328], ["coexisted", 1333], ["within", 1343], ["the", 1350], ["same", 1354], ["neurons", 1359], [",", 1366], ["they", 1368], ["were", 1373], ["clearly", 1378], ["segregated", 1386], [".", 1396], ["The", 1398], ["findings", 1402], ["of", 1411], ["our", 1414], ["present", 1418], ["cases", 1426], ["as", 1432], ["well", 1435], ["as", 1440], ["those", 1443], ["reported", 1449], ["in", 1458], ["the", 1461], ["literature", 1465], ["may", 1476], ["indicate", 1480], ["that", 1489], ["simultaneous", 1494], ["and", 1507], ["extensive", 1511], ["occurrence", 1521], ["of", 1532], ["abnormal", 1535], ["phosphorylation", 1544], ["of", 1560], ["tau", 1563], ["and", 1567], ["accumulation", 1571], ["of", 1584], ["alpha", 1587], ["-", 1592], ["synuclein", 1593], ["may", 1603], ["constitute", 1607], ["cardinal", 1618], ["pathological", 1627], ["features", 1640], ["of", 1649], ["HSS", 1652], ["with", 1656], ["protracted", 1661], ["clinical", 1672], ["course", 1681], [".", 1687]]}
{"context": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. Although MS is a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. The severity of the cephalo-facial anomalies was variable among these family members.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "d053f9773d0649b8b2acea49e06af19f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[32, 38]], "char_spans": [[202, 243]]}]}], "context_tokens": [["The", 0], ["Muenke", 4], ["syndrome", 11], ["(", 20], ["MS", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["unicoronal", 45], ["or", 56], ["bicoronal", 59], ["craniosynostosis", 69], [",", 85], ["midfacial", 87], ["hypoplasia", 97], [",", 107], ["ocular", 109], ["hypertelorism", 116], [",", 129], ["and", 131], ["a", 135], ["variety", 137], ["of", 145], ["minor", 148], ["abnormalities", 154], ["associated", 168], ["with", 179], ["a", 184], ["mutation", 186], ["in", 195], ["the", 198], ["fibroblast", 202], ["growth", 213], ["factor", 220], ["receptor", 227], ["3", 236], ["(", 238], ["FGFR3", 239], [")", 244], ["gene", 246], [".", 250], ["The", 252], ["birth", 256], ["prevalence", 262], ["is", 273], ["approximately", 276], ["one", 290], ["in", 294], ["10,000", 297], ["live", 304], ["births", 309], [",", 315], ["accounting", 317], ["for", 328], ["8", 332], ["-", 333], ["10", 334], ["%", 336], ["of", 338], ["patients", 341], ["with", 350], ["coronal", 355], ["synostosis", 363], [".", 373], ["Although", 375], ["MS", 384], ["is", 387], ["a", 390], ["relatively", 392], ["common", 403], ["diagnosis", 410], ["in", 420], ["patients", 423], ["with", 432], ["craniosynostosis", 437], ["syndromes", 454], [",", 463], ["with", 465], ["autosomal", 470], ["dominant", 480], ["inheritance", 489], [",", 500], ["there", 502], ["has", 508], ["been", 512], ["no", 517], ["report", 520], ["of", 527], ["MS", 530], [",", 532], ["in", 534], ["an", 537], ["affected", 540], ["Korean", 549], ["family", 556], ["with", 563], ["typical", 568], ["cephalo", 576], ["-", 583], ["facial", 584], ["morphology", 591], ["that", 602], ["has", 607], ["been", 611], ["confirmed", 616], ["by", 626], ["molecular", 629], ["studies", 639], [".", 646], ["Here", 648], [",", 652], ["we", 654], ["report", 657], ["a", 664], ["familial", 666], ["case", 675], ["of", 680], ["MS", 683], ["in", 686], ["a", 689], ["female", 691], ["patient", 698], ["with", 706], ["a", 711], ["Pro250Arg", 713], ["mutation", 723], ["in", 732], ["exon", 735], ["7", 740], ["(", 742], ["IgII", 743], ["-", 747], ["IGIII", 748], ["linker", 754], ["domain", 761], [")", 767], ["of", 769], ["the", 772], ["FGFR3", 776], ["gene", 782], [".", 786], ["This", 788], ["patient", 793], ["had", 801], ["mild", 805], ["midfacial", 810], ["hypoplasia", 820], [",", 830], ["hypertelorism", 832], [",", 845], ["downslanting", 847], ["palpebral", 860], ["fissures", 870], [",", 878], ["a", 880], ["beak", 882], ["shaped", 887], ["nose", 894], [",", 898], ["plagio", 900], ["-", 906], ["brachycephaly", 907], [",", 920], ["and", 922], ["mild", 926], ["neurodevelopmental", 931], ["delay", 950], [".", 955], ["The", 957], ["same", 961], ["mutation", 966], ["was", 975], ["confirmed", 979], ["in", 989], ["the", 992], ["patient", 996], ["'s", 1003], ["mother", 1006], [",", 1012], ["two", 1014], ["of", 1018], ["the", 1021], ["mother", 1025], ["'s", 1031], ["sisters", 1034], ["and", 1042], ["the", 1046], ["maternal", 1050], ["grandfather", 1059], [".", 1070], ["The", 1072], ["severity", 1076], ["of", 1085], ["the", 1088], ["cephalo", 1092], ["-", 1099], ["facial", 1100], ["anomalies", 1107], ["was", 1117], ["variable", 1121], ["among", 1130], ["these", 1136], ["family", 1142], ["members", 1149], [".", 1156]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "The first step in the management of restless legs syndrome (RLS) is to identify, and if possible to treat any condition which might cause or worsen RLS, such as iron deficiency or some drug treatments. The patients suffering from RLS should be prompted to keep a healthy sleep schedule. Drug treatment should be restricted to patients with a clear clinical diagnosis, decided on an individual basis, when the clinical impact is serious. Four drug classes are central to the treatment of RLS: dopaminergic agents, some antiepileptics, opioids, and benzodiazepines. Dopaminergic agonists are the treatment of choice, especially when daily treatment is indicated, or if the symptoms are severe. Two dopaminergic agonists are licensed in France for the treatment of RLS: ropinirole (Adartrel) and pramipexole (Sifrol). After initiation of treatment, the patients should benefit from a regular follow-up in order to evaluate the efficacy of treatment and to identify possible side-effects. Special care should be given to the detection of augmentation, a phenomenon characterized by a paradoxical worsening of the symptoms with treatment. Some particular conditions, such as RLS comorbid with renal insufficiency, during pregnancy, and in the child are discussed.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "aea77da44e294600b63d4260d7490d59", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[33, 33]], "char_spans": [[161, 164]]}]}], "context_tokens": [["The", 0], ["first", 4], ["step", 10], ["in", 15], ["the", 18], ["management", 22], ["of", 33], ["restless", 36], ["legs", 45], ["syndrome", 50], ["(", 59], ["RLS", 60], [")", 63], ["is", 65], ["to", 68], ["identify", 71], [",", 79], ["and", 81], ["if", 85], ["possible", 88], ["to", 97], ["treat", 100], ["any", 106], ["condition", 110], ["which", 120], ["might", 126], ["cause", 132], ["or", 138], ["worsen", 141], ["RLS", 148], [",", 151], ["such", 153], ["as", 158], ["iron", 161], ["deficiency", 166], ["or", 177], ["some", 180], ["drug", 185], ["treatments", 190], [".", 200], ["The", 202], ["patients", 206], ["suffering", 215], ["from", 225], ["RLS", 230], ["should", 234], ["be", 241], ["prompted", 244], ["to", 253], ["keep", 256], ["a", 261], ["healthy", 263], ["sleep", 271], ["schedule", 277], [".", 285], ["Drug", 287], ["treatment", 292], ["should", 302], ["be", 309], ["restricted", 312], ["to", 323], ["patients", 326], ["with", 335], ["a", 340], ["clear", 342], ["clinical", 348], ["diagnosis", 357], [",", 366], ["decided", 368], ["on", 376], ["an", 379], ["individual", 382], ["basis", 393], [",", 398], ["when", 400], ["the", 405], ["clinical", 409], ["impact", 418], ["is", 425], ["serious", 428], [".", 435], ["Four", 437], ["drug", 442], ["classes", 447], ["are", 455], ["central", 459], ["to", 467], ["the", 470], ["treatment", 474], ["of", 484], ["RLS", 487], [":", 490], ["dopaminergic", 492], ["agents", 505], [",", 511], ["some", 513], ["antiepileptics", 518], [",", 532], ["opioids", 534], [",", 541], ["and", 543], ["benzodiazepines", 547], [".", 562], ["Dopaminergic", 564], ["agonists", 577], ["are", 586], ["the", 590], ["treatment", 594], ["of", 604], ["choice", 607], [",", 613], ["especially", 615], ["when", 626], ["daily", 631], ["treatment", 637], ["is", 647], ["indicated", 650], [",", 659], ["or", 661], ["if", 664], ["the", 667], ["symptoms", 671], ["are", 680], ["severe", 684], [".", 690], ["Two", 692], ["dopaminergic", 696], ["agonists", 709], ["are", 718], ["licensed", 722], ["in", 731], ["France", 734], ["for", 741], ["the", 745], ["treatment", 749], ["of", 759], ["RLS", 762], [":", 765], ["ropinirole", 767], ["(", 778], ["Adartrel", 779], [")", 787], ["and", 789], ["pramipexole", 793], ["(", 805], ["Sifrol", 806], [")", 812], [".", 813], ["After", 815], ["initiation", 821], ["of", 832], ["treatment", 835], [",", 844], ["the", 846], ["patients", 850], ["should", 859], ["benefit", 866], ["from", 874], ["a", 879], ["regular", 881], ["follow", 889], ["-", 895], ["up", 896], ["in", 899], ["order", 902], ["to", 908], ["evaluate", 911], ["the", 920], ["efficacy", 924], ["of", 933], ["treatment", 936], ["and", 946], ["to", 950], ["identify", 953], ["possible", 962], ["side", 971], ["-", 975], ["effects", 976], [".", 983], ["Special", 985], ["care", 993], ["should", 998], ["be", 1005], ["given", 1008], ["to", 1014], ["the", 1017], ["detection", 1021], ["of", 1031], ["augmentation", 1034], [",", 1046], ["a", 1048], ["phenomenon", 1050], ["characterized", 1061], ["by", 1075], ["a", 1078], ["paradoxical", 1080], ["worsening", 1092], ["of", 1102], ["the", 1105], ["symptoms", 1109], ["with", 1118], ["treatment", 1123], [".", 1132], ["Some", 1134], ["particular", 1139], ["conditions", 1150], [",", 1160], ["such", 1162], ["as", 1167], ["RLS", 1170], ["comorbid", 1174], ["with", 1183], ["renal", 1188], ["insufficiency", 1194], [",", 1207], ["during", 1209], ["pregnancy", 1216], [",", 1225], ["and", 1227], ["in", 1231], ["the", 1234], ["child", 1238], ["are", 1244], ["discussed", 1248], [".", 1257]]}
{"context": "A study was performed to determine the utility of the 8-point recognition of stroke in the emergency room (ROSIER) instrument as a diagnostic tool in a large Irish emergency department. Fifty patients had ROSIER scores completed by doctors. Diagnoses achieved using the score were compared with discharge diagnoses. Relations between ROSIER score, impairment and length of stay were assessed. Forty-seven patients (94%) had a ROSIER Score > or =1 indicating a stroke, 44 (94%) of these had stroke confirmed on investigation. Two patients with stroke were missed and three were wrongly identified. Positive predictive value for the ROSIER was 94%. ROSIER correlated with Scandinavian neurological stroke score. (r = -0.414, p = 0.003) and was associated with increasing length of stay in survivors (p = 0.16, one-way ANOVA. F = 3.116, df = 6). The ROSIER is a suitable and useful adjunct in the assessment of stroke patients in Ireland.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "84e440c52ada4da9ab59b02ebf6421e1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[13, 13], [179, 179], [102, 102], [84, 84], [126, 126], [94, 94]], "char_spans": [[77, 82], [908, 913], [543, 548], [460, 465], [696, 701], [490, 495]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["performed", 12], ["to", 22], ["determine", 25], ["the", 35], ["utility", 39], ["of", 47], ["the", 50], ["8-point", 54], ["recognition", 62], ["of", 74], ["stroke", 77], ["in", 84], ["the", 87], ["emergency", 91], ["room", 101], ["(", 106], ["ROSIER", 107], [")", 113], ["instrument", 115], ["as", 126], ["a", 129], ["diagnostic", 131], ["tool", 142], ["in", 147], ["a", 150], ["large", 152], ["Irish", 158], ["emergency", 164], ["department", 174], [".", 184], ["Fifty", 186], ["patients", 192], ["had", 201], ["ROSIER", 205], ["scores", 212], ["completed", 219], ["by", 229], ["doctors", 232], [".", 239], ["Diagnoses", 241], ["achieved", 251], ["using", 260], ["the", 266], ["score", 270], ["were", 276], ["compared", 281], ["with", 290], ["discharge", 295], ["diagnoses", 305], [".", 314], ["Relations", 316], ["between", 326], ["ROSIER", 334], ["score", 341], [",", 346], ["impairment", 348], ["and", 359], ["length", 363], ["of", 370], ["stay", 373], ["were", 378], ["assessed", 383], [".", 391], ["Forty", 393], ["-", 398], ["seven", 399], ["patients", 405], ["(", 414], ["94", 415], ["%", 417], [")", 418], ["had", 420], ["a", 424], ["ROSIER", 426], ["Score", 433], [">", 439], ["or", 441], ["=", 444], ["1", 445], ["indicating", 447], ["a", 458], ["stroke", 460], [",", 466], ["44", 468], ["(", 471], ["94", 472], ["%", 474], [")", 475], ["of", 477], ["these", 480], ["had", 486], ["stroke", 490], ["confirmed", 497], ["on", 507], ["investigation", 510], [".", 523], ["Two", 525], ["patients", 529], ["with", 538], ["stroke", 543], ["were", 550], ["missed", 555], ["and", 562], ["three", 566], ["were", 572], ["wrongly", 577], ["identified", 585], [".", 595], ["Positive", 597], ["predictive", 606], ["value", 617], ["for", 623], ["the", 627], ["ROSIER", 631], ["was", 638], ["94", 642], ["%", 644], [".", 645], ["ROSIER", 647], ["correlated", 654], ["with", 665], ["Scandinavian", 670], ["neurological", 683], ["stroke", 696], ["score", 703], [".", 708], ["(", 710], ["r", 711], ["=", 713], ["-0.414", 715], [",", 721], ["p", 723], ["=", 725], ["0.003", 727], [")", 732], ["and", 734], ["was", 738], ["associated", 742], ["with", 753], ["increasing", 758], ["length", 769], ["of", 776], ["stay", 779], ["in", 784], ["survivors", 787], ["(", 797], ["p", 798], ["=", 800], ["0.16", 802], [",", 806], ["one", 808], ["-", 811], ["way", 812], ["ANOVA", 816], [".", 821], ["F", 823], ["=", 825], ["3.116", 827], [",", 832], ["df", 834], ["=", 837], ["6", 839], [")", 840], [".", 841], ["The", 843], ["ROSIER", 847], ["is", 854], ["a", 857], ["suitable", 859], ["and", 868], ["useful", 872], ["adjunct", 879], ["in", 887], ["the", 890], ["assessment", 894], ["of", 905], ["stroke", 908], ["patients", 915], ["in", 924], ["Ireland", 927], [".", 934]]}
{"context": "The objective of this study was to determine the performance of the Recognition Of Stroke In the Emergency Room (ROSIER) scale in risk-stratifying Chinese patients with suspected stroke in Hong Kong. This was a prospective cohort study in an urban academic emergency department (ED) over a 7-month period. Patients over 18 years of age with suspected stroke were recruited between June 2011 and December 2011. ROSIER scale assessment was performed in the ED triage area. Logistic regression analysis was used to estimate the impacts of diagnostic variables, including ROSIER scale, past history and ED characteristics. 715 suspected stroke patients were recruited for assessment, of whom 371 (52%) had acute cerebrovascular disease (302 ischaemic strokes, 24 transient ischaemic attacks (TIA), 45 intracerebral haemorrhages), and 344 (48%) had other illnesses i.e. stroke mimics. Common stroke mimics were spinal neuropathy, dementia, labyrinthitis and sepsis. The suggested cut-off score of>0 for the ROSIER scale for stroke diagnosis gave a sensitivity of 87% (95%CI 83-90), a specificity of 41% (95%CI 36-47), a positive predictive value of 62% (95%CI 57-66), and a negative predictive value of 75% (95%CI 68-81), and the AUC was 0.723. The overall accuracy at cut off>0 was 65% i.e. (323+141)/715. The ROSIER scale was not as effective at differentiating acute stroke from stroke mimics in Chinese patients in Hong Kong as it was in the original studies, primarily due to a much lower specificity. If the ROSIER scale is to be clinically useful in Chinese suspected stroke patients, it requires further refinement.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "382bb11c7a004d7c8c8db92c09fbed6f", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[14, 14], [64, 64], [160, 160], [309, 309], [156, 156], [184, 184], [110, 110], [273, 273], [31, 31], [271, 271]], "char_spans": [[83, 88], [351, 356], [887, 892], [1570, 1575], [865, 870], [1019, 1024], [633, 638], [1377, 1382], [179, 184], [1365, 1370]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["study", 22], ["was", 28], ["to", 32], ["determine", 35], ["the", 45], ["performance", 49], ["of", 61], ["the", 64], ["Recognition", 68], ["Of", 80], ["Stroke", 83], ["In", 90], ["the", 93], ["Emergency", 97], ["Room", 107], ["(", 112], ["ROSIER", 113], [")", 119], ["scale", 121], ["in", 127], ["risk", 130], ["-", 134], ["stratifying", 135], ["Chinese", 147], ["patients", 155], ["with", 164], ["suspected", 169], ["stroke", 179], ["in", 186], ["Hong", 189], ["Kong", 194], [".", 198], ["This", 200], ["was", 205], ["a", 209], ["prospective", 211], ["cohort", 223], ["study", 230], ["in", 236], ["an", 239], ["urban", 242], ["academic", 248], ["emergency", 257], ["department", 267], ["(", 278], ["ED", 279], [")", 281], ["over", 283], ["a", 288], ["7-month", 290], ["period", 298], [".", 304], ["Patients", 306], ["over", 315], ["18", 320], ["years", 323], ["of", 329], ["age", 332], ["with", 336], ["suspected", 341], ["stroke", 351], ["were", 358], ["recruited", 363], ["between", 373], ["June", 381], ["2011", 386], ["and", 391], ["December", 395], ["2011", 404], [".", 408], ["ROSIER", 410], ["scale", 417], ["assessment", 423], ["was", 434], ["performed", 438], ["in", 448], ["the", 451], ["ED", 455], ["triage", 458], ["area", 465], [".", 469], ["Logistic", 471], ["regression", 480], ["analysis", 491], ["was", 500], ["used", 504], ["to", 509], ["estimate", 512], ["the", 521], ["impacts", 525], ["of", 533], ["diagnostic", 536], ["variables", 547], [",", 556], ["including", 558], ["ROSIER", 568], ["scale", 575], [",", 580], ["past", 582], ["history", 587], ["and", 595], ["ED", 599], ["characteristics", 602], [".", 617], ["715", 619], ["suspected", 623], ["stroke", 633], ["patients", 640], ["were", 649], ["recruited", 654], ["for", 664], ["assessment", 668], [",", 678], ["of", 680], ["whom", 683], ["371", 688], ["(", 692], ["52", 693], ["%", 695], [")", 696], ["had", 698], ["acute", 702], ["cerebrovascular", 708], ["disease", 724], ["(", 732], ["302", 733], ["ischaemic", 737], ["strokes", 747], [",", 754], ["24", 756], ["transient", 759], ["ischaemic", 769], ["attacks", 779], ["(", 787], ["TIA", 788], [")", 791], [",", 792], ["45", 794], ["intracerebral", 797], ["haemorrhages", 811], [")", 823], [",", 824], ["and", 826], ["344", 830], ["(", 834], ["48", 835], ["%", 837], [")", 838], ["had", 840], ["other", 844], ["illnesses", 850], ["i.e.", 860], ["stroke", 865], ["mimics", 872], [".", 878], ["Common", 880], ["stroke", 887], ["mimics", 894], ["were", 901], ["spinal", 906], ["neuropathy", 913], [",", 923], ["dementia", 925], [",", 933], ["labyrinthitis", 935], ["and", 949], ["sepsis", 953], [".", 959], ["The", 961], ["suggested", 965], ["cut", 975], ["-", 978], ["off", 979], ["score", 983], ["of>0", 989], ["for", 994], ["the", 998], ["ROSIER", 1002], ["scale", 1009], ["for", 1015], ["stroke", 1019], ["diagnosis", 1026], ["gave", 1036], ["a", 1041], ["sensitivity", 1043], ["of", 1055], ["87", 1058], ["%", 1060], ["(", 1062], ["95%CI", 1063], ["83", 1069], ["-", 1071], ["90", 1072], [")", 1074], [",", 1075], ["a", 1077], ["specificity", 1079], ["of", 1091], ["41", 1094], ["%", 1096], ["(", 1098], ["95%CI", 1099], ["36", 1105], ["-", 1107], ["47", 1108], [")", 1110], [",", 1111], ["a", 1113], ["positive", 1115], ["predictive", 1124], ["value", 1135], ["of", 1141], ["62", 1144], ["%", 1146], ["(", 1148], ["95%CI", 1149], ["57", 1155], ["-", 1157], ["66", 1158], [")", 1160], [",", 1161], ["and", 1163], ["a", 1167], ["negative", 1169], ["predictive", 1178], ["value", 1189], ["of", 1195], ["75", 1198], ["%", 1200], ["(", 1202], ["95%CI", 1203], ["68", 1209], ["-", 1211], ["81", 1212], [")", 1214], [",", 1215], ["and", 1217], ["the", 1221], ["AUC", 1225], ["was", 1229], ["0.723", 1233], [".", 1238], ["The", 1240], ["overall", 1244], ["accuracy", 1252], ["at", 1261], ["cut", 1264], ["off>0", 1268], ["was", 1274], ["65", 1278], ["%", 1280], ["i.e.", 1282], ["(", 1287], ["323", 1288], ["+", 1291], ["141)/715", 1292], [".", 1300], ["The", 1302], ["ROSIER", 1306], ["scale", 1313], ["was", 1319], ["not", 1323], ["as", 1327], ["effective", 1330], ["at", 1340], ["differentiating", 1343], ["acute", 1359], ["stroke", 1365], ["from", 1372], ["stroke", 1377], ["mimics", 1384], ["in", 1391], ["Chinese", 1394], ["patients", 1402], ["in", 1411], ["Hong", 1414], ["Kong", 1419], ["as", 1424], ["it", 1427], ["was", 1430], ["in", 1434], ["the", 1437], ["original", 1441], ["studies", 1450], [",", 1457], ["primarily", 1459], ["due", 1469], ["to", 1473], ["a", 1476], ["much", 1478], ["lower", 1483], ["specificity", 1489], [".", 1500], ["If", 1502], ["the", 1505], ["ROSIER", 1509], ["scale", 1516], ["is", 1522], ["to", 1525], ["be", 1528], ["clinically", 1531], ["useful", 1542], ["in", 1549], ["Chinese", 1552], ["suspected", 1560], ["stroke", 1570], ["patients", 1577], [",", 1585], ["it", 1587], ["requires", 1590], ["further", 1599], ["refinement", 1607], [".", 1617]]}
{"context": "Aggregation of \u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. In this work, we provide a mechanistic view of the role of N-terminal acetylation on fibrillation by first establishing a quantitative relationship between monomer secondary structural propensity and fibril assembly kinetics, and secondly by demonstrating in the N-terminal acetylated form of the early onset A53T mutation, that N-terminal transient helices formed and/or inhibited by N-terminal acetylation modulate the fibril assembly rates. Using NMR chemical shifts and fluorescence experiments, we report that secondary structural propensity in residues 5-8, 14-31, and 50-57 are highly correlated to fibril growth rate. A four-way comparison of secondary structure propensity and fibril growth rates of N-terminally acetylated A53T and WT \u03b1Syn with non-acetylated A53T and WT \u03b1Syn present novel mechanistic insight into the role of N-terminal acetylation in amyloid fibril formation. We show that N-terminal acetylation inhibits the formation of the \"fibrillation promoting\" transient helix at residues 14-31 resulting from the A53T mutation in the non-acetylated variant and supports the formation of the \"fibrillation inhibiting\" transient helix in residues 1-12 thereby resulting in slower fibrillation rates relative to the previously studied non-acetylated A53T variant. Our results highlight the critical interplay of the region-specific transient secondary structure of the N-terminal region with fibrillation, and the inhibitory role of the N-terminal acetyl group in fibril formation.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "98e46197609848b39e1fb5db6b9f7fa8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[2, 4]], "char_spans": [[15, 25]]}, {"text": "\u03b1Syn", "token_spans": [[169, 169], [178, 178], [6, 6]], "char_spans": [[967, 970], [1004, 1007], [28, 31]]}]}], "context_tokens": [["Aggregation", 0], ["of", 12], ["\u03b1", 15], ["-", 16], ["synuclein", 17], ["(", 27], ["\u03b1Syn", 28], [")", 32], [",", 33], ["the", 35], ["primary", 39], ["protein", 47], ["component", 55], ["in", 65], ["Lewy", 68], ["body", 73], ["inclusions", 78], ["of", 89], ["patients", 92], ["with", 101], ["Parkinson", 106], ["'s", 115], ["disease", 118], [",", 125], ["arises", 127], ["when", 134], ["the", 139], ["normally", 143], ["soluble", 152], ["intrinsically", 160], ["disordered", 174], ["protein", 185], ["converts", 193], ["to", 202], ["amyloid", 205], ["fibrils", 213], [".", 220], ["In", 222], ["this", 225], ["work", 230], [",", 234], ["we", 236], ["provide", 239], ["a", 247], ["mechanistic", 249], ["view", 261], ["of", 266], ["the", 269], ["role", 273], ["of", 278], ["N", 281], ["-", 282], ["terminal", 283], ["acetylation", 292], ["on", 304], ["fibrillation", 307], ["by", 320], ["first", 323], ["establishing", 329], ["a", 342], ["quantitative", 344], ["relationship", 357], ["between", 370], ["monomer", 378], ["secondary", 386], ["structural", 396], ["propensity", 407], ["and", 418], ["fibril", 422], ["assembly", 429], ["kinetics", 438], [",", 446], ["and", 448], ["secondly", 452], ["by", 461], ["demonstrating", 464], ["in", 478], ["the", 481], ["N", 485], ["-", 486], ["terminal", 487], ["acetylated", 496], ["form", 507], ["of", 512], ["the", 515], ["early", 519], ["onset", 525], ["A53", 531], ["T", 534], ["mutation", 536], [",", 544], ["that", 546], ["N", 551], ["-", 552], ["terminal", 553], ["transient", 562], ["helices", 572], ["formed", 580], ["and/or", 587], ["inhibited", 594], ["by", 604], ["N", 607], ["-", 608], ["terminal", 609], ["acetylation", 618], ["modulate", 630], ["the", 639], ["fibril", 643], ["assembly", 650], ["rates", 659], [".", 664], ["Using", 666], ["NMR", 672], ["chemical", 676], ["shifts", 685], ["and", 692], ["fluorescence", 696], ["experiments", 709], [",", 720], ["we", 722], ["report", 725], ["that", 732], ["secondary", 737], ["structural", 747], ["propensity", 758], ["in", 769], ["residues", 772], ["5", 781], ["-", 782], ["8", 783], [",", 784], ["14", 786], ["-", 788], ["31", 789], [",", 791], ["and", 793], ["50", 797], ["-", 799], ["57", 800], ["are", 803], ["highly", 807], ["correlated", 814], ["to", 825], ["fibril", 828], ["growth", 835], ["rate", 842], [".", 846], ["A", 848], ["four", 850], ["-", 854], ["way", 855], ["comparison", 859], ["of", 870], ["secondary", 873], ["structure", 883], ["propensity", 893], ["and", 904], ["fibril", 908], ["growth", 915], ["rates", 922], ["of", 928], ["N", 931], ["-", 932], ["terminally", 933], ["acetylated", 944], ["A53", 955], ["T", 958], ["and", 960], ["WT", 964], ["\u03b1Syn", 967], ["with", 972], ["non", 977], ["-", 980], ["acetylated", 981], ["A53", 992], ["T", 995], ["and", 997], ["WT", 1001], ["\u03b1Syn", 1004], ["present", 1009], ["novel", 1017], ["mechanistic", 1023], ["insight", 1035], ["into", 1043], ["the", 1048], ["role", 1052], ["of", 1057], ["N", 1060], ["-", 1061], ["terminal", 1062], ["acetylation", 1071], ["in", 1083], ["amyloid", 1086], ["fibril", 1094], ["formation", 1101], [".", 1110], ["We", 1112], ["show", 1115], ["that", 1120], ["N", 1125], ["-", 1126], ["terminal", 1127], ["acetylation", 1136], ["inhibits", 1148], ["the", 1157], ["formation", 1161], ["of", 1171], ["the", 1174], ["\"", 1178], ["fibrillation", 1179], ["promoting", 1192], ["\"", 1201], ["transient", 1203], ["helix", 1213], ["at", 1219], ["residues", 1222], ["14", 1231], ["-", 1233], ["31", 1234], ["resulting", 1237], ["from", 1247], ["the", 1252], ["A53", 1256], ["T", 1259], ["mutation", 1261], ["in", 1270], ["the", 1273], ["non", 1277], ["-", 1280], ["acetylated", 1281], ["variant", 1292], ["and", 1300], ["supports", 1304], ["the", 1313], ["formation", 1317], ["of", 1327], ["the", 1330], ["\"", 1334], ["fibrillation", 1335], ["inhibiting", 1348], ["\"", 1358], ["transient", 1360], ["helix", 1370], ["in", 1376], ["residues", 1379], ["1", 1388], ["-", 1389], ["12", 1390], ["thereby", 1393], ["resulting", 1401], ["in", 1411], ["slower", 1414], ["fibrillation", 1421], ["rates", 1434], ["relative", 1440], ["to", 1449], ["the", 1452], ["previously", 1456], ["studied", 1467], ["non", 1475], ["-", 1478], ["acetylated", 1479], ["A53", 1490], ["T", 1493], ["variant", 1495], [".", 1502], ["Our", 1504], ["results", 1508], ["highlight", 1516], ["the", 1526], ["critical", 1530], ["interplay", 1539], ["of", 1549], ["the", 1552], ["region", 1556], ["-", 1562], ["specific", 1563], ["transient", 1572], ["secondary", 1582], ["structure", 1592], ["of", 1602], ["the", 1605], ["N", 1609], ["-", 1610], ["terminal", 1611], ["region", 1620], ["with", 1627], ["fibrillation", 1632], [",", 1644], ["and", 1646], ["the", 1650], ["inhibitory", 1654], ["role", 1665], ["of", 1670], ["the", 1673], ["N", 1677], ["-", 1678], ["terminal", 1679], ["acetyl", 1688], ["group", 1695], ["in", 1701], ["fibril", 1704], ["formation", 1711], [".", 1720]]}
{"context": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. Stress-induced syncope and sudden death are secondary to ventricular tachydysrhythmias. A case report of Romano-Ward syndrome complicating pregnancy is presented. Successful therapy with propranolol for life-threatening dysrhythmias was achieved. An excellent neonatal outcome occurred.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "34757c8e5ca444a192856060543f7791", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[64, 81]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["a", 24], ["subtype", 26], ["of", 34], ["prolonged", 37], ["QT", 47], ["syndrome", 50], ["with", 59], ["autosomal", 64], ["dominant", 74], ["inheritance", 83], [".", 94], ["Stress", 96], ["-", 102], ["induced", 103], ["syncope", 111], ["and", 119], ["sudden", 123], ["death", 130], ["are", 136], ["secondary", 140], ["to", 150], ["ventricular", 153], ["tachydysrhythmias", 165], [".", 182], ["A", 184], ["case", 186], ["report", 191], ["of", 198], ["Romano", 201], ["-", 207], ["Ward", 208], ["syndrome", 213], ["complicating", 222], ["pregnancy", 235], ["is", 245], ["presented", 248], [".", 257], ["Successful", 259], ["therapy", 270], ["with", 278], ["propranolol", 283], ["for", 295], ["life", 299], ["-", 303], ["threatening", 304], ["dysrhythmias", 316], ["was", 329], ["achieved", 333], [".", 341], ["An", 343], ["excellent", 346], ["neonatal", 356], ["outcome", 365], ["occurred", 373], [".", 381]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1\u03b2 are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1\u03b2-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1\u03b2 and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1\u03b2 epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1\u03b2 and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1\u03b2 is central to pathogenesis.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "f129d78a420746cd9b0364aa8ac1fa28", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[141, 141], [35, 35], [115, 115], [2, 2], [220, 220], [276, 276], [78, 78], [159, 159]], "char_spans": [[828, 832], [206, 210], [664, 668], [16, 20], [1276, 1280], [1563, 1567], [468, 472], [913, 917]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["potent", 28], ["mediator", 35], ["of", 44], ["inflammatory", 47], ["responses", 60], ["and", 70], ["plays", 74], ["a", 80], ["role", 82], ["in", 87], ["the", 90], ["differentiation", 94], ["of", 110], ["a", 113], ["number", 115], ["of", 122], ["lymphoid", 125], ["cells", 134], [".", 139], ["In", 141], ["several", 144], ["inflammatory", 152], ["and", 165], ["autoimmune", 169], ["diseases", 180], [",", 188], ["serum", 190], ["levels", 196], ["of", 203], ["IL-1\u03b2", 206], ["are", 212], ["elevated", 216], ["and", 225], ["correlate", 229], ["with", 239], ["disease", 244], ["development", 252], ["and", 264], ["severity", 268], [".", 276], ["The", 278], ["central", 282], ["role", 290], ["of", 295], ["the", 298], ["IL-1", 302], ["pathway", 307], ["in", 315], ["several", 318], ["diseases", 326], ["has", 335], ["been", 339], ["validated", 344], ["by", 354], ["inhibitors", 357], ["currently", 368], ["in", 378], ["clinical", 381], ["development", 390], ["or", 402], ["approved", 405], ["by", 414], ["the", 417], ["FDA", 421], [".", 424], ["However", 426], [",", 433], ["the", 435], ["need", 439], ["to", 444], ["effectively", 447], ["modulate", 459], ["IL-1\u03b2", 468], ["-", 473], ["mediated", 474], ["local", 483], ["inflammation", 489], ["with", 502], ["the", 507], ["systemic", 511], ["delivery", 520], ["of", 529], ["an", 532], ["efficacious", 535], [",", 546], ["safe", 548], ["and", 553], ["convenient", 557], ["drug", 568], ["still", 573], ["exists", 579], [".", 585], ["To", 587], ["meet", 590], ["these", 595], ["challenges", 601], [",", 611], ["we", 613], ["developed", 616], ["XOMA", 626], ["052", 631], ["(", 635], ["gevokizumab", 636], [")", 647], [",", 648], ["a", 650], ["potent", 652], ["anti", 659], ["-", 663], ["IL-1\u03b2", 664], ["neutralizing", 670], ["antibody", 683], ["that", 692], ["was", 697], ["designed", 701], ["in", 710], ["silico", 713], ["and", 720], ["humanized", 724], ["using", 734], ["Human", 740], ["Engineering", 746], ["\u2122", 757], ["technology", 759], [".", 769], ["XOMA", 771], ["052", 776], ["has", 780], ["a", 784], ["300", 786], ["femtomolar", 790], ["binding", 801], ["affinity", 809], ["for", 818], ["human", 822], ["IL-1\u03b2", 828], ["and", 834], ["an", 838], ["in", 841], ["vitro", 844], ["potency", 850], ["in", 858], ["the", 861], ["low", 865], ["picomolar", 869], ["range", 879], [".", 884], ["XOMA", 886], ["052", 891], ["binds", 895], ["to", 901], ["a", 904], ["unique", 906], ["IL-1\u03b2", 913], ["epitope", 919], ["where", 927], ["residues", 933], ["critical", 942], ["for", 951], ["binding", 955], ["have", 963], ["been", 968], ["identified", 973], [".", 983], ["We", 985], ["have", 988], ["previously", 993], ["reported", 1004], ["that", 1013], ["XOMA", 1018], ["052", 1023], ["is", 1027], ["efficacious", 1030], ["in", 1042], ["vivo", 1045], ["in", 1050], ["a", 1053], ["diet", 1055], ["-", 1059], ["induced", 1060], ["obesity", 1068], ["mouse", 1076], ["model", 1082], ["thought", 1088], ["to", 1096], ["be", 1099], ["driven", 1102], ["by", 1109], ["low", 1112], ["levels", 1116], ["of", 1123], ["chronic", 1126], ["inflammation", 1134], [".", 1146], ["We", 1148], ["report", 1151], ["here", 1158], ["that", 1163], ["XOMA", 1168], ["052", 1173], ["also", 1177], ["reduces", 1182], ["acute", 1190], ["inflammation", 1196], ["in", 1209], ["vivo", 1212], [",", 1216], ["neutralizing", 1218], ["the", 1231], ["effect", 1235], ["of", 1242], ["exogenously", 1245], ["administered", 1257], ["human", 1270], ["IL-1\u03b2", 1276], ["and", 1282], ["blocking", 1286], ["peritonitis", 1295], ["in", 1307], ["a", 1310], ["mouse", 1312], ["model", 1318], ["of", 1324], ["acute", 1327], ["gout", 1333], [".", 1337], ["Based", 1339], ["on", 1345], ["its", 1348], ["high", 1352], ["potency", 1357], [",", 1364], ["novel", 1366], ["mechanism", 1372], ["of", 1382], ["action", 1385], [",", 1391], ["long", 1393], ["half", 1398], ["-", 1402], ["life", 1403], [",", 1407], ["and", 1409], ["high", 1413], ["affinity", 1418], [",", 1426], ["XOMA", 1428], ["052", 1433], ["provides", 1437], ["a", 1446], ["new", 1448], ["strategy", 1452], ["for", 1461], ["the", 1465], ["treatment", 1469], ["of", 1479], ["a", 1482], ["number", 1484], ["of", 1491], ["inflammatory", 1494], [",", 1506], ["autoimmune", 1508], ["and", 1519], ["metabolic", 1523], ["diseases", 1533], ["in", 1542], ["which", 1545], ["the", 1551], ["role", 1555], ["of", 1560], ["IL-1\u03b2", 1563], ["is", 1569], ["central", 1572], ["to", 1580], ["pathogenesis", 1583], [".", 1595]]}
{"context": "The sodium-calcium exchanger (NCX) is one of the transporters contributing to the control of intracellular calcium (Ca(2+)) concentration by normally mediating net Ca(2+) efflux. However, the reverse mode of the NCX can cause intracellular Ca(2+) concentration overload, which exacerbates the myocardial tissue injury resulting from ischemia. Although the NCX inhibitor SEA0400 has been shown to therapeutically reduce myocardial injury, no in vivo technique exists to monitor intracellular Ca(2+) fluctuations produced by this drug. Cardiac manganese-enhanced MRI (MEMRI) may indirectly assess Ca(2+) efflux by estimating changes in manganese (Mn(2+)) content in vivo, since Mn(2+) has been suggested as a surrogate marker for Ca(2+). This study used the MEMRI technique to examine the temporal features of cardiac Mn(2+) efflux by implementing a T(1)-mapping method and inhibiting the NCX with SEA0400. The change in (1)H(2)O longitudinal relaxation rate, Delta R(1), in the left ventricular free wall, was calculated at different time points following infusion of 190 nmol/g manganese chloride (MnCl(2)) in healthy adult male mice. The results showed 50% MEMRI signal attenuation at 3.4 +/- 0.6 h post-MnCl(2) infusion without drug intervention. Furthermore, treatment with 50 +/- 0.2 mg/kg of SEA0400 significantly reduced the rate of decrease in Delta R(1). At 4.9-5.9 h post-MnCl(2) infusion, the average Delta R(1) values for the two groups treated with SEA0400 were 2.46 +/- 0.29 and 1.72 +/- 0.24 s(-1) for 50 and 20 mg/kg doses, respectively, as compared to the value of 1.27 +/- 0.28 s(-1) for the control group. When this in vivo data were compared to ex vivo absolute manganese content data, the MEMRI T(1)-mapping technique was shown to effectively quantify Mn(2+) efflux rates in the myocardium. Therefore, combining an NCX inhibitor with MEMRI may be a useful technique for assessing Mn(2+) transport mechanisms and rates in vivo, which may reflect changes in Ca(2+) transport.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "f0923f0865c044f8998e18a6c175e105", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[64, 64], [163, 163], [42, 42], [6, 6], [360, 360]], "char_spans": [[356, 358], [887, 889], [212, 214], [30, 32], [1835, 1837]]}]}], "context_tokens": [["The", 0], ["sodium", 4], ["-", 10], ["calcium", 11], ["exchanger", 19], ["(", 29], ["NCX", 30], [")", 33], ["is", 35], ["one", 38], ["of", 42], ["the", 45], ["transporters", 49], ["contributing", 62], ["to", 75], ["the", 78], ["control", 82], ["of", 90], ["intracellular", 93], ["calcium", 107], ["(", 115], ["Ca(2", 116], ["+", 120], [")", 121], [")", 122], ["concentration", 124], ["by", 138], ["normally", 141], ["mediating", 150], ["net", 160], ["Ca(2", 164], ["+", 168], [")", 169], ["efflux", 171], [".", 177], ["However", 179], [",", 186], ["the", 188], ["reverse", 192], ["mode", 200], ["of", 205], ["the", 208], ["NCX", 212], ["can", 216], ["cause", 220], ["intracellular", 226], ["Ca(2", 240], ["+", 244], [")", 245], ["concentration", 247], ["overload", 261], [",", 269], ["which", 271], ["exacerbates", 277], ["the", 289], ["myocardial", 293], ["tissue", 304], ["injury", 311], ["resulting", 318], ["from", 328], ["ischemia", 333], [".", 341], ["Although", 343], ["the", 352], ["NCX", 356], ["inhibitor", 360], ["SEA0400", 370], ["has", 378], ["been", 382], ["shown", 387], ["to", 393], ["therapeutically", 396], ["reduce", 412], ["myocardial", 419], ["injury", 430], [",", 436], ["no", 438], ["in", 441], ["vivo", 444], ["technique", 449], ["exists", 459], ["to", 466], ["monitor", 469], ["intracellular", 477], ["Ca(2", 491], ["+", 495], [")", 496], ["fluctuations", 498], ["produced", 511], ["by", 520], ["this", 523], ["drug", 528], [".", 532], ["Cardiac", 534], ["manganese", 542], ["-", 551], ["enhanced", 552], ["MRI", 561], ["(", 565], ["MEMRI", 566], [")", 571], ["may", 573], ["indirectly", 577], ["assess", 588], ["Ca(2", 595], ["+", 599], [")", 600], ["efflux", 602], ["by", 609], ["estimating", 612], ["changes", 623], ["in", 631], ["manganese", 634], ["(", 644], ["Mn(2", 645], ["+", 649], [")", 650], [")", 651], ["content", 653], ["in", 661], ["vivo", 664], [",", 668], ["since", 670], ["Mn(2", 676], ["+", 680], [")", 681], ["has", 683], ["been", 687], ["suggested", 692], ["as", 702], ["a", 705], ["surrogate", 707], ["marker", 717], ["for", 724], ["Ca(2", 728], ["+", 732], [")", 733], [".", 734], ["This", 736], ["study", 741], ["used", 747], ["the", 752], ["MEMRI", 756], ["technique", 762], ["to", 772], ["examine", 775], ["the", 783], ["temporal", 787], ["features", 796], ["of", 805], ["cardiac", 808], ["Mn(2", 816], ["+", 820], [")", 821], ["efflux", 823], ["by", 830], ["implementing", 833], ["a", 846], ["T(1)-mapping", 848], ["method", 861], ["and", 868], ["inhibiting", 872], ["the", 883], ["NCX", 887], ["with", 891], ["SEA0400", 896], [".", 903], ["The", 905], ["change", 909], ["in", 916], ["(", 919], ["1)H(2)O", 920], ["longitudinal", 928], ["relaxation", 941], ["rate", 952], [",", 956], ["Delta", 958], ["R(1", 964], [")", 967], [",", 968], ["in", 970], ["the", 973], ["left", 977], ["ventricular", 982], ["free", 994], ["wall", 999], [",", 1003], ["was", 1005], ["calculated", 1009], ["at", 1020], ["different", 1023], ["time", 1033], ["points", 1038], ["following", 1045], ["infusion", 1055], ["of", 1064], ["190", 1067], ["nmol", 1071], ["/", 1075], ["g", 1076], ["manganese", 1078], ["chloride", 1088], ["(", 1097], ["MnCl(2", 1098], [")", 1104], [")", 1105], ["in", 1107], ["healthy", 1110], ["adult", 1118], ["male", 1124], ["mice", 1129], [".", 1133], ["The", 1135], ["results", 1139], ["showed", 1147], ["50", 1154], ["%", 1156], ["MEMRI", 1158], ["signal", 1164], ["attenuation", 1171], ["at", 1183], ["3.4", 1186], ["+", 1190], ["/-", 1191], ["0.6", 1194], ["h", 1198], ["post", 1200], ["-", 1204], ["MnCl(2", 1205], [")", 1211], ["infusion", 1213], ["without", 1222], ["drug", 1230], ["intervention", 1235], [".", 1247], ["Furthermore", 1249], [",", 1260], ["treatment", 1262], ["with", 1272], ["50", 1277], ["+", 1280], ["/-", 1281], ["0.2", 1284], ["mg", 1288], ["/", 1290], ["kg", 1291], ["of", 1294], ["SEA0400", 1297], ["significantly", 1305], ["reduced", 1319], ["the", 1327], ["rate", 1331], ["of", 1336], ["decrease", 1339], ["in", 1348], ["Delta", 1351], ["R(1", 1357], [")", 1360], [".", 1361], ["At", 1363], ["4.9", 1366], ["-", 1369], ["5.9", 1370], ["h", 1374], ["post", 1376], ["-", 1380], ["MnCl(2", 1381], [")", 1387], ["infusion", 1389], [",", 1397], ["the", 1399], ["average", 1403], ["Delta", 1411], ["R(1", 1417], [")", 1420], ["values", 1422], ["for", 1429], ["the", 1433], ["two", 1437], ["groups", 1441], ["treated", 1448], ["with", 1456], ["SEA0400", 1461], ["were", 1469], ["2.46", 1474], ["+", 1479], ["/-", 1480], ["0.29", 1483], ["and", 1488], ["1.72", 1492], ["+", 1497], ["/-", 1498], ["0.24", 1501], ["s(-1", 1506], [")", 1510], ["for", 1512], ["50", 1516], ["and", 1519], ["20", 1523], ["mg", 1526], ["/", 1528], ["kg", 1529], ["doses", 1532], [",", 1537], ["respectively", 1539], [",", 1551], ["as", 1553], ["compared", 1556], ["to", 1565], ["the", 1568], ["value", 1572], ["of", 1578], ["1.27", 1581], ["+", 1586], ["/-", 1587], ["0.28", 1590], ["s(-1", 1595], [")", 1599], ["for", 1601], ["the", 1605], ["control", 1609], ["group", 1617], [".", 1622], ["When", 1624], ["this", 1629], ["in", 1634], ["vivo", 1637], ["data", 1642], ["were", 1647], ["compared", 1652], ["to", 1661], ["ex", 1664], ["vivo", 1667], ["absolute", 1672], ["manganese", 1681], ["content", 1691], ["data", 1699], [",", 1703], ["the", 1705], ["MEMRI", 1709], ["T(1)-mapping", 1715], ["technique", 1728], ["was", 1738], ["shown", 1742], ["to", 1748], ["effectively", 1751], ["quantify", 1763], ["Mn(2", 1772], ["+", 1776], [")", 1777], ["efflux", 1779], ["rates", 1786], ["in", 1792], ["the", 1795], ["myocardium", 1799], [".", 1809], ["Therefore", 1811], [",", 1820], ["combining", 1822], ["an", 1832], ["NCX", 1835], ["inhibitor", 1839], ["with", 1849], ["MEMRI", 1854], ["may", 1860], ["be", 1864], ["a", 1867], ["useful", 1869], ["technique", 1876], ["for", 1886], ["assessing", 1890], ["Mn(2", 1900], ["+", 1904], [")", 1905], ["transport", 1907], ["mechanisms", 1917], ["and", 1928], ["rates", 1932], ["in", 1938], ["vivo", 1941], [",", 1945], ["which", 1947], ["may", 1953], ["reflect", 1957], ["changes", 1965], ["in", 1973], ["Ca(2", 1976], ["+", 1980], [")", 1981], ["transport", 1983], [".", 1992]]}
{"context": "Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users. However, sudden death after injection is rare, giving ample opportunity for intervention. Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use).", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "6e72346d9baf4bee8b690349f4e87241", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[80, 80], [37, 37], [125, 125]], "char_spans": [[480, 487], [200, 207], [768, 775]]}]}], "context_tokens": [["Heroin", 0], ["overdose", 7], ["is", 16], ["a", 19], ["major", 21], ["cause", 27], ["of", 33], ["death", 36], ["among", 42], ["heroin", 48], ["users", 55], [",", 60], ["and", 62], ["often", 66], ["occurs", 72], ["in", 79], ["the", 82], ["company", 86], ["of", 94], ["other", 97], ["users", 103], [".", 108], ["However", 110], [",", 117], ["sudden", 119], ["death", 126], ["after", 132], ["injection", 138], ["is", 148], ["rare", 151], [",", 155], ["giving", 157], ["ample", 164], ["opportunity", 170], ["for", 182], ["intervention", 186], [".", 198], ["Naloxone", 200], ["hydrochloride", 209], [",", 222], ["an", 224], ["injectable", 227], ["opioid", 238], ["antagonist", 245], ["which", 256], ["reverses", 262], ["the", 271], ["respiratory", 275], ["depression", 287], [",", 297], ["sedation", 299], ["and", 308], ["hypotension", 312], ["associated", 324], ["with", 335], ["opioids", 340], [",", 347], ["has", 349], ["long", 353], ["been", 358], ["used", 363], ["to", 368], ["treat", 371], ["opioid", 377], ["overdose", 384], [".", 392], ["Experts", 394], ["have", 402], ["suggested", 407], ["that", 417], [",", 421], ["as", 423], ["part", 426], ["of", 431], ["a", 434], ["comprehensive", 436], ["overdose", 450], ["prevention", 459], ["strategy", 470], [",", 478], ["naloxone", 480], ["should", 489], ["be", 496], ["provided", 499], ["to", 508], ["heroin", 511], ["users", 518], ["for", 524], ["peer", 528], ["administration", 533], ["after", 548], ["an", 554], ["overdose", 557], [".", 565], ["A", 567], ["trial", 569], ["could", 575], ["be", 581], ["conducted", 584], ["to", 594], ["determine", 597], ["whether", 607], ["this", 615], ["intervention", 620], ["improves", 633], ["the", 642], ["management", 646], ["of", 657], ["overdose", 660], ["or", 669], ["results", 672], ["in", 680], ["a", 683], ["net", 685], ["increase", 689], ["in", 698], ["harm", 701], ["(", 706], ["by", 707], ["undermining", 710], ["existing", 722], ["prevention", 731], ["strategies", 742], [",", 752], ["precipitating", 754], ["naloxone", 768], ["-", 776], ["related", 777], ["complications", 785], [",", 798], ["or", 800], ["resulting", 803], ["in", 813], ["riskier", 816], ["heroin", 824], ["use", 831], [")", 834], [".", 835]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury. Feline leukemia virus subgroup C receptor (FLVCR1), a member of the SLC49 family of four paralogous genes, is a cell surface heme exporter, essential for erythropoiesis and systemic iron homeostasis. Disruption of FLVCR1 function blocks development of erythroid progenitors, likely due to heme toxicity. Mutations of SLC49A1 encoding FLVCR1 are noted in patients with a rare neurodegenerative disorder: posterior column ataxia with retinitis pigmentosa. FLVCR2 is highly homologous to FLVCR1 and may function as a cellular heme importer. Mutations of SLC49A2 encoding FLVCR2 are observed in Fowler syndrome, a rare proliferative vascular disorder of the brain. The functions of the remaining members of the SLC49 family, MFSD7 and DIRC2 (encoded by the SLC49A3 and SLC49A4 genes), are unknown, although the latter is implicated in hereditary renal carcinomas. SLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.", "qas": [{"question": "Which SLC family is FLVCR1 a member of?", "answers": ["SLC49"], "qid": "a338247c1f654179887259220bfbd8d6", "question_tokens": [["Which", 0], ["SLC", 6], ["family", 10], ["is", 17], ["FLVCR1", 20], ["a", 27], ["member", 29], ["of", 36], ["?", 38]], "detected_answers": [{"text": "SLC49", "token_spans": [[140, 140], [37, 37]], "char_spans": [[843, 847], [204, 208]]}]}], "context_tokens": [["Heme", 0], ["is", 5], ["critical", 8], ["for", 17], ["a", 21], ["variety", 23], ["of", 31], ["cellular", 34], ["processes", 43], [",", 52], ["but", 54], ["excess", 58], ["intracellular", 65], ["heme", 79], ["may", 84], ["result", 88], ["in", 95], ["oxidative", 98], ["stress", 108], ["and", 115], ["membrane", 119], ["injury", 128], [".", 134], ["Feline", 136], ["leukemia", 143], ["virus", 152], ["subgroup", 158], ["C", 167], ["receptor", 169], ["(", 178], ["FLVCR1", 179], [")", 185], [",", 186], ["a", 188], ["member", 190], ["of", 197], ["the", 200], ["SLC49", 204], ["family", 210], ["of", 217], ["four", 220], ["paralogous", 225], ["genes", 236], [",", 241], ["is", 243], ["a", 246], ["cell", 248], ["surface", 253], ["heme", 261], ["exporter", 266], [",", 274], ["essential", 276], ["for", 286], ["erythropoiesis", 290], ["and", 305], ["systemic", 309], ["iron", 318], ["homeostasis", 323], [".", 334], ["Disruption", 336], ["of", 347], ["FLVCR1", 350], ["function", 357], ["blocks", 366], ["development", 373], ["of", 385], ["erythroid", 388], ["progenitors", 398], [",", 409], ["likely", 411], ["due", 418], ["to", 422], ["heme", 425], ["toxicity", 430], [".", 438], ["Mutations", 440], ["of", 450], ["SLC49A1", 453], ["encoding", 461], ["FLVCR1", 470], ["are", 477], ["noted", 481], ["in", 487], ["patients", 490], ["with", 499], ["a", 504], ["rare", 506], ["neurodegenerative", 511], ["disorder", 529], [":", 537], ["posterior", 539], ["column", 549], ["ataxia", 556], ["with", 563], ["retinitis", 568], ["pigmentosa", 578], [".", 588], ["FLVCR2", 590], ["is", 597], ["highly", 600], ["homologous", 607], ["to", 618], ["FLVCR1", 621], ["and", 628], ["may", 632], ["function", 636], ["as", 645], ["a", 648], ["cellular", 650], ["heme", 659], ["importer", 664], [".", 672], ["Mutations", 674], ["of", 684], ["SLC49A2", 687], ["encoding", 695], ["FLVCR2", 704], ["are", 711], ["observed", 715], ["in", 724], ["Fowler", 727], ["syndrome", 734], [",", 742], ["a", 744], ["rare", 746], ["proliferative", 751], ["vascular", 765], ["disorder", 774], ["of", 783], ["the", 786], ["brain", 790], [".", 795], ["The", 797], ["functions", 801], ["of", 811], ["the", 814], ["remaining", 818], ["members", 828], ["of", 836], ["the", 839], ["SLC49", 843], ["family", 849], [",", 855], ["MFSD7", 857], ["and", 863], ["DIRC2", 867], ["(", 873], ["encoded", 874], ["by", 882], ["the", 885], ["SLC49A3", 889], ["and", 897], ["SLC49A4", 901], ["genes", 909], [")", 914], [",", 915], ["are", 917], ["unknown", 921], [",", 928], ["although", 930], ["the", 939], ["latter", 943], ["is", 950], ["implicated", 953], ["in", 964], ["hereditary", 967], ["renal", 978], ["carcinomas", 984], [".", 994], ["SLC48A1", 996], ["(", 1004], ["heme", 1005], ["responsive", 1010], ["gene-1", 1021], [",", 1027], ["HRG-1", 1029], [")", 1034], [",", 1035], ["the", 1037], ["sole", 1041], ["member", 1046], ["of", 1053], ["the", 1056], ["SLC48", 1060], ["family", 1066], [",", 1072], ["is", 1074], ["associated", 1077], ["with", 1088], ["the", 1093], ["endosome", 1097], ["and", 1106], ["appears", 1110], ["to", 1118], ["transport", 1121], ["heme", 1131], ["from", 1136], ["the", 1141], ["endosome", 1145], ["into", 1154], ["the", 1159], ["cytosol", 1163], [".", 1170]]}
{"context": "It is not clear which is preferred between iron supplement and a dopamine agonist in the treatment of restless legs syndrome (RLS) with iron deficiency. The efficacies of oral iron supplementation and pramipexole for treatment of RLS with low-normal serum ferritin (15-50 ng/ml) were compared. Thirty RLS patients who took either oral iron or pramipexole for 12 weeks and were followed at 2, 4, 8 and 12 weeks after treatment commencement were enrolled. Severities of RLS symptoms were assessed using the international RLS study group rating scale for severity (IRLS) at every visit. Treatment response was defined as a decrease in IRLS score of at least 50% from baseline. The 30 subjects were assigned equally to an iron or pramipexole group. At baseline, IRLS scores and serum ferritin levels were similar between these two groups. After 12 weeks, IRLS scores were lower than those at baseline in both groups (iron -9.1 \u00b1 7.07, P < 0.001; pramipexole -8.7 \u00b1 8.31, P = 0.001) and similar between the two groups. Changes in IRLS scores from baseline were similar between the two groups at each visit. The response rates of the groups were identical at 46.7%. Pramipexole was not different from oral iron in terms of efficacy and improvement speed in RLS patients with a low-normal serum ferritin, but response rate of either oral iron or pramipexole alone was moderate. Some proportion of RLS patients with iron deficiency might benefit from combined use of oral iron and dopamine agonists.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "2db766b5f95d4cc9915d3477fcc2df52", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[64, 64], [32, 32], [258, 258], [137, 137], [25, 25], [233, 233], [8, 8], [280, 280], [174, 174], [271, 271]], "char_spans": [[335, 338], [176, 179], [1331, 1334], [718, 721], [136, 139], [1200, 1203], [43, 46], [1464, 1467], [913, 916], [1408, 1411]]}]}], "context_tokens": [["It", 0], ["is", 3], ["not", 6], ["clear", 10], ["which", 16], ["is", 22], ["preferred", 25], ["between", 35], ["iron", 43], ["supplement", 48], ["and", 59], ["a", 63], ["dopamine", 65], ["agonist", 74], ["in", 82], ["the", 85], ["treatment", 89], ["of", 99], ["restless", 102], ["legs", 111], ["syndrome", 116], ["(", 125], ["RLS", 126], [")", 129], ["with", 131], ["iron", 136], ["deficiency", 141], [".", 151], ["The", 153], ["efficacies", 157], ["of", 168], ["oral", 171], ["iron", 176], ["supplementation", 181], ["and", 197], ["pramipexole", 201], ["for", 213], ["treatment", 217], ["of", 227], ["RLS", 230], ["with", 234], ["low", 239], ["-", 242], ["normal", 243], ["serum", 250], ["ferritin", 256], ["(", 265], ["15", 266], ["-", 268], ["50", 269], ["ng", 272], ["/", 274], ["ml", 275], [")", 277], ["were", 279], ["compared", 284], [".", 292], ["Thirty", 294], ["RLS", 301], ["patients", 305], ["who", 314], ["took", 318], ["either", 323], ["oral", 330], ["iron", 335], ["or", 340], ["pramipexole", 343], ["for", 355], ["12", 359], ["weeks", 362], ["and", 368], ["were", 372], ["followed", 377], ["at", 386], ["2", 389], [",", 390], ["4", 392], [",", 393], ["8", 395], ["and", 397], ["12", 401], ["weeks", 404], ["after", 410], ["treatment", 416], ["commencement", 426], ["were", 439], ["enrolled", 444], [".", 452], ["Severities", 454], ["of", 465], ["RLS", 468], ["symptoms", 472], ["were", 481], ["assessed", 486], ["using", 495], ["the", 501], ["international", 505], ["RLS", 519], ["study", 523], ["group", 529], ["rating", 535], ["scale", 542], ["for", 548], ["severity", 552], ["(", 561], ["IRLS", 562], [")", 566], ["at", 568], ["every", 571], ["visit", 577], [".", 582], ["Treatment", 584], ["response", 594], ["was", 603], ["defined", 607], ["as", 615], ["a", 618], ["decrease", 620], ["in", 629], ["IRLS", 632], ["score", 637], ["of", 643], ["at", 646], ["least", 649], ["50", 655], ["%", 657], ["from", 659], ["baseline", 664], [".", 672], ["The", 674], ["30", 678], ["subjects", 681], ["were", 690], ["assigned", 695], ["equally", 704], ["to", 712], ["an", 715], ["iron", 718], ["or", 723], ["pramipexole", 726], ["group", 738], [".", 743], ["At", 745], ["baseline", 748], [",", 756], ["IRLS", 758], ["scores", 763], ["and", 770], ["serum", 774], ["ferritin", 780], ["levels", 789], ["were", 796], ["similar", 801], ["between", 809], ["these", 817], ["two", 823], ["groups", 827], [".", 833], ["After", 835], ["12", 841], ["weeks", 844], [",", 849], ["IRLS", 851], ["scores", 856], ["were", 863], ["lower", 868], ["than", 874], ["those", 879], ["at", 885], ["baseline", 888], ["in", 897], ["both", 900], ["groups", 905], ["(", 912], ["iron", 913], ["-9.1", 918], ["\u00b1", 923], ["7.07", 925], [",", 929], ["P", 931], ["<", 933], ["0.001", 935], [";", 940], ["pramipexole", 942], ["-8.7", 954], ["\u00b1", 959], ["8.31", 961], [",", 965], ["P", 967], ["=", 969], ["0.001", 971], [")", 976], ["and", 978], ["similar", 982], ["between", 990], ["the", 998], ["two", 1002], ["groups", 1006], [".", 1012], ["Changes", 1014], ["in", 1022], ["IRLS", 1025], ["scores", 1030], ["from", 1037], ["baseline", 1042], ["were", 1051], ["similar", 1056], ["between", 1064], ["the", 1072], ["two", 1076], ["groups", 1080], ["at", 1087], ["each", 1090], ["visit", 1095], [".", 1100], ["The", 1102], ["response", 1106], ["rates", 1115], ["of", 1121], ["the", 1124], ["groups", 1128], ["were", 1135], ["identical", 1140], ["at", 1150], ["46.7", 1153], ["%", 1157], [".", 1158], ["Pramipexole", 1160], ["was", 1172], ["not", 1176], ["different", 1180], ["from", 1190], ["oral", 1195], ["iron", 1200], ["in", 1205], ["terms", 1208], ["of", 1214], ["efficacy", 1217], ["and", 1226], ["improvement", 1230], ["speed", 1242], ["in", 1248], ["RLS", 1251], ["patients", 1255], ["with", 1264], ["a", 1269], ["low", 1271], ["-", 1274], ["normal", 1275], ["serum", 1282], ["ferritin", 1288], [",", 1296], ["but", 1298], ["response", 1302], ["rate", 1311], ["of", 1316], ["either", 1319], ["oral", 1326], ["iron", 1331], ["or", 1336], ["pramipexole", 1339], ["alone", 1351], ["was", 1357], ["moderate", 1361], [".", 1369], ["Some", 1371], ["proportion", 1376], ["of", 1387], ["RLS", 1390], ["patients", 1394], ["with", 1403], ["iron", 1408], ["deficiency", 1413], ["might", 1424], ["benefit", 1430], ["from", 1438], ["combined", 1443], ["use", 1452], ["of", 1456], ["oral", 1459], ["iron", 1464], ["and", 1469], ["dopamine", 1473], ["agonists", 1482], [".", 1490]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hot spots in HIV infection. Men who have sex with men (MSM), transgender populations, people who inject drugs, fisherfolk, migrants, adolescents, and older adults are heavily impacted in a number of regions. Stigma contributes to risk behaviors and HIV acquisition across populations. HIV testing is a crucial first step in the HIV care continuum, and several large community-based surveys are underway in Africa to increase HIV testing, linkage to care, and uptake of antiretroviral treatment. Advances in preexposure prophylaxis (PrEP) featured prominently at CROI 2016. Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa. Data on the safety of long-acting injectable PrEP and several investigational PrEP drugs and formulations were also presented. Knowledge and use of PrEP among MSM in the United States appears to be increasing, and high uptake was seen among black MSM when provided as part of a culturally tailored support program. The use of broadly neutralizing antibodies for HIV prevention is a novel and promising approach to be evaluated in efficacy trials.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "b6d97f2cc9864e81ae3ccfefeac8cedd", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[91, 91], [74, 74], [60, 60], [136, 136], [206, 206], [65, 65], [15, 15]], "char_spans": [[509, 511], [412, 414], [333, 335], [795, 797], [1192, 1194], [369, 371], [97, 99]]}]}], "context_tokens": [["The", 0], ["2016", 4], ["Conference", 9], ["on", 20], ["Retroviruses", 23], ["and", 36], ["Opportunistic", 40], ["Infections", 54], ["(", 65], ["CROI", 66], [")", 70], ["highlighted", 72], ["hot", 84], ["spots", 88], ["in", 94], ["HIV", 97], ["infection", 101], [".", 110], ["Men", 112], ["who", 116], ["have", 120], ["sex", 125], ["with", 129], ["men", 134], ["(", 138], ["MSM", 139], [")", 142], [",", 143], ["transgender", 145], ["populations", 157], [",", 168], ["people", 170], ["who", 177], ["inject", 181], ["drugs", 188], [",", 193], ["fisherfolk", 195], [",", 205], ["migrants", 207], [",", 215], ["adolescents", 217], [",", 228], ["and", 230], ["older", 234], ["adults", 240], ["are", 247], ["heavily", 251], ["impacted", 259], ["in", 268], ["a", 271], ["number", 273], ["of", 280], ["regions", 283], [".", 290], ["Stigma", 292], ["contributes", 299], ["to", 311], ["risk", 314], ["behaviors", 319], ["and", 329], ["HIV", 333], ["acquisition", 337], ["across", 349], ["populations", 356], [".", 367], ["HIV", 369], ["testing", 373], ["is", 381], ["a", 384], ["crucial", 386], ["first", 394], ["step", 400], ["in", 405], ["the", 408], ["HIV", 412], ["care", 416], ["continuum", 421], [",", 430], ["and", 432], ["several", 436], ["large", 444], ["community", 450], ["-", 459], ["based", 460], ["surveys", 466], ["are", 474], ["underway", 478], ["in", 487], ["Africa", 490], ["to", 497], ["increase", 500], ["HIV", 509], ["testing", 513], [",", 520], ["linkage", 522], ["to", 530], ["care", 533], [",", 537], ["and", 539], ["uptake", 543], ["of", 550], ["antiretroviral", 553], ["treatment", 568], [".", 577], ["Advances", 579], ["in", 588], ["preexposure", 591], ["prophylaxis", 603], ["(", 615], ["PrEP", 616], [")", 620], ["featured", 622], ["prominently", 631], ["at", 643], ["CROI", 646], ["2016", 651], [".", 655], ["Two", 657], ["large", 661], ["efficacy", 667], ["trials", 676], ["of", 683], ["a", 686], ["vaginal", 688], ["ring", 696], ["containing", 701], ["the", 712], ["investigational", 716], ["drug", 732], ["dapivirine", 737], ["demonstrated", 748], ["efficacy", 761], ["and", 770], ["safety", 774], ["in", 781], ["preventing", 784], ["HIV", 795], ["infections", 799], ["in", 810], ["women", 813], ["in", 819], ["Africa", 822], [".", 828], ["Data", 830], ["on", 835], ["the", 838], ["safety", 842], ["of", 849], ["long", 852], ["-", 856], ["acting", 857], ["injectable", 864], ["PrEP", 875], ["and", 880], ["several", 884], ["investigational", 892], ["PrEP", 908], ["drugs", 913], ["and", 919], ["formulations", 923], ["were", 936], ["also", 941], ["presented", 946], [".", 955], ["Knowledge", 957], ["and", 967], ["use", 971], ["of", 975], ["PrEP", 978], ["among", 983], ["MSM", 989], ["in", 993], ["the", 996], ["United", 1000], ["States", 1007], ["appears", 1014], ["to", 1022], ["be", 1025], ["increasing", 1028], [",", 1038], ["and", 1040], ["high", 1044], ["uptake", 1049], ["was", 1056], ["seen", 1060], ["among", 1065], ["black", 1071], ["MSM", 1077], ["when", 1081], ["provided", 1086], ["as", 1095], ["part", 1098], ["of", 1103], ["a", 1106], ["culturally", 1108], ["tailored", 1119], ["support", 1128], ["program", 1136], [".", 1143], ["The", 1145], ["use", 1149], ["of", 1153], ["broadly", 1156], ["neutralizing", 1164], ["antibodies", 1177], ["for", 1188], ["HIV", 1192], ["prevention", 1196], ["is", 1207], ["a", 1210], ["novel", 1212], ["and", 1218], ["promising", 1222], ["approach", 1232], ["to", 1241], ["be", 1244], ["evaluated", 1247], ["in", 1257], ["efficacy", 1260], ["trials", 1269], [".", 1275]]}
{"context": "Ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (CTS). There is some evidence to suggest that immediate changes may occur in the median nerve before and after hand activity. The evidence for the validity and reliability of ultrasound for testing acute changes in the median nerve has not been systematically reviewed to date. To evaluate the evidence for visible change in ultrasound appearance of the median nerve after hand activity. A literature search was designed, and three reviewers independently selected published research for inclusion. Two reviewers independently appraised papers using the Evidence Based Library and Information Practice (EBLIP) appraisal checklist, while the third reviewer resolved discrepancies between appraisals. Ten studies were appraised and the results showed an increase in median nerve cross-sectional area following activity, with a return to normal size within 1 h following activity. Both healthy individuals and those diagnosed with CTS participated, all were small convenience samples. Ultrasonographic measurements of the median nerve were reliable in the four studies reporting this, and the studies demonstrated high quality. Good-quality evidence as identified by the EBLIP appraisal checklist suggests that following hand activity, the median nerve changes in size in the carpal tunnel. The results may not be generalizable to all people and activities due to the use of small convenience sampling and narrow range of activities studied, in all of the studies appraised.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "189f48ba6a4e4b66bd3f554956186a5b", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[32, 32], [77, 77], [179, 179], [138, 138], [55, 55], [215, 215], [8, 8]], "char_spans": [[175, 180], [448, 453], [1113, 1118], [858, 863], [313, 318], [1331, 1336], [51, 56]]}]}], "context_tokens": [["Ultrasound", 0], ["is", 11], ["an", 14], ["established", 17], ["method", 29], ["of", 36], ["viewing", 39], ["the", 47], ["median", 51], ["nerve", 58], ["in", 64], ["the", 67], ["carpal", 71], ["tunnel", 78], ["syndrome", 85], ["(", 94], ["CTS", 95], [")", 98], [".", 99], ["There", 101], ["is", 107], ["some", 110], ["evidence", 115], ["to", 124], ["suggest", 127], ["that", 135], ["immediate", 140], ["changes", 150], ["may", 158], ["occur", 162], ["in", 168], ["the", 171], ["median", 175], ["nerve", 182], ["before", 188], ["and", 195], ["after", 199], ["hand", 205], ["activity", 210], [".", 218], ["The", 220], ["evidence", 224], ["for", 233], ["the", 237], ["validity", 241], ["and", 250], ["reliability", 254], ["of", 266], ["ultrasound", 269], ["for", 280], ["testing", 284], ["acute", 292], ["changes", 298], ["in", 306], ["the", 309], ["median", 313], ["nerve", 320], ["has", 326], ["not", 330], ["been", 334], ["systematically", 339], ["reviewed", 354], ["to", 363], ["date", 366], [".", 370], ["To", 372], ["evaluate", 375], ["the", 384], ["evidence", 388], ["for", 397], ["visible", 401], ["change", 409], ["in", 416], ["ultrasound", 419], ["appearance", 430], ["of", 441], ["the", 444], ["median", 448], ["nerve", 455], ["after", 461], ["hand", 467], ["activity", 472], [".", 480], ["A", 482], ["literature", 484], ["search", 495], ["was", 502], ["designed", 506], [",", 514], ["and", 516], ["three", 520], ["reviewers", 526], ["independently", 536], ["selected", 550], ["published", 559], ["research", 569], ["for", 578], ["inclusion", 582], [".", 591], ["Two", 593], ["reviewers", 597], ["independently", 607], ["appraised", 621], ["papers", 631], ["using", 638], ["the", 644], ["Evidence", 648], ["Based", 657], ["Library", 663], ["and", 671], ["Information", 675], ["Practice", 687], ["(", 696], ["EBLIP", 697], [")", 702], ["appraisal", 704], ["checklist", 714], [",", 723], ["while", 725], ["the", 731], ["third", 735], ["reviewer", 741], ["resolved", 750], ["discrepancies", 759], ["between", 773], ["appraisals", 781], [".", 791], ["Ten", 793], ["studies", 797], ["were", 805], ["appraised", 810], ["and", 820], ["the", 824], ["results", 828], ["showed", 836], ["an", 843], ["increase", 846], ["in", 855], ["median", 858], ["nerve", 865], ["cross", 871], ["-", 876], ["sectional", 877], ["area", 887], ["following", 892], ["activity", 902], [",", 910], ["with", 912], ["a", 917], ["return", 919], ["to", 926], ["normal", 929], ["size", 936], ["within", 941], ["1", 948], ["h", 950], ["following", 952], ["activity", 962], [".", 970], ["Both", 972], ["healthy", 977], ["individuals", 985], ["and", 997], ["those", 1001], ["diagnosed", 1007], ["with", 1017], ["CTS", 1022], ["participated", 1026], [",", 1038], ["all", 1040], ["were", 1044], ["small", 1049], ["convenience", 1055], ["samples", 1067], [".", 1074], ["Ultrasonographic", 1076], ["measurements", 1093], ["of", 1106], ["the", 1109], ["median", 1113], ["nerve", 1120], ["were", 1126], ["reliable", 1131], ["in", 1140], ["the", 1143], ["four", 1147], ["studies", 1152], ["reporting", 1160], ["this", 1170], [",", 1174], ["and", 1176], ["the", 1180], ["studies", 1184], ["demonstrated", 1192], ["high", 1205], ["quality", 1210], [".", 1217], ["Good", 1219], ["-", 1223], ["quality", 1224], ["evidence", 1232], ["as", 1241], ["identified", 1244], ["by", 1255], ["the", 1258], ["EBLIP", 1262], ["appraisal", 1268], ["checklist", 1278], ["suggests", 1288], ["that", 1297], ["following", 1302], ["hand", 1312], ["activity", 1317], [",", 1325], ["the", 1327], ["median", 1331], ["nerve", 1338], ["changes", 1344], ["in", 1352], ["size", 1355], ["in", 1360], ["the", 1363], ["carpal", 1367], ["tunnel", 1374], [".", 1380], ["The", 1382], ["results", 1386], ["may", 1394], ["not", 1398], ["be", 1402], ["generalizable", 1405], ["to", 1419], ["all", 1422], ["people", 1426], ["and", 1433], ["activities", 1437], ["due", 1448], ["to", 1452], ["the", 1455], ["use", 1459], ["of", 1463], ["small", 1466], ["convenience", 1472], ["sampling", 1484], ["and", 1493], ["narrow", 1497], ["range", 1504], ["of", 1510], ["activities", 1513], ["studied", 1524], [",", 1531], ["in", 1533], ["all", 1536], ["of", 1540], ["the", 1543], ["studies", 1547], ["appraised", 1555], [".", 1564]]}
{"context": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, and competes effectively with catalase and glutathione peroxidase to scavenge low levels of hydrogen peroxide, including that derived from hemoglobin autoxidation. Low thioredoxin reductase activity in the erythrocyte is able to keep up with this basal oxidation and maintain the Prx2 in its reduced form, but exposure to exogenous hydrogen peroxide causes accumulation of the disulfide-linked dimer. The high cellular concentration means that although turnover is slow, erythrocyte Prx2 can act as a noncatalytic scavenger of hydrogen peroxide and a sink for hydrogen peroxide before turnover becomes limiting. The consequences of Prx2 oxidation for the erythrocyte are not well characterized, but mice deficient in this protein develop severe hemolytic anemia associated with Heinz body formation. Prx2, also known as calpromotin, regulates ion transport by associating with the membrane and activating the G\u00e1rdos channel. How Prx2 redox transformations are linked to membrane association and channel activation is yet to be established. In this review, we discuss the functional properties of Prx2 and its role as a major component of the erythrocyte antioxidant system.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "26a83e722adc4516a5e0f6a8f7c8caaa", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[212, 212], [7, 7]], "char_spans": [[1311, 1321], [29, 39]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["Prx2", 17], [")", 21], ["is", 23], ["an", 26], ["antioxidant", 29], ["enzyme", 41], ["that", 48], ["uses", 53], ["cysteine", 58], ["residues", 67], ["to", 76], ["decompose", 79], ["peroxides", 89], [".", 98], ["Prx2", 100], ["is", 105], ["the", 108], ["third", 112], ["most", 118], ["abundant", 123], ["protein", 132], ["in", 140], ["erythrocytes", 143], [",", 155], ["and", 157], ["competes", 161], ["effectively", 170], ["with", 182], ["catalase", 187], ["and", 196], ["glutathione", 200], ["peroxidase", 212], ["to", 223], ["scavenge", 226], ["low", 235], ["levels", 239], ["of", 246], ["hydrogen", 249], ["peroxide", 258], [",", 266], ["including", 268], ["that", 278], ["derived", 283], ["from", 291], ["hemoglobin", 296], ["autoxidation", 307], [".", 319], ["Low", 321], ["thioredoxin", 325], ["reductase", 337], ["activity", 347], ["in", 356], ["the", 359], ["erythrocyte", 363], ["is", 375], ["able", 378], ["to", 383], ["keep", 386], ["up", 391], ["with", 394], ["this", 399], ["basal", 404], ["oxidation", 410], ["and", 420], ["maintain", 424], ["the", 433], ["Prx2", 437], ["in", 442], ["its", 445], ["reduced", 449], ["form", 457], [",", 461], ["but", 463], ["exposure", 467], ["to", 476], ["exogenous", 479], ["hydrogen", 489], ["peroxide", 498], ["causes", 507], ["accumulation", 514], ["of", 527], ["the", 530], ["disulfide", 534], ["-", 543], ["linked", 544], ["dimer", 551], [".", 556], ["The", 558], ["high", 562], ["cellular", 567], ["concentration", 576], ["means", 590], ["that", 596], ["although", 601], ["turnover", 610], ["is", 619], ["slow", 622], [",", 626], ["erythrocyte", 628], ["Prx2", 640], ["can", 645], ["act", 649], ["as", 653], ["a", 656], ["noncatalytic", 658], ["scavenger", 671], ["of", 681], ["hydrogen", 684], ["peroxide", 693], ["and", 702], ["a", 706], ["sink", 708], ["for", 713], ["hydrogen", 717], ["peroxide", 726], ["before", 735], ["turnover", 742], ["becomes", 751], ["limiting", 759], [".", 767], ["The", 769], ["consequences", 773], ["of", 786], ["Prx2", 789], ["oxidation", 794], ["for", 804], ["the", 808], ["erythrocyte", 812], ["are", 824], ["not", 828], ["well", 832], ["characterized", 837], [",", 850], ["but", 852], ["mice", 856], ["deficient", 861], ["in", 871], ["this", 874], ["protein", 879], ["develop", 887], ["severe", 895], ["hemolytic", 902], ["anemia", 912], ["associated", 919], ["with", 930], ["Heinz", 935], ["body", 941], ["formation", 946], [".", 955], ["Prx2", 957], [",", 961], ["also", 963], ["known", 968], ["as", 974], ["calpromotin", 977], [",", 988], ["regulates", 990], ["ion", 1000], ["transport", 1004], ["by", 1014], ["associating", 1017], ["with", 1029], ["the", 1034], ["membrane", 1038], ["and", 1047], ["activating", 1051], ["the", 1062], ["G\u00e1rdos", 1066], ["channel", 1073], [".", 1080], ["How", 1082], ["Prx2", 1086], ["redox", 1091], ["transformations", 1097], ["are", 1113], ["linked", 1117], ["to", 1124], ["membrane", 1127], ["association", 1136], ["and", 1148], ["channel", 1152], ["activation", 1160], ["is", 1171], ["yet", 1174], ["to", 1178], ["be", 1181], ["established", 1184], [".", 1195], ["In", 1197], ["this", 1200], ["review", 1205], [",", 1211], ["we", 1213], ["discuss", 1216], ["the", 1224], ["functional", 1228], ["properties", 1239], ["of", 1250], ["Prx2", 1253], ["and", 1258], ["its", 1262], ["role", 1266], ["as", 1271], ["a", 1274], ["major", 1276], ["component", 1282], ["of", 1292], ["the", 1295], ["erythrocyte", 1299], ["antioxidant", 1311], ["system", 1323], [".", 1329]]}
{"context": "Oxidatively damaged proteins accumulate with age in almost all cell types and tissues. The activity of chaperone-mediated autophagy (CMA), a selective pathway for the degradation of cytosolic proteins in lysosomes, decreases with age. We have analyzed the possible participation of CMA in the removal of oxidized proteins in rat liver and cultured mouse fibroblasts. Added to the fact that CMA substrates, when oxidized, are more efficiently internalized into lysosomes, we have found a constitutive activation of CMA during oxidative stress. Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway. In contrast with the well characterized mechanism of CMA activation during nutritional stress, which does not require de novo synthesis of the receptor, oxidation-induced activation of CMA is attained through transcriptional up-regulation of lamp2a. We conclude that CMA is activated during oxidative stress and that the higher activity of this pathway under these conditions, along with the higher susceptibility of the oxidized proteins to be taken up by lysosomes, both contribute to the efficient removal of oxidized proteins.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "231d54cde09548338f239c48ff1fd357", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[185, 185]], "char_spans": [[1096, 1101]]}]}], "context_tokens": [["Oxidatively", 0], ["damaged", 12], ["proteins", 20], ["accumulate", 29], ["with", 40], ["age", 45], ["in", 49], ["almost", 52], ["all", 59], ["cell", 63], ["types", 68], ["and", 74], ["tissues", 78], [".", 85], ["The", 87], ["activity", 91], ["of", 100], ["chaperone", 103], ["-", 112], ["mediated", 113], ["autophagy", 122], ["(", 132], ["CMA", 133], [")", 136], [",", 137], ["a", 139], ["selective", 141], ["pathway", 151], ["for", 159], ["the", 163], ["degradation", 167], ["of", 179], ["cytosolic", 182], ["proteins", 192], ["in", 201], ["lysosomes", 204], [",", 213], ["decreases", 215], ["with", 225], ["age", 230], [".", 233], ["We", 235], ["have", 238], ["analyzed", 243], ["the", 252], ["possible", 256], ["participation", 265], ["of", 279], ["CMA", 282], ["in", 286], ["the", 289], ["removal", 293], ["of", 301], ["oxidized", 304], ["proteins", 313], ["in", 322], ["rat", 325], ["liver", 329], ["and", 335], ["cultured", 339], ["mouse", 348], ["fibroblasts", 354], [".", 365], ["Added", 367], ["to", 373], ["the", 376], ["fact", 380], ["that", 385], ["CMA", 390], ["substrates", 394], [",", 404], ["when", 406], ["oxidized", 411], [",", 419], ["are", 421], ["more", 425], ["efficiently", 430], ["internalized", 442], ["into", 455], ["lysosomes", 460], [",", 469], ["we", 471], ["have", 474], ["found", 479], ["a", 485], ["constitutive", 487], ["activation", 500], ["of", 511], ["CMA", 514], ["during", 518], ["oxidative", 525], ["stress", 535], [".", 541], ["Oxidation", 543], ["-", 552], ["induced", 553], ["activation", 561], ["of", 572], ["CMA", 575], ["correlates", 579], ["with", 590], ["higher", 595], ["levels", 602], ["of", 609], ["several", 612], ["components", 620], ["of", 631], ["the", 634], ["lysosomal", 638], ["translocation", 648], ["complex", 662], [",", 669], ["but", 671], ["in", 675], ["particular", 678], ["of", 689], ["the", 692], ["lumenal", 696], ["chaperone", 704], [",", 713], ["required", 715], ["for", 724], ["substrate", 728], ["uptake", 738], [",", 744], ["and", 746], ["of", 750], ["the", 753], ["lysosomal", 757], ["membrane", 767], ["protein", 776], ["(", 784], ["lamp", 785], [")", 789], ["type", 791], ["2a", 796], [",", 798], ["previously", 800], ["identified", 811], ["as", 822], ["a", 825], ["receptor", 827], ["for", 836], ["this", 840], ["pathway", 845], [".", 852], ["In", 854], ["contrast", 857], ["with", 866], ["the", 871], ["well", 875], ["characterized", 880], ["mechanism", 894], ["of", 904], ["CMA", 907], ["activation", 911], ["during", 922], ["nutritional", 929], ["stress", 941], [",", 947], ["which", 949], ["does", 955], ["not", 960], ["require", 964], ["de", 972], ["novo", 975], ["synthesis", 980], ["of", 990], ["the", 993], ["receptor", 997], [",", 1005], ["oxidation", 1007], ["-", 1016], ["induced", 1017], ["activation", 1025], ["of", 1036], ["CMA", 1039], ["is", 1043], ["attained", 1046], ["through", 1055], ["transcriptional", 1063], ["up", 1079], ["-", 1081], ["regulation", 1082], ["of", 1093], ["lamp2a", 1096], [".", 1102], ["We", 1104], ["conclude", 1107], ["that", 1116], ["CMA", 1121], ["is", 1125], ["activated", 1128], ["during", 1138], ["oxidative", 1145], ["stress", 1155], ["and", 1162], ["that", 1166], ["the", 1171], ["higher", 1175], ["activity", 1182], ["of", 1191], ["this", 1194], ["pathway", 1199], ["under", 1207], ["these", 1213], ["conditions", 1219], [",", 1229], ["along", 1231], ["with", 1237], ["the", 1242], ["higher", 1246], ["susceptibility", 1253], ["of", 1268], ["the", 1271], ["oxidized", 1275], ["proteins", 1284], ["to", 1293], ["be", 1296], ["taken", 1299], ["up", 1305], ["by", 1308], ["lysosomes", 1311], [",", 1320], ["both", 1322], ["contribute", 1327], ["to", 1338], ["the", 1341], ["efficient", 1345], ["removal", 1355], ["of", 1363], ["oxidized", 1366], ["proteins", 1375], [".", 1383]]}
{"context": "Mutations in the human FOXP2 gene cause speech and language impairments. The FOXP2 protein is a transcription factor that regulates the expression of many downstream genes, which may have important roles in nervous system development and function. An adequate amount of functional FOXP2 protein is thought to be critical for the proper development of the neural circuitry underlying speech and language. However, how FOXP2 gene expression is regulated is not clearly understood. The FOXP2 mRNA has an approximately 4-kb-long 3' untranslated region (3' UTR), twice as long as its protein coding region, indicating that FOXP2 can be regulated by microRNAs (miRNAs). We identified multiple miRNAs that regulate the expression of the human FOXP2 gene using sequence analysis and in vitro cell systems. Focusing on let-7a, miR-9, and miR-129-5p, three brain-enriched miRNAs, we show that these miRNAs regulate human FOXP2 expression in a dosage-dependent manner and target specific sequences in the FOXP2 3' UTR. We further show that these three miRNAs are expressed in the cerebellum of the human fetal brain, where FOXP2 is known to be expressed. Our results reveal novel regulatory functions of the human FOXP2 3' UTR sequence and regulatory interactions between multiple miRNAs and the human FOXP2 gene. The expression of let-7a, miR-9, and miR-129-5p in the human fetal cerebellum is consistent with their roles in regulating FOXP2 expression during early cerebellum development. These results suggest that various genetic and environmental factors may contribute to speech and language development and related neural developmental disorders via the miRNA-FOXP2 regulatory network.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "e6f7d1e34eb24319b5b80ce914ab3c03", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[129, 129], [45, 45], [13, 13], [202, 202], [218, 218], [258, 258], [68, 68], [4, 4], [108, 108], [164, 164], [290, 290], [232, 232], [178, 178], [79, 79]], "char_spans": [[736, 740], [281, 285], [77, 81], [1112, 1116], [1203, 1207], [1426, 1430], [417, 421], [23, 27], [618, 622], [911, 915], [1656, 1660], [1291, 1295], [994, 998], [483, 487]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["human", 17], ["FOXP2", 23], ["gene", 29], ["cause", 34], ["speech", 40], ["and", 47], ["language", 51], ["impairments", 60], [".", 71], ["The", 73], ["FOXP2", 77], ["protein", 83], ["is", 91], ["a", 94], ["transcription", 96], ["factor", 110], ["that", 117], ["regulates", 122], ["the", 132], ["expression", 136], ["of", 147], ["many", 150], ["downstream", 155], ["genes", 166], [",", 171], ["which", 173], ["may", 179], ["have", 183], ["important", 188], ["roles", 198], ["in", 204], ["nervous", 207], ["system", 215], ["development", 222], ["and", 234], ["function", 238], [".", 246], ["An", 248], ["adequate", 251], ["amount", 260], ["of", 267], ["functional", 270], ["FOXP2", 281], ["protein", 287], ["is", 295], ["thought", 298], ["to", 306], ["be", 309], ["critical", 312], ["for", 321], ["the", 325], ["proper", 329], ["development", 336], ["of", 348], ["the", 351], ["neural", 355], ["circuitry", 362], ["underlying", 372], ["speech", 383], ["and", 390], ["language", 394], [".", 402], ["However", 404], [",", 411], ["how", 413], ["FOXP2", 417], ["gene", 423], ["expression", 428], ["is", 439], ["regulated", 442], ["is", 452], ["not", 455], ["clearly", 459], ["understood", 467], [".", 477], ["The", 479], ["FOXP2", 483], ["mRNA", 489], ["has", 494], ["an", 498], ["approximately", 501], ["4-kb", 515], ["-", 519], ["long", 520], ["3", 525], ["'", 526], ["untranslated", 528], ["region", 541], ["(", 548], ["3", 549], ["'", 550], ["UTR", 552], [")", 555], [",", 556], ["twice", 558], ["as", 564], ["long", 567], ["as", 572], ["its", 575], ["protein", 579], ["coding", 587], ["region", 594], [",", 600], ["indicating", 602], ["that", 613], ["FOXP2", 618], ["can", 624], ["be", 628], ["regulated", 631], ["by", 641], ["microRNAs", 644], ["(", 654], ["miRNAs", 655], [")", 661], [".", 662], ["We", 664], ["identified", 667], ["multiple", 678], ["miRNAs", 687], ["that", 694], ["regulate", 699], ["the", 708], ["expression", 712], ["of", 723], ["the", 726], ["human", 730], ["FOXP2", 736], ["gene", 742], ["using", 747], ["sequence", 753], ["analysis", 762], ["and", 771], ["in", 775], ["vitro", 778], ["cell", 784], ["systems", 789], [".", 796], ["Focusing", 798], ["on", 807], ["let-7a", 810], [",", 816], ["miR-9", 818], [",", 823], ["and", 825], ["miR-129", 829], ["-", 836], ["5p", 837], [",", 839], ["three", 841], ["brain", 847], ["-", 852], ["enriched", 853], ["miRNAs", 862], [",", 868], ["we", 870], ["show", 873], ["that", 878], ["these", 883], ["miRNAs", 889], ["regulate", 896], ["human", 905], ["FOXP2", 911], ["expression", 917], ["in", 928], ["a", 931], ["dosage", 933], ["-", 939], ["dependent", 940], ["manner", 950], ["and", 957], ["target", 961], ["specific", 968], ["sequences", 977], ["in", 987], ["the", 990], ["FOXP2", 994], ["3", 1000], ["'", 1001], ["UTR", 1003], [".", 1006], ["We", 1008], ["further", 1011], ["show", 1019], ["that", 1024], ["these", 1029], ["three", 1035], ["miRNAs", 1041], ["are", 1048], ["expressed", 1052], ["in", 1062], ["the", 1065], ["cerebellum", 1069], ["of", 1080], ["the", 1083], ["human", 1087], ["fetal", 1093], ["brain", 1099], [",", 1104], ["where", 1106], ["FOXP2", 1112], ["is", 1118], ["known", 1121], ["to", 1127], ["be", 1130], ["expressed", 1133], [".", 1142], ["Our", 1144], ["results", 1148], ["reveal", 1156], ["novel", 1163], ["regulatory", 1169], ["functions", 1180], ["of", 1190], ["the", 1193], ["human", 1197], ["FOXP2", 1203], ["3", 1209], ["'", 1210], ["UTR", 1212], ["sequence", 1216], ["and", 1225], ["regulatory", 1229], ["interactions", 1240], ["between", 1253], ["multiple", 1261], ["miRNAs", 1270], ["and", 1277], ["the", 1281], ["human", 1285], ["FOXP2", 1291], ["gene", 1297], [".", 1301], ["The", 1303], ["expression", 1307], ["of", 1318], ["let-7a", 1321], [",", 1327], ["miR-9", 1329], [",", 1334], ["and", 1336], ["miR-129", 1340], ["-", 1347], ["5p", 1348], ["in", 1351], ["the", 1354], ["human", 1358], ["fetal", 1364], ["cerebellum", 1370], ["is", 1381], ["consistent", 1384], ["with", 1395], ["their", 1400], ["roles", 1406], ["in", 1412], ["regulating", 1415], ["FOXP2", 1426], ["expression", 1432], ["during", 1443], ["early", 1450], ["cerebellum", 1456], ["development", 1467], [".", 1478], ["These", 1480], ["results", 1486], ["suggest", 1494], ["that", 1502], ["various", 1507], ["genetic", 1515], ["and", 1523], ["environmental", 1527], ["factors", 1541], ["may", 1549], ["contribute", 1553], ["to", 1564], ["speech", 1567], ["and", 1574], ["language", 1578], ["development", 1587], ["and", 1599], ["related", 1603], ["neural", 1611], ["developmental", 1618], ["disorders", 1632], ["via", 1642], ["the", 1646], ["miRNA", 1650], ["-", 1655], ["FOXP2", 1656], ["regulatory", 1662], ["network", 1673], [".", 1680]]}
{"context": "Ehlers-Danlos syndrome is a complex hereditary connective tissue disorder that is characterized by abnormalities of the skin and joints and visceral and neurological manifestations. At present, at least 11 forms are recognized on the basis of their clinical characteristics, methods of transmission, and biochemical defect. The neurologic manifestations include cerebrovascular disease, peripheral neuropathy, plexopathy, periventricular subependymal heterotopias, and epilepsy. Previously, 2 females were reported to be affected with subependimal periventricular heterotopias and Ehlers-Danlos syndrome type 1. The authors report a new case of a 12-year-old girl with similar clinical and neuroradiological features.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10de1ab61b0a47219444a92bc141d960", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[47, 63]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["hereditary", 36], ["connective", 47], ["tissue", 58], ["disorder", 65], ["that", 74], ["is", 79], ["characterized", 82], ["by", 96], ["abnormalities", 99], ["of", 113], ["the", 116], ["skin", 120], ["and", 125], ["joints", 129], ["and", 136], ["visceral", 140], ["and", 149], ["neurological", 153], ["manifestations", 166], [".", 180], ["At", 182], ["present", 185], [",", 192], ["at", 194], ["least", 197], ["11", 203], ["forms", 206], ["are", 212], ["recognized", 216], ["on", 227], ["the", 230], ["basis", 234], ["of", 240], ["their", 243], ["clinical", 249], ["characteristics", 258], [",", 273], ["methods", 275], ["of", 283], ["transmission", 286], [",", 298], ["and", 300], ["biochemical", 304], ["defect", 316], [".", 322], ["The", 324], ["neurologic", 328], ["manifestations", 339], ["include", 354], ["cerebrovascular", 362], ["disease", 378], [",", 385], ["peripheral", 387], ["neuropathy", 398], [",", 408], ["plexopathy", 410], [",", 420], ["periventricular", 422], ["subependymal", 438], ["heterotopias", 451], [",", 463], ["and", 465], ["epilepsy", 469], [".", 477], ["Previously", 479], [",", 489], ["2", 491], ["females", 493], ["were", 501], ["reported", 506], ["to", 515], ["be", 518], ["affected", 521], ["with", 530], ["subependimal", 535], ["periventricular", 548], ["heterotopias", 564], ["and", 577], ["Ehlers", 581], ["-", 587], ["Danlos", 588], ["syndrome", 595], ["type", 604], ["1", 609], [".", 610], ["The", 612], ["authors", 616], ["report", 624], ["a", 631], ["new", 633], ["case", 637], ["of", 642], ["a", 645], ["12-year", 647], ["-", 654], ["old", 655], ["girl", 659], ["with", 664], ["similar", 669], ["clinical", 677], ["and", 686], ["neuroradiological", 690], ["features", 708], [".", 716]]}
{"context": "Ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia. Recent studies have shown that RPS19 expression decreases during terminal erythroid differentiation. Currently no information is available on the subcellular localization of normal RPS19 and the potential effects of various RPS19 mutations on cellular localization. In the present study, using wild-type and mutant RPS19 cDNA, we explored the subcellular distribution of normal and mutant proteins in a fibroblast cell line (Cos-7 cells). RPS19 was detected primarily in the nucleus, and more specifically in the nucleoli, where RPS19 colocalized with the nucleolar protein nucleolin. Using various N-terminal and C-terminal deletion constructs, we identified 2 nucleolar localization signals (NoSs) in RPS19: the first comprising amino acids Met1 to Arg16 in the NH2-terminus and the second comprising Gly120 to Asn142 in the COOH-terminus. Importantly, 2 mutations identified in DBA patients, Val15Phe and Gly127Gln, each of which localized to 1 of the 2 NoS, failed to localize RPS19 to the nucleolus. In addition to their mislocalization, there was a dramatic decrease in the expression of the 2 mutant proteins compared to the wild type. This decrease in protein expression was specific for the mutant RPS19, since expression of other proteins was normal. The present findings enable us to document the nucleolar localization signals in RPS19 and help define the phenotypic consequences of some mutations in RPS19 in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "457215d830bf41e89e644ec8a579e6a3", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[10, 13]], "char_spans": [[55, 77]]}, {"text": "DBA", "token_spans": [[173, 173], [15, 15], [269, 269]], "char_spans": [[1005, 1007], [80, 82], [1546, 1548]]}]}], "context_tokens": [["Ribosomal", 0], ["protein", 10], ["S19", 18], ["(", 22], ["RPS19", 23], [")", 28], ["is", 30], ["frequently", 33], ["mutated", 44], ["in", 52], ["Diamond", 55], ["-", 62], ["Blackfan", 63], ["anemia", 72], ["(", 79], ["DBA", 80], [")", 83], [",", 84], ["a", 86], ["rare", 88], ["congenital", 93], ["hypoplastic", 104], ["anemia", 116], [".", 122], ["Recent", 124], ["studies", 131], ["have", 139], ["shown", 144], ["that", 150], ["RPS19", 155], ["expression", 161], ["decreases", 172], ["during", 182], ["terminal", 189], ["erythroid", 198], ["differentiation", 208], [".", 223], ["Currently", 225], ["no", 235], ["information", 238], ["is", 250], ["available", 253], ["on", 263], ["the", 266], ["subcellular", 270], ["localization", 282], ["of", 295], ["normal", 298], ["RPS19", 305], ["and", 311], ["the", 315], ["potential", 319], ["effects", 329], ["of", 337], ["various", 340], ["RPS19", 348], ["mutations", 354], ["on", 364], ["cellular", 367], ["localization", 376], [".", 388], ["In", 390], ["the", 393], ["present", 397], ["study", 405], [",", 410], ["using", 412], ["wild", 418], ["-", 422], ["type", 423], ["and", 428], ["mutant", 432], ["RPS19", 439], ["cDNA", 445], [",", 449], ["we", 451], ["explored", 454], ["the", 463], ["subcellular", 467], ["distribution", 479], ["of", 492], ["normal", 495], ["and", 502], ["mutant", 506], ["proteins", 513], ["in", 522], ["a", 525], ["fibroblast", 527], ["cell", 538], ["line", 543], ["(", 548], ["Cos-7", 549], ["cells", 555], [")", 560], [".", 561], ["RPS19", 563], ["was", 569], ["detected", 573], ["primarily", 582], ["in", 592], ["the", 595], ["nucleus", 599], [",", 606], ["and", 608], ["more", 612], ["specifically", 617], ["in", 630], ["the", 633], ["nucleoli", 637], [",", 645], ["where", 647], ["RPS19", 653], ["colocalized", 659], ["with", 671], ["the", 676], ["nucleolar", 680], ["protein", 690], ["nucleolin", 698], [".", 707], ["Using", 709], ["various", 715], ["N", 723], ["-", 724], ["terminal", 725], ["and", 734], ["C", 738], ["-", 739], ["terminal", 740], ["deletion", 749], ["constructs", 758], [",", 768], ["we", 770], ["identified", 773], ["2", 784], ["nucleolar", 786], ["localization", 796], ["signals", 809], ["(", 817], ["NoSs", 818], [")", 822], ["in", 824], ["RPS19", 827], [":", 832], ["the", 834], ["first", 838], ["comprising", 844], ["amino", 855], ["acids", 861], ["Met1", 867], ["to", 872], ["Arg16", 875], ["in", 881], ["the", 884], ["NH2-terminus", 888], ["and", 901], ["the", 905], ["second", 909], ["comprising", 916], ["Gly120", 927], ["to", 934], ["Asn142", 937], ["in", 944], ["the", 947], ["COOH", 951], ["-", 955], ["terminus", 956], [".", 964], ["Importantly", 966], [",", 977], ["2", 979], ["mutations", 981], ["identified", 991], ["in", 1002], ["DBA", 1005], ["patients", 1009], [",", 1017], ["Val15Phe", 1019], ["and", 1028], ["Gly127Gln", 1032], [",", 1041], ["each", 1043], ["of", 1048], ["which", 1051], ["localized", 1057], ["to", 1067], ["1", 1070], ["of", 1072], ["the", 1075], ["2", 1079], ["NoS", 1081], [",", 1084], ["failed", 1086], ["to", 1093], ["localize", 1096], ["RPS19", 1105], ["to", 1111], ["the", 1114], ["nucleolus", 1118], [".", 1127], ["In", 1129], ["addition", 1132], ["to", 1141], ["their", 1144], ["mislocalization", 1150], [",", 1165], ["there", 1167], ["was", 1173], ["a", 1177], ["dramatic", 1179], ["decrease", 1188], ["in", 1197], ["the", 1200], ["expression", 1204], ["of", 1215], ["the", 1218], ["2", 1222], ["mutant", 1224], ["proteins", 1231], ["compared", 1240], ["to", 1249], ["the", 1252], ["wild", 1256], ["type", 1261], [".", 1265], ["This", 1267], ["decrease", 1272], ["in", 1281], ["protein", 1284], ["expression", 1292], ["was", 1303], ["specific", 1307], ["for", 1316], ["the", 1320], ["mutant", 1324], ["RPS19", 1331], [",", 1336], ["since", 1338], ["expression", 1344], ["of", 1355], ["other", 1358], ["proteins", 1364], ["was", 1373], ["normal", 1377], [".", 1383], ["The", 1385], ["present", 1389], ["findings", 1397], ["enable", 1406], ["us", 1413], ["to", 1416], ["document", 1419], ["the", 1428], ["nucleolar", 1432], ["localization", 1442], ["signals", 1455], ["in", 1463], ["RPS19", 1466], ["and", 1472], ["help", 1476], ["define", 1481], ["the", 1488], ["phenotypic", 1492], ["consequences", 1503], ["of", 1516], ["some", 1519], ["mutations", 1524], ["in", 1534], ["RPS19", 1537], ["in", 1543], ["DBA", 1546], [".", 1549]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
{"context": "Purpose To determine the frequency of, and yield after, provider overrides of evidence-based clinical decision support (CDS) for ordering computed tomographic (CT) pulmonary angiography in the emergency department (ED). Materials and Methods This HIPAA-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011, and August 31, 2013. The requirement to obtain informed consent was waived. Each CT order for pulmonary angiography was exposed to CDS on the basis of the Wells criteria. For patients with a Wells score of 4 or less, CDS alerts suggested d-dimer testing because acute PE is highly unlikely in these patients if d-dimer levels are normal. The yield of CT pulmonary angiography (number of positive PE diagnoses/total number of CT pulmonary angiographic examinations) was compared in patients in whom providers overrode CDS alerts (by performing CT pulmonary angiography in patients with a Wells score \u22644 and a normal d-dimer level or no d-dimer testing) (override group) and those in whom providers followed Wells criteria (CT pulmonary angiography only in patients with Wells score >4 or \u22644 with elevated d-dimer level) (adherent group). A validated natural language processing tool identified positive PE diagnoses, with subsegmental and/or indeterminate diagnoses removed by means of chart review. Statistical analysis was performed with the \u03c7", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "0e98ec9fa2fc434f89b5688800607a86", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[80, 81]], "char_spans": [[462, 479]]}]}], "context_tokens": [["Purpose", 0], ["To", 8], ["determine", 11], ["the", 21], ["frequency", 25], ["of", 35], [",", 37], ["and", 39], ["yield", 43], ["after", 49], [",", 54], ["provider", 56], ["overrides", 65], ["of", 75], ["evidence", 78], ["-", 86], ["based", 87], ["clinical", 93], ["decision", 102], ["support", 111], ["(", 119], ["CDS", 120], [")", 123], ["for", 125], ["ordering", 129], ["computed", 138], ["tomographic", 147], ["(", 159], ["CT", 160], [")", 162], ["pulmonary", 164], ["angiography", 174], ["in", 186], ["the", 189], ["emergency", 193], ["department", 203], ["(", 214], ["ED", 215], [")", 217], [".", 218], ["Materials", 220], ["and", 230], ["Methods", 234], ["This", 242], ["HIPAA", 247], ["-", 252], ["compliant", 253], [",", 262], ["institutional", 264], ["review", 278], ["board", 285], ["-", 290], ["approved", 291], ["study", 300], ["was", 306], ["performed", 310], ["at", 320], ["a", 323], ["tertiary", 325], ["care", 334], [",", 338], ["academic", 340], ["medical", 349], ["center", 357], ["ED", 364], ["with", 367], ["approximately", 372], ["60", 386], ["000", 389], ["annual", 393], ["visits", 400], ["and", 407], ["included", 411], ["all", 420], ["patients", 424], ["who", 433], ["were", 437], ["suspected", 442], ["of", 452], ["having", 455], ["pulmonary", 462], ["embolism", 472], ["(", 481], ["PE", 482], [")", 484], ["and", 486], ["who", 490], ["underwent", 494], ["CT", 504], ["pulmonary", 507], ["angiography", 517], ["between", 529], ["January", 537], ["1", 545], [",", 546], ["2011", 548], [",", 552], ["and", 554], ["August", 558], ["31", 565], [",", 567], ["2013", 569], [".", 573], ["The", 575], ["requirement", 579], ["to", 591], ["obtain", 594], ["informed", 601], ["consent", 610], ["was", 618], ["waived", 622], [".", 628], ["Each", 630], ["CT", 635], ["order", 638], ["for", 644], ["pulmonary", 648], ["angiography", 658], ["was", 670], ["exposed", 674], ["to", 682], ["CDS", 685], ["on", 689], ["the", 692], ["basis", 696], ["of", 702], ["the", 705], ["Wells", 709], ["criteria", 715], [".", 723], ["For", 725], ["patients", 729], ["with", 738], ["a", 743], ["Wells", 745], ["score", 751], ["of", 757], ["4", 760], ["or", 762], ["less", 765], [",", 769], ["CDS", 771], ["alerts", 775], ["suggested", 782], ["d", 792], ["-", 793], ["dimer", 794], ["testing", 800], ["because", 808], ["acute", 816], ["PE", 822], ["is", 825], ["highly", 828], ["unlikely", 835], ["in", 844], ["these", 847], ["patients", 853], ["if", 862], ["d", 865], ["-", 866], ["dimer", 867], ["levels", 873], ["are", 880], ["normal", 884], [".", 890], ["The", 892], ["yield", 896], ["of", 902], ["CT", 905], ["pulmonary", 908], ["angiography", 918], ["(", 930], ["number", 931], ["of", 938], ["positive", 941], ["PE", 950], ["diagnoses", 953], ["/", 962], ["total", 963], ["number", 969], ["of", 976], ["CT", 979], ["pulmonary", 982], ["angiographic", 992], ["examinations", 1005], [")", 1017], ["was", 1019], ["compared", 1023], ["in", 1032], ["patients", 1035], ["in", 1044], ["whom", 1047], ["providers", 1052], ["overrode", 1062], ["CDS", 1071], ["alerts", 1075], ["(", 1082], ["by", 1083], ["performing", 1086], ["CT", 1097], ["pulmonary", 1100], ["angiography", 1110], ["in", 1122], ["patients", 1125], ["with", 1134], ["a", 1139], ["Wells", 1141], ["score", 1147], ["\u22644", 1153], ["and", 1156], ["a", 1160], ["normal", 1162], ["d", 1169], ["-", 1170], ["dimer", 1171], ["level", 1177], ["or", 1183], ["no", 1186], ["d", 1189], ["-", 1190], ["dimer", 1191], ["testing", 1197], [")", 1204], ["(", 1206], ["override", 1207], ["group", 1216], [")", 1221], ["and", 1223], ["those", 1227], ["in", 1233], ["whom", 1236], ["providers", 1241], ["followed", 1251], ["Wells", 1260], ["criteria", 1266], ["(", 1275], ["CT", 1276], ["pulmonary", 1279], ["angiography", 1289], ["only", 1301], ["in", 1306], ["patients", 1309], ["with", 1318], ["Wells", 1323], ["score", 1329], [">", 1335], ["4", 1336], ["or", 1338], ["\u22644", 1341], ["with", 1344], ["elevated", 1349], ["d", 1358], ["-", 1359], ["dimer", 1360], ["level", 1366], [")", 1371], ["(", 1373], ["adherent", 1374], ["group", 1383], [")", 1388], [".", 1389], ["A", 1391], ["validated", 1393], ["natural", 1403], ["language", 1411], ["processing", 1420], ["tool", 1431], ["identified", 1436], ["positive", 1447], ["PE", 1456], ["diagnoses", 1459], [",", 1468], ["with", 1470], ["subsegmental", 1475], ["and/or", 1488], ["indeterminate", 1495], ["diagnoses", 1509], ["removed", 1519], ["by", 1527], ["means", 1530], ["of", 1536], ["chart", 1539], ["review", 1545], [".", 1551], ["Statistical", 1553], ["analysis", 1565], ["was", 1574], ["performed", 1578], ["with", 1588], ["the", 1593], ["\u03c7", 1597]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Gaucher's disease is an uncommon inborn recessive autosomal disease, due to a deficient activity of the lysosomal enzyme beta glucocerebrosidase. This disease is usually diagnosed in the first or second decade of life with the arising of bone pains, splenomegaly and hemorragic manifestations due to thrombocytopenia. When the enlarged spleen is not evident, or after splenectomy, patients may be mis-identified as having Gaucher's disease. We present here two cases of elderly patients aged 70 and 46 years respectively, in whom the disease was a surprising finding of bone marrow examination, during check up for pancytopenia.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["Beta glucocerebrosidase"], "qid": "c4ce6c58dde54eb782917fdb75d3caf0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[20, 21]], "char_spans": [[121, 143]]}]}], "context_tokens": [["Gaucher", 0], ["'s", 7], ["disease", 10], ["is", 18], ["an", 21], ["uncommon", 24], ["inborn", 33], ["recessive", 40], ["autosomal", 50], ["disease", 60], [",", 67], ["due", 69], ["to", 73], ["a", 76], ["deficient", 78], ["activity", 88], ["of", 97], ["the", 100], ["lysosomal", 104], ["enzyme", 114], ["beta", 121], ["glucocerebrosidase", 126], [".", 144], ["This", 146], ["disease", 151], ["is", 159], ["usually", 162], ["diagnosed", 170], ["in", 180], ["the", 183], ["first", 187], ["or", 193], ["second", 196], ["decade", 203], ["of", 210], ["life", 213], ["with", 218], ["the", 223], ["arising", 227], ["of", 235], ["bone", 238], ["pains", 243], [",", 248], ["splenomegaly", 250], ["and", 263], ["hemorragic", 267], ["manifestations", 278], ["due", 293], ["to", 297], ["thrombocytopenia", 300], [".", 316], ["When", 318], ["the", 323], ["enlarged", 327], ["spleen", 336], ["is", 343], ["not", 346], ["evident", 350], [",", 357], ["or", 359], ["after", 362], ["splenectomy", 368], [",", 379], ["patients", 381], ["may", 390], ["be", 394], ["mis", 397], ["-", 400], ["identified", 401], ["as", 412], ["having", 415], ["Gaucher", 422], ["'s", 429], ["disease", 432], [".", 439], ["We", 441], ["present", 444], ["here", 452], ["two", 457], ["cases", 461], ["of", 467], ["elderly", 470], ["patients", 478], ["aged", 487], ["70", 492], ["and", 495], ["46", 499], ["years", 502], ["respectively", 508], [",", 520], ["in", 522], ["whom", 525], ["the", 530], ["disease", 534], ["was", 542], ["a", 546], ["surprising", 548], ["finding", 559], ["of", 567], ["bone", 570], ["marrow", 575], ["examination", 582], [",", 593], ["during", 595], ["check", 602], ["up", 608], ["for", 611], ["pancytopenia", 615], [".", 627]]}
{"context": "Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The hallmark of CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene, which, in turn, is translated into a chimeric Bcr-Abl protein with deregulated tyrosine kinase activity. Constitutive Bcr-Abl expression has been shown to be necessary and sufficient for the transformed phenotype of CML cells. CML is unique among human cancers in that a single genetic defect, the Ph chromosome, is responsible for the transformed phenotype. Since this discovery more than 40 years ago, our understanding of the clinical course, therapy, and prognosis of patients with CML has changed significantly. These changes have culminated in the emergence of imatinib, the first rationally designed, molecularly targeted therapy for human malignancy. In this review, the authors describe the molecular biology of CML and the development of imatinib as a therapeutic agent for the treatment of CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d4a15945d8304a3898c6f391152041af", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[85, 87], [69, 71], [96, 98]], "char_spans": [[476, 482], [409, 415], [548, 554]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["results", 35], ["from", 43], ["the", 48], ["neoplastic", 52], ["transformation", 63], ["of", 78], ["primitive", 81], ["hematopoietic", 91], ["stem", 105], ["cells", 110], [",", 115], ["and", 117], ["has", 121], ["been", 125], ["classified", 130], ["as", 141], ["a", 144], ["myeloproliferative", 146], ["disorder", 165], [".", 173], ["The", 175], ["hallmark", 179], ["of", 188], ["CML", 191], ["is", 195], ["the", 198], ["presence", 202], ["of", 211], ["a", 214], ["balanced", 216], ["translocation", 225], ["between", 239], ["the", 247], ["long", 251], ["arms", 256], ["of", 261], ["chromosomes", 264], ["9", 276], ["and", 278], ["22", 282], [",", 284], ["t(9;22)(q34;q11.2", 286], [")", 303], [",", 304], ["which", 306], ["is", 312], ["known", 315], ["as", 321], ["the", 324], ["Philadelphia", 328], ["(", 341], ["Ph", 342], [")", 344], ["chromosome", 346], [".", 356], ["This", 358], ["translocation", 363], ["results", 377], ["in", 385], ["the", 388], ["formation", 392], ["of", 402], ["the", 405], ["bcr", 409], ["-", 412], ["abl", 413], ["fusion", 417], ["gene", 424], [",", 428], ["which", 430], [",", 435], ["in", 437], ["turn", 440], [",", 444], ["is", 446], ["translated", 449], ["into", 460], ["a", 465], ["chimeric", 467], ["Bcr", 476], ["-", 479], ["Abl", 480], ["protein", 484], ["with", 492], ["deregulated", 497], ["tyrosine", 509], ["kinase", 518], ["activity", 525], [".", 533], ["Constitutive", 535], ["Bcr", 548], ["-", 551], ["Abl", 552], ["expression", 556], ["has", 567], ["been", 571], ["shown", 576], ["to", 582], ["be", 585], ["necessary", 588], ["and", 598], ["sufficient", 602], ["for", 613], ["the", 617], ["transformed", 621], ["phenotype", 633], ["of", 643], ["CML", 646], ["cells", 650], [".", 655], ["CML", 657], ["is", 661], ["unique", 664], ["among", 671], ["human", 677], ["cancers", 683], ["in", 691], ["that", 694], ["a", 699], ["single", 701], ["genetic", 708], ["defect", 716], [",", 722], ["the", 724], ["Ph", 728], ["chromosome", 731], [",", 741], ["is", 743], ["responsible", 746], ["for", 758], ["the", 762], ["transformed", 766], ["phenotype", 778], [".", 787], ["Since", 789], ["this", 795], ["discovery", 800], ["more", 810], ["than", 815], ["40", 820], ["years", 823], ["ago", 829], [",", 832], ["our", 834], ["understanding", 838], ["of", 852], ["the", 855], ["clinical", 859], ["course", 868], [",", 874], ["therapy", 876], [",", 883], ["and", 885], ["prognosis", 889], ["of", 899], ["patients", 902], ["with", 911], ["CML", 916], ["has", 920], ["changed", 924], ["significantly", 932], [".", 945], ["These", 947], ["changes", 953], ["have", 961], ["culminated", 966], ["in", 977], ["the", 980], ["emergence", 984], ["of", 994], ["imatinib", 997], [",", 1005], ["the", 1007], ["first", 1011], ["rationally", 1017], ["designed", 1028], [",", 1036], ["molecularly", 1038], ["targeted", 1050], ["therapy", 1059], ["for", 1067], ["human", 1071], ["malignancy", 1077], [".", 1087], ["In", 1089], ["this", 1092], ["review", 1097], [",", 1103], ["the", 1105], ["authors", 1109], ["describe", 1117], ["the", 1126], ["molecular", 1130], ["biology", 1140], ["of", 1148], ["CML", 1151], ["and", 1155], ["the", 1159], ["development", 1163], ["of", 1175], ["imatinib", 1178], ["as", 1187], ["a", 1190], ["therapeutic", 1192], ["agent", 1204], ["for", 1210], ["the", 1214], ["treatment", 1218], ["of", 1228], ["CML", 1231], [".", 1234]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "The carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved. Its presentation is characteristic in females about 40 years of age. The diagnosis is mainly based on clinical features and is confirmed by electrical criteria. In the anamnesis it is important to consider systemic diseases as causing the abnormality. Treatment depends on the etiology. It may be medical or surgical. In the present article we report three cases with different etiology and treatment. We also review the syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "944fef283f4a45c0b0e909cc2f35bb32", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[29, 29]], "char_spans": [[138, 143]]}]}], "context_tokens": [["The", 0], ["carpal", 4], ["tunnel", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["neuropathy", 32], ["due", 43], ["to", 47], ["trapping", 50], ["(", 59], ["focal", 60], ["lesion", 66], ["of", 73], ["the", 76], ["peripheral", 80], ["nerve", 91], ["due", 97], ["to", 101], ["a", 104], ["local", 106], ["cause", 112], [")", 117], [";", 118], ["in", 120], ["this", 123], ["case", 128], [",", 132], ["the", 134], ["median", 138], ["nerve", 145], ["is", 151], ["the", 154], ["most", 158], ["commonly", 163], ["involved", 172], [".", 180], ["Its", 182], ["presentation", 186], ["is", 199], ["characteristic", 202], ["in", 217], ["females", 220], ["about", 228], ["40", 234], ["years", 237], ["of", 243], ["age", 246], [".", 249], ["The", 251], ["diagnosis", 255], ["is", 265], ["mainly", 268], ["based", 275], ["on", 281], ["clinical", 284], ["features", 293], ["and", 302], ["is", 306], ["confirmed", 309], ["by", 319], ["electrical", 322], ["criteria", 333], [".", 341], ["In", 343], ["the", 346], ["anamnesis", 350], ["it", 360], ["is", 363], ["important", 366], ["to", 376], ["consider", 379], ["systemic", 388], ["diseases", 397], ["as", 406], ["causing", 409], ["the", 417], ["abnormality", 421], [".", 432], ["Treatment", 434], ["depends", 444], ["on", 452], ["the", 455], ["etiology", 459], [".", 467], ["It", 469], ["may", 472], ["be", 476], ["medical", 479], ["or", 487], ["surgical", 490], [".", 498], ["In", 500], ["the", 503], ["present", 507], ["article", 515], ["we", 523], ["report", 526], ["three", 533], ["cases", 539], ["with", 545], ["different", 550], ["etiology", 560], ["and", 569], ["treatment", 573], [".", 582], ["We", 584], ["also", 587], ["review", 592], ["the", 599], ["syndrome", 603], [".", 611]]}
{"context": "Carpal tunnel syndrome (CTS) is the most common median nerve neuropathy, accounting for 90% of all neuropathies. Carpal tunnel syndrome presents in 3.8% of the general population, with a higher prevalence among women. There are several risk factors associated with CTS, including both medical and non medical factors. The pathophysiologic mechanisms involved in the median nerve compression and traction are thought to be complex, and as yet are not fully understood. The present review aimed to provide an overview of the pathophysiology of median nerve neuropathy in the carpal tunnel, and subsequent development of CTS.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "7d31ab9e001e4207a7f6499a2b13dd0e", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[64, 64], [95, 95], [10, 10]], "char_spans": [[366, 371], [542, 547], [48, 53]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["(", 23], ["CTS", 24], [")", 27], ["is", 29], ["the", 32], ["most", 36], ["common", 41], ["median", 48], ["nerve", 55], ["neuropathy", 61], [",", 71], ["accounting", 73], ["for", 84], ["90", 88], ["%", 90], ["of", 92], ["all", 95], ["neuropathies", 99], [".", 111], ["Carpal", 113], ["tunnel", 120], ["syndrome", 127], ["presents", 136], ["in", 145], ["3.8", 148], ["%", 151], ["of", 153], ["the", 156], ["general", 160], ["population", 168], [",", 178], ["with", 180], ["a", 185], ["higher", 187], ["prevalence", 194], ["among", 205], ["women", 211], [".", 216], ["There", 218], ["are", 224], ["several", 228], ["risk", 236], ["factors", 241], ["associated", 249], ["with", 260], ["CTS", 265], [",", 268], ["including", 270], ["both", 280], ["medical", 285], ["and", 293], ["non", 297], ["medical", 301], ["factors", 309], [".", 316], ["The", 318], ["pathophysiologic", 322], ["mechanisms", 339], ["involved", 350], ["in", 359], ["the", 362], ["median", 366], ["nerve", 373], ["compression", 379], ["and", 391], ["traction", 395], ["are", 404], ["thought", 408], ["to", 416], ["be", 419], ["complex", 422], [",", 429], ["and", 431], ["as", 435], ["yet", 438], ["are", 442], ["not", 446], ["fully", 450], ["understood", 456], [".", 466], ["The", 468], ["present", 472], ["review", 480], ["aimed", 487], ["to", 493], ["provide", 496], ["an", 504], ["overview", 507], ["of", 516], ["the", 519], ["pathophysiology", 523], ["of", 539], ["median", 542], ["nerve", 549], ["neuropathy", 555], ["in", 566], ["the", 569], ["carpal", 573], ["tunnel", 580], [",", 586], ["and", 588], ["subsequent", 592], ["development", 603], ["of", 615], ["CTS", 618], [".", 621]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "\u03b1-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that \u03b1-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions of \u03b1-synuclein remains to be elucidated. To address this issue, we investigated the subcellular localization of \u03b1-synuclein in normal and pathological conditions using primary mouse hippocampal neuronal cultures. While some neurons expressed high levels of \u03b1-synuclein in presynaptic boutons and cell bodies, other neurons either did not or only very weakly expressed the protein. These \u03b1-synuclein-negative cells were identified as inhibitory neurons by immunostaining with specific antibodies against glutamic acid decarboxylase (GAD), parvalbumin, and somatostatin. In contrast, \u03b1-synuclein-positive synapses were colocalized with the excitatory synapse marker vesicular glutamate transporter-1. This expression profile of \u03b1-synuclein was conserved in the hippocampus in vivo. In addition, we found that while presynaptic \u03b1-synuclein colocalizes with synapsin, a marker of presynaptic vesicles, it is not essential for activity-dependent membrane recycling induced by high potassium treatment. Exogenous supply of preformed fibrils generated by recombinant \u03b1-synuclein was shown to promote the formation of Lewy body (LB) -like intracellular aggregates involving endogenous \u03b1-synuclein. GAD-positive neurons did not form LB-like aggregates following treatment with preformed fibrils, however, exogenous expression of human \u03b1-synuclein allowed intracellular aggregate formation in these cells. These results suggest the presence of a different mechanism for regulation of the expression of \u03b1-synuclein between excitatory and inhibitory neurons. Furthermore, \u03b1-synuclein expression levels may determine the efficiency of intracellular aggregate formation in different neuronal subtypes.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "02aedd384e0844e18fd9364151f02926", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[195, 197], [305, 307], [176, 178], [252, 254], [316, 318], [155, 157], [77, 79], [58, 60], [232, 234], [279, 281], [25, 27], [123, 125], [0, 2], [99, 101]], "char_spans": [[1208, 1218], [1875, 1885], [1109, 1119], [1560, 1570], [1943, 1953], [965, 975], [495, 505], [386, 396], [1443, 1453], [1709, 1719], [168, 178], [770, 780], [0, 10], [640, 650]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["pathological", 25], ["component", 38], ["of", 48], ["synucleinopathies", 51], ["including", 69], ["Parkinson", 79], ["'s", 88], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [".", 128], ["Recent", 130], ["studies", 137], ["have", 145], ["demonstrated", 150], ["that", 163], ["\u03b1", 168], ["-", 169], ["synuclein", 170], ["also", 180], ["plays", 185], ["important", 191], ["roles", 201], ["in", 207], ["the", 210], ["release", 214], ["of", 222], ["synaptic", 225], ["vesicles", 234], ["and", 243], ["synaptic", 247], ["membrane", 256], ["recycling", 265], ["in", 275], ["healthy", 278], ["neurons", 286], [".", 293], ["However", 295], [",", 302], ["the", 304], ["precise", 308], ["relationship", 316], ["between", 329], ["the", 337], ["pathogenicity", 341], ["and", 355], ["physiological", 359], ["functions", 373], ["of", 383], ["\u03b1", 386], ["-", 387], ["synuclein", 388], ["remains", 398], ["to", 406], ["be", 409], ["elucidated", 412], [".", 422], ["To", 424], ["address", 427], ["this", 435], ["issue", 440], [",", 445], ["we", 447], ["investigated", 450], ["the", 463], ["subcellular", 467], ["localization", 479], ["of", 492], ["\u03b1", 495], ["-", 496], ["synuclein", 497], ["in", 507], ["normal", 510], ["and", 517], ["pathological", 521], ["conditions", 534], ["using", 545], ["primary", 551], ["mouse", 559], ["hippocampal", 565], ["neuronal", 577], ["cultures", 586], [".", 594], ["While", 596], ["some", 602], ["neurons", 607], ["expressed", 615], ["high", 625], ["levels", 630], ["of", 637], ["\u03b1", 640], ["-", 641], ["synuclein", 642], ["in", 652], ["presynaptic", 655], ["boutons", 667], ["and", 675], ["cell", 679], ["bodies", 684], [",", 690], ["other", 692], ["neurons", 698], ["either", 706], ["did", 713], ["not", 717], ["or", 721], ["only", 724], ["very", 729], ["weakly", 734], ["expressed", 741], ["the", 751], ["protein", 755], [".", 762], ["These", 764], ["\u03b1", 770], ["-", 771], ["synuclein", 772], ["-", 781], ["negative", 782], ["cells", 791], ["were", 797], ["identified", 802], ["as", 813], ["inhibitory", 816], ["neurons", 827], ["by", 835], ["immunostaining", 838], ["with", 853], ["specific", 858], ["antibodies", 867], ["against", 878], ["glutamic", 886], ["acid", 895], ["decarboxylase", 900], ["(", 914], ["GAD", 915], [")", 918], [",", 919], ["parvalbumin", 921], [",", 932], ["and", 934], ["somatostatin", 938], [".", 950], ["In", 952], ["contrast", 955], [",", 963], ["\u03b1", 965], ["-", 966], ["synuclein", 967], ["-", 976], ["positive", 977], ["synapses", 986], ["were", 995], ["colocalized", 1000], ["with", 1012], ["the", 1017], ["excitatory", 1021], ["synapse", 1032], ["marker", 1040], ["vesicular", 1047], ["glutamate", 1057], ["transporter-1", 1067], [".", 1080], ["This", 1082], ["expression", 1087], ["profile", 1098], ["of", 1106], ["\u03b1", 1109], ["-", 1110], ["synuclein", 1111], ["was", 1121], ["conserved", 1125], ["in", 1135], ["the", 1138], ["hippocampus", 1142], ["in", 1154], ["vivo", 1157], [".", 1161], ["In", 1163], ["addition", 1166], [",", 1174], ["we", 1176], ["found", 1179], ["that", 1185], ["while", 1190], ["presynaptic", 1196], ["\u03b1", 1208], ["-", 1209], ["synuclein", 1210], ["colocalizes", 1220], ["with", 1232], ["synapsin", 1237], [",", 1245], ["a", 1247], ["marker", 1249], ["of", 1256], ["presynaptic", 1259], ["vesicles", 1271], [",", 1279], ["it", 1281], ["is", 1284], ["not", 1287], ["essential", 1291], ["for", 1301], ["activity", 1305], ["-", 1313], ["dependent", 1314], ["membrane", 1324], ["recycling", 1333], ["induced", 1343], ["by", 1351], ["high", 1354], ["potassium", 1359], ["treatment", 1369], [".", 1378], ["Exogenous", 1380], ["supply", 1390], ["of", 1397], ["preformed", 1400], ["fibrils", 1410], ["generated", 1418], ["by", 1428], ["recombinant", 1431], ["\u03b1", 1443], ["-", 1444], ["synuclein", 1445], ["was", 1455], ["shown", 1459], ["to", 1465], ["promote", 1468], ["the", 1476], ["formation", 1480], ["of", 1490], ["Lewy", 1493], ["body", 1498], ["(", 1503], ["LB", 1504], [")", 1506], ["-like", 1508], ["intracellular", 1514], ["aggregates", 1528], ["involving", 1539], ["endogenous", 1549], ["\u03b1", 1560], ["-", 1561], ["synuclein", 1562], [".", 1571], ["GAD", 1573], ["-", 1576], ["positive", 1577], ["neurons", 1586], ["did", 1594], ["not", 1598], ["form", 1602], ["LB", 1607], ["-", 1609], ["like", 1610], ["aggregates", 1615], ["following", 1626], ["treatment", 1636], ["with", 1646], ["preformed", 1651], ["fibrils", 1661], [",", 1668], ["however", 1670], [",", 1677], ["exogenous", 1679], ["expression", 1689], ["of", 1700], ["human", 1703], ["\u03b1", 1709], ["-", 1710], ["synuclein", 1711], ["allowed", 1721], ["intracellular", 1729], ["aggregate", 1743], ["formation", 1753], ["in", 1763], ["these", 1766], ["cells", 1772], [".", 1777], ["These", 1779], ["results", 1785], ["suggest", 1793], ["the", 1801], ["presence", 1805], ["of", 1814], ["a", 1817], ["different", 1819], ["mechanism", 1829], ["for", 1839], ["regulation", 1843], ["of", 1854], ["the", 1857], ["expression", 1861], ["of", 1872], ["\u03b1", 1875], ["-", 1876], ["synuclein", 1877], ["between", 1887], ["excitatory", 1895], ["and", 1906], ["inhibitory", 1910], ["neurons", 1921], [".", 1928], ["Furthermore", 1930], [",", 1941], ["\u03b1", 1943], ["-", 1944], ["synuclein", 1945], ["expression", 1955], ["levels", 1966], ["may", 1973], ["determine", 1977], ["the", 1987], ["efficiency", 1991], ["of", 2002], ["intracellular", 2005], ["aggregate", 2019], ["formation", 2029], ["in", 2039], ["different", 2042], ["neuronal", 2052], ["subtypes", 2061], [".", 2069]]}
{"context": "Polycomb gene silencing requires histone methyltransferase activity of Polycomb repressive complex 2 (PRC2), which methylates lysine 27 of histone H3. Information on how PRC2 works is limited by lack of structural data on the catalytic subunit, Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain. Here we analyze missense alleles of Drosophila E(z), selected for molecular study because of their dominant genetic effects. Four missense alleles identify key E(Z) SET domain residues, and a fifth is located in the adjacent CXC domain. Analysis of mutant PRC2 complexes in vitro, and H3-K27 methylation in vivo, shows that each SET domain mutation disrupts PRC2 histone methyltransferase. Based on known SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group. In contrast, the CXC mutant retains catalytic activity, Lys-27 specificity, and trimethylation capacity. Deletion analysis also reveals a functional requirement for a conserved E(Z) domain N-terminal to CXC and SET. These results identify critical SET domain residues needed for PRC2 enzyme function, and they also emphasize functional inputs from outside the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "94917b06092641a5af6b7e211171d69d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[134, 135], [60, 61], [123, 124], [217, 218], [91, 92], [235, 236]], "char_spans": [[742, 751], [325, 334], [666, 675], [1235, 1244], [502, 511], [1347, 1356]]}]}], "context_tokens": [["Polycomb", 0], ["gene", 9], ["silencing", 14], ["requires", 24], ["histone", 33], ["methyltransferase", 41], ["activity", 59], ["of", 68], ["Polycomb", 71], ["repressive", 80], ["complex", 91], ["2", 99], ["(", 101], ["PRC2", 102], [")", 106], [",", 107], ["which", 109], ["methylates", 115], ["lysine", 126], ["27", 133], ["of", 136], ["histone", 139], ["H3", 147], [".", 149], ["Information", 151], ["on", 163], ["how", 166], ["PRC2", 170], ["works", 175], ["is", 181], ["limited", 184], ["by", 192], ["lack", 195], ["of", 200], ["structural", 203], ["data", 214], ["on", 219], ["the", 222], ["catalytic", 226], ["subunit", 236], [",", 243], ["Enhancer", 245], ["of", 254], ["zeste", 257], ["(", 263], ["E(Z", 264], [")", 267], [")", 268], [",", 269], ["and", 271], ["the", 275], ["paucity", 279], ["of", 287], ["E(z", 290], [")", 293], ["mutant", 295], ["alleles", 302], ["that", 310], ["alter", 315], ["its", 321], ["SET", 325], ["domain", 329], [".", 335], ["Here", 337], ["we", 342], ["analyze", 345], ["missense", 353], ["alleles", 362], ["of", 370], ["Drosophila", 373], ["E(z", 384], [")", 387], [",", 388], ["selected", 390], ["for", 399], ["molecular", 403], ["study", 413], ["because", 419], ["of", 427], ["their", 430], ["dominant", 436], ["genetic", 445], ["effects", 453], [".", 460], ["Four", 462], ["missense", 467], ["alleles", 476], ["identify", 484], ["key", 493], ["E(Z", 497], [")", 500], ["SET", 502], ["domain", 506], ["residues", 513], [",", 521], ["and", 523], ["a", 527], ["fifth", 529], ["is", 535], ["located", 538], ["in", 546], ["the", 549], ["adjacent", 553], ["CXC", 562], ["domain", 566], [".", 572], ["Analysis", 574], ["of", 583], ["mutant", 586], ["PRC2", 593], ["complexes", 598], ["in", 608], ["vitro", 611], [",", 616], ["and", 618], ["H3-K27", 622], ["methylation", 629], ["in", 641], ["vivo", 644], [",", 648], ["shows", 650], ["that", 656], ["each", 661], ["SET", 666], ["domain", 670], ["mutation", 677], ["disrupts", 686], ["PRC2", 695], ["histone", 700], ["methyltransferase", 708], [".", 725], ["Based", 727], ["on", 733], ["known", 736], ["SET", 742], ["domain", 746], ["structures", 753], [",", 763], ["the", 765], ["mutations", 769], ["likely", 779], ["affect", 786], ["either", 793], ["the", 800], ["lysine", 804], ["-", 810], ["substrate", 811], ["binding", 821], ["pocket", 829], [",", 835], ["the", 837], ["binding", 841], ["site", 849], ["for", 854], ["the", 858], ["adenosylmethionine", 862], ["methyl", 881], ["donor", 888], [",", 893], ["or", 895], ["a", 898], ["critical", 900], ["tyrosine", 909], ["predicted", 918], ["to", 928], ["interact", 931], ["with", 940], ["the", 945], ["substrate", 949], ["lysine", 959], ["epsilon", 966], ["-", 973], ["amino", 974], ["group", 980], [".", 985], ["In", 987], ["contrast", 990], [",", 998], ["the", 1000], ["CXC", 1004], ["mutant", 1008], ["retains", 1015], ["catalytic", 1023], ["activity", 1033], [",", 1041], ["Lys-27", 1043], ["specificity", 1050], [",", 1061], ["and", 1063], ["trimethylation", 1067], ["capacity", 1082], [".", 1090], ["Deletion", 1092], ["analysis", 1101], ["also", 1110], ["reveals", 1115], ["a", 1123], ["functional", 1125], ["requirement", 1136], ["for", 1148], ["a", 1152], ["conserved", 1154], ["E(Z", 1164], [")", 1167], ["domain", 1169], ["N", 1176], ["-", 1177], ["terminal", 1178], ["to", 1187], ["CXC", 1190], ["and", 1194], ["SET", 1198], [".", 1201], ["These", 1203], ["results", 1209], ["identify", 1217], ["critical", 1226], ["SET", 1235], ["domain", 1239], ["residues", 1246], ["needed", 1255], ["for", 1262], ["PRC2", 1266], ["enzyme", 1271], ["function", 1278], [",", 1286], ["and", 1288], ["they", 1292], ["also", 1297], ["emphasize", 1302], ["functional", 1312], ["inputs", 1323], ["from", 1330], ["outside", 1335], ["the", 1343], ["SET", 1347], ["domain", 1351], [".", 1357]]}
{"context": "Asymptomatic colonization with methicillin-resistant Staphylococcus aureus (MRSA) has been described as a risk factor for subsequent MRSA infection. MRSA is an important nosocomial pathogen but has currently been reported in patients without typical risk factors for nosocomial acquisition. This study was designed to evaluate the impact of asymptomatic nares MRSA colonization on the development of subsequent MRSA infection. The incidence of MRSA infection was examined in patients with and patients without MRSA or methicillin-susceptible S. aureus (MSSA) colonization at admission to the hospital and in those who developed colonization during hospitalization. Patients admitted to 5 representative hospital units were prospectively evaluated. Nares samples were obtained for culture at admission and during hospitalization. Laboratory culture results were monitored to identify all MRSA infections that occurred during the study period and 1 year thereafter. Of the 758 patients who had cultures of nares samples performed at admission, 3.4% were colonized with MRSA, and 21% were colonized with MSSA. A total of 19% of patients with MRSA colonization at admission and 25% who acquired MRSA colonization during hospitalization developed infection with MRSA, compared with 1.5% and 2.0% of patients colonized with MSSA (P<.01) and uncolonized (P<.01), respectively, at admission. MRSA colonization at admission increased the risk of subsequent MRSA infection, compared with MSSA colonization (relative risk [RR], 13; 95% confidence interval [CI], 2.7-64) or no staphylococcal colonization (RR, 9.5; 95% CI, 3.6-25) at admission. Acquisition of MRSA colonization also increased the risk for subsequent MRSA infection, compared with no acquisition (RR, 12; 95% CI, 4.0-38). MRSA colonization of nares, either present at admission to the hospital or acquired during hospitalization, increases the risk for MRSA infection. Identifying MRSA colonization at admission could target a high-risk population that may benefit from interventions to decrease the risk for subsequent MRSA infection.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "eb949241f90c4716aa3b61abe11efb88", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[237, 237], [341, 341], [134, 134], [363, 363], [20, 20], [184, 184], [337, 337], [68, 68], [316, 316], [78, 78], [62, 62], [193, 193], [166, 166], [295, 295], [228, 228], [23, 23], [9, 9], [55, 55], [200, 200], [287, 287]], "char_spans": [[1448, 1451], [1935, 1938], [887, 890], [2074, 2077], [133, 136], [1139, 1142], [1907, 1910], [444, 447], [1776, 1779], [510, 513], [411, 414], [1191, 1194], [1067, 1070], [1705, 1708], [1384, 1387], [149, 152], [76, 79], [360, 363], [1257, 1260], [1648, 1651]]}]}], "context_tokens": [["Asymptomatic", 0], ["colonization", 13], ["with", 26], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["has", 82], ["been", 86], ["described", 91], ["as", 101], ["a", 104], ["risk", 106], ["factor", 111], ["for", 118], ["subsequent", 122], ["MRSA", 133], ["infection", 138], [".", 147], ["MRSA", 149], ["is", 154], ["an", 157], ["important", 160], ["nosocomial", 170], ["pathogen", 181], ["but", 190], ["has", 194], ["currently", 198], ["been", 208], ["reported", 213], ["in", 222], ["patients", 225], ["without", 234], ["typical", 242], ["risk", 250], ["factors", 255], ["for", 263], ["nosocomial", 267], ["acquisition", 278], [".", 289], ["This", 291], ["study", 296], ["was", 302], ["designed", 306], ["to", 315], ["evaluate", 318], ["the", 327], ["impact", 331], ["of", 338], ["asymptomatic", 341], ["nares", 354], ["MRSA", 360], ["colonization", 365], ["on", 378], ["the", 381], ["development", 385], ["of", 397], ["subsequent", 400], ["MRSA", 411], ["infection", 416], [".", 425], ["The", 427], ["incidence", 431], ["of", 441], ["MRSA", 444], ["infection", 449], ["was", 459], ["examined", 463], ["in", 472], ["patients", 475], ["with", 484], ["and", 489], ["patients", 493], ["without", 502], ["MRSA", 510], ["or", 515], ["methicillin", 518], ["-", 529], ["susceptible", 530], ["S.", 542], ["aureus", 545], ["(", 552], ["MSSA", 553], [")", 557], ["colonization", 559], ["at", 572], ["admission", 575], ["to", 585], ["the", 588], ["hospital", 592], ["and", 601], ["in", 605], ["those", 608], ["who", 614], ["developed", 618], ["colonization", 628], ["during", 641], ["hospitalization", 648], [".", 663], ["Patients", 665], ["admitted", 674], ["to", 683], ["5", 686], ["representative", 688], ["hospital", 703], ["units", 712], ["were", 718], ["prospectively", 723], ["evaluated", 737], [".", 746], ["Nares", 748], ["samples", 754], ["were", 762], ["obtained", 767], ["for", 776], ["culture", 780], ["at", 788], ["admission", 791], ["and", 801], ["during", 805], ["hospitalization", 812], [".", 827], ["Laboratory", 829], ["culture", 840], ["results", 848], ["were", 856], ["monitored", 861], ["to", 871], ["identify", 874], ["all", 883], ["MRSA", 887], ["infections", 892], ["that", 903], ["occurred", 908], ["during", 917], ["the", 924], ["study", 928], ["period", 934], ["and", 941], ["1", 945], ["year", 947], ["thereafter", 952], [".", 962], ["Of", 964], ["the", 967], ["758", 971], ["patients", 975], ["who", 984], ["had", 988], ["cultures", 992], ["of", 1001], ["nares", 1004], ["samples", 1010], ["performed", 1018], ["at", 1028], ["admission", 1031], [",", 1040], ["3.4", 1042], ["%", 1045], ["were", 1047], ["colonized", 1052], ["with", 1062], ["MRSA", 1067], [",", 1071], ["and", 1073], ["21", 1077], ["%", 1079], ["were", 1081], ["colonized", 1086], ["with", 1096], ["MSSA", 1101], [".", 1105], ["A", 1107], ["total", 1109], ["of", 1115], ["19", 1118], ["%", 1120], ["of", 1122], ["patients", 1125], ["with", 1134], ["MRSA", 1139], ["colonization", 1144], ["at", 1157], ["admission", 1160], ["and", 1170], ["25", 1174], ["%", 1176], ["who", 1178], ["acquired", 1182], ["MRSA", 1191], ["colonization", 1196], ["during", 1209], ["hospitalization", 1216], ["developed", 1232], ["infection", 1242], ["with", 1252], ["MRSA", 1257], [",", 1261], ["compared", 1263], ["with", 1272], ["1.5", 1277], ["%", 1280], ["and", 1282], ["2.0", 1286], ["%", 1289], ["of", 1291], ["patients", 1294], ["colonized", 1303], ["with", 1313], ["MSSA", 1318], ["(", 1323], ["P<.01", 1324], [")", 1329], ["and", 1331], ["uncolonized", 1335], ["(", 1347], ["P<.01", 1348], [")", 1353], [",", 1354], ["respectively", 1356], [",", 1368], ["at", 1370], ["admission", 1373], [".", 1382], ["MRSA", 1384], ["colonization", 1389], ["at", 1402], ["admission", 1405], ["increased", 1415], ["the", 1425], ["risk", 1429], ["of", 1434], ["subsequent", 1437], ["MRSA", 1448], ["infection", 1453], [",", 1462], ["compared", 1464], ["with", 1473], ["MSSA", 1478], ["colonization", 1483], ["(", 1496], ["relative", 1497], ["risk", 1506], ["[", 1511], ["RR", 1512], ["]", 1514], [",", 1515], ["13", 1517], [";", 1519], ["95", 1521], ["%", 1523], ["confidence", 1525], ["interval", 1536], ["[", 1545], ["CI", 1546], ["]", 1548], [",", 1549], ["2.7", 1551], ["-", 1554], ["64", 1555], [")", 1557], ["or", 1559], ["no", 1562], ["staphylococcal", 1565], ["colonization", 1580], ["(", 1593], ["RR", 1594], [",", 1596], ["9.5", 1598], [";", 1601], ["95", 1603], ["%", 1605], ["CI", 1607], [",", 1609], ["3.6", 1611], ["-", 1614], ["25", 1615], [")", 1617], ["at", 1619], ["admission", 1622], [".", 1631], ["Acquisition", 1633], ["of", 1645], ["MRSA", 1648], ["colonization", 1653], ["also", 1666], ["increased", 1671], ["the", 1681], ["risk", 1685], ["for", 1690], ["subsequent", 1694], ["MRSA", 1705], ["infection", 1710], [",", 1719], ["compared", 1721], ["with", 1730], ["no", 1735], ["acquisition", 1738], ["(", 1750], ["RR", 1751], [",", 1753], ["12", 1755], [";", 1757], ["95", 1759], ["%", 1761], ["CI", 1763], [",", 1765], ["4.0", 1767], ["-", 1770], ["38", 1771], [")", 1773], [".", 1774], ["MRSA", 1776], ["colonization", 1781], ["of", 1794], ["nares", 1797], [",", 1802], ["either", 1804], ["present", 1811], ["at", 1819], ["admission", 1822], ["to", 1832], ["the", 1835], ["hospital", 1839], ["or", 1848], ["acquired", 1851], ["during", 1860], ["hospitalization", 1867], [",", 1882], ["increases", 1884], ["the", 1894], ["risk", 1898], ["for", 1903], ["MRSA", 1907], ["infection", 1912], [".", 1921], ["Identifying", 1923], ["MRSA", 1935], ["colonization", 1940], ["at", 1953], ["admission", 1956], ["could", 1966], ["target", 1972], ["a", 1979], ["high", 1981], ["-", 1985], ["risk", 1986], ["population", 1991], ["that", 2002], ["may", 2007], ["benefit", 2011], ["from", 2019], ["interventions", 2024], ["to", 2038], ["decrease", 2041], ["the", 2050], ["risk", 2054], ["for", 2059], ["subsequent", 2063], ["MRSA", 2074], ["infection", 2079], [".", 2088]]}
{"context": "Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to use this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy, we interrogated CLL membrane-specific autologous immunoglobulin G reactivity. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "692ffa1dbcd344f7b86b7f0d61e5403f", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[188, 188]], "char_spans": [[1168, 1176]]}]}], "context_tokens": [["Membrane", 0], ["antigens", 9], ["are", 18], ["critical", 22], ["to", 31], ["the", 34], ["pathogenesis", 38], ["of", 51], ["chronic", 54], ["lymphocytic", 62], ["leukemia", 74], ["(", 83], ["CLL", 84], [")", 87], ["as", 89], ["they", 92], ["facilitate", 97], ["microenvironment", 108], ["homing", 125], [",", 131], ["proliferation", 133], [",", 146], ["and", 148], ["survival", 152], [".", 160], ["Targeting", 162], ["the", 172], ["CLL", 176], ["membrane", 180], ["and", 189], ["associated", 193], ["signaling", 204], ["patterns", 214], ["is", 223], ["a", 226], ["current", 228], ["focus", 236], ["of", 242], ["therapeutic", 245], ["development", 257], [".", 268], ["Many", 270], ["tumor", 275], ["membrane", 281], ["targets", 290], ["are", 298], ["simultaneously", 302], ["targeted", 317], ["by", 326], ["humoral", 329], ["immunity", 337], [",", 345], ["thus", 347], ["forming", 352], ["recognizable", 360], ["immunoglobulin", 373], ["responses", 388], [".", 397], ["We", 399], ["sought", 402], ["to", 409], ["use", 412], ["this", 416], ["immune", 421], ["response", 428], ["to", 437], ["identify", 440], ["novel", 449], ["membrane", 455], ["-", 463], ["associated", 464], ["targets", 475], ["for", 483], ["CLL", 487], [".", 490], ["Using", 492], ["a", 498], ["novel", 500], ["strategy", 506], [",", 514], ["we", 516], ["interrogated", 519], ["CLL", 532], ["membrane", 536], ["-", 544], ["specific", 545], ["autologous", 554], ["immunoglobulin", 565], ["G", 580], ["reactivity", 582], [".", 592], ["Our", 594], ["analysis", 598], ["unveiled", 607], ["lymphocyte", 616], ["cytosolic", 627], ["protein", 637], ["1", 645], ["(", 647], ["LCP1", 648], [")", 652], [",", 653], ["a", 655], ["lymphocyte", 657], ["-", 667], ["specific", 668], ["target", 677], ["that", 684], ["is", 689], ["highly", 692], ["expressed", 699], ["in", 709], ["CLL", 712], [".", 715], ["LCP1", 717], ["plays", 722], ["a", 728], ["critical", 730], ["role", 739], ["in", 744], ["B", 747], ["-", 748], ["cell", 749], ["biology", 754], ["by", 762], ["crosslinking", 765], ["F", 778], ["-", 779], ["actin", 780], ["filaments", 786], [",", 795], ["thereby", 797], ["solidifying", 805], ["cytoskeletal", 817], ["structures", 830], ["and", 841], ["providing", 845], ["a", 855], ["scaffold", 857], ["for", 866], ["critical", 870], ["signaling", 879], ["pathways", 889], [".", 897], ["Small", 899], ["interfering", 905], ["RNA", 917], ["knockdown", 921], ["of", 931], ["LCP1", 934], ["blocked", 939], ["migration", 947], ["toward", 957], ["CXCL12", 964], ["in", 971], ["transwell", 974], ["assays", 984], ["and", 991], ["to", 995], ["bone", 998], ["marrow", 1003], ["in", 1010], ["an", 1013], ["in", 1016], ["vivo", 1019], ["xenotransplant", 1024], ["model", 1039], [",", 1044], ["confirming", 1046], ["a", 1057], ["role", 1059], ["for", 1064], ["LCP1", 1068], ["in", 1073], ["leukemia", 1076], ["migration", 1085], [".", 1094], ["Furthermore", 1096], [",", 1107], ["we", 1109], ["demonstrate", 1112], ["that", 1124], ["the", 1129], ["Bruton", 1133], ["'s", 1139], ["tyrosine", 1142], ["kinase", 1151], ["inhibitor", 1158], ["ibrutinib", 1168], ["or", 1178], ["the", 1181], ["PI3", 1185], ["K", 1188], ["inhibitor", 1190], ["idelalisib", 1200], ["block", 1211], ["B", 1217], ["-", 1218], ["cell", 1219], ["receptor", 1224], ["induced", 1233], ["activation", 1241], ["of", 1252], ["LCP1", 1255], [".", 1259], ["Our", 1261], ["data", 1265], ["demonstrate", 1270], ["a", 1282], ["novel", 1284], ["strategy", 1290], ["to", 1299], ["identify", 1302], ["cancer", 1311], ["membrane", 1318], ["target", 1327], ["antigens", 1334], ["using", 1343], ["humoral", 1349], ["anti", 1357], ["-", 1361], ["tumor", 1362], ["immunity", 1368], [".", 1376], ["In", 1378], ["addition", 1381], [",", 1389], ["we", 1391], ["identify", 1394], ["LCP1", 1403], ["as", 1408], ["a", 1411], ["membrane", 1413], ["-", 1421], ["associated", 1422], ["target", 1433], ["in", 1440], ["CLL", 1443], ["with", 1447], ["confirmed", 1452], ["pathogenic", 1462], ["significance", 1473], [".", 1485], ["This", 1487], ["clinical", 1492], ["trial", 1501], ["was", 1507], ["registered", 1511], ["at", 1522], ["clinicaltrials.gov", 1525], [";", 1543], ["study", 1545], ["ID", 1551], ["number", 1554], [":", 1560], ["OSU-0025", 1562], ["OSU-0156", 1571], [".", 1579]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "X-monosomy is a form of Turner syndrome (TS) in which an entire X chromosome is missing. It is usually assumed that neuropsychological deficits in females with TS result from insufficient dosage of gene products from alleles on the sex chromosomes. If so, then parental origin of the single X chromosome should be immaterial. However, if there are imprinted genes on the X chromosome affecting brain development, neuropsychological development will depend on the parental origin of the single X chromosome. We contrasted verbal and visuospatial memory in females with a single paternal X chromosome (45,X(p)) and those with a single maternal X (45,X(m)). Neither group showed any impairment on immediate story recall; if anything, performance was above control levels. Groups did not differ on a measure of delayed recall. However, when delayed recall was considered after adjusting for level of immediate recall, 45,X(m) females showed enhanced verbal forgetting relative to controls over a delay. On the Rey figure, both groups were poor at copying the figure, but, after adjusting scores for initial copy score and strategy, only the 45,X(p) females showed disproportionate forgetting relative to controls. We propose there may be one or more imprinted genes on the X chromosome that affect the development of lateralised brain regions important for memory function.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "0c3d11aaf8cc41e7937743b05820136c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [16, 16], [229, 229], [70, 70], [102, 102], [87, 87], [55, 55], [114, 114]], "char_spans": [[0, 0], [64, 64], [1269, 1269], [371, 371], [586, 586], [493, 493], [291, 291], [642, 642]]}]}], "context_tokens": [["X", 0], ["-", 1], ["monosomy", 2], ["is", 11], ["a", 14], ["form", 16], ["of", 21], ["Turner", 24], ["syndrome", 31], ["(", 40], ["TS", 41], [")", 43], ["in", 45], ["which", 48], ["an", 54], ["entire", 57], ["X", 64], ["chromosome", 66], ["is", 77], ["missing", 80], [".", 87], ["It", 89], ["is", 92], ["usually", 95], ["assumed", 103], ["that", 111], ["neuropsychological", 116], ["deficits", 135], ["in", 144], ["females", 147], ["with", 155], ["TS", 160], ["result", 163], ["from", 170], ["insufficient", 175], ["dosage", 188], ["of", 195], ["gene", 198], ["products", 203], ["from", 212], ["alleles", 217], ["on", 225], ["the", 228], ["sex", 232], ["chromosomes", 236], [".", 247], ["If", 249], ["so", 252], [",", 254], ["then", 256], ["parental", 261], ["origin", 270], ["of", 277], ["the", 280], ["single", 284], ["X", 291], ["chromosome", 293], ["should", 304], ["be", 311], ["immaterial", 314], [".", 324], ["However", 326], [",", 333], ["if", 335], ["there", 338], ["are", 344], ["imprinted", 348], ["genes", 358], ["on", 364], ["the", 367], ["X", 371], ["chromosome", 373], ["affecting", 384], ["brain", 394], ["development", 400], [",", 411], ["neuropsychological", 413], ["development", 432], ["will", 444], ["depend", 449], ["on", 456], ["the", 459], ["parental", 463], ["origin", 472], ["of", 479], ["the", 482], ["single", 486], ["X", 493], ["chromosome", 495], [".", 505], ["We", 507], ["contrasted", 510], ["verbal", 521], ["and", 528], ["visuospatial", 532], ["memory", 545], ["in", 552], ["females", 555], ["with", 563], ["a", 568], ["single", 570], ["paternal", 577], ["X", 586], ["chromosome", 588], ["(", 599], ["45,X(p", 600], [")", 606], [")", 607], ["and", 609], ["those", 613], ["with", 619], ["a", 624], ["single", 626], ["maternal", 633], ["X", 642], ["(", 644], ["45,X(m", 645], [")", 651], [")", 652], [".", 653], ["Neither", 655], ["group", 663], ["showed", 669], ["any", 676], ["impairment", 680], ["on", 691], ["immediate", 694], ["story", 704], ["recall", 710], [";", 716], ["if", 718], ["anything", 721], [",", 729], ["performance", 731], ["was", 743], ["above", 747], ["control", 753], ["levels", 761], [".", 767], ["Groups", 769], ["did", 776], ["not", 780], ["differ", 784], ["on", 791], ["a", 794], ["measure", 796], ["of", 804], ["delayed", 807], ["recall", 815], [".", 821], ["However", 823], [",", 830], ["when", 832], ["delayed", 837], ["recall", 845], ["was", 852], ["considered", 856], ["after", 867], ["adjusting", 873], ["for", 883], ["level", 887], ["of", 893], ["immediate", 896], ["recall", 906], [",", 912], ["45,X(m", 914], [")", 920], ["females", 922], ["showed", 930], ["enhanced", 937], ["verbal", 946], ["forgetting", 953], ["relative", 964], ["to", 973], ["controls", 976], ["over", 985], ["a", 990], ["delay", 992], [".", 997], ["On", 999], ["the", 1002], ["Rey", 1006], ["figure", 1010], [",", 1016], ["both", 1018], ["groups", 1023], ["were", 1030], ["poor", 1035], ["at", 1040], ["copying", 1043], ["the", 1051], ["figure", 1055], [",", 1061], ["but", 1063], [",", 1066], ["after", 1068], ["adjusting", 1074], ["scores", 1084], ["for", 1091], ["initial", 1095], ["copy", 1103], ["score", 1108], ["and", 1114], ["strategy", 1118], [",", 1126], ["only", 1128], ["the", 1133], ["45,X(p", 1137], [")", 1143], ["females", 1145], ["showed", 1153], ["disproportionate", 1160], ["forgetting", 1177], ["relative", 1188], ["to", 1197], ["controls", 1200], [".", 1208], ["We", 1210], ["propose", 1213], ["there", 1221], ["may", 1227], ["be", 1231], ["one", 1234], ["or", 1238], ["more", 1241], ["imprinted", 1246], ["genes", 1256], ["on", 1262], ["the", 1265], ["X", 1269], ["chromosome", 1271], ["that", 1282], ["affect", 1287], ["the", 1294], ["development", 1298], ["of", 1310], ["lateralised", 1313], ["brain", 1325], ["regions", 1331], ["important", 1339], ["for", 1349], ["memory", 1353], ["function", 1360], [".", 1368]]}
{"context": "Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. Therefore, the best practice is familial supervision and restriction of diet and environment. We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 \u00b1 3.16 years, body weight 43.98 \u00b1 23.99 kg). Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. Furthermore due to CFE supplementation, a significant decrease (P \u2264 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). There were no reported adverse effects at any dose. We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. The outcomes of this study will have a potential positive impact on PWS management.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "8b979d0ca3aa47dbbd35ea426dc78be3", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 20]]}]}], "context_tokens": [["Prader", 0], ["-", 6], ["Willi", 7], ["syndrome", 13], ["(", 22], ["PWS", 23], [")", 26], ["results", 28], ["from", 36], ["a", 41], ["deletion", 43], ["of", 52], ["the", 55], ["paternal", 59], ["genes", 68], ["in", 74], ["the", 77], ["region", 81], ["of", 88], ["chromosome", 91], ["15q11-q13", 102], [".", 111], ["PWS", 113], ["develops", 117], ["hyperphagia", 126], [",", 137], ["which", 139], ["when", 145], ["left", 150], ["unmanaged", 155], [",", 164], ["leads", 166], ["to", 172], ["an", 175], ["excessive", 178], ["ingestion", 188], ["of", 198], ["food", 201], [".", 205], ["To", 207], ["date", 210], ["there", 215], ["is", 221], ["inadequate", 224], ["pharmacological", 235], ["treatment", 251], ["or", 261], ["supplementation", 264], ["for", 280], ["modification", 284], ["of", 297], ["the", 300], ["PWS", 304], ["hyperphagia", 308], ["and/or", 320], ["the", 327], ["associated", 331], ["behaviors", 342], [".", 351], ["Therefore", 353], [",", 362], ["the", 364], ["best", 368], ["practice", 373], ["is", 382], ["familial", 385], ["supervision", 394], ["and", 406], ["restriction", 410], ["of", 422], ["diet", 425], ["and", 430], ["environment", 434], [".", 445], ["We", 447], ["aimed", 450], ["to", 456], ["determine", 459], ["if", 469], ["the", 472], ["natural", 476], ["supplement", 484], ["of", 495], ["Caralluma", 498], ["fimbriata", 508], ["extract", 518], ["(", 526], ["CFE", 527], [")", 530], ["could", 532], ["attenuate", 538], ["hyperphagia", 548], ["or", 560], ["the", 563], ["associated", 567], ["appetite", 578], ["behaviors", 587], ["in", 597], ["children", 600], ["and", 609], ["adolescents", 613], ["with", 625], ["PWS", 630], ["over", 634], ["the", 639], ["4-week", 643], ["pilot", 650], ["trial", 656], ["period", 662], [".", 668], ["We", 670], ["conducted", 673], ["a", 683], ["placebo", 685], ["-", 692], ["controlled", 693], [",", 703], ["double", 705], ["-", 711], ["blind", 712], [",", 717], ["randomized", 719], ["crossover", 730], ["trial", 740], ["over", 746], ["a", 751], ["10-week", 753], ["period", 761], ["to", 768], ["investigate", 771], ["the", 783], ["effects", 787], ["of", 795], ["CFE", 798], ["on", 802], ["hunger", 805], ["control", 812], [",", 819], ["in", 821], ["a", 824], ["cohort", 826], ["of", 833], ["children", 836], ["and", 845], ["adolescents", 849], ["with", 861], ["confirmed", 866], ["PWS", 876], ["(", 880], ["n", 881], ["=", 883], ["15", 884], [",", 886], ["mean", 888], ["age", 893], ["9.27", 897], ["\u00b1", 902], ["3.16", 904], ["years", 909], [",", 914], ["body", 916], ["weight", 921], ["43.98", 928], ["\u00b1", 934], ["23.99", 936], ["kg", 942], [")", 944], [".", 945], ["Participants", 947], ["from", 960], ["Australia", 965], ["and", 975], ["New", 979], ["Zealand", 983], ["ingested", 991], ["CFE", 1000], ["or", 1004], ["a", 1007], ["placebo", 1009], ["of", 1017], ["maltodextrin", 1020], ["/", 1032], ["cabbage", 1033], ["leaf", 1041], ["over", 1046], ["a", 1051], ["4-week", 1053], ["period", 1060], [",", 1066], ["with", 1068], ["a", 1073], ["2-week", 1075], ["washout", 1082], ["before", 1090], ["the", 1097], ["crossover", 1101], ["to", 1111], ["the", 1114], ["other", 1118], ["treatment", 1124], [".", 1133], ["Weekly", 1135], ["comparisons", 1142], ["in", 1154], ["appetite", 1157], ["behavior", 1166], [",", 1174], ["severity", 1176], [",", 1184], ["and", 1186], ["drive", 1190], ["were", 1196], ["recorded", 1201], ["by", 1210], ["parents", 1213], [",", 1220], ["as", 1222], ["scaled", 1225], ["time", 1232], ["-", 1236], ["point", 1237], ["measures", 1243], ["on", 1252], ["a", 1255], ["hyperphagia", 1257], ["questionnaire", 1269], ["validated", 1283], ["for", 1293], ["PWS", 1297], [".", 1300], ["CFE", 1302], ["administration", 1306], ["was", 1321], ["found", 1325], ["to", 1331], ["induce", 1334], ["a", 1341], ["significant", 1343], ["accumulative", 1355], ["easing", 1368], ["of", 1375], ["hyperphagia", 1378], ["(", 1390], ["P", 1391], ["=", 1393], ["0.05", 1395], [")", 1399], [",", 1400], ["with", 1402], ["decreases", 1407], ["evident", 1417], ["in", 1425], ["one", 1428], ["-", 1431], ["third", 1432], ["of", 1438], ["the", 1441], ["participants", 1445], [".", 1457], ["Furthermore", 1459], ["due", 1471], ["to", 1475], ["CFE", 1478], ["supplementation", 1482], [",", 1497], ["a", 1499], ["significant", 1501], ["decrease", 1513], ["(", 1522], ["P", 1523], ["\u2264", 1525], ["0.05", 1527], [")", 1531], ["was", 1533], ["recorded", 1537], ["in", 1546], ["the", 1549], ["category", 1553], ["of", 1562], ["behavior", 1565], ["and", 1574], ["a", 1578], ["decrease", 1580], ["in", 1589], ["hyperphagia", 1592], ["(", 1604], ["n", 1605], ["=", 1607], ["8", 1609], [",", 1610], ["P", 1612], ["=", 1614], ["0.009", 1616], [")", 1621], ["was", 1623], ["observed", 1627], ["at", 1636], ["the", 1639], ["highest", 1643], ["dose", 1651], ["1,000", 1656], ["mg", 1662], ["/", 1664], ["day", 1665], ["(", 1669], ["recommended", 1670], ["adult", 1682], ["dose", 1688], [")", 1692], [".", 1693], ["There", 1695], ["were", 1701], ["no", 1706], ["reported", 1709], ["adverse", 1718], ["effects", 1726], ["at", 1734], ["any", 1737], ["dose", 1741], [".", 1745], ["We", 1747], ["demonstrate", 1750], ["that", 1762], ["an", 1767], ["extract", 1770], ["of", 1778], ["the", 1781], ["Indian", 1785], ["cactus", 1792], ["succulent", 1799], ["Caralluma", 1809], ["fimbriata", 1819], ["eases", 1829], ["hyperphagic", 1835], ["appetite", 1847], ["behavior", 1856], ["within", 1865], ["a", 1872], ["cohort", 1874], ["of", 1881], ["children", 1884], ["and", 1893], ["adolescents", 1897], ["(", 1909], ["n", 1910], ["=", 1912], ["15", 1914], [")", 1916], ["with", 1918], ["PWS", 1923], ["without", 1927], ["notable", 1935], ["adverse", 1943], ["effects", 1951], [".", 1958], ["The", 1960], ["outcomes", 1964], ["of", 1973], ["this", 1976], ["study", 1981], ["will", 1987], ["have", 1992], ["a", 1997], ["potential", 1999], ["positive", 2009], ["impact", 2018], ["on", 2025], ["PWS", 2028], ["management", 2032], [".", 2042]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of both hospital and community infections globally. It's important to illuminate the differences between community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), but there have been confusions on the definition, especially for the MRSA isolates identified within 48\u00a0h of admission. This study aimed to determine the molecular characteristics and virulence genes profile of CA and HA-MRSA isolates identified less than 48\u00a0h after hospital admission in our region. A total 62 MRSA isolates identified within 48\u00a0h after admission and the clinical data were collected. Antimicrobial susceptibility test (AST) of collected isolates were performed according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) 2015, and staphylococcal cassette chromosome mec (SCCmec) typing, multilocus sequence typing (MLST), pulsed-field gel electrophoresis (PFGE) and virulence gene profiling were performed to explore the molecular diversity. SCCmec III and sequence type (ST) 239 were the most prevalent SCCmec type and ST in both CA and HA-MRSA groups. HA-MRSA group had higher prevalence of SCCmec III (87.2\u00a0%) and ST239 (79.5\u00a0%) compared with CA-MRSA (60.9 and 43.4\u00a0%, both P\u2009<\u20090.001), while the frequency of SCCmec IV (26.0\u00a0%) and ST59 (21.7\u00a0%) were higher in CA-MRSA than its counterpart (P\u2009<\u20090.001 and P\u2009=\u20090.003). MRSA-ST239-III was the predominant type in this study (61.3\u00a0%, 38/62), especially in HA-MRSA group (76.9\u00a0%, 30/39). However, CA-MRSA strains exhibited more diversity in genotypes in this study. Meanwhile, CA-MRSA tended to have lower resistant percentage to non-\u03b2-lactams antibiotics but more virulence genes carriage, especially the staphylococcal enterotoxins (SE) genes. Notably, seb gene was only detected in CA-MRSA isolates (52.2\u00a0%), likely a significant marker for CA-MRSA isolates. Panton-Valentine leukocidin gene (PVL) was highly detected in both groups, while appeared no significantly different between CA-MRSA (47.8\u00a0%) and HA-MRSA (43.6\u00a0%). Our findings support a difference in the molecular epidemiology and virulence genes profile of CA-MRSA and HA-MRSA. Furthermore, this study indicates a possible transmission from HA-MRSA to CA-MRSA, which may cause the overlap of the definition.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f98dd7a57739471cb2db2af4ebffa125", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[45, 45], [437, 437], [6, 6], [454, 454], [204, 204], [300, 300], [313, 313], [441, 441], [209, 209], [381, 381], [31, 31], [60, 60], [415, 415], [103, 103], [231, 231], [35, 35], [86, 86], [458, 458], [41, 41], [265, 265], [279, 279], [407, 407], [328, 328], [367, 367]], "char_spans": [[238, 241], [2158, 2161], [45, 48], [2242, 2245], [1127, 1130], [1494, 1497], [1534, 1537], [2170, 2173], [1143, 1146], [1881, 1884], [192, 195], [314, 317], [2045, 2048], [557, 560], [1235, 1238], [201, 204], [466, 469], [2253, 2256], [229, 232], [1353, 1356], [1406, 1409], [2024, 2027], [1614, 1617], [1822, 1825]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["a", 54], ["major", 56], ["cause", 62], ["of", 68], ["both", 71], ["hospital", 76], ["and", 85], ["community", 89], ["infections", 99], ["globally", 110], [".", 118], ["It", 120], ["'s", 122], ["important", 125], ["to", 135], ["illuminate", 138], ["the", 149], ["differences", 153], ["between", 165], ["community", 173], ["-", 182], ["acquired", 183], ["MRSA", 192], ["(", 197], ["CA", 198], ["-", 200], ["MRSA", 201], [")", 205], ["and", 207], ["hospital", 211], ["-", 219], ["acquired", 220], ["MRSA", 229], ["(", 234], ["HA", 235], ["-", 237], ["MRSA", 238], [")", 242], [",", 243], ["but", 245], ["there", 249], ["have", 255], ["been", 260], ["confusions", 265], ["on", 276], ["the", 279], ["definition", 283], [",", 293], ["especially", 295], ["for", 306], ["the", 310], ["MRSA", 314], ["isolates", 319], ["identified", 328], ["within", 339], ["48", 346], ["h", 349], ["of", 351], ["admission", 354], [".", 363], ["This", 365], ["study", 370], ["aimed", 376], ["to", 382], ["determine", 385], ["the", 395], ["molecular", 399], ["characteristics", 409], ["and", 425], ["virulence", 429], ["genes", 439], ["profile", 445], ["of", 453], ["CA", 456], ["and", 459], ["HA", 463], ["-", 465], ["MRSA", 466], ["isolates", 471], ["identified", 480], ["less", 491], ["than", 496], ["48", 501], ["h", 504], ["after", 506], ["hospital", 512], ["admission", 521], ["in", 531], ["our", 534], ["region", 538], [".", 544], ["A", 546], ["total", 548], ["62", 554], ["MRSA", 557], ["isolates", 562], ["identified", 571], ["within", 582], ["48", 589], ["h", 592], ["after", 594], ["admission", 600], ["and", 610], ["the", 614], ["clinical", 618], ["data", 627], ["were", 632], ["collected", 637], [".", 646], ["Antimicrobial", 648], ["susceptibility", 662], ["test", 677], ["(", 682], ["AST", 683], [")", 686], ["of", 688], ["collected", 691], ["isolates", 701], ["were", 710], ["performed", 715], ["according", 725], ["to", 735], ["the", 738], ["guidelines", 742], ["of", 753], ["Clinical", 756], ["and", 765], ["Laboratory", 769], ["Standards", 780], ["Institute", 790], ["(", 800], ["CLSI", 801], [")", 805], ["2015", 807], [",", 811], ["and", 813], ["staphylococcal", 817], ["cassette", 832], ["chromosome", 841], ["mec", 852], ["(", 856], ["SCCmec", 857], [")", 863], ["typing", 865], [",", 871], ["multilocus", 873], ["sequence", 884], ["typing", 893], ["(", 900], ["MLST", 901], [")", 905], [",", 906], ["pulsed", 908], ["-", 914], ["field", 915], ["gel", 921], ["electrophoresis", 925], ["(", 941], ["PFGE", 942], [")", 946], ["and", 948], ["virulence", 952], ["gene", 962], ["profiling", 967], ["were", 977], ["performed", 982], ["to", 992], ["explore", 995], ["the", 1003], ["molecular", 1007], ["diversity", 1017], [".", 1026], ["SCCmec", 1028], ["III", 1035], ["and", 1039], ["sequence", 1043], ["type", 1052], ["(", 1057], ["ST", 1058], [")", 1060], ["239", 1062], ["were", 1066], ["the", 1071], ["most", 1075], ["prevalent", 1080], ["SCCmec", 1090], ["type", 1097], ["and", 1102], ["ST", 1106], ["in", 1109], ["both", 1112], ["CA", 1117], ["and", 1120], ["HA", 1124], ["-", 1126], ["MRSA", 1127], ["groups", 1132], [".", 1138], ["HA", 1140], ["-", 1142], ["MRSA", 1143], ["group", 1148], ["had", 1154], ["higher", 1158], ["prevalence", 1165], ["of", 1176], ["SCCmec", 1179], ["III", 1186], ["(", 1190], ["87.2", 1191], ["%", 1196], [")", 1197], ["and", 1199], ["ST239", 1203], ["(", 1209], ["79.5", 1210], ["%", 1215], [")", 1216], ["compared", 1218], ["with", 1227], ["CA", 1232], ["-", 1234], ["MRSA", 1235], ["(", 1240], ["60.9", 1241], ["and", 1246], ["43.4", 1250], ["%", 1255], [",", 1256], ["both", 1258], ["P", 1263], ["<", 1265], ["0.001", 1267], [")", 1272], [",", 1273], ["while", 1275], ["the", 1281], ["frequency", 1285], ["of", 1295], ["SCCmec", 1298], ["IV", 1305], ["(", 1308], ["26.0", 1309], ["%", 1314], [")", 1315], ["and", 1317], ["ST59", 1321], ["(", 1326], ["21.7", 1327], ["%", 1332], [")", 1333], ["were", 1335], ["higher", 1340], ["in", 1347], ["CA", 1350], ["-", 1352], ["MRSA", 1353], ["than", 1358], ["its", 1363], ["counterpart", 1367], ["(", 1379], ["P", 1380], ["<", 1382], ["0.001", 1384], ["and", 1390], ["P", 1394], ["=", 1396], ["0.003", 1398], [")", 1403], [".", 1404], ["MRSA", 1406], ["-", 1410], ["ST239-III", 1411], ["was", 1421], ["the", 1425], ["predominant", 1429], ["type", 1441], ["in", 1446], ["this", 1449], ["study", 1454], ["(", 1460], ["61.3", 1461], ["%", 1466], [",", 1467], ["38/62", 1469], [")", 1474], [",", 1475], ["especially", 1477], ["in", 1488], ["HA", 1491], ["-", 1493], ["MRSA", 1494], ["group", 1499], ["(", 1505], ["76.9", 1506], ["%", 1511], [",", 1512], ["30/39", 1514], [")", 1519], [".", 1520], ["However", 1522], [",", 1529], ["CA", 1531], ["-", 1533], ["MRSA", 1534], ["strains", 1539], ["exhibited", 1547], ["more", 1557], ["diversity", 1562], ["in", 1572], ["genotypes", 1575], ["in", 1585], ["this", 1588], ["study", 1593], [".", 1598], ["Meanwhile", 1600], [",", 1609], ["CA", 1611], ["-", 1613], ["MRSA", 1614], ["tended", 1619], ["to", 1626], ["have", 1629], ["lower", 1634], ["resistant", 1640], ["percentage", 1650], ["to", 1661], ["non", 1664], ["-", 1667], ["\u03b2", 1668], ["-", 1669], ["lactams", 1670], ["antibiotics", 1678], ["but", 1690], ["more", 1694], ["virulence", 1699], ["genes", 1709], ["carriage", 1715], [",", 1723], ["especially", 1725], ["the", 1736], ["staphylococcal", 1740], ["enterotoxins", 1755], ["(", 1768], ["SE", 1769], [")", 1771], ["genes", 1773], [".", 1778], ["Notably", 1780], [",", 1787], ["seb", 1789], ["gene", 1793], ["was", 1798], ["only", 1802], ["detected", 1807], ["in", 1816], ["CA", 1819], ["-", 1821], ["MRSA", 1822], ["isolates", 1827], ["(", 1836], ["52.2", 1837], ["%", 1842], [")", 1843], [",", 1844], ["likely", 1846], ["a", 1853], ["significant", 1855], ["marker", 1867], ["for", 1874], ["CA", 1878], ["-", 1880], ["MRSA", 1881], ["isolates", 1886], [".", 1894], ["Panton", 1896], ["-", 1902], ["Valentine", 1903], ["leukocidin", 1913], ["gene", 1924], ["(", 1929], ["PVL", 1930], [")", 1933], ["was", 1935], ["highly", 1939], ["detected", 1946], ["in", 1955], ["both", 1958], ["groups", 1963], [",", 1969], ["while", 1971], ["appeared", 1977], ["no", 1986], ["significantly", 1989], ["different", 2003], ["between", 2013], ["CA", 2021], ["-", 2023], ["MRSA", 2024], ["(", 2029], ["47.8", 2030], ["%", 2035], [")", 2036], ["and", 2038], ["HA", 2042], ["-", 2044], ["MRSA", 2045], ["(", 2050], ["43.6", 2051], ["%", 2056], [")", 2057], [".", 2058], ["Our", 2060], ["findings", 2064], ["support", 2073], ["a", 2081], ["difference", 2083], ["in", 2094], ["the", 2097], ["molecular", 2101], ["epidemiology", 2111], ["and", 2124], ["virulence", 2128], ["genes", 2138], ["profile", 2144], ["of", 2152], ["CA", 2155], ["-", 2157], ["MRSA", 2158], ["and", 2163], ["HA", 2167], ["-", 2169], ["MRSA", 2170], [".", 2174], ["Furthermore", 2176], [",", 2187], ["this", 2189], ["study", 2194], ["indicates", 2200], ["a", 2210], ["possible", 2212], ["transmission", 2221], ["from", 2234], ["HA", 2239], ["-", 2241], ["MRSA", 2242], ["to", 2247], ["CA", 2250], ["-", 2252], ["MRSA", 2253], [",", 2257], ["which", 2259], ["may", 2265], ["cause", 2269], ["the", 2275], ["overlap", 2279], ["of", 2287], ["the", 2290], ["definition", 2294], [".", 2304]]}
{"context": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteristics similar to patients receiving anticoagulant therapy. In this randomized, double-blind, crossover study, 46 subjects (12 middle-aged, 45-64\u00a0years; 16 elderly, 65-80\u00a0years; and 18 with mild or moderate renal impairment) received dabigatran etexilate (DE; 220 or 150\u00a0mg twice daily) for 4\u00a0days. Idarucizumab doses of 1, 2.5 and 5\u00a0g or 2\u00a0\u00d7\u00a02.5\u00a0g 1\u00a0h apart, or placebo, were administered as a rapid (5\u00a0min) infusion ~2\u00a0h after DE at steady state. Dabigatran-prolonged diluted thrombin time, ecarin clotting time and activated partial thromboplastin time were reversed to baseline immediately after idarucizumab infusion in all groups. Reversal was sustained with doses \u22652.5\u00a0g. Idarucizumab was well tolerated under all conditions. No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84\u00a0%), decreased clearance and prolonged (by up to 49\u00a0%) initial half-life of idarucizumab compared with healthy middle-aged subjects. Impaired renal function was associated with increased exposure and decreased clearance of idarucizumab. Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. The results support the clinical use of a 5\u00a0g dose of idarucizumab. http://www.clinicaltrials.gov . Unique identifier: NCT01955720.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "1617e42426ba4b0483170d68366da72d", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[262, 262], [87, 87], [23, 23], [8, 8], [142, 142]], "char_spans": [[1474, 1483], [505, 514], [184, 193], [64, 73], [720, 729]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antibody", 19], ["fragment", 28], ["that", 37], ["specifically", 42], ["reverses", 55], ["dabigatran", 64], ["-", 74], ["mediated", 75], ["anticoagulation", 84], [".", 99], ["Safety", 101], [",", 107], ["pharmacokinetics", 109], ["and", 126], ["pharmacodynamics", 130], ["of", 147], ["idarucizumab", 150], ["were", 163], ["investigated", 168], ["in", 181], ["dabigatran", 184], ["-", 194], ["treated", 195], [",", 202], ["middle", 204], ["-", 210], ["aged", 211], [",", 215], ["elderly", 217], ["and", 225], ["renally", 229], ["impaired", 237], ["volunteers", 246], ["with", 257], ["characteristics", 262], ["similar", 278], ["to", 286], ["patients", 289], ["receiving", 298], ["anticoagulant", 308], ["therapy", 322], [".", 329], ["In", 331], ["this", 334], ["randomized", 339], [",", 349], ["double", 351], ["-", 357], ["blind", 358], [",", 363], ["crossover", 365], ["study", 375], [",", 380], ["46", 382], ["subjects", 385], ["(", 394], ["12", 395], ["middle", 398], ["-", 404], ["aged", 405], [",", 409], ["45", 411], ["-", 413], ["64", 414], ["years", 417], [";", 422], ["16", 424], ["elderly", 427], [",", 434], ["65", 436], ["-", 438], ["80", 439], ["years", 442], [";", 447], ["and", 449], ["18", 453], ["with", 456], ["mild", 461], ["or", 466], ["moderate", 469], ["renal", 478], ["impairment", 484], [")", 494], ["received", 496], ["dabigatran", 505], ["etexilate", 516], ["(", 526], ["DE", 527], [";", 529], ["220", 531], ["or", 535], ["150", 538], ["mg", 542], ["twice", 545], ["daily", 551], [")", 556], ["for", 558], ["4", 562], ["days", 564], [".", 568], ["Idarucizumab", 570], ["doses", 583], ["of", 589], ["1", 592], [",", 593], ["2.5", 595], ["and", 599], ["5", 603], ["g", 605], ["or", 607], ["2", 610], ["\u00d7", 612], ["2.5", 614], ["g", 618], ["1", 620], ["h", 622], ["apart", 624], [",", 629], ["or", 631], ["placebo", 634], [",", 641], ["were", 643], ["administered", 648], ["as", 661], ["a", 664], ["rapid", 666], ["(", 672], ["5", 673], ["min", 675], [")", 678], ["infusion", 680], ["~2", 689], ["h", 692], ["after", 694], ["DE", 700], ["at", 703], ["steady", 706], ["state", 713], [".", 718], ["Dabigatran", 720], ["-", 730], ["prolonged", 731], ["diluted", 741], ["thrombin", 749], ["time", 758], [",", 762], ["ecarin", 764], ["clotting", 771], ["time", 780], ["and", 785], ["activated", 789], ["partial", 799], ["thromboplastin", 807], ["time", 822], ["were", 827], ["reversed", 832], ["to", 841], ["baseline", 844], ["immediately", 853], ["after", 865], ["idarucizumab", 871], ["infusion", 884], ["in", 893], ["all", 896], ["groups", 900], [".", 906], ["Reversal", 908], ["was", 917], ["sustained", 921], ["with", 931], ["doses", 936], ["\u22652.5", 942], ["g.", 947], ["Idarucizumab", 950], ["was", 963], ["well", 967], ["tolerated", 972], ["under", 982], ["all", 988], ["conditions", 992], [".", 1002], ["No", 1004], ["impact", 1007], ["of", 1014], ["age", 1017], ["on", 1021], ["idarucizumab", 1024], ["pharmacokinetics", 1037], ["was", 1054], ["observed", 1058], [";", 1066], ["however", 1068], [",", 1075], ["subjects", 1077], ["with", 1086], ["mild", 1091], ["or", 1096], ["moderate", 1099], ["renal", 1108], ["impairment", 1114], ["demonstrated", 1125], ["increased", 1138], ["exposure", 1148], ["(", 1157], ["up", 1158], ["to", 1161], ["84", 1164], ["%", 1167], [")", 1168], [",", 1169], ["decreased", 1171], ["clearance", 1181], ["and", 1191], ["prolonged", 1195], ["(", 1205], ["by", 1206], ["up", 1209], ["to", 1212], ["49", 1215], ["%", 1218], [")", 1219], ["initial", 1221], ["half", 1229], ["-", 1233], ["life", 1234], ["of", 1239], ["idarucizumab", 1242], ["compared", 1255], ["with", 1264], ["healthy", 1269], ["middle", 1277], ["-", 1283], ["aged", 1284], ["subjects", 1289], [".", 1297], ["Impaired", 1299], ["renal", 1308], ["function", 1314], ["was", 1323], ["associated", 1327], ["with", 1338], ["increased", 1343], ["exposure", 1353], ["and", 1362], ["decreased", 1366], ["clearance", 1376], ["of", 1386], ["idarucizumab", 1389], [".", 1401], ["Idarucizumab", 1403], ["resulted", 1416], ["in", 1425], ["immediate", 1428], [",", 1437], ["complete", 1439], ["and", 1448], ["sustained", 1452], ["reversal", 1462], ["of", 1471], ["dabigatran", 1474], ["anticoagulant", 1485], ["activity", 1499], [",", 1507], ["and", 1509], ["was", 1513], ["safe", 1517], ["and", 1522], ["well", 1526], ["tolerated", 1531], ["in", 1541], ["middle", 1544], ["-", 1550], ["aged", 1551], [",", 1555], ["elderly", 1557], ["and", 1565], ["renally", 1569], ["impaired", 1577], ["volunteers", 1586], [".", 1596], ["The", 1598], ["results", 1602], ["support", 1610], ["the", 1618], ["clinical", 1622], ["use", 1631], ["of", 1635], ["a", 1638], ["5", 1640], ["g", 1642], ["dose", 1644], ["of", 1649], ["idarucizumab", 1652], [".", 1664], ["http://www.clinicaltrials.gov", 1666], [".", 1696], ["Unique", 1698], ["identifier", 1705], [":", 1715], ["NCT01955720", 1717], [".", 1728]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. Cardiac abnormalities, such as aortic root dilation have also been noted as well as several skeletal abnormalities. Its nosological status is unclear as it is hard to delineate SGS from similar disorders, such as Furlong, Marfan type II, Camurati-Engelmann and Loeys-Dietz syndromes. It has been suggested that these conditions represent a phenotypical spectrum associated with aberrant TGF-beta signalling. In support of this notion, we found a novel TGFBR2 missense mutation in a patient with features of SGS.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "9038f03f7233434d94806443d485149a", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[22, 22]], "char_spans": [[117, 132]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["a", 38], ["rare", 40], ["disorder", 45], ["characterized", 54], ["by", 68], ["a", 71], ["Marfan", 73], ["-", 79], ["like", 80], ["habitus", 85], [",", 92], ["mental", 94], ["retardation", 101], ["and", 113], ["craniosynostosis", 117], [".", 133], ["Cardiac", 135], ["abnormalities", 143], [",", 156], ["such", 158], ["as", 163], ["aortic", 166], ["root", 173], ["dilation", 178], ["have", 187], ["also", 192], ["been", 197], ["noted", 202], ["as", 208], ["well", 211], ["as", 216], ["several", 219], ["skeletal", 227], ["abnormalities", 236], [".", 249], ["Its", 251], ["nosological", 255], ["status", 267], ["is", 274], ["unclear", 277], ["as", 285], ["it", 288], ["is", 291], ["hard", 294], ["to", 299], ["delineate", 302], ["SGS", 312], ["from", 316], ["similar", 321], ["disorders", 329], [",", 338], ["such", 340], ["as", 345], ["Furlong", 348], [",", 355], ["Marfan", 357], ["type", 364], ["II", 369], [",", 371], ["Camurati", 373], ["-", 381], ["Engelmann", 382], ["and", 392], ["Loeys", 396], ["-", 401], ["Dietz", 402], ["syndromes", 408], [".", 417], ["It", 419], ["has", 422], ["been", 426], ["suggested", 431], ["that", 441], ["these", 446], ["conditions", 452], ["represent", 463], ["a", 473], ["phenotypical", 475], ["spectrum", 488], ["associated", 497], ["with", 508], ["aberrant", 513], ["TGF", 522], ["-", 525], ["beta", 526], ["signalling", 531], [".", 541], ["In", 543], ["support", 546], ["of", 554], ["this", 557], ["notion", 562], [",", 568], ["we", 570], ["found", 573], ["a", 579], ["novel", 581], ["TGFBR2", 587], ["missense", 594], ["mutation", 603], ["in", 612], ["a", 615], ["patient", 617], ["with", 625], ["features", 630], ["of", 639], ["SGS", 642], [".", 645]]}
{"context": "Universal surveillance upon patient admission is important in reducing the transmission of methicillin-resistant Staphylococcus aureus (MRSA) and associated disease in hospitals. High costs for the health care system in conjunction with MRSA have promoted the development of rapid screening methods to detect MRSA carriers. This study compared two real-time PCR methods, the BD GeneOhm MRSA assay (BDGO) and the Xpert MRSA assay, with broth-enriched culture to define their performance characteristics and rapidity in an area with low MRSA prevalence. In total, 414 swabs from the nose and 389 swabs from the groin from 425 patients were tested. Of those 425 patients, 378 had swabs from both the nose and groin in parallel. Two hundred thirty-one and 194 patients were randomly assigned to the BDGO group and the Xpert MRSA group, respectively. In general, sensitivity, specificity, and negative predictive value (NPV) were high for the BDGO (100%, 98.5%, and 100%, respectively) and the Xpert MRSA (100%, 98.2%, and 100%, respectively), irrespective of whether or not nasal and inguinal specimens were considered alone or combined. In contrast, the positive predictive value (PPV) was lower: before the resolution of discrepant results, the PPVs for nasal and inguinal specimens alone and combined were 87.5%, 86.7%, and 82.4% for the BDGO and 91.7%, 66.7%, and 92.9% for the Xpert MRSA, respectively. After the resolution of discrepant results, PPVs were 93.8%, 93.3% and 94.1% for the BDGO and 91.7%, 88.9% and 92.9% for the Xpert MRSA, respectively. With the BDGO, 4 of 16 carriers were each identified by nasal or inguinal swabs alone, whereas in the Xpert MRSA group, 4 of 13 carriers were exclusively identified by nasal swabs and 2 of 13 were identified by inguinal swabs alone. Both PCR methods showed no significant difference in the number of discrepant results (odds ratio, 0.70 [P = 0.789]), but specimens from wounds and other body sites (axilla, vagina, and throat) produced discrepancies more often than nasal and groin specimens (odds ratios, 4.724 [P = 0.058] and 12.163 [P < 0.001], respectively). The facts that no false-negative PCR results were detected and increased PPVs were found after the resolution of discrepant results point to PCR as the actual gold standard. Since both sensitivity and NPV were exceptionally high for PCR, backup cultures may, therefore, be unnecessary in an area with low prevalence and with a preemptive isolation strategy but may still be useful for PCR-positive specimens because of the lower PPV for both methods and the possibility of susceptibility testing. The median time for analysis, including extraction, hands-on time, and actual PCR was 2 h 20 min for the Xpert MRSA versus 5 h 40 min for the BDGO. Concerning reporting time, including administration and specimen collection, the Xpert MRSA was faster than the BDGO (7 h 50 min versus 17 h).", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2502a276bbc94f61908c215b2f64ddd4", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[544, 544], [47, 47], [91, 91], [149, 149], [189, 189], [275, 275], [566, 566], [36, 36], [71, 71], [311, 311], [337, 337], [18, 18], [63, 63]], "char_spans": [[2726, 2729], [309, 312], [535, 538], [820, 823], [995, 998], [1384, 1387], [2850, 2853], [237, 240], [418, 421], [1535, 1538], [1663, 1666], [136, 139], [386, 389]]}]}], "context_tokens": [["Universal", 0], ["surveillance", 10], ["upon", 23], ["patient", 28], ["admission", 36], ["is", 46], ["important", 49], ["in", 59], ["reducing", 62], ["the", 71], ["transmission", 75], ["of", 88], ["methicillin", 91], ["-", 102], ["resistant", 103], ["Staphylococcus", 113], ["aureus", 128], ["(", 135], ["MRSA", 136], [")", 140], ["and", 142], ["associated", 146], ["disease", 157], ["in", 165], ["hospitals", 168], [".", 177], ["High", 179], ["costs", 184], ["for", 190], ["the", 194], ["health", 198], ["care", 205], ["system", 210], ["in", 217], ["conjunction", 220], ["with", 232], ["MRSA", 237], ["have", 242], ["promoted", 247], ["the", 256], ["development", 260], ["of", 272], ["rapid", 275], ["screening", 281], ["methods", 291], ["to", 299], ["detect", 302], ["MRSA", 309], ["carriers", 314], [".", 322], ["This", 324], ["study", 329], ["compared", 335], ["two", 344], ["real", 348], ["-", 352], ["time", 353], ["PCR", 358], ["methods", 362], [",", 369], ["the", 371], ["BD", 375], ["GeneOhm", 378], ["MRSA", 386], ["assay", 391], ["(", 397], ["BDGO", 398], [")", 402], ["and", 404], ["the", 408], ["Xpert", 412], ["MRSA", 418], ["assay", 423], [",", 428], ["with", 430], ["broth", 435], ["-", 440], ["enriched", 441], ["culture", 450], ["to", 458], ["define", 461], ["their", 468], ["performance", 474], ["characteristics", 486], ["and", 502], ["rapidity", 506], ["in", 515], ["an", 518], ["area", 521], ["with", 526], ["low", 531], ["MRSA", 535], ["prevalence", 540], [".", 550], ["In", 552], ["total", 555], [",", 560], ["414", 562], ["swabs", 566], ["from", 572], ["the", 577], ["nose", 581], ["and", 586], ["389", 590], ["swabs", 594], ["from", 600], ["the", 605], ["groin", 609], ["from", 615], ["425", 620], ["patients", 624], ["were", 633], ["tested", 638], [".", 644], ["Of", 646], ["those", 649], ["425", 655], ["patients", 659], [",", 667], ["378", 669], ["had", 673], ["swabs", 677], ["from", 683], ["both", 688], ["the", 693], ["nose", 697], ["and", 702], ["groin", 706], ["in", 712], ["parallel", 715], [".", 723], ["Two", 725], ["hundred", 729], ["thirty", 737], ["-", 743], ["one", 744], ["and", 748], ["194", 752], ["patients", 756], ["were", 765], ["randomly", 770], ["assigned", 779], ["to", 788], ["the", 791], ["BDGO", 795], ["group", 800], ["and", 806], ["the", 810], ["Xpert", 814], ["MRSA", 820], ["group", 825], [",", 830], ["respectively", 832], [".", 844], ["In", 846], ["general", 849], [",", 856], ["sensitivity", 858], [",", 869], ["specificity", 871], [",", 882], ["and", 884], ["negative", 888], ["predictive", 897], ["value", 908], ["(", 914], ["NPV", 915], [")", 918], ["were", 920], ["high", 925], ["for", 930], ["the", 934], ["BDGO", 938], ["(", 943], ["100", 944], ["%", 947], [",", 948], ["98.5", 950], ["%", 954], [",", 955], ["and", 957], ["100", 961], ["%", 964], [",", 965], ["respectively", 967], [")", 979], ["and", 981], ["the", 985], ["Xpert", 989], ["MRSA", 995], ["(", 1000], ["100", 1001], ["%", 1004], [",", 1005], ["98.2", 1007], ["%", 1011], [",", 1012], ["and", 1014], ["100", 1018], ["%", 1021], [",", 1022], ["respectively", 1024], [")", 1036], [",", 1037], ["irrespective", 1039], ["of", 1052], ["whether", 1055], ["or", 1063], ["not", 1066], ["nasal", 1070], ["and", 1076], ["inguinal", 1080], ["specimens", 1089], ["were", 1099], ["considered", 1104], ["alone", 1115], ["or", 1121], ["combined", 1124], [".", 1132], ["In", 1134], ["contrast", 1137], [",", 1145], ["the", 1147], ["positive", 1151], ["predictive", 1160], ["value", 1171], ["(", 1177], ["PPV", 1178], [")", 1181], ["was", 1183], ["lower", 1187], [":", 1192], ["before", 1194], ["the", 1201], ["resolution", 1205], ["of", 1216], ["discrepant", 1219], ["results", 1230], [",", 1237], ["the", 1239], ["PPVs", 1243], ["for", 1248], ["nasal", 1252], ["and", 1258], ["inguinal", 1262], ["specimens", 1271], ["alone", 1281], ["and", 1287], ["combined", 1291], ["were", 1300], ["87.5", 1305], ["%", 1309], [",", 1310], ["86.7", 1312], ["%", 1316], [",", 1317], ["and", 1319], ["82.4", 1323], ["%", 1327], ["for", 1329], ["the", 1333], ["BDGO", 1337], ["and", 1342], ["91.7", 1346], ["%", 1350], [",", 1351], ["66.7", 1353], ["%", 1357], [",", 1358], ["and", 1360], ["92.9", 1364], ["%", 1368], ["for", 1370], ["the", 1374], ["Xpert", 1378], ["MRSA", 1384], [",", 1388], ["respectively", 1390], [".", 1402], ["After", 1404], ["the", 1410], ["resolution", 1414], ["of", 1425], ["discrepant", 1428], ["results", 1439], [",", 1446], ["PPVs", 1448], ["were", 1453], ["93.8", 1458], ["%", 1462], [",", 1463], ["93.3", 1465], ["%", 1469], ["and", 1471], ["94.1", 1475], ["%", 1479], ["for", 1481], ["the", 1485], ["BDGO", 1489], ["and", 1494], ["91.7", 1498], ["%", 1502], [",", 1503], ["88.9", 1505], ["%", 1509], ["and", 1511], ["92.9", 1515], ["%", 1519], ["for", 1521], ["the", 1525], ["Xpert", 1529], ["MRSA", 1535], [",", 1539], ["respectively", 1541], [".", 1553], ["With", 1555], ["the", 1560], ["BDGO", 1564], [",", 1568], ["4", 1570], ["of", 1572], ["16", 1575], ["carriers", 1578], ["were", 1587], ["each", 1592], ["identified", 1597], ["by", 1608], ["nasal", 1611], ["or", 1617], ["inguinal", 1620], ["swabs", 1629], ["alone", 1635], [",", 1640], ["whereas", 1642], ["in", 1650], ["the", 1653], ["Xpert", 1657], ["MRSA", 1663], ["group", 1668], [",", 1673], ["4", 1675], ["of", 1677], ["13", 1680], ["carriers", 1683], ["were", 1692], ["exclusively", 1697], ["identified", 1709], ["by", 1720], ["nasal", 1723], ["swabs", 1729], ["and", 1735], ["2", 1739], ["of", 1741], ["13", 1744], ["were", 1747], ["identified", 1752], ["by", 1763], ["inguinal", 1766], ["swabs", 1775], ["alone", 1781], [".", 1786], ["Both", 1788], ["PCR", 1793], ["methods", 1797], ["showed", 1805], ["no", 1812], ["significant", 1815], ["difference", 1827], ["in", 1838], ["the", 1841], ["number", 1845], ["of", 1852], ["discrepant", 1855], ["results", 1866], ["(", 1874], ["odds", 1875], ["ratio", 1880], [",", 1885], ["0.70", 1887], ["[", 1892], ["P", 1893], ["=", 1895], ["0.789", 1897], ["]", 1902], [")", 1903], [",", 1904], ["but", 1906], ["specimens", 1910], ["from", 1920], ["wounds", 1925], ["and", 1932], ["other", 1936], ["body", 1942], ["sites", 1947], ["(", 1953], ["axilla", 1954], [",", 1960], ["vagina", 1962], [",", 1968], ["and", 1970], ["throat", 1974], [")", 1980], ["produced", 1982], ["discrepancies", 1991], ["more", 2005], ["often", 2010], ["than", 2016], ["nasal", 2021], ["and", 2027], ["groin", 2031], ["specimens", 2037], ["(", 2047], ["odds", 2048], ["ratios", 2053], [",", 2059], ["4.724", 2061], ["[", 2067], ["P", 2068], ["=", 2070], ["0.058", 2072], ["]", 2077], ["and", 2079], ["12.163", 2083], ["[", 2090], ["P", 2091], ["<", 2093], ["0.001", 2095], ["]", 2100], [",", 2101], ["respectively", 2103], [")", 2115], [".", 2116], ["The", 2118], ["facts", 2122], ["that", 2128], ["no", 2133], ["false", 2136], ["-", 2141], ["negative", 2142], ["PCR", 2151], ["results", 2155], ["were", 2163], ["detected", 2168], ["and", 2177], ["increased", 2181], ["PPVs", 2191], ["were", 2196], ["found", 2201], ["after", 2207], ["the", 2213], ["resolution", 2217], ["of", 2228], ["discrepant", 2231], ["results", 2242], ["point", 2250], ["to", 2256], ["PCR", 2259], ["as", 2263], ["the", 2266], ["actual", 2270], ["gold", 2277], ["standard", 2282], [".", 2290], ["Since", 2292], ["both", 2298], ["sensitivity", 2303], ["and", 2315], ["NPV", 2319], ["were", 2323], ["exceptionally", 2328], ["high", 2342], ["for", 2347], ["PCR", 2351], [",", 2354], ["backup", 2356], ["cultures", 2363], ["may", 2372], [",", 2375], ["therefore", 2377], [",", 2386], ["be", 2388], ["unnecessary", 2391], ["in", 2403], ["an", 2406], ["area", 2409], ["with", 2414], ["low", 2419], ["prevalence", 2423], ["and", 2434], ["with", 2438], ["a", 2443], ["preemptive", 2445], ["isolation", 2456], ["strategy", 2466], ["but", 2475], ["may", 2479], ["still", 2483], ["be", 2489], ["useful", 2492], ["for", 2499], ["PCR", 2503], ["-", 2506], ["positive", 2507], ["specimens", 2516], ["because", 2526], ["of", 2534], ["the", 2537], ["lower", 2541], ["PPV", 2547], ["for", 2551], ["both", 2555], ["methods", 2560], ["and", 2568], ["the", 2572], ["possibility", 2576], ["of", 2588], ["susceptibility", 2591], ["testing", 2606], [".", 2613], ["The", 2615], ["median", 2619], ["time", 2626], ["for", 2631], ["analysis", 2635], [",", 2643], ["including", 2645], ["extraction", 2655], [",", 2665], ["hands", 2667], ["-", 2672], ["on", 2673], ["time", 2676], [",", 2680], ["and", 2682], ["actual", 2686], ["PCR", 2693], ["was", 2697], ["2", 2701], ["h", 2703], ["20", 2705], ["min", 2708], ["for", 2712], ["the", 2716], ["Xpert", 2720], ["MRSA", 2726], ["versus", 2731], ["5", 2738], ["h", 2740], ["40", 2742], ["min", 2745], ["for", 2749], ["the", 2753], ["BDGO", 2757], [".", 2761], ["Concerning", 2763], ["reporting", 2774], ["time", 2784], [",", 2788], ["including", 2790], ["administration", 2800], ["and", 2815], ["specimen", 2819], ["collection", 2828], [",", 2838], ["the", 2840], ["Xpert", 2844], ["MRSA", 2850], ["was", 2855], ["faster", 2859], ["than", 2866], ["the", 2871], ["BDGO", 2875], ["(", 2880], ["7", 2881], ["h", 2883], ["50", 2885], ["min", 2888], ["versus", 2892], ["17", 2899], ["h", 2902], [")", 2903], [".", 2904]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly-mental retardation complex caused by mutations in the Zinc Finger Homeobox 1 B gene (ZFHX1B). MWS has been reported in association with Hirschsprung disease (HSCR). MWS is sometimes difficult to diagnose clinically, especially when HSCR is absent. Thus, it is necessary to detect gene abnormalities at the molecular level. Here we report two Japanese girls with MWS, who showed a distinct facial phenotype, severe intellectual disability and epileptic seizures. Major congenital anomalies of the patients were very different. Patient 1 suffered from severe congenital heart disease, but did not show apparent HSCR. Patient 2 suffered from typical HSCR and underwent surgical treatment, but did not have congenital heart disease. According to the gene analysis using white blood cells, they had nonsense mutations in ZFHX1B, R695X and Q433X, respectively. In conclusion, molecular genetic analysis of ZFHX1B is important for a definite diagnosis of MWS which has a wide phenotypic spectrum of congenital anomalies.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "fec222083ea440d4a439d10720ceb994", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[28, 28], [155, 155], [170, 170]], "char_spans": [[146, 151], [877, 882], [961, 966]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["multiple", 33], ["congenital", 42], ["anomaly", 53], ["-", 60], ["mental", 61], ["retardation", 68], ["complex", 80], ["caused", 88], ["by", 95], ["mutations", 98], ["in", 108], ["the", 111], ["Zinc", 115], ["Finger", 120], ["Homeobox", 127], ["1", 136], ["B", 138], ["gene", 140], ["(", 145], ["ZFHX1B", 146], [")", 152], [".", 153], ["MWS", 155], ["has", 159], ["been", 163], ["reported", 168], ["in", 177], ["association", 180], ["with", 192], ["Hirschsprung", 197], ["disease", 210], ["(", 218], ["HSCR", 219], [")", 223], [".", 224], ["MWS", 226], ["is", 230], ["sometimes", 233], ["difficult", 243], ["to", 253], ["diagnose", 256], ["clinically", 265], [",", 275], ["especially", 277], ["when", 288], ["HSCR", 293], ["is", 298], ["absent", 301], [".", 307], ["Thus", 309], [",", 313], ["it", 315], ["is", 318], ["necessary", 321], ["to", 331], ["detect", 334], ["gene", 341], ["abnormalities", 346], ["at", 360], ["the", 363], ["molecular", 367], ["level", 377], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["two", 399], ["Japanese", 403], ["girls", 412], ["with", 418], ["MWS", 423], [",", 426], ["who", 428], ["showed", 432], ["a", 439], ["distinct", 441], ["facial", 450], ["phenotype", 457], [",", 466], ["severe", 468], ["intellectual", 475], ["disability", 488], ["and", 499], ["epileptic", 503], ["seizures", 513], [".", 521], ["Major", 523], ["congenital", 529], ["anomalies", 540], ["of", 550], ["the", 553], ["patients", 557], ["were", 566], ["very", 571], ["different", 576], [".", 585], ["Patient", 587], ["1", 595], ["suffered", 597], ["from", 606], ["severe", 611], ["congenital", 618], ["heart", 629], ["disease", 635], [",", 642], ["but", 644], ["did", 648], ["not", 652], ["show", 656], ["apparent", 661], ["HSCR", 670], [".", 674], ["Patient", 676], ["2", 684], ["suffered", 686], ["from", 695], ["typical", 700], ["HSCR", 708], ["and", 713], ["underwent", 717], ["surgical", 727], ["treatment", 736], [",", 745], ["but", 747], ["did", 751], ["not", 755], ["have", 759], ["congenital", 764], ["heart", 775], ["disease", 781], [".", 788], ["According", 790], ["to", 800], ["the", 803], ["gene", 807], ["analysis", 812], ["using", 821], ["white", 827], ["blood", 833], ["cells", 839], [",", 844], ["they", 846], ["had", 851], ["nonsense", 855], ["mutations", 864], ["in", 874], ["ZFHX1B", 877], [",", 883], ["R695X", 885], ["and", 891], ["Q433X", 895], [",", 900], ["respectively", 902], [".", 914], ["In", 916], ["conclusion", 919], [",", 929], ["molecular", 931], ["genetic", 941], ["analysis", 949], ["of", 958], ["ZFHX1B", 961], ["is", 968], ["important", 971], ["for", 981], ["a", 985], ["definite", 987], ["diagnosis", 996], ["of", 1006], ["MWS", 1009], ["which", 1013], ["has", 1019], ["a", 1023], ["wide", 1025], ["phenotypic", 1030], ["spectrum", 1041], ["of", 1050], ["congenital", 1053], ["anomalies", 1064], [".", 1073]]}
{"context": "Systemic autoinflammatory diseases are caused by mutations in genes that function in innate immunity. Here, we report an autoinflammatory disease caused by loss-of-function mutations in OTULIN (FAM105B), encoding a deubiquitinase with linear linkage specificity. We identified two missense and one frameshift mutations in one Pakistani and two Turkish families with four affected patients. Patients presented with neonatal-onset fever, neutrophilic dermatitis/panniculitis, and failure to thrive, but without obvious primary immunodeficiency. HEK293 cells transfected with mutated OTULIN had decreased enzyme activity relative to cells transfected with WT OTULIN, and showed a substantial defect in the linear deubiquitination of target molecules. Stimulated patients' fibroblasts and peripheral blood mononuclear cells showed evidence for increased signaling in the canonical NF-\u03baB pathway and accumulated linear ubiquitin aggregates. Levels of proinflammatory cytokines were significantly increased in the supernatants of stimulated primary cells and serum samples. This discovery adds to the emerging spectrum of human diseases caused by defects in the ubiquitin pathway and suggests a role for targeted cytokine therapies.", "qas": [{"question": "Which is the enzymatic activity of OTULIN?", "answers": ["deubiquitination"], "qid": "f85c2449871b49c598f41e1f233256be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["OTULIN", 35], ["?", 41]], "detected_answers": [{"text": "deubiquitination", "token_spans": [[114, 114]], "char_spans": [[710, 725]]}]}], "context_tokens": [["Systemic", 0], ["autoinflammatory", 9], ["diseases", 26], ["are", 35], ["caused", 39], ["by", 46], ["mutations", 49], ["in", 59], ["genes", 62], ["that", 68], ["function", 73], ["in", 82], ["innate", 85], ["immunity", 92], [".", 100], ["Here", 102], [",", 106], ["we", 108], ["report", 111], ["an", 118], ["autoinflammatory", 121], ["disease", 138], ["caused", 146], ["by", 153], ["loss", 156], ["-", 160], ["of", 161], ["-", 163], ["function", 164], ["mutations", 173], ["in", 183], ["OTULIN", 186], ["(", 193], ["FAM105B", 194], [")", 201], [",", 202], ["encoding", 204], ["a", 213], ["deubiquitinase", 215], ["with", 230], ["linear", 235], ["linkage", 242], ["specificity", 250], [".", 261], ["We", 263], ["identified", 266], ["two", 277], ["missense", 281], ["and", 290], ["one", 294], ["frameshift", 298], ["mutations", 309], ["in", 319], ["one", 322], ["Pakistani", 326], ["and", 336], ["two", 340], ["Turkish", 344], ["families", 352], ["with", 361], ["four", 366], ["affected", 371], ["patients", 380], [".", 388], ["Patients", 390], ["presented", 399], ["with", 409], ["neonatal", 414], ["-", 422], ["onset", 423], ["fever", 429], [",", 434], ["neutrophilic", 436], ["dermatitis", 449], ["/", 459], ["panniculitis", 460], [",", 472], ["and", 474], ["failure", 478], ["to", 486], ["thrive", 489], [",", 495], ["but", 497], ["without", 501], ["obvious", 509], ["primary", 517], ["immunodeficiency", 525], [".", 541], ["HEK293", 543], ["cells", 550], ["transfected", 556], ["with", 568], ["mutated", 573], ["OTULIN", 581], ["had", 588], ["decreased", 592], ["enzyme", 602], ["activity", 609], ["relative", 618], ["to", 627], ["cells", 630], ["transfected", 636], ["with", 648], ["WT", 653], ["OTULIN", 656], [",", 662], ["and", 664], ["showed", 668], ["a", 675], ["substantial", 677], ["defect", 689], ["in", 696], ["the", 699], ["linear", 703], ["deubiquitination", 710], ["of", 727], ["target", 730], ["molecules", 737], [".", 746], ["Stimulated", 748], ["patients", 759], ["'", 767], ["fibroblasts", 769], ["and", 781], ["peripheral", 785], ["blood", 796], ["mononuclear", 802], ["cells", 814], ["showed", 820], ["evidence", 827], ["for", 836], ["increased", 840], ["signaling", 850], ["in", 860], ["the", 863], ["canonical", 867], ["NF", 877], ["-", 879], ["\u03baB", 880], ["pathway", 883], ["and", 891], ["accumulated", 895], ["linear", 907], ["ubiquitin", 914], ["aggregates", 924], [".", 934], ["Levels", 936], ["of", 943], ["proinflammatory", 946], ["cytokines", 962], ["were", 972], ["significantly", 977], ["increased", 991], ["in", 1001], ["the", 1004], ["supernatants", 1008], ["of", 1021], ["stimulated", 1024], ["primary", 1035], ["cells", 1043], ["and", 1049], ["serum", 1053], ["samples", 1059], [".", 1066], ["This", 1068], ["discovery", 1073], ["adds", 1083], ["to", 1088], ["the", 1091], ["emerging", 1095], ["spectrum", 1104], ["of", 1113], ["human", 1116], ["diseases", 1122], ["caused", 1131], ["by", 1138], ["defects", 1141], ["in", 1149], ["the", 1152], ["ubiquitin", 1156], ["pathway", 1166], ["and", 1174], ["suggests", 1178], ["a", 1187], ["role", 1189], ["for", 1194], ["targeted", 1198], ["cytokine", 1207], ["therapies", 1216], [".", 1225]]}
{"context": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "2b04e73544f7459d9232316ec0e13a4a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[57, 83]]}]}], "context_tokens": [["Nivolumab", 0], ["was", 10], ["developed", 14], ["as", 24], ["a", 27], ["monoclonal", 29], ["antibody", 40], ["against", 49], ["programmed", 57], ["death", 68], ["receptor-1", 74], [",", 84], ["an", 86], ["immune", 89], ["checkpoint", 96], ["inhibitor", 107], ["which", 117], ["negatively", 123], ["regulates", 134], ["T", 144], ["-", 145], ["cell", 146], ["proliferation", 151], ["and", 165], ["activation", 169], [".", 179], ["Intravenous", 181], ["administration", 193], ["of", 208], ["nivolumab", 211], ["was", 221], ["approved", 225], ["for", 234], ["the", 238], ["treatment", 242], ["of", 252], ["unresectable", 255], ["malignant", 268], ["melanoma", 278], ["in", 287], ["2014", 290], ["in", 295], ["Japan", 298], [".", 303], ["When", 305], ["advanced", 310], ["melanoma", 319], ["patients", 328], ["were", 337], ["treated", 342], ["with", 350], ["nivolumab", 355], [",", 364], ["median", 366], ["overall", 373], ["survival", 381], ["became", 390], ["longer", 397], [".", 403], ["Overall", 405], ["survival", 413], ["rate", 422], ["was", 427], ["significantly", 431], ["better", 445], ["in", 452], ["nivolumab", 455], ["-", 464], ["treated", 465], ["melanoma", 473], ["patients", 482], ["than", 491], ["dacarbazine", 496], ["-", 507], ["treated", 508], ["melanoma", 516], ["patients", 525], [".", 533], ["Nivolumab", 535], ["had", 545], ["an", 549], ["acceptable", 552], ["long", 563], ["-", 567], ["term", 568], ["tolerability", 573], ["profile", 586], [",", 593], ["with", 595], ["22", 600], ["%", 602], ["of", 604], ["patients", 607], ["experiencing", 616], ["grade", 629], ["3", 635], ["or", 637], ["4", 640], ["adverse", 642], ["events", 650], ["related", 657], ["to", 665], ["the", 668], ["drug", 672], [".", 676], ["Therefore", 678], [",", 687], ["nivolumab", 689], ["can", 699], ["become", 703], ["an", 710], ["alternative", 713], ["therapy", 725], ["for", 733], ["advanced", 737], ["malignant", 746], ["melanoma", 756], [".", 764]]}
{"context": "In plant, primary transcripts (pri-miRNAs) transcribed from miRNA genes by RNA polymerase II are first processed into stem-loop pre-miRNAs and further chopped into \u223c21\u2009nt long miRNAs by RNase III-like enzyme DCL1. SERRATE (SE) protein is an essential component for miRNA processing by assisting DCL1 for accurate cleavage. Here we report the crystal structure of Arabidopsis SE core (residues 194-543) at 2.7\u2009\u00c5. SE core adopts the 'walking man-like' topology with N-terminal \u03b1 helices, C-terminal non-canonical zinc-finger domain and novel Middle domain resembling the leading leg, the lagging leg and the body, respectively. Pull-down assay shows that SE core provides the platform for HYL1 and DCL1 binding, whereas in vitro RNA binding and in vivo mutant rescue experiments suggest that the non-canonical zinc-finger domain coupled with C-terminal tail binds miRNA precursors. SE presumably works as a scaffold-like protein capable of binding both protein and RNA to guide the positioning of miRNA precursor toward DCL1 catalytic site within miRNA processing machinery in plant.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "1d7bdd75c990481ca677c46e2eb7a4db", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[15, 17]], "char_spans": [[75, 91]]}]}], "context_tokens": [["In", 0], ["plant", 3], [",", 8], ["primary", 10], ["transcripts", 18], ["(", 30], ["pri", 31], ["-", 34], ["miRNAs", 35], [")", 41], ["transcribed", 43], ["from", 55], ["miRNA", 60], ["genes", 66], ["by", 72], ["RNA", 75], ["polymerase", 79], ["II", 90], ["are", 93], ["first", 97], ["processed", 103], ["into", 113], ["stem", 118], ["-", 122], ["loop", 123], ["pre", 128], ["-", 131], ["miRNAs", 132], ["and", 139], ["further", 143], ["chopped", 151], ["into", 159], ["\u223c21", 164], ["nt", 168], ["long", 171], ["miRNAs", 176], ["by", 183], ["RNase", 186], ["III", 192], ["-", 195], ["like", 196], ["enzyme", 201], ["DCL1", 208], [".", 212], ["SERRATE", 214], ["(", 222], ["SE", 223], [")", 225], ["protein", 227], ["is", 235], ["an", 238], ["essential", 241], ["component", 251], ["for", 261], ["miRNA", 265], ["processing", 271], ["by", 282], ["assisting", 285], ["DCL1", 295], ["for", 300], ["accurate", 304], ["cleavage", 313], [".", 321], ["Here", 323], ["we", 328], ["report", 331], ["the", 338], ["crystal", 342], ["structure", 350], ["of", 360], ["Arabidopsis", 363], ["SE", 375], ["core", 378], ["(", 383], ["residues", 384], ["194", 393], ["-", 396], ["543", 397], [")", 400], ["at", 402], ["2.7", 405], ["\u00c5.", 409], ["SE", 412], ["core", 415], ["adopts", 420], ["the", 427], ["'", 431], ["walking", 432], ["man", 440], ["-", 443], ["like", 444], ["'", 448], ["topology", 450], ["with", 459], ["N", 464], ["-", 465], ["terminal", 466], ["\u03b1", 475], ["helices", 477], [",", 484], ["C", 486], ["-", 487], ["terminal", 488], ["non", 497], ["-", 500], ["canonical", 501], ["zinc", 511], ["-", 515], ["finger", 516], ["domain", 523], ["and", 530], ["novel", 534], ["Middle", 540], ["domain", 547], ["resembling", 554], ["the", 565], ["leading", 569], ["leg", 577], [",", 580], ["the", 582], ["lagging", 586], ["leg", 594], ["and", 598], ["the", 602], ["body", 606], [",", 610], ["respectively", 612], [".", 624], ["Pull", 626], ["-", 630], ["down", 631], ["assay", 636], ["shows", 642], ["that", 648], ["SE", 653], ["core", 656], ["provides", 661], ["the", 670], ["platform", 674], ["for", 683], ["HYL1", 687], ["and", 692], ["DCL1", 696], ["binding", 701], [",", 708], ["whereas", 710], ["in", 718], ["vitro", 721], ["RNA", 727], ["binding", 731], ["and", 739], ["in", 743], ["vivo", 746], ["mutant", 751], ["rescue", 758], ["experiments", 765], ["suggest", 777], ["that", 785], ["the", 790], ["non", 794], ["-", 797], ["canonical", 798], ["zinc", 808], ["-", 812], ["finger", 813], ["domain", 820], ["coupled", 827], ["with", 835], ["C", 840], ["-", 841], ["terminal", 842], ["tail", 851], ["binds", 856], ["miRNA", 862], ["precursors", 868], [".", 878], ["SE", 880], ["presumably", 883], ["works", 894], ["as", 900], ["a", 903], ["scaffold", 905], ["-", 913], ["like", 914], ["protein", 919], ["capable", 927], ["of", 935], ["binding", 938], ["both", 946], ["protein", 951], ["and", 959], ["RNA", 963], ["to", 967], ["guide", 970], ["the", 976], ["positioning", 980], ["of", 992], ["miRNA", 995], ["precursor", 1001], ["toward", 1011], ["DCL1", 1018], ["catalytic", 1023], ["site", 1033], ["within", 1038], ["miRNA", 1045], ["processing", 1051], ["machinery", 1062], ["in", 1072], ["plant", 1075], [".", 1080]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "N6-methyladenosine (m6A) is a common modification of mRNA with potential roles in fine-tuning the RNA life cycle. Here, we identify a dense network of proteins interacting with METTL3, a component of the methyltransferase complex, and show that three of them (WTAP, METTL14, and KIAA1429) are required for methylation. Monitoring m6A levels upon WTAP depletion allowed the definition of accurate and near single-nucleotide resolution methylation maps and their classification into WTAP-dependent and -independent sites. WTAP-dependent sites are located at internal positions in transcripts, topologically static across a variety of systems we surveyed, and inversely correlated with mRNA stability, consistent with a role in establishing \"basal\" degradation rates. WTAP-independent sites form at the first transcribed base as part of the cap structure and are present at thousands of sites, forming a previously unappreciated layer of transcriptome complexity. Our data shed light on the proteomic and transcriptional underpinnings of this RNA modification.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "c3596cdec1b2483b889a950b0ae18039", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[117, 118]], "char_spans": [[683, 696]]}]}], "context_tokens": [["N6-methyladenosine", 0], ["(", 19], ["m6A", 20], [")", 23], ["is", 25], ["a", 28], ["common", 30], ["modification", 37], ["of", 50], ["mRNA", 53], ["with", 58], ["potential", 63], ["roles", 73], ["in", 79], ["fine", 82], ["-", 86], ["tuning", 87], ["the", 94], ["RNA", 98], ["life", 102], ["cycle", 107], [".", 112], ["Here", 114], [",", 118], ["we", 120], ["identify", 123], ["a", 132], ["dense", 134], ["network", 140], ["of", 148], ["proteins", 151], ["interacting", 160], ["with", 172], ["METTL3", 177], [",", 183], ["a", 185], ["component", 187], ["of", 197], ["the", 200], ["methyltransferase", 204], ["complex", 222], [",", 229], ["and", 231], ["show", 235], ["that", 240], ["three", 245], ["of", 251], ["them", 254], ["(", 259], ["WTAP", 260], [",", 264], ["METTL14", 266], [",", 273], ["and", 275], ["KIAA1429", 279], [")", 287], ["are", 289], ["required", 293], ["for", 302], ["methylation", 306], [".", 317], ["Monitoring", 319], ["m6A", 330], ["levels", 334], ["upon", 341], ["WTAP", 346], ["depletion", 351], ["allowed", 361], ["the", 369], ["definition", 373], ["of", 384], ["accurate", 387], ["and", 396], ["near", 400], ["single", 405], ["-", 411], ["nucleotide", 412], ["resolution", 423], ["methylation", 434], ["maps", 446], ["and", 451], ["their", 455], ["classification", 461], ["into", 476], ["WTAP", 481], ["-", 485], ["dependent", 486], ["and", 496], ["-independent", 500], ["sites", 513], [".", 518], ["WTAP", 520], ["-", 524], ["dependent", 525], ["sites", 535], ["are", 541], ["located", 545], ["at", 553], ["internal", 556], ["positions", 565], ["in", 575], ["transcripts", 578], [",", 589], ["topologically", 591], ["static", 605], ["across", 612], ["a", 619], ["variety", 621], ["of", 629], ["systems", 632], ["we", 640], ["surveyed", 643], [",", 651], ["and", 653], ["inversely", 657], ["correlated", 667], ["with", 678], ["mRNA", 683], ["stability", 688], [",", 697], ["consistent", 699], ["with", 710], ["a", 715], ["role", 717], ["in", 722], ["establishing", 725], ["\"", 738], ["basal", 739], ["\"", 744], ["degradation", 746], ["rates", 758], [".", 763], ["WTAP", 765], ["-", 769], ["independent", 770], ["sites", 782], ["form", 788], ["at", 793], ["the", 796], ["first", 800], ["transcribed", 806], ["base", 818], ["as", 823], ["part", 826], ["of", 831], ["the", 834], ["cap", 838], ["structure", 842], ["and", 852], ["are", 856], ["present", 860], ["at", 868], ["thousands", 871], ["of", 881], ["sites", 884], [",", 889], ["forming", 891], ["a", 899], ["previously", 901], ["unappreciated", 912], ["layer", 926], ["of", 932], ["transcriptome", 935], ["complexity", 949], [".", 959], ["Our", 961], ["data", 965], ["shed", 970], ["light", 975], ["on", 981], ["the", 984], ["proteomic", 988], ["and", 998], ["transcriptional", 1002], ["underpinnings", 1018], ["of", 1032], ["this", 1035], ["RNA", 1040], ["modification", 1044], [".", 1056]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most common genetic disease affecting the nervous system. Patients typically develop many tumors over their lifetime, leading to increased morbidity and mortality. The NF1 gene, mutated in NF1, is also commonly mutated in sporadic glioblastoma multiforme (GBM). Because both NF1 and GBM are currently incurable, new therapeutic approaches are clearly needed. Natural products represent an opportunity to develop new therapies, as they have been evolutionarily selected to play targeted roles in organisms. Schweinfurthin A is a prenylated stilbene natural product that has previously shown specific inhibitory activity against brain and hematopoietic tumor lines. We show that patient-derived GBM and NF1 malignant peripheral nerve sheath tumor (MPNST) lines, as well as tumor lines derived from the Nf1-/+;Trp53-/+ (NPcis) mouse model of astrocytoma and MPNST are highly sensitive to inhibition by schweinfurthin A and its synthetic analogs. In contrast, primary mouse astrocytes are resistant to the growth inhibitory effects of schweinfurthin A, suggesting that schweinfurthin A may act specifically on tumor cells. Stable transfection of the GTPase-activating protein related domain of Nf1 into Nf1-/-;Trp53-/- astrocytoma cells confers resistance to schweinfurthin A. In addition, the profound effect of schweinfurthin A on dynamic reorganization of the actin cytoskeleton led us to discover that schweinfurthin A inhibits growth factor-stimulated Rho signaling. In summary, we have identified a class of small molecules that specifically inhibit growth of cells from both central and peripheral nervous system tumors and seem to act on NF1-deficient cells through cytoskeletal reorganization correlating to changes in Rho signaling.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "0d78800e67c54fad88dcb0110c4ca8f4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[203, 203], [122, 122], [4, 4], [55, 55], [39, 39], [34, 34]], "char_spans": [[1228, 1230], [739, 741], [26, 28], [313, 315], [227, 229], [206, 208]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["genetic", 50], ["disease", 58], ["affecting", 66], ["the", 76], ["nervous", 80], ["system", 88], [".", 94], ["Patients", 96], ["typically", 105], ["develop", 115], ["many", 123], ["tumors", 128], ["over", 135], ["their", 140], ["lifetime", 146], [",", 154], ["leading", 156], ["to", 164], ["increased", 167], ["morbidity", 177], ["and", 187], ["mortality", 191], [".", 200], ["The", 202], ["NF1", 206], ["gene", 210], [",", 214], ["mutated", 216], ["in", 224], ["NF1", 227], [",", 230], ["is", 232], ["also", 235], ["commonly", 240], ["mutated", 249], ["in", 257], ["sporadic", 260], ["glioblastoma", 269], ["multiforme", 282], ["(", 293], ["GBM", 294], [")", 297], [".", 298], ["Because", 300], ["both", 308], ["NF1", 313], ["and", 317], ["GBM", 321], ["are", 325], ["currently", 329], ["incurable", 339], [",", 348], ["new", 350], ["therapeutic", 354], ["approaches", 366], ["are", 377], ["clearly", 381], ["needed", 389], [".", 395], ["Natural", 397], ["products", 405], ["represent", 414], ["an", 424], ["opportunity", 427], ["to", 439], ["develop", 442], ["new", 450], ["therapies", 454], [",", 463], ["as", 465], ["they", 468], ["have", 473], ["been", 478], ["evolutionarily", 483], ["selected", 498], ["to", 507], ["play", 510], ["targeted", 515], ["roles", 524], ["in", 530], ["organisms", 533], [".", 542], ["Schweinfurthin", 544], ["A", 559], ["is", 561], ["a", 564], ["prenylated", 566], ["stilbene", 577], ["natural", 586], ["product", 594], ["that", 602], ["has", 607], ["previously", 611], ["shown", 622], ["specific", 628], ["inhibitory", 637], ["activity", 648], ["against", 657], ["brain", 665], ["and", 671], ["hematopoietic", 675], ["tumor", 689], ["lines", 695], [".", 700], ["We", 702], ["show", 705], ["that", 710], ["patient", 715], ["-", 722], ["derived", 723], ["GBM", 731], ["and", 735], ["NF1", 739], ["malignant", 743], ["peripheral", 753], ["nerve", 764], ["sheath", 770], ["tumor", 777], ["(", 783], ["MPNST", 784], [")", 789], ["lines", 791], [",", 796], ["as", 798], ["well", 801], ["as", 806], ["tumor", 809], ["lines", 815], ["derived", 821], ["from", 829], ["the", 834], ["Nf1-/+;Trp53-/+", 838], ["(", 854], ["NPcis", 855], [")", 860], ["mouse", 862], ["model", 868], ["of", 874], ["astrocytoma", 877], ["and", 889], ["MPNST", 893], ["are", 899], ["highly", 903], ["sensitive", 910], ["to", 920], ["inhibition", 923], ["by", 934], ["schweinfurthin", 937], ["A", 952], ["and", 954], ["its", 958], ["synthetic", 962], ["analogs", 972], [".", 979], ["In", 981], ["contrast", 984], [",", 992], ["primary", 994], ["mouse", 1002], ["astrocytes", 1008], ["are", 1019], ["resistant", 1023], ["to", 1033], ["the", 1036], ["growth", 1040], ["inhibitory", 1047], ["effects", 1058], ["of", 1066], ["schweinfurthin", 1069], ["A", 1084], [",", 1085], ["suggesting", 1087], ["that", 1098], ["schweinfurthin", 1103], ["A", 1118], ["may", 1120], ["act", 1124], ["specifically", 1128], ["on", 1141], ["tumor", 1144], ["cells", 1150], [".", 1155], ["Stable", 1157], ["transfection", 1164], ["of", 1177], ["the", 1180], ["GTPase", 1184], ["-", 1190], ["activating", 1191], ["protein", 1202], ["related", 1210], ["domain", 1218], ["of", 1225], ["Nf1", 1228], ["into", 1232], ["Nf1-/-;Trp53-/-", 1237], ["astrocytoma", 1253], ["cells", 1265], ["confers", 1271], ["resistance", 1279], ["to", 1290], ["schweinfurthin", 1293], ["A.", 1308], ["In", 1311], ["addition", 1314], [",", 1322], ["the", 1324], ["profound", 1328], ["effect", 1337], ["of", 1344], ["schweinfurthin", 1347], ["A", 1362], ["on", 1364], ["dynamic", 1367], ["reorganization", 1375], ["of", 1390], ["the", 1393], ["actin", 1397], ["cytoskeleton", 1403], ["led", 1416], ["us", 1420], ["to", 1423], ["discover", 1426], ["that", 1435], ["schweinfurthin", 1440], ["A", 1455], ["inhibits", 1457], ["growth", 1466], ["factor", 1473], ["-", 1479], ["stimulated", 1480], ["Rho", 1491], ["signaling", 1495], [".", 1504], ["In", 1506], ["summary", 1509], [",", 1516], ["we", 1518], ["have", 1521], ["identified", 1526], ["a", 1537], ["class", 1539], ["of", 1545], ["small", 1548], ["molecules", 1554], ["that", 1564], ["specifically", 1569], ["inhibit", 1582], ["growth", 1590], ["of", 1597], ["cells", 1600], ["from", 1606], ["both", 1611], ["central", 1616], ["and", 1624], ["peripheral", 1628], ["nervous", 1639], ["system", 1647], ["tumors", 1654], ["and", 1661], ["seem", 1665], ["to", 1670], ["act", 1673], ["on", 1677], ["NF1-deficient", 1680], ["cells", 1694], ["through", 1700], ["cytoskeletal", 1708], ["reorganization", 1721], ["correlating", 1736], ["to", 1748], ["changes", 1751], ["in", 1759], ["Rho", 1762], ["signaling", 1766], [".", 1775]]}
{"context": "The pathogenesis of restless legs syndrome (RLS) is unknown. Although iron deficiency anemia (IDA) is related with RLS, the mechanism of this relationship is still unknown. Therefore, we decided to examine some neurophysiological parameters that reflect the function of brainstem, spinal cord and peripheral nervous system. 34 patients diagnosed with IDA at the hematology department were questioned with a structured battery for RLS and additional symptoms. Of those, 14 patients had symptoms of RLS, while remaining 20 had no signs of this disorder. In both groups, electrophysiological examination including motor and sensory nerve conduction, F-responses, H-reflex, blink-reflex, and mixed nerve silent periods was performed. Neurological examination of all patients was normal. The two groups were identical for age and sex, and the difference between both groups concerning motor and sensory nerve conduction, F-wave, H-reflex, blink-reflex, and mixed nerve silent periods was insignificant. Results suggest that IDA does not cause electrophysiological changes in the peripheral nerves, spinal cord and brainstem, and therefore, measurement of these parameters in IDA patients does not seem effective for the confirmation of RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "c11e38b5379143f9895440d3ed5f0ff2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[13, 13]], "char_spans": [[70, 73]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["restless", 20], ["legs", 29], ["syndrome", 34], ["(", 43], ["RLS", 44], [")", 47], ["is", 49], ["unknown", 52], [".", 59], ["Although", 61], ["iron", 70], ["deficiency", 75], ["anemia", 86], ["(", 93], ["IDA", 94], [")", 97], ["is", 99], ["related", 102], ["with", 110], ["RLS", 115], [",", 118], ["the", 120], ["mechanism", 124], ["of", 134], ["this", 137], ["relationship", 142], ["is", 155], ["still", 158], ["unknown", 164], [".", 171], ["Therefore", 173], [",", 182], ["we", 184], ["decided", 187], ["to", 195], ["examine", 198], ["some", 206], ["neurophysiological", 211], ["parameters", 230], ["that", 241], ["reflect", 246], ["the", 254], ["function", 258], ["of", 267], ["brainstem", 270], [",", 279], ["spinal", 281], ["cord", 288], ["and", 293], ["peripheral", 297], ["nervous", 308], ["system", 316], [".", 322], ["34", 324], ["patients", 327], ["diagnosed", 336], ["with", 346], ["IDA", 351], ["at", 355], ["the", 358], ["hematology", 362], ["department", 373], ["were", 384], ["questioned", 389], ["with", 400], ["a", 405], ["structured", 407], ["battery", 418], ["for", 426], ["RLS", 430], ["and", 434], ["additional", 438], ["symptoms", 449], [".", 457], ["Of", 459], ["those", 462], [",", 467], ["14", 469], ["patients", 472], ["had", 481], ["symptoms", 485], ["of", 494], ["RLS", 497], [",", 500], ["while", 502], ["remaining", 508], ["20", 518], ["had", 521], ["no", 525], ["signs", 528], ["of", 534], ["this", 537], ["disorder", 542], [".", 550], ["In", 552], ["both", 555], ["groups", 560], [",", 566], ["electrophysiological", 568], ["examination", 589], ["including", 601], ["motor", 611], ["and", 617], ["sensory", 621], ["nerve", 629], ["conduction", 635], [",", 645], ["F", 647], ["-", 648], ["responses", 649], [",", 658], ["H", 660], ["-", 661], ["reflex", 662], [",", 668], ["blink", 670], ["-", 675], ["reflex", 676], [",", 682], ["and", 684], ["mixed", 688], ["nerve", 694], ["silent", 700], ["periods", 707], ["was", 715], ["performed", 719], [".", 728], ["Neurological", 730], ["examination", 743], ["of", 755], ["all", 758], ["patients", 762], ["was", 771], ["normal", 775], [".", 781], ["The", 783], ["two", 787], ["groups", 791], ["were", 798], ["identical", 803], ["for", 813], ["age", 817], ["and", 821], ["sex", 825], [",", 828], ["and", 830], ["the", 834], ["difference", 838], ["between", 849], ["both", 857], ["groups", 862], ["concerning", 869], ["motor", 880], ["and", 886], ["sensory", 890], ["nerve", 898], ["conduction", 904], [",", 914], ["F", 916], ["-", 917], ["wave", 918], [",", 922], ["H", 924], ["-", 925], ["reflex", 926], [",", 932], ["blink", 934], ["-", 939], ["reflex", 940], [",", 946], ["and", 948], ["mixed", 952], ["nerve", 958], ["silent", 964], ["periods", 971], ["was", 979], ["insignificant", 983], [".", 996], ["Results", 998], ["suggest", 1006], ["that", 1014], ["IDA", 1019], ["does", 1023], ["not", 1028], ["cause", 1032], ["electrophysiological", 1038], ["changes", 1059], ["in", 1067], ["the", 1070], ["peripheral", 1074], ["nerves", 1085], [",", 1091], ["spinal", 1093], ["cord", 1100], ["and", 1105], ["brainstem", 1109], [",", 1118], ["and", 1120], ["therefore", 1124], [",", 1133], ["measurement", 1135], ["of", 1147], ["these", 1150], ["parameters", 1156], ["in", 1167], ["IDA", 1170], ["patients", 1174], ["does", 1183], ["not", 1188], ["seem", 1192], ["effective", 1197], ["for", 1207], ["the", 1211], ["confirmation", 1215], ["of", 1228], ["RLS", 1231], [".", 1234]]}
{"context": "Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "631900f5ead84eacaf274c45701f595a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[27, 29]], "char_spans": [[172, 178]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI", 19], ["571", 23], [";", 26], ["Gleevec", 28], [";", 35], ["Novartis", 37], ["Pharmaceuticals", 46], [",", 61], ["Basel", 63], [",", 68], ["Switzerland", 70], [")", 81], ["is", 83], ["an", 86], ["orally", 89], ["available", 96], ["tyrosine", 106], ["kinase", 115], ["inhibitor", 122], ["that", 132], ["targets", 137], ["a", 145], ["constitutively", 147], ["activated", 162], ["BCR", 172], ["-", 175], ["ABL", 176], ["tyrosine", 180], ["kinase", 189], ["with", 196], ["additional", 201], ["inhibitory", 212], ["effects", 223], ["on", 231], ["platelet", 234], ["derived", 243], ["growth", 251], ["factor", 258], ["(", 265], ["PDGF", 266], [")", 270], ["receptors", 272], ["alpha", 282], ["and", 288], ["beta", 292], [",", 296], ["and", 298], ["KIT", 302], [".", 305], ["It", 307], ["has", 310], ["revolutionized", 314], ["the", 329], ["treatment", 333], ["of", 343], ["adult", 346], ["and", 352], ["pediatric", 356], ["patients", 366], ["with", 375], ["Philadelphia", 380], ["chromosome", 393], ["positive", 404], ["chronic", 413], ["myelogenous", 421], ["leukemia", 433], ["(", 442], ["CML", 443], [")", 446], ["and", 448], ["is", 452], ["also", 455], ["FDA", 460], ["-", 463], ["approved", 464], ["for", 473], ["KIT", 477], ["-", 480], ["positive", 481], ["advanced", 490], ["gastrointestinal", 499], ["tumor", 516], ["(", 522], ["GIST", 523], [")", 527], ["and", 529], ["dermatofibrosarcoma", 533], ["protuberans", 553], [".", 564], ["A", 566], ["wide", 568], ["spectrum", 573], ["of", 582], ["dermatologic", 585], ["toxicities", 598], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["this", 634], ["agent", 639], [",", 644], ["among", 646], ["which", 652], ["a", 658], ["maculopapular", 660], ["rash", 674], ["is", 679], ["the", 682], ["most", 686], ["common", 691], ["event", 698], [".", 703], ["In", 705], ["addition", 708], [",", 716], ["a", 718], ["variety", 720], ["of", 728], ["pigmentary", 731], ["abnormalities", 742], ["of", 756], ["the", 759], ["skin", 763], ["and", 768], ["mucosal", 772], ["surfaces", 780], ["have", 789], ["been", 794], ["reported", 799], [".", 807], ["Hypopigmentation", 809], ["is", 826], ["a", 829], ["well", 831], ["-", 835], ["recognized", 836], ["adverse", 847], ["effect", 855], [".", 861], ["In", 863], ["contrast", 866], [",", 874], ["paradoxical", 876], ["hyperpigmentation", 888], ["has", 906], ["only", 910], ["rarely", 915], ["been", 922], ["documented", 927], [".", 937], ["In", 939], ["this", 942], ["case", 947], ["report", 952], ["we", 959], ["describe", 962], ["imatinib", 971], ["-", 979], ["induced", 980], ["cutaneous", 988], ["hyperpigmentation", 998], ["and", 1016], ["graying", 1020], ["of", 1028], ["hair", 1031], ["occurring", 1036], ["in", 1046], ["the", 1049], ["same", 1053], ["patient", 1058], ["with", 1066], ["dermatofibrosarcoma", 1071], ["protuberans", 1091], ["treated", 1103], ["with", 1111], ["imatinib", 1116], [".", 1124]]}
{"context": "The natural phytoalexin resveratrol, found in grapes and red wine, recently rose to public fame for its positive effects on longevity in yeasts, worms and flies. Resveratrol anti-cancer and anti-inflammatory in vitro action on mammalian cell cultures also suggest a possible positive effect on human health and life-expectancy. To study the effects of resveratrol on vertebrate aging is obviously a particularly relevant question. We have studied resveratrol effects in a very short-lived vertebrate: the annual fish Nothobranchius furzeri. Resveratrol treatment prolonged lifespan and delayed the onset of age-related dysfunctions in this fish. This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. Moreover, being related to stickleback (Gasterosteus aculeatus) the \"pufferfishes\" Takifugu and Tetraodon, and even more closely related to medaka (Oryzias latipes), it can greatly beneficiate from the recent development of genomic resources for these fish models and in the future become a complete model system for the aging research community.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "28273676388a4bd8b10c28cc78703649", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[212, 213]], "char_spans": [[1219, 1232]]}]}], "context_tokens": [["The", 0], ["natural", 4], ["phytoalexin", 12], ["resveratrol", 24], [",", 35], ["found", 37], ["in", 43], ["grapes", 46], ["and", 53], ["red", 57], ["wine", 61], [",", 65], ["recently", 67], ["rose", 76], ["to", 81], ["public", 84], ["fame", 91], ["for", 96], ["its", 100], ["positive", 104], ["effects", 113], ["on", 121], ["longevity", 124], ["in", 134], ["yeasts", 137], [",", 143], ["worms", 145], ["and", 151], ["flies", 155], [".", 160], ["Resveratrol", 162], ["anti", 174], ["-", 178], ["cancer", 179], ["and", 186], ["anti", 190], ["-", 194], ["inflammatory", 195], ["in", 208], ["vitro", 211], ["action", 217], ["on", 224], ["mammalian", 227], ["cell", 237], ["cultures", 242], ["also", 251], ["suggest", 256], ["a", 264], ["possible", 266], ["positive", 275], ["effect", 284], ["on", 291], ["human", 294], ["health", 300], ["and", 307], ["life", 311], ["-", 315], ["expectancy", 316], [".", 326], ["To", 328], ["study", 331], ["the", 337], ["effects", 341], ["of", 349], ["resveratrol", 352], ["on", 364], ["vertebrate", 367], ["aging", 378], ["is", 384], ["obviously", 387], ["a", 397], ["particularly", 399], ["relevant", 412], ["question", 421], [".", 429], ["We", 431], ["have", 434], ["studied", 439], ["resveratrol", 447], ["effects", 459], ["in", 467], ["a", 470], ["very", 472], ["short", 477], ["-", 482], ["lived", 483], ["vertebrate", 489], [":", 499], ["the", 501], ["annual", 505], ["fish", 512], ["Nothobranchius", 517], ["furzeri", 532], [".", 539], ["Resveratrol", 541], ["treatment", 553], ["prolonged", 563], ["lifespan", 573], ["and", 582], ["delayed", 586], ["the", 594], ["onset", 598], ["of", 604], ["age", 607], ["-", 610], ["related", 611], ["dysfunctions", 619], ["in", 632], ["this", 635], ["fish", 640], [".", 644], ["This", 646], ["result", 651], ["identifies", 658], ["resveratrol", 669], ["as", 681], ["the", 684], ["first", 688], ["molecule", 694], ["which", 703], ["consistently", 709], ["retards", 722], ["aging", 730], ["in", 736], ["organisms", 739], ["as", 749], ["diverse", 752], ["as", 760], ["yeast", 763], [",", 768], ["worm", 770], [",", 774], ["fly", 776], ["and", 780], ["fish", 784], [",", 788], ["but", 790], ["it", 794], ["also", 797], ["reveals", 802], ["the", 810], ["potential", 814], ["of", 824], ["this", 827], ["short", 832], ["-", 837], ["lived", 838], ["fish", 844], ["as", 849], ["an", 852], ["animal", 855], ["model", 862], ["for", 868], ["pharmacological", 872], ["research", 888], [".", 896], ["Moreover", 898], [",", 906], ["being", 908], ["related", 914], ["to", 922], ["stickleback", 925], ["(", 937], ["Gasterosteus", 938], ["aculeatus", 951], [")", 960], ["the", 962], ["\"", 966], ["pufferfishes", 967], ["\"", 979], ["Takifugu", 981], ["and", 990], ["Tetraodon", 994], [",", 1003], ["and", 1005], ["even", 1009], ["more", 1014], ["closely", 1019], ["related", 1027], ["to", 1035], ["medaka", 1038], ["(", 1045], ["Oryzias", 1046], ["latipes", 1054], [")", 1061], [",", 1062], ["it", 1064], ["can", 1067], ["greatly", 1071], ["beneficiate", 1079], ["from", 1091], ["the", 1096], ["recent", 1100], ["development", 1107], ["of", 1119], ["genomic", 1122], ["resources", 1130], ["for", 1140], ["these", 1144], ["fish", 1150], ["models", 1155], ["and", 1162], ["in", 1166], ["the", 1169], ["future", 1173], ["become", 1180], ["a", 1187], ["complete", 1189], ["model", 1198], ["system", 1204], ["for", 1211], ["the", 1215], ["aging", 1219], ["research", 1225], ["community", 1234], [".", 1243]]}
{"context": "Restless legs syndrome is a neurological disorder characterized by an urgency to move the legs during periods of rest. Data from a variety of sources provide a compelling argument that the amount of iron in the brain is lower in individuals with restless legs syndrome compared with neurologically normal individuals. Moreover, a significant percentage of patients with restless legs syndrome are responsive to intravenous iron therapy. The mechanism underlying the decreased iron concentrations in restless legs syndrome brains is unknown. We hypothesize that the source of the brain iron deficit is at the blood-brain interface. Thus we analysed the expression of iron management proteins in the epithelial cells of the choroid plexus and the brain microvasculature in post-mortem tissues. The choroid plexus, obtained at autopsy, from 18 neurologically normal controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical staining for iron and immunostaining for iron management proteins. Iron and heavy chain ferritin staining was reduced in the epithelial cells of choroid plexus in restless legs syndrome. Divalent metal transporter, ferroportin, transferrin and its receptor were upregulated in the choroid plexus in restless legs syndrome. Microvessels were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at autopsy and quantitative immunoblot analyses was performed. Expression of heavy chain ferritin, transferrin and its receptor in the microvessels from restless legs syndrome was significantly decreased compared with the controls but divalent metal protein 1, ferroportin, prohepcidin, mitochondrial ferritin and light-chain ferritin remained unchanged. The presence of an iron regulatory protein was demonstrated in the brain microvasculature and the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier report in neuromelanin cells from the substantia nigra of restless legs syndrome brains. This study reveals that there are alterations in the iron management protein profile in restless legs syndrome compared with controls at the site of blood-brain interface suggesting fundamental differences in brain iron acquisition in individuals with restless legs syndrome. Furthermore, the decrease in transferrin receptor expression in the microvasculature in the presence of relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems associated with brain iron acquisition in restless legs syndrome. The consistent finding of loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates this protein as a factor in the underlying cause of the iron deficiency in the restless legs syndrome brain. The data herein provide evidence for regulation of iron uptake and storage within brain microvessels that challenge the existing paradigm that the blood-brain barrier is merely a transport system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "240a062b131041ab863a237c0c0a8a73", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[158, 158], [93, 93], [75, 75], [109, 109], [67, 67], [166, 166], [397, 397], [332, 332], [356, 356], [281, 281], [410, 410], [450, 450], [34, 34], [382, 382], [433, 433], [162, 162]], "char_spans": [[974, 977], [585, 588], [476, 479], [666, 669], [423, 426], [1028, 1031], [2534, 2537], [2086, 2089], [2248, 2251], [1767, 1770], [2612, 2615], [2863, 2866], [199, 202], [2428, 2431], [2759, 2762], [1002, 1005]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["is", 23], ["a", 26], ["neurological", 28], ["disorder", 41], ["characterized", 50], ["by", 64], ["an", 67], ["urgency", 70], ["to", 78], ["move", 81], ["the", 86], ["legs", 90], ["during", 95], ["periods", 102], ["of", 110], ["rest", 113], [".", 117], ["Data", 119], ["from", 124], ["a", 129], ["variety", 131], ["of", 139], ["sources", 142], ["provide", 150], ["a", 158], ["compelling", 160], ["argument", 171], ["that", 180], ["the", 185], ["amount", 189], ["of", 196], ["iron", 199], ["in", 204], ["the", 207], ["brain", 211], ["is", 217], ["lower", 220], ["in", 226], ["individuals", 229], ["with", 241], ["restless", 246], ["legs", 255], ["syndrome", 260], ["compared", 269], ["with", 278], ["neurologically", 283], ["normal", 298], ["individuals", 305], [".", 316], ["Moreover", 318], [",", 326], ["a", 328], ["significant", 330], ["percentage", 342], ["of", 353], ["patients", 356], ["with", 365], ["restless", 370], ["legs", 379], ["syndrome", 384], ["are", 393], ["responsive", 397], ["to", 408], ["intravenous", 411], ["iron", 423], ["therapy", 428], [".", 435], ["The", 437], ["mechanism", 441], ["underlying", 451], ["the", 462], ["decreased", 466], ["iron", 476], ["concentrations", 481], ["in", 496], ["restless", 499], ["legs", 508], ["syndrome", 513], ["brains", 522], ["is", 529], ["unknown", 532], [".", 539], ["We", 541], ["hypothesize", 544], ["that", 556], ["the", 561], ["source", 565], ["of", 572], ["the", 575], ["brain", 579], ["iron", 585], ["deficit", 590], ["is", 598], ["at", 601], ["the", 604], ["blood", 608], ["-", 613], ["brain", 614], ["interface", 620], [".", 629], ["Thus", 631], ["we", 636], ["analysed", 639], ["the", 648], ["expression", 652], ["of", 663], ["iron", 666], ["management", 671], ["proteins", 682], ["in", 691], ["the", 694], ["epithelial", 698], ["cells", 709], ["of", 715], ["the", 718], ["choroid", 722], ["plexus", 730], ["and", 737], ["the", 741], ["brain", 745], ["microvasculature", 751], ["in", 768], ["post", 771], ["-", 775], ["mortem", 776], ["tissues", 783], [".", 790], ["The", 792], ["choroid", 796], ["plexus", 804], [",", 810], ["obtained", 812], ["at", 821], ["autopsy", 824], [",", 831], ["from", 833], ["18", 838], ["neurologically", 841], ["normal", 856], ["controls", 863], ["and", 872], ["14", 876], ["individuals", 879], ["who", 891], ["had", 895], ["primary", 899], ["restless", 907], ["legs", 916], ["syndrome", 921], ["was", 930], ["subjected", 934], ["to", 944], ["histochemical", 947], ["staining", 961], ["for", 970], ["iron", 974], ["and", 979], ["immunostaining", 983], ["for", 998], ["iron", 1002], ["management", 1007], ["proteins", 1018], [".", 1026], ["Iron", 1028], ["and", 1033], ["heavy", 1037], ["chain", 1043], ["ferritin", 1049], ["staining", 1058], ["was", 1067], ["reduced", 1071], ["in", 1079], ["the", 1082], ["epithelial", 1086], ["cells", 1097], ["of", 1103], ["choroid", 1106], ["plexus", 1114], ["in", 1121], ["restless", 1124], ["legs", 1133], ["syndrome", 1138], [".", 1146], ["Divalent", 1148], ["metal", 1157], ["transporter", 1163], [",", 1174], ["ferroportin", 1176], [",", 1187], ["transferrin", 1189], ["and", 1201], ["its", 1205], ["receptor", 1209], ["were", 1218], ["upregulated", 1223], ["in", 1235], ["the", 1238], ["choroid", 1242], ["plexus", 1250], ["in", 1257], ["restless", 1260], ["legs", 1269], ["syndrome", 1274], [".", 1282], ["Microvessels", 1284], ["were", 1297], ["isolated", 1302], ["from", 1311], ["the", 1316], ["motor", 1320], ["cortex", 1326], ["of", 1333], ["11", 1336], ["restless", 1339], ["legs", 1348], ["syndrome", 1353], ["and", 1362], ["14", 1366], ["control", 1369], ["brains", 1377], ["obtained", 1384], ["at", 1393], ["autopsy", 1396], ["and", 1404], ["quantitative", 1408], ["immunoblot", 1421], ["analyses", 1432], ["was", 1441], ["performed", 1445], [".", 1454], ["Expression", 1456], ["of", 1467], ["heavy", 1470], ["chain", 1476], ["ferritin", 1482], [",", 1490], ["transferrin", 1492], ["and", 1504], ["its", 1508], ["receptor", 1512], ["in", 1521], ["the", 1524], ["microvessels", 1528], ["from", 1541], ["restless", 1546], ["legs", 1555], ["syndrome", 1560], ["was", 1569], ["significantly", 1573], ["decreased", 1587], ["compared", 1597], ["with", 1606], ["the", 1611], ["controls", 1615], ["but", 1624], ["divalent", 1628], ["metal", 1637], ["protein", 1643], ["1", 1651], [",", 1652], ["ferroportin", 1654], [",", 1665], ["prohepcidin", 1667], [",", 1678], ["mitochondrial", 1680], ["ferritin", 1694], ["and", 1703], ["light", 1707], ["-", 1712], ["chain", 1713], ["ferritin", 1719], ["remained", 1728], ["unchanged", 1737], [".", 1746], ["The", 1748], ["presence", 1752], ["of", 1761], ["an", 1764], ["iron", 1767], ["regulatory", 1772], ["protein", 1783], ["was", 1791], ["demonstrated", 1795], ["in", 1808], ["the", 1811], ["brain", 1815], ["microvasculature", 1821], ["and", 1838], ["the", 1842], ["activity", 1846], ["of", 1855], ["this", 1858], ["protein", 1863], ["is", 1871], ["decreased", 1874], ["in", 1884], ["restless", 1887], ["legs", 1896], ["syndrome", 1901], [";", 1909], ["a", 1911], ["finding", 1913], ["similar", 1921], ["to", 1929], ["our", 1932], ["earlier", 1936], ["report", 1944], ["in", 1951], ["neuromelanin", 1954], ["cells", 1967], ["from", 1973], ["the", 1978], ["substantia", 1982], ["nigra", 1993], ["of", 1999], ["restless", 2002], ["legs", 2011], ["syndrome", 2016], ["brains", 2025], [".", 2031], ["This", 2033], ["study", 2038], ["reveals", 2044], ["that", 2052], ["there", 2057], ["are", 2063], ["alterations", 2067], ["in", 2079], ["the", 2082], ["iron", 2086], ["management", 2091], ["protein", 2102], ["profile", 2110], ["in", 2118], ["restless", 2121], ["legs", 2130], ["syndrome", 2135], ["compared", 2144], ["with", 2153], ["controls", 2158], ["at", 2167], ["the", 2170], ["site", 2174], ["of", 2179], ["blood", 2182], ["-", 2187], ["brain", 2188], ["interface", 2194], ["suggesting", 2204], ["fundamental", 2215], ["differences", 2227], ["in", 2239], ["brain", 2242], ["iron", 2248], ["acquisition", 2253], ["in", 2265], ["individuals", 2268], ["with", 2280], ["restless", 2285], ["legs", 2294], ["syndrome", 2299], [".", 2307], ["Furthermore", 2309], [",", 2320], ["the", 2322], ["decrease", 2326], ["in", 2335], ["transferrin", 2338], ["receptor", 2350], ["expression", 2359], ["in", 2370], ["the", 2373], ["microvasculature", 2377], ["in", 2394], ["the", 2397], ["presence", 2401], ["of", 2410], ["relative", 2413], ["brain", 2422], ["iron", 2428], ["deficiency", 2433], ["reported", 2444], ["in", 2453], ["restless", 2456], ["legs", 2465], ["syndrome", 2470], ["brains", 2479], ["may", 2486], ["underlie", 2490], ["the", 2499], ["problems", 2503], ["associated", 2512], ["with", 2523], ["brain", 2528], ["iron", 2534], ["acquisition", 2539], ["in", 2551], ["restless", 2554], ["legs", 2563], ["syndrome", 2568], [".", 2576], ["The", 2578], ["consistent", 2582], ["finding", 2593], ["of", 2601], ["loss", 2604], ["of", 2609], ["iron", 2612], ["regulatory", 2617], ["protein", 2628], ["activity", 2636], ["in", 2645], ["restless", 2648], ["legs", 2657], ["syndrome", 2662], ["brain", 2671], ["tissue", 2677], ["further", 2684], ["implicates", 2692], ["this", 2703], ["protein", 2708], ["as", 2716], ["a", 2719], ["factor", 2721], ["in", 2728], ["the", 2731], ["underlying", 2735], ["cause", 2746], ["of", 2752], ["the", 2755], ["iron", 2759], ["deficiency", 2764], ["in", 2775], ["the", 2778], ["restless", 2782], ["legs", 2791], ["syndrome", 2796], ["brain", 2805], [".", 2810], ["The", 2812], ["data", 2816], ["herein", 2821], ["provide", 2828], ["evidence", 2836], ["for", 2845], ["regulation", 2849], ["of", 2860], ["iron", 2863], ["uptake", 2868], ["and", 2875], ["storage", 2879], ["within", 2887], ["brain", 2894], ["microvessels", 2900], ["that", 2913], ["challenge", 2918], ["the", 2928], ["existing", 2932], ["paradigm", 2941], ["that", 2950], ["the", 2955], ["blood", 2959], ["-", 2964], ["brain", 2965], ["barrier", 2971], ["is", 2979], ["merely", 2982], ["a", 2989], ["transport", 2991], ["system", 3001], [".", 3007]]}
{"context": "The genetic disorders xeroderma pigmentosum (XP) and Cockayne syndrome (CS) exhibit deficiencies in the repair of UV-induced DNA damage. CS fibroblasts retain proficient nucleotide excision repair (NER) of inactive (or bulk) DNA, but are deficient in the transcription-coupled repair (TCR) of active genes. In contrast, XP complementation group C (XP-C) fibroblasts retain proficient TCR, but are deficient in bulk DNA repair. The remaining NER-deficient XP groups exhibit deficiencies in both repair pathways. Ad5HCMVsp1lacZ is a recombinant adenovirus vector that is unable to replicate in human fibroblasts, but can efficiently infect and express the beta-galactosidase reporter gene in these cells. We have examined the host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ in non-irradiated and UV-irradiated normal, XP-B, XP-C, XP-D, XP-F, XP-G, CS-A and CS-B fibroblasts. HCR of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ was reduced in non-irradiated cells from each of the repair-deficient groups examined (including XP-C) relative to that in non-irradiated normal cells. Prior irradiation of cells with low UV fluences resulted in an enhancement of HCR for normal and XP-C strains, but not for the remaining XP and CS strains. HCR of the UV-damaged reporter gene in UV-irradiated XP and CS strains was similar to measurements of TCR reported previously for these cells. These results suggest that UV treatment results in an induced repair of UV-damaged DNA in the transcribed strand of an active gene in XP-C and normal cells through an enhancement of TCR or a mechanism which involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "9ee2e86c5d1a4a1a9251990f2f2d84c6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[310, 311]], "char_spans": [[1531, 1548]]}]}], "context_tokens": [["The", 0], ["genetic", 4], ["disorders", 12], ["xeroderma", 22], ["pigmentosum", 32], ["(", 44], ["XP", 45], [")", 47], ["and", 49], ["Cockayne", 53], ["syndrome", 62], ["(", 71], ["CS", 72], [")", 74], ["exhibit", 76], ["deficiencies", 84], ["in", 97], ["the", 100], ["repair", 104], ["of", 111], ["UV", 114], ["-", 116], ["induced", 117], ["DNA", 125], ["damage", 129], [".", 135], ["CS", 137], ["fibroblasts", 140], ["retain", 152], ["proficient", 159], ["nucleotide", 170], ["excision", 181], ["repair", 190], ["(", 197], ["NER", 198], [")", 201], ["of", 203], ["inactive", 206], ["(", 215], ["or", 216], ["bulk", 219], [")", 223], ["DNA", 225], [",", 228], ["but", 230], ["are", 234], ["deficient", 238], ["in", 248], ["the", 251], ["transcription", 255], ["-", 268], ["coupled", 269], ["repair", 277], ["(", 284], ["TCR", 285], [")", 288], ["of", 290], ["active", 293], ["genes", 300], [".", 305], ["In", 307], ["contrast", 310], [",", 318], ["XP", 320], ["complementation", 323], ["group", 339], ["C", 345], ["(", 347], ["XP", 348], ["-", 350], ["C", 351], [")", 352], ["fibroblasts", 354], ["retain", 366], ["proficient", 373], ["TCR", 384], [",", 387], ["but", 389], ["are", 393], ["deficient", 397], ["in", 407], ["bulk", 410], ["DNA", 415], ["repair", 419], [".", 425], ["The", 427], ["remaining", 431], ["NER", 441], ["-", 444], ["deficient", 445], ["XP", 455], ["groups", 458], ["exhibit", 465], ["deficiencies", 473], ["in", 486], ["both", 489], ["repair", 494], ["pathways", 501], [".", 509], ["Ad5HCMVsp1lacZ", 511], ["is", 526], ["a", 529], ["recombinant", 531], ["adenovirus", 543], ["vector", 554], ["that", 561], ["is", 566], ["unable", 569], ["to", 576], ["replicate", 579], ["in", 589], ["human", 592], ["fibroblasts", 598], [",", 609], ["but", 611], ["can", 615], ["efficiently", 619], ["infect", 631], ["and", 638], ["express", 642], ["the", 650], ["beta", 654], ["-", 658], ["galactosidase", 659], ["reporter", 673], ["gene", 682], ["in", 687], ["these", 690], ["cells", 696], [".", 701], ["We", 703], ["have", 706], ["examined", 711], ["the", 720], ["host", 724], ["cell", 729], ["reactivation", 734], ["(", 747], ["HCR", 748], [")", 751], ["of", 753], ["beta", 756], ["-", 760], ["galactosidase", 761], ["activity", 775], ["for", 784], ["UV", 788], ["-", 790], ["irradiated", 791], ["Ad5HCMVsp1lacZ", 802], ["in", 817], ["non", 820], ["-", 823], ["irradiated", 824], ["and", 835], ["UV", 839], ["-", 841], ["irradiated", 842], ["normal", 853], [",", 859], ["XP", 861], ["-", 863], ["B", 864], [",", 865], ["XP", 867], ["-", 869], ["C", 870], [",", 871], ["XP", 873], ["-", 875], ["D", 876], [",", 877], ["XP", 879], ["-", 881], ["F", 882], [",", 883], ["XP", 885], ["-", 887], ["G", 888], [",", 889], ["CS", 891], ["-", 893], ["A", 894], ["and", 896], ["CS", 900], ["-", 902], ["B", 903], ["fibroblasts", 905], [".", 916], ["HCR", 918], ["of", 922], ["beta", 925], ["-", 929], ["galactosidase", 930], ["activity", 944], ["for", 953], ["UV", 957], ["-", 959], ["irradiated", 960], ["Ad5HCMVsp1lacZ", 971], ["was", 986], ["reduced", 990], ["in", 998], ["non", 1001], ["-", 1004], ["irradiated", 1005], ["cells", 1016], ["from", 1022], ["each", 1027], ["of", 1032], ["the", 1035], ["repair", 1039], ["-", 1045], ["deficient", 1046], ["groups", 1056], ["examined", 1063], ["(", 1072], ["including", 1073], ["XP", 1083], ["-", 1085], ["C", 1086], [")", 1087], ["relative", 1089], ["to", 1098], ["that", 1101], ["in", 1106], ["non", 1109], ["-", 1112], ["irradiated", 1113], ["normal", 1124], ["cells", 1131], [".", 1136], ["Prior", 1138], ["irradiation", 1144], ["of", 1156], ["cells", 1159], ["with", 1165], ["low", 1170], ["UV", 1174], ["fluences", 1177], ["resulted", 1186], ["in", 1195], ["an", 1198], ["enhancement", 1201], ["of", 1213], ["HCR", 1216], ["for", 1220], ["normal", 1224], ["and", 1231], ["XP", 1235], ["-", 1237], ["C", 1238], ["strains", 1240], [",", 1247], ["but", 1249], ["not", 1253], ["for", 1257], ["the", 1261], ["remaining", 1265], ["XP", 1275], ["and", 1278], ["CS", 1282], ["strains", 1285], [".", 1292], ["HCR", 1294], ["of", 1298], ["the", 1301], ["UV", 1305], ["-", 1307], ["damaged", 1308], ["reporter", 1316], ["gene", 1325], ["in", 1330], ["UV", 1333], ["-", 1335], ["irradiated", 1336], ["XP", 1347], ["and", 1350], ["CS", 1354], ["strains", 1357], ["was", 1365], ["similar", 1369], ["to", 1377], ["measurements", 1380], ["of", 1393], ["TCR", 1396], ["reported", 1400], ["previously", 1409], ["for", 1420], ["these", 1424], ["cells", 1430], [".", 1435], ["These", 1437], ["results", 1443], ["suggest", 1451], ["that", 1459], ["UV", 1464], ["treatment", 1467], ["results", 1477], ["in", 1485], ["an", 1488], ["induced", 1491], ["repair", 1499], ["of", 1506], ["UV", 1509], ["-", 1511], ["damaged", 1512], ["DNA", 1520], ["in", 1524], ["the", 1527], ["transcribed", 1531], ["strand", 1543], ["of", 1550], ["an", 1553], ["active", 1556], ["gene", 1563], ["in", 1568], ["XP", 1571], ["-", 1573], ["C", 1574], ["and", 1576], ["normal", 1580], ["cells", 1587], ["through", 1593], ["an", 1601], ["enhancement", 1604], ["of", 1616], ["TCR", 1619], ["or", 1623], ["a", 1626], ["mechanism", 1628], ["which", 1638], ["involves", 1644], ["the", 1653], ["TCR", 1657], ["pathway", 1661], [".", 1668]]}
{"context": "The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01(E) coadministration groups. RTS,S/AS01(E) generated high anti-circumsporozoite protein and anti-hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01(E) at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation. Trial registration. ClinicalTrials.gov identifier: NCT00436007 . GlaxoSmithKline study ID number: 106369 (Malaria-050).", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "a83fcafc8fb6472ba0ed2aea6e7a78a3", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[7, 7]], "char_spans": [[18, 24]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["malaria", 18], ["candidate", 26], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunization", 67], ["of", 80], ["African", 83], ["infants", 91], ["through", 99], ["the", 107], ["Expanded", 111], ["Program", 120], ["of", 128], ["Immunization", 131], ["(", 144], ["EPI", 145], [")", 148], [".", 149], ["This", 151], ["phase", 156], ["2", 162], [",", 163], ["randomized", 165], [",", 175], ["open", 177], [",", 181], ["controlled", 183], ["trial", 194], ["conducted", 200], ["in", 210], ["Ghana", 213], [",", 218], ["Tanzania", 220], [",", 228], ["and", 230], ["Gabon", 234], ["evaluated", 240], ["the", 250], ["safety", 254], ["and", 261], ["immunogenicity", 265], ["of", 280], ["RTS", 283], [",", 286], ["S", 287], ["/", 288], ["AS01(E", 289], [")", 295], ["when", 297], ["coadministered", 302], ["with", 317], ["EPI", 322], ["vaccines", 326], [".", 334], ["Five", 336], ["hundred", 341], ["eleven", 349], ["infants", 356], ["were", 364], ["randomized", 369], ["to", 380], ["receive", 383], ["RTS", 391], [",", 394], ["S", 395], ["/", 396], ["AS01(E", 397], [")", 403], ["at", 405], ["0", 408], [",", 409], ["1", 411], [",", 412], ["and", 414], ["2", 418], ["months", 420], ["(", 427], ["in", 428], ["3", 431], ["doses", 433], ["with", 439], ["diphtheria", 444], [",", 454], ["tetanus", 456], [",", 463], ["and", 465], ["whole", 469], ["-", 474], ["cell", 475], ["pertussis", 480], ["conjugate", 490], ["[", 500], ["DTPw", 501], ["]", 505], [";", 506], ["hepatitis", 508], ["B", 518], ["[", 520], ["HepB", 521], ["]", 525], [";", 526], ["Haemophilus", 528], ["influenzae", 540], ["type", 551], ["b", 556], ["[", 558], ["Hib", 559], ["]", 562], [";", 563], ["and", 565], ["oral", 569], ["polio", 574], ["vaccine", 580], ["[", 588], ["OPV", 589], ["]", 592], [")", 593], [",", 594], ["RTS", 596], [",", 599], ["S", 600], ["/", 601], ["AS01(E", 602], [")", 608], ["at", 610], ["0", 613], [",", 614], ["1", 616], [",", 617], ["and", 619], ["7", 623], ["months", 625], ["(", 632], ["2", 633], ["doses", 635], ["with", 641], ["DTPwHepB", 646], ["/", 654], ["Hib+OPV", 655], ["and", 663], ["1", 667], ["dose", 669], ["with", 674], ["measles", 679], ["and", 687], ["yellow", 691], ["fever", 698], [")", 703], [",", 704], ["or", 706], ["EPI", 709], ["vaccines", 713], ["only", 722], [".", 726], ["The", 728], ["occurrences", 732], ["of", 744], ["serious", 747], ["adverse", 755], ["events", 763], ["were", 770], ["balanced", 775], ["across", 784], ["groups", 791], [";", 797], ["none", 799], ["were", 804], ["vaccine", 809], ["-", 816], ["related", 817], [".", 824], ["One", 826], ["child", 830], ["from", 836], ["the", 841], ["control", 845], ["group", 853], ["died", 859], [".", 863], ["Mild", 865], ["to", 870], ["moderate", 873], ["fever", 882], ["and", 888], ["diaper", 892], ["dermatitis", 899], ["occurred", 910], ["more", 919], ["frequently", 924], ["in", 935], ["the", 938], ["RTS", 942], [",", 945], ["S", 946], ["/", 947], ["AS01(E", 948], [")", 954], ["coadministration", 956], ["groups", 973], [".", 979], ["RTS", 981], [",", 984], ["S", 985], ["/", 986], ["AS01(E", 987], [")", 993], ["generated", 995], ["high", 1005], ["anti", 1010], ["-", 1014], ["circumsporozoite", 1015], ["protein", 1032], ["and", 1040], ["anti", 1044], ["-", 1048], ["hepatitis", 1049], ["B", 1059], ["surface", 1061], ["antigen", 1069], ["antibody", 1077], ["levels", 1086], [".", 1092], ["Regarding", 1094], ["EPI", 1104], ["vaccine", 1108], ["responses", 1116], ["upon", 1126], ["coadministration", 1131], ["when", 1148], ["considering", 1153], ["both", 1165], ["immunization", 1170], ["schedules", 1183], [",", 1192], ["despite", 1194], ["a", 1202], ["tendency", 1204], ["toward", 1213], ["lower", 1220], ["geometric", 1226], ["mean", 1236], ["titers", 1241], ["to", 1248], ["some", 1251], ["EPI", 1256], ["antigens", 1260], [",", 1268], ["predefined", 1270], ["noninferiority", 1281], ["criteria", 1296], ["were", 1305], ["met", 1310], ["for", 1314], ["all", 1318], ["EPI", 1322], ["antigens", 1326], ["except", 1335], ["for", 1342], ["polio", 1346], ["3", 1352], ["when", 1354], ["EPI", 1359], ["vaccines", 1363], ["were", 1372], ["given", 1377], ["with", 1383], ["RTS", 1388], [",", 1391], ["S", 1392], ["/", 1393], ["AS01(E", 1394], [")", 1400], ["at", 1402], ["0", 1405], [",", 1406], ["1", 1408], [",", 1409], ["and", 1411], ["2", 1415], ["months", 1417], [".", 1423], ["However", 1425], [",", 1432], ["when", 1434], ["antibody", 1439], ["levels", 1448], ["at", 1455], ["screening", 1458], ["were", 1468], ["taken", 1473], ["into", 1479], ["account", 1484], [",", 1491], ["the", 1493], ["rates", 1497], ["of", 1503], ["response", 1506], ["to", 1515], ["polio", 1518], ["3", 1524], ["antigens", 1526], ["were", 1535], ["comparable", 1540], ["between", 1551], ["groups", 1559], [".", 1565], ["RTS", 1567], [",", 1570], ["S", 1571], ["/", 1572], ["AS01(E", 1573], [")", 1579], ["integrated", 1581], ["in", 1592], ["the", 1595], ["EPI", 1599], ["showed", 1603], ["a", 1610], ["favorable", 1612], ["safety", 1622], ["and", 1629], ["immunogenicity", 1633], ["evaluation", 1648], [".", 1658], ["Trial", 1660], ["registration", 1666], [".", 1678], ["ClinicalTrials.gov", 1680], ["identifier", 1699], [":", 1709], ["NCT00436007", 1711], [".", 1723], ["GlaxoSmithKline", 1725], ["study", 1741], ["ID", 1747], ["number", 1750], [":", 1756], ["106369", 1758], ["(", 1765], ["Malaria-050", 1766], [")", 1777], [".", 1778]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Disruption of FOXP2, a gene encoding a forkhead-domain transcription factor, causes a severe developmental disorder of verbal communication, involving profound articulation deficits, accompanied by linguistic and grammatical impairments. Investigation of the neural basis of this disorder has been limited previously to neuroimaging of affected children and adults. The discovery of the gene responsible, FOXP2, offers a unique opportunity to explore the relevant neural mechanisms from a molecular perspective. In the present study, we have determined the detailed spatial and temporal expression pattern of FOXP2 mRNA in the developing brain of mouse and human. We find expression in several structures including the cortical plate, basal ganglia, thalamus, inferior olives and cerebellum. These data support a role for FOXP2 in the development of corticostriatal and olivocerebellar circuits involved in motor control. We find intriguing concordance between regions of early expression and later sites of pathology suggested by neuroimaging. Moreover, the homologous pattern of FOXP2/Foxp2 expression in human and mouse argues for a role for this gene in development of motor-related circuits throughout mammalian species. Overall, this study provides support for the hypothesis that impairments in sequencing of movement and procedural learning might be central to the FOXP2-related speech and language disorder.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "2c0e0f4aa55c4021a72dbdfb12a37f40", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[95, 95], [133, 133], [62, 62], [2, 2]], "char_spans": [[609, 613], [822, 826], [405, 409], [14, 18]]}]}], "context_tokens": [["Disruption", 0], ["of", 11], ["FOXP2", 14], [",", 19], ["a", 21], ["gene", 23], ["encoding", 28], ["a", 37], ["forkhead", 39], ["-", 47], ["domain", 48], ["transcription", 55], ["factor", 69], [",", 75], ["causes", 77], ["a", 84], ["severe", 86], ["developmental", 93], ["disorder", 107], ["of", 116], ["verbal", 119], ["communication", 126], [",", 139], ["involving", 141], ["profound", 151], ["articulation", 160], ["deficits", 173], [",", 181], ["accompanied", 183], ["by", 195], ["linguistic", 198], ["and", 209], ["grammatical", 213], ["impairments", 225], [".", 236], ["Investigation", 238], ["of", 252], ["the", 255], ["neural", 259], ["basis", 266], ["of", 272], ["this", 275], ["disorder", 280], ["has", 289], ["been", 293], ["limited", 298], ["previously", 306], ["to", 317], ["neuroimaging", 320], ["of", 333], ["affected", 336], ["children", 345], ["and", 354], ["adults", 358], [".", 364], ["The", 366], ["discovery", 370], ["of", 380], ["the", 383], ["gene", 387], ["responsible", 392], [",", 403], ["FOXP2", 405], [",", 410], ["offers", 412], ["a", 419], ["unique", 421], ["opportunity", 428], ["to", 440], ["explore", 443], ["the", 451], ["relevant", 455], ["neural", 464], ["mechanisms", 471], ["from", 482], ["a", 487], ["molecular", 489], ["perspective", 499], [".", 510], ["In", 512], ["the", 515], ["present", 519], ["study", 527], [",", 532], ["we", 534], ["have", 537], ["determined", 542], ["the", 553], ["detailed", 557], ["spatial", 566], ["and", 574], ["temporal", 578], ["expression", 587], ["pattern", 598], ["of", 606], ["FOXP2", 609], ["mRNA", 615], ["in", 620], ["the", 623], ["developing", 627], ["brain", 638], ["of", 644], ["mouse", 647], ["and", 653], ["human", 657], [".", 662], ["We", 664], ["find", 667], ["expression", 672], ["in", 683], ["several", 686], ["structures", 694], ["including", 705], ["the", 715], ["cortical", 719], ["plate", 728], [",", 733], ["basal", 735], ["ganglia", 741], [",", 748], ["thalamus", 750], [",", 758], ["inferior", 760], ["olives", 769], ["and", 776], ["cerebellum", 780], [".", 790], ["These", 792], ["data", 798], ["support", 803], ["a", 811], ["role", 813], ["for", 818], ["FOXP2", 822], ["in", 828], ["the", 831], ["development", 835], ["of", 847], ["corticostriatal", 850], ["and", 866], ["olivocerebellar", 870], ["circuits", 886], ["involved", 895], ["in", 904], ["motor", 907], ["control", 913], [".", 920], ["We", 922], ["find", 925], ["intriguing", 930], ["concordance", 941], ["between", 953], ["regions", 961], ["of", 969], ["early", 972], ["expression", 978], ["and", 989], ["later", 993], ["sites", 999], ["of", 1005], ["pathology", 1008], ["suggested", 1018], ["by", 1028], ["neuroimaging", 1031], [".", 1043], ["Moreover", 1045], [",", 1053], ["the", 1055], ["homologous", 1059], ["pattern", 1070], ["of", 1078], ["FOXP2/Foxp2", 1081], ["expression", 1093], ["in", 1104], ["human", 1107], ["and", 1113], ["mouse", 1117], ["argues", 1123], ["for", 1130], ["a", 1134], ["role", 1136], ["for", 1141], ["this", 1145], ["gene", 1150], ["in", 1155], ["development", 1158], ["of", 1170], ["motor", 1173], ["-", 1178], ["related", 1179], ["circuits", 1187], ["throughout", 1196], ["mammalian", 1207], ["species", 1217], [".", 1224], ["Overall", 1226], [",", 1233], ["this", 1235], ["study", 1240], ["provides", 1246], ["support", 1255], ["for", 1263], ["the", 1267], ["hypothesis", 1271], ["that", 1282], ["impairments", 1287], ["in", 1299], ["sequencing", 1302], ["of", 1313], ["movement", 1316], ["and", 1325], ["procedural", 1329], ["learning", 1340], ["might", 1349], ["be", 1355], ["central", 1358], ["to", 1366], ["the", 1369], ["FOXP2-related", 1373], ["speech", 1387], ["and", 1394], ["language", 1398], ["disorder", 1407], [".", 1415]]}
{"context": "The TNF family member receptor activator for NF-\u03baB ligand (RANKL) and its receptors RANK and osteoprotegerin are key regulators of bone remodeling but also influence cellular functions of tumor and immune effector cells. In this work, we studied the involvement of RANK-RANKL interaction in NK cell-mediated immunosurveillance of acute myeloid leukemia (AML). Substantial levels of RANKL were found to be expressed on leukemia cells in 53 of 78 (68%) investigated patients. Signaling via RANKL into the leukemia cells stimulated their metabolic activity and induced the release of cytokines involved in AML pathophysiology. In addition, the immunomodulatory factors released by AML cells upon RANKL signaling impaired the anti-leukemia reactivity of NK cells and induced RANK expression, and NK cells of AML patients displayed significantly upregulated RANK expression compared with healthy controls. Treatment of AML cells with the clinically available RANKL Ab Denosumab resulted in enhanced NK cell anti-leukemia reactivity. This was due to both blockade of the release of NK-inhibitory factors by AML cells and prevention of RANK signaling into NK cells. The latter was found to directly impair NK anti-leukemia reactivity with a more pronounced effect on IFN-\u03b3 production compared with cytotoxicity. Together, our data unravel a previously unknown function of the RANK-RANKL molecule system in AML pathophysiology as well as NK cell function and suggest that neutralization of RANKL with therapeutic Abs may serve to reinforce NK cell reactivity in leukemia patients.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "d8c9be80bd4a48e8898ad993a1531d7f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[161, 161], [256, 256], [90, 90], [68, 68], [12, 12], [121, 121], [239, 239], [49, 49]], "char_spans": [[954, 958], [1482, 1486], [488, 492], [382, 386], [59, 63], [693, 697], [1374, 1378], [270, 274]]}]}], "context_tokens": [["The", 0], ["TNF", 4], ["family", 8], ["member", 15], ["receptor", 22], ["activator", 31], ["for", 41], ["NF", 45], ["-", 47], ["\u03baB", 48], ["ligand", 51], ["(", 58], ["RANKL", 59], [")", 64], ["and", 66], ["its", 70], ["receptors", 74], ["RANK", 84], ["and", 89], ["osteoprotegerin", 93], ["are", 109], ["key", 113], ["regulators", 117], ["of", 128], ["bone", 131], ["remodeling", 136], ["but", 147], ["also", 151], ["influence", 156], ["cellular", 166], ["functions", 175], ["of", 185], ["tumor", 188], ["and", 194], ["immune", 198], ["effector", 205], ["cells", 214], [".", 219], ["In", 221], ["this", 224], ["work", 229], [",", 233], ["we", 235], ["studied", 238], ["the", 246], ["involvement", 250], ["of", 262], ["RANK", 265], ["-", 269], ["RANKL", 270], ["interaction", 276], ["in", 288], ["NK", 291], ["cell", 294], ["-", 298], ["mediated", 299], ["immunosurveillance", 308], ["of", 327], ["acute", 330], ["myeloid", 336], ["leukemia", 344], ["(", 353], ["AML", 354], [")", 357], [".", 358], ["Substantial", 360], ["levels", 372], ["of", 379], ["RANKL", 382], ["were", 388], ["found", 393], ["to", 399], ["be", 402], ["expressed", 405], ["on", 415], ["leukemia", 418], ["cells", 427], ["in", 433], ["53", 436], ["of", 439], ["78", 442], ["(", 445], ["68", 446], ["%", 448], [")", 449], ["investigated", 451], ["patients", 464], [".", 472], ["Signaling", 474], ["via", 484], ["RANKL", 488], ["into", 494], ["the", 499], ["leukemia", 503], ["cells", 512], ["stimulated", 518], ["their", 529], ["metabolic", 535], ["activity", 545], ["and", 554], ["induced", 558], ["the", 566], ["release", 570], ["of", 578], ["cytokines", 581], ["involved", 591], ["in", 600], ["AML", 603], ["pathophysiology", 607], [".", 622], ["In", 624], ["addition", 627], [",", 635], ["the", 637], ["immunomodulatory", 641], ["factors", 658], ["released", 666], ["by", 675], ["AML", 678], ["cells", 682], ["upon", 688], ["RANKL", 693], ["signaling", 699], ["impaired", 709], ["the", 718], ["anti", 722], ["-", 726], ["leukemia", 727], ["reactivity", 736], ["of", 747], ["NK", 750], ["cells", 753], ["and", 759], ["induced", 763], ["RANK", 771], ["expression", 776], [",", 786], ["and", 788], ["NK", 792], ["cells", 795], ["of", 801], ["AML", 804], ["patients", 808], ["displayed", 817], ["significantly", 827], ["upregulated", 841], ["RANK", 853], ["expression", 858], ["compared", 869], ["with", 878], ["healthy", 883], ["controls", 891], [".", 899], ["Treatment", 901], ["of", 911], ["AML", 914], ["cells", 918], ["with", 924], ["the", 929], ["clinically", 933], ["available", 944], ["RANKL", 954], ["Ab", 960], ["Denosumab", 963], ["resulted", 973], ["in", 982], ["enhanced", 985], ["NK", 994], ["cell", 997], ["anti", 1002], ["-", 1006], ["leukemia", 1007], ["reactivity", 1016], [".", 1026], ["This", 1028], ["was", 1033], ["due", 1037], ["to", 1041], ["both", 1044], ["blockade", 1049], ["of", 1058], ["the", 1061], ["release", 1065], ["of", 1073], ["NK", 1076], ["-", 1078], ["inhibitory", 1079], ["factors", 1090], ["by", 1098], ["AML", 1101], ["cells", 1105], ["and", 1111], ["prevention", 1115], ["of", 1126], ["RANK", 1129], ["signaling", 1134], ["into", 1144], ["NK", 1149], ["cells", 1152], [".", 1157], ["The", 1159], ["latter", 1163], ["was", 1170], ["found", 1174], ["to", 1180], ["directly", 1183], ["impair", 1192], ["NK", 1199], ["anti", 1202], ["-", 1206], ["leukemia", 1207], ["reactivity", 1216], ["with", 1227], ["a", 1232], ["more", 1234], ["pronounced", 1239], ["effect", 1250], ["on", 1257], ["IFN", 1260], ["-", 1263], ["\u03b3", 1264], ["production", 1266], ["compared", 1277], ["with", 1286], ["cytotoxicity", 1291], [".", 1303], ["Together", 1305], [",", 1313], ["our", 1315], ["data", 1319], ["unravel", 1324], ["a", 1332], ["previously", 1334], ["unknown", 1345], ["function", 1353], ["of", 1362], ["the", 1365], ["RANK", 1369], ["-", 1373], ["RANKL", 1374], ["molecule", 1380], ["system", 1389], ["in", 1396], ["AML", 1399], ["pathophysiology", 1403], ["as", 1419], ["well", 1422], ["as", 1427], ["NK", 1430], ["cell", 1433], ["function", 1438], ["and", 1447], ["suggest", 1451], ["that", 1459], ["neutralization", 1464], ["of", 1479], ["RANKL", 1482], ["with", 1488], ["therapeutic", 1493], ["Abs", 1505], ["may", 1509], ["serve", 1513], ["to", 1519], ["reinforce", 1522], ["NK", 1532], ["cell", 1535], ["reactivity", 1540], ["in", 1551], ["leukemia", 1554], ["patients", 1563], [".", 1571]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem. Rapid detection of MRSA-colonized patients has the potential to limit spread of the organism. We evaluated the sensitivities and specificities of MRSA detection by two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) and three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA), using 205 (101 nasal, 52 groin, and 52 axillary samples) samples from consecutive known MRSA-infected and/or -colonized patients. All detection methods had higher MRSA detection rates for nasal swabs than for axillary and groin swabs. Detection of MRSA by IDI-MRSA was the most sensitive method, independent of the site (94% for nasal samples, 80% for nonnasal samples, and 90% overall). The sensitivities of the GenoType MRSA Direct assay and the MRSA ID, MRSASelect, and CHROMagar MRSA agars with nasal swabs were 70%, 72%, 68%, and 75%, respectively. All detection methods had high specificities (95 to 99%), independent of the swab site. Extended incubation for a further 24 h with selective MRSA agars increased the detection of MRSA, with a corresponding decline in specificity secondary to a significant increase in false-positive results. There was a noticeable difference in test performance of the GenoType MRSA Direct assay in detection of MRSA (28/38 samples [74%]) compared with detection of nonmultiresistant MRSA (17/31 samples [55%]) (susceptible to two or more non-beta-lactam antibiotics). This was not observed with selective MRSA agar plates or IDI-MRSA. Although it is more expensive, in addition to rapid turnaround times of 2 to 4 h, IDI-MRSA offers greater detection of MRSA colonization, independent of the swab site, than do conventional selective agars and GenoType MRSA Direct.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b942fc23c0bf4ebe9bf8e76ac4b3a998", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[161, 161], [351, 351], [16, 16], [51, 51], [117, 117], [6, 6], [308, 308], [121, 121], [259, 259], [59, 59], [69, 69], [253, 253], [302, 302], [62, 62], [335, 335], [90, 90], [102, 102], [217, 217], [273, 273], [37, 37], [330, 330], [156, 156], [168, 168], [46, 46], [223, 223]], "char_spans": [[841, 844], [1786, 1789], [96, 99], [296, 299], [641, 644], [45, 48], [1562, 1565], [653, 656], [1344, 1347], [339, 342], [386, 389], [1310, 1313], [1538, 1541], [351, 354], [1687, 1690], [481, 484], [556, 559], [1089, 1092], [1416, 1419], [223, 226], [1654, 1657], [815, 818], [876, 879], [268, 271], [1127, 1130]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["increasing", 57], ["problem", 68], [".", 75], ["Rapid", 77], ["detection", 83], ["of", 93], ["MRSA", 96], ["-", 100], ["colonized", 101], ["patients", 111], ["has", 120], ["the", 124], ["potential", 128], ["to", 138], ["limit", 141], ["spread", 147], ["of", 154], ["the", 157], ["organism", 161], [".", 169], ["We", 171], ["evaluated", 174], ["the", 184], ["sensitivities", 188], ["and", 202], ["specificities", 206], ["of", 220], ["MRSA", 223], ["detection", 228], ["by", 238], ["two", 241], ["molecular", 245], ["methods", 255], ["(", 263], ["IDI", 264], ["-", 267], ["MRSA", 268], ["PCR", 273], ["assay", 277], ["and", 283], ["GenoType", 287], ["MRSA", 296], ["Direct", 301], ["PCR", 308], ["assay", 312], [")", 317], ["and", 319], ["three", 323], ["selective", 329], ["MRSA", 339], ["agars", 344], ["(", 350], ["MRSA", 351], ["ID", 356], [",", 358], ["MRSASelect", 360], [",", 370], ["and", 372], ["CHROMagar", 376], ["MRSA", 386], [")", 390], [",", 391], ["using", 393], ["205", 399], ["(", 403], ["101", 404], ["nasal", 408], [",", 413], ["52", 415], ["groin", 418], [",", 423], ["and", 425], ["52", 429], ["axillary", 432], ["samples", 441], [")", 448], ["samples", 450], ["from", 458], ["consecutive", 463], ["known", 475], ["MRSA", 481], ["-", 485], ["infected", 486], ["and/or", 495], ["-colonized", 502], ["patients", 513], [".", 521], ["All", 523], ["detection", 527], ["methods", 537], ["had", 545], ["higher", 549], ["MRSA", 556], ["detection", 561], ["rates", 571], ["for", 577], ["nasal", 581], ["swabs", 587], ["than", 593], ["for", 598], ["axillary", 602], ["and", 611], ["groin", 615], ["swabs", 621], [".", 626], ["Detection", 628], ["of", 638], ["MRSA", 641], ["by", 646], ["IDI", 649], ["-", 652], ["MRSA", 653], ["was", 658], ["the", 662], ["most", 666], ["sensitive", 671], ["method", 681], [",", 687], ["independent", 689], ["of", 701], ["the", 704], ["site", 708], ["(", 713], ["94", 714], ["%", 716], ["for", 718], ["nasal", 722], ["samples", 728], [",", 735], ["80", 737], ["%", 739], ["for", 741], ["nonnasal", 745], ["samples", 754], [",", 761], ["and", 763], ["90", 767], ["%", 769], ["overall", 771], [")", 778], [".", 779], ["The", 781], ["sensitivities", 785], ["of", 799], ["the", 802], ["GenoType", 806], ["MRSA", 815], ["Direct", 820], ["assay", 827], ["and", 833], ["the", 837], ["MRSA", 841], ["ID", 846], [",", 848], ["MRSASelect", 850], [",", 860], ["and", 862], ["CHROMagar", 866], ["MRSA", 876], ["agars", 881], ["with", 887], ["nasal", 892], ["swabs", 898], ["were", 904], ["70", 909], ["%", 911], [",", 912], ["72", 914], ["%", 916], [",", 917], ["68", 919], ["%", 921], [",", 922], ["and", 924], ["75", 928], ["%", 930], [",", 931], ["respectively", 933], [".", 945], ["All", 947], ["detection", 951], ["methods", 961], ["had", 969], ["high", 973], ["specificities", 978], ["(", 992], ["95", 993], ["to", 996], ["99", 999], ["%", 1001], [")", 1002], [",", 1003], ["independent", 1005], ["of", 1017], ["the", 1020], ["swab", 1024], ["site", 1029], [".", 1033], ["Extended", 1035], ["incubation", 1044], ["for", 1055], ["a", 1059], ["further", 1061], ["24", 1069], ["h", 1072], ["with", 1074], ["selective", 1079], ["MRSA", 1089], ["agars", 1094], ["increased", 1100], ["the", 1110], ["detection", 1114], ["of", 1124], ["MRSA", 1127], [",", 1131], ["with", 1133], ["a", 1138], ["corresponding", 1140], ["decline", 1154], ["in", 1162], ["specificity", 1165], ["secondary", 1177], ["to", 1187], ["a", 1190], ["significant", 1192], ["increase", 1204], ["in", 1213], ["false", 1216], ["-", 1221], ["positive", 1222], ["results", 1231], [".", 1238], ["There", 1240], ["was", 1246], ["a", 1250], ["noticeable", 1252], ["difference", 1263], ["in", 1274], ["test", 1277], ["performance", 1282], ["of", 1294], ["the", 1297], ["GenoType", 1301], ["MRSA", 1310], ["Direct", 1315], ["assay", 1322], ["in", 1328], ["detection", 1331], ["of", 1341], ["MRSA", 1344], ["(", 1349], ["28/38", 1350], ["samples", 1356], ["[", 1364], ["74", 1365], ["%", 1367], ["]", 1368], [")", 1369], ["compared", 1371], ["with", 1380], ["detection", 1385], ["of", 1395], ["nonmultiresistant", 1398], ["MRSA", 1416], ["(", 1421], ["17/31", 1422], ["samples", 1428], ["[", 1436], ["55", 1437], ["%", 1439], ["]", 1440], [")", 1441], ["(", 1443], ["susceptible", 1444], ["to", 1456], ["two", 1459], ["or", 1463], ["more", 1466], ["non", 1471], ["-", 1474], ["beta", 1475], ["-", 1479], ["lactam", 1480], ["antibiotics", 1487], [")", 1498], [".", 1499], ["This", 1501], ["was", 1506], ["not", 1510], ["observed", 1514], ["with", 1523], ["selective", 1528], ["MRSA", 1538], ["agar", 1543], ["plates", 1548], ["or", 1555], ["IDI", 1558], ["-", 1561], ["MRSA", 1562], [".", 1566], ["Although", 1568], ["it", 1577], ["is", 1580], ["more", 1583], ["expensive", 1588], [",", 1597], ["in", 1599], ["addition", 1602], ["to", 1611], ["rapid", 1614], ["turnaround", 1620], ["times", 1631], ["of", 1637], ["2", 1640], ["to", 1642], ["4", 1645], ["h", 1647], [",", 1648], ["IDI", 1650], ["-", 1653], ["MRSA", 1654], ["offers", 1659], ["greater", 1666], ["detection", 1674], ["of", 1684], ["MRSA", 1687], ["colonization", 1692], [",", 1704], ["independent", 1706], ["of", 1718], ["the", 1721], ["swab", 1725], ["site", 1730], [",", 1734], ["than", 1736], ["do", 1741], ["conventional", 1744], ["selective", 1757], ["agars", 1767], ["and", 1773], ["GenoType", 1777], ["MRSA", 1786], ["Direct", 1791], [".", 1797]]}
{"context": "An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments. To determine what hospital-associated factors drove the outbreak of this particular strain we performed a case-control study. Cases (n = 79), diagnosed with CDI due to C. difficile ribotype 027 were matched for age and treating medical specialty to four control patients (n = 316). Patients diagnosed with CDI due to other ribotypes were included as a second control group. A random selection of C. difficile ribotype 027 strains (n = 10) was genotyped by Whole Genome Sequencing (WGS). WGS showed the outbreak was likely caused by a single strain of C. difficile (two or less single-nucleotide variants between isolates). Ninety-five percent of cases had used antibiotics, compared to 56% of controls. Previous admission to the intensive care unit (ICU) (OR: 2.4, 95% CI 1.0-5.6), longer length of stay (LOS), and recent hospital admission were associated with CDI ribotype 027. Cases were less likely to have been admitted to a ward with a known isolated CDI patient (OR: 0.2, 95% CI 0.1-0.6). Analysis of patients who stayed at the ICU (35 cases; 51 controls), indicated that the use of selective decontamination of the digestive tract (SDD) and a longer LOS in the ICU were associated with CDI risk. In this large outbreak, any antibiotic use, including SDD use, appeared as a prerequisite for acquisition of the outbreak strain. The role of use of SDD and prolonged stay on the ICU could not be disentangled, but both factors can play a biologically plausible role in C. difficile acquisition and infection.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "3624fe9b9dca47c98be7dc8c2d2db870", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[5, 6], [57, 58], [199, 200], [99, 100]], "char_spans": [[37, 48], [309, 320], [994, 1005], [537, 548]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["ribotype", 37], ["027", 46], ["infection", 50], ["(", 60], ["CDI", 61], [")", 64], ["occurred", 66], ["at", 75], ["an", 78], ["university", 81], ["hospital", 92], [",", 100], ["involving", 102], ["19", 112], ["departments", 115], [".", 126], ["To", 128], ["determine", 131], ["what", 141], ["hospital", 146], ["-", 154], ["associated", 155], ["factors", 166], ["drove", 174], ["the", 180], ["outbreak", 184], ["of", 193], ["this", 196], ["particular", 201], ["strain", 212], ["we", 219], ["performed", 222], ["a", 232], ["case", 234], ["-", 238], ["control", 239], ["study", 247], [".", 252], ["Cases", 254], ["(", 260], ["n", 261], ["=", 263], ["79", 265], [")", 267], [",", 268], ["diagnosed", 270], ["with", 280], ["CDI", 285], ["due", 289], ["to", 293], ["C.", 296], ["difficile", 299], ["ribotype", 309], ["027", 318], ["were", 322], ["matched", 327], ["for", 335], ["age", 339], ["and", 343], ["treating", 347], ["medical", 356], ["specialty", 364], ["to", 374], ["four", 377], ["control", 382], ["patients", 390], ["(", 399], ["n", 400], ["=", 402], ["316", 404], [")", 407], [".", 408], ["Patients", 410], ["diagnosed", 419], ["with", 429], ["CDI", 434], ["due", 438], ["to", 442], ["other", 445], ["ribotypes", 451], ["were", 461], ["included", 466], ["as", 475], ["a", 478], ["second", 480], ["control", 487], ["group", 495], [".", 500], ["A", 502], ["random", 504], ["selection", 511], ["of", 521], ["C.", 524], ["difficile", 527], ["ribotype", 537], ["027", 546], ["strains", 550], ["(", 558], ["n", 559], ["=", 561], ["10", 563], [")", 565], ["was", 567], ["genotyped", 571], ["by", 581], ["Whole", 584], ["Genome", 590], ["Sequencing", 597], ["(", 608], ["WGS", 609], [")", 612], [".", 613], ["WGS", 615], ["showed", 619], ["the", 626], ["outbreak", 630], ["was", 639], ["likely", 643], ["caused", 650], ["by", 657], ["a", 660], ["single", 662], ["strain", 669], ["of", 676], ["C.", 679], ["difficile", 682], ["(", 692], ["two", 693], ["or", 697], ["less", 700], ["single", 705], ["-", 711], ["nucleotide", 712], ["variants", 723], ["between", 732], ["isolates", 740], [")", 748], [".", 749], ["Ninety", 751], ["-", 757], ["five", 758], ["percent", 763], ["of", 771], ["cases", 774], ["had", 780], ["used", 784], ["antibiotics", 789], [",", 800], ["compared", 802], ["to", 811], ["56", 814], ["%", 816], ["of", 818], ["controls", 821], [".", 829], ["Previous", 831], ["admission", 840], ["to", 850], ["the", 853], ["intensive", 857], ["care", 867], ["unit", 872], ["(", 877], ["ICU", 878], [")", 881], ["(", 883], ["OR", 884], [":", 886], ["2.4", 888], [",", 891], ["95", 893], ["%", 895], ["CI", 897], ["1.0", 900], ["-", 903], ["5.6", 904], [")", 907], [",", 908], ["longer", 910], ["length", 917], ["of", 924], ["stay", 927], ["(", 932], ["LOS", 933], [")", 936], [",", 937], ["and", 939], ["recent", 943], ["hospital", 950], ["admission", 959], ["were", 969], ["associated", 974], ["with", 985], ["CDI", 990], ["ribotype", 994], ["027", 1003], [".", 1006], ["Cases", 1008], ["were", 1014], ["less", 1019], ["likely", 1024], ["to", 1031], ["have", 1034], ["been", 1039], ["admitted", 1044], ["to", 1053], ["a", 1056], ["ward", 1058], ["with", 1063], ["a", 1068], ["known", 1070], ["isolated", 1076], ["CDI", 1085], ["patient", 1089], ["(", 1097], ["OR", 1098], [":", 1100], ["0.2", 1102], [",", 1105], ["95", 1107], ["%", 1109], ["CI", 1111], ["0.1", 1114], ["-", 1117], ["0.6", 1118], [")", 1121], [".", 1122], ["Analysis", 1124], ["of", 1133], ["patients", 1136], ["who", 1145], ["stayed", 1149], ["at", 1156], ["the", 1159], ["ICU", 1163], ["(", 1167], ["35", 1168], ["cases", 1171], [";", 1176], ["51", 1178], ["controls", 1181], [")", 1189], [",", 1190], ["indicated", 1192], ["that", 1202], ["the", 1207], ["use", 1211], ["of", 1215], ["selective", 1218], ["decontamination", 1228], ["of", 1244], ["the", 1247], ["digestive", 1251], ["tract", 1261], ["(", 1267], ["SDD", 1268], [")", 1271], ["and", 1273], ["a", 1277], ["longer", 1279], ["LOS", 1286], ["in", 1290], ["the", 1293], ["ICU", 1297], ["were", 1301], ["associated", 1306], ["with", 1317], ["CDI", 1322], ["risk", 1326], [".", 1330], ["In", 1332], ["this", 1335], ["large", 1340], ["outbreak", 1346], [",", 1354], ["any", 1356], ["antibiotic", 1360], ["use", 1371], [",", 1374], ["including", 1376], ["SDD", 1386], ["use", 1390], [",", 1393], ["appeared", 1395], ["as", 1404], ["a", 1407], ["prerequisite", 1409], ["for", 1422], ["acquisition", 1426], ["of", 1438], ["the", 1441], ["outbreak", 1445], ["strain", 1454], [".", 1460], ["The", 1462], ["role", 1466], ["of", 1471], ["use", 1474], ["of", 1478], ["SDD", 1481], ["and", 1485], ["prolonged", 1489], ["stay", 1499], ["on", 1504], ["the", 1507], ["ICU", 1511], ["could", 1515], ["not", 1521], ["be", 1525], ["disentangled", 1528], [",", 1540], ["but", 1542], ["both", 1546], ["factors", 1551], ["can", 1559], ["play", 1563], ["a", 1568], ["biologically", 1570], ["plausible", 1583], ["role", 1593], ["in", 1598], ["C.", 1601], ["difficile", 1604], ["acquisition", 1614], ["and", 1626], ["infection", 1630], [".", 1639]]}
{"context": "Transcription factors belonging to the nuclear factor of activated T cells (NFAT) family regulate the expression of cytokine genes and other inducible genes during the immune response. The functions of NFAT proteins are directly controlled by the calcium- and calmodulin-dependent phosphatase calcineurin. Here we show that the binding of calcineurin to NFAT is substantially increased when calcineurin is activated with calmodulin and calcium. FK506.FKBP12 drug-immunophilin complexes inhibited the interaction of NFAT with activated calcineurin much more effectively than they inhibited the interaction with inactive calcineurin, suggesting that part of the interaction with activated calcineurin involved the enzyme active site. We have previously shown that NFAT is targeted to inactive calcineurin at a region distinct from the calcineurin active site (Aramburu, J., Garcia-Cozar, F. J., Raghavan, A., Okamura, H., Rao, A., and Hogan, P. G. (1998) Mol. Cell 1, 627-637); this region is also involved in NFAT binding to activated calcineurin, since binding is inhibited by an NFAT peptide spanning the calcineurin docking site on NFAT. The interacting surfaces are located on the catalytic domain of the calcineurin A chain and on an 86-amino acid fragment of the NFAT regulatory domain. NFAT binding to the calcineurin catalytic domain was inhibited by the calcineurin autoinhibitory domain and the RII substrate peptide, which bind in the calcineurin active site, as well as by the NFAT docking site peptide, which binds to a region of calcineurin distinct from the active site. We propose that, in resting cells, NFAT is targeted to a region of the calcineurin catalytic domain that does not overlap the calcineurin active site. Upon cell activation, displacement of the autoinhibitory domain by calmodulin binding allows NFAT to bind additionally to the calcineurin active site, thus positioning NFAT for immediate dephosphorylation at functional phosphoserine residues.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "95cd880240a7419293999192f422b60e", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[194, 194], [293, 293], [93, 93], [211, 211], [82, 82], [46, 46], [182, 182], [230, 230], [237, 237], [250, 250], [55, 55], [103, 103], [324, 324], [270, 270], [120, 120], [62, 62], [301, 301], [127, 127]], "char_spans": [[1106, 1116], [1656, 1666], [619, 629], [1208, 1218], [535, 545], [293, 303], [1034, 1044], [1312, 1322], [1362, 1372], [1445, 1455], [339, 349], [687, 697], [1862, 1872], [1542, 1552], [791, 801], [391, 401], [1711, 1721], [833, 843]]}]}], "context_tokens": [["Transcription", 0], ["factors", 14], ["belonging", 22], ["to", 32], ["the", 35], ["nuclear", 39], ["factor", 47], ["of", 54], ["activated", 57], ["T", 67], ["cells", 69], ["(", 75], ["NFAT", 76], [")", 80], ["family", 82], ["regulate", 89], ["the", 98], ["expression", 102], ["of", 113], ["cytokine", 116], ["genes", 125], ["and", 131], ["other", 135], ["inducible", 141], ["genes", 151], ["during", 157], ["the", 164], ["immune", 168], ["response", 175], [".", 183], ["The", 185], ["functions", 189], ["of", 199], ["NFAT", 202], ["proteins", 207], ["are", 216], ["directly", 220], ["controlled", 229], ["by", 240], ["the", 243], ["calcium-", 247], ["and", 256], ["calmodulin", 260], ["-", 270], ["dependent", 271], ["phosphatase", 281], ["calcineurin", 293], [".", 304], ["Here", 306], ["we", 311], ["show", 314], ["that", 319], ["the", 324], ["binding", 328], ["of", 336], ["calcineurin", 339], ["to", 351], ["NFAT", 354], ["is", 359], ["substantially", 362], ["increased", 376], ["when", 386], ["calcineurin", 391], ["is", 403], ["activated", 406], ["with", 416], ["calmodulin", 421], ["and", 432], ["calcium", 436], [".", 443], ["FK506.FKBP12", 445], ["drug", 458], ["-", 462], ["immunophilin", 463], ["complexes", 476], ["inhibited", 486], ["the", 496], ["interaction", 500], ["of", 512], ["NFAT", 515], ["with", 520], ["activated", 525], ["calcineurin", 535], ["much", 547], ["more", 552], ["effectively", 557], ["than", 569], ["they", 574], ["inhibited", 579], ["the", 589], ["interaction", 593], ["with", 605], ["inactive", 610], ["calcineurin", 619], [",", 630], ["suggesting", 632], ["that", 643], ["part", 648], ["of", 653], ["the", 656], ["interaction", 660], ["with", 672], ["activated", 677], ["calcineurin", 687], ["involved", 699], ["the", 708], ["enzyme", 712], ["active", 719], ["site", 726], [".", 730], ["We", 732], ["have", 735], ["previously", 740], ["shown", 751], ["that", 757], ["NFAT", 762], ["is", 767], ["targeted", 770], ["to", 779], ["inactive", 782], ["calcineurin", 791], ["at", 803], ["a", 806], ["region", 808], ["distinct", 815], ["from", 824], ["the", 829], ["calcineurin", 833], ["active", 845], ["site", 852], ["(", 857], ["Aramburu", 858], [",", 866], ["J.", 868], [",", 870], ["Garcia", 872], ["-", 878], ["Cozar", 879], [",", 884], ["F.", 886], ["J.", 889], [",", 891], ["Raghavan", 893], [",", 901], ["A.", 903], [",", 905], ["Okamura", 907], [",", 914], ["H.", 916], [",", 918], ["Rao", 920], [",", 923], ["A.", 925], [",", 927], ["and", 929], ["Hogan", 933], [",", 938], ["P.", 940], ["G.", 943], ["(", 946], ["1998", 947], [")", 951], ["Mol", 953], [".", 956], ["Cell", 958], ["1", 963], [",", 964], ["627", 966], ["-", 969], ["637", 970], [")", 973], [";", 974], ["this", 976], ["region", 981], ["is", 988], ["also", 991], ["involved", 996], ["in", 1005], ["NFAT", 1008], ["binding", 1013], ["to", 1021], ["activated", 1024], ["calcineurin", 1034], [",", 1045], ["since", 1047], ["binding", 1053], ["is", 1061], ["inhibited", 1064], ["by", 1074], ["an", 1077], ["NFAT", 1080], ["peptide", 1085], ["spanning", 1093], ["the", 1102], ["calcineurin", 1106], ["docking", 1118], ["site", 1126], ["on", 1131], ["NFAT", 1134], [".", 1138], ["The", 1140], ["interacting", 1144], ["surfaces", 1156], ["are", 1165], ["located", 1169], ["on", 1177], ["the", 1180], ["catalytic", 1184], ["domain", 1194], ["of", 1201], ["the", 1204], ["calcineurin", 1208], ["A", 1220], ["chain", 1222], ["and", 1228], ["on", 1232], ["an", 1235], ["86-amino", 1238], ["acid", 1247], ["fragment", 1252], ["of", 1261], ["the", 1264], ["NFAT", 1268], ["regulatory", 1273], ["domain", 1284], [".", 1290], ["NFAT", 1292], ["binding", 1297], ["to", 1305], ["the", 1308], ["calcineurin", 1312], ["catalytic", 1324], ["domain", 1334], ["was", 1341], ["inhibited", 1345], ["by", 1355], ["the", 1358], ["calcineurin", 1362], ["autoinhibitory", 1374], ["domain", 1389], ["and", 1396], ["the", 1400], ["RII", 1404], ["substrate", 1408], ["peptide", 1418], [",", 1425], ["which", 1427], ["bind", 1433], ["in", 1438], ["the", 1441], ["calcineurin", 1445], ["active", 1457], ["site", 1464], [",", 1468], ["as", 1470], ["well", 1473], ["as", 1478], ["by", 1481], ["the", 1484], ["NFAT", 1488], ["docking", 1493], ["site", 1501], ["peptide", 1506], [",", 1513], ["which", 1515], ["binds", 1521], ["to", 1527], ["a", 1530], ["region", 1532], ["of", 1539], ["calcineurin", 1542], ["distinct", 1554], ["from", 1563], ["the", 1568], ["active", 1572], ["site", 1579], [".", 1583], ["We", 1585], ["propose", 1588], ["that", 1596], [",", 1600], ["in", 1602], ["resting", 1605], ["cells", 1613], [",", 1618], ["NFAT", 1620], ["is", 1625], ["targeted", 1628], ["to", 1637], ["a", 1640], ["region", 1642], ["of", 1649], ["the", 1652], ["calcineurin", 1656], ["catalytic", 1668], ["domain", 1678], ["that", 1685], ["does", 1690], ["not", 1695], ["overlap", 1699], ["the", 1707], ["calcineurin", 1711], ["active", 1723], ["site", 1730], [".", 1734], ["Upon", 1736], ["cell", 1741], ["activation", 1746], [",", 1756], ["displacement", 1758], ["of", 1771], ["the", 1774], ["autoinhibitory", 1778], ["domain", 1793], ["by", 1800], ["calmodulin", 1803], ["binding", 1814], ["allows", 1822], ["NFAT", 1829], ["to", 1834], ["bind", 1837], ["additionally", 1842], ["to", 1855], ["the", 1858], ["calcineurin", 1862], ["active", 1874], ["site", 1881], [",", 1885], ["thus", 1887], ["positioning", 1892], ["NFAT", 1904], ["for", 1909], ["immediate", 1913], ["dephosphorylation", 1923], ["at", 1941], ["functional", 1944], ["phosphoserine", 1955], ["residues", 1969], [".", 1977]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5c2cbb8eaf4742919bc8a56682ea0e5a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[138, 140], [20, 22], [28, 30]], "char_spans": [[779, 785], [98, 104], [133, 139]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["a", 13], ["dual", 15], ["Abl", 20], ["/", 23], ["Src", 24], ["tyrosine", 28], ["kinase", 37], ["inhibitor", 44], ["(", 54], ["TKI", 55], [")", 58], ["designed", 60], ["as", 69], ["a", 72], ["prototypic", 74], ["short", 85], ["-", 90], ["acting", 91], ["BCR", 98], ["-", 101], ["ABL", 102], ["-", 105], ["targeted", 106], ["TKI", 115], ["that", 119], ["inhibits", 124], ["BCR", 133], ["-", 136], ["ABL", 137], ["with", 141], ["greater", 146], ["potency", 154], ["compared", 162], ["with", 171], ["imatinib", 176], [",", 184], ["nilotinib", 186], [",", 195], ["bosutinib", 197], [",", 206], ["and", 208], ["ponatinib", 212], ["and", 222], ["has", 226], ["been", 230], ["shown", 235], ["to", 241], ["have", 244], ["potential", 249], ["immunomodulatory", 259], ["effects", 276], [".", 283], ["Dasatinib", 285], ["is", 295], ["approved", 298], ["for", 307], ["the", 311], ["treatment", 315], ["of", 325], ["all", 328], ["phases", 332], ["of", 339], ["chronic", 342], ["myeloid", 350], ["leukemia", 358], ["(", 367], ["CML", 368], [")", 371], ["and", 373], ["Philadelphia", 377], ["chromosome", 390], ["-", 400], ["positive", 401], ["acute", 410], ["lymphoblastic", 416], ["leukemia", 430], ["resistant", 439], ["or", 449], ["intolerant", 452], ["to", 463], ["prior", 466], ["imatinib", 472], ["treatment", 481], ["and", 491], ["first", 495], ["-", 500], ["line", 501], ["treatment", 506], ["for", 516], ["CML", 520], ["in", 524], ["chronic", 527], ["phase", 535], [".", 540], ["In", 542], ["this", 545], ["article", 550], [",", 557], ["the", 559], ["development", 563], ["of", 575], ["dasatinib", 578], ["as", 588], ["a", 591], ["treatment", 593], ["for", 603], ["patients", 607], ["with", 616], ["CML", 621], ["is", 625], ["reviewed", 628], [".", 636], ["This", 638], ["is", 643], ["a", 646], ["review", 648], ["of", 655], ["the", 658], ["relevant", 662], ["literature", 671], ["regarding", 682], ["dasatinib", 692], ["development", 702], ["in", 714], ["CML", 717], ["(", 721], ["2003", 722], ["-", 726], ["2013", 727], [")", 731], [".", 732], ["Dasatinib", 734], ["demonstrates", 744], ["efficacy", 757], ["against", 766], ["most", 774], ["BCR", 779], ["-", 782], ["ABL", 783], ["mutations", 787], ["arising", 797], ["during", 805], ["imatinib", 812], ["therapy", 821], ["and", 829], ["is", 833], ["effective", 836], ["in", 846], ["treating", 849], ["patients", 858], ["with", 867], ["imatinib", 872], ["resistance", 881], ["due", 892], ["to", 896], ["other", 899], ["mechanisms", 905], [".", 915], ["Randomized", 917], ["trial", 928], ["data", 934], ["show", 939], ["that", 944], ["first", 949], ["-", 954], ["line", 955], ["dasatinib", 960], ["provides", 970], ["superior", 979], ["responses", 988], ["compared", 998], ["with", 1007], ["imatinib", 1012], ["and", 1021], ["enables", 1025], ["patients", 1033], ["to", 1042], ["achieve", 1045], ["early", 1053], [",", 1058], ["deep", 1060], ["responses", 1065], ["correlated", 1075], ["with", 1086], ["improved", 1091], ["longer", 1100], ["-", 1106], ["term", 1107], ["outcomes", 1112], [".", 1120], ["Dasatinib", 1122], ["has", 1132], ["a", 1136], ["generally", 1138], ["acceptable", 1148], ["safety", 1159], ["profile", 1166], [",", 1173], ["with", 1175], ["most", 1180], ["adverse", 1185], ["events", 1193], ["(", 1200], ["AEs", 1201], [")", 1204], ["proving", 1206], ["manageable", 1214], ["and", 1225], ["reversible", 1229], [".", 1239], ["Cytopenias", 1241], ["are", 1252], ["commonly", 1256], ["observed", 1265], ["with", 1274], ["dasatinib", 1279], [",", 1288], ["and", 1290], ["some", 1294], ["nonhematologic", 1299], ["AEs", 1314], ["including", 1318], ["pleural", 1328], ["effusion", 1336], ["have", 1345], ["been", 1350], ["consistently", 1355], ["reported", 1368], [".", 1376], ["Dasatinib", 1378], ["is", 1388], ["an", 1391], ["effective", 1394], ["treatment", 1404], ["option", 1414], ["for", 1421], ["patients", 1425], ["with", 1434], ["CML", 1439], [".", 1442]]}
{"context": "OBJECTIVE Estimating the risk of a complicated course of Clostridium difficile infection (CDI) might help doctors guide treatment. We aimed to validate 3 published prediction models: Hensgens (2014), Na (2015), and Welfare (2011). METHODS The validation cohort comprised 148 patients diagnosed with CDI between May 2013 and March 2014. During this period, 70 endemic cases of CDI occurred as well as 78 cases of CDI related to an outbreak of C. difficile ribotype 027. Model calibration and discrimination were assessed for the 3 prediction rules. RESULTS A complicated course (ie, death, colectomy, or ICU admission due to CDI) was observed in 31 patients (21%), and 23 patients (16%) died within 30 days of CDI diagnosis. The performance of all 3 prediction models was poor when applied to the total validation cohort with an estimated area under the curve (AUC) of 0.68 for the Hensgens model, 0.54 for the Na model, and 0.61 for the Welfare model. For those patients diagnosed with CDI due to non-outbreak strains, the prediction model developed by Hensgens performed the best, with an AUC of 0.78. CONCLUSION All 3 prediction models performed poorly when using our total cohort, which included CDI cases from an outbreak as well as endemic cases. The prediction model of Hensgens performed relatively well for patients diagnosed with CDI due to non-outbreak strains, and this model may be useful in endemic settings. Infect Control Hosp Epidemiol 2017;38:897-905.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "25f9511121624df9b2da1467fc1efe81", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[87, 88]], "char_spans": [[455, 466]]}]}], "context_tokens": [["OBJECTIVE", 0], ["Estimating", 10], ["the", 21], ["risk", 25], ["of", 30], ["a", 33], ["complicated", 35], ["course", 47], ["of", 54], ["Clostridium", 57], ["difficile", 69], ["infection", 79], ["(", 89], ["CDI", 90], [")", 93], ["might", 95], ["help", 101], ["doctors", 106], ["guide", 114], ["treatment", 120], [".", 129], ["We", 131], ["aimed", 134], ["to", 140], ["validate", 143], ["3", 152], ["published", 154], ["prediction", 164], ["models", 175], [":", 181], ["Hensgens", 183], ["(", 192], ["2014", 193], [")", 197], [",", 198], ["Na", 200], ["(", 203], ["2015", 204], [")", 208], [",", 209], ["and", 211], ["Welfare", 215], ["(", 223], ["2011", 224], [")", 228], [".", 229], ["METHODS", 231], ["The", 239], ["validation", 243], ["cohort", 254], ["comprised", 261], ["148", 271], ["patients", 275], ["diagnosed", 284], ["with", 294], ["CDI", 299], ["between", 303], ["May", 311], ["2013", 315], ["and", 320], ["March", 324], ["2014", 330], [".", 334], ["During", 336], ["this", 343], ["period", 348], [",", 354], ["70", 356], ["endemic", 359], ["cases", 367], ["of", 373], ["CDI", 376], ["occurred", 380], ["as", 389], ["well", 392], ["as", 397], ["78", 400], ["cases", 403], ["of", 409], ["CDI", 412], ["related", 416], ["to", 424], ["an", 427], ["outbreak", 430], ["of", 439], ["C.", 442], ["difficile", 445], ["ribotype", 455], ["027", 464], [".", 467], ["Model", 469], ["calibration", 475], ["and", 487], ["discrimination", 491], ["were", 506], ["assessed", 511], ["for", 520], ["the", 524], ["3", 528], ["prediction", 530], ["rules", 541], [".", 546], ["RESULTS", 548], ["A", 556], ["complicated", 558], ["course", 570], ["(", 577], ["ie", 578], [",", 580], ["death", 582], [",", 587], ["colectomy", 589], [",", 598], ["or", 600], ["ICU", 603], ["admission", 607], ["due", 617], ["to", 621], ["CDI", 624], [")", 627], ["was", 629], ["observed", 633], ["in", 642], ["31", 645], ["patients", 648], ["(", 657], ["21", 658], ["%", 660], [")", 661], [",", 662], ["and", 664], ["23", 668], ["patients", 671], ["(", 680], ["16", 681], ["%", 683], [")", 684], ["died", 686], ["within", 691], ["30", 698], ["days", 701], ["of", 706], ["CDI", 709], ["diagnosis", 713], [".", 722], ["The", 724], ["performance", 728], ["of", 740], ["all", 743], ["3", 747], ["prediction", 749], ["models", 760], ["was", 767], ["poor", 771], ["when", 776], ["applied", 781], ["to", 789], ["the", 792], ["total", 796], ["validation", 802], ["cohort", 813], ["with", 820], ["an", 825], ["estimated", 828], ["area", 838], ["under", 843], ["the", 849], ["curve", 853], ["(", 859], ["AUC", 860], [")", 863], ["of", 865], ["0.68", 868], ["for", 873], ["the", 877], ["Hensgens", 881], ["model", 890], [",", 895], ["0.54", 897], ["for", 902], ["the", 906], ["Na", 910], ["model", 913], [",", 918], ["and", 920], ["0.61", 924], ["for", 929], ["the", 933], ["Welfare", 937], ["model", 945], [".", 950], ["For", 952], ["those", 956], ["patients", 962], ["diagnosed", 971], ["with", 981], ["CDI", 986], ["due", 990], ["to", 994], ["non", 997], ["-", 1000], ["outbreak", 1001], ["strains", 1010], [",", 1017], ["the", 1019], ["prediction", 1023], ["model", 1034], ["developed", 1040], ["by", 1050], ["Hensgens", 1053], ["performed", 1062], ["the", 1072], ["best", 1076], [",", 1080], ["with", 1082], ["an", 1087], ["AUC", 1090], ["of", 1094], ["0.78", 1097], [".", 1101], ["CONCLUSION", 1103], ["All", 1114], ["3", 1118], ["prediction", 1120], ["models", 1131], ["performed", 1138], ["poorly", 1148], ["when", 1155], ["using", 1160], ["our", 1166], ["total", 1170], ["cohort", 1176], [",", 1182], ["which", 1184], ["included", 1190], ["CDI", 1199], ["cases", 1203], ["from", 1209], ["an", 1214], ["outbreak", 1217], ["as", 1226], ["well", 1229], ["as", 1234], ["endemic", 1237], ["cases", 1245], [".", 1250], ["The", 1252], ["prediction", 1256], ["model", 1267], ["of", 1273], ["Hensgens", 1276], ["performed", 1285], ["relatively", 1295], ["well", 1306], ["for", 1311], ["patients", 1315], ["diagnosed", 1324], ["with", 1334], ["CDI", 1339], ["due", 1343], ["to", 1347], ["non", 1350], ["-", 1353], ["outbreak", 1354], ["strains", 1363], [",", 1370], ["and", 1372], ["this", 1376], ["model", 1381], ["may", 1387], ["be", 1391], ["useful", 1394], ["in", 1401], ["endemic", 1404], ["settings", 1412], [".", 1420], ["Infect", 1422], ["Control", 1429], ["Hosp", 1437], ["Epidemiol", 1442], ["2017;38:897", 1452], ["-", 1463], ["905", 1464], [".", 1467]]}
{"context": "Protein methylation is a common posttranslational modification that mostly occurs on arginine and lysine residues. Arginine methylation has been reported to regulate RNA processing, gene transcription, DNA damage repair, protein translocation, and signal transduction. Lysine methylation is best known to regulate histone function and is involved in epigenetic regulation of gene transcription. To better study protein methylation, we have developed highly specific antibodies against monomethyl arginine; asymmetric dimethyl arginine; and monomethyl, dimethyl, and trimethyl lysine motifs. These antibodies were used to perform immunoaffinity purification of methyl peptides followed by LC-MS/MS analysis to identify and quantify arginine and lysine methylation sites in several model studies. Overall, we identified over 1000 arginine methylation sites in human cell line and mouse tissues, and \u223c160 lysine methylation sites in human cell line HCT116. The number of methylation sites identified in this study exceeds those found in the literature to date. Detailed analysis of arginine-methylated proteins observed in mouse brain compared with those found in mouse embryo shows a tissue-specific distribution of arginine methylation, and extends the types of proteins that are known to be arginine methylated to include many new protein types. Many arginine-methylated proteins that we identified from the brain, including receptors, ion channels, transporters, and vesicle proteins, are involved in synaptic transmission, whereas the most abundant methylated proteins identified from mouse embryo are transcriptional regulators and RNA processing proteins.", "qas": [{"question": "Name a method for enrichment of arginine-methylated peptides.", "answers": ["Immunoaffinity purification"], "qid": "d40f8b57b37941beac2d486723c72a73", "question_tokens": [["Name", 0], ["a", 5], ["method", 7], ["for", 14], ["enrichment", 18], ["of", 29], ["arginine", 32], ["-", 40], ["methylated", 41], ["peptides", 52], [".", 60]], "detected_answers": [{"text": "Immunoaffinity purification", "token_spans": [[95, 96]], "char_spans": [[629, 655]]}]}], "context_tokens": [["Protein", 0], ["methylation", 8], ["is", 20], ["a", 23], ["common", 25], ["posttranslational", 32], ["modification", 50], ["that", 63], ["mostly", 68], ["occurs", 75], ["on", 82], ["arginine", 85], ["and", 94], ["lysine", 98], ["residues", 105], [".", 113], ["Arginine", 115], ["methylation", 124], ["has", 136], ["been", 140], ["reported", 145], ["to", 154], ["regulate", 157], ["RNA", 166], ["processing", 170], [",", 180], ["gene", 182], ["transcription", 187], [",", 200], ["DNA", 202], ["damage", 206], ["repair", 213], [",", 219], ["protein", 221], ["translocation", 229], [",", 242], ["and", 244], ["signal", 248], ["transduction", 255], [".", 267], ["Lysine", 269], ["methylation", 276], ["is", 288], ["best", 291], ["known", 296], ["to", 302], ["regulate", 305], ["histone", 314], ["function", 322], ["and", 331], ["is", 335], ["involved", 338], ["in", 347], ["epigenetic", 350], ["regulation", 361], ["of", 372], ["gene", 375], ["transcription", 380], [".", 393], ["To", 395], ["better", 398], ["study", 405], ["protein", 411], ["methylation", 419], [",", 430], ["we", 432], ["have", 435], ["developed", 440], ["highly", 450], ["specific", 457], ["antibodies", 466], ["against", 477], ["monomethyl", 485], ["arginine", 496], [";", 504], ["asymmetric", 506], ["dimethyl", 517], ["arginine", 526], [";", 534], ["and", 536], ["monomethyl", 540], [",", 550], ["dimethyl", 552], [",", 560], ["and", 562], ["trimethyl", 566], ["lysine", 576], ["motifs", 583], [".", 589], ["These", 591], ["antibodies", 597], ["were", 608], ["used", 613], ["to", 618], ["perform", 621], ["immunoaffinity", 629], ["purification", 644], ["of", 657], ["methyl", 660], ["peptides", 667], ["followed", 676], ["by", 685], ["LC", 688], ["-", 690], ["MS", 691], ["/", 693], ["MS", 694], ["analysis", 697], ["to", 706], ["identify", 709], ["and", 718], ["quantify", 722], ["arginine", 731], ["and", 740], ["lysine", 744], ["methylation", 751], ["sites", 763], ["in", 769], ["several", 772], ["model", 780], ["studies", 786], [".", 793], ["Overall", 795], [",", 802], ["we", 804], ["identified", 807], ["over", 818], ["1000", 823], ["arginine", 828], ["methylation", 837], ["sites", 849], ["in", 855], ["human", 858], ["cell", 864], ["line", 869], ["and", 874], ["mouse", 878], ["tissues", 884], [",", 891], ["and", 893], ["\u223c160", 897], ["lysine", 902], ["methylation", 909], ["sites", 921], ["in", 927], ["human", 930], ["cell", 936], ["line", 941], ["HCT116", 946], [".", 952], ["The", 954], ["number", 958], ["of", 965], ["methylation", 968], ["sites", 980], ["identified", 986], ["in", 997], ["this", 1000], ["study", 1005], ["exceeds", 1011], ["those", 1019], ["found", 1025], ["in", 1031], ["the", 1034], ["literature", 1038], ["to", 1049], ["date", 1052], [".", 1056], ["Detailed", 1058], ["analysis", 1067], ["of", 1076], ["arginine", 1079], ["-", 1087], ["methylated", 1088], ["proteins", 1099], ["observed", 1108], ["in", 1117], ["mouse", 1120], ["brain", 1126], ["compared", 1132], ["with", 1141], ["those", 1146], ["found", 1152], ["in", 1158], ["mouse", 1161], ["embryo", 1167], ["shows", 1174], ["a", 1180], ["tissue", 1182], ["-", 1188], ["specific", 1189], ["distribution", 1198], ["of", 1211], ["arginine", 1214], ["methylation", 1223], [",", 1234], ["and", 1236], ["extends", 1240], ["the", 1248], ["types", 1252], ["of", 1258], ["proteins", 1261], ["that", 1270], ["are", 1275], ["known", 1279], ["to", 1285], ["be", 1288], ["arginine", 1291], ["methylated", 1300], ["to", 1311], ["include", 1314], ["many", 1322], ["new", 1327], ["protein", 1331], ["types", 1339], [".", 1344], ["Many", 1346], ["arginine", 1351], ["-", 1359], ["methylated", 1360], ["proteins", 1371], ["that", 1380], ["we", 1385], ["identified", 1388], ["from", 1399], ["the", 1404], ["brain", 1408], [",", 1413], ["including", 1415], ["receptors", 1425], [",", 1434], ["ion", 1436], ["channels", 1440], [",", 1448], ["transporters", 1450], [",", 1462], ["and", 1464], ["vesicle", 1468], ["proteins", 1476], [",", 1484], ["are", 1486], ["involved", 1490], ["in", 1499], ["synaptic", 1502], ["transmission", 1511], [",", 1523], ["whereas", 1525], ["the", 1533], ["most", 1537], ["abundant", 1542], ["methylated", 1551], ["proteins", 1562], ["identified", 1571], ["from", 1582], ["mouse", 1587], ["embryo", 1593], ["are", 1600], ["transcriptional", 1604], ["regulators", 1620], ["and", 1631], ["RNA", 1635], ["processing", 1639], ["proteins", 1650], [".", 1658]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Screening specimens were homogenised in saline 0.9% w/v before either direct inoculation or following enrichment in broth on three chromogenic media (MRSA-ID, CHROMagar MRSA and MRSA Select) and ORSAB medium for the detection of methicillin-resistant Staphylococcus aureus (MRSA). In total, 102 of 466 specimens yielded MRSA on at least one medium. After incubation for 16-18 h, the sensitivity was 51%, 59%, 47% and 65% on MRSA-ID, CHROMagar MRSA, ORSAB and MRSA Select, respectively, compared with 82%, 75%, 67% and 80%, respectively, after 42 h, and 93%, 95%, 79% and not tested, respectively, following broth enrichment. There were significantly more MRSA colonies on MRSA-Select after 16-18 h than on ORSAB or MRSA ID (p 0.001 and 0.0022, respectively), whereas there were more MRSA colonies after 42 h on MRSA-ID and MRSA-Select than on ORSAB (p 0.0004 and 0.012, respectively). The specificity of the media for identifying MRSA based on the colour of colonies after incubation for 16-18 h was 100%, 99%, 99% and 100%, respectively, compared with 98%, 97%, 98% and 98%, respectively, after 42 h, and 100%, 99%, 100% and not tested, respectively, following broth enrichment. The speed of detection (mean time to report a positive result) was 1.65, 1.72, 2.31 and 1.35 days, respectively. For each of the three media tested following enrichment, the use of an enrichment broth increased the detection rate of MRSA by 16-24%.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "026a270369604faaa147cd6e84abe86b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[48, 48], [32, 32], [59, 59], [149, 149], [98, 98], [176, 176], [182, 182], [186, 186], [146, 146], [208, 208], [25, 25], [89, 89], [322, 322], [30, 30], [161, 161], [94, 94]], "char_spans": [[274, 277], [178, 181], [320, 323], [672, 675], [459, 462], [783, 786], [811, 814], [823, 826], [655, 658], [930, 933], [150, 153], [424, 427], [1413, 1416], [169, 172], [715, 718], [443, 446]]}]}], "context_tokens": [["Screening", 0], ["specimens", 10], ["were", 20], ["homogenised", 25], ["in", 37], ["saline", 40], ["0.9", 47], ["%", 50], ["w", 52], ["/", 53], ["v", 54], ["before", 56], ["either", 63], ["direct", 70], ["inoculation", 77], ["or", 89], ["following", 92], ["enrichment", 102], ["in", 113], ["broth", 116], ["on", 122], ["three", 125], ["chromogenic", 131], ["media", 143], ["(", 149], ["MRSA", 150], ["-", 154], ["ID", 155], [",", 157], ["CHROMagar", 159], ["MRSA", 169], ["and", 174], ["MRSA", 178], ["Select", 183], [")", 189], ["and", 191], ["ORSAB", 195], ["medium", 201], ["for", 208], ["the", 212], ["detection", 216], ["of", 226], ["methicillin", 229], ["-", 240], ["resistant", 241], ["Staphylococcus", 251], ["aureus", 266], ["(", 273], ["MRSA", 274], [")", 278], [".", 279], ["In", 281], ["total", 284], [",", 289], ["102", 291], ["of", 295], ["466", 298], ["specimens", 302], ["yielded", 312], ["MRSA", 320], ["on", 325], ["at", 328], ["least", 331], ["one", 337], ["medium", 341], [".", 347], ["After", 349], ["incubation", 355], ["for", 366], ["16", 370], ["-", 372], ["18", 373], ["h", 376], [",", 377], ["the", 379], ["sensitivity", 383], ["was", 395], ["51", 399], ["%", 401], [",", 402], ["59", 404], ["%", 406], [",", 407], ["47", 409], ["%", 411], ["and", 413], ["65", 417], ["%", 419], ["on", 421], ["MRSA", 424], ["-", 428], ["ID", 429], [",", 431], ["CHROMagar", 433], ["MRSA", 443], [",", 447], ["ORSAB", 449], ["and", 455], ["MRSA", 459], ["Select", 464], [",", 470], ["respectively", 472], [",", 484], ["compared", 486], ["with", 495], ["82", 500], ["%", 502], [",", 503], ["75", 505], ["%", 507], [",", 508], ["67", 510], ["%", 512], ["and", 514], ["80", 518], ["%", 520], [",", 521], ["respectively", 523], [",", 535], ["after", 537], ["42", 543], ["h", 546], [",", 547], ["and", 549], ["93", 553], ["%", 555], [",", 556], ["95", 558], ["%", 560], [",", 561], ["79", 563], ["%", 565], ["and", 567], ["not", 571], ["tested", 575], [",", 581], ["respectively", 583], [",", 595], ["following", 597], ["broth", 607], ["enrichment", 613], [".", 623], ["There", 625], ["were", 631], ["significantly", 636], ["more", 650], ["MRSA", 655], ["colonies", 660], ["on", 669], ["MRSA", 672], ["-", 676], ["Select", 677], ["after", 684], ["16", 690], ["-", 692], ["18", 693], ["h", 696], ["than", 698], ["on", 703], ["ORSAB", 706], ["or", 712], ["MRSA", 715], ["ID", 720], ["(", 723], ["p", 724], ["0.001", 726], ["and", 732], ["0.0022", 736], [",", 742], ["respectively", 744], [")", 756], [",", 757], ["whereas", 759], ["there", 767], ["were", 773], ["more", 778], ["MRSA", 783], ["colonies", 788], ["after", 797], ["42", 803], ["h", 806], ["on", 808], ["MRSA", 811], ["-", 815], ["ID", 816], ["and", 819], ["MRSA", 823], ["-", 827], ["Select", 828], ["than", 835], ["on", 840], ["ORSAB", 843], ["(", 849], ["p", 850], ["0.0004", 852], ["and", 859], ["0.012", 863], [",", 868], ["respectively", 870], [")", 882], [".", 883], ["The", 885], ["specificity", 889], ["of", 901], ["the", 904], ["media", 908], ["for", 914], ["identifying", 918], ["MRSA", 930], ["based", 935], ["on", 941], ["the", 944], ["colour", 948], ["of", 955], ["colonies", 958], ["after", 967], ["incubation", 973], ["for", 984], ["16", 988], ["-", 990], ["18", 991], ["h", 994], ["was", 996], ["100", 1000], ["%", 1003], [",", 1004], ["99", 1006], ["%", 1008], [",", 1009], ["99", 1011], ["%", 1013], ["and", 1015], ["100", 1019], ["%", 1022], [",", 1023], ["respectively", 1025], [",", 1037], ["compared", 1039], ["with", 1048], ["98", 1053], ["%", 1055], [",", 1056], ["97", 1058], ["%", 1060], [",", 1061], ["98", 1063], ["%", 1065], ["and", 1067], ["98", 1071], ["%", 1073], [",", 1074], ["respectively", 1076], [",", 1088], ["after", 1090], ["42", 1096], ["h", 1099], [",", 1100], ["and", 1102], ["100", 1106], ["%", 1109], [",", 1110], ["99", 1112], ["%", 1114], [",", 1115], ["100", 1117], ["%", 1120], ["and", 1122], ["not", 1126], ["tested", 1130], [",", 1136], ["respectively", 1138], [",", 1150], ["following", 1152], ["broth", 1162], ["enrichment", 1168], [".", 1178], ["The", 1180], ["speed", 1184], ["of", 1190], ["detection", 1193], ["(", 1203], ["mean", 1204], ["time", 1209], ["to", 1214], ["report", 1217], ["a", 1224], ["positive", 1226], ["result", 1235], [")", 1241], ["was", 1243], ["1.65", 1247], [",", 1251], ["1.72", 1253], [",", 1257], ["2.31", 1259], ["and", 1264], ["1.35", 1268], ["days", 1273], [",", 1277], ["respectively", 1279], [".", 1291], ["For", 1293], ["each", 1297], ["of", 1302], ["the", 1305], ["three", 1309], ["media", 1315], ["tested", 1321], ["following", 1328], ["enrichment", 1338], [",", 1348], ["the", 1350], ["use", 1354], ["of", 1358], ["an", 1361], ["enrichment", 1364], ["broth", 1375], ["increased", 1381], ["the", 1391], ["detection", 1395], ["rate", 1405], ["of", 1410], ["MRSA", 1413], ["by", 1418], ["16", 1421], ["-", 1423], ["24", 1424], ["%", 1426], [".", 1427]]}
{"context": "Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis. The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406. Three clinical studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600\u2009mg, (B) a single- and multiple-dose study of fostamatinib in aqueous suspension, with single doses ranging from 80-400\u2009mg and multiple doses at 160\u2009mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states. These studies demonstrated that when administered as a solution, R406 was rapidly absorbed. Increases in exposure were observed with doses up to 400\u2009mg. A terminal half-life of 12-21\u2009h was observed. Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration. Fostamatinib tablet and suspension exhibited similar R406 exposure. Upon co-administration with food, a delay in peak time and lower peak concentrations of R406 were observed but at the same time the overall exposure did not change. Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK. Solid dosage forms of fostamatinib overcome the challenge of low aqueous solubility of R406. The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "68d14ce5231c4bba93f1b52c90dd2f8c", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[21, 23]], "char_spans": [[107, 128]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["an", 23], ["orally", 26], ["dosed", 33], ["prodrug", 39], ["designed", 47], ["to", 56], ["deliver", 59], ["the", 67], ["active", 71], ["metabolite", 78], ["R940406", 89], ["(", 97], ["R406", 98], [")", 102], [",", 103], ["a", 105], ["spleen", 107], ["tyrosine", 114], ["kinase", 123], ["(", 130], ["SYK", 131], [")", 134], ["inhibitor", 136], [",", 145], ["for", 147], ["the", 151], ["treatment", 155], ["of", 165], ["rheumatoid", 168], ["arthritis", 179], [".", 188], ["The", 190], ["objectives", 194], ["were", 205], ["to", 210], ["evaluate", 213], ["the", 222], ["human", 226], ["pharmacokinetic", 232], ["properties", 248], ["of", 259], ["fostamatinib", 262], ["and", 275], ["R406", 279], [".", 283], ["Three", 285], ["clinical", 291], ["studies", 300], ["were", 308], ["conducted", 313], ["in", 323], ["healthy", 326], ["subjects", 334], [":", 342], ["(", 344], ["A", 345], [")", 346], ["A", 348], ["single", 350], ["ascending", 357], ["dose", 367], ["study", 372], ["for", 378], ["R406", 382], ["with", 387], ["doses", 392], ["ranging", 398], ["from", 406], ["80", 411], ["-", 413], ["600", 414], ["mg", 418], [",", 420], ["(", 422], ["B", 423], [")", 424], ["a", 426], ["single-", 428], ["and", 436], ["multiple", 440], ["-", 448], ["dose", 449], ["study", 454], ["of", 460], ["fostamatinib", 463], ["in", 476], ["aqueous", 479], ["suspension", 487], [",", 497], ["with", 499], ["single", 504], ["doses", 511], ["ranging", 517], ["from", 525], ["80", 530], ["-", 532], ["400", 533], ["mg", 537], ["and", 540], ["multiple", 544], ["doses", 553], ["at", 559], ["160", 562], ["mg", 566], ["twice", 569], ["daily", 575], ["and", 581], ["(", 585], ["C", 586], [")", 587], ["a", 589], ["study", 591], ["comparing", 597], ["suspension", 607], ["and", 618], ["tablet", 622], ["of", 629], ["fostamatinib", 632], [",", 644], ["with", 646], ["the", 651], ["latter", 655], ["tested", 662], ["in", 669], ["both", 672], ["fed", 677], ["and", 681], ["fasted", 685], ["states", 692], [".", 698], ["These", 700], ["studies", 706], ["demonstrated", 714], ["that", 727], ["when", 732], ["administered", 737], ["as", 750], ["a", 753], ["solution", 755], [",", 763], ["R406", 765], ["was", 770], ["rapidly", 774], ["absorbed", 782], [".", 790], ["Increases", 792], ["in", 802], ["exposure", 805], ["were", 814], ["observed", 819], ["with", 828], ["doses", 833], ["up", 839], ["to", 842], ["400", 845], ["mg", 849], [".", 851], ["A", 853], ["terminal", 855], ["half", 864], ["-", 868], ["life", 869], ["of", 874], ["12", 877], ["-", 879], ["21", 880], ["h", 883], ["was", 885], ["observed", 889], [".", 897], ["Similar", 899], ["R406", 907], ["exposure", 912], ["could", 921], ["be", 927], ["achieved", 930], ["with", 939], ["fostamatinib", 944], ["suspension", 957], ["and", 968], ["steady", 972], ["-", 978], ["state", 979], ["was", 985], ["achieved", 989], ["after", 998], ["3", 1004], ["-", 1005], ["4", 1006], ["days", 1008], ["following", 1013], ["twice", 1023], ["daily", 1029], ["administration", 1035], [".", 1049], ["Fostamatinib", 1051], ["tablet", 1064], ["and", 1071], ["suspension", 1075], ["exhibited", 1086], ["similar", 1096], ["R406", 1104], ["exposure", 1109], [".", 1117], ["Upon", 1119], ["co", 1124], ["-", 1126], ["administration", 1127], ["with", 1142], ["food", 1147], [",", 1151], ["a", 1153], ["delay", 1155], ["in", 1161], ["peak", 1164], ["time", 1169], ["and", 1174], ["lower", 1178], ["peak", 1184], ["concentrations", 1189], ["of", 1204], ["R406", 1207], ["were", 1212], ["observed", 1217], ["but", 1226], ["at", 1230], ["the", 1233], ["same", 1237], ["time", 1242], ["the", 1247], ["overall", 1251], ["exposure", 1259], ["did", 1268], ["not", 1272], ["change", 1276], [".", 1282], ["Fostamatinib", 1284], ["demonstrates", 1297], ["rapid", 1310], ["and", 1316], ["extensive", 1320], ["conversion", 1330], ["to", 1341], ["R406", 1344], [",", 1348], ["an", 1350], ["inhibitor", 1353], ["of", 1363], ["SYK", 1366], [".", 1369], ["Solid", 1371], ["dosage", 1377], ["forms", 1384], ["of", 1390], ["fostamatinib", 1393], ["overcome", 1406], ["the", 1415], ["challenge", 1419], ["of", 1429], ["low", 1432], ["aqueous", 1436], ["solubility", 1444], ["of", 1455], ["R406", 1458], [".", 1462], ["The", 1464], ["PK", 1468], ["profile", 1471], ["of", 1479], ["R406", 1482], ["could", 1487], ["potentially", 1493], ["allow", 1505], ["once", 1511], ["daily", 1516], ["or", 1522], ["twice", 1525], ["daily", 1531], ["oral", 1537], ["administration", 1542], ["of", 1557], ["fostamatinib", 1560], [".", 1572]]}
{"context": "Cap analysis of gene expression (CAGE) is a high-throughput method for transcriptome analysis that provides a single base-pair resolution map of transcription start sites (TSS) and their relative usage. Despite their high resolution and functional significance, published CAGE data are still underused in promoter analysis due to the absence of tools that enable its efficient manipulation and integration with other genome data types. Here we present CAGEr, an R implementation of novel methods for the analysis of differential TSS usage and promoter dynamics, integrated with CAGE data processing and promoterome mining into a first comprehensive CAGE toolbox on a common analysis platform. Crucially, we provide collections of TSSs derived from most published CAGE datasets, as well as direct access to FANTOM5 resource of TSSs for numerous human and mouse cell/tissue types from within R, greatly increasing the accessibility of precise context-specific TSS data for integrative analyses. The CAGEr package is freely available from Bioconductor at http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html.", "qas": [{"question": "Which tool is used for promoterome mining using CAGE data?", "answers": ["CAGEr"], "qid": "510b9aa3109f4e7c94f4cee443af85d9", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["promoterome", 23], ["mining", 35], ["using", 42], ["CAGE", 48], ["data", 53], ["?", 57]], "detected_answers": [{"text": "CAGEr", "token_spans": [[169, 169], [77, 77]], "char_spans": [[997, 1001], [452, 456]]}]}], "context_tokens": [["Cap", 0], ["analysis", 4], ["of", 13], ["gene", 16], ["expression", 21], ["(", 32], ["CAGE", 33], [")", 37], ["is", 39], ["a", 42], ["high", 44], ["-", 48], ["throughput", 49], ["method", 60], ["for", 67], ["transcriptome", 71], ["analysis", 85], ["that", 94], ["provides", 99], ["a", 108], ["single", 110], ["base", 117], ["-", 121], ["pair", 122], ["resolution", 127], ["map", 138], ["of", 142], ["transcription", 145], ["start", 159], ["sites", 165], ["(", 171], ["TSS", 172], [")", 175], ["and", 177], ["their", 181], ["relative", 187], ["usage", 196], [".", 201], ["Despite", 203], ["their", 211], ["high", 217], ["resolution", 222], ["and", 233], ["functional", 237], ["significance", 248], [",", 260], ["published", 262], ["CAGE", 272], ["data", 277], ["are", 282], ["still", 286], ["underused", 292], ["in", 302], ["promoter", 305], ["analysis", 314], ["due", 323], ["to", 327], ["the", 330], ["absence", 334], ["of", 342], ["tools", 345], ["that", 351], ["enable", 356], ["its", 363], ["efficient", 367], ["manipulation", 377], ["and", 390], ["integration", 394], ["with", 406], ["other", 411], ["genome", 417], ["data", 424], ["types", 429], [".", 434], ["Here", 436], ["we", 441], ["present", 444], ["CAGEr", 452], [",", 457], ["an", 459], ["R", 462], ["implementation", 464], ["of", 479], ["novel", 482], ["methods", 488], ["for", 496], ["the", 500], ["analysis", 504], ["of", 513], ["differential", 516], ["TSS", 529], ["usage", 533], ["and", 539], ["promoter", 543], ["dynamics", 552], [",", 560], ["integrated", 562], ["with", 573], ["CAGE", 578], ["data", 583], ["processing", 588], ["and", 599], ["promoterome", 603], ["mining", 615], ["into", 622], ["a", 627], ["first", 629], ["comprehensive", 635], ["CAGE", 649], ["toolbox", 654], ["on", 662], ["a", 665], ["common", 667], ["analysis", 674], ["platform", 683], [".", 691], ["Crucially", 693], [",", 702], ["we", 704], ["provide", 707], ["collections", 715], ["of", 727], ["TSSs", 730], ["derived", 735], ["from", 743], ["most", 748], ["published", 753], ["CAGE", 763], ["datasets", 768], [",", 776], ["as", 778], ["well", 781], ["as", 786], ["direct", 789], ["access", 796], ["to", 803], ["FANTOM5", 806], ["resource", 814], ["of", 823], ["TSSs", 826], ["for", 831], ["numerous", 835], ["human", 844], ["and", 850], ["mouse", 854], ["cell", 860], ["/", 864], ["tissue", 865], ["types", 872], ["from", 878], ["within", 883], ["R", 890], [",", 891], ["greatly", 893], ["increasing", 901], ["the", 912], ["accessibility", 916], ["of", 930], ["precise", 933], ["context", 941], ["-", 948], ["specific", 949], ["TSS", 958], ["data", 962], ["for", 967], ["integrative", 971], ["analyses", 983], [".", 991], ["The", 993], ["CAGEr", 997], ["package", 1003], ["is", 1011], ["freely", 1014], ["available", 1021], ["from", 1031], ["Bioconductor", 1036], ["at", 1049], ["http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html", 1052], [".", 1117]]}
{"context": "MicroRNAs (miRNAs) play a major part in the post-transcriptional regulation of gene expression. Mammalian miRNA biogenesis begins with cotranscriptional cleavage of RNA polymerase II (Pol II) transcripts by the Microprocessor complex. Although most miRNAs are located within introns of protein-coding transcripts, a substantial minority of miRNAs originate from long noncoding (lnc) RNAs, for which transcript processing is largely uncharacterized. We show, by detailed characterization of liver-specific lnc-pri-miR-122 and genome-wide analysis in human cell lines, that most lncRNA transcripts containing miRNAs (lnc-pri-miRNAs) do not use the canonical cleavage-and-polyadenylation pathway but instead use Microprocessor cleavage to terminate transcription. Microprocessor inactivation leads to extensive transcriptional readthrough of lnc-pri-miRNA and transcriptional interference with downstream genes. Consequently we define a new RNase III-mediated, polyadenylation-independent mechanism of Pol II transcription termination in mammalian cells.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cc8c050eacbc476399b7a6d1ccc9c404", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[26, 28]], "char_spans": [[165, 181]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["play", 19], ["a", 24], ["major", 26], ["part", 32], ["in", 37], ["the", 40], ["post", 44], ["-", 48], ["transcriptional", 49], ["regulation", 65], ["of", 76], ["gene", 79], ["expression", 84], [".", 94], ["Mammalian", 96], ["miRNA", 106], ["biogenesis", 112], ["begins", 123], ["with", 130], ["cotranscriptional", 135], ["cleavage", 153], ["of", 162], ["RNA", 165], ["polymerase", 169], ["II", 180], ["(", 183], ["Pol", 184], ["II", 188], [")", 190], ["transcripts", 192], ["by", 204], ["the", 207], ["Microprocessor", 211], ["complex", 226], [".", 233], ["Although", 235], ["most", 244], ["miRNAs", 249], ["are", 256], ["located", 260], ["within", 268], ["introns", 275], ["of", 283], ["protein", 286], ["-", 293], ["coding", 294], ["transcripts", 301], [",", 312], ["a", 314], ["substantial", 316], ["minority", 328], ["of", 337], ["miRNAs", 340], ["originate", 347], ["from", 357], ["long", 362], ["noncoding", 367], ["(", 377], ["lnc", 378], [")", 381], ["RNAs", 383], [",", 387], ["for", 389], ["which", 393], ["transcript", 399], ["processing", 410], ["is", 421], ["largely", 424], ["uncharacterized", 432], [".", 447], ["We", 449], ["show", 452], [",", 456], ["by", 458], ["detailed", 461], ["characterization", 470], ["of", 487], ["liver", 490], ["-", 495], ["specific", 496], ["lnc", 505], ["-", 508], ["pri", 509], ["-", 512], ["miR-122", 513], ["and", 521], ["genome", 525], ["-", 531], ["wide", 532], ["analysis", 537], ["in", 546], ["human", 549], ["cell", 555], ["lines", 560], [",", 565], ["that", 567], ["most", 572], ["lncRNA", 577], ["transcripts", 584], ["containing", 596], ["miRNAs", 607], ["(", 614], ["lnc", 615], ["-", 618], ["pri", 619], ["-", 622], ["miRNAs", 623], [")", 629], ["do", 631], ["not", 634], ["use", 638], ["the", 642], ["canonical", 646], ["cleavage", 656], ["-", 664], ["and", 665], ["-", 668], ["polyadenylation", 669], ["pathway", 685], ["but", 693], ["instead", 697], ["use", 705], ["Microprocessor", 709], ["cleavage", 724], ["to", 733], ["terminate", 736], ["transcription", 746], [".", 759], ["Microprocessor", 761], ["inactivation", 776], ["leads", 789], ["to", 795], ["extensive", 798], ["transcriptional", 808], ["readthrough", 824], ["of", 836], ["lnc", 839], ["-", 842], ["pri", 843], ["-", 846], ["miRNA", 847], ["and", 853], ["transcriptional", 857], ["interference", 873], ["with", 886], ["downstream", 891], ["genes", 902], [".", 907], ["Consequently", 909], ["we", 922], ["define", 925], ["a", 932], ["new", 934], ["RNase", 938], ["III", 944], ["-", 947], ["mediated", 948], [",", 956], ["polyadenylation", 958], ["-", 973], ["independent", 974], ["mechanism", 986], ["of", 996], ["Pol", 999], ["II", 1003], ["transcription", 1006], ["termination", 1020], ["in", 1032], ["mammalian", 1035], ["cells", 1045], [".", 1050]]}
{"context": "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "0b4eb5fc8d864052918d6cffa3730c7d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[118, 147]]}, {"text": "PTSD", "token_spans": [[48, 48], [226, 226], [93, 93], [205, 205], [138, 138], [36, 36], [68, 68], [153, 153], [215, 215], [233, 233], [24, 24], [146, 146]], "char_spans": [[267, 270], [1271, 1274], [507, 510], [1160, 1163], [752, 755], [212, 215], [383, 386], [848, 851], [1217, 1220], [1316, 1319], [150, 153], [803, 806]]}]}], "context_tokens": [["Emerging", 0], ["data", 9], ["suggest", 14], ["that", 22], ["second", 27], ["-", 33], ["generation", 34], ["antipsychotics", 45], ["such", 60], ["as", 65], ["aripiprazole", 68], ["may", 81], ["be", 85], ["effective", 88], ["in", 98], ["the", 101], ["treatment", 105], ["of", 115], ["post", 118], ["-", 122], ["traumatic", 123], ["stress", 133], ["disorder", 140], ["(", 149], ["PTSD", 150], [")", 154], [".", 155], ["However", 157], [",", 164], ["few", 166], ["clinical", 170], ["trials", 179], ["have", 186], ["used", 191], ["aripiprazole", 196], ["in", 209], ["PTSD", 212], [",", 216], ["and", 218], ["data", 222], ["are", 227], ["limited", 231], ["on", 239], ["its", 242], ["use", 246], ["in", 250], ["Veterans", 253], ["with", 262], ["PTSD", 267], [".", 271], ["The", 273], ["objective", 277], ["of", 287], ["this", 290], ["pilot", 295], ["trial", 301], ["was", 307], ["to", 311], ["investigate", 314], ["the", 326], ["safety", 330], ["and", 337], ["efficacy", 341], ["of", 350], ["aripiprazole", 353], ["in", 366], ["Veterans", 369], ["with", 378], ["PTSD", 383], [".", 387], ["Ten", 389], ["individuals", 393], ["(", 405], ["five", 406], ["men", 411], ["and", 415], ["five", 419], ["women", 424], [")", 429], ["meeting", 431], ["the", 439], ["Diagnostic", 443], ["and", 454], ["statistical", 458], ["manual", 470], ["of", 477], ["mental", 480], ["disorders", 487], [",", 496], ["4th", 498], ["ed", 502], [".", 504], [",", 505], ["PTSD", 507], ["criteria", 512], ["participated", 521], ["in", 534], ["this", 537], ["12-week", 542], [",", 549], ["open", 551], ["-", 555], ["label", 556], [",", 561], ["flexibly", 563], ["dosed", 572], ["monotherapy", 578], ["trial", 590], [".", 595], ["The", 597], ["dose", 601], ["range", 606], ["of", 612], ["aripiprazole", 615], ["was", 628], ["5", 632], ["-", 633], ["30", 634], ["mg", 637], ["/", 639], ["day", 640], [",", 643], ["titrated", 645], ["to", 654], ["tolerability", 657], ["and", 670], ["clinical", 674], ["response", 683], [".", 691], ["The", 693], ["primary", 697], ["outcome", 705], ["measure", 713], ["was", 721], ["the", 725], ["Clinician", 729], ["-", 738], ["Administered", 739], ["PTSD", 752], ["Scale", 757], [".", 762], ["Additional", 764], ["outcomes", 775], ["included", 784], ["the", 793], ["Short", 797], ["PTSD", 803], ["Rating", 808], ["Interview", 815], [",", 824], ["the", 826], ["Treatment", 830], ["Outcome", 840], ["PTSD", 848], ["Scale", 853], ["(", 859], ["Top-8", 860], [")", 865], [",", 866], ["the", 868], ["Davidson", 872], ["Trauma", 881], ["Scale", 888], [",", 893], ["the", 895], ["Positive", 899], ["and", 908], ["Negative", 912], ["Syndrome", 921], ["Scale", 930], [",", 935], ["the", 937], ["Beck", 941], ["Depression", 946], ["Inventory", 957], ["-", 966], ["Fast", 967], ["Screen", 972], [",", 978], ["and", 980], ["Clinical", 984], ["Global", 993], ["Impressions", 1000], ["-", 1011], ["Improvement", 1012], [".", 1023], ["Eight", 1025], ["participants", 1031], ["completed", 1044], ["the", 1054], ["study", 1058], [",", 1063], ["and", 1065], ["aripiprazole", 1069], ["was", 1082], ["generally", 1086], ["well", 1096], ["tolerated", 1101], ["and", 1111], ["associated", 1115], ["with", 1126], ["a", 1131], ["significant", 1133], ["improvement", 1145], ["in", 1157], ["PTSD", 1160], ["symptoms", 1165], [",", 1173], ["as", 1175], ["measured", 1178], ["by", 1187], ["the", 1190], ["Clinician", 1194], ["-", 1203], ["Administered", 1204], ["PTSD", 1217], ["Scale", 1222], ["(", 1228], ["primary", 1229], ["outcome", 1237], ["measure", 1245], [")", 1252], ["and", 1254], ["by", 1258], ["the", 1261], ["Short", 1265], ["PTSD", 1271], ["Rating", 1276], ["Interview", 1283], [",", 1292], ["the", 1294], ["Treatment", 1298], ["Outcome", 1308], ["PTSD", 1316], ["Scale", 1321], [",", 1326], ["and", 1328], ["the", 1332], ["Davidson", 1336], ["Trauma", 1345], ["Scale", 1352], [".", 1357], ["An", 1359], ["improvement", 1362], ["was", 1374], ["also", 1378], ["observed", 1383], ["on", 1392], ["all", 1395], ["three", 1399], ["Positive", 1405], ["and", 1414], ["Negative", 1418], ["Syndrome", 1427], ["Scale", 1436], ["subscales", 1442], ["and", 1452], ["the", 1456], ["Beck", 1460], ["Depression", 1465], ["Inventory", 1476], ["-", 1485], ["Fast", 1486], ["Screen", 1491], [",", 1497], ["and", 1499], ["the", 1503], ["average", 1507], ["Clinical", 1515], ["Global", 1524], ["Impressions", 1531], ["-", 1542], ["Improvement", 1543], ["ratings", 1555], ["indicated", 1563], ["that", 1573], ["patients", 1578], ["were", 1587], ["'", 1592], ["much", 1593], ["improved", 1598], ["'", 1606], [".", 1607], ["These", 1609], ["promising", 1615], ["initial", 1625], ["results", 1633], ["merit", 1641], ["further", 1647], ["investigation", 1655], ["in", 1669], ["a", 1672], ["larger", 1674], [",", 1680], ["randomized", 1682], ["-", 1692], ["controlled", 1693], ["trial", 1704], [".", 1709]]}
{"context": "Centrosome forms the backbone of cell cycle progression mechanism. Recent debates have occurred regarding the essentiality of centrosome in cell cycle regulation. CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control. A total of 31 proteins have been categorized into CEP family protein category and many more are under candidate evaluation. Furthermore, by the recent advancements in genomics and proteomics researches, several new CEP proteins have also been characterized. Here we have summarized the importance of CEP family proteins and their regulation mechanism involved in proper cell cycle progression. Further, we have reviewed the detailed molecular mechanism behind the associated pathological phenotypes and the possible therapeutic approaches. Proteins such as CEP57, CEP63, CEP152, CEP164, and CEP215 have been extensively studied with a detailed description of their molecular mechanisms, which are among the primary targets for drug discovery. Moreover, CEP27, CEP55, CEP70, CEP110, CEP120, CEP135, CEP192, CEP250, CEP290, and CEP350 also seem promising for future drug discovery approaches. Since the overview implicates that the overall researches on CEP proteins are not yet able to present significant details required for effective therapeutics development, thus, it is timely to discuss the importance of future investigations in this field.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "bc41177a6b044b729aab22fd26e9d225", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[0, 0], [32, 32], [18, 18]], "char_spans": [[0, 9], [209, 218], [126, 135]]}]}], "context_tokens": [["Centrosome", 0], ["forms", 11], ["the", 17], ["backbone", 21], ["of", 30], ["cell", 33], ["cycle", 38], ["progression", 44], ["mechanism", 56], [".", 65], ["Recent", 67], ["debates", 74], ["have", 82], ["occurred", 87], ["regarding", 96], ["the", 106], ["essentiality", 110], ["of", 123], ["centrosome", 126], ["in", 137], ["cell", 140], ["cycle", 145], ["regulation", 151], [".", 161], ["CEP", 163], ["family", 167], ["protein", 174], ["is", 182], ["the", 185], ["active", 189], ["component", 196], ["of", 206], ["centrosome", 209], ["and", 220], ["plays", 224], ["a", 230], ["vital", 232], ["role", 238], ["in", 243], ["centriole", 246], ["biogenesis", 256], ["and", 267], ["cell", 271], ["cycle", 276], ["progression", 282], ["control", 294], [".", 301], ["A", 303], ["total", 305], ["of", 311], ["31", 314], ["proteins", 317], ["have", 326], ["been", 331], ["categorized", 336], ["into", 348], ["CEP", 353], ["family", 357], ["protein", 364], ["category", 372], ["and", 381], ["many", 385], ["more", 390], ["are", 395], ["under", 399], ["candidate", 405], ["evaluation", 415], [".", 425], ["Furthermore", 427], [",", 438], ["by", 440], ["the", 443], ["recent", 447], ["advancements", 454], ["in", 467], ["genomics", 470], ["and", 479], ["proteomics", 483], ["researches", 494], [",", 504], ["several", 506], ["new", 514], ["CEP", 518], ["proteins", 522], ["have", 531], ["also", 536], ["been", 541], ["characterized", 546], [".", 559], ["Here", 561], ["we", 566], ["have", 569], ["summarized", 574], ["the", 585], ["importance", 589], ["of", 600], ["CEP", 603], ["family", 607], ["proteins", 614], ["and", 623], ["their", 627], ["regulation", 633], ["mechanism", 644], ["involved", 654], ["in", 663], ["proper", 666], ["cell", 673], ["cycle", 678], ["progression", 684], [".", 695], ["Further", 697], [",", 704], ["we", 706], ["have", 709], ["reviewed", 714], ["the", 723], ["detailed", 727], ["molecular", 736], ["mechanism", 746], ["behind", 756], ["the", 763], ["associated", 767], ["pathological", 778], ["phenotypes", 791], ["and", 802], ["the", 806], ["possible", 810], ["therapeutic", 819], ["approaches", 831], [".", 841], ["Proteins", 843], ["such", 852], ["as", 857], ["CEP57", 860], [",", 865], ["CEP63", 867], [",", 872], ["CEP152", 874], [",", 880], ["CEP164", 882], [",", 888], ["and", 890], ["CEP215", 894], ["have", 901], ["been", 906], ["extensively", 911], ["studied", 923], ["with", 931], ["a", 936], ["detailed", 938], ["description", 947], ["of", 959], ["their", 962], ["molecular", 968], ["mechanisms", 978], [",", 988], ["which", 990], ["are", 996], ["among", 1000], ["the", 1006], ["primary", 1010], ["targets", 1018], ["for", 1026], ["drug", 1030], ["discovery", 1035], [".", 1044], ["Moreover", 1046], [",", 1054], ["CEP27", 1056], [",", 1061], ["CEP55", 1063], [",", 1068], ["CEP70", 1070], [",", 1075], ["CEP110", 1077], [",", 1083], ["CEP120", 1085], [",", 1091], ["CEP135", 1093], [",", 1099], ["CEP192", 1101], [",", 1107], ["CEP250", 1109], [",", 1115], ["CEP290", 1117], [",", 1123], ["and", 1125], ["CEP350", 1129], ["also", 1136], ["seem", 1141], ["promising", 1146], ["for", 1156], ["future", 1160], ["drug", 1167], ["discovery", 1172], ["approaches", 1182], [".", 1192], ["Since", 1194], ["the", 1200], ["overview", 1204], ["implicates", 1213], ["that", 1224], ["the", 1229], ["overall", 1233], ["researches", 1241], ["on", 1252], ["CEP", 1255], ["proteins", 1259], ["are", 1268], ["not", 1272], ["yet", 1276], ["able", 1280], ["to", 1285], ["present", 1288], ["significant", 1296], ["details", 1308], ["required", 1316], ["for", 1325], ["effective", 1329], ["therapeutics", 1339], ["development", 1352], [",", 1363], ["thus", 1365], [",", 1369], ["it", 1371], ["is", 1374], ["timely", 1377], ["to", 1384], ["discuss", 1387], ["the", 1395], ["importance", 1399], ["of", 1410], ["future", 1413], ["investigations", 1420], ["in", 1435], ["this", 1438], ["field", 1443], [".", 1448]]}
{"context": "Genomic context analysis, also known as phylogenetic profiling, is widely used to infer functional interactions between proteins but rarely applied to non-coding cis-regulatory DNA elements. We were wondering whether this approach could provide insights about utlraconserved non-coding elements (UCNEs). These elements are organized as large clusters, so-called gene regulatory blocks (GRBs) around key developmental genes. Their molecular functions and the reasons for their high degree of conservation remain enigmatic. In a special setting of genomic context analysis, we analyzed the fate of GRBs after a whole-genome duplication event in five fish genomes. We found that in most cases all UCNEs were retained together as a single block, whereas the corresponding target genes were often retained in two copies, one completely devoid of UCNEs. This 'winner-takes-all' pattern suggests that UCNEs of a GRB function in a highly cooperative manner. We propose that the multitude of interactions between UCNEs is the reason for their extreme sequence conservation. Supplementary data are available at Bioinformatics online and at http://ccg.vital-it.ch/ucne/", "qas": [{"question": "How are ultraconserved elements called when they form clusters?", "answers": ["gene regulatory blocks (GRBs)"], "qid": "f7321b2110b94a3bba595a160b668297", "question_tokens": [["How", 0], ["are", 4], ["ultraconserved", 8], ["elements", 23], ["called", 32], ["when", 39], ["they", 44], ["form", 49], ["clusters", 54], ["?", 62]], "detected_answers": [{"text": "gene regulatory blocks (GRBs)", "token_spans": [[62, 66]], "char_spans": [[362, 389]]}]}], "context_tokens": [["Genomic", 0], ["context", 8], ["analysis", 16], [",", 24], ["also", 26], ["known", 31], ["as", 37], ["phylogenetic", 40], ["profiling", 53], [",", 62], ["is", 64], ["widely", 67], ["used", 74], ["to", 79], ["infer", 82], ["functional", 88], ["interactions", 99], ["between", 112], ["proteins", 120], ["but", 129], ["rarely", 133], ["applied", 140], ["to", 148], ["non", 151], ["-", 154], ["coding", 155], ["cis", 162], ["-", 165], ["regulatory", 166], ["DNA", 177], ["elements", 181], [".", 189], ["We", 191], ["were", 194], ["wondering", 199], ["whether", 209], ["this", 217], ["approach", 222], ["could", 231], ["provide", 237], ["insights", 245], ["about", 254], ["utlraconserved", 260], ["non", 275], ["-", 278], ["coding", 279], ["elements", 286], ["(", 295], ["UCNEs", 296], [")", 301], [".", 302], ["These", 304], ["elements", 310], ["are", 319], ["organized", 323], ["as", 333], ["large", 336], ["clusters", 342], [",", 350], ["so", 352], ["-", 354], ["called", 355], ["gene", 362], ["regulatory", 367], ["blocks", 378], ["(", 385], ["GRBs", 386], [")", 390], ["around", 392], ["key", 399], ["developmental", 403], ["genes", 417], [".", 422], ["Their", 424], ["molecular", 430], ["functions", 440], ["and", 450], ["the", 454], ["reasons", 458], ["for", 466], ["their", 470], ["high", 476], ["degree", 481], ["of", 488], ["conservation", 491], ["remain", 504], ["enigmatic", 511], [".", 520], ["In", 522], ["a", 525], ["special", 527], ["setting", 535], ["of", 543], ["genomic", 546], ["context", 554], ["analysis", 562], [",", 570], ["we", 572], ["analyzed", 575], ["the", 584], ["fate", 588], ["of", 593], ["GRBs", 596], ["after", 601], ["a", 607], ["whole", 609], ["-", 614], ["genome", 615], ["duplication", 622], ["event", 634], ["in", 640], ["five", 643], ["fish", 648], ["genomes", 653], [".", 660], ["We", 662], ["found", 665], ["that", 671], ["in", 676], ["most", 679], ["cases", 684], ["all", 690], ["UCNEs", 694], ["were", 700], ["retained", 705], ["together", 714], ["as", 723], ["a", 726], ["single", 728], ["block", 735], [",", 740], ["whereas", 742], ["the", 750], ["corresponding", 754], ["target", 768], ["genes", 775], ["were", 781], ["often", 786], ["retained", 792], ["in", 801], ["two", 804], ["copies", 808], [",", 814], ["one", 816], ["completely", 820], ["devoid", 831], ["of", 838], ["UCNEs", 841], [".", 846], ["This", 848], ["'", 853], ["winner", 854], ["-", 860], ["takes", 861], ["-", 866], ["all", 867], ["'", 870], ["pattern", 872], ["suggests", 880], ["that", 889], ["UCNEs", 894], ["of", 900], ["a", 903], ["GRB", 905], ["function", 909], ["in", 918], ["a", 921], ["highly", 923], ["cooperative", 930], ["manner", 942], [".", 948], ["We", 950], ["propose", 953], ["that", 961], ["the", 966], ["multitude", 970], ["of", 980], ["interactions", 983], ["between", 996], ["UCNEs", 1004], ["is", 1010], ["the", 1013], ["reason", 1017], ["for", 1024], ["their", 1028], ["extreme", 1034], ["sequence", 1042], ["conservation", 1051], [".", 1063], ["Supplementary", 1065], ["data", 1079], ["are", 1084], ["available", 1088], ["at", 1098], ["Bioinformatics", 1101], ["online", 1116], ["and", 1123], ["at", 1127], ["http://ccg.vital-it.ch/ucne/", 1130]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "The major constituent of senile plaques in Alzheimer's disease is a 42-aa peptide, referred to as beta-amyloid (Abeta). Abeta is generated from a family of differentially spliced, type-1 transmembrane domain (TM)-containing proteins, called APP, by endoproteolytic processing. The major, relatively ubiquitous pathway of APP metabolism in cell culture involves cleavage by alpha-secretase, which cleaves within the Abeta sequence, thus precluding Abeta formation and deposition. An alternate secretory pathway, enriched in neurons and brain, leads to cleavage of APP at the N terminus of the Abeta peptide by beta-secretase, thus generating a cell-associated beta-C-terminal fragment (beta-CTF). A pathogenic mutation at codons 670/671 in APP (APP \"Swedish\") leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation. An inhibitor of vacuolar ATPases, bafilomycin, selectively inhibits the action of beta-secretase in cell culture, suggesting a requirement for an acidic intracellular compartment for effective beta-secretase cleavage of APP. beta-CTF is cleaved in the TM domain by gamma-secretase(s), generating both Abeta 1-40 (90%) and Abeta 1-42 (10%). Pathogenic mutations in APP at codon 717 (APP \"London\") lead to an increased proportion of Abeta 1-42 being produced and secreted. Missense mutations in PS-1, localized to chromosome 14, are pathogenic in the majority of familial Alzheimer's pedigrees. These mutations also lead to increased production of Abeta 1-42 over Abeta 1-40. Knockout of PS-1 in transgenic animals leads to significant inhibition of production of both Abeta 1-40 and Abeta 1-42 in primary cultures, indicating that PS-1 expression is important for gamma-secretase cleavages. Peptide aldehyde inhibitors that block Abeta production by inhibiting gamma-secretase cleavage of beta-CTF have been discovered.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "2e818059dd7c4f0d898f3266677d9a3c", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["The", 0], ["major", 4], ["constituent", 10], ["of", 22], ["senile", 25], ["plaques", 32], ["in", 40], ["Alzheimer", 43], ["'s", 52], ["disease", 55], ["is", 63], ["a", 66], ["42-aa", 68], ["peptide", 74], [",", 81], ["referred", 83], ["to", 92], ["as", 95], ["beta", 98], ["-", 102], ["amyloid", 103], ["(", 111], ["Abeta", 112], [")", 117], [".", 118], ["Abeta", 120], ["is", 126], ["generated", 129], ["from", 139], ["a", 144], ["family", 146], ["of", 153], ["differentially", 156], ["spliced", 171], [",", 178], ["type-1", 180], ["transmembrane", 187], ["domain", 201], ["(", 208], ["TM)-containing", 209], ["proteins", 224], [",", 232], ["called", 234], ["APP", 241], [",", 244], ["by", 246], ["endoproteolytic", 249], ["processing", 265], [".", 275], ["The", 277], ["major", 281], [",", 286], ["relatively", 288], ["ubiquitous", 299], ["pathway", 310], ["of", 318], ["APP", 321], ["metabolism", 325], ["in", 336], ["cell", 339], ["culture", 344], ["involves", 352], ["cleavage", 361], ["by", 370], ["alpha", 373], ["-", 378], ["secretase", 379], [",", 388], ["which", 390], ["cleaves", 396], ["within", 404], ["the", 411], ["Abeta", 415], ["sequence", 421], [",", 429], ["thus", 431], ["precluding", 436], ["Abeta", 447], ["formation", 453], ["and", 463], ["deposition", 467], [".", 477], ["An", 479], ["alternate", 482], ["secretory", 492], ["pathway", 502], [",", 509], ["enriched", 511], ["in", 520], ["neurons", 523], ["and", 531], ["brain", 535], [",", 540], ["leads", 542], ["to", 548], ["cleavage", 551], ["of", 560], ["APP", 563], ["at", 567], ["the", 570], ["N", 574], ["terminus", 576], ["of", 585], ["the", 588], ["Abeta", 592], ["peptide", 598], ["by", 606], ["beta", 609], ["-", 613], ["secretase", 614], [",", 623], ["thus", 625], ["generating", 630], ["a", 641], ["cell", 643], ["-", 647], ["associated", 648], ["beta", 659], ["-", 663], ["C", 664], ["-", 665], ["terminal", 666], ["fragment", 675], ["(", 684], ["beta", 685], ["-", 689], ["CTF", 690], [")", 693], [".", 694], ["A", 696], ["pathogenic", 698], ["mutation", 709], ["at", 718], ["codons", 721], ["670/671", 728], ["in", 736], ["APP", 739], ["(", 743], ["APP", 744], ["\"", 748], ["Swedish", 749], ["\"", 756], [")", 757], ["leads", 759], ["to", 765], ["enhanced", 768], ["cleavage", 777], ["at", 786], ["the", 789], ["beta", 793], ["-", 797], ["secretase", 798], ["scissile", 808], ["bond", 817], ["and", 822], ["increased", 826], ["Abeta", 836], ["formation", 842], [".", 851], ["An", 853], ["inhibitor", 856], ["of", 866], ["vacuolar", 869], ["ATPases", 878], [",", 885], ["bafilomycin", 887], [",", 898], ["selectively", 900], ["inhibits", 912], ["the", 921], ["action", 925], ["of", 932], ["beta", 935], ["-", 939], ["secretase", 940], ["in", 950], ["cell", 953], ["culture", 958], [",", 965], ["suggesting", 967], ["a", 978], ["requirement", 980], ["for", 992], ["an", 996], ["acidic", 999], ["intracellular", 1006], ["compartment", 1020], ["for", 1032], ["effective", 1036], ["beta", 1046], ["-", 1050], ["secretase", 1051], ["cleavage", 1061], ["of", 1070], ["APP", 1073], [".", 1076], ["beta", 1078], ["-", 1082], ["CTF", 1083], ["is", 1087], ["cleaved", 1090], ["in", 1098], ["the", 1101], ["TM", 1105], ["domain", 1108], ["by", 1115], ["gamma", 1118], ["-", 1123], ["secretase(s", 1124], [")", 1135], [",", 1136], ["generating", 1138], ["both", 1149], ["Abeta", 1154], ["1", 1160], ["-", 1161], ["40", 1162], ["(", 1165], ["90", 1166], ["%", 1168], [")", 1169], ["and", 1171], ["Abeta", 1175], ["1", 1181], ["-", 1182], ["42", 1183], ["(", 1186], ["10", 1187], ["%", 1189], [")", 1190], [".", 1191], ["Pathogenic", 1193], ["mutations", 1204], ["in", 1214], ["APP", 1217], ["at", 1221], ["codon", 1224], ["717", 1230], ["(", 1234], ["APP", 1235], ["\"", 1239], ["London", 1240], ["\"", 1246], [")", 1247], ["lead", 1249], ["to", 1254], ["an", 1257], ["increased", 1260], ["proportion", 1270], ["of", 1281], ["Abeta", 1284], ["1", 1290], ["-", 1291], ["42", 1292], ["being", 1295], ["produced", 1301], ["and", 1310], ["secreted", 1314], [".", 1322], ["Missense", 1324], ["mutations", 1333], ["in", 1343], ["PS-1", 1346], [",", 1350], ["localized", 1352], ["to", 1362], ["chromosome", 1365], ["14", 1376], [",", 1378], ["are", 1380], ["pathogenic", 1384], ["in", 1395], ["the", 1398], ["majority", 1402], ["of", 1411], ["familial", 1414], ["Alzheimer", 1423], ["'s", 1432], ["pedigrees", 1435], [".", 1444], ["These", 1446], ["mutations", 1452], ["also", 1462], ["lead", 1467], ["to", 1472], ["increased", 1475], ["production", 1485], ["of", 1496], ["Abeta", 1499], ["1", 1505], ["-", 1506], ["42", 1507], ["over", 1510], ["Abeta", 1515], ["1", 1521], ["-", 1522], ["40", 1523], [".", 1525], ["Knockout", 1527], ["of", 1536], ["PS-1", 1539], ["in", 1544], ["transgenic", 1547], ["animals", 1558], ["leads", 1566], ["to", 1572], ["significant", 1575], ["inhibition", 1587], ["of", 1598], ["production", 1601], ["of", 1612], ["both", 1615], ["Abeta", 1620], ["1", 1626], ["-", 1627], ["40", 1628], ["and", 1631], ["Abeta", 1635], ["1", 1641], ["-", 1642], ["42", 1643], ["in", 1646], ["primary", 1649], ["cultures", 1657], [",", 1665], ["indicating", 1667], ["that", 1678], ["PS-1", 1683], ["expression", 1688], ["is", 1699], ["important", 1702], ["for", 1712], ["gamma", 1716], ["-", 1721], ["secretase", 1722], ["cleavages", 1732], [".", 1741], ["Peptide", 1743], ["aldehyde", 1751], ["inhibitors", 1760], ["that", 1771], ["block", 1776], ["Abeta", 1782], ["production", 1788], ["by", 1799], ["inhibiting", 1802], ["gamma", 1813], ["-", 1818], ["secretase", 1819], ["cleavage", 1829], ["of", 1838], ["beta", 1841], ["-", 1845], ["CTF", 1846], ["have", 1850], ["been", 1855], ["discovered", 1860], [".", 1870]]}
{"context": "Linkage analysis and DNA sequencing in a family exhibiting an X-linked mental retardation (XLMR) syndrome, characterized by microcephaly, epilepsy, ataxia, and absent speech and resembling Angelman syndrome, identified a deletion in the SLC9A6 gene encoding the Na(+)/H(+) exchanger NHE6. Subsequently, other mutations were found in a male with mental retardation (MR) who had been investigated for Angelman syndrome and in two XLMR families with epilepsy and ataxia, including the family designated as having Christianson syndrome. Therefore, mutations in SLC9A6 cause X-linked mental retardation. Additionally, males with findings suggestive of unexplained Angelman syndrome should be considered as potential candidates for SLC9A6 mutations.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "b926d6e0091141cb9a74f555ced0e3ae", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[95, 95], [120, 120], [41, 41]], "char_spans": [[557, 562], [726, 731], [237, 242]]}]}], "context_tokens": [["Linkage", 0], ["analysis", 8], ["and", 17], ["DNA", 21], ["sequencing", 25], ["in", 36], ["a", 39], ["family", 41], ["exhibiting", 48], ["an", 59], ["X", 62], ["-", 63], ["linked", 64], ["mental", 71], ["retardation", 78], ["(", 90], ["XLMR", 91], [")", 95], ["syndrome", 97], [",", 105], ["characterized", 107], ["by", 121], ["microcephaly", 124], [",", 136], ["epilepsy", 138], [",", 146], ["ataxia", 148], [",", 154], ["and", 156], ["absent", 160], ["speech", 167], ["and", 174], ["resembling", 178], ["Angelman", 189], ["syndrome", 198], [",", 206], ["identified", 208], ["a", 219], ["deletion", 221], ["in", 230], ["the", 233], ["SLC9A6", 237], ["gene", 244], ["encoding", 249], ["the", 258], ["Na(+)/H(+", 262], [")", 271], ["exchanger", 273], ["NHE6", 283], [".", 287], ["Subsequently", 289], [",", 301], ["other", 303], ["mutations", 309], ["were", 319], ["found", 324], ["in", 330], ["a", 333], ["male", 335], ["with", 340], ["mental", 345], ["retardation", 352], ["(", 364], ["MR", 365], [")", 367], ["who", 369], ["had", 373], ["been", 377], ["investigated", 382], ["for", 395], ["Angelman", 399], ["syndrome", 408], ["and", 417], ["in", 421], ["two", 424], ["XLMR", 428], ["families", 433], ["with", 442], ["epilepsy", 447], ["and", 456], ["ataxia", 460], [",", 466], ["including", 468], ["the", 478], ["family", 482], ["designated", 489], ["as", 500], ["having", 503], ["Christianson", 510], ["syndrome", 523], [".", 531], ["Therefore", 533], [",", 542], ["mutations", 544], ["in", 554], ["SLC9A6", 557], ["cause", 564], ["X", 570], ["-", 571], ["linked", 572], ["mental", 579], ["retardation", 586], [".", 597], ["Additionally", 599], [",", 611], ["males", 613], ["with", 619], ["findings", 624], ["suggestive", 633], ["of", 644], ["unexplained", 647], ["Angelman", 659], ["syndrome", 668], ["should", 677], ["be", 684], ["considered", 687], ["as", 698], ["potential", 701], ["candidates", 711], ["for", 722], ["SLC9A6", 726], ["mutations", 733], [".", 742]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "e7dd43f614bd4a44808e13eb2dbde1f6", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[8, 8], [75, 75]], "char_spans": [[47, 58], [414, 425]]}]}], "context_tokens": [["The", 0], ["advent", 4], ["of", 11], ["antibiotics", 14], ["for", 26], ["the", 30], ["treatment", 34], ["of", 44], ["tuberculosis", 47], ["(", 60], ["TB", 61], [")", 63], ["represented", 65], ["a", 77], ["major", 79], ["breakthrough", 85], ["in", 98], ["the", 101], ["fight", 105], ["against", 111], ["the", 119], ["disease", 123], [".", 130], ["However", 132], [",", 139], ["since", 141], ["its", 147], ["first", 151], ["use", 157], [",", 160], ["antibiotic", 162], ["therapy", 173], ["has", 181], ["been", 185], ["associated", 190], ["with", 201], ["the", 206], ["emergence", 210], ["of", 220], ["resistance", 223], ["to", 234], ["drugs", 237], [".", 242], ["The", 244], ["incorrect", 248], ["use", 258], ["of", 262], ["anti", 265], ["-", 269], ["TB", 270], ["drugs", 273], [",", 278], ["either", 280], ["due", 287], ["to", 291], ["prescription", 294], ["errors", 307], [",", 313], ["low", 315], ["patient", 319], ["compliance", 327], [",", 337], ["or", 339], ["poor", 342], ["quality", 347], ["of", 355], ["drugs", 358], [",", 363], ["led", 365], ["to", 369], ["the", 372], ["widespread", 376], ["emergence", 387], ["of", 397], ["Mycobacterium", 400], ["tuberculosis", 414], ["strains", 427], ["with", 435], ["an", 440], ["expanding", 443], ["spectrum", 453], ["of", 462], ["resistance", 465], [".", 475], ["The", 477], ["spread", 481], ["of", 488], ["multidrug", 491], ["-", 500], ["resistant", 501], ["(", 511], ["MDR", 512], [")", 515], ["strains", 517], ["(", 525], ["ie", 526], [",", 528], ["strains", 530], ["resistant", 538], ["to", 548], ["both", 551], ["isoniazid", 556], ["and", 566], ["rifampicin", 570], [")", 580], ["has", 582], ["represented", 586], ["a", 598], ["major", 600], ["threat", 606], ["to", 613], ["TB", 616], ["control", 619], ["since", 627], ["the", 633], ["1990s", 637], [".", 642], ["In", 644], ["2006", 647], [",", 651], ["the", 653], ["first", 657], ["cases", 663], ["of", 669], ["MDR", 672], ["strains", 676], ["with", 684], ["further", 689], ["resistance", 697], ["to", 708], ["fluoroquinolone", 711], ["and", 727], ["injectable", 731], ["drugs", 742], ["were", 748], ["described", 753], ["and", 763], ["named", 767], ["extensively", 773], ["drug", 785], ["-", 789], ["resistant", 790], ["TB", 800], ["(", 803], ["XDR", 804], ["-", 807], ["TB", 808], [")", 810], [".", 811], ["The", 813], ["emergence", 817], ["of", 827], ["XDR", 830], ["-", 833], ["TB", 834], ["strains", 837], ["is", 845], ["a", 848], ["result", 850], ["of", 857], ["mismanagement", 860], ["of", 874], ["MDR", 877], ["cases", 881], [",", 886], ["and", 888], ["treatment", 892], ["relies", 902], ["on", 909], ["drugs", 912], ["that", 918], ["are", 923], ["less", 927], ["potent", 932], ["and", 939], ["more", 943], ["toxic", 948], ["than", 954], ["those", 959], ["used", 965], ["to", 970], ["treat", 973], ["drug", 979], ["-", 983], ["susceptible", 984], ["or", 996], ["MDR", 999], ["strains", 1003], [".", 1010], ["Furthermore", 1012], [",", 1023], ["treatment", 1025], ["success", 1035], ["is", 1043], ["lower", 1046], ["and", 1052], ["mortality", 1056], ["higher", 1066], ["than", 1073], ["achieved", 1078], ["in", 1087], ["MDR", 1090], ["-", 1093], ["TB", 1094], ["cases", 1097], [",", 1102], ["and", 1104], ["the", 1108], ["number", 1112], ["of", 1119], ["drugs", 1122], ["necessary", 1128], ["in", 1138], ["the", 1141], ["intensive", 1145], ["phase", 1155], ["of", 1161], ["treatment", 1164], ["may", 1174], ["be", 1178], ["higher", 1181], ["than", 1188], ["the", 1193], ["four", 1197], ["drugs", 1202], ["recommended", 1208], ["for", 1220], ["MDR", 1224], ["-", 1227], ["TB", 1228], [".", 1230], ["Linezolid", 1232], ["may", 1242], ["represent", 1246], ["a", 1256], ["valuable", 1258], ["drug", 1267], ["to", 1272], ["treat", 1275], ["cases", 1281], ["of", 1287], ["XDR", 1290], ["-", 1293], ["TB", 1294], [".", 1296], ["Delamanid", 1298], [",", 1307], ["bedaquiline", 1309], [",", 1320], ["and", 1322], ["PA-824", 1326], ["are", 1333], ["new", 1337], ["anti", 1341], ["-", 1345], ["TB", 1346], ["agents", 1349], ["in", 1356], ["the", 1359], ["development", 1363], ["pipeline", 1375], ["that", 1384], ["have", 1389], ["the", 1394], ["potential", 1398], ["to", 1408], ["enhance", 1411], ["the", 1419], ["cure", 1423], ["rate", 1428], ["of", 1433], ["XDR", 1436], ["-", 1439], ["TB", 1440], [".", 1442], ["The", 1444], ["best", 1448], ["measures", 1453], ["to", 1462], ["prevent", 1465], ["new", 1473], ["cases", 1477], ["of", 1483], ["XDR", 1486], ["-", 1489], ["TB", 1490], ["are", 1493], ["the", 1497], ["correct", 1501], ["management", 1509], ["of", 1520], ["MDR", 1523], ["-", 1526], ["TB", 1527], ["patients", 1530], [",", 1538], ["early", 1540], ["detection", 1546], [",", 1555], ["and", 1557], ["proper", 1561], ["treatment", 1568], ["of", 1578], ["existing", 1581], ["patients", 1590], ["with", 1599], ["XDR", 1604], ["-", 1607], ["TB", 1608], [".", 1610]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Ataxin-3 (AT3) is the protein that triggers the inherited neurodegenerative disorder spinocerebellar ataxia type 3 when its polyglutamine (polyQ) stretch close to the C-terminus exceeds a critical length. AT3 consists of the N-terminal globular Josephin domain (JD) and the C-terminal disordered one. It cleaves isopeptide bonds between ubiquitin monomers, an event involved in protein quality control mechanisms. AT3 has been implicated in the pathway that sorts aggregated protein to aggresomes via microtubules, in which dynein and histone deacetylase 6 (HDAC6) also seem to be involved. By taking advantage of small angle X-ray scattering (SAXS) and surface plasmon resonance (SPR), we have investigated the interaction of AT3 with tubulin and HDAC6. Based on SAXS results, the AT3 oligomer, consisting of 6-7 subunits, tightly binds to the tubulin hexameric oligomer in a \"parallel\" fashion. By SPR analysis we have demonstrated that AT3 binds to tubulin dimer with a 50nM affinity. Binding fits with a Langmuir 1:1 model and involves a single binding interface. Nevertheless, the interaction surface consists of three distinct, discontinuous tubulin-binding regions (TBR), one located in the JD, and the two others in the disordered domain, upstream and downstream of the polyQ stretch. In the absence of any of the three TBRs, the affinity is drastically reduced. By SPR we have also provided the first evidence of direct binding of AT3 to HDAC6, with affinity in the range 0.1-1\u03bcM. These results shed light on the interactions among the components of the transport machinery that sorts aggregate protein to the aggresome, and pave the way to in vivo studies aimed at further clarifying their roles.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "ff352f0d6455402e93166f8e35e032b3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0]], "char_spans": [[0, 7]]}]}], "context_tokens": [["Ataxin-3", 0], ["(", 9], ["AT3", 10], [")", 13], ["is", 15], ["the", 18], ["protein", 22], ["that", 30], ["triggers", 35], ["the", 44], ["inherited", 48], ["neurodegenerative", 58], ["disorder", 76], ["spinocerebellar", 85], ["ataxia", 101], ["type", 108], ["3", 113], ["when", 115], ["its", 120], ["polyglutamine", 124], ["(", 138], ["polyQ", 139], [")", 144], ["stretch", 146], ["close", 154], ["to", 160], ["the", 163], ["C", 167], ["-", 168], ["terminus", 169], ["exceeds", 178], ["a", 186], ["critical", 188], ["length", 197], [".", 203], ["AT3", 205], ["consists", 209], ["of", 218], ["the", 221], ["N", 225], ["-", 226], ["terminal", 227], ["globular", 236], ["Josephin", 245], ["domain", 254], ["(", 261], ["JD", 262], [")", 264], ["and", 266], ["the", 270], ["C", 274], ["-", 275], ["terminal", 276], ["disordered", 285], ["one", 296], [".", 299], ["It", 301], ["cleaves", 304], ["isopeptide", 312], ["bonds", 323], ["between", 329], ["ubiquitin", 337], ["monomers", 347], [",", 355], ["an", 357], ["event", 360], ["involved", 366], ["in", 375], ["protein", 378], ["quality", 386], ["control", 394], ["mechanisms", 402], [".", 412], ["AT3", 414], ["has", 418], ["been", 422], ["implicated", 427], ["in", 438], ["the", 441], ["pathway", 445], ["that", 453], ["sorts", 458], ["aggregated", 464], ["protein", 475], ["to", 483], ["aggresomes", 486], ["via", 497], ["microtubules", 501], [",", 513], ["in", 515], ["which", 518], ["dynein", 524], ["and", 531], ["histone", 535], ["deacetylase", 543], ["6", 555], ["(", 557], ["HDAC6", 558], [")", 563], ["also", 565], ["seem", 570], ["to", 575], ["be", 578], ["involved", 581], [".", 589], ["By", 591], ["taking", 594], ["advantage", 601], ["of", 611], ["small", 614], ["angle", 620], ["X", 626], ["-", 627], ["ray", 628], ["scattering", 632], ["(", 643], ["SAXS", 644], [")", 648], ["and", 650], ["surface", 654], ["plasmon", 662], ["resonance", 670], ["(", 680], ["SPR", 681], [")", 684], [",", 685], ["we", 687], ["have", 690], ["investigated", 695], ["the", 708], ["interaction", 712], ["of", 724], ["AT3", 727], ["with", 731], ["tubulin", 736], ["and", 744], ["HDAC6", 748], [".", 753], ["Based", 755], ["on", 761], ["SAXS", 764], ["results", 769], [",", 776], ["the", 778], ["AT3", 782], ["oligomer", 786], [",", 794], ["consisting", 796], ["of", 807], ["6", 810], ["-", 811], ["7", 812], ["subunits", 814], [",", 822], ["tightly", 824], ["binds", 832], ["to", 838], ["the", 841], ["tubulin", 845], ["hexameric", 853], ["oligomer", 863], ["in", 872], ["a", 875], ["\"", 877], ["parallel", 878], ["\"", 886], ["fashion", 888], [".", 895], ["By", 897], ["SPR", 900], ["analysis", 904], ["we", 913], ["have", 916], ["demonstrated", 921], ["that", 934], ["AT3", 939], ["binds", 943], ["to", 949], ["tubulin", 952], ["dimer", 960], ["with", 966], ["a", 971], ["50nM", 973], ["affinity", 978], [".", 986], ["Binding", 988], ["fits", 996], ["with", 1001], ["a", 1006], ["Langmuir", 1008], ["1:1", 1017], ["model", 1021], ["and", 1027], ["involves", 1031], ["a", 1040], ["single", 1042], ["binding", 1049], ["interface", 1057], [".", 1066], ["Nevertheless", 1068], [",", 1080], ["the", 1082], ["interaction", 1086], ["surface", 1098], ["consists", 1106], ["of", 1115], ["three", 1118], ["distinct", 1124], [",", 1132], ["discontinuous", 1134], ["tubulin", 1148], ["-", 1155], ["binding", 1156], ["regions", 1164], ["(", 1172], ["TBR", 1173], [")", 1176], [",", 1177], ["one", 1179], ["located", 1183], ["in", 1191], ["the", 1194], ["JD", 1198], [",", 1200], ["and", 1202], ["the", 1206], ["two", 1210], ["others", 1214], ["in", 1221], ["the", 1224], ["disordered", 1228], ["domain", 1239], [",", 1245], ["upstream", 1247], ["and", 1256], ["downstream", 1260], ["of", 1271], ["the", 1274], ["polyQ", 1278], ["stretch", 1284], [".", 1291], ["In", 1293], ["the", 1296], ["absence", 1300], ["of", 1308], ["any", 1311], ["of", 1315], ["the", 1318], ["three", 1322], ["TBRs", 1328], [",", 1332], ["the", 1334], ["affinity", 1338], ["is", 1347], ["drastically", 1350], ["reduced", 1362], [".", 1369], ["By", 1371], ["SPR", 1374], ["we", 1378], ["have", 1381], ["also", 1386], ["provided", 1391], ["the", 1400], ["first", 1404], ["evidence", 1410], ["of", 1419], ["direct", 1422], ["binding", 1429], ["of", 1437], ["AT3", 1440], ["to", 1444], ["HDAC6", 1447], [",", 1452], ["with", 1454], ["affinity", 1459], ["in", 1468], ["the", 1471], ["range", 1475], ["0.1", 1481], ["-", 1484], ["1\u03bcM.", 1485], ["These", 1490], ["results", 1496], ["shed", 1504], ["light", 1509], ["on", 1515], ["the", 1518], ["interactions", 1522], ["among", 1535], ["the", 1541], ["components", 1545], ["of", 1556], ["the", 1559], ["transport", 1563], ["machinery", 1573], ["that", 1583], ["sorts", 1588], ["aggregate", 1594], ["protein", 1604], ["to", 1612], ["the", 1615], ["aggresome", 1619], [",", 1628], ["and", 1630], ["pave", 1634], ["the", 1639], ["way", 1643], ["to", 1647], ["in", 1650], ["vivo", 1653], ["studies", 1658], ["aimed", 1666], ["at", 1672], ["further", 1675], ["clarifying", 1683], ["their", 1694], ["roles", 1700], [".", 1705]]}
{"context": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They account for the activations of multiple growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR and STAT5 pathways. The BCR-ABL tyrosine kinase inhibitor imatinib is the standard treatment for Ph+ leukemia and plays efficacious role in CML. However, imatinib has few inhibitory effects on SRC tyrosine kinase with response rate of Ph+ ALL lower and relapse more frequent and quicker compared with CML. Previous studies showed that oridonin inhibits proliferation and induces apoptosis in many tumor cells. However, the anticancer activity and mechanism of oridonin in Ph+ ALL is unknown. To investigate the anticancer activity of oridonin, we examined its role in constitutively activated Akt/mTOR, Raf/MEK/ERK, STAT5 and SRC pathway, mRNA level of bcr/abl gene, cell viability and apoptosis in Ph+ ALL SUP-B15 cells. Furthermore, we detected synergetic effect of oridonin plus imatinib. Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. Oridonin plus imatinib exerted synergetic effects by overcoming imatinib defect of upregulating Akt/mTOR and LYN signaling. Additionally, we examined the effect of oridonin on the signaling pathways in the primary specimens from Ph+ ALL patients. Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "86cf7cabdc464986812d7f76361ff136", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[52, 54], [16, 18], [164, 166]], "char_spans": [[281, 287], [113, 119], [910, 916]]}]}], "context_tokens": [["Philadelphia", 0], ["chromosome", 13], ["-", 23], ["positive", 24], ["acute", 33], ["lymphoblastic", 39], ["leukemia", 53], ["(", 62], ["Ph+", 63], ["ALL", 67], [")", 70], ["is", 72], ["triggered", 75], ["by", 85], ["constitutively", 88], ["activated", 103], ["BCR", 113], ["-", 116], ["ABL", 117], ["and", 121], ["SRC", 125], ["family", 129], ["tyrosine", 136], ["kinases", 145], [".", 152], ["They", 153], ["account", 158], ["for", 166], ["the", 170], ["activations", 174], ["of", 186], ["multiple", 189], ["growth", 198], ["-", 204], ["signaling", 205], ["pathways", 215], [",", 223], ["including", 225], ["Raf", 235], ["/", 238], ["MEK", 239], ["/", 242], ["ERK", 243], [",", 246], ["Akt", 248], ["/", 251], ["mTOR", 252], ["and", 257], ["STAT5", 261], ["pathways", 267], [".", 275], ["The", 277], ["BCR", 281], ["-", 284], ["ABL", 285], ["tyrosine", 289], ["kinase", 298], ["inhibitor", 305], ["imatinib", 315], ["is", 324], ["the", 327], ["standard", 331], ["treatment", 340], ["for", 350], ["Ph+", 354], ["leukemia", 358], ["and", 367], ["plays", 371], ["efficacious", 377], ["role", 389], ["in", 394], ["CML", 397], [".", 400], ["However", 402], [",", 409], ["imatinib", 411], ["has", 420], ["few", 424], ["inhibitory", 428], ["effects", 439], ["on", 447], ["SRC", 450], ["tyrosine", 454], ["kinase", 463], ["with", 470], ["response", 475], ["rate", 484], ["of", 489], ["Ph+", 492], ["ALL", 496], ["lower", 500], ["and", 506], ["relapse", 510], ["more", 518], ["frequent", 523], ["and", 532], ["quicker", 536], ["compared", 544], ["with", 553], ["CML", 558], [".", 561], ["Previous", 563], ["studies", 572], ["showed", 580], ["that", 587], ["oridonin", 592], ["inhibits", 601], ["proliferation", 610], ["and", 624], ["induces", 628], ["apoptosis", 636], ["in", 646], ["many", 649], ["tumor", 654], ["cells", 660], [".", 665], ["However", 667], [",", 674], ["the", 676], ["anticancer", 680], ["activity", 691], ["and", 700], ["mechanism", 704], ["of", 714], ["oridonin", 717], ["in", 726], ["Ph+", 729], ["ALL", 733], ["is", 737], ["unknown", 740], [".", 747], ["To", 749], ["investigate", 752], ["the", 764], ["anticancer", 768], ["activity", 779], ["of", 788], ["oridonin", 791], [",", 799], ["we", 801], ["examined", 804], ["its", 813], ["role", 817], ["in", 822], ["constitutively", 825], ["activated", 840], ["Akt", 850], ["/", 853], ["mTOR", 854], [",", 858], ["Raf", 860], ["/", 863], ["MEK", 864], ["/", 867], ["ERK", 868], [",", 871], ["STAT5", 873], ["and", 879], ["SRC", 883], ["pathway", 887], [",", 894], ["mRNA", 896], ["level", 901], ["of", 907], ["bcr", 910], ["/", 913], ["abl", 914], ["gene", 918], [",", 922], ["cell", 924], ["viability", 929], ["and", 939], ["apoptosis", 943], ["in", 953], ["Ph+", 956], ["ALL", 960], ["SUP", 964], ["-", 967], ["B15", 968], ["cells", 972], [".", 977], ["Furthermore", 979], [",", 990], ["we", 992], ["detected", 995], ["synergetic", 1004], ["effect", 1015], ["of", 1022], ["oridonin", 1025], ["plus", 1034], ["imatinib", 1039], [".", 1047], ["Our", 1049], ["results", 1053], ["showed", 1061], ["that", 1068], ["oridonin", 1073], ["inhibiting", 1082], ["activations", 1093], ["of", 1105], ["LYN", 1108], ["(", 1112], ["one", 1113], ["of", 1117], ["SRC", 1120], ["family", 1124], ["kinases", 1131], [")", 1138], ["and", 1140], ["ABL", 1144], ["and", 1148], ["their", 1152], ["downstream", 1158], ["Akt", 1169], ["/", 1172], ["mTOR", 1173], [",", 1177], ["Raf", 1179], ["/", 1182], ["MEK", 1183], ["/", 1186], ["ERK", 1187], ["and", 1191], ["STAT5", 1195], ["pathways", 1201], [",", 1209], ["downregulated", 1211], ["Bcl-2", 1225], ["but", 1231], ["upregulated", 1235], ["Bax", 1247], ["protein", 1251], ["and", 1259], ["then", 1263], ["induced", 1268], ["apoptosis", 1276], ["in", 1286], ["Ph+", 1289], ["ALL", 1293], ["cells", 1297], [".", 1302], ["Oridonin", 1304], ["plus", 1313], ["imatinib", 1318], ["exerted", 1327], ["synergetic", 1335], ["effects", 1346], ["by", 1354], ["overcoming", 1357], ["imatinib", 1368], ["defect", 1377], ["of", 1384], ["upregulating", 1387], ["Akt", 1400], ["/", 1403], ["mTOR", 1404], ["and", 1409], ["LYN", 1413], ["signaling", 1417], [".", 1426], ["Additionally", 1428], [",", 1440], ["we", 1442], ["examined", 1445], ["the", 1454], ["effect", 1458], ["of", 1465], ["oridonin", 1468], ["on", 1477], ["the", 1480], ["signaling", 1484], ["pathways", 1494], ["in", 1503], ["the", 1506], ["primary", 1510], ["specimens", 1518], ["from", 1528], ["Ph+", 1533], ["ALL", 1537], ["patients", 1541], [".", 1549], ["Our", 1551], ["data", 1555], ["showed", 1560], ["that", 1567], ["oridonin", 1572], ["remarkably", 1581], ["suppressed", 1592], ["activations", 1603], ["of", 1615], ["Akt", 1618], ["/", 1621], ["mTOR", 1622], [",", 1626], ["Raf", 1628], ["/", 1631], ["MEK", 1632], ["and", 1636], ["STAT5", 1640], ["pathway", 1646], ["in", 1654], ["these", 1657], ["primary", 1663], ["specimens", 1671], ["and", 1681], ["oridonin", 1685], ["with", 1694], ["imatinib", 1699], ["exerted", 1708], ["synergetic", 1716], ["suppressive", 1727], ["effects", 1739], ["on", 1747], ["mTOR", 1750], [",", 1754], ["STAT5", 1756], ["and", 1762], ["LYN", 1766], ["signaling", 1770], ["in", 1780], ["one", 1783], ["imatinib", 1787], ["resistant", 1796], ["patient", 1806], ["specimen", 1814], [".", 1822], ["Additional", 1824], ["evaluation", 1835], ["of", 1846], ["oridonin", 1849], ["as", 1858], ["a", 1861], ["potential", 1863], ["therapeutic", 1873], ["agent", 1885], ["for", 1891], ["Ph+", 1895], ["ALL", 1899], ["seems", 1903], ["warranted", 1909], [".", 1918]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear. Brain iron insufficiency and altered dopaminergic function appear to play important roles in the etiology of the disorder. This concept is based partly on extensive research studies using cerebrospinal fluid (CSF), autopsy material, and brain imaging indicating reduced regional brain iron and on the clinical efficacy of dopamine receptor agonists for alleviating RLS symptoms. Finding causal relations, linking low brain iron to altered dopaminergic function in RLS, has required however the use of animal models. These models have provided insights into how alterations in brain iron homeostasis and dopaminergic system may be involved in RLS. The results of animal models of RLS and biochemical, postmortem, and imaging studies in patients with the disease suggest that disruptions in brain iron trafficking lead to disturbances in striatal dopamine neurotransmission for at least some patients with RLS. This review examines the data supporting an iron deficiency-dopamine metabolic theory of RLS by relating the results from animal model investigations of the influence of brain iron deficiency on dopaminergic systems to data from clinical studies in patients with RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "363dd991aef248d6b70acffea567a64a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["Disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["sensorimotor", 77], ["disorder", 90], ["for", 99], ["which", 103], ["the", 109], ["exact", 113], ["pathophysiology", 119], ["remains", 135], ["unclear", 143], [".", 150], ["Brain", 152], ["iron", 158], ["insufficiency", 163], ["and", 177], ["altered", 181], ["dopaminergic", 189], ["function", 202], ["appear", 211], ["to", 218], ["play", 221], ["important", 226], ["roles", 236], ["in", 242], ["the", 245], ["etiology", 249], ["of", 258], ["the", 261], ["disorder", 265], [".", 273], ["This", 275], ["concept", 280], ["is", 288], ["based", 291], ["partly", 297], ["on", 304], ["extensive", 307], ["research", 317], ["studies", 326], ["using", 334], ["cerebrospinal", 340], ["fluid", 354], ["(", 360], ["CSF", 361], [")", 364], [",", 365], ["autopsy", 367], ["material", 375], [",", 383], ["and", 385], ["brain", 389], ["imaging", 395], ["indicating", 403], ["reduced", 414], ["regional", 422], ["brain", 431], ["iron", 437], ["and", 442], ["on", 446], ["the", 449], ["clinical", 453], ["efficacy", 462], ["of", 471], ["dopamine", 474], ["receptor", 483], ["agonists", 492], ["for", 501], ["alleviating", 505], ["RLS", 517], ["symptoms", 521], [".", 529], ["Finding", 531], ["causal", 539], ["relations", 546], [",", 555], ["linking", 557], ["low", 565], ["brain", 569], ["iron", 575], ["to", 580], ["altered", 583], ["dopaminergic", 591], ["function", 604], ["in", 613], ["RLS", 616], [",", 619], ["has", 621], ["required", 625], ["however", 634], ["the", 642], ["use", 646], ["of", 650], ["animal", 653], ["models", 660], [".", 666], ["These", 668], ["models", 674], ["have", 681], ["provided", 686], ["insights", 695], ["into", 704], ["how", 709], ["alterations", 713], ["in", 725], ["brain", 728], ["iron", 734], ["homeostasis", 739], ["and", 751], ["dopaminergic", 755], ["system", 768], ["may", 775], ["be", 779], ["involved", 782], ["in", 791], ["RLS", 794], [".", 797], ["The", 799], ["results", 803], ["of", 811], ["animal", 814], ["models", 821], ["of", 828], ["RLS", 831], ["and", 835], ["biochemical", 839], [",", 850], ["postmortem", 852], [",", 862], ["and", 864], ["imaging", 868], ["studies", 876], ["in", 884], ["patients", 887], ["with", 896], ["the", 901], ["disease", 905], ["suggest", 913], ["that", 921], ["disruptions", 926], ["in", 938], ["brain", 941], ["iron", 947], ["trafficking", 952], ["lead", 964], ["to", 969], ["disturbances", 972], ["in", 985], ["striatal", 988], ["dopamine", 997], ["neurotransmission", 1006], ["for", 1024], ["at", 1028], ["least", 1031], ["some", 1037], ["patients", 1042], ["with", 1051], ["RLS", 1056], [".", 1059], ["This", 1061], ["review", 1066], ["examines", 1073], ["the", 1082], ["data", 1086], ["supporting", 1091], ["an", 1102], ["iron", 1105], ["deficiency", 1110], ["-", 1120], ["dopamine", 1121], ["metabolic", 1130], ["theory", 1140], ["of", 1147], ["RLS", 1150], ["by", 1154], ["relating", 1157], ["the", 1166], ["results", 1170], ["from", 1178], ["animal", 1183], ["model", 1190], ["investigations", 1196], ["of", 1211], ["the", 1214], ["influence", 1218], ["of", 1228], ["brain", 1231], ["iron", 1237], ["deficiency", 1242], ["on", 1253], ["dopaminergic", 1256], ["systems", 1269], ["to", 1277], ["data", 1280], ["from", 1285], ["clinical", 1290], ["studies", 1299], ["in", 1307], ["patients", 1310], ["with", 1319], ["RLS", 1324], [".", 1327]]}
{"context": "In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967. Headaches were classified based on symptoms assessed in middle age. From 2002 to 2006, 5,764 participants were reexamined to assess symptoms of parkinsonism, diagnosis of Parkinson disease (PD), family history of PD, and RLS/WED. Subjects with midlife migraine, particularly migraine with aura (MA), were in later life more likely than others to report parkinsonian symptoms (odds ratio [OR]MA = 3.6 [95% CI 2.7-4.8]) and diagnosed PD (ORMA = 2.5 [95% CI 1.2-5.2]). Women with MA were more likely than others to have a parent (ORMA = 2.26 [95% CI 1.3-4.0]) or sibling (ORMA = 1.78 [95% CI 1.1-2.9]) with PD. Late-life RLS/WED was increased for headache generally. Associations were independent of cardiovascular disease and MRI-evident presumed ischemic lesions. These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are needed to identify candidate pathways that may account for the comorbid constellation of symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "bfb32502385540e989c8cc4fc56e54bd", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[27, 29]], "char_spans": [[143, 164]]}]}], "context_tokens": [["In", 0], ["the", 3], ["present", 7], ["study", 15], [",", 20], ["we", 22], ["tested", 25], ["the", 32], ["hypothesis", 36], ["that", 47], ["having", 52], ["migraine", 59], ["in", 68], ["middle", 71], ["age", 78], ["is", 82], ["related", 85], ["to", 93], ["late", 96], ["-", 100], ["life", 101], ["parkinsonism", 106], ["and", 119], ["a", 123], ["related", 125], ["disorder", 133], [",", 141], ["restless", 143], ["legs", 152], ["syndrome", 157], ["(", 166], ["RLS", 167], [")", 170], [",", 171], ["also", 173], ["known", 178], ["as", 184], ["Willis", 187], ["-", 193], ["Ekbom", 194], ["disease", 200], ["(", 208], ["WED", 209], [")", 212], [".", 213], ["The", 215], ["AGES", 219], ["-", 223], ["Reykjavik", 224], ["cohort", 234], ["(", 241], ["born", 242], ["1907", 247], ["-", 251], ["1935", 252], [")", 256], ["has", 258], ["been", 262], ["followed", 267], ["since", 276], ["1967", 282], [".", 286], ["Headaches", 288], ["were", 298], ["classified", 303], ["based", 314], ["on", 320], ["symptoms", 323], ["assessed", 332], ["in", 341], ["middle", 344], ["age", 351], [".", 354], ["From", 356], ["2002", 361], ["to", 366], ["2006", 369], [",", 373], ["5,764", 375], ["participants", 381], ["were", 394], ["reexamined", 399], ["to", 410], ["assess", 413], ["symptoms", 420], ["of", 429], ["parkinsonism", 432], [",", 444], ["diagnosis", 446], ["of", 456], ["Parkinson", 459], ["disease", 469], ["(", 477], ["PD", 478], [")", 480], [",", 481], ["family", 483], ["history", 490], ["of", 498], ["PD", 501], [",", 503], ["and", 505], ["RLS", 509], ["/", 512], ["WED", 513], [".", 516], ["Subjects", 518], ["with", 527], ["midlife", 532], ["migraine", 540], [",", 548], ["particularly", 550], ["migraine", 563], ["with", 572], ["aura", 577], ["(", 582], ["MA", 583], [")", 585], [",", 586], ["were", 588], ["in", 593], ["later", 596], ["life", 602], ["more", 607], ["likely", 612], ["than", 619], ["others", 624], ["to", 631], ["report", 634], ["parkinsonian", 641], ["symptoms", 654], ["(", 663], ["odds", 664], ["ratio", 669], ["[", 675], ["OR]MA", 676], ["=", 682], ["3.6", 684], ["[", 688], ["95", 689], ["%", 691], ["CI", 693], ["2.7", 696], ["-", 699], ["4.8", 700], ["]", 703], [")", 704], ["and", 706], ["diagnosed", 710], ["PD", 720], ["(", 723], ["ORMA", 724], ["=", 729], ["2.5", 731], ["[", 735], ["95", 736], ["%", 738], ["CI", 740], ["1.2", 743], ["-", 746], ["5.2", 747], ["]", 750], [")", 751], [".", 752], ["Women", 754], ["with", 760], ["MA", 765], ["were", 768], ["more", 773], ["likely", 778], ["than", 785], ["others", 790], ["to", 797], ["have", 800], ["a", 805], ["parent", 807], ["(", 814], ["ORMA", 815], ["=", 820], ["2.26", 822], ["[", 827], ["95", 828], ["%", 830], ["CI", 832], ["1.3", 835], ["-", 838], ["4.0", 839], ["]", 842], [")", 843], ["or", 845], ["sibling", 848], ["(", 856], ["ORMA", 857], ["=", 862], ["1.78", 864], ["[", 869], ["95", 870], ["%", 872], ["CI", 874], ["1.1", 877], ["-", 880], ["2.9", 881], ["]", 884], [")", 885], ["with", 887], ["PD", 892], [".", 894], ["Late", 896], ["-", 900], ["life", 901], ["RLS", 906], ["/", 909], ["WED", 910], ["was", 914], ["increased", 918], ["for", 928], ["headache", 932], ["generally", 941], [".", 950], ["Associations", 952], ["were", 965], ["independent", 970], ["of", 982], ["cardiovascular", 985], ["disease", 1000], ["and", 1008], ["MRI", 1012], ["-", 1015], ["evident", 1016], ["presumed", 1024], ["ischemic", 1033], ["lesions", 1042], [".", 1049], ["These", 1051], ["findings", 1057], ["suggest", 1066], ["there", 1074], ["may", 1080], ["be", 1084], ["a", 1087], ["common", 1089], ["vulnerability", 1096], ["to", 1110], [",", 1112], ["or", 1114], ["consequences", 1117], ["of", 1130], [",", 1132], ["migraine", 1134], ["and", 1143], ["multiple", 1147], ["indicators", 1156], ["of", 1167], ["parkinsonism", 1170], [".", 1182], ["Additional", 1184], ["genetic", 1195], ["and", 1203], ["longitudinal", 1207], ["observational", 1220], ["studies", 1234], ["are", 1242], ["needed", 1246], ["to", 1253], ["identify", 1256], ["candidate", 1265], ["pathways", 1275], ["that", 1284], ["may", 1289], ["account", 1293], ["for", 1301], ["the", 1305], ["comorbid", 1309], ["constellation", 1318], ["of", 1332], ["symptoms", 1335], [".", 1343]]}
{"context": "Selenium (Se) is an essential trace element primarily found in selenoproteins as the 21st amino acid (selenocysteine, Sec, or U). Selenoproteins play an important role in growth and proliferation and are typically involved in cellular redox balance. Selenocysteine is encoded by an in-frame UGA codon specified by a stem-loop structure, the Sec insertion sequence element (SECIS), which, in eukaryotes, is located in the 3'-untranslated region (UTR). The availability of the Naegleria gruberi (ATCC 30224) genome sequence and the use of this organism as a model system for the pathogenic amoeba N. fowleri allowed us to investigate the Sec incorporation pathway in this primitive eukaryote. Using bioinformatics tools, we identified gene sequences encoding PSTK (O-phosphoseryl-tRNA(Sec) kinase), SepSecS (O-phosphoseryl-tRNA:selenocysteinyl-tRNA synthase), SelD/SPS2 (selenophosphate synthetase), EFSec (selenocysteine-specific elongation factor) and SBP (SECIS binding protein). These findings were confirmed by RT-PCR and by sequencing. A potential tRNA(Ser)Sec (SelC) gene and a putative selenoprotein with sequence similarity to a mitochondrial thioredoxin reductase (TR3) were also identified. Our results show that the selenocysteine incorporation machinery is indeed present in N. gruberi. Interestingly, the SelD/SPS2 gene is 2214 bp in length and contains two distinct domains. The N-terminal region shows sequence similarity to predicted methyltransferase proteins, and the C-terminal region is homologous to prokaryotic SelD/SPS2. Our results suggest the possibility of novel selenoproteins.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0c52975c66384d66a1af964bd53fdfc5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[181, 181], [69, 69]], "char_spans": [[957, 961], [373, 377]]}]}], "context_tokens": [["Selenium", 0], ["(", 9], ["Se", 10], [")", 12], ["is", 14], ["an", 17], ["essential", 20], ["trace", 30], ["element", 36], ["primarily", 44], ["found", 54], ["in", 60], ["selenoproteins", 63], ["as", 78], ["the", 81], ["21st", 85], ["amino", 90], ["acid", 96], ["(", 101], ["selenocysteine", 102], [",", 116], ["Sec", 118], [",", 121], ["or", 123], ["U", 126], [")", 127], [".", 128], ["Selenoproteins", 130], ["play", 145], ["an", 150], ["important", 153], ["role", 163], ["in", 168], ["growth", 171], ["and", 178], ["proliferation", 182], ["and", 196], ["are", 200], ["typically", 204], ["involved", 214], ["in", 223], ["cellular", 226], ["redox", 235], ["balance", 241], [".", 248], ["Selenocysteine", 250], ["is", 265], ["encoded", 268], ["by", 276], ["an", 279], ["in", 282], ["-", 284], ["frame", 285], ["UGA", 291], ["codon", 295], ["specified", 301], ["by", 311], ["a", 314], ["stem", 316], ["-", 320], ["loop", 321], ["structure", 326], [",", 335], ["the", 337], ["Sec", 341], ["insertion", 345], ["sequence", 355], ["element", 364], ["(", 372], ["SECIS", 373], [")", 378], [",", 379], ["which", 381], [",", 386], ["in", 388], ["eukaryotes", 391], [",", 401], ["is", 403], ["located", 406], ["in", 414], ["the", 417], ["3'-untranslated", 421], ["region", 437], ["(", 444], ["UTR", 445], [")", 448], [".", 449], ["The", 451], ["availability", 455], ["of", 468], ["the", 471], ["Naegleria", 475], ["gruberi", 485], ["(", 493], ["ATCC", 494], ["30224", 499], [")", 504], ["genome", 506], ["sequence", 513], ["and", 522], ["the", 526], ["use", 530], ["of", 534], ["this", 537], ["organism", 542], ["as", 551], ["a", 554], ["model", 556], ["system", 562], ["for", 569], ["the", 573], ["pathogenic", 577], ["amoeba", 588], ["N.", 595], ["fowleri", 598], ["allowed", 606], ["us", 614], ["to", 617], ["investigate", 620], ["the", 632], ["Sec", 636], ["incorporation", 640], ["pathway", 654], ["in", 662], ["this", 665], ["primitive", 670], ["eukaryote", 680], [".", 689], ["Using", 691], ["bioinformatics", 697], ["tools", 712], [",", 717], ["we", 719], ["identified", 722], ["gene", 733], ["sequences", 738], ["encoding", 748], ["PSTK", 757], ["(", 762], ["O", 763], ["-", 764], ["phosphoseryl", 765], ["-", 777], ["tRNA(Sec", 778], [")", 786], ["kinase", 788], [")", 794], [",", 795], ["SepSecS", 797], ["(", 805], ["O", 806], ["-", 807], ["phosphoseryl", 808], ["-", 820], ["tRNA", 821], [":", 825], ["selenocysteinyl", 826], ["-", 841], ["tRNA", 842], ["synthase", 847], [")", 855], [",", 856], ["SelD", 858], ["/", 862], ["SPS2", 863], ["(", 868], ["selenophosphate", 869], ["synthetase", 885], [")", 895], [",", 896], ["EFSec", 898], ["(", 904], ["selenocysteine", 905], ["-", 919], ["specific", 920], ["elongation", 929], ["factor", 940], [")", 946], ["and", 948], ["SBP", 952], ["(", 956], ["SECIS", 957], ["binding", 963], ["protein", 971], [")", 978], [".", 979], ["These", 981], ["findings", 987], ["were", 996], ["confirmed", 1001], ["by", 1011], ["RT", 1014], ["-", 1016], ["PCR", 1017], ["and", 1021], ["by", 1025], ["sequencing", 1028], [".", 1038], ["A", 1040], ["potential", 1042], ["tRNA(Ser)Sec", 1052], ["(", 1065], ["SelC", 1066], [")", 1070], ["gene", 1072], ["and", 1077], ["a", 1081], ["putative", 1083], ["selenoprotein", 1092], ["with", 1106], ["sequence", 1111], ["similarity", 1120], ["to", 1131], ["a", 1134], ["mitochondrial", 1136], ["thioredoxin", 1150], ["reductase", 1162], ["(", 1172], ["TR3", 1173], [")", 1176], ["were", 1178], ["also", 1183], ["identified", 1188], [".", 1198], ["Our", 1200], ["results", 1204], ["show", 1212], ["that", 1217], ["the", 1222], ["selenocysteine", 1226], ["incorporation", 1241], ["machinery", 1255], ["is", 1265], ["indeed", 1268], ["present", 1275], ["in", 1283], ["N.", 1286], ["gruberi", 1289], [".", 1296], ["Interestingly", 1298], [",", 1311], ["the", 1313], ["SelD", 1317], ["/", 1321], ["SPS2", 1322], ["gene", 1327], ["is", 1332], ["2214", 1335], ["bp", 1340], ["in", 1343], ["length", 1346], ["and", 1353], ["contains", 1357], ["two", 1366], ["distinct", 1370], ["domains", 1379], [".", 1386], ["The", 1388], ["N", 1392], ["-", 1393], ["terminal", 1394], ["region", 1403], ["shows", 1410], ["sequence", 1416], ["similarity", 1425], ["to", 1436], ["predicted", 1439], ["methyltransferase", 1449], ["proteins", 1467], [",", 1475], ["and", 1477], ["the", 1481], ["C", 1485], ["-", 1486], ["terminal", 1487], ["region", 1496], ["is", 1503], ["homologous", 1506], ["to", 1517], ["prokaryotic", 1520], ["SelD", 1532], ["/", 1536], ["SPS2", 1537], [".", 1541], ["Our", 1543], ["results", 1547], ["suggest", 1555], ["the", 1563], ["possibility", 1567], ["of", 1579], ["novel", 1582], ["selenoproteins", 1588], [".", 1602]]}
{"context": "The Ehlers-Danlos syndrome (EDS) comprises a group of hereditary connective tissue disorders. Periventricular nodular heterotopia (PNH) is a human neuronal migration disorder characterised by seizures and conglomerates of neural cells around the lateral ventricles of the brain, caused by FLNA mutations. FLNA encodes filamin A, an actin binding protein involved in cytoskeletal organisation. The amino-terminal actin binding domain (ABD) of filamins contains two tandem calponin homology domains, CHD1 and CHD2. To report clinical and genetic analyses in a Spanish family affected by a connective tissue disorder suggestive of EDS type III and PNH. A clinical and molecular study was undertaken in the three affected women. Clinical histories, physical and neurological examinations, brain magnetic resonance imaging studies, and skin biopsies were done. Genetic analysis of the FLNA gene was undertaken by direct sequencing and restriction fragment length polymorphism analysis. Mutation analysis of the FLNA gene resulted in the identification of a novel mutation in exon 3 (c.383C-->T) segregating with the combination of both syndromes. This mutation results in a substitution of an alanine residue (A128V) in CHD1. The findings suggest that the Ala128Val mutation causes the dual EDS-PNH phenotype. This association constitutes a new variant within the EDS spectrum. This is the first description of a familial EDS-PNH association with a mutation in FLNA.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "684689885e4249239d6a8040baf14481", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [100, 101]], "char_spans": [[65, 81], [587, 603]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["comprises", 33], ["a", 43], ["group", 45], ["of", 51], ["hereditary", 54], ["connective", 65], ["tissue", 76], ["disorders", 83], [".", 92], ["Periventricular", 94], ["nodular", 110], ["heterotopia", 118], ["(", 130], ["PNH", 131], [")", 134], ["is", 136], ["a", 139], ["human", 141], ["neuronal", 147], ["migration", 156], ["disorder", 166], ["characterised", 175], ["by", 189], ["seizures", 192], ["and", 201], ["conglomerates", 205], ["of", 219], ["neural", 222], ["cells", 229], ["around", 235], ["the", 242], ["lateral", 246], ["ventricles", 254], ["of", 265], ["the", 268], ["brain", 272], [",", 277], ["caused", 279], ["by", 286], ["FLNA", 289], ["mutations", 294], [".", 303], ["FLNA", 305], ["encodes", 310], ["filamin", 318], ["A", 326], [",", 327], ["an", 329], ["actin", 332], ["binding", 338], ["protein", 346], ["involved", 354], ["in", 363], ["cytoskeletal", 366], ["organisation", 379], [".", 391], ["The", 393], ["amino", 397], ["-", 402], ["terminal", 403], ["actin", 412], ["binding", 418], ["domain", 426], ["(", 433], ["ABD", 434], [")", 437], ["of", 439], ["filamins", 442], ["contains", 451], ["two", 460], ["tandem", 464], ["calponin", 471], ["homology", 480], ["domains", 489], [",", 496], ["CHD1", 498], ["and", 503], ["CHD2", 507], [".", 511], ["To", 513], ["report", 516], ["clinical", 523], ["and", 532], ["genetic", 536], ["analyses", 544], ["in", 553], ["a", 556], ["Spanish", 558], ["family", 566], ["affected", 573], ["by", 582], ["a", 585], ["connective", 587], ["tissue", 598], ["disorder", 605], ["suggestive", 614], ["of", 625], ["EDS", 628], ["type", 632], ["III", 637], ["and", 641], ["PNH", 645], [".", 648], ["A", 650], ["clinical", 652], ["and", 661], ["molecular", 665], ["study", 675], ["was", 681], ["undertaken", 685], ["in", 696], ["the", 699], ["three", 703], ["affected", 709], ["women", 718], [".", 723], ["Clinical", 725], ["histories", 734], [",", 743], ["physical", 745], ["and", 754], ["neurological", 758], ["examinations", 771], [",", 783], ["brain", 785], ["magnetic", 791], ["resonance", 800], ["imaging", 810], ["studies", 818], [",", 825], ["and", 827], ["skin", 831], ["biopsies", 836], ["were", 845], ["done", 850], [".", 854], ["Genetic", 856], ["analysis", 864], ["of", 873], ["the", 876], ["FLNA", 880], ["gene", 885], ["was", 890], ["undertaken", 894], ["by", 905], ["direct", 908], ["sequencing", 915], ["and", 926], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], [".", 979], ["Mutation", 981], ["analysis", 990], ["of", 999], ["the", 1002], ["FLNA", 1006], ["gene", 1011], ["resulted", 1016], ["in", 1025], ["the", 1028], ["identification", 1032], ["of", 1047], ["a", 1050], ["novel", 1052], ["mutation", 1058], ["in", 1067], ["exon", 1070], ["3", 1075], ["(", 1077], ["c.383C-->T", 1078], [")", 1088], ["segregating", 1090], ["with", 1102], ["the", 1107], ["combination", 1111], ["of", 1123], ["both", 1126], ["syndromes", 1131], [".", 1140], ["This", 1142], ["mutation", 1147], ["results", 1156], ["in", 1164], ["a", 1167], ["substitution", 1169], ["of", 1182], ["an", 1185], ["alanine", 1188], ["residue", 1196], ["(", 1204], ["A128V", 1205], [")", 1210], ["in", 1212], ["CHD1", 1215], [".", 1219], ["The", 1221], ["findings", 1225], ["suggest", 1234], ["that", 1242], ["the", 1247], ["Ala128Val", 1251], ["mutation", 1261], ["causes", 1270], ["the", 1277], ["dual", 1281], ["EDS", 1286], ["-", 1289], ["PNH", 1290], ["phenotype", 1294], [".", 1303], ["This", 1305], ["association", 1310], ["constitutes", 1322], ["a", 1334], ["new", 1336], ["variant", 1340], ["within", 1348], ["the", 1355], ["EDS", 1359], ["spectrum", 1363], [".", 1371], ["This", 1373], ["is", 1378], ["the", 1381], ["first", 1385], ["description", 1391], ["of", 1403], ["a", 1406], ["familial", 1408], ["EDS", 1417], ["-", 1420], ["PNH", 1421], ["association", 1425], ["with", 1437], ["a", 1442], ["mutation", 1444], ["in", 1453], ["FLNA", 1456], [".", 1460]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "The SWR1 complex (SWR1C) in yeast catalyzes the replacement of nucleosomal H2A with the H2AZ variant, which ensures full activation of underlying genes. We compared the phenotype of mutants in the homologs of SWR1C components in Arabidopsis thaliana. Mutations in Arabidopsis SWC6 (AtSWC6), SUPPRESSOR OF FRIGIDA 3 (SUF3) and PHOTOPERIOD-INDEPENDENT EARLY FLOWERING 1 (PIE1), homologs of SWC6, ARP6 and SWR1, respectively, caused similar developmental defects, including leaf serration, weak apical dominance, flowers with extra petals and early flowering by reduction in expression of FLOWERING LOCUS C (FLC), a strong floral repressor. Chromatin immunoprecipitation assays showed that AtSWC6 and SUF3 bind to the proximal region of the FLC promoter, and protoplast transfection assays showed that AtSWC6 colocalizes with SUF3. Protein interaction analyses suggested the formation of a complex between PIE1, SUF3, AtSWC6 and AtSWC2. In addition, H2AZ, a substrate of SWR1C, interacts with both PIE1 and AtSWC2. Finally, knockdown of the H2AZ genes by RNA interference or artificial microRNA caused a phenotype similar to that of atswc6 or suf3. Our results strongly support the presence of an SWR1C-like complex in Arabidopsis that ensures proper development, including floral repression through full activation of FLC.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "40d8ce56de49432180bd5735b35937f1", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[75, 75], [1, 1]], "char_spans": [[403, 406], [4, 7]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["(", 17], ["SWR1C", 18], [")", 23], ["in", 25], ["yeast", 28], ["catalyzes", 34], ["the", 44], ["replacement", 48], ["of", 60], ["nucleosomal", 63], ["H2A", 75], ["with", 79], ["the", 84], ["H2AZ", 88], ["variant", 93], [",", 100], ["which", 102], ["ensures", 108], ["full", 116], ["activation", 121], ["of", 132], ["underlying", 135], ["genes", 146], [".", 151], ["We", 153], ["compared", 156], ["the", 165], ["phenotype", 169], ["of", 179], ["mutants", 182], ["in", 190], ["the", 193], ["homologs", 197], ["of", 206], ["SWR1C", 209], ["components", 215], ["in", 226], ["Arabidopsis", 229], ["thaliana", 241], [".", 249], ["Mutations", 251], ["in", 261], ["Arabidopsis", 264], ["SWC6", 276], ["(", 281], ["AtSWC6", 282], [")", 288], [",", 289], ["SUPPRESSOR", 291], ["OF", 302], ["FRIGIDA", 305], ["3", 313], ["(", 315], ["SUF3", 316], [")", 320], ["and", 322], ["PHOTOPERIOD", 326], ["-", 337], ["INDEPENDENT", 338], ["EARLY", 350], ["FLOWERING", 356], ["1", 366], ["(", 368], ["PIE1", 369], [")", 373], [",", 374], ["homologs", 376], ["of", 385], ["SWC6", 388], [",", 392], ["ARP6", 394], ["and", 399], ["SWR1", 403], [",", 407], ["respectively", 409], [",", 421], ["caused", 423], ["similar", 430], ["developmental", 438], ["defects", 452], [",", 459], ["including", 461], ["leaf", 471], ["serration", 476], [",", 485], ["weak", 487], ["apical", 492], ["dominance", 499], [",", 508], ["flowers", 510], ["with", 518], ["extra", 523], ["petals", 529], ["and", 536], ["early", 540], ["flowering", 546], ["by", 556], ["reduction", 559], ["in", 569], ["expression", 572], ["of", 583], ["FLOWERING", 586], ["LOCUS", 596], ["C", 602], ["(", 604], ["FLC", 605], [")", 608], [",", 609], ["a", 611], ["strong", 613], ["floral", 620], ["repressor", 627], [".", 636], ["Chromatin", 638], ["immunoprecipitation", 648], ["assays", 668], ["showed", 675], ["that", 682], ["AtSWC6", 687], ["and", 694], ["SUF3", 698], ["bind", 703], ["to", 708], ["the", 711], ["proximal", 715], ["region", 724], ["of", 731], ["the", 734], ["FLC", 738], ["promoter", 742], [",", 750], ["and", 752], ["protoplast", 756], ["transfection", 767], ["assays", 780], ["showed", 787], ["that", 794], ["AtSWC6", 799], ["colocalizes", 806], ["with", 818], ["SUF3", 823], [".", 827], ["Protein", 829], ["interaction", 837], ["analyses", 849], ["suggested", 858], ["the", 868], ["formation", 872], ["of", 882], ["a", 885], ["complex", 887], ["between", 895], ["PIE1", 903], [",", 907], ["SUF3", 909], [",", 913], ["AtSWC6", 915], ["and", 922], ["AtSWC2", 926], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["H2AZ", 947], [",", 951], ["a", 953], ["substrate", 955], ["of", 965], ["SWR1C", 968], [",", 973], ["interacts", 975], ["with", 985], ["both", 990], ["PIE1", 995], ["and", 1000], ["AtSWC2", 1004], [".", 1010], ["Finally", 1012], [",", 1019], ["knockdown", 1021], ["of", 1031], ["the", 1034], ["H2AZ", 1038], ["genes", 1043], ["by", 1049], ["RNA", 1052], ["interference", 1056], ["or", 1069], ["artificial", 1072], ["microRNA", 1083], ["caused", 1092], ["a", 1099], ["phenotype", 1101], ["similar", 1111], ["to", 1119], ["that", 1122], ["of", 1127], ["atswc6", 1130], ["or", 1137], ["suf3", 1140], [".", 1144], ["Our", 1146], ["results", 1150], ["strongly", 1158], ["support", 1167], ["the", 1175], ["presence", 1179], ["of", 1188], ["an", 1191], ["SWR1C", 1194], ["-", 1199], ["like", 1200], ["complex", 1205], ["in", 1213], ["Arabidopsis", 1216], ["that", 1228], ["ensures", 1233], ["proper", 1241], ["development", 1248], [",", 1259], ["including", 1261], ["floral", 1271], ["repression", 1278], ["through", 1289], ["full", 1297], ["activation", 1302], ["of", 1313], ["FLC", 1316], [".", 1319]]}
{"context": "Using a rat model of L-DOPA-induced dyskinesia (LID), the contributions of dopamine D1 and D2 receptors to axial, limb, and orolingual (ALO) abnormal involuntary movements (AIMs) elicited by L-DOPA were examined. Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), the D2 receptor antagonist Eticlopride (0.01, 0.1, and 1.0 mg/kg; i.p.), a mixture of both antagonists (0.01, 0.1, 1.0 mg/kg each; i.p.), or vehicle 30 min prior to L-DOPA (6 mg/kg; i.p.)+Benserazide (15 mg/kg; i.p.). SCH23390 (0.1 and 1.0 mg/kg) significantly reduced axial and limb AIMs, while the same doses of Eticlopride significantly decreased axial, limb, and orolingual AIMs. Co-administration of SCH23390+Eticlopride significantly reduced axial (0.01, 0.1 and 1.0 mg/kg), limb (0.1 and 1.0 mg/kg), and orolingual (0.1 and 1.0 mg/kg) AIMs. These results indicate the importance of D1 and D2 receptors to LID and further validate the rat AIMs model.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "cef4a7fbb56948418ee4895ae79c5294", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[121, 123], [5, 7], [48, 50], [41, 43]], "char_spans": [[485, 490], [21, 26], [221, 226], [191, 196]]}]}], "context_tokens": [["Using", 0], ["a", 6], ["rat", 8], ["model", 12], ["of", 18], ["L", 21], ["-", 22], ["DOPA", 23], ["-", 27], ["induced", 28], ["dyskinesia", 36], ["(", 47], ["LID", 48], [")", 51], [",", 52], ["the", 54], ["contributions", 58], ["of", 72], ["dopamine", 75], ["D1", 84], ["and", 87], ["D2", 91], ["receptors", 94], ["to", 104], ["axial", 107], [",", 112], ["limb", 114], [",", 118], ["and", 120], ["orolingual", 124], ["(", 135], ["ALO", 136], [")", 139], ["abnormal", 141], ["involuntary", 150], ["movements", 162], ["(", 172], ["AIMs", 173], [")", 177], ["elicited", 179], ["by", 188], ["L", 191], ["-", 192], ["DOPA", 193], ["were", 198], ["examined", 203], [".", 211], ["Chronic", 213], ["L", 221], ["-", 222], ["DOPA", 223], ["-", 227], ["treated", 228], ["rats", 236], ["received", 241], ["the", 250], ["D1", 254], ["receptor", 257], ["antagonist", 266], ["SCH23390", 277], ["(", 286], ["0.01", 287], [",", 291], ["0.1", 293], [",", 296], ["and", 298], ["1.0", 302], ["mg", 306], ["/", 308], ["kg", 309], [";", 311], ["i.p", 313], [".", 316], [")", 317], [",", 318], ["the", 320], ["D2", 324], ["receptor", 327], ["antagonist", 336], ["Eticlopride", 347], ["(", 359], ["0.01", 360], [",", 364], ["0.1", 366], [",", 369], ["and", 371], ["1.0", 375], ["mg", 379], ["/", 381], ["kg", 382], [";", 384], ["i.p", 386], [".", 389], [")", 390], [",", 391], ["a", 393], ["mixture", 395], ["of", 403], ["both", 406], ["antagonists", 411], ["(", 423], ["0.01", 424], [",", 428], ["0.1", 430], [",", 433], ["1.0", 435], ["mg", 439], ["/", 441], ["kg", 442], ["each", 445], [";", 449], ["i.p", 451], [".", 454], [")", 455], [",", 456], ["or", 458], ["vehicle", 461], ["30", 469], ["min", 472], ["prior", 476], ["to", 482], ["L", 485], ["-", 486], ["DOPA", 487], ["(", 492], ["6", 493], ["mg", 495], ["/", 497], ["kg", 498], [";", 500], ["i.p.)+Benserazide", 502], ["(", 520], ["15", 521], ["mg", 524], ["/", 526], ["kg", 527], [";", 529], ["i.p", 531], [".", 534], [")", 535], [".", 536], ["SCH23390", 538], ["(", 547], ["0.1", 548], ["and", 552], ["1.0", 556], ["mg", 560], ["/", 562], ["kg", 563], [")", 565], ["significantly", 567], ["reduced", 581], ["axial", 589], ["and", 595], ["limb", 599], ["AIMs", 604], [",", 608], ["while", 610], ["the", 616], ["same", 620], ["doses", 625], ["of", 631], ["Eticlopride", 634], ["significantly", 646], ["decreased", 660], ["axial", 670], [",", 675], ["limb", 677], [",", 681], ["and", 683], ["orolingual", 687], ["AIMs", 698], [".", 702], ["Co", 704], ["-", 706], ["administration", 707], ["of", 722], ["SCH23390+Eticlopride", 725], ["significantly", 746], ["reduced", 760], ["axial", 768], ["(", 774], ["0.01", 775], [",", 779], ["0.1", 781], ["and", 785], ["1.0", 789], ["mg", 793], ["/", 795], ["kg", 796], [")", 798], [",", 799], ["limb", 801], ["(", 806], ["0.1", 807], ["and", 811], ["1.0", 815], ["mg", 819], ["/", 821], ["kg", 822], [")", 824], [",", 825], ["and", 827], ["orolingual", 831], ["(", 842], ["0.1", 843], ["and", 847], ["1.0", 851], ["mg", 855], ["/", 857], ["kg", 858], [")", 860], ["AIMs", 862], [".", 866], ["These", 868], ["results", 874], ["indicate", 882], ["the", 891], ["importance", 895], ["of", 906], ["D1", 909], ["and", 912], ["D2", 916], ["receptors", 919], ["to", 929], ["LID", 932], ["and", 936], ["further", 940], ["validate", 948], ["the", 957], ["rat", 961], ["AIMs", 965], ["model", 970], [".", 975]]}
{"context": "SET domain genes have been identified in numbers of bacterial genomes based on similarity to SET domains of eukaryotic histone methyltransferases. Herein, a Chlamydophila pneumoniae SET domain gene was clarified to be coincidently expressed with hctA and hctB genes encoding chlamydial histone H1-like proteins, Hc1 and Hc2, respectively. The SET domain protein (cpnSET) is localized in chlamydial cells and interacts with Hc1 and Hc2 through the C-terminal SET domain. As expected from conservation of catalytic sites in cpnSET, it functions as a protein methyltransferase to murine histone H3 and Hc1. However, little is known about protein methylation in the molecular pathogenesis of chlamydial infection. cpnSET may play an important role in chlamydial cell maturation due to modification of chlamydial histone H1-like proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf4ddb3d39ae4a8ebc75f6c6b7218fbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [76, 77], [27, 28], [54, 55]], "char_spans": [[0, 9], [458, 467], [182, 191], [343, 352]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["genes", 11], ["have", 17], ["been", 22], ["identified", 27], ["in", 38], ["numbers", 41], ["of", 49], ["bacterial", 52], ["genomes", 62], ["based", 70], ["on", 76], ["similarity", 79], ["to", 90], ["SET", 93], ["domains", 97], ["of", 105], ["eukaryotic", 108], ["histone", 119], ["methyltransferases", 127], [".", 145], ["Herein", 147], [",", 153], ["a", 155], ["Chlamydophila", 157], ["pneumoniae", 171], ["SET", 182], ["domain", 186], ["gene", 193], ["was", 198], ["clarified", 202], ["to", 212], ["be", 215], ["coincidently", 218], ["expressed", 231], ["with", 241], ["hctA", 246], ["and", 251], ["hctB", 255], ["genes", 260], ["encoding", 266], ["chlamydial", 275], ["histone", 286], ["H1-like", 294], ["proteins", 302], [",", 310], ["Hc1", 312], ["and", 316], ["Hc2", 320], [",", 323], ["respectively", 325], [".", 337], ["The", 339], ["SET", 343], ["domain", 347], ["protein", 354], ["(", 362], ["cpnSET", 363], [")", 369], ["is", 371], ["localized", 374], ["in", 384], ["chlamydial", 387], ["cells", 398], ["and", 404], ["interacts", 408], ["with", 418], ["Hc1", 423], ["and", 427], ["Hc2", 431], ["through", 435], ["the", 443], ["C", 447], ["-", 448], ["terminal", 449], ["SET", 458], ["domain", 462], [".", 468], ["As", 470], ["expected", 473], ["from", 482], ["conservation", 487], ["of", 500], ["catalytic", 503], ["sites", 513], ["in", 519], ["cpnSET", 522], [",", 528], ["it", 530], ["functions", 533], ["as", 543], ["a", 546], ["protein", 548], ["methyltransferase", 556], ["to", 574], ["murine", 577], ["histone", 584], ["H3", 592], ["and", 595], ["Hc1", 599], [".", 602], ["However", 604], [",", 611], ["little", 613], ["is", 620], ["known", 623], ["about", 629], ["protein", 635], ["methylation", 643], ["in", 655], ["the", 658], ["molecular", 662], ["pathogenesis", 672], ["of", 685], ["chlamydial", 688], ["infection", 699], [".", 708], ["cpnSET", 710], ["may", 717], ["play", 721], ["an", 726], ["important", 729], ["role", 739], ["in", 744], ["chlamydial", 747], ["cell", 758], ["maturation", 763], ["due", 774], ["to", 778], ["modification", 781], ["of", 794], ["chlamydial", 797], ["histone", 808], ["H1-like", 816], ["proteins", 824], [".", 832]]}
{"context": "Neurofibromatosis type 1 (NF1) is characterized primarily by tumor formation in the nervous system, but patients report other neurological complications including pain and itch. Individuals with NF1 harbor 1 mutated NF1 allele causing heterozygous expression in all of their cells. In mice, Nf1 heterozygosity leads to hyperexcitability of sensory neurons and hyperproliferation of mast cells, both of which could lead to increased hypersensitivity and scratching in response to noxious and pruritic stimuli. To determine whether Nf1 heterozygosity may increase pain and itch behaviors independent of secondary effects of tumor formation, we used mice with a targeted, heterozygous Nf1 gene deletion (Nf1\u00b1) that lack tumors. Nf1\u00b1 mice exhibited normal baseline responses to thermal and mechanical stimuli. Moreover, similar to wild-type littermates, Nf1\u00b1 mice developed inflammation-induced heat\u00a0and mechanical hypersensitivity, capsaicin-induced nocifensive behavior, histamine-dependent or -independent scratching, and chronic constriction injury-induced cold allodynia. However, Nf1\u00b1\u00a0mice exhibited an attenuated first phase of formalin-induced spontaneous behavior and expedited resolution of formalin-induced heat hypersensitivity. These results are not consistent with the hypothesis that Nf1 heterozygosity alone is sufficient to increase pain and itch sensation in mice, and they suggest that additional mechanisms may underlie reports of increased pain and itch in NF1 patients. This study assessed whether Nf1 heterozygosity in mice increased hypersensitivity and scratching following noxious and pruritic stimuli. Using Nf1\u00b1 mice lacking tumors, this study finds no increases in pain or itch behavior, suggesting that there is no predisposition for either clinical symptom solely due to Nf1 heterozygosity.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "40227f76b00344a78411177630545e7b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[48, 48], [83, 83], [107, 107], [30, 30], [205, 205], [234, 234], [285, 285], [4, 4], [34, 34], [241, 241]], "char_spans": [[291, 293], [530, 532], [682, 684], [195, 197], [1295, 1297], [1474, 1476], [1798, 1800], [26, 28], [216, 218], [1516, 1518]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["characterized", 34], ["primarily", 48], ["by", 58], ["tumor", 61], ["formation", 67], ["in", 77], ["the", 80], ["nervous", 84], ["system", 92], [",", 98], ["but", 100], ["patients", 104], ["report", 113], ["other", 120], ["neurological", 126], ["complications", 139], ["including", 153], ["pain", 163], ["and", 168], ["itch", 172], [".", 176], ["Individuals", 178], ["with", 190], ["NF1", 195], ["harbor", 199], ["1", 206], ["mutated", 208], ["NF1", 216], ["allele", 220], ["causing", 227], ["heterozygous", 235], ["expression", 248], ["in", 259], ["all", 262], ["of", 266], ["their", 269], ["cells", 275], [".", 280], ["In", 282], ["mice", 285], [",", 289], ["Nf1", 291], ["heterozygosity", 295], ["leads", 310], ["to", 316], ["hyperexcitability", 319], ["of", 337], ["sensory", 340], ["neurons", 348], ["and", 356], ["hyperproliferation", 360], ["of", 379], ["mast", 382], ["cells", 387], [",", 392], ["both", 394], ["of", 399], ["which", 402], ["could", 408], ["lead", 414], ["to", 419], ["increased", 422], ["hypersensitivity", 432], ["and", 449], ["scratching", 453], ["in", 464], ["response", 467], ["to", 476], ["noxious", 479], ["and", 487], ["pruritic", 491], ["stimuli", 500], [".", 507], ["To", 509], ["determine", 512], ["whether", 522], ["Nf1", 530], ["heterozygosity", 534], ["may", 549], ["increase", 553], ["pain", 562], ["and", 567], ["itch", 571], ["behaviors", 576], ["independent", 586], ["of", 598], ["secondary", 601], ["effects", 611], ["of", 619], ["tumor", 622], ["formation", 628], [",", 637], ["we", 639], ["used", 642], ["mice", 647], ["with", 652], ["a", 657], ["targeted", 659], [",", 667], ["heterozygous", 669], ["Nf1", 682], ["gene", 686], ["deletion", 691], ["(", 700], ["Nf1\u00b1", 701], [")", 705], ["that", 707], ["lack", 712], ["tumors", 717], [".", 723], ["Nf1\u00b1", 725], ["mice", 730], ["exhibited", 735], ["normal", 745], ["baseline", 752], ["responses", 761], ["to", 771], ["thermal", 774], ["and", 782], ["mechanical", 786], ["stimuli", 797], [".", 804], ["Moreover", 806], [",", 814], ["similar", 816], ["to", 824], ["wild", 827], ["-", 831], ["type", 832], ["littermates", 837], [",", 848], ["Nf1\u00b1", 850], ["mice", 855], ["developed", 860], ["inflammation", 870], ["-", 882], ["induced", 883], ["heat", 891], ["and", 896], ["mechanical", 900], ["hypersensitivity", 911], [",", 927], ["capsaicin", 929], ["-", 938], ["induced", 939], ["nocifensive", 947], ["behavior", 959], [",", 967], ["histamine", 969], ["-", 978], ["dependent", 979], ["or", 989], ["-independent", 992], ["scratching", 1005], [",", 1015], ["and", 1017], ["chronic", 1021], ["constriction", 1029], ["injury", 1042], ["-", 1048], ["induced", 1049], ["cold", 1057], ["allodynia", 1062], [".", 1071], ["However", 1073], [",", 1080], ["Nf1\u00b1", 1082], ["mice", 1087], ["exhibited", 1092], ["an", 1102], ["attenuated", 1105], ["first", 1116], ["phase", 1122], ["of", 1128], ["formalin", 1131], ["-", 1139], ["induced", 1140], ["spontaneous", 1148], ["behavior", 1160], ["and", 1169], ["expedited", 1173], ["resolution", 1183], ["of", 1194], ["formalin", 1197], ["-", 1205], ["induced", 1206], ["heat", 1214], ["hypersensitivity", 1219], [".", 1235], ["These", 1237], ["results", 1243], ["are", 1251], ["not", 1255], ["consistent", 1259], ["with", 1270], ["the", 1275], ["hypothesis", 1279], ["that", 1290], ["Nf1", 1295], ["heterozygosity", 1299], ["alone", 1314], ["is", 1320], ["sufficient", 1323], ["to", 1334], ["increase", 1337], ["pain", 1346], ["and", 1351], ["itch", 1355], ["sensation", 1360], ["in", 1370], ["mice", 1373], [",", 1377], ["and", 1379], ["they", 1383], ["suggest", 1388], ["that", 1396], ["additional", 1401], ["mechanisms", 1412], ["may", 1423], ["underlie", 1427], ["reports", 1436], ["of", 1444], ["increased", 1447], ["pain", 1457], ["and", 1462], ["itch", 1466], ["in", 1471], ["NF1", 1474], ["patients", 1478], [".", 1486], ["This", 1488], ["study", 1493], ["assessed", 1499], ["whether", 1508], ["Nf1", 1516], ["heterozygosity", 1520], ["in", 1535], ["mice", 1538], ["increased", 1543], ["hypersensitivity", 1553], ["and", 1570], ["scratching", 1574], ["following", 1585], ["noxious", 1595], ["and", 1603], ["pruritic", 1607], ["stimuli", 1616], [".", 1623], ["Using", 1625], ["Nf1\u00b1", 1631], ["mice", 1636], ["lacking", 1641], ["tumors", 1649], [",", 1655], ["this", 1657], ["study", 1662], ["finds", 1668], ["no", 1674], ["increases", 1677], ["in", 1687], ["pain", 1690], ["or", 1695], ["itch", 1698], ["behavior", 1703], [",", 1711], ["suggesting", 1713], ["that", 1724], ["there", 1729], ["is", 1735], ["no", 1738], ["predisposition", 1741], ["for", 1756], ["either", 1760], ["clinical", 1767], ["symptom", 1776], ["solely", 1784], ["due", 1791], ["to", 1795], ["Nf1", 1798], ["heterozygosity", 1802], [".", 1816]]}
{"context": "To evaluate the long-term impact of successive interventions on rates of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection and MRSA bacteremia in an endemic hospital-wide situation. Quasi-experimental, interrupted time-series analysis. The impact of the interventions was analyzed by use of segmented regression. Representative MRSA isolates were typed by use of pulsed-field gel electrophoresis. A 950-bed teaching hospital in Seville, Spain. All patients admitted to the hospital during the period from 1995 through 2008. Three successive interventions were studied: (1) contact precautions, with no active surveillance for MRSA; (2) targeted active surveillance for MRSA in patients and healthcare workers in specific wards, prioritized according to clinical epidemiology data; and (3) targeted active surveillance for MRSA in patients admitted from other medical centers. Neither the preintervention rate of MRSA colonization or infection (0.56 cases per 1,000 patient-days [95% confidence interval {CI}, 0.49-0.62 cases per 1,000 patient-days]) nor the slope for the rate of MRSA colonization or infection changed significantly after the first intervention. The rate decreased significantly to 0.28 cases per 1,000 patient-days (95% CI, 0.17-0.40 cases per 1,000 patient-days) after the second intervention and to 0.07 cases per 1,000 patient-days (95% CI, 0.06-0.08 cases per 1,000 patient-days) after the third intervention, and the rate remained at a similar level for 8 years. The MRSA bacteremia rate decreased by 80%, whereas the rate of bacteremia due to methicillin-susceptible S. aureus did not change. Eighty-three percent of the MRSA isolates identified were clonally related. All MRSA isolates obtained from healthcare workers were clonally related to those recovered from patients who were in their care. Our data indicate that long-term control of endemic MRSA is feasible in tertiary care centers. The use of targeted active surveillance for MRSA in patients and healthcare workers in specific wards (identified by means of analysis of clinical epidemiology data) and the use of decolonization were key to the success of the program.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "195e202a3f16414ebfc5916fde09ab66", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[351, 351], [112, 112], [160, 160], [59, 59], [19, 19], [283, 283], [25, 25], [121, 121], [199, 199], [313, 313], [146, 146], [321, 321], [366, 366]], "char_spans": [[1902, 1905], [653, 656], [939, 942], [355, 358], [118, 121], [1517, 1520], [154, 157], [696, 699], [1107, 1110], [1672, 1675], [849, 852], [1724, 1727], [1989, 1992]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["long", 16], ["-", 20], ["term", 21], ["impact", 26], ["of", 33], ["successive", 36], ["interventions", 47], ["on", 61], ["rates", 64], ["of", 70], ["methicillin", 73], ["-", 84], ["resistant", 85], ["Staphylococcus", 95], ["aureus", 110], ["(", 117], ["MRSA", 118], [")", 122], ["colonization", 124], ["or", 137], ["infection", 140], ["and", 150], ["MRSA", 154], ["bacteremia", 159], ["in", 170], ["an", 173], ["endemic", 176], ["hospital", 184], ["-", 192], ["wide", 193], ["situation", 198], [".", 207], ["Quasi", 209], ["-", 214], ["experimental", 215], [",", 227], ["interrupted", 229], ["time", 241], ["-", 245], ["series", 246], ["analysis", 253], [".", 261], ["The", 263], ["impact", 267], ["of", 274], ["the", 277], ["interventions", 281], ["was", 295], ["analyzed", 299], ["by", 308], ["use", 311], ["of", 315], ["segmented", 318], ["regression", 328], [".", 338], ["Representative", 340], ["MRSA", 355], ["isolates", 360], ["were", 369], ["typed", 374], ["by", 380], ["use", 383], ["of", 387], ["pulsed", 390], ["-", 396], ["field", 397], ["gel", 403], ["electrophoresis", 407], [".", 422], ["A", 424], ["950-bed", 426], ["teaching", 434], ["hospital", 443], ["in", 452], ["Seville", 455], [",", 462], ["Spain", 464], [".", 469], ["All", 471], ["patients", 475], ["admitted", 484], ["to", 493], ["the", 496], ["hospital", 500], ["during", 509], ["the", 516], ["period", 520], ["from", 527], ["1995", 532], ["through", 537], ["2008", 545], [".", 549], ["Three", 551], ["successive", 557], ["interventions", 568], ["were", 582], ["studied", 587], [":", 594], ["(", 596], ["1", 597], [")", 598], ["contact", 600], ["precautions", 608], [",", 619], ["with", 621], ["no", 626], ["active", 629], ["surveillance", 636], ["for", 649], ["MRSA", 653], [";", 657], ["(", 659], ["2", 660], [")", 661], ["targeted", 663], ["active", 672], ["surveillance", 679], ["for", 692], ["MRSA", 696], ["in", 701], ["patients", 704], ["and", 713], ["healthcare", 717], ["workers", 728], ["in", 736], ["specific", 739], ["wards", 748], [",", 753], ["prioritized", 755], ["according", 767], ["to", 777], ["clinical", 780], ["epidemiology", 789], ["data", 802], [";", 806], ["and", 808], ["(", 812], ["3", 813], [")", 814], ["targeted", 816], ["active", 825], ["surveillance", 832], ["for", 845], ["MRSA", 849], ["in", 854], ["patients", 857], ["admitted", 866], ["from", 875], ["other", 880], ["medical", 886], ["centers", 894], [".", 901], ["Neither", 903], ["the", 911], ["preintervention", 915], ["rate", 931], ["of", 936], ["MRSA", 939], ["colonization", 944], ["or", 957], ["infection", 960], ["(", 970], ["0.56", 971], ["cases", 976], ["per", 982], ["1,000", 986], ["patient", 992], ["-", 999], ["days", 1000], ["[", 1005], ["95", 1006], ["%", 1008], ["confidence", 1010], ["interval", 1021], ["{", 1030], ["CI", 1031], ["}", 1033], [",", 1034], ["0.49", 1036], ["-", 1040], ["0.62", 1041], ["cases", 1046], ["per", 1052], ["1,000", 1056], ["patient", 1062], ["-", 1069], ["days", 1070], ["]", 1074], [")", 1075], ["nor", 1077], ["the", 1081], ["slope", 1085], ["for", 1091], ["the", 1095], ["rate", 1099], ["of", 1104], ["MRSA", 1107], ["colonization", 1112], ["or", 1125], ["infection", 1128], ["changed", 1138], ["significantly", 1146], ["after", 1160], ["the", 1166], ["first", 1170], ["intervention", 1176], [".", 1188], ["The", 1190], ["rate", 1194], ["decreased", 1199], ["significantly", 1209], ["to", 1223], ["0.28", 1226], ["cases", 1231], ["per", 1237], ["1,000", 1241], ["patient", 1247], ["-", 1254], ["days", 1255], ["(", 1260], ["95", 1261], ["%", 1263], ["CI", 1265], [",", 1267], ["0.17", 1269], ["-", 1273], ["0.40", 1274], ["cases", 1279], ["per", 1285], ["1,000", 1289], ["patient", 1295], ["-", 1302], ["days", 1303], [")", 1307], ["after", 1309], ["the", 1315], ["second", 1319], ["intervention", 1326], ["and", 1339], ["to", 1343], ["0.07", 1346], ["cases", 1351], ["per", 1357], ["1,000", 1361], ["patient", 1367], ["-", 1374], ["days", 1375], ["(", 1380], ["95", 1381], ["%", 1383], ["CI", 1385], [",", 1387], ["0.06", 1389], ["-", 1393], ["0.08", 1394], ["cases", 1399], ["per", 1405], ["1,000", 1409], ["patient", 1415], ["-", 1422], ["days", 1423], [")", 1427], ["after", 1429], ["the", 1435], ["third", 1439], ["intervention", 1445], [",", 1457], ["and", 1459], ["the", 1463], ["rate", 1467], ["remained", 1472], ["at", 1481], ["a", 1484], ["similar", 1486], ["level", 1494], ["for", 1500], ["8", 1504], ["years", 1506], [".", 1511], ["The", 1513], ["MRSA", 1517], ["bacteremia", 1522], ["rate", 1533], ["decreased", 1538], ["by", 1548], ["80", 1551], ["%", 1553], [",", 1554], ["whereas", 1556], ["the", 1564], ["rate", 1568], ["of", 1573], ["bacteremia", 1576], ["due", 1587], ["to", 1591], ["methicillin", 1594], ["-", 1605], ["susceptible", 1606], ["S.", 1618], ["aureus", 1621], ["did", 1628], ["not", 1632], ["change", 1636], [".", 1642], ["Eighty", 1644], ["-", 1650], ["three", 1651], ["percent", 1657], ["of", 1665], ["the", 1668], ["MRSA", 1672], ["isolates", 1677], ["identified", 1686], ["were", 1697], ["clonally", 1702], ["related", 1711], [".", 1718], ["All", 1720], ["MRSA", 1724], ["isolates", 1729], ["obtained", 1738], ["from", 1747], ["healthcare", 1752], ["workers", 1763], ["were", 1771], ["clonally", 1776], ["related", 1785], ["to", 1793], ["those", 1796], ["recovered", 1802], ["from", 1812], ["patients", 1817], ["who", 1826], ["were", 1830], ["in", 1835], ["their", 1838], ["care", 1844], [".", 1848], ["Our", 1850], ["data", 1854], ["indicate", 1859], ["that", 1868], ["long", 1873], ["-", 1877], ["term", 1878], ["control", 1883], ["of", 1891], ["endemic", 1894], ["MRSA", 1902], ["is", 1907], ["feasible", 1910], ["in", 1919], ["tertiary", 1922], ["care", 1931], ["centers", 1936], [".", 1943], ["The", 1945], ["use", 1949], ["of", 1953], ["targeted", 1956], ["active", 1965], ["surveillance", 1972], ["for", 1985], ["MRSA", 1989], ["in", 1994], ["patients", 1997], ["and", 2006], ["healthcare", 2010], ["workers", 2021], ["in", 2029], ["specific", 2032], ["wards", 2041], ["(", 2047], ["identified", 2048], ["by", 2059], ["means", 2062], ["of", 2068], ["analysis", 2071], ["of", 2080], ["clinical", 2083], ["epidemiology", 2092], ["data", 2105], [")", 2109], ["and", 2111], ["the", 2115], ["use", 2119], ["of", 2123], ["decolonization", 2126], ["were", 2141], ["key", 2146], ["to", 2150], ["the", 2153], ["success", 2157], ["of", 2165], ["the", 2168], ["program", 2172], [".", 2179]]}
{"context": "Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "db7adf06a3c547ec93d26a22ee2e1de9", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [83, 83], [155, 155], [138, 138], [103, 103], [87, 87], [191, 191]], "char_spans": [[314, 316], [526, 528], [980, 982], [872, 874], [660, 662], [553, 555], [1198, 1200]]}]}], "context_tokens": [["Polyglutamine", 0], ["diseases", 14], [",", 22], ["including", 24], ["Huntington", 34], ["'s", 44], ["disease", 47], [",", 54], ["designate", 56], ["a", 66], ["group", 68], ["of", 74], ["nine", 77], ["neurodegenerative", 82], ["disorders", 100], ["characterized", 110], ["by", 124], ["the", 127], ["presence", 131], ["of", 140], ["a", 143], ["toxic", 145], ["polyglutamine", 151], ["expansion", 165], ["in", 175], ["specific", 178], ["target", 187], ["proteins", 194], [".", 202], ["Using", 204], ["cell", 210], ["and", 215], ["mouse", 219], ["models", 225], [",", 231], ["we", 233], ["have", 236], ["shown", 241], ["that", 247], ["expanded", 252], ["polyglutamine", 261], ["led", 275], ["to", 279], ["activation", 282], ["of", 293], ["the", 296], ["stress", 300], ["kinase", 307], ["JNK", 314], ["and", 318], ["the", 322], ["transcription", 326], ["factor", 340], ["AP-1", 347], [",", 351], ["which", 353], ["are", 359], ["implicated", 363], ["in", 374], ["neuronal", 377], ["death", 386], [".", 391], ["Polyglutamine", 393], ["expansion", 407], ["-", 416], ["induced", 417], ["stress", 425], ["shared", 432], ["common", 439], ["features", 446], ["with", 455], ["protein", 460], ["-", 467], ["damaging", 468], ["stress", 477], ["such", 484], ["as", 489], ["heat", 492], ["shock", 497], [",", 502], ["because", 504], ["activation", 512], ["of", 523], ["JNK", 526], ["involved", 530], ["inhibition", 539], ["of", 550], ["JNK", 553], ["phosphatase", 557], ["activities", 569], [".", 579], ["Indeed", 581], [",", 587], ["expanded", 589], ["polyglutamine", 598], ["impaired", 612], ["the", 621], ["solubility", 625], ["of", 636], ["the", 639], ["dual", 643], ["-", 647], ["specificity", 648], ["JNK", 660], ["phosphatase", 664], ["M3/6", 676], [".", 680], ["Aggregation", 682], ["of", 694], ["M3/6", 697], ["by", 702], ["polyglutamine", 705], ["expansion", 719], ["appeared", 729], ["to", 738], ["be", 741], ["indirect", 744], [",", 752], ["because", 754], ["M3/6", 762], ["was", 767], ["not", 771], ["recruited", 775], ["into", 785], ["polyglutamine", 790], ["inclusions", 804], [".", 814], ["The", 816], ["heat", 820], ["shock", 825], ["protein", 831], ["HSP70", 839], [",", 844], ["which", 846], ["is", 852], ["known", 855], ["to", 861], ["inhibit", 864], ["JNK", 872], ["during", 876], ["the", 883], ["heat", 887], ["shock", 892], ["response", 898], [",", 906], ["suppressed", 908], ["polyglutamine", 919], ["-", 932], ["mediated", 933], ["aggregation", 942], ["of", 954], ["M3/6", 957], ["and", 962], ["activation", 966], ["of", 977], ["JNK", 980], [".", 983], ["Interestingly", 985], [",", 998], ["levels", 1000], ["of", 1007], ["HSP70", 1010], ["were", 1016], ["down", 1021], ["-", 1025], ["regulated", 1026], ["by", 1036], ["polyglutamine", 1039], ["expansion", 1053], [".", 1062], ["We", 1064], ["suggest", 1067], ["that", 1075], ["reduction", 1080], ["of", 1090], ["HSP70", 1093], ["by", 1099], ["expanded", 1102], ["polyglutamine", 1111], ["is", 1125], ["implicated", 1128], ["in", 1139], ["aggregation", 1142], ["and", 1154], ["inhibition", 1158], ["of", 1169], ["M3/6", 1172], ["and", 1177], ["in", 1181], ["activation", 1184], ["of", 1195], ["JNK", 1198], ["and", 1202], ["AP-1", 1206], [".", 1210]]}
{"context": "Nucleotide excision repair (NER) is a remarkably versatile DNA repair system, essential for maintenance of genomic stability. Hereditary alterations in NER enzymes can result in increased cancer propensity, but also in developmental, neurodegenerative, and progeroid syndromes. NER can be operationally divided in three subtypes, which share many common steps: global genomic repair (GGR) operates on the whole genome level, transcription domain-associated repair (DAR) is a concentration of NER activity within transcription factories, and transcription-coupled repair (TCR) provides faster repair of the transcribed strand of active genes. Interestingly, ubiquitination plays an important role in all three classes of NER, as well as in associated phenomena, such as damage signalling by histone ubiquitination, and degradation of stalled RNA polymerase II when repair does not occur in a timely manner.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eac37c9c5ffd4618bcc7270e473097f6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[606, 623]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["remarkably", 38], ["versatile", 49], ["DNA", 59], ["repair", 63], ["system", 70], [",", 76], ["essential", 78], ["for", 88], ["maintenance", 92], ["of", 104], ["genomic", 107], ["stability", 115], [".", 124], ["Hereditary", 126], ["alterations", 137], ["in", 149], ["NER", 152], ["enzymes", 156], ["can", 164], ["result", 168], ["in", 175], ["increased", 178], ["cancer", 188], ["propensity", 195], [",", 205], ["but", 207], ["also", 211], ["in", 216], ["developmental", 219], [",", 232], ["neurodegenerative", 234], [",", 251], ["and", 253], ["progeroid", 257], ["syndromes", 267], [".", 276], ["NER", 278], ["can", 282], ["be", 286], ["operationally", 289], ["divided", 303], ["in", 311], ["three", 314], ["subtypes", 320], [",", 328], ["which", 330], ["share", 336], ["many", 342], ["common", 347], ["steps", 354], [":", 359], ["global", 361], ["genomic", 368], ["repair", 376], ["(", 383], ["GGR", 384], [")", 387], ["operates", 389], ["on", 398], ["the", 401], ["whole", 405], ["genome", 411], ["level", 418], [",", 423], ["transcription", 425], ["domain", 439], ["-", 445], ["associated", 446], ["repair", 457], ["(", 464], ["DAR", 465], [")", 468], ["is", 470], ["a", 473], ["concentration", 475], ["of", 489], ["NER", 492], ["activity", 496], ["within", 505], ["transcription", 512], ["factories", 526], [",", 535], ["and", 537], ["transcription", 541], ["-", 554], ["coupled", 555], ["repair", 563], ["(", 570], ["TCR", 571], [")", 574], ["provides", 576], ["faster", 585], ["repair", 592], ["of", 599], ["the", 602], ["transcribed", 606], ["strand", 618], ["of", 625], ["active", 628], ["genes", 635], [".", 640], ["Interestingly", 642], [",", 655], ["ubiquitination", 657], ["plays", 672], ["an", 678], ["important", 681], ["role", 691], ["in", 696], ["all", 699], ["three", 703], ["classes", 709], ["of", 717], ["NER", 720], [",", 723], ["as", 725], ["well", 728], ["as", 733], ["in", 736], ["associated", 739], ["phenomena", 750], [",", 759], ["such", 761], ["as", 766], ["damage", 769], ["signalling", 776], ["by", 787], ["histone", 790], ["ubiquitination", 798], [",", 812], ["and", 814], ["degradation", 818], ["of", 830], ["stalled", 833], ["RNA", 841], ["polymerase", 845], ["II", 856], ["when", 859], ["repair", 864], ["does", 871], ["not", 876], ["occur", 880], ["in", 886], ["a", 889], ["timely", 891], ["manner", 898], [".", 904]]}
{"context": "A study was carried out on 200 patients of ages 20-40 years suffering from acute viral hepatitis. Sera were tested for markers of hepatitis B (HBsAg, and IgM anti-HBc) and hepatitis A (IgM-anti-HAV) by the ELISA technique. Sera negative for the markers of both viruses: Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV) infection. Non-A, non-B hepatitis (NANB) was diagnosed by exclusion. The results of the study showed that 133 (66.5%) patients had evidence of HBV infection, while only 9(4.5%) were diagnosed as HAV infection. EBV and CMV were the possible etiological agents of acute viral hepatitis in (3.5%) and 1%) respectively. Accordingly the Non-A, non-B hepatitis in this study amounts to (24.5%) of the acute viral hepatitis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "c5f3d85f9a094b98b72b423fbde816d2", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[80, 83]], "char_spans": [[373, 390]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["carried", 12], ["out", 20], ["on", 24], ["200", 27], ["patients", 31], ["of", 40], ["ages", 43], ["20", 48], ["-", 50], ["40", 51], ["years", 54], ["suffering", 60], ["from", 70], ["acute", 75], ["viral", 81], ["hepatitis", 87], [".", 96], ["Sera", 98], ["were", 103], ["tested", 108], ["for", 115], ["markers", 119], ["of", 127], ["hepatitis", 130], ["B", 140], ["(", 142], ["HBsAg", 143], [",", 148], ["and", 150], ["IgM", 154], ["anti", 158], ["-", 162], ["HBc", 163], [")", 166], ["and", 168], ["hepatitis", 172], ["A", 182], ["(", 184], ["IgM", 185], ["-", 188], ["anti", 189], ["-", 193], ["HAV", 194], [")", 197], ["by", 199], ["the", 202], ["ELISA", 206], ["technique", 212], [".", 221], ["Sera", 223], ["negative", 228], ["for", 237], ["the", 241], ["markers", 245], ["of", 253], ["both", 256], ["viruses", 261], [":", 268], ["Hepatitis", 270], ["A", 280], ["(", 282], ["HAV", 283], [")", 286], ["and", 288], ["Hepatitis", 292], ["B", 302], ["(", 304], ["HBV", 305], [")", 308], ["were", 310], ["subsequently", 315], ["tested", 328], ["for", 335], ["IGM", 339], ["Heterophil", 343], ["antibodies", 354], ["against", 365], ["Epstein", 373], ["-", 380], ["Barr", 381], ["virus", 386], ["(", 392], ["EBV", 393], [")", 396], ["by", 398], ["the", 401], ["Monospot", 405], ["slide", 414], ["test", 420], ["to", 425], ["diagnose", 428], ["acute", 437], ["infectious", 443], ["mononucleosis", 454], ["and", 468], ["tested", 472], ["for", 479], ["anti", 483], ["-", 487], ["CMV", 488], ["(", 492], ["IgM", 493], [")", 496], ["by", 498], ["ELISA", 501], ["technique", 507], ["for", 517], ["the", 521], ["diagnosis", 525], ["of", 535], ["acute", 538], ["Cytomegalovirus", 544], ["(", 560], ["CMV", 561], [")", 564], ["infection", 566], [".", 575], ["Non", 577], ["-", 580], ["A", 581], [",", 582], ["non", 584], ["-", 587], ["B", 588], ["hepatitis", 590], ["(", 600], ["NANB", 601], [")", 605], ["was", 607], ["diagnosed", 611], ["by", 621], ["exclusion", 624], [".", 633], ["The", 635], ["results", 639], ["of", 647], ["the", 650], ["study", 654], ["showed", 660], ["that", 667], ["133", 672], ["(", 676], ["66.5", 677], ["%", 681], [")", 682], ["patients", 684], ["had", 693], ["evidence", 697], ["of", 706], ["HBV", 709], ["infection", 713], [",", 722], ["while", 724], ["only", 730], ["9(4.5", 735], ["%", 740], [")", 741], ["were", 743], ["diagnosed", 748], ["as", 758], ["HAV", 761], ["infection", 765], [".", 774], ["EBV", 776], ["and", 780], ["CMV", 784], ["were", 788], ["the", 793], ["possible", 797], ["etiological", 806], ["agents", 818], ["of", 825], ["acute", 828], ["viral", 834], ["hepatitis", 840], ["in", 850], ["(", 853], ["3.5", 854], ["%", 857], [")", 858], ["and", 860], ["1", 864], ["%", 865], [")", 866], ["respectively", 868], [".", 880], ["Accordingly", 882], ["the", 894], ["Non", 898], ["-", 901], ["A", 902], [",", 903], ["non", 905], ["-", 908], ["B", 909], ["hepatitis", 911], ["in", 921], ["this", 924], ["study", 929], ["amounts", 935], ["to", 943], ["(", 946], ["24.5", 947], ["%", 951], [")", 952], ["of", 954], ["the", 957], ["acute", 961], ["viral", 967], ["hepatitis", 973], [".", 982]]}
{"context": "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "db97a187c75442e883f177344a687937", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[243, 243]], "char_spans": [[1399, 1408]]}]}], "context_tokens": [["Venous", 0], ["thromboembolism", 7], ["(", 23], ["VTE", 24], [")", 27], ["is", 29], ["associated", 32], ["with", 43], ["significant", 48], ["morbidity", 60], ["and", 70], ["mortality", 74], [".", 83], ["Factors", 85], ["such", 93], ["as", 98], ["the", 101], ["presence", 105], ["of", 114], ["transient", 117], ["risk", 127], ["factors", 132], ["for", 140], ["VTE", 144], [",", 147], ["risk", 149], ["of", 154], ["bleeding", 157], [",", 165], ["and", 167], ["location", 171], ["of", 180], ["deep", 183], ["vein", 188], ["thrombosis", 193], ["(", 204], ["DVT", 205], [")", 208], ["determine", 210], ["the", 220], ["duration", 224], ["of", 233], ["anticoagulation", 236], [".", 251], ["Extended", 253], ["anticoagulation", 262], ["is", 278], ["offered", 281], ["to", 289], ["patients", 292], ["with", 301], ["unprovoked", 306], ["pulmonary", 317], ["embolism", 327], ["(", 336], ["PE", 337], [")", 339], ["or", 341], ["proximal", 344], ["DVT", 353], ["and", 357], ["a", 361], ["low", 363], ["risk", 367], ["of", 372], ["bleeding", 375], [".", 383], ["Anticoagulation", 385], ["for", 401], ["3", 405], ["months", 407], ["is", 414], ["advised", 417], ["in", 425], ["patients", 428], ["with", 437], ["provoked", 442], ["DVT", 451], ["or", 455], ["PE", 458], [",", 460], ["high", 462], ["risk", 467], ["of", 472], ["bleeding", 475], [",", 483], ["and", 485], ["isolated", 489], ["distal", 498], ["or", 505], ["upper", 508], ["extremity", 514], ["DVT", 524], [".", 527], ["In", 529], ["patients", 532], ["with", 541], ["unprovoked", 546], ["PE", 557], ["or", 560], ["proximal", 563], ["DVT", 572], ["and", 576], ["a", 580], ["low", 582], ["risk", 586], ["of", 591], ["bleeding", 594], [",", 602], ["who", 604], ["want", 608], ["to", 613], ["stop", 616], ["anticoagulation", 621], ["after", 637], ["3", 643], ["months", 645], [",", 651], ["further", 653], ["risk", 661], ["stratification", 666], ["is", 681], ["necessary", 684], [".", 693], ["Clinical", 695], ["scoring", 704], ["system", 712], [",", 718], ["and", 720], ["thrombophilia", 724], ["testing", 738], ["otherwise", 746], ["not", 756], ["routinely", 760], ["performed", 770], [",", 779], ["may", 781], ["be", 785], ["considered", 788], ["to", 799], ["measure", 802], ["risk", 810], ["of", 815], ["annual", 818], ["recurrence", 825], ["in", 836], ["such", 839], ["cases", 844], [".", 849], ["Short", 851], ["-", 856], ["term", 857], ["anticoagulation", 862], ["may", 878], ["be", 882], ["considered", 885], ["in", 896], ["subsegmental", 899], ["PE", 912], ["and", 915], ["superficial", 919], ["vein", 931], ["thrombosis", 936], [",", 946], ["particularly", 948], ["if", 961], ["patients", 964], ["are", 973], ["at", 977], ["low", 980], ["risk", 984], ["of", 989], ["bleeding", 992], ["and", 1001], ["have", 1005], ["persistent", 1010], ["risk", 1021], ["factors", 1026], ["for", 1034], ["recurrent", 1038], ["VTE", 1048], [".", 1051], ["In", 1053], ["cases", 1056], ["of", 1062], ["catheter", 1065], ["-", 1073], ["associated", 1074], ["thrombosis", 1085], [",", 1095], ["the", 1097], ["catheter", 1101], ["need", 1110], ["not", 1115], ["be", 1119], ["removed", 1122], ["routinely", 1130], [",", 1139], ["and", 1141], ["the", 1145], ["patient", 1149], ["may", 1157], ["be", 1161], ["anticoagulated", 1164], ["for", 1179], ["3", 1183], ["months", 1185], ["or", 1192], ["longer", 1195], ["if", 1202], ["the", 1205], ["catheter", 1209], ["is", 1218], ["maintained", 1221], ["in", 1232], ["patients", 1235], ["with", 1244], ["cancer", 1249], [".", 1255], ["Extensive", 1257], ["screening", 1267], ["for", 1277], ["occult", 1281], ["cancer", 1288], ["in", 1295], ["cases", 1298], ["of", 1304], ["unprovoked", 1307], ["VTE", 1318], ["is", 1322], ["not", 1325], ["beneficial", 1329], [".", 1339], ["New", 1341], ["oral", 1345], ["anticoagulants", 1350], ["such", 1365], ["as", 1370], ["apixaban", 1373], [",", 1381], ["rivaroxaban", 1383], [",", 1394], ["or", 1396], ["dabigatran", 1399], ["may", 1410], ["be", 1414], ["preferred", 1417], ["to", 1427], ["vitamin", 1430], ["K", 1438], ["antagonists", 1440], ["in", 1452], ["patients", 1455], ["without", 1464], ["cancer", 1472], ["or", 1479], ["renal", 1482], ["failure", 1488], [",", 1495], ["more", 1497], ["so", 1502], ["after", 1505], ["the", 1511], ["development", 1515], ["of", 1527], ["reversal", 1530], ["agents", 1539], ["such", 1546], ["as", 1551], ["idarucizumab", 1554], ["and", 1567], ["andexanet", 1571], ["alfa", 1581], [".", 1585]]}
{"context": "To evaluate and compare outcomes for patients with vestibular schwannoma (VS) treated in a single institution with linac-based stereotactic radiosurgery (SRS) or by fractionated stereotactic radiotherapy (SRT). One hundred and nineteen patients (SRS = 78, SRT = 41) were treated. For both SRS and SRT, beam shaping is performed by a mini-multileaf collimator. For SRS, a median single dose of 12.5 Gy (range, 11-14 Gy), prescribed to the 80% isodose line encompassing the target, was applied. Of the 42 SRT treatments, 32 treatments consisted of 10 fractions of 3-4 Gy, and 10 patients received 25 sessions of 2 Gy, prescribed to the 100% with the 95% isodose line encompassing the planning target volume. Mean largest tumor diameter was 16.6 mm in the SRS and 24.6 mm in the SRT group. Local tumor control, cranial nerve toxicity, and preservation of useful hearing were recorded. Any new treatment-induced cranial nerve neuropathy was scored as a complication. Median follow-up was 62 months (range, 6-136 months), 5 patients progressed, resulting in an overall 5-year local tumor control of 95%. The overall 5-year facial nerve preservation probability was 88% and facial nerve neuropathy was statistically significantly higher after SRS, after prior surgery, for larger tumors, and in Koos Grade \u22653. The overall 5-year trigeminal nerve preservation probability was 96%, not significantly influenced by any of the risk factors. The overall 4-year probability of preservation of useful hearing (Gardner-Robertson score 1 or 2) was 68%, not significantly different between SRS or SRT (59% vs. 82%, p = 0.089, log rank). Linac-based RT results in good local control and acceptable clinical outcome in small to medium-sized vestibular schwannomas (VSs). Radiosurgery for large VSs (Koos Grade \u22653) remains a challenge because of increased facial nerve neuropathy.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "212829ec9421495797a732770b08731b", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[8, 9]], "char_spans": [[51, 71]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["and", 12], ["compare", 16], ["outcomes", 24], ["for", 33], ["patients", 37], ["with", 46], ["vestibular", 51], ["schwannoma", 62], ["(", 73], ["VS", 74], [")", 76], ["treated", 78], ["in", 86], ["a", 89], ["single", 91], ["institution", 98], ["with", 110], ["linac", 115], ["-", 120], ["based", 121], ["stereotactic", 127], ["radiosurgery", 140], ["(", 153], ["SRS", 154], [")", 157], ["or", 159], ["by", 162], ["fractionated", 165], ["stereotactic", 178], ["radiotherapy", 191], ["(", 204], ["SRT", 205], [")", 208], [".", 209], ["One", 211], ["hundred", 215], ["and", 223], ["nineteen", 227], ["patients", 236], ["(", 245], ["SRS", 246], ["=", 250], ["78", 252], [",", 254], ["SRT", 256], ["=", 260], ["41", 262], [")", 264], ["were", 266], ["treated", 271], [".", 278], ["For", 280], ["both", 284], ["SRS", 289], ["and", 293], ["SRT", 297], [",", 300], ["beam", 302], ["shaping", 307], ["is", 315], ["performed", 318], ["by", 328], ["a", 331], ["mini", 333], ["-", 337], ["multileaf", 338], ["collimator", 348], [".", 358], ["For", 360], ["SRS", 364], [",", 367], ["a", 369], ["median", 371], ["single", 378], ["dose", 385], ["of", 390], ["12.5", 393], ["Gy", 398], ["(", 401], ["range", 402], [",", 407], ["11", 409], ["-", 411], ["14", 412], ["Gy", 415], [")", 417], [",", 418], ["prescribed", 420], ["to", 431], ["the", 434], ["80", 438], ["%", 440], ["isodose", 442], ["line", 450], ["encompassing", 455], ["the", 468], ["target", 472], [",", 478], ["was", 480], ["applied", 484], [".", 491], ["Of", 493], ["the", 496], ["42", 500], ["SRT", 503], ["treatments", 507], [",", 517], ["32", 519], ["treatments", 522], ["consisted", 533], ["of", 543], ["10", 546], ["fractions", 549], ["of", 559], ["3", 562], ["-", 563], ["4", 564], ["Gy", 566], [",", 568], ["and", 570], ["10", 574], ["patients", 577], ["received", 586], ["25", 595], ["sessions", 598], ["of", 607], ["2", 610], ["Gy", 612], [",", 614], ["prescribed", 616], ["to", 627], ["the", 630], ["100", 634], ["%", 637], ["with", 639], ["the", 644], ["95", 648], ["%", 650], ["isodose", 652], ["line", 660], ["encompassing", 665], ["the", 678], ["planning", 682], ["target", 691], ["volume", 698], [".", 704], ["Mean", 706], ["largest", 711], ["tumor", 719], ["diameter", 725], ["was", 734], ["16.6", 738], ["mm", 743], ["in", 746], ["the", 749], ["SRS", 753], ["and", 757], ["24.6", 761], ["mm", 766], ["in", 769], ["the", 772], ["SRT", 776], ["group", 780], [".", 785], ["Local", 787], ["tumor", 793], ["control", 799], [",", 806], ["cranial", 808], ["nerve", 816], ["toxicity", 822], [",", 830], ["and", 832], ["preservation", 836], ["of", 849], ["useful", 852], ["hearing", 859], ["were", 867], ["recorded", 872], [".", 880], ["Any", 882], ["new", 886], ["treatment", 890], ["-", 899], ["induced", 900], ["cranial", 908], ["nerve", 916], ["neuropathy", 922], ["was", 933], ["scored", 937], ["as", 944], ["a", 947], ["complication", 949], [".", 961], ["Median", 963], ["follow", 970], ["-", 976], ["up", 977], ["was", 980], ["62", 984], ["months", 987], ["(", 994], ["range", 995], [",", 1000], ["6", 1002], ["-", 1003], ["136", 1004], ["months", 1008], [")", 1014], [",", 1015], ["5", 1017], ["patients", 1019], ["progressed", 1028], [",", 1038], ["resulting", 1040], ["in", 1050], ["an", 1053], ["overall", 1056], ["5-year", 1064], ["local", 1071], ["tumor", 1077], ["control", 1083], ["of", 1091], ["95", 1094], ["%", 1096], [".", 1097], ["The", 1099], ["overall", 1103], ["5-year", 1111], ["facial", 1118], ["nerve", 1125], ["preservation", 1131], ["probability", 1144], ["was", 1156], ["88", 1160], ["%", 1162], ["and", 1164], ["facial", 1168], ["nerve", 1175], ["neuropathy", 1181], ["was", 1192], ["statistically", 1196], ["significantly", 1210], ["higher", 1224], ["after", 1231], ["SRS", 1237], [",", 1240], ["after", 1242], ["prior", 1248], ["surgery", 1254], [",", 1261], ["for", 1263], ["larger", 1267], ["tumors", 1274], [",", 1280], ["and", 1282], ["in", 1286], ["Koos", 1289], ["Grade", 1294], ["\u22653", 1300], [".", 1302], ["The", 1304], ["overall", 1308], ["5-year", 1316], ["trigeminal", 1323], ["nerve", 1334], ["preservation", 1340], ["probability", 1353], ["was", 1365], ["96", 1369], ["%", 1371], [",", 1372], ["not", 1374], ["significantly", 1378], ["influenced", 1392], ["by", 1403], ["any", 1406], ["of", 1410], ["the", 1413], ["risk", 1417], ["factors", 1422], [".", 1429], ["The", 1431], ["overall", 1435], ["4-year", 1443], ["probability", 1450], ["of", 1462], ["preservation", 1465], ["of", 1478], ["useful", 1481], ["hearing", 1488], ["(", 1496], ["Gardner", 1497], ["-", 1504], ["Robertson", 1505], ["score", 1515], ["1", 1521], ["or", 1523], ["2", 1526], [")", 1527], ["was", 1529], ["68", 1533], ["%", 1535], [",", 1536], ["not", 1538], ["significantly", 1542], ["different", 1556], ["between", 1566], ["SRS", 1574], ["or", 1578], ["SRT", 1581], ["(", 1585], ["59", 1586], ["%", 1588], ["vs.", 1590], ["82", 1594], ["%", 1596], [",", 1597], ["p", 1599], ["=", 1601], ["0.089", 1603], [",", 1608], ["log", 1610], ["rank", 1614], [")", 1618], [".", 1619], ["Linac", 1621], ["-", 1626], ["based", 1627], ["RT", 1633], ["results", 1636], ["in", 1644], ["good", 1647], ["local", 1652], ["control", 1658], ["and", 1666], ["acceptable", 1670], ["clinical", 1681], ["outcome", 1690], ["in", 1698], ["small", 1701], ["to", 1707], ["medium", 1710], ["-", 1716], ["sized", 1717], ["vestibular", 1723], ["schwannomas", 1734], ["(", 1746], ["VSs", 1747], [")", 1750], [".", 1751], ["Radiosurgery", 1753], ["for", 1766], ["large", 1770], ["VSs", 1776], ["(", 1780], ["Koos", 1781], ["Grade", 1786], ["\u22653", 1792], [")", 1794], ["remains", 1796], ["a", 1804], ["challenge", 1806], ["because", 1816], ["of", 1824], ["increased", 1827], ["facial", 1837], ["nerve", 1844], ["neuropathy", 1850], [".", 1860]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Cancer cells frequently induce aberrant centrosomes, which have been implicated in cancer initiation and progression. Human colorectal cancer cells, HCT116, contain aberrant centrioles composed of disorganized cylindrical microtubules and displaced appendages. These cells also express unique centrosome-related structures associated with a subset of centrosomal components, including gamma-tubulin, centrin and PCM1. During hydroxyurea treatment, these abnormal structures become more abundant and undergo a change in shape from small dots to elongated fibers. Although gamma-tubulin seems to exist as a ring complex, the abnormal structures do not support microtubule nucleation. Several lines of evidence suggest that the fibers correspond to a disorganized form of centriolar microtubules. Plk4, a mammalian homolog of ZYG-1 essential for initiation of centriole biogenesis, is not associated with the gamma-tubulin-specific abnormal centrosomes. The amount of Plk4 at each centrosome was less in cells with abnormal centrosomes than cells without gamma-tubulin-specific abnormal centrosomes. In addition, the formation of abnormal structures was abolished by expression of exogenous Plk4, but not SAS6 and Cep135/Bld10p, which are downstream regulators required for the organization of nine-triplet microtubules. These results suggest that HCT116 cells fail to organize the ninefold symmetry of centrioles due to insufficient Plk4.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edef18590b2a40aea0dfe32bad4780ea", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[156, 156], [41, 41]], "char_spans": [[978, 987], [293, 302]]}]}], "context_tokens": [["Cancer", 0], ["cells", 7], ["frequently", 13], ["induce", 24], ["aberrant", 31], ["centrosomes", 40], [",", 51], ["which", 53], ["have", 59], ["been", 64], ["implicated", 69], ["in", 80], ["cancer", 83], ["initiation", 90], ["and", 101], ["progression", 105], [".", 116], ["Human", 118], ["colorectal", 124], ["cancer", 135], ["cells", 142], [",", 147], ["HCT116", 149], [",", 155], ["contain", 157], ["aberrant", 165], ["centrioles", 174], ["composed", 185], ["of", 194], ["disorganized", 197], ["cylindrical", 210], ["microtubules", 222], ["and", 235], ["displaced", 239], ["appendages", 249], [".", 259], ["These", 261], ["cells", 267], ["also", 273], ["express", 278], ["unique", 286], ["centrosome", 293], ["-", 303], ["related", 304], ["structures", 312], ["associated", 323], ["with", 334], ["a", 339], ["subset", 341], ["of", 348], ["centrosomal", 351], ["components", 363], [",", 373], ["including", 375], ["gamma", 385], ["-", 390], ["tubulin", 391], [",", 398], ["centrin", 400], ["and", 408], ["PCM1", 412], [".", 416], ["During", 418], ["hydroxyurea", 425], ["treatment", 437], [",", 446], ["these", 448], ["abnormal", 454], ["structures", 463], ["become", 474], ["more", 481], ["abundant", 486], ["and", 495], ["undergo", 499], ["a", 507], ["change", 509], ["in", 516], ["shape", 519], ["from", 525], ["small", 530], ["dots", 536], ["to", 541], ["elongated", 544], ["fibers", 554], [".", 560], ["Although", 562], ["gamma", 571], ["-", 576], ["tubulin", 577], ["seems", 585], ["to", 591], ["exist", 594], ["as", 600], ["a", 603], ["ring", 605], ["complex", 610], [",", 617], ["the", 619], ["abnormal", 623], ["structures", 632], ["do", 643], ["not", 646], ["support", 650], ["microtubule", 658], ["nucleation", 670], [".", 680], ["Several", 682], ["lines", 690], ["of", 696], ["evidence", 699], ["suggest", 708], ["that", 716], ["the", 721], ["fibers", 725], ["correspond", 732], ["to", 743], ["a", 746], ["disorganized", 748], ["form", 761], ["of", 766], ["centriolar", 769], ["microtubules", 780], [".", 792], ["Plk4", 794], [",", 798], ["a", 800], ["mammalian", 802], ["homolog", 812], ["of", 820], ["ZYG-1", 823], ["essential", 829], ["for", 839], ["initiation", 843], ["of", 854], ["centriole", 857], ["biogenesis", 867], [",", 877], ["is", 879], ["not", 882], ["associated", 886], ["with", 897], ["the", 902], ["gamma", 906], ["-", 911], ["tubulin", 912], ["-", 919], ["specific", 920], ["abnormal", 929], ["centrosomes", 938], [".", 949], ["The", 951], ["amount", 955], ["of", 962], ["Plk4", 965], ["at", 970], ["each", 973], ["centrosome", 978], ["was", 989], ["less", 993], ["in", 998], ["cells", 1001], ["with", 1007], ["abnormal", 1012], ["centrosomes", 1021], ["than", 1033], ["cells", 1038], ["without", 1044], ["gamma", 1052], ["-", 1057], ["tubulin", 1058], ["-", 1065], ["specific", 1066], ["abnormal", 1075], ["centrosomes", 1084], [".", 1095], ["In", 1097], ["addition", 1100], [",", 1108], ["the", 1110], ["formation", 1114], ["of", 1124], ["abnormal", 1127], ["structures", 1136], ["was", 1147], ["abolished", 1151], ["by", 1161], ["expression", 1164], ["of", 1175], ["exogenous", 1178], ["Plk4", 1188], [",", 1192], ["but", 1194], ["not", 1198], ["SAS6", 1202], ["and", 1207], ["Cep135/Bld10p", 1211], [",", 1224], ["which", 1226], ["are", 1232], ["downstream", 1236], ["regulators", 1247], ["required", 1258], ["for", 1267], ["the", 1271], ["organization", 1275], ["of", 1288], ["nine", 1291], ["-", 1295], ["triplet", 1296], ["microtubules", 1304], [".", 1316], ["These", 1318], ["results", 1324], ["suggest", 1332], ["that", 1340], ["HCT116", 1345], ["cells", 1352], ["fail", 1358], ["to", 1363], ["organize", 1366], ["the", 1375], ["ninefold", 1379], ["symmetry", 1388], ["of", 1397], ["centrioles", 1400], ["due", 1411], ["to", 1415], ["insufficient", 1418], ["Plk4", 1431], [".", 1435]]}
{"context": "Neurofibromatosis type 1 (NF1) gene is a tumor suppressor gene, and the NF1 gene product, neurofibromin, can downregulate the N-ras gene. Because the N-ras gene is often mutated in acute myelogenous leukemia (AML), we wondered if the NF1 gene might be mutated in those AML samples not having N-ras mutations. We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML. Of 48 AML patients, 10 (21%) had point (missense) mutations of the N-ras gene involving codons 12, 13 and 61. However, mutations in the FLR exon of the NF1 gene were not detected in any of the AML samples. We also examined the difference of clinical response to induction therapy between AML patients with and without N-ras mutation. A significantly lower rate of complete remission was noted in individuals with N-ras gene mutations. These results suggest that mutation of the NF1 gene, at least in the FLR exon, is very rare in AML and the NF1 gene probably is not a functional complement of the N-ras gene mutation. The presence of N-ras gene mutation may be associated with a lower clinical response to antileukemic therapy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fb9d60b81eed4b7e93174fdf341800eb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [189, 189], [4, 4], [265, 265], [248, 248], [50, 50], [15, 15]], "char_spans": [[447, 449], [871, 873], [26, 28], [1261, 1263], [1197, 1199], [234, 236], [72, 74]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["gene", 31], ["is", 36], ["a", 39], ["tumor", 41], ["suppressor", 47], ["gene", 58], [",", 62], ["and", 64], ["the", 68], ["NF1", 72], ["gene", 76], ["product", 81], [",", 88], ["neurofibromin", 90], [",", 103], ["can", 105], ["downregulate", 109], ["the", 122], ["N", 126], ["-", 127], ["ras", 128], ["gene", 132], [".", 136], ["Because", 138], ["the", 146], ["N", 150], ["-", 151], ["ras", 152], ["gene", 156], ["is", 161], ["often", 164], ["mutated", 170], ["in", 178], ["acute", 181], ["myelogenous", 187], ["leukemia", 199], ["(", 208], ["AML", 209], [")", 212], [",", 213], ["we", 215], ["wondered", 218], ["if", 227], ["the", 230], ["NF1", 234], ["gene", 238], ["might", 243], ["be", 249], ["mutated", 252], ["in", 260], ["those", 263], ["AML", 269], ["samples", 273], ["not", 281], ["having", 285], ["N", 292], ["-", 293], ["ras", 294], ["mutations", 298], [".", 307], ["We", 309], ["investigated", 312], ["the", 325], ["mutational", 329], ["status", 340], ["of", 347], ["the", 350], ["N", 354], ["-", 355], ["ras", 356], ["gene", 360], ["and", 365], ["the", 369], ["FLR", 373], ["exon", 377], ["of", 382], ["codons", 385], ["1371", 392], ["-", 396], ["1423", 397], ["of", 402], ["the", 405], ["open", 409], ["reading", 414], ["frame", 422], ["of", 428], ["the", 431], ["full", 435], ["-", 439], ["length", 440], ["NF1", 447], ["cDNA", 451], [",", 455], ["which", 457], ["has", 463], ["a", 467], ["strong", 469], ["homology", 476], ["with", 485], ["the", 490], ["mammalian", 494], ["ras", 504], ["GTPase", 508], ["-", 514], ["activating", 515], ["protein", 526], ["(", 534], ["GAP", 535], [")", 538], [",", 539], ["especially", 541], ["for", 552], ["a", 556], ["stretch", 558], ["of", 566], ["three", 569], ["consecutive", 575], ["amino", 587], ["acids", 593], ["(", 599], ["F", 600], [",", 601], ["L", 603], [",", 604], ["R", 606], [")", 607], [",", 608], ["by", 610], ["single", 613], ["-", 619], ["strand", 620], ["conformation", 627], ["polymorphism", 640], ["analysis", 653], ["and", 662], ["direct", 666], ["sequencing", 673], ["in", 684], ["samples", 687], ["from", 695], ["patients", 700], ["with", 709], ["AML", 714], [".", 717], ["Of", 719], ["48", 722], ["AML", 725], ["patients", 729], [",", 737], ["10", 739], ["(", 742], ["21", 743], ["%", 745], [")", 746], ["had", 748], ["point", 752], ["(", 758], ["missense", 759], [")", 767], ["mutations", 769], ["of", 779], ["the", 782], ["N", 786], ["-", 787], ["ras", 788], ["gene", 792], ["involving", 797], ["codons", 807], ["12", 814], [",", 816], ["13", 818], ["and", 821], ["61", 825], [".", 827], ["However", 829], [",", 836], ["mutations", 838], ["in", 848], ["the", 851], ["FLR", 855], ["exon", 859], ["of", 864], ["the", 867], ["NF1", 871], ["gene", 875], ["were", 880], ["not", 885], ["detected", 889], ["in", 898], ["any", 901], ["of", 905], ["the", 908], ["AML", 912], ["samples", 916], [".", 923], ["We", 925], ["also", 928], ["examined", 933], ["the", 942], ["difference", 946], ["of", 957], ["clinical", 960], ["response", 969], ["to", 978], ["induction", 981], ["therapy", 991], ["between", 999], ["AML", 1007], ["patients", 1011], ["with", 1020], ["and", 1025], ["without", 1029], ["N", 1037], ["-", 1038], ["ras", 1039], ["mutation", 1043], [".", 1051], ["A", 1053], ["significantly", 1055], ["lower", 1069], ["rate", 1075], ["of", 1080], ["complete", 1083], ["remission", 1092], ["was", 1102], ["noted", 1106], ["in", 1112], ["individuals", 1115], ["with", 1127], ["N", 1132], ["-", 1133], ["ras", 1134], ["gene", 1138], ["mutations", 1143], [".", 1152], ["These", 1154], ["results", 1160], ["suggest", 1168], ["that", 1176], ["mutation", 1181], ["of", 1190], ["the", 1193], ["NF1", 1197], ["gene", 1201], [",", 1205], ["at", 1207], ["least", 1210], ["in", 1216], ["the", 1219], ["FLR", 1223], ["exon", 1227], [",", 1231], ["is", 1233], ["very", 1236], ["rare", 1241], ["in", 1246], ["AML", 1249], ["and", 1253], ["the", 1257], ["NF1", 1261], ["gene", 1265], ["probably", 1270], ["is", 1279], ["not", 1282], ["a", 1286], ["functional", 1288], ["complement", 1299], ["of", 1310], ["the", 1313], ["N", 1317], ["-", 1318], ["ras", 1319], ["gene", 1323], ["mutation", 1328], [".", 1336], ["The", 1338], ["presence", 1342], ["of", 1351], ["N", 1354], ["-", 1355], ["ras", 1356], ["gene", 1360], ["mutation", 1365], ["may", 1374], ["be", 1378], ["associated", 1381], ["with", 1392], ["a", 1397], ["lower", 1399], ["clinical", 1405], ["response", 1414], ["to", 1423], ["antileukemic", 1426], ["therapy", 1439], [".", 1446]]}
{"context": "The aim of this study was to assess to what extent patients with meticillin-resistant Staphylococcus aureus (MRSA) at respiratory sites shed viable MRSA into the air of hospital rooms. We also evaluated whether the distance from the patient could influence the level of contamination. Air sampling was performed directly onto MRSA-selective agar in 24 hospital rooms containing patients with MRSA colonization or infection of the respiratory tract. Samplings were performed in duplicate at 0.5, 1 and 2-3 m from the patients' heads. Clinical and environmental isolates were compared using antimicrobial resistance patterns and pulsed-field gel electrophoresis. MRSA strains were isolated from 21 out of 24 rooms, in quantities varying from between 1 and 78 cfu/m3. In each of the 21 rooms, at least one of the environmental isolates was identical to a clinical isolate from the patient in that room. There was no significant difference in MRSA counts between the distance from the patient's head and the sampler. This study demonstrates that most patients with MRSA infection or colonisation of the respiratory tract shed viable MRSA into the air of their room. The results emphasise the need to study MRSA in air in more detail in order to improve infection control recommendations.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "1a6e6e4476ac4f3694bbf44eba26b5a9", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[67, 67], [19, 19], [26, 26], [169, 169], [215, 215], [56, 56], [200, 200], [190, 190], [113, 113]], "char_spans": [[392, 395], [109, 112], [148, 151], [939, 942], [1202, 1205], [326, 329], [1129, 1132], [1061, 1064], [661, 664]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["assess", 29], ["to", 36], ["what", 39], ["extent", 44], ["patients", 51], ["with", 60], ["meticillin", 65], ["-", 75], ["resistant", 76], ["Staphylococcus", 86], ["aureus", 101], ["(", 108], ["MRSA", 109], [")", 113], ["at", 115], ["respiratory", 118], ["sites", 130], ["shed", 136], ["viable", 141], ["MRSA", 148], ["into", 153], ["the", 158], ["air", 162], ["of", 166], ["hospital", 169], ["rooms", 178], [".", 183], ["We", 185], ["also", 188], ["evaluated", 193], ["whether", 203], ["the", 211], ["distance", 215], ["from", 224], ["the", 229], ["patient", 233], ["could", 241], ["influence", 247], ["the", 257], ["level", 261], ["of", 267], ["contamination", 270], [".", 283], ["Air", 285], ["sampling", 289], ["was", 298], ["performed", 302], ["directly", 312], ["onto", 321], ["MRSA", 326], ["-", 330], ["selective", 331], ["agar", 341], ["in", 346], ["24", 349], ["hospital", 352], ["rooms", 361], ["containing", 367], ["patients", 378], ["with", 387], ["MRSA", 392], ["colonization", 397], ["or", 410], ["infection", 413], ["of", 423], ["the", 426], ["respiratory", 430], ["tract", 442], [".", 447], ["Samplings", 449], ["were", 459], ["performed", 464], ["in", 474], ["duplicate", 477], ["at", 487], ["0.5", 490], [",", 493], ["1", 495], ["and", 497], ["2", 501], ["-", 502], ["3", 503], ["m", 505], ["from", 507], ["the", 512], ["patients", 516], ["'", 524], ["heads", 526], [".", 531], ["Clinical", 533], ["and", 542], ["environmental", 546], ["isolates", 560], ["were", 569], ["compared", 574], ["using", 583], ["antimicrobial", 589], ["resistance", 603], ["patterns", 614], ["and", 623], ["pulsed", 627], ["-", 633], ["field", 634], ["gel", 640], ["electrophoresis", 644], [".", 659], ["MRSA", 661], ["strains", 666], ["were", 674], ["isolated", 679], ["from", 688], ["21", 693], ["out", 696], ["of", 700], ["24", 703], ["rooms", 706], [",", 711], ["in", 713], ["quantities", 716], ["varying", 727], ["from", 735], ["between", 740], ["1", 748], ["and", 750], ["78", 754], ["cfu", 757], ["/", 760], ["m3", 761], [".", 763], ["In", 765], ["each", 768], ["of", 773], ["the", 776], ["21", 780], ["rooms", 783], [",", 788], ["at", 790], ["least", 793], ["one", 799], ["of", 803], ["the", 806], ["environmental", 810], ["isolates", 824], ["was", 833], ["identical", 837], ["to", 847], ["a", 850], ["clinical", 852], ["isolate", 861], ["from", 869], ["the", 874], ["patient", 878], ["in", 886], ["that", 889], ["room", 894], [".", 898], ["There", 900], ["was", 906], ["no", 910], ["significant", 913], ["difference", 925], ["in", 936], ["MRSA", 939], ["counts", 944], ["between", 951], ["the", 959], ["distance", 963], ["from", 972], ["the", 977], ["patient", 981], ["'s", 988], ["head", 991], ["and", 996], ["the", 1000], ["sampler", 1004], [".", 1011], ["This", 1013], ["study", 1018], ["demonstrates", 1024], ["that", 1037], ["most", 1042], ["patients", 1047], ["with", 1056], ["MRSA", 1061], ["infection", 1066], ["or", 1076], ["colonisation", 1079], ["of", 1092], ["the", 1095], ["respiratory", 1099], ["tract", 1111], ["shed", 1117], ["viable", 1122], ["MRSA", 1129], ["into", 1134], ["the", 1139], ["air", 1143], ["of", 1147], ["their", 1150], ["room", 1156], [".", 1160], ["The", 1162], ["results", 1166], ["emphasise", 1174], ["the", 1184], ["need", 1188], ["to", 1193], ["study", 1196], ["MRSA", 1202], ["in", 1207], ["air", 1210], ["in", 1214], ["more", 1217], ["detail", 1222], ["in", 1229], ["order", 1232], ["to", 1238], ["improve", 1241], ["infection", 1249], ["control", 1259], ["recommendations", 1267], [".", 1282]]}
{"context": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ef28a6cc8b5d472b98e489b35d514e0b", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[186, 186], [108, 108], [60, 60], [84, 84], [23, 23], [114, 114], [143, 143]], "char_spans": [[1252, 1261], [689, 698], [366, 375], [529, 538], [143, 152], [732, 741], [943, 952]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["idarucizumab", 24], [",", 36], ["a", 38], ["humanized", 40], ["monoclonal", 50], ["antibody", 61], ["fragment", 70], [",", 78], ["as", 80], ["a", 83], ["specific", 85], ["reversal", 94], ["agent", 103], ["for", 109], ["the", 113], ["anticoagulant", 117], ["activity", 131], ["of", 140], ["dabigatran", 143], ["and", 154], ["to", 158], ["review", 161], ["the", 168], ["pharmacology", 172], [",", 184], ["pharmacokinetic", 186], ["properties", 202], [",", 212], ["efficacy", 214], [",", 222], ["and", 224], ["safety", 228], ["of", 235], ["this", 238], ["agent", 243], [".", 248], ["A", 250], ["literature", 252], ["search", 263], ["was", 270], ["conducted", 274], ["consisting", 284], ["of", 295], ["a", 298], ["PubMed", 300], ["database", 307], ["using", 316], ["the", 322], ["MeSH", 326], ["term", 331], ["idarucizumab", 336], ["and", 349], ["the", 353], ["key", 357], ["word", 361], ["dabigatran", 366], ["antidote", 377], [".", 385], ["Studies", 387], ["evaluating", 395], ["the", 406], ["pharmacology", 410], [",", 422], ["pharmacokinetics", 424], [",", 440], ["safety", 442], [",", 448], ["and", 450], ["efficacy", 454], ["of", 463], ["idarucizumab", 466], ["for", 479], ["the", 483], ["reversal", 487], ["of", 496], ["the", 499], ["anticoagulant", 503], ["activity", 517], ["of", 526], ["dabigatran", 529], ["were", 540], ["included", 545], [".", 553], ["Idarucizumab", 555], ["represents", 568], ["a", 579], ["novel", 581], ["treatment", 587], ["option", 597], ["as", 604], ["it", 607], ["is", 610], ["the", 613], ["only", 617], ["humanized", 622], [",", 631], ["monoclonal", 633], ["antibody", 644], ["fragment", 653], ["that", 662], ["specifically", 667], ["binds", 680], ["to", 686], ["dabigatran", 689], [".", 699], ["Studies", 701], ["evaluating", 709], ["reversal", 720], ["of", 729], ["dabigatran", 732], ["-", 742], ["induced", 743], ["anticoagulation", 751], ["have", 767], ["demonstrated", 772], ["immediate", 785], [",", 794], ["complete", 796], [",", 804], ["and", 806], ["sustained", 810], ["effects", 820], ["with", 828], ["idarucizumab", 833], [".", 845], ["Idarucizumab", 847], ["did", 860], ["not", 864], ["overcorrect", 868], ["thrombin", 880], ["generation", 889], [".", 899], ["Additionally", 901], [",", 913], ["evaluations", 915], ["have", 927], ["shown", 932], ["that", 938], ["dabigatran", 943], ["can", 954], ["be", 958], ["safely", 961], ["reinitiated", 968], ["24", 980], ["hours", 983], ["after", 989], ["the", 995], ["administration", 999], ["of", 1014], ["idarucizumab", 1017], [".", 1029], ["The", 1031], ["United", 1035], ["States", 1042], ["Food", 1049], ["and", 1054], ["Drug", 1058], ["Administration", 1063], ["granted", 1078], ["priority", 1086], ["review", 1095], ["for", 1102], ["the", 1106], ["biologic", 1110], ["license", 1119], ["application", 1127], ["and", 1139], ["accelerated", 1143], ["approval", 1155], ["for", 1164], ["idarucizumab", 1168], [".", 1180], ["Idarucizumab", 1182], ["represents", 1195], ["an", 1206], ["encouraging", 1209], ["development", 1221], ["in", 1233], ["the", 1236], ["reversal", 1240], ["of", 1249], ["dabigatran", 1252], [".", 1262], ["Its", 1264], ["novel", 1268], ["mechanism", 1274], ["of", 1284], ["action", 1287], [",", 1293], ["pharmacokinetics", 1295], [",", 1311], ["tolerability", 1313], [",", 1325], ["and", 1327], ["lack", 1331], ["of", 1336], ["thrombotic", 1339], ["events", 1350], ["contribute", 1357], ["positively", 1368], ["to", 1379], ["its", 1382], ["use", 1386], ["in", 1390], ["patients", 1393], ["who", 1402], ["experience", 1406], ["bleeding", 1417], ["or", 1426], ["for", 1429], ["those", 1433], ["who", 1439], ["require", 1443], ["emergent", 1451], ["surgery", 1460], ["or", 1468], ["procedures", 1471], [".", 1481]]}
{"context": "A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission. 6,537 infants aged 6-12 wk and 8,923 children aged 5-17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from -1 to 49, respectively; corresponding ranges among infants were -10 to 1,402 and -13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively. RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa. www.ClinicalTrials.gov NCT00866619 Please see later in the article for the Editors' Summary.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "83bbfe9e1ba04ab5b0d56e7dbde01a22", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[157, 157], [259, 259], [42, 42], [325, 325], [451, 451], [469, 469], [428, 428], [409, 409], [1, 1], [216, 216], [159, 159], [257, 257], [79, 79]], "char_spans": [[663, 669], [997, 1003], [221, 227], [1336, 1342], [1977, 1983], [2069, 2075], [1868, 1874], [1772, 1778], [2, 8], [850, 856], [672, 678], [988, 994], [398, 404]]}]}], "context_tokens": [["A", 0], ["malaria", 2], ["vaccine", 10], ["could", 18], ["be", 24], ["an", 27], ["important", 30], ["addition", 40], ["to", 49], ["current", 52], ["control", 60], ["strategies", 68], [".", 78], ["We", 80], ["report", 83], ["the", 90], ["safety", 94], ["and", 101], ["vaccine", 105], ["efficacy", 113], ["(", 122], ["VE", 123], [")", 125], ["of", 127], ["the", 130], ["RTS", 134], [",", 137], ["S", 138], ["/", 139], ["AS01", 140], ["vaccine", 145], ["during", 153], ["18", 160], ["mo", 163], ["following", 166], ["vaccination", 176], ["at", 188], ["11", 191], ["African", 194], ["sites", 202], ["with", 208], ["varying", 213], ["malaria", 221], ["transmission", 229], [".", 241], ["6,537", 243], ["infants", 249], ["aged", 257], ["6", 262], ["-", 263], ["12", 264], ["wk", 267], ["and", 270], ["8,923", 274], ["children", 280], ["aged", 289], ["5", 294], ["-", 295], ["17", 296], ["mo", 299], ["were", 302], ["randomized", 307], ["to", 318], ["receive", 321], ["three", 329], ["doses", 335], ["of", 341], ["RTS", 344], [",", 347], ["S", 348], ["/", 349], ["AS01", 350], ["or", 355], ["comparator", 358], ["vaccine", 369], [".", 376], ["VE", 378], ["against", 381], ["clinical", 389], ["malaria", 398], ["in", 406], ["children", 409], ["during", 418], ["the", 425], ["18", 429], ["mo", 432], ["after", 435], ["vaccine", 441], ["dose", 449], ["3", 454], ["(", 456], ["per", 457], ["protocol", 461], [")", 469], ["was", 471], ["46", 475], ["%", 477], ["(", 479], ["95", 480], ["%", 482], ["CI", 484], ["42", 487], ["%", 489], ["to", 491], ["50", 494], ["%", 496], [")", 497], ["(", 499], ["range", 500], ["40", 506], ["%", 508], ["to", 510], ["77", 513], ["%", 515], [";", 516], ["VE", 518], [",", 520], ["p<0.01", 522], ["across", 529], ["all", 536], ["sites", 540], [")", 545], [".", 546], ["VE", 548], ["during", 551], ["the", 558], ["20", 562], ["mo", 565], ["after", 568], ["vaccine", 574], ["dose", 582], ["1", 587], ["(", 589], ["intention", 590], ["to", 600], ["treat", 603], ["[", 609], ["ITT", 610], ["]", 613], [")", 614], ["was", 616], ["45", 620], ["%", 622], ["(", 624], ["95", 625], ["%", 627], ["CI", 629], ["41", 632], ["%", 634], ["to", 636], ["49", 639], ["%", 641], [")", 642], [".", 643], ["VE", 645], ["against", 648], ["severe", 656], ["malaria", 663], [",", 670], ["malaria", 672], ["hospitalization", 680], [",", 695], ["and", 697], ["all", 701], ["-", 704], ["cause", 705], ["hospitalization", 711], ["was", 727], ["34", 731], ["%", 733], ["(", 735], ["95", 736], ["%", 738], ["CI", 740], ["15", 743], ["%", 745], ["to", 747], ["48", 750], ["%", 752], [")", 753], [",", 754], ["41", 756], ["%", 758], ["(", 760], ["95", 761], ["%", 763], ["CI", 765], ["30", 768], ["%", 770], ["to", 772], ["50", 775], ["%", 777], [")", 778], [",", 779], ["and", 781], ["19", 785], ["%", 787], ["(", 789], ["95", 790], ["%", 792], ["CI", 794], ["11", 797], ["%", 799], ["to", 801], ["27", 804], ["%", 806], [")", 807], [",", 808], ["respectively", 810], ["(", 823], ["ITT", 824], [")", 827], [".", 828], ["VE", 830], ["against", 833], ["clinical", 841], ["malaria", 850], ["in", 858], ["infants", 861], ["was", 869], ["27", 873], ["%", 875], ["(", 877], ["95", 878], ["%", 880], ["CI", 882], ["20", 885], ["%", 887], ["to", 889], ["32", 892], ["%", 894], [",", 895], ["per", 897], ["protocol", 901], [";", 909], ["27", 911], ["%", 913], ["[", 915], ["95", 916], ["%", 918], ["CI", 920], ["21", 923], ["%", 925], ["to", 927], ["33", 930], ["%", 932], ["]", 933], [",", 934], ["ITT", 936], [")", 939], [",", 940], ["with", 942], ["no", 947], ["significant", 950], ["protection", 962], ["against", 973], ["severe", 981], ["malaria", 988], [",", 995], ["malaria", 997], ["hospitalization", 1005], [",", 1020], ["or", 1022], ["all", 1025], ["-", 1028], ["cause", 1029], ["hospitalization", 1035], [".", 1050], ["Post", 1052], ["-", 1056], ["vaccination", 1057], ["anti", 1069], ["-", 1073], ["circumsporozoite", 1074], ["antibody", 1091], ["geometric", 1100], ["mean", 1110], ["titer", 1115], ["varied", 1121], ["from", 1128], ["348", 1133], ["to", 1137], ["787", 1140], ["EU", 1144], ["/", 1146], ["ml", 1147], ["across", 1150], ["sites", 1157], ["in", 1163], ["children", 1166], ["and", 1175], ["from", 1179], ["117", 1184], ["to", 1188], ["335", 1191], ["EU", 1195], ["/", 1197], ["ml", 1198], ["in", 1201], ["infants", 1204], ["(", 1212], ["per", 1213], ["protocol", 1217], [")", 1225], [".", 1226], ["VE", 1228], ["waned", 1231], ["over", 1237], ["time", 1242], ["in", 1247], ["both", 1250], ["age", 1255], ["categories", 1259], ["(", 1270], ["Schoenfeld", 1271], ["residuals", 1282], ["p<0.001", 1292], [")", 1299], [".", 1300], ["The", 1302], ["number", 1306], ["of", 1313], ["clinical", 1316], ["and", 1325], ["severe", 1329], ["malaria", 1336], ["cases", 1344], ["averted", 1350], ["per", 1358], ["1,000", 1362], ["children", 1368], ["vaccinated", 1377], ["ranged", 1388], ["across", 1395], ["sites", 1402], ["from", 1408], ["37", 1413], ["to", 1416], ["2,365", 1419], ["and", 1425], ["from", 1429], ["-1", 1434], ["to", 1437], ["49", 1440], [",", 1442], ["respectively", 1444], [";", 1456], ["corresponding", 1458], ["ranges", 1472], ["among", 1479], ["infants", 1485], ["were", 1493], ["-10", 1498], ["to", 1502], ["1,402", 1505], ["and", 1511], ["-13", 1515], ["to", 1519], ["37", 1522], [",", 1524], ["respectively", 1526], ["(", 1539], ["ITT", 1540], [")", 1543], [".", 1544], ["Meningitis", 1546], ["was", 1557], ["reported", 1561], ["as", 1570], ["a", 1573], ["serious", 1575], ["adverse", 1583], ["event", 1591], ["in", 1597], ["16/5,949", 1600], ["and", 1609], ["1/2,974", 1613], ["children", 1621], ["and", 1630], ["in", 1634], ["9/4,358", 1637], ["and", 1645], ["3/2,179", 1649], ["infants", 1657], ["in", 1665], ["the", 1668], ["RTS", 1672], [",", 1675], ["S", 1676], ["/", 1677], ["AS01", 1678], ["and", 1683], ["control", 1687], ["groups", 1695], [",", 1701], ["respectively", 1703], [".", 1715], ["RTS", 1717], [",", 1720], ["S", 1721], ["/", 1722], ["AS01", 1723], ["prevented", 1728], ["many", 1738], ["cases", 1743], ["of", 1749], ["clinical", 1752], ["and", 1761], ["severe", 1765], ["malaria", 1772], ["over", 1780], ["the", 1785], ["18", 1789], ["mo", 1792], ["after", 1795], ["vaccine", 1801], ["dose", 1809], ["3", 1814], [",", 1815], ["with", 1817], ["the", 1822], ["highest", 1826], ["impact", 1834], ["in", 1841], ["areas", 1844], ["with", 1850], ["the", 1855], ["greatest", 1859], ["malaria", 1868], ["incidence", 1876], [".", 1885], ["VE", 1887], ["was", 1890], ["higher", 1894], ["in", 1901], ["children", 1904], ["than", 1913], ["in", 1918], ["infants", 1921], [",", 1928], ["but", 1930], ["even", 1934], ["at", 1939], ["modest", 1942], ["levels", 1949], ["of", 1956], ["VE", 1959], [",", 1961], ["the", 1963], ["number", 1967], ["of", 1974], ["malaria", 1977], ["cases", 1985], ["averted", 1991], ["was", 1999], ["substantial", 2003], [".", 2014], ["RTS", 2016], [",", 2019], ["S", 2020], ["/", 2021], ["AS01", 2022], ["could", 2027], ["be", 2033], ["an", 2036], ["important", 2039], ["addition", 2049], ["to", 2058], ["current", 2061], ["malaria", 2069], ["control", 2077], ["in", 2085], ["Africa", 2088], [".", 2094], ["www", 2096], [".", 2099], ["ClinicalTrials.gov", 2100], ["NCT00866619", 2119], ["Please", 2131], ["see", 2138], ["later", 2142], ["in", 2148], ["the", 2151], ["article", 2155], ["for", 2163], ["the", 2167], ["Editors", 2171], ["'", 2178], ["Summary", 2180], [".", 2187]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "Background Inappropriate use of antibiotic treatment for pharyngitis by community pharmacists is prevalent in developing countries. Little is known about how the pharmacists identify patients with bacterial pharyngitis. Objective To ascertain the appropriateness of diagnosis of streptococcal pharyngitis among Thai community pharmacists according to the Centor criteria and to identify factors related to antibiotic dispensing. Setting 1040 Thai community pharmacists. Method A cross-sectional survey of community pharmacists was conducted in November 2012 to March 2013. The self-administered questionnaires were mailed to 57\u00a0% of community pharmacists in the south of Thailand (n\u00a0=\u00a01040). The survey included questions on diagnosis of streptococcal pharyngitis, knowledge on pharyngitis, and attitudes and control beliefs regarding antibiotic dispensing. Main outcome measure The appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified Centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing. Results Approximately 68\u00a0% completed the questionnaires (n\u00a0=\u00a0703). Compared to the pharmacists who reported not dispensing antibiotics in the hypothetical case with common cold, those reported dispensing antibiotics were more likely to consider the following conditions-presence of cough, mild sore throat and patients with age >60\u00a0years as cues for diagnosis of streptococcal pharyngitis (p\u00a0<\u00a00.05). The use of fewer scores of the clinical prediction rules for diagnosis was observed in antibiotic dispensers, compared to who did not do so (p\u00a0<\u00a00.005). Antibiotic dispensing was positively associated with period of dispensing experience (>5\u00a0years) [odds ratio (OR) 1.52; 95\u00a0% confidence interval (CI) 1.03-2.23], belief that antibiotics could shorten duration of pharyngitis (OR 1.48; 95\u00a0% CI 1.11-1.99), belief that antibiotics could prevent the complications (OR 1.44; 95\u00a0% CI 1.09-1.91) and belief that dispensing antibiotics could satisfy the patients (OR 1.31; 95\u00a0% CI 1.01-1.71). Nonetheless, antibiotic dispensing was negatively associated with knowledge about pharyngitis (OR 0.83; 95\u00a0% CI 0.75-0.93). Conclusion Pharmacists who are knowledgeable on the Centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "fd56ae32cdb74808971cdd1f6e9b58ae", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[113, 114], [38, 39], [404, 405], [233, 234], [137, 138]], "char_spans": [[738, 762], [279, 303], [2400, 2424], [1541, 1565], [915, 939]]}]}], "context_tokens": [["Background", 0], ["Inappropriate", 11], ["use", 25], ["of", 29], ["antibiotic", 32], ["treatment", 43], ["for", 53], ["pharyngitis", 57], ["by", 69], ["community", 72], ["pharmacists", 82], ["is", 94], ["prevalent", 97], ["in", 107], ["developing", 110], ["countries", 121], [".", 130], ["Little", 132], ["is", 139], ["known", 142], ["about", 148], ["how", 154], ["the", 158], ["pharmacists", 162], ["identify", 174], ["patients", 183], ["with", 192], ["bacterial", 197], ["pharyngitis", 207], [".", 218], ["Objective", 220], ["To", 230], ["ascertain", 233], ["the", 243], ["appropriateness", 247], ["of", 263], ["diagnosis", 266], ["of", 276], ["streptococcal", 279], ["pharyngitis", 293], ["among", 305], ["Thai", 311], ["community", 316], ["pharmacists", 326], ["according", 338], ["to", 348], ["the", 351], ["Centor", 355], ["criteria", 362], ["and", 371], ["to", 375], ["identify", 378], ["factors", 387], ["related", 395], ["to", 403], ["antibiotic", 406], ["dispensing", 417], [".", 427], ["Setting", 429], ["1040", 437], ["Thai", 442], ["community", 447], ["pharmacists", 457], [".", 468], ["Method", 470], ["A", 477], ["cross", 479], ["-", 484], ["sectional", 485], ["survey", 495], ["of", 502], ["community", 505], ["pharmacists", 515], ["was", 527], ["conducted", 531], ["in", 541], ["November", 544], ["2012", 553], ["to", 558], ["March", 561], ["2013", 567], [".", 571], ["The", 573], ["self", 577], ["-", 581], ["administered", 582], ["questionnaires", 595], ["were", 610], ["mailed", 615], ["to", 622], ["57", 625], ["%", 628], ["of", 630], ["community", 633], ["pharmacists", 643], ["in", 655], ["the", 658], ["south", 662], ["of", 668], ["Thailand", 671], ["(", 680], ["n", 681], ["=", 683], ["1040", 685], [")", 689], [".", 690], ["The", 692], ["survey", 696], ["included", 703], ["questions", 712], ["on", 722], ["diagnosis", 725], ["of", 735], ["streptococcal", 738], ["pharyngitis", 752], [",", 763], ["knowledge", 765], ["on", 775], ["pharyngitis", 778], [",", 789], ["and", 791], ["attitudes", 795], ["and", 805], ["control", 809], ["beliefs", 817], ["regarding", 825], ["antibiotic", 835], ["dispensing", 846], [".", 856], ["Main", 858], ["outcome", 863], ["measure", 871], ["The", 879], ["appropriateness", 883], ["of", 899], ["diagnosis", 902], ["of", 912], ["streptococcal", 915], ["pharyngitis", 929], ["according", 941], ["to", 951], ["the", 954], ["original", 958], ["and", 967], ["modified", 971], ["Centor", 980], ["criteria", 987], ["and", 996], ["determinants", 1000], ["of", 1013], ["antibiotic", 1016], ["dispensing", 1027], ["including", 1038], ["demographic", 1048], ["characteristics", 1060], ["of", 1076], ["pharmacists", 1079], [",", 1090], ["knowledge", 1092], ["on", 1102], ["pharyngitis", 1105], [",", 1116], ["and", 1118], ["attitudes", 1122], ["and", 1132], ["control", 1136], ["beliefs", 1144], ["on", 1152], ["antibiotic", 1155], ["dispensing", 1166], [".", 1176], ["Results", 1178], ["Approximately", 1186], ["68", 1200], ["%", 1203], ["completed", 1205], ["the", 1215], ["questionnaires", 1219], ["(", 1234], ["n", 1235], ["=", 1237], ["703", 1239], [")", 1242], [".", 1243], ["Compared", 1245], ["to", 1254], ["the", 1257], ["pharmacists", 1261], ["who", 1273], ["reported", 1277], ["not", 1286], ["dispensing", 1290], ["antibiotics", 1301], ["in", 1313], ["the", 1316], ["hypothetical", 1320], ["case", 1333], ["with", 1338], ["common", 1343], ["cold", 1350], [",", 1354], ["those", 1356], ["reported", 1362], ["dispensing", 1371], ["antibiotics", 1382], ["were", 1394], ["more", 1399], ["likely", 1404], ["to", 1411], ["consider", 1414], ["the", 1423], ["following", 1427], ["conditions", 1437], ["-", 1447], ["presence", 1448], ["of", 1457], ["cough", 1460], [",", 1465], ["mild", 1467], ["sore", 1472], ["throat", 1477], ["and", 1484], ["patients", 1488], ["with", 1497], ["age", 1502], [">", 1506], ["60", 1507], ["years", 1510], ["as", 1516], ["cues", 1519], ["for", 1524], ["diagnosis", 1528], ["of", 1538], ["streptococcal", 1541], ["pharyngitis", 1555], ["(", 1567], ["p", 1568], ["<", 1570], ["0.05", 1572], [")", 1576], [".", 1577], ["The", 1579], ["use", 1583], ["of", 1587], ["fewer", 1590], ["scores", 1596], ["of", 1603], ["the", 1606], ["clinical", 1610], ["prediction", 1619], ["rules", 1630], ["for", 1636], ["diagnosis", 1640], ["was", 1650], ["observed", 1654], ["in", 1663], ["antibiotic", 1666], ["dispensers", 1677], [",", 1687], ["compared", 1689], ["to", 1698], ["who", 1701], ["did", 1705], ["not", 1709], ["do", 1713], ["so", 1716], ["(", 1719], ["p", 1720], ["<", 1722], ["0.005", 1724], [")", 1729], [".", 1730], ["Antibiotic", 1732], ["dispensing", 1743], ["was", 1754], ["positively", 1758], ["associated", 1769], ["with", 1780], ["period", 1785], ["of", 1792], ["dispensing", 1795], ["experience", 1806], ["(", 1817], [">", 1818], ["5", 1819], ["years", 1821], [")", 1826], ["[", 1828], ["odds", 1829], ["ratio", 1834], ["(", 1840], ["OR", 1841], [")", 1843], ["1.52", 1845], [";", 1849], ["95", 1851], ["%", 1854], ["confidence", 1856], ["interval", 1867], ["(", 1876], ["CI", 1877], [")", 1879], ["1.03", 1881], ["-", 1885], ["2.23", 1886], ["]", 1890], [",", 1891], ["belief", 1893], ["that", 1900], ["antibiotics", 1905], ["could", 1917], ["shorten", 1923], ["duration", 1931], ["of", 1940], ["pharyngitis", 1943], ["(", 1955], ["OR", 1956], ["1.48", 1959], [";", 1963], ["95", 1965], ["%", 1968], ["CI", 1970], ["1.11", 1973], ["-", 1977], ["1.99", 1978], [")", 1982], [",", 1983], ["belief", 1985], ["that", 1992], ["antibiotics", 1997], ["could", 2009], ["prevent", 2015], ["the", 2023], ["complications", 2027], ["(", 2041], ["OR", 2042], ["1.44", 2045], [";", 2049], ["95", 2051], ["%", 2054], ["CI", 2056], ["1.09", 2059], ["-", 2063], ["1.91", 2064], [")", 2068], ["and", 2070], ["belief", 2074], ["that", 2081], ["dispensing", 2086], ["antibiotics", 2097], ["could", 2109], ["satisfy", 2115], ["the", 2123], ["patients", 2127], ["(", 2136], ["OR", 2137], ["1.31", 2140], [";", 2144], ["95", 2146], ["%", 2149], ["CI", 2151], ["1.01", 2154], ["-", 2158], ["1.71", 2159], [")", 2163], [".", 2164], ["Nonetheless", 2166], [",", 2177], ["antibiotic", 2179], ["dispensing", 2190], ["was", 2201], ["negatively", 2205], ["associated", 2216], ["with", 2227], ["knowledge", 2232], ["about", 2242], ["pharyngitis", 2248], ["(", 2260], ["OR", 2261], ["0.83", 2264], [";", 2268], ["95", 2270], ["%", 2273], ["CI", 2275], ["0.75", 2278], ["-", 2282], ["0.93", 2283], [")", 2287], [".", 2288], ["Conclusion", 2290], ["Pharmacists", 2301], ["who", 2313], ["are", 2317], ["knowledgeable", 2321], ["on", 2335], ["the", 2338], ["Centor", 2342], ["criteria", 2349], ["are", 2358], ["more", 2362], ["likely", 2367], ["to", 2374], ["appropriately", 2377], ["diagnose", 2391], ["streptococcal", 2400], ["pharyngitis", 2414], ["and", 2426], ["less", 2430], ["likely", 2435], ["to", 2442], ["dispense", 2445], ["antibiotics", 2454], ["in", 2466], ["such", 2469], ["case", 2474], [".", 2478]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "Despite that deep brain stimulation (DBS) of the globus pallidus internus (GPi) is emerging as the favored intervention for patients with medically intractable dystonia, the pathophysiological mechanisms of dystonia are largely unclear. In eight patients with primary dystonia who were treated with bilateral chronic pallidal stimulation, we correlated symptom-related electromyogram (EMG) activity of the most affected muscles with the local field potentials (LFPs) recorded from the globus pallidus electrodes. In 5 dystonic patients with mobile involuntary movements, rhythmic EMG bursts in the contralateral muscles were coherent with the oscillations in the pallidal LFPs at the burst frequency. In contrast, no significant coherence was seen between EMG and LFPs either for the sustained activity separated out from the compound EMGs in those 5 cases, or in the EMGs in 3 other cases without mobile involuntary movements and rhythmic EMG bursts. In comparison with the resting condition, in both active and passive movements, significant modulation in the GPi LFPs was seen in the range of 8-16 Hz. The finding of significant coherence between GPi oscillations and rhythmic EMG bursts but not sustained tonic EMG activity suggests that the synchronized pallidal activity may be directly related to the rhythmic involuntary movements. In contrast, the sustained hypertonic muscle activity may be represented by less synchronized activity in the pallidum. Thus, the pallidum may play different roles in generating different components of the dystonic symptom complex.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "f2a831f2a3fc46d1a5b456712da85b80", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[10, 12]], "char_spans": [[49, 72]]}]}], "context_tokens": [["Despite", 0], ["that", 8], ["deep", 13], ["brain", 18], ["stimulation", 24], ["(", 36], ["DBS", 37], [")", 40], ["of", 42], ["the", 45], ["globus", 49], ["pallidus", 56], ["internus", 65], ["(", 74], ["GPi", 75], [")", 78], ["is", 80], ["emerging", 83], ["as", 92], ["the", 95], ["favored", 99], ["intervention", 107], ["for", 120], ["patients", 124], ["with", 133], ["medically", 138], ["intractable", 148], ["dystonia", 160], [",", 168], ["the", 170], ["pathophysiological", 174], ["mechanisms", 193], ["of", 204], ["dystonia", 207], ["are", 216], ["largely", 220], ["unclear", 228], [".", 235], ["In", 237], ["eight", 240], ["patients", 246], ["with", 255], ["primary", 260], ["dystonia", 268], ["who", 277], ["were", 281], ["treated", 286], ["with", 294], ["bilateral", 299], ["chronic", 309], ["pallidal", 317], ["stimulation", 326], [",", 337], ["we", 339], ["correlated", 342], ["symptom", 353], ["-", 360], ["related", 361], ["electromyogram", 369], ["(", 384], ["EMG", 385], [")", 388], ["activity", 390], ["of", 399], ["the", 402], ["most", 406], ["affected", 411], ["muscles", 420], ["with", 428], ["the", 433], ["local", 437], ["field", 443], ["potentials", 449], ["(", 460], ["LFPs", 461], [")", 465], ["recorded", 467], ["from", 476], ["the", 481], ["globus", 485], ["pallidus", 492], ["electrodes", 501], [".", 511], ["In", 513], ["5", 516], ["dystonic", 518], ["patients", 527], ["with", 536], ["mobile", 541], ["involuntary", 548], ["movements", 560], [",", 569], ["rhythmic", 571], ["EMG", 580], ["bursts", 584], ["in", 591], ["the", 594], ["contralateral", 598], ["muscles", 612], ["were", 620], ["coherent", 625], ["with", 634], ["the", 639], ["oscillations", 643], ["in", 656], ["the", 659], ["pallidal", 663], ["LFPs", 672], ["at", 677], ["the", 680], ["burst", 684], ["frequency", 690], [".", 699], ["In", 701], ["contrast", 704], [",", 712], ["no", 714], ["significant", 717], ["coherence", 729], ["was", 739], ["seen", 743], ["between", 748], ["EMG", 756], ["and", 760], ["LFPs", 764], ["either", 769], ["for", 776], ["the", 780], ["sustained", 784], ["activity", 794], ["separated", 803], ["out", 813], ["from", 817], ["the", 822], ["compound", 826], ["EMGs", 835], ["in", 840], ["those", 843], ["5", 849], ["cases", 851], [",", 856], ["or", 858], ["in", 861], ["the", 864], ["EMGs", 868], ["in", 873], ["3", 876], ["other", 878], ["cases", 884], ["without", 890], ["mobile", 898], ["involuntary", 905], ["movements", 917], ["and", 927], ["rhythmic", 931], ["EMG", 940], ["bursts", 944], [".", 950], ["In", 952], ["comparison", 955], ["with", 966], ["the", 971], ["resting", 975], ["condition", 983], [",", 992], ["in", 994], ["both", 997], ["active", 1002], ["and", 1009], ["passive", 1013], ["movements", 1021], [",", 1030], ["significant", 1032], ["modulation", 1044], ["in", 1055], ["the", 1058], ["GPi", 1062], ["LFPs", 1066], ["was", 1071], ["seen", 1075], ["in", 1080], ["the", 1083], ["range", 1087], ["of", 1093], ["8", 1096], ["-", 1097], ["16", 1098], ["Hz", 1101], [".", 1103], ["The", 1105], ["finding", 1109], ["of", 1117], ["significant", 1120], ["coherence", 1132], ["between", 1142], ["GPi", 1150], ["oscillations", 1154], ["and", 1167], ["rhythmic", 1171], ["EMG", 1180], ["bursts", 1184], ["but", 1191], ["not", 1195], ["sustained", 1199], ["tonic", 1209], ["EMG", 1215], ["activity", 1219], ["suggests", 1228], ["that", 1237], ["the", 1242], ["synchronized", 1246], ["pallidal", 1259], ["activity", 1268], ["may", 1277], ["be", 1281], ["directly", 1284], ["related", 1293], ["to", 1301], ["the", 1304], ["rhythmic", 1308], ["involuntary", 1317], ["movements", 1329], [".", 1338], ["In", 1340], ["contrast", 1343], [",", 1351], ["the", 1353], ["sustained", 1357], ["hypertonic", 1367], ["muscle", 1378], ["activity", 1385], ["may", 1394], ["be", 1398], ["represented", 1401], ["by", 1413], ["less", 1416], ["synchronized", 1421], ["activity", 1434], ["in", 1443], ["the", 1446], ["pallidum", 1450], [".", 1458], ["Thus", 1460], [",", 1464], ["the", 1466], ["pallidum", 1470], ["may", 1479], ["play", 1483], ["different", 1488], ["roles", 1498], ["in", 1504], ["generating", 1507], ["different", 1518], ["components", 1528], ["of", 1539], ["the", 1542], ["dystonic", 1546], ["symptom", 1555], ["complex", 1563], [".", 1570]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". In light of this, we aim to develop a protocol for behavioral observations supporting the diagnosis of WED/RLS. We investigated 26 pediatric patients (age 1-16 years, median 8) with NDCs, ICI and evidence of familial WED/RLS employing (1) \"emplotted narratives\" for description of the various \"urge-to-move\" presentations and (2) self-description and \"behavioral observations\" during a \"suggested clinical immobilization test\" (SCIT). Parental narratives reflected typical WED/RLS-related \"urge-to-move\" symptoms during day-, bed-, and nighttime in all patients. Fifteen out of 26 patients could describe the \"urge-to-move\" during the SCIT. Ten out of 26 patients, unable to describe their symptoms due to cognitive disabilities, showed patterns of \"relieving-movements\" upon observation. Sensory processing abnormalities were reported in all patients, with tactile sensitivities (26/26) (including shifted pain threshold) as the most common sensory domain. \"Emplotted narratives\" and structured \"behavioral observations\" support recognition of familial WED/RLS associated movement patterns and provide a useful tool for the diagnosis of WED/RLS in children with NDCs in a clinical office setting.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "b7c3669e630a465892c5b64dbd7a9d82", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["seems", 54], ["to", 60], ["be", 63], ["a", 66], ["frequent", 68], ["cause", 77], ["of", 83], ["intractable", 86], ["chronic", 98], ["insomnia", 106], ["(", 115], ["ICI", 116], [")", 119], ["but", 121], ["is", 125], ["under", 128], ["-", 133], ["recognized", 134], ["in", 145], ["children", 148], ["/", 156], ["adolescents", 157], ["with", 169], ["neurodevelopmental", 174], ["conditions", 193], ["(", 204], ["NDCs", 205], [")", 209], [",", 210], ["as", 212], ["many", 215], ["patients", 220], ["do", 229], ["not", 232], ["have", 236], ["the", 241], ["ability", 245], ["to", 253], ["express", 256], ["the", 264], ["underlying", 268], ["\"", 279], ["urge", 280], ["-", 284], ["to", 285], ["-", 287], ["move", 288], ["\"", 292], [".", 293], ["In", 295], ["light", 298], ["of", 304], ["this", 307], [",", 311], ["we", 313], ["aim", 316], ["to", 320], ["develop", 323], ["a", 331], ["protocol", 333], ["for", 342], ["behavioral", 346], ["observations", 357], ["supporting", 370], ["the", 381], ["diagnosis", 385], ["of", 395], ["WED", 398], ["/", 401], ["RLS", 402], [".", 405], ["We", 407], ["investigated", 410], ["26", 423], ["pediatric", 426], ["patients", 436], ["(", 445], ["age", 446], ["1", 450], ["-", 451], ["16", 452], ["years", 455], [",", 460], ["median", 462], ["8)", 469], ["with", 472], ["NDCs", 477], [",", 481], ["ICI", 483], ["and", 487], ["evidence", 491], ["of", 500], ["familial", 503], ["WED", 512], ["/", 515], ["RLS", 516], ["employing", 520], ["(", 530], ["1", 531], [")", 532], ["\"", 534], ["emplotted", 535], ["narratives", 545], ["\"", 555], ["for", 557], ["description", 561], ["of", 573], ["the", 576], ["various", 580], ["\"", 588], ["urge", 589], ["-", 593], ["to", 594], ["-", 596], ["move", 597], ["\"", 601], ["presentations", 603], ["and", 617], ["(", 621], ["2", 622], [")", 623], ["self", 625], ["-", 629], ["description", 630], ["and", 642], ["\"", 646], ["behavioral", 647], ["observations", 658], ["\"", 670], ["during", 672], ["a", 679], ["\"", 681], ["suggested", 682], ["clinical", 692], ["immobilization", 701], ["test", 716], ["\"", 720], ["(", 722], ["SCIT", 723], [")", 727], [".", 728], ["Parental", 730], ["narratives", 739], ["reflected", 750], ["typical", 760], ["WED", 768], ["/", 771], ["RLS", 772], ["-", 775], ["related", 776], ["\"", 784], ["urge", 785], ["-", 789], ["to", 790], ["-", 792], ["move", 793], ["\"", 797], ["symptoms", 799], ["during", 808], ["day-", 815], [",", 819], ["bed-", 821], [",", 825], ["and", 827], ["nighttime", 831], ["in", 841], ["all", 844], ["patients", 848], [".", 856], ["Fifteen", 858], ["out", 866], ["of", 870], ["26", 873], ["patients", 876], ["could", 885], ["describe", 891], ["the", 900], ["\"", 904], ["urge", 905], ["-", 909], ["to", 910], ["-", 912], ["move", 913], ["\"", 917], ["during", 919], ["the", 926], ["SCIT", 930], [".", 934], ["Ten", 936], ["out", 940], ["of", 944], ["26", 947], ["patients", 950], [",", 958], ["unable", 960], ["to", 967], ["describe", 970], ["their", 979], ["symptoms", 985], ["due", 994], ["to", 998], ["cognitive", 1001], ["disabilities", 1011], [",", 1023], ["showed", 1025], ["patterns", 1032], ["of", 1041], ["\"", 1044], ["relieving", 1045], ["-", 1054], ["movements", 1055], ["\"", 1064], ["upon", 1066], ["observation", 1071], [".", 1082], ["Sensory", 1084], ["processing", 1092], ["abnormalities", 1103], ["were", 1117], ["reported", 1122], ["in", 1131], ["all", 1134], ["patients", 1138], [",", 1146], ["with", 1148], ["tactile", 1153], ["sensitivities", 1161], ["(", 1175], ["26/26", 1176], [")", 1181], ["(", 1183], ["including", 1184], ["shifted", 1194], ["pain", 1202], ["threshold", 1207], [")", 1216], ["as", 1218], ["the", 1221], ["most", 1225], ["common", 1230], ["sensory", 1237], ["domain", 1245], [".", 1251], ["\"", 1253], ["Emplotted", 1254], ["narratives", 1264], ["\"", 1274], ["and", 1276], ["structured", 1280], ["\"", 1291], ["behavioral", 1292], ["observations", 1303], ["\"", 1315], ["support", 1317], ["recognition", 1325], ["of", 1337], ["familial", 1340], ["WED", 1349], ["/", 1352], ["RLS", 1353], ["associated", 1357], ["movement", 1368], ["patterns", 1377], ["and", 1386], ["provide", 1390], ["a", 1398], ["useful", 1400], ["tool", 1407], ["for", 1412], ["the", 1416], ["diagnosis", 1420], ["of", 1430], ["WED", 1433], ["/", 1436], ["RLS", 1437], ["in", 1441], ["children", 1444], ["with", 1453], ["NDCs", 1458], ["in", 1463], ["a", 1466], ["clinical", 1468], ["office", 1477], ["setting", 1484], [".", 1491]]}
{"context": "Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or in combination with other therapies to improve glycemic control in patients with T2DM. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion. This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin. Empagliflozin offers good glycemic efficacy, weight loss, blood pressure reduction, and a low risk of hypoglycemia. These attributes, coupled with the ability to be used in virtually any combination with other anti-diabetes agents and at any stage in the disease process, provide a welcome new agent to our armamentarium of drugs to help manage T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "48dc9bc52067412fa103828ee4ac558d", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[109, 109], [73, 73]], "char_spans": [[673, 677], [425, 429]]}]}], "context_tokens": [["Despite", 0], ["the", 8], ["availability", 12], ["of", 25], ["numerous", 28], ["anti", 37], ["-", 41], ["diabetes", 42], ["drugs", 51], ["and", 57], ["treatment", 61], ["guidelines", 71], [",", 81], ["many", 83], ["patients", 88], ["with", 97], ["type", 102], ["2", 107], ["diabetes", 109], ["mellitus", 118], ["(", 127], ["T2DM", 128], [")", 132], ["do", 134], ["not", 137], ["reach", 141], ["recommended", 147], ["targets", 159], ["for", 167], ["glycemic", 171], ["control", 180], [".", 187], ["There", 189], ["remains", 195], ["an", 203], ["unmet", 206], ["need", 212], ["for", 217], ["effective", 221], ["and", 231], ["well", 235], ["-", 239], ["tolerated", 240], ["anti", 250], ["-", 254], ["diabetes", 255], ["agents", 264], ["that", 271], ["can", 276], ["be", 280], ["used", 283], ["as", 288], ["monotherapy", 291], ["or", 303], ["in", 306], ["combination", 309], ["with", 321], ["other", 326], ["therapies", 332], ["to", 342], ["improve", 345], ["glycemic", 353], ["control", 362], ["in", 370], ["patients", 373], ["with", 382], ["T2DM", 387], [".", 391], ["Sodium", 393], ["glucose", 400], ["cotransporter", 408], ["2", 422], ["(", 424], ["SGLT2", 425], [")", 430], ["inhibitors", 432], ["are", 443], ["a", 447], ["new", 449], ["class", 453], ["of", 459], ["treatment", 462], ["for", 472], ["T2DM", 476], ["that", 481], ["reduce", 486], ["hyperglycemia", 493], ["by", 507], ["reducing", 510], ["renal", 519], ["glucose", 525], ["reabsorption", 533], ["and", 546], ["thereby", 550], ["increasing", 558], ["urinary", 569], ["glucose", 577], ["excretion", 585], [".", 594], ["This", 596], ["paper", 601], ["reviews", 607], ["the", 615], ["pharmacokinetic", 619], ["and", 635], ["pharmacodynamic", 639], ["properties", 655], ["of", 666], ["the", 669], ["SGLT2", 673], ["inhibitor", 679], ["empagliflozin", 689], [",", 703], ["the", 705], ["results", 709], ["of", 717], ["clinical", 720], ["trials", 729], ["investigating", 736], ["the", 750], ["efficacy", 754], ["of", 763], ["empagliflozin", 766], ["given", 780], ["as", 786], ["monotherapy", 789], ["or", 801], ["as", 804], ["add", 807], ["-", 810], ["on", 811], ["therapy", 814], ["on", 822], ["glycemic", 825], ["control", 834], [",", 841], ["body", 843], ["weight", 848], [",", 854], ["and", 856], ["blood", 860], ["pressure", 866], ["in", 875], ["patients", 878], ["with", 887], ["T2DM", 892], [",", 896], ["and", 898], ["the", 902], ["safety", 906], ["and", 913], ["tolerability", 917], ["profile", 930], ["of", 938], ["empagliflozin", 941], [".", 954], ["Empagliflozin", 956], ["offers", 970], ["good", 977], ["glycemic", 982], ["efficacy", 991], [",", 999], ["weight", 1001], ["loss", 1008], [",", 1012], ["blood", 1014], ["pressure", 1020], ["reduction", 1029], [",", 1038], ["and", 1040], ["a", 1044], ["low", 1046], ["risk", 1050], ["of", 1055], ["hypoglycemia", 1058], [".", 1070], ["These", 1072], ["attributes", 1078], [",", 1088], ["coupled", 1090], ["with", 1098], ["the", 1103], ["ability", 1107], ["to", 1115], ["be", 1118], ["used", 1121], ["in", 1126], ["virtually", 1129], ["any", 1139], ["combination", 1143], ["with", 1155], ["other", 1160], ["anti", 1166], ["-", 1170], ["diabetes", 1171], ["agents", 1180], ["and", 1187], ["at", 1191], ["any", 1194], ["stage", 1198], ["in", 1204], ["the", 1207], ["disease", 1211], ["process", 1219], [",", 1226], ["provide", 1228], ["a", 1236], ["welcome", 1238], ["new", 1246], ["agent", 1250], ["to", 1256], ["our", 1259], ["armamentarium", 1263], ["of", 1277], ["drugs", 1280], ["to", 1286], ["help", 1289], ["manage", 1294], ["T2DM", 1301], [".", 1305]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "9cce10bf0b6546509cf2de1aba61138e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["recently", 30], ["renamed", 39], ["Willis", 47], ["-", 53], ["Ekbom", 54], ["disease", 60], ["(", 68], ["WED", 69], [")", 72], [",", 73], ["is", 75], ["a", 78], ["common", 80], ["movement", 87], ["disorder", 96], [".", 104], ["It", 106], ["is", 109], ["characterised", 112], ["by", 126], ["the", 129], ["need", 133], ["to", 138], ["move", 141], ["mainly", 146], ["the", 153], ["legs", 157], ["due", 162], ["to", 166], ["uncomfortable", 169], [",", 182], ["sometimes", 184], ["painful", 194], ["sensations", 202], ["in", 213], ["the", 216], ["legs", 220], [",", 224], ["which", 226], ["have", 232], ["a", 237], ["diurnal", 239], ["variation", 247], ["and", 257], ["a", 261], ["release", 263], ["with", 271], ["movement", 276], [".", 284], ["Management", 286], ["is", 297], ["complex", 300], [".", 307], ["First", 309], [",", 314], ["centres", 316], ["should", 324], ["establish", 331], ["the", 341], ["severity", 345], ["of", 354], ["RLS", 357], ["using", 361], ["a", 367], ["simple", 369], ["10-item", 376], ["RLS", 384], ["severity", 388], ["rating", 397], ["scale", 404], ["(", 410], ["IRLS", 411], [")", 415], [".", 416], ["They", 418], ["should", 423], ["also", 430], ["exclude", 435], ["secondary", 443], ["causes", 453], [",", 459], ["in", 461], ["particular", 464], ["ensuring", 475], ["normal", 484], ["iron", 491], ["levels", 496], [".", 502], ["Mild", 504], ["cases", 509], ["can", 515], ["be", 519], ["managed", 522], ["by", 530], ["lifestyle", 533], ["changes", 543], [",", 550], ["but", 552], ["patients", 556], ["with", 565], ["a", 570], ["IRLS", 572], ["score", 577], ["above", 583], ["15", 589], ["usually", 592], ["require", 600], ["pharmacological", 608], ["treatment", 624], [".", 633], ["Dopaminergic", 635], ["therapies", 648], ["remain", 658], ["the", 665], ["mainstay", 669], ["of", 678], ["medical", 681], ["therapies", 689], [",", 698], ["with", 700], ["recent", 705], ["evidence", 712], ["suggesting", 721], ["opioids", 732], ["may", 740], ["be", 744], ["particularly", 747], ["effective", 760], [".", 769], ["This", 771], ["article", 776], ["focuses", 784], ["on", 792], ["the", 795], ["different", 799], ["treatment", 809], ["strategies", 819], ["in", 830], ["RLS", 833], [",", 836], ["their", 838], ["associated", 844], ["complications", 855], ["and", 869], ["ways", 873], ["to", 878], ["manage", 881], ["them", 888], [".", 892]]}
{"context": "Once acquired, Epstein-Barr virus (EBV), a latent virus, remains in the body for what appears to be the lifetime of the human host. Circumstantial data suggest EBV is involved in clinical disease including malignancies far more often than previously recognized. A serologic test for early antigen (EA) is more specific for diagnosing active EBV disease than the monospot or heterophile test. A case study of active Epstein-Barr infection is reported showing persistently elevated early antigen titers prior to and following malignant transformation.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "f210d60705384548a979b62bca881946", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[3, 6]], "char_spans": [[15, 32]]}]}], "context_tokens": [["Once", 0], ["acquired", 5], [",", 13], ["Epstein", 15], ["-", 22], ["Barr", 23], ["virus", 28], ["(", 34], ["EBV", 35], [")", 38], [",", 39], ["a", 41], ["latent", 43], ["virus", 50], [",", 55], ["remains", 57], ["in", 65], ["the", 68], ["body", 72], ["for", 77], ["what", 81], ["appears", 86], ["to", 94], ["be", 97], ["the", 100], ["lifetime", 104], ["of", 113], ["the", 116], ["human", 120], ["host", 126], [".", 130], ["Circumstantial", 132], ["data", 147], ["suggest", 152], ["EBV", 160], ["is", 164], ["involved", 167], ["in", 176], ["clinical", 179], ["disease", 188], ["including", 196], ["malignancies", 206], ["far", 219], ["more", 223], ["often", 228], ["than", 234], ["previously", 239], ["recognized", 250], [".", 260], ["A", 262], ["serologic", 264], ["test", 274], ["for", 279], ["early", 283], ["antigen", 289], ["(", 297], ["EA", 298], [")", 300], ["is", 302], ["more", 305], ["specific", 310], ["for", 319], ["diagnosing", 323], ["active", 334], ["EBV", 341], ["disease", 345], ["than", 353], ["the", 358], ["monospot", 362], ["or", 371], ["heterophile", 374], ["test", 386], [".", 390], ["A", 392], ["case", 394], ["study", 399], ["of", 405], ["active", 408], ["Epstein", 415], ["-", 422], ["Barr", 423], ["infection", 428], ["is", 438], ["reported", 441], ["showing", 450], ["persistently", 458], ["elevated", 471], ["early", 480], ["antigen", 486], ["titers", 494], ["prior", 501], ["to", 507], ["and", 510], ["following", 514], ["malignant", 524], ["transformation", 534], [".", 548]]}
{"context": "Metastasis is the major factor affecting patient survival in ovarian cancer. However, its molecular mechanisms remain unclear. Our study used isogenic pairs of low- and high-invasive ovarian cancer cell lines to demonstrate the downregulation of miRNA-138 in the highly invasive cells, and its functioning as an inhibitor of cell migration and invasion. An orthotopic xenograft mouse model further demonstrated that the expression of miRNA-138 inhibited ovarian cancer metastasis to other organs. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u03b1 by way of proteasome-mediated degradation. Analysis of human ovarian tumors further revealed downregulation of miR-138 and upregulation of SOX4 in late-stage tumors. Patients with miR-138(low)/SOX(high) signature are predominant in late stage and tend to have malignant phenotypes including lymph nodes metastasis, larger ascites volume and higher tumor grade. Our study demonstrates the role and clinical relevance of miR-138 in ovarian cancer cell invasion and metastasis, providing a potential therapeutic strategy for suppression of ovarian cancer metastasis by targeting SOX4 and HIF-1\u03b1 pathways.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "8975f12eced24dab8b0c41383c7ba4d8", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[212, 212], [163, 163], [82, 82]], "char_spans": [[1329, 1335], [1021, 1027], [520, 526]]}]}], "context_tokens": [["Metastasis", 0], ["is", 11], ["the", 14], ["major", 18], ["factor", 24], ["affecting", 31], ["patient", 41], ["survival", 49], ["in", 58], ["ovarian", 61], ["cancer", 69], [".", 75], ["However", 77], [",", 84], ["its", 86], ["molecular", 90], ["mechanisms", 100], ["remain", 111], ["unclear", 118], [".", 125], ["Our", 127], ["study", 131], ["used", 137], ["isogenic", 142], ["pairs", 151], ["of", 157], ["low-", 160], ["and", 165], ["high", 169], ["-", 173], ["invasive", 174], ["ovarian", 183], ["cancer", 191], ["cell", 198], ["lines", 203], ["to", 209], ["demonstrate", 212], ["the", 224], ["downregulation", 228], ["of", 243], ["miRNA-138", 246], ["in", 256], ["the", 259], ["highly", 263], ["invasive", 270], ["cells", 279], [",", 284], ["and", 286], ["its", 290], ["functioning", 294], ["as", 306], ["an", 309], ["inhibitor", 312], ["of", 322], ["cell", 325], ["migration", 330], ["and", 340], ["invasion", 344], [".", 352], ["An", 354], ["orthotopic", 357], ["xenograft", 368], ["mouse", 378], ["model", 384], ["further", 390], ["demonstrated", 398], ["that", 411], ["the", 416], ["expression", 420], ["of", 431], ["miRNA-138", 434], ["inhibited", 444], ["ovarian", 454], ["cancer", 462], ["metastasis", 469], ["to", 480], ["other", 483], ["organs", 489], [".", 495], ["Results", 497], ["indicated", 505], ["that", 515], ["miR-138", 520], ["directly", 528], ["targeted", 537], ["SRY", 546], ["-", 549], ["related", 550], ["high", 558], ["mobility", 563], ["group", 572], ["box", 578], ["4", 582], ["(", 584], ["SOX4", 585], [")", 589], ["and", 591], ["hypoxia", 595], ["-", 602], ["inducible", 603], ["factor-1\u03b1", 613], ["(", 623], ["HIF-1\u03b1", 624], [")", 630], [",", 631], ["and", 633], ["overexpression", 637], ["of", 652], ["SOX4", 655], ["and", 660], ["HIF-1\u03b1", 664], ["effectively", 671], ["reversed", 683], ["the", 692], ["miR-138-mediated", 696], ["suppression", 713], ["of", 725], ["cell", 728], ["invasion", 733], [".", 741], ["Epidermal", 743], ["growth", 753], ["factor", 760], ["receptor", 767], ["acted", 776], ["as", 782], ["the", 785], ["downstream", 789], ["molecule", 800], ["of", 809], ["SOX4", 812], ["by", 817], ["way", 820], ["of", 824], ["direct", 827], ["transcriptional", 834], ["control", 850], [",", 857], ["whereas", 859], ["Slug", 867], ["was", 872], ["the", 876], ["downstream", 880], ["molecule", 891], ["of", 900], ["HIF-1\u03b1", 903], ["by", 910], ["way", 913], ["of", 917], ["proteasome", 920], ["-", 930], ["mediated", 931], ["degradation", 940], [".", 951], ["Analysis", 953], ["of", 962], ["human", 965], ["ovarian", 971], ["tumors", 979], ["further", 986], ["revealed", 994], ["downregulation", 1003], ["of", 1018], ["miR-138", 1021], ["and", 1029], ["upregulation", 1033], ["of", 1046], ["SOX4", 1049], ["in", 1054], ["late", 1057], ["-", 1061], ["stage", 1062], ["tumors", 1068], [".", 1074], ["Patients", 1076], ["with", 1085], ["miR-138(low)/SOX(high", 1090], [")", 1111], ["signature", 1113], ["are", 1123], ["predominant", 1127], ["in", 1139], ["late", 1142], ["stage", 1147], ["and", 1153], ["tend", 1157], ["to", 1162], ["have", 1165], ["malignant", 1170], ["phenotypes", 1180], ["including", 1191], ["lymph", 1201], ["nodes", 1207], ["metastasis", 1213], [",", 1223], ["larger", 1225], ["ascites", 1232], ["volume", 1240], ["and", 1247], ["higher", 1251], ["tumor", 1258], ["grade", 1264], [".", 1269], ["Our", 1271], ["study", 1275], ["demonstrates", 1281], ["the", 1294], ["role", 1298], ["and", 1303], ["clinical", 1307], ["relevance", 1316], ["of", 1326], ["miR-138", 1329], ["in", 1337], ["ovarian", 1340], ["cancer", 1348], ["cell", 1355], ["invasion", 1360], ["and", 1369], ["metastasis", 1373], [",", 1383], ["providing", 1385], ["a", 1395], ["potential", 1397], ["therapeutic", 1407], ["strategy", 1419], ["for", 1428], ["suppression", 1432], ["of", 1444], ["ovarian", 1447], ["cancer", 1455], ["metastasis", 1462], ["by", 1473], ["targeting", 1476], ["SOX4", 1486], ["and", 1491], ["HIF-1\u03b1", 1495], ["pathways", 1502], [".", 1510]]}
{"context": "Methylation of lysine residues of histones is an important epigenetic mark that correlates with functionally distinct regions of chromatin. We present here the crystal structure of a ternary complex of the enzyme Pr-Set7 (also known as Set8) that methylates Lys 20 of histone H4 (H4-K20). We show that the enzyme is exclusively a mono-methylase and is therefore responsible for a signaling role quite distinct from that established by other enzymes that target this histone residue. We provide evidence from NMR for the C-flanking domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes. The crystal structure reveals the basis of the specificity of the enzyme for H4-K20 because a histidine residue within the substrate, close to the target lysine, is required for completion of the active site. We also show how a highly variable component of the SET domain is responsible for many of the enzymes' interactions with its target histone peptide and probably also how this part of the structure ensures that Pr-Set7 is nucleosome specific.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f424eb5bb7c24c5185b12545eb402821", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[166, 167]], "char_spans": [[928, 937]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["of", 31], ["histones", 34], ["is", 43], ["an", 46], ["important", 49], ["epigenetic", 59], ["mark", 70], ["that", 75], ["correlates", 80], ["with", 91], ["functionally", 96], ["distinct", 109], ["regions", 118], ["of", 126], ["chromatin", 129], [".", 138], ["We", 140], ["present", 143], ["here", 151], ["the", 156], ["crystal", 160], ["structure", 168], ["of", 178], ["a", 181], ["ternary", 183], ["complex", 191], ["of", 199], ["the", 202], ["enzyme", 206], ["Pr", 213], ["-", 215], ["Set7", 216], ["(", 221], ["also", 222], ["known", 227], ["as", 233], ["Set8", 236], [")", 240], ["that", 242], ["methylates", 247], ["Lys", 258], ["20", 262], ["of", 265], ["histone", 268], ["H4", 276], ["(", 279], ["H4-K20", 280], [")", 286], [".", 287], ["We", 289], ["show", 292], ["that", 297], ["the", 302], ["enzyme", 306], ["is", 313], ["exclusively", 316], ["a", 328], ["mono", 330], ["-", 334], ["methylase", 335], ["and", 345], ["is", 349], ["therefore", 352], ["responsible", 362], ["for", 374], ["a", 378], ["signaling", 380], ["role", 390], ["quite", 395], ["distinct", 401], ["from", 410], ["that", 415], ["established", 420], ["by", 432], ["other", 435], ["enzymes", 441], ["that", 449], ["target", 454], ["this", 461], ["histone", 466], ["residue", 474], [".", 481], ["We", 483], ["provide", 486], ["evidence", 494], ["from", 503], ["NMR", 508], ["for", 512], ["the", 516], ["C", 520], ["-", 521], ["flanking", 522], ["domains", 531], ["of", 539], ["SET", 542], ["proteins", 546], ["becoming", 555], ["ordered", 564], ["upon", 572], ["addition", 577], ["of", 586], ["AdoMet", 589], ["cofactor", 596], ["and", 605], ["develop", 609], ["a", 617], ["model", 619], ["for", 625], ["the", 629], ["catalytic", 633], ["cycle", 643], ["of", 649], ["these", 652], ["enzymes", 658], [".", 665], ["The", 667], ["crystal", 671], ["structure", 679], ["reveals", 689], ["the", 697], ["basis", 701], ["of", 707], ["the", 710], ["specificity", 714], ["of", 726], ["the", 729], ["enzyme", 733], ["for", 740], ["H4-K20", 744], ["because", 751], ["a", 759], ["histidine", 761], ["residue", 771], ["within", 779], ["the", 786], ["substrate", 790], [",", 799], ["close", 801], ["to", 807], ["the", 810], ["target", 814], ["lysine", 821], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["completion", 845], ["of", 856], ["the", 859], ["active", 863], ["site", 870], [".", 874], ["We", 876], ["also", 879], ["show", 884], ["how", 889], ["a", 893], ["highly", 895], ["variable", 902], ["component", 911], ["of", 921], ["the", 924], ["SET", 928], ["domain", 932], ["is", 939], ["responsible", 942], ["for", 954], ["many", 958], ["of", 963], ["the", 966], ["enzymes", 970], ["'", 977], ["interactions", 979], ["with", 992], ["its", 997], ["target", 1001], ["histone", 1008], ["peptide", 1016], ["and", 1024], ["probably", 1028], ["also", 1037], ["how", 1042], ["this", 1046], ["part", 1051], ["of", 1056], ["the", 1059], ["structure", 1063], ["ensures", 1073], ["that", 1081], ["Pr", 1086], ["-", 1088], ["Set7", 1089], ["is", 1094], ["nucleosome", 1097], ["specific", 1108], [".", 1116]]}
{"context": "Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme whose main function is H(2)O(2) reduction in cells. We aimed to study the expression patterns of PRDX2 in mouse ovaries and explore the function of this protein in apoptosis of granulosa cells (GCs). We found that the expression of the PRDX2 protein in atretic follicle GCs was markedly higher than in healthy follicle GCs. In vitro, the transfection of siRNA targeting the Prdx2 gene inhibited the proliferation and induced the apoptosis of primary cultured GCs. Furthermore, suppression of PRDX2 resulted in the augmentation of endogenous H(2)O(2), and the ability to eliminate the exogenous H(2)O(2) was attenuated. The expression of PRDX2 and nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB), whose activity was inhibited by binding to IKB, increased in GCs treated with various concentrations of H(2)O(2) for 30 min. However, no significant change in cytoplasmic IKB expression was observed. At 2 h after treatment with H(2)O(2), nuclear NFKB expression level was reduced, cytoplasmic IKB expression was increased, and PRDX2 expression was unchanged. Silencing of the Prdx2 gene caused early changes in NFKB and IKB expression in the primary cultured GCs compared to that in control cells. Taken together, these data suggest that PRDX2 plays an important role in inhibiting apoptosis in GCs and that PRDX2 actions may be related to the expression of NFKB and IKB.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "c3addb03d57c47208e8a84201cdf7608", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[12, 12]], "char_spans": [[52, 62]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["PRDX2", 17], [")", 22], ["has", 24], ["been", 28], ["known", 33], ["to", 39], ["act", 42], ["as", 46], ["an", 49], ["antioxidant", 52], ["enzyme", 64], ["whose", 71], ["main", 77], ["function", 82], ["is", 91], ["H(2)O(2", 94], [")", 101], ["reduction", 103], ["in", 113], ["cells", 116], [".", 121], ["We", 123], ["aimed", 126], ["to", 132], ["study", 135], ["the", 141], ["expression", 145], ["patterns", 156], ["of", 165], ["PRDX2", 168], ["in", 174], ["mouse", 177], ["ovaries", 183], ["and", 191], ["explore", 195], ["the", 203], ["function", 207], ["of", 216], ["this", 219], ["protein", 224], ["in", 232], ["apoptosis", 235], ["of", 245], ["granulosa", 248], ["cells", 258], ["(", 264], ["GCs", 265], [")", 268], [".", 269], ["We", 271], ["found", 274], ["that", 280], ["the", 285], ["expression", 289], ["of", 300], ["the", 303], ["PRDX2", 307], ["protein", 313], ["in", 321], ["atretic", 324], ["follicle", 332], ["GCs", 341], ["was", 345], ["markedly", 349], ["higher", 358], ["than", 365], ["in", 370], ["healthy", 373], ["follicle", 381], ["GCs", 390], [".", 393], ["In", 395], ["vitro", 398], [",", 403], ["the", 405], ["transfection", 409], ["of", 422], ["siRNA", 425], ["targeting", 431], ["the", 441], ["Prdx2", 445], ["gene", 451], ["inhibited", 456], ["the", 466], ["proliferation", 470], ["and", 484], ["induced", 488], ["the", 496], ["apoptosis", 500], ["of", 510], ["primary", 513], ["cultured", 521], ["GCs", 530], [".", 533], ["Furthermore", 535], [",", 546], ["suppression", 548], ["of", 560], ["PRDX2", 563], ["resulted", 569], ["in", 578], ["the", 581], ["augmentation", 585], ["of", 598], ["endogenous", 601], ["H(2)O(2", 612], [")", 619], [",", 620], ["and", 622], ["the", 626], ["ability", 630], ["to", 638], ["eliminate", 641], ["the", 651], ["exogenous", 655], ["H(2)O(2", 665], [")", 672], ["was", 674], ["attenuated", 678], [".", 688], ["The", 690], ["expression", 694], ["of", 705], ["PRDX2", 708], ["and", 714], ["nuclear", 718], ["factor", 726], ["kappa", 733], ["-", 738], ["light", 739], ["-", 744], ["chain", 745], ["-", 750], ["enhancer", 751], ["of", 760], ["activated", 763], ["B", 773], ["cells", 775], ["(", 781], ["NFKB", 782], [")", 786], [",", 787], ["whose", 789], ["activity", 795], ["was", 804], ["inhibited", 808], ["by", 818], ["binding", 821], ["to", 829], ["IKB", 832], [",", 835], ["increased", 837], ["in", 847], ["GCs", 850], ["treated", 854], ["with", 862], ["various", 867], ["concentrations", 875], ["of", 890], ["H(2)O(2", 893], [")", 900], ["for", 902], ["30", 906], ["min", 909], [".", 912], ["However", 914], [",", 921], ["no", 923], ["significant", 926], ["change", 938], ["in", 945], ["cytoplasmic", 948], ["IKB", 960], ["expression", 964], ["was", 975], ["observed", 979], [".", 987], ["At", 989], ["2", 992], ["h", 994], ["after", 996], ["treatment", 1002], ["with", 1012], ["H(2)O(2", 1017], [")", 1024], [",", 1025], ["nuclear", 1027], ["NFKB", 1035], ["expression", 1040], ["level", 1051], ["was", 1057], ["reduced", 1061], [",", 1068], ["cytoplasmic", 1070], ["IKB", 1082], ["expression", 1086], ["was", 1097], ["increased", 1101], [",", 1110], ["and", 1112], ["PRDX2", 1116], ["expression", 1122], ["was", 1133], ["unchanged", 1137], [".", 1146], ["Silencing", 1148], ["of", 1158], ["the", 1161], ["Prdx2", 1165], ["gene", 1171], ["caused", 1176], ["early", 1183], ["changes", 1189], ["in", 1197], ["NFKB", 1200], ["and", 1205], ["IKB", 1209], ["expression", 1213], ["in", 1224], ["the", 1227], ["primary", 1231], ["cultured", 1239], ["GCs", 1248], ["compared", 1252], ["to", 1261], ["that", 1264], ["in", 1269], ["control", 1272], ["cells", 1280], [".", 1285], ["Taken", 1287], ["together", 1293], [",", 1301], ["these", 1303], ["data", 1309], ["suggest", 1314], ["that", 1322], ["PRDX2", 1327], ["plays", 1333], ["an", 1339], ["important", 1342], ["role", 1352], ["in", 1357], ["inhibiting", 1360], ["apoptosis", 1371], ["in", 1381], ["GCs", 1384], ["and", 1388], ["that", 1392], ["PRDX2", 1397], ["actions", 1403], ["may", 1411], ["be", 1415], ["related", 1418], ["to", 1426], ["the", 1429], ["expression", 1433], ["of", 1444], ["NFKB", 1447], ["and", 1452], ["IKB", 1456], [".", 1459]]}
{"context": "The classical view of the molecular clock is based on interlocked transcriptional-translational feedback loops. Because a substantial fraction of the mammalian genome is expressed in a circadian manner, chromatin remodeling has been proposed to be crucial in clock function. Here we show that Lys4 (K4) trimethylation of histone H3 is rhythmic and follows the same profile as previously described H3 acetylation on circadian promoters. MLL1, a mammalian homolog of Drosophila trithorax, is an H3K4-specific methyltransferase implicated in transcriptional control. We demonstrate that MLL1 is essential for circadian transcription and cyclic H3K4 trimethylation. MLL1 is in a complex with CLOCK-BMAL1 and contributes to its rhythmic recruitment to circadian promoters and to H3 acetylation. Yet MLL1 fails to interact with CLOCK\u039419, providing an explanation for this mutation's dominant negative phenotype. Our results favor a scenario in which H3K4 trimethylation by MLL1 is required to establish a permissive chromatin state for circadian transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "795cf9fac2ef407ba53defde51145ed3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[153, 153], [101, 101]], "char_spans": [[944, 947], [641, 644]]}]}], "context_tokens": [["The", 0], ["classical", 4], ["view", 14], ["of", 19], ["the", 22], ["molecular", 26], ["clock", 36], ["is", 42], ["based", 45], ["on", 51], ["interlocked", 54], ["transcriptional", 66], ["-", 81], ["translational", 82], ["feedback", 96], ["loops", 105], [".", 110], ["Because", 112], ["a", 120], ["substantial", 122], ["fraction", 134], ["of", 143], ["the", 146], ["mammalian", 150], ["genome", 160], ["is", 167], ["expressed", 170], ["in", 180], ["a", 183], ["circadian", 185], ["manner", 195], [",", 201], ["chromatin", 203], ["remodeling", 213], ["has", 224], ["been", 228], ["proposed", 233], ["to", 242], ["be", 245], ["crucial", 248], ["in", 256], ["clock", 259], ["function", 265], [".", 273], ["Here", 275], ["we", 280], ["show", 283], ["that", 288], ["Lys4", 293], ["(", 298], ["K4", 299], [")", 301], ["trimethylation", 303], ["of", 318], ["histone", 321], ["H3", 329], ["is", 332], ["rhythmic", 335], ["and", 344], ["follows", 348], ["the", 356], ["same", 360], ["profile", 365], ["as", 373], ["previously", 376], ["described", 387], ["H3", 397], ["acetylation", 400], ["on", 412], ["circadian", 415], ["promoters", 425], [".", 434], ["MLL1", 436], [",", 440], ["a", 442], ["mammalian", 444], ["homolog", 454], ["of", 462], ["Drosophila", 465], ["trithorax", 476], [",", 485], ["is", 487], ["an", 490], ["H3K4-specific", 493], ["methyltransferase", 507], ["implicated", 525], ["in", 536], ["transcriptional", 539], ["control", 555], [".", 562], ["We", 564], ["demonstrate", 567], ["that", 579], ["MLL1", 584], ["is", 589], ["essential", 592], ["for", 602], ["circadian", 606], ["transcription", 616], ["and", 630], ["cyclic", 634], ["H3K4", 641], ["trimethylation", 646], [".", 660], ["MLL1", 662], ["is", 667], ["in", 670], ["a", 673], ["complex", 675], ["with", 683], ["CLOCK", 688], ["-", 693], ["BMAL1", 694], ["and", 700], ["contributes", 704], ["to", 716], ["its", 719], ["rhythmic", 723], ["recruitment", 732], ["to", 744], ["circadian", 747], ["promoters", 757], ["and", 767], ["to", 771], ["H3", 774], ["acetylation", 777], [".", 788], ["Yet", 790], ["MLL1", 794], ["fails", 799], ["to", 805], ["interact", 808], ["with", 817], ["CLOCK\u039419", 822], [",", 830], ["providing", 832], ["an", 842], ["explanation", 845], ["for", 857], ["this", 861], ["mutation", 866], ["'s", 874], ["dominant", 877], ["negative", 886], ["phenotype", 895], [".", 904], ["Our", 906], ["results", 910], ["favor", 918], ["a", 924], ["scenario", 926], ["in", 935], ["which", 938], ["H3K4", 944], ["trimethylation", 949], ["by", 964], ["MLL1", 967], ["is", 972], ["required", 975], ["to", 984], ["establish", 987], ["a", 997], ["permissive", 999], ["chromatin", 1010], ["state", 1020], ["for", 1026], ["circadian", 1030], ["transcription", 1040], [".", 1053]]}
{"context": "The literature suggests that the d -dimer is useful in patients suspected of having pulmonary embolism and who have a low pretest probability of disease. A previously defined clinical decision rule, the Wells Criteria, may provide a reliable and reproducible means of determining this pretest probability. We evaluate the interrater agreement and external validity of Wells Criteria in determining pretest probability in patients suspected of having pulmonary embolism. This was a prospective observational study. Trained research assistants enrolled patients during 120 random 8-hour shifts. Patients who underwent imaging for pulmonary embolism after a medical history, physical examination, and chest radiograph were enrolled. Treating providers and research assistants determined pretest probability according to Wells Criteria in a blinded fashion. Two d -dimer assays were run. Three-month follow-up for the diagnosis of pulmonary embolism was performed. Interrater agreement tables were created. kappa Values, sensitivities, and specificities were determined. Of the 153 eligible patients, 3 patients were missed, 16 patients declined, and 134 (88%) patients were enrolled. Sixteen (12%) patients were diagnosed with pulmonary embolism. The kappa values for Wells Criteria were 0.54 and 0.72 for the trichotomized and dichotomized scorings, respectively. When Wells Criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively. When Wells Criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively. The immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%). Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "28e8fe6709904ff19ee941b716a6183e", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[96, 97], [70, 71], [294, 295], [261, 262], [364, 365], [201, 202], [14, 15], [146, 147], [283, 284]], "char_spans": [[628, 645], [450, 467], [1682, 1699], [1530, 1547], [2059, 2076], [1224, 1241], [84, 101], [927, 944], [1639, 1656]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["suggests", 15], ["that", 24], ["the", 29], ["d", 33], ["-dimer", 35], ["is", 42], ["useful", 45], ["in", 52], ["patients", 55], ["suspected", 64], ["of", 74], ["having", 77], ["pulmonary", 84], ["embolism", 94], ["and", 103], ["who", 107], ["have", 111], ["a", 116], ["low", 118], ["pretest", 122], ["probability", 130], ["of", 142], ["disease", 145], [".", 152], ["A", 154], ["previously", 156], ["defined", 167], ["clinical", 175], ["decision", 184], ["rule", 193], [",", 197], ["the", 199], ["Wells", 203], ["Criteria", 209], [",", 217], ["may", 219], ["provide", 223], ["a", 231], ["reliable", 233], ["and", 242], ["reproducible", 246], ["means", 259], ["of", 265], ["determining", 268], ["this", 280], ["pretest", 285], ["probability", 293], [".", 304], ["We", 306], ["evaluate", 309], ["the", 318], ["interrater", 322], ["agreement", 333], ["and", 343], ["external", 347], ["validity", 356], ["of", 365], ["Wells", 368], ["Criteria", 374], ["in", 383], ["determining", 386], ["pretest", 398], ["probability", 406], ["in", 418], ["patients", 421], ["suspected", 430], ["of", 440], ["having", 443], ["pulmonary", 450], ["embolism", 460], [".", 468], ["This", 470], ["was", 475], ["a", 479], ["prospective", 481], ["observational", 493], ["study", 507], [".", 512], ["Trained", 514], ["research", 522], ["assistants", 531], ["enrolled", 542], ["patients", 551], ["during", 560], ["120", 567], ["random", 571], ["8-hour", 578], ["shifts", 585], [".", 591], ["Patients", 593], ["who", 602], ["underwent", 606], ["imaging", 616], ["for", 624], ["pulmonary", 628], ["embolism", 638], ["after", 647], ["a", 653], ["medical", 655], ["history", 663], [",", 670], ["physical", 672], ["examination", 681], [",", 692], ["and", 694], ["chest", 698], ["radiograph", 704], ["were", 715], ["enrolled", 720], [".", 728], ["Treating", 730], ["providers", 739], ["and", 749], ["research", 753], ["assistants", 762], ["determined", 773], ["pretest", 784], ["probability", 792], ["according", 804], ["to", 814], ["Wells", 817], ["Criteria", 823], ["in", 832], ["a", 835], ["blinded", 837], ["fashion", 845], [".", 852], ["Two", 854], ["d", 858], ["-dimer", 860], ["assays", 867], ["were", 874], ["run", 879], [".", 882], ["Three", 884], ["-", 889], ["month", 890], ["follow", 896], ["-", 902], ["up", 903], ["for", 906], ["the", 910], ["diagnosis", 914], ["of", 924], ["pulmonary", 927], ["embolism", 937], ["was", 946], ["performed", 950], [".", 959], ["Interrater", 961], ["agreement", 972], ["tables", 982], ["were", 989], ["created", 994], [".", 1001], ["kappa", 1003], ["Values", 1009], [",", 1015], ["sensitivities", 1017], [",", 1030], ["and", 1032], ["specificities", 1036], ["were", 1050], ["determined", 1055], [".", 1065], ["Of", 1067], ["the", 1070], ["153", 1074], ["eligible", 1078], ["patients", 1087], [",", 1095], ["3", 1097], ["patients", 1099], ["were", 1108], ["missed", 1113], [",", 1119], ["16", 1121], ["patients", 1124], ["declined", 1133], [",", 1141], ["and", 1143], ["134", 1147], ["(", 1151], ["88", 1152], ["%", 1154], [")", 1155], ["patients", 1157], ["were", 1166], ["enrolled", 1171], [".", 1179], ["Sixteen", 1181], ["(", 1189], ["12", 1190], ["%", 1192], [")", 1193], ["patients", 1195], ["were", 1204], ["diagnosed", 1209], ["with", 1219], ["pulmonary", 1224], ["embolism", 1234], [".", 1242], ["The", 1244], ["kappa", 1248], ["values", 1254], ["for", 1261], ["Wells", 1265], ["Criteria", 1271], ["were", 1280], ["0.54", 1285], ["and", 1290], ["0.72", 1294], ["for", 1299], ["the", 1303], ["trichotomized", 1307], ["and", 1321], ["dichotomized", 1325], ["scorings", 1338], [",", 1346], ["respectively", 1348], [".", 1360], ["When", 1362], ["Wells", 1367], ["Criteria", 1373], ["were", 1382], ["trichotomized", 1387], ["into", 1401], ["low", 1406], ["pretest", 1410], ["probability", 1418], ["(", 1430], ["n=59", 1431], [",", 1435], ["44", 1437], ["%", 1439], [")", 1440], [",", 1441], ["moderate", 1443], ["pretest", 1452], ["probability", 1460], ["(", 1472], ["n=61", 1473], [",", 1477], ["46", 1479], ["%", 1481], [")", 1482], [",", 1483], ["or", 1485], ["high", 1488], ["pretest", 1493], ["probability", 1501], ["(", 1513], ["n=14", 1514], [",", 1518], ["10", 1520], ["%", 1522], [")", 1523], [",", 1524], ["the", 1526], ["pulmonary", 1530], ["embolism", 1540], ["prevalence", 1549], ["was", 1560], ["2", 1564], ["%", 1565], [",", 1566], ["15", 1568], ["%", 1570], [",", 1571], ["and", 1573], ["43", 1577], ["%", 1579], [",", 1580], ["respectively", 1582], [".", 1594], ["When", 1596], ["Wells", 1601], ["Criteria", 1607], ["were", 1616], ["dichotomized", 1621], ["into", 1634], ["pulmonary", 1639], ["embolism", 1649], ["-", 1657], ["unlikely", 1658], ["(", 1667], ["n=88", 1668], [",", 1672], ["66", 1674], ["%", 1676], [")", 1677], ["or", 1679], ["pulmonary", 1682], ["embolism", 1692], ["-", 1700], ["likely", 1701], ["(", 1708], ["n=46", 1709], [",", 1713], ["34", 1715], ["%", 1717], [")", 1718], [",", 1719], ["the", 1721], ["prevalence", 1725], ["was", 1736], ["3", 1740], ["%", 1741], ["and", 1743], ["28", 1747], ["%", 1749], [",", 1750], ["respectively", 1752], [".", 1764], ["The", 1766], ["immunoturbidimetric", 1770], ["and", 1790], ["rapid", 1794], ["enzyme", 1800], ["-", 1806], ["linked", 1807], ["immunosorbent", 1814], ["assay", 1828], ["d", 1834], ["-dimer", 1836], ["assays", 1843], ["had", 1850], ["similar", 1854], ["sensitivities", 1862], ["(", 1876], ["94", 1877], ["%", 1879], [")", 1880], ["and", 1882], ["specificities", 1886], ["(", 1900], ["45", 1901], ["%", 1903], ["versus", 1905], ["46", 1912], ["%", 1914], [")", 1915], [".", 1916], ["Wells", 1918], ["Criteria", 1924], ["have", 1933], ["a", 1938], ["moderate", 1940], ["to", 1949], ["substantial", 1952], ["interrater", 1964], ["agreement", 1975], ["and", 1985], ["reliably", 1989], ["risk", 1998], ["stratify", 2003], ["pretest", 2012], ["probability", 2020], ["in", 2032], ["patients", 2035], ["with", 2044], ["suspected", 2049], ["pulmonary", 2059], ["embolism", 2069], [".", 2077]]}
{"context": "The pathogenesis of RA is a complex and ever-changing landscape but amid the chaos of the disease process we have found effective treatment regimes. However, our current therapeutics, although targeting various components of both the innate and adaptive immune response, do not result in disease remission. Protein kinase inhibitors are attractive targets due to their ability to influence downstream signalling and their oral bioavailability. Fostamatinib (R788) inhibits spleen tyrosine kinase (Syk) and has been in clinical trials involving both MTX inadequate responders (MTX-IRs) and biologic inadequate responders. Studies on the MTX-IR population revealed ACR20 responses of 67-72% at higher doses (150 mg bd and 100 mg bd), ACR50 responses of 43-57% and ACR70 responses of 28-40%. The trial in the biologic non-responder population showed no efficacy, however, post hoc analyses of the data suggested that a further trial in this population is warranted. The most common adverse events included gastrointestinal effects, hypertension, neutropenia and transaminitis. Many adverse effects were dose responsive and hypertension was amenable to treatment. Upper respiratory tract infections were more likely at higher doses, but no serious infections with tuberculosis, fungi or opportunistic infections were reported. The oral availability of these agents makes them attractive treatment options for our patients, although the literature from the oncology field suggests that patients will only choose the oral route if efficacy is equivalent. Long-term follow-up studies are ongoing and will be critical for rare side effects. The role of these agents in our current arsenal is unclear and economic analyses are awaited.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "817590b6c9a647a5aef10b85199aef9b", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[77, 79]], "char_spans": [[473, 494]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["RA", 20], ["is", 23], ["a", 26], ["complex", 28], ["and", 36], ["ever", 40], ["-", 44], ["changing", 45], ["landscape", 54], ["but", 64], ["amid", 68], ["the", 73], ["chaos", 77], ["of", 83], ["the", 86], ["disease", 90], ["process", 98], ["we", 106], ["have", 109], ["found", 114], ["effective", 120], ["treatment", 130], ["regimes", 140], [".", 147], ["However", 149], [",", 156], ["our", 158], ["current", 162], ["therapeutics", 170], [",", 182], ["although", 184], ["targeting", 193], ["various", 203], ["components", 211], ["of", 222], ["both", 225], ["the", 230], ["innate", 234], ["and", 241], ["adaptive", 245], ["immune", 254], ["response", 261], [",", 269], ["do", 271], ["not", 274], ["result", 278], ["in", 285], ["disease", 288], ["remission", 296], [".", 305], ["Protein", 307], ["kinase", 315], ["inhibitors", 322], ["are", 333], ["attractive", 337], ["targets", 348], ["due", 356], ["to", 360], ["their", 363], ["ability", 369], ["to", 377], ["influence", 380], ["downstream", 390], ["signalling", 401], ["and", 412], ["their", 416], ["oral", 422], ["bioavailability", 427], [".", 442], ["Fostamatinib", 444], ["(", 457], ["R788", 458], [")", 462], ["inhibits", 464], ["spleen", 473], ["tyrosine", 480], ["kinase", 489], ["(", 496], ["Syk", 497], [")", 500], ["and", 502], ["has", 506], ["been", 510], ["in", 515], ["clinical", 518], ["trials", 527], ["involving", 534], ["both", 544], ["MTX", 549], ["inadequate", 553], ["responders", 564], ["(", 575], ["MTX", 576], ["-", 579], ["IRs", 580], [")", 583], ["and", 585], ["biologic", 589], ["inadequate", 598], ["responders", 609], [".", 619], ["Studies", 621], ["on", 629], ["the", 632], ["MTX", 636], ["-", 639], ["IR", 640], ["population", 643], ["revealed", 654], ["ACR20", 663], ["responses", 669], ["of", 679], ["67", 682], ["-", 684], ["72", 685], ["%", 687], ["at", 689], ["higher", 692], ["doses", 699], ["(", 705], ["150", 706], ["mg", 710], ["bd", 713], ["and", 716], ["100", 720], ["mg", 724], ["bd", 727], [")", 729], [",", 730], ["ACR50", 732], ["responses", 738], ["of", 748], ["43", 751], ["-", 753], ["57", 754], ["%", 756], ["and", 758], ["ACR70", 762], ["responses", 768], ["of", 778], ["28", 781], ["-", 783], ["40", 784], ["%", 786], [".", 787], ["The", 789], ["trial", 793], ["in", 799], ["the", 802], ["biologic", 806], ["non", 815], ["-", 818], ["responder", 819], ["population", 829], ["showed", 840], ["no", 847], ["efficacy", 850], [",", 858], ["however", 860], [",", 867], ["post", 869], ["hoc", 874], ["analyses", 878], ["of", 887], ["the", 890], ["data", 894], ["suggested", 899], ["that", 909], ["a", 914], ["further", 916], ["trial", 924], ["in", 930], ["this", 933], ["population", 938], ["is", 949], ["warranted", 952], [".", 961], ["The", 963], ["most", 967], ["common", 972], ["adverse", 979], ["events", 987], ["included", 994], ["gastrointestinal", 1003], ["effects", 1020], [",", 1027], ["hypertension", 1029], [",", 1041], ["neutropenia", 1043], ["and", 1055], ["transaminitis", 1059], [".", 1072], ["Many", 1074], ["adverse", 1079], ["effects", 1087], ["were", 1095], ["dose", 1100], ["responsive", 1105], ["and", 1116], ["hypertension", 1120], ["was", 1133], ["amenable", 1137], ["to", 1146], ["treatment", 1149], [".", 1158], ["Upper", 1160], ["respiratory", 1166], ["tract", 1178], ["infections", 1184], ["were", 1195], ["more", 1200], ["likely", 1205], ["at", 1212], ["higher", 1215], ["doses", 1222], [",", 1227], ["but", 1229], ["no", 1233], ["serious", 1236], ["infections", 1244], ["with", 1255], ["tuberculosis", 1260], [",", 1272], ["fungi", 1274], ["or", 1280], ["opportunistic", 1283], ["infections", 1297], ["were", 1308], ["reported", 1313], [".", 1321], ["The", 1323], ["oral", 1327], ["availability", 1332], ["of", 1345], ["these", 1348], ["agents", 1354], ["makes", 1361], ["them", 1367], ["attractive", 1372], ["treatment", 1383], ["options", 1393], ["for", 1401], ["our", 1405], ["patients", 1409], [",", 1417], ["although", 1419], ["the", 1428], ["literature", 1432], ["from", 1443], ["the", 1448], ["oncology", 1452], ["field", 1461], ["suggests", 1467], ["that", 1476], ["patients", 1481], ["will", 1490], ["only", 1495], ["choose", 1500], ["the", 1507], ["oral", 1511], ["route", 1516], ["if", 1522], ["efficacy", 1525], ["is", 1534], ["equivalent", 1537], [".", 1547], ["Long", 1549], ["-", 1553], ["term", 1554], ["follow", 1559], ["-", 1565], ["up", 1566], ["studies", 1569], ["are", 1577], ["ongoing", 1581], ["and", 1589], ["will", 1593], ["be", 1598], ["critical", 1601], ["for", 1610], ["rare", 1614], ["side", 1619], ["effects", 1624], [".", 1631], ["The", 1633], ["role", 1637], ["of", 1642], ["these", 1645], ["agents", 1651], ["in", 1658], ["our", 1661], ["current", 1665], ["arsenal", 1673], ["is", 1681], ["unclear", 1684], ["and", 1692], ["economic", 1696], ["analyses", 1705], ["are", 1714], ["awaited", 1718], [".", 1725]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "The product of the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene, menin, is an integral component of MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4). We show that menin is a transcriptional coactivator of the nuclear receptors for estrogen and vitamin D. Activation of the endogenous estrogen-responsive TFF1 (pS2) gene results in promoter recruitment of menin and in elevated trimethylation of H3K4. Knockdown of menin reduces both activated TFF1 (pS2) transcription and H3K4 trimethylation. In addition, menin can directly interact with the estrogen receptor-alpha (ERalpha) in a hormone-dependent manner. The majority of disease-related MEN1 mutations prevent menin-ERalpha interaction. Importantly, ERalpha-interacting mutants are also defective in coactivator function. Our results indicate that menin is a critical link between recruitment of histone methyltransferase complexes and nuclear receptor-mediated transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "70cf419b833d4e9abc7eac1c6be3673c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[91, 91], [77, 77], [34, 34]], "char_spans": [[528, 531], [451, 454], [199, 202]]}]}], "context_tokens": [["The", 0], ["product", 4], ["of", 12], ["the", 15], ["multiple", 19], ["endocrine", 28], ["neoplasia", 38], ["type", 48], ["1", 53], ["(", 55], ["MEN1", 56], [")", 60], ["tumor", 62], ["suppressor", 68], ["gene", 79], [",", 83], ["menin", 85], [",", 90], ["is", 92], ["an", 95], ["integral", 98], ["component", 107], ["of", 117], ["MLL1/MLL2", 120], ["histone", 130], ["methyltransferase", 138], ["complexes", 156], ["specific", 166], ["for", 175], ["Lys4", 179], ["of", 184], ["histone", 187], ["H3", 195], ["(", 198], ["H3K4", 199], [")", 203], [".", 204], ["We", 206], ["show", 209], ["that", 214], ["menin", 219], ["is", 225], ["a", 228], ["transcriptional", 230], ["coactivator", 246], ["of", 258], ["the", 261], ["nuclear", 265], ["receptors", 273], ["for", 283], ["estrogen", 287], ["and", 296], ["vitamin", 300], ["D.", 308], ["Activation", 311], ["of", 322], ["the", 325], ["endogenous", 329], ["estrogen", 340], ["-", 348], ["responsive", 349], ["TFF1", 360], ["(", 365], ["pS2", 366], [")", 369], ["gene", 371], ["results", 376], ["in", 384], ["promoter", 387], ["recruitment", 396], ["of", 408], ["menin", 411], ["and", 417], ["in", 421], ["elevated", 424], ["trimethylation", 433], ["of", 448], ["H3K4", 451], [".", 455], ["Knockdown", 457], ["of", 467], ["menin", 470], ["reduces", 476], ["both", 484], ["activated", 489], ["TFF1", 499], ["(", 504], ["pS2", 505], [")", 508], ["transcription", 510], ["and", 524], ["H3K4", 528], ["trimethylation", 533], [".", 547], ["In", 549], ["addition", 552], [",", 560], ["menin", 562], ["can", 568], ["directly", 572], ["interact", 581], ["with", 590], ["the", 595], ["estrogen", 599], ["receptor", 608], ["-", 616], ["alpha", 617], ["(", 623], ["ERalpha", 624], [")", 631], ["in", 633], ["a", 636], ["hormone", 638], ["-", 645], ["dependent", 646], ["manner", 656], [".", 662], ["The", 664], ["majority", 668], ["of", 677], ["disease", 680], ["-", 687], ["related", 688], ["MEN1", 696], ["mutations", 701], ["prevent", 711], ["menin", 719], ["-", 724], ["ERalpha", 725], ["interaction", 733], [".", 744], ["Importantly", 746], [",", 757], ["ERalpha", 759], ["-", 766], ["interacting", 767], ["mutants", 779], ["are", 787], ["also", 791], ["defective", 796], ["in", 806], ["coactivator", 809], ["function", 821], [".", 829], ["Our", 831], ["results", 835], ["indicate", 843], ["that", 852], ["menin", 857], ["is", 863], ["a", 866], ["critical", 868], ["link", 877], ["between", 882], ["recruitment", 890], ["of", 902], ["histone", 905], ["methyltransferase", 913], ["complexes", 931], ["and", 941], ["nuclear", 945], ["receptor", 953], ["-", 961], ["mediated", 962], ["transcription", 971], [".", 984]]}
{"context": "Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common condition characterized by an irresistible urge to move the legs, concomitant with an unpleasant sensation in the lower limbs, which is typically relieved by movement. Symptoms occur predominantly at rest and prevail in the afternoon or evening. Treatment of patients with RLS/WED is indicated for those patients who suffer from clinically relevant symptoms. The management of mild forms of RLS/WED is mainly based on dopamine agonists (DA) therapy (including pramipexole and ropinirole) and \u03b1-2-\u03b4 calcium-channel ligand. Nevertheless, with passing of time, symptoms tend to become more severe and the patient can eventually develop pharmacoresistance. Furthermore, long-term treatment with dopaminergic agents may be complicated by the development of augmentation, which is defined by an increase in the severity and frequency of RLS/WED symptoms despite adequate treatment. Here, we discuss which are the best therapeutic options when RLS/WED becomes intractable, with a focus on advantages and side effects of the available medications. Prevention strategies include managing lifestyle changes and a good sleep hygiene. Different drug options are available. Switching to longer-acting dopaminergic agents may be a possibility if the patient is well-tolerating DA treatment. An association with \u03b1-2-\u03b4 calcium-channel ligand is another first-line approach. In refractory RLS/WED, opioids such as oxycodone-naloxone have demonstrated good efficacy. Other pharmacological approaches include IV iron, benzodiazepines such as clonazepam, and antiepileptic drugs, with different level of evidence of efficacy. Therefore, the final decision regarding the agent to use in treating severe RLS/WED symptoms should be tailored to the patient, taking into account the symptomatology, comorbidities, the availability of treatment and the history of the disease.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "57c7f4ca7dcc421f8be58691a3878467", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["Disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["a", 57], ["common", 59], ["condition", 66], ["characterized", 76], ["by", 90], ["an", 93], ["irresistible", 96], ["urge", 109], ["to", 114], ["move", 117], ["the", 122], ["legs", 126], [",", 130], ["concomitant", 132], ["with", 144], ["an", 149], ["unpleasant", 152], ["sensation", 163], ["in", 173], ["the", 176], ["lower", 180], ["limbs", 186], [",", 191], ["which", 193], ["is", 199], ["typically", 202], ["relieved", 212], ["by", 221], ["movement", 224], [".", 232], ["Symptoms", 234], ["occur", 243], ["predominantly", 249], ["at", 263], ["rest", 266], ["and", 271], ["prevail", 275], ["in", 283], ["the", 286], ["afternoon", 290], ["or", 300], ["evening", 303], [".", 310], ["Treatment", 312], ["of", 322], ["patients", 325], ["with", 334], ["RLS", 339], ["/", 342], ["WED", 343], ["is", 347], ["indicated", 350], ["for", 360], ["those", 364], ["patients", 370], ["who", 379], ["suffer", 383], ["from", 390], ["clinically", 395], ["relevant", 406], ["symptoms", 415], [".", 423], ["The", 425], ["management", 429], ["of", 440], ["mild", 443], ["forms", 448], ["of", 454], ["RLS", 457], ["/", 460], ["WED", 461], ["is", 465], ["mainly", 468], ["based", 475], ["on", 481], ["dopamine", 484], ["agonists", 493], ["(", 502], ["DA", 503], [")", 505], ["therapy", 507], ["(", 515], ["including", 516], ["pramipexole", 526], ["and", 538], ["ropinirole", 542], [")", 552], ["and", 554], ["\u03b1-2-\u03b4", 558], ["calcium", 564], ["-", 571], ["channel", 572], ["ligand", 580], [".", 586], ["Nevertheless", 588], [",", 600], ["with", 602], ["passing", 607], ["of", 615], ["time", 618], [",", 622], ["symptoms", 624], ["tend", 633], ["to", 638], ["become", 641], ["more", 648], ["severe", 653], ["and", 660], ["the", 664], ["patient", 668], ["can", 676], ["eventually", 680], ["develop", 691], ["pharmacoresistance", 699], [".", 717], ["Furthermore", 719], [",", 730], ["long", 732], ["-", 736], ["term", 737], ["treatment", 742], ["with", 752], ["dopaminergic", 757], ["agents", 770], ["may", 777], ["be", 781], ["complicated", 784], ["by", 796], ["the", 799], ["development", 803], ["of", 815], ["augmentation", 818], [",", 830], ["which", 832], ["is", 838], ["defined", 841], ["by", 849], ["an", 852], ["increase", 855], ["in", 864], ["the", 867], ["severity", 871], ["and", 880], ["frequency", 884], ["of", 894], ["RLS", 897], ["/", 900], ["WED", 901], ["symptoms", 905], ["despite", 914], ["adequate", 922], ["treatment", 931], [".", 940], ["Here", 942], [",", 946], ["we", 948], ["discuss", 951], ["which", 959], ["are", 965], ["the", 969], ["best", 973], ["therapeutic", 978], ["options", 990], ["when", 998], ["RLS", 1003], ["/", 1006], ["WED", 1007], ["becomes", 1011], ["intractable", 1019], [",", 1030], ["with", 1032], ["a", 1037], ["focus", 1039], ["on", 1045], ["advantages", 1048], ["and", 1059], ["side", 1063], ["effects", 1068], ["of", 1076], ["the", 1079], ["available", 1083], ["medications", 1093], [".", 1104], ["Prevention", 1106], ["strategies", 1117], ["include", 1128], ["managing", 1136], ["lifestyle", 1145], ["changes", 1155], ["and", 1163], ["a", 1167], ["good", 1169], ["sleep", 1174], ["hygiene", 1180], [".", 1187], ["Different", 1189], ["drug", 1199], ["options", 1204], ["are", 1212], ["available", 1216], [".", 1225], ["Switching", 1227], ["to", 1237], ["longer", 1240], ["-", 1246], ["acting", 1247], ["dopaminergic", 1254], ["agents", 1267], ["may", 1274], ["be", 1278], ["a", 1281], ["possibility", 1283], ["if", 1295], ["the", 1298], ["patient", 1302], ["is", 1310], ["well", 1313], ["-", 1317], ["tolerating", 1318], ["DA", 1329], ["treatment", 1332], [".", 1341], ["An", 1343], ["association", 1346], ["with", 1358], ["\u03b1-2-\u03b4", 1363], ["calcium", 1369], ["-", 1376], ["channel", 1377], ["ligand", 1385], ["is", 1392], ["another", 1395], ["first", 1403], ["-", 1408], ["line", 1409], ["approach", 1414], [".", 1422], ["In", 1424], ["refractory", 1427], ["RLS", 1438], ["/", 1441], ["WED", 1442], [",", 1445], ["opioids", 1447], ["such", 1455], ["as", 1460], ["oxycodone", 1463], ["-", 1472], ["naloxone", 1473], ["have", 1482], ["demonstrated", 1487], ["good", 1500], ["efficacy", 1505], [".", 1513], ["Other", 1515], ["pharmacological", 1521], ["approaches", 1537], ["include", 1548], ["IV", 1556], ["iron", 1559], [",", 1563], ["benzodiazepines", 1565], ["such", 1581], ["as", 1586], ["clonazepam", 1589], [",", 1599], ["and", 1601], ["antiepileptic", 1605], ["drugs", 1619], [",", 1624], ["with", 1626], ["different", 1631], ["level", 1641], ["of", 1647], ["evidence", 1650], ["of", 1659], ["efficacy", 1662], [".", 1670], ["Therefore", 1672], [",", 1681], ["the", 1683], ["final", 1687], ["decision", 1693], ["regarding", 1702], ["the", 1712], ["agent", 1716], ["to", 1722], ["use", 1725], ["in", 1729], ["treating", 1732], ["severe", 1741], ["RLS", 1748], ["/", 1751], ["WED", 1752], ["symptoms", 1756], ["should", 1765], ["be", 1772], ["tailored", 1775], ["to", 1784], ["the", 1787], ["patient", 1791], [",", 1798], ["taking", 1800], ["into", 1807], ["account", 1812], ["the", 1820], ["symptomatology", 1824], [",", 1838], ["comorbidities", 1840], [",", 1853], ["the", 1855], ["availability", 1859], ["of", 1872], ["treatment", 1875], ["and", 1885], ["the", 1889], ["history", 1893], ["of", 1901], ["the", 1904], ["disease", 1908], [".", 1915]]}
{"context": "Human apolipoprotein E (apoE) is a 299-amino-acid protein with a molecular weight of 34 kDa. The difference between the apoE3 and apoE4 isoforms is a single residue substitution involving a Cys-Arg replacement at residue 112. ApoE4 is positively associated with atherosclerosis and late-onset and sporadic Alzheimer's disease (AD). ApoE4 and its C-terminal truncated fragments have been found in the senile plaques and neurofibrillary tangles in the brain of AD patients. However, detail structural information regarding isoform and domain interaction remains poorly understood. We prepared full-length, N-, and C-terminal truncated apoE3 and apoE4 proteins and studied their structural variation. Sedimentation velocity and continuous size distribution analysis using analytical ultracentrifugation revealed apoE3(72-299) as consisting of a major species with a sedimentation coefficient of 5.9. ApoE4(72-299) showed a wider and more complicated species distribution. Both apoE3 and E4 N-terminal domain (1-191) existed with monomers as the major component together with some tetramer. The oligomerization and aggregation of apoE protein increased when the C-terminal domain (192-271) was incorporated. The structural influence of the C-terminal domain on apoE is to assist self-association with no significant isoform preference. Circular dichroism and fluorescence studies demonstrated that apoE4(72-299) possessed a more alpha-helical structure with more hydrophobic residue exposure. The structural variation of the N-terminal truncated apoE3 and apoE4 protein provides useful information that helps to explain the greater aggregation of the apoE4 isoform and thus has implication for the involvement of apoE4 in AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "84150498c316405889993b5f785ce213", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[284, 285]], "char_spans": [[1647, 1659]]}]}], "context_tokens": [["Human", 0], ["apolipoprotein", 6], ["E", 21], ["(", 23], ["apoE", 24], [")", 28], ["is", 30], ["a", 33], ["299-amino", 35], ["-", 44], ["acid", 45], ["protein", 50], ["with", 58], ["a", 63], ["molecular", 65], ["weight", 75], ["of", 82], ["34", 85], ["kDa", 88], [".", 91], ["The", 93], ["difference", 97], ["between", 108], ["the", 116], ["apoE3", 120], ["and", 126], ["apoE4", 130], ["isoforms", 136], ["is", 145], ["a", 148], ["single", 150], ["residue", 157], ["substitution", 165], ["involving", 178], ["a", 188], ["Cys", 190], ["-", 193], ["Arg", 194], ["replacement", 198], ["at", 210], ["residue", 213], ["112", 221], [".", 224], ["ApoE4", 226], ["is", 232], ["positively", 235], ["associated", 246], ["with", 257], ["atherosclerosis", 262], ["and", 278], ["late", 282], ["-", 286], ["onset", 287], ["and", 293], ["sporadic", 297], ["Alzheimer", 306], ["'s", 315], ["disease", 318], ["(", 326], ["AD", 327], [")", 329], [".", 330], ["ApoE4", 332], ["and", 338], ["its", 342], ["C", 346], ["-", 347], ["terminal", 348], ["truncated", 357], ["fragments", 367], ["have", 377], ["been", 382], ["found", 387], ["in", 393], ["the", 396], ["senile", 400], ["plaques", 407], ["and", 415], ["neurofibrillary", 419], ["tangles", 435], ["in", 443], ["the", 446], ["brain", 450], ["of", 456], ["AD", 459], ["patients", 462], [".", 470], ["However", 472], [",", 479], ["detail", 481], ["structural", 488], ["information", 499], ["regarding", 511], ["isoform", 521], ["and", 529], ["domain", 533], ["interaction", 540], ["remains", 552], ["poorly", 560], ["understood", 567], [".", 577], ["We", 579], ["prepared", 582], ["full", 591], ["-", 595], ["length", 596], [",", 602], ["N-", 604], [",", 606], ["and", 608], ["C", 612], ["-", 613], ["terminal", 614], ["truncated", 623], ["apoE3", 633], ["and", 639], ["apoE4", 643], ["proteins", 649], ["and", 658], ["studied", 662], ["their", 670], ["structural", 676], ["variation", 687], [".", 696], ["Sedimentation", 698], ["velocity", 712], ["and", 721], ["continuous", 725], ["size", 736], ["distribution", 741], ["analysis", 754], ["using", 763], ["analytical", 769], ["ultracentrifugation", 780], ["revealed", 800], ["apoE3(72", 809], ["-", 817], ["299", 818], [")", 821], ["as", 823], ["consisting", 826], ["of", 837], ["a", 840], ["major", 842], ["species", 848], ["with", 856], ["a", 861], ["sedimentation", 863], ["coefficient", 877], ["of", 889], ["5.9", 892], [".", 895], ["ApoE4(72", 897], ["-", 905], ["299", 906], [")", 909], ["showed", 911], ["a", 918], ["wider", 920], ["and", 926], ["more", 930], ["complicated", 935], ["species", 947], ["distribution", 955], [".", 967], ["Both", 969], ["apoE3", 974], ["and", 980], ["E4", 984], ["N", 987], ["-", 988], ["terminal", 989], ["domain", 998], ["(", 1005], ["1", 1006], ["-", 1007], ["191", 1008], [")", 1011], ["existed", 1013], ["with", 1021], ["monomers", 1026], ["as", 1035], ["the", 1038], ["major", 1042], ["component", 1048], ["together", 1058], ["with", 1067], ["some", 1072], ["tetramer", 1077], [".", 1085], ["The", 1087], ["oligomerization", 1091], ["and", 1107], ["aggregation", 1111], ["of", 1123], ["apoE", 1126], ["protein", 1131], ["increased", 1139], ["when", 1149], ["the", 1154], ["C", 1158], ["-", 1159], ["terminal", 1160], ["domain", 1169], ["(", 1176], ["192", 1177], ["-", 1180], ["271", 1181], [")", 1184], ["was", 1186], ["incorporated", 1190], [".", 1202], ["The", 1204], ["structural", 1208], ["influence", 1219], ["of", 1229], ["the", 1232], ["C", 1236], ["-", 1237], ["terminal", 1238], ["domain", 1247], ["on", 1254], ["apoE", 1257], ["is", 1262], ["to", 1265], ["assist", 1268], ["self", 1275], ["-", 1279], ["association", 1280], ["with", 1292], ["no", 1297], ["significant", 1300], ["isoform", 1312], ["preference", 1320], [".", 1330], ["Circular", 1332], ["dichroism", 1341], ["and", 1351], ["fluorescence", 1355], ["studies", 1368], ["demonstrated", 1376], ["that", 1389], ["apoE4(72", 1394], ["-", 1402], ["299", 1403], [")", 1406], ["possessed", 1408], ["a", 1418], ["more", 1420], ["alpha", 1425], ["-", 1430], ["helical", 1431], ["structure", 1439], ["with", 1449], ["more", 1454], ["hydrophobic", 1459], ["residue", 1471], ["exposure", 1479], [".", 1487], ["The", 1489], ["structural", 1493], ["variation", 1504], ["of", 1514], ["the", 1517], ["N", 1521], ["-", 1522], ["terminal", 1523], ["truncated", 1532], ["apoE3", 1542], ["and", 1548], ["apoE4", 1552], ["protein", 1558], ["provides", 1566], ["useful", 1575], ["information", 1582], ["that", 1594], ["helps", 1599], ["to", 1605], ["explain", 1608], ["the", 1616], ["greater", 1620], ["aggregation", 1628], ["of", 1640], ["the", 1643], ["apoE4", 1647], ["isoform", 1653], ["and", 1661], ["thus", 1665], ["has", 1670], ["implication", 1674], ["for", 1686], ["the", 1690], ["involvement", 1694], ["of", 1706], ["apoE4", 1709], ["in", 1715], ["AD", 1718], [".", 1720]]}
{"context": "The tumorigenesis of sporadic endocrine tumors is still not fully understood. It is well known that patients with von Recklinghausen syndrome (NF-1) (OMIM 162200) carrying NF1 germline mutations are predisposed to endocrine tumors including pheochromocytomas and duodenal somatostatinomas. It is unclear, however, whether the rarely reported occurrence of pancreatic insulinomas in NF-1 patients represents a coincidental finding or whether insulinomas are a rare manifestation of the NF-1 syndrome. To determine the potential association between the NF-1 syndrome and pancreatic endocrine tumors, we analyzed a NF-1 patient with a well-differentiated pancreatic endocrine carcinoma for NF1 mutation, allelic loss of the NF1 gene and its expression in peripheral blood and tumor cells. The germline mutation c. 499 del TGTT known in the family was confirmed by polymerase chain reaction (PCR) and direct sequencing of exon 4 in DNA extracted from peripheral blood. Loss of heterozygosity (LOH) analysis of the NF1 gene was carried out using 3 intragenic microsatellite markers on 17q11.2. RNA expression was examined by reverse transcription and a consecutive PCR spanning intron 3 of the NF1 gene including the mutated site in exon 4. Immunohistochemistry was used to analyze NF-1 protein expression. Mutation analysis of peripheral blood leukocytes confirmed the 4 base pair deletion in exon 4 starting at codon 167 (499 del TGTT). LOH analysis of tumor tissue revealed retention of both NF1 alleles. While reverse transcriptase-PCR of peripheral blood showed bi-allelic expression of both the wild-type NF1 and the mutated form, reverse transcriptase-PCR of tumor extracts demonstrated expression of the mutated but not the wild-type NF1 allele. Additionally, neurofibromin, the NF1 gene product, was absent in the tumor tissue of the NF-1 patient. These results show that the wild-type NF1 transcrips and protein are reduced, in the reported insulinoma, supposedly by epigenetic mechanisms. This provides strong evidence that there is a relationship between von Recklinghausen disease and the patient's insulinoma. In this line, insulinomas may be viewed as a rare manifestation of the NF-1 syndrome. Furthermore, the NF1 gene must be considered as a candidate tumor suppressor gene for sporadic insulinomas and probably other pancreatic endocrine tumors.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "c0d1452ed8b34c4d932f62aae61d37a4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[112, 112], [195, 195], [302, 302], [166, 166], [294, 294], [325, 325], [381, 381], [105, 105], [270, 270], [248, 248], [30, 30]], "char_spans": [[721, 723], [1189, 1191], [1782, 1784], [1010, 1012], [1737, 1739], [1890, 1892], [2222, 2224], [687, 689], [1606, 1608], [1490, 1492], [172, 174]]}]}], "context_tokens": [["The", 0], ["tumorigenesis", 4], ["of", 18], ["sporadic", 21], ["endocrine", 30], ["tumors", 40], ["is", 47], ["still", 50], ["not", 56], ["fully", 60], ["understood", 66], [".", 76], ["It", 78], ["is", 81], ["well", 84], ["known", 89], ["that", 95], ["patients", 100], ["with", 109], ["von", 114], ["Recklinghausen", 118], ["syndrome", 133], ["(", 142], ["NF-1", 143], [")", 147], ["(", 149], ["OMIM", 150], ["162200", 155], [")", 161], ["carrying", 163], ["NF1", 172], ["germline", 176], ["mutations", 185], ["are", 195], ["predisposed", 199], ["to", 211], ["endocrine", 214], ["tumors", 224], ["including", 231], ["pheochromocytomas", 241], ["and", 259], ["duodenal", 263], ["somatostatinomas", 272], [".", 288], ["It", 290], ["is", 293], ["unclear", 296], [",", 303], ["however", 305], [",", 312], ["whether", 314], ["the", 322], ["rarely", 326], ["reported", 333], ["occurrence", 342], ["of", 353], ["pancreatic", 356], ["insulinomas", 367], ["in", 379], ["NF-1", 382], ["patients", 387], ["represents", 396], ["a", 407], ["coincidental", 409], ["finding", 422], ["or", 430], ["whether", 433], ["insulinomas", 441], ["are", 453], ["a", 457], ["rare", 459], ["manifestation", 464], ["of", 478], ["the", 481], ["NF-1", 485], ["syndrome", 490], [".", 498], ["To", 500], ["determine", 503], ["the", 513], ["potential", 517], ["association", 527], ["between", 539], ["the", 547], ["NF-1", 551], ["syndrome", 556], ["and", 565], ["pancreatic", 569], ["endocrine", 580], ["tumors", 590], [",", 596], ["we", 598], ["analyzed", 601], ["a", 610], ["NF-1", 612], ["patient", 617], ["with", 625], ["a", 630], ["well", 632], ["-", 636], ["differentiated", 637], ["pancreatic", 652], ["endocrine", 663], ["carcinoma", 673], ["for", 683], ["NF1", 687], ["mutation", 691], [",", 699], ["allelic", 701], ["loss", 709], ["of", 714], ["the", 717], ["NF1", 721], ["gene", 725], ["and", 730], ["its", 734], ["expression", 738], ["in", 749], ["peripheral", 752], ["blood", 763], ["and", 769], ["tumor", 773], ["cells", 779], [".", 784], ["The", 786], ["germline", 790], ["mutation", 799], ["c.", 808], ["499", 811], ["del", 815], ["TGTT", 819], ["known", 824], ["in", 830], ["the", 833], ["family", 837], ["was", 844], ["confirmed", 848], ["by", 858], ["polymerase", 861], ["chain", 872], ["reaction", 878], ["(", 887], ["PCR", 888], [")", 891], ["and", 893], ["direct", 897], ["sequencing", 904], ["of", 915], ["exon", 918], ["4", 923], ["in", 925], ["DNA", 928], ["extracted", 932], ["from", 942], ["peripheral", 947], ["blood", 958], [".", 963], ["Loss", 965], ["of", 970], ["heterozygosity", 973], ["(", 988], ["LOH", 989], [")", 992], ["analysis", 994], ["of", 1003], ["the", 1006], ["NF1", 1010], ["gene", 1014], ["was", 1019], ["carried", 1023], ["out", 1031], ["using", 1035], ["3", 1041], ["intragenic", 1043], ["microsatellite", 1054], ["markers", 1069], ["on", 1077], ["17q11.2", 1080], [".", 1087], ["RNA", 1089], ["expression", 1093], ["was", 1104], ["examined", 1108], ["by", 1117], ["reverse", 1120], ["transcription", 1128], ["and", 1142], ["a", 1146], ["consecutive", 1148], ["PCR", 1160], ["spanning", 1164], ["intron", 1173], ["3", 1180], ["of", 1182], ["the", 1185], ["NF1", 1189], ["gene", 1193], ["including", 1198], ["the", 1208], ["mutated", 1212], ["site", 1220], ["in", 1225], ["exon", 1228], ["4", 1233], [".", 1234], ["Immunohistochemistry", 1236], ["was", 1257], ["used", 1261], ["to", 1266], ["analyze", 1269], ["NF-1", 1277], ["protein", 1282], ["expression", 1290], [".", 1300], ["Mutation", 1302], ["analysis", 1311], ["of", 1320], ["peripheral", 1323], ["blood", 1334], ["leukocytes", 1340], ["confirmed", 1351], ["the", 1361], ["4", 1365], ["base", 1367], ["pair", 1372], ["deletion", 1377], ["in", 1386], ["exon", 1389], ["4", 1394], ["starting", 1396], ["at", 1405], ["codon", 1408], ["167", 1414], ["(", 1418], ["499", 1419], ["del", 1423], ["TGTT", 1427], [")", 1431], [".", 1432], ["LOH", 1434], ["analysis", 1438], ["of", 1447], ["tumor", 1450], ["tissue", 1456], ["revealed", 1463], ["retention", 1472], ["of", 1482], ["both", 1485], ["NF1", 1490], ["alleles", 1494], [".", 1501], ["While", 1503], ["reverse", 1509], ["transcriptase", 1517], ["-", 1530], ["PCR", 1531], ["of", 1535], ["peripheral", 1538], ["blood", 1549], ["showed", 1555], ["bi", 1562], ["-", 1564], ["allelic", 1565], ["expression", 1573], ["of", 1584], ["both", 1587], ["the", 1592], ["wild", 1596], ["-", 1600], ["type", 1601], ["NF1", 1606], ["and", 1610], ["the", 1614], ["mutated", 1618], ["form", 1626], [",", 1630], ["reverse", 1632], ["transcriptase", 1640], ["-", 1653], ["PCR", 1654], ["of", 1658], ["tumor", 1661], ["extracts", 1667], ["demonstrated", 1676], ["expression", 1689], ["of", 1700], ["the", 1703], ["mutated", 1707], ["but", 1715], ["not", 1719], ["the", 1723], ["wild", 1727], ["-", 1731], ["type", 1732], ["NF1", 1737], ["allele", 1741], [".", 1747], ["Additionally", 1749], [",", 1761], ["neurofibromin", 1763], [",", 1776], ["the", 1778], ["NF1", 1782], ["gene", 1786], ["product", 1791], [",", 1798], ["was", 1800], ["absent", 1804], ["in", 1811], ["the", 1814], ["tumor", 1818], ["tissue", 1824], ["of", 1831], ["the", 1834], ["NF-1", 1838], ["patient", 1843], [".", 1850], ["These", 1852], ["results", 1858], ["show", 1866], ["that", 1871], ["the", 1876], ["wild", 1880], ["-", 1884], ["type", 1885], ["NF1", 1890], ["transcrips", 1894], ["and", 1905], ["protein", 1909], ["are", 1917], ["reduced", 1921], [",", 1928], ["in", 1930], ["the", 1933], ["reported", 1937], ["insulinoma", 1946], [",", 1956], ["supposedly", 1958], ["by", 1969], ["epigenetic", 1972], ["mechanisms", 1983], [".", 1993], ["This", 1995], ["provides", 2000], ["strong", 2009], ["evidence", 2016], ["that", 2025], ["there", 2030], ["is", 2036], ["a", 2039], ["relationship", 2041], ["between", 2054], ["von", 2062], ["Recklinghausen", 2066], ["disease", 2081], ["and", 2089], ["the", 2093], ["patient", 2097], ["'s", 2104], ["insulinoma", 2107], [".", 2117], ["In", 2119], ["this", 2122], ["line", 2127], [",", 2131], ["insulinomas", 2133], ["may", 2145], ["be", 2149], ["viewed", 2152], ["as", 2159], ["a", 2162], ["rare", 2164], ["manifestation", 2169], ["of", 2183], ["the", 2186], ["NF-1", 2190], ["syndrome", 2195], [".", 2203], ["Furthermore", 2205], [",", 2216], ["the", 2218], ["NF1", 2222], ["gene", 2226], ["must", 2231], ["be", 2236], ["considered", 2239], ["as", 2250], ["a", 2253], ["candidate", 2255], ["tumor", 2265], ["suppressor", 2271], ["gene", 2282], ["for", 2287], ["sporadic", 2291], ["insulinomas", 2300], ["and", 2312], ["probably", 2316], ["other", 2325], ["pancreatic", 2331], ["endocrine", 2342], ["tumors", 2352], [".", 2358]]}
{"context": "Rapid laboratory methods provide optimal support for active surveillance efforts to screen for methicillin-resistant Staphylococcus aureus (MRSA). Most laboratories struggle to determine the optimal use of resources, considering options to balance cost, speed, and diagnostic accuracy. To assess the performance of common methods, the first comparison of MRSASelect agar (MS) and CHROMagar MRSA (CA), with and without broth enrichment followed by a 24-h subculture to MS, was performed. Results were compared to those of the Xpert MRSA assay. For direct culture methods, the agreement between MS and CA was 98.8%. At 18 h, direct MS identified 93% of all positive samples from direct culture and 84% of those identified by the Xpert MRSA. For Trypticase soy broth-enriched MS culture, incubated overnight and then subcultured for an additional 24 h, the agreement with Xpert MRSA was 96%. The agreement between direct MS and Xpert MRSA was 100% when semiquantitative culture revealed a bacterial density of 2+ or greater; however, discrepancies between culture and Xpert MRSA arose for MRSA bacterial densities of 1+ or less, indicating low density as a common cause of false-negative culture results. Since 1+ or less was established as the most common MRSA carrier state, broth enrichment or PCR may be critical for the identification of all MRSA carriers who may be reservoirs for transmission. In this active-surveillance convenience sample, the use of broth enrichment followed by subculture to MS offered a low-cost but sensitive method for MRSA screening, with performance similar to that of Xpert MRSA PCR.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "3bb7162086024ef8ac8c5df12b9b21a0", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[64, 64], [93, 93], [19, 19], [198, 198], [235, 235], [251, 251], [201, 201], [297, 297], [136, 136], [287, 287], [162, 162], [174, 174]], "char_spans": [[390, 393], [531, 534], [140, 143], [1071, 1074], [1254, 1257], [1344, 1347], [1086, 1089], [1605, 1608], [733, 736], [1547, 1550], [875, 878], [931, 934]]}]}], "context_tokens": [["Rapid", 0], ["laboratory", 6], ["methods", 17], ["provide", 25], ["optimal", 33], ["support", 41], ["for", 49], ["active", 53], ["surveillance", 60], ["efforts", 73], ["to", 81], ["screen", 84], ["for", 91], ["methicillin", 95], ["-", 106], ["resistant", 107], ["Staphylococcus", 117], ["aureus", 132], ["(", 139], ["MRSA", 140], [")", 144], [".", 145], ["Most", 147], ["laboratories", 152], ["struggle", 165], ["to", 174], ["determine", 177], ["the", 187], ["optimal", 191], ["use", 199], ["of", 203], ["resources", 206], [",", 215], ["considering", 217], ["options", 229], ["to", 237], ["balance", 240], ["cost", 248], [",", 252], ["speed", 254], [",", 259], ["and", 261], ["diagnostic", 265], ["accuracy", 276], [".", 284], ["To", 286], ["assess", 289], ["the", 296], ["performance", 300], ["of", 312], ["common", 315], ["methods", 322], [",", 329], ["the", 331], ["first", 335], ["comparison", 341], ["of", 352], ["MRSASelect", 355], ["agar", 366], ["(", 371], ["MS", 372], [")", 374], ["and", 376], ["CHROMagar", 380], ["MRSA", 390], ["(", 395], ["CA", 396], [")", 398], [",", 399], ["with", 401], ["and", 406], ["without", 410], ["broth", 418], ["enrichment", 424], ["followed", 435], ["by", 444], ["a", 447], ["24-h", 449], ["subculture", 454], ["to", 465], ["MS", 468], [",", 470], ["was", 472], ["performed", 476], [".", 485], ["Results", 487], ["were", 495], ["compared", 500], ["to", 509], ["those", 512], ["of", 518], ["the", 521], ["Xpert", 525], ["MRSA", 531], ["assay", 536], [".", 541], ["For", 543], ["direct", 547], ["culture", 554], ["methods", 562], [",", 569], ["the", 571], ["agreement", 575], ["between", 585], ["MS", 593], ["and", 596], ["CA", 600], ["was", 603], ["98.8", 607], ["%", 611], [".", 612], ["At", 614], ["18", 617], ["h", 620], [",", 621], ["direct", 623], ["MS", 630], ["identified", 633], ["93", 644], ["%", 646], ["of", 648], ["all", 651], ["positive", 655], ["samples", 664], ["from", 672], ["direct", 677], ["culture", 684], ["and", 692], ["84", 696], ["%", 698], ["of", 700], ["those", 703], ["identified", 709], ["by", 720], ["the", 723], ["Xpert", 727], ["MRSA", 733], [".", 737], ["For", 739], ["Trypticase", 743], ["soy", 754], ["broth", 758], ["-", 763], ["enriched", 764], ["MS", 773], ["culture", 776], [",", 783], ["incubated", 785], ["overnight", 795], ["and", 805], ["then", 809], ["subcultured", 814], ["for", 826], ["an", 830], ["additional", 833], ["24", 844], ["h", 847], [",", 848], ["the", 850], ["agreement", 854], ["with", 864], ["Xpert", 869], ["MRSA", 875], ["was", 880], ["96", 884], ["%", 886], [".", 887], ["The", 889], ["agreement", 893], ["between", 903], ["direct", 911], ["MS", 918], ["and", 921], ["Xpert", 925], ["MRSA", 931], ["was", 936], ["100", 940], ["%", 943], ["when", 945], ["semiquantitative", 950], ["culture", 967], ["revealed", 975], ["a", 984], ["bacterial", 986], ["density", 996], ["of", 1004], ["2", 1007], ["+", 1008], ["or", 1010], ["greater", 1013], [";", 1020], ["however", 1022], [",", 1029], ["discrepancies", 1031], ["between", 1045], ["culture", 1053], ["and", 1061], ["Xpert", 1065], ["MRSA", 1071], ["arose", 1076], ["for", 1082], ["MRSA", 1086], ["bacterial", 1091], ["densities", 1101], ["of", 1111], ["1", 1114], ["+", 1115], ["or", 1117], ["less", 1120], [",", 1124], ["indicating", 1126], ["low", 1137], ["density", 1141], ["as", 1149], ["a", 1152], ["common", 1154], ["cause", 1161], ["of", 1167], ["false", 1170], ["-", 1175], ["negative", 1176], ["culture", 1185], ["results", 1193], [".", 1200], ["Since", 1202], ["1", 1208], ["+", 1209], ["or", 1211], ["less", 1214], ["was", 1219], ["established", 1223], ["as", 1235], ["the", 1238], ["most", 1242], ["common", 1247], ["MRSA", 1254], ["carrier", 1259], ["state", 1267], [",", 1272], ["broth", 1274], ["enrichment", 1280], ["or", 1291], ["PCR", 1294], ["may", 1298], ["be", 1302], ["critical", 1305], ["for", 1314], ["the", 1318], ["identification", 1322], ["of", 1337], ["all", 1340], ["MRSA", 1344], ["carriers", 1349], ["who", 1358], ["may", 1362], ["be", 1366], ["reservoirs", 1369], ["for", 1380], ["transmission", 1384], [".", 1396], ["In", 1398], ["this", 1401], ["active", 1406], ["-", 1412], ["surveillance", 1413], ["convenience", 1426], ["sample", 1438], [",", 1444], ["the", 1446], ["use", 1450], ["of", 1454], ["broth", 1457], ["enrichment", 1463], ["followed", 1474], ["by", 1483], ["subculture", 1486], ["to", 1497], ["MS", 1500], ["offered", 1503], ["a", 1511], ["low", 1513], ["-", 1516], ["cost", 1517], ["but", 1522], ["sensitive", 1526], ["method", 1536], ["for", 1543], ["MRSA", 1547], ["screening", 1552], [",", 1561], ["with", 1563], ["performance", 1568], ["similar", 1580], ["to", 1588], ["that", 1591], ["of", 1596], ["Xpert", 1599], ["MRSA", 1605], ["PCR", 1610], [".", 1613]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron deficiency from chronic hemoptysis. This is the first case that reports RLS and PLMD manifesting from iron deficiency caused by chronic hemoptysis in advanced cystic fibrosis lung disease.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cecd920cbb724d98aaf99c70c2dcc371", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[65, 65], [28, 28], [47, 47]], "char_spans": [[368, 371], [162, 165], [261, 264]]}]}], "context_tokens": [["Restless", 0], ["leg", 9], ["syndrome", 13], ["(", 22], ["RLS", 23], [")", 26], ["and", 28], ["periodic", 32], ["limb", 41], ["movement", 46], ["disorder", 55], ["(", 64], ["PLMD", 65], [")", 69], ["are", 71], ["considered", 75], ["to", 86], ["be", 89], ["a", 92], ["continuum", 94], ["of", 104], ["a", 107], ["neurological", 109], ["sleep", 122], ["disorder", 128], ["associated", 137], ["with", 148], ["abnormal", 153], ["iron", 162], ["metabolism", 167], ["or", 178], ["deficiency", 181], [".", 191], ["I", 193], ["describe", 195], ["a", 204], ["case", 206], ["of", 211], ["RLS", 214], ["and", 218], ["PLMD", 222], ["in", 227], ["a", 230], ["cystic", 232], ["fibrosis", 239], ["patient", 248], ["with", 256], ["iron", 261], ["deficiency", 266], ["from", 277], ["chronic", 282], ["hemoptysis", 290], [".", 300], ["This", 302], ["is", 307], ["the", 310], ["first", 314], ["case", 320], ["that", 325], ["reports", 330], ["RLS", 338], ["and", 342], ["PLMD", 346], ["manifesting", 351], ["from", 363], ["iron", 368], ["deficiency", 373], ["caused", 384], ["by", 391], ["chronic", 394], ["hemoptysis", 402], ["in", 413], ["advanced", 416], ["cystic", 425], ["fibrosis", 432], ["lung", 441], ["disease", 446], [".", 453]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) burden is increasing worldwide in hospitals [healthcare-associated (HA)-MRSA] and in communities [community-associated (CA)-MRSA]. However, the impact of CA-MRSA within hospitals remains limited, particularly in Latin America. A countrywide representative survey of S. aureus infections was performed in Argentina by analyzing 591 clinical isolates from 66 hospitals in a prospective cross-sectional, multicenter study (Nov-2009). This work involved healthcare-onset infections-(HAHO, >48 hospitalization hours) and community-onset (CO) infections [including both, infections (HACO) in patients with healthcare-associated risk-factors (HRFs) and infections (CACO) in those without HRFs]. MRSA strains were genetically typed as CA-MRSA and HA-MRSA genotypes (CA-MRSAG and HA-MRSAG) by SCCmec- and spa-typing, PFGE, MLST and virulence genes profile by PCR. Considering all isolates, 63% were from CO-infections and 55% were MRSA [39% CA-MRSAG and 16% HA-MRSAG]. A significantly higher MRSA proportion among CO- than HAHO-S. aureus infections was detected (58% vs 49%); mainly in children (62% vs 43%). The CA-MRSAG/HA-MRSAG have accounted for 16%/33% of HAHO-, 39%/13% of HACO- and 60.5%/0% of CACO-infections. Regarding the epidemiological associations identified in multivariate models for patients with healthcare-onset CA-MRSAG infections, CA-MRSAG behave like HA-MRSAG within hospitals but children were the highest risk group for healthcare-onset CA-MRSAG infections. Most CA-MRSAG belonged to two major clones: PFGE-type N-ST30-SCCmecIVc-t019-PVL(+) and PFGE-type I-ST5-IV-SCCmecIVa-t311-PVL(+) (45% each). The ST5-IV-PVL(+)/ST30-IV-PVL(+) clones have caused 31%/33% of all infections, 20%/4% of HAHO-, 43%/23% of HACO- and 35%/60% of CACO- infections, with significant differences by age groups (children/adults) and geographical regions. Importantly, an isolate belonging to USA300-0114-(ST8-SCCmecIVa-spat008-PVL(+)-ACME(+)) was detected for the first time in Argentina. Most of HA-MRSAG (66%) were related to the Cordobes/Chilean clone-(PFGE-type A-ST5-SCCmecI-t149) causing 18% of all infections (47% of HAHO- and 13% of HACO-infections). Results strongly suggest that the CA-MRSA clone ST5-IV-PVL(+) has begun to spread within hospitals, replacing the traditional Cordobes/Chilean-HA-MRSA clone ST5-I-PVL(-), mainly in children. Importantly, a growing MRSA reservoir in the community was associated with spreading of two CA-MRSA clones: ST5-IV-PVL(+), mainly in children with HRFs, and ST30-IV-PVL(+) in adults without HRFs. This is the first nationwide study in Argentina providing information about the molecular and clinical epidemiology of CA-MRSA, particularly within hospitals, which is essential for designing effective control measures in this country and worldwide.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d454454df5fe41c28b4fd7ea8089ab83", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[464, 464], [139, 139], [131, 131], [37, 37], [6, 6], [186, 186], [202, 202], [486, 486], [501, 501], [557, 557], [514, 514], [143, 143]], "char_spans": [[2237, 2240], [781, 784], [739, 742], [208, 211], [45, 48], [973, 976], [1034, 1037], [2346, 2349], [2414, 2417], [2709, 2712], [2486, 2489], [793, 796]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["burden", 51], ["is", 58], ["increasing", 61], ["worldwide", 72], ["in", 82], ["hospitals", 85], ["[", 95], ["healthcare", 96], ["-", 106], ["associated", 107], ["(", 118], ["HA)-MRSA", 119], ["]", 127], ["and", 129], ["in", 133], ["communities", 136], ["[", 148], ["community", 149], ["-", 158], ["associated", 159], ["(", 170], ["CA)-MRSA].", 171], ["However", 182], [",", 189], ["the", 191], ["impact", 195], ["of", 202], ["CA", 205], ["-", 207], ["MRSA", 208], ["within", 213], ["hospitals", 220], ["remains", 230], ["limited", 238], [",", 245], ["particularly", 247], ["in", 260], ["Latin", 263], ["America", 269], [".", 276], ["A", 278], ["countrywide", 280], ["representative", 292], ["survey", 307], ["of", 314], ["S.", 317], ["aureus", 320], ["infections", 327], ["was", 338], ["performed", 342], ["in", 352], ["Argentina", 355], ["by", 365], ["analyzing", 368], ["591", 378], ["clinical", 382], ["isolates", 391], ["from", 400], ["66", 405], ["hospitals", 408], ["in", 418], ["a", 421], ["prospective", 423], ["cross", 435], ["-", 440], ["sectional", 441], [",", 450], ["multicenter", 452], ["study", 464], ["(", 470], ["Nov-2009", 471], [")", 479], [".", 480], ["This", 482], ["work", 487], ["involved", 492], ["healthcare", 501], ["-", 511], ["onset", 512], ["infections-(HAHO", 518], [",", 534], [">", 536], ["48", 537], ["hospitalization", 540], ["hours", 556], [")", 561], ["and", 563], ["community", 567], ["-", 576], ["onset", 577], ["(", 583], ["CO", 584], [")", 586], ["infections", 588], ["[", 599], ["including", 600], ["both", 610], [",", 614], ["infections", 616], ["(", 627], ["HACO", 628], [")", 632], ["in", 634], ["patients", 637], ["with", 646], ["healthcare", 651], ["-", 661], ["associated", 662], ["risk", 673], ["-", 677], ["factors", 678], ["(", 686], ["HRFs", 687], [")", 691], ["and", 693], ["infections", 697], ["(", 708], ["CACO", 709], [")", 713], ["in", 715], ["those", 718], ["without", 724], ["HRFs].", 732], ["MRSA", 739], ["strains", 744], ["were", 752], ["genetically", 757], ["typed", 769], ["as", 775], ["CA", 778], ["-", 780], ["MRSA", 781], ["and", 786], ["HA", 790], ["-", 792], ["MRSA", 793], ["genotypes", 798], ["(", 808], ["CA", 809], ["-", 811], ["MRSAG", 812], ["and", 818], ["HA", 822], ["-", 824], ["MRSAG", 825], [")", 830], ["by", 832], ["SCCmec-", 835], ["and", 843], ["spa", 847], ["-", 850], ["typing", 851], [",", 857], ["PFGE", 859], [",", 863], ["MLST", 865], ["and", 870], ["virulence", 874], ["genes", 884], ["profile", 890], ["by", 898], ["PCR", 901], [".", 904], ["Considering", 906], ["all", 918], ["isolates", 922], [",", 930], ["63", 932], ["%", 934], ["were", 936], ["from", 941], ["CO", 946], ["-", 948], ["infections", 949], ["and", 960], ["55", 964], ["%", 966], ["were", 968], ["MRSA", 973], ["[", 978], ["39", 979], ["%", 981], ["CA", 983], ["-", 985], ["MRSAG", 986], ["and", 992], ["16", 996], ["%", 998], ["HA", 1000], ["-", 1002], ["MRSAG].", 1003], ["A", 1011], ["significantly", 1013], ["higher", 1027], ["MRSA", 1034], ["proportion", 1039], ["among", 1050], ["CO-", 1056], ["than", 1060], ["HAHO", 1065], ["-", 1069], ["S.", 1070], ["aureus", 1073], ["infections", 1080], ["was", 1091], ["detected", 1095], ["(", 1104], ["58", 1105], ["%", 1107], ["vs", 1109], ["49", 1112], ["%", 1114], [")", 1115], [";", 1116], ["mainly", 1118], ["in", 1125], ["children", 1128], ["(", 1137], ["62", 1138], ["%", 1140], ["vs", 1142], ["43", 1145], ["%", 1147], [")", 1148], [".", 1149], ["The", 1151], ["CA", 1155], ["-", 1157], ["MRSAG", 1158], ["/", 1163], ["HA", 1164], ["-", 1166], ["MRSAG", 1167], ["have", 1173], ["accounted", 1178], ["for", 1188], ["16%/33", 1192], ["%", 1198], ["of", 1200], ["HAHO-", 1203], [",", 1208], ["39%/13", 1210], ["%", 1216], ["of", 1218], ["HACO-", 1221], ["and", 1227], ["60.5%/0", 1231], ["%", 1238], ["of", 1240], ["CACO", 1243], ["-", 1247], ["infections", 1248], [".", 1258], ["Regarding", 1260], ["the", 1270], ["epidemiological", 1274], ["associations", 1290], ["identified", 1303], ["in", 1314], ["multivariate", 1317], ["models", 1330], ["for", 1337], ["patients", 1341], ["with", 1350], ["healthcare", 1355], ["-", 1365], ["onset", 1366], ["CA", 1372], ["-", 1374], ["MRSAG", 1375], ["infections", 1381], [",", 1391], ["CA", 1393], ["-", 1395], ["MRSAG", 1396], ["behave", 1402], ["like", 1409], ["HA", 1414], ["-", 1416], ["MRSAG", 1417], ["within", 1423], ["hospitals", 1430], ["but", 1440], ["children", 1444], ["were", 1453], ["the", 1458], ["highest", 1462], ["risk", 1470], ["group", 1475], ["for", 1481], ["healthcare", 1485], ["-", 1495], ["onset", 1496], ["CA", 1502], ["-", 1504], ["MRSAG", 1505], ["infections", 1511], [".", 1521], ["Most", 1523], ["CA", 1528], ["-", 1530], ["MRSAG", 1531], ["belonged", 1537], ["to", 1546], ["two", 1549], ["major", 1553], ["clones", 1559], [":", 1565], ["PFGE", 1567], ["-", 1571], ["type", 1572], ["N", 1577], ["-", 1578], ["ST30-SCCmecIVc", 1579], ["-", 1593], ["t019-PVL(+", 1594], [")", 1604], ["and", 1606], ["PFGE", 1610], ["-", 1614], ["type", 1615], ["I", 1620], ["-", 1621], ["ST5-IV", 1622], ["-", 1628], ["SCCmecIVa", 1629], ["-", 1638], ["t311-PVL(+", 1639], [")", 1649], ["(", 1651], ["45", 1652], ["%", 1654], ["each", 1656], [")", 1660], [".", 1661], ["The", 1663], ["ST5-IV", 1667], ["-", 1673], ["PVL(+)/ST30-IV", 1674], ["-", 1688], ["PVL(+", 1689], [")", 1694], ["clones", 1696], ["have", 1703], ["caused", 1708], ["31%/33", 1715], ["%", 1721], ["of", 1723], ["all", 1726], ["infections", 1730], [",", 1740], ["20%/4", 1742], ["%", 1747], ["of", 1749], ["HAHO-", 1752], [",", 1757], ["43%/23", 1759], ["%", 1765], ["of", 1767], ["HACO-", 1770], ["and", 1776], ["35%/60", 1780], ["%", 1786], ["of", 1788], ["CACO-", 1791], ["infections", 1797], [",", 1807], ["with", 1809], ["significant", 1814], ["differences", 1826], ["by", 1838], ["age", 1841], ["groups", 1845], ["(", 1852], ["children", 1853], ["/", 1861], ["adults", 1862], [")", 1868], ["and", 1870], ["geographical", 1874], ["regions", 1887], [".", 1894], ["Importantly", 1896], [",", 1907], ["an", 1909], ["isolate", 1912], ["belonging", 1920], ["to", 1930], ["USA300", 1933], ["-", 1939], ["0114-(ST8-SCCmecIVa", 1940], ["-", 1959], ["spat008-PVL(+)-ACME(+", 1960], [")", 1981], [")", 1982], ["was", 1984], ["detected", 1988], ["for", 1997], ["the", 2001], ["first", 2005], ["time", 2011], ["in", 2016], ["Argentina", 2019], [".", 2028], ["Most", 2030], ["of", 2035], ["HA", 2038], ["-", 2040], ["MRSAG", 2041], ["(", 2047], ["66", 2048], ["%", 2050], [")", 2051], ["were", 2053], ["related", 2058], ["to", 2066], ["the", 2069], ["Cordobes", 2073], ["/", 2081], ["Chilean", 2082], ["clone-(PFGE", 2090], ["-", 2101], ["type", 2102], ["A", 2107], ["-", 2108], ["ST5-SCCmecI", 2109], ["-", 2120], ["t149", 2121], [")", 2125], ["causing", 2127], ["18", 2135], ["%", 2137], ["of", 2139], ["all", 2142], ["infections", 2146], ["(", 2157], ["47", 2158], ["%", 2160], ["of", 2162], ["HAHO-", 2165], ["and", 2171], ["13", 2175], ["%", 2177], ["of", 2179], ["HACO", 2182], ["-", 2186], ["infections", 2187], [")", 2197], [".", 2198], ["Results", 2200], ["strongly", 2208], ["suggest", 2217], ["that", 2225], ["the", 2230], ["CA", 2234], ["-", 2236], ["MRSA", 2237], ["clone", 2242], ["ST5-IV", 2248], ["-", 2254], ["PVL(+", 2255], [")", 2260], ["has", 2262], ["begun", 2266], ["to", 2272], ["spread", 2275], ["within", 2282], ["hospitals", 2289], [",", 2298], ["replacing", 2300], ["the", 2310], ["traditional", 2314], ["Cordobes", 2326], ["/", 2334], ["Chilean", 2335], ["-", 2342], ["HA", 2343], ["-", 2345], ["MRSA", 2346], ["clone", 2351], ["ST5-I", 2357], ["-", 2362], ["PVL(-", 2363], [")", 2368], [",", 2369], ["mainly", 2371], ["in", 2378], ["children", 2381], [".", 2389], ["Importantly", 2391], [",", 2402], ["a", 2404], ["growing", 2406], ["MRSA", 2414], ["reservoir", 2419], ["in", 2429], ["the", 2432], ["community", 2436], ["was", 2446], ["associated", 2450], ["with", 2461], ["spreading", 2466], ["of", 2476], ["two", 2479], ["CA", 2483], ["-", 2485], ["MRSA", 2486], ["clones", 2491], [":", 2497], ["ST5-IV", 2499], ["-", 2505], ["PVL(+", 2506], [")", 2511], [",", 2512], ["mainly", 2514], ["in", 2521], ["children", 2524], ["with", 2533], ["HRFs", 2538], [",", 2542], ["and", 2544], ["ST30-IV", 2548], ["-", 2555], ["PVL(+", 2556], [")", 2561], ["in", 2563], ["adults", 2566], ["without", 2573], ["HRFs", 2581], [".", 2585], ["This", 2587], ["is", 2592], ["the", 2595], ["first", 2599], ["nationwide", 2605], ["study", 2616], ["in", 2622], ["Argentina", 2625], ["providing", 2635], ["information", 2645], ["about", 2657], ["the", 2663], ["molecular", 2667], ["and", 2677], ["clinical", 2681], ["epidemiology", 2690], ["of", 2703], ["CA", 2706], ["-", 2708], ["MRSA", 2709], [",", 2713], ["particularly", 2715], ["within", 2728], ["hospitals", 2735], [",", 2744], ["which", 2746], ["is", 2752], ["essential", 2755], ["for", 2765], ["designing", 2769], ["effective", 2779], ["control", 2789], ["measures", 2797], ["in", 2806], ["this", 2809], ["country", 2814], ["and", 2822], ["worldwide", 2826], [".", 2835]]}
{"context": "Acute lung injury is a life-threatening condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-\u03b1 (TNF-\u03b1) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- \u03b1 co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "5b8df96552584828a665c27a635ad167", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[15, 17]], "char_spans": [[101, 126]]}]}], "context_tokens": [["Acute", 0], ["lung", 6], ["injury", 11], ["is", 18], ["a", 21], ["life", 23], ["-", 27], ["threatening", 28], ["condition", 40], ["characterized", 50], ["by", 64], ["surfactant", 67], ["dysfunction", 78], ["and", 90], ["raised", 94], ["secretory", 101], ["phospholipase", 111], ["A2", 125], ["(", 128], ["sPLA2", 129], [")", 134], ["activity", 136], [".", 144], ["Varespladib", 146], ["is", 158], ["a", 161], ["sPLA2", 163], ["inhibitor", 169], ["shown", 179], ["to", 185], ["be", 188], ["effective", 191], ["in", 201], ["animal", 204], ["models", 211], ["of", 218], ["acute", 221], ["lung", 227], ["injury", 232], [".", 238], ["We", 240], ["aimed", 243], ["at", 249], ["investigating", 252], ["the", 266], ["effect", 270], ["of", 277], ["co", 280], ["-", 282], ["administration", 283], ["of", 298], ["surfactant", 301], ["and", 312], ["varespladib", 316], ["on", 328], ["sPLA2", 331], ["activity", 337], [".", 345], ["Alveolar", 347], ["macrophages", 356], ["were", 368], ["cultured", 373], ["and", 382], ["stimulated", 386], ["with", 397], ["lipopolysaccharide", 402], ["and", 421], ["then", 425], ["treated", 430], ["with", 438], ["either", 443], ["varespladib", 450], [",", 461], ["surfactant", 463], [",", 473], ["varespladib", 475], ["followed", 487], ["by", 496], ["surfactant", 499], ["or", 510], ["nothing", 513], [".", 520], ["sPLA2", 522], ["activity", 528], [",", 536], ["free", 538], ["fatty", 543], ["acids", 549], [",", 554], ["tumour", 556], ["necrosis", 563], ["factor", 572], ["-", 578], ["\u03b1", 579], ["(", 581], ["TNF", 582], ["-", 585], ["\u03b1", 586], [")", 587], ["and", 589], ["protein", 593], ["concentrations", 601], ["were", 616], ["measured", 621], ["in", 630], ["culture", 633], ["supernatants", 641], [".", 653], ["Treatment", 655], ["with", 665], ["varespladib", 670], ["(", 682], ["p=0.019", 683], [")", 690], ["and", 692], ["varespladib", 696], ["+", 708], ["surfactant", 710], ["(", 721], ["p=0.013", 722], [")", 729], [",", 730], ["reduced", 732], ["the", 740], ["enzyme", 744], ["activity", 751], ["by", 760], ["approximately", 763], ["15", 777], ["%", 779], ["from", 781], ["the", 786], ["basal", 790], ["level", 796], ["measured", 802], ["in", 811], ["the", 814], ["untreated", 818], ["cultures", 828], [".", 836], ["Surfactant", 838], [",", 848], ["varespladib", 850], ["and", 862], ["varespladib", 866], ["+", 878], ["surfactant", 880], [",", 890], ["respectively", 892], ["decreased", 905], ["free", 915], ["fatty", 920], ["acids", 926], ["by", 932], ["-45", 935], ["%", 938], ["(", 940], ["p=0.045", 941], [")", 948], [",", 949], ["-", 951], ["62", 953], ["%", 955], ["(", 957], ["p=0.009", 958], [")", 965], ["and", 967], ["-48", 971], ["%", 974], ["(", 976], ["p=0.015", 977], [")", 984], [",", 985], ["from", 987], ["the", 992], ["baseline", 996], ["concentration", 1005], ["of", 1019], ["the", 1022], ["untreated", 1026], ["cultures", 1036], [".", 1044], ["Varespladib", 1046], ["and", 1058], ["poractant-", 1062], ["\u03b1", 1073], ["co", 1075], ["-", 1077], ["administration", 1078], ["reduces", 1093], ["sPLA2", 1101], ["activity", 1107], ["and", 1116], ["free", 1120], ["fatty", 1125], ["acids", 1131], ["release", 1137], ["in", 1145], ["cultured", 1148], ["rat", 1157], ["alveolar", 1161], ["macrophages", 1170], [",", 1181], ["although", 1183], ["a", 1192], ["clear", 1194], ["drug", 1200], ["synergy", 1205], ["was", 1213], ["not", 1217], ["evident", 1221], [".", 1228], ["Since", 1230], ["co", 1236], ["-", 1238], ["administration", 1239], ["may", 1254], ["be", 1258], ["useful", 1261], ["to", 1268], ["reduce", 1271], ["inflammation", 1278], ["and", 1291], ["surfactant", 1295], ["inactivation", 1306], ["in", 1319], ["acute", 1322], ["lung", 1328], ["injury", 1333], [",", 1339], ["further", 1341], ["in", 1349], ["vivo", 1352], ["studies", 1357], ["are", 1365], ["warranted", 1369], ["to", 1379], ["verify", 1382], ["its", 1389], ["clinical", 1393], ["usefulness", 1402], [".", 1412]]}
{"context": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML). Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients. Twelve chronic-phase patients initially receiving 400 mg/day and 4 patients with accelerated phase initially receiving either 400 mg/day (two patients) or 600 mg/day (two patients) had their dose increased (14 to 800 mg/day and 2 to 600 mg/day) because of progressive disease (usually clonal evolution) or inadequate cytogenetic response after at least 1 year of therapy. Six patients had major cytogenetic responses after dose increase (3 complete and 3 partial). Two others had minor cytogenetic responses. Two patients with clonal evolution transiently lost the additional clonal aberrations. Almost all of the responses occurred within 6 months, and were typically 3-6 months in duration. However, 3 patients have continuing major cytogenetic responses of >18 months duration. Dose increase was well tolerated, with thrombocytopenia, mild leukopenia, and exacerbation of prior edema being the most common adverse events. Although increasing the dose of imatinib can benefit a subgroup of patients with CML with either an inadequate cytogenetic response or disease progression, our results suggest the majority will not have a sustained meaningful response, and that other options, such as allogeneic stem cell transplant or investigational therapies, also need to be considered at the time of dose increase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "52dc16109e66480083c5d9ca84eb049e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[12, 14]], "char_spans": [[76, 82]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["tyrosine", 23], ["kinase", 32], ["inhibitor", 39], ["with", 49], ["high", 54], ["affinity", 59], ["for", 68], ["the", 72], ["BCR", 76], ["-", 79], ["ABL", 80], ["fusion", 84], ["protein", 91], ["expressed", 99], ["by", 109], ["the", 112], ["hematopoietic", 116], ["cells", 130], ["in", 136], ["chronic", 139], ["myelogenous", 147], ["leukemia", 159], ["(", 168], ["CML", 169], [")", 172], [".", 173], ["Some", 175], ["patients", 180], ["with", 189], ["chronic", 194], ["-", 201], ["phase", 202], ["or", 208], ["accelerated", 211], ["-", 222], ["phase", 223], ["CML", 229], ["either", 233], ["relapse", 240], ["after", 248], ["an", 254], ["initial", 257], ["response", 265], ["or", 274], ["are", 277], ["refractory", 281], ["to", 292], ["imatinib", 295], [",", 303], ["prompting", 305], ["us", 315], ["to", 318], ["evaluate", 321], ["the", 330], ["efficacy", 334], ["of", 343], ["dose", 346], ["increase", 351], ["in", 360], ["such", 363], ["patients", 368], [".", 376], ["Twelve", 378], ["chronic", 385], ["-", 392], ["phase", 393], ["patients", 399], ["initially", 408], ["receiving", 418], ["400", 428], ["mg", 432], ["/", 434], ["day", 435], ["and", 439], ["4", 443], ["patients", 445], ["with", 454], ["accelerated", 459], ["phase", 471], ["initially", 477], ["receiving", 487], ["either", 497], ["400", 504], ["mg", 508], ["/", 510], ["day", 511], ["(", 515], ["two", 516], ["patients", 520], [")", 528], ["or", 530], ["600", 533], ["mg", 537], ["/", 539], ["day", 540], ["(", 544], ["two", 545], ["patients", 549], [")", 557], ["had", 559], ["their", 563], ["dose", 569], ["increased", 574], ["(", 584], ["14", 585], ["to", 588], ["800", 591], ["mg", 595], ["/", 597], ["day", 598], ["and", 602], ["2", 606], ["to", 608], ["600", 611], ["mg", 615], ["/", 617], ["day", 618], [")", 621], ["because", 623], ["of", 631], ["progressive", 634], ["disease", 646], ["(", 654], ["usually", 655], ["clonal", 663], ["evolution", 670], [")", 679], ["or", 681], ["inadequate", 684], ["cytogenetic", 695], ["response", 707], ["after", 716], ["at", 722], ["least", 725], ["1", 731], ["year", 733], ["of", 738], ["therapy", 741], [".", 748], ["Six", 750], ["patients", 754], ["had", 763], ["major", 767], ["cytogenetic", 773], ["responses", 785], ["after", 795], ["dose", 801], ["increase", 806], ["(", 815], ["3", 816], ["complete", 818], ["and", 827], ["3", 831], ["partial", 833], [")", 840], [".", 841], ["Two", 843], ["others", 847], ["had", 854], ["minor", 858], ["cytogenetic", 864], ["responses", 876], [".", 885], ["Two", 887], ["patients", 891], ["with", 900], ["clonal", 905], ["evolution", 912], ["transiently", 922], ["lost", 934], ["the", 939], ["additional", 943], ["clonal", 954], ["aberrations", 961], [".", 972], ["Almost", 974], ["all", 981], ["of", 985], ["the", 988], ["responses", 992], ["occurred", 1002], ["within", 1011], ["6", 1018], ["months", 1020], [",", 1026], ["and", 1028], ["were", 1032], ["typically", 1037], ["3", 1047], ["-", 1048], ["6", 1049], ["months", 1051], ["in", 1058], ["duration", 1061], [".", 1069], ["However", 1071], [",", 1078], ["3", 1080], ["patients", 1082], ["have", 1091], ["continuing", 1096], ["major", 1107], ["cytogenetic", 1113], ["responses", 1125], ["of", 1135], [">", 1138], ["18", 1139], ["months", 1142], ["duration", 1149], [".", 1157], ["Dose", 1159], ["increase", 1164], ["was", 1173], ["well", 1177], ["tolerated", 1182], [",", 1191], ["with", 1193], ["thrombocytopenia", 1198], [",", 1214], ["mild", 1216], ["leukopenia", 1221], [",", 1231], ["and", 1233], ["exacerbation", 1237], ["of", 1250], ["prior", 1253], ["edema", 1259], ["being", 1265], ["the", 1271], ["most", 1275], ["common", 1280], ["adverse", 1287], ["events", 1295], [".", 1301], ["Although", 1303], ["increasing", 1312], ["the", 1323], ["dose", 1327], ["of", 1332], ["imatinib", 1335], ["can", 1344], ["benefit", 1348], ["a", 1356], ["subgroup", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["CML", 1384], ["with", 1388], ["either", 1393], ["an", 1400], ["inadequate", 1403], ["cytogenetic", 1414], ["response", 1426], ["or", 1435], ["disease", 1438], ["progression", 1446], [",", 1457], ["our", 1459], ["results", 1463], ["suggest", 1471], ["the", 1479], ["majority", 1483], ["will", 1492], ["not", 1497], ["have", 1501], ["a", 1506], ["sustained", 1508], ["meaningful", 1518], ["response", 1529], [",", 1537], ["and", 1539], ["that", 1543], ["other", 1548], ["options", 1554], [",", 1561], ["such", 1563], ["as", 1568], ["allogeneic", 1571], ["stem", 1582], ["cell", 1587], ["transplant", 1592], ["or", 1603], ["investigational", 1606], ["therapies", 1622], [",", 1631], ["also", 1633], ["need", 1638], ["to", 1643], ["be", 1646], ["considered", 1649], ["at", 1660], ["the", 1663], ["time", 1667], ["of", 1672], ["dose", 1675], ["increase", 1680], [".", 1688]]}
{"context": "The large size of spectrin, the flexible protein promoting reversible deformation of red cells, has been an obstacle to elucidating the molecular mechanism of its function. By studying cloned fragments of the repeating unit domain, we have found a correspondence between positions of selected spectrin repeats in a tetramer with their stabilities of folding. Six fragments consisting of two spectrin repeats were selected for study primarily on the basis of the predicted secondary structures of their linker regions. Fragments with a putatively helical linker were more stable to urea- and heat-induced unfolding than those with a putatively nonhelical linker. Two of the less stably folded fragments, human erythroid alpha-spectrin repeats 13 and 14 (HEalpha13,14) and human erythroid beta-spectrin repeats 8 and 9 (HEbeta8,9), are located opposite each other on antiparallel spectrin dimers. At least partial unfolding of these repeats under physiological conditions indicates that they may serve as a hinge. Also less stably folded, the fragment of human erythroid alpha-spectrin repeats 4 and 5 (HEalpha4,5) lies opposite the site of interaction between the partial repeats at the C- and N-terminal ends of beta- and alpha-spectrin, respectively, on the opposing dimer. More stably folded fragments, human erythroid alpha-spectrin repeats 1 and 2 (HEalpha1,2) and human erythroid alpha-spectrin repeats 2 and 3 (HEalpha2,3), lie nearly opposite each other on antiparallel spectrin dimers of a tetramer. These clusterings along the spectrin tetramer of repeats with similar stabilities of folding may have relevance for spectrin function, particularly for its well known flexibility.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "47e09473d3cd4d209e14ce17285a816e", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[148, 148], [260, 260]], "char_spans": [[865, 876], [1464, 1475]]}]}], "context_tokens": [["The", 0], ["large", 4], ["size", 10], ["of", 15], ["spectrin", 18], [",", 26], ["the", 28], ["flexible", 32], ["protein", 41], ["promoting", 49], ["reversible", 59], ["deformation", 70], ["of", 82], ["red", 85], ["cells", 89], [",", 94], ["has", 96], ["been", 100], ["an", 105], ["obstacle", 108], ["to", 117], ["elucidating", 120], ["the", 132], ["molecular", 136], ["mechanism", 146], ["of", 156], ["its", 159], ["function", 163], [".", 171], ["By", 173], ["studying", 176], ["cloned", 185], ["fragments", 192], ["of", 202], ["the", 205], ["repeating", 209], ["unit", 219], ["domain", 224], [",", 230], ["we", 232], ["have", 235], ["found", 240], ["a", 246], ["correspondence", 248], ["between", 263], ["positions", 271], ["of", 281], ["selected", 284], ["spectrin", 293], ["repeats", 302], ["in", 310], ["a", 313], ["tetramer", 315], ["with", 324], ["their", 329], ["stabilities", 335], ["of", 347], ["folding", 350], [".", 357], ["Six", 359], ["fragments", 363], ["consisting", 373], ["of", 384], ["two", 387], ["spectrin", 391], ["repeats", 400], ["were", 408], ["selected", 413], ["for", 422], ["study", 426], ["primarily", 432], ["on", 442], ["the", 445], ["basis", 449], ["of", 455], ["the", 458], ["predicted", 462], ["secondary", 472], ["structures", 482], ["of", 493], ["their", 496], ["linker", 502], ["regions", 509], [".", 516], ["Fragments", 518], ["with", 528], ["a", 533], ["putatively", 535], ["helical", 546], ["linker", 554], ["were", 561], ["more", 566], ["stable", 571], ["to", 578], ["urea-", 581], ["and", 587], ["heat", 591], ["-", 595], ["induced", 596], ["unfolding", 604], ["than", 614], ["those", 619], ["with", 625], ["a", 630], ["putatively", 632], ["nonhelical", 643], ["linker", 654], [".", 660], ["Two", 662], ["of", 666], ["the", 669], ["less", 673], ["stably", 678], ["folded", 685], ["fragments", 692], [",", 701], ["human", 703], ["erythroid", 709], ["alpha", 719], ["-", 724], ["spectrin", 725], ["repeats", 734], ["13", 742], ["and", 745], ["14", 749], ["(", 752], ["HEalpha13,14", 753], [")", 765], ["and", 767], ["human", 771], ["erythroid", 777], ["beta", 787], ["-", 791], ["spectrin", 792], ["repeats", 801], ["8", 809], ["and", 811], ["9", 815], ["(", 817], ["HEbeta8,9", 818], [")", 827], [",", 828], ["are", 830], ["located", 834], ["opposite", 842], ["each", 851], ["other", 856], ["on", 862], ["antiparallel", 865], ["spectrin", 878], ["dimers", 887], [".", 893], ["At", 895], ["least", 898], ["partial", 904], ["unfolding", 912], ["of", 922], ["these", 925], ["repeats", 931], ["under", 939], ["physiological", 945], ["conditions", 959], ["indicates", 970], ["that", 980], ["they", 985], ["may", 990], ["serve", 994], ["as", 1000], ["a", 1003], ["hinge", 1005], [".", 1010], ["Also", 1012], ["less", 1017], ["stably", 1022], ["folded", 1029], [",", 1035], ["the", 1037], ["fragment", 1041], ["of", 1050], ["human", 1053], ["erythroid", 1059], ["alpha", 1069], ["-", 1074], ["spectrin", 1075], ["repeats", 1084], ["4", 1092], ["and", 1094], ["5", 1098], ["(", 1100], ["HEalpha4,5", 1101], [")", 1111], ["lies", 1113], ["opposite", 1118], ["the", 1127], ["site", 1131], ["of", 1136], ["interaction", 1139], ["between", 1151], ["the", 1159], ["partial", 1163], ["repeats", 1171], ["at", 1179], ["the", 1182], ["C-", 1186], ["and", 1189], ["N", 1193], ["-", 1194], ["terminal", 1195], ["ends", 1204], ["of", 1209], ["beta-", 1212], ["and", 1218], ["alpha", 1222], ["-", 1227], ["spectrin", 1228], [",", 1236], ["respectively", 1238], [",", 1250], ["on", 1252], ["the", 1255], ["opposing", 1259], ["dimer", 1268], [".", 1273], ["More", 1275], ["stably", 1280], ["folded", 1287], ["fragments", 1294], [",", 1303], ["human", 1305], ["erythroid", 1311], ["alpha", 1321], ["-", 1326], ["spectrin", 1327], ["repeats", 1336], ["1", 1344], ["and", 1346], ["2", 1350], ["(", 1352], ["HEalpha1,2", 1353], [")", 1363], ["and", 1365], ["human", 1369], ["erythroid", 1375], ["alpha", 1385], ["-", 1390], ["spectrin", 1391], ["repeats", 1400], ["2", 1408], ["and", 1410], ["3", 1414], ["(", 1416], ["HEalpha2,3", 1417], [")", 1427], [",", 1428], ["lie", 1430], ["nearly", 1434], ["opposite", 1441], ["each", 1450], ["other", 1455], ["on", 1461], ["antiparallel", 1464], ["spectrin", 1477], ["dimers", 1486], ["of", 1493], ["a", 1496], ["tetramer", 1498], [".", 1506], ["These", 1508], ["clusterings", 1514], ["along", 1526], ["the", 1532], ["spectrin", 1536], ["tetramer", 1545], ["of", 1554], ["repeats", 1557], ["with", 1565], ["similar", 1570], ["stabilities", 1578], ["of", 1590], ["folding", 1593], ["may", 1601], ["have", 1605], ["relevance", 1610], ["for", 1620], ["spectrin", 1624], ["function", 1633], [",", 1641], ["particularly", 1643], ["for", 1656], ["its", 1660], ["well", 1664], ["known", 1669], ["flexibility", 1675], [".", 1686]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "Recurrent syncope, malignant ventricular arrhythmias, and sudden death are complications of the long QT syndrome (LQTS). Two well-known syndromes with long QT intervals are known. The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. In the present study assessment was performed of the diagnostic importance of the ventricular derepolarization parameters, clinical features, and prevalence of JLNS among 132 children with congenital hearing loss (CHL). In the CHL group the mean QT, QTc, JT, and JTc intervals and the dispersion values (QT-d, JT-d, QTc-d, and JTc-d) were significantly longer than those of control subjects (n = 96) (P < 0.05). Patients with CHL and JLNS (n = 5) had significantly longer mean values of QT, QTc, JT, and JTc intervals and dispersion values than those of CHL without JLNS (n = 127) and control subjects (P < 0.05). The results suggest that assessment of ventricular derepolarization parameters in children with CHL will be helpful in the early detection of JLNS because infants with CHL cannot accurately describe the symptoms of syncope.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "e5d58ee5c70045e09f9863cc375814b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[74, 76]], "char_spans": [[400, 417]]}]}], "context_tokens": [["Recurrent", 0], ["syncope", 10], [",", 17], ["malignant", 19], ["ventricular", 29], ["arrhythmias", 41], [",", 52], ["and", 54], ["sudden", 58], ["death", 65], ["are", 71], ["complications", 75], ["of", 89], ["the", 92], ["long", 96], ["QT", 101], ["syndrome", 104], ["(", 113], ["LQTS", 114], [")", 118], [".", 119], ["Two", 121], ["well", 125], ["-", 129], ["known", 130], ["syndromes", 136], ["with", 146], ["long", 151], ["QT", 156], ["intervals", 159], ["are", 169], ["known", 173], [".", 178], ["The", 180], ["Jervell", 184], ["and", 192], ["Lange", 196], ["-", 201], ["Nielsen", 202], ["syndrome", 210], ["(", 219], ["JLNS", 220], [")", 224], ["is", 226], ["characterized", 229], ["by", 243], ["prolongation", 246], ["of", 259], ["the", 262], ["QT", 266], ["interval", 269], [",", 277], ["deafness", 279], [",", 287], ["and", 289], ["autosomal", 293], ["-", 302], ["recessive", 303], ["inheritance", 313], [",", 324], ["and", 326], ["the", 330], ["Romano", 334], ["-", 340], ["Ward", 341], ["syndrome", 346], ["is", 355], ["characterized", 358], ["by", 372], ["a", 375], ["prolonged", 377], ["QT", 387], ["interval", 390], [",", 398], ["autosomal", 400], ["-", 409], ["dominant", 410], ["inheritance", 419], [",", 430], ["and", 432], ["no", 436], ["deafness", 439], [".", 447], ["In", 449], ["the", 452], ["present", 456], ["study", 464], ["assessment", 470], ["was", 481], ["performed", 485], ["of", 495], ["the", 498], ["diagnostic", 502], ["importance", 513], ["of", 524], ["the", 527], ["ventricular", 531], ["derepolarization", 543], ["parameters", 560], [",", 570], ["clinical", 572], ["features", 581], [",", 589], ["and", 591], ["prevalence", 595], ["of", 606], ["JLNS", 609], ["among", 614], ["132", 620], ["children", 624], ["with", 633], ["congenital", 638], ["hearing", 649], ["loss", 657], ["(", 662], ["CHL", 663], [")", 666], [".", 667], ["In", 669], ["the", 672], ["CHL", 676], ["group", 680], ["the", 686], ["mean", 690], ["QT", 695], [",", 697], ["QTc", 699], [",", 702], ["JT", 704], [",", 706], ["and", 708], ["JTc", 712], ["intervals", 716], ["and", 726], ["the", 730], ["dispersion", 734], ["values", 745], ["(", 752], ["QT", 753], ["-", 755], ["d", 756], [",", 757], ["JT", 759], ["-", 761], ["d", 762], [",", 763], ["QTc", 765], ["-", 768], ["d", 769], [",", 770], ["and", 772], ["JTc", 776], ["-", 779], ["d", 780], [")", 781], ["were", 783], ["significantly", 788], ["longer", 802], ["than", 809], ["those", 814], ["of", 820], ["control", 823], ["subjects", 831], ["(", 840], ["n", 841], ["=", 843], ["96", 845], [")", 847], ["(", 849], ["P", 850], ["<", 852], ["0.05", 854], [")", 858], [".", 859], ["Patients", 861], ["with", 870], ["CHL", 875], ["and", 879], ["JLNS", 883], ["(", 888], ["n", 889], ["=", 891], ["5", 893], [")", 894], ["had", 896], ["significantly", 900], ["longer", 914], ["mean", 921], ["values", 926], ["of", 933], ["QT", 936], [",", 938], ["QTc", 940], [",", 943], ["JT", 945], [",", 947], ["and", 949], ["JTc", 953], ["intervals", 957], ["and", 967], ["dispersion", 971], ["values", 982], ["than", 989], ["those", 994], ["of", 1000], ["CHL", 1003], ["without", 1007], ["JLNS", 1015], ["(", 1020], ["n", 1021], ["=", 1023], ["127", 1025], [")", 1028], ["and", 1030], ["control", 1034], ["subjects", 1042], ["(", 1051], ["P", 1052], ["<", 1054], ["0.05", 1056], [")", 1060], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["assessment", 1088], ["of", 1099], ["ventricular", 1102], ["derepolarization", 1114], ["parameters", 1131], ["in", 1142], ["children", 1145], ["with", 1154], ["CHL", 1159], ["will", 1163], ["be", 1168], ["helpful", 1171], ["in", 1179], ["the", 1182], ["early", 1186], ["detection", 1192], ["of", 1202], ["JLNS", 1205], ["because", 1210], ["infants", 1218], ["with", 1226], ["CHL", 1231], ["can", 1235], ["not", 1238], ["accurately", 1242], ["describe", 1253], ["the", 1262], ["symptoms", 1266], ["of", 1275], ["syncope", 1278], [".", 1285]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "Iron is the most important transitional metal in the body, as it is implicated in many metabolic processes, mostly related to its capacity as an electron donor/acceptor. Iron deficiency has been long been known to cause anaemia, iron excess to cause haemochromatosis. As excess free iron can cause oxidative damage, it is important that the levels of iron in the body are tightly regulated which appears to be done only by digestive absorption, as there is no known regulating mechanism for elimination of iron. The amount of free iron is also kept to a minimum thanks to binding to transferrin for transport, and to ferritin for storage. Recent research has put emphasis on the possible role of excess iron in the brain in several degenerative diseases. Iron deficiency in the central nervous system is known to cause motor impairment and cognitive deficits; more recently, it has been suggested that it may play a role in the pathophysiology of the restless leg syndrome. 2001 Harcourt Publishers Ltd", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "a60d3d614fee41baa0ba11c2f3e0061f", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [32, 32], [43, 43], [139, 139], [52, 52], [92, 92], [98, 98], [130, 130], [65, 65]], "char_spans": [[0, 3], [170, 173], [229, 232], [755, 758], [283, 286], [506, 509], [531, 534], [703, 706], [351, 354]]}]}], "context_tokens": [["Iron", 0], ["is", 5], ["the", 8], ["most", 12], ["important", 17], ["transitional", 27], ["metal", 40], ["in", 46], ["the", 49], ["body", 53], [",", 57], ["as", 59], ["it", 62], ["is", 65], ["implicated", 68], ["in", 79], ["many", 82], ["metabolic", 87], ["processes", 97], [",", 106], ["mostly", 108], ["related", 115], ["to", 123], ["its", 126], ["capacity", 130], ["as", 139], ["an", 142], ["electron", 145], ["donor", 154], ["/", 159], ["acceptor", 160], [".", 168], ["Iron", 170], ["deficiency", 175], ["has", 186], ["been", 190], ["long", 195], ["been", 200], ["known", 205], ["to", 211], ["cause", 214], ["anaemia", 220], [",", 227], ["iron", 229], ["excess", 234], ["to", 241], ["cause", 244], ["haemochromatosis", 250], [".", 266], ["As", 268], ["excess", 271], ["free", 278], ["iron", 283], ["can", 288], ["cause", 292], ["oxidative", 298], ["damage", 308], [",", 314], ["it", 316], ["is", 319], ["important", 322], ["that", 332], ["the", 337], ["levels", 341], ["of", 348], ["iron", 351], ["in", 356], ["the", 359], ["body", 363], ["are", 368], ["tightly", 372], ["regulated", 380], ["which", 390], ["appears", 396], ["to", 404], ["be", 407], ["done", 410], ["only", 415], ["by", 420], ["digestive", 423], ["absorption", 433], [",", 443], ["as", 445], ["there", 448], ["is", 454], ["no", 457], ["known", 460], ["regulating", 466], ["mechanism", 477], ["for", 487], ["elimination", 491], ["of", 503], ["iron", 506], [".", 510], ["The", 512], ["amount", 516], ["of", 523], ["free", 526], ["iron", 531], ["is", 536], ["also", 539], ["kept", 544], ["to", 549], ["a", 552], ["minimum", 554], ["thanks", 562], ["to", 569], ["binding", 572], ["to", 580], ["transferrin", 583], ["for", 595], ["transport", 599], [",", 608], ["and", 610], ["to", 614], ["ferritin", 617], ["for", 626], ["storage", 630], [".", 637], ["Recent", 639], ["research", 646], ["has", 655], ["put", 659], ["emphasis", 663], ["on", 672], ["the", 675], ["possible", 679], ["role", 688], ["of", 693], ["excess", 696], ["iron", 703], ["in", 708], ["the", 711], ["brain", 715], ["in", 721], ["several", 724], ["degenerative", 732], ["diseases", 745], [".", 753], ["Iron", 755], ["deficiency", 760], ["in", 771], ["the", 774], ["central", 778], ["nervous", 786], ["system", 794], ["is", 801], ["known", 804], ["to", 810], ["cause", 813], ["motor", 819], ["impairment", 825], ["and", 836], ["cognitive", 840], ["deficits", 850], [";", 858], ["more", 860], ["recently", 865], [",", 873], ["it", 875], ["has", 878], ["been", 882], ["suggested", 887], ["that", 897], ["it", 902], ["may", 905], ["play", 909], ["a", 914], ["role", 916], ["in", 921], ["the", 924], ["pathophysiology", 928], ["of", 944], ["the", 947], ["restless", 951], ["leg", 960], ["syndrome", 964], [".", 972], ["2001", 974], ["Harcourt", 979], ["Publishers", 988], ["Ltd", 999]]}
{"context": "The performance of two proteomic sample preparation methods, \"pseudoshotgun\" (PSG) and filter-aided sample preparation (FASP) were compared in terms of the number of identified proteins, representation of cellular component GO (gene ontology) categories in the obtained list of proteins, and the efficiency of both methods in the proteomic analysis of a very low number of cells. Both methods were combined to obtain a proteomic profile of a short-term culture (passage 3) of melanoma cells, established in our laboratory from a human metastatic melanoma lesion. The data revealed that with FASP, usually more proteins are identified than with PSG when analyzing a higher number of cells (\u2265 5000/injection), whereas PSG is favorable when analyzing only a very small amount of cells (250-500/injection). PSG and FASP, however, are complementary techniques, as combining both methods further increases the number of identified proteins. Moreover, we show that it is feasible to identify a substantial number of proteins from only 250 cells/injection that is equivalent to 60 ng of protein.", "qas": [{"question": "What is the method FASP used for?", "answers": ["proteomic sample preparation"], "qid": "302b827bb3634be7b8c958d4d56fa6da", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["method", 12], ["FASP", 19], ["used", 24], ["for", 29], ["?", 32]], "detected_answers": [{"text": "proteomic sample preparation", "token_spans": [[4, 6]], "char_spans": [[23, 50]]}]}], "context_tokens": [["The", 0], ["performance", 4], ["of", 16], ["two", 19], ["proteomic", 23], ["sample", 33], ["preparation", 40], ["methods", 52], [",", 59], ["\"", 61], ["pseudoshotgun", 62], ["\"", 75], ["(", 77], ["PSG", 78], [")", 81], ["and", 83], ["filter", 87], ["-", 93], ["aided", 94], ["sample", 100], ["preparation", 107], ["(", 119], ["FASP", 120], [")", 124], ["were", 126], ["compared", 131], ["in", 140], ["terms", 143], ["of", 149], ["the", 152], ["number", 156], ["of", 163], ["identified", 166], ["proteins", 177], [",", 185], ["representation", 187], ["of", 202], ["cellular", 205], ["component", 214], ["GO", 224], ["(", 227], ["gene", 228], ["ontology", 233], [")", 241], ["categories", 243], ["in", 254], ["the", 257], ["obtained", 261], ["list", 270], ["of", 275], ["proteins", 278], [",", 286], ["and", 288], ["the", 292], ["efficiency", 296], ["of", 307], ["both", 310], ["methods", 315], ["in", 323], ["the", 326], ["proteomic", 330], ["analysis", 340], ["of", 349], ["a", 352], ["very", 354], ["low", 359], ["number", 363], ["of", 370], ["cells", 373], [".", 378], ["Both", 380], ["methods", 385], ["were", 393], ["combined", 398], ["to", 407], ["obtain", 410], ["a", 417], ["proteomic", 419], ["profile", 429], ["of", 437], ["a", 440], ["short", 442], ["-", 447], ["term", 448], ["culture", 453], ["(", 461], ["passage", 462], ["3", 470], [")", 471], ["of", 473], ["melanoma", 476], ["cells", 485], [",", 490], ["established", 492], ["in", 504], ["our", 507], ["laboratory", 511], ["from", 522], ["a", 527], ["human", 529], ["metastatic", 535], ["melanoma", 546], ["lesion", 555], [".", 561], ["The", 563], ["data", 567], ["revealed", 572], ["that", 581], ["with", 586], ["FASP", 591], [",", 595], ["usually", 597], ["more", 605], ["proteins", 610], ["are", 619], ["identified", 623], ["than", 634], ["with", 639], ["PSG", 644], ["when", 648], ["analyzing", 653], ["a", 663], ["higher", 665], ["number", 672], ["of", 679], ["cells", 682], ["(", 688], ["\u2265", 689], ["5000/injection", 691], [")", 705], [",", 706], ["whereas", 708], ["PSG", 716], ["is", 720], ["favorable", 723], ["when", 733], ["analyzing", 738], ["only", 748], ["a", 753], ["very", 755], ["small", 760], ["amount", 766], ["of", 773], ["cells", 776], ["(", 782], ["250", 783], ["-", 786], ["500/injection", 787], [")", 800], [".", 801], ["PSG", 803], ["and", 807], ["FASP", 811], [",", 815], ["however", 817], [",", 824], ["are", 826], ["complementary", 830], ["techniques", 844], [",", 854], ["as", 856], ["combining", 859], ["both", 869], ["methods", 874], ["further", 882], ["increases", 890], ["the", 900], ["number", 904], ["of", 911], ["identified", 914], ["proteins", 925], [".", 933], ["Moreover", 935], [",", 943], ["we", 945], ["show", 948], ["that", 953], ["it", 958], ["is", 961], ["feasible", 964], ["to", 973], ["identify", 976], ["a", 985], ["substantial", 987], ["number", 999], ["of", 1006], ["proteins", 1009], ["from", 1018], ["only", 1023], ["250", 1028], ["cells", 1032], ["/", 1037], ["injection", 1038], ["that", 1048], ["is", 1053], ["equivalent", 1056], ["to", 1067], ["60", 1070], ["ng", 1073], ["of", 1076], ["protein", 1079], [".", 1086]]}
{"context": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose. Flumazenil is known to induce cardiac arythmias and seizures, in part because of drug interactions. We present a 75-year-old woman, who was brought to the Emergency Department with a drug overdose following a suicide attempt. She developed generalized seizures shortly after the administration of flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b31d0f65b3754a4091a4d59b39e2a6a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[24, 24], [0, 0], [74, 74]], "char_spans": [[153, 162], [0, 9], [450, 459]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["benzodiazepine", 16], ["antagonist", 31], [".", 41], ["It", 43], ["is", 46], ["widely", 49], ["used", 56], ["as", 61], ["an", 64], ["antidote", 67], ["in", 76], ["comatose", 79], ["patients", 88], ["suspected", 97], ["of", 107], ["having", 110], ["ingested", 117], ["a", 126], ["benzodiazepine", 128], ["overdose", 143], [".", 151], ["Flumazenil", 153], ["is", 164], ["known", 167], ["to", 173], ["induce", 176], ["cardiac", 183], ["arythmias", 191], ["and", 201], ["seizures", 205], [",", 213], ["in", 215], ["part", 218], ["because", 223], ["of", 231], ["drug", 234], ["interactions", 239], [".", 251], ["We", 253], ["present", 256], ["a", 264], ["75-year", 266], ["-", 273], ["old", 274], ["woman", 278], [",", 283], ["who", 285], ["was", 289], ["brought", 293], ["to", 301], ["the", 304], ["Emergency", 308], ["Department", 318], ["with", 329], ["a", 334], ["drug", 336], ["overdose", 341], ["following", 350], ["a", 360], ["suicide", 362], ["attempt", 370], [".", 377], ["She", 379], ["developed", 383], ["generalized", 393], ["seizures", 405], ["shortly", 414], ["after", 422], ["the", 428], ["administration", 432], ["of", 447], ["flumazenil", 450], [".", 460]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "The purpose of this study is to determine the sensibility of each imaging tool in identifying focal cortical dysplasia (FCD) in children and adolescents with epilepsy and to define the prognostic factors of pediatric and adolescent epilepsy surgery. We identified 48 children with FCD who underwent resective surgery and analyzed their preoperative data. The results of various anatomic and functional neuroimaging studies were compared for accuracy in locating the lesion. We also investigated clinical factors that affected the outcome of surgical treatment. Brain magnetic resonance imaging (MRI) was able to localize FCD in 30 patients and fluorodeoxyglucose positron emission tomography (FDG-PET) and/or subtraction ictal single photon emission computed tomography (SPECT) coregistered with MRI provided additional information that helped to define the lesion in 13 patients. When comparing the pathologic results between a mild malformation of cortical development (MCD) and FCD type I and II, we noted a strong tendency for patients with FCD to have MRI abnormalities (p = 0.005). In addition, severe pathologic features (Palmini's classification, FCD type II) (p = 0.025) showed significant correlation with a better surgical outcome. To define the primary epileptogenic area, various interictal epileptiform discharges and the results of multimodal neuroimaging studies were helpful, and younger age at the time of operation could aid in more favorable surgical outcomes (p = 0.048). Our study showed a significant relationship between pathologic grade and the detectability of FCD by brain MRI. In addition, early surgery can be justified by showing that advanced neuroimaging studies in children with FCD and even with extensive epileptiform discharges have a higher rate of success.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "4e97ba94bae54666969f2d440b9221ff", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[16, 18]], "char_spans": [[94, 117]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["is", 26], ["to", 29], ["determine", 32], ["the", 42], ["sensibility", 46], ["of", 58], ["each", 61], ["imaging", 66], ["tool", 74], ["in", 79], ["identifying", 82], ["focal", 94], ["cortical", 100], ["dysplasia", 109], ["(", 119], ["FCD", 120], [")", 123], ["in", 125], ["children", 128], ["and", 137], ["adolescents", 141], ["with", 153], ["epilepsy", 158], ["and", 167], ["to", 171], ["define", 174], ["the", 181], ["prognostic", 185], ["factors", 196], ["of", 204], ["pediatric", 207], ["and", 217], ["adolescent", 221], ["epilepsy", 232], ["surgery", 241], [".", 248], ["We", 250], ["identified", 253], ["48", 264], ["children", 267], ["with", 276], ["FCD", 281], ["who", 285], ["underwent", 289], ["resective", 299], ["surgery", 309], ["and", 317], ["analyzed", 321], ["their", 330], ["preoperative", 336], ["data", 349], [".", 353], ["The", 355], ["results", 359], ["of", 367], ["various", 370], ["anatomic", 378], ["and", 387], ["functional", 391], ["neuroimaging", 402], ["studies", 415], ["were", 423], ["compared", 428], ["for", 437], ["accuracy", 441], ["in", 450], ["locating", 453], ["the", 462], ["lesion", 466], [".", 472], ["We", 474], ["also", 477], ["investigated", 482], ["clinical", 495], ["factors", 504], ["that", 512], ["affected", 517], ["the", 526], ["outcome", 530], ["of", 538], ["surgical", 541], ["treatment", 550], [".", 559], ["Brain", 561], ["magnetic", 567], ["resonance", 576], ["imaging", 586], ["(", 594], ["MRI", 595], [")", 598], ["was", 600], ["able", 604], ["to", 609], ["localize", 612], ["FCD", 621], ["in", 625], ["30", 628], ["patients", 631], ["and", 640], ["fluorodeoxyglucose", 644], ["positron", 663], ["emission", 672], ["tomography", 681], ["(", 692], ["FDG", 693], ["-", 696], ["PET", 697], [")", 700], ["and/or", 702], ["subtraction", 709], ["ictal", 721], ["single", 727], ["photon", 734], ["emission", 741], ["computed", 750], ["tomography", 759], ["(", 770], ["SPECT", 771], [")", 776], ["coregistered", 778], ["with", 791], ["MRI", 796], ["provided", 800], ["additional", 809], ["information", 820], ["that", 832], ["helped", 837], ["to", 844], ["define", 847], ["the", 854], ["lesion", 858], ["in", 865], ["13", 868], ["patients", 871], [".", 879], ["When", 881], ["comparing", 886], ["the", 896], ["pathologic", 900], ["results", 911], ["between", 919], ["a", 927], ["mild", 929], ["malformation", 934], ["of", 947], ["cortical", 950], ["development", 959], ["(", 971], ["MCD", 972], [")", 975], ["and", 977], ["FCD", 981], ["type", 985], ["I", 990], ["and", 992], ["II", 996], [",", 998], ["we", 1000], ["noted", 1003], ["a", 1009], ["strong", 1011], ["tendency", 1018], ["for", 1027], ["patients", 1031], ["with", 1040], ["FCD", 1045], ["to", 1049], ["have", 1052], ["MRI", 1057], ["abnormalities", 1061], ["(", 1075], ["p", 1076], ["=", 1078], ["0.005", 1080], [")", 1085], [".", 1086], ["In", 1088], ["addition", 1091], [",", 1099], ["severe", 1101], ["pathologic", 1108], ["features", 1119], ["(", 1128], ["Palmini", 1129], ["'s", 1136], ["classification", 1139], [",", 1153], ["FCD", 1155], ["type", 1159], ["II", 1164], [")", 1166], ["(", 1168], ["p", 1169], ["=", 1171], ["0.025", 1173], [")", 1178], ["showed", 1180], ["significant", 1187], ["correlation", 1199], ["with", 1211], ["a", 1216], ["better", 1218], ["surgical", 1225], ["outcome", 1234], [".", 1241], ["To", 1243], ["define", 1246], ["the", 1253], ["primary", 1257], ["epileptogenic", 1265], ["area", 1279], [",", 1283], ["various", 1285], ["interictal", 1293], ["epileptiform", 1304], ["discharges", 1317], ["and", 1328], ["the", 1332], ["results", 1336], ["of", 1344], ["multimodal", 1347], ["neuroimaging", 1358], ["studies", 1371], ["were", 1379], ["helpful", 1384], [",", 1391], ["and", 1393], ["younger", 1397], ["age", 1405], ["at", 1409], ["the", 1412], ["time", 1416], ["of", 1421], ["operation", 1424], ["could", 1434], ["aid", 1440], ["in", 1444], ["more", 1447], ["favorable", 1452], ["surgical", 1462], ["outcomes", 1471], ["(", 1480], ["p", 1481], ["=", 1483], ["0.048", 1485], [")", 1490], [".", 1491], ["Our", 1493], ["study", 1497], ["showed", 1503], ["a", 1510], ["significant", 1512], ["relationship", 1524], ["between", 1537], ["pathologic", 1545], ["grade", 1556], ["and", 1562], ["the", 1566], ["detectability", 1570], ["of", 1584], ["FCD", 1587], ["by", 1591], ["brain", 1594], ["MRI", 1600], [".", 1603], ["In", 1605], ["addition", 1608], [",", 1616], ["early", 1618], ["surgery", 1624], ["can", 1632], ["be", 1636], ["justified", 1639], ["by", 1649], ["showing", 1652], ["that", 1660], ["advanced", 1665], ["neuroimaging", 1674], ["studies", 1687], ["in", 1695], ["children", 1698], ["with", 1707], ["FCD", 1712], ["and", 1716], ["even", 1720], ["with", 1725], ["extensive", 1730], ["epileptiform", 1740], ["discharges", 1753], ["have", 1764], ["a", 1769], ["higher", 1771], ["rate", 1778], ["of", 1783], ["success", 1786], [".", 1793]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "1d0edfd264d5465fadb7c6268c608128", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[229, 232]], "char_spans": [[1388, 1401]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["formation", 51], ["of", 61], ["a", 64], ["BCR", 66], ["-", 69], ["ABL", 70], ["fusion", 74], ["gene", 81], [",", 85], ["usually", 87], ["as", 95], ["a", 98], ["consequence", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["(", 132], ["Ph", 133], [")", 135], ["translocation", 137], ["between", 151], ["chromosomes", 159], ["9", 171], ["and", 173], ["22", 177], [".", 179], ["Recently", 181], ["the", 190], ["development", 194], ["of", 206], ["new", 209], ["fluorescence", 213], ["in", 226], ["-", 228], ["situ", 229], ["hybridization", 234], ["(", 248], ["FISH", 249], [")", 253], ["techniques", 255], ["has", 266], ["allowed", 270], ["identification", 278], ["of", 293], ["unexpected", 296], ["deletions", 307], ["of", 317], ["the", 320], ["reciprocal", 324], ["translocation", 335], ["product", 349], [",", 356], ["the", 358], ["derivative", 362], ["chromosome", 373], ["9", 384], [",", 385], ["in", 387], ["10", 390], ["%", 392], ["to", 394], ["15", 397], ["%", 399], ["of", 401], ["patients", 404], ["with", 413], ["CML", 418], [".", 421], ["These", 423], ["deletions", 429], ["are", 439], ["large", 443], [",", 448], ["span", 450], ["the", 455], ["translocation", 459], ["breakpoint", 473], [",", 483], ["and", 485], ["occur", 489], ["at", 495], ["the", 498], ["same", 502], ["time", 507], ["as", 512], ["the", 515], ["Ph", 519], ["translocation", 522], [".", 535], ["Such", 537], ["deletions", 542], ["therefore", 552], ["give", 562], ["rise", 567], ["to", 572], ["previously", 575], ["unsuspected", 586], ["molecular", 598], ["heterogeneity", 608], ["from", 622], ["the", 627], ["very", 631], ["beginning", 636], ["of", 646], ["this", 649], ["disease", 654], [",", 661], ["and", 663], ["there", 667], ["is", 673], ["mounting", 676], ["evidence", 685], ["for", 694], ["similar", 698], ["deletions", 706], ["associated", 716], ["with", 727], ["other", 732], ["translocations", 738], [".", 752], ["Several", 754], ["studies", 762], ["have", 770], ["demonstrated", 775], ["that", 788], ["CML", 793], ["patients", 797], ["who", 806], ["carry", 810], ["derivative", 816], ["chromosome", 827], ["9", 838], ["deletions", 840], ["exhibit", 850], ["a", 858], ["more", 860], ["rapid", 865], ["progression", 871], ["to", 883], ["blast", 886], ["crisis", 892], ["and", 899], ["a", 903], ["shorter", 905], ["survival", 913], [".", 921], ["Deletion", 923], ["status", 932], ["is", 939], ["independent", 942], ["of", 954], [",", 956], ["and", 958], ["more", 962], ["powerful", 967], ["than", 976], [",", 980], ["the", 982], ["Sokal", 986], ["and", 992], ["Hasford", 996], ["/", 1003], ["European", 1004], ["prognostic", 1013], ["scoring", 1024], ["systems", 1032], [".", 1039], ["The", 1041], ["poor", 1045], ["prognosis", 1050], ["associated", 1060], ["with", 1071], ["deletions", 1076], ["is", 1086], ["seen", 1089], ["in", 1094], ["patients", 1097], ["treated", 1106], ["with", 1114], ["hydroxyurea", 1119], ["or", 1131], ["interferon", 1134], [",", 1144], ["and", 1146], ["preliminary", 1150], ["evidence", 1162], ["suggests", 1171], ["that", 1180], ["patients", 1185], ["with", 1194], ["deletions", 1199], ["may", 1209], ["also", 1213], ["have", 1218], ["a", 1223], ["worse", 1225], ["outcome", 1231], ["than", 1239], ["nondeleted", 1244], ["patients", 1255], ["following", 1264], ["stem", 1274], ["cell", 1279], ["transplantation", 1284], ["or", 1300], ["treatment", 1303], ["with", 1313], ["imatinib", 1318], [".", 1326], ["Poor", 1328], ["outcome", 1333], ["can", 1341], ["not", 1344], ["be", 1348], ["attributed", 1351], ["to", 1362], ["loss", 1365], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["fusion", 1396], ["gene", 1403], ["expression", 1408], ["alone", 1419], [",", 1424], ["and", 1426], ["is", 1430], ["likely", 1433], ["to", 1440], ["reflect", 1443], ["loss", 1451], ["of", 1456], ["one", 1459], ["or", 1463], ["more", 1466], ["critical", 1471], ["genes", 1480], ["within", 1486], ["the", 1493], ["deleted", 1497], ["region", 1505], [".", 1511], ["The", 1513], ["molecular", 1517], ["heterogeneity", 1527], ["associated", 1541], ["with", 1552], ["the", 1557], ["Philadelphia", 1561], ["translocation", 1574], ["provides", 1588], ["a", 1597], ["new", 1599], ["paradigm", 1603], ["with", 1612], ["potential", 1617], ["relevance", 1627], ["to", 1637], ["all", 1640], ["malignancies", 1644], ["associated", 1657], ["with", 1668], ["reciprocal", 1673], ["chromosomal", 1684], ["translocations", 1696], ["and/or", 1711], ["fusion", 1718], ["gene", 1725], ["formation", 1730], [".", 1739]]}
{"context": "Calcineurin signaling has been implicated in a broad spectrum of developmental processes in a variety of organ systems. Calcineurin is a calmodulin-dependent, calcium-activated protein phosphatase composed of catalytic and regulatory subunits. The serine/threonine-specific phosphatase functions within a signal transduction pathway that regulates gene expression and biological responses in many developmentally important cell types. Calcineurin signaling was first defined in T lymphocytes as a regulator of nuclear factor of activated T cells (NFAT) transcription factor nuclear translocation and activation. Recent studies have demonstrated the vital nature of calcium/calcineurin/NFAT signaling in cardiovascular and skeletal muscle development in vertebrates. Inhibition, mutation, or forced expression of calcineurin pathway genes result in defects or alterations in cardiomyocyte maturation, heart valve formation, vascular development, skeletal muscle differentiation and fiber-type switching, and cardiac and skeletal muscle hypertrophy. Conserved calcineurin genes are found in invertebrates such as Drosophila and Caenorhabditis elegans, and genetic studies have demonstrated specific myogenic functions for the phosphatase in their development. The ability to investigate calcineurin signaling pathways in vertebrates and model genetic organisms provides a great potential to more fully comprehend the functions of calcineurin and its interacting genes in heart, blood vessel, and muscle development.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "f5da104a83c341a2b668ac142d827213", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [160, 160], [19, 19], [192, 192], [124, 124], [212, 212], [103, 103], [65, 65]], "char_spans": [[0, 10], [1058, 1068], [120, 130], [1285, 1295], [812, 822], [1428, 1438], [673, 683], [435, 445]]}]}], "context_tokens": [["Calcineurin", 0], ["signaling", 12], ["has", 22], ["been", 26], ["implicated", 31], ["in", 42], ["a", 45], ["broad", 47], ["spectrum", 53], ["of", 62], ["developmental", 65], ["processes", 79], ["in", 89], ["a", 92], ["variety", 94], ["of", 102], ["organ", 105], ["systems", 111], [".", 118], ["Calcineurin", 120], ["is", 132], ["a", 135], ["calmodulin", 137], ["-", 147], ["dependent", 148], [",", 157], ["calcium", 159], ["-", 166], ["activated", 167], ["protein", 177], ["phosphatase", 185], ["composed", 197], ["of", 206], ["catalytic", 209], ["and", 219], ["regulatory", 223], ["subunits", 234], [".", 242], ["The", 244], ["serine", 248], ["/", 254], ["threonine", 255], ["-", 264], ["specific", 265], ["phosphatase", 274], ["functions", 286], ["within", 296], ["a", 303], ["signal", 305], ["transduction", 312], ["pathway", 325], ["that", 333], ["regulates", 338], ["gene", 348], ["expression", 353], ["and", 364], ["biological", 368], ["responses", 379], ["in", 389], ["many", 392], ["developmentally", 397], ["important", 413], ["cell", 423], ["types", 428], [".", 433], ["Calcineurin", 435], ["signaling", 447], ["was", 457], ["first", 461], ["defined", 467], ["in", 475], ["T", 478], ["lymphocytes", 480], ["as", 492], ["a", 495], ["regulator", 497], ["of", 507], ["nuclear", 510], ["factor", 518], ["of", 525], ["activated", 528], ["T", 538], ["cells", 540], ["(", 546], ["NFAT", 547], [")", 551], ["transcription", 553], ["factor", 567], ["nuclear", 574], ["translocation", 582], ["and", 596], ["activation", 600], [".", 610], ["Recent", 612], ["studies", 619], ["have", 627], ["demonstrated", 632], ["the", 645], ["vital", 649], ["nature", 655], ["of", 662], ["calcium", 665], ["/", 672], ["calcineurin", 673], ["/", 684], ["NFAT", 685], ["signaling", 690], ["in", 700], ["cardiovascular", 703], ["and", 718], ["skeletal", 722], ["muscle", 731], ["development", 738], ["in", 750], ["vertebrates", 753], [".", 764], ["Inhibition", 766], [",", 776], ["mutation", 778], [",", 786], ["or", 788], ["forced", 791], ["expression", 798], ["of", 809], ["calcineurin", 812], ["pathway", 824], ["genes", 832], ["result", 838], ["in", 845], ["defects", 848], ["or", 856], ["alterations", 859], ["in", 871], ["cardiomyocyte", 874], ["maturation", 888], [",", 898], ["heart", 900], ["valve", 906], ["formation", 912], [",", 921], ["vascular", 923], ["development", 932], [",", 943], ["skeletal", 945], ["muscle", 954], ["differentiation", 961], ["and", 977], ["fiber", 981], ["-", 986], ["type", 987], ["switching", 992], [",", 1001], ["and", 1003], ["cardiac", 1007], ["and", 1015], ["skeletal", 1019], ["muscle", 1028], ["hypertrophy", 1035], [".", 1046], ["Conserved", 1048], ["calcineurin", 1058], ["genes", 1070], ["are", 1076], ["found", 1080], ["in", 1086], ["invertebrates", 1089], ["such", 1103], ["as", 1108], ["Drosophila", 1111], ["and", 1122], ["Caenorhabditis", 1126], ["elegans", 1141], [",", 1148], ["and", 1150], ["genetic", 1154], ["studies", 1162], ["have", 1170], ["demonstrated", 1175], ["specific", 1188], ["myogenic", 1197], ["functions", 1206], ["for", 1216], ["the", 1220], ["phosphatase", 1224], ["in", 1236], ["their", 1239], ["development", 1245], [".", 1256], ["The", 1258], ["ability", 1262], ["to", 1270], ["investigate", 1273], ["calcineurin", 1285], ["signaling", 1297], ["pathways", 1307], ["in", 1316], ["vertebrates", 1319], ["and", 1331], ["model", 1335], ["genetic", 1341], ["organisms", 1349], ["provides", 1359], ["a", 1368], ["great", 1370], ["potential", 1376], ["to", 1386], ["more", 1389], ["fully", 1394], ["comprehend", 1400], ["the", 1411], ["functions", 1415], ["of", 1425], ["calcineurin", 1428], ["and", 1440], ["its", 1444], ["interacting", 1448], ["genes", 1460], ["in", 1466], ["heart", 1469], [",", 1474], ["blood", 1476], ["vessel", 1482], [",", 1488], ["and", 1490], ["muscle", 1494], ["development", 1501], [".", 1512]]}
{"context": "Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of AS do not have an identifiable molecular defect. It is likely that most of those individuals have an AS-like syndrome that is clinically and molecularly distinct from AS. These AS-like syndromes can be broadly classified into chromosomal microdeletion and microduplication syndromes, and single-gene disorders. The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan\u2013McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion). The single-gene disorders include Pitt\u2013Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat\u2013Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome. They also include disorders due to mutations in HERC2, adenylosuccinase lyase (ADSL), CDKL5, FOXG1, MECP2 (duplications), MEF2C, and ATRX. Although many of these single-gene disorders can be caused by chromosomal microdeletions resulting in haploinsufficiency of the critical gene, the individual disorders are often caused by intragenic mutations that cannot be detected by chromosomal microarray analysis. We provide an overview of the clinical features of these syndromes, comparing and contrasting them with AS, in the hope that it will help guide clinicians in the diagnostic work-up of individuals with AS-like syndromes.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "ddf1ff17a2ea4e5088dd93222e4a7289", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[149, 149]], "char_spans": [[879, 884]]}]}], "context_tokens": [["Angelman", 0], ["syndrome", 9], ["(", 18], ["AS", 19], [")", 21], ["is", 23], ["caused", 26], ["by", 33], ["a", 36], ["lack", 38], ["of", 43], ["expression", 46], ["of", 57], ["the", 60], ["maternally", 64], ["inherited", 75], ["UBE3A", 85], ["gene", 91], ["in", 96], ["the", 99], ["brain", 103], [".", 108], ["However", 110], [",", 117], ["about", 119], ["10", 125], ["%", 127], ["of", 129], ["individuals", 132], ["with", 144], ["a", 149], ["clinical", 151], ["diagnosis", 160], ["of", 170], ["AS", 173], ["do", 176], ["not", 179], ["have", 183], ["an", 188], ["identifiable", 191], ["molecular", 204], ["defect", 214], [".", 220], ["It", 222], ["is", 225], ["likely", 228], ["that", 235], ["most", 240], ["of", 245], ["those", 248], ["individuals", 254], ["have", 266], ["an", 271], ["AS", 274], ["-", 276], ["like", 277], ["syndrome", 282], ["that", 291], ["is", 296], ["clinically", 299], ["and", 310], ["molecularly", 314], ["distinct", 326], ["from", 335], ["AS", 340], [".", 342], ["These", 344], ["AS", 350], ["-", 352], ["like", 353], ["syndromes", 358], ["can", 368], ["be", 372], ["broadly", 375], ["classified", 383], ["into", 394], ["chromosomal", 399], ["microdeletion", 411], ["and", 425], ["microduplication", 429], ["syndromes", 446], [",", 455], ["and", 457], ["single", 461], ["-", 467], ["gene", 468], ["disorders", 473], [".", 482], ["The", 484], ["microdeletion", 488], ["/", 501], ["microduplication", 502], ["syndromes", 519], ["are", 529], ["now", 533], ["easily", 537], ["identified", 544], ["by", 555], ["chromosomal", 558], ["microarray", 570], ["analysis", 581], ["and", 590], ["include", 594], ["Phelan", 602], ["\u2013", 608], ["McDermid", 609], ["syndrome", 618], ["(", 627], ["chromosome", 628], ["22q13.3", 639], ["deletion", 647], [")", 655], [",", 656], ["MBD5", 658], ["haploinsufficiency", 663], ["syndrome", 682], ["(", 691], ["chromosome", 692], ["2q23.1", 703], ["deletion", 710], [")", 718], [",", 719], ["and", 721], ["KANSL1", 725], ["haploinsufficiency", 732], ["syndrome", 751], ["(", 760], ["chromosome", 761], ["17q21.31", 772], ["deletion", 781], [")", 789], [".", 790], ["The", 792], ["single", 796], ["-", 802], ["gene", 803], ["disorders", 808], ["include", 818], ["Pitt", 826], ["\u2013", 830], ["Hopkins", 831], ["syndrome", 839], ["(", 848], ["TCF4", 849], [")", 853], [",", 854], ["Christianson", 856], ["syndrome", 869], ["(", 878], ["SLC9A6", 879], [")", 885], [",", 886], ["Mowat", 888], ["\u2013", 893], ["Wilson", 894], ["syndrome", 901], ["(", 910], ["ZEB2", 911], [")", 915], [",", 916], ["Kleefstra", 918], ["syndrome", 928], ["(", 937], ["EHMT1", 938], [")", 943], [",", 944], ["and", 946], ["Rett", 950], ["(", 955], ["MECP2", 956], [")", 961], ["syndrome", 963], [".", 971], ["They", 973], ["also", 978], ["include", 983], ["disorders", 991], ["due", 1001], ["to", 1005], ["mutations", 1008], ["in", 1018], ["HERC2", 1021], [",", 1026], ["adenylosuccinase", 1028], ["lyase", 1045], ["(", 1051], ["ADSL", 1052], [")", 1056], [",", 1057], ["CDKL5", 1059], [",", 1064], ["FOXG1", 1066], [",", 1071], ["MECP2", 1073], ["(", 1079], ["duplications", 1080], [")", 1092], [",", 1093], ["MEF2C", 1095], [",", 1100], ["and", 1102], ["ATRX", 1106], [".", 1110], ["Although", 1112], ["many", 1121], ["of", 1126], ["these", 1129], ["single", 1135], ["-", 1141], ["gene", 1142], ["disorders", 1147], ["can", 1157], ["be", 1161], ["caused", 1164], ["by", 1171], ["chromosomal", 1174], ["microdeletions", 1186], ["resulting", 1201], ["in", 1211], ["haploinsufficiency", 1214], ["of", 1233], ["the", 1236], ["critical", 1240], ["gene", 1249], [",", 1253], ["the", 1255], ["individual", 1259], ["disorders", 1270], ["are", 1280], ["often", 1284], ["caused", 1290], ["by", 1297], ["intragenic", 1300], ["mutations", 1311], ["that", 1321], ["can", 1326], ["not", 1329], ["be", 1333], ["detected", 1336], ["by", 1345], ["chromosomal", 1348], ["microarray", 1360], ["analysis", 1371], [".", 1379], ["We", 1381], ["provide", 1384], ["an", 1392], ["overview", 1395], ["of", 1404], ["the", 1407], ["clinical", 1411], ["features", 1420], ["of", 1429], ["these", 1432], ["syndromes", 1438], [",", 1447], ["comparing", 1449], ["and", 1459], ["contrasting", 1463], ["them", 1475], ["with", 1480], ["AS", 1485], [",", 1487], ["in", 1489], ["the", 1492], ["hope", 1496], ["that", 1501], ["it", 1506], ["will", 1509], ["help", 1514], ["guide", 1519], ["clinicians", 1525], ["in", 1536], ["the", 1539], ["diagnostic", 1543], ["work", 1554], ["-", 1558], ["up", 1559], ["of", 1562], ["individuals", 1565], ["with", 1577], ["AS", 1582], ["-", 1584], ["like", 1585], ["syndromes", 1590], [".", 1599]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensory-motor neurological disorder with a circadian component. RLS is characterized by uncomfortable sensations in the extremities, generally at night or during sleep, which often leads to an uncontrollable urge to move them for relief. Recently, genomic studies identified single-nucleotide polymorphisms in BTBD9, along with three other genes, as being associated with a higher risk of RLS. Little is known about the function of BTBD9 or its potential role in the pathophysiology of RLS. We therefore examined a line of Btbd9 mutant mice we recently generated for phenotypes similar to symptoms found in RLS patients. We observed that the Btbd9 mutant mice had motor restlessness, sensory alterations likely limited to the rest phase, and decreased sleep and increased wake times during the rest phase. Additionally, the Btbd9 mutant mice had altered serum iron levels and monoamine neurotransmitter systems. Furthermore, the sensory alterations in the Btbd9 mutant mice were relieved using ropinirole, a dopaminergic agonist widely used for RLS treatment. These results, taken together, suggest that the Btbd9 mutant mice model several characteristics similar to RLS and would therefore be the first genotypic mouse model of RLS. Furthermore, our data provide further evidence that BTBD9 is involved in RLS, and future studies of the Btbd9 mutant mice will help shine light on its role in the pathophysiology of RLS. Finally, our data argue for the utility of Btbd9 mutant mice to discover and screen novel therapeutics for RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "79688e5fa4ba4c6f87957928ba8c86f4", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensory", 71], ["-", 78], ["motor", 79], ["neurological", 85], ["disorder", 98], ["with", 107], ["a", 112], ["circadian", 114], ["component", 124], [".", 133], ["RLS", 135], ["is", 139], ["characterized", 142], ["by", 156], ["uncomfortable", 159], ["sensations", 173], ["in", 184], ["the", 187], ["extremities", 191], [",", 202], ["generally", 204], ["at", 214], ["night", 217], ["or", 223], ["during", 226], ["sleep", 233], [",", 238], ["which", 240], ["often", 246], ["leads", 252], ["to", 258], ["an", 261], ["uncontrollable", 264], ["urge", 279], ["to", 284], ["move", 287], ["them", 292], ["for", 297], ["relief", 301], [".", 307], ["Recently", 309], [",", 317], ["genomic", 319], ["studies", 327], ["identified", 335], ["single", 346], ["-", 352], ["nucleotide", 353], ["polymorphisms", 364], ["in", 378], ["BTBD9", 381], [",", 386], ["along", 388], ["with", 394], ["three", 399], ["other", 405], ["genes", 411], [",", 416], ["as", 418], ["being", 421], ["associated", 427], ["with", 438], ["a", 443], ["higher", 445], ["risk", 452], ["of", 457], ["RLS", 460], [".", 463], ["Little", 465], ["is", 472], ["known", 475], ["about", 481], ["the", 487], ["function", 491], ["of", 500], ["BTBD9", 503], ["or", 509], ["its", 512], ["potential", 516], ["role", 526], ["in", 531], ["the", 534], ["pathophysiology", 538], ["of", 554], ["RLS", 557], [".", 560], ["We", 562], ["therefore", 565], ["examined", 575], ["a", 584], ["line", 586], ["of", 591], ["Btbd9", 594], ["mutant", 600], ["mice", 607], ["we", 612], ["recently", 615], ["generated", 624], ["for", 634], ["phenotypes", 638], ["similar", 649], ["to", 657], ["symptoms", 660], ["found", 669], ["in", 675], ["RLS", 678], ["patients", 682], [".", 690], ["We", 692], ["observed", 695], ["that", 704], ["the", 709], ["Btbd9", 713], ["mutant", 719], ["mice", 726], ["had", 731], ["motor", 735], ["restlessness", 741], [",", 753], ["sensory", 755], ["alterations", 763], ["likely", 775], ["limited", 782], ["to", 790], ["the", 793], ["rest", 797], ["phase", 802], [",", 807], ["and", 809], ["decreased", 813], ["sleep", 823], ["and", 829], ["increased", 833], ["wake", 843], ["times", 848], ["during", 854], ["the", 861], ["rest", 865], ["phase", 870], [".", 875], ["Additionally", 877], [",", 889], ["the", 891], ["Btbd9", 895], ["mutant", 901], ["mice", 908], ["had", 913], ["altered", 917], ["serum", 925], ["iron", 931], ["levels", 936], ["and", 943], ["monoamine", 947], ["neurotransmitter", 957], ["systems", 974], [".", 981], ["Furthermore", 983], [",", 994], ["the", 996], ["sensory", 1000], ["alterations", 1008], ["in", 1020], ["the", 1023], ["Btbd9", 1027], ["mutant", 1033], ["mice", 1040], ["were", 1045], ["relieved", 1050], ["using", 1059], ["ropinirole", 1065], [",", 1075], ["a", 1077], ["dopaminergic", 1079], ["agonist", 1092], ["widely", 1100], ["used", 1107], ["for", 1112], ["RLS", 1116], ["treatment", 1120], [".", 1129], ["These", 1131], ["results", 1137], [",", 1144], ["taken", 1146], ["together", 1152], [",", 1160], ["suggest", 1162], ["that", 1170], ["the", 1175], ["Btbd9", 1179], ["mutant", 1185], ["mice", 1192], ["model", 1197], ["several", 1203], ["characteristics", 1211], ["similar", 1227], ["to", 1235], ["RLS", 1238], ["and", 1242], ["would", 1246], ["therefore", 1252], ["be", 1262], ["the", 1265], ["first", 1269], ["genotypic", 1275], ["mouse", 1285], ["model", 1291], ["of", 1297], ["RLS", 1300], [".", 1303], ["Furthermore", 1305], [",", 1316], ["our", 1318], ["data", 1322], ["provide", 1327], ["further", 1335], ["evidence", 1343], ["that", 1352], ["BTBD9", 1357], ["is", 1363], ["involved", 1366], ["in", 1375], ["RLS", 1378], [",", 1381], ["and", 1383], ["future", 1387], ["studies", 1394], ["of", 1402], ["the", 1405], ["Btbd9", 1409], ["mutant", 1415], ["mice", 1422], ["will", 1427], ["help", 1432], ["shine", 1437], ["light", 1443], ["on", 1449], ["its", 1452], ["role", 1456], ["in", 1461], ["the", 1464], ["pathophysiology", 1468], ["of", 1484], ["RLS", 1487], [".", 1490], ["Finally", 1492], [",", 1499], ["our", 1501], ["data", 1505], ["argue", 1510], ["for", 1516], ["the", 1520], ["utility", 1524], ["of", 1532], ["Btbd9", 1535], ["mutant", 1541], ["mice", 1548], ["to", 1553], ["discover", 1556], ["and", 1565], ["screen", 1569], ["novel", 1576], ["therapeutics", 1582], ["for", 1595], ["RLS", 1599], [".", 1602]]}
{"context": "The transcriptional networks that regulate embryonic stem (ES) cell pluripotency and lineage specification are the subject of considerable attention. To date such studies have focused almost exclusively on protein-coding transcripts. However, recent transcriptome analyses show that the mammalian genome contains thousands of long noncoding RNAs (ncRNAs), many of which appear to be expressed in a developmentally regulated manner. The functions of these remain untested. To identify ncRNAs involved in ES cell biology, we used a custom-designed microarray to examine the expression profiles of mouse ES cells differentiating as embryoid bodies (EBs) over a 16-d time course. We identified 945 ncRNAs expressed during EB differentiation, of which 174 were differentially expressed, many correlating with pluripotency or specific differentiation events. Candidate ncRNAs were identified for further characterization by an integrated examination of expression profiles, genomic context, chromatin state, and promoter analysis. Many ncRNAs showed coordinated expression with genomically associated developmental genes, such as Dlx1, Dlx4, Gata6, and Ecsit. We examined two novel developmentally regulated ncRNAs, Evx1as and Hoxb5/6as, which are derived from homeotic loci and share similar expression patterns and localization in mouse embryos with their associated protein-coding genes. Using chromatin immunoprecipitation, we provide evidence that both ncRNAs are associated with trimethylated H3K4 histones and histone methyltransferase MLL1, suggesting a role in epigenetic regulation of homeotic loci during ES cell differentiation. Taken together, our data indicate that long ncRNAs are likely to be important in processes directing pluripotency and alternative differentiation programs, in some cases through engagement of the epigenetic machinery.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "7f852a929e6a4b24adcfac462afb1477", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[236, 236]], "char_spans": [[1493, 1496]]}]}], "context_tokens": [["The", 0], ["transcriptional", 4], ["networks", 20], ["that", 29], ["regulate", 34], ["embryonic", 43], ["stem", 53], ["(", 58], ["ES", 59], [")", 61], ["cell", 63], ["pluripotency", 68], ["and", 81], ["lineage", 85], ["specification", 93], ["are", 107], ["the", 111], ["subject", 115], ["of", 123], ["considerable", 126], ["attention", 139], [".", 148], ["To", 150], ["date", 153], ["such", 158], ["studies", 163], ["have", 171], ["focused", 176], ["almost", 184], ["exclusively", 191], ["on", 203], ["protein", 206], ["-", 213], ["coding", 214], ["transcripts", 221], [".", 232], ["However", 234], [",", 241], ["recent", 243], ["transcriptome", 250], ["analyses", 264], ["show", 273], ["that", 278], ["the", 283], ["mammalian", 287], ["genome", 297], ["contains", 304], ["thousands", 313], ["of", 323], ["long", 326], ["noncoding", 331], ["RNAs", 341], ["(", 346], ["ncRNAs", 347], [")", 353], [",", 354], ["many", 356], ["of", 361], ["which", 364], ["appear", 370], ["to", 377], ["be", 380], ["expressed", 383], ["in", 393], ["a", 396], ["developmentally", 398], ["regulated", 414], ["manner", 424], [".", 430], ["The", 432], ["functions", 436], ["of", 446], ["these", 449], ["remain", 455], ["untested", 462], [".", 470], ["To", 472], ["identify", 475], ["ncRNAs", 484], ["involved", 491], ["in", 500], ["ES", 503], ["cell", 506], ["biology", 511], [",", 518], ["we", 520], ["used", 523], ["a", 528], ["custom", 530], ["-", 536], ["designed", 537], ["microarray", 546], ["to", 557], ["examine", 560], ["the", 568], ["expression", 572], ["profiles", 583], ["of", 592], ["mouse", 595], ["ES", 601], ["cells", 604], ["differentiating", 610], ["as", 626], ["embryoid", 629], ["bodies", 638], ["(", 645], ["EBs", 646], [")", 649], ["over", 651], ["a", 656], ["16-d", 658], ["time", 663], ["course", 668], [".", 674], ["We", 676], ["identified", 679], ["945", 690], ["ncRNAs", 694], ["expressed", 701], ["during", 711], ["EB", 718], ["differentiation", 721], [",", 736], ["of", 738], ["which", 741], ["174", 747], ["were", 751], ["differentially", 756], ["expressed", 771], [",", 780], ["many", 782], ["correlating", 787], ["with", 799], ["pluripotency", 804], ["or", 817], ["specific", 820], ["differentiation", 829], ["events", 845], [".", 851], ["Candidate", 853], ["ncRNAs", 863], ["were", 870], ["identified", 875], ["for", 886], ["further", 890], ["characterization", 898], ["by", 915], ["an", 918], ["integrated", 921], ["examination", 932], ["of", 944], ["expression", 947], ["profiles", 958], [",", 966], ["genomic", 968], ["context", 976], [",", 983], ["chromatin", 985], ["state", 995], [",", 1000], ["and", 1002], ["promoter", 1006], ["analysis", 1015], [".", 1023], ["Many", 1025], ["ncRNAs", 1030], ["showed", 1037], ["coordinated", 1044], ["expression", 1056], ["with", 1067], ["genomically", 1072], ["associated", 1084], ["developmental", 1095], ["genes", 1109], [",", 1114], ["such", 1116], ["as", 1121], ["Dlx1", 1124], [",", 1128], ["Dlx4", 1130], [",", 1134], ["Gata6", 1136], [",", 1141], ["and", 1143], ["Ecsit", 1147], [".", 1152], ["We", 1154], ["examined", 1157], ["two", 1166], ["novel", 1170], ["developmentally", 1176], ["regulated", 1192], ["ncRNAs", 1202], [",", 1208], ["Evx1as", 1210], ["and", 1217], ["Hoxb5/6as", 1221], [",", 1230], ["which", 1232], ["are", 1238], ["derived", 1242], ["from", 1250], ["homeotic", 1255], ["loci", 1264], ["and", 1269], ["share", 1273], ["similar", 1279], ["expression", 1287], ["patterns", 1298], ["and", 1307], ["localization", 1311], ["in", 1324], ["mouse", 1327], ["embryos", 1333], ["with", 1341], ["their", 1346], ["associated", 1352], ["protein", 1363], ["-", 1370], ["coding", 1371], ["genes", 1378], [".", 1383], ["Using", 1385], ["chromatin", 1391], ["immunoprecipitation", 1401], [",", 1420], ["we", 1422], ["provide", 1425], ["evidence", 1433], ["that", 1442], ["both", 1447], ["ncRNAs", 1452], ["are", 1459], ["associated", 1463], ["with", 1474], ["trimethylated", 1479], ["H3K4", 1493], ["histones", 1498], ["and", 1507], ["histone", 1511], ["methyltransferase", 1519], ["MLL1", 1537], [",", 1541], ["suggesting", 1543], ["a", 1554], ["role", 1556], ["in", 1561], ["epigenetic", 1564], ["regulation", 1575], ["of", 1586], ["homeotic", 1589], ["loci", 1598], ["during", 1603], ["ES", 1610], ["cell", 1613], ["differentiation", 1618], [".", 1633], ["Taken", 1635], ["together", 1641], [",", 1649], ["our", 1651], ["data", 1655], ["indicate", 1660], ["that", 1669], ["long", 1674], ["ncRNAs", 1679], ["are", 1686], ["likely", 1690], ["to", 1697], ["be", 1700], ["important", 1703], ["in", 1713], ["processes", 1716], ["directing", 1726], ["pluripotency", 1736], ["and", 1749], ["alternative", 1753], ["differentiation", 1765], ["programs", 1781], [",", 1789], ["in", 1791], ["some", 1794], ["cases", 1799], ["through", 1805], ["engagement", 1813], ["of", 1824], ["the", 1827], ["epigenetic", 1831], ["machinery", 1842], [".", 1851]]}
{"context": "Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer's disease (AD). However the typical anatomic distribution of Lewy bodies in AD is distinct from PD. The most common site of occurrence is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Other common sites of occurrence include the periamygdaloid and entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of Lewy bodies in familial AD cases suggests that like neurofibrillary tangles, the formation of Lewy bodies can be induced by the pathological state caused by Abeta-amyloid overproduction. The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "842999d9925347eca644cb9699a36b65", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[244, 246], [228, 230], [203, 205]], "char_spans": [[1431, 1445], [1338, 1352], [1192, 1206]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["the", 13], ["characteristic", 17], ["pathological", 32], ["lesion", 45], ["of", 52], ["substantia", 55], ["nigra", 66], ["neurons", 72], ["in", 80], ["Parkinson", 83], ["'s", 92], ["disease", 95], ["(", 103], ["PD", 104], [")", 106], [",", 107], ["are", 109], ["frequently", 113], ["observed", 124], ["to", 133], ["accompany", 136], ["the", 146], ["amyloid", 150], ["plaque", 158], ["and", 165], ["neurofibrillary", 169], ["tangle", 185], ["pathology", 192], ["of", 202], ["Alzheimer", 205], ["'s", 214], ["disease", 217], ["(", 225], ["AD", 226], [")", 228], [".", 229], ["However", 231], ["the", 239], ["typical", 243], ["anatomic", 251], ["distribution", 260], ["of", 273], ["Lewy", 276], ["bodies", 281], ["in", 288], ["AD", 291], ["is", 294], ["distinct", 297], ["from", 306], ["PD", 311], [".", 313], ["The", 315], ["most", 319], ["common", 324], ["site", 331], ["of", 336], ["occurrence", 339], ["is", 350], ["the", 353], ["amygdala", 357], [",", 365], ["where", 367], ["Lewy", 373], ["bodies", 378], ["are", 385], ["observed", 389], ["in", 398], ["approximately", 401], ["60", 415], ["%", 417], ["of", 419], ["both", 422], ["sporadic", 427], ["and", 436], ["familial", 440], ["AD", 449], [".", 451], ["Other", 453], ["common", 459], ["sites", 466], ["of", 472], ["occurrence", 475], ["include", 486], ["the", 494], ["periamygdaloid", 498], ["and", 513], ["entorhinal", 517], ["cortex", 528], [",", 534], ["while", 536], ["neocortical", 542], ["and", 554], ["brainstem", 558], ["areas", 568], ["develop", 574], ["Lewy", 582], ["bodies", 587], ["in", 594], ["a", 597], ["lower", 599], ["percentage", 605], ["of", 616], ["cases", 619], [".", 624], ["In", 626], ["contrast", 629], [",", 637], ["dementia", 639], ["with", 648], ["Lewy", 653], ["bodies", 658], ["(", 665], ["DLB", 666], [")", 669], [",", 670], ["defined", 672], ["by", 680], ["widespread", 683], ["neocortical", 694], ["and", 706], ["brainstem", 710], ["Lewy", 720], ["bodies", 725], ["but", 732], ["frequently", 736], ["accompanied", 747], ["by", 759], ["variable", 762], ["levels", 771], ["of", 778], ["AD", 781], ["-", 783], ["type", 784], ["pathology", 789], [",", 798], ["represents", 800], ["the", 811], ["other", 815], ["end", 821], ["of", 825], ["a", 828], ["spectrum", 830], ["of", 839], ["pathology", 842], ["associated", 852], ["with", 863], ["dementia", 868], [".", 876], ["The", 878], ["observation", 882], ["of", 894], ["Lewy", 897], ["bodies", 902], ["in", 909], ["familial", 912], ["AD", 921], ["cases", 924], ["suggests", 930], ["that", 939], ["like", 944], ["neurofibrillary", 949], ["tangles", 965], [",", 972], ["the", 974], ["formation", 978], ["of", 988], ["Lewy", 991], ["bodies", 996], ["can", 1003], ["be", 1007], ["induced", 1010], ["by", 1018], ["the", 1021], ["pathological", 1025], ["state", 1038], ["caused", 1044], ["by", 1051], ["Abeta", 1054], ["-", 1059], ["amyloid", 1060], ["overproduction", 1068], [".", 1082], ["The", 1084], ["role", 1088], ["of", 1093], ["Lewy", 1096], ["body", 1101], ["formation", 1106], ["in", 1116], ["the", 1119], ["dysfunction", 1123], ["and", 1135], ["degeneration", 1139], ["of", 1152], ["neurons", 1155], ["remains", 1163], ["unclear", 1171], [".", 1178], ["The", 1180], ["protein", 1184], ["alpha", 1192], ["-", 1197], ["synuclein", 1198], ["appears", 1208], ["to", 1216], ["be", 1219], ["an", 1222], ["important", 1225], ["structural", 1235], ["component", 1246], ["of", 1256], ["Lewy", 1259], ["bodies", 1264], [",", 1270], ["an", 1272], ["observation", 1275], ["spurred", 1287], ["by", 1295], ["the", 1298], ["discovery", 1302], ["of", 1312], ["point", 1315], ["mutations", 1321], ["in", 1331], ["the", 1334], ["alpha", 1338], ["-", 1343], ["synuclein", 1344], ["gene", 1354], ["linked", 1359], ["to", 1366], ["rare", 1369], ["cases", 1374], ["of", 1380], ["autosomal", 1383], ["dominant", 1393], ["PD", 1402], [".", 1404], ["Further", 1406], ["investigation", 1414], ["of", 1428], ["alpha", 1431], ["-", 1436], ["synuclein", 1437], ["and", 1447], ["its", 1451], ["relationship", 1455], ["to", 1468], ["pathological", 1471], ["conditions", 1484], ["promoting", 1495], ["Lewy", 1505], ["body", 1510], ["formation", 1515], ["in", 1525], ["AD", 1528], [",", 1530], ["PD", 1532], [",", 1534], ["and", 1536], ["DLB", 1540], ["may", 1544], ["yield", 1548], ["further", 1554], ["insight", 1562], ["into", 1570], ["pathogenesis", 1575], ["of", 1588], ["these", 1591], ["diseases", 1597], [".", 1605]]}
{"context": "Plague is still an endemic disease in different regions of the world. Increasing reports of incidence, the discovery of antibiotic resistance strains, and concern about a potential use of the causative bacteria Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine. The use of F1 and V antigens and the derived protein fusion F1-V has shown great potential as a protective vaccine in animal studies. Plants have been extensively studied for the production of pharmaceutical proteins as an inexpensive and scalable alternative to common expression systems. In the current study the recombinant plague antigens F1, V, and fusion protein F1-V were produced by transient expression in Nicotiana benthamiana by using a deconstructed tobacco mosaic virus-based system that allowed very rapid and extremely high levels of expression. All of the plant-derived purified antigens, administered s.c. to guinea pigs, generated systemic immune responses and provided protection against an aerosol challenge of virulent Y. pestis.", "qas": [{"question": "Which bacteria caused plague?", "answers": ["Yersinia pestis"], "qid": "4ce4a14391204eb893a5d9a49f0652af", "question_tokens": [["Which", 0], ["bacteria", 6], ["caused", 15], ["plague", 22], ["?", 28]], "detected_answers": [{"text": "Yersinia pestis", "token_spans": [[35, 36]], "char_spans": [[211, 225]]}]}], "context_tokens": [["Plague", 0], ["is", 7], ["still", 10], ["an", 16], ["endemic", 19], ["disease", 27], ["in", 35], ["different", 38], ["regions", 48], ["of", 56], ["the", 59], ["world", 63], [".", 68], ["Increasing", 70], ["reports", 81], ["of", 89], ["incidence", 92], [",", 101], ["the", 103], ["discovery", 107], ["of", 117], ["antibiotic", 120], ["resistance", 131], ["strains", 142], [",", 149], ["and", 151], ["concern", 155], ["about", 163], ["a", 169], ["potential", 171], ["use", 181], ["of", 185], ["the", 188], ["causative", 192], ["bacteria", 202], ["Yersinia", 211], ["pestis", 220], ["as", 227], ["an", 230], ["agent", 233], ["of", 239], ["biological", 242], ["warfare", 253], ["have", 261], ["highlighted", 266], ["the", 278], ["need", 282], ["for", 287], ["a", 291], ["safe", 293], [",", 297], ["efficacious", 299], [",", 310], ["and", 312], ["rapidly", 316], ["producible", 324], ["vaccine", 335], [".", 342], ["The", 344], ["use", 348], ["of", 352], ["F1", 355], ["and", 358], ["V", 362], ["antigens", 364], ["and", 373], ["the", 377], ["derived", 381], ["protein", 389], ["fusion", 397], ["F1-V", 404], ["has", 409], ["shown", 413], ["great", 419], ["potential", 425], ["as", 435], ["a", 438], ["protective", 440], ["vaccine", 451], ["in", 459], ["animal", 462], ["studies", 469], [".", 476], ["Plants", 478], ["have", 485], ["been", 490], ["extensively", 495], ["studied", 507], ["for", 515], ["the", 519], ["production", 523], ["of", 534], ["pharmaceutical", 537], ["proteins", 552], ["as", 561], ["an", 564], ["inexpensive", 567], ["and", 579], ["scalable", 583], ["alternative", 592], ["to", 604], ["common", 607], ["expression", 614], ["systems", 625], [".", 632], ["In", 634], ["the", 637], ["current", 641], ["study", 649], ["the", 655], ["recombinant", 659], ["plague", 671], ["antigens", 678], ["F1", 687], [",", 689], ["V", 691], [",", 692], ["and", 694], ["fusion", 698], ["protein", 705], ["F1-V", 713], ["were", 718], ["produced", 723], ["by", 732], ["transient", 735], ["expression", 745], ["in", 756], ["Nicotiana", 759], ["benthamiana", 769], ["by", 781], ["using", 784], ["a", 790], ["deconstructed", 792], ["tobacco", 806], ["mosaic", 814], ["virus", 821], ["-", 826], ["based", 827], ["system", 833], ["that", 840], ["allowed", 845], ["very", 853], ["rapid", 858], ["and", 864], ["extremely", 868], ["high", 878], ["levels", 883], ["of", 890], ["expression", 893], [".", 903], ["All", 905], ["of", 909], ["the", 912], ["plant", 916], ["-", 921], ["derived", 922], ["purified", 930], ["antigens", 939], [",", 947], ["administered", 949], ["s.c", 962], [".", 965], ["to", 967], ["guinea", 970], ["pigs", 977], [",", 981], ["generated", 983], ["systemic", 993], ["immune", 1002], ["responses", 1009], ["and", 1019], ["provided", 1023], ["protection", 1032], ["against", 1043], ["an", 1051], ["aerosol", 1054], ["challenge", 1062], ["of", 1072], ["virulent", 1075], ["Y.", 1084], ["pestis", 1087], [".", 1093]]}
{"context": "The mature central nervous system contains precursor cells in the subventricular zone of the lateral ventricle. In this study we examined the possibility to affect fate of precursor cells through exogenous manipulations. The results indicate that administration of thyroid hormone and retinoic acid increases the expression of Ki67, a nuclear antigen associated with cell proliferation, and of nestin, a marker protein for precursor cells in the subventricular zone of adult male rats. Moreover, retinoic acid increases polysialated-neural cell adhesion molecules (PSA-NCAM)-immunoreactivity. These data suggest that nuclear receptor ligands are potential candidates for fate determination of precursor cells in the subventricular zone also in the adult brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2a963d7335cb4cfa9452f4ded58a357f", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[61, 61]], "char_spans": [[394, 399]]}]}], "context_tokens": [["The", 0], ["mature", 4], ["central", 11], ["nervous", 19], ["system", 27], ["contains", 34], ["precursor", 43], ["cells", 53], ["in", 59], ["the", 62], ["subventricular", 66], ["zone", 81], ["of", 86], ["the", 89], ["lateral", 93], ["ventricle", 101], [".", 110], ["In", 112], ["this", 115], ["study", 120], ["we", 126], ["examined", 129], ["the", 138], ["possibility", 142], ["to", 154], ["affect", 157], ["fate", 164], ["of", 169], ["precursor", 172], ["cells", 182], ["through", 188], ["exogenous", 196], ["manipulations", 206], [".", 219], ["The", 221], ["results", 225], ["indicate", 233], ["that", 242], ["administration", 247], ["of", 262], ["thyroid", 265], ["hormone", 273], ["and", 281], ["retinoic", 285], ["acid", 294], ["increases", 299], ["the", 309], ["expression", 313], ["of", 324], ["Ki67", 327], [",", 331], ["a", 333], ["nuclear", 335], ["antigen", 343], ["associated", 351], ["with", 362], ["cell", 367], ["proliferation", 372], [",", 385], ["and", 387], ["of", 391], ["nestin", 394], [",", 400], ["a", 402], ["marker", 404], ["protein", 411], ["for", 419], ["precursor", 423], ["cells", 433], ["in", 439], ["the", 442], ["subventricular", 446], ["zone", 461], ["of", 466], ["adult", 469], ["male", 475], ["rats", 480], [".", 484], ["Moreover", 486], [",", 494], ["retinoic", 496], ["acid", 505], ["increases", 510], ["polysialated", 520], ["-", 532], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecules", 554], ["(", 564], ["PSA", 565], ["-", 568], ["NCAM)-immunoreactivity", 569], [".", 591], ["These", 593], ["data", 599], ["suggest", 604], ["that", 612], ["nuclear", 617], ["receptor", 625], ["ligands", 634], ["are", 642], ["potential", 646], ["candidates", 656], ["for", 667], ["fate", 671], ["determination", 676], ["of", 690], ["precursor", 693], ["cells", 703], ["in", 709], ["the", 712], ["subventricular", 716], ["zone", 731], ["also", 736], ["in", 741], ["the", 744], ["adult", 748], ["brain", 754], [".", 759]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Hypospadias, when the urethra opens on the ventral side of the penis, is a common malformation seen in about 3 per 1,000 male births. It is a complex disorder associated with genetic and environmental factors and can be part of genetic syndromes. Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype, Hirschsprung disease, microcephaly and mental retardation. It is caused by mutations in the zinc finger homeo box 1B gene, ZFHX1B (SIP1). To date, 68 deletion/mutation-positive cases have been reported. Genitourinary anomalies are common in MWS. Here we report that hypospadias is common in males with this syndrome. In 39 patients where this information was available, hypospadias was present in 46% of patients (18/39). In the 3 Italian male cases reported here, hypospadias was always present. MWS should be considered by endocrinologists in patients with hypospadias associated with developmental delays/mental retardation, in particular in the presence of a distinct facial phenotype.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ace3060b5e2147889d7d4709d6cd1e57", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[88, 88]], "char_spans": [[486, 491]]}]}], "context_tokens": [["Hypospadias", 0], [",", 11], ["when", 13], ["the", 18], ["urethra", 22], ["opens", 30], ["on", 36], ["the", 39], ["ventral", 43], ["side", 51], ["of", 56], ["the", 59], ["penis", 63], [",", 68], ["is", 70], ["a", 73], ["common", 75], ["malformation", 82], ["seen", 95], ["in", 100], ["about", 103], ["3", 109], ["per", 111], ["1,000", 115], ["male", 121], ["births", 126], [".", 132], ["It", 134], ["is", 137], ["a", 140], ["complex", 142], ["disorder", 150], ["associated", 159], ["with", 170], ["genetic", 175], ["and", 183], ["environmental", 187], ["factors", 201], ["and", 209], ["can", 213], ["be", 217], ["part", 220], ["of", 225], ["genetic", 228], ["syndromes", 236], [".", 245], ["Mowat", 247], ["-", 252], ["Wilson", 253], ["syndrome", 260], ["(", 269], ["MWS", 270], [")", 273], ["is", 275], ["a", 278], ["multiple", 280], ["congenital", 289], ["anomaly", 300], ["syndrome", 308], ["characterized", 317], ["by", 331], ["a", 334], ["distinct", 336], ["facial", 345], ["phenotype", 352], [",", 361], ["Hirschsprung", 363], ["disease", 376], [",", 383], ["microcephaly", 385], ["and", 398], ["mental", 402], ["retardation", 409], [".", 420], ["It", 422], ["is", 425], ["caused", 428], ["by", 435], ["mutations", 438], ["in", 448], ["the", 451], ["zinc", 455], ["finger", 460], ["homeo", 467], ["box", 473], ["1B", 477], ["gene", 480], [",", 484], ["ZFHX1B", 486], ["(", 493], ["SIP1", 494], [")", 498], [".", 499], ["To", 501], ["date", 504], [",", 508], ["68", 510], ["deletion", 513], ["/", 521], ["mutation", 522], ["-", 530], ["positive", 531], ["cases", 540], ["have", 546], ["been", 551], ["reported", 556], [".", 564], ["Genitourinary", 566], ["anomalies", 580], ["are", 590], ["common", 594], ["in", 601], ["MWS", 604], [".", 607], ["Here", 609], ["we", 614], ["report", 617], ["that", 624], ["hypospadias", 629], ["is", 641], ["common", 644], ["in", 651], ["males", 654], ["with", 660], ["this", 665], ["syndrome", 670], [".", 678], ["In", 680], ["39", 683], ["patients", 686], ["where", 695], ["this", 701], ["information", 706], ["was", 718], ["available", 722], [",", 731], ["hypospadias", 733], ["was", 745], ["present", 749], ["in", 757], ["46", 760], ["%", 762], ["of", 764], ["patients", 767], ["(", 776], ["18/39", 777], [")", 782], [".", 783], ["In", 785], ["the", 788], ["3", 792], ["Italian", 794], ["male", 802], ["cases", 807], ["reported", 813], ["here", 822], [",", 826], ["hypospadias", 828], ["was", 840], ["always", 844], ["present", 851], [".", 858], ["MWS", 860], ["should", 864], ["be", 871], ["considered", 874], ["by", 885], ["endocrinologists", 888], ["in", 905], ["patients", 908], ["with", 917], ["hypospadias", 922], ["associated", 934], ["with", 945], ["developmental", 950], ["delays", 964], ["/", 970], ["mental", 971], ["retardation", 978], [",", 989], ["in", 991], ["particular", 994], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["a", 1024], ["distinct", 1026], ["facial", 1035], ["phenotype", 1042], [".", 1051]]}
{"context": "Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. It comprises Ehlers-Danlos syndrome type I and Ehlers-Danlos syndrome type II, but it is now apparent that these form a continuum of clinical findings and differ only in phenotypic severity. It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene, encoding the \u03b11 and the \u03b12-chain of type V collagen, respectively. However, because no prospective molecular studies of COL5A1 and COL5A2 have been performed in a clinically well-defined patient group, this number may underestimate the real proportion of patients with classic Ehlers-Danlos syndrome harboring a mutation in one of these genes. In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen. A smaller proportion of patients harbor a structural mutation in COL5A1 or COL5A2, causing the production of a functionally defective type V collagen protein. Most mutations identified so far result in a reduced amount of type V collagen in the connective tissues available for collagen fibrillogenesis. Inter- and intrafamilial phenotypic variability is observed, but no genotype-phenotype correlations have been observed. No treatment for the underlying defect is presently available for Ehlers-Danlos syndrome. However, a series of preventive guidelines are applicable.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "90435bdf04fb46fd88c52fcb14d2c478", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[46, 62]]}]}], "context_tokens": [["Classic", 0], ["Ehlers", 8], ["-", 14], ["Danlos", 15], ["syndrome", 22], ["is", 31], ["a", 34], ["heritable", 36], ["connective", 46], ["tissue", 57], ["disorder", 64], ["characterized", 73], ["by", 87], ["skin", 90], ["hyperextensibility", 95], [",", 113], ["fragile", 115], ["and", 123], ["soft", 127], ["skin", 132], [",", 136], ["delayed", 138], ["wound", 146], ["healing", 152], ["with", 160], ["formation", 165], ["of", 175], ["atrophic", 178], ["scars", 187], [",", 192], ["easy", 194], ["bruising", 199], [",", 207], ["and", 209], ["generalized", 213], ["joint", 225], ["hypermobility", 231], [".", 244], ["It", 246], ["comprises", 249], ["Ehlers", 259], ["-", 265], ["Danlos", 266], ["syndrome", 273], ["type", 282], ["I", 287], ["and", 289], ["Ehlers", 293], ["-", 299], ["Danlos", 300], ["syndrome", 307], ["type", 316], ["II", 321], [",", 323], ["but", 325], ["it", 329], ["is", 332], ["now", 335], ["apparent", 339], ["that", 348], ["these", 353], ["form", 359], ["a", 364], ["continuum", 366], ["of", 376], ["clinical", 379], ["findings", 388], ["and", 397], ["differ", 401], ["only", 408], ["in", 413], ["phenotypic", 416], ["severity", 427], [".", 435], ["It", 437], ["is", 440], ["currently", 443], ["estimated", 453], ["that", 463], ["approximately", 468], ["50", 482], ["%", 484], ["of", 486], ["patients", 489], ["with", 498], ["a", 503], ["clinical", 505], ["diagnosis", 514], ["of", 524], ["classic", 527], ["Ehlers", 535], ["-", 541], ["Danlos", 542], ["syndrome", 549], ["harbor", 558], ["mutations", 565], ["in", 575], ["the", 578], ["COL5A1", 582], ["and", 589], ["the", 593], ["COL5A2", 597], ["gene", 604], [",", 608], ["encoding", 610], ["the", 619], ["\u03b11", 623], ["and", 626], ["the", 630], ["\u03b12-chain", 634], ["of", 643], ["type", 646], ["V", 651], ["collagen", 653], [",", 661], ["respectively", 663], [".", 675], ["However", 677], [",", 684], ["because", 686], ["no", 694], ["prospective", 697], ["molecular", 709], ["studies", 719], ["of", 727], ["COL5A1", 730], ["and", 737], ["COL5A2", 741], ["have", 748], ["been", 753], ["performed", 758], ["in", 768], ["a", 771], ["clinically", 773], ["well", 784], ["-", 788], ["defined", 789], ["patient", 797], ["group", 805], [",", 810], ["this", 812], ["number", 817], ["may", 824], ["underestimate", 828], ["the", 842], ["real", 846], ["proportion", 851], ["of", 862], ["patients", 865], ["with", 874], ["classic", 879], ["Ehlers", 887], ["-", 893], ["Danlos", 894], ["syndrome", 901], ["harboring", 910], ["a", 920], ["mutation", 922], ["in", 931], ["one", 934], ["of", 938], ["these", 941], ["genes", 947], [".", 952], ["In", 954], ["the", 957], ["majority", 961], ["of", 970], ["patients", 973], ["with", 982], ["molecularly", 987], ["characterized", 999], ["classic", 1013], ["Ehlers", 1021], ["-", 1027], ["Danlos", 1028], ["syndrome", 1035], [",", 1043], ["the", 1045], ["disease", 1049], ["is", 1057], ["caused", 1060], ["by", 1067], ["a", 1070], ["mutation", 1072], ["leading", 1081], ["to", 1089], ["a", 1092], ["nonfunctional", 1094], ["COL5A1", 1108], ["allele", 1115], ["and", 1122], ["resulting", 1126], ["in", 1136], ["haploinsufficiency", 1139], ["of", 1158], ["type", 1161], ["V", 1166], ["collagen", 1168], [".", 1176], ["A", 1178], ["smaller", 1180], ["proportion", 1188], ["of", 1199], ["patients", 1202], ["harbor", 1211], ["a", 1218], ["structural", 1220], ["mutation", 1231], ["in", 1240], ["COL5A1", 1243], ["or", 1250], ["COL5A2", 1253], [",", 1259], ["causing", 1261], ["the", 1269], ["production", 1273], ["of", 1284], ["a", 1287], ["functionally", 1289], ["defective", 1302], ["type", 1312], ["V", 1317], ["collagen", 1319], ["protein", 1328], [".", 1335], ["Most", 1337], ["mutations", 1342], ["identified", 1352], ["so", 1363], ["far", 1366], ["result", 1370], ["in", 1377], ["a", 1380], ["reduced", 1382], ["amount", 1390], ["of", 1397], ["type", 1400], ["V", 1405], ["collagen", 1407], ["in", 1416], ["the", 1419], ["connective", 1423], ["tissues", 1434], ["available", 1442], ["for", 1452], ["collagen", 1456], ["fibrillogenesis", 1465], [".", 1480], ["Inter-", 1482], ["and", 1489], ["intrafamilial", 1493], ["phenotypic", 1507], ["variability", 1518], ["is", 1530], ["observed", 1533], [",", 1541], ["but", 1543], ["no", 1547], ["genotype", 1550], ["-", 1558], ["phenotype", 1559], ["correlations", 1569], ["have", 1582], ["been", 1587], ["observed", 1592], [".", 1600], ["No", 1602], ["treatment", 1605], ["for", 1615], ["the", 1619], ["underlying", 1623], ["defect", 1634], ["is", 1641], ["presently", 1644], ["available", 1654], ["for", 1664], ["Ehlers", 1668], ["-", 1674], ["Danlos", 1675], ["syndrome", 1682], [".", 1690], ["However", 1692], [",", 1699], ["a", 1701], ["series", 1703], ["of", 1710], ["preventive", 1713], ["guidelines", 1724], ["are", 1735], ["applicable", 1739], [".", 1749]]}
{"context": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 \u03bcg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4cf67c0ee39c479999455e6a1bb0566a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[40, 40], [208, 208], [111, 111], [66, 66]], "char_spans": [[215, 218], [1170, 1173], [574, 577], [358, 361]]}]}], "context_tokens": [["It", 0], ["was", 3], ["found", 7], ["in", 13], ["the", 16], ["present", 20], ["study", 28], ["that", 34], ["combined", 39], ["use", 48], ["of", 52], ["fusidic", 55], ["acid", 63], ["(", 68], ["FA", 69], [")", 71], ["and", 73], ["berberine", 77], ["chloride", 87], ["(", 96], ["BBR", 97], [")", 100], ["offered", 102], ["an", 110], ["in", 113], ["vitro", 116], ["synergistic", 122], ["action", 134], ["against", 141], ["7", 149], ["of", 151], ["the", 154], ["30", 158], ["clinical", 161], ["methicillin", 170], ["-", 181], ["resistant", 182], ["Staphylococcus", 192], ["aureus", 207], ["(", 214], ["MRSA", 215], [")", 219], ["strains", 221], [",", 228], ["with", 230], ["a", 235], ["fractional", 237], ["inhibitory", 248], ["concentration", 259], ["(", 273], ["FIC", 274], [")", 277], ["index", 279], ["ranging", 285], ["from", 293], ["0.5", 298], ["to", 302], ["0.19", 305], [".", 309], ["This", 311], ["synergistic", 316], ["effect", 328], ["was", 335], ["most", 339], ["pronounced", 344], ["on", 355], ["MRSA", 358], ["4806", 363], [",", 367], ["an", 369], ["FA", 372], ["-", 374], ["resistant", 375], ["isolate", 385], [",", 392], ["with", 394], ["a", 399], ["minimum", 401], ["inhibitory", 409], ["concentration", 420], ["(", 434], ["MIC", 435], [")", 438], ["value", 440], ["of", 446], ["1,024", 449], ["\u03bcg", 455], ["/", 457], ["ml", 458], [".", 460], ["The", 462], ["time", 466], ["-", 470], ["kill", 471], ["curve", 476], ["experiment", 482], ["showed", 493], ["that", 500], ["FA", 505], ["plus", 508], ["BBR", 513], ["yielded", 517], ["a", 525], ["4.2", 527], ["log10", 531], ["c.f.u./ml", 537], ["reduction", 547], ["in", 557], ["the", 560], ["number", 564], ["of", 571], ["MRSA", 574], ["4806", 579], ["bacteria", 584], ["after", 593], ["24-h", 599], ["incubation", 604], ["as", 615], ["compared", 618], ["with", 627], ["BBR", 632], ["alone", 636], [".", 641], ["Viable", 643], ["count", 650], ["analysis", 656], ["showed", 665], ["that", 672], ["FA", 677], ["plus", 680], ["BBR", 685], ["produced", 689], ["a", 698], ["3.0", 700], ["log10", 704], ["c.f.u./ml", 710], ["decrease", 720], ["in", 729], ["biofilm", 732], ["formation", 740], ["and", 750], ["a", 754], ["1.5", 756], ["log10", 760], ["c.f.u./ml", 766], ["decrease", 776], ["in", 785], ["mature", 788], ["biofilm", 795], ["in", 803], ["viable", 806], ["cell", 813], ["density", 818], ["as", 826], ["compared", 829], ["with", 838], ["BBR", 843], ["alone", 847], [".", 852], ["In", 854], ["addition", 857], [",", 865], ["phase", 867], ["contrast", 873], ["micrographs", 882], ["confirmed", 894], ["that", 904], ["biofilm", 909], ["formation", 917], ["was", 927], ["significantly", 931], ["inhibited", 945], ["and", 955], ["mature", 959], ["biofilm", 966], ["was", 974], ["obviously", 978], ["destructed", 988], ["when", 999], ["FA", 1004], ["was", 1007], ["used", 1011], ["in", 1016], ["combination", 1019], ["with", 1031], ["BBR", 1036], [".", 1039], ["These", 1041], ["results", 1047], ["provide", 1055], ["evidence", 1063], ["that", 1072], ["combined", 1077], ["use", 1086], ["of", 1090], ["FA", 1093], ["and", 1096], ["BBR", 1100], ["may", 1104], ["prove", 1108], ["to", 1114], ["be", 1117], ["a", 1120], ["promising", 1122], ["clinical", 1132], ["therapeutic", 1141], ["strategy", 1153], ["against", 1162], ["MRSA", 1170], [".", 1174]]}
{"context": "Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence. Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA) show superior specificity and sensitivity but are more expensive. The present study reports the results of a three-year TB surveillance among HCW in a large teaching hospital in Rome, using TST (by standard Mantoux technique) and IGRA (by QuantiFERON-TB) as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99 (70.2%) underwent the IGRA and 16 tested positive (16.1%). The frequency of HCW tested positive for TB seems not far from other experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo X-ray diagnosis and/or chemotherapy.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "62a1183be31d4c208669a471c24c419c", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12]], "char_spans": [[64, 75]]}]}], "context_tokens": [["Health", 0], ["care", 7], ["workers", 12], ["(", 20], ["HCW", 21], [")", 24], ["are", 26], ["particularly", 30], ["at", 43], ["risk", 46], ["of", 51], ["acquiring", 54], ["tuberculosis", 64], ["(", 77], ["TB", 78], [")", 80], [",", 81], ["even", 83], ["in", 88], ["countries", 91], ["with", 101], ["low", 106], ["TB", 110], ["incidence", 113], [".", 122], ["Therefore", 124], [",", 133], ["TB", 135], ["screening", 138], ["in", 148], ["HCW", 151], ["is", 155], ["a", 158], ["useful", 160], ["prevention", 167], ["strategy", 178], ["in", 187], ["countries", 190], ["with", 200], ["both", 205], ["low", 210], ["and", 214], ["high", 218], ["TB", 223], ["incidence", 226], [".", 235], ["Tuberculin", 237], ["skin", 248], ["test", 253], ["(", 258], ["TST", 259], [")", 262], ["is", 264], ["widely", 267], ["used", 274], ["although", 279], ["it", 288], ["suffers", 291], ["of", 299], ["low", 302], ["specificity", 306], [";", 317], ["on", 319], ["the", 322], ["contrary", 326], [",", 334], ["the", 336], ["in", 340], ["vitro", 343], ["enzyme", 349], ["immunoassay", 356], ["tests", 368], ["(", 374], ["IGRA", 375], [")", 379], ["show", 381], ["superior", 386], ["specificity", 395], ["and", 407], ["sensitivity", 411], ["but", 423], ["are", 427], ["more", 431], ["expensive", 436], [".", 445], ["The", 447], ["present", 451], ["study", 459], ["reports", 465], ["the", 473], ["results", 477], ["of", 485], ["a", 488], ["three", 490], ["-", 495], ["year", 496], ["TB", 501], ["surveillance", 504], ["among", 517], ["HCW", 523], ["in", 527], ["a", 530], ["large", 532], ["teaching", 538], ["hospital", 547], ["in", 556], ["Rome", 559], [",", 563], ["using", 565], ["TST", 571], ["(", 575], ["by", 576], ["standard", 579], ["Mantoux", 588], ["technique", 596], [")", 605], ["and", 607], ["IGRA", 611], ["(", 616], ["by", 617], ["QuantiFERON", 620], ["-", 631], ["TB", 632], [")", 634], ["as", 636], ["first-", 639], ["and", 646], ["second", 650], ["-", 656], ["level", 657], ["screening", 663], ["tests", 673], [",", 678], ["respectively", 680], [".", 692], ["Out", 694], ["of", 698], ["2290", 701], ["HCW", 706], ["enrolled", 710], [",", 718], ["141", 720], ["(", 724], ["6.1", 725], ["%", 728], [")", 729], ["had", 731], ["a", 735], ["positive", 737], ["TST", 746], [";", 749], ["among", 751], ["them", 757], [",", 761], ["99", 763], ["(", 766], ["70.2", 767], ["%", 771], [")", 772], ["underwent", 774], ["the", 784], ["IGRA", 788], ["and", 793], ["16", 797], ["tested", 800], ["positive", 807], ["(", 816], ["16.1", 817], ["%", 821], [")", 822], [".", 823], ["The", 825], ["frequency", 829], ["of", 839], ["HCW", 842], ["tested", 846], ["positive", 853], ["for", 862], ["TB", 866], ["seems", 869], ["not", 875], ["far", 879], ["from", 883], ["other", 888], ["experiences", 894], ["in", 906], ["low", 909], ["incidence", 913], ["countries", 923], [".", 932], ["Our", 934], ["results", 938], ["confirm", 946], ["the", 954], ["higher", 958], ["specificity", 965], ["of", 977], ["IGRA", 980], [",", 984], ["but", 986], [",", 989], ["due", 991], ["to", 995], ["its", 998], ["higher", 1002], ["cost", 1009], [",", 1013], ["TST", 1015], ["can", 1019], ["be", 1023], ["considered", 1026], ["a", 1037], ["good", 1039], ["first", 1044], ["level", 1050], ["screening", 1056], ["test", 1066], [",", 1070], ["whose", 1072], ["positive", 1078], ["results", 1087], ["should", 1095], ["be", 1102], ["further", 1105], ["confirmed", 1113], ["by", 1123], ["IGRA", 1126], ["before", 1131], ["the", 1138], ["patients", 1142], ["undergo", 1151], ["X", 1159], ["-", 1160], ["ray", 1161], ["diagnosis", 1165], ["and/or", 1175], ["chemotherapy", 1182], [".", 1194]]}
{"context": "With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients. Our expanding knowledge of the molecular processes underlying these conditions has resulted in novel bone targets that are currently being explored in clinical trials. Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years. Potential agents targeting the osteoclast include cathepsin K, currently in phase 3 trials, and src inhibitors. Amongst anabolic agents, inhibitors of the Wnt-inhibitor sclerostin and dickkopf-1 are promising in clinical trials. Here, we will provide a comprehensive overview of the most promising agents currently explored for the treatment of bone diseases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "ba391f992ee74328aaba8df43265479c", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[71, 71]], "char_spans": [[449, 453]]}]}], "context_tokens": [["With", 0], ["an", 5], ["ageing", 8], ["population", 15], ["and", 26], ["improving", 30], ["cancer", 40], ["therapies", 47], [",", 56], ["the", 58], ["two", 62], ["most", 66], ["common", 71], ["benign", 78], ["and", 85], ["malignant", 89], ["bone", 99], ["diseases", 104], [",", 112], ["osteoporosis", 114], ["and", 127], ["bone", 131], ["metastases", 136], [",", 146], ["will", 148], ["continue", 153], ["to", 162], ["affect", 165], ["an", 172], ["increasing", 175], ["number", 186], ["of", 193], ["patients", 196], [".", 204], ["Our", 206], ["expanding", 210], ["knowledge", 220], ["of", 230], ["the", 233], ["molecular", 237], ["processes", 247], ["underlying", 257], ["these", 268], ["conditions", 274], ["has", 285], ["resulted", 289], ["in", 298], ["novel", 301], ["bone", 307], ["targets", 312], ["that", 320], ["are", 325], ["currently", 329], ["being", 339], ["explored", 345], ["in", 354], ["clinical", 357], ["trials", 366], [".", 372], ["Clearly", 374], [",", 381], ["the", 383], ["approval", 387], ["of", 396], ["denosumab", 399], [",", 408], ["a", 410], ["monoclonal", 412], ["antibody", 423], ["directed", 432], ["against", 441], ["RANKL", 449], [",", 454], ["has", 456], ["just", 460], ["marked", 465], ["the", 472], ["beginning", 476], ["of", 486], ["a", 489], ["new", 491], ["era", 495], ["for", 499], ["bone", 503], ["therapy", 508], ["with", 516], ["several", 521], ["additional", 529], ["new", 540], ["therapies", 544], ["lining", 554], ["up", 561], ["for", 564], ["clinical", 568], ["approval", 577], ["in", 586], ["the", 589], ["coming", 593], ["years", 600], [".", 605], ["Potential", 607], ["agents", 617], ["targeting", 624], ["the", 634], ["osteoclast", 638], ["include", 649], ["cathepsin", 657], ["K", 667], [",", 668], ["currently", 670], ["in", 680], ["phase", 683], ["3", 689], ["trials", 691], [",", 697], ["and", 699], ["src", 703], ["inhibitors", 707], [".", 717], ["Amongst", 719], ["anabolic", 727], ["agents", 736], [",", 742], ["inhibitors", 744], ["of", 755], ["the", 758], ["Wnt", 762], ["-", 765], ["inhibitor", 766], ["sclerostin", 776], ["and", 787], ["dickkopf-1", 791], ["are", 802], ["promising", 806], ["in", 816], ["clinical", 819], ["trials", 828], [".", 834], ["Here", 836], [",", 840], ["we", 842], ["will", 845], ["provide", 850], ["a", 858], ["comprehensive", 860], ["overview", 874], ["of", 883], ["the", 886], ["most", 890], ["promising", 895], ["agents", 905], ["currently", 912], ["explored", 922], ["for", 931], ["the", 935], ["treatment", 939], ["of", 949], ["bone", 952], ["diseases", 957], [".", 965]]}
{"context": "The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion--based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01(E) or RTS,S/AS02(D), on a 0-1-2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02(D)/AS01(E)) of 0.88 (95% CI: 0.68-1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01(E) proved similarly as well tolerated and immunogenic as RTS,S/AS02(D), completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "b3cdf347d3884750ab5f93ca7c8f1257", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[1, 1]], "char_spans": [[4, 10]]}]}], "context_tokens": [["The", 0], ["malaria", 4], ["vaccine", 12], ["candidate", 20], ["antigen", 30], ["RTS", 38], [",", 41], ["S", 42], ["includes", 44], ["parts", 53], ["of", 59], ["the", 62], ["pre", 66], ["-", 69], ["erythrocytic", 70], ["stage", 83], ["circumsporozoite", 89], ["protein", 106], ["fused", 114], ["to", 120], ["the", 123], ["Hepatitis", 127], ["B", 137], ["surface", 139], ["antigen", 147], [".", 154], ["Two", 156], ["Adjuvant", 160], ["Systems", 169], ["are", 177], ["in", 181], ["development", 184], ["for", 196], ["this", 200], ["vaccine", 205], [",", 212], ["an", 214], ["oil", 217], ["-", 220], ["in", 221], ["water", 224], ["emulsion", 230], ["--", 238], ["based", 240], ["formulation", 246], ["(", 258], ["AS02", 259], [")", 263], ["and", 265], ["a", 269], ["formulation", 271], ["based", 283], ["on", 289], ["liposomes", 292], ["(", 302], ["AS01", 303], [")", 307], [".", 308], ["In", 310], ["this", 313], ["Phase", 318], ["II", 324], [",", 326], ["double", 328], ["-", 334], ["blind", 335], ["study", 341], ["(", 347], ["NCT00307021", 348], [")", 359], [",", 360], ["180", 362], ["healthy", 366], ["Gabonese", 374], ["children", 383], ["aged", 392], ["18", 397], ["months", 400], ["to", 407], ["4", 410], ["years", 412], ["were", 418], ["randomized", 423], ["to", 434], ["receive", 437], ["either", 445], ["RTS", 452], [",", 455], ["S", 456], ["/", 457], ["AS01(E", 458], [")", 464], ["or", 466], ["RTS", 469], [",", 472], ["S", 473], ["/", 474], ["AS02(D", 475], [")", 481], [",", 482], ["on", 484], ["a", 487], ["0", 489], ["-", 490], ["1", 491], ["-", 492], ["2", 493], ["month", 495], ["vaccination", 501], ["schedule", 513], [".", 521], ["The", 523], ["children", 527], ["were", 536], ["followed", 541], ["-", 549], ["up", 550], ["daily", 553], ["for", 559], ["six", 563], ["days", 567], ["after", 572], ["each", 578], ["vaccination", 583], ["and", 595], ["monthly", 599], ["for", 607], ["14", 611], ["months", 614], [".", 620], ["Blood", 622], ["samples", 628], ["were", 636], ["collected", 641], ["at", 651], ["4", 654], ["time", 656], ["-", 660], ["points", 661], [".", 667], ["Both", 669], ["vaccines", 674], ["were", 683], ["well", 688], ["tolerated", 693], [".", 702], ["Safety", 704], ["parameters", 711], ["were", 722], ["distributed", 727], ["similarly", 739], ["between", 749], ["the", 757], ["two", 761], ["groups", 765], [".", 771], ["Both", 773], ["vaccines", 778], ["elicited", 787], ["a", 796], ["strong", 798], ["specific", 805], ["immune", 814], ["response", 821], ["after", 830], ["Doses", 836], ["2", 842], ["and", 844], ["3", 848], ["with", 850], ["a", 855], ["ratio", 857], ["of", 863], ["anti", 866], ["-", 870], ["CS", 871], ["GMT", 874], ["titers", 878], ["(", 885], ["AS02(D)/AS01(E", 886], [")", 900], [")", 901], ["of", 903], ["0.88", 906], ["(", 911], ["95", 912], ["%", 914], ["CI", 916], [":", 918], ["0.68", 920], ["-", 924], ["1.15", 925], [")", 929], ["post", 931], ["-", 935], ["Dose", 936], ["3", 941], [".", 942], ["After", 944], ["Doses", 950], ["2", 956], ["and", 958], ["3", 962], ["of", 964], ["experimental", 967], ["vaccines", 980], [",", 988], ["anti", 990], ["-", 994], ["CS", 995], ["and", 998], ["anti", 1002], ["-", 1006], ["HBs", 1007], ["antibody", 1011], ["GMTs", 1020], ["were", 1025], ["higher", 1030], ["in", 1037], ["children", 1040], ["who", 1049], ["had", 1053], ["been", 1057], ["previously", 1062], ["vaccinated", 1073], ["with", 1084], ["at", 1089], ["least", 1092], ["one", 1098], ["dose", 1102], ["of", 1107], ["hepatitis", 1110], ["B", 1120], ["vaccine", 1122], ["compared", 1130], ["to", 1139], ["those", 1142], ["not", 1148], ["previously", 1152], ["vaccinated", 1163], [".", 1173], ["RTS", 1175], [",", 1178], ["S", 1179], ["/", 1180], ["AS01(E", 1181], [")", 1187], ["proved", 1189], ["similarly", 1196], ["as", 1206], ["well", 1209], ["tolerated", 1214], ["and", 1224], ["immunogenic", 1228], ["as", 1240], ["RTS", 1243], [",", 1246], ["S", 1247], ["/", 1248], ["AS02(D", 1249], [")", 1255], [",", 1256], ["completing", 1258], ["an", 1269], ["essential", 1272], ["step", 1282], ["in", 1287], ["the", 1290], ["age", 1294], ["de", 1298], ["-", 1300], ["escalation", 1301], ["process", 1312], ["within", 1320], ["the", 1327], ["RTS", 1331], [",", 1334], ["S", 1335], ["clinical", 1337], ["development", 1346], ["plan", 1358], [".", 1362], ["ClinicalTrials.gov", 1364], [".", 1382], ["NCT00307021", 1384], [".", 1395]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus. The clinical findings of SGS include neurological, cardiovascular, connective tissue, and skeletal abnormalities. Among these skeletal findings, developmental scoliosis is recognized in half of all patients with SGS. However, no earlier reports have described the surgical treatment of scoliosis associated with SGS. Four patients (2 boys and 2 girls; mean age at the time of surgery, 7.3\u00b14.4 y) with SGS who underwent surgical treatment for progressive scoliosis were reviewed. The radiologic findings, operative findings, and perioperative complications were evaluated. The mean preoperative Cobb angle was 102.8\u00b116.9 degrees. The curve patterns were a double curve in 2 cases and a triple curve in 2 cases. Local kyphosis at the thoracolumbar area was recognized in all the cases with a mean kyphosis angle of 49\u00b116 degrees. Growing rod procedures were performed in 2 patients, and posterior correction and fusion were performed in 2 patients. The mean correction rate was 45% in the patients who underwent the growing rod procedures at the time of growing rod placement and 51% in the patients who underwent posterior correction and fusion. Dislodgement of the proximal anchors occurred in 3 of the 4 patients. One patient developed pseudoarthrosis. Two patients developed deep wound infections, and implant removal was necessary in 1 patient. Surgical treatment for scoliosis in patients with SGS was associated with a high incidence of perioperative and postoperative complications including implant dislodgements and deep wound infections attributable to poor bone quality and a thin body habitus, which are characteristic clinical features of this syndrome. Careful preoperative surgical planning and postoperative care are critical for the surgical treatment of scoliosis associated with SGS, especially in infants requiring multiple surgeries. Level IV.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "07d30350f8434b48815eaa39fc6cedd9", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[10, 10]], "char_spans": [[55, 70]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["craniosynostosis", 55], ["and", 72], ["marfanoid", 76], ["habitus", 86], [".", 93], ["The", 95], ["clinical", 99], ["findings", 108], ["of", 117], ["SGS", 120], ["include", 124], ["neurological", 132], [",", 144], ["cardiovascular", 146], [",", 160], ["connective", 162], ["tissue", 173], [",", 179], ["and", 181], ["skeletal", 185], ["abnormalities", 194], [".", 207], ["Among", 209], ["these", 215], ["skeletal", 221], ["findings", 230], [",", 238], ["developmental", 240], ["scoliosis", 254], ["is", 264], ["recognized", 267], ["in", 278], ["half", 281], ["of", 286], ["all", 289], ["patients", 293], ["with", 302], ["SGS", 307], [".", 310], ["However", 312], [",", 319], ["no", 321], ["earlier", 324], ["reports", 332], ["have", 340], ["described", 345], ["the", 355], ["surgical", 359], ["treatment", 368], ["of", 378], ["scoliosis", 381], ["associated", 391], ["with", 402], ["SGS", 407], [".", 410], ["Four", 412], ["patients", 417], ["(", 426], ["2", 427], ["boys", 429], ["and", 434], ["2", 438], ["girls", 440], [";", 445], ["mean", 447], ["age", 452], ["at", 456], ["the", 459], ["time", 463], ["of", 468], ["surgery", 471], [",", 478], ["7.3\u00b14.4", 480], ["y", 488], [")", 489], ["with", 491], ["SGS", 496], ["who", 500], ["underwent", 504], ["surgical", 514], ["treatment", 523], ["for", 533], ["progressive", 537], ["scoliosis", 549], ["were", 559], ["reviewed", 564], [".", 572], ["The", 574], ["radiologic", 578], ["findings", 589], [",", 597], ["operative", 599], ["findings", 609], [",", 617], ["and", 619], ["perioperative", 623], ["complications", 637], ["were", 651], ["evaluated", 656], [".", 665], ["The", 667], ["mean", 671], ["preoperative", 676], ["Cobb", 689], ["angle", 694], ["was", 700], ["102.8\u00b116.9", 704], ["degrees", 715], [".", 722], ["The", 724], ["curve", 728], ["patterns", 734], ["were", 743], ["a", 748], ["double", 750], ["curve", 757], ["in", 763], ["2", 766], ["cases", 768], ["and", 774], ["a", 778], ["triple", 780], ["curve", 787], ["in", 793], ["2", 796], ["cases", 798], [".", 803], ["Local", 805], ["kyphosis", 811], ["at", 820], ["the", 823], ["thoracolumbar", 827], ["area", 841], ["was", 846], ["recognized", 850], ["in", 861], ["all", 864], ["the", 868], ["cases", 872], ["with", 878], ["a", 883], ["mean", 885], ["kyphosis", 890], ["angle", 899], ["of", 905], ["49\u00b116", 908], ["degrees", 914], [".", 921], ["Growing", 923], ["rod", 931], ["procedures", 935], ["were", 946], ["performed", 951], ["in", 961], ["2", 964], ["patients", 966], [",", 974], ["and", 976], ["posterior", 980], ["correction", 990], ["and", 1001], ["fusion", 1005], ["were", 1012], ["performed", 1017], ["in", 1027], ["2", 1030], ["patients", 1032], [".", 1040], ["The", 1042], ["mean", 1046], ["correction", 1051], ["rate", 1062], ["was", 1067], ["45", 1071], ["%", 1073], ["in", 1075], ["the", 1078], ["patients", 1082], ["who", 1091], ["underwent", 1095], ["the", 1105], ["growing", 1109], ["rod", 1117], ["procedures", 1121], ["at", 1132], ["the", 1135], ["time", 1139], ["of", 1144], ["growing", 1147], ["rod", 1155], ["placement", 1159], ["and", 1169], ["51", 1173], ["%", 1175], ["in", 1177], ["the", 1180], ["patients", 1184], ["who", 1193], ["underwent", 1197], ["posterior", 1207], ["correction", 1217], ["and", 1228], ["fusion", 1232], [".", 1238], ["Dislodgement", 1240], ["of", 1253], ["the", 1256], ["proximal", 1260], ["anchors", 1269], ["occurred", 1277], ["in", 1286], ["3", 1289], ["of", 1291], ["the", 1294], ["4", 1298], ["patients", 1300], [".", 1308], ["One", 1310], ["patient", 1314], ["developed", 1322], ["pseudoarthrosis", 1332], [".", 1347], ["Two", 1349], ["patients", 1353], ["developed", 1362], ["deep", 1372], ["wound", 1377], ["infections", 1383], [",", 1393], ["and", 1395], ["implant", 1399], ["removal", 1407], ["was", 1415], ["necessary", 1419], ["in", 1429], ["1", 1432], ["patient", 1434], [".", 1441], ["Surgical", 1443], ["treatment", 1452], ["for", 1462], ["scoliosis", 1466], ["in", 1476], ["patients", 1479], ["with", 1488], ["SGS", 1493], ["was", 1497], ["associated", 1501], ["with", 1512], ["a", 1517], ["high", 1519], ["incidence", 1524], ["of", 1534], ["perioperative", 1537], ["and", 1551], ["postoperative", 1555], ["complications", 1569], ["including", 1583], ["implant", 1593], ["dislodgements", 1601], ["and", 1615], ["deep", 1619], ["wound", 1624], ["infections", 1630], ["attributable", 1641], ["to", 1654], ["poor", 1657], ["bone", 1662], ["quality", 1667], ["and", 1675], ["a", 1679], ["thin", 1681], ["body", 1686], ["habitus", 1691], [",", 1698], ["which", 1700], ["are", 1706], ["characteristic", 1710], ["clinical", 1725], ["features", 1734], ["of", 1743], ["this", 1746], ["syndrome", 1751], [".", 1759], ["Careful", 1761], ["preoperative", 1769], ["surgical", 1782], ["planning", 1791], ["and", 1800], ["postoperative", 1804], ["care", 1818], ["are", 1823], ["critical", 1827], ["for", 1836], ["the", 1840], ["surgical", 1844], ["treatment", 1853], ["of", 1863], ["scoliosis", 1866], ["associated", 1876], ["with", 1887], ["SGS", 1892], [",", 1895], ["especially", 1897], ["in", 1908], ["infants", 1911], ["requiring", 1919], ["multiple", 1929], ["surgeries", 1938], [".", 1947], ["Level", 1949], ["IV", 1955], [".", 1957]]}
{"context": "The expression of selenoproteins requires the translational recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS), and SECIS-binding protein 2 (SBP2). This study implicates SBP2 in dictating the hierarchy of selenoprotein expression, because it is the first to show that SBP2 distinguishes between SECIS elements in vitro. Using RNA electrophoretic mobility shift assays, we demonstrate that a naturally occurring mutation in SBP2, which correlates with abnormal thyroid hormone function in humans, lies within a novel, bipartite RNA-binding domain. This mutation alters the RNA binding affinity of SBP2 such that it no longer stably interacts with a subset of SECIS elements. Assays performed under competitive conditions to mimic intracellular conditions suggest that the differential affinity of SBP2 for various SECIS elements will determine the expression pattern of the selenoproteome. We hypothesize that the selective loss of a subset of selenoproteins, including some involved in thyroid hormone homeostasis, is responsible for the abnormal thyroid hormone metabolism previously observed in the affected individuals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "4a2ea59ce04b469fb5deddf4edb5b587", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[157, 157], [37, 37], [41, 41], [73, 73], [136, 136]], "char_spans": [[950, 954], [241, 245], [253, 257], [432, 436], [795, 799]]}]}], "context_tokens": [["The", 0], ["expression", 4], ["of", 15], ["selenoproteins", 18], ["requires", 33], ["the", 42], ["translational", 46], ["recoding", 60], ["of", 69], ["the", 72], ["UGA", 76], ["stop", 80], ["codon", 85], ["to", 91], ["selenocysteine", 94], [".", 108], ["In", 110], ["eukaryotes", 113], [",", 123], ["this", 125], ["requires", 130], ["an", 139], ["RNA", 142], ["stem", 146], ["loop", 151], ["structure", 156], ["in", 166], ["the", 169], ["3'-untranslated", 173], ["region", 189], [",", 195], ["termed", 197], ["a", 204], ["selenocysteine", 206], ["insertion", 221], ["sequence", 231], ["(", 240], ["SECIS", 241], [")", 246], [",", 247], ["and", 249], ["SECIS", 253], ["-", 258], ["binding", 259], ["protein", 267], ["2", 275], ["(", 277], ["SBP2", 278], [")", 282], [".", 283], ["This", 285], ["study", 290], ["implicates", 296], ["SBP2", 307], ["in", 312], ["dictating", 315], ["the", 325], ["hierarchy", 329], ["of", 339], ["selenoprotein", 342], ["expression", 356], [",", 366], ["because", 368], ["it", 376], ["is", 379], ["the", 382], ["first", 386], ["to", 392], ["show", 395], ["that", 400], ["SBP2", 405], ["distinguishes", 410], ["between", 424], ["SECIS", 432], ["elements", 438], ["in", 447], ["vitro", 450], [".", 455], ["Using", 457], ["RNA", 463], ["electrophoretic", 467], ["mobility", 483], ["shift", 492], ["assays", 498], [",", 504], ["we", 506], ["demonstrate", 509], ["that", 521], ["a", 526], ["naturally", 528], ["occurring", 538], ["mutation", 548], ["in", 557], ["SBP2", 560], [",", 564], ["which", 566], ["correlates", 572], ["with", 583], ["abnormal", 588], ["thyroid", 597], ["hormone", 605], ["function", 613], ["in", 622], ["humans", 625], [",", 631], ["lies", 633], ["within", 638], ["a", 645], ["novel", 647], [",", 652], ["bipartite", 654], ["RNA", 664], ["-", 667], ["binding", 668], ["domain", 676], [".", 682], ["This", 684], ["mutation", 689], ["alters", 698], ["the", 705], ["RNA", 709], ["binding", 713], ["affinity", 721], ["of", 730], ["SBP2", 733], ["such", 738], ["that", 743], ["it", 748], ["no", 751], ["longer", 754], ["stably", 761], ["interacts", 768], ["with", 778], ["a", 783], ["subset", 785], ["of", 792], ["SECIS", 795], ["elements", 801], [".", 809], ["Assays", 811], ["performed", 818], ["under", 828], ["competitive", 834], ["conditions", 846], ["to", 857], ["mimic", 860], ["intracellular", 866], ["conditions", 880], ["suggest", 891], ["that", 899], ["the", 904], ["differential", 908], ["affinity", 921], ["of", 930], ["SBP2", 933], ["for", 938], ["various", 942], ["SECIS", 950], ["elements", 956], ["will", 965], ["determine", 970], ["the", 980], ["expression", 984], ["pattern", 995], ["of", 1003], ["the", 1006], ["selenoproteome", 1010], [".", 1024], ["We", 1026], ["hypothesize", 1029], ["that", 1041], ["the", 1046], ["selective", 1050], ["loss", 1060], ["of", 1065], ["a", 1068], ["subset", 1070], ["of", 1077], ["selenoproteins", 1080], [",", 1094], ["including", 1096], ["some", 1106], ["involved", 1111], ["in", 1120], ["thyroid", 1123], ["hormone", 1131], ["homeostasis", 1139], [",", 1150], ["is", 1152], ["responsible", 1155], ["for", 1167], ["the", 1171], ["abnormal", 1175], ["thyroid", 1184], ["hormone", 1192], ["metabolism", 1200], ["previously", 1211], ["observed", 1222], ["in", 1231], ["the", 1234], ["affected", 1238], ["individuals", 1247], [".", 1258]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike. CA-MRSA may express virulence factors such as Panton-Valentine leukocidin, which makes soft-tissue and hard-tissue infections due to such organisms challenging to treat. We report a case of osteomyelitis of the proximal tibia in a 10-year-old boy and discuss its management in what is to the authors' knowledge the first case report of Panton-Valentine leukocidin-positive CA-MRSA osteomyelitis in a child in the UK.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "aee842a768df4abebce2612c194f1e62", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[33, 33], [104, 104], [11, 11]], "char_spans": [[191, 194], [564, 567], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["is", 75], ["increasing", 78], ["in", 89], ["prevalence", 92], ["among", 103], ["asymptomatic", 109], ["carriers", 122], ["and", 131], ["in", 135], ["cases", 138], ["of", 144], ["paediatric", 147], ["soft", 158], ["-", 162], ["tissue", 163], ["infections", 170], ["alike", 181], [".", 186], ["CA", 188], ["-", 190], ["MRSA", 191], ["may", 196], ["express", 200], ["virulence", 208], ["factors", 218], ["such", 226], ["as", 231], ["Panton", 234], ["-", 240], ["Valentine", 241], ["leukocidin", 251], [",", 261], ["which", 263], ["makes", 269], ["soft", 275], ["-", 279], ["tissue", 280], ["and", 287], ["hard", 291], ["-", 295], ["tissue", 296], ["infections", 303], ["due", 314], ["to", 318], ["such", 321], ["organisms", 326], ["challenging", 336], ["to", 348], ["treat", 351], [".", 356], ["We", 358], ["report", 361], ["a", 368], ["case", 370], ["of", 375], ["osteomyelitis", 378], ["of", 392], ["the", 395], ["proximal", 399], ["tibia", 408], ["in", 414], ["a", 417], ["10-year", 419], ["-", 426], ["old", 427], ["boy", 431], ["and", 435], ["discuss", 439], ["its", 447], ["management", 451], ["in", 462], ["what", 465], ["is", 470], ["to", 473], ["the", 476], ["authors", 480], ["'", 487], ["knowledge", 489], ["the", 499], ["first", 503], ["case", 509], ["report", 514], ["of", 521], ["Panton", 524], ["-", 530], ["Valentine", 531], ["leukocidin", 541], ["-", 551], ["positive", 552], ["CA", 561], ["-", 563], ["MRSA", 564], ["osteomyelitis", 569], ["in", 583], ["a", 586], ["child", 588], ["in", 594], ["the", 597], ["UK", 601], [".", 603]]}
{"context": "Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemogenesis in CML. The aim of this observational cohort study was to discriminate and quantify BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis). Twenty-two patients were followed for six months during treatment. Quantitative real time polymerase chain reaction was performed before treatment and after 3 and 6 months from treatment initiation. As compared with the third month, there was a significant decrease in BCR-ABL expression in the sixth month of treatment (P = 0.0002). At the sixth month, there was a significant difference in the levels of the two major transcripts of BCR-ABL, B2A2 and B3A2 (P = 0.0347), indicating that B2A2 may be more sensitive to imatinib. The results of our study indicate that imatinib is able to modify the natural history of CML, and raise the hypothesis that patients who express the B2A2 transcript may have a better prognosis.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e19160c7bb354a72b145aeab75882fde", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[78, 80], [182, 184], [26, 28], [147, 149]], "char_spans": [[488, 494], [1048, 1054], [167, 173], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["originates", 31], ["from", 42], ["the", 47], ["hematopoietic", 51], ["stem", 65], ["cell", 70], ["and", 75], ["is", 79], ["characterized", 82], ["by", 96], ["the", 99], ["reciprocal", 103], ["translocation", 114], ["t(9;22)(q34;q11", 128], [")", 143], [",", 144], ["which", 146], ["results", 152], ["in", 160], ["the", 163], ["BCR", 167], ["-", 170], ["ABL", 171], ["fusion", 175], ["gene", 182], ["on", 187], ["chromosome", 190], ["22q-", 201], [",", 205], ["also", 207], ["known", 212], ["as", 218], ["the", 221], ["Philadelphia", 225], ["chromosome", 238], [".", 248], ["This", 250], ["chimeric", 255], ["gene", 264], ["codes", 269], ["for", 275], ["a", 279], ["cytoplasmic", 281], ["protein", 293], ["with", 301], ["constitutive", 306], ["tyrosine", 319], ["-", 327], ["kinase", 328], ["activity", 335], [",", 343], ["responsible", 345], ["for", 357], ["cellular", 361], ["transformation", 370], ["and", 385], ["leukemogenesis", 389], ["in", 404], ["CML", 407], [".", 410], ["The", 412], ["aim", 416], ["of", 420], ["this", 423], ["observational", 428], ["cohort", 442], ["study", 449], ["was", 455], ["to", 459], ["discriminate", 462], ["and", 475], ["quantify", 479], ["BCR", 488], ["-", 491], ["ABL", 492], ["transcripts", 496], ["in", 508], ["the", 511], ["peripheral", 515], ["blood", 526], ["of", 532], ["patients", 535], ["with", 544], ["CML", 549], ["who", 553], ["were", 557], ["treated", 562], ["with", 570], ["imatinib", 575], ["mesylate", 584], ["(", 593], ["Glivec", 594], [",", 600], ["Novartis", 602], [")", 610], [".", 611], ["Twenty", 613], ["-", 619], ["two", 620], ["patients", 624], ["were", 633], ["followed", 638], ["for", 647], ["six", 651], ["months", 655], ["during", 662], ["treatment", 669], [".", 678], ["Quantitative", 680], ["real", 693], ["time", 698], ["polymerase", 703], ["chain", 714], ["reaction", 720], ["was", 729], ["performed", 733], ["before", 743], ["treatment", 750], ["and", 760], ["after", 764], ["3", 770], ["and", 772], ["6", 776], ["months", 778], ["from", 785], ["treatment", 790], ["initiation", 800], [".", 810], ["As", 812], ["compared", 815], ["with", 824], ["the", 829], ["third", 833], ["month", 839], [",", 844], ["there", 846], ["was", 852], ["a", 856], ["significant", 858], ["decrease", 870], ["in", 879], ["BCR", 882], ["-", 885], ["ABL", 886], ["expression", 890], ["in", 901], ["the", 904], ["sixth", 908], ["month", 914], ["of", 920], ["treatment", 923], ["(", 933], ["P", 934], ["=", 936], ["0.0002", 938], [")", 944], [".", 945], ["At", 947], ["the", 950], ["sixth", 954], ["month", 960], [",", 965], ["there", 967], ["was", 973], ["a", 977], ["significant", 979], ["difference", 991], ["in", 1002], ["the", 1005], ["levels", 1009], ["of", 1016], ["the", 1019], ["two", 1023], ["major", 1027], ["transcripts", 1033], ["of", 1045], ["BCR", 1048], ["-", 1051], ["ABL", 1052], [",", 1055], ["B2A2", 1057], ["and", 1062], ["B3A2", 1066], ["(", 1071], ["P", 1072], ["=", 1074], ["0.0347", 1076], [")", 1082], [",", 1083], ["indicating", 1085], ["that", 1096], ["B2A2", 1101], ["may", 1106], ["be", 1110], ["more", 1113], ["sensitive", 1118], ["to", 1128], ["imatinib", 1131], [".", 1139], ["The", 1141], ["results", 1145], ["of", 1153], ["our", 1156], ["study", 1160], ["indicate", 1166], ["that", 1175], ["imatinib", 1180], ["is", 1189], ["able", 1192], ["to", 1197], ["modify", 1200], ["the", 1207], ["natural", 1211], ["history", 1219], ["of", 1227], ["CML", 1230], [",", 1233], ["and", 1235], ["raise", 1239], ["the", 1245], ["hypothesis", 1249], ["that", 1260], ["patients", 1265], ["who", 1274], ["express", 1278], ["the", 1286], ["B2A2", 1290], ["transcript", 1295], ["may", 1306], ["have", 1310], ["a", 1315], ["better", 1317], ["prognosis", 1324], [".", 1333]]}
{"context": "MicroRNAs (miRNAs) are 21 nt RNAs that regulate many biological processes in plants by mediating translational inhibition or cleavage of target transcripts. Arabidopsis mutants defective in miRNA biogenesis have overlapping and highly pleiotropic phenotypes including serrated leaves and ABA hypersensitivity. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II). Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels. Co-immunoprecipitation experiments revealed that pri-miRNAs 159, 166, 168 and 172 could be associated with CBP20 and CBP80. We found that CBP20 and CBP80 are stabilized by ABA by a post-translational mechanism, and these proteins are needed for ABA induction of miR159 during seed germination. The lack of miR159 accumulation in ABA-treated seeds of cbp20/80 mutants leads to increased MYB33 and MYB101 transcript levels, and presumably higher levels of these positive regulators result in ABA hypersensitivity. Genetic and molecular analyses show that CBP20 and 80 have overlapping function in the same developmental pathway as SE and HYL1. Our results identify new components in miRNA biogenesis.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "f8691bdd04254433a162cdef7998689e", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[53, 55]], "char_spans": [[372, 388]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["21", 23], ["nt", 26], ["RNAs", 29], ["that", 34], ["regulate", 39], ["many", 48], ["biological", 53], ["processes", 64], ["in", 74], ["plants", 77], ["by", 84], ["mediating", 87], ["translational", 97], ["inhibition", 111], ["or", 122], ["cleavage", 125], ["of", 134], ["target", 137], ["transcripts", 144], [".", 155], ["Arabidopsis", 157], ["mutants", 169], ["defective", 177], ["in", 187], ["miRNA", 190], ["biogenesis", 196], ["have", 207], ["overlapping", 212], ["and", 224], ["highly", 228], ["pleiotropic", 235], ["phenotypes", 247], ["including", 258], ["serrated", 268], ["leaves", 277], ["and", 284], ["ABA", 288], ["hypersensitivity", 292], [".", 308], ["Recent", 310], ["evidence", 317], ["indicates", 326], ["that", 336], ["miRNA", 341], ["genes", 347], ["are", 353], ["transcribed", 357], ["by", 369], ["RNA", 372], ["polymerase", 376], ["II", 387], ["(", 390], ["Pol", 391], ["II", 395], [")", 397], [".", 398], ["Since", 400], ["Pol", 406], ["II", 410], ["transcripts", 413], ["are", 425], ["capped", 429], [",", 435], ["we", 437], ["hypothesized", 440], ["that", 453], ["CBP", 458], ["(", 462], ["cap", 463], ["-", 466], ["binding", 467], ["protein", 475], [")", 482], ["20", 484], ["and", 487], ["80", 491], ["may", 494], ["bind", 498], ["to", 503], ["capped", 506], ["primary", 513], ["miRNA", 521], ["(", 527], ["pri", 528], ["-", 531], ["miRNA", 532], [")", 537], ["transcripts", 539], ["and", 551], ["play", 555], ["a", 560], ["role", 562], ["in", 567], ["their", 570], ["processing", 576], [".", 586], ["Here", 588], [",", 592], ["we", 594], ["show", 597], ["that", 602], ["cbp20", 607], ["and", 613], ["cbp80", 617], ["mutants", 623], ["have", 631], ["reduced", 636], ["miRNA", 644], ["levels", 650], ["and", 657], ["increased", 661], ["pri", 671], ["-", 674], ["miRNA", 675], ["levels", 681], [".", 687], ["Co", 689], ["-", 691], ["immunoprecipitation", 692], ["experiments", 712], ["revealed", 724], ["that", 733], ["pri", 738], ["-", 741], ["miRNAs", 742], ["159", 749], [",", 752], ["166", 754], [",", 757], ["168", 759], ["and", 763], ["172", 767], ["could", 771], ["be", 777], ["associated", 780], ["with", 791], ["CBP20", 796], ["and", 802], ["CBP80", 806], [".", 811], ["We", 813], ["found", 816], ["that", 822], ["CBP20", 827], ["and", 833], ["CBP80", 837], ["are", 843], ["stabilized", 847], ["by", 858], ["ABA", 861], ["by", 865], ["a", 868], ["post", 870], ["-", 874], ["translational", 875], ["mechanism", 889], [",", 898], ["and", 900], ["these", 904], ["proteins", 910], ["are", 919], ["needed", 923], ["for", 930], ["ABA", 934], ["induction", 938], ["of", 948], ["miR159", 951], ["during", 958], ["seed", 965], ["germination", 970], [".", 981], ["The", 983], ["lack", 987], ["of", 992], ["miR159", 995], ["accumulation", 1002], ["in", 1015], ["ABA", 1018], ["-", 1021], ["treated", 1022], ["seeds", 1030], ["of", 1036], ["cbp20/80", 1039], ["mutants", 1048], ["leads", 1056], ["to", 1062], ["increased", 1065], ["MYB33", 1075], ["and", 1081], ["MYB101", 1085], ["transcript", 1092], ["levels", 1103], [",", 1109], ["and", 1111], ["presumably", 1115], ["higher", 1126], ["levels", 1133], ["of", 1140], ["these", 1143], ["positive", 1149], ["regulators", 1158], ["result", 1169], ["in", 1176], ["ABA", 1179], ["hypersensitivity", 1183], [".", 1199], ["Genetic", 1201], ["and", 1209], ["molecular", 1213], ["analyses", 1223], ["show", 1232], ["that", 1237], ["CBP20", 1242], ["and", 1248], ["80", 1252], ["have", 1255], ["overlapping", 1260], ["function", 1272], ["in", 1281], ["the", 1284], ["same", 1288], ["developmental", 1293], ["pathway", 1307], ["as", 1315], ["SE", 1318], ["and", 1321], ["HYL1", 1325], [".", 1329], ["Our", 1331], ["results", 1335], ["identify", 1343], ["new", 1352], ["components", 1356], ["in", 1367], ["miRNA", 1370], ["biogenesis", 1376], [".", 1386]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "Malaria is one of the most devastating infectious diseases in the developing world. Until now, only one candidate malaria vaccine RTS,S/AS01 has shown modest protection in phase 3 trial in African infants. Hence the treatment of malaria still depends on the current chemotherapeutic drugs. Considering the resistance of malaria parasites to almost all used antimalarial drugs, aiming at multi-targets rather than a single target will be a more promising strategy. Previous studies have shown that myricetin and fisetin exhibited in vitro antimalarial activity against Plasmodium falciparum, but very little research focused on the molecular mechanism for their parasiticidal activity. The cysteine protease falcipain-2 and aspartic protease plasmepsin II have long been considered as important antimalarial drug targets, especially combined inhibition of these two proteases. In this study, we determined that myricetin and fisetin are dual inhibitors of falcipain-2 and plasmepsin II, which might account for their antimalarial properties. Overall, the dual inhibition of falcipain-2 and plasmepsin II by myricetin and fisetin has shed light on a possible mechanism for their antimalarial activity and provided a rationale for further development as antimalarial drugs.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "7d74ba9e281e40f4942cf692644eec7b", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[20, 20], [56, 56], [0, 0], [43, 43]], "char_spans": [[114, 120], [320, 326], [0, 6], [229, 235]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["one", 11], ["of", 15], ["the", 18], ["most", 22], ["devastating", 27], ["infectious", 39], ["diseases", 50], ["in", 59], ["the", 62], ["developing", 66], ["world", 77], [".", 82], ["Until", 84], ["now", 90], [",", 93], ["only", 95], ["one", 100], ["candidate", 104], ["malaria", 114], ["vaccine", 122], ["RTS", 130], [",", 133], ["S", 134], ["/", 135], ["AS01", 136], ["has", 141], ["shown", 145], ["modest", 151], ["protection", 158], ["in", 169], ["phase", 172], ["3", 178], ["trial", 180], ["in", 186], ["African", 189], ["infants", 197], [".", 204], ["Hence", 206], ["the", 212], ["treatment", 216], ["of", 226], ["malaria", 229], ["still", 237], ["depends", 243], ["on", 251], ["the", 254], ["current", 258], ["chemotherapeutic", 266], ["drugs", 283], [".", 288], ["Considering", 290], ["the", 302], ["resistance", 306], ["of", 317], ["malaria", 320], ["parasites", 328], ["to", 338], ["almost", 341], ["all", 348], ["used", 352], ["antimalarial", 357], ["drugs", 370], [",", 375], ["aiming", 377], ["at", 384], ["multi", 387], ["-", 392], ["targets", 393], ["rather", 401], ["than", 408], ["a", 413], ["single", 415], ["target", 422], ["will", 429], ["be", 434], ["a", 437], ["more", 439], ["promising", 444], ["strategy", 454], [".", 462], ["Previous", 464], ["studies", 473], ["have", 481], ["shown", 486], ["that", 492], ["myricetin", 497], ["and", 507], ["fisetin", 511], ["exhibited", 519], ["in", 529], ["vitro", 532], ["antimalarial", 538], ["activity", 551], ["against", 560], ["Plasmodium", 568], ["falciparum", 579], [",", 589], ["but", 591], ["very", 595], ["little", 600], ["research", 607], ["focused", 616], ["on", 624], ["the", 627], ["molecular", 631], ["mechanism", 641], ["for", 651], ["their", 655], ["parasiticidal", 661], ["activity", 675], [".", 683], ["The", 685], ["cysteine", 689], ["protease", 698], ["falcipain-2", 707], ["and", 719], ["aspartic", 723], ["protease", 732], ["plasmepsin", 741], ["II", 752], ["have", 755], ["long", 760], ["been", 765], ["considered", 770], ["as", 781], ["important", 784], ["antimalarial", 794], ["drug", 807], ["targets", 812], [",", 819], ["especially", 821], ["combined", 832], ["inhibition", 841], ["of", 852], ["these", 855], ["two", 861], ["proteases", 865], [".", 874], ["In", 876], ["this", 879], ["study", 884], [",", 889], ["we", 891], ["determined", 894], ["that", 905], ["myricetin", 910], ["and", 920], ["fisetin", 924], ["are", 932], ["dual", 936], ["inhibitors", 941], ["of", 952], ["falcipain-2", 955], ["and", 967], ["plasmepsin", 971], ["II", 982], [",", 984], ["which", 986], ["might", 992], ["account", 998], ["for", 1006], ["their", 1010], ["antimalarial", 1016], ["properties", 1029], [".", 1039], ["Overall", 1041], [",", 1048], ["the", 1050], ["dual", 1054], ["inhibition", 1059], ["of", 1070], ["falcipain-2", 1073], ["and", 1085], ["plasmepsin", 1089], ["II", 1100], ["by", 1103], ["myricetin", 1106], ["and", 1116], ["fisetin", 1120], ["has", 1128], ["shed", 1132], ["light", 1137], ["on", 1143], ["a", 1146], ["possible", 1148], ["mechanism", 1157], ["for", 1167], ["their", 1171], ["antimalarial", 1177], ["activity", 1190], ["and", 1199], ["provided", 1203], ["a", 1212], ["rationale", 1214], ["for", 1224], ["further", 1228], ["development", 1236], ["as", 1248], ["antimalarial", 1251], ["drugs", 1264], [".", 1269]]}
{"context": "Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. Patients with familial RLS/WED were significantly younger than sporadic RLS/WED, while clinical and polysomnographic characteristics were similar in both groups. No difference was found for the age-at-onset between idiopathic and secondary RLS/WED. Periodic limb movements (PLM) index and REM sleep time were higher in idiopathic RLS/WED. Time of onset of symptoms was in the evening or at bedtime in 28.04 and 37.80% of patients, respectively, while in 21.34% of patients onset was more than 1 h after sleep onset. Impulse control and compulsive behaviours (ICBs) were found in 13.29% patients on dopamine agonist therapy. Our analyses support the hypothesis that patients with a familial history of RLS/WED may have a genetic component. Nevertheless, the dichotomy between early and late onset disease seems to be less sharp than previously reported. A large proportion of RLS/WED patients can have atypical features, therefore making the diagnosis challenging. Some cases can be missed even when the patient refers to a sleep specialist, as revealed by the partial absence of daytime symptoms, the high comorbidity with insomnia and other sleep complaints and the high percentage of symptoms beginning after sleep onset. This draws attention on the importance of a careful evaluation of the patient, to recognize potentially treatable secondary forms of RLS/WED.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c287836b570a4d18b1c683334df92f91", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[7, 9]], "char_spans": [[60, 81]]}]}], "context_tokens": [["Clinical", 0], ["features", 9], ["variability", 18], ["between", 30], ["familial", 38], ["and", 47], ["sporadic", 51], ["restless", 60], ["legs", 69], ["syndrome", 74], ["/", 82], ["Willis", 83], ["-", 89], ["Ekbom", 90], ["disease", 96], ["(", 104], ["RLS", 105], ["/", 108], ["WED", 109], [")", 112], ["has", 114], ["been", 118], ["previously", 123], ["reported", 134], [".", 142], ["With", 144], ["this", 149], ["retrospective", 154], ["cohort", 168], ["study", 175], [",", 180], ["we", 182], ["aimed", 185], ["to", 191], ["determine", 194], ["the", 204], ["clinical", 208], ["and", 217], ["polysomnographic", 221], ["characteristics", 238], ["of", 254], ["400", 257], ["RLS", 261], ["/", 264], ["WED", 265], ["patients", 269], [".", 277], ["Patients", 279], ["with", 288], ["familial", 293], ["RLS", 302], ["/", 305], ["WED", 306], ["were", 310], ["significantly", 315], ["younger", 329], ["than", 337], ["sporadic", 342], ["RLS", 351], ["/", 354], ["WED", 355], [",", 358], ["while", 360], ["clinical", 366], ["and", 375], ["polysomnographic", 379], ["characteristics", 396], ["were", 412], ["similar", 417], ["in", 425], ["both", 428], ["groups", 433], [".", 439], ["No", 441], ["difference", 444], ["was", 455], ["found", 459], ["for", 465], ["the", 469], ["age", 473], ["-", 476], ["at", 477], ["-", 479], ["onset", 480], ["between", 486], ["idiopathic", 494], ["and", 505], ["secondary", 509], ["RLS", 519], ["/", 522], ["WED", 523], [".", 526], ["Periodic", 528], ["limb", 537], ["movements", 542], ["(", 552], ["PLM", 553], [")", 556], ["index", 558], ["and", 564], ["REM", 568], ["sleep", 572], ["time", 578], ["were", 583], ["higher", 588], ["in", 595], ["idiopathic", 598], ["RLS", 609], ["/", 612], ["WED", 613], [".", 616], ["Time", 618], ["of", 623], ["onset", 626], ["of", 632], ["symptoms", 635], ["was", 644], ["in", 648], ["the", 651], ["evening", 655], ["or", 663], ["at", 666], ["bedtime", 669], ["in", 677], ["28.04", 680], ["and", 686], ["37.80", 690], ["%", 695], ["of", 697], ["patients", 700], [",", 708], ["respectively", 710], [",", 722], ["while", 724], ["in", 730], ["21.34", 733], ["%", 738], ["of", 740], ["patients", 743], ["onset", 752], ["was", 758], ["more", 762], ["than", 767], ["1", 772], ["h", 774], ["after", 776], ["sleep", 782], ["onset", 788], [".", 793], ["Impulse", 795], ["control", 803], ["and", 811], ["compulsive", 815], ["behaviours", 826], ["(", 837], ["ICBs", 838], [")", 842], ["were", 844], ["found", 849], ["in", 855], ["13.29", 858], ["%", 863], ["patients", 865], ["on", 874], ["dopamine", 877], ["agonist", 886], ["therapy", 894], [".", 901], ["Our", 903], ["analyses", 907], ["support", 916], ["the", 924], ["hypothesis", 928], ["that", 939], ["patients", 944], ["with", 953], ["a", 958], ["familial", 960], ["history", 969], ["of", 977], ["RLS", 980], ["/", 983], ["WED", 984], ["may", 988], ["have", 992], ["a", 997], ["genetic", 999], ["component", 1007], [".", 1016], ["Nevertheless", 1018], [",", 1030], ["the", 1032], ["dichotomy", 1036], ["between", 1046], ["early", 1054], ["and", 1060], ["late", 1064], ["onset", 1069], ["disease", 1075], ["seems", 1083], ["to", 1089], ["be", 1092], ["less", 1095], ["sharp", 1100], ["than", 1106], ["previously", 1111], ["reported", 1122], [".", 1130], ["A", 1132], ["large", 1134], ["proportion", 1140], ["of", 1151], ["RLS", 1154], ["/", 1157], ["WED", 1158], ["patients", 1162], ["can", 1171], ["have", 1175], ["atypical", 1180], ["features", 1189], [",", 1197], ["therefore", 1199], ["making", 1209], ["the", 1216], ["diagnosis", 1220], ["challenging", 1230], [".", 1241], ["Some", 1243], ["cases", 1248], ["can", 1254], ["be", 1258], ["missed", 1261], ["even", 1268], ["when", 1273], ["the", 1278], ["patient", 1282], ["refers", 1290], ["to", 1297], ["a", 1300], ["sleep", 1302], ["specialist", 1308], [",", 1318], ["as", 1320], ["revealed", 1323], ["by", 1332], ["the", 1335], ["partial", 1339], ["absence", 1347], ["of", 1355], ["daytime", 1358], ["symptoms", 1366], [",", 1374], ["the", 1376], ["high", 1380], ["comorbidity", 1385], ["with", 1397], ["insomnia", 1402], ["and", 1411], ["other", 1415], ["sleep", 1421], ["complaints", 1427], ["and", 1438], ["the", 1442], ["high", 1446], ["percentage", 1451], ["of", 1462], ["symptoms", 1465], ["beginning", 1474], ["after", 1484], ["sleep", 1490], ["onset", 1496], [".", 1501], ["This", 1503], ["draws", 1508], ["attention", 1514], ["on", 1524], ["the", 1527], ["importance", 1531], ["of", 1542], ["a", 1545], ["careful", 1547], ["evaluation", 1555], ["of", 1566], ["the", 1569], ["patient", 1573], [",", 1580], ["to", 1582], ["recognize", 1585], ["potentially", 1595], ["treatable", 1607], ["secondary", 1617], ["forms", 1627], ["of", 1633], ["RLS", 1636], ["/", 1639], ["WED", 1640], [".", 1643]]}
{"context": "The blockage of transcription elongation by RNA polymerase II (pol II) at a DNA damage site on the transcribed strand triggers a transcription-coupled DNA repair (TCR), which rapidly removes DNA damage on the transcribed strand of the expressed gene and allows the resumption of transcription. To analyze the effect of UV-induced DNA damage on transcription elongation, an in vitro transcription elongation system using pol II and oligo(dC)-tailed templates containing a cyclobutane pyrimidine dimer (CPD) or 6-4 photoproduct (6-4PP) at a specific site was employed. The results showed that pol II incorporated nucleotides opposite the CPD and 6-4PP and then stalled. Pol II formed a stable ternary complex consisting of pol II, the DNA damage template, and the nascent transcript. Furthermore, atomic force microscopy imaging revealed that pol II stalled at the damaged region. These findings may provide the basis for analysis of the initiation step of TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6b2c71580a6f442ab8605c69fe2e4b66", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[20, 21], [40, 41]], "char_spans": [[99, 116], [209, 226]]}]}], "context_tokens": [["The", 0], ["blockage", 4], ["of", 13], ["transcription", 16], ["elongation", 30], ["by", 41], ["RNA", 44], ["polymerase", 48], ["II", 59], ["(", 62], ["pol", 63], ["II", 67], [")", 69], ["at", 71], ["a", 74], ["DNA", 76], ["damage", 80], ["site", 87], ["on", 92], ["the", 95], ["transcribed", 99], ["strand", 111], ["triggers", 118], ["a", 127], ["transcription", 129], ["-", 142], ["coupled", 143], ["DNA", 151], ["repair", 155], ["(", 162], ["TCR", 163], [")", 166], [",", 167], ["which", 169], ["rapidly", 175], ["removes", 183], ["DNA", 191], ["damage", 195], ["on", 202], ["the", 205], ["transcribed", 209], ["strand", 221], ["of", 228], ["the", 231], ["expressed", 235], ["gene", 245], ["and", 250], ["allows", 254], ["the", 261], ["resumption", 265], ["of", 276], ["transcription", 279], [".", 292], ["To", 294], ["analyze", 297], ["the", 305], ["effect", 309], ["of", 316], ["UV", 319], ["-", 321], ["induced", 322], ["DNA", 330], ["damage", 334], ["on", 341], ["transcription", 344], ["elongation", 358], [",", 368], ["an", 370], ["in", 373], ["vitro", 376], ["transcription", 382], ["elongation", 396], ["system", 407], ["using", 414], ["pol", 420], ["II", 424], ["and", 427], ["oligo(dC)-tailed", 431], ["templates", 448], ["containing", 458], ["a", 469], ["cyclobutane", 471], ["pyrimidine", 483], ["dimer", 494], ["(", 500], ["CPD", 501], [")", 504], ["or", 506], ["6", 509], ["-", 510], ["4", 511], ["photoproduct", 513], ["(", 526], ["6", 527], ["-", 528], ["4PP", 529], [")", 532], ["at", 534], ["a", 537], ["specific", 539], ["site", 548], ["was", 553], ["employed", 557], [".", 565], ["The", 567], ["results", 571], ["showed", 579], ["that", 586], ["pol", 591], ["II", 595], ["incorporated", 598], ["nucleotides", 611], ["opposite", 623], ["the", 632], ["CPD", 636], ["and", 640], ["6", 644], ["-", 645], ["4PP", 646], ["and", 650], ["then", 654], ["stalled", 659], [".", 666], ["Pol", 668], ["II", 672], ["formed", 675], ["a", 682], ["stable", 684], ["ternary", 691], ["complex", 699], ["consisting", 707], ["of", 718], ["pol", 721], ["II", 725], [",", 727], ["the", 729], ["DNA", 733], ["damage", 737], ["template", 744], [",", 752], ["and", 754], ["the", 758], ["nascent", 762], ["transcript", 770], [".", 780], ["Furthermore", 782], [",", 793], ["atomic", 795], ["force", 802], ["microscopy", 808], ["imaging", 819], ["revealed", 827], ["that", 836], ["pol", 841], ["II", 845], ["stalled", 848], ["at", 856], ["the", 859], ["damaged", 863], ["region", 871], [".", 877], ["These", 879], ["findings", 885], ["may", 894], ["provide", 898], ["the", 906], ["basis", 910], ["for", 916], ["analysis", 920], ["of", 929], ["the", 932], ["initiation", 936], ["step", 947], ["of", 952], ["TCR", 955], [".", 958]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging threat to public health, especially in correctional settings. Outbreaks have been seen in jails and prisons in Mississippi, California, Texas, and Georgia in recent years. Also, many correctional settings have seen an increase in MRSA infection greater than in the general population. This article examines the lessons that have been learned about MRSA in correctional settings and ponders what is yet to be learned about this disease in these populations.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "9b31d25da19c48398b26285c6f9b1754", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[52, 52], [71, 71], [6, 6]], "char_spans": [[296, 299], [414, 417], [45, 48]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["emerging", 57], ["threat", 66], ["to", 73], ["public", 76], ["health", 83], [",", 89], ["especially", 91], ["in", 102], ["correctional", 105], ["settings", 118], [".", 126], ["Outbreaks", 128], ["have", 138], ["been", 143], ["seen", 148], ["in", 153], ["jails", 156], ["and", 162], ["prisons", 166], ["in", 174], ["Mississippi", 177], [",", 188], ["California", 190], [",", 200], ["Texas", 202], [",", 207], ["and", 209], ["Georgia", 213], ["in", 221], ["recent", 224], ["years", 231], [".", 236], ["Also", 238], [",", 242], ["many", 244], ["correctional", 249], ["settings", 262], ["have", 271], ["seen", 276], ["an", 281], ["increase", 284], ["in", 293], ["MRSA", 296], ["infection", 301], ["greater", 311], ["than", 319], ["in", 324], ["the", 327], ["general", 331], ["population", 339], [".", 349], ["This", 351], ["article", 356], ["examines", 364], ["the", 373], ["lessons", 377], ["that", 385], ["have", 390], ["been", 395], ["learned", 400], ["about", 408], ["MRSA", 414], ["in", 419], ["correctional", 422], ["settings", 435], ["and", 444], ["ponders", 448], ["what", 456], ["is", 461], ["yet", 464], ["to", 468], ["be", 471], ["learned", 474], ["about", 482], ["this", 488], ["disease", 493], ["in", 501], ["these", 504], ["populations", 510], [".", 521]]}
{"context": "The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22;9).", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "da064d93bc6d4d6fa5b680d9a08d7890", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[95, 97], [1, 3], [51, 53]], "char_spans": [[559, 565], [4, 10], [268, 274]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["-", 7], ["ABL", 8], ["fusion", 12], ["gene", 19], ["represents", 24], ["the", 35], ["hallmark", 39], ["of", 48], ["chronic", 51], ["myelogenous", 59], ["leukemia", 71], ["(", 80], ["CML", 81], [")", 84], ["and", 86], ["is", 90], ["derived", 93], ["from", 101], ["a", 106], ["translocation", 108], ["between", 122], ["chromosome", 130], ["9", 141], ["and", 143], ["22", 147], [".", 149], ["The", 151], ["majority", 155], ["of", 164], ["CML", 167], ["patients", 171], ["have", 180], ["a", 185], ["breakpoint", 187], ["in", 198], ["the", 201], ["major", 205], ["BCR", 211], ["region", 215], ["of", 222], ["the", 225], ["BCR", 229], ["gene", 233], ["giving", 238], ["rise", 245], ["to", 250], ["e13a2", 253], ["or", 259], ["e14a2", 262], ["BCR", 268], ["-", 271], ["ABL", 272], ["transcripts", 276], [".", 287], ["Occasionally", 289], [",", 301], ["other", 303], ["BCR", 309], ["breakpoints", 313], ["occur", 325], [".", 330], ["The", 332], ["current", 336], ["report", 344], ["describes", 351], ["two", 361], ["e6a2", 365], ["CML", 370], ["patients", 374], ["with", 383], ["imatinib", 388], ["treatment", 397], ["failure", 407], ["and", 415], ["unusual", 419], ["disease", 427], ["progression", 435], [".", 446], ["One", 448], ["patient", 452], ["was", 460], ["Philadelphia", 464], ["chromosome", 477], ["positive", 488], ["and", 497], ["one", 501], ["was", 505], ["Philadelphia", 509], ["chromosome", 522], ["negative", 533], ["with", 542], ["an", 547], ["atypical", 550], ["BCR", 559], ["-", 562], ["ABL", 563], ["rearrangement", 567], [",", 580], ["ins", 582], ["(", 586], ["22;9", 587], [")", 591], [".", 592]]}
{"context": "The approval of the oral direct thrombin inhibitor, dabigatran etexilate, gave patients an alternative to oral anticoagulation with warfarin. Like all anticoagulants, the primary adverse event (AE) associated with dabigatran is bleeding. Until the FDA approval of idarucizumab, there had been no reversal agent for dabigatran-induced anticoagulation in patients with life-threatening or uncontrollable bleeding, or those requiring emergent procedures. The primary purpose of this review is to summarize the safety and efficacy of idarucizumab, a monoclonal antibody fragment, and its use as a reversal agent for dabigatran. A literature search was conducted through MEDLINE (1946 to November week 1 2015) and Embase (1980-2015 week 46) using the search term idarucizumab. Clinicaltrials.gov was consulted for a comprehensive list of ongoing and completed studies. Additional studies were identified through bibliographical citations. Clinical trials in animals and humans published in English evaluating the safety and efficacy of idarucizumab for reversal of anticoagulant treatment with dabigatran were included for review. Idarucizumab has been shown to significantly reverse the anticoagulant effects of dabigatran in both healthy volunteers and patients requiring a reversal agent because of either overt bleeding or an emergency surgery or invasive procedure. The most common AEs were headache, nasopharyngitis, back pain, skin irritation, hypokalemia, delirium, constipation, pyrexia, and pneumonia. Deaths reported in idarucizumab studies were attributed to either the index event or a preexisting comorbidity. Most adverse effects were minor, but 21 serious AEs have been reported in the published data including thrombotic events. Given the increased use of direct oral anticoagulants, such as dabigatran, a need for specific reversal agents exists. Idarucizumab has been shown to be safe and effective in the reversal of dabigatran-induced anticoagulation in patients requiring emergent or urgent surgery or in patients with severe bleeding.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2e849ad8ec784301ae7f31f0261ab00e", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[35, 35], [53, 53], [102, 102], [293, 293], [316, 316], [9, 9], [194, 194], [177, 177]], "char_spans": [[214, 223], [315, 324], [612, 621], [1804, 1813], [1932, 1941], [52, 61], [1208, 1217], [1089, 1098]]}]}], "context_tokens": [["The", 0], ["approval", 4], ["of", 13], ["the", 16], ["oral", 20], ["direct", 25], ["thrombin", 32], ["inhibitor", 41], [",", 50], ["dabigatran", 52], ["etexilate", 63], [",", 72], ["gave", 74], ["patients", 79], ["an", 88], ["alternative", 91], ["to", 103], ["oral", 106], ["anticoagulation", 111], ["with", 127], ["warfarin", 132], [".", 140], ["Like", 142], ["all", 147], ["anticoagulants", 151], [",", 165], ["the", 167], ["primary", 171], ["adverse", 179], ["event", 187], ["(", 193], ["AE", 194], [")", 196], ["associated", 198], ["with", 209], ["dabigatran", 214], ["is", 225], ["bleeding", 228], [".", 236], ["Until", 238], ["the", 244], ["FDA", 248], ["approval", 252], ["of", 261], ["idarucizumab", 264], [",", 276], ["there", 278], ["had", 284], ["been", 288], ["no", 293], ["reversal", 296], ["agent", 305], ["for", 311], ["dabigatran", 315], ["-", 325], ["induced", 326], ["anticoagulation", 334], ["in", 350], ["patients", 353], ["with", 362], ["life", 367], ["-", 371], ["threatening", 372], ["or", 384], ["uncontrollable", 387], ["bleeding", 402], [",", 410], ["or", 412], ["those", 415], ["requiring", 421], ["emergent", 431], ["procedures", 440], [".", 450], ["The", 452], ["primary", 456], ["purpose", 464], ["of", 472], ["this", 475], ["review", 480], ["is", 487], ["to", 490], ["summarize", 493], ["the", 503], ["safety", 507], ["and", 514], ["efficacy", 518], ["of", 527], ["idarucizumab", 530], [",", 542], ["a", 544], ["monoclonal", 546], ["antibody", 557], ["fragment", 566], [",", 574], ["and", 576], ["its", 580], ["use", 584], ["as", 588], ["a", 591], ["reversal", 593], ["agent", 602], ["for", 608], ["dabigatran", 612], [".", 622], ["A", 624], ["literature", 626], ["search", 637], ["was", 644], ["conducted", 648], ["through", 658], ["MEDLINE", 666], ["(", 674], ["1946", 675], ["to", 680], ["November", 683], ["week", 692], ["1", 697], ["2015", 699], [")", 703], ["and", 705], ["Embase", 709], ["(", 716], ["1980", 717], ["-", 721], ["2015", 722], ["week", 727], ["46", 732], [")", 734], ["using", 736], ["the", 742], ["search", 746], ["term", 753], ["idarucizumab", 758], [".", 770], ["Clinicaltrials.gov", 772], ["was", 791], ["consulted", 795], ["for", 805], ["a", 809], ["comprehensive", 811], ["list", 825], ["of", 830], ["ongoing", 833], ["and", 841], ["completed", 845], ["studies", 855], [".", 862], ["Additional", 864], ["studies", 875], ["were", 883], ["identified", 888], ["through", 899], ["bibliographical", 907], ["citations", 923], [".", 932], ["Clinical", 934], ["trials", 943], ["in", 950], ["animals", 953], ["and", 961], ["humans", 965], ["published", 972], ["in", 982], ["English", 985], ["evaluating", 993], ["the", 1004], ["safety", 1008], ["and", 1015], ["efficacy", 1019], ["of", 1028], ["idarucizumab", 1031], ["for", 1044], ["reversal", 1048], ["of", 1057], ["anticoagulant", 1060], ["treatment", 1074], ["with", 1084], ["dabigatran", 1089], ["were", 1100], ["included", 1105], ["for", 1114], ["review", 1118], [".", 1124], ["Idarucizumab", 1126], ["has", 1139], ["been", 1143], ["shown", 1148], ["to", 1154], ["significantly", 1157], ["reverse", 1171], ["the", 1179], ["anticoagulant", 1183], ["effects", 1197], ["of", 1205], ["dabigatran", 1208], ["in", 1219], ["both", 1222], ["healthy", 1227], ["volunteers", 1235], ["and", 1246], ["patients", 1250], ["requiring", 1259], ["a", 1269], ["reversal", 1271], ["agent", 1280], ["because", 1286], ["of", 1294], ["either", 1297], ["overt", 1304], ["bleeding", 1310], ["or", 1319], ["an", 1322], ["emergency", 1325], ["surgery", 1335], ["or", 1343], ["invasive", 1346], ["procedure", 1355], [".", 1364], ["The", 1366], ["most", 1370], ["common", 1375], ["AEs", 1382], ["were", 1386], ["headache", 1391], [",", 1399], ["nasopharyngitis", 1401], [",", 1416], ["back", 1418], ["pain", 1423], [",", 1427], ["skin", 1429], ["irritation", 1434], [",", 1444], ["hypokalemia", 1446], [",", 1457], ["delirium", 1459], [",", 1467], ["constipation", 1469], [",", 1481], ["pyrexia", 1483], [",", 1490], ["and", 1492], ["pneumonia", 1496], [".", 1505], ["Deaths", 1507], ["reported", 1514], ["in", 1523], ["idarucizumab", 1526], ["studies", 1539], ["were", 1547], ["attributed", 1552], ["to", 1563], ["either", 1566], ["the", 1573], ["index", 1577], ["event", 1583], ["or", 1589], ["a", 1592], ["preexisting", 1594], ["comorbidity", 1606], [".", 1617], ["Most", 1619], ["adverse", 1624], ["effects", 1632], ["were", 1640], ["minor", 1645], [",", 1650], ["but", 1652], ["21", 1656], ["serious", 1659], ["AEs", 1667], ["have", 1671], ["been", 1676], ["reported", 1681], ["in", 1690], ["the", 1693], ["published", 1697], ["data", 1707], ["including", 1712], ["thrombotic", 1722], ["events", 1733], [".", 1739], ["Given", 1741], ["the", 1747], ["increased", 1751], ["use", 1761], ["of", 1765], ["direct", 1768], ["oral", 1775], ["anticoagulants", 1780], [",", 1794], ["such", 1796], ["as", 1801], ["dabigatran", 1804], [",", 1814], ["a", 1816], ["need", 1818], ["for", 1823], ["specific", 1827], ["reversal", 1836], ["agents", 1845], ["exists", 1852], [".", 1858], ["Idarucizumab", 1860], ["has", 1873], ["been", 1877], ["shown", 1882], ["to", 1888], ["be", 1891], ["safe", 1894], ["and", 1899], ["effective", 1903], ["in", 1913], ["the", 1916], ["reversal", 1920], ["of", 1929], ["dabigatran", 1932], ["-", 1942], ["induced", 1943], ["anticoagulation", 1951], ["in", 1967], ["patients", 1970], ["requiring", 1979], ["emergent", 1989], ["or", 1998], ["urgent", 2001], ["surgery", 2008], ["or", 2016], ["in", 2019], ["patients", 2022], ["with", 2031], ["severe", 2036], ["bleeding", 2043], [".", 2051]]}
{"context": "The aim of this study was to analyze complications of vestibular schwannoma (VS) microsurgery. A retrospective study was performed in 333 patients with unilateral vestibular schwannoma indicated for surgical treatment between January 1997 and December 2012. Postoperative complications were assessed immediately after VS surgery as well as during outpatient followup. In all 333 patients microsurgical vestibular schwannoma (Koos grade 1: 12, grade 2: 34, grade 3: 62, and grade 4: 225) removal was performed. The main neurological complication was facial nerve dysfunction. The intermediate and poor function (HB III-VI) was observed in 124 cases (45%) immediately after surgery and in 104 cases (33%) on the last followup. We encountered disordered vestibular compensation in 13%, permanent trigeminal nerve dysfunction in 1%, and transient lower cranial nerves (IX-XI) deficit in 6%. Nonneurological complications included CSF leakage in 63% (lateral/medial variant: 99/1%), headache in 9%, and intracerebral hemorrhage in 5%. We did not encounter any case of meningitis. Our study demonstrates that despite the benefits of advanced high-tech equipment, refined microsurgical instruments, and highly developed neuroimaging technologies, there are still various and significant complications associated with vestibular schwannomas microsurgery.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "9a266ab5385a487db6485e67274c6e1d", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[60, 61], [10, 11], [27, 28]], "char_spans": [[402, 422], [54, 74], [163, 183]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["analyze", 29], ["complications", 37], ["of", 51], ["vestibular", 54], ["schwannoma", 65], ["(", 76], ["VS", 77], [")", 79], ["microsurgery", 81], [".", 93], ["A", 95], ["retrospective", 97], ["study", 111], ["was", 117], ["performed", 121], ["in", 131], ["333", 134], ["patients", 138], ["with", 147], ["unilateral", 152], ["vestibular", 163], ["schwannoma", 174], ["indicated", 185], ["for", 195], ["surgical", 199], ["treatment", 208], ["between", 218], ["January", 226], ["1997", 234], ["and", 239], ["December", 243], ["2012", 252], [".", 256], ["Postoperative", 258], ["complications", 272], ["were", 286], ["assessed", 291], ["immediately", 300], ["after", 312], ["VS", 318], ["surgery", 321], ["as", 329], ["well", 332], ["as", 337], ["during", 340], ["outpatient", 347], ["followup", 358], [".", 366], ["In", 368], ["all", 371], ["333", 375], ["patients", 379], ["microsurgical", 388], ["vestibular", 402], ["schwannoma", 413], ["(", 424], ["Koos", 425], ["grade", 430], ["1", 436], [":", 437], ["12", 439], [",", 441], ["grade", 443], ["2", 449], [":", 450], ["34", 452], [",", 454], ["grade", 456], ["3", 462], [":", 463], ["62", 465], [",", 467], ["and", 469], ["grade", 473], ["4", 479], [":", 480], ["225", 482], [")", 485], ["removal", 487], ["was", 495], ["performed", 499], [".", 508], ["The", 510], ["main", 514], ["neurological", 519], ["complication", 532], ["was", 545], ["facial", 549], ["nerve", 556], ["dysfunction", 562], [".", 573], ["The", 575], ["intermediate", 579], ["and", 592], ["poor", 596], ["function", 601], ["(", 610], ["HB", 611], ["III", 614], ["-", 617], ["VI", 618], [")", 620], ["was", 622], ["observed", 626], ["in", 635], ["124", 638], ["cases", 642], ["(", 648], ["45", 649], ["%", 651], [")", 652], ["immediately", 654], ["after", 666], ["surgery", 672], ["and", 680], ["in", 684], ["104", 687], ["cases", 691], ["(", 697], ["33", 698], ["%", 700], [")", 701], ["on", 703], ["the", 706], ["last", 710], ["followup", 715], [".", 723], ["We", 725], ["encountered", 728], ["disordered", 740], ["vestibular", 751], ["compensation", 762], ["in", 775], ["13", 778], ["%", 780], [",", 781], ["permanent", 783], ["trigeminal", 793], ["nerve", 804], ["dysfunction", 810], ["in", 822], ["1", 825], ["%", 826], [",", 827], ["and", 829], ["transient", 833], ["lower", 843], ["cranial", 849], ["nerves", 857], ["(", 864], ["IX", 865], ["-", 867], ["XI", 868], [")", 870], ["deficit", 872], ["in", 880], ["6", 883], ["%", 884], [".", 885], ["Nonneurological", 887], ["complications", 903], ["included", 917], ["CSF", 926], ["leakage", 930], ["in", 938], ["63", 941], ["%", 943], ["(", 945], ["lateral", 946], ["/", 953], ["medial", 954], ["variant", 961], [":", 968], ["99/1", 970], ["%", 974], [")", 975], [",", 976], ["headache", 978], ["in", 987], ["9", 990], ["%", 991], [",", 992], ["and", 994], ["intracerebral", 998], ["hemorrhage", 1012], ["in", 1023], ["5", 1026], ["%", 1027], [".", 1028], ["We", 1030], ["did", 1033], ["not", 1037], ["encounter", 1041], ["any", 1051], ["case", 1055], ["of", 1060], ["meningitis", 1063], [".", 1073], ["Our", 1075], ["study", 1079], ["demonstrates", 1085], ["that", 1098], ["despite", 1103], ["the", 1111], ["benefits", 1115], ["of", 1124], ["advanced", 1127], ["high", 1136], ["-", 1140], ["tech", 1141], ["equipment", 1146], [",", 1155], ["refined", 1157], ["microsurgical", 1165], ["instruments", 1179], [",", 1190], ["and", 1192], ["highly", 1196], ["developed", 1203], ["neuroimaging", 1213], ["technologies", 1226], [",", 1238], ["there", 1240], ["are", 1246], ["still", 1250], ["various", 1256], ["and", 1264], ["significant", 1268], ["complications", 1280], ["associated", 1294], ["with", 1305], ["vestibular", 1310], ["schwannomas", 1321], ["microsurgery", 1333], [".", 1345]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. Two known mutations were found in the Thanatophoric Dysplasia referred cases. No mutations were identified in the LADD syndrome patient. In Achondroplasia and Hypochondroplasia, genetic heterogeneity was present amongst the 70 clinically diagnosed patients with 5 different mutations identified. As in other studies, complex phenotypic heterogeneity amongst patients carrying the same gene defect was observed. In several cases, the new amino acids encoded, as a consequence of mutations, were related to the severity of patients' phenotype. The presence of 10 misdiagnosed cases emphasizes the importance of performing mutation analysis of the hotspot regions responsible for both dysplasias (Ach and Hch). For patients with an unquestionable clinical diagnosis, lacking the most common mutations, a complete screening of FGFR3 is necessary.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "761f9e814759455eb96445c42ae4b986", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[6, 12]], "char_spans": [[35, 76]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["gene", 17], ["that", 22], ["encodes", 27], ["Fibroblast", 35], ["Growth", 46], ["Factor", 53], ["Receptor", 60], ["3", 69], ["(", 71], ["FGFR3", 72], [")", 77], ["are", 79], ["associated", 83], ["with", 94], ["Achondroplasia", 99], ["(", 114], ["MIM", 115], ["100800", 119], [")", 125], [",", 126], ["Hypochondroplasia", 128], ["(", 146], ["MIM", 147], ["146000", 151], [")", 157], [",", 158], ["Muenke", 160], ["Syndrome", 167], ["(", 176], ["MIM", 177], ["602849", 181], [")", 187], [",", 188], ["Thanatophoric", 190], ["Dysplasia", 204], ["(", 214], ["MIM", 215], ["187600", 219], [",", 225], ["MIM", 227], ["187601", 231], [")", 237], ["and", 239], ["Lacrimo", 243], ["-", 250], ["Auriculo", 251], ["-", 259], ["Dento", 260], ["-", 265], ["Digital", 266], ["Syndrome", 274], ["(", 283], ["MIM", 284], ["149730).Here", 288], ["we", 301], ["report", 304], ["a", 311], ["clinical", 313], ["and", 322], ["molecular", 326], ["study", 336], ["in", 342], ["a", 345], ["large", 347], ["cohort", 353], ["of", 360], ["125", 363], ["Portuguese", 367], ["patients", 378], ["with", 387], ["these", 392], ["skeletal", 398], ["disorders", 407], [".", 416], ["The", 418], ["identification", 422], ["of", 437], ["the", 440], ["P250R", 444], ["mutation", 450], ["allowed", 459], ["the", 467], ["confirmation", 471], ["of", 484], ["the", 487], ["Muenke", 491], ["Syndrome", 498], ["in", 507], ["9", 510], ["out", 512], ["of", 516], ["the", 519], ["52", 523], ["cases", 526], ["referred", 532], [".", 540], ["Two", 542], ["known", 546], ["mutations", 552], ["were", 562], ["found", 567], ["in", 573], ["the", 576], ["Thanatophoric", 580], ["Dysplasia", 594], ["referred", 604], ["cases", 613], [".", 618], ["No", 620], ["mutations", 623], ["were", 633], ["identified", 638], ["in", 649], ["the", 652], ["LADD", 656], ["syndrome", 661], ["patient", 670], [".", 677], ["In", 679], ["Achondroplasia", 682], ["and", 697], ["Hypochondroplasia", 701], [",", 718], ["genetic", 720], ["heterogeneity", 728], ["was", 742], ["present", 746], ["amongst", 754], ["the", 762], ["70", 766], ["clinically", 769], ["diagnosed", 780], ["patients", 790], ["with", 799], ["5", 804], ["different", 806], ["mutations", 816], ["identified", 826], [".", 836], ["As", 838], ["in", 841], ["other", 844], ["studies", 850], [",", 857], ["complex", 859], ["phenotypic", 867], ["heterogeneity", 878], ["amongst", 892], ["patients", 900], ["carrying", 909], ["the", 918], ["same", 922], ["gene", 927], ["defect", 932], ["was", 939], ["observed", 943], [".", 951], ["In", 953], ["several", 956], ["cases", 964], [",", 969], ["the", 971], ["new", 975], ["amino", 979], ["acids", 985], ["encoded", 991], [",", 998], ["as", 1000], ["a", 1003], ["consequence", 1005], ["of", 1017], ["mutations", 1020], [",", 1029], ["were", 1031], ["related", 1036], ["to", 1044], ["the", 1047], ["severity", 1051], ["of", 1060], ["patients", 1063], ["'", 1071], ["phenotype", 1073], [".", 1082], ["The", 1084], ["presence", 1088], ["of", 1097], ["10", 1100], ["misdiagnosed", 1103], ["cases", 1116], ["emphasizes", 1122], ["the", 1133], ["importance", 1137], ["of", 1148], ["performing", 1151], ["mutation", 1162], ["analysis", 1171], ["of", 1180], ["the", 1183], ["hotspot", 1187], ["regions", 1195], ["responsible", 1203], ["for", 1215], ["both", 1219], ["dysplasias", 1224], ["(", 1235], ["Ach", 1236], ["and", 1240], ["Hch", 1244], [")", 1247], [".", 1248], ["For", 1250], ["patients", 1254], ["with", 1263], ["an", 1268], ["unquestionable", 1271], ["clinical", 1286], ["diagnosis", 1295], [",", 1304], ["lacking", 1306], ["the", 1314], ["most", 1318], ["common", 1323], ["mutations", 1330], [",", 1339], ["a", 1341], ["complete", 1343], ["screening", 1352], ["of", 1362], ["FGFR3", 1365], ["is", 1371], ["necessary", 1374], [".", 1383]]}
{"context": "Mutations in the ribosomal protein (RP)S19 gene have been found in about 25% of the cases of Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. Various mutations have been identified in the RPS19 gene, but no investigations regarding the effect of these alterations on RPS19 mRNA levels have been performed. It is well established that mutated mRNA containing a premature stop codon (PTC) or lacking a stop codon can be rapidly degraded by specific mechanisms called nonsense mediated decay (NMD) and nonstop decay. To study the involvement of such mechanisms in DBA, we analyzed immortalized lymphoblastoid cells and primary fibroblasts from patients presenting different kinds of mutations in the RPS19 gene, generating allelic deletion, missense, nonsense, and nonstop messengers. We found that RPS19 mRNA levels are decreased in the cells with allelic deletion and, to a variable extent, also in all the cell lines with PTC or nonstop mutations. Further analysis showed that translation inhibition causes a stabilization of the mutated RPS19 mRNA. Our findings indicate that NMD and nonstop decay affect the expression of mutated RPS19 genes; this may help to clarify genotype-phenotype correlations in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "141cca4558cd4f99b00b0fe5066754ca", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[19, 22]], "char_spans": [[93, 115]]}, {"text": "DBA", "token_spans": [[219, 219], [24, 24], [111, 111]], "char_spans": [[1271, 1273], [118, 120], [627, 629]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["(", 35], ["RP)S19", 36], ["gene", 43], ["have", 48], ["been", 53], ["found", 58], ["in", 64], ["about", 67], ["25", 73], ["%", 75], ["of", 77], ["the", 80], ["cases", 84], ["of", 90], ["Diamond", 93], ["-", 100], ["Blackfan", 101], ["anemia", 110], ["(", 117], ["DBA", 118], [")", 121], [",", 122], ["a", 124], ["rare", 126], ["congenital", 131], ["hypoplastic", 142], ["anemia", 154], ["that", 161], ["includes", 166], ["variable", 175], ["physical", 184], ["malformations", 193], [".", 206], ["Various", 208], ["mutations", 216], ["have", 226], ["been", 231], ["identified", 236], ["in", 247], ["the", 250], ["RPS19", 254], ["gene", 260], [",", 264], ["but", 266], ["no", 270], ["investigations", 273], ["regarding", 288], ["the", 298], ["effect", 302], ["of", 309], ["these", 312], ["alterations", 318], ["on", 330], ["RPS19", 333], ["mRNA", 339], ["levels", 344], ["have", 351], ["been", 356], ["performed", 361], [".", 370], ["It", 372], ["is", 375], ["well", 378], ["established", 383], ["that", 395], ["mutated", 400], ["mRNA", 408], ["containing", 413], ["a", 424], ["premature", 426], ["stop", 436], ["codon", 441], ["(", 447], ["PTC", 448], [")", 451], ["or", 453], ["lacking", 456], ["a", 464], ["stop", 466], ["codon", 471], ["can", 477], ["be", 481], ["rapidly", 484], ["degraded", 492], ["by", 501], ["specific", 504], ["mechanisms", 513], ["called", 524], ["nonsense", 531], ["mediated", 540], ["decay", 549], ["(", 555], ["NMD", 556], [")", 559], ["and", 561], ["nonstop", 565], ["decay", 573], [".", 578], ["To", 580], ["study", 583], ["the", 589], ["involvement", 593], ["of", 605], ["such", 608], ["mechanisms", 613], ["in", 624], ["DBA", 627], [",", 630], ["we", 632], ["analyzed", 635], ["immortalized", 644], ["lymphoblastoid", 657], ["cells", 672], ["and", 678], ["primary", 682], ["fibroblasts", 690], ["from", 702], ["patients", 707], ["presenting", 716], ["different", 727], ["kinds", 737], ["of", 743], ["mutations", 746], ["in", 756], ["the", 759], ["RPS19", 763], ["gene", 769], [",", 773], ["generating", 775], ["allelic", 786], ["deletion", 794], [",", 802], ["missense", 804], [",", 812], ["nonsense", 814], [",", 822], ["and", 824], ["nonstop", 828], ["messengers", 836], [".", 846], ["We", 848], ["found", 851], ["that", 857], ["RPS19", 862], ["mRNA", 868], ["levels", 873], ["are", 880], ["decreased", 884], ["in", 894], ["the", 897], ["cells", 901], ["with", 907], ["allelic", 912], ["deletion", 920], ["and", 929], [",", 932], ["to", 934], ["a", 937], ["variable", 939], ["extent", 948], [",", 954], ["also", 956], ["in", 961], ["all", 964], ["the", 968], ["cell", 972], ["lines", 977], ["with", 983], ["PTC", 988], ["or", 992], ["nonstop", 995], ["mutations", 1003], [".", 1012], ["Further", 1014], ["analysis", 1022], ["showed", 1031], ["that", 1038], ["translation", 1043], ["inhibition", 1055], ["causes", 1066], ["a", 1073], ["stabilization", 1075], ["of", 1089], ["the", 1092], ["mutated", 1096], ["RPS19", 1104], ["mRNA", 1110], [".", 1114], ["Our", 1116], ["findings", 1120], ["indicate", 1129], ["that", 1138], ["NMD", 1143], ["and", 1147], ["nonstop", 1151], ["decay", 1159], ["affect", 1165], ["the", 1172], ["expression", 1176], ["of", 1187], ["mutated", 1190], ["RPS19", 1198], ["genes", 1204], [";", 1209], ["this", 1211], ["may", 1216], ["help", 1220], ["to", 1225], ["clarify", 1228], ["genotype", 1236], ["-", 1244], ["phenotype", 1245], ["correlations", 1255], ["in", 1268], ["DBA", 1271], [".", 1274]]}
{"context": "To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes. We prospectively compiled data on a series of 338 patients with diabetes with 356 episodes of foot infection who were hospitalized in the Diabetic Foot Unit of La Paloma Hospital from 1 October 2002 to 31 April 2010. For each patient we did a probe-to-bone test at the time of the initial evaluation and then obtained plain X-rays of the involved foot. All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture. We calculated the sensitivity, specificity, predictive values and likelihood ratios of the procedures, using the histopathological diagnosis of osteomyelitis as the criterion standard. Overall, 72.4% of patients had histologically proven osteomyelitis, 85.2% of whom had positive bone culture. The performance characteristics of both the probe-to-bone test and plain X-rays were excellent. The sequential diagnostic approach had a sensitivity of 0.97, specificity of 0.92, positive predictive value of 0.97, negative predictive value of 0.93, positive likelihood ratio of 12.8 and negative likelihood ratio of 0.02. Only 6.6% of patients with negative results on both diagnostic studies had osteomyelitis. Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "a31831baf7b64813bd2cd193e35c0c77", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[285, 287]], "char_spans": [[1597, 1623]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["accuracy", 19], ["of", 28], ["the", 31], ["sequential", 35], ["combination", 46], ["of", 58], ["the", 61], ["probe", 65], ["-", 70], ["to", 71], ["-", 73], ["bone", 74], ["test", 79], ["and", 84], ["plain", 88], ["X", 94], ["-", 95], ["rays", 96], ["for", 101], ["diagnosing", 105], ["osteomyelitis", 116], ["in", 130], ["the", 133], ["foot", 137], ["of", 142], ["patients", 145], ["with", 154], ["diabetes", 159], [".", 167], ["We", 169], ["prospectively", 172], ["compiled", 186], ["data", 195], ["on", 200], ["a", 203], ["series", 205], ["of", 212], ["338", 215], ["patients", 219], ["with", 228], ["diabetes", 233], ["with", 242], ["356", 247], ["episodes", 251], ["of", 260], ["foot", 263], ["infection", 268], ["who", 278], ["were", 282], ["hospitalized", 287], ["in", 300], ["the", 303], ["Diabetic", 307], ["Foot", 316], ["Unit", 321], ["of", 326], ["La", 329], ["Paloma", 332], ["Hospital", 339], ["from", 348], ["1", 353], ["October", 355], ["2002", 363], ["to", 368], ["31", 371], ["April", 374], ["2010", 380], [".", 384], ["For", 386], ["each", 390], ["patient", 395], ["we", 403], ["did", 406], ["a", 410], ["probe", 412], ["-", 417], ["to", 418], ["-", 420], ["bone", 421], ["test", 426], ["at", 431], ["the", 434], ["time", 438], ["of", 443], ["the", 446], ["initial", 450], ["evaluation", 458], ["and", 469], ["then", 473], ["obtained", 478], ["plain", 487], ["X", 493], ["-", 494], ["rays", 495], ["of", 500], ["the", 503], ["involved", 507], ["foot", 516], [".", 520], ["All", 522], ["patients", 526], ["with", 535], ["positive", 540], ["results", 549], ["on", 557], ["either", 560], ["the", 567], ["probe", 571], ["-", 576], ["to", 577], ["-", 579], ["bone", 580], ["test", 585], ["or", 590], ["plain", 593], ["X", 599], ["-", 600], ["ray", 601], ["underwent", 605], ["an", 615], ["appropriate", 618], ["surgical", 630], ["procedure", 639], [",", 648], ["which", 650], ["included", 656], ["obtaining", 665], ["a", 675], ["bone", 677], ["specimen", 682], ["that", 691], ["was", 696], ["processed", 700], ["for", 710], ["histology", 714], ["and", 724], ["culture", 728], [".", 735], ["We", 737], ["calculated", 740], ["the", 751], ["sensitivity", 755], [",", 766], ["specificity", 768], [",", 779], ["predictive", 781], ["values", 792], ["and", 799], ["likelihood", 803], ["ratios", 814], ["of", 821], ["the", 824], ["procedures", 828], [",", 838], ["using", 840], ["the", 846], ["histopathological", 850], ["diagnosis", 868], ["of", 878], ["osteomyelitis", 881], ["as", 895], ["the", 898], ["criterion", 902], ["standard", 912], [".", 920], ["Overall", 922], [",", 929], ["72.4", 931], ["%", 935], ["of", 937], ["patients", 940], ["had", 949], ["histologically", 953], ["proven", 968], ["osteomyelitis", 975], [",", 988], ["85.2", 990], ["%", 994], ["of", 996], ["whom", 999], ["had", 1004], ["positive", 1008], ["bone", 1017], ["culture", 1022], [".", 1029], ["The", 1031], ["performance", 1035], ["characteristics", 1047], ["of", 1063], ["both", 1066], ["the", 1071], ["probe", 1075], ["-", 1080], ["to", 1081], ["-", 1083], ["bone", 1084], ["test", 1089], ["and", 1094], ["plain", 1098], ["X", 1104], ["-", 1105], ["rays", 1106], ["were", 1111], ["excellent", 1116], [".", 1125], ["The", 1127], ["sequential", 1131], ["diagnostic", 1142], ["approach", 1153], ["had", 1162], ["a", 1166], ["sensitivity", 1168], ["of", 1180], ["0.97", 1183], [",", 1187], ["specificity", 1189], ["of", 1201], ["0.92", 1204], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["of", 1236], ["0.97", 1239], [",", 1243], ["negative", 1245], ["predictive", 1254], ["value", 1265], ["of", 1271], ["0.93", 1274], [",", 1278], ["positive", 1280], ["likelihood", 1289], ["ratio", 1300], ["of", 1306], ["12.8", 1309], ["and", 1314], ["negative", 1318], ["likelihood", 1327], ["ratio", 1338], ["of", 1344], ["0.02", 1347], [".", 1351], ["Only", 1353], ["6.6", 1358], ["%", 1361], ["of", 1363], ["patients", 1366], ["with", 1375], ["negative", 1380], ["results", 1389], ["on", 1397], ["both", 1400], ["diagnostic", 1405], ["studies", 1416], ["had", 1424], ["osteomyelitis", 1428], [".", 1441], ["Clinicians", 1443], ["seeing", 1454], ["patients", 1461], ["in", 1470], ["a", 1473], ["setting", 1475], ["similar", 1483], ["to", 1491], ["ours", 1494], ["(", 1499], ["specialized", 1500], ["diabetic", 1512], ["foot", 1521], ["unit", 1526], ["with", 1531], ["a", 1536], ["high", 1538], ["prevalence", 1543], ["of", 1554], ["osteomyelitis", 1557], [")", 1570], ["can", 1572], ["confidently", 1576], ["diagnose", 1588], ["diabetic", 1597], ["foot", 1606], ["osteomyelitis", 1611], ["when", 1625], ["either", 1630], ["the", 1637], ["probe", 1641], ["-", 1646], ["to", 1647], ["-", 1649], ["bone", 1650], ["test", 1655], ["or", 1660], ["a", 1663], ["plain", 1665], ["X", 1671], ["-", 1672], ["ray", 1673], [",", 1676], ["or", 1678], ["especially", 1681], ["both", 1692], [",", 1696], ["are", 1698], ["positive", 1702], [".", 1710]]}
{"context": "The members of the NOX family of enzymes are expressed in a variety of tissues and serve a number of functions. There is a high level of conservation of primary protein sequence, as well as functional features, although specialized responses are beginning to emerge. In this context, our data demonstrate that the NOX1 cytoplasmic domains interact efficiently with the cytoplasmic subunits of the phagocyte NADPH oxidase and identify the second cytoplasmic loop of NOX electron transporters as a crucial domain for enzyme function. Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1. Finally, we have provided the first example of how alternative splicing of a NOX co-factor may be involved in the regulation of NADPH oxidase function.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d9e22d6ebaa441090217077e2711e57", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[104, 104], [57, 57]], "char_spans": [[613, 616], [314, 317]]}]}], "context_tokens": [["The", 0], ["members", 4], ["of", 12], ["the", 15], ["NOX", 19], ["family", 23], ["of", 30], ["enzymes", 33], ["are", 41], ["expressed", 45], ["in", 55], ["a", 58], ["variety", 60], ["of", 68], ["tissues", 71], ["and", 79], ["serve", 83], ["a", 89], ["number", 91], ["of", 98], ["functions", 101], [".", 110], ["There", 112], ["is", 118], ["a", 121], ["high", 123], ["level", 128], ["of", 134], ["conservation", 137], ["of", 150], ["primary", 153], ["protein", 161], ["sequence", 169], [",", 177], ["as", 179], ["well", 182], ["as", 187], ["functional", 190], ["features", 201], [",", 209], ["although", 211], ["specialized", 220], ["responses", 232], ["are", 242], ["beginning", 246], ["to", 256], ["emerge", 259], [".", 265], ["In", 267], ["this", 270], ["context", 275], [",", 282], ["our", 284], ["data", 288], ["demonstrate", 293], ["that", 305], ["the", 310], ["NOX1", 314], ["cytoplasmic", 319], ["domains", 331], ["interact", 339], ["efficiently", 348], ["with", 360], ["the", 365], ["cytoplasmic", 369], ["subunits", 381], ["of", 390], ["the", 393], ["phagocyte", 397], ["NADPH", 407], ["oxidase", 413], ["and", 421], ["identify", 425], ["the", 434], ["second", 438], ["cytoplasmic", 445], ["loop", 457], ["of", 462], ["NOX", 465], ["electron", 469], ["transporters", 478], ["as", 491], ["a", 494], ["crucial", 496], ["domain", 504], ["for", 511], ["enzyme", 515], ["function", 522], [".", 530], ["Studies", 532], ["of", 540], ["cytosolic", 543], ["co", 553], ["-", 555], ["factors", 556], ["showed", 564], ["that", 571], ["the", 576], ["C", 580], ["-", 581], ["terminal", 582], ["cytoplasmic", 591], ["domain", 603], ["of", 610], ["NOX1", 613], ["was", 618], ["absolutely", 622], ["required", 633], ["for", 642], ["activation", 646], ["with", 657], ["NOXO1", 662], ["and", 668], ["NOXA1", 672], ["and", 678], ["that", 682], ["this", 687], ["activity", 692], ["required", 701], ["interaction", 710], ["of", 722], ["the", 725], ["putative", 729], ["NADPH", 738], ["-", 743], ["binding", 744], ["region", 752], ["of", 759], ["this", 762], ["domain", 767], ["with", 774], ["NOXA1", 779], [".", 784], ["Finally", 786], [",", 793], ["we", 795], ["have", 798], ["provided", 803], ["the", 812], ["first", 816], ["example", 822], ["of", 830], ["how", 833], ["alternative", 837], ["splicing", 849], ["of", 858], ["a", 861], ["NOX", 863], ["co", 867], ["-", 869], ["factor", 870], ["may", 877], ["be", 881], ["involved", 884], ["in", 893], ["the", 896], ["regulation", 900], ["of", 911], ["NADPH", 914], ["oxidase", 920], ["function", 928], [".", 936]]}
{"context": "We generated a genome-wide replication profile in the genome of Lachancea kluyveri and assessed the relationship between replication and base composition. This species diverged from Saccharomyces cerevisiae before the ancestral whole genome duplication. The genome comprises eight chromosomes among which a chromosomal arm of 1 Mb has a G + C-content much higher than the rest of the genome. We identified 252 active replication origins in L. kluyveri and found considerable divergence in origin location with S. cerevisiae and with Lachancea waltii. Although some global features of S. cerevisiae replication are conserved: Centromeres replicate early, whereas telomeres replicate late, we found that replication origins both in L. kluyveri and L. waltii do not behave as evolutionary fragile sites. In L. kluyveri, replication timing along chromosomes alternates between regions of early and late activating origins, except for the 1 Mb GC-rich chromosomal arm. This chromosomal arm contains an origin consensus motif different from other chromosomes and is replicated early during S-phase. We showed that precocious replication results from the specific absence of late firing origins in this chromosomal arm. In addition, we found a correlation between GC-content and distance from replication origins as well as a lack of replication-associated compositional skew between leading and lagging strands specifically in this GC-rich chromosomal arm. These findings suggest that the unusual base composition in the genome of L. kluyveri could be linked to replication.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "d8b6714eca6845d68ff4a83b405e4a77", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[174, 174], [103, 103], [142, 142]], "char_spans": [[1071, 1075], [647, 651], [884, 888]]}]}], "context_tokens": [["We", 0], ["generated", 3], ["a", 13], ["genome", 15], ["-", 21], ["wide", 22], ["replication", 27], ["profile", 39], ["in", 47], ["the", 50], ["genome", 54], ["of", 61], ["Lachancea", 64], ["kluyveri", 74], ["and", 83], ["assessed", 87], ["the", 96], ["relationship", 100], ["between", 113], ["replication", 121], ["and", 133], ["base", 137], ["composition", 142], [".", 153], ["This", 155], ["species", 160], ["diverged", 168], ["from", 177], ["Saccharomyces", 182], ["cerevisiae", 196], ["before", 207], ["the", 214], ["ancestral", 218], ["whole", 228], ["genome", 234], ["duplication", 241], [".", 252], ["The", 254], ["genome", 258], ["comprises", 265], ["eight", 275], ["chromosomes", 281], ["among", 293], ["which", 299], ["a", 305], ["chromosomal", 307], ["arm", 319], ["of", 323], ["1", 326], ["Mb", 328], ["has", 331], ["a", 335], ["G", 337], ["+", 339], ["C", 341], ["-", 342], ["content", 343], ["much", 351], ["higher", 356], ["than", 363], ["the", 368], ["rest", 372], ["of", 377], ["the", 380], ["genome", 384], [".", 390], ["We", 392], ["identified", 395], ["252", 406], ["active", 410], ["replication", 417], ["origins", 429], ["in", 437], ["L.", 440], ["kluyveri", 443], ["and", 452], ["found", 456], ["considerable", 462], ["divergence", 475], ["in", 486], ["origin", 489], ["location", 496], ["with", 505], ["S.", 510], ["cerevisiae", 513], ["and", 524], ["with", 528], ["Lachancea", 533], ["waltii", 543], [".", 549], ["Although", 551], ["some", 560], ["global", 565], ["features", 572], ["of", 581], ["S.", 584], ["cerevisiae", 587], ["replication", 598], ["are", 610], ["conserved", 614], [":", 623], ["Centromeres", 625], ["replicate", 637], ["early", 647], [",", 652], ["whereas", 654], ["telomeres", 662], ["replicate", 672], ["late", 682], [",", 686], ["we", 688], ["found", 691], ["that", 697], ["replication", 702], ["origins", 714], ["both", 722], ["in", 727], ["L.", 730], ["kluyveri", 733], ["and", 742], ["L.", 746], ["waltii", 749], ["do", 756], ["not", 759], ["behave", 763], ["as", 770], ["evolutionary", 773], ["fragile", 786], ["sites", 794], [".", 799], ["In", 801], ["L.", 804], ["kluyveri", 807], [",", 815], ["replication", 817], ["timing", 829], ["along", 836], ["chromosomes", 842], ["alternates", 854], ["between", 865], ["regions", 873], ["of", 881], ["early", 884], ["and", 890], ["late", 894], ["activating", 899], ["origins", 910], [",", 917], ["except", 919], ["for", 926], ["the", 930], ["1", 934], ["Mb", 936], ["GC", 939], ["-", 941], ["rich", 942], ["chromosomal", 947], ["arm", 959], [".", 962], ["This", 964], ["chromosomal", 969], ["arm", 981], ["contains", 985], ["an", 994], ["origin", 997], ["consensus", 1004], ["motif", 1014], ["different", 1020], ["from", 1030], ["other", 1035], ["chromosomes", 1041], ["and", 1053], ["is", 1057], ["replicated", 1060], ["early", 1071], ["during", 1077], ["S", 1084], ["-", 1085], ["phase", 1086], [".", 1091], ["We", 1093], ["showed", 1096], ["that", 1103], ["precocious", 1108], ["replication", 1119], ["results", 1131], ["from", 1139], ["the", 1144], ["specific", 1148], ["absence", 1157], ["of", 1165], ["late", 1168], ["firing", 1173], ["origins", 1180], ["in", 1188], ["this", 1191], ["chromosomal", 1196], ["arm", 1208], [".", 1211], ["In", 1213], ["addition", 1216], [",", 1224], ["we", 1226], ["found", 1229], ["a", 1235], ["correlation", 1237], ["between", 1249], ["GC", 1257], ["-", 1259], ["content", 1260], ["and", 1268], ["distance", 1272], ["from", 1281], ["replication", 1286], ["origins", 1298], ["as", 1306], ["well", 1309], ["as", 1314], ["a", 1317], ["lack", 1319], ["of", 1324], ["replication", 1327], ["-", 1338], ["associated", 1339], ["compositional", 1350], ["skew", 1364], ["between", 1369], ["leading", 1377], ["and", 1385], ["lagging", 1389], ["strands", 1397], ["specifically", 1405], ["in", 1418], ["this", 1421], ["GC", 1426], ["-", 1428], ["rich", 1429], ["chromosomal", 1434], ["arm", 1446], [".", 1449], ["These", 1451], ["findings", 1457], ["suggest", 1466], ["that", 1474], ["the", 1479], ["unusual", 1483], ["base", 1491], ["composition", 1496], ["in", 1508], ["the", 1511], ["genome", 1515], ["of", 1522], ["L.", 1525], ["kluyveri", 1528], ["could", 1537], ["be", 1543], ["linked", 1546], ["to", 1553], ["replication", 1556], [".", 1567]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "The X-linked McLeod neuroacanthocytosis syndrome strongly resembles Huntington's disease and has been reported in various countries world-wide. Herein, we report two Chilean brothers with predominant psychiatric features at disease onset including schizophrenia-like psychosis and obsessive compulsive disorder. Molecular genetic analysis revealed a small deletion in the XK gene (938-942delCTCTA), which has been already described in a North American patient of Anglo-Saxon descent and a Japanese family, presenting with seizures, muscle atrophy or chorea yet absence of psychiatric features. These findings argue against a founder effect and indicate a profound phenotypic variability associated with the 938-942delCTCTA deletion. Our report supports the inclusion of McLeod syndrome in the differential diagnosis of Huntington's disease as well as acute psychosis in male subjects.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "709fee36b5e44977bdf24dd072d08608", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[56, 56]], "char_spans": [[372, 373]]}]}], "context_tokens": [["The", 0], ["X", 4], ["-", 5], ["linked", 6], ["McLeod", 13], ["neuroacanthocytosis", 20], ["syndrome", 40], ["strongly", 49], ["resembles", 58], ["Huntington", 68], ["'s", 78], ["disease", 81], ["and", 89], ["has", 93], ["been", 97], ["reported", 102], ["in", 111], ["various", 114], ["countries", 122], ["world", 132], ["-", 137], ["wide", 138], [".", 142], ["Herein", 144], [",", 150], ["we", 152], ["report", 155], ["two", 162], ["Chilean", 166], ["brothers", 174], ["with", 183], ["predominant", 188], ["psychiatric", 200], ["features", 212], ["at", 221], ["disease", 224], ["onset", 232], ["including", 238], ["schizophrenia", 248], ["-", 261], ["like", 262], ["psychosis", 267], ["and", 277], ["obsessive", 281], ["compulsive", 291], ["disorder", 302], [".", 310], ["Molecular", 312], ["genetic", 322], ["analysis", 330], ["revealed", 339], ["a", 348], ["small", 350], ["deletion", 356], ["in", 365], ["the", 368], ["XK", 372], ["gene", 375], ["(", 380], ["938", 381], ["-", 384], ["942delCTCTA", 385], [")", 396], [",", 397], ["which", 399], ["has", 405], ["been", 409], ["already", 414], ["described", 422], ["in", 432], ["a", 435], ["North", 437], ["American", 443], ["patient", 452], ["of", 460], ["Anglo", 463], ["-", 468], ["Saxon", 469], ["descent", 475], ["and", 483], ["a", 487], ["Japanese", 489], ["family", 498], [",", 504], ["presenting", 506], ["with", 517], ["seizures", 522], [",", 530], ["muscle", 532], ["atrophy", 539], ["or", 547], ["chorea", 550], ["yet", 557], ["absence", 561], ["of", 569], ["psychiatric", 572], ["features", 584], [".", 592], ["These", 594], ["findings", 600], ["argue", 609], ["against", 615], ["a", 623], ["founder", 625], ["effect", 633], ["and", 640], ["indicate", 644], ["a", 653], ["profound", 655], ["phenotypic", 664], ["variability", 675], ["associated", 687], ["with", 698], ["the", 703], ["938", 707], ["-", 710], ["942delCTCTA", 711], ["deletion", 723], [".", 731], ["Our", 733], ["report", 737], ["supports", 744], ["the", 753], ["inclusion", 757], ["of", 767], ["McLeod", 770], ["syndrome", 777], ["in", 786], ["the", 789], ["differential", 793], ["diagnosis", 806], ["of", 816], ["Huntington", 819], ["'s", 829], ["disease", 832], ["as", 840], ["well", 843], ["as", 848], ["acute", 851], ["psychosis", 857], ["in", 867], ["male", 870], ["subjects", 875], [".", 883]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "The subventricular zone of the rodent brain retains the capacity of generating new neurons in adulthood. The newly formed neuroblasts migrate rostrally toward the olfactory bulb, where they differentiate as granular and periglomerular interneurons. The reported presence of differentiated neurons expressing the neuronal isoform of nitric oxide synthase (NOS) in the periphery of the neurogenic region and the organization of their varicose axons as a network in which the precursors are immersed raised the hypothesis that endogenous nitric oxide (NO) may participate in the control of neurogenesis in the subventricular zone. Systemic administration of the NOS inhibitors N(omega)-nitro-L-arginine methyl ester or 7-nitroindazole to adult mice produced a dose- and time-dependent increase in the number of mitotic cells in the subventricular zone, rostral migratory stream, and olfactory bulb, but not in the dentate gyrus of the hippocampus, without affecting apoptosis. In the subventricular zone, this effect was exerted selectively on a precursor subpopulation expressing nestin but not neuronal or glial cell-specific proteins. In addition, in the olfactory bulb, analysis of maturation markers in the newly generated neurons indicated that chronic NOS inhibition caused a delay in neuronal differentiation. Postmitotic cell survival and migration were not affected when NO production was impaired. Our results suggest that NO, produced by nitrergic neurons in the adult mouse subventricular zone and olfactory bulb, exerts a negative control on the size of the undifferentiated precursor pool and promotes neuronal differentiation.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "ab3ff6a5a146419f8fd61b433587067c", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[173, 173]], "char_spans": [[1078, 1083]]}]}], "context_tokens": [["The", 0], ["subventricular", 4], ["zone", 19], ["of", 24], ["the", 27], ["rodent", 31], ["brain", 38], ["retains", 44], ["the", 52], ["capacity", 56], ["of", 65], ["generating", 68], ["new", 79], ["neurons", 83], ["in", 91], ["adulthood", 94], [".", 103], ["The", 105], ["newly", 109], ["formed", 115], ["neuroblasts", 122], ["migrate", 134], ["rostrally", 142], ["toward", 152], ["the", 159], ["olfactory", 163], ["bulb", 173], [",", 177], ["where", 179], ["they", 185], ["differentiate", 190], ["as", 204], ["granular", 207], ["and", 216], ["periglomerular", 220], ["interneurons", 235], [".", 247], ["The", 249], ["reported", 253], ["presence", 262], ["of", 271], ["differentiated", 274], ["neurons", 289], ["expressing", 297], ["the", 308], ["neuronal", 312], ["isoform", 321], ["of", 329], ["nitric", 332], ["oxide", 339], ["synthase", 345], ["(", 354], ["NOS", 355], [")", 358], ["in", 360], ["the", 363], ["periphery", 367], ["of", 377], ["the", 380], ["neurogenic", 384], ["region", 395], ["and", 402], ["the", 406], ["organization", 410], ["of", 423], ["their", 426], ["varicose", 432], ["axons", 441], ["as", 447], ["a", 450], ["network", 452], ["in", 460], ["which", 463], ["the", 469], ["precursors", 473], ["are", 484], ["immersed", 488], ["raised", 497], ["the", 504], ["hypothesis", 508], ["that", 519], ["endogenous", 524], ["nitric", 535], ["oxide", 542], ["(", 548], ["NO", 549], [")", 551], ["may", 553], ["participate", 557], ["in", 569], ["the", 572], ["control", 576], ["of", 584], ["neurogenesis", 587], ["in", 600], ["the", 603], ["subventricular", 607], ["zone", 622], [".", 626], ["Systemic", 628], ["administration", 637], ["of", 652], ["the", 655], ["NOS", 659], ["inhibitors", 663], ["N(omega)-nitro", 674], ["-", 688], ["L", 689], ["-", 690], ["arginine", 691], ["methyl", 700], ["ester", 707], ["or", 713], ["7-nitroindazole", 716], ["to", 732], ["adult", 735], ["mice", 741], ["produced", 746], ["a", 755], ["dose-", 757], ["and", 763], ["time", 767], ["-", 771], ["dependent", 772], ["increase", 782], ["in", 791], ["the", 794], ["number", 798], ["of", 805], ["mitotic", 808], ["cells", 816], ["in", 822], ["the", 825], ["subventricular", 829], ["zone", 844], [",", 848], ["rostral", 850], ["migratory", 858], ["stream", 868], [",", 874], ["and", 876], ["olfactory", 880], ["bulb", 890], [",", 894], ["but", 896], ["not", 900], ["in", 904], ["the", 907], ["dentate", 911], ["gyrus", 919], ["of", 925], ["the", 928], ["hippocampus", 932], [",", 943], ["without", 945], ["affecting", 953], ["apoptosis", 963], [".", 972], ["In", 974], ["the", 977], ["subventricular", 981], ["zone", 996], [",", 1000], ["this", 1002], ["effect", 1007], ["was", 1014], ["exerted", 1018], ["selectively", 1026], ["on", 1038], ["a", 1041], ["precursor", 1043], ["subpopulation", 1053], ["expressing", 1067], ["nestin", 1078], ["but", 1085], ["not", 1089], ["neuronal", 1093], ["or", 1102], ["glial", 1105], ["cell", 1111], ["-", 1115], ["specific", 1116], ["proteins", 1125], [".", 1133], ["In", 1135], ["addition", 1138], [",", 1146], ["in", 1148], ["the", 1151], ["olfactory", 1155], ["bulb", 1165], [",", 1169], ["analysis", 1171], ["of", 1180], ["maturation", 1183], ["markers", 1194], ["in", 1202], ["the", 1205], ["newly", 1209], ["generated", 1215], ["neurons", 1225], ["indicated", 1233], ["that", 1243], ["chronic", 1248], ["NOS", 1256], ["inhibition", 1260], ["caused", 1271], ["a", 1278], ["delay", 1280], ["in", 1286], ["neuronal", 1289], ["differentiation", 1298], [".", 1313], ["Postmitotic", 1315], ["cell", 1327], ["survival", 1332], ["and", 1341], ["migration", 1345], ["were", 1355], ["not", 1360], ["affected", 1364], ["when", 1373], ["NO", 1378], ["production", 1381], ["was", 1392], ["impaired", 1396], [".", 1404], ["Our", 1406], ["results", 1410], ["suggest", 1418], ["that", 1426], ["NO", 1431], [",", 1433], ["produced", 1435], ["by", 1444], ["nitrergic", 1447], ["neurons", 1457], ["in", 1465], ["the", 1468], ["adult", 1472], ["mouse", 1478], ["subventricular", 1484], ["zone", 1499], ["and", 1504], ["olfactory", 1508], ["bulb", 1518], [",", 1522], ["exerts", 1524], ["a", 1531], ["negative", 1533], ["control", 1542], ["on", 1550], ["the", 1553], ["size", 1557], ["of", 1562], ["the", 1565], ["undifferentiated", 1569], ["precursor", 1586], ["pool", 1596], ["and", 1601], ["promotes", 1605], ["neuronal", 1614], ["differentiation", 1623], [".", 1638]]}
{"context": "To evaluate the usefulness of the periportal free air (PPFA) sign on computed tomography (CT) to distinguish upper from lower gastrointestinal (GI) tract perforation. During a 30-month period, we retrospectively analyzed abdominal CT images of 53 consecutive patients with surgically proven GI tract perforation. We divided the patients into two groups, i.e. upper and lower GI tract perforation groups. According to the distribution of free air, we divided the peritoneal cavity into supramesocolic compartment and inframesocolic compartment. We observed the presence or absence of free air in each compartment in each group. When there was free air in the periportal area, it was defined as periportal free air (PPFA) and the sign was positive. To evaluate the usefulness of the PPFA sign, we compared the PPFA sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known CT signs of pneumoperitoneum. Statistical analyses were performed with univariate and multivariate analyses using SPSS version 11.5 for significant findings among the CT signs. Free air was seen in supramesocolic compartment in 29 of 30 (97%) patients in the upper GI perforation group and in 17 of 23 (74%) in the lower GI perforation group. Free air in inframesocolic compartment did not show significant difference in either group (p=.16). The PPFA sign was seen in 28 of 30 (93%) patients with upper GI tract perforation, but in only 8 of 23 (35%) patients with lower GI tract perforation (p<.0001). The falciform ligament sign was seen in 24 of 30 (80%) patients with upper GI tract perforation and in 10 of 23 (43%) patients with lower GI tract perforation (p=.020). The ligamentum teres sign was seen in 16 of 30 (53%) patients with upper GI tract perforation and in 2 of 23 (8%) patients with lower GI tract perforation (p=.008). Multivariate logistic regression analysis showed that the PPFA sign was the only variable, which adjusted odds ratio of 15.5 (p=.002). The PPFA sign is a useful finding which can help to distinguish upper from lower GI tract perforation. When this sign is present, upper GI tract perforation is strongly suggested.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "7b02cb46d87c4b849e37b82396d1c3b0", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[167, 167]], "char_spans": [[923, 938]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["usefulness", 16], ["of", 27], ["the", 30], ["periportal", 34], ["free", 45], ["air", 50], ["(", 54], ["PPFA", 55], [")", 59], ["sign", 61], ["on", 66], ["computed", 69], ["tomography", 78], ["(", 89], ["CT", 90], [")", 92], ["to", 94], ["distinguish", 97], ["upper", 109], ["from", 115], ["lower", 120], ["gastrointestinal", 126], ["(", 143], ["GI", 144], [")", 146], ["tract", 148], ["perforation", 154], [".", 165], ["During", 167], ["a", 174], ["30-month", 176], ["period", 185], [",", 191], ["we", 193], ["retrospectively", 196], ["analyzed", 212], ["abdominal", 221], ["CT", 231], ["images", 234], ["of", 241], ["53", 244], ["consecutive", 247], ["patients", 259], ["with", 268], ["surgically", 273], ["proven", 284], ["GI", 291], ["tract", 294], ["perforation", 300], [".", 311], ["We", 313], ["divided", 316], ["the", 324], ["patients", 328], ["into", 337], ["two", 342], ["groups", 346], [",", 352], ["i.e.", 354], ["upper", 359], ["and", 365], ["lower", 369], ["GI", 375], ["tract", 378], ["perforation", 384], ["groups", 396], [".", 402], ["According", 404], ["to", 414], ["the", 417], ["distribution", 421], ["of", 434], ["free", 437], ["air", 442], [",", 445], ["we", 447], ["divided", 450], ["the", 458], ["peritoneal", 462], ["cavity", 473], ["into", 480], ["supramesocolic", 485], ["compartment", 500], ["and", 512], ["inframesocolic", 516], ["compartment", 531], [".", 542], ["We", 544], ["observed", 547], ["the", 556], ["presence", 560], ["or", 569], ["absence", 572], ["of", 580], ["free", 583], ["air", 588], ["in", 592], ["each", 595], ["compartment", 600], ["in", 612], ["each", 615], ["group", 620], [".", 625], ["When", 627], ["there", 632], ["was", 638], ["free", 642], ["air", 647], ["in", 651], ["the", 654], ["periportal", 658], ["area", 669], [",", 673], ["it", 675], ["was", 678], ["defined", 682], ["as", 690], ["periportal", 693], ["free", 704], ["air", 709], ["(", 713], ["PPFA", 714], [")", 718], ["and", 720], ["the", 724], ["sign", 728], ["was", 733], ["positive", 737], [".", 745], ["To", 747], ["evaluate", 750], ["the", 759], ["usefulness", 763], ["of", 774], ["the", 777], ["PPFA", 781], ["sign", 786], [",", 790], ["we", 792], ["compared", 795], ["the", 804], ["PPFA", 808], ["sign", 813], ["with", 818], ["the", 823], ["falciform", 827], ["ligament", 837], ["sign", 846], ["and", 851], ["the", 855], ["ligamentum", 859], ["teres", 870], ["sign", 876], [",", 880], ["both", 882], ["of", 887], ["which", 890], ["are", 896], ["well", 900], ["-", 904], ["known", 905], ["CT", 911], ["signs", 914], ["of", 920], ["pneumoperitoneum", 923], [".", 939], ["Statistical", 941], ["analyses", 953], ["were", 962], ["performed", 967], ["with", 977], ["univariate", 982], ["and", 993], ["multivariate", 997], ["analyses", 1010], ["using", 1019], ["SPSS", 1025], ["version", 1030], ["11.5", 1038], ["for", 1043], ["significant", 1047], ["findings", 1059], ["among", 1068], ["the", 1074], ["CT", 1078], ["signs", 1081], [".", 1086], ["Free", 1088], ["air", 1093], ["was", 1097], ["seen", 1101], ["in", 1106], ["supramesocolic", 1109], ["compartment", 1124], ["in", 1136], ["29", 1139], ["of", 1142], ["30", 1145], ["(", 1148], ["97", 1149], ["%", 1151], [")", 1152], ["patients", 1154], ["in", 1163], ["the", 1166], ["upper", 1170], ["GI", 1176], ["perforation", 1179], ["group", 1191], ["and", 1197], ["in", 1201], ["17", 1204], ["of", 1207], ["23", 1210], ["(", 1213], ["74", 1214], ["%", 1216], [")", 1217], ["in", 1219], ["the", 1222], ["lower", 1226], ["GI", 1232], ["perforation", 1235], ["group", 1247], [".", 1252], ["Free", 1254], ["air", 1259], ["in", 1263], ["inframesocolic", 1266], ["compartment", 1281], ["did", 1293], ["not", 1297], ["show", 1301], ["significant", 1306], ["difference", 1318], ["in", 1329], ["either", 1332], ["group", 1339], ["(", 1345], ["p=.16", 1346], [")", 1351], [".", 1352], ["The", 1354], ["PPFA", 1358], ["sign", 1363], ["was", 1368], ["seen", 1372], ["in", 1377], ["28", 1380], ["of", 1383], ["30", 1386], ["(", 1389], ["93", 1390], ["%", 1392], [")", 1393], ["patients", 1395], ["with", 1404], ["upper", 1409], ["GI", 1415], ["tract", 1418], ["perforation", 1424], [",", 1435], ["but", 1437], ["in", 1441], ["only", 1444], ["8", 1449], ["of", 1451], ["23", 1454], ["(", 1457], ["35", 1458], ["%", 1460], [")", 1461], ["patients", 1463], ["with", 1472], ["lower", 1477], ["GI", 1483], ["tract", 1486], ["perforation", 1492], ["(", 1504], ["p<.0001", 1505], [")", 1512], [".", 1513], ["The", 1515], ["falciform", 1519], ["ligament", 1529], ["sign", 1538], ["was", 1543], ["seen", 1547], ["in", 1552], ["24", 1555], ["of", 1558], ["30", 1561], ["(", 1564], ["80", 1565], ["%", 1567], [")", 1568], ["patients", 1570], ["with", 1579], ["upper", 1584], ["GI", 1590], ["tract", 1593], ["perforation", 1599], ["and", 1611], ["in", 1615], ["10", 1618], ["of", 1621], ["23", 1624], ["(", 1627], ["43", 1628], ["%", 1630], [")", 1631], ["patients", 1633], ["with", 1642], ["lower", 1647], ["GI", 1653], ["tract", 1656], ["perforation", 1662], ["(", 1674], ["p=.020", 1675], [")", 1681], [".", 1682], ["The", 1684], ["ligamentum", 1688], ["teres", 1699], ["sign", 1705], ["was", 1710], ["seen", 1714], ["in", 1719], ["16", 1722], ["of", 1725], ["30", 1728], ["(", 1731], ["53", 1732], ["%", 1734], [")", 1735], ["patients", 1737], ["with", 1746], ["upper", 1751], ["GI", 1757], ["tract", 1760], ["perforation", 1766], ["and", 1778], ["in", 1782], ["2", 1785], ["of", 1787], ["23", 1790], ["(", 1793], ["8", 1794], ["%", 1795], [")", 1796], ["patients", 1798], ["with", 1807], ["lower", 1812], ["GI", 1818], ["tract", 1821], ["perforation", 1827], ["(", 1839], ["p=.008", 1840], [")", 1846], [".", 1847], ["Multivariate", 1849], ["logistic", 1862], ["regression", 1871], ["analysis", 1882], ["showed", 1891], ["that", 1898], ["the", 1903], ["PPFA", 1907], ["sign", 1912], ["was", 1917], ["the", 1921], ["only", 1925], ["variable", 1930], [",", 1938], ["which", 1940], ["adjusted", 1946], ["odds", 1955], ["ratio", 1960], ["of", 1966], ["15.5", 1969], ["(", 1974], ["p=.002", 1975], [")", 1981], [".", 1982], ["The", 1984], ["PPFA", 1988], ["sign", 1993], ["is", 1998], ["a", 2001], ["useful", 2003], ["finding", 2010], ["which", 2018], ["can", 2024], ["help", 2028], ["to", 2033], ["distinguish", 2036], ["upper", 2048], ["from", 2054], ["lower", 2059], ["GI", 2065], ["tract", 2068], ["perforation", 2074], [".", 2085], ["When", 2087], ["this", 2092], ["sign", 2097], ["is", 2102], ["present", 2105], [",", 2112], ["upper", 2114], ["GI", 2120], ["tract", 2123], ["perforation", 2129], ["is", 2141], ["strongly", 2144], ["suggested", 2153], [".", 2162]]}
{"context": "Parkinson's disease (PD) and related Lewy body diseases are characterized by deposition of \u03b1-synuclein aggregates in both the central nervous system and peripheral nervous system. Synucleinopathy lesions spread to larger brain areas as the disease progresses, and prion-like cell-to-cell transmission of aggregated \u03b1-synuclein is thought to be the underlying mechanism for this pathological spreading. LRRK2 is another protein linked to the pathogenesis of PD, and its presence in Lewy bodies has attracted much attention as to whether LRRK2 and \u03b1-synuclein interplay during the pathogenesis of PD. However, the relationship between these two crucial proteins still remains unclear. In this review article, we will discuss the current state of knowledge in terms of how these proteins cause the disease and provide the hypothetical mechanisms by which LRRK2 might modify the generation and progression of synucleinopathy.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "ab5ce079faa34a7b97b77449fa304a3f", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["related", 29], ["Lewy", 37], ["body", 42], ["diseases", 47], ["are", 56], ["characterized", 60], ["by", 74], ["deposition", 77], ["of", 88], ["\u03b1", 91], ["-", 92], ["synuclein", 93], ["aggregates", 103], ["in", 114], ["both", 117], ["the", 122], ["central", 126], ["nervous", 134], ["system", 142], ["and", 149], ["peripheral", 153], ["nervous", 164], ["system", 172], [".", 178], ["Synucleinopathy", 180], ["lesions", 196], ["spread", 204], ["to", 211], ["larger", 214], ["brain", 221], ["areas", 227], ["as", 233], ["the", 236], ["disease", 240], ["progresses", 248], [",", 258], ["and", 260], ["prion", 264], ["-", 269], ["like", 270], ["cell", 275], ["-", 279], ["to", 280], ["-", 282], ["cell", 283], ["transmission", 288], ["of", 301], ["aggregated", 304], ["\u03b1", 315], ["-", 316], ["synuclein", 317], ["is", 327], ["thought", 330], ["to", 338], ["be", 341], ["the", 344], ["underlying", 348], ["mechanism", 359], ["for", 369], ["this", 373], ["pathological", 378], ["spreading", 391], [".", 400], ["LRRK2", 402], ["is", 408], ["another", 411], ["protein", 419], ["linked", 427], ["to", 434], ["the", 437], ["pathogenesis", 441], ["of", 454], ["PD", 457], [",", 459], ["and", 461], ["its", 465], ["presence", 469], ["in", 478], ["Lewy", 481], ["bodies", 486], ["has", 493], ["attracted", 497], ["much", 507], ["attention", 512], ["as", 522], ["to", 525], ["whether", 528], ["LRRK2", 536], ["and", 542], ["\u03b1", 546], ["-", 547], ["synuclein", 548], ["interplay", 558], ["during", 568], ["the", 575], ["pathogenesis", 579], ["of", 592], ["PD", 595], [".", 597], ["However", 599], [",", 606], ["the", 608], ["relationship", 612], ["between", 625], ["these", 633], ["two", 639], ["crucial", 643], ["proteins", 651], ["still", 660], ["remains", 666], ["unclear", 674], [".", 681], ["In", 683], ["this", 686], ["review", 691], ["article", 698], [",", 705], ["we", 707], ["will", 710], ["discuss", 715], ["the", 723], ["current", 727], ["state", 735], ["of", 741], ["knowledge", 744], ["in", 754], ["terms", 757], ["of", 763], ["how", 766], ["these", 770], ["proteins", 776], ["cause", 785], ["the", 791], ["disease", 795], ["and", 803], ["provide", 807], ["the", 815], ["hypothetical", 819], ["mechanisms", 832], ["by", 843], ["which", 846], ["LRRK2", 852], ["might", 858], ["modify", 864], ["the", 871], ["generation", 875], ["and", 886], ["progression", 890], ["of", 902], ["synucleinopathy", 905], [".", 920]]}
{"context": "Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 \u03bcg per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P\u22640.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.).", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "cf8660626db24842b789111d454df139", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[44, 46], [3, 5]], "char_spans": [[269, 287], [24, 42]]}]}], "context_tokens": [["Increased", 0], ["expression", 10], ["of", 21], ["nerve", 24], ["growth", 30], ["factor", 37], ["in", 44], ["injured", 47], ["or", 55], ["inflamed", 58], ["tissue", 67], ["is", 74], ["associated", 77], ["with", 88], ["increased", 93], ["pain", 103], [".", 107], ["This", 109], ["proof", 114], ["-", 119], ["of", 120], ["-", 122], ["concept", 123], ["study", 131], ["was", 137], ["designed", 141], ["to", 150], ["investigate", 153], ["the", 165], ["safety", 169], ["and", 176], ["analgesic", 180], ["efficacy", 190], ["of", 199], ["tanezumab", 202], [",", 211], ["a", 213], ["humanized", 215], ["monoclonal", 225], ["antibody", 236], ["that", 245], ["binds", 250], ["and", 256], ["inhibits", 260], ["nerve", 269], ["growth", 275], ["factor", 282], [".", 288], ["We", 290], ["randomly", 293], ["assigned", 302], ["450", 311], ["patients", 315], ["with", 324], ["osteoarthritis", 329], ["of", 344], ["the", 347], ["knee", 351], ["to", 356], ["receive", 359], ["tanezumab", 367], ["(", 377], ["administered", 378], ["at", 391], ["a", 394], ["dose", 396], ["of", 401], ["10", 404], [",", 406], ["25", 408], [",", 410], ["50", 412], [",", 414], ["100", 416], [",", 419], ["or", 421], ["200", 424], ["\u03bcg", 428], ["per", 431], ["kilogram", 435], ["of", 444], ["body", 447], ["weight", 452], [")", 458], ["or", 460], ["placebo", 463], ["on", 471], ["days", 474], ["1", 479], ["and", 481], ["56", 485], [".", 487], ["The", 489], ["primary", 493], ["efficacy", 501], ["measures", 510], ["were", 519], ["knee", 524], ["pain", 529], ["while", 534], ["walking", 540], ["and", 548], ["the", 552], ["patient", 556], ["'s", 563], ["global", 566], ["assessment", 573], ["of", 584], ["response", 587], ["to", 596], ["therapy", 599], [".", 606], ["We", 608], ["also", 611], ["assessed", 616], ["pain", 625], [",", 629], ["stiffness", 631], [",", 640], ["and", 642], ["physical", 646], ["function", 655], ["using", 664], ["the", 670], ["Western", 674], ["Ontario", 682], ["and", 690], ["McMaster", 694], ["Universities", 703], ["Osteoarthritis", 716], ["Index", 731], ["(", 737], ["WOMAC", 738], [")", 743], [";", 744], ["the", 746], ["rate", 750], ["of", 755], ["response", 758], ["using", 767], ["the", 773], ["criteria", 777], ["of", 786], ["the", 789], ["Outcome", 793], ["Measures", 801], ["for", 810], ["Rheumatology", 814], ["Committee", 827], ["and", 837], ["Osteoarthritis", 841], ["Research", 856], ["Society", 865], ["International", 873], ["Standing", 887], ["Committee", 896], ["for", 906], ["Clinical", 910], ["Trials", 919], ["Response", 926], ["Criteria", 935], ["Initiative", 944], ["(", 955], ["OMERACT", 956], ["-", 963], ["OARSI", 964], [")", 969], [";", 970], ["and", 972], ["safety", 976], [".", 982], ["When", 984], ["averaged", 989], ["over", 998], ["weeks", 1003], ["1", 1009], ["through", 1011], ["16", 1019], [",", 1021], ["the", 1023], ["mean", 1027], ["reductions", 1032], ["from", 1043], ["baseline", 1048], ["in", 1057], ["knee", 1060], ["pain", 1065], ["while", 1070], ["walking", 1076], ["ranged", 1084], ["from", 1091], ["45", 1096], ["to", 1099], ["62", 1102], ["%", 1104], ["with", 1106], ["various", 1111], ["doses", 1119], ["of", 1125], ["tanezumab", 1128], [",", 1137], ["as", 1139], ["compared", 1142], ["with", 1151], ["22", 1156], ["%", 1158], ["with", 1160], ["placebo", 1165], ["(", 1173], ["P<0.001", 1174], [")", 1181], [".", 1182], ["Tanezumab", 1184], [",", 1193], ["as", 1195], ["compared", 1198], ["with", 1207], ["placebo", 1212], [",", 1219], ["was", 1221], ["also", 1225], ["associated", 1230], ["with", 1241], ["significantly", 1246], ["greater", 1260], ["improvements", 1268], ["in", 1281], ["the", 1284], ["response", 1288], ["to", 1297], ["therapy", 1300], ["as", 1308], ["assessed", 1311], ["with", 1320], ["the", 1325], ["use", 1329], ["of", 1333], ["the", 1336], ["patients", 1340], ["'", 1348], ["global", 1350], ["assessment", 1357], ["measure", 1368], ["(", 1376], ["mean", 1377], ["increases", 1382], ["in", 1392], ["score", 1395], ["of", 1401], ["29", 1404], ["to", 1407], ["47", 1410], ["%", 1412], ["with", 1414], ["various", 1419], ["doses", 1427], ["of", 1433], ["tanezumab", 1436], [",", 1445], ["as", 1447], ["compared", 1450], ["with", 1459], ["19", 1464], ["%", 1466], ["with", 1468], ["placebo", 1473], [";", 1480], ["P\u22640.001", 1482], [")", 1489], [".", 1490], ["The", 1492], ["rate", 1496], ["of", 1501], ["response", 1504], ["according", 1513], ["to", 1523], ["the", 1526], ["OMERACT", 1530], ["-", 1537], ["OARSI", 1538], ["criteria", 1544], ["ranged", 1553], ["from", 1560], ["74", 1565], ["to", 1568], ["93", 1571], ["%", 1573], ["with", 1575], ["tanezumab", 1580], ["treatment", 1590], [",", 1599], ["as", 1601], ["compared", 1604], ["with", 1613], ["44", 1618], ["%", 1620], ["with", 1622], ["placebo", 1627], ["(", 1635], ["P<0.001", 1636], [")", 1643], [".", 1644], ["The", 1646], ["rates", 1650], ["of", 1656], ["adverse", 1659], ["events", 1667], ["were", 1674], ["68", 1679], ["%", 1681], ["and", 1683], ["55", 1687], ["%", 1689], ["in", 1691], ["the", 1694], ["tanezumab", 1698], ["and", 1708], ["placebo", 1712], ["groups", 1720], [",", 1726], ["respectively", 1728], [".", 1740], ["The", 1742], ["most", 1746], ["common", 1751], ["adverse", 1758], ["events", 1766], ["among", 1773], ["tanezumab", 1779], ["-", 1788], ["treated", 1789], ["patients", 1797], ["were", 1806], ["headache", 1811], ["(", 1820], ["9", 1821], ["%", 1822], ["of", 1824], ["the", 1827], ["patients", 1831], [")", 1839], [",", 1840], ["upper", 1842], ["respiratory", 1848], ["tract", 1860], ["infection", 1866], ["(", 1876], ["7", 1877], ["%", 1878], [")", 1879], [",", 1880], ["and", 1882], ["paresthesia", 1886], ["(", 1898], ["7", 1899], ["%", 1900], [")", 1901], [".", 1902], ["In", 1904], ["this", 1907], ["proof", 1912], ["-", 1917], ["of", 1918], ["-", 1920], ["concept", 1921], ["study", 1929], [",", 1934], ["treatment", 1936], ["with", 1946], ["tanezumab", 1951], ["was", 1961], ["associated", 1965], ["with", 1976], ["a", 1981], ["reduction", 1983], ["in", 1993], ["joint", 1996], ["pain", 2002], ["and", 2007], ["improvement", 2011], ["in", 2023], ["function", 2026], [",", 2034], ["with", 2036], ["mild", 2041], ["and", 2046], ["moderate", 2050], ["adverse", 2059], ["events", 2067], [",", 2073], ["among", 2075], ["patients", 2081], ["with", 2090], ["moderate", 2095], ["-", 2103], ["to", 2104], ["-", 2106], ["severe", 2107], ["osteoarthritis", 2114], ["of", 2129], ["the", 2132], ["knee", 2136], [".", 2140], ["(", 2142], ["Funded", 2143], ["by", 2150], ["Rinat", 2153], ["Neuroscience", 2159], [";", 2171], ["ClinicalTrials.gov", 2173], ["number", 2192], [",", 2198], ["NCT00394563", 2200], [".", 2211], [")", 2212], [".", 2213]]}
{"context": "Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30\u2009mg/kg weekly, beginning gestation day (GD) 20 through parturition (\u223cGD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4\u2009mg/kg (n\u2009=\u20099) and 30\u2009mg/kg (n\u2009=\u20091). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "341ad31d93c34ba196d196dbeca4aa12", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[5, 7]], "char_spans": [[26, 44]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["an", 11], ["antibody", 14], ["to", 23], ["nerve", 26], ["growth", 32], ["factor", 39], [",", 45], ["was", 47], ["administered", 51], ["to", 64], ["pregnant", 67], ["cynomolgus", 76], ["monkeys", 87], ["at", 95], ["0", 98], [",", 99], ["0.5", 101], [",", 104], ["4", 106], [",", 107], ["and", 109], ["30", 113], ["mg", 116], ["/", 118], ["kg", 119], ["weekly", 122], [",", 128], ["beginning", 130], ["gestation", 140], ["day", 150], ["(", 154], ["GD", 155], [")", 157], ["20", 159], ["through", 162], ["parturition", 170], ["(", 182], ["\u223cGD165", 183], [")", 189], [".", 190], ["Maternal", 192], ["tanezumab", 201], ["administration", 211], ["appeared", 226], ["to", 235], ["increase", 238], ["stillbirths", 247], ["and", 259], ["infant", 263], ["mortality", 270], [",", 279], ["but", 281], ["no", 285], ["consistent", 288], ["pattern", 299], ["of", 307], ["gross", 310], ["and/or", 316], ["microscopic", 323], ["change", 335], ["was", 342], ["detected", 346], ["to", 355], ["explain", 358], ["the", 366], ["mortality", 370], [".", 379], ["Offspring", 381], ["exposed", 391], ["in", 399], ["utero", 402], ["were", 408], ["evaluated", 413], ["at", 423], ["12", 426], ["months", 429], ["of", 436], ["age", 439], ["using", 443], ["light", 449], ["microscopy", 455], ["(", 466], ["all", 467], ["tissues", 471], [")", 478], [",", 479], ["stereology", 481], ["(", 492], ["basal", 493], ["forebrain", 499], ["cholinergic", 509], ["and", 521], ["dorsal", 525], ["root", 532], ["ganglia", 537], ["neurons", 545], [")", 552], [",", 553], ["and", 555], ["morphometry", 559], ["(", 571], ["sural", 572], ["nerve", 578], [")", 583], [".", 584], ["Light", 586], ["microscopy", 592], ["revealed", 603], ["decreased", 612], ["number", 622], ["of", 629], ["neurons", 632], ["in", 640], ["sympathetic", 643], ["ganglia", 655], ["(", 663], ["superior", 664], ["mesenteric", 673], [",", 683], ["cervicothoracic", 685], [",", 700], ["and", 702], ["ganglia", 706], ["in", 714], ["the", 717], ["thoracic", 721], ["sympathetic", 730], ["trunk", 742], [")", 747], [".", 748], ["Stereologic", 750], ["assessment", 762], ["indicated", 773], ["an", 783], ["overall", 786], ["decrease", 794], ["in", 803], ["dorsal", 806], ["root", 813], ["ganglion", 818], ["(", 827], ["thoracic", 828], [")", 836], ["volume", 838], ["and", 845], ["number", 849], ["of", 856], ["neurons", 859], ["in", 867], ["animals", 870], ["exposed", 878], ["to", 886], ["tanezumab", 889], ["4", 899], ["mg", 901], ["/", 903], ["kg", 904], ["(", 907], ["n", 908], ["=", 910], ["9", 912], [")", 913], ["and", 915], ["30", 919], ["mg", 922], ["/", 924], ["kg", 925], ["(", 928], ["n", 929], ["=", 931], ["1", 933], [")", 934], [".", 935], ["At", 937], ["all", 940], ["tanezumab", 944], ["doses", 954], [",", 959], ["the", 961], ["sural", 965], ["nerve", 971], ["was", 977], ["small", 981], ["due", 987], ["to", 991], ["decreases", 994], ["in", 1004], ["myelinated", 1007], ["and", 1018], ["unmyelinated", 1022], ["axons", 1035], [".", 1040], ["Existing", 1042], ["axons", 1051], ["/", 1056], ["myelin", 1057], ["sheaths", 1064], ["appeared", 1072], ["normal", 1081], ["when", 1088], ["viewed", 1093], ["with", 1100], ["light", 1105], ["and", 1111], ["transmission", 1115], ["electron", 1128], ["microscopy", 1137], [".", 1147], ["There", 1149], ["was", 1155], ["no", 1159], ["indication", 1162], ["of", 1173], ["tanezumab", 1176], ["-", 1185], ["related", 1186], [",", 1193], ["active", 1195], ["neuron", 1202], ["/", 1208], ["nerve", 1209], ["fiber", 1215], ["degeneration", 1221], ["/", 1233], ["necrosis", 1234], ["in", 1243], ["any", 1246], ["tissue", 1250], [",", 1256], ["indicating", 1258], ["decreased", 1269], ["sensory", 1279], ["/", 1286], ["sympathetic", 1287], ["neurons", 1299], ["and", 1307], ["axonal", 1311], ["changes", 1318], ["were", 1326], ["due", 1331], ["to", 1335], ["hypoplasia", 1338], ["or", 1349], ["atrophy", 1352], [".", 1359], ["These", 1361], ["changes", 1367], ["in", 1375], ["the", 1378], ["sensory", 1382], ["and", 1390], ["sympathetic", 1394], ["portions", 1406], ["of", 1415], ["the", 1418], ["peripheral", 1422], ["nervous", 1433], ["system", 1441], ["suggest", 1448], ["some", 1456], ["degree", 1461], ["of", 1468], ["developmental", 1471], ["neurotoxicity", 1485], [",", 1498], ["although", 1500], ["what", 1509], ["effect", 1514], [",", 1520], ["if", 1522], ["any", 1525], [",", 1528], ["the", 1530], ["changes", 1534], ["had", 1542], ["on", 1546], ["normal", 1549], ["function", 1556], ["and", 1565], ["survival", 1569], ["was", 1578], ["not", 1582], ["apparent", 1586], [".", 1594], ["Overall", 1596], [",", 1603], ["these", 1605], ["changes", 1611], ["were", 1619], ["consistent", 1624], ["with", 1635], ["published", 1640], ["data", 1650], ["from", 1655], ["rodent", 1660], ["studies", 1667], [".", 1674]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. Ehlers-Danlos syndrome type IV places patients at risk for life-threatening, spontaneous, vascular or visceral rupture due to reduced or abnormal secretion of type III collagen. We present an adolescent male who was found to have a perisigmoid abscess with a fistula connecting to adjacent sigmoid colon secondary to undiagnosed EDS type IV. Conservative management with antibiotics and bowel rest was pursued to allow for elective resection for his acute complicated diverticulitis at a safer time.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "4e62eca3bf0e4c1ebc9b576649a1ebc5", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[12, 13]], "char_spans": [[49, 65]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["group", 40], ["of", 46], ["connective", 49], ["tissue", 60], ["disorders", 67], ["characterized", 77], ["by", 91], ["triad", 94], ["of", 100], ["joint", 103], ["hypermobility", 109], [",", 122], ["skin", 124], ["extensibility", 129], [",", 142], ["and", 144], ["tissue", 148], ["fragility", 155], [".", 164], ["Ehlers", 166], ["-", 172], ["Danlos", 173], ["syndrome", 180], ["type", 189], ["IV", 194], ["places", 197], ["patients", 204], ["at", 213], ["risk", 216], ["for", 221], ["life", 225], ["-", 229], ["threatening", 230], [",", 241], ["spontaneous", 243], [",", 254], ["vascular", 256], ["or", 265], ["visceral", 268], ["rupture", 277], ["due", 285], ["to", 289], ["reduced", 292], ["or", 300], ["abnormal", 303], ["secretion", 312], ["of", 322], ["type", 325], ["III", 330], ["collagen", 334], [".", 342], ["We", 344], ["present", 347], ["an", 355], ["adolescent", 358], ["male", 369], ["who", 374], ["was", 378], ["found", 382], ["to", 388], ["have", 391], ["a", 396], ["perisigmoid", 398], ["abscess", 410], ["with", 418], ["a", 423], ["fistula", 425], ["connecting", 433], ["to", 444], ["adjacent", 447], ["sigmoid", 456], ["colon", 464], ["secondary", 470], ["to", 480], ["undiagnosed", 483], ["EDS", 495], ["type", 499], ["IV", 504], [".", 506], ["Conservative", 508], ["management", 521], ["with", 532], ["antibiotics", 537], ["and", 549], ["bowel", 553], ["rest", 559], ["was", 564], ["pursued", 568], ["to", 576], ["allow", 579], ["for", 585], ["elective", 589], ["resection", 598], ["for", 608], ["his", 612], ["acute", 616], ["complicated", 622], ["diverticulitis", 634], ["at", 649], ["a", 652], ["safer", 654], ["time", 660], [".", 664]]}
{"context": "A significant role for IFN\u03b1 in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFN\u03b1 monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFN\u03b2 locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFN\u03b2. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "ee9066e593e54642861b2b0705b2a15a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[71, 72], [95, 96]], "char_spans": [[457, 476], [588, 607]]}]}], "context_tokens": [["A", 0], ["significant", 2], ["role", 14], ["for", 19], ["IFN\u03b1", 23], ["in", 28], ["the", 31], ["pathogenesis", 35], ["of", 48], ["systemic", 51], ["lupus", 60], ["erythematosus", 66], ["is", 80], ["well", 83], ["supported", 88], [",", 97], ["and", 99], ["clinical", 103], ["trials", 112], ["of", 119], ["anti", 122], ["-", 126], ["IFN\u03b1", 127], ["monoclonal", 132], ["antibodies", 143], ["are", 154], ["in", 158], ["progress", 161], ["in", 170], ["this", 173], ["disease", 178], [".", 185], ["In", 187], ["other", 190], ["autoimmune", 196], ["diseases", 207], ["characterized", 216], ["by", 230], ["substantial", 233], ["inflammation", 245], ["and", 258], ["tissue", 262], ["destruction", 269], [",", 280], ["the", 282], ["role", 286], ["of", 291], ["type", 294], ["I", 299], ["interferons", 301], ["is", 313], ["less", 316], ["clear", 321], [".", 326], ["Gene", 328], ["expression", 333], ["analysis", 344], ["of", 353], ["peripheral", 356], ["blood", 367], ["cells", 373], ["from", 379], ["patients", 384], ["with", 393], ["rheumatoid", 398], ["arthritis", 409], ["and", 419], ["multiple", 423], ["sclerosis", 432], ["demonstrate", 442], ["an", 454], ["interferon", 457], ["signature", 468], ["similar", 478], ["to", 486], ["but", 489], ["less", 493], ["intense", 498], ["than", 506], ["that", 511], ["seen", 516], ["in", 521], ["patients", 524], ["with", 533], ["lupus", 538], [".", 543], ["In", 545], ["both", 548], ["of", 553], ["those", 556], ["diseases", 562], [",", 570], ["presence", 572], ["of", 581], ["the", 584], ["interferon", 588], ["signature", 599], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["more", 634], ["significant", 639], ["clinical", 651], ["manifestations", 660], [".", 674], ["At", 676], ["the", 679], ["same", 683], ["time", 688], [",", 692], ["evidence", 694], ["supports", 703], ["an", 712], ["anti", 715], ["-", 719], ["inflammatory", 720], ["and", 733], ["beneficial", 737], ["role", 748], ["of", 753], ["IFN\u03b2", 756], ["locally", 761], ["in", 769], ["the", 772], ["joints", 776], ["of", 783], ["patients", 786], ["with", 795], ["rheumatoid", 800], ["arthritis", 811], ["and", 821], ["in", 825], ["murine", 828], ["arthritis", 835], ["models", 845], [",", 851], ["and", 853], ["many", 857], ["patients", 862], ["with", 871], ["multiple", 876], ["sclerosis", 885], ["show", 895], ["a", 900], ["clinical", 902], ["response", 911], ["to", 920], ["recombinant", 923], ["IFN\u03b2", 935], [".", 939], ["As", 941], ["can", 944], ["also", 948], ["be", 953], ["proposed", 956], ["for", 965], ["type", 969], ["I", 974], ["diabetes", 976], ["mellitus", 985], [",", 993], ["type", 995], ["I", 1000], ["interferon", 1002], ["appears", 1013], ["to", 1021], ["contribute", 1024], ["to", 1035], ["the", 1038], ["development", 1042], ["of", 1054], ["autoimmunity", 1057], ["and", 1070], ["disease", 1074], ["progression", 1082], ["in", 1094], ["multiple", 1097], ["autoimmune", 1106], ["diseases", 1117], [",", 1125], ["while", 1127], ["maintaining", 1133], ["some", 1145], ["capacity", 1150], ["to", 1159], ["control", 1162], ["established", 1170], ["disease", 1182], ["-", 1190], ["particularly", 1192], ["at", 1205], ["local", 1208], ["sites", 1214], ["of", 1220], ["inflammation", 1223], [".", 1235], ["Recent", 1237], ["studies", 1244], ["in", 1252], ["both", 1255], ["rheumatoid", 1260], ["arthritis", 1271], ["and", 1281], ["multiple", 1285], ["sclerosis", 1294], ["suggest", 1304], ["that", 1312], ["quantification", 1317], ["of", 1332], ["type", 1335], ["I", 1340], ["interferon", 1342], ["activity", 1353], ["or", 1362], ["target", 1365], ["gene", 1372], ["expression", 1377], ["might", 1388], ["be", 1394], ["informative", 1397], ["in", 1409], ["predicting", 1412], ["responses", 1423], ["to", 1433], ["distinct", 1436], ["classes", 1445], ["of", 1453], ["therapeutic", 1456], ["agents", 1468], [".", 1474]]}
{"context": "Because of their rarity, outcomes regarding spinal atypical meningiomas (AMs) remain unclear. To describe the recurrence rate and postoperative outcomes after resection of spinal AMs, and to discuss an appropriate resection strategy and adjuvant therapy for spinal AMs. Data from all patients who presented with spinal AMs to 2 tertiary referral centers between 1998 and 2013 were obtained by chart review. From 102 patients with spinal meningioma, 20 AM tumors (7 cervical, 11 thoracic, 2 thoracolumbar) were identified in 18 patients (median age, 50 years [range, 19-75] at time of resection; 11% male; median follow-up, 32 months [range, 1-179] after resection). Before resection, patients had sensory deficits (70%), pain (70%), weakness (60%), ataxia (50%), spasticity (65%), and incontinence (35%). One tumor presented asymptomatically. Simpson grade I, II, III, and IV resection were achieved in 3 (15%), 13 (65%), 2 (10%), and 2 (10%) tumors, respectively. One patient that underwent Simpson grade III resection received adjuvant radiation therapy. After Simpson grade I-III or gross total resection, no tumors recurred (0%; confidence interval, 0%-17.6%). After Simpson grade IV resection, 1 tumor recurred (50%; confidence interval, 1.3%-98.7%). With the exception of 1 patient who had bilateral paraplegia perioperatively, all other patients experienced improvement of preoperative symptoms after surgery (median time, 3.6 months [range, 1-13] after resection). Despite published cases suggesting an aggressive clinical course for spinal AMs, this series of spinal AMs reports that gross total resection without adjuvant radiation therapy resulted in symptom resolution and low recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "af9599c5e867435a9e2d2a9b430d46b0", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[73, 73]], "char_spans": [[437, 446]]}]}], "context_tokens": [["Because", 0], ["of", 8], ["their", 11], ["rarity", 17], [",", 23], ["outcomes", 25], ["regarding", 34], ["spinal", 44], ["atypical", 51], ["meningiomas", 60], ["(", 72], ["AMs", 73], [")", 76], ["remain", 78], ["unclear", 85], [".", 92], ["To", 94], ["describe", 97], ["the", 106], ["recurrence", 110], ["rate", 121], ["and", 126], ["postoperative", 130], ["outcomes", 144], ["after", 153], ["resection", 159], ["of", 169], ["spinal", 172], ["AMs", 179], [",", 182], ["and", 184], ["to", 188], ["discuss", 191], ["an", 199], ["appropriate", 202], ["resection", 214], ["strategy", 224], ["and", 233], ["adjuvant", 237], ["therapy", 246], ["for", 254], ["spinal", 258], ["AMs", 265], [".", 268], ["Data", 270], ["from", 275], ["all", 280], ["patients", 284], ["who", 293], ["presented", 297], ["with", 307], ["spinal", 312], ["AMs", 319], ["to", 323], ["2", 326], ["tertiary", 328], ["referral", 337], ["centers", 346], ["between", 354], ["1998", 362], ["and", 367], ["2013", 371], ["were", 376], ["obtained", 381], ["by", 390], ["chart", 393], ["review", 399], [".", 405], ["From", 407], ["102", 412], ["patients", 416], ["with", 425], ["spinal", 430], ["meningioma", 437], [",", 447], ["20", 449], ["AM", 452], ["tumors", 455], ["(", 462], ["7", 463], ["cervical", 465], [",", 473], ["11", 475], ["thoracic", 478], [",", 486], ["2", 488], ["thoracolumbar", 490], [")", 503], ["were", 505], ["identified", 510], ["in", 521], ["18", 524], ["patients", 527], ["(", 536], ["median", 537], ["age", 544], [",", 547], ["50", 549], ["years", 552], ["[", 558], ["range", 559], [",", 564], ["19", 566], ["-", 568], ["75", 569], ["]", 571], ["at", 573], ["time", 576], ["of", 581], ["resection", 584], [";", 593], ["11", 595], ["%", 597], ["male", 599], [";", 603], ["median", 605], ["follow", 612], ["-", 618], ["up", 619], [",", 621], ["32", 623], ["months", 626], ["[", 633], ["range", 634], [",", 639], ["1", 641], ["-", 642], ["179", 643], ["]", 646], ["after", 648], ["resection", 654], [")", 663], [".", 664], ["Before", 666], ["resection", 673], [",", 682], ["patients", 684], ["had", 693], ["sensory", 697], ["deficits", 705], ["(", 714], ["70", 715], ["%", 717], [")", 718], [",", 719], ["pain", 721], ["(", 726], ["70", 727], ["%", 729], [")", 730], [",", 731], ["weakness", 733], ["(", 742], ["60", 743], ["%", 745], [")", 746], [",", 747], ["ataxia", 749], ["(", 756], ["50", 757], ["%", 759], [")", 760], [",", 761], ["spasticity", 763], ["(", 774], ["65", 775], ["%", 777], [")", 778], [",", 779], ["and", 781], ["incontinence", 785], ["(", 798], ["35", 799], ["%", 801], [")", 802], [".", 803], ["One", 805], ["tumor", 809], ["presented", 815], ["asymptomatically", 825], [".", 841], ["Simpson", 843], ["grade", 851], ["I", 857], [",", 858], ["II", 860], [",", 862], ["III", 864], [",", 867], ["and", 869], ["IV", 873], ["resection", 876], ["were", 886], ["achieved", 891], ["in", 900], ["3", 903], ["(", 905], ["15", 906], ["%", 908], [")", 909], [",", 910], ["13", 912], ["(", 915], ["65", 916], ["%", 918], [")", 919], [",", 920], ["2", 922], ["(", 924], ["10", 925], ["%", 927], [")", 928], [",", 929], ["and", 931], ["2", 935], ["(", 937], ["10", 938], ["%", 940], [")", 941], ["tumors", 943], [",", 949], ["respectively", 951], [".", 963], ["One", 965], ["patient", 969], ["that", 977], ["underwent", 982], ["Simpson", 992], ["grade", 1000], ["III", 1006], ["resection", 1010], ["received", 1020], ["adjuvant", 1029], ["radiation", 1038], ["therapy", 1048], [".", 1055], ["After", 1057], ["Simpson", 1063], ["grade", 1071], ["I", 1077], ["-", 1078], ["III", 1079], ["or", 1083], ["gross", 1086], ["total", 1092], ["resection", 1098], [",", 1107], ["no", 1109], ["tumors", 1112], ["recurred", 1119], ["(", 1128], ["0", 1129], ["%", 1130], [";", 1131], ["confidence", 1133], ["interval", 1144], [",", 1152], ["0%-17.6", 1154], ["%", 1161], [")", 1162], [".", 1163], ["After", 1165], ["Simpson", 1171], ["grade", 1179], ["IV", 1185], ["resection", 1188], [",", 1197], ["1", 1199], ["tumor", 1201], ["recurred", 1207], ["(", 1216], ["50", 1217], ["%", 1219], [";", 1220], ["confidence", 1222], ["interval", 1233], [",", 1241], ["1.3%-98.7", 1243], ["%", 1252], [")", 1253], [".", 1254], ["With", 1256], ["the", 1261], ["exception", 1265], ["of", 1275], ["1", 1278], ["patient", 1280], ["who", 1288], ["had", 1292], ["bilateral", 1296], ["paraplegia", 1306], ["perioperatively", 1317], [",", 1332], ["all", 1334], ["other", 1338], ["patients", 1344], ["experienced", 1353], ["improvement", 1365], ["of", 1377], ["preoperative", 1380], ["symptoms", 1393], ["after", 1402], ["surgery", 1408], ["(", 1416], ["median", 1417], ["time", 1424], [",", 1428], ["3.6", 1430], ["months", 1434], ["[", 1441], ["range", 1442], [",", 1447], ["1", 1449], ["-", 1450], ["13", 1451], ["]", 1453], ["after", 1455], ["resection", 1461], [")", 1470], [".", 1471], ["Despite", 1473], ["published", 1481], ["cases", 1491], ["suggesting", 1497], ["an", 1508], ["aggressive", 1511], ["clinical", 1522], ["course", 1531], ["for", 1538], ["spinal", 1542], ["AMs", 1549], [",", 1552], ["this", 1554], ["series", 1559], ["of", 1566], ["spinal", 1569], ["AMs", 1576], ["reports", 1580], ["that", 1588], ["gross", 1593], ["total", 1599], ["resection", 1605], ["without", 1615], ["adjuvant", 1623], ["radiation", 1632], ["therapy", 1642], ["resulted", 1650], ["in", 1659], ["symptom", 1662], ["resolution", 1670], ["and", 1681], ["low", 1685], ["recurrence", 1689], [".", 1699]]}
{"context": "Viroids are plant subviral pathogens whose genomes are constituted by a single-stranded and covalently closed small RNA molecule that does not encode for any protein. Despite this genomic simplicity, they are able of inducing devastating symptoms in susceptible plants. Most of the 29 described viroid species fold into a rodlike or quasi-rodlike structure, whereas a few of them fold as branched structures. The shape of these RNA structures is perhaps one of the most characteristic properties of viroids and sometimes is considered their only phenotype. Here we use RNA thermodynamic secondary structure prediction algorithms to compare the mutational robustness of all viroid species. After characterizing the statistical properties of the distribution of mutational effects on structure stability and the wideness of neutral neighborhood for each viroid species, we show an evolutionary trend toward increased structural robustness during viroid radiation, giving support to the adaptive value of robustness. Differences in robustness among the 2 viroid families can be explained by the larger fragility of branched structures compared with the rodlike ones. We also show that genomic redundancy can contribute to the robustness of these simple RNA genomes.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "8eceba755842479382ec48217193b107", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[0, 0], [86, 86]], "char_spans": [[0, 6], [499, 505]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["plant", 12], ["subviral", 18], ["pathogens", 27], ["whose", 37], ["genomes", 43], ["are", 51], ["constituted", 55], ["by", 67], ["a", 70], ["single", 72], ["-", 78], ["stranded", 79], ["and", 88], ["covalently", 92], ["closed", 103], ["small", 110], ["RNA", 116], ["molecule", 120], ["that", 129], ["does", 134], ["not", 139], ["encode", 143], ["for", 150], ["any", 154], ["protein", 158], [".", 165], ["Despite", 167], ["this", 175], ["genomic", 180], ["simplicity", 188], [",", 198], ["they", 200], ["are", 205], ["able", 209], ["of", 214], ["inducing", 217], ["devastating", 226], ["symptoms", 238], ["in", 247], ["susceptible", 250], ["plants", 262], [".", 268], ["Most", 270], ["of", 275], ["the", 278], ["29", 282], ["described", 285], ["viroid", 295], ["species", 302], ["fold", 310], ["into", 315], ["a", 320], ["rodlike", 322], ["or", 330], ["quasi", 333], ["-", 338], ["rodlike", 339], ["structure", 347], [",", 356], ["whereas", 358], ["a", 366], ["few", 368], ["of", 372], ["them", 375], ["fold", 380], ["as", 385], ["branched", 388], ["structures", 397], [".", 407], ["The", 409], ["shape", 413], ["of", 419], ["these", 422], ["RNA", 428], ["structures", 432], ["is", 443], ["perhaps", 446], ["one", 454], ["of", 458], ["the", 461], ["most", 465], ["characteristic", 470], ["properties", 485], ["of", 496], ["viroids", 499], ["and", 507], ["sometimes", 511], ["is", 521], ["considered", 524], ["their", 535], ["only", 541], ["phenotype", 546], [".", 555], ["Here", 557], ["we", 562], ["use", 565], ["RNA", 569], ["thermodynamic", 573], ["secondary", 587], ["structure", 597], ["prediction", 607], ["algorithms", 618], ["to", 629], ["compare", 632], ["the", 640], ["mutational", 644], ["robustness", 655], ["of", 666], ["all", 669], ["viroid", 673], ["species", 680], [".", 687], ["After", 689], ["characterizing", 695], ["the", 710], ["statistical", 714], ["properties", 726], ["of", 737], ["the", 740], ["distribution", 744], ["of", 757], ["mutational", 760], ["effects", 771], ["on", 779], ["structure", 782], ["stability", 792], ["and", 802], ["the", 806], ["wideness", 810], ["of", 819], ["neutral", 822], ["neighborhood", 830], ["for", 843], ["each", 847], ["viroid", 852], ["species", 859], [",", 866], ["we", 868], ["show", 871], ["an", 876], ["evolutionary", 879], ["trend", 892], ["toward", 898], ["increased", 905], ["structural", 915], ["robustness", 926], ["during", 937], ["viroid", 944], ["radiation", 951], [",", 960], ["giving", 962], ["support", 969], ["to", 977], ["the", 980], ["adaptive", 984], ["value", 993], ["of", 999], ["robustness", 1002], [".", 1012], ["Differences", 1014], ["in", 1026], ["robustness", 1029], ["among", 1040], ["the", 1046], ["2", 1050], ["viroid", 1052], ["families", 1059], ["can", 1068], ["be", 1072], ["explained", 1075], ["by", 1085], ["the", 1088], ["larger", 1092], ["fragility", 1099], ["of", 1109], ["branched", 1112], ["structures", 1121], ["compared", 1132], ["with", 1141], ["the", 1146], ["rodlike", 1150], ["ones", 1158], [".", 1162], ["We", 1164], ["also", 1167], ["show", 1172], ["that", 1177], ["genomic", 1182], ["redundancy", 1190], ["can", 1201], ["contribute", 1205], ["to", 1216], ["the", 1219], ["robustness", 1223], ["of", 1234], ["these", 1237], ["simple", 1243], ["RNA", 1250], ["genomes", 1254], [".", 1261]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most frequent neurocutaneous disorder with autosomal dominant inheritance. Phenotype variability is high ranging from merely several caf\u00e9-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas. Identification of genetic factors that modify the NF1 phenotype would contribute to the understanding of NF1 pathophysiology and improve patient counselling. As even monozygotic (MZ) twins with NF1 may differ phenotypically, we wondered whether these variations might be inherited in a non-Mendelian fashion. Mitochondrial DNA (mtDNA) is inherited extrachromosomally through the cytoplasm of the oocyte and often harbours heteroplasmic sequence variations. At the time of blastomere separation, these variants may be skewedly distributed and effect phenotypic differences. Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation. MtDNA was extracted from nucleated blood cells of four pairs of discordant MZ twins with NF1 and from cutaneous neurofibromas of one twin pair. We sequenced the entire mitochondrial genome and determined the state of heteroplasmy by investigating a microsatellite region of the mitochondrial D-loop (D310-tract). The clinical diagnosis was confirmed in all patients by detection of pathogenic mutations in the NF1 gene. Monozygosity was verified by genotyping. However, we did not detect evidence for mtDNA sequence differences or for different degrees of heteroplasmy between individuals of the same twin pair. The phenotypic discordance of MZ twins with NF1 cannot be explained by skewed distribution of mtDNA mutations or polymorphisms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1c8a233817e24aaf970974c3d66dfce4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[59, 59], [51, 51], [150, 150], [74, 74], [227, 227], [4, 4], [268, 268], [175, 175]], "char_spans": [[396, 398], [341, 343], [966, 968], [485, 487], [1451, 1453], [26, 28], [1697, 1699], [1130, 1132]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["frequent", 43], ["neurocutaneous", 52], ["disorder", 67], ["with", 76], ["autosomal", 81], ["dominant", 91], ["inheritance", 100], [".", 111], ["Phenotype", 113], ["variability", 123], ["is", 135], ["high", 138], ["ranging", 143], ["from", 151], ["merely", 156], ["several", 163], ["caf\u00e9", 171], ["-", 175], ["au", 176], ["-", 178], ["lait", 179], ["spots", 184], ["to", 190], ["malignant", 193], ["peripheral", 203], ["nerve", 214], ["sheath", 220], ["tumors", 227], ["or", 234], ["severe", 237], ["disfigurement", 244], ["through", 258], ["plexiform", 266], ["neurofibromas", 276], [".", 289], ["Identification", 291], ["of", 306], ["genetic", 309], ["factors", 317], ["that", 325], ["modify", 330], ["the", 337], ["NF1", 341], ["phenotype", 345], ["would", 355], ["contribute", 361], ["to", 372], ["the", 375], ["understanding", 379], ["of", 393], ["NF1", 396], ["pathophysiology", 400], ["and", 416], ["improve", 420], ["patient", 428], ["counselling", 436], [".", 447], ["As", 449], ["even", 452], ["monozygotic", 457], ["(", 469], ["MZ", 470], [")", 472], ["twins", 474], ["with", 480], ["NF1", 485], ["may", 489], ["differ", 493], ["phenotypically", 500], [",", 514], ["we", 516], ["wondered", 519], ["whether", 528], ["these", 536], ["variations", 542], ["might", 553], ["be", 559], ["inherited", 562], ["in", 572], ["a", 575], ["non", 577], ["-", 580], ["Mendelian", 581], ["fashion", 591], [".", 598], ["Mitochondrial", 600], ["DNA", 614], ["(", 618], ["mtDNA", 619], [")", 624], ["is", 626], ["inherited", 629], ["extrachromosomally", 639], ["through", 658], ["the", 666], ["cytoplasm", 670], ["of", 680], ["the", 683], ["oocyte", 687], ["and", 694], ["often", 698], ["harbours", 704], ["heteroplasmic", 713], ["sequence", 727], ["variations", 736], [".", 746], ["At", 748], ["the", 751], ["time", 755], ["of", 760], ["blastomere", 763], ["separation", 774], [",", 784], ["these", 786], ["variants", 792], ["may", 801], ["be", 805], ["skewedly", 808], ["distributed", 817], ["and", 829], ["effect", 833], ["phenotypic", 840], ["differences", 851], [".", 862], ["Because", 864], ["of", 872], ["their", 875], ["co", 881], ["-", 883], ["localization", 884], ["with", 897], ["the", 902], ["tumor", 906], ["suppressor", 912], ["protein", 923], ["neurofibromin", 931], [",", 944], ["which", 946], ["is", 952], ["mutated", 955], ["in", 963], ["NF1", 966], [",", 969], ["mitochondria", 971], ["were", 984], ["particular", 989], ["attractive", 1000], ["candidates", 1011], ["for", 1022], ["investigation", 1026], [".", 1039], ["MtDNA", 1041], ["was", 1047], ["extracted", 1051], ["from", 1061], ["nucleated", 1066], ["blood", 1076], ["cells", 1082], ["of", 1088], ["four", 1091], ["pairs", 1096], ["of", 1102], ["discordant", 1105], ["MZ", 1116], ["twins", 1119], ["with", 1125], ["NF1", 1130], ["and", 1134], ["from", 1138], ["cutaneous", 1143], ["neurofibromas", 1153], ["of", 1167], ["one", 1170], ["twin", 1174], ["pair", 1179], [".", 1183], ["We", 1185], ["sequenced", 1188], ["the", 1198], ["entire", 1202], ["mitochondrial", 1209], ["genome", 1223], ["and", 1230], ["determined", 1234], ["the", 1245], ["state", 1249], ["of", 1255], ["heteroplasmy", 1258], ["by", 1271], ["investigating", 1274], ["a", 1288], ["microsatellite", 1290], ["region", 1305], ["of", 1312], ["the", 1315], ["mitochondrial", 1319], ["D", 1333], ["-", 1334], ["loop", 1335], ["(", 1340], ["D310-tract", 1341], [")", 1351], [".", 1352], ["The", 1354], ["clinical", 1358], ["diagnosis", 1367], ["was", 1377], ["confirmed", 1381], ["in", 1391], ["all", 1394], ["patients", 1398], ["by", 1407], ["detection", 1410], ["of", 1420], ["pathogenic", 1423], ["mutations", 1434], ["in", 1444], ["the", 1447], ["NF1", 1451], ["gene", 1455], [".", 1459], ["Monozygosity", 1461], ["was", 1474], ["verified", 1478], ["by", 1487], ["genotyping", 1490], [".", 1500], ["However", 1502], [",", 1509], ["we", 1511], ["did", 1514], ["not", 1518], ["detect", 1522], ["evidence", 1529], ["for", 1538], ["mtDNA", 1542], ["sequence", 1548], ["differences", 1557], ["or", 1569], ["for", 1572], ["different", 1576], ["degrees", 1586], ["of", 1594], ["heteroplasmy", 1597], ["between", 1610], ["individuals", 1618], ["of", 1630], ["the", 1633], ["same", 1637], ["twin", 1642], ["pair", 1647], [".", 1651], ["The", 1653], ["phenotypic", 1657], ["discordance", 1668], ["of", 1680], ["MZ", 1683], ["twins", 1686], ["with", 1692], ["NF1", 1697], ["can", 1701], ["not", 1704], ["be", 1708], ["explained", 1711], ["by", 1721], ["skewed", 1724], ["distribution", 1731], ["of", 1744], ["mtDNA", 1747], ["mutations", 1753], ["or", 1763], ["polymorphisms", 1766], [".", 1779]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "Transactivation response DNA-binding protein 43 (TDP-43) proteinopathies are classified based upon the extent of modified TDP-43 and include a growing number of neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration with ubiquitin-immunoreactive, tau-negative inclusions and frontotemporal lobar degeneration with motor neuron disease. The purpose of the study was to examine whether proteolytic modifications of TDP-43 are a relevant finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A novel site-directed caspase cleavage antibody, termed TDP caspase cleavage product antibody (TDPccp), was utilized based upon a known caspase 3 cleavage consensus site within TDP-43 at position 219. Application of this antibody to postmortem brain sections from PD and DLB patients revealed the presence of caspase-cleaved TDP-43 in Lewy bodies and Hirano bodies in all cases examined. Colocalization of TDPccp with an antibody to alpha-synuclein (alpha-Syn), which served as a general marker for Lewy bodies, was evident within the substantia nigra in both alpha-synucleinopathies. Interestingly, the TDPccp antibody detected a greater number of Lewy bodies in PD and DLB compared to the alpha-Syn antibody. In addition, a semiquantitative analysis in both diseases confirmed this finding by indicating that the percentage of caspase-cleaved TDP-43 single-labeled Lewy bodies was approximately twice that of alpha-Syn labeling (in DLB 13.4 vs. 5.5%, while in PD 34.6 vs. 17.6%). Collectively, these data have identified caspase-cleaved TDP-43 as a primary component of Lewy and Hirano bodies in PD and DLB, and suggest that the TDPccp antibody is an effective marker for the detection of Lewy bodies in these neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4a93e831ea4b4c5fb6f059f0b2cca5be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[163, 165]], "char_spans": [[986, 1000]]}]}], "context_tokens": [["Transactivation", 0], ["response", 16], ["DNA", 25], ["-", 28], ["binding", 29], ["protein", 37], ["43", 45], ["(", 48], ["TDP-43", 49], [")", 55], ["proteinopathies", 57], ["are", 73], ["classified", 77], ["based", 88], ["upon", 94], ["the", 99], ["extent", 103], ["of", 110], ["modified", 113], ["TDP-43", 122], ["and", 129], ["include", 133], ["a", 141], ["growing", 143], ["number", 151], ["of", 158], ["neurodegenerative", 161], ["diseases", 179], ["such", 188], ["as", 193], ["amyotrophic", 196], ["lateral", 208], ["sclerosis", 216], [",", 225], ["frontotemporal", 227], ["lobar", 242], ["degeneration", 248], ["with", 261], ["ubiquitin", 266], ["-", 275], ["immunoreactive", 276], [",", 290], ["tau", 292], ["-", 295], ["negative", 296], ["inclusions", 305], ["and", 316], ["frontotemporal", 320], ["lobar", 335], ["degeneration", 341], ["with", 354], ["motor", 359], ["neuron", 365], ["disease", 372], [".", 379], ["The", 381], ["purpose", 385], ["of", 393], ["the", 396], ["study", 400], ["was", 406], ["to", 410], ["examine", 413], ["whether", 421], ["proteolytic", 429], ["modifications", 441], ["of", 455], ["TDP-43", 458], ["are", 465], ["a", 469], ["relevant", 471], ["finding", 480], ["in", 488], ["Parkinson", 491], ["'s", 500], ["disease", 503], ["(", 511], ["PD", 512], [")", 514], ["and", 516], ["dementia", 520], ["with", 529], ["Lewy", 534], ["bodies", 539], ["(", 546], ["DLB", 547], [")", 550], [".", 551], ["A", 553], ["novel", 555], ["site", 561], ["-", 565], ["directed", 566], ["caspase", 575], ["cleavage", 583], ["antibody", 592], [",", 600], ["termed", 602], ["TDP", 609], ["caspase", 613], ["cleavage", 621], ["product", 630], ["antibody", 638], ["(", 647], ["TDPccp", 648], [")", 654], [",", 655], ["was", 657], ["utilized", 661], ["based", 670], ["upon", 676], ["a", 681], ["known", 683], ["caspase", 689], ["3", 697], ["cleavage", 699], ["consensus", 708], ["site", 718], ["within", 723], ["TDP-43", 730], ["at", 737], ["position", 740], ["219", 749], [".", 752], ["Application", 754], ["of", 766], ["this", 769], ["antibody", 774], ["to", 783], ["postmortem", 786], ["brain", 797], ["sections", 803], ["from", 812], ["PD", 817], ["and", 820], ["DLB", 824], ["patients", 828], ["revealed", 837], ["the", 846], ["presence", 850], ["of", 859], ["caspase", 862], ["-", 869], ["cleaved", 870], ["TDP-43", 878], ["in", 885], ["Lewy", 888], ["bodies", 893], ["and", 900], ["Hirano", 904], ["bodies", 911], ["in", 918], ["all", 921], ["cases", 925], ["examined", 931], [".", 939], ["Colocalization", 941], ["of", 956], ["TDPccp", 959], ["with", 966], ["an", 971], ["antibody", 974], ["to", 983], ["alpha", 986], ["-", 991], ["synuclein", 992], ["(", 1002], ["alpha", 1003], ["-", 1008], ["Syn", 1009], [")", 1012], [",", 1013], ["which", 1015], ["served", 1021], ["as", 1028], ["a", 1031], ["general", 1033], ["marker", 1041], ["for", 1048], ["Lewy", 1052], ["bodies", 1057], [",", 1063], ["was", 1065], ["evident", 1069], ["within", 1077], ["the", 1084], ["substantia", 1088], ["nigra", 1099], ["in", 1105], ["both", 1108], ["alpha", 1113], ["-", 1118], ["synucleinopathies", 1119], [".", 1136], ["Interestingly", 1138], [",", 1151], ["the", 1153], ["TDPccp", 1157], ["antibody", 1164], ["detected", 1173], ["a", 1182], ["greater", 1184], ["number", 1192], ["of", 1199], ["Lewy", 1202], ["bodies", 1207], ["in", 1214], ["PD", 1217], ["and", 1220], ["DLB", 1224], ["compared", 1228], ["to", 1237], ["the", 1240], ["alpha", 1244], ["-", 1249], ["Syn", 1250], ["antibody", 1254], [".", 1262], ["In", 1264], ["addition", 1267], [",", 1275], ["a", 1277], ["semiquantitative", 1279], ["analysis", 1296], ["in", 1305], ["both", 1308], ["diseases", 1313], ["confirmed", 1322], ["this", 1332], ["finding", 1337], ["by", 1345], ["indicating", 1348], ["that", 1359], ["the", 1364], ["percentage", 1368], ["of", 1379], ["caspase", 1382], ["-", 1389], ["cleaved", 1390], ["TDP-43", 1398], ["single", 1405], ["-", 1411], ["labeled", 1412], ["Lewy", 1420], ["bodies", 1425], ["was", 1432], ["approximately", 1436], ["twice", 1450], ["that", 1456], ["of", 1461], ["alpha", 1464], ["-", 1469], ["Syn", 1470], ["labeling", 1474], ["(", 1483], ["in", 1484], ["DLB", 1487], ["13.4", 1491], ["vs.", 1496], ["5.5", 1500], ["%", 1503], [",", 1504], ["while", 1506], ["in", 1512], ["PD", 1515], ["34.6", 1518], ["vs.", 1523], ["17.6", 1527], ["%", 1531], [")", 1532], [".", 1533], ["Collectively", 1535], [",", 1547], ["these", 1549], ["data", 1555], ["have", 1560], ["identified", 1565], ["caspase", 1576], ["-", 1583], ["cleaved", 1584], ["TDP-43", 1592], ["as", 1599], ["a", 1602], ["primary", 1604], ["component", 1612], ["of", 1622], ["Lewy", 1625], ["and", 1630], ["Hirano", 1634], ["bodies", 1641], ["in", 1648], ["PD", 1651], ["and", 1654], ["DLB", 1658], [",", 1661], ["and", 1663], ["suggest", 1667], ["that", 1675], ["the", 1680], ["TDPccp", 1684], ["antibody", 1691], ["is", 1700], ["an", 1703], ["effective", 1706], ["marker", 1716], ["for", 1723], ["the", 1727], ["detection", 1731], ["of", 1741], ["Lewy", 1744], ["bodies", 1749], ["in", 1756], ["these", 1759], ["neurodegenerative", 1765], ["diseases", 1783], [".", 1791]]}
{"context": "The economic impact of Clostridium difficile infection (CDI) on the healthcare system is significant. From May 2013 to May 2014, an outbreak of C.\u00a0difficile ribotype 027 occurred in a Dutch tertiary care hospital, involving 72 patients. The primary aim of this study was to provide insight into the financial burden that this CDI outbreak brought upon this hospital. A retrospective analysis was performed to estimate the costs of a one-year-long C.\u00a0difficile ribotype 027 outbreak. Medical charts were reviewed for patient data. In addition, all costs associated with the outbreak control measures were collected. The attributable costs of the whole outbreak were estimated to be \u20ac1,222,376. The main contributing factor was missed revenue due to increased length of stay of CDI patients and closure of beds to enable contact isolation of CDI patients (36%). A second important cost component was extra surveillance and activities of the Department of Medical Microbiology and Infection Control (25%). To the authors' knowledge, this is the first study to provide insight into the attributable costs of CDI in an outbreak setting, and to delineate the major cost items. It is clear that the economic consequences of CDI are significant. The high costs associated with a CDI outbreak should help to justify the use of additional resources for CDI prevention and control.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "6158805862de438691239d93f7ce71aa", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[29, 30], [84, 85]], "char_spans": [[157, 168], [460, 471]]}]}], "context_tokens": [["The", 0], ["economic", 4], ["impact", 13], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["infection", 45], ["(", 55], ["CDI", 56], [")", 59], ["on", 61], ["the", 64], ["healthcare", 68], ["system", 79], ["is", 86], ["significant", 89], [".", 100], ["From", 102], ["May", 107], ["2013", 111], ["to", 116], ["May", 119], ["2014", 123], [",", 127], ["an", 129], ["outbreak", 132], ["of", 141], ["C.", 144], ["difficile", 147], ["ribotype", 157], ["027", 166], ["occurred", 170], ["in", 179], ["a", 182], ["Dutch", 184], ["tertiary", 190], ["care", 199], ["hospital", 204], [",", 212], ["involving", 214], ["72", 224], ["patients", 227], [".", 235], ["The", 237], ["primary", 241], ["aim", 249], ["of", 253], ["this", 256], ["study", 261], ["was", 267], ["to", 271], ["provide", 274], ["insight", 282], ["into", 290], ["the", 295], ["financial", 299], ["burden", 309], ["that", 316], ["this", 321], ["CDI", 326], ["outbreak", 330], ["brought", 339], ["upon", 347], ["this", 352], ["hospital", 357], [".", 365], ["A", 367], ["retrospective", 369], ["analysis", 383], ["was", 392], ["performed", 396], ["to", 406], ["estimate", 409], ["the", 418], ["costs", 422], ["of", 428], ["a", 431], ["one", 433], ["-", 436], ["year", 437], ["-", 441], ["long", 442], ["C.", 447], ["difficile", 450], ["ribotype", 460], ["027", 469], ["outbreak", 473], [".", 481], ["Medical", 483], ["charts", 491], ["were", 498], ["reviewed", 503], ["for", 512], ["patient", 516], ["data", 524], [".", 528], ["In", 530], ["addition", 533], [",", 541], ["all", 543], ["costs", 547], ["associated", 553], ["with", 564], ["the", 569], ["outbreak", 573], ["control", 582], ["measures", 590], ["were", 599], ["collected", 604], [".", 613], ["The", 615], ["attributable", 619], ["costs", 632], ["of", 638], ["the", 641], ["whole", 645], ["outbreak", 651], ["were", 660], ["estimated", 665], ["to", 675], ["be", 678], ["\u20ac", 681], ["1,222,376", 682], [".", 691], ["The", 693], ["main", 697], ["contributing", 702], ["factor", 715], ["was", 722], ["missed", 726], ["revenue", 733], ["due", 741], ["to", 745], ["increased", 748], ["length", 758], ["of", 765], ["stay", 768], ["of", 773], ["CDI", 776], ["patients", 780], ["and", 789], ["closure", 793], ["of", 801], ["beds", 804], ["to", 809], ["enable", 812], ["contact", 819], ["isolation", 827], ["of", 837], ["CDI", 840], ["patients", 844], ["(", 853], ["36", 854], ["%", 856], [")", 857], [".", 858], ["A", 860], ["second", 862], ["important", 869], ["cost", 879], ["component", 884], ["was", 894], ["extra", 898], ["surveillance", 904], ["and", 917], ["activities", 921], ["of", 932], ["the", 935], ["Department", 939], ["of", 950], ["Medical", 953], ["Microbiology", 961], ["and", 974], ["Infection", 978], ["Control", 988], ["(", 996], ["25", 997], ["%", 999], [")", 1000], [".", 1001], ["To", 1003], ["the", 1006], ["authors", 1010], ["'", 1017], ["knowledge", 1019], [",", 1028], ["this", 1030], ["is", 1035], ["the", 1038], ["first", 1042], ["study", 1048], ["to", 1054], ["provide", 1057], ["insight", 1065], ["into", 1073], ["the", 1078], ["attributable", 1082], ["costs", 1095], ["of", 1101], ["CDI", 1104], ["in", 1108], ["an", 1111], ["outbreak", 1114], ["setting", 1123], [",", 1130], ["and", 1132], ["to", 1136], ["delineate", 1139], ["the", 1149], ["major", 1153], ["cost", 1159], ["items", 1164], [".", 1169], ["It", 1171], ["is", 1174], ["clear", 1177], ["that", 1183], ["the", 1188], ["economic", 1192], ["consequences", 1201], ["of", 1214], ["CDI", 1217], ["are", 1221], ["significant", 1225], [".", 1236], ["The", 1238], ["high", 1242], ["costs", 1247], ["associated", 1253], ["with", 1264], ["a", 1269], ["CDI", 1271], ["outbreak", 1275], ["should", 1284], ["help", 1291], ["to", 1296], ["justify", 1299], ["the", 1307], ["use", 1311], ["of", 1315], ["additional", 1318], ["resources", 1329], ["for", 1339], ["CDI", 1343], ["prevention", 1347], ["and", 1358], ["control", 1362], [".", 1369]]}
{"context": "The restless legs syndrome is characterized by an unpleasant sensation in the legs which causes an imperative need to move the legs and is therefore considered to be a disorder of movement. When it appears before going to sleep, it may interfere with falling asleep and lead to a sleep-deficit. It is a clinical condition with a satisfactory treatment, and improvement of the associated sleep disorder. The etiology is unknown, sometimes it is familial. The syndrome is increasingly often diagnosed, particularly in association with iron deficiency, during pregnancy, in chronic renal failure and in patients with peripheral neuropathy. Polysomnography is not necessary, unless one suspects an associated disorder of periodic leg movements. Treatment is by dopaminergic, opiate, benzodiazepine, anticonvulsant drugs or clonidine.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "d4042c8ae89c41c5b5b34e283593ecf2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[94, 94]], "char_spans": [[533, 536]]}]}], "context_tokens": [["The", 0], ["restless", 4], ["legs", 13], ["syndrome", 18], ["is", 27], ["characterized", 30], ["by", 44], ["an", 47], ["unpleasant", 50], ["sensation", 61], ["in", 71], ["the", 74], ["legs", 78], ["which", 83], ["causes", 89], ["an", 96], ["imperative", 99], ["need", 110], ["to", 115], ["move", 118], ["the", 123], ["legs", 127], ["and", 132], ["is", 136], ["therefore", 139], ["considered", 149], ["to", 160], ["be", 163], ["a", 166], ["disorder", 168], ["of", 177], ["movement", 180], [".", 188], ["When", 190], ["it", 195], ["appears", 198], ["before", 206], ["going", 213], ["to", 219], ["sleep", 222], [",", 227], ["it", 229], ["may", 232], ["interfere", 236], ["with", 246], ["falling", 251], ["asleep", 259], ["and", 266], ["lead", 270], ["to", 275], ["a", 278], ["sleep", 280], ["-", 285], ["deficit", 286], [".", 293], ["It", 295], ["is", 298], ["a", 301], ["clinical", 303], ["condition", 312], ["with", 322], ["a", 327], ["satisfactory", 329], ["treatment", 342], [",", 351], ["and", 353], ["improvement", 357], ["of", 369], ["the", 372], ["associated", 376], ["sleep", 387], ["disorder", 393], [".", 401], ["The", 403], ["etiology", 407], ["is", 416], ["unknown", 419], [",", 426], ["sometimes", 428], ["it", 438], ["is", 441], ["familial", 444], [".", 452], ["The", 454], ["syndrome", 458], ["is", 467], ["increasingly", 470], ["often", 483], ["diagnosed", 489], [",", 498], ["particularly", 500], ["in", 513], ["association", 516], ["with", 528], ["iron", 533], ["deficiency", 538], [",", 548], ["during", 550], ["pregnancy", 557], [",", 566], ["in", 568], ["chronic", 571], ["renal", 579], ["failure", 585], ["and", 593], ["in", 597], ["patients", 600], ["with", 609], ["peripheral", 614], ["neuropathy", 625], [".", 635], ["Polysomnography", 637], ["is", 653], ["not", 656], ["necessary", 660], [",", 669], ["unless", 671], ["one", 678], ["suspects", 682], ["an", 691], ["associated", 694], ["disorder", 705], ["of", 714], ["periodic", 717], ["leg", 726], ["movements", 730], [".", 739], ["Treatment", 741], ["is", 751], ["by", 754], ["dopaminergic", 757], [",", 769], ["opiate", 771], [",", 777], ["benzodiazepine", 779], [",", 793], ["anticonvulsant", 795], ["drugs", 810], ["or", 816], ["clonidine", 819], [".", 828]]}
{"context": "Transcription factor forkhead box protein P2 (FOXP2) plays an essential role in the development of language and speech. However, the transcriptional activity of FOXP2 regulated by the post-translational modifications remains unknown. Here, we demonstrated that FOXP2 is clearly defined as a SUMO target protein at the cellular levels as FOXP2 is covalently modified by both SUMO1 and SUMO3. Furthermore, SUMOylation of FOXP2 was significantly decreased by SENP2 (a specific SUMOylation protease). We further showed that FOXP2 is selectively SUMOylated in vivo on a phylogenetically conserved lysine 674 but the SUMOylation does not alter subcellular localization and stability of FOXP2. Interestingly, we observed that human etiological FOXP2 R553H mutation robustly reduces its SUMOylation potential as compared to wild-type FOXP2. In addition, the acidic residues downstream the core SUMO motif on FOXP2 are required for its full SUMOylation capacity. Finally, our functional analysis using reporter gene assays showed that SUMOylation may modulate transcriptional activity of FOXP2 in regulating downstream target genes (DISC1, SRPX2, and MiR200c). Altogether, we provide the first evidence that FOXP2 is a substrate for SUMOylation and SUMOylation of FOXP2 plays a functional role in regulating its transcriptional activity.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a7027ca777994cbab2cb50fc3cfbf62c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[43, 43], [27, 27], [134, 134], [197, 197], [148, 148], [71, 71], [57, 57], [7, 7], [88, 88], [120, 120], [206, 206], [174, 174], [111, 111]], "char_spans": [[261, 265], [161, 165], [826, 830], [1199, 1203], [900, 904], [419, 423], [337, 341], [46, 50], [520, 524], [737, 741], [1255, 1259], [1079, 1083], [680, 684]]}]}], "context_tokens": [["Transcription", 0], ["factor", 14], ["forkhead", 21], ["box", 30], ["protein", 34], ["P2", 42], ["(", 45], ["FOXP2", 46], [")", 51], ["plays", 53], ["an", 59], ["essential", 62], ["role", 72], ["in", 77], ["the", 80], ["development", 84], ["of", 96], ["language", 99], ["and", 108], ["speech", 112], [".", 118], ["However", 120], [",", 127], ["the", 129], ["transcriptional", 133], ["activity", 149], ["of", 158], ["FOXP2", 161], ["regulated", 167], ["by", 177], ["the", 180], ["post", 184], ["-", 188], ["translational", 189], ["modifications", 203], ["remains", 217], ["unknown", 225], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["demonstrated", 243], ["that", 256], ["FOXP2", 261], ["is", 267], ["clearly", 270], ["defined", 278], ["as", 286], ["a", 289], ["SUMO", 291], ["target", 296], ["protein", 303], ["at", 311], ["the", 314], ["cellular", 318], ["levels", 327], ["as", 334], ["FOXP2", 337], ["is", 343], ["covalently", 346], ["modified", 357], ["by", 366], ["both", 369], ["SUMO1", 374], ["and", 380], ["SUMO3", 384], [".", 389], ["Furthermore", 391], [",", 402], ["SUMOylation", 404], ["of", 416], ["FOXP2", 419], ["was", 425], ["significantly", 429], ["decreased", 443], ["by", 453], ["SENP2", 456], ["(", 462], ["a", 463], ["specific", 465], ["SUMOylation", 474], ["protease", 486], [")", 494], [".", 495], ["We", 497], ["further", 500], ["showed", 508], ["that", 515], ["FOXP2", 520], ["is", 526], ["selectively", 529], ["SUMOylated", 541], ["in", 552], ["vivo", 555], ["on", 560], ["a", 563], ["phylogenetically", 565], ["conserved", 582], ["lysine", 592], ["674", 599], ["but", 603], ["the", 607], ["SUMOylation", 611], ["does", 623], ["not", 628], ["alter", 632], ["subcellular", 638], ["localization", 650], ["and", 663], ["stability", 667], ["of", 677], ["FOXP2", 680], [".", 685], ["Interestingly", 687], [",", 700], ["we", 702], ["observed", 705], ["that", 714], ["human", 719], ["etiological", 725], ["FOXP2", 737], ["R553H", 743], ["mutation", 749], ["robustly", 758], ["reduces", 767], ["its", 775], ["SUMOylation", 779], ["potential", 791], ["as", 801], ["compared", 804], ["to", 813], ["wild", 816], ["-", 820], ["type", 821], ["FOXP2", 826], [".", 831], ["In", 833], ["addition", 836], [",", 844], ["the", 846], ["acidic", 850], ["residues", 857], ["downstream", 866], ["the", 877], ["core", 881], ["SUMO", 886], ["motif", 891], ["on", 897], ["FOXP2", 900], ["are", 906], ["required", 910], ["for", 919], ["its", 923], ["full", 927], ["SUMOylation", 932], ["capacity", 944], [".", 952], ["Finally", 954], [",", 961], ["our", 963], ["functional", 967], ["analysis", 978], ["using", 987], ["reporter", 993], ["gene", 1002], ["assays", 1007], ["showed", 1014], ["that", 1021], ["SUMOylation", 1026], ["may", 1038], ["modulate", 1042], ["transcriptional", 1051], ["activity", 1067], ["of", 1076], ["FOXP2", 1079], ["in", 1085], ["regulating", 1088], ["downstream", 1099], ["target", 1110], ["genes", 1117], ["(", 1123], ["DISC1", 1124], [",", 1129], ["SRPX2", 1131], [",", 1136], ["and", 1138], ["MiR200c", 1142], [")", 1149], [".", 1150], ["Altogether", 1152], [",", 1162], ["we", 1164], ["provide", 1167], ["the", 1175], ["first", 1179], ["evidence", 1185], ["that", 1194], ["FOXP2", 1199], ["is", 1205], ["a", 1208], ["substrate", 1210], ["for", 1220], ["SUMOylation", 1224], ["and", 1236], ["SUMOylation", 1240], ["of", 1252], ["FOXP2", 1255], ["plays", 1261], ["a", 1267], ["functional", 1269], ["role", 1280], ["in", 1285], ["regulating", 1288], ["its", 1299], ["transcriptional", 1303], ["activity", 1319], [".", 1327]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation. On other hand, EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib. We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases. 192 adenocarcinoma cases were included. The presence or absence of EGFR polymorphism of exon 13 was analyzed by PCR-RFLP method. EGFR mutations at kinase domain were found from 95 of 225 lung cancer patients. In 86.2% of patients, homo- or heterozygous Lys497 allele was present. No correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes. EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. In node-negative patients, R497KEGFR genotype was not correlated with disease outcome. In node-positive patients, however, R497K EGFR was significantly associated with better overall survival. This association was attributable to neo-adjuvant or adjuvant chemotherapy. In 46 total gefitinib treated NSCLC patients, the prognosis was not different between the EGFR wild type (GG) patients and AG+AA patients. R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "98bf14cf3f54411fb46b808b1029b76d", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[56, 99]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["reported", 12], ["that", 21], ["the", 26], ["R497", 30], ["K", 34], ["polymorphism", 36], ["of", 49], ["the", 52], ["epidermal", 56], ["growth", 66], ["factor", 73], ["receptor", 80], ["(", 89], ["EGFR", 90], [")", 94], ["gene", 96], ["has", 101], ["attenuated", 105], ["functions", 116], ["in", 126], ["ligand", 129], ["binding", 136], [",", 143], ["tyrosine", 145], ["kinase", 154], ["activation", 161], [",", 171], ["and", 173], ["growth", 177], ["stimulation", 184], [".", 195], ["On", 197], ["other", 200], ["hand", 206], [",", 210], ["EGFR", 212], ["gene", 217], ["mutations", 222], ["at", 232], ["kinase", 235], ["domain", 242], ["in", 249], ["non", 252], ["-", 255], ["small", 256], ["cell", 262], ["lung", 267], ["cancer", 272], ["(", 279], ["NSCLC", 280], [")", 285], ["have", 287], ["been", 292], ["examined", 297], ["for", 306], ["their", 310], ["ability", 316], ["to", 324], ["predict", 327], ["sensitivity", 335], ["to", 347], ["gefitinib", 350], ["or", 360], ["erlotinib", 363], [".", 372], ["We", 374], ["investigated", 377], ["the", 390], ["EGFR", 394], ["mutations", 399], ["and/or", 409], ["R497", 416], ["K", 420], ["polymorphism", 422], ["statuses", 435], ["in", 444], ["225", 447], ["surgically", 451], ["treated", 462], ["NSCLC", 470], ["cases", 476], [".", 481], ["192", 483], ["adenocarcinoma", 487], ["cases", 502], ["were", 508], ["included", 513], [".", 521], ["The", 523], ["presence", 527], ["or", 536], ["absence", 539], ["of", 547], ["EGFR", 550], ["polymorphism", 555], ["of", 568], ["exon", 571], ["13", 576], ["was", 579], ["analyzed", 583], ["by", 592], ["PCR", 595], ["-", 598], ["RFLP", 599], ["method", 604], [".", 610], ["EGFR", 612], ["mutations", 617], ["at", 627], ["kinase", 630], ["domain", 637], ["were", 644], ["found", 649], ["from", 655], ["95", 660], ["of", 663], ["225", 666], ["lung", 670], ["cancer", 675], ["patients", 682], [".", 690], ["In", 692], ["86.2", 695], ["%", 699], ["of", 701], ["patients", 704], [",", 712], ["homo-", 714], ["or", 720], ["heterozygous", 723], ["Lys497", 736], ["allele", 743], ["was", 750], ["present", 754], [".", 761], ["No", 763], ["correlation", 766], ["existed", 778], ["between", 786], ["R497", 794], ["K", 798], ["EGFR", 800], ["genotype", 805], ["and", 814], ["clinico", 818], ["-", 825], ["pathological", 826], ["features", 839], [",", 847], ["such", 849], ["as", 854], ["gender", 857], [",", 863], ["smoking", 865], ["status", 873], [",", 879], ["and", 881], ["pathological", 885], ["subtypes", 898], [".", 906], ["EGFR", 908], ["mutation", 913], ["status", 922], ["was", 929], ["not", 933], ["correlated", 937], ["with", 948], ["R497KEGFR", 953], ["genotype", 963], ["of", 972], ["lung", 975], ["cancers", 980], [".", 987], ["In", 989], ["node", 992], ["-", 996], ["negative", 997], ["patients", 1006], [",", 1014], ["R497KEGFR", 1016], ["genotype", 1026], ["was", 1035], ["not", 1039], ["correlated", 1043], ["with", 1054], ["disease", 1059], ["outcome", 1067], [".", 1074], ["In", 1076], ["node", 1079], ["-", 1083], ["positive", 1084], ["patients", 1093], [",", 1101], ["however", 1103], [",", 1110], ["R497", 1112], ["K", 1116], ["EGFR", 1118], ["was", 1123], ["significantly", 1127], ["associated", 1141], ["with", 1152], ["better", 1157], ["overall", 1164], ["survival", 1172], [".", 1180], ["This", 1182], ["association", 1187], ["was", 1199], ["attributable", 1203], ["to", 1216], ["neo", 1219], ["-", 1222], ["adjuvant", 1223], ["or", 1232], ["adjuvant", 1235], ["chemotherapy", 1244], [".", 1256], ["In", 1258], ["46", 1261], ["total", 1264], ["gefitinib", 1270], ["treated", 1280], ["NSCLC", 1288], ["patients", 1294], [",", 1302], ["the", 1304], ["prognosis", 1308], ["was", 1318], ["not", 1322], ["different", 1326], ["between", 1336], ["the", 1344], ["EGFR", 1348], ["wild", 1353], ["type", 1358], ["(", 1363], ["GG", 1364], [")", 1366], ["patients", 1368], ["and", 1377], ["AG+AA", 1381], ["patients", 1387], [".", 1395], ["R497KEGFR", 1397], ["polymorphism", 1407], ["might", 1420], ["be", 1426], ["associated", 1429], ["with", 1440], ["favorable", 1445], ["prognosis", 1455], ["of", 1465], ["advanced", 1468], ["lung", 1477], ["cancers", 1482], ["and", 1490], ["correlated", 1494], ["with", 1505], ["chemosensitivity", 1510], [".", 1526]]}
{"context": "Seven women in three generations of a family have been affected by Turner syndrome. Turner phenotype in this family is the result of deletion of the entire short arm of one X chromosome. The short arm deletion is transmitted by carriers of a balanced X-1 translocation. Autoradiographic findings showed that the deleted X chromosome was late labeling in those persons with Turner syndrome, whereas the normal X chromosome was late replicating in carriers of the balanced translocation. The results of Xga typing of erythrocytes suggest that the Xg locus is on the short arm of the X chromosome. Because of the clinical implications, we believe that families of persons with structural chromosomal abnormalities should be studied to exclude familial transmission.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "8a95f412e40d4b0ba12e01f67102652b", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[32, 32], [55, 55], [101, 101], [70, 70]], "char_spans": [[173, 173], [320, 320], [581, 581], [409, 409]]}]}], "context_tokens": [["Seven", 0], ["women", 6], ["in", 12], ["three", 15], ["generations", 21], ["of", 33], ["a", 36], ["family", 38], ["have", 45], ["been", 50], ["affected", 55], ["by", 64], ["Turner", 67], ["syndrome", 74], [".", 82], ["Turner", 84], ["phenotype", 91], ["in", 101], ["this", 104], ["family", 109], ["is", 116], ["the", 119], ["result", 123], ["of", 130], ["deletion", 133], ["of", 142], ["the", 145], ["entire", 149], ["short", 156], ["arm", 162], ["of", 166], ["one", 169], ["X", 173], ["chromosome", 175], [".", 185], ["The", 187], ["short", 191], ["arm", 197], ["deletion", 201], ["is", 210], ["transmitted", 213], ["by", 225], ["carriers", 228], ["of", 237], ["a", 240], ["balanced", 242], ["X-1", 251], ["translocation", 255], [".", 268], ["Autoradiographic", 270], ["findings", 287], ["showed", 296], ["that", 303], ["the", 308], ["deleted", 312], ["X", 320], ["chromosome", 322], ["was", 333], ["late", 337], ["labeling", 342], ["in", 351], ["those", 354], ["persons", 360], ["with", 368], ["Turner", 373], ["syndrome", 380], [",", 388], ["whereas", 390], ["the", 398], ["normal", 402], ["X", 409], ["chromosome", 411], ["was", 422], ["late", 426], ["replicating", 431], ["in", 443], ["carriers", 446], ["of", 455], ["the", 458], ["balanced", 462], ["translocation", 471], [".", 484], ["The", 486], ["results", 490], ["of", 498], ["Xga", 501], ["typing", 505], ["of", 512], ["erythrocytes", 515], ["suggest", 528], ["that", 536], ["the", 541], ["Xg", 545], ["locus", 548], ["is", 554], ["on", 557], ["the", 560], ["short", 564], ["arm", 570], ["of", 574], ["the", 577], ["X", 581], ["chromosome", 583], [".", 593], ["Because", 595], ["of", 603], ["the", 606], ["clinical", 610], ["implications", 619], [",", 631], ["we", 633], ["believe", 636], ["that", 644], ["families", 649], ["of", 658], ["persons", 661], ["with", 669], ["structural", 674], ["chromosomal", 685], ["abnormalities", 697], ["should", 711], ["be", 718], ["studied", 721], ["to", 729], ["exclude", 732], ["familial", 740], ["transmission", 749], [".", 761]]}
{"context": "The aim of the study was to determine the frequency and type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital, Isfahan, Iran. In an analytic descriptive survey in 2005 and early 2006, patients admitted to the hospital who contracted S. aureus nosocomial infections were enrolled in the study. All isolates were identified by the conventional laboratory tests. Minimal Inhibitory Concentration (MIC) of oxacillin on isolated bacteria was determined by E-Test method. According to Clinical and Laboratory Standard Institute (CLSI) criteria all strains with MIC of > or = 4 microg for oxacillin were identified as MRSA. Intrinsic high level resistance (mecA positive) and borderline oxacillin resistant Staphylococcus aureus (BORSA) were detected by amoxicillin-clavulanate E-test strips. Strains with MIC of > or = 4 microg for oxacillin and > or = 8 microg for amoxicillin-clavulanate were identified as mecA positive MRSA. Other staphylococcus with MIC > or = 4 microg for oxacillin and < or = 4 for amoxicillin-clavulanate were identified as mecA negative MRSA (BORSA). MIC of vancomycin also was determined on isolated bacteria. Data were analyzed by SPSS version 13 and Who net version 5. Out of 134 Staphylococcus aureus samples which were isolated from nosocomial infections 90 (67.2%) were MRSA. Sixty seven out of 90 (74.5%) MRSA were mecA positive and 23 out of 90 (25.5%) were mecA negative (BORSA). Although most of the MRSA strains were isolated from surgical site infections, there were no statistically significant differences between types of Staphylococcus aureus growing from variant sites of infections. Only one (1.49) of the mecA positive MRSA had reduced susceptibility to vancomycin but all of the mecA-negative MRSA (BORSA) were sensitive to it. Because one fourth of our staphylococcus strains are mecA negative BORSA and there is no alternative for vancomycin against mecA positive MRSA and Enterococcus spp. in our hospital, vancomycin should be reserved only for life threatening infections due to these organisms. Thus MRSA typing should be done to choose appropriate antibiotic for optimal treatment of MRSA infections.", "qas": [{"question": "What is BORSA?", "answers": ["borderline oxacillin resistant Staphylococcus aureus", "Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "d3cb2ae20ed644fa9da62fd47344b395", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[122, 126]], "char_spans": [[687, 738]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["determine", 28], ["the", 38], ["frequency", 42], ["and", 52], ["type", 56], ["of", 61], ["MRSA", 64], ["strains", 69], ["and", 77], ["antibiotic", 81], ["susceptibility", 92], ["in", 107], ["Al", 110], ["-", 112], ["Zahra", 113], ["Hospital", 119], [",", 127], ["Isfahan", 129], [",", 136], ["Iran", 138], [".", 142], ["In", 144], ["an", 147], ["analytic", 150], ["descriptive", 159], ["survey", 171], ["in", 178], ["2005", 181], ["and", 186], ["early", 190], ["2006", 196], [",", 200], ["patients", 202], ["admitted", 211], ["to", 220], ["the", 223], ["hospital", 227], ["who", 236], ["contracted", 240], ["S.", 251], ["aureus", 254], ["nosocomial", 261], ["infections", 272], ["were", 283], ["enrolled", 288], ["in", 297], ["the", 300], ["study", 304], [".", 309], ["All", 311], ["isolates", 315], ["were", 324], ["identified", 329], ["by", 340], ["the", 343], ["conventional", 347], ["laboratory", 360], ["tests", 371], [".", 376], ["Minimal", 378], ["Inhibitory", 386], ["Concentration", 397], ["(", 411], ["MIC", 412], [")", 415], ["of", 417], ["oxacillin", 420], ["on", 430], ["isolated", 433], ["bacteria", 442], ["was", 451], ["determined", 455], ["by", 466], ["E", 469], ["-", 470], ["Test", 471], ["method", 476], [".", 482], ["According", 484], ["to", 494], ["Clinical", 497], ["and", 506], ["Laboratory", 510], ["Standard", 521], ["Institute", 530], ["(", 540], ["CLSI", 541], [")", 545], ["criteria", 547], ["all", 556], ["strains", 560], ["with", 568], ["MIC", 573], ["of", 577], [">", 580], ["or", 582], ["=", 585], ["4", 587], ["microg", 589], ["for", 596], ["oxacillin", 600], ["were", 610], ["identified", 615], ["as", 626], ["MRSA", 629], [".", 633], ["Intrinsic", 635], ["high", 645], ["level", 650], ["resistance", 656], ["(", 667], ["mecA", 668], ["positive", 673], [")", 681], ["and", 683], ["borderline", 687], ["oxacillin", 698], ["resistant", 708], ["Staphylococcus", 718], ["aureus", 733], ["(", 740], ["BORSA", 741], [")", 746], ["were", 748], ["detected", 753], ["by", 762], ["amoxicillin", 765], ["-", 776], ["clavulanate", 777], ["E", 789], ["-", 790], ["test", 791], ["strips", 796], [".", 802], ["Strains", 804], ["with", 812], ["MIC", 817], ["of", 821], [">", 824], ["or", 826], ["=", 829], ["4", 831], ["microg", 833], ["for", 840], ["oxacillin", 844], ["and", 854], [">", 858], ["or", 860], ["=", 863], ["8", 865], ["microg", 867], ["for", 874], ["amoxicillin", 878], ["-", 889], ["clavulanate", 890], ["were", 902], ["identified", 907], ["as", 918], ["mecA", 921], ["positive", 926], ["MRSA", 935], [".", 939], ["Other", 941], ["staphylococcus", 947], ["with", 962], ["MIC", 967], [">", 971], ["or", 973], ["=", 976], ["4", 978], ["microg", 980], ["for", 987], ["oxacillin", 991], ["and", 1001], ["<", 1005], ["or", 1007], ["=", 1010], ["4", 1012], ["for", 1014], ["amoxicillin", 1018], ["-", 1029], ["clavulanate", 1030], ["were", 1042], ["identified", 1047], ["as", 1058], ["mecA", 1061], ["negative", 1066], ["MRSA", 1075], ["(", 1080], ["BORSA", 1081], [")", 1086], [".", 1087], ["MIC", 1089], ["of", 1093], ["vancomycin", 1096], ["also", 1107], ["was", 1112], ["determined", 1116], ["on", 1127], ["isolated", 1130], ["bacteria", 1139], [".", 1147], ["Data", 1149], ["were", 1154], ["analyzed", 1159], ["by", 1168], ["SPSS", 1171], ["version", 1176], ["13", 1184], ["and", 1187], ["Who", 1191], ["net", 1195], ["version", 1199], ["5", 1207], [".", 1208], ["Out", 1210], ["of", 1214], ["134", 1217], ["Staphylococcus", 1221], ["aureus", 1236], ["samples", 1243], ["which", 1251], ["were", 1257], ["isolated", 1262], ["from", 1271], ["nosocomial", 1276], ["infections", 1287], ["90", 1298], ["(", 1301], ["67.2", 1302], ["%", 1306], [")", 1307], ["were", 1309], ["MRSA", 1314], [".", 1318], ["Sixty", 1320], ["seven", 1326], ["out", 1332], ["of", 1336], ["90", 1339], ["(", 1342], ["74.5", 1343], ["%", 1347], [")", 1348], ["MRSA", 1350], ["were", 1355], ["mecA", 1360], ["positive", 1365], ["and", 1374], ["23", 1378], ["out", 1381], ["of", 1385], ["90", 1388], ["(", 1391], ["25.5", 1392], ["%", 1396], [")", 1397], ["were", 1399], ["mecA", 1404], ["negative", 1409], ["(", 1418], ["BORSA", 1419], [")", 1424], [".", 1425], ["Although", 1427], ["most", 1436], ["of", 1441], ["the", 1444], ["MRSA", 1448], ["strains", 1453], ["were", 1461], ["isolated", 1466], ["from", 1475], ["surgical", 1480], ["site", 1489], ["infections", 1494], [",", 1504], ["there", 1506], ["were", 1512], ["no", 1517], ["statistically", 1520], ["significant", 1534], ["differences", 1546], ["between", 1558], ["types", 1566], ["of", 1572], ["Staphylococcus", 1575], ["aureus", 1590], ["growing", 1597], ["from", 1605], ["variant", 1610], ["sites", 1618], ["of", 1624], ["infections", 1627], [".", 1637], ["Only", 1639], ["one", 1644], ["(", 1648], ["1.49", 1649], [")", 1653], ["of", 1655], ["the", 1658], ["mecA", 1662], ["positive", 1667], ["MRSA", 1676], ["had", 1681], ["reduced", 1685], ["susceptibility", 1693], ["to", 1708], ["vancomycin", 1711], ["but", 1722], ["all", 1726], ["of", 1730], ["the", 1733], ["mecA", 1737], ["-", 1741], ["negative", 1742], ["MRSA", 1751], ["(", 1756], ["BORSA", 1757], [")", 1762], ["were", 1764], ["sensitive", 1769], ["to", 1779], ["it", 1782], [".", 1784], ["Because", 1786], ["one", 1794], ["fourth", 1798], ["of", 1805], ["our", 1808], ["staphylococcus", 1812], ["strains", 1827], ["are", 1835], ["mecA", 1839], ["negative", 1844], ["BORSA", 1853], ["and", 1859], ["there", 1863], ["is", 1869], ["no", 1872], ["alternative", 1875], ["for", 1887], ["vancomycin", 1891], ["against", 1902], ["mecA", 1910], ["positive", 1915], ["MRSA", 1924], ["and", 1929], ["Enterococcus", 1933], ["spp", 1946], [".", 1949], ["in", 1951], ["our", 1954], ["hospital", 1958], [",", 1966], ["vancomycin", 1968], ["should", 1979], ["be", 1986], ["reserved", 1989], ["only", 1998], ["for", 2003], ["life", 2007], ["threatening", 2012], ["infections", 2024], ["due", 2035], ["to", 2039], ["these", 2042], ["organisms", 2048], [".", 2057], ["Thus", 2059], ["MRSA", 2064], ["typing", 2069], ["should", 2076], ["be", 2083], ["done", 2086], ["to", 2091], ["choose", 2094], ["appropriate", 2101], ["antibiotic", 2113], ["for", 2124], ["optimal", 2128], ["treatment", 2136], ["of", 2146], ["MRSA", 2149], ["infections", 2154], [".", 2164]]}
{"context": "Anticoagulation therapy is indicated for management of various clinical conditions to prevent adverse events and introduction of direct oral anticoagulants (DOACs) has ushered in a new era in anticoagulation therapy. Major advantages of DOACS include fewer drug interactions and that they do not need periodic monitoring. Several patients who were not on anticoagulation before due to older age, polypharmacy/drug interaction concerns, and logistics of periodic monitoring are now on anticoagulation with DOACs. Despite their many advantages, a challenge while prescribing DOACs is very limited availability of specific reversal agents and lack of understanding or guidance about the treatment strategy in case of major life threatening bleeding or need for urgent surgery. So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran. Several other reversal agents are under final phases of development such as andexanet alfa and PER977 (ciraparantag) and will help in developing specific strategies for reversal of these agents. In this article, we review current strategies to manage bleeding with DOACs and provide guidance to clinicians of inhibiting LF activity in vitro and in cells, as well as in animal models of anthrax infection.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "92d38fcd3d864c5aa90a01fe0e5787f2", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[149, 149]], "char_spans": [[906, 915]]}]}], "context_tokens": [["Anticoagulation", 0], ["therapy", 16], ["is", 24], ["indicated", 27], ["for", 37], ["management", 41], ["of", 52], ["various", 55], ["clinical", 63], ["conditions", 72], ["to", 83], ["prevent", 86], ["adverse", 94], ["events", 102], ["and", 109], ["introduction", 113], ["of", 126], ["direct", 129], ["oral", 136], ["anticoagulants", 141], ["(", 156], ["DOACs", 157], [")", 162], ["has", 164], ["ushered", 168], ["in", 176], ["a", 179], ["new", 181], ["era", 185], ["in", 189], ["anticoagulation", 192], ["therapy", 208], [".", 215], ["Major", 217], ["advantages", 223], ["of", 234], ["DOACS", 237], ["include", 243], ["fewer", 251], ["drug", 257], ["interactions", 262], ["and", 275], ["that", 279], ["they", 284], ["do", 289], ["not", 292], ["need", 296], ["periodic", 301], ["monitoring", 310], [".", 320], ["Several", 322], ["patients", 330], ["who", 339], ["were", 343], ["not", 348], ["on", 352], ["anticoagulation", 355], ["before", 371], ["due", 378], ["to", 382], ["older", 385], ["age", 391], [",", 394], ["polypharmacy", 396], ["/", 408], ["drug", 409], ["interaction", 414], ["concerns", 426], [",", 434], ["and", 436], ["logistics", 440], ["of", 450], ["periodic", 453], ["monitoring", 462], ["are", 473], ["now", 477], ["on", 481], ["anticoagulation", 484], ["with", 500], ["DOACs", 505], [".", 510], ["Despite", 512], ["their", 520], ["many", 526], ["advantages", 531], [",", 541], ["a", 543], ["challenge", 545], ["while", 555], ["prescribing", 561], ["DOACs", 573], ["is", 579], ["very", 582], ["limited", 587], ["availability", 595], ["of", 608], ["specific", 611], ["reversal", 620], ["agents", 629], ["and", 636], ["lack", 640], ["of", 645], ["understanding", 648], ["or", 662], ["guidance", 665], ["about", 674], ["the", 680], ["treatment", 684], ["strategy", 694], ["in", 703], ["case", 706], ["of", 711], ["major", 714], ["life", 720], ["threatening", 725], ["bleeding", 737], ["or", 746], ["need", 749], ["for", 754], ["urgent", 758], ["surgery", 765], [".", 772], ["So", 774], ["far", 777], ["only", 781], ["one", 786], ["reversal", 790], ["agent", 799], ["has", 805], ["been", 809], ["approved", 814], ["by", 823], ["the", 826], ["Food", 830], ["and", 835], ["Drug", 839], ["Administration", 844], ["(", 859], ["FDA", 860], [")", 863], [",", 864], ["idarucizumab", 866], ["for", 879], ["one", 883], ["of", 887], ["the", 890], ["DOACs", 894], ["i.e.", 900], [",", 904], ["dabigatran", 906], [".", 916], ["Several", 918], ["other", 926], ["reversal", 932], ["agents", 941], ["are", 948], ["under", 952], ["final", 958], ["phases", 964], ["of", 971], ["development", 974], ["such", 986], ["as", 991], ["andexanet", 994], ["alfa", 1004], ["and", 1009], ["PER977", 1013], ["(", 1020], ["ciraparantag", 1021], [")", 1033], ["and", 1035], ["will", 1039], ["help", 1044], ["in", 1049], ["developing", 1052], ["specific", 1063], ["strategies", 1072], ["for", 1083], ["reversal", 1087], ["of", 1096], ["these", 1099], ["agents", 1105], [".", 1111], ["In", 1113], ["this", 1116], ["article", 1121], [",", 1128], ["we", 1130], ["review", 1133], ["current", 1140], ["strategies", 1148], ["to", 1159], ["manage", 1162], ["bleeding", 1169], ["with", 1178], ["DOACs", 1183], ["and", 1189], ["provide", 1193], ["guidance", 1201], ["to", 1210], ["clinicians", 1213], ["of", 1224], ["inhibiting", 1227], ["LF", 1238], ["activity", 1241], ["in", 1250], ["vitro", 1253], ["and", 1259], ["in", 1263], ["cells", 1266], [",", 1271], ["as", 1273], ["well", 1276], ["as", 1281], ["in", 1284], ["animal", 1287], ["models", 1294], ["of", 1301], ["anthrax", 1304], ["infection", 1312], [".", 1321]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose. Thirteen emergency departments enrolled 326 patients in this double-blind, placebo-controlled trial; 162 patients were randomly allocated to receive flumazenil (maximum dose, 30 ml, providing 3 mg of flumazenil), and 164 were allocated to receive placebo (maximum dose, 30 ml). A successful response was the attainment of a score of 1 or 2 on the Clinical Global Impression Scale (CGIS), denoting a very much improved or much improved status, 10 minutes after the start of intravenous administration of the test drug. Among those patients whose drug screen revealed the presence of benzodiazepines, 75 (77%) of 97 patients given flumazenil and 13 (16%) of 83 given placebo attained such a response. The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo. As determined by the Neurobehavioral Assessment Scale, 61% of patients who initially responded became resedated; in these patients, the effect of flumazenil lasted a median of 90 minutes. At the investigator's discretion, patients who did not achieve a criterion response in the double-blind trial could receive open-label flumazenil, titrated as in the double-blind phase. Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded. Safety was assessed in all 326 patients given the test drug. The most frequent adverse experiences after the administration of flumazenil were agitation (7%), vomiting (7%), abnormal crying (4%), and nausea (4%); these effects were observed with a lower frequency in the placebo group. Serious adverse experiences were reported in 4 patients; these included seizures and cardiac arrhythmias. Of the 3 patients with seizures, 2 had ingested large doses of cyclic antidepressants in addition to the benzodiazepine. The toxicology screen for 1 of the 2 showed 1900 ng/ml of amoxapine and 900 ng/ml of nortriptyline; the toxicology screen for the other, who also had ventricular tachycardia, showed 1928 ng/ml of loxapine and 301 ng/ml of amoxapine. The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose. This was accomplished irrespective of the presence of coingested drugs. Flumazenil is not recommended for patients with serious cyclic antidepressant poisoning or those who use benzodiazepines therapeutically to control seizure disorders. When used as recommended, however, flumazenil has been shown to have an acceptable safety level.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c0676b791a034e7e90ddf7a04c68ddd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [272, 272], [43, 43], [205, 205], [170, 170], [266, 266], [502, 502], [140, 140], [308, 308], [55, 55], [473, 473], [238, 238], [449, 449]], "char_spans": [[0, 9], [1467, 1476], [281, 290], [1118, 1127], [915, 924], [1422, 1431], [2729, 2738], [761, 770], [1667, 1676], [332, 341], [2527, 2536], [1295, 1304], [2357, 2366]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["was", 50], ["evaluated", 54], ["as", 64], ["adjunctive", 67], ["therapy", 78], ["in", 86], ["the", 89], ["management", 93], ["of", 104], ["benzodiazepine", 107], ["overdose", 122], [".", 130], ["Thirteen", 132], ["emergency", 141], ["departments", 151], ["enrolled", 163], ["326", 172], ["patients", 176], ["in", 185], ["this", 188], ["double", 193], ["-", 199], ["blind", 200], [",", 205], ["placebo", 207], ["-", 214], ["controlled", 215], ["trial", 226], [";", 231], ["162", 233], ["patients", 237], ["were", 246], ["randomly", 251], ["allocated", 260], ["to", 270], ["receive", 273], ["flumazenil", 281], ["(", 292], ["maximum", 293], ["dose", 301], [",", 305], ["30", 307], ["ml", 310], [",", 312], ["providing", 314], ["3", 324], ["mg", 326], ["of", 329], ["flumazenil", 332], [")", 342], [",", 343], ["and", 345], ["164", 349], ["were", 353], ["allocated", 358], ["to", 368], ["receive", 371], ["placebo", 379], ["(", 387], ["maximum", 388], ["dose", 396], [",", 400], ["30", 402], ["ml", 405], [")", 407], [".", 408], ["A", 410], ["successful", 412], ["response", 423], ["was", 432], ["the", 436], ["attainment", 440], ["of", 451], ["a", 454], ["score", 456], ["of", 462], ["1", 465], ["or", 467], ["2", 470], ["on", 472], ["the", 475], ["Clinical", 479], ["Global", 488], ["Impression", 495], ["Scale", 506], ["(", 512], ["CGIS", 513], [")", 517], [",", 518], ["denoting", 520], ["a", 529], ["very", 531], ["much", 536], ["improved", 541], ["or", 550], ["much", 553], ["improved", 558], ["status", 567], [",", 573], ["10", 575], ["minutes", 578], ["after", 586], ["the", 592], ["start", 596], ["of", 602], ["intravenous", 605], ["administration", 617], ["of", 632], ["the", 635], ["test", 639], ["drug", 644], [".", 648], ["Among", 650], ["those", 656], ["patients", 662], ["whose", 671], ["drug", 677], ["screen", 682], ["revealed", 689], ["the", 698], ["presence", 702], ["of", 711], ["benzodiazepines", 714], [",", 729], ["75", 731], ["(", 734], ["77", 735], ["%", 737], [")", 738], ["of", 740], ["97", 743], ["patients", 746], ["given", 755], ["flumazenil", 761], ["and", 772], ["13", 776], ["(", 779], ["16", 780], ["%", 782], [")", 783], ["of", 785], ["83", 788], ["given", 791], ["placebo", 797], ["attained", 805], ["such", 814], ["a", 819], ["response", 821], [".", 829], ["The", 831], ["mean", 835], ["CGIS", 840], ["score", 845], ["at", 851], ["10", 854], ["minutes", 857], ["for", 865], ["benzodiazepine", 869], ["-", 883], ["positive", 884], ["patients", 893], ["treated", 902], ["with", 910], ["flumazenil", 915], ["was", 926], ["1.95", 930], ["versus", 935], ["3.58", 942], ["for", 947], ["those", 951], ["given", 957], ["placebo", 963], [".", 970], ["As", 972], ["determined", 975], ["by", 986], ["the", 989], ["Neurobehavioral", 993], ["Assessment", 1009], ["Scale", 1020], [",", 1025], ["61", 1027], ["%", 1029], ["of", 1031], ["patients", 1034], ["who", 1043], ["initially", 1047], ["responded", 1057], ["became", 1067], ["resedated", 1074], [";", 1083], ["in", 1085], ["these", 1088], ["patients", 1094], [",", 1102], ["the", 1104], ["effect", 1108], ["of", 1115], ["flumazenil", 1118], ["lasted", 1129], ["a", 1136], ["median", 1138], ["of", 1145], ["90", 1148], ["minutes", 1151], [".", 1158], ["At", 1160], ["the", 1163], ["investigator", 1167], ["'s", 1179], ["discretion", 1182], [",", 1192], ["patients", 1194], ["who", 1203], ["did", 1207], ["not", 1211], ["achieve", 1215], ["a", 1223], ["criterion", 1225], ["response", 1235], ["in", 1244], ["the", 1247], ["double", 1251], ["-", 1257], ["blind", 1258], ["trial", 1264], ["could", 1270], ["receive", 1276], ["open", 1284], ["-", 1288], ["label", 1289], ["flumazenil", 1295], [",", 1305], ["titrated", 1307], ["as", 1316], ["in", 1319], ["the", 1322], ["double", 1326], ["-", 1332], ["blind", 1333], ["phase", 1339], [".", 1344], ["Among", 1346], ["the", 1352], ["benzodiazepine", 1356], ["-", 1370], ["positive", 1371], ["patients", 1380], [",", 1388], ["9", 1390], ["(", 1392], ["53", 1393], ["%", 1395], [")", 1396], ["of", 1398], ["17", 1401], ["patients", 1404], ["from", 1413], ["the", 1418], ["flumazenil", 1422], ["group", 1433], ["responded", 1439], ["to", 1449], ["the", 1452], ["additional", 1456], ["flumazenil", 1467], [",", 1477], ["and", 1479], ["58", 1483], ["(", 1486], ["81", 1487], ["%", 1489], [")", 1490], ["of", 1492], ["patients", 1495], ["previously", 1504], ["given", 1515], ["placebo", 1521], ["responded", 1529], [".", 1538], ["Safety", 1540], ["was", 1547], ["assessed", 1551], ["in", 1560], ["all", 1563], ["326", 1567], ["patients", 1571], ["given", 1580], ["the", 1586], ["test", 1590], ["drug", 1595], [".", 1599], ["The", 1601], ["most", 1605], ["frequent", 1610], ["adverse", 1619], ["experiences", 1627], ["after", 1639], ["the", 1645], ["administration", 1649], ["of", 1664], ["flumazenil", 1667], ["were", 1678], ["agitation", 1683], ["(", 1693], ["7", 1694], ["%", 1695], [")", 1696], [",", 1697], ["vomiting", 1699], ["(", 1708], ["7", 1709], ["%", 1710], [")", 1711], [",", 1712], ["abnormal", 1714], ["crying", 1723], ["(", 1730], ["4", 1731], ["%", 1732], [")", 1733], [",", 1734], ["and", 1736], ["nausea", 1740], ["(", 1747], ["4", 1748], ["%", 1749], [")", 1750], [";", 1751], ["these", 1753], ["effects", 1759], ["were", 1767], ["observed", 1772], ["with", 1781], ["a", 1786], ["lower", 1788], ["frequency", 1794], ["in", 1804], ["the", 1807], ["placebo", 1811], ["group", 1819], [".", 1824], ["Serious", 1826], ["adverse", 1834], ["experiences", 1842], ["were", 1854], ["reported", 1859], ["in", 1868], ["4", 1871], ["patients", 1873], [";", 1881], ["these", 1883], ["included", 1889], ["seizures", 1898], ["and", 1907], ["cardiac", 1911], ["arrhythmias", 1919], [".", 1930], ["Of", 1932], ["the", 1935], ["3", 1939], ["patients", 1941], ["with", 1950], ["seizures", 1955], [",", 1963], ["2", 1965], ["had", 1967], ["ingested", 1971], ["large", 1980], ["doses", 1986], ["of", 1992], ["cyclic", 1995], ["antidepressants", 2002], ["in", 2018], ["addition", 2021], ["to", 2030], ["the", 2033], ["benzodiazepine", 2037], [".", 2051], ["The", 2053], ["toxicology", 2057], ["screen", 2068], ["for", 2075], ["1", 2079], ["of", 2081], ["the", 2084], ["2", 2088], ["showed", 2090], ["1900", 2097], ["ng", 2102], ["/", 2104], ["ml", 2105], ["of", 2108], ["amoxapine", 2111], ["and", 2121], ["900", 2125], ["ng", 2129], ["/", 2131], ["ml", 2132], ["of", 2135], ["nortriptyline", 2138], [";", 2151], ["the", 2153], ["toxicology", 2157], ["screen", 2168], ["for", 2175], ["the", 2179], ["other", 2183], [",", 2188], ["who", 2190], ["also", 2194], ["had", 2199], ["ventricular", 2203], ["tachycardia", 2215], [",", 2226], ["showed", 2228], ["1928", 2235], ["ng", 2240], ["/", 2242], ["ml", 2243], ["of", 2246], ["loxapine", 2249], ["and", 2258], ["301", 2262], ["ng", 2266], ["/", 2268], ["ml", 2269], ["of", 2272], ["amoxapine", 2275], [".", 2284], ["The", 2286], ["results", 2290], ["of", 2298], ["this", 2301], ["study", 2306], ["confirm", 2312], ["published", 2320], ["reports", 2330], ["of", 2338], ["the", 2341], ["efficacy", 2345], ["of", 2354], ["flumazenil", 2357], ["in", 2368], ["reversing", 2371], ["benzodiazepine", 2381], ["-", 2395], ["induced", 2396], ["sedation", 2404], ["in", 2413], ["patients", 2416], ["with", 2425], ["benzodiazepine", 2430], ["overdose", 2445], [".", 2453], ["This", 2455], ["was", 2460], ["accomplished", 2464], ["irrespective", 2477], ["of", 2490], ["the", 2493], ["presence", 2497], ["of", 2506], ["coingested", 2509], ["drugs", 2520], [".", 2525], ["Flumazenil", 2527], ["is", 2538], ["not", 2541], ["recommended", 2545], ["for", 2557], ["patients", 2561], ["with", 2570], ["serious", 2575], ["cyclic", 2583], ["antidepressant", 2590], ["poisoning", 2605], ["or", 2615], ["those", 2618], ["who", 2624], ["use", 2628], ["benzodiazepines", 2632], ["therapeutically", 2648], ["to", 2664], ["control", 2667], ["seizure", 2675], ["disorders", 2683], [".", 2692], ["When", 2694], ["used", 2699], ["as", 2704], ["recommended", 2707], [",", 2718], ["however", 2720], [",", 2727], ["flumazenil", 2729], ["has", 2740], ["been", 2744], ["shown", 2749], ["to", 2755], ["have", 2758], ["an", 2763], ["acceptable", 2766], ["safety", 2777], ["level", 2784], [".", 2789]]}
{"context": "Bazex syndrome, or acrokeratosis paraneoplastica, is a cutaneous paraneoplastic syndrome characterized by psoriasiform lesions associated with, usually, a squamous cell carcinoma of the upper aerodigestive tract. We present a case of Bazex syndrome associated with metastatic cervical squamous cell carcinoma with an unknown primary. The features of the condition are discussed in the light of current knowledge.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "13712b1db9094ec2bd023d0036495b5d", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[0, 1], [36, 37]], "char_spans": [[0, 13], [234, 247]]}]}], "context_tokens": [["Bazex", 0], ["syndrome", 6], [",", 14], ["or", 16], ["acrokeratosis", 19], ["paraneoplastica", 33], [",", 48], ["is", 50], ["a", 53], ["cutaneous", 55], ["paraneoplastic", 65], ["syndrome", 80], ["characterized", 89], ["by", 103], ["psoriasiform", 106], ["lesions", 119], ["associated", 127], ["with", 138], [",", 142], ["usually", 144], [",", 151], ["a", 153], ["squamous", 155], ["cell", 164], ["carcinoma", 169], ["of", 179], ["the", 182], ["upper", 186], ["aerodigestive", 192], ["tract", 206], [".", 211], ["We", 213], ["present", 216], ["a", 224], ["case", 226], ["of", 231], ["Bazex", 234], ["syndrome", 240], ["associated", 249], ["with", 260], ["metastatic", 265], ["cervical", 276], ["squamous", 285], ["cell", 294], ["carcinoma", 299], ["with", 309], ["an", 314], ["unknown", 317], ["primary", 325], [".", 332], ["The", 334], ["features", 338], ["of", 347], ["the", 350], ["condition", 354], ["are", 364], ["discussed", 368], ["in", 378], ["the", 381], ["light", 385], ["of", 391], ["current", 394], ["knowledge", 402], [".", 411]]}
{"context": "The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP amylose column. The columns were extensively washed with low ionic strength buffer, and bound proteins were eluted with buffer containing 1M sodium chloride. Eluted proteins were separated by denaturing sodium-dodecyl sulfate gel electrophoresis and were identified by mass spectrometry. Several previously unidentified full-length sclerostin-interacting proteins such as alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, and collagen \u03b11, which have established roles in bone formation or resorption processes, were bound to the sclerostin-MBP amylose resin but not to the MBP amylose resin. Other full-length sclerostin-interacting proteins such as casein kinase II and secreted frizzled related protein 4 that modulate Wnt signaling were identified. Several peptides derived from proteins such as Phex, asporin and follistatin that regulate bone metabolism also bound sclerostin. Sclerostin interacts with multiple proteins that alter bone formation and resorption and is likely to function by altering several biologically relevant pathways in bone.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "c769d26d6d6e49a8bccbfa8ca3020245", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[208, 209]], "char_spans": [[1238, 1252]]}]}], "context_tokens": [["The", 0], ["secreted", 4], ["glycoprotein", 13], [",", 25], ["sclerostin", 27], ["alters", 38], ["bone", 45], ["formation", 50], [".", 59], ["To", 61], ["gain", 64], ["insights", 69], ["into", 78], ["the", 83], ["mechanism", 87], ["of", 97], ["action", 100], ["of", 107], ["sclerostin", 110], [",", 120], ["we", 122], ["examined", 125], ["the", 134], ["interactions", 138], ["of", 151], ["sclerostin", 154], ["with", 165], ["bone", 170], ["proteins", 175], ["using", 184], ["a", 190], ["sclerostin", 192], ["affinity", 203], ["capture", 212], ["technique", 220], [".", 229], ["Proteins", 231], ["from", 240], ["decalcified", 245], ["rat", 257], ["bone", 261], ["were", 266], ["captured", 271], ["on", 280], ["a", 283], ["sclerostin", 285], ["-", 295], ["maltose", 296], ["binding", 304], ["protein", 312], ["(", 320], ["MBP", 321], [")", 324], ["amylose", 326], ["column", 334], [",", 340], ["or", 342], ["on", 345], ["a", 348], ["MBP", 350], ["amylose", 354], ["column", 362], [".", 368], ["The", 370], ["columns", 374], ["were", 382], ["extensively", 387], ["washed", 399], ["with", 406], ["low", 411], ["ionic", 415], ["strength", 421], ["buffer", 430], [",", 436], ["and", 438], ["bound", 442], ["proteins", 448], ["were", 457], ["eluted", 462], ["with", 469], ["buffer", 474], ["containing", 481], ["1", 492], ["M", 493], ["sodium", 495], ["chloride", 502], [".", 510], ["Eluted", 512], ["proteins", 519], ["were", 528], ["separated", 533], ["by", 543], ["denaturing", 546], ["sodium", 557], ["-", 563], ["dodecyl", 564], ["sulfate", 572], ["gel", 580], ["electrophoresis", 584], ["and", 600], ["were", 604], ["identified", 609], ["by", 620], ["mass", 623], ["spectrometry", 628], [".", 640], ["Several", 642], ["previously", 650], ["unidentified", 661], ["full", 674], ["-", 678], ["length", 679], ["sclerostin", 686], ["-", 696], ["interacting", 697], ["proteins", 709], ["such", 718], ["as", 723], ["alkaline", 726], ["phosphatase", 735], [",", 746], ["carbonic", 748], ["anhydrase", 757], [",", 766], ["gremlin-1", 768], [",", 777], ["fetuin", 779], ["A", 786], [",", 787], ["midkine", 789], [",", 796], ["annexin", 798], ["A1", 806], ["and", 809], ["A2", 813], [",", 815], ["and", 817], ["collagen", 821], ["\u03b11", 830], [",", 832], ["which", 834], ["have", 840], ["established", 845], ["roles", 857], ["in", 863], ["bone", 866], ["formation", 871], ["or", 881], ["resorption", 884], ["processes", 895], [",", 904], ["were", 906], ["bound", 911], ["to", 917], ["the", 920], ["sclerostin", 924], ["-", 934], ["MBP", 935], ["amylose", 939], ["resin", 947], ["but", 953], ["not", 957], ["to", 961], ["the", 964], ["MBP", 968], ["amylose", 972], ["resin", 980], [".", 985], ["Other", 987], ["full", 993], ["-", 997], ["length", 998], ["sclerostin", 1005], ["-", 1015], ["interacting", 1016], ["proteins", 1028], ["such", 1037], ["as", 1042], ["casein", 1045], ["kinase", 1052], ["II", 1059], ["and", 1062], ["secreted", 1066], ["frizzled", 1075], ["related", 1084], ["protein", 1092], ["4", 1100], ["that", 1102], ["modulate", 1107], ["Wnt", 1116], ["signaling", 1120], ["were", 1130], ["identified", 1135], [".", 1145], ["Several", 1147], ["peptides", 1155], ["derived", 1164], ["from", 1172], ["proteins", 1177], ["such", 1186], ["as", 1191], ["Phex", 1194], [",", 1198], ["asporin", 1200], ["and", 1208], ["follistatin", 1212], ["that", 1224], ["regulate", 1229], ["bone", 1238], ["metabolism", 1243], ["also", 1254], ["bound", 1259], ["sclerostin", 1265], [".", 1275], ["Sclerostin", 1277], ["interacts", 1288], ["with", 1298], ["multiple", 1303], ["proteins", 1312], ["that", 1321], ["alter", 1326], ["bone", 1332], ["formation", 1337], ["and", 1347], ["resorption", 1351], ["and", 1362], ["is", 1366], ["likely", 1369], ["to", 1376], ["function", 1379], ["by", 1388], ["altering", 1391], ["several", 1400], ["biologically", 1408], ["relevant", 1421], ["pathways", 1430], ["in", 1439], ["bone", 1442], [".", 1446]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare genetic condition where variable and multiple congenital anomalies including Hirschsprung's disease, intellectual disability, and prominent facial features are present. At molecular level, MWS is characterized by many different described mutations in the zinc finger E-box protein 2 (ZEB2) gene, ultimately leading to loss of gene function. This report is the first to describe the association of MWS with two different asynchronous malignant brain tumors (medulloblastoma and glioblastoma) occurring in a child.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "1d067f852f5b46409f02c83de355022e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[55, 55]], "char_spans": [[322, 325]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["genetic", 38], ["condition", 46], ["where", 56], ["variable", 62], ["and", 71], ["multiple", 75], ["congenital", 84], ["anomalies", 95], ["including", 105], ["Hirschsprung", 115], ["'s", 127], ["disease", 130], [",", 137], ["intellectual", 139], ["disability", 152], [",", 162], ["and", 164], ["prominent", 168], ["facial", 178], ["features", 185], ["are", 194], ["present", 198], [".", 205], ["At", 207], ["molecular", 210], ["level", 220], [",", 225], ["MWS", 227], ["is", 231], ["characterized", 234], ["by", 248], ["many", 251], ["different", 256], ["described", 266], ["mutations", 276], ["in", 286], ["the", 289], ["zinc", 293], ["finger", 298], ["E", 305], ["-", 306], ["box", 307], ["protein", 311], ["2", 319], ["(", 321], ["ZEB2", 322], [")", 326], ["gene", 328], [",", 332], ["ultimately", 334], ["leading", 345], ["to", 353], ["loss", 356], ["of", 361], ["gene", 364], ["function", 369], [".", 377], ["This", 379], ["report", 384], ["is", 391], ["the", 394], ["first", 398], ["to", 404], ["describe", 407], ["the", 416], ["association", 420], ["of", 432], ["MWS", 435], ["with", 439], ["two", 444], ["different", 448], ["asynchronous", 458], ["malignant", 471], ["brain", 481], ["tumors", 487], ["(", 494], ["medulloblastoma", 495], ["and", 511], ["glioblastoma", 515], [")", 527], ["occurring", 529], ["in", 539], ["a", 542], ["child", 544], [".", 549]]}
{"context": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy. Using antibodies specific for the cytosolic tail of lamp2a and others recognizing all lamp2 isoforms, we found that in rat liver lamp2a represents 25% of lamp2s in the lysosome. We show that lamp2a levels in the lysosomal membrane in rat liver and fibroblasts in culture directly correlate with rates of chaperone-mediated autophagy in a variety of physiological and pathological conditions. The concentration of other lamp2s in the lysosomal membrane show no correlation under the same conditions. Furthermore, substrate proteins bind to lamp2a but not to other lamp2s. Four positively-charged amino acids uniquely present in the cytosolic tail of lamp2a are required for the binding of substrate proteins. Lamp2a also distributes to an unique subpopulation of perinuclear lysosomes in cultured fibroblasts in response to serum withdrawal, and lamp2a, more than other lamp2s, tends to multimerize. These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "4688b81a249a4edd87b46d5ce300cfcf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[0, 0], [107, 107], [53, 53], [26, 26], [157, 157], [137, 137], [40, 40], [174, 174], [127, 127]], "char_spans": [[0, 5], [647, 652], [299, 304], [160, 165], [953, 958], [816, 821], [237, 242], [1050, 1055], [757, 762]]}]}], "context_tokens": [["Lamp2a", 0], ["acts", 7], ["as", 12], ["a", 15], ["receptor", 17], ["in", 26], ["the", 29], ["lysosomal", 33], ["membrane", 43], ["for", 52], ["substrate", 56], ["proteins", 66], ["of", 75], ["chaperone", 78], ["-", 87], ["mediated", 88], ["autophagy", 97], [".", 106], ["Using", 108], ["antibodies", 114], ["specific", 125], ["for", 134], ["the", 138], ["cytosolic", 142], ["tail", 152], ["of", 157], ["lamp2a", 160], ["and", 167], ["others", 171], ["recognizing", 178], ["all", 190], ["lamp2", 194], ["isoforms", 200], [",", 208], ["we", 210], ["found", 213], ["that", 219], ["in", 224], ["rat", 227], ["liver", 231], ["lamp2a", 237], ["represents", 244], ["25", 255], ["%", 257], ["of", 259], ["lamp2s", 262], ["in", 269], ["the", 272], ["lysosome", 276], [".", 284], ["We", 286], ["show", 289], ["that", 294], ["lamp2a", 299], ["levels", 306], ["in", 313], ["the", 316], ["lysosomal", 320], ["membrane", 330], ["in", 339], ["rat", 342], ["liver", 346], ["and", 352], ["fibroblasts", 356], ["in", 368], ["culture", 371], ["directly", 379], ["correlate", 388], ["with", 398], ["rates", 403], ["of", 409], ["chaperone", 412], ["-", 421], ["mediated", 422], ["autophagy", 431], ["in", 441], ["a", 444], ["variety", 446], ["of", 454], ["physiological", 457], ["and", 471], ["pathological", 475], ["conditions", 488], [".", 498], ["The", 500], ["concentration", 504], ["of", 518], ["other", 521], ["lamp2s", 527], ["in", 534], ["the", 537], ["lysosomal", 541], ["membrane", 551], ["show", 560], ["no", 565], ["correlation", 568], ["under", 580], ["the", 586], ["same", 590], ["conditions", 595], [".", 605], ["Furthermore", 607], [",", 618], ["substrate", 620], ["proteins", 630], ["bind", 639], ["to", 644], ["lamp2a", 647], ["but", 654], ["not", 658], ["to", 662], ["other", 665], ["lamp2s", 671], [".", 677], ["Four", 679], ["positively", 684], ["-", 694], ["charged", 695], ["amino", 703], ["acids", 709], ["uniquely", 715], ["present", 724], ["in", 732], ["the", 735], ["cytosolic", 739], ["tail", 749], ["of", 754], ["lamp2a", 757], ["are", 764], ["required", 768], ["for", 777], ["the", 781], ["binding", 785], ["of", 793], ["substrate", 796], ["proteins", 806], [".", 814], ["Lamp2a", 816], ["also", 823], ["distributes", 828], ["to", 840], ["an", 843], ["unique", 846], ["subpopulation", 853], ["of", 867], ["perinuclear", 870], ["lysosomes", 882], ["in", 892], ["cultured", 895], ["fibroblasts", 904], ["in", 916], ["response", 919], ["to", 928], ["serum", 931], ["withdrawal", 937], [",", 947], ["and", 949], ["lamp2a", 953], [",", 959], ["more", 961], ["than", 966], ["other", 971], ["lamp2s", 977], [",", 983], ["tends", 985], ["to", 991], ["multimerize", 994], [".", 1005], ["These", 1007], ["characteristics", 1013], ["may", 1029], ["be", 1033], ["important", 1036], ["for", 1046], ["lamp2a", 1050], ["to", 1057], ["act", 1060], ["as", 1064], ["a", 1067], ["receptor", 1069], ["for", 1078], ["chaperone", 1082], ["-", 1091], ["mediated", 1092], ["autophagy", 1101], [".", 1110]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "The vacuolar H(+)-ATPase (V-ATPase) along with ion channels and transporters maintains vacuolar pH. V-ATPase ATP hydrolysis is coupled with proton transport and establishes an electrochemical gradient between the cytosol and vacuolar lumen for coupled transport of metabolites. Btn1p, the yeast homolog to human CLN3 that is defective in Batten disease, localizes to the vacuole. We previously reported that Btn1p is required for vacuolar pH maintenance and ATP-dependent vacuolar arginine transport. We report that extracellular pH alters both V-ATPase activity and proton transport into the vacuole of wild-type Saccharomyces cerevisiae. V-ATPase activity is modulated through the assembly and disassembly of the V(0) and V(1) V-ATPase subunits located in the vacuolar membrane and on the cytosolic side of the vacuolar membrane, respectively. V-ATPase assembly is increased in yeast cells grown in high extracellular pH. In addition, at elevated extracellular pH, S. cerevisiae lacking BTN1 (btn1-Delta), have decreased V-ATPase activity while proton transport into the vacuole remains similar to that for wild type. Thus, coupling of V-ATPase activity and proton transport in btn1-Delta is altered. We show that down-regulation of V-ATPase activity compensates the vacuolar pH imbalance for btn1-Delta at early growth phases. We therefore propose that Btn1p is required for tight regulation of vacuolar pH to maintain the vacuolar luminal content and optimal activity of this organelle and that disruption in Btn1p function leads to a modulation of V-ATPase activity to maintain cellular pH homeostasis and vacuolar luminal content.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "bb74435049ca4f75a40f7eeaf2c5dd00", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[56, 57]], "char_spans": [[338, 351]]}]}], "context_tokens": [["The", 0], ["vacuolar", 4], ["H(+)-ATPase", 13], ["(", 25], ["V", 26], ["-", 27], ["ATPase", 28], [")", 34], ["along", 36], ["with", 42], ["ion", 47], ["channels", 51], ["and", 60], ["transporters", 64], ["maintains", 77], ["vacuolar", 87], ["pH.", 96], ["V", 100], ["-", 101], ["ATPase", 102], ["ATP", 109], ["hydrolysis", 113], ["is", 124], ["coupled", 127], ["with", 135], ["proton", 140], ["transport", 147], ["and", 157], ["establishes", 161], ["an", 173], ["electrochemical", 176], ["gradient", 192], ["between", 201], ["the", 209], ["cytosol", 213], ["and", 221], ["vacuolar", 225], ["lumen", 234], ["for", 240], ["coupled", 244], ["transport", 252], ["of", 262], ["metabolites", 265], [".", 276], ["Btn1p", 278], [",", 283], ["the", 285], ["yeast", 289], ["homolog", 295], ["to", 303], ["human", 306], ["CLN3", 312], ["that", 317], ["is", 322], ["defective", 325], ["in", 335], ["Batten", 338], ["disease", 345], [",", 352], ["localizes", 354], ["to", 364], ["the", 367], ["vacuole", 371], [".", 378], ["We", 380], ["previously", 383], ["reported", 394], ["that", 403], ["Btn1p", 408], ["is", 414], ["required", 417], ["for", 426], ["vacuolar", 430], ["pH", 439], ["maintenance", 442], ["and", 454], ["ATP", 458], ["-", 461], ["dependent", 462], ["vacuolar", 472], ["arginine", 481], ["transport", 490], [".", 499], ["We", 501], ["report", 504], ["that", 511], ["extracellular", 516], ["pH", 530], ["alters", 533], ["both", 540], ["V", 545], ["-", 546], ["ATPase", 547], ["activity", 554], ["and", 563], ["proton", 567], ["transport", 574], ["into", 584], ["the", 589], ["vacuole", 593], ["of", 601], ["wild", 604], ["-", 608], ["type", 609], ["Saccharomyces", 614], ["cerevisiae", 628], [".", 638], ["V", 640], ["-", 641], ["ATPase", 642], ["activity", 649], ["is", 658], ["modulated", 661], ["through", 671], ["the", 679], ["assembly", 683], ["and", 692], ["disassembly", 696], ["of", 708], ["the", 711], ["V(0", 715], [")", 718], ["and", 720], ["V(1", 724], [")", 727], ["V", 729], ["-", 730], ["ATPase", 731], ["subunits", 738], ["located", 747], ["in", 755], ["the", 758], ["vacuolar", 762], ["membrane", 771], ["and", 780], ["on", 784], ["the", 787], ["cytosolic", 791], ["side", 801], ["of", 806], ["the", 809], ["vacuolar", 813], ["membrane", 822], [",", 830], ["respectively", 832], [".", 844], ["V", 846], ["-", 847], ["ATPase", 848], ["assembly", 855], ["is", 864], ["increased", 867], ["in", 877], ["yeast", 880], ["cells", 886], ["grown", 892], ["in", 898], ["high", 901], ["extracellular", 906], ["pH.", 920], ["In", 924], ["addition", 927], [",", 935], ["at", 937], ["elevated", 940], ["extracellular", 949], ["pH", 963], [",", 965], ["S.", 967], ["cerevisiae", 970], ["lacking", 981], ["BTN1", 989], ["(", 994], ["btn1-Delta", 995], [")", 1005], [",", 1006], ["have", 1008], ["decreased", 1013], ["V", 1023], ["-", 1024], ["ATPase", 1025], ["activity", 1032], ["while", 1041], ["proton", 1047], ["transport", 1054], ["into", 1064], ["the", 1069], ["vacuole", 1073], ["remains", 1081], ["similar", 1089], ["to", 1097], ["that", 1100], ["for", 1105], ["wild", 1109], ["type", 1114], [".", 1118], ["Thus", 1120], [",", 1124], ["coupling", 1126], ["of", 1135], ["V", 1138], ["-", 1139], ["ATPase", 1140], ["activity", 1147], ["and", 1156], ["proton", 1160], ["transport", 1167], ["in", 1177], ["btn1-Delta", 1180], ["is", 1191], ["altered", 1194], [".", 1201], ["We", 1203], ["show", 1206], ["that", 1211], ["down", 1216], ["-", 1220], ["regulation", 1221], ["of", 1232], ["V", 1235], ["-", 1236], ["ATPase", 1237], ["activity", 1244], ["compensates", 1253], ["the", 1265], ["vacuolar", 1269], ["pH", 1278], ["imbalance", 1281], ["for", 1291], ["btn1-Delta", 1295], ["at", 1306], ["early", 1309], ["growth", 1315], ["phases", 1322], [".", 1328], ["We", 1330], ["therefore", 1333], ["propose", 1343], ["that", 1351], ["Btn1p", 1356], ["is", 1362], ["required", 1365], ["for", 1374], ["tight", 1378], ["regulation", 1384], ["of", 1395], ["vacuolar", 1398], ["pH", 1407], ["to", 1410], ["maintain", 1413], ["the", 1422], ["vacuolar", 1426], ["luminal", 1435], ["content", 1443], ["and", 1451], ["optimal", 1455], ["activity", 1463], ["of", 1472], ["this", 1475], ["organelle", 1480], ["and", 1490], ["that", 1494], ["disruption", 1499], ["in", 1510], ["Btn1p", 1513], ["function", 1519], ["leads", 1528], ["to", 1534], ["a", 1537], ["modulation", 1539], ["of", 1550], ["V", 1553], ["-", 1554], ["ATPase", 1555], ["activity", 1562], ["to", 1571], ["maintain", 1574], ["cellular", 1583], ["pH", 1592], ["homeostasis", 1595], ["and", 1607], ["vacuolar", 1611], ["luminal", 1620], ["content", 1628], [".", 1635]]}
{"context": "Theories for restless legs syndrome (RLS) pathogenesis include iron deficiency, dopamine dysregulation and peripheral neuropathy. Increased prevalence of small intestinal bacterial overgrowth (SIBO) in controlled studies in RLS and case reports of post-infectious RLS suggest potential roles for inflammation and immunological alterations. A literature search for all conditions associated with RLS was performed. These included secondary RLS disorders and factors that may exacerbate RLS. All of these conditions were reviewed with respect to potential pathogenesis including reports of iron deficiency, neuropathy, SIBO, inflammation and immune changes. A condition was defined as highly-associated if there was a prevalence study that utilized an appropriate control group. Small case reports were recorded but not included as definite RLS-associated conditions. Fifty four diseases, syndromes and conditions have been reported to cause and/or exacerbate RLS. Of these, 38 have been reported to have a higher prevalence than age-matched controls, 9 have adequate sized reports and have general acceptance as RLS-associated conditions and 7 have been reported in case report form. Overall, 42 of the 47 RLS-associated conditions (89%) have also been associated with inflammatory and/or immune changes. In addition, 43% have been associated with peripheral iron deficiency, 40% with peripheral neuropathy and 32% with SIBO. Most of the remaining conditions have yet to be studied for these factors. The fact that 95% of the 38 highly-associated RLS conditions are also associated with inflammatory/immune changes suggests the possibility that RLS may be mediated or affected through these mechanisms. Inflammation can be responsible for iron deficiency and hypothetically could cause central nervous system iron deficiency-induced RLS. Alternatively, an immune reaction to gastrointestinal bacteria or other antigens may hypothetically cause RLS by a direct immunological attack on the central or peripheral nervous system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cf13cc1b9e0a4705a20d0630e0acbe2a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[229, 229], [10, 10], [297, 297], [89, 89], [306, 306]], "char_spans": [[1358, 1361], [63, 66], [1738, 1741], [588, 591], [1808, 1811]]}]}], "context_tokens": [["Theories", 0], ["for", 9], ["restless", 13], ["legs", 22], ["syndrome", 27], ["(", 36], ["RLS", 37], [")", 40], ["pathogenesis", 42], ["include", 55], ["iron", 63], ["deficiency", 68], [",", 78], ["dopamine", 80], ["dysregulation", 89], ["and", 103], ["peripheral", 107], ["neuropathy", 118], [".", 128], ["Increased", 130], ["prevalence", 140], ["of", 151], ["small", 154], ["intestinal", 160], ["bacterial", 171], ["overgrowth", 181], ["(", 192], ["SIBO", 193], [")", 197], ["in", 199], ["controlled", 202], ["studies", 213], ["in", 221], ["RLS", 224], ["and", 228], ["case", 232], ["reports", 237], ["of", 245], ["post", 248], ["-", 252], ["infectious", 253], ["RLS", 264], ["suggest", 268], ["potential", 276], ["roles", 286], ["for", 292], ["inflammation", 296], ["and", 309], ["immunological", 313], ["alterations", 327], [".", 338], ["A", 340], ["literature", 342], ["search", 353], ["for", 360], ["all", 364], ["conditions", 368], ["associated", 379], ["with", 390], ["RLS", 395], ["was", 399], ["performed", 403], [".", 412], ["These", 414], ["included", 420], ["secondary", 429], ["RLS", 439], ["disorders", 443], ["and", 453], ["factors", 457], ["that", 465], ["may", 470], ["exacerbate", 474], ["RLS", 485], [".", 488], ["All", 490], ["of", 494], ["these", 497], ["conditions", 503], ["were", 514], ["reviewed", 519], ["with", 528], ["respect", 533], ["to", 541], ["potential", 544], ["pathogenesis", 554], ["including", 567], ["reports", 577], ["of", 585], ["iron", 588], ["deficiency", 593], [",", 603], ["neuropathy", 605], [",", 615], ["SIBO", 617], [",", 621], ["inflammation", 623], ["and", 636], ["immune", 640], ["changes", 647], [".", 654], ["A", 656], ["condition", 658], ["was", 668], ["defined", 672], ["as", 680], ["highly", 683], ["-", 689], ["associated", 690], ["if", 701], ["there", 704], ["was", 710], ["a", 714], ["prevalence", 716], ["study", 727], ["that", 733], ["utilized", 738], ["an", 747], ["appropriate", 750], ["control", 762], ["group", 770], [".", 775], ["Small", 777], ["case", 783], ["reports", 788], ["were", 796], ["recorded", 801], ["but", 810], ["not", 814], ["included", 818], ["as", 827], ["definite", 830], ["RLS", 839], ["-", 842], ["associated", 843], ["conditions", 854], [".", 864], ["Fifty", 866], ["four", 872], ["diseases", 877], [",", 885], ["syndromes", 887], ["and", 897], ["conditions", 901], ["have", 912], ["been", 917], ["reported", 922], ["to", 931], ["cause", 934], ["and/or", 940], ["exacerbate", 947], ["RLS", 958], [".", 961], ["Of", 963], ["these", 966], [",", 971], ["38", 973], ["have", 976], ["been", 981], ["reported", 986], ["to", 995], ["have", 998], ["a", 1003], ["higher", 1005], ["prevalence", 1012], ["than", 1023], ["age", 1028], ["-", 1031], ["matched", 1032], ["controls", 1040], [",", 1048], ["9", 1050], ["have", 1052], ["adequate", 1057], ["sized", 1066], ["reports", 1072], ["and", 1080], ["have", 1084], ["general", 1089], ["acceptance", 1097], ["as", 1108], ["RLS", 1111], ["-", 1114], ["associated", 1115], ["conditions", 1126], ["and", 1137], ["7", 1141], ["have", 1143], ["been", 1148], ["reported", 1153], ["in", 1162], ["case", 1165], ["report", 1170], ["form", 1177], [".", 1181], ["Overall", 1183], [",", 1190], ["42", 1192], ["of", 1195], ["the", 1198], ["47", 1202], ["RLS", 1205], ["-", 1208], ["associated", 1209], ["conditions", 1220], ["(", 1231], ["89", 1232], ["%", 1234], [")", 1235], ["have", 1237], ["also", 1242], ["been", 1247], ["associated", 1252], ["with", 1263], ["inflammatory", 1268], ["and/or", 1281], ["immune", 1288], ["changes", 1295], [".", 1302], ["In", 1304], ["addition", 1307], [",", 1315], ["43", 1317], ["%", 1319], ["have", 1321], ["been", 1326], ["associated", 1331], ["with", 1342], ["peripheral", 1347], ["iron", 1358], ["deficiency", 1363], [",", 1373], ["40", 1375], ["%", 1377], ["with", 1379], ["peripheral", 1384], ["neuropathy", 1395], ["and", 1406], ["32", 1410], ["%", 1412], ["with", 1414], ["SIBO", 1419], [".", 1423], ["Most", 1425], ["of", 1430], ["the", 1433], ["remaining", 1437], ["conditions", 1447], ["have", 1458], ["yet", 1463], ["to", 1467], ["be", 1470], ["studied", 1473], ["for", 1481], ["these", 1485], ["factors", 1491], [".", 1498], ["The", 1500], ["fact", 1504], ["that", 1509], ["95", 1514], ["%", 1516], ["of", 1518], ["the", 1521], ["38", 1525], ["highly", 1528], ["-", 1534], ["associated", 1535], ["RLS", 1546], ["conditions", 1550], ["are", 1561], ["also", 1565], ["associated", 1570], ["with", 1581], ["inflammatory", 1586], ["/", 1598], ["immune", 1599], ["changes", 1606], ["suggests", 1614], ["the", 1623], ["possibility", 1627], ["that", 1639], ["RLS", 1644], ["may", 1648], ["be", 1652], ["mediated", 1655], ["or", 1664], ["affected", 1667], ["through", 1676], ["these", 1684], ["mechanisms", 1690], [".", 1700], ["Inflammation", 1702], ["can", 1715], ["be", 1719], ["responsible", 1722], ["for", 1734], ["iron", 1738], ["deficiency", 1743], ["and", 1754], ["hypothetically", 1758], ["could", 1773], ["cause", 1779], ["central", 1785], ["nervous", 1793], ["system", 1801], ["iron", 1808], ["deficiency", 1813], ["-", 1823], ["induced", 1824], ["RLS", 1832], [".", 1835], ["Alternatively", 1837], [",", 1850], ["an", 1852], ["immune", 1855], ["reaction", 1862], ["to", 1871], ["gastrointestinal", 1874], ["bacteria", 1891], ["or", 1900], ["other", 1903], ["antigens", 1909], ["may", 1918], ["hypothetically", 1922], ["cause", 1937], ["RLS", 1943], ["by", 1947], ["a", 1950], ["direct", 1952], ["immunological", 1959], ["attack", 1973], ["on", 1980], ["the", 1983], ["central", 1987], ["or", 1995], ["peripheral", 1998], ["nervous", 2009], ["system", 2017], [".", 2023]]}
{"context": "The spleen tyrosine kinase (Syk) inhibitor R406 is orally administered as the prodrug R788. Following administration of R788 (12.5 mg kg(-1), 20 microCi kg(-1 14)C-R788) to intact and bile duct-cannulated cynomolgus monkeys, drug-related radioactivity was rapidly observed in plasma. No R788 was observed in plasma, while R406 was the major radioactive peak observed at all time points. Only low levels of metabolites were observed in plasma. The half-life for plasma radioactivity was 2.0-2.8 h. The majority (68.9%) of drug-related radioactivity was eliminated into bile. No intact R406 was observed in excreta. Biliary and urinary metabolites consisted of glucuronide and sulfate conjugates of the para-O-demethylated metabolite of R406 (R529), and a direct N-glucuronide of R406. The major metabolite in faeces from intact and bile duct-cannulated monkeys was a unique 3,5-benzene diol metabolite of R406. This metabolite was formed following the sequential O-demethylation and para-dehydroxylation of R529 by anaerobic gut bacteria.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "ea2c422448e642a6989d21e8c090f77a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[1, 3]], "char_spans": [[4, 25]]}]}], "context_tokens": [["The", 0], ["spleen", 4], ["tyrosine", 11], ["kinase", 20], ["(", 27], ["Syk", 28], [")", 31], ["inhibitor", 33], ["R406", 43], ["is", 48], ["orally", 51], ["administered", 58], ["as", 71], ["the", 74], ["prodrug", 78], ["R788", 86], [".", 90], ["Following", 92], ["administration", 102], ["of", 117], ["R788", 120], ["(", 125], ["12.5", 126], ["mg", 131], ["kg(-1", 134], [")", 139], [",", 140], ["20", 142], ["microCi", 145], ["kg(-1", 153], ["14)C", 159], ["-", 163], ["R788", 164], [")", 168], ["to", 170], ["intact", 173], ["and", 180], ["bile", 184], ["duct", 189], ["-", 193], ["cannulated", 194], ["cynomolgus", 205], ["monkeys", 216], [",", 223], ["drug", 225], ["-", 229], ["related", 230], ["radioactivity", 238], ["was", 252], ["rapidly", 256], ["observed", 264], ["in", 273], ["plasma", 276], [".", 282], ["No", 284], ["R788", 287], ["was", 292], ["observed", 296], ["in", 305], ["plasma", 308], [",", 314], ["while", 316], ["R406", 322], ["was", 327], ["the", 331], ["major", 335], ["radioactive", 341], ["peak", 353], ["observed", 358], ["at", 367], ["all", 370], ["time", 374], ["points", 379], [".", 385], ["Only", 387], ["low", 392], ["levels", 396], ["of", 403], ["metabolites", 406], ["were", 418], ["observed", 423], ["in", 432], ["plasma", 435], [".", 441], ["The", 443], ["half", 447], ["-", 451], ["life", 452], ["for", 457], ["plasma", 461], ["radioactivity", 468], ["was", 482], ["2.0", 486], ["-", 489], ["2.8", 490], ["h.", 494], ["The", 497], ["majority", 501], ["(", 510], ["68.9", 511], ["%", 515], [")", 516], ["of", 518], ["drug", 521], ["-", 525], ["related", 526], ["radioactivity", 534], ["was", 548], ["eliminated", 552], ["into", 563], ["bile", 568], [".", 572], ["No", 574], ["intact", 577], ["R406", 584], ["was", 589], ["observed", 593], ["in", 602], ["excreta", 605], [".", 612], ["Biliary", 614], ["and", 622], ["urinary", 626], ["metabolites", 634], ["consisted", 646], ["of", 656], ["glucuronide", 659], ["and", 671], ["sulfate", 675], ["conjugates", 683], ["of", 694], ["the", 697], ["para", 701], ["-", 705], ["O", 706], ["-", 707], ["demethylated", 708], ["metabolite", 721], ["of", 732], ["R406", 735], ["(", 740], ["R529", 741], [")", 745], [",", 746], ["and", 748], ["a", 752], ["direct", 754], ["N", 761], ["-", 762], ["glucuronide", 763], ["of", 775], ["R406", 778], [".", 782], ["The", 784], ["major", 788], ["metabolite", 794], ["in", 805], ["faeces", 808], ["from", 815], ["intact", 820], ["and", 827], ["bile", 831], ["duct", 836], ["-", 840], ["cannulated", 841], ["monkeys", 852], ["was", 860], ["a", 864], ["unique", 866], ["3,5-benzene", 873], ["diol", 885], ["metabolite", 890], ["of", 901], ["R406", 904], [".", 908], ["This", 910], ["metabolite", 915], ["was", 926], ["formed", 930], ["following", 937], ["the", 947], ["sequential", 951], ["O", 962], ["-", 963], ["demethylation", 964], ["and", 978], ["para", 982], ["-", 986], ["dehydroxylation", 987], ["of", 1003], ["R529", 1006], ["by", 1011], ["anaerobic", 1014], ["gut", 1024], ["bacteria", 1028], [".", 1036]]}
{"context": "Turner's syndrome is defined as a congenital disease determining by quantitative and/or structural aberrations of one from two X chromosomes with frequent presence of mosaicism. Clinically it is characterized by growth and body proportion abnormalities, gonadal dysgenesis resulting in sexual infantilism, primary amenorrhoea, infertility, characteristic stigmata, anomalies of heart, renal and bones and the presence of some diseases like Hashimoto thyroiditis with hypothyroidism, diabetes mellitus type 2, osteoporosis, hypertension. Turner's syndrome occurs in 1:2000 to 1:2500 female livebirth. The most frequent X chromosome aberrations in patients with phenotype of Turner syndrome are as follows: X monosomy - 45,X; mosaicism (50-75%), including 45,X/46,XX (10-15%), 45,X/46,XY (2-6%), 45,X/46,X,i(Xq), 45,X/46,X,del(Xp), 45,X/46,XX/47,XXX; aberration of X structure: total or partial deletion of short arm of X chromosome (46,X,del(Xp)) isochromosom of long arm of X chromosome (46,X,(i(Xq)), ring chromosome (46, X,r(X)), marker chromosome (46,X+m). Searching of X chromosome and mapping and sequencing of genes located at this chromosome (such as SHOX, ODG2, VSPA, SOX 3) have made possible to look for linkage between phenotypes and adequate genes or regions of X chromosome. In this paper current data concerning correlation between phenotype and karyotype in patients with TS have been presented.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f06f14b35c864f9093f9fae1b78fcd15", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[109, 109], [19, 19], [177, 177], [189, 189], [203, 203], [164, 164], [153, 153], [242, 242], [95, 95]], "char_spans": [[705, 705], [127, 127], [974, 974], [1023, 1023], [1073, 1073], [918, 918], [863, 863], [1274, 1274], [618, 618]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["is", 18], ["defined", 21], ["as", 29], ["a", 32], ["congenital", 34], ["disease", 45], ["determining", 53], ["by", 65], ["quantitative", 68], ["and/or", 81], ["structural", 88], ["aberrations", 99], ["of", 111], ["one", 114], ["from", 118], ["two", 123], ["X", 127], ["chromosomes", 129], ["with", 141], ["frequent", 146], ["presence", 155], ["of", 164], ["mosaicism", 167], [".", 176], ["Clinically", 178], ["it", 189], ["is", 192], ["characterized", 195], ["by", 209], ["growth", 212], ["and", 219], ["body", 223], ["proportion", 228], ["abnormalities", 239], [",", 252], ["gonadal", 254], ["dysgenesis", 262], ["resulting", 273], ["in", 283], ["sexual", 286], ["infantilism", 293], [",", 304], ["primary", 306], ["amenorrhoea", 314], [",", 325], ["infertility", 327], [",", 338], ["characteristic", 340], ["stigmata", 355], [",", 363], ["anomalies", 365], ["of", 375], ["heart", 378], [",", 383], ["renal", 385], ["and", 391], ["bones", 395], ["and", 401], ["the", 405], ["presence", 409], ["of", 418], ["some", 421], ["diseases", 426], ["like", 435], ["Hashimoto", 440], ["thyroiditis", 450], ["with", 462], ["hypothyroidism", 467], [",", 481], ["diabetes", 483], ["mellitus", 492], ["type", 501], ["2", 506], [",", 507], ["osteoporosis", 509], [",", 521], ["hypertension", 523], [".", 535], ["Turner", 537], ["'s", 543], ["syndrome", 546], ["occurs", 555], ["in", 562], ["1:2000", 565], ["to", 572], ["1:2500", 575], ["female", 582], ["livebirth", 589], [".", 598], ["The", 600], ["most", 604], ["frequent", 609], ["X", 618], ["chromosome", 620], ["aberrations", 631], ["in", 643], ["patients", 646], ["with", 655], ["phenotype", 660], ["of", 670], ["Turner", 673], ["syndrome", 680], ["are", 689], ["as", 693], ["follows", 696], [":", 703], ["X", 705], ["monosomy", 707], ["-", 716], ["45,X", 718], [";", 722], ["mosaicism", 724], ["(", 734], ["50", 735], ["-", 737], ["75", 738], ["%", 740], [")", 741], [",", 742], ["including", 744], ["45,X/46,XX", 754], ["(", 765], ["10", 766], ["-", 768], ["15", 769], ["%", 771], [")", 772], [",", 773], ["45,X/46,XY", 775], ["(", 786], ["2", 787], ["-", 788], ["6", 789], ["%", 790], [")", 791], [",", 792], ["45,X/46,X", 794], [",", 803], ["i(Xq", 804], [")", 808], [",", 809], ["45,X/46,X", 811], [",", 820], ["del(Xp", 821], [")", 827], [",", 828], ["45,X/46,XX/47,XXX", 830], [";", 847], ["aberration", 849], ["of", 860], ["X", 863], ["structure", 865], [":", 874], ["total", 876], ["or", 882], ["partial", 885], ["deletion", 893], ["of", 902], ["short", 905], ["arm", 911], ["of", 915], ["X", 918], ["chromosome", 920], ["(", 931], ["46,X", 932], [",", 936], ["del(Xp", 937], [")", 943], [")", 944], ["isochromosom", 946], ["of", 959], ["long", 962], ["arm", 967], ["of", 971], ["X", 974], ["chromosome", 976], ["(", 987], ["46,X,(i(Xq", 988], [")", 998], [")", 999], [",", 1000], ["ring", 1002], ["chromosome", 1007], ["(", 1018], ["46", 1019], [",", 1021], ["X", 1023], [",", 1024], ["r(X", 1025], [")", 1028], [")", 1029], [",", 1030], ["marker", 1032], ["chromosome", 1039], ["(", 1050], ["46,X+m", 1051], [")", 1057], [".", 1058], ["Searching", 1060], ["of", 1070], ["X", 1073], ["chromosome", 1075], ["and", 1086], ["mapping", 1090], ["and", 1098], ["sequencing", 1102], ["of", 1113], ["genes", 1116], ["located", 1122], ["at", 1130], ["this", 1133], ["chromosome", 1138], ["(", 1149], ["such", 1150], ["as", 1155], ["SHOX", 1158], [",", 1162], ["ODG2", 1164], [",", 1168], ["VSPA", 1170], [",", 1174], ["SOX", 1176], ["3", 1180], [")", 1181], ["have", 1183], ["made", 1188], ["possible", 1193], ["to", 1202], ["look", 1205], ["for", 1210], ["linkage", 1214], ["between", 1222], ["phenotypes", 1230], ["and", 1241], ["adequate", 1245], ["genes", 1254], ["or", 1260], ["regions", 1263], ["of", 1271], ["X", 1274], ["chromosome", 1276], [".", 1286], ["In", 1288], ["this", 1291], ["paper", 1296], ["current", 1302], ["data", 1310], ["concerning", 1315], ["correlation", 1326], ["between", 1338], ["phenotype", 1346], ["and", 1356], ["karyotype", 1360], ["in", 1370], ["patients", 1373], ["with", 1382], ["TS", 1387], ["have", 1390], ["been", 1395], ["presented", 1400], [".", 1409]]}
{"context": "The present case-control study was conducted to investigate the relationship between smoking and rheumatoid arthritis, and to investigate formally the interaction between sex, smoking, and risk for developing rheumatoid arthritis. The study was performed in the Central District of Finland. Cases were patients with rheumatoid arthritis and the control group was a random sample of the general population. Logistic regression models were used to evaluate the effect of smoking on risk for rheumatoid arthritis, after adjusting for the effects of age, education, body mass index, and indices of general health and pain. Overall, 1095 patients with rheumatoid arthritis and 1530 control individuals were included. Patients were older, less well educated, more disabled, and had poorer levels of general health as compared with control individuals (all P < 0.01). Preliminary analyses revealed the presence of substantial statistical interaction between smoking and sex (P < 0.001). In separate multivariable analyses, past history of smoking was associated with increased risk for rheumatoid arthritis overall in men (odds ratio 2.0, 95% confidence interval 1.2-3.2) but not in women. Among men, this effect was seen only for rheumatoid factor-positive rheumatoid arthritis. There were significant interactions between smoking and age among women but not among men. We conclude that sex is a biologic effect modifier in the association between smoking and rheumatoid arthritis. The role of menopause in the etiology of rheumatoid arthritis merits further research.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "69fcba3609b5468a8fd5f00111a3756d", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[204, 204], [231, 231]], "char_spans": [[1176, 1180], [1339, 1343]]}]}], "context_tokens": [["The", 0], ["present", 4], ["case", 12], ["-", 16], ["control", 17], ["study", 25], ["was", 31], ["conducted", 35], ["to", 45], ["investigate", 48], ["the", 60], ["relationship", 64], ["between", 77], ["smoking", 85], ["and", 93], ["rheumatoid", 97], ["arthritis", 108], [",", 117], ["and", 119], ["to", 123], ["investigate", 126], ["formally", 138], ["the", 147], ["interaction", 151], ["between", 163], ["sex", 171], [",", 174], ["smoking", 176], [",", 183], ["and", 185], ["risk", 189], ["for", 194], ["developing", 198], ["rheumatoid", 209], ["arthritis", 220], [".", 229], ["The", 231], ["study", 235], ["was", 241], ["performed", 245], ["in", 255], ["the", 258], ["Central", 262], ["District", 270], ["of", 279], ["Finland", 282], [".", 289], ["Cases", 291], ["were", 297], ["patients", 302], ["with", 311], ["rheumatoid", 316], ["arthritis", 327], ["and", 337], ["the", 341], ["control", 345], ["group", 353], ["was", 359], ["a", 363], ["random", 365], ["sample", 372], ["of", 379], ["the", 382], ["general", 386], ["population", 394], [".", 404], ["Logistic", 406], ["regression", 415], ["models", 426], ["were", 433], ["used", 438], ["to", 443], ["evaluate", 446], ["the", 455], ["effect", 459], ["of", 466], ["smoking", 469], ["on", 477], ["risk", 480], ["for", 485], ["rheumatoid", 489], ["arthritis", 500], [",", 509], ["after", 511], ["adjusting", 517], ["for", 527], ["the", 531], ["effects", 535], ["of", 543], ["age", 546], [",", 549], ["education", 551], [",", 560], ["body", 562], ["mass", 567], ["index", 572], [",", 577], ["and", 579], ["indices", 583], ["of", 591], ["general", 594], ["health", 602], ["and", 609], ["pain", 613], [".", 617], ["Overall", 619], [",", 626], ["1095", 628], ["patients", 633], ["with", 642], ["rheumatoid", 647], ["arthritis", 658], ["and", 668], ["1530", 672], ["control", 677], ["individuals", 685], ["were", 697], ["included", 702], [".", 710], ["Patients", 712], ["were", 721], ["older", 726], [",", 731], ["less", 733], ["well", 738], ["educated", 743], [",", 751], ["more", 753], ["disabled", 758], [",", 766], ["and", 768], ["had", 772], ["poorer", 776], ["levels", 783], ["of", 790], ["general", 793], ["health", 801], ["as", 808], ["compared", 811], ["with", 820], ["control", 825], ["individuals", 833], ["(", 845], ["all", 846], ["P", 850], ["<", 852], ["0.01", 854], [")", 858], [".", 859], ["Preliminary", 861], ["analyses", 873], ["revealed", 882], ["the", 891], ["presence", 895], ["of", 904], ["substantial", 907], ["statistical", 919], ["interaction", 931], ["between", 943], ["smoking", 951], ["and", 959], ["sex", 963], ["(", 967], ["P", 968], ["<", 970], ["0.001", 972], [")", 977], [".", 978], ["In", 980], ["separate", 983], ["multivariable", 992], ["analyses", 1006], [",", 1014], ["past", 1016], ["history", 1021], ["of", 1029], ["smoking", 1032], ["was", 1040], ["associated", 1044], ["with", 1055], ["increased", 1060], ["risk", 1070], ["for", 1075], ["rheumatoid", 1079], ["arthritis", 1090], ["overall", 1100], ["in", 1108], ["men", 1111], ["(", 1115], ["odds", 1116], ["ratio", 1121], ["2.0", 1127], [",", 1130], ["95", 1132], ["%", 1134], ["confidence", 1136], ["interval", 1147], ["1.2", 1156], ["-", 1159], ["3.2", 1160], [")", 1163], ["but", 1165], ["not", 1169], ["in", 1173], ["women", 1176], [".", 1181], ["Among", 1183], ["men", 1189], [",", 1192], ["this", 1194], ["effect", 1199], ["was", 1206], ["seen", 1210], ["only", 1215], ["for", 1220], ["rheumatoid", 1224], ["factor", 1235], ["-", 1241], ["positive", 1242], ["rheumatoid", 1251], ["arthritis", 1262], [".", 1271], ["There", 1273], ["were", 1279], ["significant", 1284], ["interactions", 1296], ["between", 1309], ["smoking", 1317], ["and", 1325], ["age", 1329], ["among", 1333], ["women", 1339], ["but", 1345], ["not", 1349], ["among", 1353], ["men", 1359], [".", 1362], ["We", 1364], ["conclude", 1367], ["that", 1376], ["sex", 1381], ["is", 1385], ["a", 1388], ["biologic", 1390], ["effect", 1399], ["modifier", 1406], ["in", 1415], ["the", 1418], ["association", 1422], ["between", 1434], ["smoking", 1442], ["and", 1450], ["rheumatoid", 1454], ["arthritis", 1465], [".", 1474], ["The", 1476], ["role", 1480], ["of", 1485], ["menopause", 1488], ["in", 1498], ["the", 1501], ["etiology", 1505], ["of", 1514], ["rheumatoid", 1517], ["arthritis", 1528], ["merits", 1538], ["further", 1545], ["research", 1553], [".", 1561]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective form of autophagy whose distinctive feature is the fact that substrate proteins are translocated directly from the cytosol across the lysosomal membrane for degradation inside lysosomes. CMA substrates are cytosolic proteins bearing a pentapeptide motif in their sequence that, when recognized by the cytosolic chaperone HSPA8/HSC70, targets them to the surface of the lysosomes. Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. CMA is constitutively active in most cells but it is maximally activated under conditions of stress.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "00514408a6c643d68ffbd2cf86d20e0e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[86, 86]], "char_spans": [[528, 533]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["form", 50], ["of", 55], ["autophagy", 58], ["whose", 68], ["distinctive", 74], ["feature", 86], ["is", 94], ["the", 97], ["fact", 101], ["that", 106], ["substrate", 111], ["proteins", 121], ["are", 130], ["translocated", 134], ["directly", 147], ["from", 156], ["the", 161], ["cytosol", 165], ["across", 173], ["the", 180], ["lysosomal", 184], ["membrane", 194], ["for", 203], ["degradation", 207], ["inside", 219], ["lysosomes", 226], [".", 235], ["CMA", 237], ["substrates", 241], ["are", 252], ["cytosolic", 256], ["proteins", 266], ["bearing", 275], ["a", 283], ["pentapeptide", 285], ["motif", 298], ["in", 304], ["their", 307], ["sequence", 313], ["that", 322], [",", 326], ["when", 328], ["recognized", 333], ["by", 344], ["the", 347], ["cytosolic", 351], ["chaperone", 361], ["HSPA8/HSC70", 371], [",", 382], ["targets", 384], ["them", 392], ["to", 397], ["the", 400], ["surface", 404], ["of", 412], ["the", 415], ["lysosomes", 419], [".", 428], ["Once", 430], ["there", 435], [",", 440], ["substrate", 442], ["proteins", 452], ["bind", 461], ["to", 466], ["the", 469], ["lysosome", 473], ["-", 481], ["associated", 482], ["membrane", 493], ["protein", 502], ["type", 510], ["2", 515], ["isoform", 517], ["A", 525], ["(", 527], ["LAMP2A", 528], [")", 534], [",", 535], ["inducing", 537], ["assembly", 546], ["of", 555], ["this", 558], ["receptor", 563], ["protein", 572], ["into", 580], ["a", 585], ["higher", 587], ["molecular", 594], ["weight", 604], ["protein", 611], ["complex", 619], ["that", 627], ["is", 632], ["used", 635], ["by", 640], ["the", 643], ["substrate", 647], ["proteins", 657], ["to", 666], ["reach", 669], ["the", 675], ["lysosomal", 679], ["lumen", 689], [".", 694], ["CMA", 696], ["is", 700], ["constitutively", 703], ["active", 718], ["in", 725], ["most", 728], ["cells", 733], ["but", 739], ["it", 743], ["is", 746], ["maximally", 749], ["activated", 759], ["under", 769], ["conditions", 775], ["of", 786], ["stress", 789], [".", 795]]}
{"context": "The APP/PS1ki mouse model for Alzheimer's disease (AD) exhibits robust brain and spinal cord axonal degeneration and hippocampal CA1 neuron loss starting at 6 months of age. It expresses human mutant APP751 with the Swedish and London mutations together with two FAD-linked knocked-in mutations (PS1 M233T and PS1 L235P) in the murine PS1 gene. The present report covers a phenotypical analysis of this model using either behavioral tests for working memory and motor performance, as well as an analysis of weight development and body shape. At the age of 6 months, a dramatic, age-dependent change in all of these properties and characteristics was observed, accompanied by a significantly reduced ability to perform working memory and motor tasks. The APP/PS1ki mice were smaller and showed development of a thoracolumbar kyphosis, together with an incremental loss of body weight. While 2-month-old APP/PS1ki mice were inconspicuous in all of these tasks and properties, there is a massive age-related impairment in all tested behavioral paradigms. We have previously reported robust axonal degeneration in brain and spinal cord, as well as abundant hippocampal CA1 neuron loss starting at 6 months of age in the APP/PS1ki mouse model, which coincides with the onset of motor and memory deficits described in the present report.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "8060a2992f724000a8c3de198bfabc09", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[7, 9]], "char_spans": [[30, 48]]}, {"text": "AD", "token_spans": [[11, 11]], "char_spans": [[51, 52]]}]}], "context_tokens": [["The", 0], ["APP", 4], ["/", 7], ["PS1ki", 8], ["mouse", 14], ["model", 20], ["for", 26], ["Alzheimer", 30], ["'s", 39], ["disease", 42], ["(", 50], ["AD", 51], [")", 53], ["exhibits", 55], ["robust", 64], ["brain", 71], ["and", 77], ["spinal", 81], ["cord", 88], ["axonal", 93], ["degeneration", 100], ["and", 113], ["hippocampal", 117], ["CA1", 129], ["neuron", 133], ["loss", 140], ["starting", 145], ["at", 154], ["6", 157], ["months", 159], ["of", 166], ["age", 169], [".", 172], ["It", 174], ["expresses", 177], ["human", 187], ["mutant", 193], ["APP751", 200], ["with", 207], ["the", 212], ["Swedish", 216], ["and", 224], ["London", 228], ["mutations", 235], ["together", 245], ["with", 254], ["two", 259], ["FAD", 263], ["-", 266], ["linked", 267], ["knocked", 274], ["-", 281], ["in", 282], ["mutations", 285], ["(", 295], ["PS1", 296], ["M233", 300], ["T", 304], ["and", 306], ["PS1", 310], ["L235P", 314], [")", 319], ["in", 321], ["the", 324], ["murine", 328], ["PS1", 335], ["gene", 339], [".", 343], ["The", 345], ["present", 349], ["report", 357], ["covers", 364], ["a", 371], ["phenotypical", 373], ["analysis", 386], ["of", 395], ["this", 398], ["model", 403], ["using", 409], ["either", 415], ["behavioral", 422], ["tests", 433], ["for", 439], ["working", 443], ["memory", 451], ["and", 458], ["motor", 462], ["performance", 468], [",", 479], ["as", 481], ["well", 484], ["as", 489], ["an", 492], ["analysis", 495], ["of", 504], ["weight", 507], ["development", 514], ["and", 526], ["body", 530], ["shape", 535], [".", 540], ["At", 542], ["the", 545], ["age", 549], ["of", 553], ["6", 556], ["months", 558], [",", 564], ["a", 566], ["dramatic", 568], [",", 576], ["age", 578], ["-", 581], ["dependent", 582], ["change", 592], ["in", 599], ["all", 602], ["of", 606], ["these", 609], ["properties", 615], ["and", 626], ["characteristics", 630], ["was", 646], ["observed", 650], [",", 658], ["accompanied", 660], ["by", 672], ["a", 675], ["significantly", 677], ["reduced", 691], ["ability", 699], ["to", 707], ["perform", 710], ["working", 718], ["memory", 726], ["and", 733], ["motor", 737], ["tasks", 743], [".", 748], ["The", 750], ["APP", 754], ["/", 757], ["PS1ki", 758], ["mice", 764], ["were", 769], ["smaller", 774], ["and", 782], ["showed", 786], ["development", 793], ["of", 805], ["a", 808], ["thoracolumbar", 810], ["kyphosis", 824], [",", 832], ["together", 834], ["with", 843], ["an", 848], ["incremental", 851], ["loss", 863], ["of", 868], ["body", 871], ["weight", 876], [".", 882], ["While", 884], ["2-month", 890], ["-", 897], ["old", 898], ["APP", 902], ["/", 905], ["PS1ki", 906], ["mice", 912], ["were", 917], ["inconspicuous", 922], ["in", 936], ["all", 939], ["of", 943], ["these", 946], ["tasks", 952], ["and", 958], ["properties", 962], [",", 972], ["there", 974], ["is", 980], ["a", 983], ["massive", 985], ["age", 993], ["-", 996], ["related", 997], ["impairment", 1005], ["in", 1016], ["all", 1019], ["tested", 1023], ["behavioral", 1030], ["paradigms", 1041], [".", 1050], ["We", 1052], ["have", 1055], ["previously", 1060], ["reported", 1071], ["robust", 1080], ["axonal", 1087], ["degeneration", 1094], ["in", 1107], ["brain", 1110], ["and", 1116], ["spinal", 1120], ["cord", 1127], [",", 1131], ["as", 1133], ["well", 1136], ["as", 1141], ["abundant", 1144], ["hippocampal", 1153], ["CA1", 1165], ["neuron", 1169], ["loss", 1176], ["starting", 1181], ["at", 1190], ["6", 1193], ["months", 1195], ["of", 1202], ["age", 1205], ["in", 1209], ["the", 1212], ["APP", 1216], ["/", 1219], ["PS1ki", 1220], ["mouse", 1226], ["model", 1232], [",", 1237], ["which", 1239], ["coincides", 1245], ["with", 1255], ["the", 1260], ["onset", 1264], ["of", 1270], ["motor", 1273], ["and", 1279], ["memory", 1283], ["deficits", 1290], ["described", 1299], ["in", 1309], ["the", 1312], ["present", 1316], ["report", 1324], [".", 1330]]}
{"context": "Na\u00efve and primed pluripotent states retain distinct molecular properties, yet limited knowledge exists on how their state transitions are regulated. Here, we identify Mettl3, an N(6)-methyladenosine (m(6)A) transferase, as a regulator for terminating murine na\u00efve pluripotency. Mettl3 knockout preimplantation epiblasts and na\u00efve embryonic stem cells are depleted for m(6)A in mRNAs, yet are viable. However, they fail to adequately terminate their na\u00efve state and, subsequently, undergo aberrant and restricted lineage priming at the postimplantation stage, which leads to early embryonic lethality. m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. This study highlights a critical role for an mRNA epigenetic modification in vivo and identifies regulatory modules that functionally influence na\u00efve and primed pluripotency in an opposing manner.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "e2dccc6fa3a84b67a72cd87b03a0db2e", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[101, 102]], "char_spans": [[642, 655]]}]}], "context_tokens": [["Na\u00efve", 0], ["and", 6], ["primed", 10], ["pluripotent", 17], ["states", 29], ["retain", 36], ["distinct", 43], ["molecular", 52], ["properties", 62], [",", 72], ["yet", 74], ["limited", 78], ["knowledge", 86], ["exists", 96], ["on", 103], ["how", 106], ["their", 110], ["state", 116], ["transitions", 122], ["are", 134], ["regulated", 138], [".", 147], ["Here", 149], [",", 153], ["we", 155], ["identify", 158], ["Mettl3", 167], [",", 173], ["an", 175], ["N(6)-methyladenosine", 178], ["(", 199], ["m(6)A", 200], [")", 205], ["transferase", 207], [",", 218], ["as", 220], ["a", 223], ["regulator", 225], ["for", 235], ["terminating", 239], ["murine", 251], ["na\u00efve", 258], ["pluripotency", 264], [".", 276], ["Mettl3", 278], ["knockout", 285], ["preimplantation", 294], ["epiblasts", 310], ["and", 320], ["na\u00efve", 324], ["embryonic", 330], ["stem", 340], ["cells", 345], ["are", 351], ["depleted", 355], ["for", 364], ["m(6)A", 368], ["in", 374], ["mRNAs", 377], [",", 382], ["yet", 384], ["are", 388], ["viable", 392], [".", 398], ["However", 400], [",", 407], ["they", 409], ["fail", 414], ["to", 419], ["adequately", 422], ["terminate", 433], ["their", 443], ["na\u00efve", 449], ["state", 455], ["and", 461], [",", 464], ["subsequently", 466], [",", 478], ["undergo", 480], ["aberrant", 488], ["and", 497], ["restricted", 501], ["lineage", 512], ["priming", 520], ["at", 528], ["the", 531], ["postimplantation", 535], ["stage", 552], [",", 557], ["which", 559], ["leads", 565], ["to", 571], ["early", 574], ["embryonic", 580], ["lethality", 590], [".", 599], ["m(6)A", 601], ["predominantly", 607], ["and", 621], ["directly", 625], ["reduces", 634], ["mRNA", 642], ["stability", 647], [",", 656], ["including", 658], ["that", 668], ["of", 673], ["key", 676], ["na\u00efve", 680], ["pluripotency", 686], ["-", 698], ["promoting", 699], ["transcripts", 709], [".", 720], ["This", 722], ["study", 727], ["highlights", 733], ["a", 744], ["critical", 746], ["role", 755], ["for", 760], ["an", 764], ["mRNA", 767], ["epigenetic", 772], ["modification", 783], ["in", 796], ["vivo", 799], ["and", 804], ["identifies", 808], ["regulatory", 819], ["modules", 830], ["that", 838], ["functionally", 843], ["influence", 856], ["na\u00efve", 866], ["and", 872], ["primed", 876], ["pluripotency", 883], ["in", 896], ["an", 899], ["opposing", 902], ["manner", 911], [".", 917]]}
{"context": "The complex expression patterns observed for many genes are often regulated by distal transcription enhancers. Changes in the nucleotide sequences of enhancers may therefore lead to changes in gene expression, representing a central mechanism by which organisms evolve. With the development of the experimental technique of chromatin immunoprecipitation (ChIP), in which discrete regions of the genome bound by specific proteins can be identified, it is now possible to identify transcription factor binding events (putative cis-regulatory elements) in entire genomes. Comparing protein-DNA binding maps allows us, for the first time, to attempt to identify regulatory differences and infer global patterns of change in gene expression across species. Here, we review studies that used genome-wide ChIP to study the evolution of enhancers. The trend is one of high divergence of cis-regulatory elements between species, possibly compensated by extensive creation and loss of regulatory elements and rewiring of their target genes. We speculate on the meaning of the differences observed and discuss that although ChIP experiments identify the biochemical event of protein-DNA interaction, it cannot determine whether the event results in a biological function, and therefore more studies are required to establish the effect of divergence of binding events on species-specific gene expression.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "2127733422e64157bc1703f3baf19fbd", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[22, 22], [139, 139], [14, 14]], "char_spans": [[150, 158], [829, 837], [100, 108]]}]}], "context_tokens": [["The", 0], ["complex", 4], ["expression", 12], ["patterns", 23], ["observed", 32], ["for", 41], ["many", 45], ["genes", 50], ["are", 56], ["often", 60], ["regulated", 66], ["by", 76], ["distal", 79], ["transcription", 86], ["enhancers", 100], [".", 109], ["Changes", 111], ["in", 119], ["the", 122], ["nucleotide", 126], ["sequences", 137], ["of", 147], ["enhancers", 150], ["may", 160], ["therefore", 164], ["lead", 174], ["to", 179], ["changes", 182], ["in", 190], ["gene", 193], ["expression", 198], [",", 208], ["representing", 210], ["a", 223], ["central", 225], ["mechanism", 233], ["by", 243], ["which", 246], ["organisms", 252], ["evolve", 262], [".", 268], ["With", 270], ["the", 275], ["development", 279], ["of", 291], ["the", 294], ["experimental", 298], ["technique", 311], ["of", 321], ["chromatin", 324], ["immunoprecipitation", 334], ["(", 354], ["ChIP", 355], [")", 359], [",", 360], ["in", 362], ["which", 365], ["discrete", 371], ["regions", 380], ["of", 388], ["the", 391], ["genome", 395], ["bound", 402], ["by", 408], ["specific", 411], ["proteins", 420], ["can", 429], ["be", 433], ["identified", 436], [",", 446], ["it", 448], ["is", 451], ["now", 454], ["possible", 458], ["to", 467], ["identify", 470], ["transcription", 479], ["factor", 493], ["binding", 500], ["events", 508], ["(", 515], ["putative", 516], ["cis", 525], ["-", 528], ["regulatory", 529], ["elements", 540], [")", 548], ["in", 550], ["entire", 553], ["genomes", 560], [".", 567], ["Comparing", 569], ["protein", 579], ["-", 586], ["DNA", 587], ["binding", 591], ["maps", 599], ["allows", 604], ["us", 611], [",", 613], ["for", 615], ["the", 619], ["first", 623], ["time", 629], [",", 633], ["to", 635], ["attempt", 638], ["to", 646], ["identify", 649], ["regulatory", 658], ["differences", 669], ["and", 681], ["infer", 685], ["global", 691], ["patterns", 698], ["of", 707], ["change", 710], ["in", 717], ["gene", 720], ["expression", 725], ["across", 736], ["species", 743], [".", 750], ["Here", 752], [",", 756], ["we", 758], ["review", 761], ["studies", 768], ["that", 776], ["used", 781], ["genome", 786], ["-", 792], ["wide", 793], ["ChIP", 798], ["to", 803], ["study", 806], ["the", 812], ["evolution", 816], ["of", 826], ["enhancers", 829], [".", 838], ["The", 840], ["trend", 844], ["is", 850], ["one", 853], ["of", 857], ["high", 860], ["divergence", 865], ["of", 876], ["cis", 879], ["-", 882], ["regulatory", 883], ["elements", 894], ["between", 903], ["species", 911], [",", 918], ["possibly", 920], ["compensated", 929], ["by", 941], ["extensive", 944], ["creation", 954], ["and", 963], ["loss", 967], ["of", 972], ["regulatory", 975], ["elements", 986], ["and", 995], ["rewiring", 999], ["of", 1008], ["their", 1011], ["target", 1017], ["genes", 1024], [".", 1029], ["We", 1031], ["speculate", 1034], ["on", 1044], ["the", 1047], ["meaning", 1051], ["of", 1059], ["the", 1062], ["differences", 1066], ["observed", 1078], ["and", 1087], ["discuss", 1091], ["that", 1099], ["although", 1104], ["ChIP", 1113], ["experiments", 1118], ["identify", 1130], ["the", 1139], ["biochemical", 1143], ["event", 1155], ["of", 1161], ["protein", 1164], ["-", 1171], ["DNA", 1172], ["interaction", 1176], [",", 1187], ["it", 1189], ["can", 1192], ["not", 1195], ["determine", 1199], ["whether", 1209], ["the", 1217], ["event", 1221], ["results", 1227], ["in", 1235], ["a", 1238], ["biological", 1240], ["function", 1251], [",", 1259], ["and", 1261], ["therefore", 1265], ["more", 1275], ["studies", 1280], ["are", 1288], ["required", 1292], ["to", 1301], ["establish", 1304], ["the", 1314], ["effect", 1318], ["of", 1325], ["divergence", 1328], ["of", 1339], ["binding", 1342], ["events", 1350], ["on", 1357], ["species", 1360], ["-", 1367], ["specific", 1368], ["gene", 1377], ["expression", 1382], [".", 1392]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been implicated in several physiological and pathophysiological processes. To date seven members of this family have been reported, including Nox1-5 and Duox1 and 2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity. Recently, we identified the c-Src substrate proteins Tks4 and Tks5 as functional members of a p47(phox)-related organizer superfamily. As a functional consequence of this interaction, Nox1 localizes to invadopodia, actin-rich membrane protrusions of cancer cells which facilitate pericellular proteolysis and invasive behavior. Here, we report that Tks4 and Tks5 directly bind to NoxA1. Moreover, the integrity of the N-terminal PRR of NoxA1 is essential for this direct interaction with the Tks proteins. When the PRR in NoxA1 is disrupted, Tks proteins cannot bind NoxA1 and lose their ability to support Nox1-dependent ROS generation. Consistent with this, Tks4 and Tks5 are unable to act as organizers for Nox2 because of their inability to interact with p67(phox), which lacks the N-terminal PRR, thus conferring a unique specificity to Tks4 and 5. Taken together, these results clarify the molecular basis for the interaction between NoxA1 and the Tks proteins and may provide new insights into the pharmacological design of a more effective anti-metastatic strategy.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "809980294d6346f88b44bf8f45d50ed7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[137, 137], [45, 45], [70, 70]], "char_spans": [[753, 756], [259, 262], [373, 376]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["implicated", 122], ["in", 133], ["several", 136], ["physiological", 144], ["and", 158], ["pathophysiological", 162], ["processes", 181], [".", 190], ["To", 192], ["date", 195], ["seven", 200], ["members", 206], ["of", 214], ["this", 217], ["family", 222], ["have", 229], ["been", 234], ["reported", 239], [",", 247], ["including", 249], ["Nox1", 259], ["-", 263], ["5", 264], ["and", 266], ["Duox1", 270], ["and", 276], ["2", 280], [".", 281], ["With", 283], ["the", 288], ["exception", 292], ["of", 302], ["Nox2", 305], [",", 309], ["the", 311], ["regulation", 315], ["of", 326], ["the", 329], ["Nox", 333], ["enzymes", 337], ["is", 345], ["still", 348], ["poorly", 354], ["understood", 361], [".", 371], ["Nox1", 373], ["is", 378], ["highly", 381], ["expressed", 388], ["in", 398], ["the", 401], ["colon", 405], [",", 410], ["and", 412], ["requires", 416], ["two", 425], ["cytosolic", 429], ["regulators", 439], [",", 449], ["the", 451], ["organizer", 455], ["subunit", 465], ["NoxO1", 473], ["and", 479], ["the", 483], ["activator", 487], ["subunit", 497], ["NoxA1", 505], [",", 510], ["as", 512], ["well", 515], ["as", 520], ["the", 523], ["binding", 527], ["of", 535], ["Rac1", 538], ["GTPase", 543], [",", 549], ["for", 551], ["its", 555], ["activity", 559], [".", 567], ["Recently", 569], [",", 577], ["we", 579], ["identified", 582], ["the", 593], ["c", 597], ["-", 598], ["Src", 599], ["substrate", 603], ["proteins", 613], ["Tks4", 622], ["and", 627], ["Tks5", 631], ["as", 636], ["functional", 639], ["members", 650], ["of", 658], ["a", 661], ["p47(phox)-related", 663], ["organizer", 681], ["superfamily", 691], [".", 702], ["As", 704], ["a", 707], ["functional", 709], ["consequence", 720], ["of", 732], ["this", 735], ["interaction", 740], [",", 751], ["Nox1", 753], ["localizes", 758], ["to", 768], ["invadopodia", 771], [",", 782], ["actin", 784], ["-", 789], ["rich", 790], ["membrane", 795], ["protrusions", 804], ["of", 816], ["cancer", 819], ["cells", 826], ["which", 832], ["facilitate", 838], ["pericellular", 849], ["proteolysis", 862], ["and", 874], ["invasive", 878], ["behavior", 887], [".", 895], ["Here", 897], [",", 901], ["we", 903], ["report", 906], ["that", 913], ["Tks4", 918], ["and", 923], ["Tks5", 927], ["directly", 932], ["bind", 941], ["to", 946], ["NoxA1", 949], [".", 954], ["Moreover", 956], [",", 964], ["the", 966], ["integrity", 970], ["of", 980], ["the", 983], ["N", 987], ["-", 988], ["terminal", 989], ["PRR", 998], ["of", 1002], ["NoxA1", 1005], ["is", 1011], ["essential", 1014], ["for", 1024], ["this", 1028], ["direct", 1033], ["interaction", 1040], ["with", 1052], ["the", 1057], ["Tks", 1061], ["proteins", 1065], [".", 1073], ["When", 1075], ["the", 1080], ["PRR", 1084], ["in", 1088], ["NoxA1", 1091], ["is", 1097], ["disrupted", 1100], [",", 1109], ["Tks", 1111], ["proteins", 1115], ["can", 1124], ["not", 1127], ["bind", 1131], ["NoxA1", 1136], ["and", 1142], ["lose", 1146], ["their", 1151], ["ability", 1157], ["to", 1165], ["support", 1168], ["Nox1-dependent", 1176], ["ROS", 1191], ["generation", 1195], [".", 1205], ["Consistent", 1207], ["with", 1218], ["this", 1223], [",", 1227], ["Tks4", 1229], ["and", 1234], ["Tks5", 1238], ["are", 1243], ["unable", 1247], ["to", 1254], ["act", 1257], ["as", 1261], ["organizers", 1264], ["for", 1275], ["Nox2", 1279], ["because", 1284], ["of", 1292], ["their", 1295], ["inability", 1301], ["to", 1311], ["interact", 1314], ["with", 1323], ["p67(phox", 1328], [")", 1336], [",", 1337], ["which", 1339], ["lacks", 1345], ["the", 1351], ["N", 1355], ["-", 1356], ["terminal", 1357], ["PRR", 1366], [",", 1369], ["thus", 1371], ["conferring", 1376], ["a", 1387], ["unique", 1389], ["specificity", 1396], ["to", 1408], ["Tks4", 1411], ["and", 1416], ["5", 1420], [".", 1421], ["Taken", 1423], ["together", 1429], [",", 1437], ["these", 1439], ["results", 1445], ["clarify", 1453], ["the", 1461], ["molecular", 1465], ["basis", 1475], ["for", 1481], ["the", 1485], ["interaction", 1489], ["between", 1501], ["NoxA1", 1509], ["and", 1515], ["the", 1519], ["Tks", 1523], ["proteins", 1527], ["and", 1536], ["may", 1540], ["provide", 1544], ["new", 1552], ["insights", 1556], ["into", 1565], ["the", 1570], ["pharmacological", 1574], ["design", 1590], ["of", 1597], ["a", 1600], ["more", 1602], ["effective", 1607], ["anti", 1617], ["-", 1621], ["metastatic", 1622], ["strategy", 1633], [".", 1641]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. The purpose of this study was to evaluate the effect of moderate liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD; effect on COMT activity) of OPC. An open-label, parallel-group study in patients (n\u2009=\u20098) with moderate liver impairment (Child-Pugh category B, score of 7 to 9) and matched healthy subjects (n\u2009=\u20098, control) with normal liver function. All subjects received a single 50-mg oral dose of OPC, with plasma and urine concentrations of opicapone and its metabolites measured up to 72\u00a0h post-dose, including soluble COMT (S-COMT) activity. A one-way analysis of variance (ANOVA) was used to compare the main PK and PD parameters between groups. Point estimates (PE) of geometric mean ratios (GMR) and corresponding 90\u00a0% confidence intervals (90%CI) for the ratio hepatic/control subjects of each parameter were calculated and compared with the reference interval (80-125\u00a0%). Exposure to opicapone (AUC and Cmax) increased significantly in patients with moderate hepatic impairment (PE [90%CI]: AUC0-\u221e, 184\u00a0% [135-250\u00a0%]; Cmax, 189\u00a0% [144-249\u00a0%]). Although apparent total clearance (CL/F) of opicapone was decreased by \u223c35\u00a0%, similar elimination half-life and unbound/bound fractions of opicapone were observed between the two groups. Both rate and extent of exposure to BIA 9-1103 were higher in the hepatically impaired group, but not statistically significant compared with the control group. Similar to the parent (opicapone), the observed increase in exposure to BIA 9-1106 was statistically significant in the hepatically impaired group over the control group. BIA 9-1106 was the only metabolite detected in urine and its urine PK parameters were in accordance with plasma data. Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100\u00a0% and 91.2\u00a0% for the hepatically impaired and control groups respectively. Both Emax and AUEC for the hepatically impaired group reached statistical significance over the control group. OPC was well tolerated in both hepatically impaired and control groups. The bioavailability of an orally administered single dose of 50\u00a0mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect. As the tolerability profile of OPC was favourable under the conditions of this study and its exposure is completely purged from systemic circulation before the subsequent dose administration, no OPC dose adjustment is needed in patients with mild to moderate chronic hepatic impairment. However, as OPC is under clinical development for use as adjunctive therapy in levodopa-treated patients with Parkinson's disease, an adjustment of levodopa and/or OPC regimens in patients should be carefully considered based on a potentially enhanced levodopa dopaminergic response and the associated tolerability.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "6bedca90e5b9429482c8374aa747b8c4", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[7, 11]], "char_spans": [[27, 54]]}]}], "context_tokens": [["Opicapone", 0], ["(", 10], ["OPC", 11], [")", 14], ["is", 16], ["a", 19], ["novel", 21], ["catechol", 27], ["-", 35], ["O", 36], ["-", 37], ["methyltransferase", 38], ["(", 56], ["COMT", 57], [")", 61], ["inhibitor", 63], ["to", 73], ["be", 76], ["used", 79], ["as", 84], ["adjunctive", 87], ["therapy", 98], ["in", 106], ["levodopa", 109], ["-", 117], ["treated", 118], ["patients", 126], ["with", 135], ["Parkinson", 140], ["'s", 149], ["disease", 152], [".", 159], ["The", 161], ["purpose", 165], ["of", 173], ["this", 176], ["study", 181], ["was", 187], ["to", 191], ["evaluate", 194], ["the", 203], ["effect", 207], ["of", 214], ["moderate", 217], ["liver", 226], ["impairment", 232], ["on", 243], ["the", 246], ["pharmacokinetics", 250], ["(", 267], ["PK", 268], [")", 270], ["and", 272], ["pharmacodynamics", 276], ["(", 293], ["PD", 294], [";", 296], ["effect", 298], ["on", 305], ["COMT", 308], ["activity", 313], [")", 321], ["of", 323], ["OPC", 326], [".", 329], ["An", 331], ["open", 334], ["-", 338], ["label", 339], [",", 344], ["parallel", 346], ["-", 354], ["group", 355], ["study", 361], ["in", 367], ["patients", 370], ["(", 379], ["n", 380], ["=", 382], ["8)", 384], ["with", 387], ["moderate", 392], ["liver", 401], ["impairment", 407], ["(", 418], ["Child", 419], ["-", 424], ["Pugh", 425], ["category", 430], ["B", 439], [",", 440], ["score", 442], ["of", 448], ["7", 451], ["to", 453], ["9", 456], [")", 457], ["and", 459], ["matched", 463], ["healthy", 471], ["subjects", 479], ["(", 488], ["n", 489], ["=", 491], ["8", 493], [",", 494], ["control", 496], [")", 503], ["with", 505], ["normal", 510], ["liver", 517], ["function", 523], [".", 531], ["All", 533], ["subjects", 537], ["received", 546], ["a", 555], ["single", 557], ["50-mg", 564], ["oral", 570], ["dose", 575], ["of", 580], ["OPC", 583], [",", 586], ["with", 588], ["plasma", 593], ["and", 600], ["urine", 604], ["concentrations", 610], ["of", 625], ["opicapone", 628], ["and", 638], ["its", 642], ["metabolites", 646], ["measured", 658], ["up", 667], ["to", 670], ["72", 673], ["h", 676], ["post", 678], ["-", 682], ["dose", 683], [",", 687], ["including", 689], ["soluble", 699], ["COMT", 707], ["(", 712], ["S", 713], ["-", 714], ["COMT", 715], [")", 719], ["activity", 721], [".", 729], ["A", 731], ["one", 733], ["-", 736], ["way", 737], ["analysis", 741], ["of", 750], ["variance", 753], ["(", 762], ["ANOVA", 763], [")", 768], ["was", 770], ["used", 774], ["to", 779], ["compare", 782], ["the", 790], ["main", 794], ["PK", 799], ["and", 802], ["PD", 806], ["parameters", 809], ["between", 820], ["groups", 828], [".", 834], ["Point", 836], ["estimates", 842], ["(", 852], ["PE", 853], [")", 855], ["of", 857], ["geometric", 860], ["mean", 870], ["ratios", 875], ["(", 882], ["GMR", 883], [")", 886], ["and", 888], ["corresponding", 892], ["90", 906], ["%", 909], ["confidence", 911], ["intervals", 922], ["(", 932], ["90%CI", 933], [")", 938], ["for", 940], ["the", 944], ["ratio", 948], ["hepatic", 954], ["/", 961], ["control", 962], ["subjects", 970], ["of", 979], ["each", 982], ["parameter", 987], ["were", 997], ["calculated", 1002], ["and", 1013], ["compared", 1017], ["with", 1026], ["the", 1031], ["reference", 1035], ["interval", 1045], ["(", 1054], ["80", 1055], ["-", 1057], ["125", 1058], ["%", 1062], [")", 1063], [".", 1064], ["Exposure", 1066], ["to", 1075], ["opicapone", 1078], ["(", 1088], ["AUC", 1089], ["and", 1093], ["Cmax", 1097], [")", 1101], ["increased", 1103], ["significantly", 1113], ["in", 1127], ["patients", 1130], ["with", 1139], ["moderate", 1144], ["hepatic", 1153], ["impairment", 1161], ["(", 1172], ["PE", 1173], ["[", 1176], ["90%CI", 1177], ["]", 1182], [":", 1183], ["AUC0-\u221e", 1185], [",", 1191], ["184", 1193], ["%", 1197], ["[", 1199], ["135", 1200], ["-", 1203], ["250", 1204], ["%", 1208], ["]", 1209], [";", 1210], ["Cmax", 1212], [",", 1216], ["189", 1218], ["%", 1222], ["[", 1224], ["144", 1225], ["-", 1228], ["249", 1229], ["%", 1233], ["]", 1234], [")", 1235], [".", 1236], ["Although", 1238], ["apparent", 1247], ["total", 1256], ["clearance", 1262], ["(", 1272], ["CL", 1273], ["/", 1275], ["F", 1276], [")", 1277], ["of", 1279], ["opicapone", 1282], ["was", 1292], ["decreased", 1296], ["by", 1306], ["\u223c35", 1309], ["%", 1313], [",", 1314], ["similar", 1316], ["elimination", 1324], ["half", 1336], ["-", 1340], ["life", 1341], ["and", 1346], ["unbound", 1350], ["/", 1357], ["bound", 1358], ["fractions", 1364], ["of", 1374], ["opicapone", 1377], ["were", 1387], ["observed", 1392], ["between", 1401], ["the", 1409], ["two", 1413], ["groups", 1417], [".", 1423], ["Both", 1425], ["rate", 1430], ["and", 1435], ["extent", 1439], ["of", 1446], ["exposure", 1449], ["to", 1458], ["BIA", 1461], ["9", 1465], ["-", 1466], ["1103", 1467], ["were", 1472], ["higher", 1477], ["in", 1484], ["the", 1487], ["hepatically", 1491], ["impaired", 1503], ["group", 1512], [",", 1517], ["but", 1519], ["not", 1523], ["statistically", 1527], ["significant", 1541], ["compared", 1553], ["with", 1562], ["the", 1567], ["control", 1571], ["group", 1579], [".", 1584], ["Similar", 1586], ["to", 1594], ["the", 1597], ["parent", 1601], ["(", 1608], ["opicapone", 1609], [")", 1618], [",", 1619], ["the", 1621], ["observed", 1625], ["increase", 1634], ["in", 1643], ["exposure", 1646], ["to", 1655], ["BIA", 1658], ["9", 1662], ["-", 1663], ["1106", 1664], ["was", 1669], ["statistically", 1673], ["significant", 1687], ["in", 1699], ["the", 1702], ["hepatically", 1706], ["impaired", 1718], ["group", 1727], ["over", 1733], ["the", 1738], ["control", 1742], ["group", 1750], [".", 1755], ["BIA", 1757], ["9", 1761], ["-", 1762], ["1106", 1763], ["was", 1768], ["the", 1772], ["only", 1776], ["metabolite", 1781], ["detected", 1792], ["in", 1801], ["urine", 1804], ["and", 1810], ["its", 1814], ["urine", 1818], ["PK", 1824], ["parameters", 1827], ["were", 1838], ["in", 1843], ["accordance", 1846], ["with", 1857], ["plasma", 1862], ["data", 1869], [".", 1873], ["Maximum", 1875], ["S", 1883], ["-", 1884], ["COMT", 1885], ["inhibition", 1890], ["(", 1901], ["Emax", 1902], [")", 1906], ["occurred", 1908], ["earlier", 1917], ["for", 1925], ["the", 1929], ["hepatically", 1933], ["impaired", 1945], ["group", 1954], ["with", 1960], ["values", 1965], ["of", 1972], ["100", 1975], ["%", 1979], ["and", 1981], ["91.2", 1985], ["%", 1990], ["for", 1992], ["the", 1996], ["hepatically", 2000], ["impaired", 2012], ["and", 2021], ["control", 2025], ["groups", 2033], ["respectively", 2040], [".", 2052], ["Both", 2054], ["Emax", 2059], ["and", 2064], ["AUEC", 2068], ["for", 2073], ["the", 2077], ["hepatically", 2081], ["impaired", 2093], ["group", 2102], ["reached", 2108], ["statistical", 2116], ["significance", 2128], ["over", 2141], ["the", 2146], ["control", 2150], ["group", 2158], [".", 2163], ["OPC", 2165], ["was", 2169], ["well", 2173], ["tolerated", 2178], ["in", 2188], ["both", 2191], ["hepatically", 2196], ["impaired", 2208], ["and", 2217], ["control", 2221], ["groups", 2229], [".", 2235], ["The", 2237], ["bioavailability", 2241], ["of", 2257], ["an", 2260], ["orally", 2263], ["administered", 2270], ["single", 2283], ["dose", 2290], ["of", 2295], ["50", 2298], ["mg", 2301], ["OPC", 2304], ["was", 2308], ["significantly", 2312], ["higher", 2326], ["in", 2333], ["patients", 2336], ["with", 2345], ["moderate", 2350], ["chronic", 2359], ["hepatic", 2367], ["impairment", 2375], [",", 2385], ["perhaps", 2387], ["by", 2395], ["a", 2398], ["reduced", 2400], ["first", 2408], ["-", 2413], ["pass", 2414], ["effect", 2419], [".", 2425], ["As", 2427], ["the", 2430], ["tolerability", 2434], ["profile", 2447], ["of", 2455], ["OPC", 2458], ["was", 2462], ["favourable", 2466], ["under", 2477], ["the", 2483], ["conditions", 2487], ["of", 2498], ["this", 2501], ["study", 2506], ["and", 2512], ["its", 2516], ["exposure", 2520], ["is", 2529], ["completely", 2532], ["purged", 2543], ["from", 2550], ["systemic", 2555], ["circulation", 2564], ["before", 2576], ["the", 2583], ["subsequent", 2587], ["dose", 2598], ["administration", 2603], [",", 2617], ["no", 2619], ["OPC", 2622], ["dose", 2626], ["adjustment", 2631], ["is", 2642], ["needed", 2645], ["in", 2652], ["patients", 2655], ["with", 2664], ["mild", 2669], ["to", 2674], ["moderate", 2677], ["chronic", 2686], ["hepatic", 2694], ["impairment", 2702], [".", 2712], ["However", 2714], [",", 2721], ["as", 2723], ["OPC", 2726], ["is", 2730], ["under", 2733], ["clinical", 2739], ["development", 2748], ["for", 2760], ["use", 2764], ["as", 2768], ["adjunctive", 2771], ["therapy", 2782], ["in", 2790], ["levodopa", 2793], ["-", 2801], ["treated", 2802], ["patients", 2810], ["with", 2819], ["Parkinson", 2824], ["'s", 2833], ["disease", 2836], [",", 2843], ["an", 2845], ["adjustment", 2848], ["of", 2859], ["levodopa", 2862], ["and/or", 2871], ["OPC", 2878], ["regimens", 2882], ["in", 2891], ["patients", 2894], ["should", 2903], ["be", 2910], ["carefully", 2913], ["considered", 2923], ["based", 2934], ["on", 2940], ["a", 2943], ["potentially", 2945], ["enhanced", 2957], ["levodopa", 2966], ["dopaminergic", 2975], ["response", 2988], ["and", 2997], ["the", 3001], ["associated", 3005], ["tolerability", 3016], [".", 3028]]}
{"context": "Activity-dependent modifications of excitatory synapses contribute to synaptic maturation and plasticity, and are critical for learning and memory. Consequently, impairments in synapse formation or synaptic transmission are thought to be responsible for several types of mental disabilities. BRAG1 is a guanine nucleotide exchange factor for the small GTP-binding protein Arf6 that localizes to the postsynaptic density of excitatory synapses. Mutations in BRAG1 have been identified in families with X-linked intellectual disability (XLID). These mutations mapped to either the catalytic domain or an IQ-like motif; however, the pathophysiological basis of these mutations remains unknown. Here, we show that the BRAG1 IQ motif binds apo-calmodulin (CaM), and that calcium-induced CaM release triggers a reversible conformational change in human BRAG1. We demonstrate that BRAG1 activity, stimulated by activation of NMDA-sensitive glutamate receptors, depresses AMPA receptor (AMPA-R)-mediated transmission via JNK-mediated synaptic removal of GluA1-containing AMPA-Rs in rat hippocampal neurons. Importantly, a BRAG1 mutant that fails to activate Arf6 also fails to depress AMPA-R signaling, indicating that Arf6 activity is necessary for this process. Conversely, a mutation in the BRAG1 IQ-like motif that impairs CaM binding results in hyperactivation of Arf6 signaling and constitutive depression of AMPA transmission. Our findings reveal a role for BRAG1 in response to neuronal activity with possible clinical relevance to nonsyndromic XLID.", "qas": [{"question": "Which disease is linked to mutations within BRAG1?", "answers": ["X-linked intellectual disability"], "qid": "8c77296f28c84ecf8c27e74782380f94", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["linked", 17], ["to", 24], ["mutations", 27], ["within", 37], ["BRAG1", 44], ["?", 49]], "detected_answers": [{"text": "X-linked intellectual disability", "token_spans": [[77, 81]], "char_spans": [[501, 532]]}]}], "context_tokens": [["Activity", 0], ["-", 8], ["dependent", 9], ["modifications", 19], ["of", 33], ["excitatory", 36], ["synapses", 47], ["contribute", 56], ["to", 67], ["synaptic", 70], ["maturation", 79], ["and", 90], ["plasticity", 94], [",", 104], ["and", 106], ["are", 110], ["critical", 114], ["for", 123], ["learning", 127], ["and", 136], ["memory", 140], [".", 146], ["Consequently", 148], [",", 160], ["impairments", 162], ["in", 174], ["synapse", 177], ["formation", 185], ["or", 195], ["synaptic", 198], ["transmission", 207], ["are", 220], ["thought", 224], ["to", 232], ["be", 235], ["responsible", 238], ["for", 250], ["several", 254], ["types", 262], ["of", 268], ["mental", 271], ["disabilities", 278], [".", 290], ["BRAG1", 292], ["is", 298], ["a", 301], ["guanine", 303], ["nucleotide", 311], ["exchange", 322], ["factor", 331], ["for", 338], ["the", 342], ["small", 346], ["GTP", 352], ["-", 355], ["binding", 356], ["protein", 364], ["Arf6", 372], ["that", 377], ["localizes", 382], ["to", 392], ["the", 395], ["postsynaptic", 399], ["density", 412], ["of", 420], ["excitatory", 423], ["synapses", 434], [".", 442], ["Mutations", 444], ["in", 454], ["BRAG1", 457], ["have", 463], ["been", 468], ["identified", 473], ["in", 484], ["families", 487], ["with", 496], ["X", 501], ["-", 502], ["linked", 503], ["intellectual", 510], ["disability", 523], ["(", 534], ["XLID", 535], [")", 539], [".", 540], ["These", 542], ["mutations", 548], ["mapped", 558], ["to", 565], ["either", 568], ["the", 575], ["catalytic", 579], ["domain", 589], ["or", 596], ["an", 599], ["IQ", 602], ["-", 604], ["like", 605], ["motif", 610], [";", 615], ["however", 617], [",", 624], ["the", 626], ["pathophysiological", 630], ["basis", 649], ["of", 655], ["these", 658], ["mutations", 664], ["remains", 674], ["unknown", 682], [".", 689], ["Here", 691], [",", 695], ["we", 697], ["show", 700], ["that", 705], ["the", 710], ["BRAG1", 714], ["IQ", 720], ["motif", 723], ["binds", 729], ["apo", 735], ["-", 738], ["calmodulin", 739], ["(", 750], ["CaM", 751], [")", 754], [",", 755], ["and", 757], ["that", 761], ["calcium", 766], ["-", 773], ["induced", 774], ["CaM", 782], ["release", 786], ["triggers", 794], ["a", 803], ["reversible", 805], ["conformational", 816], ["change", 831], ["in", 838], ["human", 841], ["BRAG1", 847], [".", 852], ["We", 854], ["demonstrate", 857], ["that", 869], ["BRAG1", 874], ["activity", 880], [",", 888], ["stimulated", 890], ["by", 901], ["activation", 904], ["of", 915], ["NMDA", 918], ["-", 922], ["sensitive", 923], ["glutamate", 933], ["receptors", 943], [",", 952], ["depresses", 954], ["AMPA", 964], ["receptor", 969], ["(", 978], ["AMPA", 979], ["-", 983], ["R)-mediated", 984], ["transmission", 996], ["via", 1009], ["JNK", 1013], ["-", 1016], ["mediated", 1017], ["synaptic", 1026], ["removal", 1035], ["of", 1043], ["GluA1-containing", 1046], ["AMPA", 1063], ["-", 1067], ["Rs", 1068], ["in", 1071], ["rat", 1074], ["hippocampal", 1078], ["neurons", 1090], [".", 1097], ["Importantly", 1099], [",", 1110], ["a", 1112], ["BRAG1", 1114], ["mutant", 1120], ["that", 1127], ["fails", 1132], ["to", 1138], ["activate", 1141], ["Arf6", 1150], ["also", 1155], ["fails", 1160], ["to", 1166], ["depress", 1169], ["AMPA", 1177], ["-", 1181], ["R", 1182], ["signaling", 1184], [",", 1193], ["indicating", 1195], ["that", 1206], ["Arf6", 1211], ["activity", 1216], ["is", 1225], ["necessary", 1228], ["for", 1238], ["this", 1242], ["process", 1247], [".", 1254], ["Conversely", 1256], [",", 1266], ["a", 1268], ["mutation", 1270], ["in", 1279], ["the", 1282], ["BRAG1", 1286], ["IQ", 1292], ["-", 1294], ["like", 1295], ["motif", 1300], ["that", 1306], ["impairs", 1311], ["CaM", 1319], ["binding", 1323], ["results", 1331], ["in", 1339], ["hyperactivation", 1342], ["of", 1358], ["Arf6", 1361], ["signaling", 1366], ["and", 1376], ["constitutive", 1380], ["depression", 1393], ["of", 1404], ["AMPA", 1407], ["transmission", 1412], [".", 1424], ["Our", 1426], ["findings", 1430], ["reveal", 1439], ["a", 1446], ["role", 1448], ["for", 1453], ["BRAG1", 1457], ["in", 1463], ["response", 1466], ["to", 1475], ["neuronal", 1478], ["activity", 1487], ["with", 1496], ["possible", 1501], ["clinical", 1510], ["relevance", 1519], ["to", 1529], ["nonsyndromic", 1532], ["XLID", 1545], [".", 1549]]}
{"context": "The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity following repeated doses of opicapone. This randomized, placebo-controlled, double-blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30\u2009mg for 8 days. Opicapone was well tolerated. Its systemic exposure increased in an approximately dose-proportional manner with an apparent terminal half-life of 1.0 to 1.4\u2009h. Sulphation was the main metabolic pathway. Opicapone metabolites recovered in urine accounted for less than 3% of the amount of opicapone administered suggesting that bile is likely the main route of excretion. Maximum S-COMT inhibition (Emax ) ranged from 69.9% to 98.0% following the last dose of opicapone. The opicapone-induced S-COMT inhibition showed a half-life in excess of 100\u2009h, which was dose-independent and much longer than plasma drug exposure. Such a half-life translates into a putative underlying rate constant that is comparable with the estimated dissociation rate constant of the COMT-opicapone complex. Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "a304967557fb41c5a6ef72141bdd17f8", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[18, 22]], "char_spans": [[116, 143]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["assess", 29], ["the", 36], ["tolerability", 40], [",", 52], ["pharmacokinetics", 54], ["and", 71], ["inhibitory", 75], ["effect", 86], ["on", 93], ["erythrocyte", 96], ["soluble", 108], ["catechol", 116], ["-", 124], ["O", 125], ["-", 126], ["methyltransferase", 127], ["(", 145], ["S", 146], ["-", 147], ["COMT", 148], [")", 152], ["activity", 154], ["following", 163], ["repeated", 173], ["doses", 182], ["of", 188], ["opicapone", 191], [".", 200], ["This", 202], ["randomized", 207], [",", 217], ["placebo", 219], ["-", 226], ["controlled", 227], [",", 237], ["double", 239], ["-", 245], ["blind", 246], ["study", 252], ["enrolled", 258], ["healthy", 267], ["male", 275], ["subjects", 280], ["who", 289], ["received", 293], ["either", 302], ["once", 309], ["daily", 314], ["placebo", 320], ["or", 328], ["opicapone", 331], ["5", 341], [",", 342], ["10", 344], [",", 346], ["20", 348], ["or", 351], ["30", 354], ["mg", 357], ["for", 360], ["8", 364], ["days", 366], [".", 370], ["Opicapone", 372], ["was", 382], ["well", 386], ["tolerated", 391], [".", 400], ["Its", 402], ["systemic", 406], ["exposure", 415], ["increased", 424], ["in", 434], ["an", 437], ["approximately", 440], ["dose", 454], ["-", 458], ["proportional", 459], ["manner", 472], ["with", 479], ["an", 484], ["apparent", 487], ["terminal", 496], ["half", 505], ["-", 509], ["life", 510], ["of", 515], ["1.0", 518], ["to", 522], ["1.4", 525], ["h.", 529], ["Sulphation", 532], ["was", 543], ["the", 547], ["main", 551], ["metabolic", 556], ["pathway", 566], [".", 573], ["Opicapone", 575], ["metabolites", 585], ["recovered", 597], ["in", 607], ["urine", 610], ["accounted", 616], ["for", 626], ["less", 630], ["than", 635], ["3", 640], ["%", 641], ["of", 643], ["the", 646], ["amount", 650], ["of", 657], ["opicapone", 660], ["administered", 670], ["suggesting", 683], ["that", 694], ["bile", 699], ["is", 704], ["likely", 707], ["the", 714], ["main", 718], ["route", 723], ["of", 729], ["excretion", 732], [".", 741], ["Maximum", 743], ["S", 751], ["-", 752], ["COMT", 753], ["inhibition", 758], ["(", 769], ["Emax", 770], [")", 775], ["ranged", 777], ["from", 784], ["69.9", 789], ["%", 793], ["to", 795], ["98.0", 798], ["%", 802], ["following", 804], ["the", 814], ["last", 818], ["dose", 823], ["of", 828], ["opicapone", 831], [".", 840], ["The", 842], ["opicapone", 846], ["-", 855], ["induced", 856], ["S", 864], ["-", 865], ["COMT", 866], ["inhibition", 871], ["showed", 882], ["a", 889], ["half", 891], ["-", 895], ["life", 896], ["in", 901], ["excess", 904], ["of", 911], ["100", 914], ["h", 918], [",", 919], ["which", 921], ["was", 927], ["dose", 931], ["-", 935], ["independent", 936], ["and", 948], ["much", 952], ["longer", 957], ["than", 964], ["plasma", 969], ["drug", 976], ["exposure", 981], [".", 989], ["Such", 991], ["a", 996], ["half", 998], ["-", 1002], ["life", 1003], ["translates", 1008], ["into", 1019], ["a", 1024], ["putative", 1026], ["underlying", 1035], ["rate", 1046], ["constant", 1051], ["that", 1060], ["is", 1065], ["comparable", 1068], ["with", 1079], ["the", 1084], ["estimated", 1088], ["dissociation", 1098], ["rate", 1111], ["constant", 1116], ["of", 1125], ["the", 1128], ["COMT", 1132], ["-", 1136], ["opicapone", 1137], ["complex", 1147], [".", 1154], ["Despite", 1156], ["its", 1164], ["short", 1168], ["elimination", 1174], ["half", 1186], ["-", 1190], ["life", 1191], [",", 1195], ["opicapone", 1197], ["markedly", 1207], ["and", 1216], ["sustainably", 1220], ["inhibited", 1232], ["erythrocyte", 1242], ["S", 1254], ["-", 1255], ["COMT", 1256], ["activity", 1261], ["making", 1270], ["it", 1277], ["suitable", 1280], ["for", 1289], ["a", 1293], ["once", 1295], ["daily", 1300], ["regimen", 1306], [".", 1313]]}
{"context": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/d) is only one third of its maximum tolerated dose, whereas the dose of erlotinib (150 mg/d) is at its maximum tolerated dose. In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC. To study the inhibitory concentrations of gefitinib and erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255, PC-9, and H1975) to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI. Gefitinib and erlotinib generated similar inhibitory curves across our panel of EGFR-mutated NSCLC cell lines with overlapping mean 50% inhibitory concentration 95% confidence intervals for HCC827, PC-9, and H1975. Both drugs also displayed a high degree of correlation in mean 50% inhibitory concentration (Pearson's r = 0.99, p = 0.0417). Of the seven patients, five patients (71.5%) had partial responses to erlotinib 25 mg/d. Median progression-free survival was 17 months (95% confidence interval, 6-35 months). Toxicities were minimal, with only two (28.5%) patients having a rash and none experiencing (0%) diarrhea. In NSCLC cell lines, gefitinib and erlotinib have similar inhibitory profiles. In patients with NSCLC and EGFR-activating mutations, a dose of erlotinib 25 mg/d (equivalent to gefitinib 250 mg/d) leads to impressive response rates and progression-free survival similar to the growing experience with the approved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d). Identifying prospectively the lowest and clinically active dose ranges of erlotinib and gefitinib will help further to personalize care for patients with tumors harboring EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "2e559521de4543c0bcd36ddc1c47fc44", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[23, 30]], "char_spans": [[121, 164]]}]}], "context_tokens": [["The", 0], ["tyrosine", 4], ["kinase", 13], ["inhibitors", 20], ["(", 31], ["TKIs", 32], [")", 36], ["gefitinib", 38], ["and", 48], ["erlotinib", 52], ["are", 62], ["effective", 66], ["in", 76], ["non", 79], ["-", 82], ["small", 83], ["cell", 89], ["lung", 94], ["cancers", 99], ["(", 107], ["NSCLCs", 108], [")", 114], ["with", 116], ["epidermal", 121], ["growth", 131], ["factor", 138], ["receptor", 145], ["(", 154], ["EGFR", 155], [")", 159], ["gene", 161], ["mutations", 166], [".", 175], ["The", 177], ["usual", 181], ["clinical", 187], ["dose", 196], ["of", 201], ["gefitinib", 204], ["(", 214], ["250", 215], ["mg", 219], ["/", 221], ["d", 222], [")", 223], ["is", 225], ["only", 228], ["one", 233], ["third", 237], ["of", 243], ["its", 246], ["maximum", 250], ["tolerated", 258], ["dose", 268], [",", 272], ["whereas", 274], ["the", 282], ["dose", 286], ["of", 291], ["erlotinib", 294], ["(", 304], ["150", 305], ["mg", 309], ["/", 311], ["d", 312], [")", 313], ["is", 315], ["at", 318], ["its", 321], ["maximum", 325], ["tolerated", 333], ["dose", 343], [".", 347], ["In", 349], ["NSCLC", 352], ["cell", 358], ["lines", 363], [",", 368], ["both", 370], ["TKIs", 375], ["have", 380], ["similar", 385], ["micromolar", 393], ["inhibitory", 404], ["concentrations", 415], [".", 429], ["We", 431], ["explored", 434], ["whether", 443], ["erlotinib", 451], ["at", 461], ["25", 464], ["mg", 467], ["/", 469], ["d", 470], ["(", 472], ["trough", 473], ["serum", 480], ["concentration", 486], ["similar", 500], ["to", 508], ["gefitinib", 511], ["250", 521], ["mg", 525], ["/", 527], ["d", 528], [")", 529], ["would", 531], ["be", 537], ["efficacious", 540], ["in", 552], ["EGFR", 555], ["-", 559], ["mutated", 560], ["NSCLC", 568], [".", 573], ["To", 575], ["study", 578], ["the", 584], ["inhibitory", 588], ["concentrations", 599], ["of", 614], ["gefitinib", 617], ["and", 627], ["erlotinib", 631], [",", 640], ["we", 642], ["exposed", 645], ["EGFR", 653], ["-", 657], ["mutated", 658], ["cell", 666], ["lines", 671], ["(", 677], ["HCC827", 678], [",", 684], ["H3255", 686], [",", 691], ["PC-9", 693], [",", 697], ["and", 699], ["H1975", 703], [")", 708], ["to", 710], ["increasing", 713], ["concentrations", 724], ["of", 739], ["these", 742], ["TKIs", 748], [".", 752], ["Further", 754], ["on", 762], [",", 764], ["we", 766], ["performed", 769], ["a", 779], ["retrospective", 781], ["evaluation", 795], ["of", 806], ["seven", 809], ["patients", 815], ["with", 824], ["advanced", 829], ["EGFR", 838], ["-", 842], ["mutated", 843], ["(", 851], ["exon", 852], ["19", 857], ["deletions", 860], ["and", 870], ["L858R", 874], [")", 879], ["NSCLC", 881], ["that", 887], ["were", 892], ["given", 897], ["erlotinib", 903], ["at", 913], ["25", 916], ["mg", 919], ["/", 921], ["d", 922], ["as", 924], ["their", 927], ["first", 933], ["EGFR", 939], ["TKI", 944], [".", 947], ["Gefitinib", 949], ["and", 959], ["erlotinib", 963], ["generated", 973], ["similar", 983], ["inhibitory", 991], ["curves", 1002], ["across", 1009], ["our", 1016], ["panel", 1020], ["of", 1026], ["EGFR", 1029], ["-", 1033], ["mutated", 1034], ["NSCLC", 1042], ["cell", 1048], ["lines", 1053], ["with", 1059], ["overlapping", 1064], ["mean", 1076], ["50", 1081], ["%", 1083], ["inhibitory", 1085], ["concentration", 1096], ["95", 1110], ["%", 1112], ["confidence", 1114], ["intervals", 1125], ["for", 1135], ["HCC827", 1139], [",", 1145], ["PC-9", 1147], [",", 1151], ["and", 1153], ["H1975", 1157], [".", 1162], ["Both", 1164], ["drugs", 1169], ["also", 1175], ["displayed", 1180], ["a", 1190], ["high", 1192], ["degree", 1197], ["of", 1204], ["correlation", 1207], ["in", 1219], ["mean", 1222], ["50", 1227], ["%", 1229], ["inhibitory", 1231], ["concentration", 1242], ["(", 1256], ["Pearson", 1257], ["'s", 1264], ["r", 1267], ["=", 1269], ["0.99", 1271], [",", 1275], ["p", 1277], ["=", 1279], ["0.0417", 1281], [")", 1287], [".", 1288], ["Of", 1290], ["the", 1293], ["seven", 1297], ["patients", 1303], [",", 1311], ["five", 1313], ["patients", 1318], ["(", 1327], ["71.5", 1328], ["%", 1332], [")", 1333], ["had", 1335], ["partial", 1339], ["responses", 1347], ["to", 1357], ["erlotinib", 1360], ["25", 1370], ["mg", 1373], ["/", 1375], ["d", 1376], [".", 1377], ["Median", 1379], ["progression", 1386], ["-", 1397], ["free", 1398], ["survival", 1403], ["was", 1412], ["17", 1416], ["months", 1419], ["(", 1426], ["95", 1427], ["%", 1429], ["confidence", 1431], ["interval", 1442], [",", 1450], ["6", 1452], ["-", 1453], ["35", 1454], ["months", 1457], [")", 1463], [".", 1464], ["Toxicities", 1466], ["were", 1477], ["minimal", 1482], [",", 1489], ["with", 1491], ["only", 1496], ["two", 1501], ["(", 1505], ["28.5", 1506], ["%", 1510], [")", 1511], ["patients", 1513], ["having", 1522], ["a", 1529], ["rash", 1531], ["and", 1536], ["none", 1540], ["experiencing", 1545], ["(", 1558], ["0", 1559], ["%", 1560], [")", 1561], ["diarrhea", 1563], [".", 1571], ["In", 1573], ["NSCLC", 1576], ["cell", 1582], ["lines", 1587], [",", 1592], ["gefitinib", 1594], ["and", 1604], ["erlotinib", 1608], ["have", 1618], ["similar", 1623], ["inhibitory", 1631], ["profiles", 1642], [".", 1650], ["In", 1652], ["patients", 1655], ["with", 1664], ["NSCLC", 1669], ["and", 1675], ["EGFR", 1679], ["-", 1683], ["activating", 1684], ["mutations", 1695], [",", 1704], ["a", 1706], ["dose", 1708], ["of", 1713], ["erlotinib", 1716], ["25", 1726], ["mg", 1729], ["/", 1731], ["d", 1732], ["(", 1734], ["equivalent", 1735], ["to", 1746], ["gefitinib", 1749], ["250", 1759], ["mg", 1763], ["/", 1765], ["d", 1766], [")", 1767], ["leads", 1769], ["to", 1775], ["impressive", 1778], ["response", 1789], ["rates", 1798], ["and", 1804], ["progression", 1808], ["-", 1819], ["free", 1820], ["survival", 1825], ["similar", 1834], ["to", 1842], ["the", 1845], ["growing", 1849], ["experience", 1857], ["with", 1868], ["the", 1873], ["approved", 1877], ["doses", 1886], ["of", 1892], ["gefitinib", 1895], ["(", 1905], ["250", 1906], ["mg", 1910], ["/", 1912], ["d", 1913], [")", 1914], ["and", 1916], ["erlotinib", 1920], ["(", 1930], ["150", 1931], ["mg", 1935], ["/", 1937], ["d", 1938], [")", 1939], [".", 1940], ["Identifying", 1942], ["prospectively", 1954], ["the", 1968], ["lowest", 1972], ["and", 1979], ["clinically", 1983], ["active", 1994], ["dose", 2001], ["ranges", 2006], ["of", 2013], ["erlotinib", 2016], ["and", 2026], ["gefitinib", 2030], ["will", 2040], ["help", 2045], ["further", 2050], ["to", 2058], ["personalize", 2061], ["care", 2073], ["for", 2078], ["patients", 2082], ["with", 2091], ["tumors", 2096], ["harboring", 2103], ["EGFR", 2113], ["mutations", 2118], [".", 2127]]}
{"context": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6. These findings expand the clinical spectrum of the syndrome and indicate NHE6 dysfunction as a new cause of electrical status epilepticus during slow-wave sleep (ESES).", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9051b478ee6f41f98b58e2be06353573", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[100, 100], [13, 13]], "char_spans": [[576, 581], [64, 69]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["solute", 17], ["carrier", 24], ["family", 32], ["9", 39], [",", 40], ["subfamily", 42], ["A", 52], ["member", 54], ["6", 61], ["(", 63], ["SLC9A6", 64], [")", 70], ["gene", 72], [",", 76], ["encoding", 78], ["the", 87], ["endosomal", 91], ["Na+/H+", 101], ["exchanger", 108], ["6", 118], ["(", 120], ["NHE6", 121], [")", 125], ["are", 127], ["associated", 131], ["with", 142], ["Christianson", 147], ["syndrome", 160], [",", 168], ["a", 170], ["syndromic", 172], ["form", 182], ["of", 187], ["X", 190], ["-", 191], ["linked", 192], ["intellectual", 199], ["disability", 212], ["characterized", 223], ["by", 237], ["microcephaly", 240], [",", 252], ["severe", 254], ["global", 261], ["developmental", 268], ["delay", 282], [",", 287], ["autistic", 289], ["behavior", 298], [",", 306], ["early", 308], ["onset", 314], ["seizures", 320], ["and", 329], ["ataxia", 333], [".", 339], ["In", 341], ["a", 344], ["7-year", 346], ["-", 352], ["old", 353], ["boy", 357], ["with", 361], ["characteristic", 366], ["clinical", 381], ["and", 390], ["neuroimaging", 394], ["features", 407], ["of", 416], ["Christianson", 419], ["syndrome", 432], ["and", 441], ["epileptic", 445], ["encephalopathy", 455], ["with", 470], ["continuous", 475], ["spikes", 486], ["and", 493], ["waves", 497], ["during", 503], ["sleep", 510], [",", 515], ["we", 517], ["identified", 520], ["a", 531], ["novel", 533], ["splice", 539], ["site", 546], ["mutation", 551], ["(", 560], ["IVS10", 561], ["-", 566], ["1G", 567], [">", 569], ["A", 570], [")", 571], ["in", 573], ["SLC9A6", 576], [".", 582], ["These", 584], ["findings", 590], ["expand", 599], ["the", 606], ["clinical", 610], ["spectrum", 619], ["of", 628], ["the", 631], ["syndrome", 635], ["and", 644], ["indicate", 648], ["NHE6", 657], ["dysfunction", 662], ["as", 674], ["a", 677], ["new", 679], ["cause", 683], ["of", 689], ["electrical", 692], ["status", 703], ["epilepticus", 710], ["during", 722], ["slow", 729], ["-", 733], ["wave", 734], ["sleep", 739], ["(", 745], ["ESES", 746], [")", 750], [".", 751]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "aac69dde3c754b6ab56366207d37f1f7", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[214, 214]], "char_spans": [[1199, 1205]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["important", 23], ["post", 33], ["-", 37], ["transcriptional", 38], ["regulators", 54], ["of", 65], ["gene", 68], ["expression", 73], ["that", 84], ["act", 89], ["by", 93], ["direct", 96], ["base", 103], ["pairing", 108], ["to", 116], ["target", 119], ["sites", 126], ["within", 132], ["untranslated", 139], ["regions", 152], ["of", 160], ["messenger", 163], ["RNAs", 173], [".", 177], ["Recently", 179], [",", 187], ["miRNA", 189], ["activity", 195], ["has", 204], ["been", 208], ["shown", 213], ["to", 219], ["be", 222], ["affected", 225], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["miRNA", 253], ["sponge", 259], ["transcripts", 266], [",", 277], ["the", 279], ["so", 283], ["-", 285], ["called", 286], ["competing", 293], ["endogenous", 303], ["RNA", 314], ["in", 318], ["humans", 321], ["and", 328], ["target", 332], ["mimicry", 339], ["in", 347], ["plants", 350], [".", 356], ["We", 358], ["previously", 361], ["identified", 372], ["a", 383], ["highly", 385], ["expressed", 392], ["circular", 402], ["RNA", 411], ["(", 415], ["circRNA", 416], [")", 423], ["in", 425], ["human", 428], ["and", 434], ["mouse", 438], ["brain", 444], [".", 449], ["Here", 451], ["we", 456], ["show", 459], ["that", 464], ["this", 469], ["circRNA", 474], ["acts", 482], ["as", 487], ["a", 490], ["miR-7", 492], ["sponge", 498], [";", 504], ["we", 506], ["term", 509], ["this", 514], ["circular", 519], ["transcript", 528], ["ciRS-7", 539], ["(", 546], ["circular", 547], ["RNA", 556], ["sponge", 560], ["for", 567], ["miR-7", 571], [")", 576], [".", 577], ["ciRS-7", 579], ["contains", 586], ["more", 595], ["than", 600], ["70", 605], ["selectively", 608], ["conserved", 620], ["miRNA", 630], ["target", 636], ["sites", 643], [",", 648], ["and", 650], ["it", 654], ["is", 657], ["highly", 660], ["and", 667], ["widely", 671], ["associated", 678], ["with", 689], ["Argonaute", 694], ["(", 704], ["AGO", 705], [")", 708], ["proteins", 710], ["in", 719], ["a", 722], ["miR-7-dependent", 724], ["manner", 740], [".", 746], ["Although", 748], ["the", 757], ["circRNA", 761], ["is", 769], ["completely", 772], ["resistant", 783], ["to", 793], ["miRNA", 796], ["-", 801], ["mediated", 802], ["target", 811], ["destabilization", 818], [",", 833], ["it", 835], ["strongly", 838], ["suppresses", 847], ["miR-7", 858], ["activity", 864], [",", 872], ["resulting", 874], ["in", 884], ["increased", 887], ["levels", 897], ["of", 904], ["miR-7", 907], ["targets", 913], [".", 920], ["In", 922], ["the", 925], ["mouse", 929], ["brain", 935], [",", 940], ["we", 942], ["observe", 945], ["overlapping", 953], ["co", 965], ["-", 967], ["expression", 968], ["of", 979], ["ciRS-7", 982], ["and", 989], ["miR-7", 993], [",", 998], ["particularly", 1000], ["in", 1013], ["neocortical", 1016], ["and", 1028], ["hippocampal", 1032], ["neurons", 1044], [",", 1051], ["suggesting", 1053], ["a", 1064], ["high", 1066], ["degree", 1071], ["of", 1078], ["endogenous", 1081], ["interaction", 1092], [".", 1103], ["We", 1105], ["further", 1108], ["show", 1116], ["that", 1121], ["the", 1126], ["testis", 1130], ["-", 1136], ["specific", 1137], ["circRNA", 1146], [",", 1153], ["sex", 1155], ["-", 1158], ["determining", 1159], ["region", 1171], ["Y", 1178], ["(", 1180], ["Sry", 1181], [")", 1184], [",", 1185], ["serves", 1187], ["as", 1194], ["a", 1197], ["miR-138", 1199], ["sponge", 1207], [",", 1213], ["suggesting", 1215], ["that", 1226], ["miRNA", 1231], ["sponge", 1237], ["effects", 1244], ["achieved", 1252], ["by", 1261], ["circRNA", 1264], ["formation", 1272], ["are", 1282], ["a", 1286], ["general", 1288], ["phenomenon", 1296], [".", 1306], ["This", 1308], ["study", 1313], ["serves", 1319], ["as", 1326], ["the", 1329], ["first", 1333], [",", 1338], ["to", 1340], ["our", 1343], ["knowledge", 1347], [",", 1356], ["functional", 1358], ["analysis", 1369], ["of", 1378], ["a", 1381], ["naturally", 1383], ["expressed", 1393], ["circRNA", 1403], [".", 1410]]}
{"context": "Selenocysteine, a selenium-containing analog of cysteine, is found in the prokaryotic and eukaryotic kingdoms in active sites of enzymes involved in oxidation-reduction reactions. Its biosynthesis and cotranslational insertion into selenoproteins is performed by an outstanding mechanism, implying the participation of several gene products. The tRNA(Sec) is one of these. In eukaryotes, its transcription mode by RNA polymerase III differs from that of classical tRNA genes, both at the level of the promoter elements and transcription factors involved. In addition, enhanced transcription is afforded by a newly characterized zinc finger activator. Not only transcription of the gene, but also the tRNA(Sec) itself is atypical since its 2D and 3D structures exhibit features which set it apart from classical tRNAs. Decoding of eukaryotic selenocysteine UGA codons requires a stem-loop structure in the 3'UTR of mRNAs, the selenocysteine insertion sequence (SECIS) element. Structure probing and sequence comparisons led us to propose a 2D structure model for the SECIS element, containing a novel RNA motif composed of four consecutive non-Watson-Crick base-pairs. A 3D model, rationalizing the accessibility data, was elaborated by computer modeling. It yields indicative or suggestive evidence for the role that could play some conserved residues and/or structural features in SECIS function. These might act as signals for interaction with SBP, the SECIS binding protein that we have characterized.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "8588c6a6d2b34d4ba7cbf44f2320db4d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[160, 160], [248, 248], [179, 179], [234, 234]], "char_spans": [[960, 964], [1455, 1459], [1066, 1070], [1382, 1386]]}]}], "context_tokens": [["Selenocysteine", 0], [",", 14], ["a", 16], ["selenium", 18], ["-", 26], ["containing", 27], ["analog", 38], ["of", 45], ["cysteine", 48], [",", 56], ["is", 58], ["found", 61], ["in", 67], ["the", 70], ["prokaryotic", 74], ["and", 86], ["eukaryotic", 90], ["kingdoms", 101], ["in", 110], ["active", 113], ["sites", 120], ["of", 126], ["enzymes", 129], ["involved", 137], ["in", 146], ["oxidation", 149], ["-", 158], ["reduction", 159], ["reactions", 169], [".", 178], ["Its", 180], ["biosynthesis", 184], ["and", 197], ["cotranslational", 201], ["insertion", 217], ["into", 227], ["selenoproteins", 232], ["is", 247], ["performed", 250], ["by", 260], ["an", 263], ["outstanding", 266], ["mechanism", 278], [",", 287], ["implying", 289], ["the", 298], ["participation", 302], ["of", 316], ["several", 319], ["gene", 327], ["products", 332], [".", 340], ["The", 342], ["tRNA(Sec", 346], [")", 354], ["is", 356], ["one", 359], ["of", 363], ["these", 366], [".", 371], ["In", 373], ["eukaryotes", 376], [",", 386], ["its", 388], ["transcription", 392], ["mode", 406], ["by", 411], ["RNA", 414], ["polymerase", 418], ["III", 429], ["differs", 433], ["from", 441], ["that", 446], ["of", 451], ["classical", 454], ["tRNA", 464], ["genes", 469], [",", 474], ["both", 476], ["at", 481], ["the", 484], ["level", 488], ["of", 494], ["the", 497], ["promoter", 501], ["elements", 510], ["and", 519], ["transcription", 523], ["factors", 537], ["involved", 545], [".", 553], ["In", 555], ["addition", 558], [",", 566], ["enhanced", 568], ["transcription", 577], ["is", 591], ["afforded", 594], ["by", 603], ["a", 606], ["newly", 608], ["characterized", 614], ["zinc", 628], ["finger", 633], ["activator", 640], [".", 649], ["Not", 651], ["only", 655], ["transcription", 660], ["of", 674], ["the", 677], ["gene", 681], [",", 685], ["but", 687], ["also", 691], ["the", 696], ["tRNA(Sec", 700], [")", 708], ["itself", 710], ["is", 717], ["atypical", 720], ["since", 729], ["its", 735], ["2D", 739], ["and", 742], ["3D", 746], ["structures", 749], ["exhibit", 760], ["features", 768], ["which", 777], ["set", 783], ["it", 787], ["apart", 790], ["from", 796], ["classical", 801], ["tRNAs", 811], [".", 816], ["Decoding", 818], ["of", 827], ["eukaryotic", 830], ["selenocysteine", 841], ["UGA", 856], ["codons", 860], ["requires", 867], ["a", 876], ["stem", 878], ["-", 882], ["loop", 883], ["structure", 888], ["in", 898], ["the", 901], ["3'UTR", 905], ["of", 911], ["mRNAs", 914], [",", 919], ["the", 921], ["selenocysteine", 925], ["insertion", 940], ["sequence", 950], ["(", 959], ["SECIS", 960], [")", 965], ["element", 967], [".", 974], ["Structure", 976], ["probing", 986], ["and", 994], ["sequence", 998], ["comparisons", 1007], ["led", 1019], ["us", 1023], ["to", 1026], ["propose", 1029], ["a", 1037], ["2D", 1039], ["structure", 1042], ["model", 1052], ["for", 1058], ["the", 1062], ["SECIS", 1066], ["element", 1072], [",", 1079], ["containing", 1081], ["a", 1092], ["novel", 1094], ["RNA", 1100], ["motif", 1104], ["composed", 1110], ["of", 1119], ["four", 1122], ["consecutive", 1127], ["non", 1139], ["-", 1142], ["Watson", 1143], ["-", 1149], ["Crick", 1150], ["base", 1156], ["-", 1160], ["pairs", 1161], [".", 1166], ["A", 1168], ["3D", 1170], ["model", 1173], [",", 1178], ["rationalizing", 1180], ["the", 1194], ["accessibility", 1198], ["data", 1212], [",", 1216], ["was", 1218], ["elaborated", 1222], ["by", 1233], ["computer", 1236], ["modeling", 1245], [".", 1253], ["It", 1255], ["yields", 1258], ["indicative", 1265], ["or", 1276], ["suggestive", 1279], ["evidence", 1290], ["for", 1299], ["the", 1303], ["role", 1307], ["that", 1312], ["could", 1317], ["play", 1323], ["some", 1328], ["conserved", 1333], ["residues", 1343], ["and/or", 1352], ["structural", 1359], ["features", 1370], ["in", 1379], ["SECIS", 1382], ["function", 1388], [".", 1396], ["These", 1398], ["might", 1404], ["act", 1410], ["as", 1414], ["signals", 1417], ["for", 1425], ["interaction", 1429], ["with", 1441], ["SBP", 1446], [",", 1449], ["the", 1451], ["SECIS", 1455], ["binding", 1461], ["protein", 1469], ["that", 1477], ["we", 1482], ["have", 1485], ["characterized", 1490], [".", 1503]]}
{"context": "More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278 bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179 or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper, or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar: 47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to exon 47. Of all sequence variants determined in our study, <20% represent C-->T or G-->A transitions within a CpG dinucleotide, and only six different mutations also occur in NF1 pseudogenes, with five being typical C-->T transitions in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%) missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, the GAP-related domain (GRD) and an upstream gene segment comprising exons 11-17. The latter forms a so-called cysteine/serine-rich domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those conserved between human and Drosophila strongly suggest significant functional relevance of this region, with major roles played by exons 12a and 15 and part of exon 16.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "beeb58f583fa4c9192e2fdb72f727d1a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[224, 224], [18, 18], [256, 256], [10, 10]], "char_spans": [[1174, 1176], [104, 106], [1382, 1384], [64, 66]]}]}], "context_tokens": [["More", 0], ["than", 5], ["500", 10], ["unrelated", 14], ["patients", 24], ["with", 33], ["neurofibromatosis", 38], ["type", 56], ["1", 61], ["(", 63], ["NF1", 64], [")", 67], ["were", 69], ["screened", 74], ["for", 83], ["mutations", 87], ["in", 97], ["the", 100], ["NF1", 104], ["gene", 108], [".", 112], ["For", 114], ["each", 118], ["patient", 123], [",", 130], ["the", 132], ["whole", 136], ["coding", 142], ["sequence", 149], ["and", 158], ["all", 162], ["splice", 166], ["sites", 173], ["were", 179], ["studied", 184], ["for", 192], ["aberrations", 196], [",", 207], ["either", 209], ["by", 216], ["the", 219], ["protein", 223], ["truncation", 231], ["test", 242], ["(", 247], ["PTT", 248], [")", 251], [",", 252], ["temperature", 254], ["-", 265], ["gradient", 266], ["gel", 275], ["electrophoresis", 279], ["(", 295], ["TGGE", 296], [")", 300], ["of", 302], ["genomic", 305], ["PCR", 313], ["products", 317], [",", 325], ["or", 327], [",", 329], ["most", 331], ["often", 336], [",", 341], ["by", 343], ["direct", 346], ["genomic", 353], ["sequencing", 361], ["(", 372], ["DGS", 373], [")", 376], ["of", 378], ["all", 381], ["individual", 385], ["exons", 396], [".", 401], ["A", 403], ["total", 405], ["of", 411], ["301", 414], ["sequence", 418], ["variants", 427], [",", 435], ["including", 437], ["278", 447], ["bona", 451], ["fide", 456], ["pathogenic", 461], ["mutations", 472], [",", 481], ["were", 483], ["identified", 488], [".", 498], ["As", 500], ["many", 503], ["as", 508], ["216", 511], ["or", 515], ["183", 518], ["of", 522], ["the", 525], ["genuine", 529], ["mutations", 537], [",", 546], ["comprising", 548], ["179", 559], ["or", 563], ["161", 566], ["different", 570], ["ones", 580], [",", 584], ["can", 586], ["be", 590], ["considered", 593], ["novel", 604], ["when", 610], ["compared", 615], ["to", 624], ["the", 627], ["recent", 631], ["findings", 638], ["of", 647], ["Upadhyaya", 650], ["and", 660], ["Cooper", 664], [",", 670], ["or", 672], ["to", 675], ["the", 678], ["NNFF", 682], ["mutation", 687], ["database", 696], [".", 704], ["Mutation", 706], ["-", 714], ["detection", 715], ["efficiencies", 725], ["of", 738], ["the", 741], ["various", 745], ["screening", 753], ["methods", 763], ["were", 771], ["similar", 776], [":", 783], ["47.1", 785], ["%", 789], ["for", 791], ["PTT", 795], [",", 798], ["53.7", 800], ["%", 804], ["for", 806], ["TGGE", 810], [",", 814], ["and", 816], ["54.9", 820], ["%", 824], ["for", 826], ["DGS", 830], [".", 833], ["Some", 835], ["224", 840], ["mutations", 844], ["(", 854], ["80.2", 855], ["%", 859], [")", 860], ["yielded", 862], ["directly", 870], ["or", 879], ["indirectly", 882], ["premature", 893], ["termination", 903], ["codons", 915], [".", 921], ["These", 923], ["mutations", 929], ["showed", 939], ["even", 946], ["distribution", 951], ["over", 964], ["the", 969], ["whole", 973], ["gene", 979], ["from", 984], ["exon", 989], ["1", 994], ["to", 996], ["exon", 999], ["47", 1004], [".", 1006], ["Of", 1008], ["all", 1011], ["sequence", 1015], ["variants", 1024], ["determined", 1033], ["in", 1044], ["our", 1047], ["study", 1051], [",", 1056], ["<", 1058], ["20", 1059], ["%", 1061], ["represent", 1063], ["C-->T", 1073], ["or", 1079], ["G-->A", 1082], ["transitions", 1088], ["within", 1100], ["a", 1107], ["CpG", 1109], ["dinucleotide", 1113], [",", 1125], ["and", 1127], ["only", 1131], ["six", 1136], ["different", 1140], ["mutations", 1150], ["also", 1160], ["occur", 1165], ["in", 1171], ["NF1", 1174], ["pseudogenes", 1178], [",", 1189], ["with", 1191], ["five", 1196], ["being", 1201], ["typical", 1207], ["C-->T", 1215], ["transitions", 1221], ["in", 1233], ["a", 1236], ["CpG.", 1238], ["Thus", 1243], [",", 1247], ["neither", 1249], ["frequent", 1257], ["deamination", 1266], ["of", 1278], ["5-methylcytosines", 1281], ["nor", 1299], ["interchromosomal", 1303], ["gene", 1320], ["conversion", 1325], ["may", 1336], ["account", 1340], ["for", 1348], ["the", 1352], ["high", 1356], ["mutation", 1361], ["rate", 1370], ["of", 1375], ["the", 1378], ["NF1", 1382], ["gene", 1386], [".", 1390], ["As", 1392], ["opposed", 1395], ["to", 1403], ["the", 1406], ["truncating", 1410], ["mutations", 1421], [",", 1430], ["the", 1432], ["28", 1436], ["(", 1439], ["10.1", 1440], ["%", 1444], [")", 1445], ["missense", 1447], ["or", 1456], ["single", 1459], ["-", 1465], ["amino", 1466], ["-", 1471], ["acid", 1472], ["-", 1476], ["deletion", 1477], ["mutations", 1486], ["identified", 1496], ["clustered", 1507], ["in", 1517], ["two", 1520], ["distinct", 1524], ["regions", 1533], [",", 1540], ["the", 1542], ["GAP", 1546], ["-", 1549], ["related", 1550], ["domain", 1558], ["(", 1565], ["GRD", 1566], [")", 1569], ["and", 1571], ["an", 1575], ["upstream", 1578], ["gene", 1587], ["segment", 1592], ["comprising", 1600], ["exons", 1611], ["11", 1617], ["-", 1619], ["17", 1620], [".", 1622], ["The", 1624], ["latter", 1628], ["forms", 1635], ["a", 1641], ["so", 1643], ["-", 1645], ["called", 1646], ["cysteine", 1653], ["/", 1661], ["serine", 1662], ["-", 1668], ["rich", 1669], ["domain", 1674], ["with", 1681], ["three", 1686], ["cysteine", 1692], ["pairs", 1701], ["suggestive", 1707], ["of", 1718], ["ATP", 1721], ["binding", 1725], [",", 1732], ["as", 1734], ["well", 1737], ["as", 1742], ["three", 1745], ["potential", 1751], ["cAMP", 1761], ["-", 1765], ["dependent", 1766], ["protein", 1776], ["kinase", 1784], ["(", 1791], ["PKA", 1792], [")", 1795], ["recognition", 1797], ["sites", 1809], ["obviously", 1815], ["phosphorylated", 1825], ["by", 1840], ["PKA", 1843], [".", 1846], ["Coincidence", 1848], ["of", 1860], ["mutated", 1863], ["amino", 1871], ["acids", 1877], ["and", 1883], ["those", 1887], ["conserved", 1893], ["between", 1903], ["human", 1911], ["and", 1917], ["Drosophila", 1921], ["strongly", 1932], ["suggest", 1941], ["significant", 1949], ["functional", 1961], ["relevance", 1972], ["of", 1982], ["this", 1985], ["region", 1990], [",", 1996], ["with", 1998], ["major", 2003], ["roles", 2009], ["played", 2015], ["by", 2022], ["exons", 2025], ["12a", 2031], ["and", 2035], ["15", 2039], ["and", 2042], ["part", 2046], ["of", 2051], ["exon", 2054], ["16", 2059], [".", 2061]]}
{"context": "Recently, bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia. A male infant developed severe hyperglycemia (446\u2009mg/dL) within 24\u2009h of birth. Acute abdominal concerns by day five necessitated exploratory surgery that revealed duodenal atresia, gallbladder agenesis, annular pancreas and intestinal malrotation. He also exhibited chronic diarrhea and feeding intolerance, cholestatic jaundice, and subsequent liver failure. He died of sepsis at four months old while awaiting liver transplantation. The phenotype of neonatal diabetes with intestinal atresia and biliary agenesis clearly pointed to RFX6 as the causative gene; indeed, whole exome sequencing revealed a novel homozygous RFX6 mutation c.779A>C; p.Lys260Thr (K260T). This missense mutation also changes the consensus 5' splice donor site before intron 7 and is thus predicted to cause disruption in splicing. Both parents, who were not known to be related, were heterozygous carriers. Targeted genetic testing based on consideration of phenotypic features may reveal a cause among the many genes now associated with heterogeneous forms of monogenic neonatal diabetes. Our study demonstrates the feasibility of using modern sequencing technology to identify one such rare cause. Continued research is needed to determine the possible cost-effectiveness of this approach, especially when clear phenotypic clues are absent. Further study of patients with RFX6 mutations should clarify its role in pancreatic, intestinal and enteroendocrine cellular development and explain features such as the diarrhea exhibited in our case.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "2e07fab624c345f486c1445ba1811034", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[120, 120], [135, 135], [261, 261], [10, 10]], "char_spans": [[750, 753], [837, 840], [1567, 1570], [59, 62]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["bi", 10], ["-", 12], ["allelic", 13], ["mutations", 21], ["in", 31], ["the", 34], ["transcription", 38], ["factor", 52], ["RFX6", 59], ["were", 64], ["described", 69], ["as", 79], ["the", 82], ["cause", 86], ["of", 92], ["a", 95], ["rare", 97], ["condition", 102], ["characterized", 112], ["by", 126], ["neonatal", 129], ["diabetes", 138], ["with", 147], ["pancreatic", 152], ["and", 163], ["biliary", 167], ["hypoplasia", 175], ["and", 186], ["duodenal", 190], ["/", 198], ["jejunal", 199], ["atresia", 207], [".", 214], ["A", 216], ["male", 218], ["infant", 223], ["developed", 230], ["severe", 240], ["hyperglycemia", 247], ["(", 261], ["446", 262], ["mg", 266], ["/", 268], ["dL", 269], [")", 271], ["within", 273], ["24", 280], ["h", 283], ["of", 285], ["birth", 288], [".", 293], ["Acute", 295], ["abdominal", 301], ["concerns", 311], ["by", 320], ["day", 323], ["five", 327], ["necessitated", 332], ["exploratory", 345], ["surgery", 357], ["that", 365], ["revealed", 370], ["duodenal", 379], ["atresia", 388], [",", 395], ["gallbladder", 397], ["agenesis", 409], [",", 417], ["annular", 419], ["pancreas", 427], ["and", 436], ["intestinal", 440], ["malrotation", 451], [".", 462], ["He", 464], ["also", 467], ["exhibited", 472], ["chronic", 482], ["diarrhea", 490], ["and", 499], ["feeding", 503], ["intolerance", 511], [",", 522], ["cholestatic", 524], ["jaundice", 536], [",", 544], ["and", 546], ["subsequent", 550], ["liver", 561], ["failure", 567], [".", 574], ["He", 576], ["died", 579], ["of", 584], ["sepsis", 587], ["at", 594], ["four", 597], ["months", 602], ["old", 609], ["while", 613], ["awaiting", 619], ["liver", 628], ["transplantation", 634], [".", 649], ["The", 651], ["phenotype", 655], ["of", 665], ["neonatal", 668], ["diabetes", 677], ["with", 686], ["intestinal", 691], ["atresia", 702], ["and", 710], ["biliary", 714], ["agenesis", 722], ["clearly", 731], ["pointed", 739], ["to", 747], ["RFX6", 750], ["as", 755], ["the", 758], ["causative", 762], ["gene", 772], [";", 776], ["indeed", 778], [",", 784], ["whole", 786], ["exome", 792], ["sequencing", 798], ["revealed", 809], ["a", 818], ["novel", 820], ["homozygous", 826], ["RFX6", 837], ["mutation", 842], ["c.779A", 851], [">", 857], ["C", 858], [";", 859], ["p", 861], [".", 862], ["Lys260Thr", 863], ["(", 873], ["K260", 874], ["T", 878], [")", 879], [".", 880], ["This", 882], ["missense", 887], ["mutation", 896], ["also", 905], ["changes", 910], ["the", 918], ["consensus", 922], ["5", 932], ["'", 933], ["splice", 935], ["donor", 942], ["site", 948], ["before", 953], ["intron", 960], ["7", 967], ["and", 969], ["is", 973], ["thus", 976], ["predicted", 981], ["to", 991], ["cause", 994], ["disruption", 1000], ["in", 1011], ["splicing", 1014], [".", 1022], ["Both", 1024], ["parents", 1029], [",", 1036], ["who", 1038], ["were", 1042], ["not", 1047], ["known", 1051], ["to", 1057], ["be", 1060], ["related", 1063], [",", 1070], ["were", 1072], ["heterozygous", 1077], ["carriers", 1090], [".", 1098], ["Targeted", 1100], ["genetic", 1109], ["testing", 1117], ["based", 1125], ["on", 1131], ["consideration", 1134], ["of", 1148], ["phenotypic", 1151], ["features", 1162], ["may", 1171], ["reveal", 1175], ["a", 1182], ["cause", 1184], ["among", 1190], ["the", 1196], ["many", 1200], ["genes", 1205], ["now", 1211], ["associated", 1215], ["with", 1226], ["heterogeneous", 1231], ["forms", 1245], ["of", 1251], ["monogenic", 1254], ["neonatal", 1264], ["diabetes", 1273], [".", 1281], ["Our", 1283], ["study", 1287], ["demonstrates", 1293], ["the", 1306], ["feasibility", 1310], ["of", 1322], ["using", 1325], ["modern", 1331], ["sequencing", 1338], ["technology", 1349], ["to", 1360], ["identify", 1363], ["one", 1372], ["such", 1376], ["rare", 1381], ["cause", 1386], [".", 1391], ["Continued", 1393], ["research", 1403], ["is", 1412], ["needed", 1415], ["to", 1422], ["determine", 1425], ["the", 1435], ["possible", 1439], ["cost", 1448], ["-", 1452], ["effectiveness", 1453], ["of", 1467], ["this", 1470], ["approach", 1475], [",", 1483], ["especially", 1485], ["when", 1496], ["clear", 1501], ["phenotypic", 1507], ["clues", 1518], ["are", 1524], ["absent", 1528], [".", 1534], ["Further", 1536], ["study", 1544], ["of", 1550], ["patients", 1553], ["with", 1562], ["RFX6", 1567], ["mutations", 1572], ["should", 1582], ["clarify", 1589], ["its", 1597], ["role", 1601], ["in", 1606], ["pancreatic", 1609], [",", 1619], ["intestinal", 1621], ["and", 1632], ["enteroendocrine", 1636], ["cellular", 1652], ["development", 1661], ["and", 1673], ["explain", 1677], ["features", 1685], ["such", 1694], ["as", 1699], ["the", 1702], ["diarrhea", 1706], ["exhibited", 1715], ["in", 1725], ["our", 1728], ["case", 1732], [".", 1736]]}
{"context": "MicroRNAs (miRNAs) are non-coding RNAs with important roles in regulating gene expression. Recent studies indicate that transcription and cleavage of miRNA are coupled, and that chromatin structure may influence miRNA transcription. However, little is known about the relationship between the chromatin structure and cleavage of pre-miRNA from pri-miRNA. By analysis of genome-wide nucleosome positioning data sets from human and Caenorhabditis elegans (C. elegans), we found an enrichment of positioned nucleosome on pre-miRNA genomic sequences, which is highly correlated with GC content within pre-miRNA. In addition, obvious enrichments of three histone modifications (H2BK5me1, H3K36me3 and H4K20me1) as well as RNA Polymerase II (RNAPII) were observed on pre-miRNA genomic sequences corresponding to the active-promoter miRNAs and expressed miRNAs. Our results revealed the chromatin structure characteristics of pre-miRNA genomic sequences, and implied potential mechanisms that can recognize these characteristics, thus improving pre-miRNA cleavage.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "800083a0aff44406b0a95cb46cf7343b", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[126, 128]], "char_spans": [[717, 733]]}, {"text": "RNAPII", "token_spans": [[130, 130]], "char_spans": [[736, 741]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], ["RNAs", 34], ["with", 39], ["important", 44], ["roles", 54], ["in", 60], ["regulating", 63], ["gene", 74], ["expression", 79], [".", 89], ["Recent", 91], ["studies", 98], ["indicate", 106], ["that", 115], ["transcription", 120], ["and", 134], ["cleavage", 138], ["of", 147], ["miRNA", 150], ["are", 156], ["coupled", 160], [",", 167], ["and", 169], ["that", 173], ["chromatin", 178], ["structure", 188], ["may", 198], ["influence", 202], ["miRNA", 212], ["transcription", 218], [".", 231], ["However", 233], [",", 240], ["little", 242], ["is", 249], ["known", 252], ["about", 258], ["the", 264], ["relationship", 268], ["between", 281], ["the", 289], ["chromatin", 293], ["structure", 303], ["and", 313], ["cleavage", 317], ["of", 326], ["pre", 329], ["-", 332], ["miRNA", 333], ["from", 339], ["pri", 344], ["-", 347], ["miRNA", 348], [".", 353], ["By", 355], ["analysis", 358], ["of", 367], ["genome", 370], ["-", 376], ["wide", 377], ["nucleosome", 382], ["positioning", 393], ["data", 405], ["sets", 410], ["from", 415], ["human", 420], ["and", 426], ["Caenorhabditis", 430], ["elegans", 445], ["(", 453], ["C.", 454], ["elegans", 457], [")", 464], [",", 465], ["we", 467], ["found", 470], ["an", 476], ["enrichment", 479], ["of", 490], ["positioned", 493], ["nucleosome", 504], ["on", 515], ["pre", 518], ["-", 521], ["miRNA", 522], ["genomic", 528], ["sequences", 536], [",", 545], ["which", 547], ["is", 553], ["highly", 556], ["correlated", 563], ["with", 574], ["GC", 579], ["content", 582], ["within", 590], ["pre", 597], ["-", 600], ["miRNA", 601], [".", 606], ["In", 608], ["addition", 611], [",", 619], ["obvious", 621], ["enrichments", 629], ["of", 641], ["three", 644], ["histone", 650], ["modifications", 658], ["(", 672], ["H2BK5me1", 673], [",", 681], ["H3K36me3", 683], ["and", 692], ["H4K20me1", 696], [")", 704], ["as", 706], ["well", 709], ["as", 714], ["RNA", 717], ["Polymerase", 721], ["II", 732], ["(", 735], ["RNAPII", 736], [")", 742], ["were", 744], ["observed", 749], ["on", 758], ["pre", 761], ["-", 764], ["miRNA", 765], ["genomic", 771], ["sequences", 779], ["corresponding", 789], ["to", 803], ["the", 806], ["active", 810], ["-", 816], ["promoter", 817], ["miRNAs", 826], ["and", 833], ["expressed", 837], ["miRNAs", 847], [".", 853], ["Our", 855], ["results", 859], ["revealed", 867], ["the", 876], ["chromatin", 880], ["structure", 890], ["characteristics", 900], ["of", 916], ["pre", 919], ["-", 922], ["miRNA", 923], ["genomic", 929], ["sequences", 937], [",", 946], ["and", 948], ["implied", 952], ["potential", 960], ["mechanisms", 970], ["that", 981], ["can", 986], ["recognize", 990], ["these", 1000], ["characteristics", 1006], [",", 1021], ["thus", 1023], ["improving", 1028], ["pre", 1038], ["-", 1041], ["miRNA", 1042], ["cleavage", 1048], [".", 1056]]}
{"context": "Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available. We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology. In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets. Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "bf0da804130241878073b33d36565f05", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[229, 229], [21, 21], [201, 201], [82, 82], [65, 65]], "char_spans": [[1255, 1257], [145, 147], [1119, 1121], [481, 483], [382, 384]]}]}], "context_tokens": [["Research", 0], ["is", 9], ["ongoing", 12], ["to", 20], ["develop", 23], ["multipurpose", 31], ["vaginal", 44], ["rings", 52], ["to", 58], ["be", 61], ["used", 64], ["continuously", 69], ["for", 82], ["contraception", 86], ["and", 100], ["to", 104], ["prevent", 107], ["Human", 115], ["Immunodeficiency", 121], ["Virus", 138], ["(", 144], ["HIV", 145], [")", 148], ["infection", 150], [".", 159], ["Contraceptive", 161], ["vaginal", 175], ["rings", 183], ["(", 189], ["CVRs", 190], [")", 194], ["are", 196], ["available", 200], ["in", 210], ["a", 213], ["number", 215], ["of", 222], ["countries", 225], ["and", 235], ["are", 239], ["most", 243], ["of", 248], ["the", 251], ["time", 255], ["used", 260], ["intermittently", 265], ["i.e.", 280], ["three", 285], ["weeks", 291], ["out", 297], ["of", 301], ["a", 304], ["4-week", 306], ["cycle", 313], [".", 318], ["Efficacy", 320], ["trials", 329], ["with", 336], ["a", 341], ["dapivirine", 343], ["-", 353], ["containing", 354], ["vaginal", 365], ["ring", 373], ["for", 378], ["HIV", 382], ["prevention", 386], ["are", 397], ["ongoing", 401], ["and", 409], ["plans", 413], ["to", 419], ["develop", 422], ["multi", 430], ["-", 435], ["purpose", 436], ["vaginal", 444], ["rings", 452], ["for", 458], ["prevention", 462], ["of", 473], ["both", 476], ["HIV", 481], ["and", 485], ["pregnancy", 489], ["have", 499], ["been", 504], ["elaborated", 509], [".", 519], ["In", 521], ["contrast", 524], ["with", 533], ["the", 538], ["CVRs", 542], [",", 546], ["multi", 548], ["-", 553], ["purpose", 554], ["vaginal", 562], ["rings", 570], ["will", 576], ["have", 581], ["to", 586], ["be", 589], ["used", 592], ["continuously", 597], [".", 609], ["Women", 611], ["who", 617], ["continuously", 621], ["use", 634], ["a", 638], ["CVR", 640], ["will", 644], ["no", 649], ["longer", 652], ["have", 659], ["menses", 664], [".", 670], ["Furthermore", 672], [",", 683], ["some", 685], ["safety", 690], ["aspects", 697], ["of", 705], ["CVR", 708], ["use", 712], ["have", 716], ["never", 721], ["been", 727], ["studied", 732], ["in", 740], ["-", 742], ["depth", 743], ["in", 749], ["the", 752], ["past", 756], [",", 760], ["such", 762], ["as", 767], ["the", 770], ["impact", 774], ["of", 781], ["the", 784], ["vaginal", 788], ["ring", 796], ["on", 801], ["the", 804], ["vaginal", 808], ["microbiota", 816], [",", 826], ["biofilm", 828], ["formation", 836], ["and", 846], ["induction", 850], ["of", 860], ["inflammation", 863], [".", 875], ["We", 877], ["studied", 880], ["acceptability", 888], ["and", 902], ["these", 906], ["novel", 912], ["aspects", 918], ["of", 926], ["safety", 929], ["in", 936], ["Rwandan", 939], ["women", 947], [".", 952], ["Although", 954], ["significant", 963], ["progress", 975], ["has", 984], ["been", 988], ["made", 993], ["over", 998], ["the", 1003], ["past", 1007], ["decade", 1012], [",", 1018], ["Rwanda", 1020], ["still", 1027], ["has", 1033], ["a", 1037], ["high", 1039], ["unmet", 1044], ["need", 1050], ["for", 1055], ["contraception", 1059], ["(", 1073], ["with", 1074], ["47", 1079], ["%", 1081], ["unplanned", 1083], ["births", 1093], [")", 1099], ["and", 1101], ["a", 1105], ["generalized", 1107], ["HIV", 1119], ["epidemic", 1123], [",", 1131], ["and", 1133], ["CVRs", 1137], ["are", 1142], ["not", 1146], ["yet", 1150], ["available", 1154], [".", 1163], ["We", 1165], ["will", 1168], ["conduct", 1173], ["an", 1181], ["open", 1184], ["label", 1189], [",", 1194], ["single", 1196], ["centre", 1203], [",", 1209], ["randomized", 1211], ["controlled", 1222], ["trial", 1233], [".", 1238], ["A", 1240], ["total", 1242], ["of", 1248], ["120", 1251], ["HIV", 1255], ["-", 1258], ["negative", 1259], ["women", 1268], ["will", 1274], ["be", 1279], ["randomized", 1282], ["to", 1293], ["intermittent", 1296], ["CVR", 1309], ["use", 1313], ["(", 1317], ["to", 1318], ["allow", 1321], ["menstruation", 1327], [")", 1339], ["or", 1341], ["continuous", 1344], ["CVR", 1355], ["use", 1359], [".", 1362], ["Women", 1364], ["will", 1370], ["be", 1375], ["followed", 1378], ["for", 1387], ["a", 1391], ["maximum", 1393], ["of", 1401], ["14", 1404], ["weeks", 1407], [".", 1412], ["In", 1414], ["parallel", 1417], [",", 1425], ["we", 1427], ["will", 1430], ["conduct", 1435], ["a", 1443], ["qualitative", 1445], ["study", 1457], ["using", 1463], ["in", 1469], ["-", 1471], ["depth", 1472], ["interview", 1478], ["and", 1488], ["focus", 1492], ["group", 1498], ["discussion", 1504], ["methodology", 1515], [".", 1526], ["In", 1528], ["addition", 1531], ["to", 1540], ["evaluating", 1543], ["the", 1554], ["safety", 1558], ["and", 1565], ["acceptability", 1569], ["of", 1583], ["intermittent", 1586], ["and", 1599], ["continuous", 1603], ["CVR", 1614], ["use", 1618], ["in", 1622], ["Rwandan", 1625], ["women", 1633], [",", 1638], ["we", 1640], ["hope", 1643], ["that", 1648], ["our", 1653], ["findings", 1657], ["will", 1666], ["inform", 1671], ["the", 1678], ["development", 1682], ["of", 1694], ["future", 1697], ["multipurpose", 1704], ["vaginal", 1717], ["rings", 1725], [",", 1730], ["will", 1732], ["prepare", 1737], ["Rwandan", 1745], ["study", 1753], ["populations", 1759], ["for", 1771], ["future", 1775], ["clinical", 1782], ["trials", 1791], ["of", 1798], ["multipurpose", 1801], ["vaginal", 1814], ["rings", 1822], [",", 1827], ["and", 1829], ["will", 1833], ["pave", 1838], ["the", 1843], ["way", 1847], ["for", 1851], ["introduction", 1855], ["of", 1868], ["CVRs", 1871], ["on", 1876], ["African", 1879], ["markets", 1887], [".", 1894], ["Clinicaltrials.gov", 1896], ["NCT01796613", 1915], [".", 1927], ["Registered", 1929], ["14", 1940], ["February", 1943], ["2013", 1952], [".", 1956]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a9464ddc76874f33bc3080db5c5c07b9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[34, 35]], "char_spans": [[214, 231]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "McLeod syndrome is caused by mutations of XK, an X-chromosomal gene of unknown function. Originally defined as a peculiar Kell blood group variant, the disease affects multiple organs, including the nervous system, but is certainly underdiagnosed. We analyzed the mutations and clinical findings of 22 affected men, aged 27 to 72 years. Fifteen different XK mutations were found, nine of which were novel, including the one of the eponymous case McLeod. Their common result is predicted absence or truncation of the XK protein. All patients showed elevated levels of muscle creatine phosphokinase, but clinical myopathy was less common. A peripheral neuropathy with areflexia was found in all but 2 patients. The central nervous system was affected in 15 patients, as obvious from the occurrence of seizures, cognitive impairment, psychopathology, and choreatic movements. Neuroimaging emphasized the particular involvement of the basal ganglia, which was also detected in 1 asymptomatic young patient. Most features develop with age, mainly after the fourth decade. The resemblance of McLeod syndrome with Huntington's disease and with autosomal recessive chorea-acanthocytosis suggests that the corresponding proteins--XK, huntingtin, and chorein--might belong to a common pathway, the dysfunction of which causes degeneration of the basal ganglia.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "8f600aec47fb4b109b628824fc85d81f", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[64, 64], [208, 208], [7, 7], [94, 94]], "char_spans": [[355, 356], [1221, 1222], [42, 43], [516, 517]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["caused", 19], ["by", 26], ["mutations", 29], ["of", 39], ["XK", 42], [",", 44], ["an", 46], ["X", 49], ["-", 50], ["chromosomal", 51], ["gene", 63], ["of", 68], ["unknown", 71], ["function", 79], [".", 87], ["Originally", 89], ["defined", 100], ["as", 108], ["a", 111], ["peculiar", 113], ["Kell", 122], ["blood", 127], ["group", 133], ["variant", 139], [",", 146], ["the", 148], ["disease", 152], ["affects", 160], ["multiple", 168], ["organs", 177], [",", 183], ["including", 185], ["the", 195], ["nervous", 199], ["system", 207], [",", 213], ["but", 215], ["is", 219], ["certainly", 222], ["underdiagnosed", 232], [".", 246], ["We", 248], ["analyzed", 251], ["the", 260], ["mutations", 264], ["and", 274], ["clinical", 278], ["findings", 287], ["of", 296], ["22", 299], ["affected", 302], ["men", 311], [",", 314], ["aged", 316], ["27", 321], ["to", 324], ["72", 327], ["years", 330], [".", 335], ["Fifteen", 337], ["different", 345], ["XK", 355], ["mutations", 358], ["were", 368], ["found", 373], [",", 378], ["nine", 380], ["of", 385], ["which", 388], ["were", 394], ["novel", 399], [",", 404], ["including", 406], ["the", 416], ["one", 420], ["of", 424], ["the", 427], ["eponymous", 431], ["case", 441], ["McLeod", 446], [".", 452], ["Their", 454], ["common", 460], ["result", 467], ["is", 474], ["predicted", 477], ["absence", 487], ["or", 495], ["truncation", 498], ["of", 509], ["the", 512], ["XK", 516], ["protein", 519], [".", 526], ["All", 528], ["patients", 532], ["showed", 541], ["elevated", 548], ["levels", 557], ["of", 564], ["muscle", 567], ["creatine", 574], ["phosphokinase", 583], [",", 596], ["but", 598], ["clinical", 602], ["myopathy", 611], ["was", 620], ["less", 624], ["common", 629], [".", 635], ["A", 637], ["peripheral", 639], ["neuropathy", 650], ["with", 661], ["areflexia", 666], ["was", 676], ["found", 680], ["in", 686], ["all", 689], ["but", 693], ["2", 697], ["patients", 699], [".", 707], ["The", 709], ["central", 713], ["nervous", 721], ["system", 729], ["was", 736], ["affected", 740], ["in", 749], ["15", 752], ["patients", 755], [",", 763], ["as", 765], ["obvious", 768], ["from", 776], ["the", 781], ["occurrence", 785], ["of", 796], ["seizures", 799], [",", 807], ["cognitive", 809], ["impairment", 819], [",", 829], ["psychopathology", 831], [",", 846], ["and", 848], ["choreatic", 852], ["movements", 862], [".", 871], ["Neuroimaging", 873], ["emphasized", 886], ["the", 897], ["particular", 901], ["involvement", 912], ["of", 924], ["the", 927], ["basal", 931], ["ganglia", 937], [",", 944], ["which", 946], ["was", 952], ["also", 956], ["detected", 961], ["in", 970], ["1", 973], ["asymptomatic", 975], ["young", 988], ["patient", 994], [".", 1001], ["Most", 1003], ["features", 1008], ["develop", 1017], ["with", 1025], ["age", 1030], [",", 1033], ["mainly", 1035], ["after", 1042], ["the", 1048], ["fourth", 1052], ["decade", 1059], [".", 1065], ["The", 1067], ["resemblance", 1071], ["of", 1083], ["McLeod", 1086], ["syndrome", 1093], ["with", 1102], ["Huntington", 1107], ["'s", 1117], ["disease", 1120], ["and", 1128], ["with", 1132], ["autosomal", 1137], ["recessive", 1147], ["chorea", 1157], ["-", 1163], ["acanthocytosis", 1164], ["suggests", 1179], ["that", 1188], ["the", 1193], ["corresponding", 1197], ["proteins", 1211], ["--", 1219], ["XK", 1221], [",", 1223], ["huntingtin", 1225], [",", 1235], ["and", 1237], ["chorein", 1241], ["--", 1248], ["might", 1250], ["belong", 1256], ["to", 1263], ["a", 1266], ["common", 1268], ["pathway", 1275], [",", 1282], ["the", 1284], ["dysfunction", 1288], ["of", 1300], ["which", 1303], ["causes", 1309], ["degeneration", 1316], ["of", 1329], ["the", 1332], ["basal", 1336], ["ganglia", 1342], [".", 1349]]}
{"context": "To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. An 800-bed, teaching, university-affiliated hospital. Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant \"waking\" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "703c26f6e3614fc3ad84fedea34fc7ed", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[416, 416], [213, 213], [363, 363], [134, 134], [294, 294], [605, 605], [12, 12], [564, 564], [105, 105], [233, 233], [505, 505], [585, 585], [15, 15]], "char_spans": [[2297, 2306], [1230, 1239], [1959, 1968], [704, 713], [1667, 1676], [3464, 3473], [59, 68], [3188, 3197], [539, 548], [1317, 1326], [2830, 2839], [3319, 3328], [84, 93]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], [",", 22], ["usefulness", 24], [",", 34], ["safety", 36], [",", 42], ["and", 44], ["dosages", 48], ["of", 56], ["flumazenil", 59], ["required", 70], ["when", 79], ["flumazenil", 84], ["is", 95], ["used", 98], ["in", 103], ["the", 106], ["diagnosis", 110], ["of", 120], ["benzodiazepine", 123], ["-", 137], ["induced", 138], ["coma", 146], ["(", 151], ["vs.", 152], ["other", 156], ["drug", 162], ["-", 166], ["induced", 167], ["coma", 175], [")", 179], [",", 180], ["and", 182], ["to", 186], ["reverse", 189], ["or", 197], ["prevent", 200], ["the", 208], ["recurrence", 212], ["of", 223], ["unconsciousness", 226], [".", 241], ["A", 243], ["two", 245], ["-", 248], ["phase", 249], ["study", 255], [":", 260], ["a", 262], ["controlled", 264], [",", 274], ["randomized", 276], [",", 286], ["double", 288], ["-", 294], ["blind", 295], ["study", 301], ["followed", 307], ["by", 316], ["a", 319], ["prospective", 321], [",", 332], ["open", 334], ["study", 339], [".", 344], ["An", 346], ["800-bed", 349], [",", 356], ["teaching", 358], [",", 366], ["university", 368], ["-", 378], ["affiliated", 379], ["hospital", 390], [".", 398], ["Unconscious", 400], ["patients", 412], ["(", 421], ["n", 422], ["=", 424], ["110", 426], [")", 429], ["suspected", 431], ["of", 441], ["benzodiazepine", 444], ["overdose", 459], [",", 467], ["graded", 469], ["2", 476], ["to", 478], ["4", 481], ["on", 483], ["the", 486], ["Matthew", 490], ["and", 498], ["Lawson", 502], ["coma", 509], ["scale", 514], [",", 519], ["were", 521], ["treated", 526], ["with", 534], ["flumazenil", 539], [",", 549], ["the", 551], ["specific", 555], ["benzodiazepine", 564], ["receptor", 579], ["antagonist", 588], [".", 598], ["The", 600], ["first", 604], ["31", 610], ["patients", 613], ["were", 622], ["studied", 627], ["in", 635], ["a", 638], ["double", 640], ["-", 646], ["blind", 647], ["fashion", 653], [",", 660], ["while", 662], ["the", 668], ["rest", 672], ["of", 677], ["the", 680], ["patients", 684], ["were", 693], ["given", 698], ["flumazenil", 704], ["according", 715], ["to", 725], ["an", 728], ["open", 731], ["protocol", 736], [".", 744], ["INTERVENTIONS", 746], [";", 759], ["All", 761], ["patients", 765], ["received", 774], ["supplemental", 783], ["oxygen", 796], [";", 802], ["endotracheal", 804], ["intubation", 817], ["was", 828], ["performed", 832], [",", 841], ["and", 843], ["synchronized", 847], ["intermittent", 860], ["mandatory", 873], ["ventilation", 883], ["was", 895], ["initiated", 899], ["whenever", 909], ["it", 918], ["was", 921], ["deemed", 925], ["necessary", 932], [".", 941], ["A", 943], ["peripheral", 945], ["intravenous", 956], ["cannula", 968], ["was", 976], ["inserted", 980], [",", 988], ["as", 990], ["were", 993], ["indwelling", 998], ["arterial", 1009], ["and", 1018], ["urinary", 1022], ["bladder", 1030], ["catheters", 1038], [".", 1047], ["Blood", 1049], ["pressure", 1055], [",", 1063], ["electrocardiogram", 1065], [",", 1082], ["respiratory", 1084], ["rate", 1096], [",", 1100], ["end", 1102], ["-", 1105], ["tidal", 1106], ["CO2", 1112], [",", 1115], ["and", 1117], ["core", 1121], ["temperature", 1126], ["were", 1138], ["continuously", 1143], ["monitored", 1156], [".", 1165], ["The", 1167], ["first", 1171], ["31", 1177], ["double", 1180], ["-", 1186], ["blind", 1187], ["patients", 1193], ["received", 1202], ["either", 1211], ["intravenous", 1218], ["flumazenil", 1230], ["(", 1241], ["to", 1242], ["a", 1245], ["maximum", 1247], ["of", 1255], ["1", 1258], ["mg", 1260], [")", 1262], ["or", 1264], ["saline", 1267], [",", 1273], ["while", 1275], ["the", 1281], ["rest", 1285], ["of", 1290], ["the", 1293], ["patients", 1297], ["were", 1306], ["given", 1311], ["flumazenil", 1317], ["until", 1328], ["either", 1334], ["regaining", 1341], ["consciousness", 1351], ["or", 1365], ["a", 1368], ["maximum", 1370], ["of", 1378], ["2.5", 1381], ["mg", 1385], ["was", 1388], ["injected", 1392], [".", 1400], ["Patients", 1402], ["remaining", 1411], ["unconscious", 1421], ["among", 1433], ["double", 1439], ["-", 1445], ["blind", 1446], ["patients", 1452], ["or", 1461], ["those", 1464], ["patients", 1470], ["relapsing", 1479], ["into", 1489], ["coma", 1494], ["after", 1499], ["the", 1505], ["first", 1509], ["dose", 1515], ["were", 1520], ["later", 1525], ["treated", 1531], ["in", 1539], ["the", 1542], ["open", 1546], ["phase", 1551], ["of", 1557], ["the", 1560], ["study", 1564], [".", 1569], ["Treatment", 1571], ["continued", 1581], ["by", 1591], ["boluses", 1594], ["or", 1602], ["infusion", 1605], ["as", 1614], ["long", 1617], ["as", 1622], ["efficacious", 1625], [".", 1636], ["Fourteen", 1638], ["of", 1647], ["17", 1650], ["double", 1653], ["-", 1659], ["blind", 1660], [",", 1665], ["flumazenil", 1667], ["-", 1677], ["treated", 1678], ["patients", 1686], ["woke", 1695], ["after", 1700], ["a", 1706], ["mean", 1708], ["of", 1713], ["0.8", 1716], ["+", 1720], ["/-", 1721], ["0.3", 1724], ["(", 1728], ["SD", 1729], [")", 1731], ["mg", 1733], ["vs.", 1736], ["one", 1740], ["of", 1744], ["14", 1747], ["placebo", 1750], ["patients", 1758], ["(", 1767], ["p", 1768], ["<", 1770], [".001", 1772], [")", 1776], [".", 1777], ["Seventy", 1779], ["-", 1786], ["five", 1787], ["percent", 1792], ["of", 1800], ["the", 1803], ["aggregated", 1807], ["controlled", 1818], ["and", 1829], ["uncontrolled", 1833], ["patients", 1846], ["awoke", 1855], ["from", 1861], ["coma", 1866], ["scores", 1871], ["of", 1878], ["3.1", 1881], ["+", 1885], ["/-", 1886], ["0.6", 1889], ["to", 1893], ["0.4", 1896], ["+", 1900], ["/-", 1901], ["0.5", 1904], ["(", 1908], ["p", 1909], ["<", 1911], [".01", 1913], [")", 1916], ["after", 1918], ["the", 1924], ["injection", 1928], ["of", 1938], ["0.7", 1941], ["+", 1945], ["/-", 1946], ["0.3", 1949], ["mg", 1953], ["of", 1956], ["flumazenil", 1959], [".", 1969], ["These", 1971], ["patients", 1977], ["had", 1986], ["high", 1990], ["benzodiazepine", 1995], ["serum", 2010], ["blood", 2016], ["concentrations", 2022], [".", 2036], ["Twenty", 2038], ["-", 2044], ["five", 2045], ["percent", 2050], ["of", 2058], ["the", 2061], ["patients", 2065], ["did", 2074], ["not", 2078], ["regain", 2082], ["consciousness", 2089], [".", 2102], ["These", 2104], ["patients", 2110], ["had", 2119], ["very", 2123], ["high", 2128], ["serum", 2133], ["concentrations", 2139], ["of", 2154], ["nonbenzodiazepine", 2157], ["drugs", 2175], [".", 2180], ["Sixty", 2182], ["percent", 2188], ["of", 2196], ["the", 2199], ["responders", 2203], ["who", 2214], ["had", 2218], ["primarily", 2222], ["ingested", 2232], ["benzodiazepines", 2241], ["remained", 2257], ["awake", 2266], ["for", 2272], ["72", 2276], ["+", 2279], ["/-", 2280], ["37", 2283], ["mins", 2286], ["after", 2291], ["flumazenil", 2297], ["administration", 2308], [";", 2322], ["40", 2324], ["%", 2326], ["relapsed", 2328], ["into", 2337], ["coma", 2342], ["after", 2347], ["18", 2353], ["+", 2356], ["/-", 2357], ["7", 2360], ["mins", 2362], ["and", 2367], ["various", 2371], ["central", 2379], ["nervous", 2387], ["system", 2395], ["depressant", 2402], ["drugs", 2413], ["were", 2419], ["detected", 2424], ["in", 2433], ["their", 2436], ["blood", 2442], ["in", 2448], ["addition", 2451], ["to", 2460], ["benzodiazepines", 2463], [".", 2478], ["Seventy", 2480], ["-", 2487], ["one", 2488], ["percent", 2492], ["of", 2500], ["the", 2503], ["patients", 2507], ["had", 2516], ["ingested", 2520], ["tricyclic", 2529], ["antidepressants", 2539], [".", 2554], ["Seventy", 2556], ["-", 2563], ["eight", 2564], ["percent", 2570], ["of", 2578], ["the", 2581], ["responders", 2585], ["were", 2596], ["continually", 2601], ["and", 2613], ["efficaciously", 2617], ["treated", 2631], ["for", 2639], ["<", 2643], ["or", 2645], ["=", 2648], ["8", 2650], ["days", 2652], [".", 2656], ["Fourteen", 2658], ["(", 2667], ["25", 2668], ["%", 2670], [")", 2671], ["of", 2673], ["the", 2676], ["intubated", 2680], ["patients", 2690], ["were", 2699], ["extubated", 2704], ["safely", 2714], ["while", 2721], ["12", 2727], ["patients", 2730], [",", 2738], ["who", 2740], ["had", 2744], ["shown", 2748], ["increased", 2754], ["respiratory", 2764], ["insufficiency", 2776], [",", 2789], ["resumed", 2791], ["satisfactory", 2799], ["respiration", 2812], ["after", 2824], ["flumazenil", 2830], ["injection", 2841], [".", 2850], ["Five", 2852], ["cases", 2857], ["of", 2863], ["transient", 2866], ["increase", 2876], ["in", 2885], ["blood", 2888], ["pressure", 2894], ["and", 2903], ["heart", 2907], ["rate", 2913], ["were", 2918], ["encountered", 2923], [".", 2934], ["There", 2936], ["were", 2942], ["27", 2947], ["mildly", 2950], ["unpleasant", 2957], ["\"", 2968], ["waking", 2969], ["\"", 2975], ["episodes", 2977], [",", 2985], ["such", 2987], ["as", 2992], ["anxiety", 2995], [",", 3002], ["restlessness", 3004], [",", 3016], ["and", 3018], ["aggression", 3022], [",", 3032], ["but", 3034], ["no", 3038], ["patient", 3041], ["had", 3049], ["benzodiazepine", 3053], ["withdrawal", 3068], ["signs", 3079], [",", 3084], ["convulsions", 3086], [",", 3097], ["or", 3099], ["dysrhythmia", 3102], [",", 3113], ["most", 3115], ["noticeably", 3120], ["absent", 3131], ["in", 3138], ["tricyclic", 3141], ["antidepressant", 3151], ["-", 3165], ["intoxicated", 3166], ["patients", 3178], [".", 3186], ["Flumazenil", 3188], ["is", 3199], ["a", 3202], ["valid", 3204], ["diagnostic", 3210], ["tool", 3221], ["for", 3226], ["distinguishing", 3230], ["pure", 3245], ["benzodiazepine", 3250], ["from", 3265], ["mixed", 3270], ["-", 3275], ["drug", 3276], ["intoxication", 3281], ["or", 3294], ["nondrug", 3297], ["-", 3304], ["induced", 3305], ["coma", 3313], [".", 3317], ["Flumazenil", 3319], ["is", 3330], ["effective", 3333], ["in", 3343], ["preventing", 3346], ["recurrence", 3357], ["of", 3368], ["benzodiazepine", 3371], ["-", 3385], ["induced", 3386], ["coma", 3394], [".", 3398], ["Respiratory", 3400], ["insufficiency", 3412], ["is", 3426], ["reversed", 3429], ["after", 3438], ["its", 3444], ["administration", 3448], [".", 3462], ["Flumazenil", 3464], ["is", 3475], ["safe", 3478], ["when", 3483], ["administered", 3488], ["cautiously", 3501], [",", 3511], ["even", 3513], ["in", 3518], ["patients", 3521], ["with", 3530], ["coma", 3535], ["caused", 3540], ["by", 3547], ["a", 3550], ["mixed", 3552], ["overdose", 3558], ["of", 3567], ["benzodiazepine", 3570], ["plus", 3585], ["tricyclic", 3590], ["antidepressants", 3600], [".", 3615]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 \u03bcg were used. Bioequivalence between 8 x 200 \u03bcg and a new 1,600 \u03bcg tablet was evaluated at steady state in healthy male subjects. This was an open-label, 2-treatment, 2-period, crossover, up-titration, phase 1 study. The treatments were selexipag at 1,600 \u03bcg b.i.d. for 4.5 days either as 8 x 200 \u03bcg tablets (reference: A) or 1 x 1,600 \u03bcg tablet (test: B), both preceded by an up-titration phase starting from 400 \u03bcg b.i.d. doses, in 200-\u03bcg steps every 4th day. Subjects were randomized 1 : 1 to the A-B or B-A sequence. The pharmacokinetics and tolerability of selexipag and its active metabolite, ACT-333679, were investigated. 80 subjects were enrolled in the study: 65 subjects completed the study according to protocol, and 15 subjects withdrew from the study. The most frequent adverse events (AEs) were headache (86%), myalgia (73%), and jaw pain (73%). There was no difference in nature and overall frequency of AEs between the two treatments. Steady state was attained within 3 days of the selexipag 1,600 \u00ce\u00bcg b.i.d. The 90% confidence intervals (CIs) of the geometric mean ratio (B/A) at steady state for AUC\u00cf\u0084 and Cmax,ss were within (0.80, 1.25) bioequivalence interval: (0.92, 1.06) and (0.95, 1.14), respectively, for selexipag and (0.95, 1.06) and (0.94, 1.07), respectively, for the active metabolite, ACT-333679. Bioequivalence was demonstrated between 8 x 200 \u03bcg and 1 x 1,600 \u03bcg selexipag at steady state.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "990c3fbed6b34ba08dd9a7685e257613", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[21, 23]], "char_spans": [[120, 150]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["novel", 15], [",", 20], ["oral", 22], [",", 26], ["selective", 28], ["prostacyclin", 38], ["(", 51], ["PGI2", 52], [")", 56], ["receptor", 58], ["agonist", 67], ["in", 75], ["clinical", 78], ["development", 87], ["for", 99], ["the", 103], ["treatment", 107], ["of", 117], ["pulmonary", 120], ["arterial", 130], ["hypertension", 139], [".", 151], ["Film", 153], ["-", 157], ["coated", 158], ["tablets", 165], ["with", 173], ["strength", 178], ["between", 187], ["200", 195], ["and", 199], ["1,600", 203], ["\u03bcg", 209], ["were", 212], ["used", 217], [".", 221], ["Bioequivalence", 223], ["between", 238], ["8", 246], ["x", 248], ["200", 250], ["\u03bcg", 254], ["and", 257], ["a", 261], ["new", 263], ["1,600", 267], ["\u03bcg", 273], ["tablet", 276], ["was", 283], ["evaluated", 287], ["at", 297], ["steady", 300], ["state", 307], ["in", 313], ["healthy", 316], ["male", 324], ["subjects", 329], [".", 337], ["This", 339], ["was", 344], ["an", 348], ["open", 351], ["-", 355], ["label", 356], [",", 361], ["2-treatment", 363], [",", 374], ["2-period", 376], [",", 384], ["crossover", 386], [",", 395], ["up", 397], ["-", 399], ["titration", 400], [",", 409], ["phase", 411], ["1", 417], ["study", 419], [".", 424], ["The", 426], ["treatments", 430], ["were", 441], ["selexipag", 446], ["at", 456], ["1,600", 459], ["\u03bcg", 465], ["b.i.d", 468], [".", 473], ["for", 475], ["4.5", 479], ["days", 483], ["either", 488], ["as", 495], ["8", 498], ["x", 500], ["200", 502], ["\u03bcg", 506], ["tablets", 509], ["(", 517], ["reference", 518], [":", 527], ["A", 529], [")", 530], ["or", 532], ["1", 535], ["x", 537], ["1,600", 539], ["\u03bcg", 545], ["tablet", 548], ["(", 555], ["test", 556], [":", 560], ["B", 562], [")", 563], [",", 564], ["both", 566], ["preceded", 571], ["by", 580], ["an", 583], ["up", 586], ["-", 588], ["titration", 589], ["phase", 599], ["starting", 605], ["from", 614], ["400", 619], ["\u03bcg", 623], ["b.i.d", 626], [".", 631], ["doses", 633], [",", 638], ["in", 640], ["200-\u03bcg", 643], ["steps", 650], ["every", 656], ["4th", 662], ["day", 666], [".", 669], ["Subjects", 671], ["were", 680], ["randomized", 685], ["1", 696], [":", 698], ["1", 700], ["to", 702], ["the", 705], ["A", 709], ["-", 710], ["B", 711], ["or", 713], ["B", 716], ["-", 717], ["A", 718], ["sequence", 720], [".", 728], ["The", 730], ["pharmacokinetics", 734], ["and", 751], ["tolerability", 755], ["of", 768], ["selexipag", 771], ["and", 781], ["its", 785], ["active", 789], ["metabolite", 796], [",", 806], ["ACT-333679", 808], [",", 818], ["were", 820], ["investigated", 825], [".", 837], ["80", 839], ["subjects", 842], ["were", 851], ["enrolled", 856], ["in", 865], ["the", 868], ["study", 872], [":", 877], ["65", 879], ["subjects", 882], ["completed", 891], ["the", 901], ["study", 905], ["according", 911], ["to", 921], ["protocol", 924], [",", 932], ["and", 934], ["15", 938], ["subjects", 941], ["withdrew", 950], ["from", 959], ["the", 964], ["study", 968], [".", 973], ["The", 975], ["most", 979], ["frequent", 984], ["adverse", 993], ["events", 1001], ["(", 1008], ["AEs", 1009], [")", 1012], ["were", 1014], ["headache", 1019], ["(", 1028], ["86", 1029], ["%", 1031], [")", 1032], [",", 1033], ["myalgia", 1035], ["(", 1043], ["73", 1044], ["%", 1046], [")", 1047], [",", 1048], ["and", 1050], ["jaw", 1054], ["pain", 1058], ["(", 1063], ["73", 1064], ["%", 1066], [")", 1067], [".", 1068], ["There", 1070], ["was", 1076], ["no", 1080], ["difference", 1083], ["in", 1094], ["nature", 1097], ["and", 1104], ["overall", 1108], ["frequency", 1116], ["of", 1126], ["AEs", 1129], ["between", 1133], ["the", 1141], ["two", 1145], ["treatments", 1149], [".", 1159], ["Steady", 1161], ["state", 1168], ["was", 1174], ["attained", 1178], ["within", 1187], ["3", 1194], ["days", 1196], ["of", 1201], ["the", 1204], ["selexipag", 1208], ["1,600", 1218], ["\u00ce\u00bcg", 1224], ["b.i.d", 1228], [".", 1233], ["The", 1235], ["90", 1239], ["%", 1241], ["confidence", 1243], ["intervals", 1254], ["(", 1264], ["CIs", 1265], [")", 1268], ["of", 1270], ["the", 1273], ["geometric", 1277], ["mean", 1287], ["ratio", 1292], ["(", 1298], ["B", 1299], ["/", 1300], ["A", 1301], [")", 1302], ["at", 1304], ["steady", 1307], ["state", 1314], ["for", 1320], ["AUC\u00cf\u0084", 1324], ["and", 1330], ["Cmax", 1334], [",", 1338], ["ss", 1339], ["were", 1342], ["within", 1347], ["(", 1354], ["0.80", 1355], [",", 1359], ["1.25", 1361], [")", 1365], ["bioequivalence", 1367], ["interval", 1382], [":", 1390], ["(", 1392], ["0.92", 1393], [",", 1397], ["1.06", 1399], [")", 1403], ["and", 1405], ["(", 1409], ["0.95", 1410], [",", 1414], ["1.14", 1416], [")", 1420], [",", 1421], ["respectively", 1423], [",", 1435], ["for", 1437], ["selexipag", 1441], ["and", 1451], ["(", 1455], ["0.95", 1456], [",", 1460], ["1.06", 1462], [")", 1466], ["and", 1468], ["(", 1472], ["0.94", 1473], [",", 1477], ["1.07", 1479], [")", 1483], [",", 1484], ["respectively", 1486], [",", 1498], ["for", 1500], ["the", 1504], ["active", 1508], ["metabolite", 1515], [",", 1525], ["ACT-333679", 1527], [".", 1537], ["Bioequivalence", 1539], ["was", 1554], ["demonstrated", 1558], ["between", 1571], ["8", 1579], ["x", 1581], ["200", 1583], ["\u03bcg", 1587], ["and", 1590], ["1", 1594], ["x", 1596], ["1,600", 1598], ["\u03bcg", 1604], ["selexipag", 1607], ["at", 1617], ["steady", 1620], ["state", 1627], [".", 1632]]}
{"context": "Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD). Recent evidence suggests that impairment of lysosomal pathways (i.e. autophagy) involved in alpha-synuclein clearance might play an important role. For this reason, we sought to examine the expression levels of members of the autophagy pathway in brains of patients with DLB and Alzheimer's Disease (AD) and in alpha-synuclein transgenic mice. By immunoblot analysis, compared to controls and AD, in DLB cases levels of mTor were elevated and Atg7 were reduced. Levels of other components of the autophagy pathway such as Atg5, Atg10, Atg12 and Beclin-1 were not different in DLB compared to controls. In DLB brains, mTor was more abundant in neurons displaying alpha-synuclein accumulation. These neurons also showed abnormal expression of lysosomal markers such as LC3, and ultrastructural analysis revealed the presence of abundant and abnormal autophagosomes. Similar alterations were observed in the brains of alpha-synuclein transgenic mice. Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations. This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and alpha-synuclein transgenic models and supports the possibility that modulators of the autophagy pathway might have potential therapeutic effects.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "2fa17a29be5d4cdb8b61ce90ede60e4a", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[26, 30]], "char_spans": [[170, 192]]}]}], "context_tokens": [["Lewy", 0], ["body", 5], ["disease", 10], ["is", 18], ["a", 21], ["heterogeneous", 23], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["disorders", 64], ["characterized", 74], ["by", 88], ["alpha", 91], ["-", 96], ["synuclein", 97], ["accumulation", 107], ["that", 120], ["includes", 125], ["dementia", 134], ["with", 143], ["Lewy", 148], ["bodies", 153], ["(", 160], ["DLB", 161], [")", 164], ["and", 166], ["Parkinson", 170], ["'s", 179], ["Disease", 182], ["(", 190], ["PD", 191], [")", 193], [".", 194], ["Recent", 196], ["evidence", 203], ["suggests", 212], ["that", 221], ["impairment", 226], ["of", 237], ["lysosomal", 240], ["pathways", 250], ["(", 259], ["i.e.", 260], ["autophagy", 265], [")", 274], ["involved", 276], ["in", 285], ["alpha", 288], ["-", 293], ["synuclein", 294], ["clearance", 304], ["might", 314], ["play", 320], ["an", 325], ["important", 328], ["role", 338], [".", 342], ["For", 344], ["this", 348], ["reason", 353], [",", 359], ["we", 361], ["sought", 364], ["to", 371], ["examine", 374], ["the", 382], ["expression", 386], ["levels", 397], ["of", 404], ["members", 407], ["of", 415], ["the", 418], ["autophagy", 422], ["pathway", 432], ["in", 440], ["brains", 443], ["of", 450], ["patients", 453], ["with", 462], ["DLB", 467], ["and", 471], ["Alzheimer", 475], ["'s", 484], ["Disease", 487], ["(", 495], ["AD", 496], [")", 498], ["and", 500], ["in", 504], ["alpha", 507], ["-", 512], ["synuclein", 513], ["transgenic", 523], ["mice", 534], [".", 538], ["By", 540], ["immunoblot", 543], ["analysis", 554], [",", 562], ["compared", 564], ["to", 573], ["controls", 576], ["and", 585], ["AD", 589], [",", 591], ["in", 593], ["DLB", 596], ["cases", 600], ["levels", 606], ["of", 613], ["mTor", 616], ["were", 621], ["elevated", 626], ["and", 635], ["Atg7", 639], ["were", 644], ["reduced", 649], [".", 656], ["Levels", 658], ["of", 665], ["other", 668], ["components", 674], ["of", 685], ["the", 688], ["autophagy", 692], ["pathway", 702], ["such", 710], ["as", 715], ["Atg5", 718], [",", 722], ["Atg10", 724], [",", 729], ["Atg12", 731], ["and", 737], ["Beclin-1", 741], ["were", 750], ["not", 755], ["different", 759], ["in", 769], ["DLB", 772], ["compared", 776], ["to", 785], ["controls", 788], [".", 796], ["In", 798], ["DLB", 801], ["brains", 805], [",", 811], ["mTor", 813], ["was", 818], ["more", 822], ["abundant", 827], ["in", 836], ["neurons", 839], ["displaying", 847], ["alpha", 858], ["-", 863], ["synuclein", 864], ["accumulation", 874], [".", 886], ["These", 888], ["neurons", 894], ["also", 902], ["showed", 907], ["abnormal", 914], ["expression", 923], ["of", 934], ["lysosomal", 937], ["markers", 947], ["such", 955], ["as", 960], ["LC3", 963], [",", 966], ["and", 968], ["ultrastructural", 972], ["analysis", 988], ["revealed", 997], ["the", 1006], ["presence", 1010], ["of", 1019], ["abundant", 1022], ["and", 1031], ["abnormal", 1035], ["autophagosomes", 1044], [".", 1058], ["Similar", 1060], ["alterations", 1068], ["were", 1080], ["observed", 1085], ["in", 1094], ["the", 1097], ["brains", 1101], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["transgenic", 1127], ["mice", 1138], [".", 1142], ["Intra", 1144], ["-", 1149], ["cerebral", 1150], ["infusion", 1159], ["of", 1168], ["rapamycin", 1171], [",", 1180], ["an", 1182], ["inhibitor", 1185], ["of", 1195], ["mTor", 1198], [",", 1202], ["or", 1204], ["injection", 1207], ["of", 1217], ["a", 1220], ["lentiviral", 1222], ["vector", 1233], ["expressing", 1240], ["Atg7", 1251], ["resulted", 1256], ["in", 1265], ["reduced", 1268], ["accumulation", 1276], ["of", 1289], ["alpha", 1292], ["-", 1297], ["synuclein", 1298], ["in", 1308], ["transgenic", 1311], ["mice", 1322], ["and", 1327], ["amelioration", 1331], ["of", 1344], ["associated", 1347], ["neurodegenerative", 1358], ["alterations", 1376], [".", 1387], ["This", 1389], ["study", 1394], ["supports", 1400], ["the", 1409], ["notion", 1413], ["that", 1420], ["defects", 1425], ["in", 1433], ["the", 1436], ["autophagy", 1440], ["pathway", 1450], ["and", 1458], ["more", 1462], ["specifically", 1467], ["in", 1480], ["mTor", 1483], ["and", 1488], ["Atg7", 1492], ["are", 1497], ["associated", 1501], ["with", 1512], ["neurodegeneration", 1517], ["in", 1535], ["DLB", 1538], ["cases", 1542], ["and", 1548], ["alpha", 1552], ["-", 1557], ["synuclein", 1558], ["transgenic", 1568], ["models", 1579], ["and", 1586], ["supports", 1590], ["the", 1599], ["possibility", 1603], ["that", 1615], ["modulators", 1620], ["of", 1631], ["the", 1634], ["autophagy", 1638], ["pathway", 1648], ["might", 1656], ["have", 1662], ["potential", 1667], ["therapeutic", 1677], ["effects", 1689], [".", 1696]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "Parkinson's disease (PD) is one of many neurodegenerative diseases that are characterized by amyloid fibril formation. Alpha-synuclein is a primary component of the fibrillar neuronal inclusions, known as Lewy bodies, that are diagnostic of PD. In addition, the alpha-synuclein gene is linked to familial PD. Fibril formation by alpha-synuclein proceeds via discrete beta-sheet-rich oligomers, or protofibrils, that are consumed as fibrils grow. Both FPD mutations accelerate formation of protofibrils, suggesting that these intermediates, rather than the fibril product, trigger neuronal loss. In idiopathic PD, other factors may be responsible for accelerating protofibril formation by wild-type alpha-synuclein. One possible factor could be molecular crowding in the neuronal cytoplasm. We demonstrate here that crowding using inert polymers significantly reduced the lag time for protofibril formation and the conversion of the protofibril to the fibril, but did not affect the morphology of either species. Physiologically realistic changes in the degree of in vitro crowding have significant kinetic consequences. Thus, nonspecific changes in the total cytoplasmic protein concentration, induced by cell volume changes and/or altered protein degradation, could promote formation of and stabilize the alpha-synuclein protofibril.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "7206b07769574e8793fa79da4f2aab29", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[124, 126], [20, 22], [61, 63], [48, 50], [219, 221]], "char_spans": [[698, 712], [119, 133], [329, 343], [262, 276], [1306, 1320]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["one", 28], ["of", 32], ["many", 35], ["neurodegenerative", 40], ["diseases", 58], ["that", 67], ["are", 72], ["characterized", 76], ["by", 90], ["amyloid", 93], ["fibril", 101], ["formation", 108], [".", 117], ["Alpha", 119], ["-", 124], ["synuclein", 125], ["is", 135], ["a", 138], ["primary", 140], ["component", 148], ["of", 158], ["the", 161], ["fibrillar", 165], ["neuronal", 175], ["inclusions", 184], [",", 194], ["known", 196], ["as", 202], ["Lewy", 205], ["bodies", 210], [",", 216], ["that", 218], ["are", 223], ["diagnostic", 227], ["of", 238], ["PD", 241], [".", 243], ["In", 245], ["addition", 248], [",", 256], ["the", 258], ["alpha", 262], ["-", 267], ["synuclein", 268], ["gene", 278], ["is", 283], ["linked", 286], ["to", 293], ["familial", 296], ["PD", 305], [".", 307], ["Fibril", 309], ["formation", 316], ["by", 326], ["alpha", 329], ["-", 334], ["synuclein", 335], ["proceeds", 345], ["via", 354], ["discrete", 358], ["beta", 367], ["-", 371], ["sheet", 372], ["-", 377], ["rich", 378], ["oligomers", 383], [",", 392], ["or", 394], ["protofibrils", 397], [",", 409], ["that", 411], ["are", 416], ["consumed", 420], ["as", 429], ["fibrils", 432], ["grow", 440], [".", 444], ["Both", 446], ["FPD", 451], ["mutations", 455], ["accelerate", 465], ["formation", 476], ["of", 486], ["protofibrils", 489], [",", 501], ["suggesting", 503], ["that", 514], ["these", 519], ["intermediates", 525], [",", 538], ["rather", 540], ["than", 547], ["the", 552], ["fibril", 556], ["product", 563], [",", 570], ["trigger", 572], ["neuronal", 580], ["loss", 589], [".", 593], ["In", 595], ["idiopathic", 598], ["PD", 609], [",", 611], ["other", 613], ["factors", 619], ["may", 627], ["be", 631], ["responsible", 634], ["for", 646], ["accelerating", 650], ["protofibril", 663], ["formation", 675], ["by", 685], ["wild", 688], ["-", 692], ["type", 693], ["alpha", 698], ["-", 703], ["synuclein", 704], [".", 713], ["One", 715], ["possible", 719], ["factor", 728], ["could", 735], ["be", 741], ["molecular", 744], ["crowding", 754], ["in", 763], ["the", 766], ["neuronal", 770], ["cytoplasm", 779], [".", 788], ["We", 790], ["demonstrate", 793], ["here", 805], ["that", 810], ["crowding", 815], ["using", 824], ["inert", 830], ["polymers", 836], ["significantly", 845], ["reduced", 859], ["the", 867], ["lag", 871], ["time", 875], ["for", 880], ["protofibril", 884], ["formation", 896], ["and", 906], ["the", 910], ["conversion", 914], ["of", 925], ["the", 928], ["protofibril", 932], ["to", 944], ["the", 947], ["fibril", 951], [",", 957], ["but", 959], ["did", 963], ["not", 967], ["affect", 971], ["the", 978], ["morphology", 982], ["of", 993], ["either", 996], ["species", 1003], [".", 1010], ["Physiologically", 1012], ["realistic", 1028], ["changes", 1038], ["in", 1046], ["the", 1049], ["degree", 1053], ["of", 1060], ["in", 1063], ["vitro", 1066], ["crowding", 1072], ["have", 1081], ["significant", 1086], ["kinetic", 1098], ["consequences", 1106], [".", 1118], ["Thus", 1120], [",", 1124], ["nonspecific", 1126], ["changes", 1138], ["in", 1146], ["the", 1149], ["total", 1153], ["cytoplasmic", 1159], ["protein", 1171], ["concentration", 1179], [",", 1192], ["induced", 1194], ["by", 1202], ["cell", 1205], ["volume", 1210], ["changes", 1217], ["and/or", 1225], ["altered", 1232], ["protein", 1240], ["degradation", 1248], [",", 1259], ["could", 1261], ["promote", 1267], ["formation", 1275], ["of", 1285], ["and", 1288], ["stabilize", 1292], ["the", 1302], ["alpha", 1306], ["-", 1311], ["synuclein", 1312], ["protofibril", 1322], [".", 1333]]}
{"context": "Both non-Group A streptococcal (non-GAS) pharyngitis and Group A streptococcal (GAS) pharyngitis are commonly found in patients with sore throat. It is not known whether or not they present with similar signs and symptoms compared to patients with non-streptococcal pharyngitis. MEDLINE was searched for prospective studies that reported throat culture for both GAS and non-GAS as a reference standard, and reported at least one sign, symptom, or the Centor score. Summary estimates of sensitivity, specificity, likelihood ratios (LR+ and LR-), and diagnostic odds ratios (DOR) were calculated using a bivariate random effects model. Summary receiver operating characteristic (ROC) curves were created for key signs and symptoms. Eight studies met our inclusion criteria. Tonsillar exudate had the highest LR+ for both GAS and non-GAS pharyngitis (1.53 versus 1.71). The confidence intervals of sensitivity, LR+, LR-, and DOR for all signs, symptoms, and the Centor score between two groups overlapped, with the relative difference between sensitivities within 15% for arthralgia or myalgia, fever, injected throat, tonsillar enlargement, and tonsillar exudate. Larger differences in sensitivities were observed for sore throat, cervical adenopathy, and lack of a cough, although the difference for lack of a cough largely due to a single outlier. Signs and symptoms of patients with GAS and non-GAS pharyngitis are generally similar. No signs or symptoms clearly distinguish GAS from non-GAS infection. Further work is needed to determine whether Group C streptococcus is a pathogen that should be treated.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "6952c83e31114a20b979dc5962329901", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[49, 50]], "char_spans": [[252, 276]]}]}], "context_tokens": [["Both", 0], ["non", 5], ["-", 8], ["Group", 9], ["A", 15], ["streptococcal", 17], ["(", 31], ["non", 32], ["-", 35], ["GAS", 36], [")", 39], ["pharyngitis", 41], ["and", 53], ["Group", 57], ["A", 63], ["streptococcal", 65], ["(", 79], ["GAS", 80], [")", 83], ["pharyngitis", 85], ["are", 97], ["commonly", 101], ["found", 110], ["in", 116], ["patients", 119], ["with", 128], ["sore", 133], ["throat", 138], [".", 144], ["It", 146], ["is", 149], ["not", 152], ["known", 156], ["whether", 162], ["or", 170], ["not", 173], ["they", 177], ["present", 182], ["with", 190], ["similar", 195], ["signs", 203], ["and", 209], ["symptoms", 213], ["compared", 222], ["to", 231], ["patients", 234], ["with", 243], ["non", 248], ["-", 251], ["streptococcal", 252], ["pharyngitis", 266], [".", 277], ["MEDLINE", 279], ["was", 287], ["searched", 291], ["for", 300], ["prospective", 304], ["studies", 316], ["that", 324], ["reported", 329], ["throat", 338], ["culture", 345], ["for", 353], ["both", 357], ["GAS", 362], ["and", 366], ["non", 370], ["-", 373], ["GAS", 374], ["as", 378], ["a", 381], ["reference", 383], ["standard", 393], [",", 401], ["and", 403], ["reported", 407], ["at", 416], ["least", 419], ["one", 425], ["sign", 429], [",", 433], ["symptom", 435], [",", 442], ["or", 444], ["the", 447], ["Centor", 451], ["score", 458], [".", 463], ["Summary", 465], ["estimates", 473], ["of", 483], ["sensitivity", 486], [",", 497], ["specificity", 499], [",", 510], ["likelihood", 512], ["ratios", 523], ["(", 530], ["LR+", 531], ["and", 535], ["LR-", 539], [")", 542], [",", 543], ["and", 545], ["diagnostic", 549], ["odds", 560], ["ratios", 565], ["(", 572], ["DOR", 573], [")", 576], ["were", 578], ["calculated", 583], ["using", 594], ["a", 600], ["bivariate", 602], ["random", 612], ["effects", 619], ["model", 627], [".", 632], ["Summary", 634], ["receiver", 642], ["operating", 651], ["characteristic", 661], ["(", 676], ["ROC", 677], [")", 680], ["curves", 682], ["were", 689], ["created", 694], ["for", 702], ["key", 706], ["signs", 710], ["and", 716], ["symptoms", 720], [".", 728], ["Eight", 730], ["studies", 736], ["met", 744], ["our", 748], ["inclusion", 752], ["criteria", 762], [".", 770], ["Tonsillar", 772], ["exudate", 782], ["had", 790], ["the", 794], ["highest", 798], ["LR+", 806], ["for", 810], ["both", 814], ["GAS", 819], ["and", 823], ["non", 827], ["-", 830], ["GAS", 831], ["pharyngitis", 835], ["(", 847], ["1.53", 848], ["versus", 853], ["1.71", 860], [")", 864], [".", 865], ["The", 867], ["confidence", 871], ["intervals", 882], ["of", 892], ["sensitivity", 895], [",", 906], ["LR+", 908], [",", 911], ["LR-", 913], [",", 916], ["and", 918], ["DOR", 922], ["for", 926], ["all", 930], ["signs", 934], [",", 939], ["symptoms", 941], [",", 949], ["and", 951], ["the", 955], ["Centor", 959], ["score", 966], ["between", 972], ["two", 980], ["groups", 984], ["overlapped", 991], [",", 1001], ["with", 1003], ["the", 1008], ["relative", 1012], ["difference", 1021], ["between", 1032], ["sensitivities", 1040], ["within", 1054], ["15", 1061], ["%", 1063], ["for", 1065], ["arthralgia", 1069], ["or", 1080], ["myalgia", 1083], [",", 1090], ["fever", 1092], [",", 1097], ["injected", 1099], ["throat", 1108], [",", 1114], ["tonsillar", 1116], ["enlargement", 1126], [",", 1137], ["and", 1139], ["tonsillar", 1143], ["exudate", 1153], [".", 1160], ["Larger", 1162], ["differences", 1169], ["in", 1181], ["sensitivities", 1184], ["were", 1198], ["observed", 1203], ["for", 1212], ["sore", 1216], ["throat", 1221], [",", 1227], ["cervical", 1229], ["adenopathy", 1238], [",", 1248], ["and", 1250], ["lack", 1254], ["of", 1259], ["a", 1262], ["cough", 1264], [",", 1269], ["although", 1271], ["the", 1280], ["difference", 1284], ["for", 1295], ["lack", 1299], ["of", 1304], ["a", 1307], ["cough", 1309], ["largely", 1315], ["due", 1323], ["to", 1327], ["a", 1330], ["single", 1332], ["outlier", 1339], [".", 1346], ["Signs", 1348], ["and", 1354], ["symptoms", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["GAS", 1384], ["and", 1388], ["non", 1392], ["-", 1395], ["GAS", 1396], ["pharyngitis", 1400], ["are", 1412], ["generally", 1416], ["similar", 1426], [".", 1433], ["No", 1435], ["signs", 1438], ["or", 1444], ["symptoms", 1447], ["clearly", 1456], ["distinguish", 1464], ["GAS", 1476], ["from", 1480], ["non", 1485], ["-", 1488], ["GAS", 1489], ["infection", 1493], [".", 1502], ["Further", 1504], ["work", 1512], ["is", 1517], ["needed", 1520], ["to", 1527], ["determine", 1530], ["whether", 1540], ["Group", 1548], ["C", 1554], ["streptococcus", 1556], ["is", 1570], ["a", 1573], ["pathogen", 1575], ["that", 1584], ["should", 1589], ["be", 1596], ["treated", 1599], [".", 1606]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "The organic cation transporter 3 (OCT3) is a widely expressed transporter for endogenous and exogenous organic cations. Of particular interest is OCT3 expression and function in the brain, where it plays a role in serotonin clearance and influences mood and behavior. Protein kinase signaling mediates rapid modulation of cerebral processes, but little is known about acute regulation of OCT3 by protein kinases. Therefore, we cloned mouse OCT3 (mOCT3) and generated a human embryonic kidney cell line stably expressing the transporter to study transport characteristics, acute regulation by protein kinases, and interaction with psychotropic drugs. Uptake measurement was performed using the fluorescent cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+), 1\u00a0\u03bcM) as a substrate. The translational value of these findings was determined by comparing results obtained with cloned mouse and human OCT3. mOCT3-mediated transport is membrane potential dependent and pH independent. ASP(+) uptake by mOCT3 and human OCT3 (hOCT3) was efficiently inhibited by 1-methyl-4-phenylpyridinium, tetrapentylammonium (TPA(+)), corticosterone, serotonin, and histamine and by the drugs ketamine, fluoxetine, and diazepam. The half maximal inhibitory concentrations of mOCT3 and hOCT3 for TPA(+), serotonin, diazepam, and ketamine are significantly different. Diazepam is a non-transported inhibitor. Furthermore, the activities of mOCT3 and hOCT3 are acutely regulated by the p56 (lck) tyrosine kinase by decreasing their V max. Studies with freshly isolated renal proximal tubules from mOCT1/2(-/-) mice, in which mOCT3 is the only OCT present, confirmed this regulation pathway. Only the activity of hOCT3 is regulated by calmodulin. These findings suggest that even though many transport properties of mOCT3 and hOCT3 are similar, there are also species-specific aspects of OCT3 function.", "qas": [{"question": "How is OCT3 associated with serotonin?", "answers": ["serotonin clearance"], "qid": "bf90e54a60234266b05dd70fed882e86", "question_tokens": [["How", 0], ["is", 4], ["OCT3", 7], ["associated", 12], ["with", 23], ["serotonin", 28], ["?", 37]], "detected_answers": [{"text": "serotonin clearance", "token_spans": [[38, 39]], "char_spans": [[214, 232]]}]}], "context_tokens": [["The", 0], ["organic", 4], ["cation", 12], ["transporter", 19], ["3", 31], ["(", 33], ["OCT3", 34], [")", 38], ["is", 40], ["a", 43], ["widely", 45], ["expressed", 52], ["transporter", 62], ["for", 74], ["endogenous", 78], ["and", 89], ["exogenous", 93], ["organic", 103], ["cations", 111], [".", 118], ["Of", 120], ["particular", 123], ["interest", 134], ["is", 143], ["OCT3", 146], ["expression", 151], ["and", 162], ["function", 166], ["in", 175], ["the", 178], ["brain", 182], [",", 187], ["where", 189], ["it", 195], ["plays", 198], ["a", 204], ["role", 206], ["in", 211], ["serotonin", 214], ["clearance", 224], ["and", 234], ["influences", 238], ["mood", 249], ["and", 254], ["behavior", 258], [".", 266], ["Protein", 268], ["kinase", 276], ["signaling", 283], ["mediates", 293], ["rapid", 302], ["modulation", 308], ["of", 319], ["cerebral", 322], ["processes", 331], [",", 340], ["but", 342], ["little", 346], ["is", 353], ["known", 356], ["about", 362], ["acute", 368], ["regulation", 374], ["of", 385], ["OCT3", 388], ["by", 393], ["protein", 396], ["kinases", 404], [".", 411], ["Therefore", 413], [",", 422], ["we", 424], ["cloned", 427], ["mouse", 434], ["OCT3", 440], ["(", 445], ["mOCT3", 446], [")", 451], ["and", 453], ["generated", 457], ["a", 467], ["human", 469], ["embryonic", 475], ["kidney", 485], ["cell", 492], ["line", 497], ["stably", 502], ["expressing", 509], ["the", 520], ["transporter", 524], ["to", 536], ["study", 539], ["transport", 545], ["characteristics", 555], [",", 570], ["acute", 572], ["regulation", 578], ["by", 589], ["protein", 592], ["kinases", 600], [",", 607], ["and", 609], ["interaction", 613], ["with", 625], ["psychotropic", 630], ["drugs", 643], [".", 648], ["Uptake", 650], ["measurement", 657], ["was", 669], ["performed", 673], ["using", 683], ["the", 689], ["fluorescent", 693], ["cation", 705], ["4-(4-(dimethylamino)styryl)-N", 712], ["-", 741], ["methylpyridinium", 742], ["iodide", 759], ["(", 766], ["ASP(+", 767], [")", 772], [",", 773], ["1", 775], ["\u03bcM", 777], [")", 779], ["as", 781], ["a", 784], ["substrate", 786], [".", 795], ["The", 797], ["translational", 801], ["value", 815], ["of", 821], ["these", 824], ["findings", 830], ["was", 839], ["determined", 843], ["by", 854], ["comparing", 857], ["results", 867], ["obtained", 875], ["with", 884], ["cloned", 889], ["mouse", 896], ["and", 902], ["human", 906], ["OCT3", 912], [".", 916], ["mOCT3-mediated", 918], ["transport", 933], ["is", 943], ["membrane", 946], ["potential", 955], ["dependent", 965], ["and", 975], ["pH", 979], ["independent", 982], [".", 993], ["ASP(+", 995], [")", 1000], ["uptake", 1002], ["by", 1009], ["mOCT3", 1012], ["and", 1018], ["human", 1022], ["OCT3", 1028], ["(", 1033], ["hOCT3", 1034], [")", 1039], ["was", 1041], ["efficiently", 1045], ["inhibited", 1057], ["by", 1067], ["1-methyl-4-phenylpyridinium", 1070], [",", 1097], ["tetrapentylammonium", 1099], ["(", 1119], ["TPA(+", 1120], [")", 1125], [")", 1126], [",", 1127], ["corticosterone", 1129], [",", 1143], ["serotonin", 1145], [",", 1154], ["and", 1156], ["histamine", 1160], ["and", 1170], ["by", 1174], ["the", 1177], ["drugs", 1181], ["ketamine", 1187], [",", 1195], ["fluoxetine", 1197], [",", 1207], ["and", 1209], ["diazepam", 1213], [".", 1221], ["The", 1223], ["half", 1227], ["maximal", 1232], ["inhibitory", 1240], ["concentrations", 1251], ["of", 1266], ["mOCT3", 1269], ["and", 1275], ["hOCT3", 1279], ["for", 1285], ["TPA(+", 1289], [")", 1294], [",", 1295], ["serotonin", 1297], [",", 1306], ["diazepam", 1308], [",", 1316], ["and", 1318], ["ketamine", 1322], ["are", 1331], ["significantly", 1335], ["different", 1349], [".", 1358], ["Diazepam", 1360], ["is", 1369], ["a", 1372], ["non", 1374], ["-", 1377], ["transported", 1378], ["inhibitor", 1390], [".", 1399], ["Furthermore", 1401], [",", 1412], ["the", 1414], ["activities", 1418], ["of", 1429], ["mOCT3", 1432], ["and", 1438], ["hOCT3", 1442], ["are", 1448], ["acutely", 1452], ["regulated", 1460], ["by", 1470], ["the", 1473], ["p56", 1477], ["(", 1481], ["lck", 1482], [")", 1485], ["tyrosine", 1487], ["kinase", 1496], ["by", 1503], ["decreasing", 1506], ["their", 1517], ["V", 1523], ["max", 1525], [".", 1528], ["Studies", 1530], ["with", 1538], ["freshly", 1543], ["isolated", 1551], ["renal", 1560], ["proximal", 1566], ["tubules", 1575], ["from", 1583], ["mOCT1/2(-/-", 1588], [")", 1599], ["mice", 1601], [",", 1605], ["in", 1607], ["which", 1610], ["mOCT3", 1616], ["is", 1622], ["the", 1625], ["only", 1629], ["OCT", 1634], ["present", 1638], [",", 1645], ["confirmed", 1647], ["this", 1657], ["regulation", 1662], ["pathway", 1673], [".", 1680], ["Only", 1682], ["the", 1687], ["activity", 1691], ["of", 1700], ["hOCT3", 1703], ["is", 1709], ["regulated", 1712], ["by", 1722], ["calmodulin", 1725], [".", 1735], ["These", 1737], ["findings", 1743], ["suggest", 1752], ["that", 1760], ["even", 1765], ["though", 1770], ["many", 1777], ["transport", 1782], ["properties", 1792], ["of", 1803], ["mOCT3", 1806], ["and", 1812], ["hOCT3", 1816], ["are", 1822], ["similar", 1826], [",", 1833], ["there", 1835], ["are", 1841], ["also", 1845], ["species", 1850], ["-", 1857], ["specific", 1858], ["aspects", 1867], ["of", 1875], ["OCT3", 1878], ["function", 1883], [".", 1891]]}
{"context": "Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "f8585ae680a84b258cfa4b315d1378ba", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[48, 48]], "char_spans": [[309, 311]]}]}], "context_tokens": [["Nonnucleoside", 0], ["reverse", 14], ["transcriptase", 22], ["inhibitors", 36], ["(", 47], ["NNRTIs", 48], [")", 54], ["are", 56], ["widely", 60], ["used", 67], ["to", 72], ["treat", 75], ["HIV-1-infected", 81], ["individuals", 96], [";", 107], ["indeed", 109], ["most", 116], ["first", 121], ["-", 126], ["line", 127], ["antiretroviral", 132], ["therapies", 147], ["typically", 157], ["include", 167], ["one", 175], ["NNRTI", 179], ["in", 185], ["combination", 188], ["with", 200], ["two", 205], ["nucleoside", 209], ["analogs", 220], [".", 227], ["In", 229], ["2008", 232], [",", 236], ["the", 238], ["next", 242], ["-", 246], ["generation", 247], ["NNRTI", 258], ["etravirine", 264], ["was", 275], ["approved", 279], ["for", 288], ["the", 292], ["treatment", 296], ["of", 306], ["HIV", 309], ["-", 312], ["infected", 313], ["antiretroviral", 322], ["therapy", 337], ["-", 344], ["experienced", 345], ["individuals", 357], [",", 368], ["including", 370], ["those", 380], ["with", 386], ["prior", 391], ["NNRTI", 397], ["exposure", 403], [".", 411], ["NNRTIs", 413], ["are", 420], ["also", 424], ["increasingly", 429], ["being", 442], ["included", 448], ["in", 457], ["strategies", 460], ["to", 471], ["prevent", 474], ["HIV-1", 482], ["infection", 488], [".", 497], ["For", 499], ["example", 503], [":", 510], ["(", 512], ["1", 513], [")", 514], ["nevirapine", 516], ["is", 527], ["used", 530], ["to", 535], ["prevent", 538], ["mother", 546], ["-", 552], ["to", 553], ["-", 555], ["child", 556], ["transmission", 562], [";", 574], ["(", 576], ["2", 577], [")", 578], ["the", 580], ["ASPIRE", 584], ["(", 591], ["MTN", 592], ["020", 596], [")", 599], ["study", 601], ["will", 607], ["test", 612], ["whether", 617], ["a", 625], ["vaginal", 627], ["ring", 635], ["containing", 640], ["dapivirine", 651], ["can", 662], ["prevent", 666], ["HIV-1", 674], ["infection", 680], ["in", 690], ["women", 693], [";", 698], ["(", 700], ["3", 701], [")", 702], ["a", 704], ["microbicide", 706], ["gel", 718], ["formulation", 722], ["containing", 734], ["the", 745], ["urea", 749], ["-", 753], ["PETT", 754], ["derivative", 759], ["MIV-150", 770], ["is", 778], ["in", 781], ["a", 784], ["phase", 786], ["I", 792], ["study", 794], ["to", 800], ["evaluate", 803], ["safety", 812], [",", 818], ["pharmacokinetics", 820], [",", 836], ["pharmacodynamics", 838], ["and", 855], ["acceptability", 859], [";", 872], ["and", 874], ["(", 878], ["4", 879], [")", 880], ["a", 882], ["long", 884], ["acting", 889], ["rilpivirine", 896], ["formulation", 908], ["is", 920], ["under", 923], ["-", 928], ["development", 929], ["for", 941], ["pre", 945], ["-", 948], ["exposure", 949], ["prophylaxis", 958], [".", 969], ["Given", 971], ["their", 977], ["widespread", 983], ["use", 994], [",", 997], ["particularly", 999], ["in", 1012], ["resource", 1015], ["-", 1023], ["limited", 1024], ["settings", 1032], [",", 1040], ["as", 1042], ["well", 1045], ["as", 1050], ["their", 1053], ["low", 1059], ["genetic", 1063], ["barriers", 1071], ["to", 1080], ["resistance", 1083], [",", 1093], ["there", 1095], ["are", 1101], ["concerns", 1105], ["about", 1114], ["overlapping", 1120], ["resistance", 1132], ["between", 1143], ["the", 1151], ["different", 1155], ["NNRTIs", 1165], [".", 1171], ["Consequently", 1173], [",", 1185], ["a", 1187], ["better", 1189], ["understanding", 1196], ["of", 1210], ["the", 1213], ["resistance", 1217], ["and", 1228], ["cross", 1232], ["-", 1237], ["resistance", 1238], ["profiles", 1249], ["among", 1258], ["the", 1264], ["NNRTI", 1268], ["class", 1274], ["is", 1280], ["important", 1283], ["for", 1293], ["predicting", 1297], ["response", 1308], ["to", 1317], ["treatment", 1320], [",", 1329], ["and", 1331], ["surveillance", 1335], ["of", 1348], ["transmitted", 1351], ["drug", 1363], ["-", 1367], ["resistance", 1368], [".", 1378]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running race. Blood was collected immediately before (Pre), upon completion/retirement (Post), and following the race at Day 1, Day 7 and Day 28. Lymphocyte lysates were examined for PRDX-2 by reducing and non-reducing SDS-PAGE with western blotting. In a sub-group of men who completed the race (n = 4), PRDX-2 oligomeric state (indicative of redox status) was investigated. Ultra-endurance exercise caused significant changes in lymphocyte PRDX-2 (F(4,32) 3.409, p = 0.020, \u03b7(2) = 0.299): 7 days after the race, PRDX-2 levels in lymphocytes had fallen to 30% of pre-race values (p = 0.013) and returned to near-normal levels at Day 28. Non-reducing gels demonstrated that dimeric PRDX-2 (intracellular reduced PRDX-2 monomers) was increased in three of four race completers immediately post-race, indicative of an 'antioxidant response'. Moreover, monomeric PRDX-2 was also increased immediately post-race in two of four race-completing subjects, indicative of oxidative damage, which was not detectable by Day 7. Lymphocyte PRDX-2 was decreased below normal levels 7 days after ultra-endurance exercise. Excessive accumulation of reactive oxygen species induced by ultra-endurance exercise may underlie depletion of lymphocyte PRDX-2 by triggering its turnover after oxidation. Low levels of lymphocyte PRDX-2 could influence cell function and might, in part, explain reports of dysregulated immunity following ultra-endurance exercise.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "5972815d8210470eb84c3da30f0aa090", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[234, 234], [6, 6]], "char_spans": [[1127, 1137], [31, 41]]}]}], "context_tokens": [["Peroxiredoxin-2", 0], ["(", 16], ["PRDX-2", 17], [")", 23], ["is", 25], ["an", 28], ["antioxidant", 31], ["and", 43], ["chaperone", 47], ["-", 56], ["like", 57], ["protein", 62], ["critical", 70], ["for", 79], ["cell", 83], ["function", 88], [".", 96], ["This", 98], ["study", 103], ["examined", 109], ["whether", 118], ["the", 126], ["levels", 130], ["of", 137], ["lymphocyte", 140], ["PRDX-2", 151], ["are", 158], ["altered", 162], ["over", 170], ["1", 175], ["month", 177], ["following", 183], ["ultra", 193], ["-", 198], ["endurance", 199], ["exercise", 209], [".", 217], ["Nine", 219], ["middle", 224], ["-", 230], ["aged", 231], ["men", 236], ["undertook", 240], ["a", 250], ["single", 252], ["-", 258], ["stage", 259], [",", 264], ["multi", 266], ["-", 271], ["day", 272], ["233", 276], ["km", 280], ["(", 283], ["145", 284], ["mile", 288], [")", 292], ["ultra", 294], ["-", 299], ["endurance", 300], ["running", 310], ["race", 318], [".", 322], ["Blood", 324], ["was", 330], ["collected", 334], ["immediately", 344], ["before", 356], ["(", 363], ["Pre", 364], [")", 367], [",", 368], ["upon", 370], ["completion", 375], ["/", 385], ["retirement", 386], ["(", 397], ["Post", 398], [")", 402], [",", 403], ["and", 405], ["following", 409], ["the", 419], ["race", 423], ["at", 428], ["Day", 431], ["1", 435], [",", 436], ["Day", 438], ["7", 442], ["and", 444], ["Day", 448], ["28", 452], [".", 454], ["Lymphocyte", 456], ["lysates", 467], ["were", 475], ["examined", 480], ["for", 489], ["PRDX-2", 493], ["by", 500], ["reducing", 503], ["and", 512], ["non", 516], ["-", 519], ["reducing", 520], ["SDS", 529], ["-", 532], ["PAGE", 533], ["with", 538], ["western", 543], ["blotting", 551], [".", 559], ["In", 561], ["a", 564], ["sub", 566], ["-", 569], ["group", 570], ["of", 576], ["men", 579], ["who", 583], ["completed", 587], ["the", 597], ["race", 601], ["(", 606], ["n", 607], ["=", 609], ["4", 611], [")", 612], [",", 613], ["PRDX-2", 615], ["oligomeric", 622], ["state", 633], ["(", 639], ["indicative", 640], ["of", 651], ["redox", 654], ["status", 660], [")", 666], ["was", 668], ["investigated", 672], [".", 684], ["Ultra", 686], ["-", 691], ["endurance", 692], ["exercise", 702], ["caused", 711], ["significant", 718], ["changes", 730], ["in", 738], ["lymphocyte", 741], ["PRDX-2", 752], ["(", 759], ["F(4,32", 760], [")", 766], ["3.409", 768], [",", 773], ["p", 775], ["=", 777], ["0.020", 779], [",", 784], ["\u03b7(2", 786], [")", 789], ["=", 791], ["0.299", 793], [")", 798], [":", 799], ["7", 801], ["days", 803], ["after", 808], ["the", 814], ["race", 818], [",", 822], ["PRDX-2", 824], ["levels", 831], ["in", 838], ["lymphocytes", 841], ["had", 853], ["fallen", 857], ["to", 864], ["30", 867], ["%", 869], ["of", 871], ["pre", 874], ["-", 877], ["race", 878], ["values", 883], ["(", 890], ["p", 891], ["=", 893], ["0.013", 895], [")", 900], ["and", 902], ["returned", 906], ["to", 915], ["near", 918], ["-", 922], ["normal", 923], ["levels", 930], ["at", 937], ["Day", 940], ["28", 944], [".", 946], ["Non", 948], ["-", 951], ["reducing", 952], ["gels", 961], ["demonstrated", 966], ["that", 979], ["dimeric", 984], ["PRDX-2", 992], ["(", 999], ["intracellular", 1000], ["reduced", 1014], ["PRDX-2", 1022], ["monomers", 1029], [")", 1037], ["was", 1039], ["increased", 1043], ["in", 1053], ["three", 1056], ["of", 1062], ["four", 1065], ["race", 1070], ["completers", 1075], ["immediately", 1086], ["post", 1098], ["-", 1102], ["race", 1103], [",", 1107], ["indicative", 1109], ["of", 1120], ["an", 1123], ["'", 1126], ["antioxidant", 1127], ["response", 1139], ["'", 1147], [".", 1148], ["Moreover", 1150], [",", 1158], ["monomeric", 1160], ["PRDX-2", 1170], ["was", 1177], ["also", 1181], ["increased", 1186], ["immediately", 1196], ["post", 1208], ["-", 1212], ["race", 1213], ["in", 1218], ["two", 1221], ["of", 1225], ["four", 1228], ["race", 1233], ["-", 1237], ["completing", 1238], ["subjects", 1249], [",", 1257], ["indicative", 1259], ["of", 1270], ["oxidative", 1273], ["damage", 1283], [",", 1289], ["which", 1291], ["was", 1297], ["not", 1301], ["detectable", 1305], ["by", 1316], ["Day", 1319], ["7", 1323], [".", 1324], ["Lymphocyte", 1326], ["PRDX-2", 1337], ["was", 1344], ["decreased", 1348], ["below", 1358], ["normal", 1364], ["levels", 1371], ["7", 1378], ["days", 1380], ["after", 1385], ["ultra", 1391], ["-", 1396], ["endurance", 1397], ["exercise", 1407], [".", 1415], ["Excessive", 1417], ["accumulation", 1427], ["of", 1440], ["reactive", 1443], ["oxygen", 1452], ["species", 1459], ["induced", 1467], ["by", 1475], ["ultra", 1478], ["-", 1483], ["endurance", 1484], ["exercise", 1494], ["may", 1503], ["underlie", 1507], ["depletion", 1516], ["of", 1526], ["lymphocyte", 1529], ["PRDX-2", 1540], ["by", 1547], ["triggering", 1550], ["its", 1561], ["turnover", 1565], ["after", 1574], ["oxidation", 1580], [".", 1589], ["Low", 1591], ["levels", 1595], ["of", 1602], ["lymphocyte", 1605], ["PRDX-2", 1616], ["could", 1623], ["influence", 1629], ["cell", 1639], ["function", 1644], ["and", 1653], ["might", 1657], [",", 1662], ["in", 1664], ["part", 1667], [",", 1671], ["explain", 1673], ["reports", 1681], ["of", 1689], ["dysregulated", 1692], ["immunity", 1705], ["following", 1714], ["ultra", 1724], ["-", 1729], ["endurance", 1730], ["exercise", 1740], [".", 1748]]}
{"context": "Mutant ataxin-3 is aberrantly folded and proteolytically cleaved in spinocerebellar ataxia type 3. The C-terminal region of the protein includes a polyglutamine stretch that is expanded in spinocerebellar ataxia type 3. Here, we report on the analysis of an ataxin-3 mutant mouse that has been obtained by gene trap integration. The ataxin-3 fusion protein encompasses 259\u2009N-terminal amino acids including the Josephin domain and an ubiquitin-interacting motif but lacks the C-terminus with the polyglutamine stretch, the valosin-containing protein binding region and part of the ubiquitin-interacting motif 2. Homozygous ataxin-3 mutant mice were viable and showed no apparent anatomical defects at birth. However, at the age of 9 months, homozygous and heterozygous mutant mice revealed significantly altered behaviour and progressing deficits of motor coordination followed by premature death at \u223c12 months. At this time, prominent extranuclear protein aggregates and neuronal cell death was found in mutant mice. This was associated with disturbances of the endoplasmic reticulum-mediated unfolded protein response, consistent with the normal role of ataxin-3 in endoplasmic reticulum homeostasis. Thus, the ataxin-3 gene trap model provides evidence for a contribution of the non-polyglutamine containing ataxin-3\u2009N-terminus, which mimics a calpain fragment that has been observed in spinocerebellar ataxia type 3. Consistent with the disease in humans, gene trap mice develop cytoplasmic inclusion bodies and implicate impaired unfolded protein response in the pathogenesis of spinocerebellar ataxia type 3.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "b4fcd51ad7b44e5b973a0b67bc523ce8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[106, 106], [44, 44], [57, 57], [215, 215], [1, 1], [200, 200], [191, 191]], "char_spans": [[622, 629], [258, 265], [333, 340], [1310, 1317], [7, 14], [1212, 1219], [1155, 1162]]}]}], "context_tokens": [["Mutant", 0], ["ataxin-3", 7], ["is", 16], ["aberrantly", 19], ["folded", 30], ["and", 37], ["proteolytically", 41], ["cleaved", 57], ["in", 65], ["spinocerebellar", 68], ["ataxia", 84], ["type", 91], ["3", 96], [".", 97], ["The", 99], ["C", 103], ["-", 104], ["terminal", 105], ["region", 114], ["of", 121], ["the", 124], ["protein", 128], ["includes", 136], ["a", 145], ["polyglutamine", 147], ["stretch", 161], ["that", 169], ["is", 174], ["expanded", 177], ["in", 186], ["spinocerebellar", 189], ["ataxia", 205], ["type", 212], ["3", 217], [".", 218], ["Here", 220], [",", 224], ["we", 226], ["report", 229], ["on", 236], ["the", 239], ["analysis", 243], ["of", 252], ["an", 255], ["ataxin-3", 258], ["mutant", 267], ["mouse", 274], ["that", 280], ["has", 285], ["been", 289], ["obtained", 294], ["by", 303], ["gene", 306], ["trap", 311], ["integration", 316], [".", 327], ["The", 329], ["ataxin-3", 333], ["fusion", 342], ["protein", 349], ["encompasses", 357], ["259", 369], ["N", 373], ["-", 374], ["terminal", 375], ["amino", 384], ["acids", 390], ["including", 396], ["the", 406], ["Josephin", 410], ["domain", 419], ["and", 426], ["an", 430], ["ubiquitin", 433], ["-", 442], ["interacting", 443], ["motif", 455], ["but", 461], ["lacks", 465], ["the", 471], ["C", 475], ["-", 476], ["terminus", 477], ["with", 486], ["the", 491], ["polyglutamine", 495], ["stretch", 509], [",", 516], ["the", 518], ["valosin", 522], ["-", 529], ["containing", 530], ["protein", 541], ["binding", 549], ["region", 557], ["and", 564], ["part", 568], ["of", 573], ["the", 576], ["ubiquitin", 580], ["-", 589], ["interacting", 590], ["motif", 602], ["2", 608], [".", 609], ["Homozygous", 611], ["ataxin-3", 622], ["mutant", 631], ["mice", 638], ["were", 643], ["viable", 648], ["and", 655], ["showed", 659], ["no", 666], ["apparent", 669], ["anatomical", 678], ["defects", 689], ["at", 697], ["birth", 700], [".", 705], ["However", 707], [",", 714], ["at", 716], ["the", 719], ["age", 723], ["of", 727], ["9", 730], ["months", 732], [",", 738], ["homozygous", 740], ["and", 751], ["heterozygous", 755], ["mutant", 768], ["mice", 775], ["revealed", 780], ["significantly", 789], ["altered", 803], ["behaviour", 811], ["and", 821], ["progressing", 825], ["deficits", 837], ["of", 846], ["motor", 849], ["coordination", 855], ["followed", 868], ["by", 877], ["premature", 880], ["death", 890], ["at", 896], ["\u223c12", 899], ["months", 903], [".", 909], ["At", 911], ["this", 914], ["time", 919], [",", 923], ["prominent", 925], ["extranuclear", 935], ["protein", 948], ["aggregates", 956], ["and", 967], ["neuronal", 971], ["cell", 980], ["death", 985], ["was", 991], ["found", 995], ["in", 1001], ["mutant", 1004], ["mice", 1011], [".", 1015], ["This", 1017], ["was", 1022], ["associated", 1026], ["with", 1037], ["disturbances", 1042], ["of", 1055], ["the", 1058], ["endoplasmic", 1062], ["reticulum", 1074], ["-", 1083], ["mediated", 1084], ["unfolded", 1093], ["protein", 1102], ["response", 1110], [",", 1118], ["consistent", 1120], ["with", 1131], ["the", 1136], ["normal", 1140], ["role", 1147], ["of", 1152], ["ataxin-3", 1155], ["in", 1164], ["endoplasmic", 1167], ["reticulum", 1179], ["homeostasis", 1189], [".", 1200], ["Thus", 1202], [",", 1206], ["the", 1208], ["ataxin-3", 1212], ["gene", 1221], ["trap", 1226], ["model", 1231], ["provides", 1237], ["evidence", 1246], ["for", 1255], ["a", 1259], ["contribution", 1261], ["of", 1274], ["the", 1277], ["non", 1281], ["-", 1284], ["polyglutamine", 1285], ["containing", 1299], ["ataxin-3", 1310], ["N", 1319], ["-", 1320], ["terminus", 1321], [",", 1329], ["which", 1331], ["mimics", 1337], ["a", 1344], ["calpain", 1346], ["fragment", 1354], ["that", 1363], ["has", 1368], ["been", 1372], ["observed", 1377], ["in", 1386], ["spinocerebellar", 1389], ["ataxia", 1405], ["type", 1412], ["3", 1417], [".", 1418], ["Consistent", 1420], ["with", 1431], ["the", 1436], ["disease", 1440], ["in", 1448], ["humans", 1451], [",", 1457], ["gene", 1459], ["trap", 1464], ["mice", 1469], ["develop", 1474], ["cytoplasmic", 1482], ["inclusion", 1494], ["bodies", 1504], ["and", 1511], ["implicate", 1515], ["impaired", 1525], ["unfolded", 1534], ["protein", 1543], ["response", 1551], ["in", 1560], ["the", 1563], ["pathogenesis", 1567], ["of", 1580], ["spinocerebellar", 1583], ["ataxia", 1599], ["type", 1606], ["3", 1611], [".", 1612]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "The Ehlers-Danlos syndromes comprise a clinically and genetically heterogeneous group of heritable connective tissue disorders characterized by articular hypermobility, skin extensibility, and tissue fragility. Surgical treatment of scoliosis associated with Ehlers-Danlos syndrome poses a challenge to spine surgeons because of the high risk of major complications. There is a paucity of evidence in the literature on surgical treatment for scoliosis in the Ehlers-Danlos syndrome patient.This article describes 3 adolescent patients diagnosed with Ehlers-Danlos syndrome, kyphoscoliosis type, which was treated by posterior spinal fusion only. After unsuccessful conservative treatment for at least 1 year, the patients underwent posterior spinal surgery for the correction of spinal deformity. A satisfactory correction in the spinal curve was achieved, with no obvious loss of correction during follow-up. No intra- or postoperative major complications were observed.Our experience supports that a satisfactory correction of scoliosis can be achieved by posterior spinal fusion only in patients with Ehlers-Danlos syndrome, kyphoscoliosis type.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "6e14727992524632b60951a020c5b358", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[14, 15]], "char_spans": [[99, 115]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["comprise", 28], ["a", 37], ["clinically", 39], ["and", 50], ["genetically", 54], ["heterogeneous", 66], ["group", 80], ["of", 86], ["heritable", 89], ["connective", 99], ["tissue", 110], ["disorders", 117], ["characterized", 127], ["by", 141], ["articular", 144], ["hypermobility", 154], [",", 167], ["skin", 169], ["extensibility", 174], [",", 187], ["and", 189], ["tissue", 193], ["fragility", 200], [".", 209], ["Surgical", 211], ["treatment", 220], ["of", 230], ["scoliosis", 233], ["associated", 243], ["with", 254], ["Ehlers", 259], ["-", 265], ["Danlos", 266], ["syndrome", 273], ["poses", 282], ["a", 288], ["challenge", 290], ["to", 300], ["spine", 303], ["surgeons", 309], ["because", 318], ["of", 326], ["the", 329], ["high", 333], ["risk", 338], ["of", 343], ["major", 346], ["complications", 352], [".", 365], ["There", 367], ["is", 373], ["a", 376], ["paucity", 378], ["of", 386], ["evidence", 389], ["in", 398], ["the", 401], ["literature", 405], ["on", 416], ["surgical", 419], ["treatment", 428], ["for", 438], ["scoliosis", 442], ["in", 452], ["the", 455], ["Ehlers", 459], ["-", 465], ["Danlos", 466], ["syndrome", 473], ["patient", 482], [".", 489], ["This", 490], ["article", 495], ["describes", 503], ["3", 513], ["adolescent", 515], ["patients", 526], ["diagnosed", 535], ["with", 545], ["Ehlers", 550], ["-", 556], ["Danlos", 557], ["syndrome", 564], [",", 572], ["kyphoscoliosis", 574], ["type", 589], [",", 593], ["which", 595], ["was", 601], ["treated", 605], ["by", 613], ["posterior", 616], ["spinal", 626], ["fusion", 633], ["only", 640], [".", 644], ["After", 646], ["unsuccessful", 652], ["conservative", 665], ["treatment", 678], ["for", 688], ["at", 692], ["least", 695], ["1", 701], ["year", 703], [",", 707], ["the", 709], ["patients", 713], ["underwent", 722], ["posterior", 732], ["spinal", 742], ["surgery", 749], ["for", 757], ["the", 761], ["correction", 765], ["of", 776], ["spinal", 779], ["deformity", 786], [".", 795], ["A", 797], ["satisfactory", 799], ["correction", 812], ["in", 823], ["the", 826], ["spinal", 830], ["curve", 837], ["was", 843], ["achieved", 847], [",", 855], ["with", 857], ["no", 862], ["obvious", 865], ["loss", 873], ["of", 878], ["correction", 881], ["during", 892], ["follow", 899], ["-", 905], ["up", 906], [".", 908], ["No", 910], ["intra-", 913], ["or", 920], ["postoperative", 923], ["major", 937], ["complications", 943], ["were", 957], ["observed", 962], [".", 970], ["Our", 971], ["experience", 975], ["supports", 986], ["that", 995], ["a", 1000], ["satisfactory", 1002], ["correction", 1015], ["of", 1026], ["scoliosis", 1029], ["can", 1039], ["be", 1043], ["achieved", 1046], ["by", 1055], ["posterior", 1058], ["spinal", 1068], ["fusion", 1075], ["only", 1082], ["in", 1087], ["patients", 1090], ["with", 1099], ["Ehlers", 1104], ["-", 1110], ["Danlos", 1111], ["syndrome", 1118], [",", 1126], ["kyphoscoliosis", 1128], ["type", 1143], [".", 1147]]}
{"context": "Phosphorylation of cytoplasmic polyadenylation element binding protein (CPEB) regulates protein synthesis in hippocampal dendrites. CPEB binds the 3' untranslated region (UTR) of cytoplasmic mRNAs and, when phosphorylated, initiates mRNA polyadenylation and translation. We report that, of the protein kinases activated in the hippocampus during synaptic plasticity, calcium/calmodulin-dependent protein kinase II (CaMKII) robustly phosphorylated the regulatory site (threonine 171) in CPEB in vitro. In postsynaptic density fractions or hippocampal neurons, CPEB phosphorylation increased when CaMKII was activated. These increases in CPEB phosphorylation were attenuated by a specific peptide inhibitor of CaMKII and by the general CaM-kinase inhibitor KN-93. Inhibitors of protein phosphatase 1 increased basal CPEB phosphorylation in neurons; this was also attenuated by a CaM-kinase inhibitor. To determine whether CaM-kinase activity regulates CPEB-dependent mRNA translation, hippocampal neurons were transfected with luciferase fused to a 3' UTR containing CPE-binding elements. Depolarization of neurons stimulated synthesis of luciferase; this was abrogated by inhibitors of protein synthesis, mRNA polyadenylation, and CaMKII. These results demonstrate that CPEB phosphorylation and translation are regulated by CaMKII activity and provide a possible mechanism for how dendritic protein synthesis in the hippocampus may be stimulated during synaptic plasticity.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "7d3d225c01ba4d0daa3bfa2341e0caf8", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[57, 64]], "char_spans": [[367, 412]]}]}], "context_tokens": [["Phosphorylation", 0], ["of", 16], ["cytoplasmic", 19], ["polyadenylation", 31], ["element", 47], ["binding", 55], ["protein", 63], ["(", 71], ["CPEB", 72], [")", 76], ["regulates", 78], ["protein", 88], ["synthesis", 96], ["in", 106], ["hippocampal", 109], ["dendrites", 121], [".", 130], ["CPEB", 132], ["binds", 137], ["the", 143], ["3", 147], ["'", 148], ["untranslated", 150], ["region", 163], ["(", 170], ["UTR", 171], [")", 174], ["of", 176], ["cytoplasmic", 179], ["mRNAs", 191], ["and", 197], [",", 200], ["when", 202], ["phosphorylated", 207], [",", 221], ["initiates", 223], ["mRNA", 233], ["polyadenylation", 238], ["and", 254], ["translation", 258], [".", 269], ["We", 271], ["report", 274], ["that", 281], [",", 285], ["of", 287], ["the", 290], ["protein", 294], ["kinases", 302], ["activated", 310], ["in", 320], ["the", 323], ["hippocampus", 327], ["during", 339], ["synaptic", 346], ["plasticity", 355], [",", 365], ["calcium", 367], ["/", 374], ["calmodulin", 375], ["-", 385], ["dependent", 386], ["protein", 396], ["kinase", 404], ["II", 411], ["(", 414], ["CaMKII", 415], [")", 421], ["robustly", 423], ["phosphorylated", 432], ["the", 447], ["regulatory", 451], ["site", 462], ["(", 467], ["threonine", 468], ["171", 478], [")", 481], ["in", 483], ["CPEB", 486], ["in", 491], ["vitro", 494], [".", 499], ["In", 501], ["postsynaptic", 504], ["density", 517], ["fractions", 525], ["or", 535], ["hippocampal", 538], ["neurons", 550], [",", 557], ["CPEB", 559], ["phosphorylation", 564], ["increased", 580], ["when", 590], ["CaMKII", 595], ["was", 602], ["activated", 606], [".", 615], ["These", 617], ["increases", 623], ["in", 633], ["CPEB", 636], ["phosphorylation", 641], ["were", 657], ["attenuated", 662], ["by", 673], ["a", 676], ["specific", 678], ["peptide", 687], ["inhibitor", 695], ["of", 705], ["CaMKII", 708], ["and", 715], ["by", 719], ["the", 722], ["general", 726], ["CaM", 734], ["-", 737], ["kinase", 738], ["inhibitor", 745], ["KN-93", 755], [".", 760], ["Inhibitors", 762], ["of", 773], ["protein", 776], ["phosphatase", 784], ["1", 796], ["increased", 798], ["basal", 808], ["CPEB", 814], ["phosphorylation", 819], ["in", 835], ["neurons", 838], [";", 845], ["this", 847], ["was", 852], ["also", 856], ["attenuated", 861], ["by", 872], ["a", 875], ["CaM", 877], ["-", 880], ["kinase", 881], ["inhibitor", 888], [".", 897], ["To", 899], ["determine", 902], ["whether", 912], ["CaM", 920], ["-", 923], ["kinase", 924], ["activity", 931], ["regulates", 940], ["CPEB", 950], ["-", 954], ["dependent", 955], ["mRNA", 965], ["translation", 970], [",", 981], ["hippocampal", 983], ["neurons", 995], ["were", 1003], ["transfected", 1008], ["with", 1020], ["luciferase", 1025], ["fused", 1036], ["to", 1042], ["a", 1045], ["3", 1047], ["'", 1048], ["UTR", 1050], ["containing", 1054], ["CPE", 1065], ["-", 1068], ["binding", 1069], ["elements", 1077], [".", 1085], ["Depolarization", 1087], ["of", 1102], ["neurons", 1105], ["stimulated", 1113], ["synthesis", 1124], ["of", 1134], ["luciferase", 1137], [";", 1147], ["this", 1149], ["was", 1154], ["abrogated", 1158], ["by", 1168], ["inhibitors", 1171], ["of", 1182], ["protein", 1185], ["synthesis", 1193], [",", 1202], ["mRNA", 1204], ["polyadenylation", 1209], [",", 1224], ["and", 1226], ["CaMKII", 1230], [".", 1236], ["These", 1238], ["results", 1244], ["demonstrate", 1252], ["that", 1264], ["CPEB", 1269], ["phosphorylation", 1274], ["and", 1290], ["translation", 1294], ["are", 1306], ["regulated", 1310], ["by", 1320], ["CaMKII", 1323], ["activity", 1330], ["and", 1339], ["provide", 1343], ["a", 1351], ["possible", 1353], ["mechanism", 1362], ["for", 1372], ["how", 1376], ["dendritic", 1380], ["protein", 1390], ["synthesis", 1398], ["in", 1408], ["the", 1411], ["hippocampus", 1415], ["may", 1427], ["be", 1431], ["stimulated", 1434], ["during", 1445], ["synaptic", 1452], ["plasticity", 1461], [".", 1471]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Antibody-mediated glomerulonephritis, including that resulting from immune complexes, is an important cause of renal failure and is in need of more specific and effective treatment. Binding of antibody or immune complexes to Fc receptors activates intracellular signal transduction pathways, including spleen tyrosine kinase (Syk), leading to the production of inflammatory cytokines. We examined the effect of R788 (fostamatinib disodium), an oral prodrug of the selective Syk inhibitor R406, in nephrotoxic nephritis in Wistar-Kyoto rats. Treatment with R788 reduced proteinuria, tissue injury, glomerular macrophage and CD8+ cell numbers, and renal monocyte chemoattractant protein-1 (MCP-1) and IL-1beta, even when we started treatment after the onset of glomerulonephritis. When we administered R788 from days 4 to 10, glomerular crescents reduced by 100% (P < 0.01) compared with the vehicle group. When we administered R788 treatment from days 7 to 14, established glomerular crescents reversed (reduced by 21%, P < 0.001), and renal function was better than the vehicle group (P < 0.001). In vitro, R406 downregulated MCP-1 production from mesangial cells and macrophages stimulated with aggregated IgG. These results suggest that Syk is an important therapeutic target for the treatment of glomerulonephritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "5742d0bc42aa44c8a4614ab95fa1c3ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[46, 48]], "char_spans": [[302, 323]]}]}], "context_tokens": [["Antibody", 0], ["-", 8], ["mediated", 9], ["glomerulonephritis", 18], [",", 36], ["including", 38], ["that", 48], ["resulting", 53], ["from", 63], ["immune", 68], ["complexes", 75], [",", 84], ["is", 86], ["an", 89], ["important", 92], ["cause", 102], ["of", 108], ["renal", 111], ["failure", 117], ["and", 125], ["is", 129], ["in", 132], ["need", 135], ["of", 140], ["more", 143], ["specific", 148], ["and", 157], ["effective", 161], ["treatment", 171], [".", 180], ["Binding", 182], ["of", 190], ["antibody", 193], ["or", 202], ["immune", 205], ["complexes", 212], ["to", 222], ["Fc", 225], ["receptors", 228], ["activates", 238], ["intracellular", 248], ["signal", 262], ["transduction", 269], ["pathways", 282], [",", 290], ["including", 292], ["spleen", 302], ["tyrosine", 309], ["kinase", 318], ["(", 325], ["Syk", 326], [")", 329], [",", 330], ["leading", 332], ["to", 340], ["the", 343], ["production", 347], ["of", 358], ["inflammatory", 361], ["cytokines", 374], [".", 383], ["We", 385], ["examined", 388], ["the", 397], ["effect", 401], ["of", 408], ["R788", 411], ["(", 416], ["fostamatinib", 417], ["disodium", 430], [")", 438], [",", 439], ["an", 441], ["oral", 444], ["prodrug", 449], ["of", 457], ["the", 460], ["selective", 464], ["Syk", 474], ["inhibitor", 478], ["R406", 488], [",", 492], ["in", 494], ["nephrotoxic", 497], ["nephritis", 509], ["in", 519], ["Wistar", 522], ["-", 528], ["Kyoto", 529], ["rats", 535], [".", 539], ["Treatment", 541], ["with", 551], ["R788", 556], ["reduced", 561], ["proteinuria", 569], [",", 580], ["tissue", 582], ["injury", 589], [",", 595], ["glomerular", 597], ["macrophage", 608], ["and", 619], ["CD8", 623], ["+", 626], ["cell", 628], ["numbers", 633], [",", 640], ["and", 642], ["renal", 646], ["monocyte", 652], ["chemoattractant", 661], ["protein-1", 677], ["(", 687], ["MCP-1", 688], [")", 693], ["and", 695], ["IL-1beta", 699], [",", 707], ["even", 709], ["when", 714], ["we", 719], ["started", 722], ["treatment", 730], ["after", 740], ["the", 746], ["onset", 750], ["of", 756], ["glomerulonephritis", 759], [".", 777], ["When", 779], ["we", 784], ["administered", 787], ["R788", 800], ["from", 805], ["days", 810], ["4", 815], ["to", 817], ["10", 820], [",", 822], ["glomerular", 824], ["crescents", 835], ["reduced", 845], ["by", 853], ["100", 856], ["%", 859], ["(", 861], ["P", 862], ["<", 864], ["0.01", 866], [")", 870], ["compared", 872], ["with", 881], ["the", 886], ["vehicle", 890], ["group", 898], [".", 903], ["When", 905], ["we", 910], ["administered", 913], ["R788", 926], ["treatment", 931], ["from", 941], ["days", 946], ["7", 951], ["to", 953], ["14", 956], [",", 958], ["established", 960], ["glomerular", 972], ["crescents", 983], ["reversed", 993], ["(", 1002], ["reduced", 1003], ["by", 1011], ["21", 1014], ["%", 1016], [",", 1017], ["P", 1019], ["<", 1021], ["0.001", 1023], [")", 1028], [",", 1029], ["and", 1031], ["renal", 1035], ["function", 1041], ["was", 1050], ["better", 1054], ["than", 1061], ["the", 1066], ["vehicle", 1070], ["group", 1078], ["(", 1084], ["P", 1085], ["<", 1087], ["0.001", 1089], [")", 1094], [".", 1095], ["In", 1097], ["vitro", 1100], [",", 1105], ["R406", 1107], ["downregulated", 1112], ["MCP-1", 1126], ["production", 1132], ["from", 1143], ["mesangial", 1148], ["cells", 1158], ["and", 1164], ["macrophages", 1168], ["stimulated", 1180], ["with", 1191], ["aggregated", 1196], ["IgG.", 1207], ["These", 1212], ["results", 1218], ["suggest", 1226], ["that", 1234], ["Syk", 1239], ["is", 1243], ["an", 1246], ["important", 1249], ["therapeutic", 1259], ["target", 1271], ["for", 1278], ["the", 1282], ["treatment", 1286], ["of", 1296], ["glomerulonephritis", 1299], [".", 1317]]}
{"context": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1. The phosphorylation of cytosolic regulatory components by multiple kinases plays important roles in assembly and activity of the phagocyte NADPH oxidase (Nox2) system, but little is known about regulation by phosphorylation in the Nox1 system. Here we identify Ser(172) and Ser(461) of NoxA1 as phosphorylation sites for protein kinase A (PKA). A consequence of this phosphorylation was the enhancement of NoxA1 complex formation with 14-3-3 proteins. Using both a transfected human embryonic kidney 293 cell Nox1 model system and endogenous Nox1 in colon cell lines, we showed that the elevation of cAMP inhibits, whereas the inhibition of PKA enhances, Nox1-dependent ROS production through effects on NoxA1. Inhibition of Nox1 activity was intensified by the availability of 14-3-3zeta protein, and this regulatory interaction was dependent on PKA-phosphorylatable sites at Ser(172) and Ser(461) in NoxA1. We showed that phosphorylation and 14-3-3 binding induce the dissociation of NoxA1 from the Nox1 complex at the plasma membrane, suggesting a mechanism for the inhibitory effect on Nox1 activity. Our data establish that PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein(s) and that this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d136608f31e4ac89782b0aa4082ddf6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[272, 272], [74, 74], [164, 164], [36, 36], [132, 132], [217, 217], [232, 232], [127, 127]], "char_spans": [[1472, 1475], [417, 420], [911, 914], [180, 183], [728, 731], [1187, 1190], [1276, 1279], [695, 698]]}]}], "context_tokens": [["Nox", 0], ["activator", 4], ["1", 14], ["(", 16], ["NoxA1", 17], [")", 22], ["is", 24], ["a", 27], ["homologue", 29], ["of", 39], ["p67(phox", 42], [")", 50], ["that", 52], ["acts", 57], ["in", 62], ["conjunction", 65], ["with", 77], ["Nox", 82], ["organizer", 86], ["1", 96], ["(", 98], ["NoxO1", 99], [")", 104], ["to", 106], ["regulate", 109], ["reactive", 118], ["oxygen", 127], ["species", 134], ["(", 142], ["ROS", 143], [")", 146], ["production", 148], ["by", 159], ["the", 162], ["NADPH", 166], ["oxidase", 172], ["Nox1", 180], [".", 184], ["The", 186], ["phosphorylation", 190], ["of", 206], ["cytosolic", 209], ["regulatory", 219], ["components", 230], ["by", 241], ["multiple", 244], ["kinases", 253], ["plays", 261], ["important", 267], ["roles", 277], ["in", 283], ["assembly", 286], ["and", 295], ["activity", 299], ["of", 308], ["the", 311], ["phagocyte", 315], ["NADPH", 325], ["oxidase", 331], ["(", 339], ["Nox2", 340], [")", 344], ["system", 346], [",", 352], ["but", 354], ["little", 358], ["is", 365], ["known", 368], ["about", 374], ["regulation", 380], ["by", 391], ["phosphorylation", 394], ["in", 410], ["the", 413], ["Nox1", 417], ["system", 422], [".", 428], ["Here", 430], ["we", 435], ["identify", 438], ["Ser(172", 447], [")", 454], ["and", 456], ["Ser(461", 460], [")", 467], ["of", 469], ["NoxA1", 472], ["as", 478], ["phosphorylation", 481], ["sites", 497], ["for", 503], ["protein", 507], ["kinase", 515], ["A", 522], ["(", 524], ["PKA", 525], [")", 528], [".", 529], ["A", 531], ["consequence", 533], ["of", 545], ["this", 548], ["phosphorylation", 553], ["was", 569], ["the", 573], ["enhancement", 577], ["of", 589], ["NoxA1", 592], ["complex", 598], ["formation", 606], ["with", 616], ["14", 621], ["-", 623], ["3", 624], ["-", 625], ["3", 626], ["proteins", 628], [".", 636], ["Using", 638], ["both", 644], ["a", 649], ["transfected", 651], ["human", 663], ["embryonic", 669], ["kidney", 679], ["293", 686], ["cell", 690], ["Nox1", 695], ["model", 700], ["system", 706], ["and", 713], ["endogenous", 717], ["Nox1", 728], ["in", 733], ["colon", 736], ["cell", 742], ["lines", 747], [",", 752], ["we", 754], ["showed", 757], ["that", 764], ["the", 769], ["elevation", 773], ["of", 783], ["cAMP", 786], ["inhibits", 791], [",", 799], ["whereas", 801], ["the", 809], ["inhibition", 813], ["of", 824], ["PKA", 827], ["enhances", 831], [",", 839], ["Nox1-dependent", 841], ["ROS", 856], ["production", 860], ["through", 871], ["effects", 879], ["on", 887], ["NoxA1", 890], [".", 895], ["Inhibition", 897], ["of", 908], ["Nox1", 911], ["activity", 916], ["was", 925], ["intensified", 929], ["by", 941], ["the", 944], ["availability", 948], ["of", 961], ["14", 964], ["-", 966], ["3", 967], ["-", 968], ["3zeta", 969], ["protein", 975], [",", 982], ["and", 984], ["this", 988], ["regulatory", 993], ["interaction", 1004], ["was", 1016], ["dependent", 1020], ["on", 1030], ["PKA", 1033], ["-", 1036], ["phosphorylatable", 1037], ["sites", 1054], ["at", 1060], ["Ser(172", 1063], [")", 1070], ["and", 1072], ["Ser(461", 1076], [")", 1083], ["in", 1085], ["NoxA1", 1088], [".", 1093], ["We", 1095], ["showed", 1098], ["that", 1105], ["phosphorylation", 1110], ["and", 1126], ["14", 1130], ["-", 1132], ["3", 1133], ["-", 1134], ["3", 1135], ["binding", 1137], ["induce", 1145], ["the", 1152], ["dissociation", 1156], ["of", 1169], ["NoxA1", 1172], ["from", 1178], ["the", 1183], ["Nox1", 1187], ["complex", 1192], ["at", 1200], ["the", 1203], ["plasma", 1207], ["membrane", 1214], [",", 1222], ["suggesting", 1224], ["a", 1235], ["mechanism", 1237], ["for", 1247], ["the", 1251], ["inhibitory", 1255], ["effect", 1266], ["on", 1273], ["Nox1", 1276], ["activity", 1281], [".", 1289], ["Our", 1291], ["data", 1295], ["establish", 1300], ["that", 1310], ["PKA", 1315], ["-", 1318], ["phosphorylated", 1319], ["NoxA1", 1334], ["is", 1340], ["a", 1343], ["new", 1345], ["binding", 1349], ["partner", 1357], ["of", 1365], ["14", 1368], ["-", 1370], ["3", 1371], ["-", 1372], ["3", 1373], ["protein(s", 1375], [")", 1384], ["and", 1386], ["that", 1390], ["this", 1395], ["forms", 1400], ["the", 1406], ["basis", 1410], ["of", 1416], ["a", 1419], ["novel", 1421], ["mechanism", 1427], ["regulating", 1437], ["the", 1448], ["formation", 1452], ["of", 1462], ["ROS", 1465], ["by", 1469], ["Nox1", 1472], ["and", 1477], [",", 1480], ["potentially", 1482], [",", 1493], ["other", 1495], ["NoxA1-regulated", 1501], ["Nox", 1517], ["family", 1521], ["members", 1528], [".", 1535]]}
{"context": "In neurodegenerative diseases, it remains unclear why certain brain regions are selectively vulnerable to protein aggregation. In transgenic mice expressing human A53T \u03b1-synuclein, the brainstem and spinal cord develop the most prominent \u03b1-synuclein inclusions which correlate with age-dependent motor dysfunction. Herein we present the novel finding that this selective aggregation is in part dependent on the inability of chaperone-mediated autophagy (CMA) to effectively degrade \u03b1-synuclein in these brain regions. Lysosomal assays revealed that CMA activity was significantly decreased in aggregation-prone regions compared to the remainder of the brain. Previously, CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a. Using antibodies, brain tissue from Lamp-2a null mice, enzymatic deglycosylation, and mass spectrometry, we identified Lamp2a as a novel 72kDa glycoprotein in the mouse brain. Examination of Lamp-2a levels revealed differences in expression across brain regions. The brainstem and the spinal cord had a more than three-fold greater levels of Lamp-2a as compared to regions less vulnerable to aggregation and exhibited a selective upregulation of Lamp-2a during development of \u03b1-synuclein inclusions. Despite this dynamic response of Lamp-2a, the levels of substrates bound to the brain lysosomes as well as the rates of substrate uptake and degradation were not proportional to the levels of Lamp-2a. These regional differences in CMA activity and Lamp-2a expression were found in both non-transgenic mice as well as A53T \u03b1-syn mice. Therefore, these are inherent variations and not a transgene-specific effect. However, differences in CMA activity may render select brain regions vulnerable to homeostatic dysfunction in the presence of stressors such as overexpression of human A53T \u03b1-syn. Collectively, the data provide a potential mechanism to explain the dichotomy of vulnerability or resistance that underlies brain regions during aggregate formation in neurodegenerative disease.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "fdc608c223704b0ca4a61d478dc8dbe2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[146, 146]], "char_spans": [[876, 881]]}]}], "context_tokens": [["In", 0], ["neurodegenerative", 3], ["diseases", 21], [",", 29], ["it", 31], ["remains", 34], ["unclear", 42], ["why", 50], ["certain", 54], ["brain", 62], ["regions", 68], ["are", 76], ["selectively", 80], ["vulnerable", 92], ["to", 103], ["protein", 106], ["aggregation", 114], [".", 125], ["In", 127], ["transgenic", 130], ["mice", 141], ["expressing", 146], ["human", 157], ["A53", 163], ["T", 166], ["\u03b1", 168], ["-", 169], ["synuclein", 170], [",", 179], ["the", 181], ["brainstem", 185], ["and", 195], ["spinal", 199], ["cord", 206], ["develop", 211], ["the", 219], ["most", 223], ["prominent", 228], ["\u03b1", 238], ["-", 239], ["synuclein", 240], ["inclusions", 250], ["which", 261], ["correlate", 267], ["with", 277], ["age", 282], ["-", 285], ["dependent", 286], ["motor", 296], ["dysfunction", 302], [".", 313], ["Herein", 315], ["we", 322], ["present", 325], ["the", 333], ["novel", 337], ["finding", 343], ["that", 351], ["this", 356], ["selective", 361], ["aggregation", 371], ["is", 383], ["in", 386], ["part", 389], ["dependent", 394], ["on", 404], ["the", 407], ["inability", 411], ["of", 421], ["chaperone", 424], ["-", 433], ["mediated", 434], ["autophagy", 443], ["(", 453], ["CMA", 454], [")", 457], ["to", 459], ["effectively", 462], ["degrade", 474], ["\u03b1", 482], ["-", 483], ["synuclein", 484], ["in", 494], ["these", 497], ["brain", 503], ["regions", 509], [".", 516], ["Lysosomal", 518], ["assays", 528], ["revealed", 535], ["that", 544], ["CMA", 549], ["activity", 553], ["was", 562], ["significantly", 566], ["decreased", 580], ["in", 590], ["aggregation", 593], ["-", 604], ["prone", 605], ["regions", 611], ["compared", 619], ["to", 628], ["the", 631], ["remainder", 635], ["of", 645], ["the", 648], ["brain", 652], [".", 657], ["Previously", 659], [",", 669], ["CMA", 671], ["activity", 675], ["has", 684], ["been", 688], ["shown", 693], ["to", 699], ["be", 702], ["proportional", 705], ["to", 718], ["levels", 721], ["of", 728], ["the", 731], ["CMA", 735], ["receptor", 739], ["Lamp-2a", 748], [".", 755], ["Using", 757], ["antibodies", 763], [",", 773], ["brain", 775], ["tissue", 781], ["from", 788], ["Lamp-2a", 793], ["null", 801], ["mice", 806], [",", 810], ["enzymatic", 812], ["deglycosylation", 822], [",", 837], ["and", 839], ["mass", 843], ["spectrometry", 848], [",", 860], ["we", 862], ["identified", 865], ["Lamp2a", 876], ["as", 883], ["a", 886], ["novel", 888], ["72kDa", 894], ["glycoprotein", 900], ["in", 913], ["the", 916], ["mouse", 920], ["brain", 926], [".", 931], ["Examination", 933], ["of", 945], ["Lamp-2a", 948], ["levels", 956], ["revealed", 963], ["differences", 972], ["in", 984], ["expression", 987], ["across", 998], ["brain", 1005], ["regions", 1011], [".", 1018], ["The", 1020], ["brainstem", 1024], ["and", 1034], ["the", 1038], ["spinal", 1042], ["cord", 1049], ["had", 1054], ["a", 1058], ["more", 1060], ["than", 1065], ["three", 1070], ["-", 1075], ["fold", 1076], ["greater", 1081], ["levels", 1089], ["of", 1096], ["Lamp-2a", 1099], ["as", 1107], ["compared", 1110], ["to", 1119], ["regions", 1122], ["less", 1130], ["vulnerable", 1135], ["to", 1146], ["aggregation", 1149], ["and", 1161], ["exhibited", 1165], ["a", 1175], ["selective", 1177], ["upregulation", 1187], ["of", 1200], ["Lamp-2a", 1203], ["during", 1211], ["development", 1218], ["of", 1230], ["\u03b1", 1233], ["-", 1234], ["synuclein", 1235], ["inclusions", 1245], [".", 1255], ["Despite", 1257], ["this", 1265], ["dynamic", 1270], ["response", 1278], ["of", 1287], ["Lamp-2a", 1290], [",", 1297], ["the", 1299], ["levels", 1303], ["of", 1310], ["substrates", 1313], ["bound", 1324], ["to", 1330], ["the", 1333], ["brain", 1337], ["lysosomes", 1343], ["as", 1353], ["well", 1356], ["as", 1361], ["the", 1364], ["rates", 1368], ["of", 1374], ["substrate", 1377], ["uptake", 1387], ["and", 1394], ["degradation", 1398], ["were", 1410], ["not", 1415], ["proportional", 1419], ["to", 1432], ["the", 1435], ["levels", 1439], ["of", 1446], ["Lamp-2a", 1449], [".", 1456], ["These", 1458], ["regional", 1464], ["differences", 1473], ["in", 1485], ["CMA", 1488], ["activity", 1492], ["and", 1501], ["Lamp-2a", 1505], ["expression", 1513], ["were", 1524], ["found", 1529], ["in", 1535], ["both", 1538], ["non", 1543], ["-", 1546], ["transgenic", 1547], ["mice", 1558], ["as", 1563], ["well", 1566], ["as", 1571], ["A53", 1574], ["T", 1577], ["\u03b1", 1579], ["-", 1580], ["syn", 1581], ["mice", 1585], [".", 1589], ["Therefore", 1591], [",", 1600], ["these", 1602], ["are", 1608], ["inherent", 1612], ["variations", 1621], ["and", 1632], ["not", 1636], ["a", 1640], ["transgene", 1642], ["-", 1651], ["specific", 1652], ["effect", 1661], [".", 1667], ["However", 1669], [",", 1676], ["differences", 1678], ["in", 1690], ["CMA", 1693], ["activity", 1697], ["may", 1706], ["render", 1710], ["select", 1717], ["brain", 1724], ["regions", 1730], ["vulnerable", 1738], ["to", 1749], ["homeostatic", 1752], ["dysfunction", 1764], ["in", 1776], ["the", 1779], ["presence", 1783], ["of", 1792], ["stressors", 1795], ["such", 1805], ["as", 1810], ["overexpression", 1813], ["of", 1828], ["human", 1831], ["A53", 1837], ["T", 1840], ["\u03b1", 1842], ["-", 1843], ["syn", 1844], [".", 1847], ["Collectively", 1849], [",", 1861], ["the", 1863], ["data", 1867], ["provide", 1872], ["a", 1880], ["potential", 1882], ["mechanism", 1892], ["to", 1902], ["explain", 1905], ["the", 1913], ["dichotomy", 1917], ["of", 1927], ["vulnerability", 1930], ["or", 1944], ["resistance", 1947], ["that", 1958], ["underlies", 1963], ["brain", 1973], ["regions", 1979], ["during", 1987], ["aggregate", 1994], ["formation", 2004], ["in", 2014], ["neurodegenerative", 2017], ["disease", 2035], [".", 2042]]}
{"context": "Infections generally occur in intravenous drug abuse (IVDA) patients, most commonly affecting the spine and proximal joints. Numerous serious musculoskeletal complications of IVDA may involve the upper extremity, however. Soft-tissue complications in the upper extremity of IVDA patients include cellulitis, ulceration, abscess, pyomyositis, septic bursitis, tenosynovitis, and necrotizing fasciitis. Foreign bodies in soft tissue due to needle fragments are common findings. Primary bone and joint IVDA complications include osteomyelitis (acute and chronic) and septic arthritis. Other IVDA complications in the upper extremity affecting blood vessels and lymphatics include hematoma, arterial aneurysm and pseudoaneurysm, thrombosis, thrombophlebitis, \"puffy hand\" syndrome, and lymphadenopathy. These complications usually present as urgent issues requiring prompt and accurate evaluation in the acute setting. Diagnostic imaging not only aids in making the correct diagnosis but also permits precise definition of the location and extent of these abnormalities. We review the imaging findings and illustrate a wide range of disabling and even life-threatening complications affecting the upper extremity of IVDA patients that require early diagnosis for optimal outcome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "b303b77c66f64d6c905ec9262e272043", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[4, 6]], "char_spans": [[30, 51]]}]}], "context_tokens": [["Infections", 0], ["generally", 11], ["occur", 21], ["in", 27], ["intravenous", 30], ["drug", 42], ["abuse", 47], ["(", 53], ["IVDA", 54], [")", 58], ["patients", 60], [",", 68], ["most", 70], ["commonly", 75], ["affecting", 84], ["the", 94], ["spine", 98], ["and", 104], ["proximal", 108], ["joints", 117], [".", 123], ["Numerous", 125], ["serious", 134], ["musculoskeletal", 142], ["complications", 158], ["of", 172], ["IVDA", 175], ["may", 180], ["involve", 184], ["the", 192], ["upper", 196], ["extremity", 202], [",", 211], ["however", 213], [".", 220], ["Soft", 222], ["-", 226], ["tissue", 227], ["complications", 234], ["in", 248], ["the", 251], ["upper", 255], ["extremity", 261], ["of", 271], ["IVDA", 274], ["patients", 279], ["include", 288], ["cellulitis", 296], [",", 306], ["ulceration", 308], [",", 318], ["abscess", 320], [",", 327], ["pyomyositis", 329], [",", 340], ["septic", 342], ["bursitis", 349], [",", 357], ["tenosynovitis", 359], [",", 372], ["and", 374], ["necrotizing", 378], ["fasciitis", 390], [".", 399], ["Foreign", 401], ["bodies", 409], ["in", 416], ["soft", 419], ["tissue", 424], ["due", 431], ["to", 435], ["needle", 438], ["fragments", 445], ["are", 455], ["common", 459], ["findings", 466], [".", 474], ["Primary", 476], ["bone", 484], ["and", 489], ["joint", 493], ["IVDA", 499], ["complications", 504], ["include", 518], ["osteomyelitis", 526], ["(", 540], ["acute", 541], ["and", 547], ["chronic", 551], [")", 558], ["and", 560], ["septic", 564], ["arthritis", 571], [".", 580], ["Other", 582], ["IVDA", 588], ["complications", 593], ["in", 607], ["the", 610], ["upper", 614], ["extremity", 620], ["affecting", 630], ["blood", 640], ["vessels", 646], ["and", 654], ["lymphatics", 658], ["include", 669], ["hematoma", 677], [",", 685], ["arterial", 687], ["aneurysm", 696], ["and", 705], ["pseudoaneurysm", 709], [",", 723], ["thrombosis", 725], [",", 735], ["thrombophlebitis", 737], [",", 753], ["\"", 755], ["puffy", 756], ["hand", 762], ["\"", 766], ["syndrome", 768], [",", 776], ["and", 778], ["lymphadenopathy", 782], [".", 797], ["These", 799], ["complications", 805], ["usually", 819], ["present", 827], ["as", 835], ["urgent", 838], ["issues", 845], ["requiring", 852], ["prompt", 862], ["and", 869], ["accurate", 873], ["evaluation", 882], ["in", 893], ["the", 896], ["acute", 900], ["setting", 906], [".", 913], ["Diagnostic", 915], ["imaging", 926], ["not", 934], ["only", 938], ["aids", 943], ["in", 948], ["making", 951], ["the", 958], ["correct", 962], ["diagnosis", 970], ["but", 980], ["also", 984], ["permits", 989], ["precise", 997], ["definition", 1005], ["of", 1016], ["the", 1019], ["location", 1023], ["and", 1032], ["extent", 1036], ["of", 1043], ["these", 1046], ["abnormalities", 1052], [".", 1065], ["We", 1067], ["review", 1070], ["the", 1077], ["imaging", 1081], ["findings", 1089], ["and", 1098], ["illustrate", 1102], ["a", 1113], ["wide", 1115], ["range", 1120], ["of", 1126], ["disabling", 1129], ["and", 1139], ["even", 1143], ["life", 1148], ["-", 1152], ["threatening", 1153], ["complications", 1165], ["affecting", 1179], ["the", 1189], ["upper", 1193], ["extremity", 1199], ["of", 1209], ["IVDA", 1212], ["patients", 1217], ["that", 1226], ["require", 1231], ["early", 1239], ["diagnosis", 1245], ["for", 1255], ["optimal", 1259], ["outcome", 1267], [".", 1274]]}
{"context": "Two spontaneous mutant beige rats, with phenotypes resembling human Chediak- Higashi syndrome (CHS), were found independently in two inbred strains. Both beige mutations were identified to be recessive alleles in the Lyst locus on rat chromosome 17 and the alleles were denoted Lyst(bg) and Lyst(bg-Kyo). As it is almost impossible to discriminate these mutations phenotypically, we developed an allele-specific genotyping method for the Lyst gene. The nested PCR amplification was followed by restriction fragment length polymorphism (RFLP) analysis. By this method, we could discriminate the mutant Lyst(bg), Lyst(bg-Kyo) alleles, and the normal Lyst allele, easily and accurately.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome", "Chediak- Higashi syndrome"], "qid": "23bd86de677a400e8ee3c4a56c6f39e1", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[10, 12]], "char_spans": [[68, 92]]}]}], "context_tokens": [["Two", 0], ["spontaneous", 4], ["mutant", 16], ["beige", 23], ["rats", 29], [",", 33], ["with", 35], ["phenotypes", 40], ["resembling", 51], ["human", 62], ["Chediak-", 68], ["Higashi", 77], ["syndrome", 85], ["(", 94], ["CHS", 95], [")", 98], [",", 99], ["were", 101], ["found", 106], ["independently", 112], ["in", 126], ["two", 129], ["inbred", 133], ["strains", 140], [".", 147], ["Both", 149], ["beige", 154], ["mutations", 160], ["were", 170], ["identified", 175], ["to", 186], ["be", 189], ["recessive", 192], ["alleles", 202], ["in", 210], ["the", 213], ["Lyst", 217], ["locus", 222], ["on", 228], ["rat", 231], ["chromosome", 235], ["17", 246], ["and", 249], ["the", 253], ["alleles", 257], ["were", 265], ["denoted", 270], ["Lyst(bg", 278], [")", 285], ["and", 287], ["Lyst(bg", 291], ["-", 298], ["Kyo", 299], [")", 302], [".", 303], ["As", 305], ["it", 308], ["is", 311], ["almost", 314], ["impossible", 321], ["to", 332], ["discriminate", 335], ["these", 348], ["mutations", 354], ["phenotypically", 364], [",", 378], ["we", 380], ["developed", 383], ["an", 393], ["allele", 396], ["-", 402], ["specific", 403], ["genotyping", 412], ["method", 423], ["for", 430], ["the", 434], ["Lyst", 438], ["gene", 443], [".", 447], ["The", 449], ["nested", 453], ["PCR", 460], ["amplification", 464], ["was", 478], ["followed", 482], ["by", 491], ["restriction", 494], ["fragment", 506], ["length", 515], ["polymorphism", 522], ["(", 535], ["RFLP", 536], [")", 540], ["analysis", 542], [".", 550], ["By", 552], ["this", 555], ["method", 560], [",", 566], ["we", 568], ["could", 571], ["discriminate", 577], ["the", 590], ["mutant", 594], ["Lyst(bg", 601], [")", 608], [",", 609], ["Lyst(bg", 611], ["-", 618], ["Kyo", 619], [")", 622], ["alleles", 624], [",", 631], ["and", 633], ["the", 637], ["normal", 641], ["Lyst", 648], ["allele", 653], [",", 659], ["easily", 661], ["and", 668], ["accurately", 672], [".", 682]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "56f2ae49145640039f519cc53fd849b2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "9366db61286b41f79e9e069494d2c271", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively. The IC(50) values of another NCX inhibitor KB-R7943 were 1.8 and 3.7 microM, respectively. These results indicate that SEA0400 is about 40 times more potent than KB-R7943 in inhibiting NCX working in the reverse mode. In intact cells, SEA0400 and KB-R7943 inhibited CA release induced by acetylcholine and DMPP. The IC(50) values of SEA0400 were 5.1 and 4.5 microM and the values of KB-R7943 were 2.6 and 2.1 microM against the release induced by acetylcholine and DMPP, respectively, indicating that the potency of SEA0400 is about a half of that of KB-R7943 in inhibiting the nicotinic receptor-mediated CA release. The binding of [(3)H]nicotine with nicotinic receptors was inhibited by SEA0400 (IC(50) = 90 microM) and KB-R7943 (IC(50) = 12 microM). From these results, it is concluded that unlike KB-R7943, SEA0400 has a potent and selective action on NCX in bovine adrenal chromaffin cells.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "5d94e2adbfb64ff1b3a5b25d968b5828", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[10, 13]], "char_spans": [[53, 74]]}, {"text": "NCX", "token_spans": [[81, 81], [111, 111], [15, 15], [249, 249]], "char_spans": [[419, 421], [575, 577], [77, 79], [1247, 1249]]}]}], "context_tokens": [["The", 0], ["effects", 4], ["of", 12], ["SEA0400", 15], [",", 22], ["a", 24], ["selective", 26], ["inhibitor", 36], ["of", 46], ["the", 49], ["Na(+)/Ca(2", 53], ["+", 63], [")", 64], ["exchanger", 66], ["(", 76], ["NCX", 77], [")", 80], [",", 81], ["on", 83], ["Na(+)-dependent", 86], ["Ca(2", 102], ["+", 106], [")", 107], ["uptake", 109], ["and", 116], ["catecholamine", 120], ["(", 134], ["CA", 135], [")", 137], ["release", 139], ["were", 147], ["examined", 152], ["in", 161], ["bovine", 164], ["adrenal", 171], ["chromaffin", 179], ["cells", 190], ["that", 196], ["were", 201], ["loaded", 206], ["with", 213], ["Na(+", 218], [")", 222], ["by", 224], ["treatment", 227], ["with", 237], ["ouabain", 242], ["and", 250], ["veratridine", 254], [".", 265], ["SEA0400", 267], ["inhibited", 275], ["Na(+)-dependent", 285], ["(", 301], ["45)Ca(2", 302], ["+", 309], [")", 310], ["uptake", 312], ["and", 319], ["CA", 323], ["release", 326], [",", 333], ["with", 335], ["the", 340], ["IC(50", 344], [")", 349], ["values", 351], ["of", 358], ["40", 361], ["and", 364], ["100", 368], ["nM", 372], [",", 374], ["respectively", 376], [".", 388], ["The", 390], ["IC(50", 394], [")", 399], ["values", 401], ["of", 408], ["another", 411], ["NCX", 419], ["inhibitor", 423], ["KB", 433], ["-", 435], ["R7943", 436], ["were", 442], ["1.8", 447], ["and", 451], ["3.7", 455], ["microM", 459], [",", 465], ["respectively", 467], [".", 479], ["These", 481], ["results", 487], ["indicate", 495], ["that", 504], ["SEA0400", 509], ["is", 517], ["about", 520], ["40", 526], ["times", 529], ["more", 535], ["potent", 540], ["than", 547], ["KB", 552], ["-", 554], ["R7943", 555], ["in", 561], ["inhibiting", 564], ["NCX", 575], ["working", 579], ["in", 587], ["the", 590], ["reverse", 594], ["mode", 602], [".", 606], ["In", 608], ["intact", 611], ["cells", 618], [",", 623], ["SEA0400", 625], ["and", 633], ["KB", 637], ["-", 639], ["R7943", 640], ["inhibited", 646], ["CA", 656], ["release", 659], ["induced", 667], ["by", 675], ["acetylcholine", 678], ["and", 692], ["DMPP", 696], [".", 700], ["The", 702], ["IC(50", 706], [")", 711], ["values", 713], ["of", 720], ["SEA0400", 723], ["were", 731], ["5.1", 736], ["and", 740], ["4.5", 744], ["microM", 748], ["and", 755], ["the", 759], ["values", 763], ["of", 770], ["KB", 773], ["-", 775], ["R7943", 776], ["were", 782], ["2.6", 787], ["and", 791], ["2.1", 795], ["microM", 799], ["against", 806], ["the", 814], ["release", 818], ["induced", 826], ["by", 834], ["acetylcholine", 837], ["and", 851], ["DMPP", 855], [",", 859], ["respectively", 861], [",", 873], ["indicating", 875], ["that", 886], ["the", 891], ["potency", 895], ["of", 903], ["SEA0400", 906], ["is", 914], ["about", 917], ["a", 923], ["half", 925], ["of", 930], ["that", 933], ["of", 938], ["KB", 941], ["-", 943], ["R7943", 944], ["in", 950], ["inhibiting", 953], ["the", 964], ["nicotinic", 968], ["receptor", 978], ["-", 986], ["mediated", 987], ["CA", 996], ["release", 999], [".", 1006], ["The", 1008], ["binding", 1012], ["of", 1020], ["[", 1023], ["(", 1024], ["3)H]nicotine", 1025], ["with", 1038], ["nicotinic", 1043], ["receptors", 1053], ["was", 1063], ["inhibited", 1067], ["by", 1077], ["SEA0400", 1080], ["(", 1088], ["IC(50", 1089], [")", 1094], ["=", 1096], ["90", 1098], ["microM", 1101], [")", 1107], ["and", 1109], ["KB", 1113], ["-", 1115], ["R7943", 1116], ["(", 1122], ["IC(50", 1123], [")", 1128], ["=", 1130], ["12", 1132], ["microM", 1135], [")", 1141], [".", 1142], ["From", 1144], ["these", 1149], ["results", 1155], [",", 1162], ["it", 1164], ["is", 1167], ["concluded", 1170], ["that", 1180], ["unlike", 1185], ["KB", 1192], ["-", 1194], ["R7943", 1195], [",", 1200], ["SEA0400", 1202], ["has", 1210], ["a", 1214], ["potent", 1216], ["and", 1223], ["selective", 1227], ["action", 1237], ["on", 1244], ["NCX", 1247], ["in", 1251], ["bovine", 1254], ["adrenal", 1261], ["chromaffin", 1269], ["cells", 1280], [".", 1285]]}
{"context": "We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. Multivariable logistic regression models were used to evaluate prognostic indicators of complete hematological response (CHR), complete cytogenetic response (CCyR), and complete or major molecular response (C/MMR). Among patients treated with first-line imatinib, CHR at three months, CCyR at 12 months, and C/MMR at 18 months were observed in 53, 53.1, and 57.8 % of patients, respectively. Among patients treated with second-line dasatinib or nilotinib, CHR was achieved at three months in 49 and 42 %, CCyR at 12 months in 32 and 23 %, and MMR at 18 months in 30.5 and 26.1 % of patients, respectively. Prognostic indicators of first-line response included age, race, and Sokal score. For second-line treatment, duration of first-line hematological response and choice of drug used were also significant.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7f2a7d1273d0421f802f06a3bb2fdbbe", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[67, 69]], "char_spans": [[394, 400]]}]}], "context_tokens": [["We", 0], ["conducted", 3], ["a", 13], ["review", 15], ["of", 22], ["patient", 25], ["medical", 33], ["records", 41], ["to", 49], ["assess", 52], ["treatment", 59], ["response", 69], ["patterns", 78], ["and", 87], ["prognostic", 91], ["indicators", 102], ["of", 113], ["response", 116], ["among", 125], ["chronic", 131], ["myeloid", 139], ["leukemia", 147], ["(", 156], ["CML", 157], [")", 160], ["patients", 162], ["in", 171], ["the", 174], ["United", 178], ["States", 185], [",", 191], ["the", 193], ["United", 197], ["Kingdom", 204], [",", 211], ["Germany", 213], [",", 220], ["and", 222], ["Japan", 226], [".", 231], ["All", 233], ["1,063", 237], ["patients", 243], ["selected", 252], ["met", 261], ["the", 265], ["following", 269], ["inclusion", 279], ["criteria", 289], [":", 297], ["aged", 299], ["18", 304], ["or", 307], ["older", 310], ["and", 316], ["in", 320], ["chronic", 323], ["phase", 331], ["at", 337], ["the", 340], ["time", 344], ["of", 349], ["diagnosis", 352], [",", 361], ["Philadelphia", 363], ["chromosome", 376], ["and/or", 387], ["BCR", 394], ["-", 397], ["ABL", 398], ["positive", 402], [",", 410], ["received", 412], ["first", 421], ["-", 426], ["line", 427], ["treatment", 432], ["with", 442], ["imatinib", 447], [",", 455], ["and", 457], ["not", 461], ["enrolled", 465], ["in", 474], ["a", 477], ["randomized", 479], ["clinical", 490], ["trial", 499], ["during", 505], ["the", 512], ["period", 516], ["of", 523], ["retrospective", 526], ["review", 540], [".", 546], ["Multivariable", 548], ["logistic", 562], ["regression", 571], ["models", 582], ["were", 589], ["used", 594], ["to", 599], ["evaluate", 602], ["prognostic", 611], ["indicators", 622], ["of", 633], ["complete", 636], ["hematological", 645], ["response", 659], ["(", 668], ["CHR", 669], [")", 672], [",", 673], ["complete", 675], ["cytogenetic", 684], ["response", 696], ["(", 705], ["CCyR", 706], [")", 710], [",", 711], ["and", 713], ["complete", 717], ["or", 726], ["major", 729], ["molecular", 735], ["response", 745], ["(", 754], ["C", 755], ["/", 756], ["MMR", 757], [")", 760], [".", 761], ["Among", 763], ["patients", 769], ["treated", 778], ["with", 786], ["first", 791], ["-", 796], ["line", 797], ["imatinib", 802], [",", 810], ["CHR", 812], ["at", 816], ["three", 819], ["months", 825], [",", 831], ["CCyR", 833], ["at", 838], ["12", 841], ["months", 844], [",", 850], ["and", 852], ["C", 856], ["/", 857], ["MMR", 858], ["at", 862], ["18", 865], ["months", 868], ["were", 875], ["observed", 880], ["in", 889], ["53", 892], [",", 894], ["53.1", 896], [",", 900], ["and", 902], ["57.8", 906], ["%", 911], ["of", 913], ["patients", 916], [",", 924], ["respectively", 926], [".", 938], ["Among", 940], ["patients", 946], ["treated", 955], ["with", 963], ["second", 968], ["-", 974], ["line", 975], ["dasatinib", 980], ["or", 990], ["nilotinib", 993], [",", 1002], ["CHR", 1004], ["was", 1008], ["achieved", 1012], ["at", 1021], ["three", 1024], ["months", 1030], ["in", 1037], ["49", 1040], ["and", 1043], ["42", 1047], ["%", 1050], [",", 1051], ["CCyR", 1053], ["at", 1058], ["12", 1061], ["months", 1064], ["in", 1071], ["32", 1074], ["and", 1077], ["23", 1081], ["%", 1084], [",", 1085], ["and", 1087], ["MMR", 1091], ["at", 1095], ["18", 1098], ["months", 1101], ["in", 1108], ["30.5", 1111], ["and", 1116], ["26.1", 1120], ["%", 1125], ["of", 1127], ["patients", 1130], [",", 1138], ["respectively", 1140], [".", 1152], ["Prognostic", 1154], ["indicators", 1165], ["of", 1176], ["first", 1179], ["-", 1184], ["line", 1185], ["response", 1190], ["included", 1199], ["age", 1208], [",", 1211], ["race", 1213], [",", 1217], ["and", 1219], ["Sokal", 1223], ["score", 1229], [".", 1234], ["For", 1236], ["second", 1240], ["-", 1246], ["line", 1247], ["treatment", 1252], [",", 1261], ["duration", 1263], ["of", 1272], ["first", 1275], ["-", 1280], ["line", 1281], ["hematological", 1286], ["response", 1300], ["and", 1309], ["choice", 1313], ["of", 1320], ["drug", 1323], ["used", 1328], ["were", 1333], ["also", 1338], ["significant", 1343], [".", 1354]]}
{"context": "ATP13A2 (PARK9) loss of function mutations are a genetic cause of an early-onset form of Parkinson's disease (PD), with in vitro studies showing that ATP13A2 deficits lead to lysosomal and mitochondrial dysfunction and \u03b1-synuclein accumulation, while elevated ATP13A2 expression reduces \u03b1-synuclein toxicity. The three human brain tissue studies assessing changes in ATP13A2 expression in PD produced divergent results; mRNA is increased while protein levels were observed to be either increased or decreased. This apparent conflict in protein levels might have arisen from examining Lewy body disease cases with coexisting Alzheimer-type pathologies.To assess whether ATP13A2 levels in Lewy body disease are modified by Alzheimer-type \u03b2-amyloid deposition, we evaluated cases of pure PD and pure dementia with Lewy bodies (DLB) for changes in ATP13A2, \u03b1-synuclein and \u03b2-amyloid protein levels in cortical regions with and without Lewy bodies. In all Lewy body disease cases, we identified decreased ATP13A2 protein levels that correlated with increases in both \u03b1-synuclein and \u03b2-amyloid. Partial colocalization was observed between ATP13A2 and \u03b1-synuclein in Lewy bodies, whereas ATP13A2 did not colocalize with pathological \u03b2-amyloid deposition. Our data show that patients with Lewy body diseases have an overall deficit in ATP13A2 protein levels, with the remaining protein being more insoluble and partially redistributing towards Lewy bodies. This supports the concept that increasing ATP13A2 levels may offer potential therapeutic benefits to patients with Lewy body diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "5c8a8c9ddaa24aa699e91a1ac4502ebb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[150, 152], [202, 204], [51, 53], [41, 43], [187, 189]], "char_spans": [[853, 863], [1145, 1155], [287, 297], [219, 229], [1062, 1072]]}]}], "context_tokens": [["ATP13A2", 0], ["(", 8], ["PARK9", 9], [")", 14], ["loss", 16], ["of", 21], ["function", 24], ["mutations", 33], ["are", 43], ["a", 47], ["genetic", 49], ["cause", 57], ["of", 63], ["an", 66], ["early", 69], ["-", 74], ["onset", 75], ["form", 81], ["of", 86], ["Parkinson", 89], ["'s", 98], ["disease", 101], ["(", 109], ["PD", 110], [")", 112], [",", 113], ["with", 115], ["in", 120], ["vitro", 123], ["studies", 129], ["showing", 137], ["that", 145], ["ATP13A2", 150], ["deficits", 158], ["lead", 167], ["to", 172], ["lysosomal", 175], ["and", 185], ["mitochondrial", 189], ["dysfunction", 203], ["and", 215], ["\u03b1", 219], ["-", 220], ["synuclein", 221], ["accumulation", 231], [",", 243], ["while", 245], ["elevated", 251], ["ATP13A2", 260], ["expression", 268], ["reduces", 279], ["\u03b1", 287], ["-", 288], ["synuclein", 289], ["toxicity", 299], [".", 307], ["The", 309], ["three", 313], ["human", 319], ["brain", 325], ["tissue", 331], ["studies", 338], ["assessing", 346], ["changes", 356], ["in", 364], ["ATP13A2", 367], ["expression", 375], ["in", 386], ["PD", 389], ["produced", 392], ["divergent", 401], ["results", 411], [";", 418], ["mRNA", 420], ["is", 425], ["increased", 428], ["while", 438], ["protein", 444], ["levels", 452], ["were", 459], ["observed", 464], ["to", 473], ["be", 476], ["either", 479], ["increased", 486], ["or", 496], ["decreased", 499], [".", 508], ["This", 510], ["apparent", 515], ["conflict", 524], ["in", 533], ["protein", 536], ["levels", 544], ["might", 551], ["have", 557], ["arisen", 562], ["from", 569], ["examining", 574], ["Lewy", 584], ["body", 589], ["disease", 594], ["cases", 602], ["with", 608], ["coexisting", 613], ["Alzheimer", 624], ["-", 633], ["type", 634], ["pathologies", 639], [".", 650], ["To", 651], ["assess", 654], ["whether", 661], ["ATP13A2", 669], ["levels", 677], ["in", 684], ["Lewy", 687], ["body", 692], ["disease", 697], ["are", 705], ["modified", 709], ["by", 718], ["Alzheimer", 721], ["-", 730], ["type", 731], ["\u03b2", 736], ["-", 737], ["amyloid", 738], ["deposition", 746], [",", 756], ["we", 758], ["evaluated", 761], ["cases", 771], ["of", 777], ["pure", 780], ["PD", 785], ["and", 788], ["pure", 792], ["dementia", 797], ["with", 806], ["Lewy", 811], ["bodies", 816], ["(", 823], ["DLB", 824], [")", 827], ["for", 829], ["changes", 833], ["in", 841], ["ATP13A2", 844], [",", 851], ["\u03b1", 853], ["-", 854], ["synuclein", 855], ["and", 865], ["\u03b2", 869], ["-", 870], ["amyloid", 871], ["protein", 879], ["levels", 887], ["in", 894], ["cortical", 897], ["regions", 906], ["with", 914], ["and", 919], ["without", 923], ["Lewy", 931], ["bodies", 936], [".", 942], ["In", 944], ["all", 947], ["Lewy", 951], ["body", 956], ["disease", 961], ["cases", 969], [",", 974], ["we", 976], ["identified", 979], ["decreased", 990], ["ATP13A2", 1000], ["protein", 1008], ["levels", 1016], ["that", 1023], ["correlated", 1028], ["with", 1039], ["increases", 1044], ["in", 1054], ["both", 1057], ["\u03b1", 1062], ["-", 1063], ["synuclein", 1064], ["and", 1074], ["\u03b2", 1078], ["-", 1079], ["amyloid", 1080], [".", 1087], ["Partial", 1089], ["colocalization", 1097], ["was", 1112], ["observed", 1116], ["between", 1125], ["ATP13A2", 1133], ["and", 1141], ["\u03b1", 1145], ["-", 1146], ["synuclein", 1147], ["in", 1157], ["Lewy", 1160], ["bodies", 1165], [",", 1171], ["whereas", 1173], ["ATP13A2", 1181], ["did", 1189], ["not", 1193], ["colocalize", 1197], ["with", 1208], ["pathological", 1213], ["\u03b2", 1226], ["-", 1227], ["amyloid", 1228], ["deposition", 1236], [".", 1246], ["Our", 1248], ["data", 1252], ["show", 1257], ["that", 1262], ["patients", 1267], ["with", 1276], ["Lewy", 1281], ["body", 1286], ["diseases", 1291], ["have", 1300], ["an", 1305], ["overall", 1308], ["deficit", 1316], ["in", 1324], ["ATP13A2", 1327], ["protein", 1335], ["levels", 1343], [",", 1349], ["with", 1351], ["the", 1356], ["remaining", 1360], ["protein", 1370], ["being", 1378], ["more", 1384], ["insoluble", 1389], ["and", 1399], ["partially", 1403], ["redistributing", 1413], ["towards", 1428], ["Lewy", 1436], ["bodies", 1441], [".", 1447], ["This", 1449], ["supports", 1454], ["the", 1463], ["concept", 1467], ["that", 1475], ["increasing", 1480], ["ATP13A2", 1491], ["levels", 1499], ["may", 1506], ["offer", 1510], ["potential", 1516], ["therapeutic", 1526], ["benefits", 1538], ["to", 1547], ["patients", 1550], ["with", 1559], ["Lewy", 1564], ["body", 1569], ["diseases", 1574], [".", 1582]]}
{"context": "Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22(phox). The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22(phox), further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "e662d0daac3047e6bbb879f08d0a56eb", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[45, 45], [126, 126]], "char_spans": [[246, 249], [757, 760]]}]}], "context_tokens": [["Nox3", 0], [",", 4], ["a", 6], ["member", 8], ["of", 15], ["the", 18], ["superoxide", 22], ["-", 32], ["producing", 33], ["NADPH", 43], ["oxidase", 49], ["(", 57], ["Nox", 58], [")", 61], ["family", 63], [",", 69], ["participates", 71], ["in", 84], ["otoconia", 87], ["formation", 96], ["in", 106], ["mouse", 109], ["inner", 115], ["ears", 121], [",", 125], ["which", 127], ["is", 133], ["required", 136], ["for", 145], ["perception", 149], ["of", 160], ["balance", 163], ["and", 171], ["gravity", 175], [".", 182], ["The", 184], ["activity", 188], ["of", 197], ["other", 200], ["Nox", 206], ["enzymes", 210], ["such", 218], ["as", 223], ["gp91(phox)/Nox2", 226], ["and", 242], ["Nox1", 246], ["is", 251], ["known", 254], ["to", 260], ["absolutely", 263], ["require", 274], ["both", 282], ["an", 287], ["organizer", 290], ["protein", 300], ["(", 308], ["p47(phox", 309], [")", 317], ["or", 319], ["Noxo1", 322], [")", 327], ["andanactivatorprotein", 329], ["(", 351], ["p67(phox", 352], [")", 360], ["or", 362], ["Noxa1", 365], [")", 370], [";", 371], ["for", 373], ["the", 377], ["p47(phox)-dependent", 381], ["activation", 401], ["of", 412], ["these", 415], ["oxidases", 421], [",", 429], ["treatment", 431], ["of", 441], ["cells", 444], ["with", 450], ["stimulants", 455], ["such", 466], ["as", 471], ["phorbol", 474], ["12-myristate", 482], ["13-acetate", 495], ["is", 506], ["also", 509], ["indispensable", 514], [".", 527], ["Here", 529], ["we", 534], ["show", 537], ["that", 542], ["ectopic", 547], ["expression", 555], ["of", 566], ["Nox3", 569], ["in", 574], ["various", 577], ["types", 585], ["of", 591], ["cells", 594], ["leads", 600], ["to", 606], ["phorbol", 609], ["12-myristate", 617], ["13-acetate", 630], ["-", 640], ["independent", 641], ["constitutive", 653], ["production", 666], ["of", 677], ["a", 680], ["substantial", 682], ["amount", 694], ["of", 701], ["superoxide", 704], ["under", 715], ["the", 721], ["conditions", 725], ["where", 736], ["gp91(phox", 742], [")", 751], ["and", 753], ["Nox1", 757], ["fail", 762], ["to", 767], ["generate", 770], ["superoxide", 779], [",", 789], ["i.e.", 791], ["in", 796], ["the", 799], ["absence", 803], ["of", 811], ["the", 814], ["oxidase", 818], ["organizers", 826], ["and", 837], ["activators", 841], [".", 851], ["Nox3", 853], ["likely", 858], ["forms", 865], ["a", 871], ["functional", 873], ["complex", 884], ["with", 892], ["p22(phox", 897], [")", 905], [";", 906], ["Nox3", 908], ["physically", 913], ["interacts", 924], ["with", 934], ["and", 939], ["stabilizes", 943], ["p22(phox", 954], [")", 962], [",", 963], ["and", 965], ["the", 969], ["Nox3-dependent", 973], ["superoxide", 988], ["production", 999], ["is", 1010], ["totally", 1013], ["dependent", 1021], ["on", 1031], ["p22(phox", 1034], [")", 1042], [".", 1043], ["The", 1045], ["organizers", 1049], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["Noxo1", 1074], ["are", 1080], ["capable", 1084], ["of", 1092], ["enhancing", 1095], ["the", 1105], ["superoxide", 1109], ["production", 1120], ["by", 1131], ["Nox3", 1134], ["in", 1139], ["the", 1142], ["absence", 1146], ["of", 1154], ["the", 1157], ["activators", 1161], [",", 1171], ["and", 1173], ["the", 1177], ["enhancement", 1181], ["requires", 1193], ["the", 1202], ["interaction", 1206], ["of", 1218], ["the", 1221], ["organizers", 1225], ["with", 1236], ["p22(phox", 1241], [")", 1249], [",", 1250], ["further", 1252], ["indicating", 1260], ["a", 1271], ["link", 1273], ["between", 1278], ["Nox3", 1286], ["and", 1291], ["p22(phox", 1295], [")", 1303], [".", 1304], ["The", 1306], ["p47(phox)-enhanced", 1310], ["Nox3", 1329], ["activity", 1334], ["is", 1343], ["further", 1346], ["facilitated", 1354], ["by", 1366], ["p67(phox", 1369], [")", 1377], ["or", 1379], ["Noxa1", 1382], [",", 1387], ["whereas", 1389], ["the", 1397], ["activators", 1401], ["cancel", 1412], ["the", 1419], ["Noxo1-induced", 1423], ["enhancement", 1437], [".", 1448], ["On", 1450], ["the", 1453], ["other", 1457], ["hand", 1463], [",", 1467], ["the", 1469], ["small", 1473], ["GTPase", 1479], ["Rac", 1486], [",", 1489], ["essential", 1491], ["for", 1501], ["the", 1505], ["gp91(phox", 1509], [")", 1518], ["activity", 1520], [",", 1528], ["is", 1530], ["likely", 1533], ["dispensable", 1540], ["to", 1552], ["the", 1555], ["Nox3", 1559], ["system", 1564], [".", 1570], ["Thus", 1572], ["Nox3", 1577], ["functions", 1582], ["together", 1592], ["with", 1601], ["p22(phox", 1606], [")", 1614], ["as", 1616], ["an", 1619], ["enzyme", 1622], ["constitutively", 1629], ["producing", 1644], ["superoxide", 1654], [",", 1664], ["which", 1666], ["can", 1672], ["be", 1676], ["distinctly", 1679], ["regulated", 1690], ["by", 1700], ["combinatorial", 1703], ["use", 1717], ["of", 1721], ["the", 1724], ["organizers", 1728], ["and", 1739], ["activators", 1743], [".", 1753]]}
{"context": "By using monoclonal antibodies raised against isolated clam centrosomes, we have identified a novel 135-kD centrosomal protein (Cep135), present in a wide range of organisms. Cep135 is located at the centrosome throughout the cell cycle, and localization is independent of the microtubule network. It distributes throughout the centrosomal area in association with the electron-dense material surrounding centrioles. Sequence analysis of cDNA isolated from CHO cells predicted a protein of 1,145-amino acid residues with extensive alpha-helical domains. Expression of a series of deletion constructs revealed the presence of three independent centrosome-targeting domains. Overexpression of Cep135 resulted in the accumulation of unique whorl-like particles in both the centrosome and the cytoplasm. Although their size, shape, and number varied according to the level of protein expression, these whorls were composed of parallel dense lines arranged in a 6-nm space. Altered levels of Cep135 by protein overexpression and/or suppression of endogenous Cep135 by RNA interference caused disorganization of interphase and mitotic spindle microtubules. Thus, Cep135 may play an important role in the centrosomal function of organizing microtubules in mammalian cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "531659cef16e4f2d9ad354129f13c0c8", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[123, 123], [35, 35], [102, 102]], "char_spans": [[770, 779], [200, 209], [643, 652]]}]}], "context_tokens": [["By", 0], ["using", 3], ["monoclonal", 9], ["antibodies", 20], ["raised", 31], ["against", 38], ["isolated", 46], ["clam", 55], ["centrosomes", 60], [",", 71], ["we", 73], ["have", 76], ["identified", 81], ["a", 92], ["novel", 94], ["135-kD", 100], ["centrosomal", 107], ["protein", 119], ["(", 127], ["Cep135", 128], [")", 134], [",", 135], ["present", 137], ["in", 145], ["a", 148], ["wide", 150], ["range", 155], ["of", 161], ["organisms", 164], [".", 173], ["Cep135", 175], ["is", 182], ["located", 185], ["at", 193], ["the", 196], ["centrosome", 200], ["throughout", 211], ["the", 222], ["cell", 226], ["cycle", 231], [",", 236], ["and", 238], ["localization", 242], ["is", 255], ["independent", 258], ["of", 270], ["the", 273], ["microtubule", 277], ["network", 289], [".", 296], ["It", 298], ["distributes", 301], ["throughout", 313], ["the", 324], ["centrosomal", 328], ["area", 340], ["in", 345], ["association", 348], ["with", 360], ["the", 365], ["electron", 369], ["-", 377], ["dense", 378], ["material", 384], ["surrounding", 393], ["centrioles", 405], [".", 415], ["Sequence", 417], ["analysis", 426], ["of", 435], ["cDNA", 438], ["isolated", 443], ["from", 452], ["CHO", 457], ["cells", 461], ["predicted", 467], ["a", 477], ["protein", 479], ["of", 487], ["1,145-amino", 490], ["acid", 502], ["residues", 507], ["with", 516], ["extensive", 521], ["alpha", 531], ["-", 536], ["helical", 537], ["domains", 545], [".", 552], ["Expression", 554], ["of", 565], ["a", 568], ["series", 570], ["of", 577], ["deletion", 580], ["constructs", 589], ["revealed", 600], ["the", 609], ["presence", 613], ["of", 622], ["three", 625], ["independent", 631], ["centrosome", 643], ["-", 653], ["targeting", 654], ["domains", 664], [".", 671], ["Overexpression", 673], ["of", 688], ["Cep135", 691], ["resulted", 698], ["in", 707], ["the", 710], ["accumulation", 714], ["of", 727], ["unique", 730], ["whorl", 737], ["-", 742], ["like", 743], ["particles", 748], ["in", 758], ["both", 761], ["the", 766], ["centrosome", 770], ["and", 781], ["the", 785], ["cytoplasm", 789], [".", 798], ["Although", 800], ["their", 809], ["size", 815], [",", 819], ["shape", 821], [",", 826], ["and", 828], ["number", 832], ["varied", 839], ["according", 846], ["to", 856], ["the", 859], ["level", 863], ["of", 869], ["protein", 872], ["expression", 880], [",", 890], ["these", 892], ["whorls", 898], ["were", 905], ["composed", 910], ["of", 919], ["parallel", 922], ["dense", 931], ["lines", 937], ["arranged", 943], ["in", 952], ["a", 955], ["6-nm", 957], ["space", 962], [".", 967], ["Altered", 969], ["levels", 977], ["of", 984], ["Cep135", 987], ["by", 994], ["protein", 997], ["overexpression", 1005], ["and/or", 1020], ["suppression", 1027], ["of", 1039], ["endogenous", 1042], ["Cep135", 1053], ["by", 1060], ["RNA", 1063], ["interference", 1067], ["caused", 1080], ["disorganization", 1087], ["of", 1103], ["interphase", 1106], ["and", 1117], ["mitotic", 1121], ["spindle", 1129], ["microtubules", 1137], [".", 1149], ["Thus", 1151], [",", 1155], ["Cep135", 1157], ["may", 1164], ["play", 1168], ["an", 1173], ["important", 1176], ["role", 1186], ["in", 1191], ["the", 1194], ["centrosomal", 1198], ["function", 1210], ["of", 1219], ["organizing", 1222], ["microtubules", 1233], ["in", 1246], ["mammalian", 1249], ["cells", 1259], [".", 1264]]}
{"context": "RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. Recoding RNA editing is more widespread in Drosophila than in vertebrates. Editing levels rise strongly at metamorphosis, and Adar(5G1) null mutant flies lack editing events in hundreds of CNS transcripts; mutant flies have reduced viability, severely defective locomotion and age-dependent neurodegeneration. On the other hand, overexpressing an adult dADAR isoform with high enzymatic activity ubiquitously during larval and pupal stages is lethal. Advantage was taken of this to screen for genetic modifiers; Adar overexpression lethality is rescued by reduced dosage of the Rdl (Resistant to dieldrin), gene encoding a subunit of inhibitory GABA receptors. Reduced dosage of the Gad1 gene encoding the GABA synthetase also rescues Adar overexpression lethality. Drosophila Adar(5G1) mutant phenotypes are ameliorated by feeding GABA modulators. We demonstrate that neuronal excitability is linked to dADAR expression levels in individual neurons; Adar-overexpressing larval motor neurons show reduced excitability whereas Adar(5G1) null mutant or targeted Adar knockdown motor neurons exhibit increased excitability. GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "8c9513c5db4344709452efcb0a8fca01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[104, 104], [189, 189], [173, 173], [142, 142]], "char_spans": [[645, 648], [1193, 1196], [1084, 1087], [868, 871]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["by", 12], ["deamination", 15], ["of", 27], ["specific", 30], ["adenosine", 39], ["bases", 49], ["to", 55], ["inosines", 58], ["during", 67], ["pre", 74], ["-", 77], ["mRNA", 78], ["processing", 83], ["generates", 94], ["edited", 104], ["isoforms", 111], ["of", 120], ["proteins", 123], [".", 131], ["Recoding", 133], ["RNA", 142], ["editing", 146], ["is", 154], ["more", 157], ["widespread", 162], ["in", 173], ["Drosophila", 176], ["than", 187], ["in", 192], ["vertebrates", 195], [".", 206], ["Editing", 208], ["levels", 216], ["rise", 223], ["strongly", 228], ["at", 237], ["metamorphosis", 240], [",", 253], ["and", 255], ["Adar(5G1", 259], [")", 267], ["null", 269], ["mutant", 274], ["flies", 281], ["lack", 287], ["editing", 292], ["events", 300], ["in", 307], ["hundreds", 310], ["of", 319], ["CNS", 322], ["transcripts", 326], [";", 337], ["mutant", 339], ["flies", 346], ["have", 352], ["reduced", 357], ["viability", 365], [",", 374], ["severely", 376], ["defective", 385], ["locomotion", 395], ["and", 406], ["age", 410], ["-", 413], ["dependent", 414], ["neurodegeneration", 424], [".", 441], ["On", 443], ["the", 446], ["other", 450], ["hand", 456], [",", 460], ["overexpressing", 462], ["an", 477], ["adult", 480], ["dADAR", 486], ["isoform", 492], ["with", 500], ["high", 505], ["enzymatic", 510], ["activity", 520], ["ubiquitously", 529], ["during", 542], ["larval", 549], ["and", 556], ["pupal", 560], ["stages", 566], ["is", 573], ["lethal", 576], [".", 582], ["Advantage", 584], ["was", 594], ["taken", 598], ["of", 604], ["this", 607], ["to", 612], ["screen", 615], ["for", 622], ["genetic", 626], ["modifiers", 634], [";", 643], ["Adar", 645], ["overexpression", 650], ["lethality", 665], ["is", 675], ["rescued", 678], ["by", 686], ["reduced", 689], ["dosage", 697], ["of", 704], ["the", 707], ["Rdl", 711], ["(", 715], ["Resistant", 716], ["to", 726], ["dieldrin", 729], [")", 737], [",", 738], ["gene", 740], ["encoding", 745], ["a", 754], ["subunit", 756], ["of", 764], ["inhibitory", 767], ["GABA", 778], ["receptors", 783], [".", 792], ["Reduced", 794], ["dosage", 802], ["of", 809], ["the", 812], ["Gad1", 816], ["gene", 821], ["encoding", 826], ["the", 835], ["GABA", 839], ["synthetase", 844], ["also", 855], ["rescues", 860], ["Adar", 868], ["overexpression", 873], ["lethality", 888], [".", 897], ["Drosophila", 899], ["Adar(5G1", 910], [")", 918], ["mutant", 920], ["phenotypes", 927], ["are", 938], ["ameliorated", 942], ["by", 954], ["feeding", 957], ["GABA", 965], ["modulators", 970], [".", 980], ["We", 982], ["demonstrate", 985], ["that", 997], ["neuronal", 1002], ["excitability", 1011], ["is", 1024], ["linked", 1027], ["to", 1034], ["dADAR", 1037], ["expression", 1043], ["levels", 1054], ["in", 1061], ["individual", 1064], ["neurons", 1075], [";", 1082], ["Adar", 1084], ["-", 1088], ["overexpressing", 1089], ["larval", 1104], ["motor", 1111], ["neurons", 1117], ["show", 1125], ["reduced", 1130], ["excitability", 1138], ["whereas", 1151], ["Adar(5G1", 1159], [")", 1167], ["null", 1169], ["mutant", 1174], ["or", 1181], ["targeted", 1184], ["Adar", 1193], ["knockdown", 1198], ["motor", 1208], ["neurons", 1214], ["exhibit", 1222], ["increased", 1230], ["excitability", 1240], [".", 1252], ["GABA", 1254], ["inhibitory", 1259], ["signalling", 1270], ["is", 1281], ["impaired", 1284], ["in", 1293], ["human", 1296], ["epileptic", 1302], ["and", 1312], ["autistic", 1316], ["conditions", 1325], [",", 1335], ["and", 1337], ["vertebrate", 1341], ["ADARs", 1352], ["may", 1358], ["have", 1362], ["a", 1367], ["relevant", 1369], ["evolutionarily", 1378], ["conserved", 1393], ["control", 1403], ["over", 1411], ["neuronal", 1416], ["excitability", 1425], [".", 1437]]}
{"context": "The inflammatory cytokine IL-1\u03b2 has an essential role in the innate immune response. High levels of IL-1\u03b2 have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1\u03b2, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1\u03b2 and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Beh\u00e7et's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "e156bae24ed442c581112e4b34e212a5", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[17, 17], [63, 63], [3, 3], [79, 79]], "char_spans": [[100, 104], [344, 348], [26, 30], [434, 438]]}]}], "context_tokens": [["The", 0], ["inflammatory", 4], ["cytokine", 17], ["IL-1\u03b2", 26], ["has", 32], ["an", 36], ["essential", 39], ["role", 49], ["in", 54], ["the", 57], ["innate", 61], ["immune", 68], ["response", 75], [".", 83], ["High", 85], ["levels", 90], ["of", 97], ["IL-1\u03b2", 100], ["have", 106], ["been", 111], ["implicated", 116], ["in", 127], ["the", 130], ["development", 134], ["of", 146], ["many", 149], ["diseases", 154], [",", 162], ["including", 164], ["type", 174], ["1", 179], ["and", 181], ["2", 185], ["diabetes", 187], ["(", 196], ["T1D", 197], ["and", 201], ["T2D", 205], [")", 208], [",", 209], ["rheumatoid", 211], ["arthritis", 222], ["(", 232], ["RA", 233], [")", 235], ["and", 237], ["cardiovascular", 241], ["disease", 256], [".", 263], ["XOMA", 265], ["is", 270], ["developing", 273], ["gevokizumab", 284], ["(", 296], ["XOMA-052", 297], [")", 305], [",", 306], ["an", 308], ["IgG2", 311], ["humanized", 316], ["mAb", 326], ["against", 330], ["human", 338], ["IL-1\u03b2", 344], [",", 349], ["for", 351], ["the", 355], ["potential", 359], ["treatment", 369], ["of", 379], ["these", 382], ["diseases", 388], [".", 396], ["Gevokizumab", 398], ["has", 410], ["a", 414], ["high", 416], ["affinity", 421], ["for", 430], ["IL-1\u03b2", 434], ["and", 440], ["a", 444], ["long", 446], ["t1/2", 451], [",", 455], ["which", 457], ["would", 463], ["allow", 469], ["for", 475], ["once", 479], ["-", 483], ["monthly", 484], ["dosing", 492], ["and", 499], ["offer", 503], ["a", 509], ["considerable", 511], ["advantage", 524], ["for", 534], ["patients", 538], ["over", 547], ["agents", 552], ["requiring", 559], ["more", 569], ["frequent", 574], ["dosing", 583], [".", 589], ["Data", 591], ["from", 596], ["preclinical", 601], ["studies", 613], ["and", 621], ["clinical", 625], ["trials", 634], ["suggest", 641], ["that", 649], ["gevokizumab", 654], ["is", 666], ["a", 669], ["potentially", 671], ["effective", 683], ["and", 693], ["well", 697], ["-", 701], ["tolerated", 702], ["treatment", 712], ["for", 722], ["the", 726], ["indicated", 730], ["diseases", 740], [".", 748], ["At", 750], ["the", 753], ["time", 757], ["of", 762], ["publication", 765], [",", 776], ["phase", 778], ["II", 784], ["clinical", 787], ["trials", 796], ["were", 803], ["ongoing", 808], ["in", 816], ["patients", 819], ["with", 828], ["T1D", 833], [",", 836], ["T2D", 838], ["and", 842], ["RA", 846], [",", 848], ["with", 850], ["the", 855], ["T2D", 859], ["trials", 863], ["assessing", 870], ["key", 880], ["cardiovascular", 884], ["markers", 899], [".", 906], ["Following", 908], ["promising", 918], ["data", 928], ["from", 933], ["a", 938], ["recent", 940], ["pilot", 947], ["trial", 953], [",", 958], ["XOMA", 960], ["was", 965], ["also", 969], ["planning", 974], ["a", 983], ["phase", 985], ["I", 991], ["/", 992], ["II", 993], ["trial", 996], ["of", 1002], ["gevokizumab", 1005], ["for", 1017], ["the", 1021], ["potential", 1025], ["treatment", 1035], ["of", 1045], ["uveitis", 1048], ["in", 1056], ["patients", 1059], ["with", 1068], ["the", 1073], ["vasculitic", 1077], ["inflammatory", 1088], ["disorder", 1101], ["Beh\u00e7et", 1110], ["'s", 1116], ["disease", 1119], ["and", 1127], ["the", 1131], ["autoinflammatory", 1135], ["conditions", 1152], ["familial", 1163], ["cold", 1172], ["autoinflammatory", 1177], ["syndrome", 1194], ["and", 1203], ["Muckle", 1207], ["-", 1213], ["Wells", 1214], ["syndrome", 1220], [".", 1228]]}
{"context": "Finkelstein's test is the classic diagnostic test for de Quervain's disease. Finkelstein hypothesized that the entry of the muscle bellies of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons into the first extensor compartment was responsible for the findings observed in his now eponymous test. We agree with Finkelstein's hypothesis and further hypothesize that this position would induce measurable bulk (muscle mass within the retinaculum) and tethering (stretching of synovial tissue) effects within the compartment. To test this latter hypothesis we measured the excursion and gliding resistance of the EPB and APL tendons within the first compartment. Fifteen fresh-frozen cadavers were used. Gliding resistance and excursion were measured in 4 different wrist positions, including the wrist position of Finkelstein's test (30 degrees ulnar deviation). The bulk and tethering effect was calculated based on the mean gliding resistance over the tendon proximal/distal excursion cycle and the gliding resistance at the terminal distal excursion. The EPB tendon excursion was significantly more distal in 30 degrees ulnar deviation than in 60 degrees extension. Additionally the bulk and tethering resistance was significantly greater in 30 degrees ulnar deviation compared with 60 degrees extension. For the APL tendon there was no significant difference in either the tendon excursion or the bulk and tethering resistance between 30 degrees ulnar deviation and 60 degrees extension. We showed that in the position of Finkelstein's test the EPB tendon is significantly more distal and has significantly greater bulk and tethering effect compared with the other EPB positions. This is not the case for the APL tendon in the position of Finkelstein's test. These results suggest that an abnormal Finkelstein's test reflects differences of the EPB more than it does the APL.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "0f8cd91547cb45a1a13bab044219379b", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[9, 12]], "char_spans": [[54, 74]]}]}], "context_tokens": [["Finkelstein", 0], ["'s", 11], ["test", 14], ["is", 19], ["the", 22], ["classic", 26], ["diagnostic", 34], ["test", 45], ["for", 50], ["de", 54], ["Quervain", 57], ["'s", 65], ["disease", 68], [".", 75], ["Finkelstein", 77], ["hypothesized", 89], ["that", 102], ["the", 107], ["entry", 111], ["of", 117], ["the", 120], ["muscle", 124], ["bellies", 131], ["of", 139], ["the", 142], ["extensor", 146], ["pollicis", 155], ["brevis", 164], ["(", 171], ["EPB", 172], [")", 175], ["and", 177], ["abductor", 181], ["pollicis", 190], ["longus", 199], ["(", 206], ["APL", 207], [")", 210], ["tendons", 212], ["into", 220], ["the", 225], ["first", 229], ["extensor", 235], ["compartment", 244], ["was", 256], ["responsible", 260], ["for", 272], ["the", 276], ["findings", 280], ["observed", 289], ["in", 298], ["his", 301], ["now", 305], ["eponymous", 309], ["test", 319], [".", 323], ["We", 325], ["agree", 328], ["with", 334], ["Finkelstein", 339], ["'s", 350], ["hypothesis", 353], ["and", 364], ["further", 368], ["hypothesize", 376], ["that", 388], ["this", 393], ["position", 398], ["would", 407], ["induce", 413], ["measurable", 420], ["bulk", 431], ["(", 436], ["muscle", 437], ["mass", 444], ["within", 449], ["the", 456], ["retinaculum", 460], [")", 471], ["and", 473], ["tethering", 477], ["(", 487], ["stretching", 488], ["of", 499], ["synovial", 502], ["tissue", 511], [")", 517], ["effects", 519], ["within", 527], ["the", 534], ["compartment", 538], [".", 549], ["To", 551], ["test", 554], ["this", 559], ["latter", 564], ["hypothesis", 571], ["we", 582], ["measured", 585], ["the", 594], ["excursion", 598], ["and", 608], ["gliding", 612], ["resistance", 620], ["of", 631], ["the", 634], ["EPB", 638], ["and", 642], ["APL", 646], ["tendons", 650], ["within", 658], ["the", 665], ["first", 669], ["compartment", 675], [".", 686], ["Fifteen", 688], ["fresh", 696], ["-", 701], ["frozen", 702], ["cadavers", 709], ["were", 718], ["used", 723], [".", 727], ["Gliding", 729], ["resistance", 737], ["and", 748], ["excursion", 752], ["were", 762], ["measured", 767], ["in", 776], ["4", 779], ["different", 781], ["wrist", 791], ["positions", 797], [",", 806], ["including", 808], ["the", 818], ["wrist", 822], ["position", 828], ["of", 837], ["Finkelstein", 840], ["'s", 851], ["test", 854], ["(", 859], ["30", 860], ["degrees", 863], ["ulnar", 871], ["deviation", 877], [")", 886], [".", 887], ["The", 889], ["bulk", 893], ["and", 898], ["tethering", 902], ["effect", 912], ["was", 919], ["calculated", 923], ["based", 934], ["on", 940], ["the", 943], ["mean", 947], ["gliding", 952], ["resistance", 960], ["over", 971], ["the", 976], ["tendon", 980], ["proximal", 987], ["/", 995], ["distal", 996], ["excursion", 1003], ["cycle", 1013], ["and", 1019], ["the", 1023], ["gliding", 1027], ["resistance", 1035], ["at", 1046], ["the", 1049], ["terminal", 1053], ["distal", 1062], ["excursion", 1069], [".", 1078], ["The", 1080], ["EPB", 1084], ["tendon", 1088], ["excursion", 1095], ["was", 1105], ["significantly", 1109], ["more", 1123], ["distal", 1128], ["in", 1135], ["30", 1138], ["degrees", 1141], ["ulnar", 1149], ["deviation", 1155], ["than", 1165], ["in", 1170], ["60", 1173], ["degrees", 1176], ["extension", 1184], [".", 1193], ["Additionally", 1195], ["the", 1208], ["bulk", 1212], ["and", 1217], ["tethering", 1221], ["resistance", 1231], ["was", 1242], ["significantly", 1246], ["greater", 1260], ["in", 1268], ["30", 1271], ["degrees", 1274], ["ulnar", 1282], ["deviation", 1288], ["compared", 1298], ["with", 1307], ["60", 1312], ["degrees", 1315], ["extension", 1323], [".", 1332], ["For", 1334], ["the", 1338], ["APL", 1342], ["tendon", 1346], ["there", 1353], ["was", 1359], ["no", 1363], ["significant", 1366], ["difference", 1378], ["in", 1389], ["either", 1392], ["the", 1399], ["tendon", 1403], ["excursion", 1410], ["or", 1420], ["the", 1423], ["bulk", 1427], ["and", 1432], ["tethering", 1436], ["resistance", 1446], ["between", 1457], ["30", 1465], ["degrees", 1468], ["ulnar", 1476], ["deviation", 1482], ["and", 1492], ["60", 1496], ["degrees", 1499], ["extension", 1507], [".", 1516], ["We", 1518], ["showed", 1521], ["that", 1528], ["in", 1533], ["the", 1536], ["position", 1540], ["of", 1549], ["Finkelstein", 1552], ["'s", 1563], ["test", 1566], ["the", 1571], ["EPB", 1575], ["tendon", 1579], ["is", 1586], ["significantly", 1589], ["more", 1603], ["distal", 1608], ["and", 1615], ["has", 1619], ["significantly", 1623], ["greater", 1637], ["bulk", 1645], ["and", 1650], ["tethering", 1654], ["effect", 1664], ["compared", 1671], ["with", 1680], ["the", 1685], ["other", 1689], ["EPB", 1695], ["positions", 1699], [".", 1708], ["This", 1710], ["is", 1715], ["not", 1718], ["the", 1722], ["case", 1726], ["for", 1731], ["the", 1735], ["APL", 1739], ["tendon", 1743], ["in", 1750], ["the", 1753], ["position", 1757], ["of", 1766], ["Finkelstein", 1769], ["'s", 1780], ["test", 1783], [".", 1787], ["These", 1789], ["results", 1795], ["suggest", 1803], ["that", 1811], ["an", 1816], ["abnormal", 1819], ["Finkelstein", 1828], ["'s", 1839], ["test", 1842], ["reflects", 1847], ["differences", 1856], ["of", 1868], ["the", 1871], ["EPB", 1875], ["more", 1879], ["than", 1884], ["it", 1889], ["does", 1892], ["the", 1897], ["APL", 1901], [".", 1904]]}
{"context": "For the first time a causal treatment of hepatic encephalopathy may be possible by the benzodiazepine antagonist flumazenil. In contrast to all other treatments used so far by flumazenil hepatic encephalopathy improves within minutes. Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose. For treatment of hepatic encephalopathy development of a new antagonist with a longer half-life is desirable. However, ut should be stressed that the current experience with flumazenil is limited and that the effects of flumazenil on hepatic encephalopathy is not proven by randomized controlled studies. Therefore, this drug should only be used in clinical studies.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "fc13d80c19934d369960cc64e8a7ed87", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[29, 29], [97, 97], [36, 36], [89, 89], [17, 17]], "char_spans": [[176, 185], [601, 610], [235, 244], [555, 564], [113, 122]]}]}], "context_tokens": [["For", 0], ["the", 4], ["first", 8], ["time", 14], ["a", 19], ["causal", 21], ["treatment", 28], ["of", 38], ["hepatic", 41], ["encephalopathy", 49], ["may", 64], ["be", 68], ["possible", 71], ["by", 80], ["the", 83], ["benzodiazepine", 87], ["antagonist", 102], ["flumazenil", 113], [".", 123], ["In", 125], ["contrast", 128], ["to", 137], ["all", 140], ["other", 144], ["treatments", 150], ["used", 161], ["so", 166], ["far", 169], ["by", 173], ["flumazenil", 176], ["hepatic", 187], ["encephalopathy", 195], ["improves", 210], ["within", 219], ["minutes", 226], [".", 233], ["Flumazenil", 235], ["is", 246], ["the", 249], ["first", 253], ["benzodiazepine", 259], ["antagonist", 274], ["which", 285], ["can", 291], ["be", 295], ["used", 298], ["in", 303], ["humans", 306], ["and", 313], ["is", 317], ["a", 320], ["well", 322], ["established", 327], ["for", 339], ["treatment", 343], ["of", 353], ["benzodiazepine", 356], ["overdose", 371], [".", 379], ["For", 381], ["treatment", 385], ["of", 395], ["hepatic", 398], ["encephalopathy", 406], ["development", 421], ["of", 433], ["a", 436], ["new", 438], ["antagonist", 442], ["with", 453], ["a", 458], ["longer", 460], ["half", 467], ["-", 471], ["life", 472], ["is", 477], ["desirable", 480], [".", 489], ["However", 491], [",", 498], ["ut", 500], ["should", 503], ["be", 510], ["stressed", 513], ["that", 522], ["the", 527], ["current", 531], ["experience", 539], ["with", 550], ["flumazenil", 555], ["is", 566], ["limited", 569], ["and", 577], ["that", 581], ["the", 586], ["effects", 590], ["of", 598], ["flumazenil", 601], ["on", 612], ["hepatic", 615], ["encephalopathy", 623], ["is", 638], ["not", 641], ["proven", 645], ["by", 652], ["randomized", 655], ["controlled", 666], ["studies", 677], [".", 684], ["Therefore", 686], [",", 695], ["this", 697], ["drug", 702], ["should", 707], ["only", 714], ["be", 719], ["used", 722], ["in", 727], ["clinical", 730], ["studies", 739], [".", 746]]}
{"context": "To evaluate the impact of a more limited paraurethral dissection, avoidance of perforating the obturator membrane with scissors or guide, and a more medial trajectory of the trocar in positioning the TVT-O device on stress urinary incontinence cure rates. One hundred and ten patients were recruited for this randomized, single blind, multicenter, non-inferiority study, with a 1:1 ratio to undergo the traditional (n=55) or the modified (n=55) technique. Preoperatively, patients underwent POP-Q staging, Q-tip test, challenge stress test and urodynamics, and completed the I-QoL, PISQ-12, and PGI-S questionnaires. During the post-operative period, patients attributed a pain VAS score 1, 3, 6, 12 and 24h after the procedure and were followed up at 12 months, undergoing the same baseline evaluations. The primary outcome was the cure rate (absence of urine leaks at the challenge stress test or urodynamic testing) one year after the procedure. The primary outcome was evaluated using a non-inferiority test. No differences were observed in cure rates (traditional technique 92.3% vs. modified technique 88.8% and non-inferiority P<0.05) and in questionnaire scores between the two groups. Post-operative pain was significantly lower in the modified technique group at each time point assessed, with the exception of 12h post-operatively. No differences between the two groups were observed in the number of analgesic vials administered. The modified technique does not seem to reduce the efficacy of TVT-O, but induces a reduction of post-operative pain.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "aee1887f35d54a65b4bb576170e07197", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[38, 40]], "char_spans": [[216, 242]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["impact", 16], ["of", 23], ["a", 26], ["more", 28], ["limited", 33], ["paraurethral", 41], ["dissection", 54], [",", 64], ["avoidance", 66], ["of", 76], ["perforating", 79], ["the", 91], ["obturator", 95], ["membrane", 105], ["with", 114], ["scissors", 119], ["or", 128], ["guide", 131], [",", 136], ["and", 138], ["a", 142], ["more", 144], ["medial", 149], ["trajectory", 156], ["of", 167], ["the", 170], ["trocar", 174], ["in", 181], ["positioning", 184], ["the", 196], ["TVT", 200], ["-", 203], ["O", 204], ["device", 206], ["on", 213], ["stress", 216], ["urinary", 223], ["incontinence", 231], ["cure", 244], ["rates", 249], [".", 254], ["One", 256], ["hundred", 260], ["and", 268], ["ten", 272], ["patients", 276], ["were", 285], ["recruited", 290], ["for", 300], ["this", 304], ["randomized", 309], [",", 319], ["single", 321], ["blind", 328], [",", 333], ["multicenter", 335], [",", 346], ["non", 348], ["-", 351], ["inferiority", 352], ["study", 364], [",", 369], ["with", 371], ["a", 376], ["1:1", 378], ["ratio", 382], ["to", 388], ["undergo", 391], ["the", 399], ["traditional", 403], ["(", 415], ["n=55", 416], [")", 420], ["or", 422], ["the", 425], ["modified", 429], ["(", 438], ["n=55", 439], [")", 443], ["technique", 445], [".", 454], ["Preoperatively", 456], [",", 470], ["patients", 472], ["underwent", 481], ["POP", 491], ["-", 494], ["Q", 495], ["staging", 497], [",", 504], ["Q", 506], ["-", 507], ["tip", 508], ["test", 512], [",", 516], ["challenge", 518], ["stress", 528], ["test", 535], ["and", 540], ["urodynamics", 544], [",", 555], ["and", 557], ["completed", 561], ["the", 571], ["I", 575], ["-", 576], ["QoL", 577], [",", 580], ["PISQ-12", 582], [",", 589], ["and", 591], ["PGI", 595], ["-", 598], ["S", 599], ["questionnaires", 601], [".", 615], ["During", 617], ["the", 624], ["post", 628], ["-", 632], ["operative", 633], ["period", 643], [",", 649], ["patients", 651], ["attributed", 660], ["a", 671], ["pain", 673], ["VAS", 678], ["score", 682], ["1", 688], [",", 689], ["3", 691], [",", 692], ["6", 694], [",", 695], ["12", 697], ["and", 700], ["24h", 704], ["after", 708], ["the", 714], ["procedure", 718], ["and", 728], ["were", 732], ["followed", 737], ["up", 746], ["at", 749], ["12", 752], ["months", 755], [",", 761], ["undergoing", 763], ["the", 774], ["same", 778], ["baseline", 783], ["evaluations", 792], [".", 803], ["The", 805], ["primary", 809], ["outcome", 817], ["was", 825], ["the", 829], ["cure", 833], ["rate", 838], ["(", 843], ["absence", 844], ["of", 852], ["urine", 855], ["leaks", 861], ["at", 867], ["the", 870], ["challenge", 874], ["stress", 884], ["test", 891], ["or", 896], ["urodynamic", 899], ["testing", 910], [")", 917], ["one", 919], ["year", 923], ["after", 928], ["the", 934], ["procedure", 938], [".", 947], ["The", 949], ["primary", 953], ["outcome", 961], ["was", 969], ["evaluated", 973], ["using", 983], ["a", 989], ["non", 991], ["-", 994], ["inferiority", 995], ["test", 1007], [".", 1011], ["No", 1013], ["differences", 1016], ["were", 1028], ["observed", 1033], ["in", 1042], ["cure", 1045], ["rates", 1050], ["(", 1056], ["traditional", 1057], ["technique", 1069], ["92.3", 1079], ["%", 1083], ["vs.", 1085], ["modified", 1089], ["technique", 1098], ["88.8", 1108], ["%", 1112], ["and", 1114], ["non", 1118], ["-", 1121], ["inferiority", 1122], ["P<0.05", 1134], [")", 1140], ["and", 1142], ["in", 1146], ["questionnaire", 1149], ["scores", 1163], ["between", 1170], ["the", 1178], ["two", 1182], ["groups", 1186], [".", 1192], ["Post", 1194], ["-", 1198], ["operative", 1199], ["pain", 1209], ["was", 1214], ["significantly", 1218], ["lower", 1232], ["in", 1238], ["the", 1241], ["modified", 1245], ["technique", 1254], ["group", 1264], ["at", 1270], ["each", 1273], ["time", 1278], ["point", 1283], ["assessed", 1289], [",", 1297], ["with", 1299], ["the", 1304], ["exception", 1308], ["of", 1318], ["12h", 1321], ["post", 1325], ["-", 1329], ["operatively", 1330], [".", 1341], ["No", 1343], ["differences", 1346], ["between", 1358], ["the", 1366], ["two", 1370], ["groups", 1374], ["were", 1381], ["observed", 1386], ["in", 1395], ["the", 1398], ["number", 1402], ["of", 1409], ["analgesic", 1412], ["vials", 1422], ["administered", 1428], [".", 1440], ["The", 1442], ["modified", 1446], ["technique", 1455], ["does", 1465], ["not", 1470], ["seem", 1474], ["to", 1479], ["reduce", 1482], ["the", 1489], ["efficacy", 1493], ["of", 1502], ["TVT", 1505], ["-", 1508], ["O", 1509], [",", 1510], ["but", 1512], ["induces", 1516], ["a", 1524], ["reduction", 1526], ["of", 1536], ["post", 1539], ["-", 1543], ["operative", 1544], ["pain", 1554], [".", 1558]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "Attempts to prevent HIV infection through pre-exposure prophylaxis (PrEP) include topical application of anti-HIV drugs to the mucosal sites of infection; however, a potential role for local drug metabolizing enzymes in modulating the exposure of the mucosal tissues to these drugs has yet to be explored. Here we present the first report that enzymes belonging to the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) families of drug metabolizing enzymes are expressed and active in vaginal and colorectal tissue using biopsies collected from healthy volunteers. In doing so, we discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor and an entry inhibitor currently in development as microbicides for HIV PrEP, are differentially metabolized in colorectal tissue and vaginal tissue. Taken together, these data should help to guide the optimization of small molecules being developed for HIV PrEP.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "a245513a68e54764b2b701bf8135c90a", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[157, 157], [19, 19], [127, 127], [3, 3]], "char_spans": [[936, 938], [110, 112], [750, 752], [20, 22]]}]}], "context_tokens": [["Attempts", 0], ["to", 9], ["prevent", 12], ["HIV", 20], ["infection", 24], ["through", 34], ["pre", 42], ["-", 45], ["exposure", 46], ["prophylaxis", 55], ["(", 67], ["PrEP", 68], [")", 72], ["include", 74], ["topical", 82], ["application", 90], ["of", 102], ["anti", 105], ["-", 109], ["HIV", 110], ["drugs", 114], ["to", 120], ["the", 123], ["mucosal", 127], ["sites", 135], ["of", 141], ["infection", 144], [";", 153], ["however", 155], [",", 162], ["a", 164], ["potential", 166], ["role", 176], ["for", 181], ["local", 185], ["drug", 191], ["metabolizing", 196], ["enzymes", 209], ["in", 217], ["modulating", 220], ["the", 231], ["exposure", 235], ["of", 244], ["the", 247], ["mucosal", 251], ["tissues", 259], ["to", 267], ["these", 270], ["drugs", 276], ["has", 282], ["yet", 286], ["to", 290], ["be", 293], ["explored", 296], [".", 304], ["Here", 306], ["we", 311], ["present", 314], ["the", 322], ["first", 326], ["report", 332], ["that", 339], ["enzymes", 344], ["belonging", 352], ["to", 362], ["the", 365], ["cytochrome", 369], ["P450", 380], ["(", 385], ["CYP", 386], [")", 389], ["and", 391], ["UDP", 395], ["-", 398], ["glucuronosyltransferase", 399], ["(", 423], ["UGT", 424], [")", 427], ["families", 429], ["of", 438], ["drug", 441], ["metabolizing", 446], ["enzymes", 459], ["are", 467], ["expressed", 471], ["and", 481], ["active", 485], ["in", 492], ["vaginal", 495], ["and", 503], ["colorectal", 507], ["tissue", 518], ["using", 525], ["biopsies", 531], ["collected", 540], ["from", 550], ["healthy", 555], ["volunteers", 563], [".", 573], ["In", 575], ["doing", 578], ["so", 584], [",", 586], ["we", 588], ["discovered", 591], ["that", 602], ["dapivirine", 607], ["and", 618], ["maraviroc", 622], [",", 631], ["a", 633], ["non", 635], ["-", 638], ["nucleoside", 639], ["reverse", 650], ["transcriptase", 658], ["inhibitor", 672], ["and", 682], ["an", 686], ["entry", 689], ["inhibitor", 695], ["currently", 705], ["in", 715], ["development", 718], ["as", 730], ["microbicides", 733], ["for", 746], ["HIV", 750], ["PrEP", 754], [",", 758], ["are", 760], ["differentially", 764], ["metabolized", 779], ["in", 791], ["colorectal", 794], ["tissue", 805], ["and", 812], ["vaginal", 816], ["tissue", 824], [".", 830], ["Taken", 832], ["together", 838], [",", 846], ["these", 848], ["data", 854], ["should", 859], ["help", 866], ["to", 871], ["guide", 874], ["the", 880], ["optimization", 884], ["of", 897], ["small", 900], ["molecules", 906], ["being", 916], ["developed", 922], ["for", 932], ["HIV", 936], ["PrEP", 940], [".", 944]]}
{"context": "Pulmonary hypertension (PH) is a progressive disease that is accompanied by a poor prognosis. Pulmonary vasoconstriction is facilitated through multiple pathways and results in increased pulmonary vascular pressure leading to cell proliferation, vascular remodeling, right ventricular hypertrophy/failure, and ultimately death. Until recently, just six medications were approved -all for one subclass of PH. On October 8, 2013, riociguat (Adempas\u00ae) became the first medication approved for multiple etiologies of PH. Preclinical studies have demonstrated safety and efficacy with significant clinical trials supporting its advancement into phase IV trials. Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "1a49f6b645ff49e59f4946d1e6242dc5", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[121, 121], [70, 70]], "char_spans": [[743, 751], [428, 436]]}]}], "context_tokens": [["Pulmonary", 0], ["hypertension", 10], ["(", 23], ["PH", 24], [")", 26], ["is", 28], ["a", 31], ["progressive", 33], ["disease", 45], ["that", 53], ["is", 58], ["accompanied", 61], ["by", 73], ["a", 76], ["poor", 78], ["prognosis", 83], [".", 92], ["Pulmonary", 94], ["vasoconstriction", 104], ["is", 121], ["facilitated", 124], ["through", 136], ["multiple", 144], ["pathways", 153], ["and", 162], ["results", 166], ["in", 174], ["increased", 177], ["pulmonary", 187], ["vascular", 197], ["pressure", 206], ["leading", 215], ["to", 223], ["cell", 226], ["proliferation", 231], [",", 244], ["vascular", 246], ["remodeling", 255], [",", 265], ["right", 267], ["ventricular", 273], ["hypertrophy", 285], ["/", 296], ["failure", 297], [",", 304], ["and", 306], ["ultimately", 310], ["death", 321], [".", 326], ["Until", 328], ["recently", 334], [",", 342], ["just", 344], ["six", 349], ["medications", 353], ["were", 365], ["approved", 370], ["-all", 379], ["for", 384], ["one", 388], ["subclass", 392], ["of", 401], ["PH", 404], [".", 406], ["On", 408], ["October", 411], ["8", 419], [",", 420], ["2013", 422], [",", 426], ["riociguat", 428], ["(", 438], ["Adempas", 439], ["\u00ae", 446], [")", 447], ["became", 449], ["the", 456], ["first", 460], ["medication", 466], ["approved", 477], ["for", 486], ["multiple", 490], ["etiologies", 499], ["of", 510], ["PH", 513], [".", 515], ["Preclinical", 517], ["studies", 529], ["have", 537], ["demonstrated", 542], ["safety", 555], ["and", 562], ["efficacy", 566], ["with", 575], ["significant", 580], ["clinical", 592], ["trials", 601], ["supporting", 608], ["its", 619], ["advancement", 623], ["into", 635], ["phase", 640], ["IV", 646], ["trials", 649], [".", 655], ["Although", 657], ["long", 666], ["-", 670], ["term", 671], ["safety", 676], ["and", 683], ["efficacy", 687], ["and", 696], ["place", 700], ["in", 706], ["therapy", 709], ["remain", 717], ["to", 724], ["be", 727], ["established", 730], [",", 741], ["riociguat", 743], ["presents", 753], ["as", 762], ["an", 765], ["exciting", 768], ["new", 777], ["option", 781], ["for", 788], ["the", 792], ["treatment", 796], ["of", 806], ["PH", 809], ["and", 812], ["potentially", 816], ["has", 828], ["additional", 832], ["indications", 843], ["in", 855], ["the", 858], ["near", 862], ["future", 867], [".", 873]]}
{"context": "The calcium-regulated protein phosphatase calcineurin (PP2B) functions as a regulator of gene expression in diverse tissues through the dephosphorylation and activation of a family of transcription factors known as nuclear factor of activated T cells (NFAT). Here we show that NFATc3, in addition to being calcium responsive, is regulated through an indirect recruitment of class II histone deacetylases (HDACs). Specifically, yeast two-hybrid screening with the rel homology domain of NFATc3 identified the chaperone mammalian relative of DnaJ (Mrj) as a specific interacting factor. Mrj and NFATc3 were shown to directly associate with one another in mammalian cells and in vitro. Mrj served as a potent inhibitor of NFAT transcriptional activity within the nucleus through a mechanism involving histone deacetylase recruitment in conjunction with heat shock stimulation. Indeed, Mrj was determined to interact with class II histone deacetylases, each of which translocated to the nucleus following heat shock stimulation. Mrj also decreased NFATc3 occupancy of the tumor necrosis factor-alpha promoter in cardiomyocytes in an HDAC-dependent manner, and Mrj blocked calcineurin-induced cardiomyocyte hypertrophic growth. Conversely, small-interfering-RNA-mediated reduction of Mrj augmented NFAT transcriptional activity and spontaneously induced cardiac myocyte growth. Collectively, our results define a novel response pathway whereby NFATc3 is negatively regulated by class II histone deacetylases through the DnaJ (heat shock protein-40) superfamily member Mrj.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "ed2c56657551418794065dae4cc3bb3c", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[196, 196], [6, 6]], "char_spans": [[1168, 1178], [42, 52]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["regulated", 12], ["protein", 22], ["phosphatase", 30], ["calcineurin", 42], ["(", 54], ["PP2B", 55], [")", 59], ["functions", 61], ["as", 71], ["a", 74], ["regulator", 76], ["of", 86], ["gene", 89], ["expression", 94], ["in", 105], ["diverse", 108], ["tissues", 116], ["through", 124], ["the", 132], ["dephosphorylation", 136], ["and", 154], ["activation", 158], ["of", 169], ["a", 172], ["family", 174], ["of", 181], ["transcription", 184], ["factors", 198], ["known", 206], ["as", 212], ["nuclear", 215], ["factor", 223], ["of", 230], ["activated", 233], ["T", 243], ["cells", 245], ["(", 251], ["NFAT", 252], [")", 256], [".", 257], ["Here", 259], ["we", 264], ["show", 267], ["that", 272], ["NFATc3", 277], [",", 283], ["in", 285], ["addition", 288], ["to", 297], ["being", 300], ["calcium", 306], ["responsive", 314], [",", 324], ["is", 326], ["regulated", 329], ["through", 339], ["an", 347], ["indirect", 350], ["recruitment", 359], ["of", 371], ["class", 374], ["II", 380], ["histone", 383], ["deacetylases", 391], ["(", 404], ["HDACs", 405], [")", 410], [".", 411], ["Specifically", 413], [",", 425], ["yeast", 427], ["two", 433], ["-", 436], ["hybrid", 437], ["screening", 444], ["with", 454], ["the", 459], ["rel", 463], ["homology", 467], ["domain", 476], ["of", 483], ["NFATc3", 486], ["identified", 493], ["the", 504], ["chaperone", 508], ["mammalian", 518], ["relative", 528], ["of", 537], ["DnaJ", 540], ["(", 545], ["Mrj", 546], [")", 549], ["as", 551], ["a", 554], ["specific", 556], ["interacting", 565], ["factor", 577], [".", 583], ["Mrj", 585], ["and", 589], ["NFATc3", 593], ["were", 600], ["shown", 605], ["to", 611], ["directly", 614], ["associate", 623], ["with", 633], ["one", 638], ["another", 642], ["in", 650], ["mammalian", 653], ["cells", 663], ["and", 669], ["in", 673], ["vitro", 676], [".", 681], ["Mrj", 683], ["served", 687], ["as", 694], ["a", 697], ["potent", 699], ["inhibitor", 706], ["of", 716], ["NFAT", 719], ["transcriptional", 724], ["activity", 740], ["within", 749], ["the", 756], ["nucleus", 760], ["through", 768], ["a", 776], ["mechanism", 778], ["involving", 788], ["histone", 798], ["deacetylase", 806], ["recruitment", 818], ["in", 830], ["conjunction", 833], ["with", 845], ["heat", 850], ["shock", 855], ["stimulation", 861], [".", 872], ["Indeed", 874], [",", 880], ["Mrj", 882], ["was", 886], ["determined", 890], ["to", 901], ["interact", 904], ["with", 913], ["class", 918], ["II", 924], ["histone", 927], ["deacetylases", 935], [",", 947], ["each", 949], ["of", 954], ["which", 957], ["translocated", 963], ["to", 976], ["the", 979], ["nucleus", 983], ["following", 991], ["heat", 1001], ["shock", 1006], ["stimulation", 1012], [".", 1023], ["Mrj", 1025], ["also", 1029], ["decreased", 1034], ["NFATc3", 1044], ["occupancy", 1051], ["of", 1061], ["the", 1064], ["tumor", 1068], ["necrosis", 1074], ["factor", 1083], ["-", 1089], ["alpha", 1090], ["promoter", 1096], ["in", 1105], ["cardiomyocytes", 1108], ["in", 1123], ["an", 1126], ["HDAC", 1129], ["-", 1133], ["dependent", 1134], ["manner", 1144], [",", 1150], ["and", 1152], ["Mrj", 1156], ["blocked", 1160], ["calcineurin", 1168], ["-", 1179], ["induced", 1180], ["cardiomyocyte", 1188], ["hypertrophic", 1202], ["growth", 1215], [".", 1221], ["Conversely", 1223], [",", 1233], ["small", 1235], ["-", 1240], ["interfering", 1241], ["-", 1252], ["RNA", 1253], ["-", 1256], ["mediated", 1257], ["reduction", 1266], ["of", 1276], ["Mrj", 1279], ["augmented", 1283], ["NFAT", 1293], ["transcriptional", 1298], ["activity", 1314], ["and", 1323], ["spontaneously", 1327], ["induced", 1341], ["cardiac", 1349], ["myocyte", 1357], ["growth", 1365], [".", 1371], ["Collectively", 1373], [",", 1385], ["our", 1387], ["results", 1391], ["define", 1399], ["a", 1406], ["novel", 1408], ["response", 1414], ["pathway", 1423], ["whereby", 1431], ["NFATc3", 1439], ["is", 1446], ["negatively", 1449], ["regulated", 1460], ["by", 1470], ["class", 1473], ["II", 1479], ["histone", 1482], ["deacetylases", 1490], ["through", 1503], ["the", 1511], ["DnaJ", 1515], ["(", 1520], ["heat", 1521], ["shock", 1526], ["protein-40", 1532], [")", 1542], ["superfamily", 1544], ["member", 1556], ["Mrj", 1563], [".", 1566]]}
{"context": "Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-kappaB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer- related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1alpha, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are b riefly described.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "3e9485482dda405c9488b643f9e2b125", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[105, 105], [130, 130]], "char_spans": [[634, 638], [787, 791]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["multiple", 14], ["myeloma", 23], ["(", 31], ["MM", 32], [")", 34], ["experience", 36], ["pathologic", 47], ["fractures", 58], [",", 67], ["bone", 69], ["pain", 74], [",", 78], ["hypercalcemia", 80], [",", 93], ["neurologic", 95], ["symptoms", 106], [",", 114], ["and", 116], ["renal", 120], ["insufficiency", 126], ["with", 140], ["substantial", 145], ["morbidity", 157], ["and", 167], ["mortality", 171], [".", 180], ["Bisphosphonates", 182], ["have", 198], ["been", 203], ["used", 208], ["successfully", 213], ["for", 226], ["the", 230], ["management", 234], ["of", 245], ["MM", 248], ["-", 250], ["related", 251], ["bone", 259], ["disease", 264], [".", 271], ["Increased", 273], ["incidence", 283], ["of", 293], ["osteonecrosis", 296], ["of", 310], ["the", 313], ["jaw", 317], ["has", 321], ["been", 325], ["observed", 330], ["in", 339], ["patients", 342], ["with", 351], ["cancer", 356], ["receiving", 363], ["bisphosphonate", 373], ["therapy", 388], [".", 395], ["Recent", 397], ["advances", 404], ["in", 413], ["the", 416], ["pathobiology", 420], ["of", 433], ["MM", 436], ["-", 438], ["related", 439], ["bone", 447], ["disease", 452], ["and", 460], ["other", 464], ["cancer", 470], ["-", 476], ["related", 477], ["bone", 485], ["metastases", 490], ["have", 501], ["led", 506], ["to", 510], ["the", 513], ["identification", 517], ["of", 532], ["novel", 535], ["therapeutic", 541], ["targets", 553], [",", 560], ["such", 562], ["as", 567], ["receptor", 570], ["activator", 579], ["of", 589], ["nuclear", 592], ["factor", 600], ["-", 606], ["kappaB", 607], ["(", 614], ["RANK", 615], [")", 619], [";", 620], ["its", 622], ["ligand", 626], ["(", 633], ["RANKL", 634], [")", 639], [";", 640], ["and", 642], ["a", 646], ["decoy", 648], ["receptor", 654], [",", 662], ["osteoprotegerin", 664], [",", 679], ["for", 681], ["the", 685], ["development", 689], ["of", 701], ["potential", 704], ["targeted", 714], ["agents", 723], [".", 729], ["Initials", 731], ["studies", 740], ["have", 748], ["demonstrated", 753], ["that", 766], ["targeting", 771], ["RANK/", 781], ["RANKL", 787], ["signaling", 793], ["with", 803], ["the", 808], ["fully", 812], ["human", 818], ["monoclonal", 824], ["antibody", 835], ["denosumab", 844], ["prevented", 854], ["skeletal", 864], ["complications", 873], ["in", 887], ["patients", 890], ["with", 899], ["MM", 904], ["and", 907], ["other", 911], ["cancers", 917], ["with", 925], ["bone", 930], ["metastases", 935], [".", 945], ["Ongoing", 947], ["studies", 955], ["evaluating", 963], ["the", 974], ["clinical", 978], ["utility", 987], ["of", 995], ["denosumab", 998], ["in", 1008], ["cancer-", 1011], ["related", 1019], ["bone", 1027], ["destruction", 1032], ["have", 1044], ["been", 1049], ["discussed", 1054], [".", 1063], ["In", 1065], ["addition", 1068], [",", 1076], ["several", 1078], ["potential", 1086], ["targets", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["macrophage", 1113], ["inflammatory", 1124], ["protein-1alpha", 1137], [",", 1151], ["chemokine", 1153], ["receptors", 1163], ["1", 1173], ["and", 1175], ["5", 1179], [",", 1180], ["interleukin-3", 1182], [",", 1195], ["and", 1197], ["Wnt", 1201], ["signaling", 1205], [",", 1214], ["are", 1216], ["b", 1220], ["riefly", 1222], ["described", 1229], [".", 1238]]}
{"context": "to determine the rate of MRSA-carrier among patients, family members and health care providers, and the association between MRSA-carrier family members and health care providers on MRSA infection patient after orthopaedic surgery. this is a cross-sectional analytical study. Samples were taken consecutively during December 2010 to December 2011, consisting of postoperative patients infected with MRSA, attending family members, and the medical officers with history of contact with the patient. Swab culture were taken from nasal and axilla of all subjects. The incidence of MRSA infection, and MRSA-carrier on the patient, family members and medical officers were presented descriptively, while their association with MRSA infection was statistically tested using Fischer exact test. during the study period, there were 759 surgeries, with 4 (0.5%) patients were identified to have MRSA infection. Of these four cases, 48 subjects were enrolled. The rate of MRSA-carrier among patients, family and health care providers were 50%, 25% and 0% respectively. There were no significant association between MRSA and the rates of MRSA-carrier on the family member or health care providers. the incidence of MRSA infection, MRSA-carrier patient, MRSA-carrier health care providers, and family member carrier were 0.5%, 50%, 0%, and 25% respectively. No significant association found between MRSA-carrier on the family member or health care providers and MRSA infection patient. There were no MRSA infection found on the health care provider.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "5b64caa5cdd9442cbac616d39d8d3854", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [256, 256], [5, 5], [197, 197], [22, 22], [102, 102], [122, 122], [202, 202], [220, 220], [268, 268], [153, 153], [169, 169], [217, 217], [275, 275], [225, 225], [98, 98], [65, 65]], "char_spans": [[181, 184], [1386, 1389], [25, 28], [1104, 1107], [124, 127], [597, 600], [721, 724], [1126, 1129], [1219, 1222], [1449, 1452], [885, 888], [961, 964], [1203, 1206], [1487, 1490], [1241, 1244], [577, 580], [398, 401]]}]}], "context_tokens": [["to", 0], ["determine", 3], ["the", 13], ["rate", 17], ["of", 22], ["MRSA", 25], ["-", 29], ["carrier", 30], ["among", 38], ["patients", 44], [",", 52], ["family", 54], ["members", 61], ["and", 69], ["health", 73], ["care", 80], ["providers", 85], [",", 94], ["and", 96], ["the", 100], ["association", 104], ["between", 116], ["MRSA", 124], ["-", 128], ["carrier", 129], ["family", 137], ["members", 144], ["and", 152], ["health", 156], ["care", 163], ["providers", 168], ["on", 178], ["MRSA", 181], ["infection", 186], ["patient", 196], ["after", 204], ["orthopaedic", 210], ["surgery", 222], [".", 229], ["this", 231], ["is", 236], ["a", 239], ["cross", 241], ["-", 246], ["sectional", 247], ["analytical", 257], ["study", 268], [".", 273], ["Samples", 275], ["were", 283], ["taken", 288], ["consecutively", 294], ["during", 308], ["December", 315], ["2010", 324], ["to", 329], ["December", 332], ["2011", 341], [",", 345], ["consisting", 347], ["of", 358], ["postoperative", 361], ["patients", 375], ["infected", 384], ["with", 393], ["MRSA", 398], [",", 402], ["attending", 404], ["family", 414], ["members", 421], [",", 428], ["and", 430], ["the", 434], ["medical", 438], ["officers", 446], ["with", 455], ["history", 460], ["of", 468], ["contact", 471], ["with", 479], ["the", 484], ["patient", 488], [".", 495], ["Swab", 497], ["culture", 502], ["were", 510], ["taken", 515], ["from", 521], ["nasal", 526], ["and", 532], ["axilla", 536], ["of", 543], ["all", 546], ["subjects", 550], [".", 558], ["The", 560], ["incidence", 564], ["of", 574], ["MRSA", 577], ["infection", 582], [",", 591], ["and", 593], ["MRSA", 597], ["-", 601], ["carrier", 602], ["on", 610], ["the", 613], ["patient", 617], [",", 624], ["family", 626], ["members", 633], ["and", 641], ["medical", 645], ["officers", 653], ["were", 662], ["presented", 667], ["descriptively", 677], [",", 690], ["while", 692], ["their", 698], ["association", 704], ["with", 716], ["MRSA", 721], ["infection", 726], ["was", 736], ["statistically", 740], ["tested", 754], ["using", 761], ["Fischer", 767], ["exact", 775], ["test", 781], [".", 785], ["during", 787], ["the", 794], ["study", 798], ["period", 804], [",", 810], ["there", 812], ["were", 818], ["759", 823], ["surgeries", 827], [",", 836], ["with", 838], ["4", 843], ["(", 845], ["0.5", 846], ["%", 849], [")", 850], ["patients", 852], ["were", 861], ["identified", 866], ["to", 877], ["have", 880], ["MRSA", 885], ["infection", 890], [".", 899], ["Of", 901], ["these", 904], ["four", 910], ["cases", 915], [",", 920], ["48", 922], ["subjects", 925], ["were", 934], ["enrolled", 939], [".", 947], ["The", 949], ["rate", 953], ["of", 958], ["MRSA", 961], ["-", 965], ["carrier", 966], ["among", 974], ["patients", 980], [",", 988], ["family", 990], ["and", 997], ["health", 1001], ["care", 1008], ["providers", 1013], ["were", 1023], ["50", 1028], ["%", 1030], [",", 1031], ["25", 1033], ["%", 1035], ["and", 1037], ["0", 1041], ["%", 1042], ["respectively", 1044], [".", 1056], ["There", 1058], ["were", 1064], ["no", 1069], ["significant", 1072], ["association", 1084], ["between", 1096], ["MRSA", 1104], ["and", 1109], ["the", 1113], ["rates", 1117], ["of", 1123], ["MRSA", 1126], ["-", 1130], ["carrier", 1131], ["on", 1139], ["the", 1142], ["family", 1146], ["member", 1153], ["or", 1160], ["health", 1163], ["care", 1170], ["providers", 1175], [".", 1184], ["the", 1186], ["incidence", 1190], ["of", 1200], ["MRSA", 1203], ["infection", 1208], [",", 1217], ["MRSA", 1219], ["-", 1223], ["carrier", 1224], ["patient", 1232], [",", 1239], ["MRSA", 1241], ["-", 1245], ["carrier", 1246], ["health", 1254], ["care", 1261], ["providers", 1266], [",", 1275], ["and", 1277], ["family", 1281], ["member", 1288], ["carrier", 1295], ["were", 1303], ["0.5", 1308], ["%", 1311], [",", 1312], ["50", 1314], ["%", 1316], [",", 1317], ["0", 1319], ["%", 1320], [",", 1321], ["and", 1323], ["25", 1327], ["%", 1329], ["respectively", 1331], [".", 1343], ["No", 1345], ["significant", 1348], ["association", 1360], ["found", 1372], ["between", 1378], ["MRSA", 1386], ["-", 1390], ["carrier", 1391], ["on", 1399], ["the", 1402], ["family", 1406], ["member", 1413], ["or", 1420], ["health", 1423], ["care", 1430], ["providers", 1435], ["and", 1445], ["MRSA", 1449], ["infection", 1454], ["patient", 1464], [".", 1471], ["There", 1473], ["were", 1479], ["no", 1484], ["MRSA", 1487], ["infection", 1492], ["found", 1502], ["on", 1508], ["the", 1511], ["health", 1515], ["care", 1522], ["provider", 1527], [".", 1535]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Protective protein/cathepsin A (PPCA) has a serine carboxypeptidase activity of unknown physiological function. We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA). Degradation of lamp2a is important because its level in the lysosomal membrane is a rate-limiting step of CMA. Cells defective in PPCA show reduced rates of lamp2a degradation, higher levels of lamp2a and higher rates of CMA. Restoration of PPCA protease activity increases rates of lamp2a degradation, reduces levels of lysosomal lamp2a and reduces rates of CMA. PPCA associates with lamp2a on the lysosomal membrane and cleaves lamp2a near the boundary between the luminal and transmembrane domains. In addition to the well-studied role of PPCA in targeting and protecting two lysosomal glycosidases, we have defined a role for the proteolytic activity of this multifunctional protein.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "a636a925df634cada0c2d6964688e93a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[109, 109], [54, 54], [102, 102], [38, 38], [87, 87], [119, 119], [126, 126], [81, 81]], "char_spans": [[628, 633], [312, 317], [580, 585], [237, 242], [491, 496], [682, 687], [727, 732], [454, 459]]}]}], "context_tokens": [["Protective", 0], ["protein", 11], ["/", 18], ["cathepsin", 19], ["A", 29], ["(", 31], ["PPCA", 32], [")", 36], ["has", 38], ["a", 42], ["serine", 44], ["carboxypeptidase", 51], ["activity", 68], ["of", 77], ["unknown", 80], ["physiological", 88], ["function", 102], [".", 110], ["We", 112], ["now", 115], ["demonstrate", 119], ["that", 131], ["this", 136], ["protease", 141], ["activity", 150], ["triggers", 159], ["the", 168], ["degradation", 172], ["of", 184], ["the", 187], ["lysosome", 191], ["-", 199], ["associated", 200], ["membrane", 211], ["protein", 220], ["type", 228], ["2a", 233], ["(", 236], ["lamp2a", 237], [")", 243], [",", 244], ["a", 246], ["receptor", 248], ["for", 257], ["chaperone", 261], ["-", 270], ["mediated", 271], ["autophagy", 280], ["(", 290], ["CMA", 291], [")", 294], [".", 295], ["Degradation", 297], ["of", 309], ["lamp2a", 312], ["is", 319], ["important", 322], ["because", 332], ["its", 340], ["level", 344], ["in", 350], ["the", 353], ["lysosomal", 357], ["membrane", 367], ["is", 376], ["a", 379], ["rate", 381], ["-", 385], ["limiting", 386], ["step", 395], ["of", 400], ["CMA", 403], [".", 406], ["Cells", 408], ["defective", 414], ["in", 424], ["PPCA", 427], ["show", 432], ["reduced", 437], ["rates", 445], ["of", 451], ["lamp2a", 454], ["degradation", 461], [",", 472], ["higher", 474], ["levels", 481], ["of", 488], ["lamp2a", 491], ["and", 498], ["higher", 502], ["rates", 509], ["of", 515], ["CMA", 518], [".", 521], ["Restoration", 523], ["of", 535], ["PPCA", 538], ["protease", 543], ["activity", 552], ["increases", 561], ["rates", 571], ["of", 577], ["lamp2a", 580], ["degradation", 587], [",", 598], ["reduces", 600], ["levels", 608], ["of", 615], ["lysosomal", 618], ["lamp2a", 628], ["and", 635], ["reduces", 639], ["rates", 647], ["of", 653], ["CMA", 656], [".", 659], ["PPCA", 661], ["associates", 666], ["with", 677], ["lamp2a", 682], ["on", 689], ["the", 692], ["lysosomal", 696], ["membrane", 706], ["and", 715], ["cleaves", 719], ["lamp2a", 727], ["near", 734], ["the", 739], ["boundary", 743], ["between", 752], ["the", 760], ["luminal", 764], ["and", 772], ["transmembrane", 776], ["domains", 790], [".", 797], ["In", 799], ["addition", 802], ["to", 811], ["the", 814], ["well", 818], ["-", 822], ["studied", 823], ["role", 831], ["of", 836], ["PPCA", 839], ["in", 844], ["targeting", 847], ["and", 857], ["protecting", 861], ["two", 872], ["lysosomal", 876], ["glycosidases", 886], [",", 898], ["we", 900], ["have", 903], ["defined", 908], ["a", 916], ["role", 918], ["for", 923], ["the", 927], ["proteolytic", 931], ["activity", 943], ["of", 952], ["this", 955], ["multifunctional", 960], ["protein", 976], [".", 983]]}
{"context": "Detection of methicillin (meticillin)-resistant Staphylococcus aureus colonization was assessed using combined nose and groin swabs in two commercial PCR assays (the Xpert MRSA assay and the BD GeneOhm MRSA assay). Compared to routine culture, both had similar sensitivities (87.0% versus 84.8%, respectively) and specificities (93.8% versus 92.7%, respectively). Combined PCR assays provide a rapid and more-complete assessment of colonization at a cost similar to that of single-site analysis.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a21e993c7e5d4f7f8143bd59329ed432", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[24, 24], [30, 30]], "char_spans": [[172, 175], [202, 205]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["methicillin", 13], ["(", 25], ["meticillin)-resistant", 26], ["Staphylococcus", 48], ["aureus", 63], ["colonization", 70], ["was", 83], ["assessed", 87], ["using", 96], ["combined", 102], ["nose", 111], ["and", 116], ["groin", 120], ["swabs", 126], ["in", 132], ["two", 135], ["commercial", 139], ["PCR", 150], ["assays", 154], ["(", 161], ["the", 162], ["Xpert", 166], ["MRSA", 172], ["assay", 177], ["and", 183], ["the", 187], ["BD", 191], ["GeneOhm", 194], ["MRSA", 202], ["assay", 207], [")", 212], [".", 213], ["Compared", 215], ["to", 224], ["routine", 227], ["culture", 235], [",", 242], ["both", 244], ["had", 249], ["similar", 253], ["sensitivities", 261], ["(", 275], ["87.0", 276], ["%", 280], ["versus", 282], ["84.8", 289], ["%", 293], [",", 294], ["respectively", 296], [")", 308], ["and", 310], ["specificities", 314], ["(", 328], ["93.8", 329], ["%", 333], ["versus", 335], ["92.7", 342], ["%", 346], [",", 347], ["respectively", 349], [")", 361], [".", 362], ["Combined", 364], ["PCR", 373], ["assays", 377], ["provide", 384], ["a", 392], ["rapid", 394], ["and", 400], ["more", 404], ["-", 408], ["complete", 409], ["assessment", 418], ["of", 429], ["colonization", 432], ["at", 445], ["a", 448], ["cost", 450], ["similar", 455], ["to", 463], ["that", 466], ["of", 471], ["single", 474], ["-", 480], ["site", 481], ["analysis", 486], [".", 494]]}
{"context": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium. Endothelial dysfunction is associated with Fabry disease and excessive cellular Gb3. We previously demonstrated that excessive vascular Gb3 in a mouse model of Fabry disease, the Gla-knockout (Gla(-/0)) mouse, results in abnormal vascular function, which includes abnormal endothelium-dependent contractions, a vascular phenomenon known to involve cyclooxygenase (COX). Therefore, we hypothesized that the vasculopathy in the Gla knockout mouse may be due to a vasoactive COX-derived product. To test this hypothesis, vascular reactivity experiments were performed in aortic rings from wild-type (Gla(+/0)) and Gla(-/0) mice in the presence and absence of specific and nonspecific COX inhibitors. Specific inhibition of COX1 or COX2 in endothelium-intact rings from Gla(-/0) mice decreased overall phenylephrine contractility compared with untreated Gla(-/0) rings, whereas COX inhibitors had no effect on contractility in endothelium-denuded rings. Nonspecific inhibition of COX with indomethacin (10 micromol/l) or COX1 inhibition with valeryl salicylate (3 mmol/l) improved endothelial function in rings from Gla(-/0) mice, but COX2 inhibition with NS-398 (1 micromol/l) further increased endothelial dysfunction in rings from Gla(-/0) mice. These results suggest that, in the Gla(-/0) mice, COX1 and COX2 activity are increased and localized in the endothelium, producing vasopressor and vasorelaxant products, which contribute to the Fabry-related vasculopathy.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "16952fa330f540e6884c87a1a0567566", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[27, 29]], "char_spans": [[182, 200]]}]}], "context_tokens": [["The", 0], ["lysosomal", 4], ["storage", 14], ["disorder", 22], ["Fabry", 31], ["disease", 37], ["is", 45], ["characterized", 48], ["by", 62], ["excessive", 65], ["globotriaosylceramide", 75], ["(", 97], ["Gb3", 98], [")", 101], ["accumulation", 103], ["in", 116], ["major", 119], ["organs", 125], ["such", 132], ["as", 137], ["the", 140], ["heart", 144], ["and", 150], ["kidney", 154], [".", 160], ["Defective", 162], ["lysosomal", 172], ["alpha", 182], ["-", 187], ["galactosidase", 188], ["A", 202], ["(", 204], ["Gla", 205], [")", 208], ["is", 210], ["responsible", 213], ["for", 225], ["excessive", 229], ["Gb3", 239], ["accumulation", 243], [",", 255], ["and", 257], ["one", 261], ["cell", 265], ["sensitive", 270], ["to", 280], ["the", 283], ["effects", 287], ["of", 295], ["Gb3", 298], ["accumulation", 302], ["is", 315], ["vascular", 318], ["endothelium", 327], [".", 338], ["Endothelial", 340], ["dysfunction", 352], ["is", 364], ["associated", 367], ["with", 378], ["Fabry", 383], ["disease", 389], ["and", 397], ["excessive", 401], ["cellular", 411], ["Gb3", 420], [".", 423], ["We", 425], ["previously", 428], ["demonstrated", 439], ["that", 452], ["excessive", 457], ["vascular", 467], ["Gb3", 476], ["in", 480], ["a", 483], ["mouse", 485], ["model", 491], ["of", 497], ["Fabry", 500], ["disease", 506], [",", 513], ["the", 515], ["Gla", 519], ["-", 522], ["knockout", 523], ["(", 532], ["Gla(-/0", 533], [")", 540], [")", 541], ["mouse", 543], [",", 548], ["results", 550], ["in", 558], ["abnormal", 561], ["vascular", 570], ["function", 579], [",", 587], ["which", 589], ["includes", 595], ["abnormal", 604], ["endothelium", 613], ["-", 624], ["dependent", 625], ["contractions", 635], [",", 647], ["a", 649], ["vascular", 651], ["phenomenon", 660], ["known", 671], ["to", 677], ["involve", 680], ["cyclooxygenase", 688], ["(", 703], ["COX", 704], [")", 707], [".", 708], ["Therefore", 710], [",", 719], ["we", 721], ["hypothesized", 724], ["that", 737], ["the", 742], ["vasculopathy", 746], ["in", 759], ["the", 762], ["Gla", 766], ["knockout", 770], ["mouse", 779], ["may", 785], ["be", 789], ["due", 792], ["to", 796], ["a", 799], ["vasoactive", 801], ["COX", 812], ["-", 815], ["derived", 816], ["product", 824], [".", 831], ["To", 833], ["test", 836], ["this", 841], ["hypothesis", 846], [",", 856], ["vascular", 858], ["reactivity", 867], ["experiments", 878], ["were", 890], ["performed", 895], ["in", 905], ["aortic", 908], ["rings", 915], ["from", 921], ["wild", 926], ["-", 930], ["type", 931], ["(", 936], ["Gla(+/0", 937], [")", 944], [")", 945], ["and", 947], ["Gla(-/0", 951], [")", 958], ["mice", 960], ["in", 965], ["the", 968], ["presence", 972], ["and", 981], ["absence", 985], ["of", 993], ["specific", 996], ["and", 1005], ["nonspecific", 1009], ["COX", 1021], ["inhibitors", 1025], [".", 1035], ["Specific", 1037], ["inhibition", 1046], ["of", 1057], ["COX1", 1060], ["or", 1065], ["COX2", 1068], ["in", 1073], ["endothelium", 1076], ["-", 1087], ["intact", 1088], ["rings", 1095], ["from", 1101], ["Gla(-/0", 1106], [")", 1113], ["mice", 1115], ["decreased", 1120], ["overall", 1130], ["phenylephrine", 1138], ["contractility", 1152], ["compared", 1166], ["with", 1175], ["untreated", 1180], ["Gla(-/0", 1190], [")", 1197], ["rings", 1199], [",", 1204], ["whereas", 1206], ["COX", 1214], ["inhibitors", 1218], ["had", 1229], ["no", 1233], ["effect", 1236], ["on", 1243], ["contractility", 1246], ["in", 1260], ["endothelium", 1263], ["-", 1274], ["denuded", 1275], ["rings", 1283], [".", 1288], ["Nonspecific", 1290], ["inhibition", 1302], ["of", 1313], ["COX", 1316], ["with", 1320], ["indomethacin", 1325], ["(", 1338], ["10", 1339], ["micromol", 1342], ["/", 1350], ["l", 1351], [")", 1352], ["or", 1354], ["COX1", 1357], ["inhibition", 1362], ["with", 1373], ["valeryl", 1378], ["salicylate", 1386], ["(", 1397], ["3", 1398], ["mmol", 1400], ["/", 1404], ["l", 1405], [")", 1406], ["improved", 1408], ["endothelial", 1417], ["function", 1429], ["in", 1438], ["rings", 1441], ["from", 1447], ["Gla(-/0", 1452], [")", 1459], ["mice", 1461], [",", 1465], ["but", 1467], ["COX2", 1471], ["inhibition", 1476], ["with", 1487], ["NS-398", 1492], ["(", 1499], ["1", 1500], ["micromol", 1502], ["/", 1510], ["l", 1511], [")", 1512], ["further", 1514], ["increased", 1522], ["endothelial", 1532], ["dysfunction", 1544], ["in", 1556], ["rings", 1559], ["from", 1565], ["Gla(-/0", 1570], [")", 1577], ["mice", 1579], [".", 1583], ["These", 1585], ["results", 1591], ["suggest", 1599], ["that", 1607], [",", 1611], ["in", 1613], ["the", 1616], ["Gla(-/0", 1620], [")", 1627], ["mice", 1629], [",", 1633], ["COX1", 1635], ["and", 1640], ["COX2", 1644], ["activity", 1649], ["are", 1658], ["increased", 1662], ["and", 1672], ["localized", 1676], ["in", 1686], ["the", 1689], ["endothelium", 1693], [",", 1704], ["producing", 1706], ["vasopressor", 1716], ["and", 1728], ["vasorelaxant", 1732], ["products", 1745], [",", 1753], ["which", 1755], ["contribute", 1761], ["to", 1772], ["the", 1775], ["Fabry", 1779], ["-", 1784], ["related", 1785], ["vasculopathy", 1793], [".", 1805]]}
{"context": "Spinocerebellar ataxia type 3 (SCA3) is an inherited spinocerebellar ataxia caused by the expansion of trinucleotide CAG repeats in the gene encoding ataxin-3. The clinical manifestations of SCA3 include peripheral neuropathy, which is an important cause of disability in a subset of patients. Although the loss of neurones in the dorsal root ganglion (DRG) has been postulated to be the cause of this neuropathy, the precise mechanism remains to be elucidated. To clarify the clinicopathological characteristics of SCA3-associated peripheral neuropathy, we performed nerve conduction studies and histopathological analyses. Nerve conduction studies were carried out in 18 SCA3 patients. Immunohistochemical analyses of the anterior and posterior roots of the spinal cord and peripheral nerves were performed in five SCA3 patients. We also employed immunohistochemistry and immunoelectron microscopy analyses with an anti-polyglutamine antibody. The mean sensory nerve action potentials of the SCA3 patients were half of the normal values. The motor conduction velocities were decreased, and the distal latencies were also significantly prolonged in the nerves studied relative to the those in normal controls. Histopathological analyses detected axonal sprouting and myelin thinning in all cases. Ataxin-3 aggregates were found in the cytoplasm of Schwann cells in all of the SCA3 patients examined but not in control subjects. In addition to the previously reported neuronopathy, the results of the present study indicate that Schwann cells are involved in the formation of the pathogenic intracytoplasmic ataxin-3 protein aggregates in patients with SCA3-associated neuropathy.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "d3819cb8ec4f4b7ca419852b254520d5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[24, 24], [203, 203], [253, 253]], "char_spans": [[150, 157], [1298, 1305], [1608, 1615]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["(", 30], ["SCA3", 31], [")", 35], ["is", 37], ["an", 40], ["inherited", 43], ["spinocerebellar", 53], ["ataxia", 69], ["caused", 76], ["by", 83], ["the", 86], ["expansion", 90], ["of", 100], ["trinucleotide", 103], ["CAG", 117], ["repeats", 121], ["in", 129], ["the", 132], ["gene", 136], ["encoding", 141], ["ataxin-3", 150], [".", 158], ["The", 160], ["clinical", 164], ["manifestations", 173], ["of", 188], ["SCA3", 191], ["include", 196], ["peripheral", 204], ["neuropathy", 215], [",", 225], ["which", 227], ["is", 233], ["an", 236], ["important", 239], ["cause", 249], ["of", 255], ["disability", 258], ["in", 269], ["a", 272], ["subset", 274], ["of", 281], ["patients", 284], [".", 292], ["Although", 294], ["the", 303], ["loss", 307], ["of", 312], ["neurones", 315], ["in", 324], ["the", 327], ["dorsal", 331], ["root", 338], ["ganglion", 343], ["(", 352], ["DRG", 353], [")", 356], ["has", 358], ["been", 362], ["postulated", 367], ["to", 378], ["be", 381], ["the", 384], ["cause", 388], ["of", 394], ["this", 397], ["neuropathy", 402], [",", 412], ["the", 414], ["precise", 418], ["mechanism", 426], ["remains", 436], ["to", 444], ["be", 447], ["elucidated", 450], [".", 460], ["To", 462], ["clarify", 465], ["the", 473], ["clinicopathological", 477], ["characteristics", 497], ["of", 513], ["SCA3-associated", 516], ["peripheral", 532], ["neuropathy", 543], [",", 553], ["we", 555], ["performed", 558], ["nerve", 568], ["conduction", 574], ["studies", 585], ["and", 593], ["histopathological", 597], ["analyses", 615], [".", 623], ["Nerve", 625], ["conduction", 631], ["studies", 642], ["were", 650], ["carried", 655], ["out", 663], ["in", 667], ["18", 670], ["SCA3", 673], ["patients", 678], [".", 686], ["Immunohistochemical", 688], ["analyses", 708], ["of", 717], ["the", 720], ["anterior", 724], ["and", 733], ["posterior", 737], ["roots", 747], ["of", 753], ["the", 756], ["spinal", 760], ["cord", 767], ["and", 772], ["peripheral", 776], ["nerves", 787], ["were", 794], ["performed", 799], ["in", 809], ["five", 812], ["SCA3", 817], ["patients", 822], [".", 830], ["We", 832], ["also", 835], ["employed", 840], ["immunohistochemistry", 849], ["and", 870], ["immunoelectron", 874], ["microscopy", 889], ["analyses", 900], ["with", 909], ["an", 914], ["anti", 917], ["-", 921], ["polyglutamine", 922], ["antibody", 936], [".", 944], ["The", 946], ["mean", 950], ["sensory", 955], ["nerve", 963], ["action", 969], ["potentials", 976], ["of", 987], ["the", 990], ["SCA3", 994], ["patients", 999], ["were", 1008], ["half", 1013], ["of", 1018], ["the", 1021], ["normal", 1025], ["values", 1032], [".", 1038], ["The", 1040], ["motor", 1044], ["conduction", 1050], ["velocities", 1061], ["were", 1072], ["decreased", 1077], [",", 1086], ["and", 1088], ["the", 1092], ["distal", 1096], ["latencies", 1103], ["were", 1113], ["also", 1118], ["significantly", 1123], ["prolonged", 1137], ["in", 1147], ["the", 1150], ["nerves", 1154], ["studied", 1161], ["relative", 1169], ["to", 1178], ["the", 1181], ["those", 1185], ["in", 1191], ["normal", 1194], ["controls", 1201], [".", 1209], ["Histopathological", 1211], ["analyses", 1229], ["detected", 1238], ["axonal", 1247], ["sprouting", 1254], ["and", 1264], ["myelin", 1268], ["thinning", 1275], ["in", 1284], ["all", 1287], ["cases", 1291], [".", 1296], ["Ataxin-3", 1298], ["aggregates", 1307], ["were", 1318], ["found", 1323], ["in", 1329], ["the", 1332], ["cytoplasm", 1336], ["of", 1346], ["Schwann", 1349], ["cells", 1357], ["in", 1363], ["all", 1366], ["of", 1370], ["the", 1373], ["SCA3", 1377], ["patients", 1382], ["examined", 1391], ["but", 1400], ["not", 1404], ["in", 1408], ["control", 1411], ["subjects", 1419], [".", 1427], ["In", 1429], ["addition", 1432], ["to", 1441], ["the", 1444], ["previously", 1448], ["reported", 1459], ["neuronopathy", 1468], [",", 1480], ["the", 1482], ["results", 1486], ["of", 1494], ["the", 1497], ["present", 1501], ["study", 1509], ["indicate", 1515], ["that", 1524], ["Schwann", 1529], ["cells", 1537], ["are", 1543], ["involved", 1547], ["in", 1556], ["the", 1559], ["formation", 1563], ["of", 1573], ["the", 1576], ["pathogenic", 1580], ["intracytoplasmic", 1591], ["ataxin-3", 1608], ["protein", 1617], ["aggregates", 1625], ["in", 1636], ["patients", 1639], ["with", 1648], ["SCA3-associated", 1653], ["neuropathy", 1669], [".", 1679]]}
{"context": "Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. Drugs inhibiting this transporter have recently been approved for clinical use and have been suggested to have potential renoprotective benefits by limiting glycotoxicity in the proximal tubule. We aimed to determine the renoprotective benefits of empagliflozin, an SGLT2 inhibitor, independent of its glucose lowering effect. We induced diabetes using a low dose streptozotocin protocol in 7-8 week old endothelial nitric oxide (eNOS) synthase knockout mice. We measured fasting blood glucose on a monthly basis, terminal urinary albumin/creatinine ratio. Renal histology was assessed for inflammatory and fibrotic changes. Renal cortical mRNA transcription of inflammatory and profibrotic cytokines, glucose transporters and protein expression of SGLT2 and GLUT1 were determined. Outcomes were compared to diabetic animals receiving the angiotensin receptor blocker telmisartan (current best practice). Diabetic mice had high matched blood glucose levels. Empagliflozin did not attenuate diabetes-induced albuminuria, unlike telmisartan. Empagliflozin did not improve glomerulosclerosis, tubular atrophy, tubulointerstitial inflammation or fibrosis, while telmisartan attenuated these. Empagliflozin did not modify tubular toll-like receptor-2 expression in diabetic mice. Empagliflozin did not reduce the upregulation of macrophage chemoattractant protein-1 (MCP-1), transforming growth factor \u03b21 and fibronectin mRNA observed in the diabetic animals, while telmisartan decreased transcription of MCP-1 and fibronectin. Empagliflozin increased GLUT1 mRNA expression and telmisartan increased SGLT2 mRNA expression in comparison to untreated diabetic mice. However no significant difference was found in protein expression of GLUT1 or SGLT2 among the different groups. Hence SGLT2 inhibition does not have renoprotective benefits independent of glucose lowering.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "7319749c99d7437480b077f9c67163c7", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[144, 144], [288, 288], [5, 5], [266, 266], [295, 295], [66, 66], [17, 17]], "char_spans": [[914, 918], [1902, 1906], [32, 36], [1760, 1764], [1942, 1946], [431, 435], [94, 98]]}]}], "context_tokens": [["Sodium", 0], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["is", 39], ["the", 42], ["main", 46], ["luminal", 51], ["glucose", 59], ["transporter", 67], ["in", 79], ["the", 82], ["kidney", 86], [".", 92], ["SGLT2", 94], ["inhibition", 100], ["results", 111], ["in", 119], ["glycosuria", 122], ["and", 133], ["improved", 137], ["glycaemic", 146], ["control", 156], [".", 163], ["Drugs", 165], ["inhibiting", 171], ["this", 182], ["transporter", 187], ["have", 199], ["recently", 204], ["been", 213], ["approved", 218], ["for", 227], ["clinical", 231], ["use", 240], ["and", 244], ["have", 248], ["been", 253], ["suggested", 258], ["to", 268], ["have", 271], ["potential", 276], ["renoprotective", 286], ["benefits", 301], ["by", 310], ["limiting", 313], ["glycotoxicity", 322], ["in", 336], ["the", 339], ["proximal", 343], ["tubule", 352], [".", 358], ["We", 360], ["aimed", 363], ["to", 369], ["determine", 372], ["the", 382], ["renoprotective", 386], ["benefits", 401], ["of", 410], ["empagliflozin", 413], [",", 426], ["an", 428], ["SGLT2", 431], ["inhibitor", 437], [",", 446], ["independent", 448], ["of", 460], ["its", 463], ["glucose", 467], ["lowering", 475], ["effect", 484], [".", 490], ["We", 492], ["induced", 495], ["diabetes", 503], ["using", 512], ["a", 518], ["low", 520], ["dose", 524], ["streptozotocin", 529], ["protocol", 544], ["in", 553], ["7", 556], ["-", 557], ["8", 558], ["week", 560], ["old", 565], ["endothelial", 569], ["nitric", 581], ["oxide", 588], ["(", 594], ["eNOS", 595], [")", 599], ["synthase", 601], ["knockout", 610], ["mice", 619], [".", 623], ["We", 625], ["measured", 628], ["fasting", 637], ["blood", 645], ["glucose", 651], ["on", 659], ["a", 662], ["monthly", 664], ["basis", 672], [",", 677], ["terminal", 679], ["urinary", 688], ["albumin", 696], ["/", 703], ["creatinine", 704], ["ratio", 715], [".", 720], ["Renal", 722], ["histology", 728], ["was", 738], ["assessed", 742], ["for", 751], ["inflammatory", 755], ["and", 768], ["fibrotic", 772], ["changes", 781], [".", 788], ["Renal", 790], ["cortical", 796], ["mRNA", 805], ["transcription", 810], ["of", 824], ["inflammatory", 827], ["and", 840], ["profibrotic", 844], ["cytokines", 856], [",", 865], ["glucose", 867], ["transporters", 875], ["and", 888], ["protein", 892], ["expression", 900], ["of", 911], ["SGLT2", 914], ["and", 920], ["GLUT1", 924], ["were", 930], ["determined", 935], [".", 945], ["Outcomes", 947], ["were", 956], ["compared", 961], ["to", 970], ["diabetic", 973], ["animals", 982], ["receiving", 990], ["the", 1000], ["angiotensin", 1004], ["receptor", 1016], ["blocker", 1025], ["telmisartan", 1033], ["(", 1045], ["current", 1046], ["best", 1054], ["practice", 1059], [")", 1067], [".", 1068], ["Diabetic", 1070], ["mice", 1079], ["had", 1084], ["high", 1088], ["matched", 1093], ["blood", 1101], ["glucose", 1107], ["levels", 1115], [".", 1121], ["Empagliflozin", 1123], ["did", 1137], ["not", 1141], ["attenuate", 1145], ["diabetes", 1155], ["-", 1163], ["induced", 1164], ["albuminuria", 1172], [",", 1183], ["unlike", 1185], ["telmisartan", 1192], [".", 1203], ["Empagliflozin", 1205], ["did", 1219], ["not", 1223], ["improve", 1227], ["glomerulosclerosis", 1235], [",", 1253], ["tubular", 1255], ["atrophy", 1263], [",", 1270], ["tubulointerstitial", 1272], ["inflammation", 1291], ["or", 1304], ["fibrosis", 1307], [",", 1315], ["while", 1317], ["telmisartan", 1323], ["attenuated", 1335], ["these", 1346], [".", 1351], ["Empagliflozin", 1353], ["did", 1367], ["not", 1371], ["modify", 1375], ["tubular", 1382], ["toll", 1390], ["-", 1394], ["like", 1395], ["receptor-2", 1400], ["expression", 1411], ["in", 1422], ["diabetic", 1425], ["mice", 1434], [".", 1438], ["Empagliflozin", 1440], ["did", 1454], ["not", 1458], ["reduce", 1462], ["the", 1469], ["upregulation", 1473], ["of", 1486], ["macrophage", 1489], ["chemoattractant", 1500], ["protein-1", 1516], ["(", 1526], ["MCP-1", 1527], [")", 1532], [",", 1533], ["transforming", 1535], ["growth", 1548], ["factor", 1555], ["\u03b21", 1562], ["and", 1565], ["fibronectin", 1569], ["mRNA", 1581], ["observed", 1586], ["in", 1595], ["the", 1598], ["diabetic", 1602], ["animals", 1611], [",", 1618], ["while", 1620], ["telmisartan", 1626], ["decreased", 1638], ["transcription", 1648], ["of", 1662], ["MCP-1", 1665], ["and", 1671], ["fibronectin", 1675], [".", 1686], ["Empagliflozin", 1688], ["increased", 1702], ["GLUT1", 1712], ["mRNA", 1718], ["expression", 1723], ["and", 1734], ["telmisartan", 1738], ["increased", 1750], ["SGLT2", 1760], ["mRNA", 1766], ["expression", 1771], ["in", 1782], ["comparison", 1785], ["to", 1796], ["untreated", 1799], ["diabetic", 1809], ["mice", 1818], [".", 1822], ["However", 1824], ["no", 1832], ["significant", 1835], ["difference", 1847], ["was", 1858], ["found", 1862], ["in", 1868], ["protein", 1871], ["expression", 1879], ["of", 1890], ["GLUT1", 1893], ["or", 1899], ["SGLT2", 1902], ["among", 1908], ["the", 1914], ["different", 1918], ["groups", 1928], [".", 1934], ["Hence", 1936], ["SGLT2", 1942], ["inhibition", 1948], ["does", 1959], ["not", 1964], ["have", 1968], ["renoprotective", 1973], ["benefits", 1988], ["independent", 1997], ["of", 2009], ["glucose", 2012], ["lowering", 2020], [".", 2028]]}
{"context": "The clear connection between ribosome biogenesis dysfunction and specific hematopoiesis-related disorders prompted us to examine the role of critical lineage-specific transcription factors in the transcriptional regulation of ribosomal protein (RP) genes during terminal erythroid differentiation. By applying EMSA and ChIP methodologies in mouse erythroleukemia cells we show that GATA1 and PU.1 bind in vitro and in vivo the proximal promoter region of the RPS19 gene which is frequently mutated in Diamond-Blackfan Anemia. Moreover, ChIPseq data analysis also demonstrates that several RP genes are enriched as potential GATA1 and PU.1 gene targets in mouse and human erythroid cells, with GATA1 binding showing an association with higher ribosomal protein gene expression levels during terminal erythroid differentiation in human and mouse. Our results suggest that RP gene expression and hence balanced ribosome biosynthesis may be specifically and selectively regulated by lineage specific transcription factors during hematopoiesis, a finding which may be clinically relevant to ribosomopathies.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "35f2d4aeaa304a9d9c6fb6f5340d5589", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[77, 80]], "char_spans": [[501, 523]]}]}], "context_tokens": [["The", 0], ["clear", 4], ["connection", 10], ["between", 21], ["ribosome", 29], ["biogenesis", 38], ["dysfunction", 49], ["and", 61], ["specific", 65], ["hematopoiesis", 74], ["-", 87], ["related", 88], ["disorders", 96], ["prompted", 106], ["us", 115], ["to", 118], ["examine", 121], ["the", 129], ["role", 133], ["of", 138], ["critical", 141], ["lineage", 150], ["-", 157], ["specific", 158], ["transcription", 167], ["factors", 181], ["in", 189], ["the", 192], ["transcriptional", 196], ["regulation", 212], ["of", 223], ["ribosomal", 226], ["protein", 236], ["(", 244], ["RP", 245], [")", 247], ["genes", 249], ["during", 255], ["terminal", 262], ["erythroid", 271], ["differentiation", 281], [".", 296], ["By", 298], ["applying", 301], ["EMSA", 310], ["and", 315], ["ChIP", 319], ["methodologies", 324], ["in", 338], ["mouse", 341], ["erythroleukemia", 347], ["cells", 363], ["we", 369], ["show", 372], ["that", 377], ["GATA1", 382], ["and", 388], ["PU.1", 392], ["bind", 397], ["in", 402], ["vitro", 405], ["and", 411], ["in", 415], ["vivo", 418], ["the", 423], ["proximal", 427], ["promoter", 436], ["region", 445], ["of", 452], ["the", 455], ["RPS19", 459], ["gene", 465], ["which", 470], ["is", 476], ["frequently", 479], ["mutated", 490], ["in", 498], ["Diamond", 501], ["-", 508], ["Blackfan", 509], ["Anemia", 518], [".", 524], ["Moreover", 526], [",", 534], ["ChIPseq", 536], ["data", 544], ["analysis", 549], ["also", 558], ["demonstrates", 563], ["that", 576], ["several", 581], ["RP", 589], ["genes", 592], ["are", 598], ["enriched", 602], ["as", 611], ["potential", 614], ["GATA1", 624], ["and", 630], ["PU.1", 634], ["gene", 639], ["targets", 644], ["in", 652], ["mouse", 655], ["and", 661], ["human", 665], ["erythroid", 671], ["cells", 681], [",", 686], ["with", 688], ["GATA1", 693], ["binding", 699], ["showing", 707], ["an", 715], ["association", 718], ["with", 730], ["higher", 735], ["ribosomal", 742], ["protein", 752], ["gene", 760], ["expression", 765], ["levels", 776], ["during", 783], ["terminal", 790], ["erythroid", 799], ["differentiation", 809], ["in", 825], ["human", 828], ["and", 834], ["mouse", 838], [".", 843], ["Our", 845], ["results", 849], ["suggest", 857], ["that", 865], ["RP", 870], ["gene", 873], ["expression", 878], ["and", 889], ["hence", 893], ["balanced", 899], ["ribosome", 908], ["biosynthesis", 917], ["may", 930], ["be", 934], ["specifically", 937], ["and", 950], ["selectively", 954], ["regulated", 966], ["by", 976], ["lineage", 979], ["specific", 987], ["transcription", 996], ["factors", 1010], ["during", 1018], ["hematopoiesis", 1025], [",", 1038], ["a", 1040], ["finding", 1042], ["which", 1050], ["may", 1056], ["be", 1060], ["clinically", 1063], ["relevant", 1074], ["to", 1083], ["ribosomopathies", 1086], [".", 1101]]}
{"context": "Rates of remission were examined in two controlled 12-week studies of sertraline and placebo for post-traumatic stress disorder (PTSD). The performance of three scales was evaluated: the self-rated Davidson Trauma Scale (DTS), and two interviewer scales: the Clinician Administered PTSD Scale (CAPS) and Clinical Global Impressions (CGI). Sertraline proved significantly superior to placebo with respect to remission on all three ratings. Rates of remission were very similar for all scales, ranging from 23.1-26.3% for sertraline and 13.9-14.9% for placebo. Traditional thresholds for the CAPS and DTS were tested relative to the CGI and to each other. The CAPS and DTS thresholds of < 20 and < 18 were found to be valid.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b086ca841a4040e58142b56004268573", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[15, 19]], "char_spans": [[97, 126]]}, {"text": "PTSD", "token_spans": [[21, 21], [51, 51]], "char_spans": [[129, 132], [282, 285]]}]}], "context_tokens": [["Rates", 0], ["of", 6], ["remission", 9], ["were", 19], ["examined", 24], ["in", 33], ["two", 36], ["controlled", 40], ["12-week", 51], ["studies", 59], ["of", 67], ["sertraline", 70], ["and", 81], ["placebo", 85], ["for", 93], ["post", 97], ["-", 101], ["traumatic", 102], ["stress", 112], ["disorder", 119], ["(", 128], ["PTSD", 129], [")", 133], [".", 134], ["The", 136], ["performance", 140], ["of", 152], ["three", 155], ["scales", 161], ["was", 168], ["evaluated", 172], [":", 181], ["the", 183], ["self", 187], ["-", 191], ["rated", 192], ["Davidson", 198], ["Trauma", 207], ["Scale", 214], ["(", 220], ["DTS", 221], [")", 224], [",", 225], ["and", 227], ["two", 231], ["interviewer", 235], ["scales", 247], [":", 253], ["the", 255], ["Clinician", 259], ["Administered", 269], ["PTSD", 282], ["Scale", 287], ["(", 293], ["CAPS", 294], [")", 298], ["and", 300], ["Clinical", 304], ["Global", 313], ["Impressions", 320], ["(", 332], ["CGI", 333], [")", 336], [".", 337], ["Sertraline", 339], ["proved", 350], ["significantly", 357], ["superior", 371], ["to", 380], ["placebo", 383], ["with", 391], ["respect", 396], ["to", 404], ["remission", 407], ["on", 417], ["all", 420], ["three", 424], ["ratings", 430], [".", 437], ["Rates", 439], ["of", 445], ["remission", 448], ["were", 458], ["very", 463], ["similar", 468], ["for", 476], ["all", 480], ["scales", 484], [",", 490], ["ranging", 492], ["from", 500], ["23.1", 505], ["-", 509], ["26.3", 510], ["%", 514], ["for", 516], ["sertraline", 520], ["and", 531], ["13.9", 535], ["-", 539], ["14.9", 540], ["%", 544], ["for", 546], ["placebo", 550], [".", 557], ["Traditional", 559], ["thresholds", 571], ["for", 582], ["the", 586], ["CAPS", 590], ["and", 595], ["DTS", 599], ["were", 603], ["tested", 608], ["relative", 615], ["to", 624], ["the", 627], ["CGI", 631], ["and", 635], ["to", 639], ["each", 642], ["other", 647], [".", 652], ["The", 654], ["CAPS", 658], ["and", 663], ["DTS", 667], ["thresholds", 671], ["of", 682], ["<", 685], ["20", 687], ["and", 690], ["<", 694], ["18", 696], ["were", 699], ["found", 704], ["to", 710], ["be", 713], ["valid", 716], [".", 721]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2ff9e79323fb48ad9fe911c391aecaa8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[81, 81], [53, 53], [255, 255], [5, 5]], "char_spans": [[479, 481], [296, 298], [1516, 1518], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["inherited", 40], ["bone", 50], ["marrow", 55], ["failure", 62], ["syndrome", 70], ["that", 79], ["is", 84], ["characterized", 87], ["by", 101], ["pure", 104], ["red", 109], ["-", 112], ["cell", 113], ["aplasia", 118], ["and", 126], ["associated", 130], ["physical", 141], ["deformities", 150], [".", 161], ["It", 163], ["has", 166], ["been", 170], ["proven", 175], ["that", 182], ["defects", 187], ["of", 195], ["ribosomal", 198], ["proteins", 208], ["can", 217], ["lead", 221], ["to", 226], ["this", 229], ["disease", 234], ["and", 242], ["that", 246], ["RPS19", 251], ["is", 257], ["the", 260], ["most", 264], ["frequently", 269], ["mutated", 280], ["gene", 288], ["in", 293], ["DBA", 296], ["patients", 300], [".", 308], ["Previous", 310], ["studies", 319], ["suggest", 327], ["that", 335], ["p53-dependent", 340], ["genes", 354], ["and", 360], ["pathways", 364], ["play", 373], ["important", 378], ["roles", 388], ["in", 394], ["RPS19-deficient", 397], ["embryos", 413], [".", 420], ["However", 422], [",", 429], ["whether", 431], ["there", 439], ["are", 445], ["other", 449], ["vital", 455], ["factors", 461], ["linked", 469], ["to", 476], ["DBA", 479], ["has", 483], ["not", 487], ["been", 491], ["fully", 496], ["clarified", 502], [".", 511], ["In", 513], ["this", 516], ["study", 521], [",", 526], ["we", 528], ["compared", 531], ["the", 540], ["whole", 544], ["genome", 550], ["RNA", 557], ["-", 560], ["Seq", 561], ["data", 565], ["of", 570], ["zebrafish", 573], ["embryos", 583], ["injected", 591], ["with", 600], ["RPS19", 605], ["morpholino", 611], ["(", 622], ["RPS19", 623], ["MO", 629], [")", 631], [",", 632], ["RPS19", 634], ["and", 640], ["p53", 644], ["morpholino", 648], ["simultaneously", 659], ["(", 674], ["RPS19+p53", 675], ["MO", 685], [")", 687], ["and", 689], ["control", 693], ["morpholino", 701], ["(", 712], ["control", 713], [")", 720], [".", 721], ["We", 723], ["found", 726], ["that", 732], ["genes", 737], ["enriched", 743], ["in", 752], ["the", 755], ["functions", 759], ["of", 769], ["hematological", 772], ["systems", 786], [",", 793], ["nervous", 795], ["system", 803], ["development", 810], ["and", 822], ["skeletal", 826], ["and", 835], ["muscular", 839], ["disorders", 848], ["had", 858], ["significant", 862], ["differential", 874], ["expression", 887], ["in", 898], ["RPS19", 901], ["MO", 907], ["embryos", 910], ["compared", 918], ["with", 927], ["controls", 932], [".", 940], ["Co", 942], ["-", 944], ["inhibition", 945], ["of", 956], ["p53", 959], ["partially", 963], ["alleviates", 973], ["the", 984], ["abnormalities", 988], ["for", 1002], ["RPS19-deficient", 1006], ["embryos", 1022], [".", 1029], ["However", 1031], [",", 1038], ["the", 1040], ["hematopoietic", 1044], ["genes", 1058], [",", 1063], ["which", 1065], ["were", 1071], ["down", 1076], ["-", 1080], ["regulated", 1081], ["significantly", 1091], ["in", 1105], ["RPS19", 1108], ["MO", 1114], ["embryos", 1117], [",", 1124], ["were", 1126], ["not", 1131], ["completely", 1135], ["recovered", 1146], ["by", 1156], ["the", 1159], ["co", 1163], ["-", 1165], ["inhibition", 1166], ["of", 1177], ["p53", 1180], [".", 1183], ["Furthermore", 1185], [",", 1196], ["we", 1198], ["identified", 1201], ["the", 1212], ["genome", 1216], ["-", 1222], ["wide", 1223], ["p53-dependent", 1228], ["and", 1242], ["-independent", 1246], ["genes", 1259], ["and", 1265], ["pathways", 1269], [".", 1277], ["These", 1279], ["results", 1285], ["indicate", 1293], ["that", 1302], ["not", 1307], ["only", 1311], ["p53", 1316], ["family", 1320], ["members", 1327], ["but", 1335], ["also", 1339], ["other", 1344], ["factors", 1350], ["have", 1358], ["important", 1363], ["impacts", 1373], ["on", 1381], ["RPS19-deficient", 1384], ["embryos", 1400], [".", 1407], ["The", 1409], ["detection", 1413], ["of", 1423], ["potential", 1426], ["pathogenic", 1436], ["genes", 1447], ["and", 1453], ["pathways", 1457], ["provides", 1466], ["us", 1475], ["a", 1478], ["new", 1480], ["paradigm", 1484], ["for", 1493], ["future", 1497], ["research", 1504], ["on", 1513], ["DBA", 1516], [",", 1519], ["which", 1521], ["is", 1527], ["a", 1530], ["systematic", 1532], ["and", 1543], ["complex", 1547], ["hereditary", 1555], ["disease", 1566], [".", 1573]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "A central goal of evolutionary biology is to understand the genetic origin of morphological novelties-i.e. anatomical structures unique to a taxonomic group. Elaboration of morphology during development depends on networks of regulatory genes that activate patterned gene expression through transcriptional enhancer regions. We summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise. We also discuss how these enhancer-originating mechanisms have clarified the history of genetic networks underlying diversification of genital structures in flies, limbs and neural crest in chordates, and plant leaves. These studies have identified enhancers that were pivotal for morphological divergence and highlighted how novel genetic networks shaping form emerged from pre-existing ones.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "444e58e7c396480e8fcad64fbbced173", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[65, 65], [107, 107]], "char_spans": [[445, 453], [711, 719]]}]}], "context_tokens": [["A", 0], ["central", 2], ["goal", 10], ["of", 15], ["evolutionary", 18], ["biology", 31], ["is", 39], ["to", 42], ["understand", 45], ["the", 56], ["genetic", 60], ["origin", 68], ["of", 75], ["morphological", 78], ["novelties", 92], ["-", 101], ["i.e", 102], [".", 105], ["anatomical", 107], ["structures", 118], ["unique", 129], ["to", 136], ["a", 139], ["taxonomic", 141], ["group", 151], [".", 156], ["Elaboration", 158], ["of", 170], ["morphology", 173], ["during", 184], ["development", 191], ["depends", 203], ["on", 211], ["networks", 214], ["of", 223], ["regulatory", 226], ["genes", 237], ["that", 243], ["activate", 248], ["patterned", 257], ["gene", 267], ["expression", 272], ["through", 283], ["transcriptional", 291], ["enhancer", 307], ["regions", 316], [".", 323], ["We", 325], ["summarize", 328], ["recent", 338], ["case", 345], ["studies", 350], ["and", 358], ["genome", 362], ["-", 368], ["wide", 369], ["investigations", 374], ["that", 389], ["have", 394], ["uncovered", 399], ["diverse", 409], ["mechanisms", 417], ["though", 428], ["which", 435], ["new", 441], ["enhancers", 445], ["arise", 455], [".", 460], ["We", 462], ["also", 465], ["discuss", 470], ["how", 478], ["these", 482], ["enhancer", 488], ["-", 496], ["originating", 497], ["mechanisms", 509], ["have", 520], ["clarified", 525], ["the", 535], ["history", 539], ["of", 547], ["genetic", 550], ["networks", 558], ["underlying", 567], ["diversification", 578], ["of", 594], ["genital", 597], ["structures", 605], ["in", 616], ["flies", 619], [",", 624], ["limbs", 626], ["and", 632], ["neural", 636], ["crest", 643], ["in", 649], ["chordates", 652], [",", 661], ["and", 663], ["plant", 667], ["leaves", 673], [".", 679], ["These", 681], ["studies", 687], ["have", 695], ["identified", 700], ["enhancers", 711], ["that", 721], ["were", 726], ["pivotal", 731], ["for", 739], ["morphological", 743], ["divergence", 757], ["and", 768], ["highlighted", 772], ["how", 784], ["novel", 788], ["genetic", 794], ["networks", 802], ["shaping", 811], ["form", 819], ["emerged", 824], ["from", 832], ["pre", 837], ["-", 840], ["existing", 841], ["ones", 850], [".", 854]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5900db93e2d94cedaf489326063c2ede", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[258, 260], [10, 12], [275, 277]], "char_spans": [[1284, 1290], [55, 61], [1358, 1364]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["Glivec", 19], [")", 25], ["is", 27], ["a", 30], ["selective", 32], ["inhibitor", 42], ["of", 52], ["bcr", 55], ["-", 58], ["abl", 59], ["tyrosine", 63], ["kinase", 72], [",", 78], ["the", 80], ["product", 84], ["of", 92], ["the", 95], ["Philadelphia", 99], ["chromosome", 112], [",", 122], ["which", 124], ["is", 130], ["the", 133], ["hallmark", 137], ["of", 146], ["chronic", 149], ["myeloid", 157], ["leukaemia", 165], ["(", 175], ["CML", 176], [")", 179], [".", 180], ["With", 182], ["imatinib", 187], [",", 195], ["complete", 197], ["cytogenetic", 206], ["response", 218], ["(", 227], ["CCR", 228], [")", 231], ["can", 233], ["be", 237], ["achieved", 240], ["in", 249], ["over", 252], ["70", 257], ["%", 259], ["of", 261], ["newly", 264], ["diagnosed", 270], ["patients", 280], ["with", 289], ["CML", 294], [".", 297], ["However", 299], [",", 306], ["the", 308], ["optimal", 312], ["long", 320], ["-", 324], ["term", 325], ["management", 330], ["of", 341], ["patients", 344], ["who", 353], ["achieve", 357], ["CCR", 365], ["after", 369], ["imatinib", 375], ["is", 384], ["unknown", 387], [".", 394], ["With", 396], ["longer", 401], ["follow", 408], ["-", 414], ["up", 415], [",", 417], ["it", 419], ["is", 422], ["anticipated", 425], ["that", 437], ["some", 442], ["patients", 447], ["are", 456], ["likely", 460], ["to", 467], ["progress", 470], ["and", 479], ["become", 483], ["candidates", 490], ["for", 501], ["autologous", 505], ["transplantation", 516], [".", 531], ["We", 533], ["studied", 536], ["filgrastim", 544], ["(", 555], ["r", 556], ["-", 557], ["metHuG", 558], ["-", 564], ["CSF", 565], [")", 568], ["mobilisation", 570], ["of", 583], ["peripheral", 586], ["blood", 597], ["stem", 603], ["cells", 608], ["(", 614], ["PBSC", 615], [")", 619], ["in", 621], ["32", 624], ["patients", 627], ["who", 636], ["have", 640], ["achieved", 645], ["CCR", 654], ["with", 658], ["imatinib", 663], [".", 671], ["Our", 673], ["data", 677], ["demonstrate", 682], ["that", 694], ["(", 699], ["1", 700], [")", 701], ["the", 703], ["target", 707], ["CD34(+", 714], [")", 720], ["cell", 722], ["yields", 727], ["of", 734], [">", 737], ["/=2.0", 738], ["x", 744], ["10(6)/kg", 746], ["were", 755], ["attained", 760], ["with", 769], ["filgrastim", 774], ["10", 785], ["microg", 788], ["/", 794], ["kg", 795], ["/", 797], ["day", 798], [",", 801], ["in", 803], ["9/18", 806], ["(", 811], ["50", 812], ["%", 814], [")", 815], ["of", 817], ["patients", 820], ["during", 829], ["uninterrupted", 836], ["imatinib", 850], ["therapy", 859], [",", 866], ["and", 868], ["in", 872], ["10/14", 875], ["(", 881], ["70", 882], ["%", 884], [")", 885], ["when", 887], ["imatinib", 892], ["was", 901], ["temporarily", 905], ["withheld", 917], [".", 925], ["The", 927], ["median", 931], ["CD34(+", 938], [")", 944], ["cell", 946], ["yield", 951], ["per", 957], ["aphaeresis", 961], ["was", 972], ["0.70", 976], ["x", 981], ["10(6)/kg", 983], ["(", 992], ["range", 993], ["0.14", 999], ["-", 1003], ["2.18", 1004], [")", 1008], ["and", 1010], ["2.90", 1014], ["x", 1019], ["10(6)/kg", 1021], ["(", 1030], ["range", 1031], ["0.15", 1037], ["-", 1041], ["8.71", 1042], [")", 1046], ["in", 1048], ["the", 1051], ["two", 1055], ["groups", 1059], [",", 1065], ["respectively", 1067], ["(", 1080], ["P&<0.005", 1081], [")", 1089], [".", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["The", 1096], ["cell", 1100], ["yields", 1105], ["did", 1112], ["not", 1116], ["correlate", 1120], ["with", 1130], ["the", 1135], ["duration", 1139], ["of", 1148], ["imatinib", 1151], ["administration", 1160], [".", 1174], ["(", 1176], ["3", 1177], [")", 1178], ["There", 1180], ["was", 1186], ["no", 1190], ["impact", 1193], ["of", 1200], ["the", 1203], ["mobilisation", 1207], ["procedure", 1220], ["on", 1230], ["the", 1233], ["level", 1237], ["of", 1243], ["leukaemia", 1246], ["as", 1256], ["measured", 1259], ["by", 1268], ["serial", 1271], ["blood", 1278], ["bcr", 1284], ["-", 1287], ["abl", 1288], ["levels", 1292], ["using", 1299], ["real", 1305], ["-", 1309], ["time", 1310], ["quantitative", 1315], ["PCR", 1328], ["with", 1332], ["either", 1337], ["protocol", 1344], [".", 1352], ["(", 1354], ["4", 1355], [")", 1356], ["bcr", 1358], ["-", 1361], ["abl", 1362], ["remained", 1366], ["detectable", 1375], ["at", 1386], ["low", 1389], ["levels", 1393], ["in", 1400], ["the", 1403], ["harvests", 1407], ["in", 1416], ["most", 1419], ["but", 1424], ["not", 1428], ["all", 1432], ["patients", 1436], [".", 1444], ["In", 1446], ["conclusion", 1449], [",", 1459], ["filgrastim", 1461], ["can", 1472], ["safely", 1476], ["be", 1483], ["used", 1486], ["to", 1491], ["mobilise", 1494], ["PBSC", 1503], ["in", 1508], ["patients", 1511], ["who", 1520], ["have", 1524], ["achieved", 1529], ["CCR", 1538], ["with", 1542], ["imatinib", 1547], [",", 1555], ["but", 1557], ["CD34(+", 1561], [")", 1567], ["cell", 1569], ["yields", 1574], ["are", 1581], ["significantly", 1585], ["improved", 1599], ["when", 1608], ["imatinib", 1613], ["is", 1622], ["temporarily", 1625], ["withheld", 1637], [".", 1645]]}
{"context": "Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "cdffae7e17c6461b9d318dade835ff28", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["a", 32], ["cytoplasmic", 34], ["tyrosine", 46], ["kinase", 55], ["involved", 62], ["in", 71], ["signalling", 74], ["in", 85], ["many", 88], ["of", 93], ["the", 96], ["cells", 100], ["that", 106], ["drive", 111], ["immune", 117], ["inflammation", 124], [".", 136], ["The", 138], ["development", 142], ["of", 154], ["small", 157], ["molecules", 163], ["that", 173], ["inhibit", 178], ["Syk", 186], ["kinase", 190], ["may", 197], ["change", 201], ["the", 208], ["way", 212], ["we", 216], ["treat", 219], ["disorders", 225], ["such", 235], ["as", 240], ["rheumatoid", 243], ["arthritis", 254], ["(", 264], ["RA", 265], [")", 267], [",", 268], ["as", 270], ["well", 273], ["as", 278], ["a", 281], ["range", 283], ["of", 289], ["other", 292], ["inflammatory", 298], ["diseases", 311], [".", 319], ["Fostamatinib", 321], ["(", 334], ["R-788", 335], [")", 340], ["is", 342], ["an", 345], ["orally", 348], ["bioavailable", 355], ["small", 368], ["molecule", 374], [".", 382], ["It", 384], ["is", 387], ["the", 390], ["prodrug", 394], ["of", 402], ["R406", 405], [",", 409], ["which", 411], ["is", 417], ["a", 420], ["potent", 422], ["Syk", 429], ["inhibitor", 433], [".", 442], ["Fostamatinib", 444], ["was", 457], ["developed", 461], ["because", 471], ["it", 479], ["has", 482], ["more", 486], ["favourable", 491], ["physiochemical", 502], ["properties", 517], [".", 527], ["It", 529], ["is", 532], ["rapidly", 535], ["converted", 543], ["to", 553], ["R406", 556], ["by", 561], ["intestinal", 564], ["enterocytes", 575], [".", 586], ["It", 588], ["has", 591], ["been", 595], ["evaluated", 600], ["in", 610], ["experimental", 613], ["models", 626], ["of", 633], ["RA", 636], [",", 638], ["such", 640], ["as", 645], ["collagen", 648], ["-", 656], ["induced", 657], ["arthritis", 665], [".", 674], ["In", 676], ["these", 679], ["models", 685], [",", 691], ["fostamatinib", 693], ["suppressed", 706], ["clinical", 717], ["arthritis", 726], [",", 735], ["bone", 737], ["erosions", 742], [",", 750], ["pannus", 752], ["formation", 759], ["and", 769], ["synovitis", 773], [".", 782], ["A", 784], ["phase", 786], ["II", 792], ["programme", 795], ["with", 805], ["fostamatinib", 810], ["has", 823], ["largely", 827], ["been", 835], ["completed", 840], [".", 849], ["Three", 851], ["key", 857], ["trials", 861], ["have", 868], ["been", 873], ["published", 878], [",", 887], ["lasting", 889], ["12", 897], ["-", 899], ["26", 900], ["weeks", 903], ["and", 909], ["each", 913], ["enrolling", 918], ["189", 928], ["-", 931], ["457", 932], ["patients", 936], ["(", 945], ["875", 946], ["in", 950], ["total", 953], [")", 958], [".", 959], ["All", 961], ["these", 965], ["trials", 971], ["involved", 978], ["placebo", 987], ["therapy", 995], ["and", 1003], ["patients", 1007], ["continued", 1016], ["to", 1026], ["receive", 1029], ["methotrexate", 1037], ["in", 1050], ["addition", 1053], ["to", 1062], ["active", 1065], ["treatment", 1072], ["with", 1082], ["fostamatinib", 1087], [".", 1099], ["The", 1101], ["first", 1105], ["dose", 1111], ["-", 1115], ["ranging", 1116], ["trial", 1124], ["evaluated", 1130], ["three", 1140], ["treatment", 1146], ["doses", 1156], ["in", 1162], ["RA", 1165], ["patients", 1168], ["who", 1177], ["had", 1181], ["not", 1185], ["fully", 1189], ["responded", 1195], ["to", 1205], ["methotrexate", 1208], ["therapy", 1221], [".", 1228], ["The", 1230], ["second", 1234], ["trial", 1241], ["compared", 1247], ["two", 1256], ["treatment", 1260], ["doses", 1270], ["in", 1276], ["patients", 1279], ["who", 1288], ["had", 1292], ["not", 1296], ["responded", 1300], ["to", 1310], ["methotrexate", 1313], ["therapy", 1326], [".", 1333], ["The", 1335], ["third", 1339], ["trial", 1345], ["compared", 1351], ["a", 1360], ["single", 1362], ["treatment", 1369], ["dose", 1379], ["with", 1384], ["placebo", 1389], ["in", 1397], ["patients", 1400], ["who", 1409], ["had", 1413], ["not", 1417], ["responded", 1421], ["to", 1431], ["biological", 1434], ["therapy", 1445], [".", 1452], ["The", 1454], ["primary", 1458], ["outcome", 1466], ["measure", 1474], ["was", 1482], ["the", 1486], ["number", 1490], ["of", 1497], ["patients", 1500], ["achieving", 1509], ["American", 1519], ["College", 1528], ["of", 1536], ["Rheumatology", 1539], ["(", 1552], ["ACR", 1553], [")", 1556], ["20", 1558], ["%", 1560], ["(", 1562], ["ACR20", 1563], [")", 1568], ["responses", 1570], [".", 1579], ["Placebo", 1581], ["ACR20", 1589], ["response", 1595], ["rates", 1604], ["in", 1610], ["all", 1613], ["three", 1617], ["trials", 1623], ["were", 1630], ["similar", 1635], ["(", 1643], ["35", 1644], ["-", 1646], ["38", 1647], ["%", 1649], [")", 1650], [".", 1651], ["All", 1653], ["three", 1657], ["trials", 1663], ["involved", 1670], ["one", 1679], ["treatment", 1683], ["arm", 1693], ["receiving", 1697], ["fostamatinib", 1707], ["100", 1720], ["mg", 1724], ["twice", 1727], ["daily", 1733], [";", 1738], ["ACR20", 1740], ["responses", 1746], ["with", 1756], ["this", 1761], ["active", 1766], ["treatment", 1773], ["ranged", 1783], ["from", 1790], ["38", 1795], ["%", 1797], ["to", 1799], ["67", 1802], ["%", 1804], [".", 1805], ["A", 1807], ["meta", 1809], ["-", 1813], ["analysis", 1814], ["of", 1823], ["ACR", 1826], ["responses", 1830], ["in", 1840], ["these", 1843], ["trials", 1849], [",", 1855], ["using", 1857], ["responses", 1863], ["to", 1873], ["the", 1876], ["highest", 1880], ["dose", 1888], ["in", 1893], ["each", 1896], ["trial", 1901], ["for", 1907], ["comparisons", 1911], ["with", 1923], ["placebo", 1928], ["therapy", 1936], ["in", 1944], ["a", 1947], ["random", 1949], ["effects", 1956], ["model", 1964], [",", 1969], ["showed", 1971], ["a", 1978], ["borderline", 1980], ["benefit", 1991], ["with", 1999], ["ACR20", 2004], ["responses", 2010], [".", 2019], ["There", 2021], ["were", 2027], ["more", 2032], ["significant", 2037], ["differences", 2049], ["with", 2061], ["ACR50", 2066], ["and", 2072], ["ACR70", 2076], ["responses", 2082], [".", 2091], ["The", 2093], ["reason", 2097], ["that", 2104], ["this", 2109], ["meta", 2114], ["-", 2118], ["analysis", 2119], ["was", 2128], ["not", 2132], ["more", 2136], ["strongly", 2141], ["positive", 2150], ["is", 2159], ["that", 2162], ["the", 2167], ["third", 2171], ["trial", 2177], [",", 2182], ["which", 2184], ["evaluated", 2190], ["patients", 2200], ["who", 2209], ["had", 2213], ["failed", 2217], ["to", 2224], ["respond", 2227], ["to", 2235], ["biological", 2238], ["treatments", 2249], [",", 2259], ["gave", 2261], ["negative", 2266], ["results", 2275], [".", 2282], ["Individual", 2284], ["ACR", 2295], ["response", 2299], ["components", 2308], [",", 2318], ["such", 2320], ["as", 2325], ["changes", 2328], ["in", 2336], ["swollen", 2339], ["joint", 2347], ["counts", 2353], [",", 2359], ["showed", 2361], ["significant", 2368], ["differences", 2380], ["in", 2392], ["the", 2395], ["first", 2399], ["two", 2405], ["trials", 2409], [",", 2415], ["but", 2417], ["there", 2421], ["were", 2427], ["no", 2432], ["definite", 2435], ["treatment", 2444], ["benefits", 2454], ["in", 2463], ["the", 2466], ["third", 2470], ["trial", 2476], [".", 2481], ["Overall", 2483], [",", 2490], ["the", 2492], ["differences", 2496], ["were", 2508], ["significant", 2513], ["in", 2525], ["a", 2528], ["meta", 2530], ["-", 2534], ["analysis", 2535], ["of", 2544], ["all", 2547], ["three", 2551], ["trials", 2557], [".", 2563], ["The", 2565], ["most", 2569], ["important", 2574], ["adverse", 2584], ["reactions", 2592], ["were", 2602], ["diarrhoea", 2607], [",", 2616], ["neutropenia", 2618], ["and", 2630], ["raised", 2634], ["ALT", 2641], ["levels", 2645], [",", 2651], ["which", 2653], ["all", 2659], ["showed", 2663], ["significant", 2670], ["excesses", 2682], ["with", 2691], ["active", 2696], ["treatment", 2703], ["compared", 2713], ["with", 2722], ["placebo", 2727], [".", 2734], ["Too", 2736], ["few", 2740], ["patients", 2744], ["have", 2753], ["been", 2758], ["studied", 2763], ["for", 2771], ["a", 2775], ["definitive", 2777], ["safety", 2788], ["profile", 2795], ["to", 2803], ["be", 2806], ["known", 2809], [".", 2814], ["Overall", 2816], [",", 2823], ["the", 2825], ["results", 2829], ["of", 2837], ["the", 2840], ["phase", 2844], ["II", 2850], ["trials", 2853], ["were", 2860], ["sufficiently", 2865], ["encouraging", 2878], ["for", 2890], ["a", 2894], ["phase", 2896], ["III", 2902], ["programme", 2906], ["to", 2916], ["be", 2919], ["initiated", 2922], [".", 2931], ["It", 2933], ["will", 2936], ["be", 2941], ["some", 2944], ["years", 2949], ["before", 2955], ["their", 2962], ["definitive", 2968], ["results", 2979], ["are", 2987], ["available", 2991], [".", 3000]]}
{"context": "The authors reported a 73-year-old alcoholic man with previously-unrecognized situs inversus totalis suffering from left upper quadrant pain. Acute myocardial infarction was diagnosed and coronary angioplasty was performed immediately. However, the massive bleeding from the previously-unfound hepatomas caused hypovolemic shock and fatal outcome. Situs inversus totalis is a rare congenital anomaly with a complete mirror image of the thoracic and abdominal organs. Although being considered a benign entity, it would disturb diagnosis-making of the visceral diseases owing to the altered anatomy. To our knowledge, the coexistence of the coronary artery disease and ruptured hepatomas in situs inversus totalis, as in our patient, is never described. Recognition of any situs anomalies in time is the key to avoid misdiagnosis, inappropriate managements, and unwanted consequences.", "qas": [{"question": "What is situs inversus?", "answers": ["Situs inversus totalis is a rare congenital anomaly with a complete mirror image of the thoracic and abdominal organs."], "qid": "30297cdd9b004604bfbf3798dd6ebe86", "question_tokens": [["What", 0], ["is", 5], ["situs", 8], ["inversus", 14], ["?", 22]], "detected_answers": [{"text": "Situs inversus totalis is a rare congenital anomaly with a complete mirror image of the thoracic and abdominal organs.", "token_spans": [[53, 71]], "char_spans": [[348, 464]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["reported", 12], ["a", 21], ["73-year", 23], ["-", 30], ["old", 31], ["alcoholic", 35], ["man", 45], ["with", 49], ["previously", 54], ["-", 64], ["unrecognized", 65], ["situs", 78], ["inversus", 84], ["totalis", 93], ["suffering", 101], ["from", 111], ["left", 116], ["upper", 121], ["quadrant", 127], ["pain", 136], [".", 140], ["Acute", 142], ["myocardial", 148], ["infarction", 159], ["was", 170], ["diagnosed", 174], ["and", 184], ["coronary", 188], ["angioplasty", 197], ["was", 209], ["performed", 213], ["immediately", 223], [".", 234], ["However", 236], [",", 243], ["the", 245], ["massive", 249], ["bleeding", 257], ["from", 266], ["the", 271], ["previously", 275], ["-", 285], ["unfound", 286], ["hepatomas", 294], ["caused", 304], ["hypovolemic", 311], ["shock", 323], ["and", 329], ["fatal", 333], ["outcome", 339], [".", 346], ["Situs", 348], ["inversus", 354], ["totalis", 363], ["is", 371], ["a", 374], ["rare", 376], ["congenital", 381], ["anomaly", 392], ["with", 400], ["a", 405], ["complete", 407], ["mirror", 416], ["image", 423], ["of", 429], ["the", 432], ["thoracic", 436], ["and", 445], ["abdominal", 449], ["organs", 459], [".", 465], ["Although", 467], ["being", 476], ["considered", 482], ["a", 493], ["benign", 495], ["entity", 502], [",", 508], ["it", 510], ["would", 513], ["disturb", 519], ["diagnosis", 527], ["-", 536], ["making", 537], ["of", 544], ["the", 547], ["visceral", 551], ["diseases", 560], ["owing", 569], ["to", 575], ["the", 578], ["altered", 582], ["anatomy", 590], [".", 597], ["To", 599], ["our", 602], ["knowledge", 606], [",", 615], ["the", 617], ["coexistence", 621], ["of", 633], ["the", 636], ["coronary", 640], ["artery", 649], ["disease", 656], ["and", 664], ["ruptured", 668], ["hepatomas", 677], ["in", 687], ["situs", 690], ["inversus", 696], ["totalis", 705], [",", 712], ["as", 714], ["in", 717], ["our", 720], ["patient", 724], [",", 731], ["is", 733], ["never", 736], ["described", 742], [".", 751], ["Recognition", 753], ["of", 765], ["any", 768], ["situs", 772], ["anomalies", 778], ["in", 788], ["time", 791], ["is", 796], ["the", 799], ["key", 803], ["to", 807], ["avoid", 810], ["misdiagnosis", 816], [",", 828], ["inappropriate", 830], ["managements", 844], [",", 855], ["and", 857], ["unwanted", 861], ["consequences", 870], [".", 882]]}
{"context": "Clinical evidence for failure with beta-lactam therapy has been lacking for patients with borderline oxacillin-resistant Staphylococcus aureus (BORSA) infections. We describe a failure of cloxacillin for a patient with endocarditis due to BORSA. The isolate also had false-negative thermonuclease and coagulase test results.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6b5bba7ac78e49bf91eca71131576311", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[15, 20]], "char_spans": [[90, 141]]}]}], "context_tokens": [["Clinical", 0], ["evidence", 9], ["for", 18], ["failure", 22], ["with", 30], ["beta", 35], ["-", 39], ["lactam", 40], ["therapy", 47], ["has", 55], ["been", 59], ["lacking", 64], ["for", 72], ["patients", 76], ["with", 85], ["borderline", 90], ["oxacillin", 101], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["BORSA", 144], [")", 149], ["infections", 151], [".", 161], ["We", 163], ["describe", 166], ["a", 175], ["failure", 177], ["of", 185], ["cloxacillin", 188], ["for", 200], ["a", 204], ["patient", 206], ["with", 214], ["endocarditis", 219], ["due", 232], ["to", 236], ["BORSA", 239], [".", 244], ["The", 246], ["isolate", 250], ["also", 258], ["had", 263], ["false", 267], ["-", 272], ["negative", 273], ["thermonuclease", 282], ["and", 297], ["coagulase", 301], ["test", 311], ["results", 316], [".", 323]]}
{"context": "MicroRNAs (miRNAs) are non-coding, short (21-23nt) regulators of protein-coding genes that are generally transcribed first into primary miRNA (pri-miR), followed by the generation of precursor miRNA (pre-miR). This finally leads to the production of the mature miRNA. A large amount of information is available on the pre- and mature miRNAs. However, very little is known about the pri-miRs, due to a lack of knowledge about their transcription start sites (TSSs). Based on the genomic loci, miRNAs can be categorized into two types --intragenic (intra-miR) and intergenic (inter-miR). While it is already an established fact that intra-miRs are commonly transcribed in conjunction with their host genes, the transcription machinery of inter-miRs is poorly understood. Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs. In this paper, we concentrate on the problem of TSS prediction for miRNAs. The present study begins with the identification of positive and negative promoter samples from recently published data stemming from RNA-sequencing studies. From these samples of experimentally validated miRNA TSSs, a number of standard sequence features are extracted. Furthermore, to account for potential footprints related to promoter regulation by CpG dinucleotide targeted DNA methylation, a number of novel features are defined. We develop a support vector machine (SVM) with RBF kernel for the prediction of miRNA TSSs trained on human miRNA promoters. A novel feature reduction technique based on archived multi-objective simulated annealing (AMOSA) identifies the final set of features. The resulting model trained on miRNA promoters shows improved performance over the one trained on protein-coding gene promoters in terms of classification accuracy, sensitivity and specificity. Results are also reported for a completely independent biologically validated test set. In a part of the investigation, the proposed approach is used to predict protein-coding gene TSSs. It shows a significantly improved performance when compared to previously published gene TSS prediction methods.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cdd96acd2fc94e268b146391bc401383", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[179, 181]], "char_spans": [[887, 903]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["short", 35], ["(", 41], ["21", 42], ["-", 44], ["23nt", 45], [")", 49], ["regulators", 51], ["of", 62], ["protein", 65], ["-", 72], ["coding", 73], ["genes", 80], ["that", 86], ["are", 91], ["generally", 95], ["transcribed", 105], ["first", 117], ["into", 123], ["primary", 128], ["miRNA", 136], ["(", 142], ["pri", 143], ["-", 146], ["miR", 147], [")", 150], [",", 151], ["followed", 153], ["by", 162], ["the", 165], ["generation", 169], ["of", 180], ["precursor", 183], ["miRNA", 193], ["(", 199], ["pre", 200], ["-", 203], ["miR", 204], [")", 207], [".", 208], ["This", 210], ["finally", 215], ["leads", 223], ["to", 229], ["the", 232], ["production", 236], ["of", 247], ["the", 250], ["mature", 254], ["miRNA", 261], [".", 266], ["A", 268], ["large", 270], ["amount", 276], ["of", 283], ["information", 286], ["is", 298], ["available", 301], ["on", 311], ["the", 314], ["pre-", 318], ["and", 323], ["mature", 327], ["miRNAs", 334], [".", 340], ["However", 342], [",", 349], ["very", 351], ["little", 356], ["is", 363], ["known", 366], ["about", 372], ["the", 378], ["pri", 382], ["-", 385], ["miRs", 386], [",", 390], ["due", 392], ["to", 396], ["a", 399], ["lack", 401], ["of", 406], ["knowledge", 409], ["about", 419], ["their", 425], ["transcription", 431], ["start", 445], ["sites", 451], ["(", 457], ["TSSs", 458], [")", 462], [".", 463], ["Based", 465], ["on", 471], ["the", 474], ["genomic", 478], ["loci", 486], [",", 490], ["miRNAs", 492], ["can", 499], ["be", 503], ["categorized", 506], ["into", 518], ["two", 523], ["types", 527], ["--intragenic", 533], ["(", 546], ["intra", 547], ["-", 552], ["miR", 553], [")", 556], ["and", 558], ["intergenic", 562], ["(", 573], ["inter", 574], ["-", 579], ["miR", 580], [")", 583], [".", 584], ["While", 586], ["it", 592], ["is", 595], ["already", 598], ["an", 606], ["established", 609], ["fact", 621], ["that", 626], ["intra", 631], ["-", 636], ["miRs", 637], ["are", 642], ["commonly", 646], ["transcribed", 655], ["in", 667], ["conjunction", 670], ["with", 682], ["their", 687], ["host", 693], ["genes", 698], [",", 703], ["the", 705], ["transcription", 709], ["machinery", 723], ["of", 733], ["inter", 736], ["-", 741], ["miRs", 742], ["is", 747], ["poorly", 750], ["understood", 757], [".", 767], ["Although", 769], ["it", 778], ["is", 781], ["assumed", 784], ["that", 792], ["miRNA", 797], ["promoters", 803], ["are", 813], ["similar", 817], ["in", 825], ["structure", 828], ["to", 838], ["gene", 841], ["promoters", 846], [",", 855], ["since", 857], ["both", 863], ["are", 868], ["transcribed", 872], ["by", 884], ["RNA", 887], ["polymerase", 891], ["II", 902], ["(", 905], ["Pol", 906], ["II", 910], [")", 912], [",", 913], ["computational", 915], ["validations", 929], ["exhibit", 941], ["poor", 949], ["performance", 954], ["of", 966], ["gene", 969], ["promoter", 974], ["prediction", 983], ["methods", 994], ["on", 1002], ["miRNAs", 1005], [".", 1011], ["In", 1013], ["this", 1016], ["paper", 1021], [",", 1026], ["we", 1028], ["concentrate", 1031], ["on", 1043], ["the", 1046], ["problem", 1050], ["of", 1058], ["TSS", 1061], ["prediction", 1065], ["for", 1076], ["miRNAs", 1080], [".", 1086], ["The", 1088], ["present", 1092], ["study", 1100], ["begins", 1106], ["with", 1113], ["the", 1118], ["identification", 1122], ["of", 1137], ["positive", 1140], ["and", 1149], ["negative", 1153], ["promoter", 1162], ["samples", 1171], ["from", 1179], ["recently", 1184], ["published", 1193], ["data", 1203], ["stemming", 1208], ["from", 1217], ["RNA", 1222], ["-", 1225], ["sequencing", 1226], ["studies", 1237], [".", 1244], ["From", 1246], ["these", 1251], ["samples", 1257], ["of", 1265], ["experimentally", 1268], ["validated", 1283], ["miRNA", 1293], ["TSSs", 1299], [",", 1303], ["a", 1305], ["number", 1307], ["of", 1314], ["standard", 1317], ["sequence", 1326], ["features", 1335], ["are", 1344], ["extracted", 1348], [".", 1357], ["Furthermore", 1359], [",", 1370], ["to", 1372], ["account", 1375], ["for", 1383], ["potential", 1387], ["footprints", 1397], ["related", 1408], ["to", 1416], ["promoter", 1419], ["regulation", 1428], ["by", 1439], ["CpG", 1442], ["dinucleotide", 1446], ["targeted", 1459], ["DNA", 1468], ["methylation", 1472], [",", 1483], ["a", 1485], ["number", 1487], ["of", 1494], ["novel", 1497], ["features", 1503], ["are", 1512], ["defined", 1516], [".", 1523], ["We", 1525], ["develop", 1528], ["a", 1536], ["support", 1538], ["vector", 1546], ["machine", 1553], ["(", 1561], ["SVM", 1562], [")", 1565], ["with", 1567], ["RBF", 1572], ["kernel", 1576], ["for", 1583], ["the", 1587], ["prediction", 1591], ["of", 1602], ["miRNA", 1605], ["TSSs", 1611], ["trained", 1616], ["on", 1624], ["human", 1627], ["miRNA", 1633], ["promoters", 1639], [".", 1648], ["A", 1650], ["novel", 1652], ["feature", 1658], ["reduction", 1666], ["technique", 1676], ["based", 1686], ["on", 1692], ["archived", 1695], ["multi", 1704], ["-", 1709], ["objective", 1710], ["simulated", 1720], ["annealing", 1730], ["(", 1740], ["AMOSA", 1741], [")", 1746], ["identifies", 1748], ["the", 1759], ["final", 1763], ["set", 1769], ["of", 1773], ["features", 1776], [".", 1784], ["The", 1786], ["resulting", 1790], ["model", 1800], ["trained", 1806], ["on", 1814], ["miRNA", 1817], ["promoters", 1823], ["shows", 1833], ["improved", 1839], ["performance", 1848], ["over", 1860], ["the", 1865], ["one", 1869], ["trained", 1873], ["on", 1881], ["protein", 1884], ["-", 1891], ["coding", 1892], ["gene", 1899], ["promoters", 1904], ["in", 1914], ["terms", 1917], ["of", 1923], ["classification", 1926], ["accuracy", 1941], [",", 1949], ["sensitivity", 1951], ["and", 1963], ["specificity", 1967], [".", 1978], ["Results", 1980], ["are", 1988], ["also", 1992], ["reported", 1997], ["for", 2006], ["a", 2010], ["completely", 2012], ["independent", 2023], ["biologically", 2035], ["validated", 2048], ["test", 2058], ["set", 2063], [".", 2066], ["In", 2068], ["a", 2071], ["part", 2073], ["of", 2078], ["the", 2081], ["investigation", 2085], [",", 2098], ["the", 2100], ["proposed", 2104], ["approach", 2113], ["is", 2122], ["used", 2125], ["to", 2130], ["predict", 2133], ["protein", 2141], ["-", 2148], ["coding", 2149], ["gene", 2156], ["TSSs", 2161], [".", 2165], ["It", 2167], ["shows", 2170], ["a", 2176], ["significantly", 2178], ["improved", 2192], ["performance", 2201], ["when", 2213], ["compared", 2218], ["to", 2227], ["previously", 2230], ["published", 2241], ["gene", 2251], ["TSS", 2256], ["prediction", 2260], ["methods", 2271], [".", 2278]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare multiorgan disease entity with autosomal recessive inheritance characterized by oculocutaneous albinism, bleeding tendency, recurrent bacterial infections and various neurological symptoms. Intracellular vesicle formation is deficient, resulting in giant granules in many cells, e.g. giant melanosomes in the melanocytes. Diagnosis has been based on morphological examination of peripheral blood and bone marrow, with giant granules seen in cells of the myeloid lineage and in lymphocytes. The ultimate diagnostic test is to look for a mutated LYST gene. Most patients develop an accelerated phase of the disease with deposition of lymphohistiocytes in the liver, spleen, lymph nodes and bone marrow, resulting in hepatosplenomegaly, bone marrow infiltration and haemophagocytosis. Peripheral blood neutropenia becomes more profound as anaemia and thrombocytopenia develop. Most patients succumb before the age of 10 years. Four patients with CHS are described, one of whom is a long-term survivor after successful allogeneic bone marrow transplantation, two succumbed during the accelerated phase and one is living with a chronic form of the disease. Allogeneic bone marrow transplantation from an HLA-matched sibling is the therapy of choice and should be performed early. If there is no matched family donor, an unrelated donor or a placental blood graft is a good alternative. The clinical picture of CHS is heterogeneous and therapeutic decisions need to be made on an individual basis.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "9d193028d5e04fa68360de77146992cd", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[92, 93]], "char_spans": [[585, 593]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["multiorgan", 41], ["disease", 52], ["entity", 60], ["with", 67], ["autosomal", 72], ["recessive", 82], ["inheritance", 92], ["characterized", 104], ["by", 118], ["oculocutaneous", 121], ["albinism", 136], [",", 144], ["bleeding", 146], ["tendency", 155], [",", 163], ["recurrent", 165], ["bacterial", 175], ["infections", 185], ["and", 196], ["various", 200], ["neurological", 208], ["symptoms", 221], [".", 229], ["Intracellular", 231], ["vesicle", 245], ["formation", 253], ["is", 263], ["deficient", 266], [",", 275], ["resulting", 277], ["in", 287], ["giant", 290], ["granules", 296], ["in", 305], ["many", 308], ["cells", 313], [",", 318], ["e.g.", 320], ["giant", 325], ["melanosomes", 331], ["in", 343], ["the", 346], ["melanocytes", 350], [".", 361], ["Diagnosis", 363], ["has", 373], ["been", 377], ["based", 382], ["on", 388], ["morphological", 391], ["examination", 405], ["of", 417], ["peripheral", 420], ["blood", 431], ["and", 437], ["bone", 441], ["marrow", 446], [",", 452], ["with", 454], ["giant", 459], ["granules", 465], ["seen", 474], ["in", 479], ["cells", 482], ["of", 488], ["the", 491], ["myeloid", 495], ["lineage", 503], ["and", 511], ["in", 515], ["lymphocytes", 518], [".", 529], ["The", 531], ["ultimate", 535], ["diagnostic", 544], ["test", 555], ["is", 560], ["to", 563], ["look", 566], ["for", 571], ["a", 575], ["mutated", 577], ["LYST", 585], ["gene", 590], [".", 594], ["Most", 596], ["patients", 601], ["develop", 610], ["an", 618], ["accelerated", 621], ["phase", 633], ["of", 639], ["the", 642], ["disease", 646], ["with", 654], ["deposition", 659], ["of", 670], ["lymphohistiocytes", 673], ["in", 691], ["the", 694], ["liver", 698], [",", 703], ["spleen", 705], [",", 711], ["lymph", 713], ["nodes", 719], ["and", 725], ["bone", 729], ["marrow", 734], [",", 740], ["resulting", 742], ["in", 752], ["hepatosplenomegaly", 755], [",", 773], ["bone", 775], ["marrow", 780], ["infiltration", 787], ["and", 800], ["haemophagocytosis", 804], [".", 821], ["Peripheral", 823], ["blood", 834], ["neutropenia", 840], ["becomes", 852], ["more", 860], ["profound", 865], ["as", 874], ["anaemia", 877], ["and", 885], ["thrombocytopenia", 889], ["develop", 906], [".", 913], ["Most", 915], ["patients", 920], ["succumb", 929], ["before", 937], ["the", 944], ["age", 948], ["of", 952], ["10", 955], ["years", 958], [".", 963], ["Four", 965], ["patients", 970], ["with", 979], ["CHS", 984], ["are", 988], ["described", 992], [",", 1001], ["one", 1003], ["of", 1007], ["whom", 1010], ["is", 1015], ["a", 1018], ["long", 1020], ["-", 1024], ["term", 1025], ["survivor", 1030], ["after", 1039], ["successful", 1045], ["allogeneic", 1056], ["bone", 1067], ["marrow", 1072], ["transplantation", 1079], [",", 1094], ["two", 1096], ["succumbed", 1100], ["during", 1110], ["the", 1117], ["accelerated", 1121], ["phase", 1133], ["and", 1139], ["one", 1143], ["is", 1147], ["living", 1150], ["with", 1157], ["a", 1162], ["chronic", 1164], ["form", 1172], ["of", 1177], ["the", 1180], ["disease", 1184], [".", 1191], ["Allogeneic", 1193], ["bone", 1204], ["marrow", 1209], ["transplantation", 1216], ["from", 1232], ["an", 1237], ["HLA", 1240], ["-", 1243], ["matched", 1244], ["sibling", 1252], ["is", 1260], ["the", 1263], ["therapy", 1267], ["of", 1275], ["choice", 1278], ["and", 1285], ["should", 1289], ["be", 1296], ["performed", 1299], ["early", 1309], [".", 1314], ["If", 1316], ["there", 1319], ["is", 1325], ["no", 1328], ["matched", 1331], ["family", 1339], ["donor", 1346], [",", 1351], ["an", 1353], ["unrelated", 1356], ["donor", 1366], ["or", 1372], ["a", 1375], ["placental", 1377], ["blood", 1387], ["graft", 1393], ["is", 1399], ["a", 1402], ["good", 1404], ["alternative", 1409], [".", 1420], ["The", 1422], ["clinical", 1426], ["picture", 1435], ["of", 1443], ["CHS", 1446], ["is", 1450], ["heterogeneous", 1453], ["and", 1467], ["therapeutic", 1471], ["decisions", 1483], ["need", 1493], ["to", 1498], ["be", 1501], ["made", 1504], ["on", 1509], ["an", 1512], ["individual", 1515], ["basis", 1526], [".", 1531]]}
{"context": "Treatment of CLL patients with conventional cytotoxic agents is often combined with significant toxicity that prevents broad application especially in elderly patients. In addition, relapse frequently occurs after application of conventional chemotherapy in CLL. Recently several new chemo-free treatment options have been introduced within clinical trials. Among them are monoclonal antibodies, most of them targeting the CD20 molecule: besides the licensed drugs rituximab and ofatumumab obinutuzumab, although in combination with chemotherapy, has recently shown high clinical efficacy in front-line treatment of elderly patients with CLL. Lenalidomide as monotherapy has demonstrated clinical efficacy in patients with relapsed disease and first data within clinical trials have been generated in the front-line setting. A promising class of novel agents has been designed to block aberrant signaling from the B-cell receptor. Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. Another class of drugs with potential impact for chemo-free treatment strategies in CLL are the BH3-mimetic inhibitors of the Bcl-2 family of pro-survival proteins. Other interesting candidate drugs that are currently explored for CLL patients include small modular immunopharmaceutical (SMIP) proteins (e. g. TRU-016), CDK inhibitors (e. g. dinaciclib), HDAC inhibitors and others. Given all these novel agents and targets, chemo-free or at least chemo-reduced concepts may become reality in the near future for our patients suffering from CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f2a99dbd8b2344b8b93f9e08e0029f24", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[146, 146]], "char_spans": [[931, 939]]}]}], "context_tokens": [["Treatment", 0], ["of", 10], ["CLL", 13], ["patients", 17], ["with", 26], ["conventional", 31], ["cytotoxic", 44], ["agents", 54], ["is", 61], ["often", 64], ["combined", 70], ["with", 79], ["significant", 84], ["toxicity", 96], ["that", 105], ["prevents", 110], ["broad", 119], ["application", 125], ["especially", 137], ["in", 148], ["elderly", 151], ["patients", 159], [".", 167], ["In", 169], ["addition", 172], [",", 180], ["relapse", 182], ["frequently", 190], ["occurs", 201], ["after", 208], ["application", 214], ["of", 226], ["conventional", 229], ["chemotherapy", 242], ["in", 255], ["CLL", 258], [".", 261], ["Recently", 263], ["several", 272], ["new", 280], ["chemo", 284], ["-", 289], ["free", 290], ["treatment", 295], ["options", 305], ["have", 313], ["been", 318], ["introduced", 323], ["within", 334], ["clinical", 341], ["trials", 350], [".", 356], ["Among", 358], ["them", 364], ["are", 369], ["monoclonal", 373], ["antibodies", 384], [",", 394], ["most", 396], ["of", 401], ["them", 404], ["targeting", 409], ["the", 419], ["CD20", 423], ["molecule", 428], [":", 436], ["besides", 438], ["the", 446], ["licensed", 450], ["drugs", 459], ["rituximab", 465], ["and", 475], ["ofatumumab", 479], ["obinutuzumab", 490], [",", 502], ["although", 504], ["in", 513], ["combination", 516], ["with", 528], ["chemotherapy", 533], [",", 545], ["has", 547], ["recently", 551], ["shown", 560], ["high", 566], ["clinical", 571], ["efficacy", 580], ["in", 589], ["front", 592], ["-", 597], ["line", 598], ["treatment", 603], ["of", 613], ["elderly", 616], ["patients", 624], ["with", 633], ["CLL", 638], [".", 641], ["Lenalidomide", 643], ["as", 656], ["monotherapy", 659], ["has", 671], ["demonstrated", 675], ["clinical", 688], ["efficacy", 697], ["in", 706], ["patients", 709], ["with", 718], ["relapsed", 723], ["disease", 732], ["and", 740], ["first", 744], ["data", 750], ["within", 755], ["clinical", 762], ["trials", 771], ["have", 778], ["been", 783], ["generated", 788], ["in", 798], ["the", 801], ["front", 805], ["-", 810], ["line", 811], ["setting", 816], [".", 823], ["A", 825], ["promising", 827], ["class", 837], ["of", 843], ["novel", 846], ["agents", 852], ["has", 859], ["been", 863], ["designed", 868], ["to", 877], ["block", 880], ["aberrant", 886], ["signaling", 895], ["from", 905], ["the", 910], ["B", 914], ["-", 915], ["cell", 916], ["receptor", 921], [".", 929], ["Ibrutinib", 931], ["acts", 941], ["by", 946], ["inhibiting", 949], ["the", 960], ["Bruton", 964], ["'s", 970], ["tyrosine", 973], ["kinase", 982], ["(", 989], ["BTK", 990], [")", 993], ["while", 995], ["idelalisib", 1001], ["represents", 1012], ["a", 1023], ["first", 1025], ["-", 1030], ["in", 1031], ["-", 1033], ["class", 1034], ["specific", 1040], ["inhibitor", 1049], ["of", 1059], ["the", 1062], ["phosphoinositol-3", 1066], ["kinase", 1084], ["(", 1091], ["PI3", 1092], ["K", 1095], [")", 1096], ["delta", 1098], ["isoform", 1104], [".", 1111], ["Another", 1113], ["class", 1121], ["of", 1127], ["drugs", 1130], ["with", 1136], ["potential", 1141], ["impact", 1151], ["for", 1158], ["chemo", 1162], ["-", 1167], ["free", 1168], ["treatment", 1173], ["strategies", 1183], ["in", 1194], ["CLL", 1197], ["are", 1201], ["the", 1205], ["BH3-mimetic", 1209], ["inhibitors", 1221], ["of", 1232], ["the", 1235], ["Bcl-2", 1239], ["family", 1245], ["of", 1252], ["pro", 1255], ["-", 1258], ["survival", 1259], ["proteins", 1268], [".", 1276], ["Other", 1278], ["interesting", 1284], ["candidate", 1296], ["drugs", 1306], ["that", 1312], ["are", 1317], ["currently", 1321], ["explored", 1331], ["for", 1340], ["CLL", 1344], ["patients", 1348], ["include", 1357], ["small", 1365], ["modular", 1371], ["immunopharmaceutical", 1379], ["(", 1400], ["SMIP", 1401], [")", 1405], ["proteins", 1407], ["(", 1416], ["e.", 1417], ["g.", 1420], ["TRU-016", 1423], [")", 1430], [",", 1431], ["CDK", 1433], ["inhibitors", 1437], ["(", 1448], ["e.", 1449], ["g.", 1452], ["dinaciclib", 1455], [")", 1465], [",", 1466], ["HDAC", 1468], ["inhibitors", 1473], ["and", 1484], ["others", 1488], [".", 1494], ["Given", 1496], ["all", 1502], ["these", 1506], ["novel", 1512], ["agents", 1518], ["and", 1525], ["targets", 1529], [",", 1536], ["chemo", 1538], ["-", 1543], ["free", 1544], ["or", 1549], ["at", 1552], ["least", 1555], ["chemo", 1561], ["-", 1566], ["reduced", 1567], ["concepts", 1575], ["may", 1584], ["become", 1588], ["reality", 1595], ["in", 1603], ["the", 1606], ["near", 1610], ["future", 1615], ["for", 1622], ["our", 1626], ["patients", 1630], ["suffering", 1639], ["from", 1649], ["CLL", 1654], [".", 1657]]}
{"context": "Reactive oxygen species are involved in ovulation. The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. Administration of antioxidants in vivo reduced ovulation rate and cumulus expansion. LH treatment increased H(2)O(2) levels within 15 min, which, in turn, induced Srx gene expression in cultured preovulatory follicles. Treatment of preovulatory follicles with catalase suppressed the stimulatory effect of LH on Akt phosphorylation. LH- or H(2)O(2)-stimulated Srx mRNA levels were suppressed by inhibitors of antioxidant agents and MAPK kinase. An in vivo injection of equine chorionic gonadotropin-human chorionic gonadotropin (hCG) stimulated Srx mRNA within 1 h in granulosa but not thecal cells of preovulatory follicles. Srx protein levels were stimulated from 3 h post-hCG injection. Immunofluorescence analysis revealed that oocytes expressed the Srx protein. Furthermore, hCG treatment increased Srx expression in mural granulosa, theca and cumulus cells, but the Srx protein was not detected in corpora lutea. Gene expression of PRDX2, identified as an Srx-dependent modified enzyme, was stimulated by gonadotropins. In situ hybridization analysis demonstrated that PRDX2 mRNA was detected in oocytes and theca cells as well as granulosa cells of some antral and preovulatory follicles. High levels of PRDX2 mRNA were detected in corpora lutea. Total levels of PRDX2 protein were not changed by gonadotropins. However, levels of hyperoxidized PRDX2 increased within 2-3 h after the hCG injection. Taken together, gonadotropin stimulation of Srx expression and PRDX2 modification in the ovary suggest the existence of an antioxidant system to maintain H(2)O(2) production and elimination during the periovulatory period.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "b7b765a669484522bfdfa013ced2bc9d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[104, 104], [295, 295], [19, 19]], "char_spans": [[657, 667], [1777, 1787], [115, 125]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["are", 24], ["involved", 28], ["in", 37], ["ovulation", 40], [".", 49], ["The", 51], ["aim", 55], ["of", 59], ["this", 62], ["study", 67], ["was", 73], ["to", 77], ["examine", 80], ["gonadotropin", 88], ["regulation", 101], ["of", 112], ["antioxidant", 115], ["enzyme", 127], ["sulfiredoxin", 134], ["(", 147], ["Srx", 148], [")", 151], ["and", 153], ["peroxiredoxin", 157], ["2", 171], ["(", 173], ["PRDX2", 174], [")", 179], ["expressions", 181], ["and", 193], ["modification", 197], ["during", 210], ["the", 217], ["ovulatory", 221], ["process", 231], ["in", 239], ["rats", 242], [".", 246], ["Administration", 248], ["of", 263], ["antioxidants", 266], ["in", 279], ["vivo", 282], ["reduced", 287], ["ovulation", 295], ["rate", 305], ["and", 310], ["cumulus", 314], ["expansion", 322], [".", 331], ["LH", 333], ["treatment", 336], ["increased", 346], ["H(2)O(2", 356], [")", 363], ["levels", 365], ["within", 372], ["15", 379], ["min", 382], [",", 385], ["which", 387], [",", 392], ["in", 394], ["turn", 397], [",", 401], ["induced", 403], ["Srx", 411], ["gene", 415], ["expression", 420], ["in", 431], ["cultured", 434], ["preovulatory", 443], ["follicles", 456], [".", 465], ["Treatment", 467], ["of", 477], ["preovulatory", 480], ["follicles", 493], ["with", 503], ["catalase", 508], ["suppressed", 517], ["the", 528], ["stimulatory", 532], ["effect", 544], ["of", 551], ["LH", 554], ["on", 557], ["Akt", 560], ["phosphorylation", 564], [".", 579], ["LH-", 581], ["or", 585], ["H(2)O(2)-stimulated", 588], ["Srx", 608], ["mRNA", 612], ["levels", 617], ["were", 624], ["suppressed", 629], ["by", 640], ["inhibitors", 643], ["of", 654], ["antioxidant", 657], ["agents", 669], ["and", 676], ["MAPK", 680], ["kinase", 685], [".", 691], ["An", 693], ["in", 696], ["vivo", 699], ["injection", 704], ["of", 714], ["equine", 717], ["chorionic", 724], ["gonadotropin", 734], ["-", 746], ["human", 747], ["chorionic", 753], ["gonadotropin", 763], ["(", 776], ["hCG", 777], [")", 780], ["stimulated", 782], ["Srx", 793], ["mRNA", 797], ["within", 802], ["1", 809], ["h", 811], ["in", 813], ["granulosa", 816], ["but", 826], ["not", 830], ["thecal", 834], ["cells", 841], ["of", 847], ["preovulatory", 850], ["follicles", 863], [".", 872], ["Srx", 874], ["protein", 878], ["levels", 886], ["were", 893], ["stimulated", 898], ["from", 909], ["3", 914], ["h", 916], ["post", 918], ["-", 922], ["hCG", 923], ["injection", 927], [".", 936], ["Immunofluorescence", 938], ["analysis", 957], ["revealed", 966], ["that", 975], ["oocytes", 980], ["expressed", 988], ["the", 998], ["Srx", 1002], ["protein", 1006], [".", 1013], ["Furthermore", 1015], [",", 1026], ["hCG", 1028], ["treatment", 1032], ["increased", 1042], ["Srx", 1052], ["expression", 1056], ["in", 1067], ["mural", 1070], ["granulosa", 1076], [",", 1085], ["theca", 1087], ["and", 1093], ["cumulus", 1097], ["cells", 1105], [",", 1110], ["but", 1112], ["the", 1116], ["Srx", 1120], ["protein", 1124], ["was", 1132], ["not", 1136], ["detected", 1140], ["in", 1149], ["corpora", 1152], ["lutea", 1160], [".", 1165], ["Gene", 1167], ["expression", 1172], ["of", 1183], ["PRDX2", 1186], [",", 1191], ["identified", 1193], ["as", 1204], ["an", 1207], ["Srx", 1210], ["-", 1213], ["dependent", 1214], ["modified", 1224], ["enzyme", 1233], [",", 1239], ["was", 1241], ["stimulated", 1245], ["by", 1256], ["gonadotropins", 1259], [".", 1272], ["In", 1274], ["situ", 1277], ["hybridization", 1282], ["analysis", 1296], ["demonstrated", 1305], ["that", 1318], ["PRDX2", 1323], ["mRNA", 1329], ["was", 1334], ["detected", 1338], ["in", 1347], ["oocytes", 1350], ["and", 1358], ["theca", 1362], ["cells", 1368], ["as", 1374], ["well", 1377], ["as", 1382], ["granulosa", 1385], ["cells", 1395], ["of", 1401], ["some", 1404], ["antral", 1409], ["and", 1416], ["preovulatory", 1420], ["follicles", 1433], [".", 1442], ["High", 1444], ["levels", 1449], ["of", 1456], ["PRDX2", 1459], ["mRNA", 1465], ["were", 1470], ["detected", 1475], ["in", 1484], ["corpora", 1487], ["lutea", 1495], [".", 1500], ["Total", 1502], ["levels", 1508], ["of", 1515], ["PRDX2", 1518], ["protein", 1524], ["were", 1532], ["not", 1537], ["changed", 1541], ["by", 1549], ["gonadotropins", 1552], [".", 1565], ["However", 1567], [",", 1574], ["levels", 1576], ["of", 1583], ["hyperoxidized", 1586], ["PRDX2", 1600], ["increased", 1606], ["within", 1616], ["2", 1623], ["-", 1624], ["3", 1625], ["h", 1627], ["after", 1629], ["the", 1635], ["hCG", 1639], ["injection", 1643], [".", 1652], ["Taken", 1654], ["together", 1660], [",", 1668], ["gonadotropin", 1670], ["stimulation", 1683], ["of", 1695], ["Srx", 1698], ["expression", 1702], ["and", 1713], ["PRDX2", 1717], ["modification", 1723], ["in", 1736], ["the", 1739], ["ovary", 1743], ["suggest", 1749], ["the", 1757], ["existence", 1761], ["of", 1771], ["an", 1774], ["antioxidant", 1777], ["system", 1789], ["to", 1796], ["maintain", 1799], ["H(2)O(2", 1808], [")", 1815], ["production", 1817], ["and", 1828], ["elimination", 1832], ["during", 1844], ["the", 1851], ["periovulatory", 1855], ["period", 1869], [".", 1875]]}
{"context": "Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "549c82a2fcb04e38a84c3f7661eeeaf0", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[7, 30]], "char_spans": [[50, 153]]}]}], "context_tokens": [["Biallelic", 0], ["mutations", 10], ["of", 20], ["the", 23], ["DNA", 27], ["annealing", 31], ["helicase", 41], ["SMARCAL1", 50], ["(", 59], ["SWI", 60], ["/", 63], ["SNF", 64], ["-", 67], ["related", 68], [",", 75], ["matrix", 77], ["-", 83], ["associated", 84], [",", 94], ["actin", 96], ["-", 101], ["dependent", 102], ["regulator", 112], ["of", 122], ["chromatin", 125], [",", 134], ["subfamily", 136], ["a", 146], ["-", 147], ["like", 148], ["1", 153], [")", 154], ["cause", 156], ["Schimke", 162], ["immuno", 170], ["-", 176], ["osseous", 177], ["dysplasia", 185], ["(", 195], ["SIOD", 196], [",", 200], ["MIM", 202], ["242900", 206], [")", 212], [",", 213], ["an", 215], ["incompletely", 218], ["penetrant", 231], ["autosomal", 241], ["recessive", 251], ["disorder", 261], [".", 269], ["Using", 271], ["human", 277], [",", 282], ["Drosophila", 284], ["and", 295], ["mouse", 299], ["models", 305], [",", 311], ["we", 313], ["show", 316], ["that", 321], ["the", 326], ["proteins", 330], ["encoded", 339], ["by", 347], ["SMARCAL1", 350], ["orthologs", 359], ["localize", 369], ["to", 378], ["transcriptionally", 381], ["active", 399], ["chromatin", 406], ["and", 416], ["modulate", 420], ["gene", 429], ["expression", 434], [".", 444], ["We", 446], ["also", 449], ["show", 454], ["that", 459], [",", 463], ["as", 465], ["found", 468], ["in", 474], ["SIOD", 477], ["patients", 482], [",", 490], ["deficiency", 492], ["of", 503], ["the", 506], ["SMARCAL1", 510], ["orthologs", 519], ["alone", 529], ["is", 535], ["insufficient", 538], ["to", 551], ["cause", 554], ["disease", 560], ["in", 568], ["fruit", 571], ["flies", 577], ["and", 583], ["mice", 587], [",", 591], ["although", 593], ["such", 602], ["deficiency", 607], ["causes", 618], ["modest", 625], ["diffuse", 632], ["alterations", 640], ["in", 652], ["gene", 655], ["expression", 660], [".", 670], ["Rather", 672], [",", 678], ["disease", 680], ["manifests", 688], ["when", 698], ["SMARCAL1", 703], ["deficiency", 712], ["interacts", 723], ["with", 733], ["genetic", 738], ["and", 746], ["environmental", 750], ["factors", 764], ["that", 772], ["further", 777], ["alter", 785], ["gene", 791], ["expression", 796], [".", 806], ["We", 808], ["conclude", 811], ["that", 820], ["the", 825], ["SMARCAL1", 829], ["annealing", 838], ["helicase", 848], ["buffers", 857], ["fluctuations", 865], ["in", 878], ["gene", 881], ["expression", 886], ["and", 897], ["that", 901], ["alterations", 906], ["in", 918], ["gene", 921], ["expression", 926], ["contribute", 937], ["to", 948], ["the", 951], ["penetrance", 955], ["of", 966], ["SIOD", 969], [".", 973]]}
{"context": "Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), may be the most common dominantly inherited ataxia in the world. Here I will review historical, clinical, neuropathological, genetic, and pathogenic features of MJD, and finish with a brief discussion of present, and possible future, treatment for this currently incurable disorder. Like many other dominantly inherited ataxias, MJD/SCA3 shows remarkable clinical heterogeneity, reflecting the underlying genetic defect: an unstable CAG trinucleotide repeat that varies in size among affected persons. This pathogenic repeat in MJD/SCA3 encodes an expanded tract of the amino acid glutamine in the disease protein, which is known as ataxin-3. MJD/SCA3 is one of nine identified polyglutamine neurodegenerative diseases which share features of pathogenesis centered on protein misfolding and accumulation. The specific properties of MJD/SCA3 and its disease protein are discussed in light of what is known about the entire class of polyglutamine diseases.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "789a207c9dc24db295601719ba0be075", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[128, 128]], "char_spans": [[715, 722]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["spinocerebellar", 44], ["ataxia", 60], ["type", 67], ["3", 72], ["(", 74], ["SCA3", 75], [")", 79], [",", 80], ["may", 82], ["be", 86], ["the", 89], ["most", 93], ["common", 98], ["dominantly", 105], ["inherited", 116], ["ataxia", 126], ["in", 133], ["the", 136], ["world", 140], [".", 145], ["Here", 147], ["I", 152], ["will", 154], ["review", 159], ["historical", 166], [",", 176], ["clinical", 178], [",", 186], ["neuropathological", 188], [",", 205], ["genetic", 207], [",", 214], ["and", 216], ["pathogenic", 220], ["features", 231], ["of", 240], ["MJD", 243], [",", 246], ["and", 248], ["finish", 252], ["with", 259], ["a", 264], ["brief", 266], ["discussion", 272], ["of", 283], ["present", 286], [",", 293], ["and", 295], ["possible", 299], ["future", 308], [",", 314], ["treatment", 316], ["for", 326], ["this", 330], ["currently", 335], ["incurable", 345], ["disorder", 355], [".", 363], ["Like", 365], ["many", 370], ["other", 375], ["dominantly", 381], ["inherited", 392], ["ataxias", 402], [",", 409], ["MJD", 411], ["/", 414], ["SCA3", 415], ["shows", 420], ["remarkable", 426], ["clinical", 437], ["heterogeneity", 446], [",", 459], ["reflecting", 461], ["the", 472], ["underlying", 476], ["genetic", 487], ["defect", 495], [":", 501], ["an", 503], ["unstable", 506], ["CAG", 515], ["trinucleotide", 519], ["repeat", 533], ["that", 540], ["varies", 545], ["in", 552], ["size", 555], ["among", 560], ["affected", 566], ["persons", 575], [".", 582], ["This", 584], ["pathogenic", 589], ["repeat", 600], ["in", 607], ["MJD", 610], ["/", 613], ["SCA3", 614], ["encodes", 619], ["an", 627], ["expanded", 630], ["tract", 639], ["of", 645], ["the", 648], ["amino", 652], ["acid", 658], ["glutamine", 663], ["in", 673], ["the", 676], ["disease", 680], ["protein", 688], [",", 695], ["which", 697], ["is", 703], ["known", 706], ["as", 712], ["ataxin-3", 715], [".", 723], ["MJD", 725], ["/", 728], ["SCA3", 729], ["is", 734], ["one", 737], ["of", 741], ["nine", 744], ["identified", 749], ["polyglutamine", 760], ["neurodegenerative", 774], ["diseases", 792], ["which", 801], ["share", 807], ["features", 813], ["of", 822], ["pathogenesis", 825], ["centered", 838], ["on", 847], ["protein", 850], ["misfolding", 858], ["and", 869], ["accumulation", 873], [".", 885], ["The", 887], ["specific", 891], ["properties", 900], ["of", 911], ["MJD", 914], ["/", 917], ["SCA3", 918], ["and", 923], ["its", 927], ["disease", 931], ["protein", 939], ["are", 947], ["discussed", 951], ["in", 961], ["light", 964], ["of", 970], ["what", 973], ["is", 978], ["known", 981], ["about", 987], ["the", 993], ["entire", 997], ["class", 1004], ["of", 1010], ["polyglutamine", 1013], ["diseases", 1027], [".", 1035]]}
{"context": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. The index case presented with an exacerbation of torsades de pointes ventricular tachycardia from diuretic induced hypokalaemia, and responded to diuretic withdrawal and beta blocker therapy.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "f3e0556321574bc9984f02992df32320", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[193, 210]]}]}], "context_tokens": [["A", 0], ["family", 2], ["with", 9], ["the", 14], ["Romano", 18], ["-", 24], ["Ward", 25], ["syndrome", 30], ["is", 39], ["presented", 42], [".", 51], ["This", 53], ["family", 58], ["showed", 65], ["typical", 72], ["features", 80], ["of", 89], ["this", 92], ["syndrome", 97], ["with", 106], ["QT", 111], ["prolongation", 114], [",", 126], ["torsades", 128], ["de", 137], ["pointes", 140], ["ventricular", 148], ["tachycardia", 160], [",", 171], ["sudden", 173], ["death", 180], ["and", 186], ["an", 190], ["autosomal", 193], ["dominant", 203], ["inheritance", 212], ["pattern", 224], [".", 231], ["The", 233], ["index", 237], ["case", 243], ["presented", 248], ["with", 258], ["an", 263], ["exacerbation", 266], ["of", 279], ["torsades", 282], ["de", 291], ["pointes", 294], ["ventricular", 302], ["tachycardia", 314], ["from", 326], ["diuretic", 331], ["induced", 340], ["hypokalaemia", 348], [",", 360], ["and", 362], ["responded", 366], ["to", 376], ["diuretic", 379], ["withdrawal", 388], ["and", 399], ["beta", 403], ["blocker", 408], ["therapy", 416], [".", 423]]}
{"context": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1), also known as HARP, is an ATP-dependent annealing helicase that stabilizes replication forks during DNA damage. Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions. In this review, we summarize the main roles of SMARCAL1 in DNA repair, telomere maintenance and replication fork stability in response to DNA replication stress.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "HARP"], "qid": "94ca9bf4ee72459085a2b6464d531562", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[0, 20]], "char_spans": [[0, 103]]}, {"text": "HARP", "token_spans": [[26, 26]], "char_spans": [[121, 124]]}]}], "context_tokens": [["SMARCAL1", 0], ["(", 9], ["SWI", 10], ["/", 13], ["SNF", 14], ["Related", 18], [",", 25], ["Matrix", 27], ["Associated", 34], [",", 44], ["Actin", 46], ["Dependent", 52], ["Regulator", 62], ["Of", 72], ["Chromatin", 75], [",", 84], ["Subfamily", 86], ["A", 96], ["-", 97], ["Like", 98], ["1", 103], [")", 104], [",", 105], ["also", 107], ["known", 112], ["as", 118], ["HARP", 121], [",", 125], ["is", 127], ["an", 130], ["ATP", 133], ["-", 136], ["dependent", 137], ["annealing", 147], ["helicase", 157], ["that", 166], ["stabilizes", 171], ["replication", 182], ["forks", 194], ["during", 200], ["DNA", 207], ["damage", 211], [".", 217], ["Mutations", 219], ["in", 229], ["this", 232], ["gene", 237], ["are", 242], ["the", 246], ["cause", 250], ["of", 256], ["Schimke", 259], ["immune", 267], ["-", 273], ["osseous", 274], ["dysplasia", 282], ["(", 292], ["SIOD", 293], [")", 297], [",", 298], ["an", 300], ["autosomal", 303], ["recessive", 313], ["disorder", 323], ["characterized", 332], ["by", 346], ["T", 349], ["-", 350], ["cell", 351], ["immunodeficiency", 356], ["and", 373], ["growth", 377], ["dysfunctions", 384], [".", 396], ["In", 398], ["this", 401], ["review", 406], [",", 412], ["we", 414], ["summarize", 417], ["the", 427], ["main", 431], ["roles", 436], ["of", 442], ["SMARCAL1", 445], ["in", 454], ["DNA", 457], ["repair", 461], [",", 467], ["telomere", 469], ["maintenance", 478], ["and", 490], ["replication", 494], ["fork", 506], ["stability", 511], ["in", 521], ["response", 524], ["to", 533], ["DNA", 536], ["replication", 540], ["stress", 552], [".", 558]]}
{"context": "During 1970 and 1971, I discovered that a devastating disease of potato plants is not caused by a virus, as had been assumed, but by a new type of subviral pathogen, the viroid. Viroids are so small--one fiftieth of the size of the smallest viruses--that many scientists initially doubted their existence. We now know that viroids cause many damaging diseases of crop plants. Fortunately, new methods that are based on the unique properties of viroids now promise effective control.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "bb93a89c6e904635a4afe3015d50c0e3", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[65, 65], [86, 86], [38, 38]], "char_spans": [[323, 329], [444, 450], [178, 184]]}]}], "context_tokens": [["During", 0], ["1970", 7], ["and", 12], ["1971", 16], [",", 20], ["I", 22], ["discovered", 24], ["that", 35], ["a", 40], ["devastating", 42], ["disease", 54], ["of", 62], ["potato", 65], ["plants", 72], ["is", 79], ["not", 82], ["caused", 86], ["by", 93], ["a", 96], ["virus", 98], [",", 103], ["as", 105], ["had", 108], ["been", 112], ["assumed", 117], [",", 124], ["but", 126], ["by", 130], ["a", 133], ["new", 135], ["type", 139], ["of", 144], ["subviral", 147], ["pathogen", 156], [",", 164], ["the", 166], ["viroid", 170], [".", 176], ["Viroids", 178], ["are", 186], ["so", 190], ["small", 193], ["--", 198], ["one", 200], ["fiftieth", 204], ["of", 213], ["the", 216], ["size", 220], ["of", 225], ["the", 228], ["smallest", 232], ["viruses", 241], ["--", 248], ["that", 250], ["many", 255], ["scientists", 260], ["initially", 271], ["doubted", 281], ["their", 289], ["existence", 295], [".", 304], ["We", 306], ["now", 309], ["know", 313], ["that", 318], ["viroids", 323], ["cause", 331], ["many", 337], ["damaging", 342], ["diseases", 351], ["of", 360], ["crop", 363], ["plants", 368], [".", 374], ["Fortunately", 376], [",", 387], ["new", 389], ["methods", 393], ["that", 401], ["are", 406], ["based", 410], ["on", 416], ["the", 419], ["unique", 423], ["properties", 430], ["of", 441], ["viroids", 444], ["now", 452], ["promise", 456], ["effective", 464], ["control", 474], [".", 481]]}
{"context": "Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease. Although the pathogenic mechanisms of RLS are not entirely understood, it is becoming increasingly evident that many diseases such as RLS can be attributed to an epistasis. The study objectives were to evaluate whether the associations of RLS with all loci determined in previous GWAS for Caucasians can be replicated significantly for the Korean population and to elucidate whether an epistasis plays a role in the pathogenesis of RLS. DNA from 320 patients with RLS and 320 age- and sex-matched controls were genotyped for variants in the RLS loci. A significant association was found for rs3923809 and rs9296249 in BTBD9 (P < 0.0001 and P = 0.001, respectively); the odds ratio (OR) for rs3923809 was 1.61 (P < 0.0001) to 1.88 (P < 0.0001) and the OR for rs9296249 was 1.44 (P = 0.001) to 1.73 (P = 0.002), according to the model of inheritance. The OR for the interaction between rs3923809 in BTBD9 and rs4626664 in PTPRD was 2.05 (P < 0.0001) in the additive model, 1.80 (P = 0.002) in the dominant model and 2.47 (P = 0.004) in the recessive model. There was no significant association between genotypes of all tested single nucleotide polymorphisms and the mean value of serum iron parameters. Our results suggest that the role of BTBD9 in the pathogenesis of restless legs syndrome is more universal across populations than previously reported and more efforts should be focused on the role of epistasis in the genetic architecture of restless legs syndrome.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "82ca01123a974473aaa47dcd81f47ba5", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23], [284, 286], [311, 313]], "char_spans": [[142, 163], [1475, 1496], [1651, 1672]]}]}], "context_tokens": [["Recent", 0], ["genome", 7], ["-", 13], ["wide", 14], ["association", 19], ["studies", 31], ["(", 39], ["GWAS", 40], [")", 44], ["for", 46], ["Caucasians", 50], ["identified", 61], ["several", 72], ["allelic", 80], ["variants", 88], ["associated", 97], ["with", 108], ["increased", 113], ["risk", 123], ["of", 128], ["developing", 131], ["restless", 142], ["legs", 151], ["syndrome", 156], ["(", 165], ["RLS", 166], [")", 169], [",", 170], ["also", 172], ["known", 177], ["as", 183], ["Willis", 186], ["-", 192], ["Ekbom", 193], ["disease", 199], [".", 206], ["Although", 208], ["the", 217], ["pathogenic", 221], ["mechanisms", 232], ["of", 243], ["RLS", 246], ["are", 250], ["not", 254], ["entirely", 258], ["understood", 267], [",", 277], ["it", 279], ["is", 282], ["becoming", 285], ["increasingly", 294], ["evident", 307], ["that", 315], ["many", 320], ["diseases", 325], ["such", 334], ["as", 339], ["RLS", 342], ["can", 346], ["be", 350], ["attributed", 353], ["to", 364], ["an", 367], ["epistasis", 370], [".", 379], ["The", 381], ["study", 385], ["objectives", 391], ["were", 402], ["to", 407], ["evaluate", 410], ["whether", 419], ["the", 427], ["associations", 431], ["of", 444], ["RLS", 447], ["with", 451], ["all", 456], ["loci", 460], ["determined", 465], ["in", 476], ["previous", 479], ["GWAS", 488], ["for", 493], ["Caucasians", 497], ["can", 508], ["be", 512], ["replicated", 515], ["significantly", 526], ["for", 540], ["the", 544], ["Korean", 548], ["population", 555], ["and", 566], ["to", 570], ["elucidate", 573], ["whether", 583], ["an", 591], ["epistasis", 594], ["plays", 604], ["a", 610], ["role", 612], ["in", 617], ["the", 620], ["pathogenesis", 624], ["of", 637], ["RLS", 640], [".", 643], ["DNA", 645], ["from", 649], ["320", 654], ["patients", 658], ["with", 667], ["RLS", 672], ["and", 676], ["320", 680], ["age-", 684], ["and", 689], ["sex", 693], ["-", 696], ["matched", 697], ["controls", 705], ["were", 714], ["genotyped", 719], ["for", 729], ["variants", 733], ["in", 742], ["the", 745], ["RLS", 749], ["loci", 753], [".", 757], ["A", 759], ["significant", 761], ["association", 773], ["was", 785], ["found", 789], ["for", 795], ["rs3923809", 799], ["and", 809], ["rs9296249", 813], ["in", 823], ["BTBD9", 826], ["(", 832], ["P", 833], ["<", 835], ["0.0001", 837], ["and", 844], ["P", 848], ["=", 850], ["0.001", 852], [",", 857], ["respectively", 859], [")", 871], [";", 872], ["the", 874], ["odds", 878], ["ratio", 883], ["(", 889], ["OR", 890], [")", 892], ["for", 894], ["rs3923809", 898], ["was", 908], ["1.61", 912], ["(", 917], ["P", 918], ["<", 920], ["0.0001", 922], [")", 928], ["to", 930], ["1.88", 933], ["(", 938], ["P", 939], ["<", 941], ["0.0001", 943], [")", 949], ["and", 951], ["the", 955], ["OR", 959], ["for", 962], ["rs9296249", 966], ["was", 976], ["1.44", 980], ["(", 985], ["P", 986], ["=", 988], ["0.001", 990], [")", 995], ["to", 997], ["1.73", 1000], ["(", 1005], ["P", 1006], ["=", 1008], ["0.002", 1010], [")", 1015], [",", 1016], ["according", 1018], ["to", 1028], ["the", 1031], ["model", 1035], ["of", 1041], ["inheritance", 1044], [".", 1055], ["The", 1057], ["OR", 1061], ["for", 1064], ["the", 1068], ["interaction", 1072], ["between", 1084], ["rs3923809", 1092], ["in", 1102], ["BTBD9", 1105], ["and", 1111], ["rs4626664", 1115], ["in", 1125], ["PTPRD", 1128], ["was", 1134], ["2.05", 1138], ["(", 1143], ["P", 1144], ["<", 1146], ["0.0001", 1148], [")", 1154], ["in", 1156], ["the", 1159], ["additive", 1163], ["model", 1172], [",", 1177], ["1.80", 1179], ["(", 1184], ["P", 1185], ["=", 1187], ["0.002", 1189], [")", 1194], ["in", 1196], ["the", 1199], ["dominant", 1203], ["model", 1212], ["and", 1218], ["2.47", 1222], ["(", 1227], ["P", 1228], ["=", 1230], ["0.004", 1232], [")", 1237], ["in", 1239], ["the", 1242], ["recessive", 1246], ["model", 1256], [".", 1261], ["There", 1263], ["was", 1269], ["no", 1273], ["significant", 1276], ["association", 1288], ["between", 1300], ["genotypes", 1308], ["of", 1318], ["all", 1321], ["tested", 1325], ["single", 1332], ["nucleotide", 1339], ["polymorphisms", 1350], ["and", 1364], ["the", 1368], ["mean", 1372], ["value", 1377], ["of", 1383], ["serum", 1386], ["iron", 1392], ["parameters", 1397], [".", 1407], ["Our", 1409], ["results", 1413], ["suggest", 1421], ["that", 1429], ["the", 1434], ["role", 1438], ["of", 1443], ["BTBD9", 1446], ["in", 1452], ["the", 1455], ["pathogenesis", 1459], ["of", 1472], ["restless", 1475], ["legs", 1484], ["syndrome", 1489], ["is", 1498], ["more", 1501], ["universal", 1506], ["across", 1516], ["populations", 1523], ["than", 1535], ["previously", 1540], ["reported", 1551], ["and", 1560], ["more", 1564], ["efforts", 1569], ["should", 1577], ["be", 1584], ["focused", 1587], ["on", 1595], ["the", 1598], ["role", 1602], ["of", 1607], ["epistasis", 1610], ["in", 1620], ["the", 1623], ["genetic", 1627], ["architecture", 1635], ["of", 1648], ["restless", 1651], ["legs", 1660], ["syndrome", 1665], [".", 1673]]}
{"context": "Recent reports have described a distinct and recurrent pattern of systemic malformation that associates craniosynostosis and neurodevelopmental abnormalities with many clinical features of the Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular microfibril caused by defects in the gene encoding fibrillin-1, FBN1 (ref. 8). Additional common findings include other craniofacial anomalies, hypotonia, obstructive apnea, foot deformity, and congenital weakness of the abdominal wall. So far, only 11 cases have been reported precluding the assignment of definitive diagnostic criteria. While it remains unclear whether these cases represent a discrete clinical entity with a single aetiology, they have been pragmatically grouped under the rubric Marfanoid-craniosynostosis or Shprintzen-Goldberg syndrome (SGS). Because of the significant clinical overlap between MFS and SGS, we proposed that they may be caused by allelic mutations. We now report two SGS patients who harbour mutations in FBN1. While it remains unclear whether these mutations are sufficient for the clinical expression of the entire SGS phenotype, these data suggest a role for fibrillin-1 in early craniofacial and central nervous system development. Our recent observation that FBN1 transcript is expressed as early as the 8-cell stage of human embryogenesis is consistent with this hypothesis.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0d848258b8d84a2a99aa7452c73c0752", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[121, 121], [14, 14]], "char_spans": [[778, 793], [104, 119]]}]}], "context_tokens": [["Recent", 0], ["reports", 7], ["have", 15], ["described", 20], ["a", 30], ["distinct", 32], ["and", 41], ["recurrent", 45], ["pattern", 55], ["of", 63], ["systemic", 66], ["malformation", 75], ["that", 88], ["associates", 93], ["craniosynostosis", 104], ["and", 121], ["neurodevelopmental", 125], ["abnormalities", 144], ["with", 158], ["many", 163], ["clinical", 168], ["features", 177], ["of", 186], ["the", 189], ["Marfan", 193], ["syndrome", 200], ["(", 209], ["MFS", 210], [")", 213], [",", 214], ["an", 216], ["autosomal", 219], ["dominant", 229], ["disorder", 238], ["of", 247], ["the", 250], ["extracellular", 254], ["microfibril", 268], ["caused", 280], ["by", 287], ["defects", 290], ["in", 298], ["the", 301], ["gene", 305], ["encoding", 310], ["fibrillin-1", 319], [",", 330], ["FBN1", 332], ["(", 337], ["ref", 338], [".", 341], ["8)", 343], [".", 345], ["Additional", 347], ["common", 358], ["findings", 365], ["include", 374], ["other", 382], ["craniofacial", 388], ["anomalies", 401], [",", 410], ["hypotonia", 412], [",", 421], ["obstructive", 423], ["apnea", 435], [",", 440], ["foot", 442], ["deformity", 447], [",", 456], ["and", 458], ["congenital", 462], ["weakness", 473], ["of", 482], ["the", 485], ["abdominal", 489], ["wall", 499], [".", 503], ["So", 505], ["far", 508], [",", 511], ["only", 513], ["11", 518], ["cases", 521], ["have", 527], ["been", 532], ["reported", 537], ["precluding", 546], ["the", 557], ["assignment", 561], ["of", 572], ["definitive", 575], ["diagnostic", 586], ["criteria", 597], [".", 605], ["While", 607], ["it", 613], ["remains", 616], ["unclear", 624], ["whether", 632], ["these", 640], ["cases", 646], ["represent", 652], ["a", 662], ["discrete", 664], ["clinical", 673], ["entity", 682], ["with", 689], ["a", 694], ["single", 696], ["aetiology", 703], [",", 712], ["they", 714], ["have", 719], ["been", 724], ["pragmatically", 729], ["grouped", 743], ["under", 751], ["the", 757], ["rubric", 761], ["Marfanoid", 768], ["-", 777], ["craniosynostosis", 778], ["or", 795], ["Shprintzen", 798], ["-", 808], ["Goldberg", 809], ["syndrome", 818], ["(", 827], ["SGS", 828], [")", 831], [".", 832], ["Because", 834], ["of", 842], ["the", 845], ["significant", 849], ["clinical", 861], ["overlap", 870], ["between", 878], ["MFS", 886], ["and", 890], ["SGS", 894], [",", 897], ["we", 899], ["proposed", 902], ["that", 911], ["they", 916], ["may", 921], ["be", 925], ["caused", 928], ["by", 935], ["allelic", 938], ["mutations", 946], [".", 955], ["We", 957], ["now", 960], ["report", 964], ["two", 971], ["SGS", 975], ["patients", 979], ["who", 988], ["harbour", 992], ["mutations", 1000], ["in", 1010], ["FBN1", 1013], [".", 1017], ["While", 1019], ["it", 1025], ["remains", 1028], ["unclear", 1036], ["whether", 1044], ["these", 1052], ["mutations", 1058], ["are", 1068], ["sufficient", 1072], ["for", 1083], ["the", 1087], ["clinical", 1091], ["expression", 1100], ["of", 1111], ["the", 1114], ["entire", 1118], ["SGS", 1125], ["phenotype", 1129], [",", 1138], ["these", 1140], ["data", 1146], ["suggest", 1151], ["a", 1159], ["role", 1161], ["for", 1166], ["fibrillin-1", 1170], ["in", 1182], ["early", 1185], ["craniofacial", 1191], ["and", 1204], ["central", 1208], ["nervous", 1216], ["system", 1224], ["development", 1231], [".", 1242], ["Our", 1244], ["recent", 1248], ["observation", 1255], ["that", 1267], ["FBN1", 1272], ["transcript", 1277], ["is", 1288], ["expressed", 1291], ["as", 1301], ["early", 1304], ["as", 1310], ["the", 1313], ["8-cell", 1317], ["stage", 1324], ["of", 1330], ["human", 1333], ["embryogenesis", 1339], ["is", 1353], ["consistent", 1356], ["with", 1367], ["this", 1372], ["hypothesis", 1377], [".", 1387]]}
{"context": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells. The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs. Mouse embryomic fibroblasts (MEFs) lacking TIA-1 exhibit impaired ability to form SGs, although they exhibit normal phosphorylation of eukaryotic initiation factor (eIF)2alpha in response to arsenite. Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress.", "qas": [{"question": "Which domain of TIA-1 is necessary for stress granule assembly?", "answers": ["The glutamine-rich prion-related domain (PRD)"], "qid": "b0c5cb7e458c48f9a369b023a6f154ef", "question_tokens": [["Which", 0], ["domain", 6], ["of", 13], ["TIA-1", 16], ["is", 22], ["necessary", 25], ["for", 35], ["stress", 39], ["granule", 46], ["assembly", 54], ["?", 62]], "detected_answers": [{"text": "The glutamine-rich prion-related domain (PRD)", "token_spans": [[46, 54]], "char_spans": [[291, 330]]}]}], "context_tokens": [["TIA-1", 0], ["is", 6], ["an", 9], ["RNA", 12], ["binding", 16], ["protein", 24], ["that", 32], ["promotes", 37], ["the", 46], ["assembly", 50], ["of", 59], ["stress", 62], ["granules", 69], ["(", 78], ["SGs", 79], [")", 82], [",", 83], ["discrete", 85], ["cytoplasmic", 94], ["inclusions", 106], ["into", 117], ["which", 122], ["stalled", 128], ["translation", 136], ["initiation", 148], ["complexes", 159], ["are", 169], ["dynamically", 173], ["recruited", 185], ["in", 195], ["cells", 198], ["subjected", 204], ["to", 214], ["environmental", 217], ["stress", 231], [".", 237], ["The", 239], ["RNA", 243], ["recognition", 247], ["motifs", 259], ["of", 266], ["TIA-1", 269], ["are", 275], ["linked", 279], ["to", 286], ["a", 289], ["glutamine", 291], ["-", 300], ["rich", 301], ["prion", 306], ["-", 311], ["related", 312], ["domain", 320], ["(", 327], ["PRD", 328], [")", 331], [".", 332], ["Truncation", 334], ["mutants", 345], ["lacking", 353], ["the", 361], ["PRD", 365], ["domain", 369], ["do", 376], ["not", 379], ["induce", 383], ["spontaneous", 390], ["SGs", 402], ["and", 406], ["are", 410], ["not", 414], ["recruited", 418], ["to", 428], ["arsenite", 431], ["-", 439], ["induced", 440], ["SGs", 448], [",", 451], ["whereas", 453], ["the", 461], ["PRD", 465], ["forms", 469], ["aggregates", 475], ["that", 486], ["are", 491], ["recruited", 495], ["to", 505], ["SGs", 508], ["in", 512], ["low", 515], ["-", 518], ["level", 519], ["-", 524], ["expressing", 525], ["cells", 536], ["but", 542], ["prevent", 546], ["SG", 554], ["assembly", 557], ["in", 566], ["high", 569], ["-", 573], ["level", 574], ["-", 579], ["expressing", 580], ["cells", 591], [".", 596], ["The", 598], ["PRD", 602], ["of", 606], ["TIA-1", 609], ["exhibits", 615], ["many", 624], ["characteristics", 629], ["of", 645], ["prions", 648], [":", 654], ["concentration", 656], ["-", 669], ["dependent", 670], ["aggregation", 680], ["that", 692], ["is", 697], ["inhibited", 700], ["by", 710], ["the", 713], ["molecular", 717], ["chaperone", 727], ["heat", 737], ["shock", 742], ["protein", 748], ["(", 756], ["HSP)70", 757], [";", 763], ["resistance", 765], ["to", 776], ["protease", 779], ["digestion", 788], [";", 797], ["sequestration", 799], ["of", 813], ["HSP27", 816], [",", 821], ["HSP40", 823], [",", 828], ["and", 830], ["HSP70", 834], [";", 839], ["and", 841], ["induction", 845], ["of", 855], ["HSP70", 858], [",", 863], ["a", 865], ["feedback", 867], ["regulator", 876], ["of", 886], ["PRD", 889], ["disaggregation", 893], [".", 907], ["Substitution", 909], ["of", 922], ["the", 925], ["PRD", 929], ["with", 933], ["the", 938], ["aggregation", 942], ["domain", 954], ["of", 961], ["a", 964], ["yeast", 966], ["prion", 972], [",", 977], ["SUP35-NM", 979], [",", 987], ["reconstitutes", 989], ["SG", 1003], ["assembly", 1006], [",", 1014], ["confirming", 1016], ["that", 1027], ["a", 1032], ["prion", 1034], ["domain", 1040], ["can", 1047], ["mediate", 1051], ["the", 1059], ["assembly", 1063], ["of", 1072], ["SGs", 1075], [".", 1078], ["Mouse", 1080], ["embryomic", 1086], ["fibroblasts", 1096], ["(", 1108], ["MEFs", 1109], [")", 1113], ["lacking", 1115], ["TIA-1", 1123], ["exhibit", 1129], ["impaired", 1137], ["ability", 1146], ["to", 1154], ["form", 1157], ["SGs", 1162], [",", 1165], ["although", 1167], ["they", 1176], ["exhibit", 1181], ["normal", 1189], ["phosphorylation", 1196], ["of", 1212], ["eukaryotic", 1215], ["initiation", 1226], ["factor", 1237], ["(", 1244], ["eIF)2alpha", 1245], ["in", 1256], ["response", 1259], ["to", 1268], ["arsenite", 1271], [".", 1279], ["Our", 1281], ["results", 1285], ["reveal", 1293], ["that", 1300], ["prion", 1305], ["-", 1310], ["like", 1311], ["aggregation", 1316], ["of", 1328], ["TIA-1", 1331], ["regulates", 1337], ["SG", 1347], ["formation", 1350], ["downstream", 1360], ["of", 1371], ["eIF2alpha", 1374], ["phosphorylation", 1384], ["in", 1400], ["response", 1403], ["to", 1412], ["stress", 1415], [".", 1421]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. The under-expression of PRDX2 observed in DS samples was confirmed by real-time PCR (0.73-fold). To test whether decreased expression is associated with enhanced sensitivity of DS neurons to reactive oxygen species, we down-regulated PRDX2 through stable transfections of SH-SY5Y neuroblastoma cells with antisense contructs of the complete PRDX2 coding sequence. In addition, we over-expressed SOD1 and compared the effects of the two genes on cell viability. Cells transfected with either construct showed similar sensitivity to oxidative stress in addition to increased apoptosis under basal conditions and after treatment with oxidative cytotoxic agents. This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "733e977ad4f14caf9148b8dbb151fd8c", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[30, 30]], "char_spans": [[195, 205]]}]}], "context_tokens": [["Suppression", 0], ["subtractive", 12], ["hybridization", 24], ["performed", 38], ["on", 48], ["Down", 51], ["syndrome", 56], ["(", 65], ["DS", 66], [")", 68], ["versus", 70], ["control", 77], ["fetal", 85], ["brains", 91], ["revealed", 98], ["differential", 107], ["expression", 120], ["of", 131], ["peroxiredoxin", 134], ["2", 148], ["(", 150], ["PRDX2", 151], [")", 156], [",", 157], ["mapped", 159], ["at", 166], ["13q12", 169], [".", 174], ["Peroxiredoxins", 176], ["are", 191], ["antioxidant", 195], ["enzymes", 207], ["involved", 215], ["in", 224], ["protein", 227], ["and", 235], ["lipid", 239], ["protection", 245], ["against", 256], ["oxidative", 264], ["injury", 274], ["and", 281], ["in", 285], ["cellular", 288], ["signalling", 297], ["pathways", 308], ["regulating", 317], ["apoptosis", 328], [".", 337], ["The", 339], ["under", 343], ["-", 348], ["expression", 349], ["of", 360], ["PRDX2", 363], ["observed", 369], ["in", 378], ["DS", 381], ["samples", 384], ["was", 392], ["confirmed", 396], ["by", 406], ["real", 409], ["-", 413], ["time", 414], ["PCR", 419], ["(", 423], ["0.73-fold", 424], [")", 433], [".", 434], ["To", 436], ["test", 439], ["whether", 444], ["decreased", 452], ["expression", 462], ["is", 473], ["associated", 476], ["with", 487], ["enhanced", 492], ["sensitivity", 501], ["of", 513], ["DS", 516], ["neurons", 519], ["to", 527], ["reactive", 530], ["oxygen", 539], ["species", 546], [",", 553], ["we", 555], ["down", 558], ["-", 562], ["regulated", 563], ["PRDX2", 573], ["through", 579], ["stable", 587], ["transfections", 594], ["of", 608], ["SH", 611], ["-", 613], ["SY5Y", 614], ["neuroblastoma", 619], ["cells", 633], ["with", 639], ["antisense", 644], ["contructs", 654], ["of", 664], ["the", 667], ["complete", 671], ["PRDX2", 680], ["coding", 686], ["sequence", 693], [".", 701], ["In", 703], ["addition", 706], [",", 714], ["we", 716], ["over", 719], ["-", 723], ["expressed", 724], ["SOD1", 734], ["and", 739], ["compared", 743], ["the", 752], ["effects", 756], ["of", 764], ["the", 767], ["two", 771], ["genes", 775], ["on", 781], ["cell", 784], ["viability", 789], [".", 798], ["Cells", 800], ["transfected", 806], ["with", 818], ["either", 823], ["construct", 830], ["showed", 840], ["similar", 847], ["sensitivity", 855], ["to", 867], ["oxidative", 870], ["stress", 880], ["in", 887], ["addition", 890], ["to", 899], ["increased", 902], ["apoptosis", 912], ["under", 922], ["basal", 928], ["conditions", 934], ["and", 945], ["after", 949], ["treatment", 955], ["with", 965], ["oxidative", 970], ["cytotoxic", 980], ["agents", 990], [".", 996], ["This", 998], ["suggests", 1003], ["that", 1012], ["the", 1017], ["decreased", 1021], ["expression", 1031], ["of", 1042], ["PRDX2", 1045], ["may", 1051], ["contribute", 1055], ["to", 1066], ["the", 1069], ["altered", 1073], ["redox", 1081], ["state", 1087], ["in", 1093], ["DS", 1096], ["at", 1099], ["levels", 1102], ["comparable", 1109], ["to", 1120], ["that", 1123], ["of", 1128], ["the", 1131], ["increased", 1135], ["expression", 1145], ["of", 1156], ["SOD1", 1159], [".", 1163]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "A monoclonal antibody (mAb) has been produced which reacts with human mitofilin, a mitochondrial inner membrane protein. This mAb immunocaptures its target protein in association with six other proteins, metaxins 1 and 2, SAM50, CHCHD3, CHCHD6 and DnaJC11, respectively. The first three are outer membrane proteins, CHCHD3 has been assigned to the matrix space, and the other two proteins have not been described in mitochondria previously. The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", "qas": [{"question": "What is the localization of the protein encoded by the gene DNAJC11?", "answers": ["mitochondrial inner membrane"], "qid": "8c2a0605602f461d93cb146b331734aa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["localization", 12], ["of", 25], ["the", 28], ["protein", 32], ["encoded", 40], ["by", 48], ["the", 51], ["gene", 55], ["DNAJC11", 60], ["?", 67]], "detected_answers": [{"text": "mitochondrial inner membrane", "token_spans": [[16, 18]], "char_spans": [[83, 110]]}]}], "context_tokens": [["A", 0], ["monoclonal", 2], ["antibody", 13], ["(", 22], ["mAb", 23], [")", 26], ["has", 28], ["been", 32], ["produced", 37], ["which", 46], ["reacts", 52], ["with", 59], ["human", 64], ["mitofilin", 70], [",", 79], ["a", 81], ["mitochondrial", 83], ["inner", 97], ["membrane", 103], ["protein", 112], [".", 119], ["This", 121], ["mAb", 126], ["immunocaptures", 130], ["its", 145], ["target", 149], ["protein", 156], ["in", 164], ["association", 167], ["with", 179], ["six", 184], ["other", 188], ["proteins", 194], [",", 202], ["metaxins", 204], ["1", 213], ["and", 215], ["2", 219], [",", 220], ["SAM50", 222], [",", 227], ["CHCHD3", 229], [",", 235], ["CHCHD6", 237], ["and", 244], ["DnaJC11", 248], [",", 255], ["respectively", 257], [".", 269], ["The", 271], ["first", 275], ["three", 281], ["are", 287], ["outer", 291], ["membrane", 297], ["proteins", 306], [",", 314], ["CHCHD3", 316], ["has", 323], ["been", 327], ["assigned", 332], ["to", 341], ["the", 344], ["matrix", 348], ["space", 355], [",", 360], ["and", 362], ["the", 366], ["other", 370], ["two", 376], ["proteins", 380], ["have", 389], ["not", 394], ["been", 398], ["described", 403], ["in", 413], ["mitochondria", 416], ["previously", 429], [".", 439], ["The", 441], ["functional", 445], ["role", 456], ["of", 461], ["this", 464], ["new", 469], ["complex", 473], ["is", 481], ["uncertain", 484], [".", 493], ["However", 495], [",", 502], ["a", 504], ["role", 506], ["in", 511], ["protein", 514], ["import", 522], ["related", 529], ["to", 537], ["maintenance", 540], ["of", 552], ["mitochondrial", 555], ["structure", 569], ["is", 579], ["suggested", 582], ["as", 592], ["mitofilin", 595], ["helps", 605], ["regulate", 611], ["mitochondrial", 620], ["morphology", 634], ["and", 645], ["at", 649], ["least", 652], ["four", 658], ["of", 663], ["the", 666], ["associated", 670], ["proteins", 681], ["(", 690], ["metaxins", 691], ["1", 700], ["and", 702], ["2", 706], [",", 707], ["SAM50", 709], ["and", 715], ["CHCHD3", 719], [")", 725], ["have", 727], ["been", 732], ["implicated", 737], ["in", 748], ["protein", 751], ["import", 759], [",", 765], ["while", 767], ["DnaJC11", 773], ["is", 781], ["a", 784], ["chaperone", 786], ["-", 795], ["like", 796], ["protein", 801], ["that", 809], ["may", 814], ["have", 818], ["a", 823], ["similar", 825], ["role", 833], [".", 837]]}
{"context": "Sotos syndrome is a genetic disorder characterized by a typical facial appearance, macrocephaly, accelerated growth, developmental delay, and a variable range of associated abnormalities. The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified. A significant ethnic difference is found in the prevalence of different types of mutation, with a high percentage of microdeletions identified in Japanese Sotos syndrome patients and with intragenic mutations in most non-Japanese patients. NSD1 aberrations are rather specific for Sotos syndrome, but have also been detected in patients lacking one or more major criteria of the disorder, namely overgrowth, macrocephaly, and advanced bone age. Thus, new diagnostic criteria should be considered. Studies have reported different frequencies of mutations versus non-mutations in Sotos syndrome, thus indicating allelic or locus hetereogeneity. Although some authors have suggested genotype/phenotype correlations, further studies are needed.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "e3fcd872a2a34c279d4633b77cd0d266", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[30, 31]], "char_spans": [[192, 200]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["genetic", 20], ["disorder", 28], ["characterized", 37], ["by", 51], ["a", 54], ["typical", 56], ["facial", 64], ["appearance", 71], [",", 81], ["macrocephaly", 83], [",", 95], ["accelerated", 97], ["growth", 109], [",", 115], ["developmental", 117], ["delay", 131], [",", 136], ["and", 138], ["a", 142], ["variable", 144], ["range", 153], ["of", 159], ["associated", 162], ["abnormalities", 173], [".", 186], ["The", 188], ["NSD1", 192], ["gene", 197], ["was", 202], ["recently", 206], ["found", 215], ["to", 221], ["be", 224], ["responsible", 227], ["for", 239], ["Sotos", 243], ["syndrome", 249], [",", 257], ["and", 259], ["more", 263], ["than", 268], ["150", 273], ["patients", 277], ["with", 286], ["NSD1", 291], ["alterations", 296], ["have", 308], ["been", 313], ["identified", 318], [".", 328], ["A", 330], ["significant", 332], ["ethnic", 344], ["difference", 351], ["is", 362], ["found", 365], ["in", 371], ["the", 374], ["prevalence", 378], ["of", 389], ["different", 392], ["types", 402], ["of", 408], ["mutation", 411], [",", 419], ["with", 421], ["a", 426], ["high", 428], ["percentage", 433], ["of", 444], ["microdeletions", 447], ["identified", 462], ["in", 473], ["Japanese", 476], ["Sotos", 485], ["syndrome", 491], ["patients", 500], ["and", 509], ["with", 513], ["intragenic", 518], ["mutations", 529], ["in", 539], ["most", 542], ["non", 547], ["-", 550], ["Japanese", 551], ["patients", 560], [".", 568], ["NSD1", 570], ["aberrations", 575], ["are", 587], ["rather", 591], ["specific", 598], ["for", 607], ["Sotos", 611], ["syndrome", 617], [",", 625], ["but", 627], ["have", 631], ["also", 636], ["been", 641], ["detected", 646], ["in", 655], ["patients", 658], ["lacking", 667], ["one", 675], ["or", 679], ["more", 682], ["major", 687], ["criteria", 693], ["of", 702], ["the", 705], ["disorder", 709], [",", 717], ["namely", 719], ["overgrowth", 726], [",", 736], ["macrocephaly", 738], [",", 750], ["and", 752], ["advanced", 756], ["bone", 765], ["age", 770], [".", 773], ["Thus", 775], [",", 779], ["new", 781], ["diagnostic", 785], ["criteria", 796], ["should", 805], ["be", 812], ["considered", 815], [".", 825], ["Studies", 827], ["have", 835], ["reported", 840], ["different", 849], ["frequencies", 859], ["of", 871], ["mutations", 874], ["versus", 884], ["non", 891], ["-", 894], ["mutations", 895], ["in", 905], ["Sotos", 908], ["syndrome", 914], [",", 922], ["thus", 924], ["indicating", 929], ["allelic", 940], ["or", 948], ["locus", 951], ["hetereogeneity", 957], [".", 971], ["Although", 973], ["some", 982], ["authors", 987], ["have", 995], ["suggested", 1000], ["genotype", 1010], ["/", 1018], ["phenotype", 1019], ["correlations", 1029], [",", 1041], ["further", 1043], ["studies", 1051], ["are", 1059], ["needed", 1063], [".", 1069]]}
{"context": "De Quervain's disease has different clinical features. Different tests have been described in the past, the most popular test being the Eichhoff's test, often wrongly named as the Finkelstein's test. Over the years, a misinterpretation has occurred between these two tests, the latter being confused with the first. To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy). The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound. The wrist hyperflexion and abduction of the thumb test revealed greater sensitivity (0.99) and an improved specificity (0.29) together with a slightly better positive predictive value (0.95) and an improved negative predictive value (0.67). Moreover, the study showed us that the wrist hyperflexion and abduction of the thumb test is very valuable in diagnosing dynamic instability after successful decompression of the first extensor compartment. Our results support that the wrist hyperflexion and abduction of the thumb test is a more precise tool for the diagnosis of de Quervain's disease than the Eichhoff's test and thus could be adopted to guide clinical diagnosis in the early stages of de Quervain's tendinopathy.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "8e529191f1b142e8bc214514c56ad188", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[264, 267], [0, 3], [150, 153]], "char_spans": [[1461, 1481], [0, 20], [786, 806]]}]}], "context_tokens": [["De", 0], ["Quervain", 3], ["'s", 11], ["disease", 14], ["has", 22], ["different", 26], ["clinical", 36], ["features", 45], [".", 53], ["Different", 55], ["tests", 65], ["have", 71], ["been", 76], ["described", 81], ["in", 91], ["the", 94], ["past", 98], [",", 102], ["the", 104], ["most", 108], ["popular", 113], ["test", 121], ["being", 126], ["the", 132], ["Eichhoff", 136], ["'s", 144], ["test", 147], [",", 151], ["often", 153], ["wrongly", 159], ["named", 167], ["as", 173], ["the", 176], ["Finkelstein", 180], ["'s", 191], ["test", 194], [".", 198], ["Over", 200], ["the", 205], ["years", 209], [",", 214], ["a", 216], ["misinterpretation", 218], ["has", 236], ["occurred", 240], ["between", 249], ["these", 257], ["two", 263], ["tests", 267], [",", 272], ["the", 274], ["latter", 278], ["being", 285], ["confused", 291], ["with", 300], ["the", 305], ["first", 309], [".", 314], ["To", 316], ["compare", 319], ["the", 327], ["Eichhoff", 331], ["'s", 339], ["test", 342], ["with", 347], ["a", 352], ["new", 354], ["test", 358], [",", 362], ["the", 364], ["wrist", 368], ["hyperflexion", 374], ["and", 387], ["abduction", 391], ["of", 401], ["the", 404], ["thumb", 408], ["test", 414], [",", 418], ["we", 420], ["set", 423], ["up", 427], ["a", 430], ["prospective", 432], ["study", 444], ["over", 450], ["a", 455], ["period", 457], ["of", 464], ["three", 467], ["years", 473], ["for", 479], ["a", 483], ["cohort", 485], ["of", 492], ["100", 495], ["patients", 499], ["(", 508], ["88", 509], ["women", 512], [",", 517], ["12", 519], ["men", 522], [")", 525], ["presenting", 527], ["spontaneous", 538], ["pain", 550], ["over", 555], ["the", 560], ["radial", 564], ["side", 571], ["of", 576], ["the", 579], ["styloid", 583], ["of", 591], ["the", 594], ["radius", 598], ["(", 605], ["de", 606], ["Quervain", 609], ["tendinopathy", 618], [")", 630], [".", 631], ["The", 633], ["purpose", 637], ["of", 645], ["the", 648], ["study", 652], ["was", 658], ["to", 662], ["compare", 665], ["the", 673], ["accuracy", 677], ["of", 686], ["the", 689], ["Eichhoff", 693], ["'s", 701], ["test", 704], ["and", 709], ["wrist", 713], ["hyperflexion", 719], ["and", 732], ["abduction", 736], ["of", 746], ["the", 749], ["thumb", 753], ["test", 759], ["to", 764], ["diagnose", 767], ["correctly", 776], ["de", 786], ["Quervain", 789], ["'s", 797], ["disease", 800], ["by", 808], ["comparing", 811], ["clinical", 821], ["findings", 830], ["using", 839], ["those", 845], ["tests", 851], ["with", 857], ["the", 862], ["results", 866], ["on", 874], ["ultrasound", 877], [".", 887], ["The", 889], ["wrist", 893], ["hyperflexion", 899], ["and", 912], ["abduction", 916], ["of", 926], ["the", 929], ["thumb", 933], ["test", 939], ["revealed", 944], ["greater", 953], ["sensitivity", 961], ["(", 973], ["0.99", 974], [")", 978], ["and", 980], ["an", 984], ["improved", 987], ["specificity", 996], ["(", 1008], ["0.29", 1009], [")", 1013], ["together", 1015], ["with", 1024], ["a", 1029], ["slightly", 1031], ["better", 1040], ["positive", 1047], ["predictive", 1056], ["value", 1067], ["(", 1073], ["0.95", 1074], [")", 1078], ["and", 1080], ["an", 1084], ["improved", 1087], ["negative", 1096], ["predictive", 1105], ["value", 1116], ["(", 1122], ["0.67", 1123], [")", 1127], [".", 1128], ["Moreover", 1130], [",", 1138], ["the", 1140], ["study", 1144], ["showed", 1150], ["us", 1157], ["that", 1160], ["the", 1165], ["wrist", 1169], ["hyperflexion", 1175], ["and", 1188], ["abduction", 1192], ["of", 1202], ["the", 1205], ["thumb", 1209], ["test", 1215], ["is", 1220], ["very", 1223], ["valuable", 1228], ["in", 1237], ["diagnosing", 1240], ["dynamic", 1251], ["instability", 1259], ["after", 1271], ["successful", 1277], ["decompression", 1288], ["of", 1302], ["the", 1305], ["first", 1309], ["extensor", 1315], ["compartment", 1324], [".", 1335], ["Our", 1337], ["results", 1341], ["support", 1349], ["that", 1357], ["the", 1362], ["wrist", 1366], ["hyperflexion", 1372], ["and", 1385], ["abduction", 1389], ["of", 1399], ["the", 1402], ["thumb", 1406], ["test", 1412], ["is", 1417], ["a", 1420], ["more", 1422], ["precise", 1427], ["tool", 1435], ["for", 1440], ["the", 1444], ["diagnosis", 1448], ["of", 1458], ["de", 1461], ["Quervain", 1464], ["'s", 1472], ["disease", 1475], ["than", 1483], ["the", 1488], ["Eichhoff", 1492], ["'s", 1500], ["test", 1503], ["and", 1508], ["thus", 1512], ["could", 1517], ["be", 1523], ["adopted", 1526], ["to", 1534], ["guide", 1537], ["clinical", 1543], ["diagnosis", 1552], ["in", 1562], ["the", 1565], ["early", 1569], ["stages", 1575], ["of", 1582], ["de", 1585], ["Quervain", 1588], ["'s", 1596], ["tendinopathy", 1599], [".", 1611]]}
{"context": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus. Eleven cases were reported previously. We present 4 new patients and review one of the patients of the original report of Shprintzen and Goldberg [1982: J Craniofac Genet Dev Biol 2:65-74], 15 years later. The clinical and radiologic findings on our patients are compared with those of the previously reported patients and also with those of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224], who share many of the characteristics of Shprintzen-Goldberg syndrome. Some of the clinical data are helpful in determining if the patients of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224] have a separate syndrome or represent a variant of Shprintzen-Goldberg syndrome. However, radiologic investigations appear to be more specific, since an abnormality of the first and second cervical vertebrae, hydrocephalus, dilatation of the lateral ventricles, and a Chiari-I malformation of the brain were found only in the patients with Shprintzen-Goldberg syndrome. The apparently diagnostic findings of the 15 patients with this syndrome may be helpful in differentiating between Shprintzen-Goldberg syndrome and other syndromes with craniosynostosis and marfanoid habitus.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "3dfda990261e42298551bc5ea767d706", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[257, 257], [13, 13]], "char_spans": [[1356, 1371], [77, 92]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["is", 29], ["one", 32], ["of", 36], ["a", 39], ["group", 41], ["of", 47], ["disorders", 50], ["characterized", 60], ["by", 74], ["craniosynostosis", 77], ["and", 94], ["marfanoid", 98], ["habitus", 108], [".", 115], ["Eleven", 117], ["cases", 124], ["were", 130], ["reported", 135], ["previously", 144], [".", 154], ["We", 156], ["present", 159], ["4", 167], ["new", 169], ["patients", 173], ["and", 182], ["review", 186], ["one", 193], ["of", 197], ["the", 200], ["patients", 204], ["of", 213], ["the", 216], ["original", 220], ["report", 229], ["of", 236], ["Shprintzen", 239], ["and", 250], ["Goldberg", 254], ["[", 263], ["1982", 264], [":", 268], ["J", 270], ["Craniofac", 272], ["Genet", 282], ["Dev", 288], ["Biol", 292], ["2:65", 297], ["-", 301], ["74", 302], ["]", 304], [",", 305], ["15", 307], ["years", 310], ["later", 316], [".", 321], ["The", 323], ["clinical", 327], ["and", 336], ["radiologic", 340], ["findings", 351], ["on", 360], ["our", 363], ["patients", 367], ["are", 376], ["compared", 380], ["with", 389], ["those", 394], ["of", 400], ["the", 403], ["previously", 407], ["reported", 418], ["patients", 427], ["and", 436], ["also", 440], ["with", 445], ["those", 450], ["of", 456], ["Furlong", 459], ["et", 467], ["al", 470], [".", 472], ["[", 474], ["1987", 475], [":", 479], ["Am", 481], ["J", 484], ["Med", 486], ["Genet", 490], ["26:599", 496], ["-", 502], ["604", 503], ["]", 506], ["and", 508], ["Lacombe", 512], ["and", 520], ["Battin", 524], ["[", 531], ["1993", 532], [":", 536], ["Clin", 538], ["Dysmorphol", 543], ["2", 554], [":", 555], ["220", 557], ["-", 560], ["224", 561], ["]", 564], [",", 565], ["who", 567], ["share", 571], ["many", 577], ["of", 582], ["the", 585], ["characteristics", 589], ["of", 605], ["Shprintzen", 608], ["-", 618], ["Goldberg", 619], ["syndrome", 628], [".", 636], ["Some", 638], ["of", 643], ["the", 646], ["clinical", 650], ["data", 659], ["are", 664], ["helpful", 668], ["in", 676], ["determining", 679], ["if", 691], ["the", 694], ["patients", 698], ["of", 707], ["Furlong", 710], ["et", 718], ["al", 721], [".", 723], ["[", 725], ["1987", 726], [":", 730], ["Am", 732], ["J", 735], ["Med", 737], ["Genet", 741], ["26:599", 747], ["-", 753], ["604", 754], ["]", 757], ["and", 759], ["Lacombe", 763], ["and", 771], ["Battin", 775], ["[", 782], ["1993", 783], [":", 787], ["Clin", 789], ["Dysmorphol", 794], ["2", 805], [":", 806], ["220", 808], ["-", 811], ["224", 812], ["]", 815], ["have", 817], ["a", 822], ["separate", 824], ["syndrome", 833], ["or", 842], ["represent", 845], ["a", 855], ["variant", 857], ["of", 865], ["Shprintzen", 868], ["-", 878], ["Goldberg", 879], ["syndrome", 888], [".", 896], ["However", 898], [",", 905], ["radiologic", 907], ["investigations", 918], ["appear", 933], ["to", 940], ["be", 943], ["more", 946], ["specific", 951], [",", 959], ["since", 961], ["an", 967], ["abnormality", 970], ["of", 982], ["the", 985], ["first", 989], ["and", 995], ["second", 999], ["cervical", 1006], ["vertebrae", 1015], [",", 1024], ["hydrocephalus", 1026], [",", 1039], ["dilatation", 1041], ["of", 1052], ["the", 1055], ["lateral", 1059], ["ventricles", 1067], [",", 1077], ["and", 1079], ["a", 1083], ["Chiari", 1085], ["-", 1091], ["I", 1092], ["malformation", 1094], ["of", 1107], ["the", 1110], ["brain", 1114], ["were", 1120], ["found", 1125], ["only", 1131], ["in", 1136], ["the", 1139], ["patients", 1143], ["with", 1152], ["Shprintzen", 1157], ["-", 1167], ["Goldberg", 1168], ["syndrome", 1177], [".", 1185], ["The", 1187], ["apparently", 1191], ["diagnostic", 1202], ["findings", 1213], ["of", 1222], ["the", 1225], ["15", 1229], ["patients", 1232], ["with", 1241], ["this", 1246], ["syndrome", 1251], ["may", 1260], ["be", 1264], ["helpful", 1267], ["in", 1275], ["differentiating", 1278], ["between", 1294], ["Shprintzen", 1302], ["-", 1312], ["Goldberg", 1313], ["syndrome", 1322], ["and", 1331], ["other", 1335], ["syndromes", 1341], ["with", 1351], ["craniosynostosis", 1356], ["and", 1373], ["marfanoid", 1377], ["habitus", 1387], [".", 1394]]}
{"context": "The discovery of the Hippo pathway can be traced back to two areas of research. Genetic screens in fruit flies led to the identification of the Hippo pathway kinases and scaffolding proteins that function together to suppress cell proliferation and tumor growth. Independent research, often in the context of muscle biology, described Tead (TEA domain) transcription factors, which bind CATTCC DNA motifs to regulate gene expression. These two research areas were joined by the finding that the Hippo pathway regulates the activity of Tead transcription factors mainly through phosphorylation of the transcriptional coactivators Yap and Taz, which bind to and activate Teads. Additionally, many other signal transduction proteins crosstalk to members of the Hippo pathway forming a Hippo signal transduction network. We discuss evidence that the Hippo signal transduction network plays important roles in myogenesis, regeneration, muscular dystrophy, and rhabdomyosarcoma in skeletal muscle, as well as in myogenesis, organ size control, and regeneration of the heart. Understanding the role of Hippo kinases in skeletal and heart muscle physiology could have important implications for translational research.", "qas": [{"question": "Which are the coactivators of the Yes-associated protein (yap)?", "answers": ["Tead (TEA domain) transcription factors."], "qid": "42652e9339554e27af6c273cfd698386", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["coactivators", 14], ["of", 27], ["the", 30], ["Yes", 34], ["-", 37], ["associated", 38], ["protein", 49], ["(", 57], ["yap", 58], [")", 61], ["?", 62]], "detected_answers": [{"text": "Tead (TEA domain) transcription factors.", "token_spans": [[56, 62]], "char_spans": [[335, 373]]}]}], "context_tokens": [["The", 0], ["discovery", 4], ["of", 14], ["the", 17], ["Hippo", 21], ["pathway", 27], ["can", 35], ["be", 39], ["traced", 42], ["back", 49], ["to", 54], ["two", 57], ["areas", 61], ["of", 67], ["research", 70], [".", 78], ["Genetic", 80], ["screens", 88], ["in", 96], ["fruit", 99], ["flies", 105], ["led", 111], ["to", 115], ["the", 118], ["identification", 122], ["of", 137], ["the", 140], ["Hippo", 144], ["pathway", 150], ["kinases", 158], ["and", 166], ["scaffolding", 170], ["proteins", 182], ["that", 191], ["function", 196], ["together", 205], ["to", 214], ["suppress", 217], ["cell", 226], ["proliferation", 231], ["and", 245], ["tumor", 249], ["growth", 255], [".", 261], ["Independent", 263], ["research", 275], [",", 283], ["often", 285], ["in", 291], ["the", 294], ["context", 298], ["of", 306], ["muscle", 309], ["biology", 316], [",", 323], ["described", 325], ["Tead", 335], ["(", 340], ["TEA", 341], ["domain", 345], [")", 351], ["transcription", 353], ["factors", 367], [",", 374], ["which", 376], ["bind", 382], ["CATTCC", 387], ["DNA", 394], ["motifs", 398], ["to", 405], ["regulate", 408], ["gene", 417], ["expression", 422], [".", 432], ["These", 434], ["two", 440], ["research", 444], ["areas", 453], ["were", 459], ["joined", 464], ["by", 471], ["the", 474], ["finding", 478], ["that", 486], ["the", 491], ["Hippo", 495], ["pathway", 501], ["regulates", 509], ["the", 519], ["activity", 523], ["of", 532], ["Tead", 535], ["transcription", 540], ["factors", 554], ["mainly", 562], ["through", 569], ["phosphorylation", 577], ["of", 593], ["the", 596], ["transcriptional", 600], ["coactivators", 616], ["Yap", 629], ["and", 633], ["Taz", 637], [",", 640], ["which", 642], ["bind", 648], ["to", 653], ["and", 656], ["activate", 660], ["Teads", 669], [".", 674], ["Additionally", 676], [",", 688], ["many", 690], ["other", 695], ["signal", 701], ["transduction", 708], ["proteins", 721], ["crosstalk", 730], ["to", 740], ["members", 743], ["of", 751], ["the", 754], ["Hippo", 758], ["pathway", 764], ["forming", 772], ["a", 780], ["Hippo", 782], ["signal", 788], ["transduction", 795], ["network", 808], [".", 815], ["We", 817], ["discuss", 820], ["evidence", 828], ["that", 837], ["the", 842], ["Hippo", 846], ["signal", 852], ["transduction", 859], ["network", 872], ["plays", 880], ["important", 886], ["roles", 896], ["in", 902], ["myogenesis", 905], [",", 915], ["regeneration", 917], [",", 929], ["muscular", 931], ["dystrophy", 940], [",", 949], ["and", 951], ["rhabdomyosarcoma", 955], ["in", 972], ["skeletal", 975], ["muscle", 984], [",", 990], ["as", 992], ["well", 995], ["as", 1000], ["in", 1003], ["myogenesis", 1006], [",", 1016], ["organ", 1018], ["size", 1024], ["control", 1029], [",", 1036], ["and", 1038], ["regeneration", 1042], ["of", 1055], ["the", 1058], ["heart", 1062], [".", 1067], ["Understanding", 1069], ["the", 1083], ["role", 1087], ["of", 1092], ["Hippo", 1095], ["kinases", 1101], ["in", 1109], ["skeletal", 1112], ["and", 1121], ["heart", 1125], ["muscle", 1131], ["physiology", 1138], ["could", 1149], ["have", 1155], ["important", 1160], ["implications", 1170], ["for", 1183], ["translational", 1187], ["research", 1201], [".", 1209]]}
{"context": "Self-report questionnaires are frequently used to identify PTSD among U.S. military personnel and Veterans. Two common scoring methods used to classify PTSD include: (1) a cut score threshold and (2) endorsement of PTSD symptoms meeting DSM-IV-TR symptom cluster criteria (SCM). A third method requiring a cut score in addition to SCM has been proposed, but has received little study. The current study examined the diagnostic accuracy of three scoring methods for the Davidson Trauma Scale (DTS) among 804 Afghanistan and Iraq war-era military Service Members and Veterans. Data were weighted to approximate the prevalence of PTSD and other Axis I disorders in VA primary care. As expected, adding a cut score criterion to SCM improved specificity and positive predictive power. However, a cut score of 68-72 provided optimal diagnostic accuracy. The utility of the DTS, the role of baseline prevalence, and recommendations for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "30101ccbda904d208ed2525e9f6e992c", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[117, 117], [24, 24], [9, 9], [40, 40]], "char_spans": [[627, 630], [152, 155], [59, 62], [215, 218]]}]}], "context_tokens": [["Self", 0], ["-", 4], ["report", 5], ["questionnaires", 12], ["are", 27], ["frequently", 31], ["used", 42], ["to", 47], ["identify", 50], ["PTSD", 59], ["among", 64], ["U.S.", 70], ["military", 75], ["personnel", 84], ["and", 94], ["Veterans", 98], [".", 106], ["Two", 108], ["common", 112], ["scoring", 119], ["methods", 127], ["used", 135], ["to", 140], ["classify", 143], ["PTSD", 152], ["include", 157], [":", 164], ["(", 166], ["1", 167], [")", 168], ["a", 170], ["cut", 172], ["score", 176], ["threshold", 182], ["and", 192], ["(", 196], ["2", 197], [")", 198], ["endorsement", 200], ["of", 212], ["PTSD", 215], ["symptoms", 220], ["meeting", 229], ["DSM", 237], ["-", 240], ["IV", 241], ["-", 243], ["TR", 244], ["symptom", 247], ["cluster", 255], ["criteria", 263], ["(", 272], ["SCM", 273], [")", 276], [".", 277], ["A", 279], ["third", 281], ["method", 287], ["requiring", 294], ["a", 304], ["cut", 306], ["score", 310], ["in", 316], ["addition", 319], ["to", 328], ["SCM", 331], ["has", 335], ["been", 339], ["proposed", 344], [",", 352], ["but", 354], ["has", 358], ["received", 362], ["little", 371], ["study", 378], [".", 383], ["The", 385], ["current", 389], ["study", 397], ["examined", 403], ["the", 412], ["diagnostic", 416], ["accuracy", 427], ["of", 436], ["three", 439], ["scoring", 445], ["methods", 453], ["for", 461], ["the", 465], ["Davidson", 469], ["Trauma", 478], ["Scale", 485], ["(", 491], ["DTS", 492], [")", 495], ["among", 497], ["804", 503], ["Afghanistan", 507], ["and", 519], ["Iraq", 523], ["war", 528], ["-", 531], ["era", 532], ["military", 536], ["Service", 545], ["Members", 553], ["and", 561], ["Veterans", 565], [".", 573], ["Data", 575], ["were", 580], ["weighted", 585], ["to", 594], ["approximate", 597], ["the", 609], ["prevalence", 613], ["of", 624], ["PTSD", 627], ["and", 632], ["other", 636], ["Axis", 642], ["I", 647], ["disorders", 649], ["in", 659], ["VA", 662], ["primary", 665], ["care", 673], [".", 677], ["As", 679], ["expected", 682], [",", 690], ["adding", 692], ["a", 699], ["cut", 701], ["score", 705], ["criterion", 711], ["to", 721], ["SCM", 724], ["improved", 728], ["specificity", 737], ["and", 749], ["positive", 753], ["predictive", 762], ["power", 773], [".", 778], ["However", 780], [",", 787], ["a", 789], ["cut", 791], ["score", 795], ["of", 801], ["68", 804], ["-", 806], ["72", 807], ["provided", 810], ["optimal", 819], ["diagnostic", 827], ["accuracy", 838], [".", 846], ["The", 848], ["utility", 852], ["of", 860], ["the", 863], ["DTS", 867], [",", 870], ["the", 872], ["role", 876], ["of", 881], ["baseline", 884], ["prevalence", 893], [",", 903], ["and", 905], ["recommendations", 909], ["for", 925], ["future", 929], ["research", 936], ["are", 945], ["discussed", 949], [".", 958]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA molecules. CircRNAs are conserved across different species and display specific organization, sequence, and expression in disease. Moreover, circRNAs' closed ring structure, insensitivity to RNase, and stability are advantages over linear RNAs in terms of development and application as a new kind of clinical marker. In addition, according to recent studies, circular RNA-7 (ciRS-7) acts as a sponge of miR-7 and thus inhibits its activity. Numerous evidences have confirmed expression of miR-7 is dysregulated in cancer tissues, however, whether ciRS-7 invovled in oncogenesis by acting as sponge of miR-7 remains unclear. Most recently, a study reported ciRS-7 acted as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. This suggest ciRS-7/ miR-7 axis affects oncogenesis, and it provides a new perspective on the mechanisms of decreased miR-7 expression in cancer tissues. Discovery of sponge role of circRNAs caused researchers to more closely explore the underlying mechanism of carcinogenesis and has significant clinical implications, and may open a new chapter in research on the pathology and treatment of cancers. This review summarizes the structure and function of circRNAs and provides evidence for the impact of ciRS-7 in promoting the development of cancer by acting as sponge of miR-7.", "qas": [{"question": "Which miRNA is associated with the circular RNA ciRS-7?", "answers": ["miR-7"], "qid": "8d3460a44ce34647a536fc55cd18a4e1", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["associated", 15], ["with", 26], ["the", 31], ["circular", 35], ["RNA", 44], ["ciRS-7", 48], ["?", 54]], "detected_answers": [{"text": "miR-7", "token_spans": [[161, 161], [139, 139], [234, 234], [100, 100], [119, 119], [87, 87], [145, 145]], "char_spans": [[939, 943], [803, 807], [1394, 1398], [562, 566], [674, 678], [476, 480], [842, 846]]}]}], "context_tokens": [["Circular", 0], ["RNAs", 9], ["(", 14], ["circRNAs", 15], [")", 23], ["are", 25], ["a", 29], ["class", 31], ["of", 37], ["newly", 40], ["-", 45], ["identified", 46], ["non", 57], ["-", 60], ["coding", 61], ["RNA", 68], ["molecules", 72], [".", 81], ["CircRNAs", 83], ["are", 92], ["conserved", 96], ["across", 106], ["different", 113], ["species", 123], ["and", 131], ["display", 135], ["specific", 143], ["organization", 152], [",", 164], ["sequence", 166], [",", 174], ["and", 176], ["expression", 180], ["in", 191], ["disease", 194], [".", 201], ["Moreover", 203], [",", 211], ["circRNAs", 213], ["'", 221], ["closed", 223], ["ring", 230], ["structure", 235], [",", 244], ["insensitivity", 246], ["to", 260], ["RNase", 263], [",", 268], ["and", 270], ["stability", 274], ["are", 284], ["advantages", 288], ["over", 299], ["linear", 304], ["RNAs", 311], ["in", 316], ["terms", 319], ["of", 325], ["development", 328], ["and", 340], ["application", 344], ["as", 356], ["a", 359], ["new", 361], ["kind", 365], ["of", 370], ["clinical", 373], ["marker", 382], [".", 388], ["In", 390], ["addition", 393], [",", 401], ["according", 403], ["to", 413], ["recent", 416], ["studies", 423], [",", 430], ["circular", 432], ["RNA-7", 441], ["(", 447], ["ciRS-7", 448], [")", 454], ["acts", 456], ["as", 461], ["a", 464], ["sponge", 466], ["of", 473], ["miR-7", 476], ["and", 482], ["thus", 486], ["inhibits", 491], ["its", 500], ["activity", 504], [".", 512], ["Numerous", 514], ["evidences", 523], ["have", 533], ["confirmed", 538], ["expression", 548], ["of", 559], ["miR-7", 562], ["is", 568], ["dysregulated", 571], ["in", 584], ["cancer", 587], ["tissues", 594], [",", 601], ["however", 603], [",", 610], ["whether", 612], ["ciRS-7", 620], ["invovled", 627], ["in", 636], ["oncogenesis", 639], ["by", 651], ["acting", 654], ["as", 661], ["sponge", 664], ["of", 671], ["miR-7", 674], ["remains", 680], ["unclear", 688], [".", 695], ["Most", 697], ["recently", 702], [",", 710], ["a", 712], ["study", 714], ["reported", 720], ["ciRS-7", 729], ["acted", 736], ["as", 742], ["an", 745], ["oncogene", 748], ["in", 757], ["hepatocellular", 760], ["carcinoma", 775], ["through", 785], ["targeting", 793], ["miR-7", 803], ["expression", 809], [".", 819], ["This", 821], ["suggest", 826], ["ciRS-7/", 834], ["miR-7", 842], ["axis", 848], ["affects", 853], ["oncogenesis", 861], [",", 872], ["and", 874], ["it", 878], ["provides", 881], ["a", 890], ["new", 892], ["perspective", 896], ["on", 908], ["the", 911], ["mechanisms", 915], ["of", 926], ["decreased", 929], ["miR-7", 939], ["expression", 945], ["in", 956], ["cancer", 959], ["tissues", 966], [".", 973], ["Discovery", 975], ["of", 985], ["sponge", 988], ["role", 995], ["of", 1000], ["circRNAs", 1003], ["caused", 1012], ["researchers", 1019], ["to", 1031], ["more", 1034], ["closely", 1039], ["explore", 1047], ["the", 1055], ["underlying", 1059], ["mechanism", 1070], ["of", 1080], ["carcinogenesis", 1083], ["and", 1098], ["has", 1102], ["significant", 1106], ["clinical", 1118], ["implications", 1127], [",", 1139], ["and", 1141], ["may", 1145], ["open", 1149], ["a", 1154], ["new", 1156], ["chapter", 1160], ["in", 1168], ["research", 1171], ["on", 1180], ["the", 1183], ["pathology", 1187], ["and", 1197], ["treatment", 1201], ["of", 1211], ["cancers", 1214], [".", 1221], ["This", 1223], ["review", 1228], ["summarizes", 1235], ["the", 1246], ["structure", 1250], ["and", 1260], ["function", 1264], ["of", 1273], ["circRNAs", 1276], ["and", 1285], ["provides", 1289], ["evidence", 1298], ["for", 1307], ["the", 1311], ["impact", 1315], ["of", 1322], ["ciRS-7", 1325], ["in", 1332], ["promoting", 1335], ["the", 1345], ["development", 1349], ["of", 1361], ["cancer", 1364], ["by", 1371], ["acting", 1374], ["as", 1381], ["sponge", 1384], ["of", 1391], ["miR-7", 1394], [".", 1399]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described but their frequency, nature and impact are poorly known. We aimed to assess digestive features in a national cohort of EDS patients. A questionnaire has been sent to 212 EDS patients through the French patient support group, all of which had been formally diagnosed according to the Villefranche criteria. The questionnaire included questions about digestive functional symptoms, the GIQLI (Gastrointestinal Quality of Life Index), KESS scoring system and the Rome III criteria. Overall, 135 patients (64% response rate) completed the questionnaire and 134 were analyzable (123 women; 91%). Mean age and Body Mass Index were respectively 35\u00b114.7 years and 24.3\u00b16.1 kg/m(2). The most common EDS subtype was hypermobility form (n=108; 80.6%). GIQLI and KESS median values were respectively 63.5 (27-117) and 19 [13.5-22]. Eighty four percent of patients had functional bowel disorders (FBD) according to the Rome III criteria. An irritable bowel syndrome according to the same criteria was observed in 64 patients (48%) and 48 patients (36%) reported functional constipation. A gastro-esophageal reflux disease (GERD) was reported in 90 patients (68.7%), significantly associated with a poorer GIQLI (60.5\u00b116.8 versus 75.9\u00b120.3; p<0.0001). GIQLI was also negatively impacted by the presence of an irritable bowel syndrome or functional constipation (p=0.007). There was a significant correlation between FBD and GERD. Natural frequency of gastrointestinal manifestations in EDS seems higher than previously assessed. FBD and GERD are very common in our study population, the largest ever published until now. Their impact is herein shown to be important. A systematic clinical assessment of digestive features should be recommended in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "922ae9318d264f8ea1e929e98b4bbe0b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["heritable", 59], ["connective", 69], ["tissue", 80], ["disorders", 87], [".", 96], ["Gastrointestinal", 98], ["manifestations", 115], ["in", 130], ["EDS", 133], ["have", 137], ["been", 142], ["described", 147], ["but", 157], ["their", 161], ["frequency", 167], [",", 176], ["nature", 178], ["and", 185], ["impact", 189], ["are", 196], ["poorly", 200], ["known", 207], [".", 212], ["We", 214], ["aimed", 217], ["to", 223], ["assess", 226], ["digestive", 233], ["features", 243], ["in", 252], ["a", 255], ["national", 257], ["cohort", 266], ["of", 273], ["EDS", 276], ["patients", 280], [".", 288], ["A", 290], ["questionnaire", 292], ["has", 306], ["been", 310], ["sent", 315], ["to", 320], ["212", 323], ["EDS", 327], ["patients", 331], ["through", 340], ["the", 348], ["French", 352], ["patient", 359], ["support", 367], ["group", 375], [",", 380], ["all", 382], ["of", 386], ["which", 389], ["had", 395], ["been", 399], ["formally", 404], ["diagnosed", 413], ["according", 423], ["to", 433], ["the", 436], ["Villefranche", 440], ["criteria", 453], [".", 461], ["The", 463], ["questionnaire", 467], ["included", 481], ["questions", 490], ["about", 500], ["digestive", 506], ["functional", 516], ["symptoms", 527], [",", 535], ["the", 537], ["GIQLI", 541], ["(", 547], ["Gastrointestinal", 548], ["Quality", 565], ["of", 573], ["Life", 576], ["Index", 581], [")", 586], [",", 587], ["KESS", 589], ["scoring", 594], ["system", 602], ["and", 609], ["the", 613], ["Rome", 617], ["III", 622], ["criteria", 626], [".", 634], ["Overall", 636], [",", 643], ["135", 645], ["patients", 649], ["(", 658], ["64", 659], ["%", 661], ["response", 663], ["rate", 672], [")", 676], ["completed", 678], ["the", 688], ["questionnaire", 692], ["and", 706], ["134", 710], ["were", 714], ["analyzable", 719], ["(", 730], ["123", 731], ["women", 735], [";", 740], ["91", 742], ["%", 744], [")", 745], [".", 746], ["Mean", 748], ["age", 753], ["and", 757], ["Body", 761], ["Mass", 766], ["Index", 771], ["were", 777], ["respectively", 782], ["35\u00b114.7", 795], ["years", 803], ["and", 809], ["24.3\u00b16.1", 813], ["kg", 822], ["/", 824], ["m(2", 825], [")", 828], [".", 829], ["The", 831], ["most", 835], ["common", 840], ["EDS", 847], ["subtype", 851], ["was", 859], ["hypermobility", 863], ["form", 877], ["(", 882], ["n=108", 883], [";", 888], ["80.6", 890], ["%", 894], [")", 895], [".", 896], ["GIQLI", 898], ["and", 904], ["KESS", 908], ["median", 913], ["values", 920], ["were", 927], ["respectively", 932], ["63.5", 945], ["(", 950], ["27", 951], ["-", 953], ["117", 954], [")", 957], ["and", 959], ["19", 963], ["[", 966], ["13.5", 967], ["-", 971], ["22].", 972], ["Eighty", 977], ["four", 984], ["percent", 989], ["of", 997], ["patients", 1000], ["had", 1009], ["functional", 1013], ["bowel", 1024], ["disorders", 1030], ["(", 1040], ["FBD", 1041], [")", 1044], ["according", 1046], ["to", 1056], ["the", 1059], ["Rome", 1063], ["III", 1068], ["criteria", 1072], [".", 1080], ["An", 1082], ["irritable", 1085], ["bowel", 1095], ["syndrome", 1101], ["according", 1110], ["to", 1120], ["the", 1123], ["same", 1127], ["criteria", 1132], ["was", 1141], ["observed", 1145], ["in", 1154], ["64", 1157], ["patients", 1160], ["(", 1169], ["48", 1170], ["%", 1172], [")", 1173], ["and", 1175], ["48", 1179], ["patients", 1182], ["(", 1191], ["36", 1192], ["%", 1194], [")", 1195], ["reported", 1197], ["functional", 1206], ["constipation", 1217], [".", 1229], ["A", 1231], ["gastro", 1233], ["-", 1239], ["esophageal", 1240], ["reflux", 1251], ["disease", 1258], ["(", 1266], ["GERD", 1267], [")", 1271], ["was", 1273], ["reported", 1277], ["in", 1286], ["90", 1289], ["patients", 1292], ["(", 1301], ["68.7", 1302], ["%", 1306], [")", 1307], [",", 1308], ["significantly", 1310], ["associated", 1324], ["with", 1335], ["a", 1340], ["poorer", 1342], ["GIQLI", 1349], ["(", 1355], ["60.5\u00b116.8", 1356], ["versus", 1366], ["75.9\u00b120.3", 1373], [";", 1382], ["p<0.0001", 1384], [")", 1392], [".", 1393], ["GIQLI", 1395], ["was", 1401], ["also", 1405], ["negatively", 1410], ["impacted", 1421], ["by", 1430], ["the", 1433], ["presence", 1437], ["of", 1446], ["an", 1449], ["irritable", 1452], ["bowel", 1462], ["syndrome", 1468], ["or", 1477], ["functional", 1480], ["constipation", 1491], ["(", 1504], ["p=0.007", 1505], [")", 1512], [".", 1513], ["There", 1515], ["was", 1521], ["a", 1525], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["FBD", 1559], ["and", 1563], ["GERD", 1567], [".", 1571], ["Natural", 1573], ["frequency", 1581], ["of", 1591], ["gastrointestinal", 1594], ["manifestations", 1611], ["in", 1626], ["EDS", 1629], ["seems", 1633], ["higher", 1639], ["than", 1646], ["previously", 1651], ["assessed", 1662], [".", 1670], ["FBD", 1672], ["and", 1676], ["GERD", 1680], ["are", 1685], ["very", 1689], ["common", 1694], ["in", 1701], ["our", 1704], ["study", 1708], ["population", 1714], [",", 1724], ["the", 1726], ["largest", 1730], ["ever", 1738], ["published", 1743], ["until", 1753], ["now", 1759], [".", 1762], ["Their", 1764], ["impact", 1770], ["is", 1777], ["herein", 1780], ["shown", 1787], ["to", 1793], ["be", 1796], ["important", 1799], [".", 1808], ["A", 1810], ["systematic", 1812], ["clinical", 1823], ["assessment", 1832], ["of", 1843], ["digestive", 1846], ["features", 1856], ["should", 1865], ["be", 1872], ["recommended", 1875], ["in", 1887], ["EDS", 1890], [".", 1893]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "The RTS,S/AS01(E) malaria vaccine candidate has recently entered Phase 3 testing. Reaching this important milestone is the culmination of more than 20 years of research and development by GlaxoSmithKline and partners and collaborators. The vaccine has been developed to protect young children and infants living in Sub-Saharan Africa against clinical and severe disease caused by Plasmodium falciparum infection. Over the past 9 years, RTS,S/AS has been evaluated in multiple Phase 2 studies. The vaccine was shown to have a favorable safety profile and to be well tolerated in all age groups in which it was tested, including the intended target population of infants and young children in Sub-Saharan Africa. Data obtained so far suggest that RTS,S/AS can be co-administered with other vaccines included in the routine Expanded Program of Immunization (EPI). In Phase 2 testing, the vaccine candidate was shown to confer significant protection against P. falciparum infection and clinical disease, including severe malaria. Furthermore, a trend towards an indirect beneficial effect of the vaccine on non-malarial morbidities has been observed in several trials. In this paper, we will describe the genesis of the RTS,S/AS concept, including the rationale for selecting the circumsporozoite protein (CSP) as the target antigen. Early development history of the vaccine will be briefly described. We will present the most salient results from recent Phase 2 studies conducted in the target pediatric population, which have led to the decision to progress RTS,S/AS to Phase 3 testing. If the Phase 3 results confirm the observations made during Phase 2 testing, the RTS,S/AS vaccine, when broadly implemented and judiciously integrated with other malaria-prevention measures, would have a major public-health impact in Sub-Saharan Africa.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "3926de0ae12f43be8eb6f2e7dbc0cee7", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[184, 184], [7, 7], [322, 322]], "char_spans": [[1017, 1023], [18, 24], [1747, 1753]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["malaria", 18], ["vaccine", 26], ["candidate", 34], ["has", 44], ["recently", 48], ["entered", 57], ["Phase", 65], ["3", 71], ["testing", 73], [".", 80], ["Reaching", 82], ["this", 91], ["important", 96], ["milestone", 106], ["is", 116], ["the", 119], ["culmination", 123], ["of", 135], ["more", 138], ["than", 143], ["20", 148], ["years", 151], ["of", 157], ["research", 160], ["and", 169], ["development", 173], ["by", 185], ["GlaxoSmithKline", 188], ["and", 204], ["partners", 208], ["and", 217], ["collaborators", 221], [".", 234], ["The", 236], ["vaccine", 240], ["has", 248], ["been", 252], ["developed", 257], ["to", 267], ["protect", 270], ["young", 278], ["children", 284], ["and", 293], ["infants", 297], ["living", 305], ["in", 312], ["Sub", 315], ["-", 318], ["Saharan", 319], ["Africa", 327], ["against", 334], ["clinical", 342], ["and", 351], ["severe", 355], ["disease", 362], ["caused", 370], ["by", 377], ["Plasmodium", 380], ["falciparum", 391], ["infection", 402], [".", 411], ["Over", 413], ["the", 418], ["past", 422], ["9", 427], ["years", 429], [",", 434], ["RTS", 436], [",", 439], ["S", 440], ["/", 441], ["AS", 442], ["has", 445], ["been", 449], ["evaluated", 454], ["in", 464], ["multiple", 467], ["Phase", 476], ["2", 482], ["studies", 484], [".", 491], ["The", 493], ["vaccine", 497], ["was", 505], ["shown", 509], ["to", 515], ["have", 518], ["a", 523], ["favorable", 525], ["safety", 535], ["profile", 542], ["and", 550], ["to", 554], ["be", 557], ["well", 560], ["tolerated", 565], ["in", 575], ["all", 578], ["age", 582], ["groups", 586], ["in", 593], ["which", 596], ["it", 602], ["was", 605], ["tested", 609], [",", 615], ["including", 617], ["the", 627], ["intended", 631], ["target", 640], ["population", 647], ["of", 658], ["infants", 661], ["and", 669], ["young", 673], ["children", 679], ["in", 688], ["Sub", 691], ["-", 694], ["Saharan", 695], ["Africa", 703], [".", 709], ["Data", 711], ["obtained", 716], ["so", 725], ["far", 728], ["suggest", 732], ["that", 740], ["RTS", 745], [",", 748], ["S", 749], ["/", 750], ["AS", 751], ["can", 754], ["be", 758], ["co", 761], ["-", 763], ["administered", 764], ["with", 777], ["other", 782], ["vaccines", 788], ["included", 797], ["in", 806], ["the", 809], ["routine", 813], ["Expanded", 821], ["Program", 830], ["of", 838], ["Immunization", 841], ["(", 854], ["EPI", 855], [")", 858], [".", 859], ["In", 861], ["Phase", 864], ["2", 870], ["testing", 872], [",", 879], ["the", 881], ["vaccine", 885], ["candidate", 893], ["was", 903], ["shown", 907], ["to", 913], ["confer", 916], ["significant", 923], ["protection", 935], ["against", 946], ["P.", 954], ["falciparum", 957], ["infection", 968], ["and", 978], ["clinical", 982], ["disease", 991], [",", 998], ["including", 1000], ["severe", 1010], ["malaria", 1017], [".", 1024], ["Furthermore", 1026], [",", 1037], ["a", 1039], ["trend", 1041], ["towards", 1047], ["an", 1055], ["indirect", 1058], ["beneficial", 1067], ["effect", 1078], ["of", 1085], ["the", 1088], ["vaccine", 1092], ["on", 1100], ["non", 1103], ["-", 1106], ["malarial", 1107], ["morbidities", 1116], ["has", 1128], ["been", 1132], ["observed", 1137], ["in", 1146], ["several", 1149], ["trials", 1157], [".", 1163], ["In", 1165], ["this", 1168], ["paper", 1173], [",", 1178], ["we", 1180], ["will", 1183], ["describe", 1188], ["the", 1197], ["genesis", 1201], ["of", 1209], ["the", 1212], ["RTS", 1216], [",", 1219], ["S", 1220], ["/", 1221], ["AS", 1222], ["concept", 1225], [",", 1232], ["including", 1234], ["the", 1244], ["rationale", 1248], ["for", 1258], ["selecting", 1262], ["the", 1272], ["circumsporozoite", 1276], ["protein", 1293], ["(", 1301], ["CSP", 1302], [")", 1305], ["as", 1307], ["the", 1310], ["target", 1314], ["antigen", 1321], [".", 1328], ["Early", 1330], ["development", 1336], ["history", 1348], ["of", 1356], ["the", 1359], ["vaccine", 1363], ["will", 1371], ["be", 1376], ["briefly", 1379], ["described", 1387], [".", 1396], ["We", 1398], ["will", 1401], ["present", 1406], ["the", 1414], ["most", 1418], ["salient", 1423], ["results", 1431], ["from", 1439], ["recent", 1444], ["Phase", 1451], ["2", 1457], ["studies", 1459], ["conducted", 1467], ["in", 1477], ["the", 1480], ["target", 1484], ["pediatric", 1491], ["population", 1501], [",", 1511], ["which", 1513], ["have", 1519], ["led", 1524], ["to", 1528], ["the", 1531], ["decision", 1535], ["to", 1544], ["progress", 1547], ["RTS", 1556], [",", 1559], ["S", 1560], ["/", 1561], ["AS", 1562], ["to", 1565], ["Phase", 1568], ["3", 1574], ["testing", 1576], [".", 1583], ["If", 1585], ["the", 1588], ["Phase", 1592], ["3", 1598], ["results", 1600], ["confirm", 1608], ["the", 1616], ["observations", 1620], ["made", 1633], ["during", 1638], ["Phase", 1645], ["2", 1651], ["testing", 1653], [",", 1660], ["the", 1662], ["RTS", 1666], [",", 1669], ["S", 1670], ["/", 1671], ["AS", 1672], ["vaccine", 1675], [",", 1682], ["when", 1684], ["broadly", 1689], ["implemented", 1697], ["and", 1709], ["judiciously", 1713], ["integrated", 1725], ["with", 1736], ["other", 1741], ["malaria", 1747], ["-", 1754], ["prevention", 1755], ["measures", 1766], [",", 1774], ["would", 1776], ["have", 1782], ["a", 1787], ["major", 1789], ["public", 1795], ["-", 1801], ["health", 1802], ["impact", 1809], ["in", 1816], ["Sub", 1819], ["-", 1822], ["Saharan", 1823], ["Africa", 1831], [".", 1837]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Beh\u00e7et disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "a00c444bb61f44519190db6046039820", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["is", 21], ["a", 24], ["pleiotropic", 26], ["cytokine", 38], ["implicated", 47], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["immune", 86], ["-", 92], ["mediated", 93], ["disorders", 102], ["including", 112], ["several", 122], ["types", 130], ["of", 136], ["non", 139], ["-", 142], ["infectious", 143], ["uveitis", 154], [".", 161], ["These", 163], ["uveitic", 169], ["conditions", 177], ["include", 188], ["Vogt", 196], ["-", 200], ["Koyanagi", 201], ["-", 209], ["Harada", 210], ["syndrome", 217], [",", 225], ["uveitis", 227], ["associated", 235], ["with", 246], ["Beh\u00e7et", 251], ["disease", 258], [",", 265], ["and", 267], ["sarcoidosis", 271], [".", 282], ["This", 284], ["review", 289], ["summarizes", 296], ["the", 307], ["role", 311], ["of", 316], ["IL-6", 319], ["in", 324], ["immunity", 327], [",", 335], ["highlighting", 337], ["its", 350], ["effect", 354], ["on", 361], ["Th17", 364], [",", 368], ["Th1", 370], [",", 373], ["and", 375], ["plasmablast", 379], ["differentiation", 391], [".", 406], ["It", 408], ["reviews", 411], ["the", 419], ["downstream", 423], ["mediators", 434], ["activated", 444], ["in", 454], ["the", 457], ["process", 461], ["of", 469], ["IL-6", 472], ["binding", 477], ["to", 485], ["its", 488], ["receptor", 492], ["complex", 501], [".", 508], ["This", 510], ["review", 515], ["also", 522], ["summarizes", 527], ["the", 538], ["biologics", 542], ["targeting", 552], ["either", 562], ["IL-6", 569], ["or", 574], ["the", 577], ["IL-6", 581], ["receptor", 586], [",", 594], ["including", 596], ["tocilizumab", 606], [",", 617], ["sarilumab", 619], [",", 628], ["sirukumab", 630], [",", 639], ["olokizumab", 641], [",", 651], ["clazakizumab", 653], [",", 665], ["and", 667], ["siltuximab", 671], [".", 681], ["The", 683], ["target", 687], [",", 693], ["dosage", 695], [",", 701], ["potential", 703], ["side", 713], ["effects", 718], [",", 725], ["and", 727], ["potential", 731], ["uses", 741], ["of", 746], ["these", 749], ["biologics", 755], ["are", 765], ["summarized", 769], ["in", 780], ["this", 783], ["article", 788], ["based", 796], ["on", 802], ["the", 805], ["existing", 809], ["literature", 818], [".", 828], ["In", 830], ["summary", 833], [",", 840], ["anti", 842], ["-", 846], ["IL-6", 847], ["therapy", 852], ["for", 860], ["non", 864], ["-", 867], ["infectious", 868], ["uveitis", 879], ["shows", 887], ["promise", 893], ["in", 901], ["terms", 904], ["of", 910], ["efficacy", 913], ["and", 922], ["side", 926], ["effect", 931], ["profile", 938], [".", 945]]}
{"context": "Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "93b3fce4ac844f3493818175471378b0", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[7, 7]], "char_spans": [[35, 39]]}]}], "context_tokens": [["Empagliflozin", 0], ["(", 14], ["Jardiance", 15], [")", 24], [":", 25], ["a", 27], ["novel", 29], ["SGLT2", 35], ["inhibitor", 41], ["for", 51], ["the", 55], ["treatment", 59], ["of", 69], ["type-2", 72], ["diabetes", 79], [".", 87]]}
{"context": "Angiopoietin-like protein 3 (ANGPTL3) affects lipid metabolism by inhibiting the activity of lipoprotein and endothelial lipases. Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. Recently, 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations. We resequenced ANGPTL3 in 4 members of 3 kindreds originally identified for very low levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (0.97\u00b10.16 and 0.56\u00b10.20 mmol/L, respectively) in whom no mutations of known candidate genes for monogenic hypobetalipoproteinemia and hypoalphalipoproteinemia had been detected. These subjects were found to be homozygous or compound heterozygous for ANGPTL3 loss-of-function mutations (p.G400VfsX5, p.I19LfsX22/p.N147X) associated with the absence of ANGPTL3 in plasma. They had reduced plasma levels of triglyceride-containing lipoproteins and of HDL particles that contained only apolipoprotein A-I and pre-\u03b2-high-density lipoprotein. In addition, their apolipoprotein B-depleted sera had a reduced capacity to promote cell cholesterol efflux through the various pathways (ABCA1-, SR-BI-, and ABCG1-mediated efflux); however, these subjects had no clinical evidence of accelerated atherosclerosis. Heterozygous carriers of the ANGPTL3 mutations had low plasma ANGPTL3 and moderately reduced low-density lipoprotein cholesterol (2.52\u00b10.38 mmol/L) but normal plasma high-density lipoprotein cholesterol. Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum. Partial ANGPTL3 deficiency is associated only with a moderate reduction of low-density lipoprotein.", "qas": [{"question": "What is the results of inactivated ANGPLT3?", "answers": ["Recessive hypolipidemia"], "qid": "945a16348aeb4d0eb69c3c58a1a53610", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["results", 12], ["of", 20], ["inactivated", 23], ["ANGPLT3", 35], ["?", 42]], "detected_answers": [{"text": "Recessive hypolipidemia", "token_spans": [[297, 298]], "char_spans": [[1756, 1778]]}]}], "context_tokens": [["Angiopoietin", 0], ["-", 12], ["like", 13], ["protein", 18], ["3", 26], ["(", 28], ["ANGPTL3", 29], [")", 36], ["affects", 38], ["lipid", 46], ["metabolism", 52], ["by", 63], ["inhibiting", 66], ["the", 77], ["activity", 81], ["of", 90], ["lipoprotein", 93], ["and", 105], ["endothelial", 109], ["lipases", 121], [".", 128], ["Angptl3", 130], ["knockout", 138], ["mice", 147], ["have", 152], ["marked", 157], ["hypolipidemia", 164], [",", 177], ["and", 179], ["heterozygous", 183], ["carriers", 196], ["of", 205], ["ANGPLT3", 208], [",", 215], ["loss", 217], ["-", 221], ["of", 222], ["-", 224], ["function", 225], ["mutations", 234], ["were", 244], ["found", 249], ["among", 255], ["individuals", 261], ["in", 273], ["the", 276], ["lowest", 280], ["quartile", 287], ["of", 296], ["plasma", 299], ["triglycerides", 306], ["in", 320], ["population", 323], ["studies", 334], [".", 341], ["Recently", 343], [",", 351], ["4", 353], ["related", 355], ["individuals", 363], ["with", 375], ["primary", 380], ["hypolipidemia", 388], ["were", 402], ["found", 407], ["to", 413], ["be", 416], ["compound", 419], ["heterozygotes", 428], ["for", 442], ["ANGPTL3", 446], ["loss", 454], ["-", 458], ["of", 459], ["-", 461], ["function", 462], ["mutations", 471], [".", 480], ["We", 482], ["resequenced", 485], ["ANGPTL3", 497], ["in", 505], ["4", 508], ["members", 510], ["of", 518], ["3", 521], ["kindreds", 523], ["originally", 532], ["identified", 543], ["for", 554], ["very", 558], ["low", 563], ["levels", 567], ["of", 574], ["low", 577], ["-", 580], ["density", 581], ["lipoprotein", 589], ["cholesterol", 601], ["and", 613], ["high", 617], ["-", 621], ["density", 622], ["lipoprotein", 630], ["cholesterol", 642], ["(", 654], ["0.97\u00b10.16", 655], ["and", 665], ["0.56\u00b10.20", 669], ["mmol", 679], ["/", 683], ["L", 684], [",", 685], ["respectively", 687], [")", 699], ["in", 701], ["whom", 704], ["no", 709], ["mutations", 712], ["of", 722], ["known", 725], ["candidate", 731], ["genes", 741], ["for", 747], ["monogenic", 751], ["hypobetalipoproteinemia", 761], ["and", 785], ["hypoalphalipoproteinemia", 789], ["had", 814], ["been", 818], ["detected", 823], [".", 831], ["These", 833], ["subjects", 839], ["were", 848], ["found", 853], ["to", 859], ["be", 862], ["homozygous", 865], ["or", 876], ["compound", 879], ["heterozygous", 888], ["for", 901], ["ANGPTL3", 905], ["loss", 913], ["-", 917], ["of", 918], ["-", 920], ["function", 921], ["mutations", 930], ["(", 940], ["p", 941], [".", 942], ["G400VfsX5", 943], [",", 952], ["p", 954], [".", 955], ["I19LfsX22/p", 956], [".", 967], ["N147X", 968], [")", 973], ["associated", 975], ["with", 986], ["the", 991], ["absence", 995], ["of", 1003], ["ANGPTL3", 1006], ["in", 1014], ["plasma", 1017], [".", 1023], ["They", 1025], ["had", 1030], ["reduced", 1034], ["plasma", 1042], ["levels", 1049], ["of", 1056], ["triglyceride", 1059], ["-", 1071], ["containing", 1072], ["lipoproteins", 1083], ["and", 1096], ["of", 1100], ["HDL", 1103], ["particles", 1107], ["that", 1117], ["contained", 1122], ["only", 1132], ["apolipoprotein", 1137], ["A", 1152], ["-", 1153], ["I", 1154], ["and", 1156], ["pre", 1160], ["-", 1163], ["\u03b2", 1164], ["-", 1165], ["high", 1166], ["-", 1170], ["density", 1171], ["lipoprotein", 1179], [".", 1190], ["In", 1192], ["addition", 1195], [",", 1203], ["their", 1205], ["apolipoprotein", 1211], ["B", 1226], ["-", 1227], ["depleted", 1228], ["sera", 1237], ["had", 1242], ["a", 1246], ["reduced", 1248], ["capacity", 1256], ["to", 1265], ["promote", 1268], ["cell", 1276], ["cholesterol", 1281], ["efflux", 1293], ["through", 1300], ["the", 1308], ["various", 1312], ["pathways", 1320], ["(", 1329], ["ABCA1-", 1330], [",", 1336], ["SR", 1338], ["-", 1340], ["BI-", 1341], [",", 1344], ["and", 1346], ["ABCG1-mediated", 1350], ["efflux", 1365], [")", 1371], [";", 1372], ["however", 1374], [",", 1381], ["these", 1383], ["subjects", 1389], ["had", 1398], ["no", 1402], ["clinical", 1405], ["evidence", 1414], ["of", 1423], ["accelerated", 1426], ["atherosclerosis", 1438], [".", 1453], ["Heterozygous", 1455], ["carriers", 1468], ["of", 1477], ["the", 1480], ["ANGPTL3", 1484], ["mutations", 1492], ["had", 1502], ["low", 1506], ["plasma", 1510], ["ANGPTL3", 1517], ["and", 1525], ["moderately", 1529], ["reduced", 1540], ["low", 1548], ["-", 1551], ["density", 1552], ["lipoprotein", 1560], ["cholesterol", 1572], ["(", 1584], ["2.52\u00b10.38", 1585], ["mmol", 1595], ["/", 1599], ["L", 1600], [")", 1601], ["but", 1603], ["normal", 1607], ["plasma", 1614], ["high", 1621], ["-", 1625], ["density", 1626], ["lipoprotein", 1634], ["cholesterol", 1646], [".", 1657], ["Complete", 1659], ["ANGPTL3", 1668], ["deficiency", 1676], ["caused", 1687], ["by", 1694], ["loss", 1697], ["-", 1701], ["of", 1702], ["-", 1704], ["function", 1705], ["mutations", 1714], ["of", 1724], ["ANGPTL3", 1727], ["is", 1735], ["associated", 1738], ["with", 1749], ["a", 1754], ["recessive", 1756], ["hypolipidemia", 1766], ["characterized", 1780], ["by", 1794], ["a", 1797], ["reduction", 1799], ["of", 1809], ["apolipoprotein", 1812], ["B", 1827], ["and", 1829], ["apolipoprotein", 1833], ["A", 1848], ["-", 1849], ["I", 1850], ["-", 1851], ["containing", 1852], ["lipoproteins", 1863], [",", 1875], ["changes", 1877], ["in", 1885], ["subclasses", 1888], ["of", 1899], ["high", 1902], ["-", 1906], ["density", 1907], ["lipoprotein", 1915], [",", 1926], ["and", 1928], ["reduced", 1932], ["cholesterol", 1940], ["efflux", 1952], ["potential", 1959], ["of", 1969], ["serum", 1972], [".", 1977], ["Partial", 1979], ["ANGPTL3", 1987], ["deficiency", 1995], ["is", 2006], ["associated", 2009], ["only", 2020], ["with", 2025], ["a", 2030], ["moderate", 2032], ["reduction", 2041], ["of", 2051], ["low", 2054], ["-", 2057], ["density", 2058], ["lipoprotein", 2066], [".", 2077]]}
{"context": "In this study psychometric properties of seven self-report measures of posttraumatic stress disorder (PTSD) were compared. The seven scales evaluated were the Davidson Trauma Scale (DTS), the PTSD Checklist (PCL), the Posttraumatic Stress Diagnostic Scale (PDS), the Civilian Mississippi Scale (CMS), the Impact of Event Scale-Revised (IES-R), the Penn Inventory for Posttraumatic Stress Disorder (Penn), and the PK scale of the MMPI-2 (PK). Participants were 239 (79 male and 160 female) trauma-exposed undergraduates. All seven measures exhibited good test-retest reliability and internal consistency. The PDS, PCL and DTS demonstrated the best convergent validity; the IES-R, PDS, and PCL demonstrated the best discriminant validity; and the PDS, PCL, and IES-R demonstrated the best diagnostic utility. Overall, results most strongly support the use of the PDS and the PCL for the assessment of PTSD in this population.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c59a1bea5cff48498990324b541702a8", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[16, 16], [35, 35], [182, 182]], "char_spans": [[102, 105], [192, 195], [899, 902]]}]}], "context_tokens": [["In", 0], ["this", 3], ["study", 8], ["psychometric", 14], ["properties", 27], ["of", 38], ["seven", 41], ["self", 47], ["-", 51], ["report", 52], ["measures", 59], ["of", 68], ["posttraumatic", 71], ["stress", 85], ["disorder", 92], ["(", 101], ["PTSD", 102], [")", 106], ["were", 108], ["compared", 113], [".", 121], ["The", 123], ["seven", 127], ["scales", 133], ["evaluated", 140], ["were", 150], ["the", 155], ["Davidson", 159], ["Trauma", 168], ["Scale", 175], ["(", 181], ["DTS", 182], [")", 185], [",", 186], ["the", 188], ["PTSD", 192], ["Checklist", 197], ["(", 207], ["PCL", 208], [")", 211], [",", 212], ["the", 214], ["Posttraumatic", 218], ["Stress", 232], ["Diagnostic", 239], ["Scale", 250], ["(", 256], ["PDS", 257], [")", 260], [",", 261], ["the", 263], ["Civilian", 267], ["Mississippi", 276], ["Scale", 288], ["(", 294], ["CMS", 295], [")", 298], [",", 299], ["the", 301], ["Impact", 305], ["of", 312], ["Event", 315], ["Scale", 321], ["-", 326], ["Revised", 327], ["(", 335], ["IES", 336], ["-", 339], ["R", 340], [")", 341], [",", 342], ["the", 344], ["Penn", 348], ["Inventory", 353], ["for", 363], ["Posttraumatic", 367], ["Stress", 381], ["Disorder", 388], ["(", 397], ["Penn", 398], [")", 402], [",", 403], ["and", 405], ["the", 409], ["PK", 413], ["scale", 416], ["of", 422], ["the", 425], ["MMPI-2", 429], ["(", 436], ["PK", 437], [")", 439], [".", 440], ["Participants", 442], ["were", 455], ["239", 460], ["(", 464], ["79", 465], ["male", 468], ["and", 473], ["160", 477], ["female", 481], [")", 487], ["trauma", 489], ["-", 495], ["exposed", 496], ["undergraduates", 504], [".", 518], ["All", 520], ["seven", 524], ["measures", 530], ["exhibited", 539], ["good", 549], ["test", 554], ["-", 558], ["retest", 559], ["reliability", 566], ["and", 578], ["internal", 582], ["consistency", 591], [".", 602], ["The", 604], ["PDS", 608], [",", 611], ["PCL", 613], ["and", 617], ["DTS", 621], ["demonstrated", 625], ["the", 638], ["best", 642], ["convergent", 647], ["validity", 658], [";", 666], ["the", 668], ["IES", 672], ["-", 675], ["R", 676], [",", 677], ["PDS", 679], [",", 682], ["and", 684], ["PCL", 688], ["demonstrated", 692], ["the", 705], ["best", 709], ["discriminant", 714], ["validity", 727], [";", 735], ["and", 737], ["the", 741], ["PDS", 745], [",", 748], ["PCL", 750], [",", 753], ["and", 755], ["IES", 759], ["-", 762], ["R", 763], ["demonstrated", 765], ["the", 778], ["best", 782], ["diagnostic", 787], ["utility", 798], [".", 805], ["Overall", 807], [",", 814], ["results", 816], ["most", 824], ["strongly", 829], ["support", 838], ["the", 846], ["use", 850], ["of", 854], ["the", 857], ["PDS", 861], ["and", 865], ["the", 869], ["PCL", 873], ["for", 877], ["the", 881], ["assessment", 885], ["of", 896], ["PTSD", 899], ["in", 904], ["this", 907], ["population", 912], [".", 922]]}
{"context": "To determine the utility of the Recognition of Stroke in the Emergency Room (ROSIER) scale as a stroke recognition tool among Chinese patients in the prehospital setting. Compared with the Cincinnati Prehospital Stroke Scale (CPSS), emergency physicians prospectively used the ROSIER as a stroke recognition tool on suspected patients in the prehospital setting. And, the final discharge diagnosis of stroke or transient ischemic attack made by neurologists, after assessment and review of clinical symptomatology and brain imaging findings, was used as the reference standard for diagnosis in the study. Then, the ROSIER and the CPSS like sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), related coefficient (r) and Kappa value were calculated. In this study, 540 of 582 suspected stroke patients met the study criteria. The CPSS showed a diagnostic Se of 88.77% (95% confidence intervals [CI] 86.11-91.43%), Sp of 68.79% (95% CI 64.88-72.70%), PPV of 87.40% (95% CI 85.97-88.83%), NPV of 71.52% (95% CI 67.71-75.33%) and r of 0.503. Relatively, the ROSIER showed a diagnostic Se of 89.97% (95% CI 87.44-92.64%), Sp of 83.23% (95% CI 80.08-86.38%), PPV of 92.66% (95% CI 90.46-94.86%), NPV of 77.91% (95% CI 74.41-81.41%) and r of 0.584. According to the final discharge diagnosis, both the ROSIER and the CPSS were associated with the final discharge diagnosis (P < 0.05).The Kappa statistic value of the ROSIER and the CPSS were 0.718 and 0.582, respectively. However, there was no statistical significance of the positive rate between the ROSIER and the CPSS in this study (P > 0.05). The ROSIER is a sensitive and specific stroke recognition tool for health providers' use among Chinese patients in the prehospital setting. However, it cannot be used to confidently rule out or identify stroke as a diagnosis. Comprehensive clinical assessment and further examination on potential stroke patients are still important and cannot be replaced. When it is difficult to objectively complete the ROSIER for patients, the CPSS could replace it in the prehospital setting.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "25d0a087f52d435dbd25e710f1920dd1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[367, 367], [35, 35], [67, 67], [19, 19], [396, 396], [151, 151], [409, 409], [8, 8], [49, 49]], "char_spans": [[1681, 1686], [212, 217], [401, 406], [96, 101], [1845, 1850], [835, 840], [1939, 1944], [47, 52], [289, 294]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["utility", 17], ["of", 25], ["the", 28], ["Recognition", 32], ["of", 44], ["Stroke", 47], ["in", 54], ["the", 57], ["Emergency", 61], ["Room", 71], ["(", 76], ["ROSIER", 77], [")", 83], ["scale", 85], ["as", 91], ["a", 94], ["stroke", 96], ["recognition", 103], ["tool", 115], ["among", 120], ["Chinese", 126], ["patients", 134], ["in", 143], ["the", 146], ["prehospital", 150], ["setting", 162], [".", 169], ["Compared", 171], ["with", 180], ["the", 185], ["Cincinnati", 189], ["Prehospital", 200], ["Stroke", 212], ["Scale", 219], ["(", 225], ["CPSS", 226], [")", 230], [",", 231], ["emergency", 233], ["physicians", 243], ["prospectively", 254], ["used", 268], ["the", 273], ["ROSIER", 277], ["as", 284], ["a", 287], ["stroke", 289], ["recognition", 296], ["tool", 308], ["on", 313], ["suspected", 316], ["patients", 326], ["in", 335], ["the", 338], ["prehospital", 342], ["setting", 354], [".", 361], ["And", 363], [",", 366], ["the", 368], ["final", 372], ["discharge", 378], ["diagnosis", 388], ["of", 398], ["stroke", 401], ["or", 408], ["transient", 411], ["ischemic", 421], ["attack", 430], ["made", 437], ["by", 442], ["neurologists", 445], [",", 457], ["after", 459], ["assessment", 465], ["and", 476], ["review", 480], ["of", 487], ["clinical", 490], ["symptomatology", 499], ["and", 514], ["brain", 518], ["imaging", 524], ["findings", 532], [",", 540], ["was", 542], ["used", 546], ["as", 551], ["the", 554], ["reference", 558], ["standard", 568], ["for", 577], ["diagnosis", 581], ["in", 591], ["the", 594], ["study", 598], [".", 603], ["Then", 605], [",", 609], ["the", 611], ["ROSIER", 615], ["and", 622], ["the", 626], ["CPSS", 630], ["like", 635], ["sensitivity", 640], ["(", 652], ["Se", 653], [")", 655], [",", 656], ["specificity", 658], ["(", 670], ["Sp", 671], [")", 673], [",", 674], ["positive", 676], ["predictive", 685], ["value", 696], ["(", 702], ["PPV", 703], [")", 706], [",", 707], ["negative", 709], ["predictive", 718], ["value", 729], ["(", 735], ["NPV", 736], [")", 739], [",", 740], ["related", 742], ["coefficient", 750], ["(", 762], ["r", 763], [")", 764], ["and", 766], ["Kappa", 770], ["value", 776], ["were", 782], ["calculated", 787], [".", 797], ["In", 799], ["this", 802], ["study", 807], [",", 812], ["540", 814], ["of", 818], ["582", 821], ["suspected", 825], ["stroke", 835], ["patients", 842], ["met", 851], ["the", 855], ["study", 859], ["criteria", 865], [".", 873], ["The", 875], ["CPSS", 879], ["showed", 884], ["a", 891], ["diagnostic", 893], ["Se", 904], ["of", 907], ["88.77", 910], ["%", 915], ["(", 917], ["95", 918], ["%", 920], ["confidence", 922], ["intervals", 933], ["[", 943], ["CI", 944], ["]", 946], ["86.11", 948], ["-", 953], ["91.43", 954], ["%", 959], [")", 960], [",", 961], ["Sp", 963], ["of", 966], ["68.79", 969], ["%", 974], ["(", 976], ["95", 977], ["%", 979], ["CI", 981], ["64.88", 984], ["-", 989], ["72.70", 990], ["%", 995], [")", 996], [",", 997], ["PPV", 999], ["of", 1003], ["87.40", 1006], ["%", 1011], ["(", 1013], ["95", 1014], ["%", 1016], ["CI", 1018], ["85.97", 1021], ["-", 1026], ["88.83", 1027], ["%", 1032], [")", 1033], [",", 1034], ["NPV", 1036], ["of", 1040], ["71.52", 1043], ["%", 1048], ["(", 1050], ["95", 1051], ["%", 1053], ["CI", 1055], ["67.71", 1058], ["-", 1063], ["75.33", 1064], ["%", 1069], [")", 1070], ["and", 1072], ["r", 1076], ["of", 1078], ["0.503", 1081], [".", 1086], ["Relatively", 1088], [",", 1098], ["the", 1100], ["ROSIER", 1104], ["showed", 1111], ["a", 1118], ["diagnostic", 1120], ["Se", 1131], ["of", 1134], ["89.97", 1137], ["%", 1142], ["(", 1144], ["95", 1145], ["%", 1147], ["CI", 1149], ["87.44", 1152], ["-", 1157], ["92.64", 1158], ["%", 1163], [")", 1164], [",", 1165], ["Sp", 1167], ["of", 1170], ["83.23", 1173], ["%", 1178], ["(", 1180], ["95", 1181], ["%", 1183], ["CI", 1185], ["80.08", 1188], ["-", 1193], ["86.38", 1194], ["%", 1199], [")", 1200], [",", 1201], ["PPV", 1203], ["of", 1207], ["92.66", 1210], ["%", 1215], ["(", 1217], ["95", 1218], ["%", 1220], ["CI", 1222], ["90.46", 1225], ["-", 1230], ["94.86", 1231], ["%", 1236], [")", 1237], [",", 1238], ["NPV", 1240], ["of", 1244], ["77.91", 1247], ["%", 1252], ["(", 1254], ["95", 1255], ["%", 1257], ["CI", 1259], ["74.41", 1262], ["-", 1267], ["81.41", 1268], ["%", 1273], [")", 1274], ["and", 1276], ["r", 1280], ["of", 1282], ["0.584", 1285], [".", 1290], ["According", 1292], ["to", 1302], ["the", 1305], ["final", 1309], ["discharge", 1315], ["diagnosis", 1325], [",", 1334], ["both", 1336], ["the", 1341], ["ROSIER", 1345], ["and", 1352], ["the", 1356], ["CPSS", 1360], ["were", 1365], ["associated", 1370], ["with", 1381], ["the", 1386], ["final", 1390], ["discharge", 1396], ["diagnosis", 1406], ["(", 1416], ["P", 1417], ["<", 1419], ["0.05).The", 1421], ["Kappa", 1431], ["statistic", 1437], ["value", 1447], ["of", 1453], ["the", 1456], ["ROSIER", 1460], ["and", 1467], ["the", 1471], ["CPSS", 1475], ["were", 1480], ["0.718", 1485], ["and", 1491], ["0.582", 1495], [",", 1500], ["respectively", 1502], [".", 1514], ["However", 1516], [",", 1523], ["there", 1525], ["was", 1531], ["no", 1535], ["statistical", 1538], ["significance", 1550], ["of", 1563], ["the", 1566], ["positive", 1570], ["rate", 1579], ["between", 1584], ["the", 1592], ["ROSIER", 1596], ["and", 1603], ["the", 1607], ["CPSS", 1611], ["in", 1616], ["this", 1619], ["study", 1624], ["(", 1630], ["P", 1631], [">", 1633], ["0.05", 1635], [")", 1639], [".", 1640], ["The", 1642], ["ROSIER", 1646], ["is", 1653], ["a", 1656], ["sensitive", 1658], ["and", 1668], ["specific", 1672], ["stroke", 1681], ["recognition", 1688], ["tool", 1700], ["for", 1705], ["health", 1709], ["providers", 1716], ["'", 1725], ["use", 1727], ["among", 1731], ["Chinese", 1737], ["patients", 1745], ["in", 1754], ["the", 1757], ["prehospital", 1761], ["setting", 1773], [".", 1780], ["However", 1782], [",", 1789], ["it", 1791], ["can", 1794], ["not", 1797], ["be", 1801], ["used", 1804], ["to", 1809], ["confidently", 1812], ["rule", 1824], ["out", 1829], ["or", 1833], ["identify", 1836], ["stroke", 1845], ["as", 1852], ["a", 1855], ["diagnosis", 1857], [".", 1866], ["Comprehensive", 1868], ["clinical", 1882], ["assessment", 1891], ["and", 1902], ["further", 1906], ["examination", 1914], ["on", 1926], ["potential", 1929], ["stroke", 1939], ["patients", 1946], ["are", 1955], ["still", 1959], ["important", 1965], ["and", 1975], ["can", 1979], ["not", 1982], ["be", 1986], ["replaced", 1989], [".", 1997], ["When", 1999], ["it", 2004], ["is", 2007], ["difficult", 2010], ["to", 2020], ["objectively", 2023], ["complete", 2035], ["the", 2044], ["ROSIER", 2048], ["for", 2055], ["patients", 2059], [",", 2067], ["the", 2069], ["CPSS", 2073], ["could", 2078], ["replace", 2084], ["it", 2092], ["in", 2095], ["the", 2098], ["prehospital", 2102], ["setting", 2114], [".", 2121]]}
{"context": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrythmogenic disease characterized by exercise--or stress--induced ventricular tachyarrythmias, syncope, or sudden death, usually in the pediatric age group. Familial occurrence has been noted in about 30% of cases. Inheritance may be autosomal dominant or recessive, usually with high penetrance. The causative genes have been mapped to chromosome 1. Mutations of the cardiac ryanodine receptor gene (RyR2) have been identified in autosomal dominant pedigrees, while calsequestrin gene (CASQ2) mutations are seen in recessive cases. Due to its potential lethal outcome, exclusion or confirmation of catecholaminergic polymorphic ventricular tachycardia in children with physical and emotional syncope is mandatory. We report a case of catecholaminergic polymorphic ventricular tachycardia in a three-year-old child only diagnosed by genetic mapping.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "023fcc86e5c846d2b6220e8e9e90de4c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[85, 86], [51, 52]], "char_spans": [[504, 521], [307, 324]]}]}], "context_tokens": [["Catecholaminergic", 0], ["polymorphic", 18], ["ventricular", 30], ["tachycardia", 42], ["(", 54], ["CPVT", 55], [")", 59], ["is", 61], ["a", 64], ["rare", 66], ["arrythmogenic", 71], ["disease", 85], ["characterized", 93], ["by", 107], ["exercise", 110], ["--", 118], ["or", 120], ["stress", 123], ["--", 129], ["induced", 131], ["ventricular", 139], ["tachyarrythmias", 151], [",", 166], ["syncope", 168], [",", 175], ["or", 177], ["sudden", 180], ["death", 187], [",", 192], ["usually", 194], ["in", 202], ["the", 205], ["pediatric", 209], ["age", 219], ["group", 223], [".", 228], ["Familial", 230], ["occurrence", 239], ["has", 250], ["been", 254], ["noted", 259], ["in", 265], ["about", 268], ["30", 274], ["%", 276], ["of", 278], ["cases", 281], [".", 286], ["Inheritance", 288], ["may", 300], ["be", 304], ["autosomal", 307], ["dominant", 317], ["or", 326], ["recessive", 329], [",", 338], ["usually", 340], ["with", 348], ["high", 353], ["penetrance", 358], [".", 368], ["The", 370], ["causative", 374], ["genes", 384], ["have", 390], ["been", 395], ["mapped", 400], ["to", 407], ["chromosome", 410], ["1", 421], [".", 422], ["Mutations", 424], ["of", 434], ["the", 437], ["cardiac", 441], ["ryanodine", 449], ["receptor", 459], ["gene", 468], ["(", 473], ["RyR2", 474], [")", 478], ["have", 480], ["been", 485], ["identified", 490], ["in", 501], ["autosomal", 504], ["dominant", 514], ["pedigrees", 523], [",", 532], ["while", 534], ["calsequestrin", 540], ["gene", 554], ["(", 559], ["CASQ2", 560], [")", 565], ["mutations", 567], ["are", 577], ["seen", 581], ["in", 586], ["recessive", 589], ["cases", 599], [".", 604], ["Due", 606], ["to", 610], ["its", 613], ["potential", 617], ["lethal", 627], ["outcome", 634], [",", 641], ["exclusion", 643], ["or", 653], ["confirmation", 656], ["of", 669], ["catecholaminergic", 672], ["polymorphic", 690], ["ventricular", 702], ["tachycardia", 714], ["in", 726], ["children", 729], ["with", 738], ["physical", 743], ["and", 752], ["emotional", 756], ["syncope", 766], ["is", 774], ["mandatory", 777], [".", 786], ["We", 788], ["report", 791], ["a", 798], ["case", 800], ["of", 805], ["catecholaminergic", 808], ["polymorphic", 826], ["ventricular", 838], ["tachycardia", 850], ["in", 862], ["a", 865], ["three", 867], ["-", 872], ["year", 873], ["-", 877], ["old", 878], ["child", 882], ["only", 888], ["diagnosed", 893], ["by", 903], ["genetic", 906], ["mapping", 914], [".", 921]]}
{"context": "Although malaria has become a serious public health problem in Mauritania since the late 1990s, few documented data on its epidemiology exist. The objective of this study was to assess the morbidity of clinical malaria among children in Nouakchott. Three hundred and one febrile children, consulting at three health facilities of Nouakchott, were screened for malaria in 2009 (n=216) and 2010 (n=85). Plasmodium species identification and parasite density were determined by microscopic examination of Giemsa-stained thin and thick films and confirmed by rapid diagnostic test and nested PCR. Of 301 febrile children, 105 (34.9%) were malaria-positive by nested PCR and 87 (28.9%) by microscopy. Plasmodium vivax represented 97.1% (102/105) and P. falciparum accounted for 2.9% (3/105) of positive cases. All positive children under five years old were infected with P. vivax. The highest numbers of malaria positives were found during or shortly after the rainy season and the lowest during the dry season. Fifty-four of 105 (51.4%) malaria cases, all with P. vivax, had never travelled outside Nouakchott. Individuals belonging to the Moors ethnic group represented 97.0% of P. vivax cases. Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent. Regular surveillance is required to monitor malaria prevalence and incidence, and further measures are needed to counter the possible spread of malaria in the country.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "03a16d0eb3134070ad262ad943d2c738", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[72, 73]], "char_spans": [[401, 418]]}]}], "context_tokens": [["Although", 0], ["malaria", 9], ["has", 17], ["become", 21], ["a", 28], ["serious", 30], ["public", 38], ["health", 45], ["problem", 52], ["in", 60], ["Mauritania", 63], ["since", 74], ["the", 80], ["late", 84], ["1990s", 89], [",", 94], ["few", 96], ["documented", 100], ["data", 111], ["on", 116], ["its", 119], ["epidemiology", 123], ["exist", 136], [".", 141], ["The", 143], ["objective", 147], ["of", 157], ["this", 160], ["study", 165], ["was", 171], ["to", 175], ["assess", 178], ["the", 185], ["morbidity", 189], ["of", 199], ["clinical", 202], ["malaria", 211], ["among", 219], ["children", 225], ["in", 234], ["Nouakchott", 237], [".", 247], ["Three", 249], ["hundred", 255], ["and", 263], ["one", 267], ["febrile", 271], ["children", 279], [",", 287], ["consulting", 289], ["at", 300], ["three", 303], ["health", 309], ["facilities", 316], ["of", 327], ["Nouakchott", 330], [",", 340], ["were", 342], ["screened", 347], ["for", 356], ["malaria", 360], ["in", 368], ["2009", 371], ["(", 376], ["n=216", 377], [")", 382], ["and", 384], ["2010", 388], ["(", 393], ["n=85", 394], [")", 398], [".", 399], ["Plasmodium", 401], ["species", 412], ["identification", 420], ["and", 435], ["parasite", 439], ["density", 448], ["were", 456], ["determined", 461], ["by", 472], ["microscopic", 475], ["examination", 487], ["of", 499], ["Giemsa", 502], ["-", 508], ["stained", 509], ["thin", 517], ["and", 522], ["thick", 526], ["films", 532], ["and", 538], ["confirmed", 542], ["by", 552], ["rapid", 555], ["diagnostic", 561], ["test", 572], ["and", 577], ["nested", 581], ["PCR", 588], [".", 591], ["Of", 593], ["301", 596], ["febrile", 600], ["children", 608], [",", 616], ["105", 618], ["(", 622], ["34.9", 623], ["%", 627], [")", 628], ["were", 630], ["malaria", 635], ["-", 642], ["positive", 643], ["by", 652], ["nested", 655], ["PCR", 662], ["and", 666], ["87", 670], ["(", 673], ["28.9", 674], ["%", 678], [")", 679], ["by", 681], ["microscopy", 684], [".", 694], ["Plasmodium", 696], ["vivax", 707], ["represented", 713], ["97.1", 725], ["%", 729], ["(", 731], ["102/105", 732], [")", 739], ["and", 741], ["P.", 745], ["falciparum", 748], ["accounted", 759], ["for", 769], ["2.9", 773], ["%", 776], ["(", 778], ["3/105", 779], [")", 784], ["of", 786], ["positive", 789], ["cases", 798], [".", 803], ["All", 805], ["positive", 809], ["children", 818], ["under", 827], ["five", 833], ["years", 838], ["old", 844], ["were", 848], ["infected", 853], ["with", 862], ["P.", 867], ["vivax", 870], [".", 875], ["The", 877], ["highest", 881], ["numbers", 889], ["of", 897], ["malaria", 900], ["positives", 908], ["were", 918], ["found", 923], ["during", 929], ["or", 936], ["shortly", 939], ["after", 947], ["the", 953], ["rainy", 957], ["season", 963], ["and", 970], ["the", 974], ["lowest", 978], ["during", 985], ["the", 992], ["dry", 996], ["season", 1000], [".", 1006], ["Fifty", 1008], ["-", 1013], ["four", 1014], ["of", 1019], ["105", 1022], ["(", 1026], ["51.4", 1027], ["%", 1031], [")", 1032], ["malaria", 1034], ["cases", 1042], [",", 1047], ["all", 1049], ["with", 1053], ["P.", 1058], ["vivax", 1061], [",", 1066], ["had", 1068], ["never", 1072], ["travelled", 1078], ["outside", 1088], ["Nouakchott", 1096], [".", 1106], ["Individuals", 1108], ["belonging", 1120], ["to", 1130], ["the", 1133], ["Moors", 1137], ["ethnic", 1143], ["group", 1150], ["represented", 1156], ["97.0", 1168], ["%", 1172], ["of", 1174], ["P.", 1177], ["vivax", 1180], ["cases", 1186], [".", 1191], ["Results", 1193], ["of", 1201], ["the", 1204], ["present", 1208], ["study", 1216], ["indicate", 1222], ["that", 1231], ["malaria", 1236], ["is", 1244], ["endemic", 1247], ["in", 1255], ["Nouakchott", 1258], ["and", 1269], ["that", 1273], ["P.", 1278], ["vivax", 1281], ["is", 1287], ["the", 1290], ["principal", 1294], ["causative", 1304], ["agent", 1314], [".", 1319], ["Regular", 1321], ["surveillance", 1329], ["is", 1342], ["required", 1345], ["to", 1354], ["monitor", 1357], ["malaria", 1365], ["prevalence", 1373], ["and", 1384], ["incidence", 1388], [",", 1397], ["and", 1399], ["further", 1403], ["measures", 1411], ["are", 1420], ["needed", 1424], ["to", 1431], ["counter", 1434], ["the", 1442], ["possible", 1446], ["spread", 1455], ["of", 1462], ["malaria", 1465], ["in", 1473], ["the", 1476], ["country", 1480], [".", 1487]]}
{"context": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB). These defects were unaltered in rrm3 sir2 cells. When the RFB binding Fob1p was deleted, rrm3-generated defects at the RFB were eliminated, but defects at other rDNA sites were not affected. Thus, specific protein-DNA complexes make replication Rrm3p-dependent. Because rrm3-induced increases in recombination and cell cycle length were only partially suppressed in rrm3 fob1 cells, which still required checkpoint and fork restart activities for viability, non-RFB rrm3-induced defects contribute to rDNA fragility and genome instability.", "qas": [{"question": "What is the effect of the absence of Saccharomyces cerevisiae Rrm3p?", "answers": ["Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB)."], "qid": "04968485f4484dcc9b26ebe6b289ca4e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["the", 22], ["absence", 26], ["of", 34], ["Saccharomyces", 37], ["cerevisiae", 51], ["Rrm3p", 62], ["?", 67]], "detected_answers": [{"text": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB).", "token_spans": [[0, 27]], "char_spans": [[0, 156]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["the", 8], ["yeast", 12], ["Rrm3p", 18], ["DNA", 24], ["helicase", 28], ["causes", 37], ["replication", 44], ["defects", 56], ["at", 64], ["multiple", 67], ["sites", 76], ["within", 82], ["ribosomal", 89], ["DNA", 99], ["(", 103], ["rDNA", 104], [")", 108], [",", 109], ["including", 111], ["at", 121], ["the", 124], ["replication", 128], ["fork", 140], ["barrier", 145], ["(", 153], ["RFB", 154], [")", 157], [".", 158], ["These", 160], ["defects", 166], ["were", 174], ["unaltered", 179], ["in", 189], ["rrm3", 192], ["sir2", 197], ["cells", 202], [".", 207], ["When", 209], ["the", 214], ["RFB", 218], ["binding", 222], ["Fob1p", 230], ["was", 236], ["deleted", 240], [",", 247], ["rrm3-generated", 249], ["defects", 264], ["at", 272], ["the", 275], ["RFB", 279], ["were", 283], ["eliminated", 288], [",", 298], ["but", 300], ["defects", 304], ["at", 312], ["other", 315], ["rDNA", 321], ["sites", 326], ["were", 332], ["not", 337], ["affected", 341], [".", 349], ["Thus", 351], [",", 355], ["specific", 357], ["protein", 366], ["-", 373], ["DNA", 374], ["complexes", 378], ["make", 388], ["replication", 393], ["Rrm3p", 405], ["-", 410], ["dependent", 411], [".", 420], ["Because", 422], ["rrm3-induced", 430], ["increases", 443], ["in", 453], ["recombination", 456], ["and", 470], ["cell", 474], ["cycle", 479], ["length", 485], ["were", 492], ["only", 497], ["partially", 502], ["suppressed", 512], ["in", 523], ["rrm3", 526], ["fob1", 531], ["cells", 536], [",", 541], ["which", 543], ["still", 549], ["required", 555], ["checkpoint", 564], ["and", 575], ["fork", 579], ["restart", 584], ["activities", 592], ["for", 603], ["viability", 607], [",", 616], ["non", 618], ["-", 621], ["RFB", 622], ["rrm3-induced", 626], ["defects", 639], ["contribute", 647], ["to", 658], ["rDNA", 661], ["fragility", 666], ["and", 676], ["genome", 680], ["instability", 687], [".", 698]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "Although first described as early as 1898 and long considered a vestigial organelle of little functional importance, the primary cilium has become one of the hottest research topics in modern cell biology and physiology. Primary cilia are nonmotile sensory organelles present in a single copy on the surface of most growth-arrested or differentiated mammalian cells, and defects in their assembly or function are tightly coupled to many developmental defects, diseases and disorders. In normal tissues, the primary cilium coordinates a series of signal transduction pathways, including Hedgehog, Wnt, PDGFRalpha and integrin signaling. In the kidney, the primary cilium may function as a mechano-, chemo- and osmosensing unit that probes the extracellular environment and transmits signals to the cell via, e.g., polycystins, which depend on ciliary localization for appropriate function. Indeed, hypomorphic mutations in the mouse ift88 (previously called Tg737) gene, which encodes a ciliogenic intraflagellar transport protein, result in malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD). While PKD was one of the first diseases to be linked to dysfunctional primary cilia, defects in this organelle have subsequently been associated with many other phenotypes, including cancer, obesity, diabetes as well as a number of developmental defects. Collectively, these disorders of the cilium are now referred to as the ciliopathies. In this review, we provide a brief overview of the structure and function of primary cilia and some of their roles in coordinating signal transduction pathways in mammalian development, health and disease.", "qas": [{"question": "Which is the most common disease attributed to malfunction or absence of primary cilia?", "answers": ["Polycystic kidney disease (PKD)"], "qid": "f11dbef10d7344129874377bdcfdef01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["disease", 25], ["attributed", 33], ["to", 44], ["malfunction", 47], ["or", 59], ["absence", 62], ["of", 70], ["primary", 73], ["cilia", 81], ["?", 86]], "detected_answers": [{"text": "Polycystic kidney disease (PKD)", "token_spans": [[193, 197]], "char_spans": [[1176, 1205]]}]}], "context_tokens": [["Although", 0], ["first", 9], ["described", 15], ["as", 25], ["early", 28], ["as", 34], ["1898", 37], ["and", 42], ["long", 46], ["considered", 51], ["a", 62], ["vestigial", 64], ["organelle", 74], ["of", 84], ["little", 87], ["functional", 94], ["importance", 105], [",", 115], ["the", 117], ["primary", 121], ["cilium", 129], ["has", 136], ["become", 140], ["one", 147], ["of", 151], ["the", 154], ["hottest", 158], ["research", 166], ["topics", 175], ["in", 182], ["modern", 185], ["cell", 192], ["biology", 197], ["and", 205], ["physiology", 209], [".", 219], ["Primary", 221], ["cilia", 229], ["are", 235], ["nonmotile", 239], ["sensory", 249], ["organelles", 257], ["present", 268], ["in", 276], ["a", 279], ["single", 281], ["copy", 288], ["on", 293], ["the", 296], ["surface", 300], ["of", 308], ["most", 311], ["growth", 316], ["-", 322], ["arrested", 323], ["or", 332], ["differentiated", 335], ["mammalian", 350], ["cells", 360], [",", 365], ["and", 367], ["defects", 371], ["in", 379], ["their", 382], ["assembly", 388], ["or", 397], ["function", 400], ["are", 409], ["tightly", 413], ["coupled", 421], ["to", 429], ["many", 432], ["developmental", 437], ["defects", 451], [",", 458], ["diseases", 460], ["and", 469], ["disorders", 473], [".", 482], ["In", 484], ["normal", 487], ["tissues", 494], [",", 501], ["the", 503], ["primary", 507], ["cilium", 515], ["coordinates", 522], ["a", 534], ["series", 536], ["of", 543], ["signal", 546], ["transduction", 553], ["pathways", 566], [",", 574], ["including", 576], ["Hedgehog", 586], [",", 594], ["Wnt", 596], [",", 599], ["PDGFRalpha", 601], ["and", 612], ["integrin", 616], ["signaling", 625], [".", 634], ["In", 636], ["the", 639], ["kidney", 643], [",", 649], ["the", 651], ["primary", 655], ["cilium", 663], ["may", 670], ["function", 674], ["as", 683], ["a", 686], ["mechano-", 688], [",", 696], ["chemo-", 698], ["and", 705], ["osmosensing", 709], ["unit", 721], ["that", 726], ["probes", 731], ["the", 738], ["extracellular", 742], ["environment", 756], ["and", 768], ["transmits", 772], ["signals", 782], ["to", 790], ["the", 793], ["cell", 797], ["via", 802], [",", 805], ["e.g.", 807], [",", 811], ["polycystins", 813], [",", 824], ["which", 826], ["depend", 832], ["on", 839], ["ciliary", 842], ["localization", 850], ["for", 863], ["appropriate", 867], ["function", 879], [".", 887], ["Indeed", 889], [",", 895], ["hypomorphic", 897], ["mutations", 909], ["in", 919], ["the", 922], ["mouse", 926], ["ift88", 932], ["(", 938], ["previously", 939], ["called", 950], ["Tg737", 957], [")", 962], ["gene", 964], [",", 968], ["which", 970], ["encodes", 976], ["a", 984], ["ciliogenic", 986], ["intraflagellar", 997], ["transport", 1012], ["protein", 1022], [",", 1029], ["result", 1031], ["in", 1038], ["malformation", 1041], ["of", 1054], ["primary", 1057], ["cilia", 1065], [",", 1070], ["and", 1072], ["in", 1076], ["the", 1079], ["collecting", 1083], ["ducts", 1094], ["of", 1100], ["kidney", 1103], ["tubules", 1110], ["this", 1118], ["is", 1123], ["accompanied", 1126], ["by", 1138], ["development", 1141], ["of", 1153], ["autosomal", 1156], ["recessive", 1166], ["polycystic", 1176], ["kidney", 1187], ["disease", 1194], ["(", 1202], ["PKD", 1203], [")", 1206], [".", 1207], ["While", 1209], ["PKD", 1215], ["was", 1219], ["one", 1223], ["of", 1227], ["the", 1230], ["first", 1234], ["diseases", 1240], ["to", 1249], ["be", 1252], ["linked", 1255], ["to", 1262], ["dysfunctional", 1265], ["primary", 1279], ["cilia", 1287], [",", 1292], ["defects", 1294], ["in", 1302], ["this", 1305], ["organelle", 1310], ["have", 1320], ["subsequently", 1325], ["been", 1338], ["associated", 1343], ["with", 1354], ["many", 1359], ["other", 1364], ["phenotypes", 1370], [",", 1380], ["including", 1382], ["cancer", 1392], [",", 1398], ["obesity", 1400], [",", 1407], ["diabetes", 1409], ["as", 1418], ["well", 1421], ["as", 1426], ["a", 1429], ["number", 1431], ["of", 1438], ["developmental", 1441], ["defects", 1455], [".", 1462], ["Collectively", 1464], [",", 1476], ["these", 1478], ["disorders", 1484], ["of", 1494], ["the", 1497], ["cilium", 1501], ["are", 1508], ["now", 1512], ["referred", 1516], ["to", 1525], ["as", 1528], ["the", 1531], ["ciliopathies", 1535], [".", 1547], ["In", 1549], ["this", 1552], ["review", 1557], [",", 1563], ["we", 1565], ["provide", 1568], ["a", 1576], ["brief", 1578], ["overview", 1584], ["of", 1593], ["the", 1596], ["structure", 1600], ["and", 1610], ["function", 1614], ["of", 1623], ["primary", 1626], ["cilia", 1634], ["and", 1640], ["some", 1644], ["of", 1649], ["their", 1652], ["roles", 1658], ["in", 1664], ["coordinating", 1667], ["signal", 1680], ["transduction", 1687], ["pathways", 1700], ["in", 1709], ["mammalian", 1712], ["development", 1722], [",", 1733], ["health", 1735], ["and", 1742], ["disease", 1746], [".", 1753]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "To determine if flumazenil, when used in doses higher than those currently recommended, could reverse the effects of a benzodiazepine (BDZ) overdose in patients who might not otherwise respond and whether the higher dose was associated with increased adverse effects. Multicenter, randomized, double-blind, placebo-controlled, balanced, with parallel groups. Open-label flumazenil administration was available if a patient failed to respond or became resedated. Sixteen emergency departments in the United States. Patients presenting to the ED with clinically significant signs and symptoms of a known or suspected BDZ overdose. Patients were randomized to receive 10 mL/min of placebo or flumazenil (1 mg/10 mL) each minute for ten minutes. If there was no response, up to 3 mg of open-label flumazenil could be administered. Of 170 patients enrolled, 87 received flumazenil and 83 received placebo. The demographic characteristics of both groups were comparable. Ten minutes after the beginning of study drug infusion, patients were evaluated using the Clinical Global Impression Scale (CGIS), Glasgow Coma Scale (GSC), and Neurobehavioral Assessment Scale (NAS). The mean +/- SD CGIS score at ten minutes for BDZ-positive patients was 1.41 +/- 0.72 for patients who received flumazenil and 3.41 +/- 0.91 for the placebo group (P < .01). There was no difference in the mean CGIS score between the flumazenil (3.25 +/- 1.15) and placebo (3.75 +/- 0.69) groups in BDZ-negative patients. The GCS and NAS were also significantly better in patients who were BDZ-positive and received flumazenil. The mean +/- SD dose of flumazenil administered during the double-blind phase was 71.3 +/- 34.2 mL (7.13 mg) compared with 95.06 +/- 16.03 mL of placebo. Of the 39 patients who had BDZ-positive drug screens and received flumazenil, 29 (74%) responded to 3 mg or less. Six additional patients responded to 4 or 5 mg, and one patient responded to 8 mg. The most common adverse effects in patients who received flumazenil were injection site pain (10.3%), agitation (8%), vomiting (3.4%), dizziness (3.4%), headache (3.4%), tachycardia (3.4%), and crying (3.4%). Three patients developed seizures. Two were associated with significant tricyclic antidepressant overdoses and one with propoxyphene ingestion. Two patients had positive drug screens for BDZ. Flumazenil rapidly and effectively reverses the clinical signs and symptoms of a BDZ overdose. Most patients will respond to 3 mg or less, but a small number may require a higher dose for reversal of clinical symptoms. Patients with concomitant tricyclic antidepressant overdose may be at risk for developing seizures.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "bdaa9885c8734f2a9a3843206e721bc1", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[157, 157], [3, 3], [234, 234], [261, 261], [309, 309], [466, 466], [300, 300], [119, 119], [391, 391], [66, 66], [145, 145], [350, 350]], "char_spans": [[865, 874], [16, 25], [1278, 1287], [1399, 1408], [1617, 1626], [2345, 2354], [1581, 1590], [689, 698], [2001, 2010], [370, 379], [793, 802], [1813, 1822]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["if", 13], ["flumazenil", 16], [",", 26], ["when", 28], ["used", 33], ["in", 38], ["doses", 41], ["higher", 47], ["than", 54], ["those", 59], ["currently", 65], ["recommended", 75], [",", 86], ["could", 88], ["reverse", 94], ["the", 102], ["effects", 106], ["of", 114], ["a", 117], ["benzodiazepine", 119], ["(", 134], ["BDZ", 135], [")", 138], ["overdose", 140], ["in", 149], ["patients", 152], ["who", 161], ["might", 165], ["not", 171], ["otherwise", 175], ["respond", 185], ["and", 193], ["whether", 197], ["the", 205], ["higher", 209], ["dose", 216], ["was", 221], ["associated", 225], ["with", 236], ["increased", 241], ["adverse", 251], ["effects", 259], [".", 266], ["Multicenter", 268], [",", 279], ["randomized", 281], [",", 291], ["double", 293], ["-", 299], ["blind", 300], [",", 305], ["placebo", 307], ["-", 314], ["controlled", 315], [",", 325], ["balanced", 327], [",", 335], ["with", 337], ["parallel", 342], ["groups", 351], [".", 357], ["Open", 359], ["-", 363], ["label", 364], ["flumazenil", 370], ["administration", 381], ["was", 396], ["available", 400], ["if", 410], ["a", 413], ["patient", 415], ["failed", 423], ["to", 430], ["respond", 433], ["or", 441], ["became", 444], ["resedated", 451], [".", 460], ["Sixteen", 462], ["emergency", 470], ["departments", 480], ["in", 492], ["the", 495], ["United", 499], ["States", 506], [".", 512], ["Patients", 514], ["presenting", 523], ["to", 534], ["the", 537], ["ED", 541], ["with", 544], ["clinically", 549], ["significant", 560], ["signs", 572], ["and", 578], ["symptoms", 582], ["of", 591], ["a", 594], ["known", 596], ["or", 602], ["suspected", 605], ["BDZ", 615], ["overdose", 619], [".", 627], ["Patients", 629], ["were", 638], ["randomized", 643], ["to", 654], ["receive", 657], ["10", 665], ["mL", 668], ["/", 670], ["min", 671], ["of", 675], ["placebo", 678], ["or", 686], ["flumazenil", 689], ["(", 700], ["1", 701], ["mg/10", 703], ["mL", 709], [")", 711], ["each", 713], ["minute", 718], ["for", 725], ["ten", 729], ["minutes", 733], [".", 740], ["If", 742], ["there", 745], ["was", 751], ["no", 755], ["response", 758], [",", 766], ["up", 768], ["to", 771], ["3", 774], ["mg", 776], ["of", 779], ["open", 782], ["-", 786], ["label", 787], ["flumazenil", 793], ["could", 804], ["be", 810], ["administered", 813], [".", 825], ["Of", 827], ["170", 830], ["patients", 834], ["enrolled", 843], [",", 851], ["87", 853], ["received", 856], ["flumazenil", 865], ["and", 876], ["83", 880], ["received", 883], ["placebo", 892], [".", 899], ["The", 901], ["demographic", 905], ["characteristics", 917], ["of", 933], ["both", 936], ["groups", 941], ["were", 948], ["comparable", 953], [".", 963], ["Ten", 965], ["minutes", 969], ["after", 977], ["the", 983], ["beginning", 987], ["of", 997], ["study", 1000], ["drug", 1006], ["infusion", 1011], [",", 1019], ["patients", 1021], ["were", 1030], ["evaluated", 1035], ["using", 1045], ["the", 1051], ["Clinical", 1055], ["Global", 1064], ["Impression", 1071], ["Scale", 1082], ["(", 1088], ["CGIS", 1089], [")", 1093], [",", 1094], ["Glasgow", 1096], ["Coma", 1104], ["Scale", 1109], ["(", 1115], ["GSC", 1116], [")", 1119], [",", 1120], ["and", 1122], ["Neurobehavioral", 1126], ["Assessment", 1142], ["Scale", 1153], ["(", 1159], ["NAS", 1160], [")", 1163], [".", 1164], ["The", 1166], ["mean", 1170], ["+", 1175], ["/-", 1176], ["SD", 1179], ["CGIS", 1182], ["score", 1187], ["at", 1193], ["ten", 1196], ["minutes", 1200], ["for", 1208], ["BDZ", 1212], ["-", 1215], ["positive", 1216], ["patients", 1225], ["was", 1234], ["1.41", 1238], ["+", 1243], ["/-", 1244], ["0.72", 1247], ["for", 1252], ["patients", 1256], ["who", 1265], ["received", 1269], ["flumazenil", 1278], ["and", 1289], ["3.41", 1293], ["+", 1298], ["/-", 1299], ["0.91", 1302], ["for", 1307], ["the", 1311], ["placebo", 1315], ["group", 1323], ["(", 1329], ["P", 1330], ["<", 1332], [".01", 1334], [")", 1337], [".", 1338], ["There", 1340], ["was", 1346], ["no", 1350], ["difference", 1353], ["in", 1364], ["the", 1367], ["mean", 1371], ["CGIS", 1376], ["score", 1381], ["between", 1387], ["the", 1395], ["flumazenil", 1399], ["(", 1410], ["3.25", 1411], ["+", 1416], ["/-", 1417], ["1.15", 1420], [")", 1424], ["and", 1426], ["placebo", 1430], ["(", 1438], ["3.75", 1439], ["+", 1444], ["/-", 1445], ["0.69", 1448], [")", 1452], ["groups", 1454], ["in", 1461], ["BDZ", 1464], ["-", 1467], ["negative", 1468], ["patients", 1477], [".", 1485], ["The", 1487], ["GCS", 1491], ["and", 1495], ["NAS", 1499], ["were", 1503], ["also", 1508], ["significantly", 1513], ["better", 1527], ["in", 1534], ["patients", 1537], ["who", 1546], ["were", 1550], ["BDZ", 1555], ["-", 1558], ["positive", 1559], ["and", 1568], ["received", 1572], ["flumazenil", 1581], [".", 1591], ["The", 1593], ["mean", 1597], ["+", 1602], ["/-", 1603], ["SD", 1606], ["dose", 1609], ["of", 1614], ["flumazenil", 1617], ["administered", 1628], ["during", 1641], ["the", 1648], ["double", 1652], ["-", 1658], ["blind", 1659], ["phase", 1665], ["was", 1671], ["71.3", 1675], ["+", 1680], ["/-", 1681], ["34.2", 1684], ["mL", 1689], ["(", 1692], ["7.13", 1693], ["mg", 1698], [")", 1700], ["compared", 1702], ["with", 1711], ["95.06", 1716], ["+", 1722], ["/-", 1723], ["16.03", 1726], ["mL", 1732], ["of", 1735], ["placebo", 1738], [".", 1745], ["Of", 1747], ["the", 1750], ["39", 1754], ["patients", 1757], ["who", 1766], ["had", 1770], ["BDZ", 1774], ["-", 1777], ["positive", 1778], ["drug", 1787], ["screens", 1792], ["and", 1800], ["received", 1804], ["flumazenil", 1813], [",", 1823], ["29", 1825], ["(", 1828], ["74", 1829], ["%", 1831], [")", 1832], ["responded", 1834], ["to", 1844], ["3", 1847], ["mg", 1849], ["or", 1852], ["less", 1855], [".", 1859], ["Six", 1861], ["additional", 1865], ["patients", 1876], ["responded", 1885], ["to", 1895], ["4", 1898], ["or", 1900], ["5", 1903], ["mg", 1905], [",", 1907], ["and", 1909], ["one", 1913], ["patient", 1917], ["responded", 1925], ["to", 1935], ["8", 1938], ["mg", 1940], [".", 1942], ["The", 1944], ["most", 1948], ["common", 1953], ["adverse", 1960], ["effects", 1968], ["in", 1976], ["patients", 1979], ["who", 1988], ["received", 1992], ["flumazenil", 2001], ["were", 2012], ["injection", 2017], ["site", 2027], ["pain", 2032], ["(", 2037], ["10.3", 2038], ["%", 2042], [")", 2043], [",", 2044], ["agitation", 2046], ["(", 2056], ["8", 2057], ["%", 2058], [")", 2059], [",", 2060], ["vomiting", 2062], ["(", 2071], ["3.4", 2072], ["%", 2075], [")", 2076], [",", 2077], ["dizziness", 2079], ["(", 2089], ["3.4", 2090], ["%", 2093], [")", 2094], [",", 2095], ["headache", 2097], ["(", 2106], ["3.4", 2107], ["%", 2110], [")", 2111], [",", 2112], ["tachycardia", 2114], ["(", 2126], ["3.4", 2127], ["%", 2130], [")", 2131], [",", 2132], ["and", 2134], ["crying", 2138], ["(", 2145], ["3.4", 2146], ["%", 2149], [")", 2150], [".", 2151], ["Three", 2153], ["patients", 2159], ["developed", 2168], ["seizures", 2178], [".", 2186], ["Two", 2188], ["were", 2192], ["associated", 2197], ["with", 2208], ["significant", 2213], ["tricyclic", 2225], ["antidepressant", 2235], ["overdoses", 2250], ["and", 2260], ["one", 2264], ["with", 2268], ["propoxyphene", 2273], ["ingestion", 2286], [".", 2295], ["Two", 2297], ["patients", 2301], ["had", 2310], ["positive", 2314], ["drug", 2323], ["screens", 2328], ["for", 2336], ["BDZ", 2340], [".", 2343], ["Flumazenil", 2345], ["rapidly", 2356], ["and", 2364], ["effectively", 2368], ["reverses", 2380], ["the", 2389], ["clinical", 2393], ["signs", 2402], ["and", 2408], ["symptoms", 2412], ["of", 2421], ["a", 2424], ["BDZ", 2426], ["overdose", 2430], [".", 2438], ["Most", 2440], ["patients", 2445], ["will", 2454], ["respond", 2459], ["to", 2467], ["3", 2470], ["mg", 2472], ["or", 2475], ["less", 2478], [",", 2482], ["but", 2484], ["a", 2488], ["small", 2490], ["number", 2496], ["may", 2503], ["require", 2507], ["a", 2515], ["higher", 2517], ["dose", 2524], ["for", 2529], ["reversal", 2533], ["of", 2542], ["clinical", 2545], ["symptoms", 2554], [".", 2562], ["Patients", 2564], ["with", 2573], ["concomitant", 2578], ["tricyclic", 2590], ["antidepressant", 2600], ["overdose", 2615], ["may", 2624], ["be", 2628], ["at", 2631], ["risk", 2634], ["for", 2639], ["developing", 2643], ["seizures", 2654], [".", 2662]]}
{"context": "Nucleotide excision repair (NER) mechanism is the major pathway responsible for the removal of a large variety of bulky lesions from the genome. Two different NER subpathways have been identified, i.e. the transcription-coupled and the global genome repair pathways. For DNA-damage induced by ultraviolet light both transcription-coupled repair and global genome repair are essential to confer resistance to cytotoxic effects. To gain further insight into the contribution of NER subpathways in the repair of bulky lesions and in their prevention of biological effects we measured the rate of repair of dG-C8-AF in active and inactive genes in normal human cells, XP-C cells (only transcription-coupled repair) and XP-A cells (completely NER-deficient) exposed to NA-AAF. XP-C cells are only slightly more sensitive to NA-AAF than normal cells and, like normal cells, they are able to recover RNA synthesis repressed by the treatment. In contrast, XP-A cells are sensitive to NA-AAF and unable to recover from RNA synthesis inhibition. Repair of dG-C8-AF in the active ADA gene proceeds in a biphasic way and without strand specificity, with a subclass of lesions quickly repaired during the first 8 h after treatment. Repair in the inactive 754 gene occurs more slowly than in the ADA gene. In XP-C cells, repair of dG-C8-AF in the ADA gene is confined to the transcribed strand and occurs at about half the rate of repair seen in normal cells. Repair in the inactive 754 gene in XP-C cells is virtually absent. Consistent with these results we found that repair replication in XP-C is drastically reduced when compared with normal cells and abolished by alpha-amanitin indicating that the repair in XP-C cells is mediated by transcription-coupled repair only. Our data suggest that dG-C8-AF is a target for transcription-coupled repair and that this repair pathway is the main pathway or recovery of RNA synthesis inhibition conferring resistance to cytotoxic effects of NA-AAF. In spite of this, repair of dG-C8-AF in active genes in normal cells by transcription-coupled repair and global genome repair is not additive, but dominated by global genome repair. This indicates that the subset of lesions which are capable of stalling RNA polymerase II, and are, therefore, a substrate for TCR, are also the lesions which are very efficiently recognized by the global genome repair system.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bcb2d242686c440fb698f05cac959004", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[268, 269]], "char_spans": [[1361, 1378]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["mechanism", 33], ["is", 43], ["the", 46], ["major", 50], ["pathway", 56], ["responsible", 64], ["for", 76], ["the", 80], ["removal", 84], ["of", 92], ["a", 95], ["large", 97], ["variety", 103], ["of", 111], ["bulky", 114], ["lesions", 120], ["from", 128], ["the", 133], ["genome", 137], [".", 143], ["Two", 145], ["different", 149], ["NER", 159], ["subpathways", 163], ["have", 175], ["been", 180], ["identified", 185], [",", 195], ["i.e.", 197], ["the", 202], ["transcription", 206], ["-", 219], ["coupled", 220], ["and", 228], ["the", 232], ["global", 236], ["genome", 243], ["repair", 250], ["pathways", 257], [".", 265], ["For", 267], ["DNA", 271], ["-", 274], ["damage", 275], ["induced", 282], ["by", 290], ["ultraviolet", 293], ["light", 305], ["both", 311], ["transcription", 316], ["-", 329], ["coupled", 330], ["repair", 338], ["and", 345], ["global", 349], ["genome", 356], ["repair", 363], ["are", 370], ["essential", 374], ["to", 384], ["confer", 387], ["resistance", 394], ["to", 405], ["cytotoxic", 408], ["effects", 418], [".", 425], ["To", 427], ["gain", 430], ["further", 435], ["insight", 443], ["into", 451], ["the", 456], ["contribution", 460], ["of", 473], ["NER", 476], ["subpathways", 480], ["in", 492], ["the", 495], ["repair", 499], ["of", 506], ["bulky", 509], ["lesions", 515], ["and", 523], ["in", 527], ["their", 530], ["prevention", 536], ["of", 547], ["biological", 550], ["effects", 561], ["we", 569], ["measured", 572], ["the", 581], ["rate", 585], ["of", 590], ["repair", 593], ["of", 600], ["dG", 603], ["-", 605], ["C8-AF", 606], ["in", 612], ["active", 615], ["and", 622], ["inactive", 626], ["genes", 635], ["in", 641], ["normal", 644], ["human", 651], ["cells", 657], [",", 662], ["XP", 664], ["-", 666], ["C", 667], ["cells", 669], ["(", 675], ["only", 676], ["transcription", 681], ["-", 694], ["coupled", 695], ["repair", 703], [")", 709], ["and", 711], ["XP", 715], ["-", 717], ["A", 718], ["cells", 720], ["(", 726], ["completely", 727], ["NER", 738], ["-", 741], ["deficient", 742], [")", 751], ["exposed", 753], ["to", 761], ["NA", 764], ["-", 766], ["AAF", 767], [".", 770], ["XP", 772], ["-", 774], ["C", 775], ["cells", 777], ["are", 783], ["only", 787], ["slightly", 792], ["more", 801], ["sensitive", 806], ["to", 816], ["NA", 819], ["-", 821], ["AAF", 822], ["than", 826], ["normal", 831], ["cells", 838], ["and", 844], [",", 847], ["like", 849], ["normal", 854], ["cells", 861], [",", 866], ["they", 868], ["are", 873], ["able", 877], ["to", 882], ["recover", 885], ["RNA", 893], ["synthesis", 897], ["repressed", 907], ["by", 917], ["the", 920], ["treatment", 924], [".", 933], ["In", 935], ["contrast", 938], [",", 946], ["XP", 948], ["-", 950], ["A", 951], ["cells", 953], ["are", 959], ["sensitive", 963], ["to", 973], ["NA", 976], ["-", 978], ["AAF", 979], ["and", 983], ["unable", 987], ["to", 994], ["recover", 997], ["from", 1005], ["RNA", 1010], ["synthesis", 1014], ["inhibition", 1024], [".", 1034], ["Repair", 1036], ["of", 1043], ["dG", 1046], ["-", 1048], ["C8-AF", 1049], ["in", 1055], ["the", 1058], ["active", 1062], ["ADA", 1069], ["gene", 1073], ["proceeds", 1078], ["in", 1087], ["a", 1090], ["biphasic", 1092], ["way", 1101], ["and", 1105], ["without", 1109], ["strand", 1117], ["specificity", 1124], [",", 1135], ["with", 1137], ["a", 1142], ["subclass", 1144], ["of", 1153], ["lesions", 1156], ["quickly", 1164], ["repaired", 1172], ["during", 1181], ["the", 1188], ["first", 1192], ["8", 1198], ["h", 1200], ["after", 1202], ["treatment", 1208], [".", 1217], ["Repair", 1219], ["in", 1226], ["the", 1229], ["inactive", 1233], ["754", 1242], ["gene", 1246], ["occurs", 1251], ["more", 1258], ["slowly", 1263], ["than", 1270], ["in", 1275], ["the", 1278], ["ADA", 1282], ["gene", 1286], [".", 1290], ["In", 1292], ["XP", 1295], ["-", 1297], ["C", 1298], ["cells", 1300], [",", 1305], ["repair", 1307], ["of", 1314], ["dG", 1317], ["-", 1319], ["C8-AF", 1320], ["in", 1326], ["the", 1329], ["ADA", 1333], ["gene", 1337], ["is", 1342], ["confined", 1345], ["to", 1354], ["the", 1357], ["transcribed", 1361], ["strand", 1373], ["and", 1380], ["occurs", 1384], ["at", 1391], ["about", 1394], ["half", 1400], ["the", 1405], ["rate", 1409], ["of", 1414], ["repair", 1417], ["seen", 1424], ["in", 1429], ["normal", 1432], ["cells", 1439], [".", 1444], ["Repair", 1446], ["in", 1453], ["the", 1456], ["inactive", 1460], ["754", 1469], ["gene", 1473], ["in", 1478], ["XP", 1481], ["-", 1483], ["C", 1484], ["cells", 1486], ["is", 1492], ["virtually", 1495], ["absent", 1505], [".", 1511], ["Consistent", 1513], ["with", 1524], ["these", 1529], ["results", 1535], ["we", 1543], ["found", 1546], ["that", 1552], ["repair", 1557], ["replication", 1564], ["in", 1576], ["XP", 1579], ["-", 1581], ["C", 1582], ["is", 1584], ["drastically", 1587], ["reduced", 1599], ["when", 1607], ["compared", 1612], ["with", 1621], ["normal", 1626], ["cells", 1633], ["and", 1639], ["abolished", 1643], ["by", 1653], ["alpha", 1656], ["-", 1661], ["amanitin", 1662], ["indicating", 1671], ["that", 1682], ["the", 1687], ["repair", 1691], ["in", 1698], ["XP", 1701], ["-", 1703], ["C", 1704], ["cells", 1706], ["is", 1712], ["mediated", 1715], ["by", 1724], ["transcription", 1727], ["-", 1740], ["coupled", 1741], ["repair", 1749], ["only", 1756], [".", 1760], ["Our", 1762], ["data", 1766], ["suggest", 1771], ["that", 1779], ["dG", 1784], ["-", 1786], ["C8-AF", 1787], ["is", 1793], ["a", 1796], ["target", 1798], ["for", 1805], ["transcription", 1809], ["-", 1822], ["coupled", 1823], ["repair", 1831], ["and", 1838], ["that", 1842], ["this", 1847], ["repair", 1852], ["pathway", 1859], ["is", 1867], ["the", 1870], ["main", 1874], ["pathway", 1879], ["or", 1887], ["recovery", 1890], ["of", 1899], ["RNA", 1902], ["synthesis", 1906], ["inhibition", 1916], ["conferring", 1927], ["resistance", 1938], ["to", 1949], ["cytotoxic", 1952], ["effects", 1962], ["of", 1970], ["NA", 1973], ["-", 1975], ["AAF", 1976], [".", 1979], ["In", 1981], ["spite", 1984], ["of", 1990], ["this", 1993], [",", 1997], ["repair", 1999], ["of", 2006], ["dG", 2009], ["-", 2011], ["C8-AF", 2012], ["in", 2018], ["active", 2021], ["genes", 2028], ["in", 2034], ["normal", 2037], ["cells", 2044], ["by", 2050], ["transcription", 2053], ["-", 2066], ["coupled", 2067], ["repair", 2075], ["and", 2082], ["global", 2086], ["genome", 2093], ["repair", 2100], ["is", 2107], ["not", 2110], ["additive", 2114], [",", 2122], ["but", 2124], ["dominated", 2128], ["by", 2138], ["global", 2141], ["genome", 2148], ["repair", 2155], [".", 2161], ["This", 2163], ["indicates", 2168], ["that", 2178], ["the", 2183], ["subset", 2187], ["of", 2194], ["lesions", 2197], ["which", 2205], ["are", 2211], ["capable", 2215], ["of", 2223], ["stalling", 2226], ["RNA", 2235], ["polymerase", 2239], ["II", 2250], [",", 2252], ["and", 2254], ["are", 2258], [",", 2261], ["therefore", 2263], [",", 2272], ["a", 2274], ["substrate", 2276], ["for", 2286], ["TCR", 2290], [",", 2293], ["are", 2295], ["also", 2299], ["the", 2304], ["lesions", 2308], ["which", 2316], ["are", 2322], ["very", 2326], ["efficiently", 2331], ["recognized", 2343], ["by", 2354], ["the", 2357], ["global", 2361], ["genome", 2368], ["repair", 2375], ["system", 2382], [".", 2388]]}
{"context": "Treslin/TICRR (TopBP1-interacting, replication stimulating protein/TopBP1-interacting, checkpoint, and replication regulator), the human ortholog of the yeast Sld3 protein, is an essential DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle. We show that MTBP depletion by means of small interfering RNA inhibits DNA replication by preventing assembly of the CMG (Cdc45-MCM-GINS) holohelicase during origin firing. Although MTBP has been implicated in the function of the p53 tumor suppressor, we found MTBP is required for DNA replication irrespective of a cell's p53 status. We propose that MTBP acts with Treslin/TICRR to integrate signals from cell cycle and DNA damage response pathways to control the initiation of DNA replication in human cells.", "qas": [{"question": "Which factor interacts with Treslin/TICRR throughout the cell cycle of human cells?", "answers": ["MDM two binding protein (MTBP)"], "qid": "470f42e7c572482a84dd8e9d4a279059", "question_tokens": [["Which", 0], ["factor", 6], ["interacts", 13], ["with", 23], ["Treslin", 28], ["/", 35], ["TICRR", 36], ["throughout", 42], ["the", 53], ["cell", 57], ["cycle", 62], ["of", 68], ["human", 71], ["cells", 77], ["?", 82]], "detected_answers": [{"text": "MDM two binding protein (MTBP)", "token_spans": [[50, 55]], "char_spans": [[303, 331]]}]}], "context_tokens": [["Treslin", 0], ["/", 7], ["TICRR", 8], ["(", 14], ["TopBP1-interacting", 15], [",", 33], ["replication", 35], ["stimulating", 47], ["protein", 59], ["/", 66], ["TopBP1-interacting", 67], [",", 85], ["checkpoint", 87], [",", 97], ["and", 99], ["replication", 103], ["regulator", 115], [")", 124], [",", 125], ["the", 127], ["human", 131], ["ortholog", 137], ["of", 146], ["the", 149], ["yeast", 153], ["Sld3", 159], ["protein", 164], [",", 171], ["is", 173], ["an", 176], ["essential", 179], ["DNA", 189], ["replication", 193], ["factor", 205], ["that", 212], ["is", 217], ["regulated", 220], ["by", 230], ["cyclin", 233], ["-", 239], ["dependent", 240], ["kinases", 250], ["and", 258], ["the", 262], ["DNA", 266], ["damage", 270], ["checkpoint", 277], [".", 287], ["We", 289], ["identified", 292], ["MDM", 303], ["two", 307], ["binding", 311], ["protein", 319], ["(", 327], ["MTBP", 328], [")", 332], ["as", 334], ["a", 337], ["factor", 339], ["that", 346], ["interacts", 351], ["with", 361], ["Treslin", 366], ["/", 373], ["TICRR", 374], ["throughout", 380], ["the", 391], ["cell", 395], ["cycle", 400], [".", 405], ["We", 407], ["show", 410], ["that", 415], ["MTBP", 420], ["depletion", 425], ["by", 435], ["means", 438], ["of", 444], ["small", 447], ["interfering", 453], ["RNA", 465], ["inhibits", 469], ["DNA", 478], ["replication", 482], ["by", 494], ["preventing", 497], ["assembly", 508], ["of", 517], ["the", 520], ["CMG", 524], ["(", 528], ["Cdc45-MCM", 529], ["-", 538], ["GINS", 539], [")", 543], ["holohelicase", 545], ["during", 558], ["origin", 565], ["firing", 572], [".", 578], ["Although", 580], ["MTBP", 589], ["has", 594], ["been", 598], ["implicated", 603], ["in", 614], ["the", 617], ["function", 621], ["of", 630], ["the", 633], ["p53", 637], ["tumor", 641], ["suppressor", 647], [",", 657], ["we", 659], ["found", 662], ["MTBP", 668], ["is", 673], ["required", 676], ["for", 685], ["DNA", 689], ["replication", 693], ["irrespective", 705], ["of", 718], ["a", 721], ["cell", 723], ["'s", 727], ["p53", 730], ["status", 734], [".", 740], ["We", 742], ["propose", 745], ["that", 753], ["MTBP", 758], ["acts", 763], ["with", 768], ["Treslin", 773], ["/", 780], ["TICRR", 781], ["to", 787], ["integrate", 790], ["signals", 800], ["from", 808], ["cell", 813], ["cycle", 818], ["and", 824], ["DNA", 828], ["damage", 832], ["response", 839], ["pathways", 848], ["to", 857], ["control", 860], ["the", 868], ["initiation", 872], ["of", 883], ["DNA", 886], ["replication", 890], ["in", 902], ["human", 905], ["cells", 911], [".", 916]]}
{"context": "Molecular remodeling in heart failure includes slowing of repolarization, leading to proarrhythmia. To evaluate the effects of Na(+)/Ca(2+) exchanger (NCX) inhibition on repolarization as a novel antiarrhythmic concept in chronic heart failure (CHF). CHF was induced by rapid ventricular pacing in rabbits. Left ventricular function was assessed by echocardiography. Monophasic action potentials (MAPs) showed a prolongation of repolarization in CHF after atrioventricular block and stimulation at different cycle lengths. Sotalol (100 \u03bcM, n = 13) or veratridine (0.5 \u03bcM; n = 15) resulted in a further significant increase in the MAP duration. CHF was associated with an increased dispersion of repolarization, as compared with sotalol-treated (+22 \u00b1 7 ms; P < .05) and veratridine-treated (+20 \u00b1 6 ms; P < .05) sham hearts. In the presence of a low potassium concentration, sotalol and veratridine reproducibly induced early afterdepolarizations (EADs) and polymorphic ventricular tachyarrhythmias (VTs). SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). It suppressed EAD in 6 of 13 sotalol-treated failing hearts and in 9 of 10 veratridine-treated failing hearts, leading to a reduction in VT (60% in sotalol-treated failing hearts and 83% in veratridine-treated failing hearts). Simulations using a mathematical model showed a reduction in the action potential duration and the number of EADs by the NCX block in all subgroups. In an experimental model of CHF, the acute inhibition of NCX (1) reduces the MAP duration, (2) decreases dispersion of repolarization, and (3) suppresses EAD and VT. Our observations indicate for the first time that pharmacological NCX inhibition increases repolarization reserve and protects against VTs in heart failure.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "71fee14086b941aea68a85c15ba9b987", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[19, 22]], "char_spans": [[127, 148]]}, {"text": "NCX", "token_spans": [[283, 283], [335, 335], [300, 300], [24, 24], [193, 193]], "char_spans": [[1491, 1493], [1751, 1753], [1576, 1578], [151, 153], [1053, 1055]]}]}], "context_tokens": [["Molecular", 0], ["remodeling", 10], ["in", 21], ["heart", 24], ["failure", 30], ["includes", 38], ["slowing", 47], ["of", 55], ["repolarization", 58], [",", 72], ["leading", 74], ["to", 82], ["proarrhythmia", 85], [".", 98], ["To", 100], ["evaluate", 103], ["the", 112], ["effects", 116], ["of", 124], ["Na(+)/Ca(2", 127], ["+", 137], [")", 138], ["exchanger", 140], ["(", 150], ["NCX", 151], [")", 154], ["inhibition", 156], ["on", 167], ["repolarization", 170], ["as", 185], ["a", 188], ["novel", 190], ["antiarrhythmic", 196], ["concept", 211], ["in", 219], ["chronic", 222], ["heart", 230], ["failure", 236], ["(", 244], ["CHF", 245], [")", 248], [".", 249], ["CHF", 251], ["was", 255], ["induced", 259], ["by", 267], ["rapid", 270], ["ventricular", 276], ["pacing", 288], ["in", 295], ["rabbits", 298], [".", 305], ["Left", 307], ["ventricular", 312], ["function", 324], ["was", 333], ["assessed", 337], ["by", 346], ["echocardiography", 349], [".", 365], ["Monophasic", 367], ["action", 378], ["potentials", 385], ["(", 396], ["MAPs", 397], [")", 401], ["showed", 403], ["a", 410], ["prolongation", 412], ["of", 425], ["repolarization", 428], ["in", 443], ["CHF", 446], ["after", 450], ["atrioventricular", 456], ["block", 473], ["and", 479], ["stimulation", 483], ["at", 495], ["different", 498], ["cycle", 508], ["lengths", 514], [".", 521], ["Sotalol", 523], ["(", 531], ["100", 532], ["\u03bcM", 536], [",", 538], ["n", 540], ["=", 542], ["13", 544], [")", 546], ["or", 548], ["veratridine", 551], ["(", 563], ["0.5", 564], ["\u03bcM", 568], [";", 570], ["n", 572], ["=", 574], ["15", 576], [")", 578], ["resulted", 580], ["in", 589], ["a", 592], ["further", 594], ["significant", 602], ["increase", 614], ["in", 623], ["the", 626], ["MAP", 630], ["duration", 634], [".", 642], ["CHF", 644], ["was", 648], ["associated", 652], ["with", 663], ["an", 668], ["increased", 671], ["dispersion", 681], ["of", 692], ["repolarization", 695], [",", 709], ["as", 711], ["compared", 714], ["with", 723], ["sotalol", 728], ["-", 735], ["treated", 736], ["(", 744], ["+22", 745], ["\u00b1", 749], ["7", 751], ["ms", 753], [";", 755], ["P", 757], ["<", 759], [".05", 761], [")", 764], ["and", 766], ["veratridine", 770], ["-", 781], ["treated", 782], ["(", 790], ["+20", 791], ["\u00b1", 795], ["6", 797], ["ms", 799], [";", 801], ["P", 803], ["<", 805], [".05", 807], [")", 810], ["sham", 812], ["hearts", 817], [".", 823], ["In", 825], ["the", 828], ["presence", 832], ["of", 841], ["a", 844], ["low", 846], ["potassium", 850], ["concentration", 860], [",", 873], ["sotalol", 875], ["and", 883], ["veratridine", 887], ["reproducibly", 899], ["induced", 912], ["early", 920], ["afterdepolarizations", 926], ["(", 947], ["EADs", 948], [")", 952], ["and", 954], ["polymorphic", 958], ["ventricular", 970], ["tachyarrhythmias", 982], ["(", 999], ["VTs", 1000], [")", 1003], [".", 1004], ["SEA0400", 1006], ["(", 1014], ["1", 1015], ["\u03bcM", 1017], [")", 1019], [",", 1020], ["a", 1022], ["pharmacological", 1024], ["inhibitor", 1040], ["of", 1050], ["NCX", 1053], [",", 1056], ["significantly", 1058], ["shortened", 1072], ["the", 1082], ["MAP", 1086], ["duration", 1090], ["(", 1099], ["P", 1100], ["<", 1102], [".01", 1104], [")", 1107], ["and", 1109], ["reduced", 1113], ["dispersion", 1121], ["(", 1132], ["P", 1133], ["<", 1135], [".05", 1137], [")", 1140], [".", 1141], ["It", 1143], ["suppressed", 1146], ["EAD", 1157], ["in", 1161], ["6", 1164], ["of", 1166], ["13", 1169], ["sotalol", 1172], ["-", 1179], ["treated", 1180], ["failing", 1188], ["hearts", 1196], ["and", 1203], ["in", 1207], ["9", 1210], ["of", 1212], ["10", 1215], ["veratridine", 1218], ["-", 1229], ["treated", 1230], ["failing", 1238], ["hearts", 1246], [",", 1252], ["leading", 1254], ["to", 1262], ["a", 1265], ["reduction", 1267], ["in", 1277], ["VT", 1280], ["(", 1283], ["60", 1284], ["%", 1286], ["in", 1288], ["sotalol", 1291], ["-", 1298], ["treated", 1299], ["failing", 1307], ["hearts", 1315], ["and", 1322], ["83", 1326], ["%", 1328], ["in", 1330], ["veratridine", 1333], ["-", 1344], ["treated", 1345], ["failing", 1353], ["hearts", 1361], [")", 1367], [".", 1368], ["Simulations", 1370], ["using", 1382], ["a", 1388], ["mathematical", 1390], ["model", 1403], ["showed", 1409], ["a", 1416], ["reduction", 1418], ["in", 1428], ["the", 1431], ["action", 1435], ["potential", 1442], ["duration", 1452], ["and", 1461], ["the", 1465], ["number", 1469], ["of", 1476], ["EADs", 1479], ["by", 1484], ["the", 1487], ["NCX", 1491], ["block", 1495], ["in", 1501], ["all", 1504], ["subgroups", 1508], [".", 1517], ["In", 1519], ["an", 1522], ["experimental", 1525], ["model", 1538], ["of", 1544], ["CHF", 1547], [",", 1550], ["the", 1552], ["acute", 1556], ["inhibition", 1562], ["of", 1573], ["NCX", 1576], ["(", 1580], ["1", 1581], [")", 1582], ["reduces", 1584], ["the", 1592], ["MAP", 1596], ["duration", 1600], [",", 1608], ["(", 1610], ["2", 1611], [")", 1612], ["decreases", 1614], ["dispersion", 1624], ["of", 1635], ["repolarization", 1638], [",", 1652], ["and", 1654], ["(", 1658], ["3", 1659], [")", 1660], ["suppresses", 1662], ["EAD", 1673], ["and", 1677], ["VT", 1681], [".", 1683], ["Our", 1685], ["observations", 1689], ["indicate", 1702], ["for", 1711], ["the", 1715], ["first", 1719], ["time", 1725], ["that", 1730], ["pharmacological", 1735], ["NCX", 1751], ["inhibition", 1755], ["increases", 1766], ["repolarization", 1776], ["reserve", 1791], ["and", 1799], ["protects", 1803], ["against", 1812], ["VTs", 1820], ["in", 1824], ["heart", 1827], ["failure", 1833], [".", 1840]]}
{"context": "We evaluated the predictive value of serum biomarkers and various clinical risk scales for the 28-day mortality of community-acquired pneumonia (CAP). Serum biomarkers including procalcitonin (PCT) and C-reactive protein (CRP) were evaluated in the emergency department. Scores for the pneumonia severity index (PSI); CURB65 (confusion, urea, respiration, blood pressure; age >65\u2009years); Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) guidelines for severe CAP; Acute Physiology, Chronic Health Evaluation (APACHE) II; Sequential Organ Failure Assessment (SOFA); and quick SOFA (qSOFA) were calculated. Receiver-operating characteristic curves for 28-day mortality were calculated for each predictor using cut-off values, and we applied logistic regression models and area under the curve (AUC) analysis to compare the performance of predictors. Of the 125 enrolled patients, 13 died within 28\u2009days. The AUCs of the PCT and CRP were 0.83 and 0.77, respectively. Using a PCT level >5.6\u2009\u03bcg/L as the cut-off, the sensitivity and specificity for mortality were 76.9% and 90.2%, respectively. The three pneumonia severity scales showed an AUC of 0.86 (PSI), 0.87 (IDSA/ATS) and 0.77 (CURB65). The AUCs of the APACHE II, SOFA and qSOFA scores were 0.85, 0.83 and 0.81, respectively. The models combining CRP and/or PCT with PSI or the IDSA/ATS guidelines demonstrated superior performance to those of either PSI or the IDAS/ATS guidelines alone. In conclusion, serum PCT is a reliable single predictor for short-term mortality. Inclusion of CRP and/or PCT could significantly improve the performance of the PSI and IDAS/ATS guidelines.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "7c707712084d4ceda79cb8580017408e", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[21, 21], [51, 51], [222, 222]], "char_spans": [[134, 142], [286, 294], [1132, 1140]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["predictive", 17], ["value", 28], ["of", 34], ["serum", 37], ["biomarkers", 43], ["and", 54], ["various", 58], ["clinical", 66], ["risk", 75], ["scales", 80], ["for", 87], ["the", 91], ["28-day", 95], ["mortality", 102], ["of", 112], ["community", 115], ["-", 124], ["acquired", 125], ["pneumonia", 134], ["(", 144], ["CAP", 145], [")", 148], [".", 149], ["Serum", 151], ["biomarkers", 157], ["including", 168], ["procalcitonin", 178], ["(", 192], ["PCT", 193], [")", 196], ["and", 198], ["C", 202], ["-", 203], ["reactive", 204], ["protein", 213], ["(", 221], ["CRP", 222], [")", 225], ["were", 227], ["evaluated", 232], ["in", 242], ["the", 245], ["emergency", 249], ["department", 259], [".", 269], ["Scores", 271], ["for", 278], ["the", 282], ["pneumonia", 286], ["severity", 296], ["index", 305], ["(", 311], ["PSI", 312], [")", 315], [";", 316], ["CURB65", 318], ["(", 325], ["confusion", 326], [",", 335], ["urea", 337], [",", 341], ["respiration", 343], [",", 354], ["blood", 356], ["pressure", 362], [";", 370], ["age", 372], [">", 376], ["65", 377], ["years", 380], [")", 385], [";", 386], ["Infectious", 388], ["Disease", 399], ["Society", 407], ["of", 415], ["America", 418], ["(", 426], ["IDSA", 427], [")", 431], ["and", 433], ["American", 437], ["Thoracic", 446], ["Society", 455], ["(", 463], ["ATS", 464], [")", 467], ["guidelines", 469], ["for", 480], ["severe", 484], ["CAP", 491], [";", 494], ["Acute", 496], ["Physiology", 502], [",", 512], ["Chronic", 514], ["Health", 522], ["Evaluation", 529], ["(", 540], ["APACHE", 541], [")", 547], ["II", 549], [";", 551], ["Sequential", 553], ["Organ", 564], ["Failure", 570], ["Assessment", 578], ["(", 589], ["SOFA", 590], [")", 594], [";", 595], ["and", 597], ["quick", 601], ["SOFA", 607], ["(", 612], ["qSOFA", 613], [")", 618], ["were", 620], ["calculated", 625], [".", 635], ["Receiver", 637], ["-", 645], ["operating", 646], ["characteristic", 656], ["curves", 671], ["for", 678], ["28-day", 682], ["mortality", 689], ["were", 699], ["calculated", 704], ["for", 715], ["each", 719], ["predictor", 724], ["using", 734], ["cut", 740], ["-", 743], ["off", 744], ["values", 748], [",", 754], ["and", 756], ["we", 760], ["applied", 763], ["logistic", 771], ["regression", 780], ["models", 791], ["and", 798], ["area", 802], ["under", 807], ["the", 813], ["curve", 817], ["(", 823], ["AUC", 824], [")", 827], ["analysis", 829], ["to", 838], ["compare", 841], ["the", 849], ["performance", 853], ["of", 865], ["predictors", 868], [".", 878], ["Of", 880], ["the", 883], ["125", 887], ["enrolled", 891], ["patients", 900], [",", 908], ["13", 910], ["died", 913], ["within", 918], ["28", 925], ["days", 928], [".", 932], ["The", 934], ["AUCs", 938], ["of", 943], ["the", 946], ["PCT", 950], ["and", 954], ["CRP", 958], ["were", 962], ["0.83", 967], ["and", 972], ["0.77", 976], [",", 980], ["respectively", 982], [".", 994], ["Using", 996], ["a", 1002], ["PCT", 1004], ["level", 1008], [">", 1014], ["5.6", 1015], ["\u03bcg", 1019], ["/", 1021], ["L", 1022], ["as", 1024], ["the", 1027], ["cut", 1031], ["-", 1034], ["off", 1035], [",", 1038], ["the", 1040], ["sensitivity", 1044], ["and", 1056], ["specificity", 1060], ["for", 1072], ["mortality", 1076], ["were", 1086], ["76.9", 1091], ["%", 1095], ["and", 1097], ["90.2", 1101], ["%", 1105], [",", 1106], ["respectively", 1108], [".", 1120], ["The", 1122], ["three", 1126], ["pneumonia", 1132], ["severity", 1142], ["scales", 1151], ["showed", 1158], ["an", 1165], ["AUC", 1168], ["of", 1172], ["0.86", 1175], ["(", 1180], ["PSI", 1181], [")", 1184], [",", 1185], ["0.87", 1187], ["(", 1192], ["IDSA", 1193], ["/", 1197], ["ATS", 1198], [")", 1201], ["and", 1203], ["0.77", 1207], ["(", 1212], ["CURB65", 1213], [")", 1219], [".", 1220], ["The", 1222], ["AUCs", 1226], ["of", 1231], ["the", 1234], ["APACHE", 1238], ["II", 1245], [",", 1247], ["SOFA", 1249], ["and", 1254], ["qSOFA", 1258], ["scores", 1264], ["were", 1271], ["0.85", 1276], [",", 1280], ["0.83", 1282], ["and", 1287], ["0.81", 1291], [",", 1295], ["respectively", 1297], [".", 1309], ["The", 1311], ["models", 1315], ["combining", 1322], ["CRP", 1332], ["and/or", 1336], ["PCT", 1343], ["with", 1347], ["PSI", 1352], ["or", 1356], ["the", 1359], ["IDSA", 1363], ["/", 1367], ["ATS", 1368], ["guidelines", 1372], ["demonstrated", 1383], ["superior", 1396], ["performance", 1405], ["to", 1417], ["those", 1420], ["of", 1426], ["either", 1429], ["PSI", 1436], ["or", 1440], ["the", 1443], ["IDAS", 1447], ["/", 1451], ["ATS", 1452], ["guidelines", 1456], ["alone", 1467], [".", 1472], ["In", 1474], ["conclusion", 1477], [",", 1487], ["serum", 1489], ["PCT", 1495], ["is", 1499], ["a", 1502], ["reliable", 1504], ["single", 1513], ["predictor", 1520], ["for", 1530], ["short", 1534], ["-", 1539], ["term", 1540], ["mortality", 1545], [".", 1554], ["Inclusion", 1556], ["of", 1566], ["CRP", 1569], ["and/or", 1573], ["PCT", 1580], ["could", 1584], ["significantly", 1590], ["improve", 1604], ["the", 1612], ["performance", 1616], ["of", 1628], ["the", 1631], ["PSI", 1635], ["and", 1639], ["IDAS", 1643], ["/", 1647], ["ATS", 1648], ["guidelines", 1652], [".", 1662]]}
{"context": "The actions of benzodiazepines are due to the potentiation of the neural inhibition that is mediated by gamma-aminobutyric acid (GABA). Practically all effects of the benzodiazepines result from their actions on the ionotropic GABA(A) receptors in the central nervous system. Benzodiazepines do not activate GABA(A) receptors directly but they require GABA. The main effects of benzodiazepines are sedation, hypnosis, decreased anxiety, anterograde amnesia, centrally mediated muscle relaxation and anti-convulsant activity. In addition to their action on the central nervous system, benzodiazepines have a dose-dependent ventilatory depressant effect and they also cause a modest reduction in arterial blood pressure and an increase in heart rate as a result of a decrease of systemic vascular resistance. The four benzodiazepines, widely used in clinical anaesthesia, are the agonists midazolam, diazepam and lorazepam and the antagonist flumazenil. Midazolam, diazepam and flumazenil are metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation whereas lorazepam directly undergoes glucuronide conjugation. CYP3A4 is important in the biotransformation of both midazolam and diazepam. CYP2C19 is important in the biotransformation of diazepam. Liver and renal dysfunction have only a minor effect on the pharmacokinetics of lorazepam but they slow down the elimination of the other benzodiazepines used in clinical anaesthesia. The duration of action of all benzodiazepines is strongly dependent on the duration of their administration. Based on clinical studies and computer simulations, midazolam has the shortest recovery profile followed by lorazepam and diazepam. Being metabolized by CYP enzymes, midazolam and diazepam have many clinically significant interactions with inhibitors and inducers of CYP3A4 and 2C19. In addition to pharmacokinetic interactions, benzodiazepines have synergistic interactions with other hypnotics and opioids. Midazolam, diazepam and lorazepam are widely used for sedation and to some extent also for induction and maintenance of anaesthesia. Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0652e34262bc426d97340af838f8da7e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[161, 161], [155, 155], [330, 330]], "char_spans": [[976, 985], [940, 949], [2100, 2109]]}]}], "context_tokens": [["The", 0], ["actions", 4], ["of", 12], ["benzodiazepines", 15], ["are", 31], ["due", 35], ["to", 39], ["the", 42], ["potentiation", 46], ["of", 59], ["the", 62], ["neural", 66], ["inhibition", 73], ["that", 84], ["is", 89], ["mediated", 92], ["by", 101], ["gamma", 104], ["-", 109], ["aminobutyric", 110], ["acid", 123], ["(", 128], ["GABA", 129], [")", 133], [".", 134], ["Practically", 136], ["all", 148], ["effects", 152], ["of", 160], ["the", 163], ["benzodiazepines", 167], ["result", 183], ["from", 190], ["their", 195], ["actions", 201], ["on", 209], ["the", 212], ["ionotropic", 216], ["GABA(A", 227], [")", 233], ["receptors", 235], ["in", 245], ["the", 248], ["central", 252], ["nervous", 260], ["system", 268], [".", 274], ["Benzodiazepines", 276], ["do", 292], ["not", 295], ["activate", 299], ["GABA(A", 308], [")", 314], ["receptors", 316], ["directly", 326], ["but", 335], ["they", 339], ["require", 344], ["GABA", 352], [".", 356], ["The", 358], ["main", 362], ["effects", 367], ["of", 375], ["benzodiazepines", 378], ["are", 394], ["sedation", 398], [",", 406], ["hypnosis", 408], [",", 416], ["decreased", 418], ["anxiety", 428], [",", 435], ["anterograde", 437], ["amnesia", 449], [",", 456], ["centrally", 458], ["mediated", 468], ["muscle", 477], ["relaxation", 484], ["and", 495], ["anti", 499], ["-", 503], ["convulsant", 504], ["activity", 515], [".", 523], ["In", 525], ["addition", 528], ["to", 537], ["their", 540], ["action", 546], ["on", 553], ["the", 556], ["central", 560], ["nervous", 568], ["system", 576], [",", 582], ["benzodiazepines", 584], ["have", 600], ["a", 605], ["dose", 607], ["-", 611], ["dependent", 612], ["ventilatory", 622], ["depressant", 634], ["effect", 645], ["and", 652], ["they", 656], ["also", 661], ["cause", 666], ["a", 672], ["modest", 674], ["reduction", 681], ["in", 691], ["arterial", 694], ["blood", 703], ["pressure", 709], ["and", 718], ["an", 722], ["increase", 725], ["in", 734], ["heart", 737], ["rate", 743], ["as", 748], ["a", 751], ["result", 753], ["of", 760], ["a", 763], ["decrease", 765], ["of", 774], ["systemic", 777], ["vascular", 786], ["resistance", 795], [".", 805], ["The", 807], ["four", 811], ["benzodiazepines", 816], [",", 831], ["widely", 833], ["used", 840], ["in", 845], ["clinical", 848], ["anaesthesia", 857], [",", 868], ["are", 870], ["the", 874], ["agonists", 878], ["midazolam", 887], [",", 896], ["diazepam", 898], ["and", 907], ["lorazepam", 911], ["and", 921], ["the", 925], ["antagonist", 929], ["flumazenil", 940], [".", 950], ["Midazolam", 952], [",", 961], ["diazepam", 963], ["and", 972], ["flumazenil", 976], ["are", 987], ["metabolized", 991], ["by", 1003], ["cytochrome", 1006], ["P450", 1017], ["(", 1022], ["CYP", 1023], [")", 1026], ["enzymes", 1028], ["and", 1036], ["by", 1040], ["glucuronide", 1043], ["conjugation", 1055], ["whereas", 1067], ["lorazepam", 1075], ["directly", 1085], ["undergoes", 1094], ["glucuronide", 1104], ["conjugation", 1116], [".", 1127], ["CYP3A4", 1129], ["is", 1136], ["important", 1139], ["in", 1149], ["the", 1152], ["biotransformation", 1156], ["of", 1174], ["both", 1177], ["midazolam", 1182], ["and", 1192], ["diazepam", 1196], [".", 1204], ["CYP2C19", 1206], ["is", 1214], ["important", 1217], ["in", 1227], ["the", 1230], ["biotransformation", 1234], ["of", 1252], ["diazepam", 1255], [".", 1263], ["Liver", 1265], ["and", 1271], ["renal", 1275], ["dysfunction", 1281], ["have", 1293], ["only", 1298], ["a", 1303], ["minor", 1305], ["effect", 1311], ["on", 1318], ["the", 1321], ["pharmacokinetics", 1325], ["of", 1342], ["lorazepam", 1345], ["but", 1355], ["they", 1359], ["slow", 1364], ["down", 1369], ["the", 1374], ["elimination", 1378], ["of", 1390], ["the", 1393], ["other", 1397], ["benzodiazepines", 1403], ["used", 1419], ["in", 1424], ["clinical", 1427], ["anaesthesia", 1436], [".", 1447], ["The", 1449], ["duration", 1453], ["of", 1462], ["action", 1465], ["of", 1472], ["all", 1475], ["benzodiazepines", 1479], ["is", 1495], ["strongly", 1498], ["dependent", 1507], ["on", 1517], ["the", 1520], ["duration", 1524], ["of", 1533], ["their", 1536], ["administration", 1542], [".", 1556], ["Based", 1558], ["on", 1564], ["clinical", 1567], ["studies", 1576], ["and", 1584], ["computer", 1588], ["simulations", 1597], [",", 1608], ["midazolam", 1610], ["has", 1620], ["the", 1624], ["shortest", 1628], ["recovery", 1637], ["profile", 1646], ["followed", 1654], ["by", 1663], ["lorazepam", 1666], ["and", 1676], ["diazepam", 1680], [".", 1688], ["Being", 1690], ["metabolized", 1696], ["by", 1708], ["CYP", 1711], ["enzymes", 1715], [",", 1722], ["midazolam", 1724], ["and", 1734], ["diazepam", 1738], ["have", 1747], ["many", 1752], ["clinically", 1757], ["significant", 1768], ["interactions", 1780], ["with", 1793], ["inhibitors", 1798], ["and", 1809], ["inducers", 1813], ["of", 1822], ["CYP3A4", 1825], ["and", 1832], ["2C19", 1836], [".", 1840], ["In", 1842], ["addition", 1845], ["to", 1854], ["pharmacokinetic", 1857], ["interactions", 1873], [",", 1885], ["benzodiazepines", 1887], ["have", 1903], ["synergistic", 1908], ["interactions", 1920], ["with", 1933], ["other", 1938], ["hypnotics", 1944], ["and", 1954], ["opioids", 1958], [".", 1965], ["Midazolam", 1967], [",", 1976], ["diazepam", 1978], ["and", 1987], ["lorazepam", 1991], ["are", 2001], ["widely", 2005], ["used", 2012], ["for", 2017], ["sedation", 2021], ["and", 2030], ["to", 2034], ["some", 2037], ["extent", 2042], ["also", 2049], ["for", 2054], ["induction", 2058], ["and", 2068], ["maintenance", 2072], ["of", 2084], ["anaesthesia", 2087], [".", 2098], ["Flumazenil", 2100], ["is", 2111], ["very", 2114], ["useful", 2119], ["in", 2126], ["reversing", 2129], ["benzodiazepine", 2139], ["-", 2153], ["induced", 2154], ["sedation", 2162], ["as", 2171], ["well", 2174], ["as", 2179], ["to", 2182], ["diagnose", 2185], ["or", 2194], ["treat", 2197], ["benzodiazepine", 2203], ["overdose", 2218], [".", 2226]]}
{"context": "Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "9dd06b2102304cdc8188c97c503ffb35", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[165, 165], [374, 374], [76, 76], [359, 359], [40, 40]], "char_spans": [[933, 944], [2152, 2163], [455, 466], [2045, 2056], [239, 250]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["OPC-67683", 11], [")", 20], [",", 21], ["a", 23], ["nitro", 25], ["-", 30], ["dihydro", 31], ["-", 38], ["imidazooxazole", 39], ["derivative", 54], [",", 64], ["is", 66], ["a", 69], ["new", 71], ["antituberculosis", 75], ["medication", 92], ["that", 103], ["inhibits", 108], ["mycolic", 117], ["acid", 125], ["synthesis", 130], ["and", 140], ["has", 144], ["shown", 148], ["potent", 154], ["in", 161], ["vitro", 164], ["and", 170], ["in", 174], ["vivo", 177], ["activity", 182], ["against", 191], ["drug", 199], ["-", 203], ["resistant", 204], ["strains", 214], ["of", 222], ["Mycobacterium", 225], ["tuberculosis", 239], [".", 251], ["In", 253], ["this", 256], ["randomized", 261], [",", 271], ["placebo", 273], ["-", 280], ["controlled", 281], [",", 291], ["multinational", 293], ["clinical", 307], ["trial", 316], [",", 321], ["we", 323], ["assigned", 326], ["481", 335], ["patients", 339], ["(", 348], ["nearly", 349], ["all", 356], ["of", 360], ["whom", 363], ["were", 368], ["negative", 373], ["for", 382], ["the", 386], ["human", 390], ["immunodeficiency", 396], ["virus", 413], [")", 418], ["with", 420], ["pulmonary", 425], ["multidrug", 435], ["-", 444], ["resistant", 445], ["tuberculosis", 455], ["to", 468], ["receive", 471], ["delamanid", 479], [",", 488], ["at", 490], ["a", 493], ["dose", 495], ["of", 500], ["100", 503], ["mg", 507], ["twice", 510], ["daily", 516], ["(", 522], ["161", 523], ["patients", 527], [")", 535], ["or", 537], ["200", 540], ["mg", 544], ["twice", 547], ["daily", 553], ["(", 559], ["160", 560], ["patients", 564], [")", 572], [",", 573], ["or", 575], ["placebo", 578], ["(", 586], ["160", 587], ["patients", 591], [")", 599], ["for", 601], ["2", 605], ["months", 607], ["in", 614], ["combination", 617], ["with", 629], ["a", 634], ["background", 636], ["drug", 647], ["regimen", 652], ["developed", 660], ["according", 670], ["to", 680], ["World", 683], ["Health", 689], ["Organization", 696], ["guidelines", 709], [".", 719], ["Sputum", 721], ["cultures", 728], ["were", 737], ["assessed", 742], ["weekly", 751], ["with", 758], ["the", 763], ["use", 767], ["of", 771], ["both", 774], ["liquid", 779], ["broth", 786], ["and", 792], ["solid", 796], ["medium", 802], [";", 808], ["sputum", 810], ["-", 816], ["culture", 817], ["conversion", 825], ["was", 836], ["defined", 840], ["as", 848], ["a", 851], ["series", 853], ["of", 860], ["five", 863], ["or", 868], ["more", 871], ["consecutive", 876], ["cultures", 888], ["that", 897], ["were", 902], ["negative", 907], ["for", 916], ["growth", 920], ["of", 927], ["M.", 930], ["tuberculosis", 933], [".", 945], ["The", 947], ["primary", 951], ["efficacy", 959], ["end", 968], ["point", 972], ["was", 978], ["the", 982], ["proportion", 986], ["of", 997], ["patients", 1000], ["with", 1009], ["sputum", 1014], ["-", 1020], ["culture", 1021], ["conversion", 1029], ["in", 1040], ["liquid", 1043], ["broth", 1050], ["medium", 1056], ["at", 1063], ["2", 1066], ["months", 1068], [".", 1074], ["Among", 1076], ["patients", 1082], ["who", 1091], ["received", 1095], ["a", 1104], ["background", 1106], ["drug", 1117], ["regimen", 1122], ["plus", 1130], ["100", 1135], ["mg", 1139], ["of", 1142], ["delamanid", 1145], ["twice", 1155], ["daily", 1161], [",", 1166], ["45.4", 1168], ["%", 1172], ["had", 1174], ["sputum", 1178], ["-", 1184], ["culture", 1185], ["conversion", 1193], ["in", 1204], ["liquid", 1207], ["broth", 1214], ["at", 1220], ["2", 1223], ["months", 1225], [",", 1231], ["as", 1233], ["compared", 1236], ["with", 1245], ["29.6", 1250], ["%", 1254], ["of", 1256], ["patients", 1259], ["who", 1268], ["received", 1272], ["a", 1281], ["background", 1283], ["drug", 1294], ["regimen", 1299], ["plus", 1307], ["placebo", 1312], ["(", 1320], ["P=0.008", 1321], [")", 1328], [".", 1329], ["Likewise", 1331], [",", 1339], ["as", 1341], ["compared", 1344], ["with", 1353], ["the", 1358], ["placebo", 1362], ["group", 1370], [",", 1375], ["the", 1377], ["group", 1381], ["that", 1387], ["received", 1392], ["the", 1401], ["background", 1405], ["drug", 1416], ["regimen", 1421], ["plus", 1429], ["200", 1434], ["mg", 1438], ["of", 1441], ["delamanid", 1444], ["twice", 1454], ["daily", 1460], ["had", 1466], ["a", 1470], ["higher", 1472], ["proportion", 1479], ["of", 1490], ["patients", 1493], ["with", 1502], ["sputum", 1507], ["-", 1513], ["culture", 1514], ["conversion", 1522], ["(", 1533], ["41.9", 1534], ["%", 1538], [",", 1539], ["P=0.04", 1541], [")", 1547], [".", 1548], ["The", 1550], ["findings", 1554], ["were", 1563], ["similar", 1568], ["with", 1576], ["assessment", 1581], ["of", 1592], ["sputum", 1595], ["-", 1601], ["culture", 1602], ["conversion", 1610], ["in", 1621], ["solid", 1624], ["medium", 1630], [".", 1636], ["Most", 1638], ["adverse", 1643], ["events", 1651], ["were", 1658], ["mild", 1663], ["to", 1668], ["moderate", 1671], ["in", 1680], ["severity", 1683], ["and", 1692], ["were", 1696], ["evenly", 1701], ["distributed", 1708], ["across", 1720], ["groups", 1727], [".", 1733], ["Although", 1735], ["no", 1744], ["clinical", 1747], ["events", 1756], ["due", 1763], ["to", 1767], ["QT", 1770], ["prolongation", 1773], ["on", 1786], ["electrocardiography", 1789], ["were", 1809], ["observed", 1814], [",", 1822], ["QT", 1824], ["prolongation", 1827], ["was", 1840], ["reported", 1844], ["significantly", 1853], ["more", 1867], ["frequently", 1872], ["in", 1883], ["the", 1886], ["groups", 1890], ["that", 1897], ["received", 1902], ["delamanid", 1911], [".", 1920], ["Delamanid", 1922], ["was", 1932], ["associated", 1936], ["with", 1947], ["an", 1952], ["increase", 1955], ["in", 1964], ["sputum", 1967], ["-", 1973], ["culture", 1974], ["conversion", 1982], ["at", 1993], ["2", 1996], ["months", 1998], ["among", 2005], ["patients", 2011], ["with", 2020], ["multidrug", 2025], ["-", 2034], ["resistant", 2035], ["tuberculosis", 2045], [".", 2057], ["This", 2059], ["finding", 2064], ["suggests", 2072], ["that", 2081], ["delamanid", 2086], ["could", 2096], ["enhance", 2102], ["treatment", 2110], ["options", 2120], ["for", 2128], ["multidrug", 2132], ["-", 2141], ["resistant", 2142], ["tuberculosis", 2152], [".", 2164], ["(", 2166], ["Funded", 2167], ["by", 2174], ["Otsuka", 2177], ["Pharmaceutical", 2184], ["Development", 2199], ["and", 2211], ["Commercialization", 2215], [";", 2232], ["ClinicalTrials.gov", 2234], ["number", 2253], [",", 2259], ["NCT00685360", 2261], [".", 2272], [")", 2273], [".", 2274]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common familial tumour syndrome with multiple clinical features such as neurofibromas, caf\u00e9-au-lait spots (CLS), iris Lisch nodules, axillary freckling, optic glioma, specific bone lesions and an increased risk of malignant tumours. It is caused by a wide spectrum of mutations affecting the NF1 gene. Most mutations result in the loss of one allele at the DNA, mRNA or protein level and thus in the loss of any function of the gene product neurofibromin. The idea of the simultaneous loss of several different neurofibromin functions has been postulated to explain the pleiotropic effects of its loss. However, we have identified a novel missense mutation in a family with a classical multi-symptomatic NF1 phenotype, including a malignant schwannoma, that specifically abolishes the Ras-GTPase-activating function of neurofibromin. In this family, Arg1276 had mutated into proline. Based on complex biochemical studies as well as the analysis of the crystal structure of the GTPase-activating protein (GAP) domain of p120GAP in the presence of Ras, we unequivocally identified this amino acid as the arginine finger of the neurofibromin GAP-related domain (GRD)-the most essential catalytic element for RasGAP activity. Here, we present data demonstrating that the mutation R1276P, unlike previously reported missense mutations of the GRD region, does not impair the secondary and tertiary protein structure. It neither reduces the level of cellular neurofibromin nor influences its binding to Ras substantially, but it does completely disable GAP activity. Our findings provide direct evidence that failure of neurofibromin GAP activity is the critical element of NF1 pathogenesis. Thus, therapeutic approaches aimed at the reduction of Ras.GTP levels in neural crest-derived cells can be expected to relieve most of the NF1 symptoms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "6f4df195db2e4569b74922aec8abb058", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[298, 298], [4, 4], [137, 137], [328, 328], [62, 62]], "char_spans": [[1703, 1705], [26, 28], [740, 742], [1860, 1862], [328, 330]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["familial", 43], ["tumour", 52], ["syndrome", 59], ["with", 68], ["multiple", 73], ["clinical", 82], ["features", 91], ["such", 100], ["as", 105], ["neurofibromas", 108], [",", 121], ["caf\u00e9", 123], ["-", 127], ["au", 128], ["-", 130], ["lait", 131], ["spots", 136], ["(", 142], ["CLS", 143], [")", 146], [",", 147], ["iris", 149], ["Lisch", 154], ["nodules", 160], [",", 167], ["axillary", 169], ["freckling", 178], [",", 187], ["optic", 189], ["glioma", 195], [",", 201], ["specific", 203], ["bone", 212], ["lesions", 217], ["and", 225], ["an", 229], ["increased", 232], ["risk", 242], ["of", 247], ["malignant", 250], ["tumours", 260], [".", 267], ["It", 269], ["is", 272], ["caused", 275], ["by", 282], ["a", 285], ["wide", 287], ["spectrum", 292], ["of", 301], ["mutations", 304], ["affecting", 314], ["the", 324], ["NF1", 328], ["gene", 332], [".", 336], ["Most", 338], ["mutations", 343], ["result", 353], ["in", 360], ["the", 363], ["loss", 367], ["of", 372], ["one", 375], ["allele", 379], ["at", 386], ["the", 389], ["DNA", 393], [",", 396], ["mRNA", 398], ["or", 403], ["protein", 406], ["level", 414], ["and", 420], ["thus", 424], ["in", 429], ["the", 432], ["loss", 436], ["of", 441], ["any", 444], ["function", 448], ["of", 457], ["the", 460], ["gene", 464], ["product", 469], ["neurofibromin", 477], [".", 490], ["The", 492], ["idea", 496], ["of", 501], ["the", 504], ["simultaneous", 508], ["loss", 521], ["of", 526], ["several", 529], ["different", 537], ["neurofibromin", 547], ["functions", 561], ["has", 571], ["been", 575], ["postulated", 580], ["to", 591], ["explain", 594], ["the", 602], ["pleiotropic", 606], ["effects", 618], ["of", 626], ["its", 629], ["loss", 633], [".", 637], ["However", 639], [",", 646], ["we", 648], ["have", 651], ["identified", 656], ["a", 667], ["novel", 669], ["missense", 675], ["mutation", 684], ["in", 693], ["a", 696], ["family", 698], ["with", 705], ["a", 710], ["classical", 712], ["multi", 722], ["-", 727], ["symptomatic", 728], ["NF1", 740], ["phenotype", 744], [",", 753], ["including", 755], ["a", 765], ["malignant", 767], ["schwannoma", 777], [",", 787], ["that", 789], ["specifically", 794], ["abolishes", 807], ["the", 817], ["Ras", 821], ["-", 824], ["GTPase", 825], ["-", 831], ["activating", 832], ["function", 843], ["of", 852], ["neurofibromin", 855], [".", 868], ["In", 870], ["this", 873], ["family", 878], [",", 884], ["Arg1276", 886], ["had", 894], ["mutated", 898], ["into", 906], ["proline", 911], [".", 918], ["Based", 920], ["on", 926], ["complex", 929], ["biochemical", 937], ["studies", 949], ["as", 957], ["well", 960], ["as", 965], ["the", 968], ["analysis", 972], ["of", 981], ["the", 984], ["crystal", 988], ["structure", 996], ["of", 1006], ["the", 1009], ["GTPase", 1013], ["-", 1019], ["activating", 1020], ["protein", 1031], ["(", 1039], ["GAP", 1040], [")", 1043], ["domain", 1045], ["of", 1052], ["p120GAP", 1055], ["in", 1063], ["the", 1066], ["presence", 1070], ["of", 1079], ["Ras", 1082], [",", 1085], ["we", 1087], ["unequivocally", 1090], ["identified", 1104], ["this", 1115], ["amino", 1120], ["acid", 1126], ["as", 1131], ["the", 1134], ["arginine", 1138], ["finger", 1147], ["of", 1154], ["the", 1157], ["neurofibromin", 1161], ["GAP", 1175], ["-", 1178], ["related", 1179], ["domain", 1187], ["(", 1194], ["GRD)-the", 1195], ["most", 1204], ["essential", 1209], ["catalytic", 1219], ["element", 1229], ["for", 1237], ["RasGAP", 1241], ["activity", 1248], [".", 1256], ["Here", 1258], [",", 1262], ["we", 1264], ["present", 1267], ["data", 1275], ["demonstrating", 1280], ["that", 1294], ["the", 1299], ["mutation", 1303], ["R1276P", 1312], [",", 1318], ["unlike", 1320], ["previously", 1327], ["reported", 1338], ["missense", 1347], ["mutations", 1356], ["of", 1366], ["the", 1369], ["GRD", 1373], ["region", 1377], [",", 1383], ["does", 1385], ["not", 1390], ["impair", 1394], ["the", 1401], ["secondary", 1405], ["and", 1415], ["tertiary", 1419], ["protein", 1428], ["structure", 1436], [".", 1445], ["It", 1447], ["neither", 1450], ["reduces", 1458], ["the", 1466], ["level", 1470], ["of", 1476], ["cellular", 1479], ["neurofibromin", 1488], ["nor", 1502], ["influences", 1506], ["its", 1517], ["binding", 1521], ["to", 1529], ["Ras", 1532], ["substantially", 1536], [",", 1549], ["but", 1551], ["it", 1555], ["does", 1558], ["completely", 1563], ["disable", 1574], ["GAP", 1582], ["activity", 1586], [".", 1594], ["Our", 1596], ["findings", 1600], ["provide", 1609], ["direct", 1617], ["evidence", 1624], ["that", 1633], ["failure", 1638], ["of", 1646], ["neurofibromin", 1649], ["GAP", 1663], ["activity", 1667], ["is", 1676], ["the", 1679], ["critical", 1683], ["element", 1692], ["of", 1700], ["NF1", 1703], ["pathogenesis", 1707], [".", 1719], ["Thus", 1721], [",", 1725], ["therapeutic", 1727], ["approaches", 1739], ["aimed", 1750], ["at", 1756], ["the", 1759], ["reduction", 1763], ["of", 1773], ["Ras", 1776], [".", 1779], ["GTP", 1780], ["levels", 1784], ["in", 1791], ["neural", 1794], ["crest", 1801], ["-", 1806], ["derived", 1807], ["cells", 1815], ["can", 1821], ["be", 1825], ["expected", 1828], ["to", 1837], ["relieve", 1840], ["most", 1848], ["of", 1853], ["the", 1856], ["NF1", 1860], ["symptoms", 1864], [".", 1872]]}
{"context": "Recent evidence suggests that abnormal activation of cyclin-dependent kinase 5 (cdk5) is a critical prodeath signal in stroke. However, the mechanism(s) by which cdk5 promotes death is unclear. Complicating the role of cdk5 are the observations that cdk5 can exist in multiple cellular regions and possess both prosurvival and prodeath characteristics. In particular, the critical role of cytoplasmic or nuclear cdk5 in neuronal jury, in vivo, is unclear. Therefore, we determined where cdk5 was activated in models of ischemia and how manipulation of cdk5 in differing compartments may affect neuronal death. Here, we show a critical function for cytoplasmic cdk5 in both focal and global models of stroke, in vivo. Cdk5 is activated in the cytoplasm and expression of DNcdk5 localized to the cytoplasm is protective. Importantly, we also demonstrate the antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5. In contrast, the role of cdk5 in the nucleus is context-dependent. Following focal ischemia, nuclear cdk5 is activated and functionally relevant while there is no evidence for such activation following global ischemia. Importantly, myocyte enhancer factor 2D (MEF2D), a previously described nuclear target of cdk5 in vitro, is also phosphorylated by cdk5 following focal ischemia. In addition, MEF2D expression in this paradigm ameliorates death. Together, our results address the critical issue of cdk5 activity compartmentalization, as well as define critical substrates for both cytoplasmic and nuclear cdk5 activity in adult models of stroke.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "1907600356cb4afeb53267a9f83291d7", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[151, 151]], "char_spans": [[856, 866]]}]}], "context_tokens": [["Recent", 0], ["evidence", 7], ["suggests", 16], ["that", 25], ["abnormal", 30], ["activation", 39], ["of", 50], ["cyclin", 53], ["-", 59], ["dependent", 60], ["kinase", 70], ["5", 77], ["(", 79], ["cdk5", 80], [")", 84], ["is", 86], ["a", 89], ["critical", 91], ["prodeath", 100], ["signal", 109], ["in", 116], ["stroke", 119], [".", 125], ["However", 127], [",", 134], ["the", 136], ["mechanism(s", 140], [")", 151], ["by", 153], ["which", 156], ["cdk5", 162], ["promotes", 167], ["death", 176], ["is", 182], ["unclear", 185], [".", 192], ["Complicating", 194], ["the", 207], ["role", 211], ["of", 216], ["cdk5", 219], ["are", 224], ["the", 228], ["observations", 232], ["that", 245], ["cdk5", 250], ["can", 255], ["exist", 259], ["in", 265], ["multiple", 268], ["cellular", 277], ["regions", 286], ["and", 294], ["possess", 298], ["both", 306], ["prosurvival", 311], ["and", 323], ["prodeath", 327], ["characteristics", 336], [".", 351], ["In", 353], ["particular", 356], [",", 366], ["the", 368], ["critical", 372], ["role", 381], ["of", 386], ["cytoplasmic", 389], ["or", 401], ["nuclear", 404], ["cdk5", 412], ["in", 417], ["neuronal", 420], ["jury", 429], [",", 433], ["in", 435], ["vivo", 438], [",", 442], ["is", 444], ["unclear", 447], [".", 454], ["Therefore", 456], [",", 465], ["we", 467], ["determined", 470], ["where", 481], ["cdk5", 487], ["was", 492], ["activated", 496], ["in", 506], ["models", 509], ["of", 516], ["ischemia", 519], ["and", 528], ["how", 532], ["manipulation", 536], ["of", 549], ["cdk5", 552], ["in", 557], ["differing", 560], ["compartments", 570], ["may", 583], ["affect", 587], ["neuronal", 594], ["death", 603], [".", 608], ["Here", 610], [",", 614], ["we", 616], ["show", 619], ["a", 624], ["critical", 626], ["function", 635], ["for", 644], ["cytoplasmic", 648], ["cdk5", 660], ["in", 665], ["both", 668], ["focal", 673], ["and", 679], ["global", 683], ["models", 690], ["of", 697], ["stroke", 700], [",", 706], ["in", 708], ["vivo", 711], [".", 715], ["Cdk5", 717], ["is", 722], ["activated", 725], ["in", 735], ["the", 738], ["cytoplasm", 742], ["and", 752], ["expression", 756], ["of", 767], ["DNcdk5", 770], ["localized", 777], ["to", 787], ["the", 790], ["cytoplasm", 794], ["is", 804], ["protective", 807], [".", 817], ["Importantly", 819], [",", 830], ["we", 832], ["also", 835], ["demonstrate", 840], ["the", 852], ["antioxidant", 856], ["enzyme", 868], ["Prx2", 875], ["(", 880], ["peroxiredoxin", 881], ["2", 895], [")", 896], ["as", 898], ["a", 901], ["critical", 903], ["cytoplasmic", 912], ["target", 924], ["of", 931], ["cdk5", 934], [".", 938], ["In", 940], ["contrast", 943], [",", 951], ["the", 953], ["role", 957], ["of", 962], ["cdk5", 965], ["in", 970], ["the", 973], ["nucleus", 977], ["is", 985], ["context", 988], ["-", 995], ["dependent", 996], [".", 1005], ["Following", 1007], ["focal", 1017], ["ischemia", 1023], [",", 1031], ["nuclear", 1033], ["cdk5", 1041], ["is", 1046], ["activated", 1049], ["and", 1059], ["functionally", 1063], ["relevant", 1076], ["while", 1085], ["there", 1091], ["is", 1097], ["no", 1100], ["evidence", 1103], ["for", 1112], ["such", 1116], ["activation", 1121], ["following", 1132], ["global", 1142], ["ischemia", 1149], [".", 1157], ["Importantly", 1159], [",", 1170], ["myocyte", 1172], ["enhancer", 1180], ["factor", 1189], ["2D", 1196], ["(", 1199], ["MEF2D", 1200], [")", 1205], [",", 1206], ["a", 1208], ["previously", 1210], ["described", 1221], ["nuclear", 1231], ["target", 1239], ["of", 1246], ["cdk5", 1249], ["in", 1254], ["vitro", 1257], [",", 1262], ["is", 1264], ["also", 1267], ["phosphorylated", 1272], ["by", 1287], ["cdk5", 1290], ["following", 1295], ["focal", 1305], ["ischemia", 1311], [".", 1319], ["In", 1321], ["addition", 1324], [",", 1332], ["MEF2D", 1334], ["expression", 1340], ["in", 1351], ["this", 1354], ["paradigm", 1359], ["ameliorates", 1368], ["death", 1380], [".", 1385], ["Together", 1387], [",", 1395], ["our", 1397], ["results", 1401], ["address", 1409], ["the", 1417], ["critical", 1421], ["issue", 1430], ["of", 1436], ["cdk5", 1439], ["activity", 1444], ["compartmentalization", 1453], [",", 1473], ["as", 1475], ["well", 1478], ["as", 1483], ["define", 1486], ["critical", 1493], ["substrates", 1502], ["for", 1513], ["both", 1517], ["cytoplasmic", 1522], ["and", 1534], ["nuclear", 1538], ["cdk5", 1546], ["activity", 1551], ["in", 1560], ["adult", 1563], ["models", 1569], ["of", 1576], ["stroke", 1579], [".", 1585]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). This study was undertaken to investigate the effect of food on the pharmacokinetics of 25 mg empagliflozin and to assess dose proportionality between 10 mg and 25 mg empagliflozin under fasted conditions. In this open-label, 3-way, cross-over study, 18 healthy volunteers received 3 single doses of empagliflozin in a randomized sequence (25 mg empagliflozin under fasted conditions, 25 mg empagliflozin after a high-fat, high-calorie breakfast and 10 mg empagliflozin under fasted conditions), each separated by a washout period of at least 7 days. Serial plasma samples were collected at selected time points over a period of 72 hours. Administration with food had no clinically relevant effect on the area under the plasma concentration-time curve (AUC0-\u221e) of empagliflozin (geometric mean ratio (GMR): 84.04, 90% confidence interval (CI): 80.86 - 87.34). The decrease observed in the maximum plasma concentrations (Cmax) of empagliflozin (GMR: 63.22, 90% CI: 56.74 - 70.44) when administered with food was not considered clinically meaningful. The increases in AUC0-\u221e and Cmax for 10 mg vs. 25 mg empagliflozin administered under fasting conditions were roughly dose-proportional, as demonstrated by the slope \u03b2 of the regression lines being slightly less than 1 (slope \u03b2 for AUC0-\u221e: 0.94, 95% CI: 0.90 - 0.97; slope \u03b2 for Cmax: 0.91, 95% CI: 0.80 - 1.01). Empagliflozin was well tolerated under fed and fasting conditions. The results support administration of empagliflozin tablets independently of food. Increases in empagliflozin exposure under fasting conditions were roughly dose-proportional between 10 mg and 25 mg empagliflozin.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "1ac6a774b34748d0b2f90a6dd51379eb", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[18, 18]], "char_spans": [[115, 119]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["an", 17], ["orally", 20], ["available", 27], [",", 36], ["potent", 38], ["and", 45], ["highly", 49], ["selective", 56], ["inhibitor", 66], ["of", 76], ["the", 79], ["sodium", 83], ["glucose", 90], ["cotransporter", 98], ["2", 112], ["(", 114], ["SGLT2", 115], [")", 120], [".", 121], ["This", 123], ["study", 128], ["was", 134], ["undertaken", 138], ["to", 149], ["investigate", 152], ["the", 164], ["effect", 168], ["of", 175], ["food", 178], ["on", 183], ["the", 186], ["pharmacokinetics", 190], ["of", 207], ["25", 210], ["mg", 213], ["empagliflozin", 216], ["and", 230], ["to", 234], ["assess", 237], ["dose", 244], ["proportionality", 249], ["between", 265], ["10", 273], ["mg", 276], ["and", 279], ["25", 283], ["mg", 286], ["empagliflozin", 289], ["under", 303], ["fasted", 309], ["conditions", 316], [".", 326], ["In", 328], ["this", 331], ["open", 336], ["-", 340], ["label", 341], [",", 346], ["3-way", 348], [",", 353], ["cross", 355], ["-", 360], ["over", 361], ["study", 366], [",", 371], ["18", 373], ["healthy", 376], ["volunteers", 384], ["received", 395], ["3", 404], ["single", 406], ["doses", 413], ["of", 419], ["empagliflozin", 422], ["in", 436], ["a", 439], ["randomized", 441], ["sequence", 452], ["(", 461], ["25", 462], ["mg", 465], ["empagliflozin", 468], ["under", 482], ["fasted", 488], ["conditions", 495], [",", 505], ["25", 507], ["mg", 510], ["empagliflozin", 513], ["after", 527], ["a", 533], ["high", 535], ["-", 539], ["fat", 540], [",", 543], ["high", 545], ["-", 549], ["calorie", 550], ["breakfast", 558], ["and", 568], ["10", 572], ["mg", 575], ["empagliflozin", 578], ["under", 592], ["fasted", 598], ["conditions", 605], [")", 615], [",", 616], ["each", 618], ["separated", 623], ["by", 633], ["a", 636], ["washout", 638], ["period", 646], ["of", 653], ["at", 656], ["least", 659], ["7", 665], ["days", 667], [".", 671], ["Serial", 673], ["plasma", 680], ["samples", 687], ["were", 695], ["collected", 700], ["at", 710], ["selected", 713], ["time", 722], ["points", 727], ["over", 734], ["a", 739], ["period", 741], ["of", 748], ["72", 751], ["hours", 754], [".", 759], ["Administration", 761], ["with", 776], ["food", 781], ["had", 786], ["no", 790], ["clinically", 793], ["relevant", 804], ["effect", 813], ["on", 820], ["the", 823], ["area", 827], ["under", 832], ["the", 838], ["plasma", 842], ["concentration", 849], ["-", 862], ["time", 863], ["curve", 868], ["(", 874], ["AUC0-\u221e", 875], [")", 881], ["of", 883], ["empagliflozin", 886], ["(", 900], ["geometric", 901], ["mean", 911], ["ratio", 916], ["(", 922], ["GMR", 923], [")", 926], [":", 927], ["84.04", 929], [",", 934], ["90", 936], ["%", 938], ["confidence", 940], ["interval", 951], ["(", 960], ["CI", 961], [")", 963], [":", 964], ["80.86", 966], ["-", 972], ["87.34", 974], [")", 979], [".", 980], ["The", 982], ["decrease", 986], ["observed", 995], ["in", 1004], ["the", 1007], ["maximum", 1011], ["plasma", 1019], ["concentrations", 1026], ["(", 1041], ["Cmax", 1042], [")", 1046], ["of", 1048], ["empagliflozin", 1051], ["(", 1065], ["GMR", 1066], [":", 1069], ["63.22", 1071], [",", 1076], ["90", 1078], ["%", 1080], ["CI", 1082], [":", 1084], ["56.74", 1086], ["-", 1092], ["70.44", 1094], [")", 1099], ["when", 1101], ["administered", 1106], ["with", 1119], ["food", 1124], ["was", 1129], ["not", 1133], ["considered", 1137], ["clinically", 1148], ["meaningful", 1159], [".", 1169], ["The", 1171], ["increases", 1175], ["in", 1185], ["AUC0-\u221e", 1188], ["and", 1195], ["Cmax", 1199], ["for", 1204], ["10", 1208], ["mg", 1211], ["vs.", 1214], ["25", 1218], ["mg", 1221], ["empagliflozin", 1224], ["administered", 1238], ["under", 1251], ["fasting", 1257], ["conditions", 1265], ["were", 1276], ["roughly", 1281], ["dose", 1289], ["-", 1293], ["proportional", 1294], [",", 1306], ["as", 1308], ["demonstrated", 1311], ["by", 1324], ["the", 1327], ["slope", 1331], ["\u03b2", 1337], ["of", 1339], ["the", 1342], ["regression", 1346], ["lines", 1357], ["being", 1363], ["slightly", 1369], ["less", 1378], ["than", 1383], ["1", 1388], ["(", 1390], ["slope", 1391], ["\u03b2", 1397], ["for", 1399], ["AUC0-\u221e", 1403], [":", 1409], ["0.94", 1411], [",", 1415], ["95", 1417], ["%", 1419], ["CI", 1421], [":", 1423], ["0.90", 1425], ["-", 1430], ["0.97", 1432], [";", 1436], ["slope", 1438], ["\u03b2", 1444], ["for", 1446], ["Cmax", 1450], [":", 1454], ["0.91", 1456], [",", 1460], ["95", 1462], ["%", 1464], ["CI", 1466], [":", 1468], ["0.80", 1470], ["-", 1475], ["1.01", 1477], [")", 1481], [".", 1482], ["Empagliflozin", 1484], ["was", 1498], ["well", 1502], ["tolerated", 1507], ["under", 1517], ["fed", 1523], ["and", 1527], ["fasting", 1531], ["conditions", 1539], [".", 1549], ["The", 1551], ["results", 1555], ["support", 1563], ["administration", 1571], ["of", 1586], ["empagliflozin", 1589], ["tablets", 1603], ["independently", 1611], ["of", 1625], ["food", 1628], [".", 1632], ["Increases", 1634], ["in", 1644], ["empagliflozin", 1647], ["exposure", 1661], ["under", 1670], ["fasting", 1676], ["conditions", 1684], ["were", 1695], ["roughly", 1700], ["dose", 1708], ["-", 1712], ["proportional", 1713], ["between", 1726], ["10", 1734], ["mg", 1737], ["and", 1740], ["25", 1744], ["mg", 1747], ["empagliflozin", 1750], [".", 1763]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA, which typically function as stop codon. The function of HSelP remains unclear, in part due to the inability to express it by gene recombinant technique. This study is to investigate expression and purification of recombinant HSelP in prokaryotic expression system, and its activity to induce apoptosis in vitro. The shorter HSelP isoform was cloned. After the selenocysteine (SeCys) at 40th position from N terminus of the HSelP shorter isoform was mutated into cysteine by PCR, it was expressed in E. coli. The expressed product was purified with DEAE column and identified by Western blot. Subsequently, its function on induction of mitochondrial apoptotic activity was studied. The mutant HSelP shorter isoform expressed in prokaryotic system was purified by DEAE column to 90% homogeneity. The purified product, HSelP280m, induced the opening of mitochondrial permeability transition pore (PTP) and decreased the transmembrane potential in a dose-dependent manner. These events could be abolished by PTP specific inhibitors. HSelP280m can induce the opening of mitochondrial PTP, which provides a basis for investigating the structure and function of recombinant HSelP.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "c67a56187ba94d478fbc8c8608cabb52", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[1, 2]], "char_spans": [[6, 20]]}]}], "context_tokens": [["Human", 0], ["selenoprotein", 6], ["P", 20], ["(", 22], ["HSelP", 23], [")", 28], ["is", 30], ["unique", 33], ["protein", 40], ["that", 48], ["contains", 53], ["10", 62], ["selenocysteines", 65], ["encoded", 81], ["by", 89], ["10", 92], ["inframe", 95], ["UGA", 103], [",", 106], ["which", 108], ["typically", 114], ["function", 124], ["as", 133], ["stop", 136], ["codon", 141], [".", 146], ["The", 148], ["function", 152], ["of", 161], ["HSelP", 164], ["remains", 170], ["unclear", 178], [",", 185], ["in", 187], ["part", 190], ["due", 195], ["to", 199], ["the", 202], ["inability", 206], ["to", 216], ["express", 219], ["it", 227], ["by", 230], ["gene", 233], ["recombinant", 238], ["technique", 250], [".", 259], ["This", 261], ["study", 266], ["is", 272], ["to", 275], ["investigate", 278], ["expression", 290], ["and", 301], ["purification", 305], ["of", 318], ["recombinant", 321], ["HSelP", 333], ["in", 339], ["prokaryotic", 342], ["expression", 354], ["system", 365], [",", 371], ["and", 373], ["its", 377], ["activity", 381], ["to", 390], ["induce", 393], ["apoptosis", 400], ["in", 410], ["vitro", 413], [".", 418], ["The", 420], ["shorter", 424], ["HSelP", 432], ["isoform", 438], ["was", 446], ["cloned", 450], [".", 456], ["After", 458], ["the", 464], ["selenocysteine", 468], ["(", 483], ["SeCys", 484], [")", 489], ["at", 491], ["40th", 494], ["position", 499], ["from", 508], ["N", 513], ["terminus", 515], ["of", 524], ["the", 527], ["HSelP", 531], ["shorter", 537], ["isoform", 545], ["was", 553], ["mutated", 557], ["into", 565], ["cysteine", 570], ["by", 579], ["PCR", 582], [",", 585], ["it", 587], ["was", 590], ["expressed", 594], ["in", 604], ["E.", 607], ["coli", 610], [".", 614], ["The", 616], ["expressed", 620], ["product", 630], ["was", 638], ["purified", 642], ["with", 651], ["DEAE", 656], ["column", 661], ["and", 668], ["identified", 672], ["by", 683], ["Western", 686], ["blot", 694], [".", 698], ["Subsequently", 700], [",", 712], ["its", 714], ["function", 718], ["on", 727], ["induction", 730], ["of", 740], ["mitochondrial", 743], ["apoptotic", 757], ["activity", 767], ["was", 776], ["studied", 780], [".", 787], ["The", 789], ["mutant", 793], ["HSelP", 800], ["shorter", 806], ["isoform", 814], ["expressed", 822], ["in", 832], ["prokaryotic", 835], ["system", 847], ["was", 854], ["purified", 858], ["by", 867], ["DEAE", 870], ["column", 875], ["to", 882], ["90", 885], ["%", 887], ["homogeneity", 889], [".", 900], ["The", 902], ["purified", 906], ["product", 915], [",", 922], ["HSelP280", 924], ["m", 932], [",", 933], ["induced", 935], ["the", 943], ["opening", 947], ["of", 955], ["mitochondrial", 958], ["permeability", 972], ["transition", 985], ["pore", 996], ["(", 1001], ["PTP", 1002], [")", 1005], ["and", 1007], ["decreased", 1011], ["the", 1021], ["transmembrane", 1025], ["potential", 1039], ["in", 1049], ["a", 1052], ["dose", 1054], ["-", 1058], ["dependent", 1059], ["manner", 1069], [".", 1075], ["These", 1077], ["events", 1083], ["could", 1090], ["be", 1096], ["abolished", 1099], ["by", 1109], ["PTP", 1112], ["specific", 1116], ["inhibitors", 1125], [".", 1135], ["HSelP280", 1137], ["m", 1145], ["can", 1147], ["induce", 1151], ["the", 1158], ["opening", 1162], ["of", 1170], ["mitochondrial", 1173], ["PTP", 1187], [",", 1190], ["which", 1192], ["provides", 1198], ["a", 1207], ["basis", 1209], ["for", 1215], ["investigating", 1219], ["the", 1233], ["structure", 1237], ["and", 1247], ["function", 1251], ["of", 1260], ["recombinant", 1263], ["HSelP.", 1275]]}
{"context": "We review the current evidence for medical and surgical treatments of spontaneous intracerebral hemorrhage (ICH). Therapy with hemostatic agents (e.g. factor VIIa and tranexamic acid) if started early after bleeding onset may reduce hematoma expansion, but their clinical effectiveness has not been shown. Rapid anticoagulation reversal with prothrombin concentrates (PCC) plus vitamin K is the first choice in vitamin K antagonist-related ICH. In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab. PCC are recommended for ICH related to FXa inhibitors, whereas specific reversal agents are not yet approved. While awaiting ongoing trials studying minimally invasive approaches or hemicraniectomy, the role of surgery in ICH remains to be defined. Therapies targeting downstream molecular cascades in order to prevent secondary neuronal damage are promising, but the complexity and multi-phased nature of ICH pathophysiology is challenging. Finally, in addition to blood pressure control, antithrombotic prevention after ICH has to consider the risk of recurrent bleeding as well as the risk of ischemic events. Treatment of acute ICH remains challenging, and many promising interventions for acute ICH await further evidence from trials.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d40ca4a4e2a1425fbe7308353258a879", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[78, 78]], "char_spans": [[463, 472]]}]}], "context_tokens": [["We", 0], ["review", 3], ["the", 10], ["current", 14], ["evidence", 22], ["for", 31], ["medical", 35], ["and", 43], ["surgical", 47], ["treatments", 56], ["of", 67], ["spontaneous", 70], ["intracerebral", 82], ["hemorrhage", 96], ["(", 107], ["ICH", 108], [")", 111], [".", 112], ["Therapy", 114], ["with", 122], ["hemostatic", 127], ["agents", 138], ["(", 145], ["e.g.", 146], ["factor", 151], ["VIIa", 158], ["and", 163], ["tranexamic", 167], ["acid", 178], [")", 182], ["if", 184], ["started", 187], ["early", 195], ["after", 201], ["bleeding", 207], ["onset", 216], ["may", 222], ["reduce", 226], ["hematoma", 233], ["expansion", 242], [",", 251], ["but", 253], ["their", 257], ["clinical", 263], ["effectiveness", 272], ["has", 286], ["not", 290], ["been", 294], ["shown", 299], [".", 304], ["Rapid", 306], ["anticoagulation", 312], ["reversal", 328], ["with", 337], ["prothrombin", 342], ["concentrates", 354], ["(", 367], ["PCC", 368], [")", 371], ["plus", 373], ["vitamin", 378], ["K", 386], ["is", 388], ["the", 391], ["first", 395], ["choice", 401], ["in", 408], ["vitamin", 411], ["K", 419], ["antagonist", 421], ["-", 431], ["related", 432], ["ICH", 440], [".", 443], ["In", 445], ["ICH", 448], ["related", 452], ["to", 460], ["dabigatran", 463], [",", 473], ["anticoagulation", 475], ["can", 491], ["be", 495], ["rapidly", 498], ["reversed", 506], ["with", 515], ["idarucizumab", 520], [".", 532], ["PCC", 534], ["are", 538], ["recommended", 542], ["for", 554], ["ICH", 558], ["related", 562], ["to", 570], ["FXa", 573], ["inhibitors", 577], [",", 587], ["whereas", 589], ["specific", 597], ["reversal", 606], ["agents", 615], ["are", 622], ["not", 626], ["yet", 630], ["approved", 634], [".", 642], ["While", 644], ["awaiting", 650], ["ongoing", 659], ["trials", 667], ["studying", 674], ["minimally", 683], ["invasive", 693], ["approaches", 702], ["or", 713], ["hemicraniectomy", 716], [",", 731], ["the", 733], ["role", 737], ["of", 742], ["surgery", 745], ["in", 753], ["ICH", 756], ["remains", 760], ["to", 768], ["be", 771], ["defined", 774], [".", 781], ["Therapies", 783], ["targeting", 793], ["downstream", 803], ["molecular", 814], ["cascades", 824], ["in", 833], ["order", 836], ["to", 842], ["prevent", 845], ["secondary", 853], ["neuronal", 863], ["damage", 872], ["are", 879], ["promising", 883], [",", 892], ["but", 894], ["the", 898], ["complexity", 902], ["and", 913], ["multi", 917], ["-", 922], ["phased", 923], ["nature", 930], ["of", 937], ["ICH", 940], ["pathophysiology", 944], ["is", 960], ["challenging", 963], [".", 974], ["Finally", 976], [",", 983], ["in", 985], ["addition", 988], ["to", 997], ["blood", 1000], ["pressure", 1006], ["control", 1015], [",", 1022], ["antithrombotic", 1024], ["prevention", 1039], ["after", 1050], ["ICH", 1056], ["has", 1060], ["to", 1064], ["consider", 1067], ["the", 1076], ["risk", 1080], ["of", 1085], ["recurrent", 1088], ["bleeding", 1098], ["as", 1107], ["well", 1110], ["as", 1115], ["the", 1118], ["risk", 1122], ["of", 1127], ["ischemic", 1130], ["events", 1139], [".", 1145], ["Treatment", 1147], ["of", 1157], ["acute", 1160], ["ICH", 1166], ["remains", 1170], ["challenging", 1178], [",", 1189], ["and", 1191], ["many", 1195], ["promising", 1200], ["interventions", 1210], ["for", 1224], ["acute", 1228], ["ICH", 1234], ["await", 1238], ["further", 1244], ["evidence", 1252], ["from", 1261], ["trials", 1266], [".", 1272]]}
{"context": "Reperfusion injury to tissue following an ischemic event occurs as a consequence of an acute inflammatory response that can cause significant morbidity and mortality. Components of both the innate (complement, immunoglobulin, monocytes, and neutrophils) and adaptive (B and T lymphocytes) immune systems have been demonstrated to mediate tissue injury. Spleen tyrosine kinase (Syk) is responsible for membrane-mediated signaling in various cell types including B lymphocytes, macrophages, and T cells. We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury. Mice were fed with chow containing a Syk inhibitor for 6 days before the performance of intestinal I/R, which resulted in silencing of the expression of the active phosphorylated Syk. Syk inhibition significantly suppressed both local and remote lung injury. The beneficial effect was associated with reduced IgM and complement 3 deposition in the tissues and significant reduction of polymorphonuclear cell infiltration. Our data place Syk upstream of events leading to the binding of natural antibodies to the ischemia-conditioned tissues and urge the consideration of the use of Syk inhibitors in the prevention or improvement of tissue injury of organs exposed to ischemia or hypoperfusion.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "c39a985f3db547f193720f8ea9d1d8ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[58, 60]], "char_spans": [[353, 374]]}]}], "context_tokens": [["Reperfusion", 0], ["injury", 12], ["to", 19], ["tissue", 22], ["following", 29], ["an", 39], ["ischemic", 42], ["event", 51], ["occurs", 57], ["as", 64], ["a", 67], ["consequence", 69], ["of", 81], ["an", 84], ["acute", 87], ["inflammatory", 93], ["response", 106], ["that", 115], ["can", 120], ["cause", 124], ["significant", 130], ["morbidity", 142], ["and", 152], ["mortality", 156], [".", 165], ["Components", 167], ["of", 178], ["both", 181], ["the", 186], ["innate", 190], ["(", 197], ["complement", 198], [",", 208], ["immunoglobulin", 210], [",", 224], ["monocytes", 226], [",", 235], ["and", 237], ["neutrophils", 241], [")", 252], ["and", 254], ["adaptive", 258], ["(", 267], ["B", 268], ["and", 270], ["T", 274], ["lymphocytes", 276], [")", 287], ["immune", 289], ["systems", 296], ["have", 304], ["been", 309], ["demonstrated", 314], ["to", 327], ["mediate", 330], ["tissue", 338], ["injury", 345], [".", 351], ["Spleen", 353], ["tyrosine", 360], ["kinase", 369], ["(", 376], ["Syk", 377], [")", 380], ["is", 382], ["responsible", 385], ["for", 397], ["membrane", 401], ["-", 409], ["mediated", 410], ["signaling", 419], ["in", 429], ["various", 432], ["cell", 440], ["types", 445], ["including", 451], ["B", 461], ["lymphocytes", 463], [",", 474], ["macrophages", 476], [",", 487], ["and", 489], ["T", 493], ["cells", 495], [".", 500], ["We", 502], ["investigated", 505], ["the", 518], ["ability", 522], ["of", 530], ["a", 533], ["small", 535], ["drug", 541], ["Syk", 546], ["inhibitor", 550], [",", 559], ["R788", 561], [",", 565], ["to", 567], ["protect", 570], ["mice", 578], ["against", 583], ["mesenteric", 591], ["ischemia", 602], ["-", 610], ["reperfusion", 611], ["(", 623], ["I", 624], ["/", 625], ["R)-induced", 626], ["local", 637], ["(", 643], ["intestine", 644], [")", 653], ["and", 655], ["remote", 659], ["lung", 666], ["injury", 671], [".", 677], ["Mice", 679], ["were", 684], ["fed", 689], ["with", 693], ["chow", 698], ["containing", 703], ["a", 714], ["Syk", 716], ["inhibitor", 720], ["for", 730], ["6", 734], ["days", 736], ["before", 741], ["the", 748], ["performance", 752], ["of", 764], ["intestinal", 767], ["I", 778], ["/", 779], ["R", 780], [",", 781], ["which", 783], ["resulted", 789], ["in", 798], ["silencing", 801], ["of", 811], ["the", 814], ["expression", 818], ["of", 829], ["the", 832], ["active", 836], ["phosphorylated", 843], ["Syk", 858], [".", 861], ["Syk", 863], ["inhibition", 867], ["significantly", 878], ["suppressed", 892], ["both", 903], ["local", 908], ["and", 914], ["remote", 918], ["lung", 925], ["injury", 930], [".", 936], ["The", 938], ["beneficial", 942], ["effect", 953], ["was", 960], ["associated", 964], ["with", 975], ["reduced", 980], ["IgM", 988], ["and", 992], ["complement", 996], ["3", 1007], ["deposition", 1009], ["in", 1020], ["the", 1023], ["tissues", 1027], ["and", 1035], ["significant", 1039], ["reduction", 1051], ["of", 1061], ["polymorphonuclear", 1064], ["cell", 1082], ["infiltration", 1087], [".", 1099], ["Our", 1101], ["data", 1105], ["place", 1110], ["Syk", 1116], ["upstream", 1120], ["of", 1129], ["events", 1132], ["leading", 1139], ["to", 1147], ["the", 1150], ["binding", 1154], ["of", 1162], ["natural", 1165], ["antibodies", 1173], ["to", 1184], ["the", 1187], ["ischemia", 1191], ["-", 1199], ["conditioned", 1200], ["tissues", 1212], ["and", 1220], ["urge", 1224], ["the", 1229], ["consideration", 1233], ["of", 1247], ["the", 1250], ["use", 1254], ["of", 1258], ["Syk", 1261], ["inhibitors", 1265], ["in", 1276], ["the", 1279], ["prevention", 1283], ["or", 1294], ["improvement", 1297], ["of", 1309], ["tissue", 1312], ["injury", 1319], ["of", 1326], ["organs", 1329], ["exposed", 1336], ["to", 1344], ["ischemia", 1347], ["or", 1356], ["hypoperfusion", 1359], [".", 1372]]}
{"context": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients. We report on the sixth known patient with this condition. The findings which distinguish our patient from others reported previously are that she was ascertained prenatally as having a cloverleaf skull; this is the first female patient described with this condition. Postnatally, she presented with arachnodactyly, camptodactyly, and clover-leaf skull. Imaging studies of the brain documented microcephaly with malformed brain, hydrocephaly, and hypoplasia of the corpus callosum. She also had choanal atresia and stenosis, a clinical finding previously reported only once, in this disorder.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "78c142601b5048dd9ab83e39d4e8e15f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[3, 3]], "char_spans": [[25, 40]]}]}], "context_tokens": [["Marfanoid", 0], ["phenotype", 10], ["with", 20], ["craniosynostosis", 25], ["(", 42], ["Shprintzen", 43], ["-", 53], ["Goldberg", 54], ["syndrome", 63], [")", 71], ["is", 73], ["a", 76], ["rare", 78], ["disorder", 83], ["previously", 92], ["described", 103], ["in", 113], ["only", 116], ["5", 121], ["patients", 123], [".", 131], ["We", 133], ["report", 136], ["on", 143], ["the", 146], ["sixth", 150], ["known", 156], ["patient", 162], ["with", 170], ["this", 175], ["condition", 180], [".", 189], ["The", 191], ["findings", 195], ["which", 204], ["distinguish", 210], ["our", 222], ["patient", 226], ["from", 234], ["others", 239], ["reported", 246], ["previously", 255], ["are", 266], ["that", 270], ["she", 275], ["was", 279], ["ascertained", 283], ["prenatally", 295], ["as", 306], ["having", 309], ["a", 316], ["cloverleaf", 318], ["skull", 329], [";", 334], ["this", 336], ["is", 341], ["the", 344], ["first", 348], ["female", 354], ["patient", 361], ["described", 369], ["with", 379], ["this", 384], ["condition", 389], [".", 398], ["Postnatally", 400], [",", 411], ["she", 413], ["presented", 417], ["with", 427], ["arachnodactyly", 432], [",", 446], ["camptodactyly", 448], [",", 461], ["and", 463], ["clover", 467], ["-", 473], ["leaf", 474], ["skull", 479], [".", 484], ["Imaging", 486], ["studies", 494], ["of", 502], ["the", 505], ["brain", 509], ["documented", 515], ["microcephaly", 526], ["with", 539], ["malformed", 544], ["brain", 554], [",", 559], ["hydrocephaly", 561], [",", 573], ["and", 575], ["hypoplasia", 579], ["of", 590], ["the", 593], ["corpus", 597], ["callosum", 604], [".", 612], ["She", 614], ["also", 618], ["had", 623], ["choanal", 627], ["atresia", 635], ["and", 643], ["stenosis", 647], [",", 655], ["a", 657], ["clinical", 659], ["finding", 668], ["previously", 676], ["reported", 687], ["only", 696], ["once", 701], [",", 705], ["in", 707], ["this", 710], ["disorder", 715], [".", 723]]}
{"context": "Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for posttraumatic stress disorder (PTSD). Serotonergic (5HT) attenuation of stress sensitivity is postulated from SSRIs' effects in other anxiety disorders, and we studied this in PTSD. Ten patients with PTSD fully recovered on SSRIs (Clinical Global Impression Scale-I 1 and 2) were enrolled in the study. Patients were tested on two occasions 1 week apart; in each session, they received a drink containing large neutral amino acids (LNAAs) either with (sham tryptophan depletion [STD], control) or without (acute tryptophan depletion [ATD]) tryptophan. At 5.5 hours after the drink, subjects were exposed to a trauma-related exposure challenge. Self-reports of PTSD (visual analogue scales [VAS] and the Davidson Trauma Scale [DTS]), anxiety (Spielberger State Inventory [STAI] Form Y-1), and mood (Profile of Mood States [POMS]) were obtained. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were also measured. The trauma-related exposure challenge induced anxiety on both days, with more marked responses on the ATD day according to VAS, DTS, POMS, and DBP (p < .05). A trend of significance (.1 > p > .05) was observed for STAI Form Y-1, HR, and SBP. These data demonstrate that ATD accentuates responses to trauma-related stimuli in SSRI-recovered PTSD. They also suggest that SSRI-induced increases in serotonin function restrain PTSD symptoms, especially under provocation, supporting a role for serotonin in mediating stress resilience.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "a197452996814e96bc9331b41b870709", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[283, 283], [44, 44], [297, 297], [17, 17], [143, 143], [49, 49]], "char_spans": [[1349, 1352], [254, 257], [1432, 1435], [109, 112], [738, 741], [278, 281]]}]}], "context_tokens": [["Selective", 0], ["serotonin", 10], ["reuptake", 20], ["inhibitors", 29], ["(", 40], ["SSRIs", 41], [")", 46], ["are", 48], ["first", 52], ["-", 57], ["line", 58], ["treatments", 63], ["for", 74], ["posttraumatic", 78], ["stress", 92], ["disorder", 99], ["(", 108], ["PTSD", 109], [")", 113], [".", 114], ["Serotonergic", 116], ["(", 129], ["5HT", 130], [")", 133], ["attenuation", 135], ["of", 147], ["stress", 150], ["sensitivity", 157], ["is", 169], ["postulated", 172], ["from", 183], ["SSRIs", 188], ["'", 193], ["effects", 195], ["in", 203], ["other", 206], ["anxiety", 212], ["disorders", 220], [",", 229], ["and", 231], ["we", 235], ["studied", 238], ["this", 246], ["in", 251], ["PTSD", 254], [".", 258], ["Ten", 260], ["patients", 264], ["with", 273], ["PTSD", 278], ["fully", 283], ["recovered", 289], ["on", 299], ["SSRIs", 302], ["(", 308], ["Clinical", 309], ["Global", 318], ["Impression", 325], ["Scale", 336], ["-", 341], ["I", 342], ["1", 344], ["and", 346], ["2", 350], [")", 351], ["were", 353], ["enrolled", 358], ["in", 367], ["the", 370], ["study", 374], [".", 379], ["Patients", 381], ["were", 390], ["tested", 395], ["on", 402], ["two", 405], ["occasions", 409], ["1", 419], ["week", 421], ["apart", 426], [";", 431], ["in", 433], ["each", 436], ["session", 441], [",", 448], ["they", 450], ["received", 455], ["a", 464], ["drink", 466], ["containing", 472], ["large", 483], ["neutral", 489], ["amino", 497], ["acids", 503], ["(", 509], ["LNAAs", 510], [")", 515], ["either", 517], ["with", 524], ["(", 529], ["sham", 530], ["tryptophan", 535], ["depletion", 546], ["[", 556], ["STD", 557], ["]", 560], [",", 561], ["control", 563], [")", 570], ["or", 572], ["without", 575], ["(", 583], ["acute", 584], ["tryptophan", 590], ["depletion", 601], ["[", 611], ["ATD", 612], ["]", 615], [")", 616], ["tryptophan", 618], [".", 628], ["At", 630], ["5.5", 633], ["hours", 637], ["after", 643], ["the", 649], ["drink", 653], [",", 658], ["subjects", 660], ["were", 669], ["exposed", 674], ["to", 682], ["a", 685], ["trauma", 687], ["-", 693], ["related", 694], ["exposure", 702], ["challenge", 711], [".", 720], ["Self", 722], ["-", 726], ["reports", 727], ["of", 735], ["PTSD", 738], ["(", 743], ["visual", 744], ["analogue", 751], ["scales", 760], ["[", 767], ["VAS", 768], ["]", 771], ["and", 773], ["the", 777], ["Davidson", 781], ["Trauma", 790], ["Scale", 797], ["[", 803], ["DTS", 804], ["]", 807], [")", 808], [",", 809], ["anxiety", 811], ["(", 819], ["Spielberger", 820], ["State", 832], ["Inventory", 838], ["[", 848], ["STAI", 849], ["]", 853], ["Form", 855], ["Y-1", 860], [")", 863], [",", 864], ["and", 866], ["mood", 870], ["(", 875], ["Profile", 876], ["of", 884], ["Mood", 887], ["States", 892], ["[", 899], ["POMS", 900], ["]", 904], [")", 905], ["were", 907], ["obtained", 912], [".", 920], ["Heart", 922], ["rate", 928], ["(", 933], ["HR", 934], [")", 936], [",", 937], ["systolic", 939], ["(", 948], ["SBP", 949], [")", 952], ["and", 954], ["diastolic", 958], ["(", 968], ["DBP", 969], [")", 972], ["blood", 974], ["pressure", 980], ["were", 989], ["also", 994], ["measured", 999], [".", 1007], ["The", 1009], ["trauma", 1013], ["-", 1019], ["related", 1020], ["exposure", 1028], ["challenge", 1037], ["induced", 1047], ["anxiety", 1055], ["on", 1063], ["both", 1066], ["days", 1071], [",", 1075], ["with", 1077], ["more", 1082], ["marked", 1087], ["responses", 1094], ["on", 1104], ["the", 1107], ["ATD", 1111], ["day", 1115], ["according", 1119], ["to", 1129], ["VAS", 1132], [",", 1135], ["DTS", 1137], [",", 1140], ["POMS", 1142], [",", 1146], ["and", 1148], ["DBP", 1152], ["(", 1156], ["p", 1157], ["<", 1159], [".05", 1161], [")", 1164], [".", 1165], ["A", 1167], ["trend", 1169], ["of", 1175], ["significance", 1178], ["(", 1191], [".1", 1192], [">", 1195], ["p", 1197], [">", 1199], [".05", 1201], [")", 1204], ["was", 1206], ["observed", 1210], ["for", 1219], ["STAI", 1223], ["Form", 1228], ["Y-1", 1233], [",", 1236], ["HR", 1238], [",", 1240], ["and", 1242], ["SBP", 1246], [".", 1249], ["These", 1251], ["data", 1257], ["demonstrate", 1262], ["that", 1274], ["ATD", 1279], ["accentuates", 1283], ["responses", 1295], ["to", 1305], ["trauma", 1308], ["-", 1314], ["related", 1315], ["stimuli", 1323], ["in", 1331], ["SSRI", 1334], ["-", 1338], ["recovered", 1339], ["PTSD", 1349], [".", 1353], ["They", 1355], ["also", 1360], ["suggest", 1365], ["that", 1373], ["SSRI", 1378], ["-", 1382], ["induced", 1383], ["increases", 1391], ["in", 1401], ["serotonin", 1404], ["function", 1414], ["restrain", 1423], ["PTSD", 1432], ["symptoms", 1437], [",", 1445], ["especially", 1447], ["under", 1458], ["provocation", 1464], [",", 1475], ["supporting", 1477], ["a", 1488], ["role", 1490], ["for", 1495], ["serotonin", 1499], ["in", 1509], ["mediating", 1512], ["stress", 1522], ["resilience", 1529], [".", 1539]]}
{"context": "The histone variant H2AZ marks nucleosomes flanking the promoters of most genes of budding yeast. The incorporation of H2AZ into chromatin is dependent on the SWR1 complex, which catalyses the replacement of conventional histone H2A with H2AZ. In cells, the pool of unincorporated histone H2AZ has previously been found in association with Nap1, a chaperone for conventional histone H2A-H2B. Here, we report the discovery of Chz1, a histone chaperone that has preference for H2AZ and can also deliver a source of the histone variant for SWR1-dependent histone replacement. Bacterially expressed Chz1 forms a heterotrimer with H2AZ-H2B, stabilizing the association of the histone dimer. We have identified a conserved motif important for histone variant recognition within the H2AZ-interacting domain of Chz1. The presence of this motif in other metazoan proteins suggests that H2AZ-specific chaperones may be widely conserved.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "a537bf47b5b549fba4cd70b3f5e9286d", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[26, 26]], "char_spans": [[159, 162]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["marks", 25], ["nucleosomes", 31], ["flanking", 43], ["the", 52], ["promoters", 56], ["of", 66], ["most", 69], ["genes", 74], ["of", 80], ["budding", 83], ["yeast", 91], [".", 96], ["The", 98], ["incorporation", 102], ["of", 116], ["H2AZ", 119], ["into", 124], ["chromatin", 129], ["is", 139], ["dependent", 142], ["on", 152], ["the", 155], ["SWR1", 159], ["complex", 164], [",", 171], ["which", 173], ["catalyses", 179], ["the", 189], ["replacement", 193], ["of", 205], ["conventional", 208], ["histone", 221], ["H2A", 229], ["with", 233], ["H2AZ", 238], [".", 242], ["In", 244], ["cells", 247], [",", 252], ["the", 254], ["pool", 258], ["of", 263], ["unincorporated", 266], ["histone", 281], ["H2AZ", 289], ["has", 294], ["previously", 298], ["been", 309], ["found", 314], ["in", 320], ["association", 323], ["with", 335], ["Nap1", 340], [",", 344], ["a", 346], ["chaperone", 348], ["for", 358], ["conventional", 362], ["histone", 375], ["H2A", 383], ["-", 386], ["H2B.", 387], ["Here", 392], [",", 396], ["we", 398], ["report", 401], ["the", 408], ["discovery", 412], ["of", 422], ["Chz1", 425], [",", 429], ["a", 431], ["histone", 433], ["chaperone", 441], ["that", 451], ["has", 456], ["preference", 460], ["for", 471], ["H2AZ", 475], ["and", 480], ["can", 484], ["also", 488], ["deliver", 493], ["a", 501], ["source", 503], ["of", 510], ["the", 513], ["histone", 517], ["variant", 525], ["for", 533], ["SWR1-dependent", 537], ["histone", 552], ["replacement", 560], [".", 571], ["Bacterially", 573], ["expressed", 585], ["Chz1", 595], ["forms", 600], ["a", 606], ["heterotrimer", 608], ["with", 621], ["H2AZ", 626], ["-", 630], ["H2B", 631], [",", 634], ["stabilizing", 636], ["the", 648], ["association", 652], ["of", 664], ["the", 667], ["histone", 671], ["dimer", 679], [".", 684], ["We", 686], ["have", 689], ["identified", 694], ["a", 705], ["conserved", 707], ["motif", 717], ["important", 723], ["for", 733], ["histone", 737], ["variant", 745], ["recognition", 753], ["within", 765], ["the", 772], ["H2AZ", 776], ["-", 780], ["interacting", 781], ["domain", 793], ["of", 800], ["Chz1", 803], [".", 807], ["The", 809], ["presence", 813], ["of", 822], ["this", 825], ["motif", 830], ["in", 836], ["other", 839], ["metazoan", 845], ["proteins", 854], ["suggests", 863], ["that", 872], ["H2AZ", 877], ["-", 881], ["specific", 882], ["chaperones", 891], ["may", 902], ["be", 906], ["widely", 909], ["conserved", 916], [".", 925]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. The pathophysiology is only partially known and a genetic component together with dopaminergic and brain iron dysregulation plays an important role. Secondary causes for RLS need to be excluded. Treatment depends on the severity and frequency of RLS symptoms, comprises non-pharmacological (eg lifestyle changes) and pharmacological interventions (eg dopaminergic medication, alpha-2-delta calcium channel ligands, opioids) and relieves symptoms only. Augmentation is the main complication of long-term dopaminergic treatment of RLS. This article will provide a clinically useful overview of RLS with provision of diagnostic criteria, differential diagnoses, possible investigations and different treatment strategies with their associated complications.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ee27b6a18fa848d0a07f50eae299fa52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["common", 77], ["movement", 84], ["disorder", 93], ["characterised", 102], ["by", 116], ["an", 119], ["uncontrollable", 122], ["urge", 137], ["to", 142], ["move", 145], ["because", 150], ["of", 158], ["uncomfortable", 161], [",", 174], ["sometimes", 176], ["painful", 186], ["sensations", 194], ["in", 205], ["the", 208], ["legs", 212], ["with", 217], ["a", 222], ["diurnal", 224], ["variation", 232], ["and", 242], ["a", 246], ["release", 248], ["with", 256], ["movement", 261], [".", 269], ["The", 271], ["pathophysiology", 275], ["is", 291], ["only", 294], ["partially", 299], ["known", 309], ["and", 315], ["a", 319], ["genetic", 321], ["component", 329], ["together", 339], ["with", 348], ["dopaminergic", 353], ["and", 366], ["brain", 370], ["iron", 376], ["dysregulation", 381], ["plays", 395], ["an", 401], ["important", 404], ["role", 414], [".", 418], ["Secondary", 420], ["causes", 430], ["for", 437], ["RLS", 441], ["need", 445], ["to", 450], ["be", 453], ["excluded", 456], [".", 464], ["Treatment", 466], ["depends", 476], ["on", 484], ["the", 487], ["severity", 491], ["and", 500], ["frequency", 504], ["of", 514], ["RLS", 517], ["symptoms", 521], [",", 529], ["comprises", 531], ["non", 541], ["-", 544], ["pharmacological", 545], ["(", 561], ["eg", 562], ["lifestyle", 565], ["changes", 575], [")", 582], ["and", 584], ["pharmacological", 588], ["interventions", 604], ["(", 618], ["eg", 619], ["dopaminergic", 622], ["medication", 635], [",", 645], ["alpha-2-delta", 647], ["calcium", 661], ["channel", 669], ["ligands", 677], [",", 684], ["opioids", 686], [")", 693], ["and", 695], ["relieves", 699], ["symptoms", 708], ["only", 717], [".", 721], ["Augmentation", 723], ["is", 736], ["the", 739], ["main", 743], ["complication", 748], ["of", 761], ["long", 764], ["-", 768], ["term", 769], ["dopaminergic", 774], ["treatment", 787], ["of", 797], ["RLS", 800], [".", 803], ["This", 805], ["article", 810], ["will", 818], ["provide", 823], ["a", 831], ["clinically", 833], ["useful", 844], ["overview", 851], ["of", 860], ["RLS", 863], ["with", 867], ["provision", 872], ["of", 882], ["diagnostic", 885], ["criteria", 896], [",", 904], ["differential", 906], ["diagnoses", 919], [",", 928], ["possible", 930], ["investigations", 939], ["and", 954], ["different", 958], ["treatment", 968], ["strategies", 978], ["with", 989], ["their", 994], ["associated", 1000], ["complications", 1011], [".", 1024]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Understanding gene regulation in Plasmodium, the causative agent of malaria, is an important step in deciphering its complex life cycle as well as leading to possible new targets for therapeutic applications. Very little is known about gene regulation in Plasmodium, and in particular, few regulatory elements have been identified. Such discovery has been significantly hampered by the high A-T content of some of the genomes of Plasmodium species, as well as the challenge in associating discovered regulatory elements to gene regulatory cascades due to Plasmodium's complex life cycle. We report a new method of using comparative genomics to systematically discover motifs in Plasmodium without requiring any functional data. Different from previous methods, our method does not depend on sequence alignments, and thus is particularly suitable for highly divergent genomes. We applied our method to discovering regulatory motifs between the human parasite, P.falciparum, and its rodent-infectious relative, P.yoelii. We also tested our procedure against comparisons between P.falciparum and the primate-infectious, P.knowlesi. Our computational effort leads to an initial catalog of 38 distinct motifs, corresponding to over 16 200 sites in the Plasmodium genome. The functionality of these motifs was further supported by their defined distribution within the genome as well as a correlation with gene expression patterns. This initial map provides a systematic view of gene regulation in Plasmodium, which can be refined as additional genomes become available. The new algorithm, named motif discovery using orthologous sequences (MDOS), is available at http://www.ics.uci.edu/ approximately xhx/project/mdos/.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "1a5db1bc1c094524a9cf3fcac627a7f9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[74, 75]], "char_spans": [[429, 446]]}]}], "context_tokens": [["Understanding", 0], ["gene", 14], ["regulation", 19], ["in", 30], ["Plasmodium", 33], [",", 43], ["the", 45], ["causative", 49], ["agent", 59], ["of", 65], ["malaria", 68], [",", 75], ["is", 77], ["an", 80], ["important", 83], ["step", 93], ["in", 98], ["deciphering", 101], ["its", 113], ["complex", 117], ["life", 125], ["cycle", 130], ["as", 136], ["well", 139], ["as", 144], ["leading", 147], ["to", 155], ["possible", 158], ["new", 167], ["targets", 171], ["for", 179], ["therapeutic", 183], ["applications", 195], [".", 207], ["Very", 209], ["little", 214], ["is", 221], ["known", 224], ["about", 230], ["gene", 236], ["regulation", 241], ["in", 252], ["Plasmodium", 255], [",", 265], ["and", 267], ["in", 271], ["particular", 274], [",", 284], ["few", 286], ["regulatory", 290], ["elements", 301], ["have", 310], ["been", 315], ["identified", 320], [".", 330], ["Such", 332], ["discovery", 337], ["has", 347], ["been", 351], ["significantly", 356], ["hampered", 370], ["by", 379], ["the", 382], ["high", 386], ["A", 391], ["-", 392], ["T", 393], ["content", 395], ["of", 403], ["some", 406], ["of", 411], ["the", 414], ["genomes", 418], ["of", 426], ["Plasmodium", 429], ["species", 440], [",", 447], ["as", 449], ["well", 452], ["as", 457], ["the", 460], ["challenge", 464], ["in", 474], ["associating", 477], ["discovered", 489], ["regulatory", 500], ["elements", 511], ["to", 520], ["gene", 523], ["regulatory", 528], ["cascades", 539], ["due", 548], ["to", 552], ["Plasmodium", 555], ["'s", 565], ["complex", 568], ["life", 576], ["cycle", 581], [".", 586], ["We", 588], ["report", 591], ["a", 598], ["new", 600], ["method", 604], ["of", 611], ["using", 614], ["comparative", 620], ["genomics", 632], ["to", 641], ["systematically", 644], ["discover", 659], ["motifs", 668], ["in", 675], ["Plasmodium", 678], ["without", 689], ["requiring", 697], ["any", 707], ["functional", 711], ["data", 722], [".", 726], ["Different", 728], ["from", 738], ["previous", 743], ["methods", 752], [",", 759], ["our", 761], ["method", 765], ["does", 772], ["not", 777], ["depend", 781], ["on", 788], ["sequence", 791], ["alignments", 800], [",", 810], ["and", 812], ["thus", 816], ["is", 821], ["particularly", 824], ["suitable", 837], ["for", 846], ["highly", 850], ["divergent", 857], ["genomes", 867], [".", 874], ["We", 876], ["applied", 879], ["our", 887], ["method", 891], ["to", 898], ["discovering", 901], ["regulatory", 913], ["motifs", 924], ["between", 931], ["the", 939], ["human", 943], ["parasite", 949], [",", 957], ["P.falciparum", 959], [",", 971], ["and", 973], ["its", 977], ["rodent", 981], ["-", 987], ["infectious", 988], ["relative", 999], [",", 1007], ["P.yoelii", 1009], [".", 1017], ["We", 1019], ["also", 1022], ["tested", 1027], ["our", 1034], ["procedure", 1038], ["against", 1048], ["comparisons", 1056], ["between", 1068], ["P.falciparum", 1076], ["and", 1089], ["the", 1093], ["primate", 1097], ["-", 1104], ["infectious", 1105], [",", 1115], ["P.knowlesi", 1117], [".", 1127], ["Our", 1129], ["computational", 1133], ["effort", 1147], ["leads", 1154], ["to", 1160], ["an", 1163], ["initial", 1166], ["catalog", 1174], ["of", 1182], ["38", 1185], ["distinct", 1188], ["motifs", 1197], [",", 1203], ["corresponding", 1205], ["to", 1219], ["over", 1222], ["16", 1227], ["200", 1230], ["sites", 1234], ["in", 1240], ["the", 1243], ["Plasmodium", 1247], ["genome", 1258], [".", 1264], ["The", 1266], ["functionality", 1270], ["of", 1284], ["these", 1287], ["motifs", 1293], ["was", 1300], ["further", 1304], ["supported", 1312], ["by", 1322], ["their", 1325], ["defined", 1331], ["distribution", 1339], ["within", 1352], ["the", 1359], ["genome", 1363], ["as", 1370], ["well", 1373], ["as", 1378], ["a", 1381], ["correlation", 1383], ["with", 1395], ["gene", 1400], ["expression", 1405], ["patterns", 1416], [".", 1424], ["This", 1426], ["initial", 1431], ["map", 1439], ["provides", 1443], ["a", 1452], ["systematic", 1454], ["view", 1465], ["of", 1470], ["gene", 1473], ["regulation", 1478], ["in", 1489], ["Plasmodium", 1492], [",", 1502], ["which", 1504], ["can", 1510], ["be", 1514], ["refined", 1517], ["as", 1525], ["additional", 1528], ["genomes", 1539], ["become", 1547], ["available", 1554], [".", 1563], ["The", 1565], ["new", 1569], ["algorithm", 1573], [",", 1582], ["named", 1584], ["motif", 1590], ["discovery", 1596], ["using", 1606], ["orthologous", 1612], ["sequences", 1624], ["(", 1634], ["MDOS", 1635], [")", 1639], [",", 1640], ["is", 1642], ["available", 1645], ["at", 1655], ["http://www.ics.uci.edu/", 1658], ["approximately", 1682], ["xhx", 1696], ["/", 1699], ["project", 1700], ["/", 1707], ["mdos/.", 1708]]}
{"context": "Restless legs syndrome (RLS)/Willis-Ekbom disease (WED) has a significant negative effect on quality of life. The decreased quality of life is similar to that of other chronic diseases, such as diabetes type 2, depression, and osteoarthritis. RLS/WED disrupts sleep length, sleep quality, and daytime alertness. Sleep disruption can contribute to depression. RLS/WED has been associated with cardiovascular disease and high blood pressure, possibly because of increased sympathetic tone caused by periodic limb movements of sleep. RLS/WED is underdiagnosed, leading to chronic sleep disruption and daytime consequences. Patients with RLS/WED have decreased productivity at work, which potentially has far-reaching economic consequences.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f67084a71c774272be8ec7fc8baa5f52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS)/Willis", 24], ["-", 35], ["Ekbom", 36], ["disease", 42], ["(", 50], ["WED", 51], [")", 54], ["has", 56], ["a", 60], ["significant", 62], ["negative", 74], ["effect", 83], ["on", 90], ["quality", 93], ["of", 101], ["life", 104], [".", 108], ["The", 110], ["decreased", 114], ["quality", 124], ["of", 132], ["life", 135], ["is", 140], ["similar", 143], ["to", 151], ["that", 154], ["of", 159], ["other", 162], ["chronic", 168], ["diseases", 176], [",", 184], ["such", 186], ["as", 191], ["diabetes", 194], ["type", 203], ["2", 208], [",", 209], ["depression", 211], [",", 221], ["and", 223], ["osteoarthritis", 227], [".", 241], ["RLS", 243], ["/", 246], ["WED", 247], ["disrupts", 251], ["sleep", 260], ["length", 266], [",", 272], ["sleep", 274], ["quality", 280], [",", 287], ["and", 289], ["daytime", 293], ["alertness", 301], [".", 310], ["Sleep", 312], ["disruption", 318], ["can", 329], ["contribute", 333], ["to", 344], ["depression", 347], [".", 357], ["RLS", 359], ["/", 362], ["WED", 363], ["has", 367], ["been", 371], ["associated", 376], ["with", 387], ["cardiovascular", 392], ["disease", 407], ["and", 415], ["high", 419], ["blood", 424], ["pressure", 430], [",", 438], ["possibly", 440], ["because", 449], ["of", 457], ["increased", 460], ["sympathetic", 470], ["tone", 482], ["caused", 487], ["by", 494], ["periodic", 497], ["limb", 506], ["movements", 511], ["of", 521], ["sleep", 524], [".", 529], ["RLS", 531], ["/", 534], ["WED", 535], ["is", 539], ["underdiagnosed", 542], [",", 556], ["leading", 558], ["to", 566], ["chronic", 569], ["sleep", 577], ["disruption", 583], ["and", 594], ["daytime", 598], ["consequences", 606], [".", 618], ["Patients", 620], ["with", 629], ["RLS", 634], ["/", 637], ["WED", 638], ["have", 642], ["decreased", 647], ["productivity", 657], ["at", 670], ["work", 673], [",", 677], ["which", 679], ["potentially", 685], ["has", 697], ["far", 701], ["-", 704], ["reaching", 705], ["economic", 714], ["consequences", 723], [".", 735]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ed0c4a0629ff46d1b8993188f8a0e5c4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[326, 326], [90, 90], [28, 28], [217, 217], [55, 55]], "char_spans": [[1870, 1879], [538, 547], [177, 186], [1232, 1241], [348, 357]]}]}], "context_tokens": [["Specific", 0], ["reversal", 9], ["agents", 18], ["for", 25], ["non", 29], ["-", 32], ["vitamin", 33], ["K", 41], ["antagonist", 43], ["oral", 54], ["anticoagulants", 59], ["are", 74], ["lacking", 78], [".", 85], ["Idarucizumab", 87], [",", 99], ["an", 101], ["antibody", 104], ["fragment", 113], [",", 121], ["was", 123], ["developed", 127], ["to", 137], ["reverse", 140], ["the", 148], ["anticoagulant", 152], ["effects", 166], ["of", 174], ["dabigatran", 177], [".", 187], ["We", 189], ["undertook", 192], ["this", 202], ["prospective", 207], ["cohort", 219], ["study", 226], ["to", 232], ["determine", 235], ["the", 245], ["safety", 249], ["of", 256], ["5", 259], ["g", 261], ["of", 263], ["intravenous", 266], ["idarucizumab", 278], ["and", 291], ["its", 295], ["capacity", 299], ["to", 308], ["reverse", 311], ["the", 319], ["anticoagulant", 323], ["effects", 337], ["of", 345], ["dabigatran", 348], ["in", 359], ["patients", 362], ["who", 371], ["had", 375], ["serious", 379], ["bleeding", 387], ["(", 396], ["group", 397], ["A", 403], [")", 404], ["or", 406], ["required", 409], ["an", 418], ["urgent", 421], ["procedure", 428], ["(", 438], ["group", 439], ["B", 445], [")", 446], [".", 447], ["The", 449], ["primary", 453], ["end", 461], ["point", 465], ["was", 471], ["the", 475], ["maximum", 479], ["percentage", 487], ["reversal", 498], ["of", 507], ["the", 510], ["anticoagulant", 514], ["effect", 528], ["of", 535], ["dabigatran", 538], ["within", 549], ["4", 556], ["hours", 558], ["after", 564], ["the", 570], ["administration", 574], ["of", 589], ["idarucizumab", 592], [",", 604], ["on", 606], ["the", 609], ["basis", 613], ["of", 619], ["the", 622], ["determination", 626], ["at", 640], ["a", 643], ["central", 645], ["laboratory", 653], ["of", 664], ["the", 667], ["dilute", 671], ["thrombin", 678], ["time", 687], ["or", 692], ["ecarin", 695], ["clotting", 702], ["time", 711], [".", 715], ["A", 717], ["key", 719], ["secondary", 723], ["end", 733], ["point", 737], ["was", 743], ["the", 747], ["restoration", 751], ["of", 763], ["hemostasis", 766], [".", 776], ["This", 778], ["interim", 783], ["analysis", 791], ["included", 800], ["90", 809], ["patients", 812], ["who", 821], ["received", 825], ["idarucizumab", 834], ["(", 847], ["51", 848], ["patients", 851], ["in", 860], ["group", 863], ["A", 869], ["and", 871], ["39", 875], ["in", 878], ["group", 881], ["B", 887], [")", 888], [".", 889], ["Among", 891], ["68", 897], ["patients", 900], ["with", 909], ["an", 914], ["elevated", 917], ["dilute", 926], ["thrombin", 933], ["time", 942], ["and", 947], ["81", 951], ["with", 954], ["an", 959], ["elevated", 962], ["ecarin", 971], ["clotting", 978], ["time", 987], ["at", 992], ["baseline", 995], [",", 1003], ["the", 1005], ["median", 1009], ["maximum", 1016], ["percentage", 1024], ["reversal", 1035], ["was", 1044], ["100", 1048], ["%", 1051], ["(", 1053], ["95", 1054], ["%", 1056], ["confidence", 1058], ["interval", 1069], [",", 1077], ["100", 1079], ["to", 1083], ["100", 1086], [")", 1089], [".", 1090], ["Idarucizumab", 1092], ["normalized", 1105], ["the", 1116], ["test", 1120], ["results", 1125], ["in", 1133], ["88", 1136], ["to", 1139], ["98", 1142], ["%", 1144], ["of", 1146], ["the", 1149], ["patients", 1153], [",", 1161], ["an", 1163], ["effect", 1166], ["that", 1173], ["was", 1178], ["evident", 1182], ["within", 1190], ["minutes", 1197], [".", 1204], ["Concentrations", 1206], ["of", 1221], ["unbound", 1224], ["dabigatran", 1232], ["remained", 1243], ["below", 1252], ["20", 1258], ["ng", 1261], ["per", 1264], ["milliliter", 1268], ["at", 1279], ["24", 1282], ["hours", 1285], ["in", 1291], ["79", 1294], ["%", 1296], ["of", 1298], ["the", 1301], ["patients", 1305], [".", 1313], ["Among", 1315], ["35", 1321], ["patients", 1324], ["in", 1333], ["group", 1336], ["A", 1342], ["who", 1344], ["could", 1348], ["be", 1354], ["assessed", 1357], [",", 1365], ["hemostasis", 1367], [",", 1377], ["as", 1379], ["determined", 1382], ["by", 1393], ["local", 1396], ["investigators", 1402], [",", 1415], ["was", 1417], ["restored", 1421], ["at", 1430], ["a", 1433], ["median", 1435], ["of", 1442], ["11.4", 1445], ["hours", 1450], [".", 1455], ["Among", 1457], ["36", 1463], ["patients", 1466], ["in", 1475], ["group", 1478], ["B", 1484], ["who", 1486], ["underwent", 1490], ["a", 1500], ["procedure", 1502], [",", 1511], ["normal", 1513], ["intraoperative", 1520], ["hemostasis", 1535], ["was", 1546], ["reported", 1550], ["in", 1559], ["33", 1562], [",", 1564], ["and", 1566], ["mildly", 1570], ["or", 1577], ["moderately", 1580], ["abnormal", 1591], ["hemostasis", 1600], ["was", 1611], ["reported", 1615], ["in", 1624], ["2", 1627], ["patients", 1629], ["and", 1638], ["1", 1642], ["patient", 1644], [",", 1651], ["respectively", 1653], [".", 1665], ["One", 1667], ["thrombotic", 1671], ["event", 1682], ["occurred", 1688], ["within", 1697], ["72", 1704], ["hours", 1707], ["after", 1713], ["idarucizumab", 1719], ["administration", 1732], ["in", 1747], ["a", 1750], ["patient", 1752], ["in", 1760], ["whom", 1763], ["anticoagulants", 1768], ["had", 1783], ["not", 1787], ["been", 1791], ["reinitiated", 1796], [".", 1807], ["Idarucizumab", 1809], ["completely", 1822], ["reversed", 1833], ["the", 1842], ["anticoagulant", 1846], ["effect", 1860], ["of", 1867], ["dabigatran", 1870], ["within", 1881], ["minutes", 1888], [".", 1895], ["(", 1897], ["Funded", 1898], ["by", 1905], ["Boehringer", 1908], ["Ingelheim", 1919], [";", 1928], ["RE", 1930], ["-", 1932], ["VERSE", 1933], ["AD", 1939], ["ClinicalTrials.gov", 1942], ["number", 1961], [",", 1967], ["NCT02104947", 1969], [".", 1980], [")", 1981], [".", 1982]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing. The meiotic or mitotic origin of most cases remains unknown due to the difficulty in detecting hidden mosaicism and to the lack of meiotic segregation studies. We analyzed 15 Turner patients, 10 with a 45,X whereas the rest had a second cell line with abnormal X-chromosomes: a pseudodicentric, an isochromosome, one large and one small ring, and the last with a long arm deletion. Our aims were: to detect X cryptic mosaicism in patients with a 45,X constitution; to determine the parental origin of the abnormality; to infer the zygotic origin of the karyotype and to suggest the timing and mechanism of the error(s) leading to the formation of abnormal X chromosomes from maternal origin. Molecular investigation did not revealed heterozygosity for any microsatellite, excluding X mosaicism in the 45,X cases. Parental origin of the single X chromosome was maternal in 90% of these patients. Three of the structurally abnormal Xs were maternally derived whereas the other two were paternal. These results allowed us to corroborate breakpoints in these abnormal X chromosomes and suggest that the pseudodicentric chromosome originated from post-zygotic sister chromatid exchange, whereas the Xq deleted chromosome probably arose after a recombination event during maternal meiosis.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "fb9765068c0047e8994ba18eabf79e88", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[13, 13], [97, 97], [141, 141], [170, 170], [158, 158], [65, 65], [207, 207]], "char_spans": [[70, 70], [502, 502], [751, 751], [938, 938], [877, 877], [356, 356], [1159, 1159]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["chromosomal", 21], ["disorder", 33], ["in", 42], ["which", 45], ["all", 51], ["or", 55], ["part", 58], ["of", 63], ["one", 66], ["X", 70], ["chromosome", 72], ["is", 83], ["missing", 86], [".", 93], ["The", 95], ["meiotic", 99], ["or", 107], ["mitotic", 110], ["origin", 118], ["of", 125], ["most", 128], ["cases", 133], ["remains", 139], ["unknown", 147], ["due", 155], ["to", 159], ["the", 162], ["difficulty", 166], ["in", 177], ["detecting", 180], ["hidden", 190], ["mosaicism", 197], ["and", 207], ["to", 211], ["the", 214], ["lack", 218], ["of", 223], ["meiotic", 226], ["segregation", 234], ["studies", 246], [".", 253], ["We", 255], ["analyzed", 258], ["15", 267], ["Turner", 270], ["patients", 277], [",", 285], ["10", 287], ["with", 290], ["a", 295], ["45,X", 297], ["whereas", 302], ["the", 310], ["rest", 314], ["had", 319], ["a", 323], ["second", 325], ["cell", 332], ["line", 337], ["with", 342], ["abnormal", 347], ["X", 356], ["-", 357], ["chromosomes", 358], [":", 369], ["a", 371], ["pseudodicentric", 373], [",", 388], ["an", 390], ["isochromosome", 393], [",", 406], ["one", 408], ["large", 412], ["and", 418], ["one", 422], ["small", 426], ["ring", 432], [",", 436], ["and", 438], ["the", 442], ["last", 446], ["with", 451], ["a", 456], ["long", 458], ["arm", 463], ["deletion", 467], [".", 475], ["Our", 477], ["aims", 481], ["were", 486], [":", 490], ["to", 492], ["detect", 495], ["X", 502], ["cryptic", 504], ["mosaicism", 512], ["in", 522], ["patients", 525], ["with", 534], ["a", 539], ["45,X", 541], ["constitution", 546], [";", 558], ["to", 560], ["determine", 563], ["the", 573], ["parental", 577], ["origin", 586], ["of", 593], ["the", 596], ["abnormality", 600], [";", 611], ["to", 613], ["infer", 616], ["the", 622], ["zygotic", 626], ["origin", 634], ["of", 641], ["the", 644], ["karyotype", 648], ["and", 658], ["to", 662], ["suggest", 665], ["the", 673], ["timing", 677], ["and", 684], ["mechanism", 688], ["of", 698], ["the", 701], ["error(s", 705], [")", 712], ["leading", 714], ["to", 722], ["the", 725], ["formation", 729], ["of", 739], ["abnormal", 742], ["X", 751], ["chromosomes", 753], ["from", 765], ["maternal", 770], ["origin", 779], [".", 785], ["Molecular", 787], ["investigation", 797], ["did", 811], ["not", 815], ["revealed", 819], ["heterozygosity", 828], ["for", 843], ["any", 847], ["microsatellite", 851], [",", 865], ["excluding", 867], ["X", 877], ["mosaicism", 879], ["in", 889], ["the", 892], ["45,X", 896], ["cases", 901], [".", 906], ["Parental", 908], ["origin", 917], ["of", 924], ["the", 927], ["single", 931], ["X", 938], ["chromosome", 940], ["was", 951], ["maternal", 955], ["in", 964], ["90", 967], ["%", 969], ["of", 971], ["these", 974], ["patients", 980], [".", 988], ["Three", 990], ["of", 996], ["the", 999], ["structurally", 1003], ["abnormal", 1016], ["Xs", 1025], ["were", 1028], ["maternally", 1033], ["derived", 1044], ["whereas", 1052], ["the", 1060], ["other", 1064], ["two", 1070], ["were", 1074], ["paternal", 1079], [".", 1087], ["These", 1089], ["results", 1095], ["allowed", 1103], ["us", 1111], ["to", 1114], ["corroborate", 1117], ["breakpoints", 1129], ["in", 1141], ["these", 1144], ["abnormal", 1150], ["X", 1159], ["chromosomes", 1161], ["and", 1173], ["suggest", 1177], ["that", 1185], ["the", 1190], ["pseudodicentric", 1194], ["chromosome", 1210], ["originated", 1221], ["from", 1232], ["post", 1237], ["-", 1241], ["zygotic", 1242], ["sister", 1250], ["chromatid", 1257], ["exchange", 1267], [",", 1275], ["whereas", 1277], ["the", 1285], ["Xq", 1289], ["deleted", 1292], ["chromosome", 1300], ["probably", 1311], ["arose", 1320], ["after", 1326], ["a", 1332], ["recombination", 1334], ["event", 1348], ["during", 1354], ["maternal", 1361], ["meiosis", 1370], [".", 1377]]}
